drugbank-id,description,name
DB00267,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefmenoxime.,Cefmenoxime
DB00274,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefmetazole.,Cefmetazole
DB00430,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefpiramide.,Cefpiramide
DB00438,The therapeutic efficacy of Abciximab can be decreased when used in combination with Ceftazidime.,Ceftazidime
DB00447,The therapeutic efficacy of Abciximab can be decreased when used in combination with Loracarbef.,Loracarbef
DB00456,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefalotin.,Cefalotin
DB00493,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefotaxime.,Cefotaxime
DB00535,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefdinir.,Cefdinir
DB00567,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cephalexin.,Cephalexin
DB00671,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefixime.,Cefixime
DB00689,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cephaloglycin.,Cephaloglycin
DB00833,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefaclor.,Cefaclor
DB00923,The therapeutic efficacy of Abciximab can be decreased when used in combination with Ceforanide.,Ceforanide
DB01066,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefditoren.,Cefditoren
DB01112,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefuroxime.,Cefuroxime
DB01139,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefapirin.,Cefapirin
DB01140,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefadroxil.,Cefadroxil
DB01150,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefprozil.,Cefprozil
DB01212,The therapeutic efficacy of Abciximab can be decreased when used in combination with Ceftriaxone.,Ceftriaxone
DB01326,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefamandole.,Cefamandole
DB01327,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefazolin.,Cefazolin
DB01328,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefonicid.,Cefonicid
DB01329,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefoperazone.,Cefoperazone
DB01330,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefotetan.,Cefotetan
DB01331,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefoxitin.,Cefoxitin
DB01332,The therapeutic efficacy of Abciximab can be decreased when used in combination with Ceftizoxime.,Ceftizoxime
DB01333,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefradine.,Cefradine
DB01413,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefepime.,Cefepime
DB01414,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefacetrile.,Cefacetrile
DB01415,The therapeutic efficacy of Abciximab can be decreased when used in combination with Ceftibuten.,Ceftibuten
DB01416,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefpodoxime.,Cefpodoxime
DB04570,The therapeutic efficacy of Abciximab can be decreased when used in combination with Latamoxef.,Latamoxef
DB04918,The therapeutic efficacy of Abciximab can be decreased when used in combination with Ceftobiprole.,Ceftobiprole
DB06590,The therapeutic efficacy of Abciximab can be decreased when used in combination with Ceftaroline fosamil.,Ceftaroline fosamil
DB09008,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefaloridine.,Cefaloridine
DB09050,The therapeutic efficacy of Abciximab can be decreased when used in combination with Ceftolozane.,Ceftolozane
DB09062,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefminox.,Cefminox
DB11367,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefroxadine.,Cefroxadine
DB11935,The therapeutic efficacy of Abciximab can be decreased when used in combination with Flomoxef.,Flomoxef
DB13266,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefatrizine.,Cefatrizine
DB13461,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefcapene.,Cefcapene
DB13470,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefodizime.,Cefodizime
DB13499,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefsulodin.,Cefsulodin
DB13504,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefetamet.,Cefetamet
DB13638,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefbuperazone.,Cefbuperazone
DB13667,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefozopran.,Cefozopran
DB13682,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefpirome.,Cefpirome
DB13778,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefazedone.,Cefazedone
DB13821,The therapeutic efficacy of Abciximab can be decreased when used in combination with Ceftezole.,Ceftezole
DB14725,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefamandole nafate.,Cefamandole nafate
DB00254,The risk or severity of bleeding can be increased when Doxycycline is combined with Abciximab.,Doxycycline
DB00207,The risk or severity of adverse effects can be increased when Azithromycin is combined with Abciximab.,Azithromycin
DB09539,The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Abciximab.,Omega-3-acid ethyl esters
DB00945,Acetylsalicylic acid may increase the antiplatelet activities of Abciximab.,Acetylsalicylic acid
DB01050,The risk or severity of bleeding can be increased when Ibuprofen is combined with Abciximab.,Ibuprofen
DB09213,The risk or severity of bleeding can be increased when Dexibuprofen is combined with Abciximab.,Dexibuprofen
DB01606,The risk or severity of bleeding can be increased when Tazobactam is combined with Abciximab.,Tazobactam
DB00199,The risk or severity of bleeding can be increased when Erythromycin is combined with Abciximab.,Erythromycin
DB00656,The risk or severity of bleeding can be increased when Trazodone is combined with Abciximab.,Trazodone
DB00620,The therapeutic efficacy of Abciximab can be decreased when used in combination with Triamcinolone.,Triamcinolone
DB09079,The risk or severity of bleeding can be increased when Abciximab is combined with Nintedanib.,Nintedanib
DB01175,The risk or severity of bleeding can be increased when Escitalopram is combined with Abciximab.,Escitalopram
DB01104,The risk or severity of bleeding can be increased when Sertraline is combined with Abciximab.,Sertraline
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Abciximab.","Ebola Zaire vaccine (live, attenuated)"
DB00232,The therapeutic efficacy of Abciximab can be decreased when used in combination with Methyclothiazide.,Methyclothiazide
DB00436,The therapeutic efficacy of Abciximab can be decreased when used in combination with Bendroflumethiazide.,Bendroflumethiazide
DB00562,The therapeutic efficacy of Abciximab can be decreased when used in combination with Benzthiazide.,Benzthiazide
DB00606,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cyclothiazide.,Cyclothiazide
DB00774,The therapeutic efficacy of Abciximab can be decreased when used in combination with Hydroflumethiazide.,Hydroflumethiazide
DB00880,The therapeutic efficacy of Abciximab can be decreased when used in combination with Chlorothiazide.,Chlorothiazide
DB00999,The therapeutic efficacy of Abciximab can be decreased when used in combination with Hydrochlorothiazide.,Hydrochlorothiazide
DB01021,The therapeutic efficacy of Abciximab can be decreased when used in combination with Trichlormethiazide.,Trichlormethiazide
DB01324,The therapeutic efficacy of Abciximab can be decreased when used in combination with Polythiazide.,Polythiazide
DB13430,The therapeutic efficacy of Abciximab can be decreased when used in combination with Mebutizide.,Mebutizide
DB13532,The therapeutic efficacy of Abciximab can be decreased when used in combination with Cyclopenthiazide.,Cyclopenthiazide
DB06605,Apixaban may increase the anticoagulant activities of Drotrecogin alfa.,Apixaban
DB06695,Dabigatran etexilate may increase the anticoagulant activities of Drotrecogin alfa.,Dabigatran etexilate
DB01254,The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Drotrecogin alfa.,Dasatinib
DB01609,The risk or severity of gastrointestinal bleeding can be increased when Drotrecogin alfa is combined with Deferasirox.,Deferasirox
DB01586,The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Ursodeoxycholic acid.,Ursodeoxycholic acid
DB02123,The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Glycochenodeoxycholic Acid.,Glycochenodeoxycholic Acid
DB02659,The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Cholic Acid.,Cholic Acid
DB02691,The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Glycocholic acid.,Glycocholic acid
DB03619,The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Deoxycholic acid.,Deoxycholic acid
DB04348,The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Taurocholic acid.,Taurocholic acid
DB05990,The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Obeticholic acid.,Obeticholic acid
DB06777,The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Chenodeoxycholic acid.,Chenodeoxycholic acid
DB08833,The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Taurochenodeoxycholic acid.,Taurochenodeoxycholic acid
DB08834,The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Tauroursodeoxycholic acid.,Tauroursodeoxycholic acid
DB08857,The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Bamet-UD2.,Bamet-UD2
DB11622,The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Dehydrocholic acid.,Dehydrocholic acid
DB11789,The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Hyodeoxycholic Acid.,Hyodeoxycholic Acid
DB09075,The risk or severity of bleeding can be increased when Edoxaban is combined with Drotrecogin alfa.,Edoxaban
DB09053,The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Drotrecogin alfa.,Ibrutinib
DB08935,The risk or severity of bleeding and hemorrhage can be increased when Drotrecogin alfa is combined with Obinutuzumab.,Obinutuzumab
DB06228,Drotrecogin alfa may increase the anticoagulant activities of Rivaroxaban.,Rivaroxaban
DB06206,The risk or severity of bleeding and hemorrhage can be increased when Drotrecogin alfa is combined with Sugammadex.,Sugammadex
DB09070,Tibolone may increase the anticoagulant activities of Drotrecogin alfa.,Tibolone
DB00932,The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Drotrecogin alfa.,Tipranavir
DB00013,Urokinase may increase the anticoagulant activities of Drotrecogin alfa.,Urokinase
DB00163,Vitamin E may increase the anticoagulant activities of Drotrecogin alfa.,Vitamin E
DB09030,The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Drotrecogin alfa.,Vorapaxar
DB06692,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Aprotinin.,Aprotinin
DB01381,The therapeutic efficacy of Drotrecogin alfa can be increased when used in combination with Ginkgo biloba.,Ginkgo biloba
DB01181,The risk or severity of bleeding can be increased when Ifosfamide is combined with Drotrecogin alfa.,Ifosfamide
DB00468,The therapeutic efficacy of Drotrecogin alfa can be increased when used in combination with Quinine.,Quinine
DB00908,The therapeutic efficacy of Drotrecogin alfa can be increased when used in combination with Quinidine.,Quinidine
DB00675,The risk or severity of bleeding can be increased when Tamoxifen is combined with Drotrecogin alfa.,Tamoxifen
DB00539,The risk or severity of bleeding can be increased when Toremifene is combined with Drotrecogin alfa.,Toremifene
DB00806,The therapeutic efficacy of Drotrecogin alfa can be increased when used in combination with Pentoxifylline.,Pentoxifylline
DB00686,Pentosan polysulfate may increase the anticoagulant activities of Drotrecogin alfa.,Pentosan polysulfate
DB00583,The therapeutic efficacy of Drotrecogin alfa can be increased when used in combination with Levocarnitine.,Levocarnitine
DB00255,Diethylstilbestrol may decrease the anticoagulant activities of Drotrecogin alfa.,Diethylstilbestrol
DB00269,Chlorotrianisene may decrease the anticoagulant activities of Drotrecogin alfa.,Chlorotrianisene
DB00286,Conjugated estrogens may decrease the anticoagulant activities of Drotrecogin alfa.,Conjugated estrogens
DB00783,Estradiol may decrease the anticoagulant activities of Drotrecogin alfa.,Estradiol
DB00977,Ethinylestradiol may decrease the anticoagulant activities of Drotrecogin alfa.,Ethinylestradiol
DB01357,Mestranol may decrease the anticoagulant activities of Drotrecogin alfa.,Mestranol
DB04573,Estriol may decrease the anticoagulant activities of Drotrecogin alfa.,Estriol
DB04574,Estrone sulfate may decrease the anticoagulant activities of Drotrecogin alfa.,Estrone sulfate
DB04575,Quinestrol may decrease the anticoagulant activities of Drotrecogin alfa.,Quinestrol
DB07931,Hexestrol may decrease the anticoagulant activities of Drotrecogin alfa.,Hexestrol
DB09317,"Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Drotrecogin alfa.","Synthetic Conjugated Estrogens, A"
DB09318,"Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Drotrecogin alfa.","Synthetic Conjugated Estrogens, B"
DB09369,Polyestradiol phosphate may decrease the anticoagulant activities of Drotrecogin alfa.,Polyestradiol phosphate
DB09381,Esterified estrogens may decrease the anticoagulant activities of Drotrecogin alfa.,Esterified estrogens
DB11478,Zeranol may decrease the anticoagulant activities of Drotrecogin alfa.,Zeranol
DB11674,Equol may decrease the anticoagulant activities of Drotrecogin alfa.,Equol
DB12487,Promestriene may decrease the anticoagulant activities of Drotrecogin alfa.,Promestriene
DB13143,Methallenestril may decrease the anticoagulant activities of Drotrecogin alfa.,Methallenestril
DB13386,Epimestrol may decrease the anticoagulant activities of Drotrecogin alfa.,Epimestrol
DB13418,Moxestrol may decrease the anticoagulant activities of Drotrecogin alfa.,Moxestrol
DB13952,Estradiol acetate may decrease the anticoagulant activities of Drotrecogin alfa.,Estradiol acetate
DB13953,Estradiol benzoate may decrease the anticoagulant activities of Drotrecogin alfa.,Estradiol benzoate
DB13954,Estradiol cypionate may decrease the anticoagulant activities of Drotrecogin alfa.,Estradiol cypionate
DB13956,Estradiol valerate may decrease the anticoagulant activities of Drotrecogin alfa.,Estradiol valerate
DB15334,Biochanin A may decrease the anticoagulant activities of Drotrecogin alfa.,Biochanin A
DB15335,Formononetin may decrease the anticoagulant activities of Drotrecogin alfa.,Formononetin
DB00159,The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Drotrecogin alfa.,Icosapent
DB00244,The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Drotrecogin alfa.,Mesalazine
DB00328,The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Drotrecogin alfa.,Indomethacin
DB00461,The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Drotrecogin alfa.,Nabumetone
DB00465,The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Drotrecogin alfa.,Ketorolac
DB00469,The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Drotrecogin alfa.,Tenoxicam
DB00482,The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Drotrecogin alfa.,Celecoxib
DB00500,The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Drotrecogin alfa.,Tolmetin
DB00533,The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Drotrecogin alfa.,Rofecoxib
DB00554,The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Drotrecogin alfa.,Piroxicam
DB00573,The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Drotrecogin alfa.,Fenoprofen
DB00580,The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Drotrecogin alfa.,Valdecoxib
DB00586,The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Drotrecogin alfa.,Diclofenac
DB00605,The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Drotrecogin alfa.,Sulindac
DB00712,The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Drotrecogin alfa.,Flurbiprofen
DB00749,The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Drotrecogin alfa.,Etodolac
DB00784,The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Drotrecogin alfa.,Mefenamic acid
DB00788,The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Drotrecogin alfa.,Naproxen
DB00795,The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Drotrecogin alfa.,Sulfasalazine
DB00812,The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Drotrecogin alfa.,Phenylbutazone
DB00814,The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Drotrecogin alfa.,Meloxicam
DB00821,The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Drotrecogin alfa.,Carprofen
DB00861,The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Drotrecogin alfa.,Diflunisal
DB00936,The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Drotrecogin alfa.,Salicylic acid
DB00939,The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Drotrecogin alfa.,Meclofenamic acid
DB00991,The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Drotrecogin alfa.,Oxaprozin
DB01009,The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Drotrecogin alfa.,Ketoprofen
DB01014,The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Drotrecogin alfa.,Balsalazide
DB01250,The risk or severity of bleeding and hemorrhage can be increased when Olsalazine is combined with Drotrecogin alfa.,Olsalazine
DB01283,The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Drotrecogin alfa.,Lumiracoxib
DB01397,The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Drotrecogin alfa.,Magnesium salicylate
DB01399,The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Drotrecogin alfa.,Salsalate
DB01401,The risk or severity of bleeding and hemorrhage can be increased when Choline magnesium trisalicylate is combined with Drotrecogin alfa.,Choline magnesium trisalicylate
DB01419,The risk or severity of bleeding and hemorrhage can be increased when Antrafenine is combined with Drotrecogin alfa.,Antrafenine
DB01424,The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Drotrecogin alfa.,Aminophenazone
DB01435,The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Drotrecogin alfa.,Antipyrine
DB01600,The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Drotrecogin alfa.,Tiaprofenic acid
DB01628,The risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Drotrecogin alfa.,Etoricoxib
DB02224,The risk or severity of bleeding and hemorrhage can be increased when Taxifolin is combined with Drotrecogin alfa.,Taxifolin
DB03585,The risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with Drotrecogin alfa.,Oxyphenbutazone
DB04552,The risk or severity of bleeding and hemorrhage can be increased when Niflumic acid is combined with Drotrecogin alfa.,Niflumic acid
DB04725,The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Drotrecogin alfa.,Licofelone
DB04812,The risk or severity of bleeding and hemorrhage can be increased when Benoxaprofen is combined with Drotrecogin alfa.,Benoxaprofen
DB04817,The risk or severity of bleeding and hemorrhage can be increased when Metamizole is combined with Drotrecogin alfa.,Metamizole
DB04828,The risk or severity of bleeding and hemorrhage can be increased when Zomepirac is combined with Drotrecogin alfa.,Zomepirac
DB05095,The risk or severity of bleeding and hemorrhage can be increased when Cimicoxib is combined with Drotrecogin alfa.,Cimicoxib
DB06725,The risk or severity of bleeding and hemorrhage can be increased when Lornoxicam is combined with Drotrecogin alfa.,Lornoxicam
DB06736,The risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Drotrecogin alfa.,Aceclofenac
DB06737,The risk or severity of bleeding and hemorrhage can be increased when Zaltoprofen is combined with Drotrecogin alfa.,Zaltoprofen
DB07402,The risk or severity of bleeding and hemorrhage can be increased when Azapropazone is combined with Drotrecogin alfa.,Azapropazone
DB07477,The risk or severity of bleeding and hemorrhage can be increased when Felbinac is combined with Drotrecogin alfa.,Felbinac
DB08439,The risk or severity of bleeding and hemorrhage can be increased when Parecoxib is combined with Drotrecogin alfa.,Parecoxib
DB08797,The risk or severity of bleeding and hemorrhage can be increased when Salicylamide is combined with Drotrecogin alfa.,Salicylamide
DB08940,The risk or severity of bleeding and hemorrhage can be increased when Kebuzone is combined with Drotrecogin alfa.,Kebuzone
DB08942,The risk or severity of bleeding and hemorrhage can be increased when Isoxicam is combined with Drotrecogin alfa.,Isoxicam
DB08951,The risk or severity of bleeding and hemorrhage can be increased when Indoprofen is combined with Drotrecogin alfa.,Indoprofen
DB08955,The risk or severity of bleeding and hemorrhage can be increased when Ibuproxam is combined with Drotrecogin alfa.,Ibuproxam
DB08976,The risk or severity of bleeding and hemorrhage can be increased when Floctafenine is combined with Drotrecogin alfa.,Floctafenine
DB08981,The risk or severity of bleeding and hemorrhage can be increased when Fenbufen is combined with Drotrecogin alfa.,Fenbufen
DB08984,The risk or severity of bleeding and hemorrhage can be increased when Etofenamate is combined with Drotrecogin alfa.,Etofenamate
DB08991,The risk or severity of bleeding and hemorrhage can be increased when Epirizole is combined with Drotrecogin alfa.,Epirizole
DB09084,The risk or severity of bleeding and hemorrhage can be increased when Benzydamine is combined with Drotrecogin alfa.,Benzydamine
DB09212,The risk or severity of bleeding and hemorrhage can be increased when Loxoprofen is combined with Drotrecogin alfa.,Loxoprofen
DB09214,The risk or severity of bleeding and hemorrhage can be increased when Dexketoprofen is combined with Drotrecogin alfa.,Dexketoprofen
DB09215,The risk or severity of bleeding and hemorrhage can be increased when Droxicam is combined with Drotrecogin alfa.,Droxicam
DB09216,The risk or severity of bleeding and hemorrhage can be increased when Tolfenamic acid is combined with Drotrecogin alfa.,Tolfenamic acid
DB09217,The risk or severity of bleeding and hemorrhage can be increased when Firocoxib is combined with Drotrecogin alfa.,Firocoxib
DB09218,The risk or severity of bleeding and hemorrhage can be increased when Clonixin is combined with Drotrecogin alfa.,Clonixin
DB09285,The risk or severity of bleeding and hemorrhage can be increased when Morniflumate is combined with Drotrecogin alfa.,Morniflumate
DB09288,The risk or severity of bleeding and hemorrhage can be increased when Propacetamol is combined with Drotrecogin alfa.,Propacetamol
DB09295,The risk or severity of bleeding and hemorrhage can be increased when Talniflumate is combined with Drotrecogin alfa.,Talniflumate
DB11455,The risk or severity of bleeding and hemorrhage can be increased when Robenacoxib is combined with Drotrecogin alfa.,Robenacoxib
DB11466,The risk or severity of bleeding and hemorrhage can be increased when Tepoxalin is combined with Drotrecogin alfa.,Tepoxalin
DB11518,The risk or severity of bleeding and hemorrhage can be increased when Flunixin is combined with Drotrecogin alfa.,Flunixin
DB12399,The risk or severity of bleeding and hemorrhage can be increased when Polmacoxib is combined with Drotrecogin alfa.,Polmacoxib
DB12480,The risk or severity of bleeding and hemorrhage can be increased when Betulinic Acid is combined with Drotrecogin alfa.,Betulinic Acid
DB12610,The risk or severity of bleeding and hemorrhage can be increased when Ebselen is combined with Drotrecogin alfa.,Ebselen
DB13001,The risk or severity of bleeding and hemorrhage can be increased when Tinoridine is combined with Drotrecogin alfa.,Tinoridine
DB13167,The risk or severity of bleeding and hemorrhage can be increased when Alclofenac is combined with Drotrecogin alfa.,Alclofenac
DB13217,The risk or severity of bleeding and hemorrhage can be increased when Fentiazac is combined with Drotrecogin alfa.,Fentiazac
DB13232,The risk or severity of bleeding and hemorrhage can be increased when Suxibuzone is combined with Drotrecogin alfa.,Suxibuzone
DB13286,The risk or severity of bleeding and hemorrhage can be increased when Bumadizone is combined with Drotrecogin alfa.,Bumadizone
DB13314,The risk or severity of bleeding and hemorrhage can be increased when Alminoprofen is combined with Drotrecogin alfa.,Alminoprofen
DB13317,The risk or severity of bleeding and hemorrhage can be increased when Flunoxaprofen is combined with Drotrecogin alfa.,Flunoxaprofen
DB13364,The risk or severity of bleeding and hemorrhage can be increased when Feprazone is combined with Drotrecogin alfa.,Feprazone
DB13371,The risk or severity of bleeding and hemorrhage can be increased when Difenpiramide is combined with Drotrecogin alfa.,Difenpiramide
DB13407,The risk or severity of bleeding and hemorrhage can be increased when Nifenazone is combined with Drotrecogin alfa.,Nifenazone
DB13432,The risk or severity of bleeding and hemorrhage can be increased when Lonazolac is combined with Drotrecogin alfa.,Lonazolac
DB13481,The risk or severity of bleeding and hemorrhage can be increased when Tenidap is combined with Drotrecogin alfa.,Tenidap
DB13501,The risk or severity of bleeding and hemorrhage can be increased when Bendazac is combined with Drotrecogin alfa.,Bendazac
DB13514,The risk or severity of bleeding and hemorrhage can be increased when Pranoprofen is combined with Drotrecogin alfa.,Pranoprofen
DB13524,The risk or severity of bleeding and hemorrhage can be increased when Propyphenazone is combined with Drotrecogin alfa.,Propyphenazone
DB13527,The risk or severity of bleeding and hemorrhage can be increased when Proglumetacin is combined with Drotrecogin alfa.,Proglumetacin
DB13538,The risk or severity of bleeding and hemorrhage can be increased when Guacetisal is combined with Drotrecogin alfa.,Guacetisal
DB13544,The risk or severity of bleeding and hemorrhage can be increased when Ethenzamide is combined with Drotrecogin alfa.,Ethenzamide
DB13612,The risk or severity of bleeding and hemorrhage can be increased when Carbaspirin calcium is combined with Drotrecogin alfa.,Carbaspirin calcium
DB13629,The risk or severity of bleeding and hemorrhage can be increased when Mofebutazone is combined with Drotrecogin alfa.,Mofebutazone
DB13649,The risk or severity of bleeding and hemorrhage can be increased when Proquazone is combined with Drotrecogin alfa.,Proquazone
DB13657,The risk or severity of bleeding and hemorrhage can be increased when Benorilate is combined with Drotrecogin alfa.,Benorilate
DB13722,The risk or severity of bleeding and hemorrhage can be increased when Pirprofen is combined with Drotrecogin alfa.,Pirprofen
DB13860,The risk or severity of bleeding and hemorrhage can be increased when Imidazole salicylate is combined with Drotrecogin alfa.,Imidazole salicylate
DB14059,The risk or severity of bleeding and hemorrhage can be increased when SC-236 is combined with Drotrecogin alfa.,SC-236
DB14060,The risk or severity of bleeding and hemorrhage can be increased when NS-398 is combined with Drotrecogin alfa.,NS-398
DB14938,The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen axetil is combined with Drotrecogin alfa.,Flurbiprofen axetil
DB04865,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Omacetaxine mepesuccinate.,Omacetaxine mepesuccinate
DB11133,Omega-3 fatty acids may increase the anticoagulant activities of Drotrecogin alfa.,Omega-3 fatty acids
DB00081,The risk or severity of bleeding and hemorrhage can be increased when Drotrecogin alfa is combined with Tositumomab.,Tositumomab
DB09211,The risk or severity of adverse effects can be increased when Limaprost is combined with Drotrecogin alfa.,Limaprost
DB00048,The risk or severity of adverse effects can be increased when Drotrecogin alfa is combined with Collagenase clostridium histolyticum.,Collagenase clostridium histolyticum
DB00389,Carbimazole may increase the anticoagulant activities of Drotrecogin alfa.,Carbimazole
DB00550,Propylthiouracil may increase the anticoagulant activities of Drotrecogin alfa.,Propylthiouracil
DB00763,Methimazole may increase the anticoagulant activities of Drotrecogin alfa.,Methimazole
DB03374,"3,5-Diiodotyrosine may increase the anticoagulant activities of Drotrecogin alfa.","3,5-Diiodotyrosine"
DB06715,Potassium Iodide may increase the anticoagulant activities of Drotrecogin alfa.,Potassium Iodide
DB07637,Dibromotyrosine may increase the anticoagulant activities of Drotrecogin alfa.,Dibromotyrosine
DB09418,Potassium perchlorate may increase the anticoagulant activities of Drotrecogin alfa.,Potassium perchlorate
DB13644,Methylthiouracil may increase the anticoagulant activities of Drotrecogin alfa.,Methylthiouracil
DB13804,Benzylthiouracil may increase the anticoagulant activities of Drotrecogin alfa.,Benzylthiouracil
DB00834,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Mifepristone.,Mifepristone
DB04066,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with p-Coumaric acid.,p-Coumaric acid
DB04682,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Octylphenoxy polyethoxyethanol.,Octylphenoxy polyethoxyethanol
DB05830,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Trestolone.,Trestolone
DB06266,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Lonidamine.,Lonidamine
DB08867,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Ulipristal.,Ulipristal
DB09401,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Isosorbide.,Isosorbide
DB11507,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cloprostenol.,Cloprostenol
DB12025,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Triptolide.,Triptolide
DB13044,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Gossypol.,Gossypol
DB13310,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Ormeloxifene.,Ormeloxifene
DB00294,Etonogestrel may decrease the anticoagulant activities of Drotrecogin alfa.,Etonogestrel
DB00304,Desogestrel may decrease the anticoagulant activities of Drotrecogin alfa.,Desogestrel
DB00351,Megestrol acetate may decrease the anticoagulant activities of Drotrecogin alfa.,Megestrol acetate
DB00367,Levonorgestrel may decrease the anticoagulant activities of Drotrecogin alfa.,Levonorgestrel
DB00378,Dydrogesterone may decrease the anticoagulant activities of Drotrecogin alfa.,Dydrogesterone
DB00396,Progesterone may decrease the anticoagulant activities of Drotrecogin alfa.,Progesterone
DB00603,Medroxyprogesterone acetate may decrease the anticoagulant activities of Drotrecogin alfa.,Medroxyprogesterone acetate
DB00717,Norethisterone may decrease the anticoagulant activities of Drotrecogin alfa.,Norethisterone
DB00823,Ethynodiol diacetate may decrease the anticoagulant activities of Drotrecogin alfa.,Ethynodiol diacetate
DB00957,Norgestimate may decrease the anticoagulant activities of Drotrecogin alfa.,Norgestimate
DB01395,Drospirenone may decrease the anticoagulant activities of Drotrecogin alfa.,Drospirenone
DB01431,Allylestrenol may decrease the anticoagulant activities of Drotrecogin alfa.,Allylestrenol
DB04839,Cyproterone acetate may decrease the anticoagulant activities of Drotrecogin alfa.,Cyproterone acetate
DB06713,Norelgestromin may decrease the anticoagulant activities of Drotrecogin alfa.,Norelgestromin
DB06730,Gestodene may decrease the anticoagulant activities of Drotrecogin alfa.,Gestodene
DB06789,Hydroxyprogesterone caproate may decrease the anticoagulant activities of Drotrecogin alfa.,Hydroxyprogesterone caproate
DB09123,Dienogest may decrease the anticoagulant activities of Drotrecogin alfa.,Dienogest
DB09124,Medrogestone may decrease the anticoagulant activities of Drotrecogin alfa.,Medrogestone
DB09371,Norethynodrel may decrease the anticoagulant activities of Drotrecogin alfa.,Norethynodrel
DB09389,Norgestrel may decrease the anticoagulant activities of Drotrecogin alfa.,Norgestrel
DB11372,Altrenogest may decrease the anticoagulant activities of Drotrecogin alfa.,Altrenogest
DB11619,Gestrinone may decrease the anticoagulant activities of Drotrecogin alfa.,Gestrinone
DB11636,Nomegestrol may decrease the anticoagulant activities of Drotrecogin alfa.,Nomegestrol
DB12474,Lynestrenol may decrease the anticoagulant activities of Drotrecogin alfa.,Lynestrenol
DB13230,Gestonorone may decrease the anticoagulant activities of Drotrecogin alfa.,Gestonorone
DB13528,Chlormadinone may decrease the anticoagulant activities of Drotrecogin alfa.,Chlormadinone
DB13533,Methylestrenolone may decrease the anticoagulant activities of Drotrecogin alfa.,Methylestrenolone
DB13563,Norgestrienone may decrease the anticoagulant activities of Drotrecogin alfa.,Norgestrienone
DB13602,Promegestone may decrease the anticoagulant activities of Drotrecogin alfa.,Promegestone
DB13685,Quingestanol may decrease the anticoagulant activities of Drotrecogin alfa.,Quingestanol
DB13857,Demegestone may decrease the anticoagulant activities of Drotrecogin alfa.,Demegestone
DB13866,Etynodiol may decrease the anticoagulant activities of Drotrecogin alfa.,Etynodiol
DB13981,Nomegestrol acetate may decrease the anticoagulant activities of Drotrecogin alfa.,Nomegestrol acetate
DB14570,Hydroxyprogesterone may decrease the anticoagulant activities of Drotrecogin alfa.,Hydroxyprogesterone
DB14678,Norethindrone enanthate may decrease the anticoagulant activities of Drotrecogin alfa.,Norethindrone enanthate
DB14679,Quingestanol acetate may decrease the anticoagulant activities of Drotrecogin alfa.,Quingestanol acetate
DB00233,The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Drotrecogin alfa.,Aminosalicylic acid
DB01294,The risk or severity of bleeding can be increased when Bismuth subsalicylate is combined with Drotrecogin alfa.,Bismuth subsalicylate
DB06251,The risk or severity of bleeding can be increased when Dersalazine is combined with Drotrecogin alfa.,Dersalazine
DB06807,The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Drotrecogin alfa.,Phenyl aminosalicylate
DB09543,The risk or severity of bleeding can be increased when Methyl salicylate is combined with Drotrecogin alfa.,Methyl salicylate
DB11079,The risk or severity of bleeding can be increased when Trolamine salicylate is combined with Drotrecogin alfa.,Trolamine salicylate
DB13509,The risk or severity of bleeding can be increased when Aloxiprin is combined with Drotrecogin alfa.,Aloxiprin
DB14006,The risk or severity of bleeding can be increased when Choline salicylate is combined with Drotrecogin alfa.,Choline salicylate
DB14026,The risk or severity of bleeding can be increased when Thiosalicylic acid is combined with Drotrecogin alfa.,Thiosalicylic acid
DB00054,The risk or severity of bleeding can be increased when Abciximab is combined with Drotrecogin alfa.,Abciximab
DB00063,The risk or severity of bleeding can be increased when Eptifibatide is combined with Drotrecogin alfa.,Eptifibatide
DB00208,The risk or severity of bleeding can be increased when Ticlopidine is combined with Drotrecogin alfa.,Ticlopidine
DB00261,The risk or severity of bleeding can be increased when Anagrelide is combined with Drotrecogin alfa.,Anagrelide
DB00758,The risk or severity of bleeding can be increased when Clopidogrel is combined with Drotrecogin alfa.,Clopidogrel
DB00775,The risk or severity of bleeding can be increased when Tirofiban is combined with Drotrecogin alfa.,Tirofiban
DB00975,The risk or severity of bleeding can be increased when Dipyridamole is combined with Drotrecogin alfa.,Dipyridamole
DB01088,The risk or severity of bleeding can be increased when Iloprost is combined with Drotrecogin alfa.,Iloprost
DB01138,The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Drotrecogin alfa.,Sulfinpyrazone
DB01166,The risk or severity of bleeding can be increased when Cilostazol is combined with Drotrecogin alfa.,Cilostazol
DB01207,The risk or severity of bleeding can be increased when Ridogrel is combined with Drotrecogin alfa.,Ridogrel
DB01236,The risk or severity of bleeding can be increased when Sevoflurane is combined with Drotrecogin alfa.,Sevoflurane
DB01240,The risk or severity of bleeding can be increased when Epoprostenol is combined with Drotrecogin alfa.,Epoprostenol
DB02709,The risk or severity of bleeding can be increased when Resveratrol is combined with Drotrecogin alfa.,Resveratrol
DB04743,The risk or severity of bleeding can be increased when Nimesulide is combined with Drotrecogin alfa.,Nimesulide
DB04905,The risk or severity of bleeding can be increased when Tesmilifene is combined with Drotrecogin alfa.,Tesmilifene
DB04932,The risk or severity of bleeding can be increased when Defibrotide is combined with Drotrecogin alfa.,Defibrotide
DB05229,The risk or severity of bleeding can be increased when Beraprost is combined with Drotrecogin alfa.,Beraprost
DB05266,The risk or severity of bleeding can be increased when Ibudilast is combined with Drotrecogin alfa.,Ibudilast
DB05767,The risk or severity of bleeding can be increased when Andrographolide is combined with Drotrecogin alfa.,Andrographolide
DB06081,The risk or severity of bleeding can be increased when Caplacizumab is combined with Drotrecogin alfa.,Caplacizumab
DB06209,The risk or severity of bleeding can be increased when Prasugrel is combined with Drotrecogin alfa.,Prasugrel
DB06441,The risk or severity of bleeding can be increased when Cangrelor is combined with Drotrecogin alfa.,Cangrelor
DB07615,The risk or severity of bleeding can be increased when Tranilast is combined with Drotrecogin alfa.,Tranilast
DB08814,The risk or severity of bleeding can be increased when Triflusal is combined with Drotrecogin alfa.,Triflusal
DB08816,The risk or severity of bleeding can be increased when Ticagrelor is combined with Drotrecogin alfa.,Ticagrelor
DB08887,The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Drotrecogin alfa.,Icosapent ethyl
DB09283,The risk or severity of bleeding can be increased when Trapidil is combined with Drotrecogin alfa.,Trapidil
DB12092,The risk or severity of bleeding can be increased when Naftopidil is combined with Drotrecogin alfa.,Naftopidil
DB12163,The risk or severity of bleeding can be increased when Sarpogrelate is combined with Drotrecogin alfa.,Sarpogrelate
DB12321,The risk or severity of bleeding can be increased when Ifetroban is combined with Drotrecogin alfa.,Ifetroban
DB12445,The risk or severity of bleeding can be increased when Nitroaspirin is combined with Drotrecogin alfa.,Nitroaspirin
DB12465,The risk or severity of bleeding can be increased when Ketanserin is combined with Drotrecogin alfa.,Ketanserin
DB12545,The risk or severity of bleeding can be increased when Indobufen is combined with Drotrecogin alfa.,Indobufen
DB12749,The risk or severity of bleeding can be increased when Butylphthalide is combined with Drotrecogin alfa.,Butylphthalide
DB12771,The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Drotrecogin alfa.,Hydroxytyrosol
DB13036,The risk or severity of bleeding can be increased when Ramatroban is combined with Drotrecogin alfa.,Ramatroban
DB13327,The risk or severity of bleeding can be increased when Picotamide is combined with Drotrecogin alfa.,Picotamide
DB13367,The risk or severity of bleeding can be increased when Cloricromen is combined with Drotrecogin alfa.,Cloricromen
DB13400,The risk or severity of bleeding can be increased when Linsidomine is combined with Drotrecogin alfa.,Linsidomine
DB13510,The risk or severity of bleeding can be increased when Buflomedil is combined with Drotrecogin alfa.,Buflomedil
DB13929,The risk or severity of bleeding can be increased when Relcovaptan is combined with Drotrecogin alfa.,Relcovaptan
DB00374,The risk or severity of adverse effects can be increased when Drotrecogin alfa is combined with Treprostinil.,Treprostinil
DB03404,Hemin may increase the anticoagulant activities of Drotrecogin alfa.,Hemin
DB13783,The risk or severity of bleeding and hemorrhage can be increased when Acemetacin is combined with Drotrecogin alfa.,Acemetacin
DB00624,Testosterone may increase the anticoagulant activities of Drotrecogin alfa.,Testosterone
DB01420,Testosterone propionate may increase the anticoagulant activities of Drotrecogin alfa.,Testosterone propionate
DB01481,1-Testosterone may increase the anticoagulant activities of Drotrecogin alfa.,1-Testosterone
DB01485,4-Hydroxytestosterone may increase the anticoagulant activities of Drotrecogin alfa.,4-Hydroxytestosterone
DB01510,Dehydrochloromethyltestosterone may increase the anticoagulant activities of Drotrecogin alfa.,Dehydrochloromethyltestosterone
DB01541,Boldenone may increase the anticoagulant activities of Drotrecogin alfa.,Boldenone
DB01543,18-methyl-19-nortestosterone may increase the anticoagulant activities of Drotrecogin alfa.,18-methyl-19-nortestosterone
DB01564,Calusterone may increase the anticoagulant activities of Drotrecogin alfa.,Calusterone
DB01569,Formebolone may increase the anticoagulant activities of Drotrecogin alfa.,Formebolone
DB01572,Methyl-1-testosterone may increase the anticoagulant activities of Drotrecogin alfa.,Methyl-1-testosterone
DB02901,Stanolone may increase the anticoagulant activities of Drotrecogin alfa.,Stanolone
DB07447,5beta-dihydrotestosterone may increase the anticoagulant activities of Drotrecogin alfa.,5beta-dihydrotestosterone
DB08619,Testosterone succinate may increase the anticoagulant activities of Drotrecogin alfa.,Testosterone succinate
DB11429,Mibolerone may increase the anticoagulant activities of Drotrecogin alfa.,Mibolerone
DB13943,Testosterone cypionate may increase the anticoagulant activities of Drotrecogin alfa.,Testosterone cypionate
DB13944,Testosterone enanthate may increase the anticoagulant activities of Drotrecogin alfa.,Testosterone enanthate
DB13946,Testosterone undecanoate may increase the anticoagulant activities of Drotrecogin alfa.,Testosterone undecanoate
DB13947,Testosterone enantate benzilic acid hydrazone may increase the anticoagulant activities of Drotrecogin alfa.,Testosterone enantate benzilic acid hydrazone
DB13951,Stanolone acetate may increase the anticoagulant activities of Drotrecogin alfa.,Stanolone acetate
DB13958,Trestolone acetate may increase the anticoagulant activities of Drotrecogin alfa.,Trestolone acetate
DB14093,"(1,2,6,7-3H)Testosterone may increase the anticoagulant activities of Drotrecogin alfa.","(1,2,6,7-3H)Testosterone"
DB14655,Drostanolone propionate may increase the anticoagulant activities of Drotrecogin alfa.,Drostanolone propionate
DB11051,The risk or severity of adverse effects can be increased when Drotrecogin alfa is combined with Azficel-T.,Azficel-T
DB09568,The therapeutic efficacy of Drotrecogin alfa can be increased when used in combination with Omega-3-carboxylic acids.,Omega-3-carboxylic acids
DB00258,The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Drotrecogin alfa.,Calcium acetate
DB01164,The therapeutic efficacy of Calcium chloride can be decreased when used in combination with Drotrecogin alfa.,Calcium chloride
DB01373,The therapeutic efficacy of Calcium can be decreased when used in combination with Drotrecogin alfa.,Calcium
DB11126,The therapeutic efficacy of Calcium gluconate can be decreased when used in combination with Drotrecogin alfa.,Calcium gluconate
DB11608,The therapeutic efficacy of Eftrenonacog alfa can be decreased when used in combination with Drotrecogin alfa.,Eftrenonacog alfa
DB13884,The therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Drotrecogin alfa.,Albutrepenonacog alfa
DB13923,The therapeutic efficacy of Emicizumab can be decreased when used in combination with Drotrecogin alfa.,Emicizumab
DB14738,The therapeutic efficacy of Turoctocog alfa pegol can be decreased when used in combination with Drotrecogin alfa.,Turoctocog alfa pegol
DB00025,"The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Drotrecogin alfa.","Antihemophilic factor, human recombinant"
DB00036,The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Drotrecogin alfa.,Coagulation factor VIIa Recombinant Human
DB00100,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Drotrecogin alfa.,Coagulation Factor IX (Recombinant)
DB01783,The therapeutic efficacy of Pantothenic acid can be decreased when used in combination with Drotrecogin alfa.,Pantothenic acid
DB01942,The therapeutic efficacy of Formic acid can be decreased when used in combination with Drotrecogin alfa.,Formic acid
DB02261,The therapeutic efficacy of Platelet Activating Factor can be decreased when used in combination with Drotrecogin alfa.,Platelet Activating Factor
DB06724,The therapeutic efficacy of Calcium carbonate can be decreased when used in combination with Drotrecogin alfa.,Calcium carbonate
DB09109,The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Drotrecogin alfa.,Turoctocog alfa
DB09222,The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Drotrecogin alfa.,Fibrinogen human
DB09310,The therapeutic efficacy of Catridecacog can be decreased when used in combination with Drotrecogin alfa.,Catridecacog
DB09329,"The therapeutic efficacy of Antihemophilic Factor (Recombinant), PEGylated can be decreased when used in combination with Drotrecogin alfa.","Antihemophilic Factor (Recombinant), PEGylated"
DB11093,The therapeutic efficacy of Calcium citrate can be decreased when used in combination with Drotrecogin alfa.,Calcium citrate
DB11168,The therapeutic efficacy of Calcium threonate can be decreased when used in combination with Drotrecogin alfa.,Calcium threonate
DB11311,The therapeutic efficacy of Prothrombin can be decreased when used in combination with Drotrecogin alfa.,Prothrombin
DB11330,The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Drotrecogin alfa.,Factor IX Complex (Human)
DB11348,The therapeutic efficacy of Calcium Phosphate can be decreased when used in combination with Drotrecogin alfa.,Calcium Phosphate
DB11606,The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Drotrecogin alfa.,Susoctocog alfa
DB11668,The therapeutic efficacy of Rusalatide acetate can be decreased when used in combination with Drotrecogin alfa.,Rusalatide acetate
DB12409,The therapeutic efficacy of Vatreptacog alfa can be decreased when used in combination with Drotrecogin alfa.,Vatreptacog alfa
DB12909,The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Drotrecogin alfa.,Factor XIII (human)
DB13133,The therapeutic efficacy of Von Willebrand Factor Human can be decreased when used in combination with Drotrecogin alfa.,Von Willebrand Factor Human
DB13148,The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Drotrecogin alfa.,Coagulation factor X human
DB13150,The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Drotrecogin alfa.,Coagulation factor VII human
DB13151,The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Drotrecogin alfa.,Anti-inhibitor coagulant complex
DB13152,The therapeutic efficacy of Coagulation Factor IX Human can be decreased when used in combination with Drotrecogin alfa.,Coagulation Factor IX Human
DB13192,The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Drotrecogin alfa.,Antihemophilic factor human
DB13197,The therapeutic efficacy of Kallidinogenase can be decreased when used in combination with Drotrecogin alfa.,Kallidinogenase
DB13201,The therapeutic efficacy of Trenonacog alfa can be decreased when used in combination with Drotrecogin alfa.,Trenonacog alfa
DB13933,The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Drotrecogin alfa.,Nonacog beta pegol
DB13999,The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Drotrecogin alfa.,Moroctocog alfa
DB14473,The therapeutic efficacy of Beroctocog alfa can be decreased when used in combination with Drotrecogin alfa.,Beroctocog alfa
DB14562,The therapeutic efficacy of Andexanet alfa can be decreased when used in combination with Drotrecogin alfa.,Andexanet alfa
DB14577,The therapeutic efficacy of Calcium cation can be decreased when used in combination with Drotrecogin alfa.,Calcium cation
DB14700,The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Drotrecogin alfa.,Damoctocog alfa pegol
DB00176,The risk or severity of hemorrhage can be increased when Fluvoxamine is combined with Drotrecogin alfa.,Fluvoxamine
DB00215,The risk or severity of hemorrhage can be increased when Citalopram is combined with Drotrecogin alfa.,Citalopram
DB00472,The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Drotrecogin alfa.,Fluoxetine
DB00715,The risk or severity of hemorrhage can be increased when Paroxetine is combined with Drotrecogin alfa.,Paroxetine
DB01149,The risk or severity of hemorrhage can be increased when Nefazodone is combined with Drotrecogin alfa.,Nefazodone
DB04832,The risk or severity of hemorrhage can be increased when Zimelidine is combined with Drotrecogin alfa.,Zimelidine
DB04884,The risk or severity of hemorrhage can be increased when Dapoxetine is combined with Drotrecogin alfa.,Dapoxetine
DB06731,The risk or severity of hemorrhage can be increased when Seproxetine is combined with Drotrecogin alfa.,Seproxetine
DB08953,The risk or severity of hemorrhage can be increased when Indalpine is combined with Drotrecogin alfa.,Indalpine
DB12693,The risk or severity of hemorrhage can be increased when Ritanserin is combined with Drotrecogin alfa.,Ritanserin
DB13233,The risk or severity of hemorrhage can be increased when Alaproclate is combined with Drotrecogin alfa.,Alaproclate
DB00476,The risk or severity of hemorrhage can be increased when Duloxetine is combined with Drotrecogin alfa.,Duloxetine
DB01105,The risk or severity of hemorrhage can be increased when Sibutramine is combined with Drotrecogin alfa.,Sibutramine
DB04896,The risk or severity of hemorrhage can be increased when Milnacipran is combined with Drotrecogin alfa.,Milnacipran
DB06700,The risk or severity of hemorrhage can be increased when Desvenlafaxine is combined with Drotrecogin alfa.,Desvenlafaxine
DB08918,The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Drotrecogin alfa.,Levomilnacipran
DB00285,Venlafaxine may increase the antiplatelet activities of Drotrecogin alfa.,Venlafaxine
DB00182,The risk or severity of bleeding and hemorrhage can be increased when Amphetamine is combined with Drotrecogin alfa.,Amphetamine
DB00601,The risk or severity of bleeding and hemorrhage can be increased when Linezolid is combined with Drotrecogin alfa.,Linezolid
DB00614,The risk or severity of bleeding and hemorrhage can be increased when Furazolidone is combined with Drotrecogin alfa.,Furazolidone
DB00721,The risk or severity of bleeding and hemorrhage can be increased when Procaine is combined with Drotrecogin alfa.,Procaine
DB00752,The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Drotrecogin alfa.,Tranylcypromine
DB00780,The risk or severity of bleeding and hemorrhage can be increased when Phenelzine is combined with Drotrecogin alfa.,Phenelzine
DB00805,The risk or severity of bleeding and hemorrhage can be increased when Minaprine is combined with Drotrecogin alfa.,Minaprine
DB01037,The risk or severity of bleeding and hemorrhage can be increased when Selegiline is combined with Drotrecogin alfa.,Selegiline
DB01168,The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Drotrecogin alfa.,Procarbazine
DB01171,The risk or severity of bleeding and hemorrhage can be increased when Moclobemide is combined with Drotrecogin alfa.,Moclobemide
DB01247,The risk or severity of bleeding and hemorrhage can be increased when Isocarboxazid is combined with Drotrecogin alfa.,Isocarboxazid
DB01367,The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Drotrecogin alfa.,Rasagiline
DB01626,The risk or severity of bleeding and hemorrhage can be increased when Pargyline is combined with Drotrecogin alfa.,Pargyline
DB04017,The risk or severity of bleeding and hemorrhage can be increased when Clorgiline is combined with Drotrecogin alfa.,Clorgiline
DB04818,The risk or severity of bleeding and hemorrhage can be increased when Iproniazid is combined with Drotrecogin alfa.,Iproniazid
DB04820,The risk or severity of bleeding and hemorrhage can be increased when Nialamide is combined with Drotrecogin alfa.,Nialamide
DB06654,The risk or severity of bleeding and hemorrhage can be increased when Safinamide is combined with Drotrecogin alfa.,Safinamide
DB08550,"The risk or severity of bleeding and hemorrhage can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Drotrecogin alfa.","7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline"
DB09241,The risk or severity of bleeding and hemorrhage can be increased when Methylene blue is combined with Drotrecogin alfa.,Methylene blue
DB09243,The risk or severity of bleeding and hemorrhage can be increased when Hydracarbazine is combined with Drotrecogin alfa.,Hydracarbazine
DB09244,The risk or severity of bleeding and hemorrhage can be increased when Pirlindole is combined with Drotrecogin alfa.,Pirlindole
DB09245,The risk or severity of bleeding and hemorrhage can be increased when Toloxatone is combined with Drotrecogin alfa.,Toloxatone
DB09246,The risk or severity of bleeding and hemorrhage can be increased when Benmoxin is combined with Drotrecogin alfa.,Benmoxin
DB09248,The risk or severity of bleeding and hemorrhage can be increased when Mebanazine is combined with Drotrecogin alfa.,Mebanazine
DB09249,The risk or severity of bleeding and hemorrhage can be increased when Octamoxin is combined with Drotrecogin alfa.,Octamoxin
DB09250,The risk or severity of bleeding and hemorrhage can be increased when Pheniprazine is combined with Drotrecogin alfa.,Pheniprazine
DB09251,The risk or severity of bleeding and hemorrhage can be increased when Phenoxypropazine is combined with Drotrecogin alfa.,Phenoxypropazine
DB09252,The risk or severity of bleeding and hemorrhage can be increased when Pivhydrazine is combined with Drotrecogin alfa.,Pivhydrazine
DB09253,The risk or severity of bleeding and hemorrhage can be increased when Safrazine is combined with Drotrecogin alfa.,Safrazine
DB09254,The risk or severity of bleeding and hemorrhage can be increased when Caroxazone is combined with Drotrecogin alfa.,Caroxazone
DB13875,The risk or severity of bleeding and hemorrhage can be increased when Harmaline is combined with Drotrecogin alfa.,Harmaline
DB13876,The risk or severity of bleeding and hemorrhage can be increased when Brofaromine is combined with Drotrecogin alfa.,Brofaromine
DB00006,The risk or severity of bleeding can be increased when Bivalirudin is combined with Drotrecogin alfa.,Bivalirudin
DB00266,The risk or severity of bleeding can be increased when Dicoumarol is combined with Drotrecogin alfa.,Dicoumarol
DB00278,The risk or severity of bleeding can be increased when Argatroban is combined with Drotrecogin alfa.,Argatroban
DB00407,The risk or severity of bleeding can be increased when Ardeparin is combined with Drotrecogin alfa.,Ardeparin
DB00498,The risk or severity of bleeding can be increased when Phenindione is combined with Drotrecogin alfa.,Phenindione
DB00569,The risk or severity of bleeding can be increased when Fondaparinux is combined with Drotrecogin alfa.,Fondaparinux
DB00682,The risk or severity of bleeding can be increased when Warfarin is combined with Drotrecogin alfa.,Warfarin
DB00946,The risk or severity of bleeding can be increased when Phenprocoumon is combined with Drotrecogin alfa.,Phenprocoumon
DB00974,The risk or severity of bleeding can be increased when Edetic acid is combined with Drotrecogin alfa.,Edetic acid
DB01109,The risk or severity of bleeding can be increased when Heparin is combined with Drotrecogin alfa.,Heparin
DB01225,The risk or severity of bleeding can be increased when Enoxaparin is combined with Drotrecogin alfa.,Enoxaparin
DB01418,The risk or severity of bleeding can be increased when Acenocoumarol is combined with Drotrecogin alfa.,Acenocoumarol
DB04898,The risk or severity of bleeding can be increased when Ximelagatran is combined with Drotrecogin alfa.,Ximelagatran
DB05099,The risk or severity of bleeding can be increased when Ancrod is combined with Drotrecogin alfa.,Ancrod
DB06271,The risk or severity of bleeding can be increased when Sulodexide is combined with Drotrecogin alfa.,Sulodexide
DB06406,The risk or severity of bleeding can be increased when Idraparinux is combined with Drotrecogin alfa.,Idraparinux
DB06635,The risk or severity of bleeding can be increased when Otamixaban is combined with Drotrecogin alfa.,Otamixaban
DB06754,The risk or severity of bleeding can be increased when Danaparoid is combined with Drotrecogin alfa.,Danaparoid
DB06779,The risk or severity of bleeding can be increased when Dalteparin is combined with Drotrecogin alfa.,Dalteparin
DB07767,The risk or severity of bleeding can be increased when Ferulic acid is combined with Drotrecogin alfa.,Ferulic acid
DB08794,The risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Drotrecogin alfa.,Ethyl biscoumacetate
DB08813,The risk or severity of bleeding can be increased when Nadroparin is combined with Drotrecogin alfa.,Nadroparin
DB09255,The risk or severity of bleeding can be increased when Dextran is combined with Drotrecogin alfa.,Dextran
DB09259,The risk or severity of bleeding can be increased when Reviparin is combined with Drotrecogin alfa.,Reviparin
DB09261,The risk or severity of bleeding can be increased when Certoparin is combined with Drotrecogin alfa.,Certoparin
DB11095,The risk or severity of bleeding can be increased when Desirudin is combined with Drotrecogin alfa.,Desirudin
DB11268,The risk or severity of bleeding can be increased when Protocatechualdehyde is combined with Drotrecogin alfa.,Protocatechualdehyde
DB11312,The risk or severity of bleeding can be increased when Protein C is combined with Drotrecogin alfa.,Protein C
DB11598,The risk or severity of bleeding can be increased when Antithrombin III human is combined with Drotrecogin alfa.,Antithrombin III human
DB11984,The risk or severity of bleeding can be increased when Letaxaban is combined with Drotrecogin alfa.,Letaxaban
DB12289,The risk or severity of bleeding can be increased when Darexaban is combined with Drotrecogin alfa.,Darexaban
DB12598,The risk or severity of bleeding can be increased when Nafamostat is combined with Drotrecogin alfa.,Nafamostat
DB12831,The risk or severity of bleeding can be increased when Gabexate is combined with Drotrecogin alfa.,Gabexate
DB13124,The risk or severity of bleeding can be increased when Troxerutin is combined with Drotrecogin alfa.,Troxerutin
DB13136,The risk or severity of bleeding can be increased when Fluindione is combined with Drotrecogin alfa.,Fluindione
DB13149,The risk or severity of bleeding can be increased when Protein S human is combined with Drotrecogin alfa.,Protein S human
DB13616,The risk or severity of bleeding can be increased when Melagatran is combined with Drotrecogin alfa.,Melagatran
DB09125,The risk or severity of bleeding can be increased when Potassium citrate is combined with Drotrecogin alfa.,Potassium citrate
DB09154,The risk or severity of bleeding can be increased when Sodium citrate is combined with Drotrecogin alfa.,Sodium citrate
DB00031,The risk or severity of bleeding can be increased when Tenecteplase is combined with Drotrecogin alfa.,Tenecteplase
DB06822,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Tinzaparin.,Tinzaparin
DB13199,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Brinase.,Brinase
DB13646,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Saruplase.,Saruplase
DB00086,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Streptokinase.,Streptokinase
DB04925,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Desmoteplase.,Desmoteplase
DB05254,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Fibrinolysin.,Fibrinolysin
DB06543,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Astaxanthin.,Astaxanthin
DB08994,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Ditazole.,Ditazole
DB09258,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Bemiparin.,Bemiparin
DB09260,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Parnaparin.,Parnaparin
DB13275,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Clorindione.,Clorindione
DB13347,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Diphenadione.,Diphenadione
DB13451,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Tioclomarol.,Tioclomarol
DB00001,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Lepirudin.,Lepirudin
DB00009,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Alteplase.,Alteplase
DB00015,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Reteplase.,Reteplase
DB00029,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Anistreplase.,Anistreplase
DB14094,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Tocopherylquinone.,Tocopherylquinone
DB06679,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Amediplase.,Amediplase
DB03410,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with 4-hydroxycoumarin.,4-hydroxycoumarin
DB08496,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with (R)-warfarin.,(R)-warfarin
DB14055,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with (S)-Warfarin.,(S)-Warfarin
DB12364,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Betrixaban.,Betrixaban
DB14598,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Edetate calcium disodium anhydrous.,Edetate calcium disodium anhydrous
DB11154,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Zinc citrate.,Zinc citrate
DB11166,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Antithrombin Alfa.,Antithrombin Alfa
DB04665,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Coumarin.,Coumarin
DB14726,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Dabigatran.,Dabigatran
DB06294,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Semuloparin.,Semuloparin
DB12726,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Monteplase.,Monteplase
DB00203,The risk or severity of hemorrhage can be increased when Drotrecogin alfa is combined with Sildenafil.,Sildenafil
DB00008,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Peginterferon alfa-2a.,Peginterferon alfa-2a
DB00011,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Interferon alfa-n1.,Interferon alfa-n1
DB00018,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Interferon alfa-n3.,Interferon alfa-n3
DB00022,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Peginterferon alfa-2b.,Peginterferon alfa-2b
DB00033,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Interferon gamma-1b.,Interferon gamma-1b
DB00034,"The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Interferon alfa-2a, Recombinant.","Interferon alfa-2a, Recombinant"
DB00041,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Aldesleukin.,Aldesleukin
DB00056,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Gemtuzumab ozogamicin.,Gemtuzumab ozogamicin
DB00068,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Interferon beta-1b.,Interferon beta-1b
DB00069,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Interferon alfacon-1.,Interferon alfacon-1
DB00073,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Rituximab.,Rituximab
DB00078,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Ibritumomab tiuxetan.,Ibritumomab tiuxetan
DB00087,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Alemtuzumab.,Alemtuzumab
DB00105,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Interferon alfa-2b.,Interferon alfa-2b
DB00120,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Phenylalanine.,Phenylalanine
DB00188,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Bortezomib.,Bortezomib
DB00242,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Cladribine.,Cladribine
DB00262,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Carmustine.,Carmustine
DB00276,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Amsacrine.,Amsacrine
DB00291,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Chlorambucil.,Chlorambucil
DB00293,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Raltitrexed.,Raltitrexed
DB00305,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Mitomycin.,Mitomycin
DB00307,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Bexarotene.,Bexarotene
DB00309,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Vindesine.,Vindesine
DB00322,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Floxuridine.,Floxuridine
DB00352,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Tioguanine.,Tioguanine
DB00361,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Vinorelbine.,Vinorelbine
DB00380,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Dexrazoxane.,Dexrazoxane
DB00398,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Sorafenib.,Sorafenib
DB00428,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Streptozocin.,Streptozocin
DB00441,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Gemcitabine.,Gemcitabine
DB00444,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Teniposide.,Teniposide
DB00445,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Epirubicin.,Epirubicin
DB00446,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Chloramphenicol.,Chloramphenicol
DB00480,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Lenalidomide.,Lenalidomide
DB00488,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Altretamine.,Altretamine
DB00495,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Zidovudine.,Zidovudine
DB00515,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Cisplatin.,Cisplatin
DB00526,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Oxaliplatin.,Oxaliplatin
DB00531,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Cyclophosphamide.,Cyclophosphamide
DB00544,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Fluorouracil.,Fluorouracil
DB00552,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Pentostatin.,Pentostatin
DB00563,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Methotrexate.,Methotrexate
DB00564,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Carbamazepine.,Carbamazepine
DB00570,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Vinblastine.,Vinblastine
DB00619,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Imatinib.,Imatinib
DB00631,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Clofarabine.,Clofarabine
DB00642,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Pemetrexed.,Pemetrexed
DB00694,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Daunorubicin.,Daunorubicin
DB00762,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Irinotecan.,Irinotecan
DB00773,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Etoposide.,Etoposide
DB00851,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Dacarbazine.,Dacarbazine
DB00853,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Temozolomide.,Temozolomide
DB00859,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Penicillamine.,Penicillamine
DB00864,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Tacrolimus.,Tacrolimus
DB00877,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Sirolimus.,Sirolimus
DB00888,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Mechlorethamine.,Mechlorethamine
DB00928,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Azacitidine.,Azacitidine
DB00958,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Carboplatin.,Carboplatin
DB00970,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Dactinomycin.,Dactinomycin
DB00987,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Cytarabine.,Cytarabine
DB00997,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Doxorubicin.,Doxorubicin
DB01005,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Hydroxyurea.,Hydroxyurea
DB01008,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Busulfan.,Busulfan
DB01030,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Topotecan.,Topotecan
DB01033,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Mercaptopurine.,Mercaptopurine
DB01041,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Thalidomide.,Thalidomide
DB01042,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Melphalan.,Melphalan
DB01073,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Fludarabine.,Fludarabine
DB01099,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Flucytosine.,Flucytosine
DB01101,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Capecitabine.,Capecitabine
DB01169,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Arsenic trioxide.,Arsenic trioxide
DB01177,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Idarubicin.,Idarubicin
DB01204,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Mitoxantrone.,Mitoxantrone
DB01206,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Lomustine.,Lomustine
DB01229,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Paclitaxel.,Paclitaxel
DB01248,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Docetaxel.,Docetaxel
DB01262,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Decitabine.,Decitabine
DB01280,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Nelarabine.,Nelarabine
DB01590,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Everolimus.,Everolimus
DB02546,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Vorinostat.,Vorinostat
DB04572,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Thiotepa.,Thiotepa
DB04845,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Ixabepilone.,Ixabepilone
DB04868,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Nilotinib.,Nilotinib
DB05015,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Belinostat.,Belinostat
DB05109,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Trabectedin.,Trabectedin
DB05258,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Interferon alfa.,Interferon alfa
DB05472,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with omega interferon.,omega interferon
DB05773,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Trastuzumab emtansine.,Trastuzumab emtansine
DB06287,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Temsirolimus.,Temsirolimus
DB06616,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Bosutinib.,Bosutinib
DB06769,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Bendamustine.,Bendamustine
DB06772,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Cabazitaxel.,Cabazitaxel
DB08871,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Eribulin.,Eribulin
DB08877,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Ruxolitinib.,Ruxolitinib
DB08889,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Carfilzomib.,Carfilzomib
DB08895,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Tofacitinib.,Tofacitinib
DB08901,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Ponatinib.,Ponatinib
DB08910,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Pomalidomide.,Pomalidomide
DB09042,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Tedizolid phosphate.,Tedizolid phosphate
DB09052,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Blinatumomab.,Blinatumomab
DB09073,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Palbociclib.,Palbociclib
DB09074,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Olaparib.,Olaparib
DB09077,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Dinutuximab.,Dinutuximab
DB09122,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Peginterferon beta-1a.,Peginterferon beta-1a
DB12814,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Cepeginterferon alfa-2B.,Cepeginterferon alfa-2B
DB00229,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefotiam.,Cefotiam
DB00267,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefmenoxime.,Cefmenoxime
DB00274,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefmetazole.,Cefmetazole
DB00430,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefpiramide.,Cefpiramide
DB00438,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Ceftazidime.,Ceftazidime
DB00447,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Loracarbef.,Loracarbef
DB00456,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefalotin.,Cefalotin
DB00493,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefotaxime.,Cefotaxime
DB00535,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefdinir.,Cefdinir
DB00567,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cephalexin.,Cephalexin
DB00671,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefixime.,Cefixime
DB00689,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cephaloglycin.,Cephaloglycin
DB00833,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefaclor.,Cefaclor
DB00923,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Ceforanide.,Ceforanide
DB01066,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefditoren.,Cefditoren
DB01112,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefuroxime.,Cefuroxime
DB01139,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefapirin.,Cefapirin
DB01140,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefadroxil.,Cefadroxil
DB01150,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefprozil.,Cefprozil
DB01212,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Ceftriaxone.,Ceftriaxone
DB01326,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefamandole.,Cefamandole
DB01327,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefazolin.,Cefazolin
DB01328,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefonicid.,Cefonicid
DB01329,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefoperazone.,Cefoperazone
DB01330,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefotetan.,Cefotetan
DB01331,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefoxitin.,Cefoxitin
DB01332,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Ceftizoxime.,Ceftizoxime
DB01333,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefradine.,Cefradine
DB01413,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefepime.,Cefepime
DB01414,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefacetrile.,Cefacetrile
DB01415,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Ceftibuten.,Ceftibuten
DB01416,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefpodoxime.,Cefpodoxime
DB04570,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Latamoxef.,Latamoxef
DB04918,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Ceftobiprole.,Ceftobiprole
DB06590,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Ceftaroline fosamil.,Ceftaroline fosamil
DB09008,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefaloridine.,Cefaloridine
DB09050,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Ceftolozane.,Ceftolozane
DB09062,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefminox.,Cefminox
DB11367,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefroxadine.,Cefroxadine
DB11935,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Flomoxef.,Flomoxef
DB13266,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefatrizine.,Cefatrizine
DB13461,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefcapene.,Cefcapene
DB13470,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefodizime.,Cefodizime
DB13499,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefsulodin.,Cefsulodin
DB13504,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefetamet.,Cefetamet
DB13638,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefbuperazone.,Cefbuperazone
DB13667,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefozopran.,Cefozopran
DB13682,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefpirome.,Cefpirome
DB13778,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefazedone.,Cefazedone
DB13821,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Ceftezole.,Ceftezole
DB14725,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cefamandole nafate.,Cefamandole nafate
DB00254,The risk or severity of bleeding can be increased when Doxycycline is combined with Drotrecogin alfa.,Doxycycline
DB00207,The risk or severity of adverse effects can be increased when Azithromycin is combined with Drotrecogin alfa.,Azithromycin
DB09539,The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Drotrecogin alfa.,Omega-3-acid ethyl esters
DB00945,Acetylsalicylic acid may increase the anticoagulant activities of Drotrecogin alfa.,Acetylsalicylic acid
DB01606,The risk or severity of bleeding can be increased when Tazobactam is combined with Drotrecogin alfa.,Tazobactam
DB00199,The risk or severity of bleeding can be increased when Erythromycin is combined with Drotrecogin alfa.,Erythromycin
DB00656,The risk or severity of bleeding can be increased when Trazodone is combined with Drotrecogin alfa.,Trazodone
DB00620,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Triamcinolone.,Triamcinolone
DB09079,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Nintedanib.,Nintedanib
DB01175,The risk or severity of bleeding can be increased when Escitalopram is combined with Drotrecogin alfa.,Escitalopram
DB01104,The risk or severity of bleeding can be increased when Sertraline is combined with Drotrecogin alfa.,Sertraline
DB00232,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Methyclothiazide.,Methyclothiazide
DB00436,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Bendroflumethiazide.,Bendroflumethiazide
DB00562,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Benzthiazide.,Benzthiazide
DB00606,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cyclothiazide.,Cyclothiazide
DB00774,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Hydroflumethiazide.,Hydroflumethiazide
DB00880,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Chlorothiazide.,Chlorothiazide
DB00999,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Hydrochlorothiazide.,Hydrochlorothiazide
DB01021,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Trichlormethiazide.,Trichlormethiazide
DB01324,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Polythiazide.,Polythiazide
DB13430,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Mebutizide.,Mebutizide
DB13532,The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Cyclopenthiazide.,Cyclopenthiazide
DB06643,The risk or severity of adverse effects can be increased when Denosumab is combined with Gemtuzumab ozogamicin.,Denosumab
DB00005,The risk or severity of adverse effects can be increased when Etanercept is combined with Gemtuzumab ozogamicin.,Etanercept
DB00008,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Gemtuzumab ozogamicin.,Peginterferon alfa-2a
DB00011,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Gemtuzumab ozogamicin.,Interferon alfa-n1
DB00018,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Gemtuzumab ozogamicin.,Interferon alfa-n3
DB00022,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Gemtuzumab ozogamicin.,Peginterferon alfa-2b
DB00026,The risk or severity of adverse effects can be increased when Anakinra is combined with Gemtuzumab ozogamicin.,Anakinra
DB00033,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Gemtuzumab ozogamicin.,Interferon gamma-1b
DB00034,"The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Gemtuzumab ozogamicin.","Interferon alfa-2a, Recombinant"
DB00041,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Gemtuzumab ozogamicin.,Aldesleukin
DB00051,The risk or severity of adverse effects can be increased when Adalimumab is combined with Gemtuzumab ozogamicin.,Adalimumab
DB00059,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pegaspargase.,Pegaspargase
DB00065,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Infliximab.,Infliximab
DB00068,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Interferon beta-1b.,Interferon beta-1b
DB00069,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Interferon alfacon-1.,Interferon alfacon-1
DB00073,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Rituximab.,Rituximab
DB00074,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Basiliximab.,Basiliximab
DB00075,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Muromonab.,Muromonab
DB00078,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ibritumomab tiuxetan.,Ibritumomab tiuxetan
DB00081,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tositumomab.,Tositumomab
DB00087,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Alemtuzumab.,Alemtuzumab
DB00092,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Alefacept.,Alefacept
DB00095,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Efalizumab.,Efalizumab
DB00098,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Antithymocyte immunoglobulin (rabbit).,Antithymocyte immunoglobulin (rabbit)
DB00105,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Interferon alfa-2b.,Interferon alfa-2b
DB00111,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Daclizumab.,Daclizumab
DB00112,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bevacizumab.,Bevacizumab
DB00120,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Phenylalanine.,Phenylalanine
DB00180,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Flunisolide.,Flunisolide
DB00188,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bortezomib.,Bortezomib
DB00242,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cladribine.,Cladribine
DB00262,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Carmustine.,Carmustine
DB00276,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Amsacrine.,Amsacrine
DB00290,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bleomycin.,Bleomycin
DB00291,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Chlorambucil.,Chlorambucil
DB00293,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Raltitrexed.,Raltitrexed
DB00305,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mitomycin.,Mitomycin
DB00307,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bexarotene.,Bexarotene
DB00309,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vindesine.,Vindesine
DB00322,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Floxuridine.,Floxuridine
DB00328,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Indomethacin.,Indomethacin
DB00352,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tioguanine.,Tioguanine
DB00361,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vinorelbine.,Vinorelbine
DB00380,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dexrazoxane.,Dexrazoxane
DB00394,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Beclomethasone dipropionate.,Beclomethasone dipropionate
DB00398,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sorafenib.,Sorafenib
DB00428,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Streptozocin.,Streptozocin
DB00432,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Trifluridine.,Trifluridine
DB00441,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Gemcitabine.,Gemcitabine
DB00443,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Betamethasone.,Betamethasone
DB00444,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Teniposide.,Teniposide
DB00445,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Epirubicin.,Epirubicin
DB00446,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Chloramphenicol.,Chloramphenicol
DB00480,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lenalidomide.,Lenalidomide
DB00488,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Altretamine.,Altretamine
DB00495,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Zidovudine.,Zidovudine
DB00515,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cisplatin.,Cisplatin
DB00526,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Oxaliplatin.,Oxaliplatin
DB00531,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cyclophosphamide.,Cyclophosphamide
DB00541,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vincristine.,Vincristine
DB00544,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluorouracil.,Fluorouracil
DB00550,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Propylthiouracil.,Propylthiouracil
DB00552,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pentostatin.,Pentostatin
DB00563,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Methotrexate.,Methotrexate
DB00564,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Carbamazepine.,Carbamazepine
DB00570,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vinblastine.,Vinblastine
DB00588,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluticasone propionate.,Fluticasone propionate
DB00591,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluocinolone acetonide.,Fluocinolone acetonide
DB00601,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Linezolid.,Linezolid
DB00619,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Imatinib.,Imatinib
DB00620,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Triamcinolone.,Triamcinolone
DB00631,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Clofarabine.,Clofarabine
DB00635,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Prednisone.,Prednisone
DB00642,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pemetrexed.,Pemetrexed
DB00687,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fludrocortisone.,Fludrocortisone
DB00688,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mycophenolate mofetil.,Mycophenolate mofetil
DB00694,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Daunorubicin.,Daunorubicin
DB00755,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tretinoin.,Tretinoin
DB00762,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Irinotecan.,Irinotecan
DB00763,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Methimazole.,Methimazole
DB00764,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mometasone.,Mometasone
DB00773,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Etoposide.,Etoposide
DB00795,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sulfasalazine.,Sulfasalazine
DB00851,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dacarbazine.,Dacarbazine
DB00853,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Temozolomide.,Temozolomide
DB00859,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Penicillamine.,Penicillamine
DB00860,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Prednisolone.,Prednisolone
DB00877,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sirolimus.,Sirolimus
DB00888,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mechlorethamine.,Mechlorethamine
DB00928,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Azacitidine.,Azacitidine
DB00958,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Carboplatin.,Carboplatin
DB00959,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Methylprednisolone.,Methylprednisolone
DB00970,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dactinomycin.,Dactinomycin
DB00987,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cytarabine.,Cytarabine
DB00993,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Azathioprine.,Azathioprine
DB00997,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Doxorubicin.,Doxorubicin
DB01005,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Hydroxyurea.,Hydroxyurea
DB01008,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Busulfan.,Busulfan
DB01024,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mycophenolic acid.,Mycophenolic acid
DB01030,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Topotecan.,Topotecan
DB01033,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mercaptopurine.,Mercaptopurine
DB01041,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Thalidomide.,Thalidomide
DB01042,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Melphalan.,Melphalan
DB01073,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fludarabine.,Fludarabine
DB01099,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Flucytosine.,Flucytosine
DB01101,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Capecitabine.,Capecitabine
DB01108,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Trilostane.,Trilostane
DB01168,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Procarbazine.,Procarbazine
DB01169,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Arsenic trioxide.,Arsenic trioxide
DB01177,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Idarubicin.,Idarubicin
DB01181,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ifosfamide.,Ifosfamide
DB01196,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Estramustine.,Estramustine
DB01204,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mitoxantrone.,Mitoxantrone
DB01206,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lomustine.,Lomustine
DB01222,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Budesonide.,Budesonide
DB01229,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Paclitaxel.,Paclitaxel
DB01234,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dexamethasone.,Dexamethasone
DB01248,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Docetaxel.,Docetaxel
DB01254,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dasatinib.,Dasatinib
DB01257,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Eculizumab.,Eculizumab
DB01262,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Decitabine.,Decitabine
DB01268,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sunitinib.,Sunitinib
DB01280,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Nelarabine.,Nelarabine
DB01281,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Abatacept.,Abatacept
DB01285,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Corticotropin.,Corticotropin
DB01380,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cortisone acetate.,Cortisone acetate
DB01384,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Paramethasone.,Paramethasone
DB01394,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Colchicine.,Colchicine
DB01410,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ciclesonide.,Ciclesonide
DB01423,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Stepronin.,Stepronin
DB01590,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Everolimus.,Everolimus
DB01611,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Hydroxychloroquine.,Hydroxychloroquine
DB01816,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Castanospermine.,Castanospermine
DB02546,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vorinostat.,Vorinostat
DB02806,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with 2-Methoxyethanol.,2-Methoxyethanol
DB03523,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Brequinar.,Brequinar
DB04572,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Thiotepa.,Thiotepa
DB04630,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Aldosterone.,Aldosterone
DB04845,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ixabepilone.,Ixabepilone
DB04868,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Nilotinib.,Nilotinib
DB04951,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pirfenidone.,Pirfenidone
DB04956,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Afelimomab.,Afelimomab
DB05015,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Belinostat.,Belinostat
DB05109,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Trabectedin.,Trabectedin
DB05258,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Interferon alfa.,Interferon alfa
DB05259,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Glatiramer.,Glatiramer
DB05260,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Gallium nitrate.,Gallium nitrate
DB05459,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Briakinumab.,Briakinumab
DB05472,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with omega interferon.,omega interferon
DB05676,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Apremilast.,Apremilast
DB05773,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Trastuzumab emtansine.,Trastuzumab emtansine
DB06168,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Canakinumab.,Canakinumab
DB06273,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tocilizumab.,Tocilizumab
DB06287,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Temsirolimus.,Temsirolimus
DB06372,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Rilonacept.,Rilonacept
DB06589,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pazopanib.,Pazopanib
DB06603,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Panobinostat.,Panobinostat
DB06612,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mepolizumab.,Mepolizumab
DB06616,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bosutinib.,Bosutinib
DB06662,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Abetimus.,Abetimus
DB06674,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Golimumab.,Golimumab
DB06681,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Belatacept.,Belatacept
DB06769,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bendamustine.,Bendamustine
DB06772,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cabazitaxel.,Cabazitaxel
DB06813,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pralatrexate.,Pralatrexate
DB08059,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Wortmannin.,Wortmannin
DB08870,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Brentuximab vedotin.,Brentuximab vedotin
DB08871,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Eribulin.,Eribulin
DB08877,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ruxolitinib.,Ruxolitinib
DB08879,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Belimumab.,Belimumab
DB08880,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Teriflunomide.,Teriflunomide
DB08889,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Carfilzomib.,Carfilzomib
DB08901,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ponatinib.,Ponatinib
DB08904,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Certolizumab pegol.,Certolizumab pegol
DB08906,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluticasone furoate.,Fluticasone furoate
DB08908,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dimethyl fumarate.,Dimethyl fumarate
DB08910,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pomalidomide.,Pomalidomide
DB08935,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Obinutuzumab.,Obinutuzumab
DB08970,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluprednidene.,Fluprednidene
DB08971,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluocortolone.,Fluocortolone
DB09029,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Secukinumab.,Secukinumab
DB09033,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vedolizumab.,Vedolizumab
DB09036,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Siltuximab.,Siltuximab
DB09052,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Blinatumomab.,Blinatumomab
DB09053,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ibrutinib.,Ibrutinib
DB09054,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Idelalisib.,Idelalisib
DB09073,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Palbociclib.,Palbociclib
DB09074,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Olaparib.,Olaparib
DB09077,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dinutuximab.,Dinutuximab
DB09082,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vilanterol.,Vilanterol
DB09091,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tixocortol.,Tixocortol
DB09122,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Peginterferon beta-1a.,Peginterferon beta-1a
DB09312,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Antilymphocyte immunoglobulin (horse).,Antilymphocyte immunoglobulin (horse)
DB09378,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluprednisolone.,Fluprednisolone
DB09383,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Meprednisone.,Meprednisone
DB11466,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tepoxalin.,Tepoxalin
DB11487,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dexamethasone isonicotinate.,Dexamethasone isonicotinate
DB11529,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Melengestrol.,Melengestrol
DB11569,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ixekizumab.,Ixekizumab
DB11580,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ravulizumab.,Ravulizumab
DB11616,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pirarubicin.,Pirarubicin
DB11693,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Voclosporin.,Voclosporin
DB11708,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Peficitinib.,Peficitinib
DB11750,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Clobetasol.,Clobetasol
DB11767,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sarilumab.,Sarilumab
DB11776,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Brodalumab.,Brodalumab
DB11803,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sirukumab.,Sirukumab
DB11817,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Baricitinib.,Baricitinib
DB11834,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Guselkumab.,Guselkumab
DB11921,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Deflazacort.,Deflazacort
DB12025,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Triptolide.,Triptolide
DB12371,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Siponimod.,Siponimod
DB12612,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ozanimod.,Ozanimod
DB12617,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mizoribine.,Mizoribine
DB12692,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Gusperimus.,Gusperimus
DB12814,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cepeginterferon alfa-2B.,Cepeginterferon alfa-2B
DB12902,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Trofosfamide.,Trofosfamide
DB12947,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Doxifluridine.,Doxifluridine
DB12991,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Deoxyspergualin.,Deoxyspergualin
DB12996,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Acteoside.,Acteoside
DB13003,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cortivazol.,Cortivazol
DB13014,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Hypericin.,Hypericin
DB13068,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.,9-(N-methyl-L-isoleucine)-cyclosporin A
DB13208,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Prednylidene.,Prednylidene
DB13223,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluocortin.,Fluocortin
DB13241,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Begelomab.,Begelomab
DB13491,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluperolone.,Fluperolone
DB13664,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Formocortal.,Formocortal
DB13728,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Halometasone.,Halometasone
DB13843,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cloprednol.,Cloprednol
DB13856,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluclorolone.,Fluclorolone
DB13867,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluticasone.,Fluticasone
DB14066,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tetrandrine.,Tetrandrine
DB14219,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Monomethyl fumarate.,Monomethyl fumarate
DB14512,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mometasone furoate.,Mometasone furoate
DB14538,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Hydrocortisone aceponate.,Hydrocortisone aceponate
DB14539,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Hydrocortisone acetate.,Hydrocortisone acetate
DB14545,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Hydrocortisone succinate.,Hydrocortisone succinate
DB14724,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Emapalumab.,Emapalumab
DB14762,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Risankizumab.,Risankizumab
DB14919,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Rozanolixizumab.,Rozanolixizumab
DB15253,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bleselumab.,Bleselumab
DB00108,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Natalizumab.,Natalizumab
DB00337,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Gemtuzumab ozogamicin.,Pimecrolimus
DB01656,Roflumilast may increase the immunosuppressive activities of Gemtuzumab ozogamicin.,Roflumilast
DB06688,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Gemtuzumab ozogamicin.,Sipuleucel-T
DB00363,The risk or severity of neutropenia can be increased when Gemtuzumab ozogamicin is combined with Clozapine.,Clozapine
DB00012,The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Gemtuzumab ozogamicin.,Darbepoetin alfa
DB00016,The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Gemtuzumab ozogamicin.,Erythropoietin
DB08894,The risk or severity of Thrombosis can be increased when Peginesatide is combined with Gemtuzumab ozogamicin.,Peginesatide
DB09107,The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Gemtuzumab ozogamicin.,Methoxy polyethylene glycol-epoetin beta
DB01015,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Gemtuzumab ozogamicin.,Sulfamethoxazole
DB00255,Diethylstilbestrol may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Diethylstilbestrol
DB00269,Chlorotrianisene may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Chlorotrianisene
DB00286,Conjugated estrogens may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Conjugated estrogens
DB00655,Estrone may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Estrone
DB00783,Estradiol may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Estradiol
DB00890,Dienestrol may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Dienestrol
DB00977,Ethinylestradiol may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Ethinylestradiol
DB01357,Mestranol may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Mestranol
DB04573,Estriol may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Estriol
DB04574,Estrone sulfate may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Estrone sulfate
DB04575,Quinestrol may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Quinestrol
DB07931,Hexestrol may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Hexestrol
DB09070,Tibolone may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Tibolone
DB09317,"Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Gemtuzumab ozogamicin.","Synthetic Conjugated Estrogens, A"
DB09318,"Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Gemtuzumab ozogamicin.","Synthetic Conjugated Estrogens, B"
DB09369,Polyestradiol phosphate may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Polyestradiol phosphate
DB09381,Esterified estrogens may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Esterified estrogens
DB11478,Zeranol may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Zeranol
DB11674,Equol may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Equol
DB12487,Promestriene may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Promestriene
DB13143,Methallenestril may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Methallenestril
DB13386,Epimestrol may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Epimestrol
DB13418,Moxestrol may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Moxestrol
DB13952,Estradiol acetate may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Estradiol acetate
DB13953,Estradiol benzoate may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Estradiol benzoate
DB13954,Estradiol cypionate may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Estradiol cypionate
DB13956,Estradiol valerate may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Estradiol valerate
DB15334,Biochanin A may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Biochanin A
DB15335,Formononetin may increase the thrombogenic activities of Gemtuzumab ozogamicin.,Formononetin
DB01097,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Leflunomide.,Leflunomide
DB08895,Gemtuzumab ozogamicin may increase the immunosuppressive activities of Tofacitinib.,Tofacitinib
DB00072,Trastuzumab may increase the neutropenic activities of Gemtuzumab ozogamicin.,Trastuzumab
DB08868,Gemtuzumab ozogamicin may increase the immunosuppressive activities of Fingolimod.,Fingolimod
DB00864,Tacrolimus may increase the immunosuppressive activities of Gemtuzumab ozogamicin.,Tacrolimus
DB04914,The therapeutic efficacy of G17DT can be decreased when used in combination with Gemtuzumab ozogamicin.,G17DT
DB05144,The therapeutic efficacy of PEV3A can be decreased when used in combination with Gemtuzumab ozogamicin.,PEV3A
DB05325,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Gemtuzumab ozogamicin.,INGN 225
DB05374,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Gemtuzumab ozogamicin.,Rindopepimut
DB05440,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Gemtuzumab ozogamicin.,SRP 299
DB05942,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Gemtuzumab ozogamicin.,GI-5005
DB06400,The therapeutic efficacy of Vitespen can be decreased when used in combination with Gemtuzumab ozogamicin.,Vitespen
DB06584,The therapeutic efficacy of TG4010 can be decreased when used in combination with Gemtuzumab ozogamicin.,TG4010
DB09057,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Gemtuzumab ozogamicin.,Anthrax immune globulin human
DB10062,"The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Gemtuzumab ozogamicin.","Rabies virus inactivated antigen, B"
DB10076,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Gemtuzumab ozogamicin.,Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen
DB10276,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Gemtuzumab ozogamicin.,Rotavirus vaccine
DB10283,"The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Gemtuzumab ozogamicin.","Rabies virus inactivated antigen, A"
DB10342,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Gemtuzumab ozogamicin.,Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen
DB10583,The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.,Clostridium tetani toxoid antigen (formaldehyde inactivated)
DB10584,The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.,Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
DB10600,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.,Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated)
DB10769,The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.,Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)
DB10794,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.,Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated)
DB10803,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Gemtuzumab ozogamicin.,Typhoid Vi polysaccharide vaccine
DB10989,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Gemtuzumab ozogamicin.,Hepatitis A Vaccine
DB10990,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Gemtuzumab ozogamicin.,Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
DB11038,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.,Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated)
DB11040,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated)
DB11041,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.,Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)
DB11044,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.,Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated)
DB11603,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Gemtuzumab ozogamicin.,Human rabies virus immune globulin
DB11627,The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Gemtuzumab ozogamicin.,Hepatitis B Vaccine (Recombinant)
DB12568,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Gemtuzumab ozogamicin.,Tecemotide
DB14022,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Gemtuzumab ozogamicin.,Typhoid vaccine
DB14384,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated)
DB14385,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)
DB14394,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Gemtuzumab ozogamicin.,Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen
DB14445,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated)
DB14449,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Gemtuzumab ozogamicin.,Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen
DB14619,The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.,Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated)
DB14620,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.,Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated)
DB14711,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Gemtuzumab ozogamicin.,Vaccinia virus strain new york city board of health live antigen
DB15274,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Gemtuzumab ozogamicin.,Pertussis vaccine
DB15461,The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.,Yersinia pestis 195/p antigen (formaldehyde inactivated)
DB13924,The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Gemtuzumab ozogamicin.,Varicella Zoster Vaccine (Recombinant)
DB15483,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Gemtuzumab ozogamicin.,Modified vaccinia ankara
DB00063,The risk or severity of bleeding can be increased when Eptifibatide is combined with Gemtuzumab ozogamicin.,Eptifibatide
DB00208,The risk or severity of bleeding can be increased when Ticlopidine is combined with Gemtuzumab ozogamicin.,Ticlopidine
DB00261,The risk or severity of bleeding can be increased when Anagrelide is combined with Gemtuzumab ozogamicin.,Anagrelide
DB00758,The risk or severity of bleeding can be increased when Clopidogrel is combined with Gemtuzumab ozogamicin.,Clopidogrel
DB00775,The risk or severity of bleeding can be increased when Tirofiban is combined with Gemtuzumab ozogamicin.,Tirofiban
DB00806,The risk or severity of bleeding can be increased when Pentoxifylline is combined with Gemtuzumab ozogamicin.,Pentoxifylline
DB00945,The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Gemtuzumab ozogamicin.,Acetylsalicylic acid
DB00975,The risk or severity of bleeding can be increased when Dipyridamole is combined with Gemtuzumab ozogamicin.,Dipyridamole
DB01088,The risk or severity of bleeding can be increased when Iloprost is combined with Gemtuzumab ozogamicin.,Iloprost
DB01138,The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Gemtuzumab ozogamicin.,Sulfinpyrazone
DB01166,The risk or severity of bleeding can be increased when Cilostazol is combined with Gemtuzumab ozogamicin.,Cilostazol
DB01207,The risk or severity of bleeding can be increased when Ridogrel is combined with Gemtuzumab ozogamicin.,Ridogrel
DB01236,The risk or severity of bleeding can be increased when Sevoflurane is combined with Gemtuzumab ozogamicin.,Sevoflurane
DB01240,The risk or severity of bleeding can be increased when Epoprostenol is combined with Gemtuzumab ozogamicin.,Epoprostenol
DB02709,The risk or severity of bleeding can be increased when Resveratrol is combined with Gemtuzumab ozogamicin.,Resveratrol
DB04743,The risk or severity of bleeding can be increased when Nimesulide is combined with Gemtuzumab ozogamicin.,Nimesulide
DB04905,The risk or severity of bleeding can be increased when Tesmilifene is combined with Gemtuzumab ozogamicin.,Tesmilifene
DB04932,The risk or severity of bleeding can be increased when Defibrotide is combined with Gemtuzumab ozogamicin.,Defibrotide
DB05229,The risk or severity of bleeding can be increased when Beraprost is combined with Gemtuzumab ozogamicin.,Beraprost
DB05266,The risk or severity of bleeding can be increased when Ibudilast is combined with Gemtuzumab ozogamicin.,Ibudilast
DB05767,The risk or severity of bleeding can be increased when Andrographolide is combined with Gemtuzumab ozogamicin.,Andrographolide
DB06209,The risk or severity of bleeding can be increased when Prasugrel is combined with Gemtuzumab ozogamicin.,Prasugrel
DB06441,The risk or severity of bleeding can be increased when Cangrelor is combined with Gemtuzumab ozogamicin.,Cangrelor
DB07615,The risk or severity of bleeding can be increased when Tranilast is combined with Gemtuzumab ozogamicin.,Tranilast
DB08814,The risk or severity of bleeding can be increased when Triflusal is combined with Gemtuzumab ozogamicin.,Triflusal
DB08816,The risk or severity of bleeding can be increased when Ticagrelor is combined with Gemtuzumab ozogamicin.,Ticagrelor
DB08887,The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Gemtuzumab ozogamicin.,Icosapent ethyl
DB09030,The risk or severity of bleeding can be increased when Vorapaxar is combined with Gemtuzumab ozogamicin.,Vorapaxar
DB09283,The risk or severity of bleeding can be increased when Trapidil is combined with Gemtuzumab ozogamicin.,Trapidil
DB12092,The risk or severity of bleeding can be increased when Naftopidil is combined with Gemtuzumab ozogamicin.,Naftopidil
DB12163,The risk or severity of bleeding can be increased when Sarpogrelate is combined with Gemtuzumab ozogamicin.,Sarpogrelate
DB12321,The risk or severity of bleeding can be increased when Ifetroban is combined with Gemtuzumab ozogamicin.,Ifetroban
DB12445,The risk or severity of bleeding can be increased when Nitroaspirin is combined with Gemtuzumab ozogamicin.,Nitroaspirin
DB12465,The risk or severity of bleeding can be increased when Ketanserin is combined with Gemtuzumab ozogamicin.,Ketanserin
DB12545,The risk or severity of bleeding can be increased when Indobufen is combined with Gemtuzumab ozogamicin.,Indobufen
DB12749,The risk or severity of bleeding can be increased when Butylphthalide is combined with Gemtuzumab ozogamicin.,Butylphthalide
DB12771,The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Gemtuzumab ozogamicin.,Hydroxytyrosol
DB13036,The risk or severity of bleeding can be increased when Ramatroban is combined with Gemtuzumab ozogamicin.,Ramatroban
DB13327,The risk or severity of bleeding can be increased when Picotamide is combined with Gemtuzumab ozogamicin.,Picotamide
DB13367,The risk or severity of bleeding can be increased when Cloricromen is combined with Gemtuzumab ozogamicin.,Cloricromen
DB13400,The risk or severity of bleeding can be increased when Linsidomine is combined with Gemtuzumab ozogamicin.,Linsidomine
DB13510,The risk or severity of bleeding can be increased when Buflomedil is combined with Gemtuzumab ozogamicin.,Buflomedil
DB13929,The risk or severity of bleeding can be increased when Relcovaptan is combined with Gemtuzumab ozogamicin.,Relcovaptan
DB11988,Ocrelizumab may increase the immunosuppressive activities of Gemtuzumab ozogamicin.,Ocrelizumab
DB13200,Gemtuzumab ozogamicin may increase the myelosuppressive activities of Lipegfilgrastim.,Lipegfilgrastim
DB10317,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Gemtuzumab ozogamicin.,Rubella virus vaccine
DB10318,The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Gemtuzumab ozogamicin.,Varicella Zoster Vaccine (Live/attenuated)
DB10343,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Gemtuzumab ozogamicin.,Bacillus calmette-guerin substrain tice live antigen
DB10804,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Gemtuzumab ozogamicin.,Bacillus calmette-guerin substrain connaught live antigen
DB10805,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Gemtuzumab ozogamicin.,Yellow Fever Vaccine
DB11003,The risk or severity of infection can be increased when Anthrax vaccine is combined with Gemtuzumab ozogamicin.,Anthrax vaccine
DB11050,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Gemtuzumab ozogamicin.,Typhoid Vaccine Live
DB12386,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Gemtuzumab ozogamicin.,Bacillus calmette-guerin substrain danish 1331 live antigen
DB12768,The risk or severity of infection can be increased when BCG vaccine is combined with Gemtuzumab ozogamicin.,BCG vaccine
DB14409,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Gemtuzumab ozogamicin.,Human adenovirus e serotype 4 strain cl-68578 antigen
DB14443,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Gemtuzumab ozogamicin.,Vibrio cholerae CVD 103-HgR strain live antigen
DB14685,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Gemtuzumab ozogamicin.,Adenovirus type 7 vaccine live
DB00002,The risk or severity of adverse effects can be increased when Cetuximab is combined with Gemtuzumab ozogamicin.,Cetuximab
DB00028,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Gemtuzumab ozogamicin.,Human immunoglobulin G
DB00043,The risk or severity of adverse effects can be increased when Omalizumab is combined with Gemtuzumab ozogamicin.,Omalizumab
DB00054,The risk or severity of adverse effects can be increased when Abciximab is combined with Gemtuzumab ozogamicin.,Abciximab
DB00057,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Indium In-111 satumomab pendetide.,Indium In-111 satumomab pendetide
DB00076,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Digoxin Immune Fab (Ovine).,Digoxin Immune Fab (Ovine)
DB00089,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Capromab pendetide.,Capromab pendetide
DB00110,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Palivizumab.,Palivizumab
DB00113,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Technetium Tc-99m arcitumomab.,Technetium Tc-99m arcitumomab
DB01269,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Panitumumab.,Panitumumab
DB01270,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ranibizumab.,Ranibizumab
DB04901,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Galiximab.,Galiximab
DB04949,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pexelizumab.,Pexelizumab
DB04958,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Epratuzumab.,Epratuzumab
DB04962,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bectumomab.,Bectumomab
DB04964,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Oregovomab.,Oregovomab
DB04988,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with IGN311.,IGN311
DB05006,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Adecatumumab.,Adecatumumab
DB05097,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Labetuzumab.,Labetuzumab
DB05101,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Matuzumab.,Matuzumab
DB05111,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fontolizumab.,Fontolizumab
DB05136,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bavituximab.,Bavituximab
DB05139,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with CR002.,CR002
DB05209,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Rozrolimupab.,Rozrolimupab
DB05304,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Girentuximab.,Girentuximab
DB05336,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Obiltoxaximab.,Obiltoxaximab
DB05405,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with XTL-001.,XTL-001
DB05437,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with NAV 1800.,NAV 1800
DB05496,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Otelixizumab.,Otelixizumab
DB05545,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with AMG 108.,AMG 108
DB05550,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Iratumumab.,Iratumumab
DB05555,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Enokizumab.,Enokizumab
DB05578,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ramucirumab.,Ramucirumab
DB05595,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Farletuzumab.,Farletuzumab
DB05656,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Veltuzumab.,Veltuzumab
DB05793,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with PRO-542.,PRO-542
DB05797,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with TNX-901.,TNX-901
DB05889,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Inotuzumab ozogamicin.,Inotuzumab ozogamicin
DB05892,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with RI 624.,RI 624
DB05915,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with MYO-029.,MYO-029
DB05916,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with CT-011.,CT-011
DB05941,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Leronlimab.,Leronlimab
DB05996,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Glembatumumab vedotin.,Glembatumumab vedotin
DB06043,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Olaratumab.,Olaratumab
DB06049,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with IPH 2101.,IPH 2101
DB06050,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with TB-402.,TB-402
DB06081,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Caplacizumab.,Caplacizumab
DB06101,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with IMC-1C11.,IMC-1C11
DB06116,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Eldelumab.,Eldelumab
DB06162,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lumiliximab.,Lumiliximab
DB06186,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ipilimumab.,Ipilimumab
DB06192,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Nimotuzumab.,Nimotuzumab
DB06241,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Clenoliximab.,Clenoliximab
DB06304,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with BIIB015.,BIIB015
DB06305,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sonepcizumab.,Sonepcizumab
DB06310,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Motavizumab.,Motavizumab
DB06317,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Elotuzumab.,Elotuzumab
DB06318,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with AVE9633.,AVE9633
DB06322,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Carotuximab.,Carotuximab
DB06324,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with XmAb 2513.,XmAb 2513
DB06342,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Coltuximab ravtansine.,Coltuximab ravtansine
DB06343,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Teprotumumab.,Teprotumumab
DB06360,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lucatumumab.,Lucatumumab
DB06366,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pertuzumab.,Pertuzumab
DB06371,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Siplizumab.,Siplizumab
DB06467,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Apolizumab.,Apolizumab
DB06474,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sibrotuzumab.,Sibrotuzumab
DB06550,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bivatuzumab.,Bivatuzumab
DB06557,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lerdelimumab.,Lerdelimumab
DB06599,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lexatumumab.,Lexatumumab
DB06602,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Reslizumab.,Reslizumab
DB06606,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Teplizumab.,Teplizumab
DB06607,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Catumaxomab.,Catumaxomab
DB06647,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Volociximab.,Volociximab
DB06650,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ofatumumab.,Ofatumumab
DB08902,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Raxibacumab.,Raxibacumab
DB09035,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Nivolumab.,Nivolumab
DB09037,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pembrolizumab.,Pembrolizumab
DB09045,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dulaglutide.,Dulaglutide
DB09105,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Asfotase alfa.,Asfotase alfa
DB09264,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Idarucizumab.,Idarucizumab
DB09302,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Alirocumab.,Alirocumab
DB09303,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Evolocumab.,Evolocumab
DB09331,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Daratumumab.,Daratumumab
DB09559,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Necitumumab.,Necitumumab
DB11595,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Atezolizumab.,Atezolizumab
DB11604,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tetanus Immune Globulin.,Tetanus Immune Globulin
DB11608,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Eftrenonacog alfa.,Eftrenonacog alfa
DB11621,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Human Varicella-Zoster Immune Globulin.,Human Varicella-Zoster Immune Globulin
DB11646,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Conatumumab.,Conatumumab
DB11657,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tabalumab.,Tabalumab
DB11680,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ficlatuzumab.,Ficlatuzumab
DB11685,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Figitumumab.,Figitumumab
DB11714,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Durvalumab.,Durvalumab
DB11715,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bapineuzumab.,Bapineuzumab
DB11731,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Depatuxizumab mafodotin.,Depatuxizumab mafodotin
DB11746,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Onartuzumab.,Onartuzumab
DB11756,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Solanezumab.,Solanezumab
DB11771,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tremelimumab.,Tremelimumab
DB11826,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lampalizumab.,Lampalizumab
DB11840,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dalotuzumab.,Dalotuzumab
DB11849,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Emibetuzumab.,Emibetuzumab
DB11850,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ublituximab.,Ublituximab
DB11856,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ligelizumab.,Ligelizumab
DB11857,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Seribantumab.,Seribantumab
DB11862,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Landogrozumab.,Landogrozumab
DB11866,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Romosozumab.,Romosozumab
DB11884,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vadastuximab Talirine.,Vadastuximab Talirine
DB11914,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lebrikizumab.,Lebrikizumab
DB11930,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Varlilumab.,Varlilumab
DB11945,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Avelumab.,Avelumab
DB11959,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Crenezumab.,Crenezumab
DB11972,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Rilotumumab.,Rilotumumab
DB11976,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Anifrolumab.,Anifrolumab
DB12023,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Benralizumab.,Benralizumab
DB12034,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Gantenerumab.,Gantenerumab
DB12053,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Visilizumab.,Visilizumab
DB12077,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Urelumab.,Urelumab
DB12089,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lorvotuzumab mertansine.,Lorvotuzumab mertansine
DB12090,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Patritumab.,Patritumab
DB12102,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fulranumab.,Fulranumab
DB12104,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tarextumab.,Tarextumab
DB12118,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sotatercept.,Sotatercept
DB12119,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Gevokizumab.,Gevokizumab
DB12142,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Duligotuzumab.,Duligotuzumab
DB12152,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Simtuzumab.,Simtuzumab
DB12157,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fasinumab.,Fasinumab
DB12159,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dupilumab.,Dupilumab
DB12169,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tralokinumab.,Tralokinumab
DB12189,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Etrolizumab.,Etrolizumab
DB12202,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Zalutumumab.,Zalutumumab
DB12205,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ganitumab.,Ganitumab
DB12213,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Etaracizumab.,Etaracizumab
DB12240,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Polatuzumab vedotin.,Polatuzumab vedotin
DB12246,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Inclacumab.,Inclacumab
DB12250,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cixutumumab.,Cixutumumab
DB12261,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ascrinvacumab.,Ascrinvacumab
DB12274,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Aducanumab.,Aducanumab
DB12281,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Luspatercept.,Luspatercept
DB12296,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with GS-5745.,GS-5745
DB12317,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vanucizumab.,Vanucizumab
DB12331,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Labetuzumab govitecan.,Labetuzumab govitecan
DB12335,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tanezumab.,Tanezumab
DB12342,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ensituximab.,Ensituximab
DB12344,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fezakinumab.,Fezakinumab
DB12363,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dusigitumab.,Dusigitumab
DB12396,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fresolimumab.,Fresolimumab
DB12413,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Indusatumab vedotin.,Indusatumab vedotin
DB12456,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bococizumab.,Bococizumab
DB12489,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mirvetuximab Soravtansine.,Mirvetuximab Soravtansine
DB12498,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mogamulizumab.,Mogamulizumab
DB12520,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Plozalizumab.,Plozalizumab
DB12534,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mavrilimumab.,Mavrilimumab
DB12560,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Blosozumab.,Blosozumab
DB12584,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bimagrumab.,Bimagrumab
DB12589,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dacetuzumab.,Dacetuzumab
DB12609,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tovetumab.,Tovetumab
DB12683,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lumretuzumab.,Lumretuzumab
DB12698,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ibalizumab.,Ibalizumab
DB12701,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Intetumumab.,Intetumumab
DB12718,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Carlumab.,Carlumab
DB12734,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Demcizumab.,Demcizumab
DB12773,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sifalimumab.,Sifalimumab
DB12775,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Abituzumab.,Abituzumab
DB12797,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ecromeximab.,Ecromeximab
DB12807,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Naptumomab Estafenatox.,Naptumomab Estafenatox
DB12815,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Crotedumab.,Crotedumab
DB12820,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Concizumab.,Concizumab
DB12826,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Depatuxizumab.,Depatuxizumab
DB12844,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Rontalizumab.,Rontalizumab
DB12845,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Amatuximab.,Amatuximab
DB12849,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Clazakizumab.,Clazakizumab
DB12891,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ozanezumab.,Ozanezumab
DB12893,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sacituzumab govitecan.,Sacituzumab govitecan
DB12917,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bimekizumab.,Bimekizumab
DB12943,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Milatuzumab.,Milatuzumab
DB12976,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Robatumumab.,Robatumumab
DB13017,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Rovalpituzumab Tesirine.,Rovalpituzumab Tesirine
DB13037,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Namilumab.,Namilumab
DB13045,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Racotumomab.,Racotumomab
DB13073,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tregalizumab.,Tregalizumab
DB13127,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Olokizumab.,Olokizumab
DB13140,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bezlotoxumab.,Bezlotoxumab
DB13375,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Edrecolomab.,Edrecolomab
DB13535,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Nebacumab.,Nebacumab
DB13886,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Human cytomegalovirus immune globulin.,Human cytomegalovirus immune globulin
DB13923,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Emicizumab.,Emicizumab
DB13976,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sulesomab.,Sulesomab
DB13979,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Besilesomab.,Besilesomab
DB14012,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Burosumab.,Burosumab
DB14039,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Erenumab.,Erenumab
DB14040,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Eptinezumab.,Eptinezumab
DB14041,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fremanezumab.,Fremanezumab
DB14042,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Galcanezumab.,Galcanezumab
DB14211,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fanolesomab.,Fanolesomab
DB14580,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lecanemab.,Lecanemab
DB14597,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lanadelumab.,Lanadelumab
DB14707,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cemiplimab.,Cemiplimab
DB14776,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Camrelizumab.,Camrelizumab
DB14778,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Setrusumab.,Setrusumab
DB14784,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Gancotamab.,Gancotamab
DB14809,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Anetumab ravtansine.,Anetumab ravtansine
DB14811,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Isatuximab.,Isatuximab
DB14824,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Icrucumab.,Icrucumab
DB14843,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Codrituzumab.,Codrituzumab
DB14864,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Brolucizumab.,Brolucizumab
DB14871,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Xentuzumab.,Xentuzumab
DB14877,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lintuzumab.,Lintuzumab
DB14891,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vobarilizumab.,Vobarilizumab
DB14897,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Parsatuzumab.,Parsatuzumab
DB14905,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Emactuzumab.,Emactuzumab
DB14907,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bevacizumab zirconium Zr-89.,Bevacizumab zirconium Zr-89
DB14908,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Refanezumab.,Refanezumab
DB14947,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bermekimab.,Bermekimab
DB14952,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pamrevlumab.,Pamrevlumab
DB14959,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Opicinumab.,Opicinumab
DB14962,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Trastuzumab deruxtecan.,Trastuzumab deruxtecan
DB14967,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Margetuximab.,Margetuximab
DB14988,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dalantercept.,Dalantercept
DB14997,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pateclizumab.,Pateclizumab
DB15014,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Gremubamab.,Gremubamab
DB15022,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Apomab.,Apomab
DB15044,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tafasitamab.,Tafasitamab
DB15045,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ipafricept.,Ipafricept
DB15076,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Abrilumab.,Abrilumab
DB15089,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Frovocimab.,Frovocimab
DB15090,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tezepelumab.,Tezepelumab
DB15101,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tigatuzumab.,Tigatuzumab
DB15104,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Telisotuzumab vedotin.,Telisotuzumab vedotin
DB15113,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Utomilumab.,Utomilumab
DB15118,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Zolbetuximab.,Zolbetuximab
DB15135,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ponezumab.,Ponezumab
DB15160,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Asunercept.,Asunercept
DB15172,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Suvratoxumab.,Suvratoxumab
DB15225,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mitazalimab.,Mitazalimab
DB15252,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Nemolizumab.,Nemolizumab
DB15277,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Gedivumab.,Gedivumab
DB15336,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Valanafusp alfa.,Valanafusp alfa
DB15349,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sofituzumab vedotin.,Sofituzumab vedotin
DB15354,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Evinacumab.,Evinacumab
DB15363,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Istiratumab.,Istiratumab
DB15383,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pidilizumab.,Pidilizumab
DB15397,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with GMA-161.,GMA-161
DB15409,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ladiratuzumab vedotin.,Ladiratuzumab vedotin
DB15415,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tomaralimab.,Tomaralimab
DB15428,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vesencumab.,Vesencumab
DB15432,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pinatuzumab vedotin.,Pinatuzumab vedotin
DB15441,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lulizumab pegol.,Lulizumab pegol
DB15443,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lorukafusp alfa.,Lorukafusp alfa
DB15453,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Naratuximab emtansine.,Naratuximab emtansine
DB14004,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tildrakizumab.,Tildrakizumab
DB05679,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ustekinumab.,Ustekinumab
DB15559,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Zenocutuzumab.,Zenocutuzumab
DB00039,The therapeutic efficacy of Palifermin can be decreased when used in combination with Gemtuzumab ozogamicin.,Palifermin
DB00001,The risk or severity of bleeding can be increased when Lepirudin is combined with Gemtuzumab ozogamicin.,Lepirudin
DB00006,The risk or severity of bleeding can be increased when Bivalirudin is combined with Gemtuzumab ozogamicin.,Bivalirudin
DB00009,The risk or severity of bleeding can be increased when Alteplase is combined with Gemtuzumab ozogamicin.,Alteplase
DB00013,The risk or severity of bleeding can be increased when Urokinase is combined with Gemtuzumab ozogamicin.,Urokinase
DB00015,The risk or severity of bleeding can be increased when Reteplase is combined with Gemtuzumab ozogamicin.,Reteplase
DB00029,The risk or severity of bleeding can be increased when Anistreplase is combined with Gemtuzumab ozogamicin.,Anistreplase
DB00031,The risk or severity of bleeding can be increased when Tenecteplase is combined with Gemtuzumab ozogamicin.,Tenecteplase
DB00055,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Gemtuzumab ozogamicin.,Drotrecogin alfa
DB00086,The risk or severity of bleeding can be increased when Streptokinase is combined with Gemtuzumab ozogamicin.,Streptokinase
DB00266,The risk or severity of bleeding can be increased when Dicoumarol is combined with Gemtuzumab ozogamicin.,Dicoumarol
DB00278,The risk or severity of bleeding can be increased when Argatroban is combined with Gemtuzumab ozogamicin.,Argatroban
DB00407,The risk or severity of bleeding can be increased when Ardeparin is combined with Gemtuzumab ozogamicin.,Ardeparin
DB00498,The risk or severity of bleeding can be increased when Phenindione is combined with Gemtuzumab ozogamicin.,Phenindione
DB00569,The risk or severity of bleeding can be increased when Fondaparinux is combined with Gemtuzumab ozogamicin.,Fondaparinux
DB00682,The risk or severity of bleeding can be increased when Warfarin is combined with Gemtuzumab ozogamicin.,Warfarin
DB00686,The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Gemtuzumab ozogamicin.,Pentosan polysulfate
DB00946,The risk or severity of bleeding can be increased when Phenprocoumon is combined with Gemtuzumab ozogamicin.,Phenprocoumon
DB01109,The risk or severity of bleeding can be increased when Heparin is combined with Gemtuzumab ozogamicin.,Heparin
DB01225,The risk or severity of bleeding can be increased when Enoxaparin is combined with Gemtuzumab ozogamicin.,Enoxaparin
DB01418,The risk or severity of bleeding can be increased when Acenocoumarol is combined with Gemtuzumab ozogamicin.,Acenocoumarol
DB03410,The risk or severity of bleeding can be increased when 4-hydroxycoumarin is combined with Gemtuzumab ozogamicin.,4-hydroxycoumarin
DB04665,The risk or severity of bleeding can be increased when Coumarin is combined with Gemtuzumab ozogamicin.,Coumarin
DB04898,The risk or severity of bleeding can be increased when Ximelagatran is combined with Gemtuzumab ozogamicin.,Ximelagatran
DB04925,The risk or severity of bleeding can be increased when Desmoteplase is combined with Gemtuzumab ozogamicin.,Desmoteplase
DB05099,The risk or severity of bleeding can be increased when Ancrod is combined with Gemtuzumab ozogamicin.,Ancrod
DB05254,The risk or severity of bleeding can be increased when Fibrinolysin is combined with Gemtuzumab ozogamicin.,Fibrinolysin
DB06228,The risk or severity of bleeding can be increased when Rivaroxaban is combined with Gemtuzumab ozogamicin.,Rivaroxaban
DB06271,The risk or severity of bleeding can be increased when Sulodexide is combined with Gemtuzumab ozogamicin.,Sulodexide
DB06294,The risk or severity of bleeding can be increased when Semuloparin is combined with Gemtuzumab ozogamicin.,Semuloparin
DB06406,The risk or severity of bleeding can be increased when Idraparinux is combined with Gemtuzumab ozogamicin.,Idraparinux
DB06543,The risk or severity of bleeding can be increased when Astaxanthin is combined with Gemtuzumab ozogamicin.,Astaxanthin
DB06605,The risk or severity of bleeding can be increased when Apixaban is combined with Gemtuzumab ozogamicin.,Apixaban
DB06635,The risk or severity of bleeding can be increased when Otamixaban is combined with Gemtuzumab ozogamicin.,Otamixaban
DB06679,The risk or severity of bleeding can be increased when Amediplase is combined with Gemtuzumab ozogamicin.,Amediplase
DB06695,The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Gemtuzumab ozogamicin.,Dabigatran etexilate
DB06754,The risk or severity of bleeding can be increased when Danaparoid is combined with Gemtuzumab ozogamicin.,Danaparoid
DB06779,The risk or severity of bleeding can be increased when Dalteparin is combined with Gemtuzumab ozogamicin.,Dalteparin
DB06822,The risk or severity of bleeding can be increased when Tinzaparin is combined with Gemtuzumab ozogamicin.,Tinzaparin
DB07767,The risk or severity of bleeding can be increased when Ferulic acid is combined with Gemtuzumab ozogamicin.,Ferulic acid
DB08496,The risk or severity of bleeding can be increased when (R)-warfarin is combined with Gemtuzumab ozogamicin.,(R)-warfarin
DB08794,The risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Gemtuzumab ozogamicin.,Ethyl biscoumacetate
DB08813,The risk or severity of bleeding can be increased when Nadroparin is combined with Gemtuzumab ozogamicin.,Nadroparin
DB08994,The risk or severity of bleeding can be increased when Ditazole is combined with Gemtuzumab ozogamicin.,Ditazole
DB09075,The risk or severity of bleeding can be increased when Edoxaban is combined with Gemtuzumab ozogamicin.,Edoxaban
DB09125,The risk or severity of bleeding can be increased when Potassium citrate is combined with Gemtuzumab ozogamicin.,Potassium citrate
DB09154,The risk or severity of bleeding can be increased when Sodium citrate is combined with Gemtuzumab ozogamicin.,Sodium citrate
DB09255,The risk or severity of bleeding can be increased when Dextran is combined with Gemtuzumab ozogamicin.,Dextran
DB09258,The risk or severity of bleeding can be increased when Bemiparin is combined with Gemtuzumab ozogamicin.,Bemiparin
DB09259,The risk or severity of bleeding can be increased when Reviparin is combined with Gemtuzumab ozogamicin.,Reviparin
DB09260,The risk or severity of bleeding can be increased when Parnaparin is combined with Gemtuzumab ozogamicin.,Parnaparin
DB09261,The risk or severity of bleeding can be increased when Certoparin is combined with Gemtuzumab ozogamicin.,Certoparin
DB11095,The risk or severity of bleeding can be increased when Desirudin is combined with Gemtuzumab ozogamicin.,Desirudin
DB11154,The risk or severity of bleeding can be increased when Zinc citrate is combined with Gemtuzumab ozogamicin.,Zinc citrate
DB11166,The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Gemtuzumab ozogamicin.,Antithrombin Alfa
DB11312,The risk or severity of bleeding can be increased when Protein C is combined with Gemtuzumab ozogamicin.,Protein C
DB11598,The risk or severity of bleeding can be increased when Antithrombin III human is combined with Gemtuzumab ozogamicin.,Antithrombin III human
DB11984,The risk or severity of bleeding can be increased when Letaxaban is combined with Gemtuzumab ozogamicin.,Letaxaban
DB12289,The risk or severity of bleeding can be increased when Darexaban is combined with Gemtuzumab ozogamicin.,Darexaban
DB12364,The risk or severity of bleeding can be increased when Betrixaban is combined with Gemtuzumab ozogamicin.,Betrixaban
DB12598,The risk or severity of bleeding can be increased when Nafamostat is combined with Gemtuzumab ozogamicin.,Nafamostat
DB12726,The risk or severity of bleeding can be increased when Monteplase is combined with Gemtuzumab ozogamicin.,Monteplase
DB12831,The risk or severity of bleeding can be increased when Gabexate is combined with Gemtuzumab ozogamicin.,Gabexate
DB13136,The risk or severity of bleeding can be increased when Fluindione is combined with Gemtuzumab ozogamicin.,Fluindione
DB13149,The risk or severity of bleeding can be increased when Protein S human is combined with Gemtuzumab ozogamicin.,Protein S human
DB13199,The risk or severity of bleeding can be increased when Brinase is combined with Gemtuzumab ozogamicin.,Brinase
DB13275,The risk or severity of bleeding can be increased when Clorindione is combined with Gemtuzumab ozogamicin.,Clorindione
DB13347,The risk or severity of bleeding can be increased when Diphenadione is combined with Gemtuzumab ozogamicin.,Diphenadione
DB13451,The risk or severity of bleeding can be increased when Tioclomarol is combined with Gemtuzumab ozogamicin.,Tioclomarol
DB13616,The risk or severity of bleeding can be increased when Melagatran is combined with Gemtuzumab ozogamicin.,Melagatran
DB13646,The risk or severity of bleeding can be increased when Saruplase is combined with Gemtuzumab ozogamicin.,Saruplase
DB14055,The risk or severity of bleeding can be increased when (S)-Warfarin is combined with Gemtuzumab ozogamicin.,(S)-Warfarin
DB14094,The risk or severity of bleeding can be increased when Tocopherylquinone is combined with Gemtuzumab ozogamicin.,Tocopherylquinone
DB14598,The risk or severity of bleeding can be increased when Edetate calcium disodium anhydrous is combined with Gemtuzumab ozogamicin.,Edetate calcium disodium anhydrous
DB14726,The risk or severity of bleeding can be increased when Dabigatran is combined with Gemtuzumab ozogamicin.,Dabigatran
DB00232,The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Gemtuzumab ozogamicin.,Methyclothiazide
DB00436,The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Gemtuzumab ozogamicin.,Bendroflumethiazide
DB00562,The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Gemtuzumab ozogamicin.,Benzthiazide
DB00606,The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Gemtuzumab ozogamicin.,Cyclothiazide
DB00774,The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Gemtuzumab ozogamicin.,Hydroflumethiazide
DB00880,The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Gemtuzumab ozogamicin.,Chlorothiazide
DB00999,The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Gemtuzumab ozogamicin.,Hydrochlorothiazide
DB01021,The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Gemtuzumab ozogamicin.,Trichlormethiazide
DB01324,The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Gemtuzumab ozogamicin.,Polythiazide
DB13430,The risk or severity of neutropenia and thrombocytopenia can be increased when Mebutizide is combined with Gemtuzumab ozogamicin.,Mebutizide
DB13532,The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Gemtuzumab ozogamicin.,Cyclopenthiazide
DB09042,The risk or severity of myelosuppression can be increased when Gemtuzumab ozogamicin is combined with Tedizolid phosphate.,Tedizolid phosphate
DB00091,Gemtuzumab ozogamicin may increase the immunosuppressive activities of Cyclosporine.,Cyclosporine
DB00115,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Gemtuzumab ozogamicin.,Cyanocobalamin
DB00437,The risk or severity of adverse effects can be increased when Allopurinol is combined with Gemtuzumab ozogamicin.,Allopurinol
DB12978,Gemtuzumab ozogamicin may increase the hepatotoxic activities of Pexidartinib.,Pexidartinib
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Gemtuzumab ozogamicin.","Ebola Zaire vaccine (live, attenuated)"
DB14513,The serum concentration of Magnesium can be decreased when it is combined with Gemtuzumab ozogamicin.,Magnesium
DB01601,The serum concentration of Gemtuzumab ozogamicin can be increased when it is combined with Lopinavir.,Lopinavir
DB12530,The risk or severity of infection can be increased when Gemtuzumab ozogamicin is combined with Inebilizumab.,Inebilizumab
DB00255,Diethylstilbestrol may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Diethylstilbestrol
DB00269,Chlorotrianisene may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Chlorotrianisene
DB00286,Conjugated estrogens may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Conjugated estrogens
DB00655,Estrone may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Estrone
DB00783,Estradiol may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Estradiol
DB00890,Dienestrol may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Dienestrol
DB00977,Ethinylestradiol may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Ethinylestradiol
DB01357,Mestranol may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Mestranol
DB04573,Estriol may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Estriol
DB04574,Estrone sulfate may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Estrone sulfate
DB04575,Quinestrol may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Quinestrol
DB07931,Hexestrol may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Hexestrol
DB09070,Tibolone may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Tibolone
DB09317,"Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Indium In-111 satumomab pendetide.","Synthetic Conjugated Estrogens, A"
DB09318,"Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Indium In-111 satumomab pendetide.","Synthetic Conjugated Estrogens, B"
DB09369,Polyestradiol phosphate may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Polyestradiol phosphate
DB09381,Esterified estrogens may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Esterified estrogens
DB11478,Zeranol may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Zeranol
DB11674,Equol may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Equol
DB12487,Promestriene may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Promestriene
DB13143,Methallenestril may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Methallenestril
DB13386,Epimestrol may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Epimestrol
DB13418,Moxestrol may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Moxestrol
DB13952,Estradiol acetate may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Estradiol acetate
DB13953,Estradiol benzoate may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Estradiol benzoate
DB13954,Estradiol cypionate may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Estradiol cypionate
DB13956,Estradiol valerate may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Estradiol valerate
DB15334,Biochanin A may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Biochanin A
DB15335,Formononetin may increase the thrombogenic activities of Indium In-111 satumomab pendetide.,Formononetin
DB00002,The risk or severity of adverse effects can be increased when Cetuximab is combined with Indium In-111 satumomab pendetide.,Cetuximab
DB00028,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Indium In-111 satumomab pendetide.,Human immunoglobulin G
DB00043,The risk or severity of adverse effects can be increased when Omalizumab is combined with Indium In-111 satumomab pendetide.,Omalizumab
DB00051,The risk or severity of adverse effects can be increased when Adalimumab is combined with Indium In-111 satumomab pendetide.,Adalimumab
DB00054,The risk or severity of adverse effects can be increased when Abciximab is combined with Indium In-111 satumomab pendetide.,Abciximab
DB00056,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Indium In-111 satumomab pendetide.,Gemtuzumab ozogamicin
DB00065,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Infliximab.,Infliximab
DB00072,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Trastuzumab.,Trastuzumab
DB00073,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Rituximab.,Rituximab
DB00074,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Basiliximab.,Basiliximab
DB00075,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Muromonab.,Muromonab
DB00076,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Digoxin Immune Fab (Ovine).,Digoxin Immune Fab (Ovine)
DB00078,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ibritumomab tiuxetan.,Ibritumomab tiuxetan
DB00081,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tositumomab.,Tositumomab
DB00087,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Alemtuzumab.,Alemtuzumab
DB00089,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Capromab pendetide.,Capromab pendetide
DB00095,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Efalizumab.,Efalizumab
DB00098,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Antithymocyte immunoglobulin (rabbit).,Antithymocyte immunoglobulin (rabbit)
DB00108,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Natalizumab.,Natalizumab
DB00110,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Palivizumab.,Palivizumab
DB00111,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Daclizumab.,Daclizumab
DB00112,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bevacizumab.,Bevacizumab
DB00113,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Technetium Tc-99m arcitumomab.,Technetium Tc-99m arcitumomab
DB01257,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Eculizumab.,Eculizumab
DB01269,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Panitumumab.,Panitumumab
DB01270,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ranibizumab.,Ranibizumab
DB04901,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Galiximab.,Galiximab
DB04949,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Pexelizumab.,Pexelizumab
DB04956,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Afelimomab.,Afelimomab
DB04958,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Epratuzumab.,Epratuzumab
DB04962,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bectumomab.,Bectumomab
DB04964,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Oregovomab.,Oregovomab
DB04988,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with IGN311.,IGN311
DB05006,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Adecatumumab.,Adecatumumab
DB05097,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Labetuzumab.,Labetuzumab
DB05101,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Matuzumab.,Matuzumab
DB05111,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Fontolizumab.,Fontolizumab
DB05136,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bavituximab.,Bavituximab
DB05139,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with CR002.,CR002
DB05209,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Rozrolimupab.,Rozrolimupab
DB05304,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Girentuximab.,Girentuximab
DB05336,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Obiltoxaximab.,Obiltoxaximab
DB05405,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with XTL-001.,XTL-001
DB05437,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with NAV 1800.,NAV 1800
DB05459,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Briakinumab.,Briakinumab
DB05496,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Otelixizumab.,Otelixizumab
DB05545,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with AMG 108.,AMG 108
DB05550,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Iratumumab.,Iratumumab
DB05555,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Enokizumab.,Enokizumab
DB05578,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ramucirumab.,Ramucirumab
DB05595,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Farletuzumab.,Farletuzumab
DB05656,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Veltuzumab.,Veltuzumab
DB05679,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ustekinumab.,Ustekinumab
DB05773,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Trastuzumab emtansine.,Trastuzumab emtansine
DB05793,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with PRO-542.,PRO-542
DB05797,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with TNX-901.,TNX-901
DB05889,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Inotuzumab ozogamicin.,Inotuzumab ozogamicin
DB05892,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with RI 624.,RI 624
DB05915,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with MYO-029.,MYO-029
DB05916,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with CT-011.,CT-011
DB05941,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Leronlimab.,Leronlimab
DB05996,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Glembatumumab vedotin.,Glembatumumab vedotin
DB06043,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Olaratumab.,Olaratumab
DB06049,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with IPH 2101.,IPH 2101
DB06050,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with TB-402.,TB-402
DB06081,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Caplacizumab.,Caplacizumab
DB06101,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with IMC-1C11.,IMC-1C11
DB06116,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Eldelumab.,Eldelumab
DB06162,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Lumiliximab.,Lumiliximab
DB06168,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Canakinumab.,Canakinumab
DB06186,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ipilimumab.,Ipilimumab
DB06192,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Nimotuzumab.,Nimotuzumab
DB06241,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Clenoliximab.,Clenoliximab
DB06273,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tocilizumab.,Tocilizumab
DB06304,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with BIIB015.,BIIB015
DB06305,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Sonepcizumab.,Sonepcizumab
DB06310,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Motavizumab.,Motavizumab
DB06317,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Elotuzumab.,Elotuzumab
DB06318,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with AVE9633.,AVE9633
DB06322,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Carotuximab.,Carotuximab
DB06324,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with XmAb 2513.,XmAb 2513
DB06342,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Coltuximab ravtansine.,Coltuximab ravtansine
DB06343,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Teprotumumab.,Teprotumumab
DB06360,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Lucatumumab.,Lucatumumab
DB06366,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Pertuzumab.,Pertuzumab
DB06371,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Siplizumab.,Siplizumab
DB06467,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Apolizumab.,Apolizumab
DB06474,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Sibrotuzumab.,Sibrotuzumab
DB06550,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bivatuzumab.,Bivatuzumab
DB06557,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Lerdelimumab.,Lerdelimumab
DB06599,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Lexatumumab.,Lexatumumab
DB06602,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Reslizumab.,Reslizumab
DB06606,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Teplizumab.,Teplizumab
DB06607,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Catumaxomab.,Catumaxomab
DB06612,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Mepolizumab.,Mepolizumab
DB06643,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Denosumab.,Denosumab
DB06647,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Volociximab.,Volociximab
DB06650,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ofatumumab.,Ofatumumab
DB06674,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Golimumab.,Golimumab
DB08870,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Brentuximab vedotin.,Brentuximab vedotin
DB08879,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Belimumab.,Belimumab
DB08902,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Raxibacumab.,Raxibacumab
DB08904,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Certolizumab pegol.,Certolizumab pegol
DB08935,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Obinutuzumab.,Obinutuzumab
DB09029,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Secukinumab.,Secukinumab
DB09033,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Vedolizumab.,Vedolizumab
DB09035,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Nivolumab.,Nivolumab
DB09036,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Siltuximab.,Siltuximab
DB09037,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Pembrolizumab.,Pembrolizumab
DB09045,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Dulaglutide.,Dulaglutide
DB09052,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Blinatumomab.,Blinatumomab
DB09057,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Anthrax immune globulin human.,Anthrax immune globulin human
DB09077,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Dinutuximab.,Dinutuximab
DB09105,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Asfotase alfa.,Asfotase alfa
DB09264,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Idarucizumab.,Idarucizumab
DB09302,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Alirocumab.,Alirocumab
DB09303,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Evolocumab.,Evolocumab
DB09312,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Antilymphocyte immunoglobulin (horse).,Antilymphocyte immunoglobulin (horse)
DB09331,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Daratumumab.,Daratumumab
DB09559,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Necitumumab.,Necitumumab
DB11569,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ixekizumab.,Ixekizumab
DB11580,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ravulizumab.,Ravulizumab
DB11595,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Atezolizumab.,Atezolizumab
DB11604,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tetanus Immune Globulin.,Tetanus Immune Globulin
DB11608,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Eftrenonacog alfa.,Eftrenonacog alfa
DB11621,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Human Varicella-Zoster Immune Globulin.,Human Varicella-Zoster Immune Globulin
DB11646,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Conatumumab.,Conatumumab
DB11657,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tabalumab.,Tabalumab
DB11680,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ficlatuzumab.,Ficlatuzumab
DB11685,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Figitumumab.,Figitumumab
DB11714,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Durvalumab.,Durvalumab
DB11715,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bapineuzumab.,Bapineuzumab
DB11731,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Depatuxizumab mafodotin.,Depatuxizumab mafodotin
DB11746,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Onartuzumab.,Onartuzumab
DB11756,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Solanezumab.,Solanezumab
DB11767,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Sarilumab.,Sarilumab
DB11771,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tremelimumab.,Tremelimumab
DB11776,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Brodalumab.,Brodalumab
DB11803,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Sirukumab.,Sirukumab
DB11826,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Lampalizumab.,Lampalizumab
DB11834,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Guselkumab.,Guselkumab
DB11840,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Dalotuzumab.,Dalotuzumab
DB11849,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Emibetuzumab.,Emibetuzumab
DB11850,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ublituximab.,Ublituximab
DB11856,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ligelizumab.,Ligelizumab
DB11857,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Seribantumab.,Seribantumab
DB11862,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Landogrozumab.,Landogrozumab
DB11866,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Romosozumab.,Romosozumab
DB11884,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Vadastuximab Talirine.,Vadastuximab Talirine
DB11914,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Lebrikizumab.,Lebrikizumab
DB11930,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Varlilumab.,Varlilumab
DB11945,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Avelumab.,Avelumab
DB11959,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Crenezumab.,Crenezumab
DB11972,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Rilotumumab.,Rilotumumab
DB11976,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Anifrolumab.,Anifrolumab
DB11988,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ocrelizumab.,Ocrelizumab
DB12023,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Benralizumab.,Benralizumab
DB12034,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Gantenerumab.,Gantenerumab
DB12053,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Visilizumab.,Visilizumab
DB12077,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Urelumab.,Urelumab
DB12089,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Lorvotuzumab mertansine.,Lorvotuzumab mertansine
DB12090,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Patritumab.,Patritumab
DB12102,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Fulranumab.,Fulranumab
DB12104,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tarextumab.,Tarextumab
DB12118,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Sotatercept.,Sotatercept
DB12119,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Gevokizumab.,Gevokizumab
DB12142,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Duligotuzumab.,Duligotuzumab
DB12152,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Simtuzumab.,Simtuzumab
DB12157,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Fasinumab.,Fasinumab
DB12159,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Dupilumab.,Dupilumab
DB12169,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tralokinumab.,Tralokinumab
DB12189,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Etrolizumab.,Etrolizumab
DB12202,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Zalutumumab.,Zalutumumab
DB12205,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ganitumab.,Ganitumab
DB12213,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Etaracizumab.,Etaracizumab
DB12240,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Polatuzumab vedotin.,Polatuzumab vedotin
DB12246,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Inclacumab.,Inclacumab
DB12250,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Cixutumumab.,Cixutumumab
DB12261,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ascrinvacumab.,Ascrinvacumab
DB12274,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Aducanumab.,Aducanumab
DB12281,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Luspatercept.,Luspatercept
DB12296,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with GS-5745.,GS-5745
DB12317,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Vanucizumab.,Vanucizumab
DB12331,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Labetuzumab govitecan.,Labetuzumab govitecan
DB12335,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tanezumab.,Tanezumab
DB12342,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ensituximab.,Ensituximab
DB12344,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Fezakinumab.,Fezakinumab
DB12363,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Dusigitumab.,Dusigitumab
DB12396,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Fresolimumab.,Fresolimumab
DB12413,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Indusatumab vedotin.,Indusatumab vedotin
DB12456,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bococizumab.,Bococizumab
DB12489,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Mirvetuximab Soravtansine.,Mirvetuximab Soravtansine
DB12498,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Mogamulizumab.,Mogamulizumab
DB12520,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Plozalizumab.,Plozalizumab
DB12530,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Inebilizumab.,Inebilizumab
DB12534,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Mavrilimumab.,Mavrilimumab
DB12560,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Blosozumab.,Blosozumab
DB12584,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bimagrumab.,Bimagrumab
DB12589,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Dacetuzumab.,Dacetuzumab
DB12609,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tovetumab.,Tovetumab
DB12683,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Lumretuzumab.,Lumretuzumab
DB12698,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ibalizumab.,Ibalizumab
DB12701,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Intetumumab.,Intetumumab
DB12718,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Carlumab.,Carlumab
DB12734,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Demcizumab.,Demcizumab
DB12773,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Sifalimumab.,Sifalimumab
DB12775,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Abituzumab.,Abituzumab
DB12797,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ecromeximab.,Ecromeximab
DB12807,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Naptumomab Estafenatox.,Naptumomab Estafenatox
DB12815,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Crotedumab.,Crotedumab
DB12820,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Concizumab.,Concizumab
DB12826,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Depatuxizumab.,Depatuxizumab
DB12844,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Rontalizumab.,Rontalizumab
DB12845,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Amatuximab.,Amatuximab
DB12849,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Clazakizumab.,Clazakizumab
DB12891,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ozanezumab.,Ozanezumab
DB12893,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Sacituzumab govitecan.,Sacituzumab govitecan
DB12917,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bimekizumab.,Bimekizumab
DB12943,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Milatuzumab.,Milatuzumab
DB12976,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Robatumumab.,Robatumumab
DB13017,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Rovalpituzumab Tesirine.,Rovalpituzumab Tesirine
DB13037,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Namilumab.,Namilumab
DB13045,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Racotumomab.,Racotumomab
DB13073,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tregalizumab.,Tregalizumab
DB13127,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Olokizumab.,Olokizumab
DB13140,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bezlotoxumab.,Bezlotoxumab
DB13375,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Edrecolomab.,Edrecolomab
DB13535,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Nebacumab.,Nebacumab
DB13886,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Human cytomegalovirus immune globulin.,Human cytomegalovirus immune globulin
DB13923,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Emicizumab.,Emicizumab
DB13976,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Sulesomab.,Sulesomab
DB13979,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Besilesomab.,Besilesomab
DB14004,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tildrakizumab.,Tildrakizumab
DB14012,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Burosumab.,Burosumab
DB14039,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Erenumab.,Erenumab
DB14040,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Eptinezumab.,Eptinezumab
DB14041,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Fremanezumab.,Fremanezumab
DB14042,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Galcanezumab.,Galcanezumab
DB14211,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Fanolesomab.,Fanolesomab
DB14580,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Lecanemab.,Lecanemab
DB14597,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Lanadelumab.,Lanadelumab
DB14707,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Cemiplimab.,Cemiplimab
DB14724,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Emapalumab.,Emapalumab
DB14762,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Risankizumab.,Risankizumab
DB14776,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Camrelizumab.,Camrelizumab
DB14778,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Setrusumab.,Setrusumab
DB14784,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Gancotamab.,Gancotamab
DB14809,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Anetumab ravtansine.,Anetumab ravtansine
DB14811,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Isatuximab.,Isatuximab
DB14824,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Icrucumab.,Icrucumab
DB14843,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Codrituzumab.,Codrituzumab
DB14864,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Brolucizumab.,Brolucizumab
DB14871,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Xentuzumab.,Xentuzumab
DB14877,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Lintuzumab.,Lintuzumab
DB14891,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Vobarilizumab.,Vobarilizumab
DB14897,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Parsatuzumab.,Parsatuzumab
DB14905,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Emactuzumab.,Emactuzumab
DB14907,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bevacizumab zirconium Zr-89.,Bevacizumab zirconium Zr-89
DB14908,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Refanezumab.,Refanezumab
DB14919,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Rozanolixizumab.,Rozanolixizumab
DB14947,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bermekimab.,Bermekimab
DB14952,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Pamrevlumab.,Pamrevlumab
DB14959,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Opicinumab.,Opicinumab
DB14962,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Trastuzumab deruxtecan.,Trastuzumab deruxtecan
DB14967,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Margetuximab.,Margetuximab
DB14988,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Dalantercept.,Dalantercept
DB14997,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Pateclizumab.,Pateclizumab
DB15014,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Gremubamab.,Gremubamab
DB15022,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Apomab.,Apomab
DB15044,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tafasitamab.,Tafasitamab
DB15045,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ipafricept.,Ipafricept
DB15076,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Abrilumab.,Abrilumab
DB15089,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Frovocimab.,Frovocimab
DB15090,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tezepelumab.,Tezepelumab
DB15101,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tigatuzumab.,Tigatuzumab
DB15104,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Telisotuzumab vedotin.,Telisotuzumab vedotin
DB15113,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Utomilumab.,Utomilumab
DB15118,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Zolbetuximab.,Zolbetuximab
DB15135,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ponezumab.,Ponezumab
DB15160,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Asunercept.,Asunercept
DB15172,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Suvratoxumab.,Suvratoxumab
DB15225,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Mitazalimab.,Mitazalimab
DB15252,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Nemolizumab.,Nemolizumab
DB15253,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bleselumab.,Bleselumab
DB15277,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Gedivumab.,Gedivumab
DB15336,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Valanafusp alfa.,Valanafusp alfa
DB15349,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Sofituzumab vedotin.,Sofituzumab vedotin
DB15354,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Evinacumab.,Evinacumab
DB15363,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Istiratumab.,Istiratumab
DB15383,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Pidilizumab.,Pidilizumab
DB15397,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with GMA-161.,GMA-161
DB15409,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ladiratuzumab vedotin.,Ladiratuzumab vedotin
DB15415,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tomaralimab.,Tomaralimab
DB15428,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Vesencumab.,Vesencumab
DB15432,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Pinatuzumab vedotin.,Pinatuzumab vedotin
DB15441,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Lulizumab pegol.,Lulizumab pegol
DB15443,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Lorukafusp alfa.,Lorukafusp alfa
DB15453,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Naratuximab emtansine.,Naratuximab emtansine
DB15559,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Zenocutuzumab.,Zenocutuzumab
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Indium In-111 satumomab pendetide.","Ebola Zaire vaccine (live, attenuated)"
DB00170,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Menadione.,Menadione
DB00302,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Tranexamic acid.,Tranexamic acid
DB00513,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Aminocaproic acid.,Aminocaproic acid
DB06692,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Aprotinin.,Aprotinin
DB11091,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Hydrogen peroxide.,Hydrogen peroxide
DB13244,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Aminomethylbenzoic acid.,Aminomethylbenzoic acid
DB13729,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Camostat.,Camostat
DB09222,The therapeutic efficacy of Fibrinogen human can be increased when used in combination with Alpha-1-proteinase inhibitor.,Fibrinogen human
DB00755,The risk or severity of Thrombosis can be increased when Tretinoin is combined with Alpha-1-proteinase inhibitor.,Tretinoin
DB00025,"Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Antihemophilic factor, human recombinant.","Antihemophilic factor, human recombinant"
DB00036,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Coagulation factor VIIa Recombinant Human.,Coagulation factor VIIa Recombinant Human
DB00100,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Coagulation Factor IX (Recombinant).,Coagulation Factor IX (Recombinant)
DB00258,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Calcium acetate.,Calcium acetate
DB01164,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Calcium chloride.,Calcium chloride
DB01373,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Calcium.,Calcium
DB01783,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Pantothenic acid.,Pantothenic acid
DB01942,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Formic acid.,Formic acid
DB02261,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Platelet Activating Factor.,Platelet Activating Factor
DB06724,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Calcium carbonate.,Calcium carbonate
DB09109,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Turoctocog alfa.,Turoctocog alfa
DB09310,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Catridecacog.,Catridecacog
DB09329,"Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Antihemophilic Factor (Recombinant), PEGylated.","Antihemophilic Factor (Recombinant), PEGylated"
DB11093,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Calcium citrate.,Calcium citrate
DB11126,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Calcium gluconate.,Calcium gluconate
DB11168,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Calcium threonate.,Calcium threonate
DB11311,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Prothrombin.,Prothrombin
DB11330,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Factor IX Complex (Human).,Factor IX Complex (Human)
DB11348,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Calcium Phosphate.,Calcium Phosphate
DB11606,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Susoctocog alfa.,Susoctocog alfa
DB11608,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Eftrenonacog alfa.,Eftrenonacog alfa
DB11668,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Rusalatide acetate.,Rusalatide acetate
DB12409,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Vatreptacog alfa.,Vatreptacog alfa
DB12909,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Factor XIII (human).,Factor XIII (human)
DB13133,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Von Willebrand Factor Human.,Von Willebrand Factor Human
DB13148,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Coagulation factor X human.,Coagulation factor X human
DB13150,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Coagulation factor VII human.,Coagulation factor VII human
DB13151,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Anti-inhibitor coagulant complex.,Anti-inhibitor coagulant complex
DB13152,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Coagulation Factor IX Human.,Coagulation Factor IX Human
DB13192,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Antihemophilic factor human.,Antihemophilic factor human
DB13197,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Kallidinogenase.,Kallidinogenase
DB13201,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Trenonacog alfa.,Trenonacog alfa
DB13884,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Albutrepenonacog alfa.,Albutrepenonacog alfa
DB13923,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Emicizumab.,Emicizumab
DB13933,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Nonacog beta pegol.,Nonacog beta pegol
DB13999,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Moroctocog alfa.,Moroctocog alfa
DB14473,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Beroctocog alfa.,Beroctocog alfa
DB14562,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Andexanet alfa.,Andexanet alfa
DB14577,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Calcium cation.,Calcium cation
DB14700,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Damoctocog alfa pegol.,Damoctocog alfa pegol
DB14738,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Turoctocog alfa pegol.,Turoctocog alfa pegol
DB06643,The risk or severity of adverse effects can be increased when Denosumab is combined with Pegaspargase.,Denosumab
DB00005,The risk or severity of adverse effects can be increased when Etanercept is combined with Pegaspargase.,Etanercept
DB00008,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Pegaspargase.,Peginterferon alfa-2a
DB00011,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Pegaspargase.,Interferon alfa-n1
DB00018,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Pegaspargase.,Interferon alfa-n3
DB00022,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Pegaspargase.,Peginterferon alfa-2b
DB00026,The risk or severity of adverse effects can be increased when Anakinra is combined with Pegaspargase.,Anakinra
DB00033,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Pegaspargase.,Interferon gamma-1b
DB00034,"The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Pegaspargase.","Interferon alfa-2a, Recombinant"
DB00041,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Pegaspargase.,Aldesleukin
DB00051,The risk or severity of adverse effects can be increased when Adalimumab is combined with Pegaspargase.,Adalimumab
DB00056,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pegaspargase.,Gemtuzumab ozogamicin
DB00065,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Infliximab.,Infliximab
DB00068,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Interferon beta-1b.,Interferon beta-1b
DB00069,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Interferon alfacon-1.,Interferon alfacon-1
DB00073,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Rituximab.,Rituximab
DB00074,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Basiliximab.,Basiliximab
DB00075,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Muromonab.,Muromonab
DB00078,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ibritumomab tiuxetan.,Ibritumomab tiuxetan
DB00081,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Tositumomab.,Tositumomab
DB00087,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Alemtuzumab.,Alemtuzumab
DB00092,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Alefacept.,Alefacept
DB00095,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Efalizumab.,Efalizumab
DB00098,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Antithymocyte immunoglobulin (rabbit).,Antithymocyte immunoglobulin (rabbit)
DB00105,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Interferon alfa-2b.,Interferon alfa-2b
DB00111,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Daclizumab.,Daclizumab
DB00112,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Bevacizumab.,Bevacizumab
DB00120,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Phenylalanine.,Phenylalanine
DB00180,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Flunisolide.,Flunisolide
DB00188,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Bortezomib.,Bortezomib
DB00242,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Cladribine.,Cladribine
DB00262,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Carmustine.,Carmustine
DB00276,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Amsacrine.,Amsacrine
DB00290,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Bleomycin.,Bleomycin
DB00291,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Chlorambucil.,Chlorambucil
DB00293,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Raltitrexed.,Raltitrexed
DB00305,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Mitomycin.,Mitomycin
DB00307,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Bexarotene.,Bexarotene
DB00309,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Vindesine.,Vindesine
DB00322,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Floxuridine.,Floxuridine
DB00328,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Indomethacin.,Indomethacin
DB00352,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Tioguanine.,Tioguanine
DB00361,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Vinorelbine.,Vinorelbine
DB00380,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Dexrazoxane.,Dexrazoxane
DB00394,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Beclomethasone dipropionate.,Beclomethasone dipropionate
DB00398,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Sorafenib.,Sorafenib
DB00428,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Streptozocin.,Streptozocin
DB00432,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Trifluridine.,Trifluridine
DB00441,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Gemcitabine.,Gemcitabine
DB00443,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Betamethasone.,Betamethasone
DB00444,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Teniposide.,Teniposide
DB00445,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Epirubicin.,Epirubicin
DB00446,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Chloramphenicol.,Chloramphenicol
DB00480,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Lenalidomide.,Lenalidomide
DB00488,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Altretamine.,Altretamine
DB00495,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Zidovudine.,Zidovudine
DB00515,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Cisplatin.,Cisplatin
DB00526,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Oxaliplatin.,Oxaliplatin
DB00531,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Cyclophosphamide.,Cyclophosphamide
DB00541,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Vincristine.,Vincristine
DB00544,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fluorouracil.,Fluorouracil
DB00550,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Propylthiouracil.,Propylthiouracil
DB00552,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Pentostatin.,Pentostatin
DB00564,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Carbamazepine.,Carbamazepine
DB00570,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Vinblastine.,Vinblastine
DB00588,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fluticasone propionate.,Fluticasone propionate
DB00591,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fluocinolone acetonide.,Fluocinolone acetonide
DB00601,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Linezolid.,Linezolid
DB00620,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Triamcinolone.,Triamcinolone
DB00631,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Clofarabine.,Clofarabine
DB00635,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Prednisone.,Prednisone
DB00642,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Pemetrexed.,Pemetrexed
DB00687,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fludrocortisone.,Fludrocortisone
DB00688,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Mycophenolate mofetil.,Mycophenolate mofetil
DB00694,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Daunorubicin.,Daunorubicin
DB00755,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Tretinoin.,Tretinoin
DB00762,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Irinotecan.,Irinotecan
DB00763,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Methimazole.,Methimazole
DB00764,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Mometasone.,Mometasone
DB00773,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Etoposide.,Etoposide
DB00795,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Sulfasalazine.,Sulfasalazine
DB00851,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Dacarbazine.,Dacarbazine
DB00853,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Temozolomide.,Temozolomide
DB00859,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Penicillamine.,Penicillamine
DB00860,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Prednisolone.,Prednisolone
DB00877,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Sirolimus.,Sirolimus
DB00888,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Mechlorethamine.,Mechlorethamine
DB00928,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Azacitidine.,Azacitidine
DB00958,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Carboplatin.,Carboplatin
DB00959,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Methylprednisolone.,Methylprednisolone
DB00970,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Dactinomycin.,Dactinomycin
DB00987,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Cytarabine.,Cytarabine
DB00993,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Azathioprine.,Azathioprine
DB00997,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Doxorubicin.,Doxorubicin
DB01005,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Hydroxyurea.,Hydroxyurea
DB01008,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Busulfan.,Busulfan
DB01024,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Mycophenolic acid.,Mycophenolic acid
DB01030,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Topotecan.,Topotecan
DB01033,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Mercaptopurine.,Mercaptopurine
DB01041,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Thalidomide.,Thalidomide
DB01042,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Melphalan.,Melphalan
DB01073,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fludarabine.,Fludarabine
DB01099,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Flucytosine.,Flucytosine
DB01101,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Capecitabine.,Capecitabine
DB01108,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Trilostane.,Trilostane
DB01168,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Procarbazine.,Procarbazine
DB01169,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Arsenic trioxide.,Arsenic trioxide
DB01177,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Idarubicin.,Idarubicin
DB01181,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ifosfamide.,Ifosfamide
DB01196,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Estramustine.,Estramustine
DB01204,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Mitoxantrone.,Mitoxantrone
DB01206,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Lomustine.,Lomustine
DB01222,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Budesonide.,Budesonide
DB01229,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Paclitaxel.,Paclitaxel
DB01248,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Docetaxel.,Docetaxel
DB01254,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Dasatinib.,Dasatinib
DB01257,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Eculizumab.,Eculizumab
DB01262,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Decitabine.,Decitabine
DB01268,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Sunitinib.,Sunitinib
DB01280,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Nelarabine.,Nelarabine
DB01281,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Abatacept.,Abatacept
DB01285,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Corticotropin.,Corticotropin
DB01380,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Cortisone acetate.,Cortisone acetate
DB01384,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Paramethasone.,Paramethasone
DB01394,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Colchicine.,Colchicine
DB01410,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ciclesonide.,Ciclesonide
DB01423,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Stepronin.,Stepronin
DB01590,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Everolimus.,Everolimus
DB01611,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Hydroxychloroquine.,Hydroxychloroquine
DB01816,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Castanospermine.,Castanospermine
DB02546,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Vorinostat.,Vorinostat
DB02806,The risk or severity of adverse effects can be increased when Pegaspargase is combined with 2-Methoxyethanol.,2-Methoxyethanol
DB03523,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Brequinar.,Brequinar
DB04572,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Thiotepa.,Thiotepa
DB04630,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Aldosterone.,Aldosterone
DB04845,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ixabepilone.,Ixabepilone
DB04868,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Nilotinib.,Nilotinib
DB04951,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Pirfenidone.,Pirfenidone
DB04956,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Afelimomab.,Afelimomab
DB05015,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Belinostat.,Belinostat
DB05109,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Trabectedin.,Trabectedin
DB05258,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Interferon alfa.,Interferon alfa
DB05259,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Glatiramer.,Glatiramer
DB05260,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Gallium nitrate.,Gallium nitrate
DB05459,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Briakinumab.,Briakinumab
DB05472,The risk or severity of adverse effects can be increased when Pegaspargase is combined with omega interferon.,omega interferon
DB05676,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Apremilast.,Apremilast
DB05773,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Trastuzumab emtansine.,Trastuzumab emtansine
DB06168,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Canakinumab.,Canakinumab
DB06273,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Tocilizumab.,Tocilizumab
DB06287,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Temsirolimus.,Temsirolimus
DB06372,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Rilonacept.,Rilonacept
DB06589,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Pazopanib.,Pazopanib
DB06603,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Panobinostat.,Panobinostat
DB06612,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Mepolizumab.,Mepolizumab
DB06616,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Bosutinib.,Bosutinib
DB06662,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Abetimus.,Abetimus
DB06674,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Golimumab.,Golimumab
DB06681,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Belatacept.,Belatacept
DB06769,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Bendamustine.,Bendamustine
DB06772,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Cabazitaxel.,Cabazitaxel
DB06813,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Pralatrexate.,Pralatrexate
DB08059,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Wortmannin.,Wortmannin
DB08870,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Brentuximab vedotin.,Brentuximab vedotin
DB08871,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Eribulin.,Eribulin
DB08877,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ruxolitinib.,Ruxolitinib
DB08879,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Belimumab.,Belimumab
DB08880,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Teriflunomide.,Teriflunomide
DB08889,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Carfilzomib.,Carfilzomib
DB08901,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ponatinib.,Ponatinib
DB08904,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Certolizumab pegol.,Certolizumab pegol
DB08906,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fluticasone furoate.,Fluticasone furoate
DB08908,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Dimethyl fumarate.,Dimethyl fumarate
DB08910,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Pomalidomide.,Pomalidomide
DB08935,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Obinutuzumab.,Obinutuzumab
DB08970,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fluprednidene.,Fluprednidene
DB08971,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fluocortolone.,Fluocortolone
DB09029,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Secukinumab.,Secukinumab
DB09033,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Vedolizumab.,Vedolizumab
DB09036,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Siltuximab.,Siltuximab
DB09052,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Blinatumomab.,Blinatumomab
DB09053,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ibrutinib.,Ibrutinib
DB09054,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Idelalisib.,Idelalisib
DB09073,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Palbociclib.,Palbociclib
DB09074,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Olaparib.,Olaparib
DB09077,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Dinutuximab.,Dinutuximab
DB09082,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Vilanterol.,Vilanterol
DB09091,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Tixocortol.,Tixocortol
DB09122,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Peginterferon beta-1a.,Peginterferon beta-1a
DB09312,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Antilymphocyte immunoglobulin (horse).,Antilymphocyte immunoglobulin (horse)
DB09378,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fluprednisolone.,Fluprednisolone
DB09383,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Meprednisone.,Meprednisone
DB11466,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Tepoxalin.,Tepoxalin
DB11487,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Dexamethasone isonicotinate.,Dexamethasone isonicotinate
DB11529,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Melengestrol.,Melengestrol
DB11569,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ixekizumab.,Ixekizumab
DB11580,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ravulizumab.,Ravulizumab
DB11616,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Pirarubicin.,Pirarubicin
DB11693,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Voclosporin.,Voclosporin
DB11708,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Peficitinib.,Peficitinib
DB11750,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Clobetasol.,Clobetasol
DB11767,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Sarilumab.,Sarilumab
DB11776,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Brodalumab.,Brodalumab
DB11803,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Sirukumab.,Sirukumab
DB11817,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Baricitinib.,Baricitinib
DB11834,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Guselkumab.,Guselkumab
DB11921,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Deflazacort.,Deflazacort
DB12025,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Triptolide.,Triptolide
DB12371,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Siponimod.,Siponimod
DB12612,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ozanimod.,Ozanimod
DB12617,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Mizoribine.,Mizoribine
DB12692,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Gusperimus.,Gusperimus
DB12814,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Cepeginterferon alfa-2B.,Cepeginterferon alfa-2B
DB12902,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Trofosfamide.,Trofosfamide
DB12947,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Doxifluridine.,Doxifluridine
DB12991,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Deoxyspergualin.,Deoxyspergualin
DB12996,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Acteoside.,Acteoside
DB13003,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Cortivazol.,Cortivazol
DB13014,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Hypericin.,Hypericin
DB13068,The risk or severity of adverse effects can be increased when Pegaspargase is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.,9-(N-methyl-L-isoleucine)-cyclosporin A
DB13208,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Prednylidene.,Prednylidene
DB13223,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fluocortin.,Fluocortin
DB13241,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Begelomab.,Begelomab
DB13491,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fluperolone.,Fluperolone
DB13664,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Formocortal.,Formocortal
DB13728,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Halometasone.,Halometasone
DB13843,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Cloprednol.,Cloprednol
DB13856,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fluclorolone.,Fluclorolone
DB13867,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fluticasone.,Fluticasone
DB14066,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Tetrandrine.,Tetrandrine
DB14219,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Monomethyl fumarate.,Monomethyl fumarate
DB14512,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Mometasone furoate.,Mometasone furoate
DB14538,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Hydrocortisone aceponate.,Hydrocortisone aceponate
DB14539,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Hydrocortisone acetate.,Hydrocortisone acetate
DB14545,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Hydrocortisone succinate.,Hydrocortisone succinate
DB14724,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Emapalumab.,Emapalumab
DB14762,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Risankizumab.,Risankizumab
DB14919,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Rozanolixizumab.,Rozanolixizumab
DB15253,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Bleselumab.,Bleselumab
DB00108,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Natalizumab.,Natalizumab
DB00337,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pegaspargase.,Pimecrolimus
DB01656,Roflumilast may increase the immunosuppressive activities of Pegaspargase.,Roflumilast
DB06688,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pegaspargase.,Sipuleucel-T
DB08894,The risk or severity of Thrombosis can be increased when Pegaspargase is combined with Peginesatide.,Peginesatide
DB09107,The risk or severity of Thrombosis can be increased when Pegaspargase is combined with Methoxy polyethylene glycol-epoetin beta.,Methoxy polyethylene glycol-epoetin beta
DB00012,The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pegaspargase.,Darbepoetin alfa
DB00016,The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Pegaspargase.,Erythropoietin
DB01015,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Pegaspargase.,Sulfamethoxazole
DB01097,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Leflunomide.,Leflunomide
DB08895,Pegaspargase may increase the immunosuppressive activities of Tofacitinib.,Tofacitinib
DB00072,Trastuzumab may increase the neutropenic activities of Pegaspargase.,Trastuzumab
DB00019,The therapeutic efficacy of Pegaspargase can be decreased when used in combination with Pegfilgrastim.,Pegfilgrastim
DB00061,The therapeutic efficacy of Pegademase can be decreased when used in combination with Pegaspargase.,Pegademase
DB00082,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pegaspargase.,Pegvisomant
DB01839,The therapeutic efficacy of Propylene glycol can be decreased when used in combination with Pegaspargase.,Propylene glycol
DB03394,The therapeutic efficacy of Heptaethylene glycol can be decreased when used in combination with Pegaspargase.,Heptaethylene glycol
DB04895,The therapeutic efficacy of Pegaptanib can be decreased when used in combination with Pegaspargase.,Pegaptanib
DB05202,The therapeutic efficacy of Egaptivon pegol can be decreased when used in combination with Pegaspargase.,Egaptivon pegol
DB05321,The therapeutic efficacy of PEG-uricase can be decreased when used in combination with Pegaspargase.,PEG-uricase
DB05860,The therapeutic efficacy of Peginterferon alfacon-1 can be decreased when used in combination with Pegaspargase.,Peginterferon alfacon-1
DB06022,The therapeutic efficacy of GlycoPEG-GCSF can be decreased when used in combination with Pegaspargase.,GlycoPEG-GCSF
DB06293,The therapeutic efficacy of Pegnivacogin can be decreased when used in combination with Pegaspargase.,Pegnivacogin
DB06325,The therapeutic efficacy of Pegpleranib can be decreased when used in combination with Pegaspargase.,Pegpleranib
DB06611,The therapeutic efficacy of Pegsunercept can be decreased when used in combination with Pegaspargase.,Pegsunercept
DB06811,The therapeutic efficacy of Polidocanol can be decreased when used in combination with Pegaspargase.,Polidocanol
DB09208,The therapeutic efficacy of Pegloticase can be decreased when used in combination with Pegaspargase.,Pegloticase
DB09287,The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pegaspargase.,Polyethylene glycol
DB09329,"The therapeutic efficacy of Antihemophilic Factor (Recombinant), PEGylated can be decreased when used in combination with Pegaspargase.","Antihemophilic Factor (Recombinant), PEGylated"
DB11077,The therapeutic efficacy of Polyethylene glycol 400 can be decreased when used in combination with Pegaspargase.,Polyethylene glycol 400
DB11567,The therapeutic efficacy of Insulin peglispro can be decreased when used in combination with Pegaspargase.,Insulin peglispro
DB11661,The therapeutic efficacy of Eptacog alfa pegol (activated) can be decreased when used in combination with Pegaspargase.,Eptacog alfa pegol (activated)
DB11707,The therapeutic efficacy of Olaptesed Pegol can be decreased when used in combination with Pegaspargase.,Olaptesed Pegol
DB12258,The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Pegaspargase.,Abicipar Pegol
DB12578,The therapeutic efficacy of Lexaptepid Pegol can be decreased when used in combination with Pegaspargase.,Lexaptepid Pegol
DB12839,The therapeutic efficacy of Pegvaliase can be decreased when used in combination with Pegaspargase.,Pegvaliase
DB12842,The therapeutic efficacy of Pegamotecan can be decreased when used in combination with Pegaspargase.,Pegamotecan
DB13200,The therapeutic efficacy of Lipegfilgrastim can be decreased when used in combination with Pegaspargase.,Lipegfilgrastim
DB13933,The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Pegaspargase.,Nonacog beta pegol
DB14700,The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Pegaspargase.,Damoctocog alfa pegol
DB14712,The therapeutic efficacy of Elapegademase can be decreased when used in combination with Pegaspargase.,Elapegademase
DB08868,Pegaspargase may increase the immunosuppressive activities of Fingolimod.,Fingolimod
DB00864,Tacrolimus may increase the immunosuppressive activities of Pegaspargase.,Tacrolimus
DB01234,The serum concentration of Dexamethasone can be increased when it is combined with Pegaspargase.,Dexamethasone
DB04914,The therapeutic efficacy of G17DT can be decreased when used in combination with Pegaspargase.,G17DT
DB05144,The therapeutic efficacy of PEV3A can be decreased when used in combination with Pegaspargase.,PEV3A
DB05325,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Pegaspargase.,INGN 225
DB05374,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Pegaspargase.,Rindopepimut
DB05440,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Pegaspargase.,SRP 299
DB05942,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Pegaspargase.,GI-5005
DB06400,The therapeutic efficacy of Vitespen can be decreased when used in combination with Pegaspargase.,Vitespen
DB06584,The therapeutic efficacy of TG4010 can be decreased when used in combination with Pegaspargase.,TG4010
DB09057,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Pegaspargase.,Anthrax immune globulin human
DB10062,"The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Pegaspargase.","Rabies virus inactivated antigen, B"
DB10076,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Pegaspargase.,Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen
DB10276,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Pegaspargase.,Rotavirus vaccine
DB10283,"The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Pegaspargase.","Rabies virus inactivated antigen, A"
DB10342,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Pegaspargase.,Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen
DB10583,The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Pegaspargase.,Clostridium tetani toxoid antigen (formaldehyde inactivated)
DB10584,The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Pegaspargase.,Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
DB10600,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Pegaspargase.,Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated)
DB10769,The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Pegaspargase.,Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)
DB10794,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Pegaspargase.,Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated)
DB10803,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Pegaspargase.,Typhoid Vi polysaccharide vaccine
DB10989,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Pegaspargase.,Hepatitis A Vaccine
DB10990,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Pegaspargase.,Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
DB11038,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Pegaspargase.,Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated)
DB11040,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Pegaspargase.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated)
DB11041,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Pegaspargase.,Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)
DB11044,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Pegaspargase.,Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated)
DB11603,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Pegaspargase.,Human rabies virus immune globulin
DB11627,The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Pegaspargase.,Hepatitis B Vaccine (Recombinant)
DB12568,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Pegaspargase.,Tecemotide
DB14022,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Pegaspargase.,Typhoid vaccine
DB14384,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Pegaspargase.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated)
DB14385,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Pegaspargase.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)
DB14394,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Pegaspargase.,Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen
DB14445,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Pegaspargase.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated)
DB14449,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Pegaspargase.,Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen
DB14619,The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Pegaspargase.,Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated)
DB14620,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Pegaspargase.,Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated)
DB14711,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Pegaspargase.,Vaccinia virus strain new york city board of health live antigen
DB15274,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Pegaspargase.,Pertussis vaccine
DB15461,The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Pegaspargase.,Yersinia pestis 195/p antigen (formaldehyde inactivated)
DB13924,The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Pegaspargase.,Varicella Zoster Vaccine (Recombinant)
DB15483,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Pegaspargase.,Modified vaccinia ankara
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Pegaspargase.","Ebola Zaire vaccine (live, attenuated)"
DB11988,Ocrelizumab may increase the immunosuppressive activities of Pegaspargase.,Ocrelizumab
DB10317,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Pegaspargase.,Rubella virus vaccine
DB10318,The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Pegaspargase.,Varicella Zoster Vaccine (Live/attenuated)
DB10343,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Pegaspargase.,Bacillus calmette-guerin substrain tice live antigen
DB10804,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Pegaspargase.,Bacillus calmette-guerin substrain connaught live antigen
DB10805,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Pegaspargase.,Yellow Fever Vaccine
DB11003,The risk or severity of infection can be increased when Anthrax vaccine is combined with Pegaspargase.,Anthrax vaccine
DB11050,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Pegaspargase.,Typhoid Vaccine Live
DB12386,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Pegaspargase.,Bacillus calmette-guerin substrain danish 1331 live antigen
DB12768,The risk or severity of infection can be increased when BCG vaccine is combined with Pegaspargase.,BCG vaccine
DB14409,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Pegaspargase.,Human adenovirus e serotype 4 strain cl-68578 antigen
DB14443,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Pegaspargase.,Vibrio cholerae CVD 103-HgR strain live antigen
DB14685,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Pegaspargase.,Adenovirus type 7 vaccine live
DB00563,The therapeutic efficacy of Methotrexate can be decreased when used in combination with Pegaspargase.,Methotrexate
DB00619,The risk or severity of liver damage can be increased when Pegaspargase is combined with Imatinib.,Imatinib
DB00091,Pegaspargase may increase the immunosuppressive activities of Cyclosporine.,Cyclosporine
DB00252,The therapeutic efficacy of Phenytoin can be increased when used in combination with Pegaspargase.,Phenytoin
DB00279,The therapeutic efficacy of Liothyronine can be increased when used in combination with Pegaspargase.,Liothyronine
DB00451,The therapeutic efficacy of Levothyroxine can be increased when used in combination with Pegaspargase.,Levothyroxine
DB00532,The therapeutic efficacy of Mephenytoin can be increased when used in combination with Pegaspargase.,Mephenytoin
DB00695,The therapeutic efficacy of Furosemide can be increased when used in combination with Pegaspargase.,Furosemide
DB00698,The therapeutic efficacy of Nitrofurantoin can be increased when used in combination with Pegaspargase.,Nitrofurantoin
DB00754,The therapeutic efficacy of Ethotoin can be increased when used in combination with Pegaspargase.,Ethotoin
DB00939,The therapeutic efficacy of Meclofenamic acid can be increased when used in combination with Pegaspargase.,Meclofenamic acid
DB01109,The therapeutic efficacy of Heparin can be increased when used in combination with Pegaspargase.,Heparin
DB01219,The therapeutic efficacy of Dantrolene can be increased when used in combination with Pegaspargase.,Dantrolene
DB01320,The therapeutic efficacy of Fosphenytoin can be increased when used in combination with Pegaspargase.,Fosphenytoin
DB01583,The therapeutic efficacy of Liotrix can be increased when used in combination with Pegaspargase.,Liotrix
DB08899,The therapeutic efficacy of Enzalutamide can be increased when used in combination with Pegaspargase.,Enzalutamide
DB08984,The therapeutic efficacy of Etofenamate can be increased when used in combination with Pegaspargase.,Etofenamate
DB12425,The therapeutic efficacy of Liothyronine I-131 can be increased when used in combination with Pegaspargase.,Liothyronine I-131
DB13396,The therapeutic efficacy of Neocitrullamon can be increased when used in combination with Pegaspargase.,Neocitrullamon
DB14513,The serum concentration of Magnesium can be decreased when it is combined with Pegaspargase.,Magnesium
DB01601,The serum concentration of Pegaspargase can be increased when it is combined with Lopinavir.,Lopinavir
DB12530,The risk or severity of infection can be increased when Pegaspargase is combined with Inebilizumab.,Inebilizumab
DB00315,The metabolism of Zolmitriptan can be decreased when combined with Interferon beta-1a.,Zolmitriptan
DB00201,The metabolism of Caffeine can be decreased when combined with Interferon beta-1a.,Caffeine
DB00651,The metabolism of Dyphylline can be decreased when combined with Interferon beta-1a.,Dyphylline
DB00806,The metabolism of Pentoxifylline can be decreased when combined with Interferon beta-1a.,Pentoxifylline
DB01033,The metabolism of Mercaptopurine can be decreased when combined with Interferon beta-1a.,Mercaptopurine
DB01303,The metabolism of Oxtriphylline can be decreased when combined with Interferon beta-1a.,Oxtriphylline
DB01412,The metabolism of Theobromine can be decreased when combined with Interferon beta-1a.,Theobromine
DB01482,The metabolism of Fenethylline can be decreased when combined with Interferon beta-1a.,Fenethylline
DB01667,The metabolism of 8-azaguanine can be decreased when combined with Interferon beta-1a.,8-azaguanine
DB01978,"The metabolism of 7,9-Dimethylguanine can be decreased when combined with Interferon beta-1a.","7,9-Dimethylguanine"
DB02134,The metabolism of Xanthine can be decreased when combined with Interferon beta-1a.,Xanthine
DB02245,The metabolism of 7-Deazaguanine can be decreased when combined with Interferon beta-1a.,7-Deazaguanine
DB02377,The metabolism of Guanine can be decreased when combined with Interferon beta-1a.,Guanine
DB02489,The metabolism of 9-Methylguanine can be decreased when combined with Interferon beta-1a.,9-Methylguanine
DB02568,The metabolism of Peldesine can be decreased when combined with Interferon beta-1a.,Peldesine
DB04076,The metabolism of Hypoxanthine can be decreased when combined with Interferon beta-1a.,Hypoxanthine
DB04356,The metabolism of 9-Deazaguanine can be decreased when combined with Interferon beta-1a.,9-Deazaguanine
DB06479,The metabolism of Propentofylline can be decreased when combined with Interferon beta-1a.,Propentofylline
DB06575,The metabolism of Valomaciclovir can be decreased when combined with Interferon beta-1a.,Valomaciclovir
DB07954,The metabolism of 3-isobutyl-1-methyl-7H-xanthine can be decreased when combined with Interferon beta-1a.,3-isobutyl-1-methyl-7H-xanthine
DB08844,The metabolism of Uric acid can be decreased when combined with Interferon beta-1a.,Uric acid
DB09273,The metabolism of Doxofylline can be decreased when combined with Interferon beta-1a.,Doxofylline
DB11919,The metabolism of 6-O-benzylguanine can be decreased when combined with Interferon beta-1a.,6-O-benzylguanine
DB12406,The metabolism of Lisofylline can be decreased when combined with Interferon beta-1a.,Lisofylline
DB12531,The metabolism of Lobucavir can be decreased when combined with Interferon beta-1a.,Lobucavir
DB12926,The metabolism of Cafedrine can be decreased when combined with Interferon beta-1a.,Cafedrine
DB12927,The metabolism of Theodrenaline can be decreased when combined with Interferon beta-1a.,Theodrenaline
DB13203,The metabolism of Bamifylline can be decreased when combined with Interferon beta-1a.,Bamifylline
DB13449,The metabolism of Proxyphylline can be decreased when combined with Interferon beta-1a.,Proxyphylline
DB13573,The metabolism of Acefylline can be decreased when combined with Interferon beta-1a.,Acefylline
DB13592,The metabolism of Etamiphylline can be decreased when combined with Interferon beta-1a.,Etamiphylline
DB13634,The metabolism of Pentifylline can be decreased when combined with Interferon beta-1a.,Pentifylline
DB13812,The metabolism of Bufylline can be decreased when combined with Interferon beta-1a.,Bufylline
DB14018,The metabolism of Bromotheophylline can be decreased when combined with Interferon beta-1a.,Bromotheophylline
DB14029,The metabolism of Furafylline can be decreased when combined with Interferon beta-1a.,Furafylline
DB14132,The metabolism of 8-chlorotheophylline can be decreased when combined with Interferon beta-1a.,8-chlorotheophylline
DB15122,The metabolism of PCS-499 can be decreased when combined with Interferon beta-1a.,PCS-499
DB00176,The metabolism of Fluvoxamine can be decreased when combined with Interferon beta-1a.,Fluvoxamine
DB00184,The metabolism of Nicotine can be decreased when combined with Interferon beta-1a.,Nicotine
DB00188,The metabolism of Bortezomib can be decreased when combined with Interferon beta-1a.,Bortezomib
DB00195,The metabolism of Betaxolol can be decreased when combined with Interferon beta-1a.,Betaxolol
DB00261,The metabolism of Anagrelide can be decreased when combined with Interferon beta-1a.,Anagrelide
DB00262,The metabolism of Carmustine can be decreased when combined with Interferon beta-1a.,Carmustine
DB00280,The metabolism of Disopyramide can be decreased when combined with Interferon beta-1a.,Disopyramide
DB00281,The metabolism of Lidocaine can be decreased when combined with Interferon beta-1a.,Lidocaine
DB00286,The metabolism of Conjugated estrogens can be decreased when combined with Interferon beta-1a.,Conjugated estrogens
DB00296,The metabolism of Ropivacaine can be decreased when combined with Interferon beta-1a.,Ropivacaine
DB00316,The metabolism of Acetaminophen can be decreased when combined with Interferon beta-1a.,Acetaminophen
DB00334,The metabolism of Olanzapine can be decreased when combined with Interferon beta-1a.,Olanzapine
DB00356,The metabolism of Chlorzoxazone can be decreased when combined with Interferon beta-1a.,Chlorzoxazone
DB00363,The metabolism of Clozapine can be decreased when combined with Interferon beta-1a.,Clozapine
DB00365,The metabolism of Grepafloxacin can be decreased when combined with Interferon beta-1a.,Grepafloxacin
DB00370,The metabolism of Mirtazapine can be decreased when combined with Interferon beta-1a.,Mirtazapine
DB00379,The metabolism of Mexiletine can be decreased when combined with Interferon beta-1a.,Mexiletine
DB00382,The metabolism of Tacrine can be decreased when combined with Interferon beta-1a.,Tacrine
DB00384,The metabolism of Triamterene can be decreased when combined with Interferon beta-1a.,Triamterene
DB00420,The metabolism of Promazine can be decreased when combined with Interferon beta-1a.,Promazine
DB00425,The metabolism of Zolpidem can be decreased when combined with Interferon beta-1a.,Zolpidem
DB00442,The metabolism of Entecavir can be decreased when combined with Interferon beta-1a.,Entecavir
DB00461,The metabolism of Nabumetone can be decreased when combined with Interferon beta-1a.,Nabumetone
DB00468,The metabolism of Quinine can be decreased when combined with Interferon beta-1a.,Quinine
DB00472,The metabolism of Fluoxetine can be decreased when combined with Interferon beta-1a.,Fluoxetine
DB00476,The metabolism of Duloxetine can be decreased when combined with Interferon beta-1a.,Duloxetine
DB00477,The metabolism of Chlorpromazine can be decreased when combined with Interferon beta-1a.,Chlorpromazine
DB00499,The metabolism of Flutamide can be decreased when combined with Interferon beta-1a.,Flutamide
DB00502,The metabolism of Haloperidol can be decreased when combined with Interferon beta-1a.,Haloperidol
DB00518,The metabolism of Albendazole can be decreased when combined with Interferon beta-1a.,Albendazole
DB00533,The metabolism of Rofecoxib can be decreased when combined with Interferon beta-1a.,Rofecoxib
DB00544,The metabolism of Fluorouracil can be decreased when combined with Interferon beta-1a.,Fluorouracil
DB00568,The metabolism of Cinnarizine can be decreased when combined with Interferon beta-1a.,Cinnarizine
DB00571,The metabolism of Propranolol can be decreased when combined with Interferon beta-1a.,Propranolol
DB00586,The metabolism of Diclofenac can be decreased when combined with Interferon beta-1a.,Diclofenac
DB00619,The metabolism of Imatinib can be decreased when combined with Interferon beta-1a.,Imatinib
DB00629,The metabolism of Guanabenz can be decreased when combined with Interferon beta-1a.,Guanabenz
DB00642,The metabolism of Pemetrexed can be decreased when combined with Interferon beta-1a.,Pemetrexed
DB00661,The metabolism of Verapamil can be decreased when combined with Interferon beta-1a.,Verapamil
DB00715,The metabolism of Paroxetine can be decreased when combined with Interferon beta-1a.,Paroxetine
DB00730,The metabolism of Thiabendazole can be decreased when combined with Interferon beta-1a.,Thiabendazole
DB00740,The metabolism of Riluzole can be decreased when combined with Interferon beta-1a.,Riluzole
DB00744,The metabolism of Zileuton can be decreased when combined with Interferon beta-1a.,Zileuton
DB00758,The metabolism of Clopidogrel can be decreased when combined with Interferon beta-1a.,Clopidogrel
DB00783,The metabolism of Estradiol can be decreased when combined with Interferon beta-1a.,Estradiol
DB00787,The metabolism of Acyclovir can be decreased when combined with Interferon beta-1a.,Acyclovir
DB00788,The metabolism of Naproxen can be decreased when combined with Interferon beta-1a.,Naproxen
DB00831,The metabolism of Trifluoperazine can be decreased when combined with Interferon beta-1a.,Trifluoperazine
DB00850,The metabolism of Perphenazine can be decreased when combined with Interferon beta-1a.,Perphenazine
DB00857,The metabolism of Terbinafine can be decreased when combined with Interferon beta-1a.,Terbinafine
DB00863,The metabolism of Ranitidine can be decreased when combined with Interferon beta-1a.,Ranitidine
DB00898,The metabolism of Ethanol can be decreased when combined with Interferon beta-1a.,Ethanol
DB00934,The metabolism of Maprotiline can be decreased when combined with Interferon beta-1a.,Maprotiline
DB00969,The metabolism of Alosetron can be decreased when combined with Interferon beta-1a.,Alosetron
DB00978,The metabolism of Lomefloxacin can be decreased when combined with Interferon beta-1a.,Lomefloxacin
DB00980,The metabolism of Ramelteon can be decreased when combined with Interferon beta-1a.,Ramelteon
DB00993,The metabolism of Azathioprine can be decreased when combined with Interferon beta-1a.,Azathioprine
DB00998,The metabolism of Frovatriptan can be decreased when combined with Interferon beta-1a.,Frovatriptan
DB01002,The metabolism of Levobupivacaine can be decreased when combined with Interferon beta-1a.,Levobupivacaine
DB01012,The metabolism of Cinacalcet can be decreased when combined with Interferon beta-1a.,Cinacalcet
DB01037,The metabolism of Selegiline can be decreased when combined with Interferon beta-1a.,Selegiline
DB01056,The metabolism of Tocainide can be decreased when combined with Interferon beta-1a.,Tocainide
DB01058,The metabolism of Praziquantel can be decreased when combined with Interferon beta-1a.,Praziquantel
DB01065,The metabolism of Melatonin can be decreased when combined with Interferon beta-1a.,Melatonin
DB01087,The metabolism of Primaquine can be decreased when combined with Interferon beta-1a.,Primaquine
DB01094,The metabolism of Hesperetin can be decreased when combined with Interferon beta-1a.,Hesperetin
DB01097,The metabolism of Leflunomide can be decreased when combined with Interferon beta-1a.,Leflunomide
DB01115,The metabolism of Nifedipine can be decreased when combined with Interferon beta-1a.,Nifedipine
DB01136,The metabolism of Carvedilol can be decreased when combined with Interferon beta-1a.,Carvedilol
DB01166,The metabolism of Cilostazol can be decreased when combined with Interferon beta-1a.,Cilostazol
DB01182,The metabolism of Propafenone can be decreased when combined with Interferon beta-1a.,Propafenone
DB01184,The metabolism of Domperidone can be decreased when combined with Interferon beta-1a.,Domperidone
DB01191,The metabolism of Dexfenfluramine can be decreased when combined with Interferon beta-1a.,Dexfenfluramine
DB01367,The metabolism of Rasagiline can be decreased when combined with Interferon beta-1a.,Rasagiline
DB01405,The metabolism of Temafloxacin can be decreased when combined with Interferon beta-1a.,Temafloxacin
DB01424,The metabolism of Aminophenazone can be decreased when combined with Interferon beta-1a.,Aminophenazone
DB01435,The metabolism of Antipyrine can be decreased when combined with Interferon beta-1a.,Antipyrine
DB01558,The metabolism of Bromazepam can be decreased when combined with Interferon beta-1a.,Bromazepam
DB01623,The metabolism of Thiothixene can be decreased when combined with Interferon beta-1a.,Thiothixene
DB01628,The metabolism of Etoricoxib can be decreased when combined with Interferon beta-1a.,Etoricoxib
DB01645,The metabolism of Genistein can be decreased when combined with Interferon beta-1a.,Genistein
DB02709,The metabolism of Resveratrol can be decreased when combined with Interferon beta-1a.,Resveratrol
DB03783,The metabolism of Phenacetin can be decreased when combined with Interferon beta-1a.,Phenacetin
DB04574,The metabolism of Estrone sulfate can be decreased when combined with Interferon beta-1a.,Estrone sulfate
DB04841,The metabolism of Flunarizine can be decreased when combined with Interferon beta-1a.,Flunarizine
DB04871,The metabolism of Lorcaserin can be decreased when combined with Interferon beta-1a.,Lorcaserin
DB04948,The metabolism of Lofexidine can be decreased when combined with Interferon beta-1a.,Lofexidine
DB04951,The metabolism of Pirfenidone can be decreased when combined with Interferon beta-1a.,Pirfenidone
DB05676,The metabolism of Apremilast can be decreased when combined with Interferon beta-1a.,Apremilast
DB06148,The metabolism of Mianserin can be decreased when combined with Interferon beta-1a.,Mianserin
DB06210,The metabolism of Eltrombopag can be decreased when combined with Interferon beta-1a.,Eltrombopag
DB06216,The metabolism of Asenapine can be decreased when combined with Interferon beta-1a.,Asenapine
DB06235,The metabolism of Vadimezan can be decreased when combined with Interferon beta-1a.,Vadimezan
DB06292,The metabolism of Dapagliflozin can be decreased when combined with Interferon beta-1a.,Dapagliflozin
DB06589,The metabolism of Pazopanib can be decreased when combined with Interferon beta-1a.,Pazopanib
DB06594,The metabolism of Agomelatine can be decreased when combined with Interferon beta-1a.,Agomelatine
DB06626,The metabolism of Axitinib can be decreased when combined with Interferon beta-1a.,Axitinib
DB06769,The metabolism of Bendamustine can be decreased when combined with Interferon beta-1a.,Bendamustine
DB06770,The metabolism of Benzyl alcohol can be decreased when combined with Interferon beta-1a.,Benzyl alcohol
DB06774,The metabolism of Capsaicin can be decreased when combined with Interferon beta-1a.,Capsaicin
DB08496,The metabolism of (R)-warfarin can be decreased when combined with Interferon beta-1a.,(R)-warfarin
DB08883,The metabolism of Perampanel can be decreased when combined with Interferon beta-1a.,Perampanel
DB09071,The metabolism of Tasimelteon can be decreased when combined with Interferon beta-1a.,Tasimelteon
DB09118,The metabolism of Stiripentol can be decreased when combined with Interferon beta-1a.,Stiripentol
DB09225,The metabolism of Zotepine can be decreased when combined with Interferon beta-1a.,Zotepine
DB09288,The metabolism of Propacetamol can be decreased when combined with Interferon beta-1a.,Propacetamol
DB09290,The metabolism of Ramosetron can be decreased when combined with Interferon beta-1a.,Ramosetron
DB11967,The metabolism of Binimetinib can be decreased when combined with Interferon beta-1a.,Binimetinib
DB12026,The metabolism of Voxilaprevir can be decreased when combined with Interferon beta-1a.,Voxilaprevir
DB12245,The metabolism of Triclabendazole can be decreased when combined with Interferon beta-1a.,Triclabendazole
DB12332,The metabolism of Rucaparib can be decreased when combined with Interferon beta-1a.,Rucaparib
DB12945,The metabolism of Dihydralazine can be decreased when combined with Interferon beta-1a.,Dihydralazine
DB13952,The metabolism of Estradiol acetate can be decreased when combined with Interferon beta-1a.,Estradiol acetate
DB13953,The metabolism of Estradiol benzoate can be decreased when combined with Interferon beta-1a.,Estradiol benzoate
DB13954,The metabolism of Estradiol cypionate can be decreased when combined with Interferon beta-1a.,Estradiol cypionate
DB13955,The metabolism of Estradiol dienanthate can be decreased when combined with Interferon beta-1a.,Estradiol dienanthate
DB13956,The metabolism of Estradiol valerate can be decreased when combined with Interferon beta-1a.,Estradiol valerate
DB11757,The metabolism of Istradefylline can be decreased when combined with Interferon beta-1a.,Istradefylline
DB00972,The metabolism of Azelastine can be decreased when combined with Interferon beta-1a.,Azelastine
DB00625,The metabolism of Efavirenz can be decreased when combined with Interferon beta-1a.,Efavirenz
DB01233,The metabolism of Metoclopramide can be decreased when combined with Interferon beta-1a.,Metoclopramide
DB04889,The metabolism of Bicifadine can be decreased when combined with Interferon beta-1a.,Bicifadine
DB05708,The metabolism of GTS-21 can be decreased when combined with Interferon beta-1a.,GTS-21
DB01195,The metabolism of Flecainide can be decreased when combined with Interferon beta-1a.,Flecainide
DB00977,The metabolism of Ethinylestradiol can be decreased when combined with Interferon beta-1a.,Ethinylestradiol
DB00321,The metabolism of Amitriptyline can be decreased when combined with Interferon beta-1a.,Amitriptyline
DB00458,The metabolism of Imipramine can be decreased when combined with Interferon beta-1a.,Imipramine
DB01142,The metabolism of Doxepin can be decreased when combined with Interferon beta-1a.,Doxepin
DB00532,The metabolism of Mephenytoin can be decreased when combined with Interferon beta-1a.,Mephenytoin
DB00540,The metabolism of Nortriptyline can be decreased when combined with Interferon beta-1a.,Nortriptyline
DB00575,The metabolism of Clonidine can be decreased when combined with Interferon beta-1a.,Clonidine
DB00924,The metabolism of Cyclobenzaprine can be decreased when combined with Interferon beta-1a.,Cyclobenzaprine
DB01151,The metabolism of Desipramine can be decreased when combined with Interferon beta-1a.,Desipramine
DB01242,The metabolism of Clomipramine can be decreased when combined with Interferon beta-1a.,Clomipramine
DB11689,The metabolism of Selumetinib can be decreased when combined with Interferon beta-1a.,Selumetinib
DB00277,The metabolism of Theophylline can be decreased when combined with Interferon beta-1a.,Theophylline
DB00564,The metabolism of Carbamazepine can be decreased when combined with Interferon beta-1a.,Carbamazepine
DB00682,The metabolism of Warfarin can be decreased when combined with Interferon beta-1a.,Warfarin
DB00697,The metabolism of Tizanidine can be decreased when combined with Interferon beta-1a.,Tizanidine
DB01100,The metabolism of Pimozide can be decreased when combined with Interferon beta-1a.,Pimozide
DB01223,The metabolism of Aminophylline can be decreased when combined with Interferon beta-1a.,Aminophylline
DB01418,The metabolism of Acenocoumarol can be decreased when combined with Interferon beta-1a.,Acenocoumarol
DB00398,The metabolism of Sorafenib can be decreased when combined with Interferon beta-1a.,Sorafenib
DB00530,The metabolism of Erlotinib can be decreased when combined with Interferon beta-1a.,Erlotinib
DB00773,The metabolism of Etoposide can be decreased when combined with Interferon beta-1a.,Etoposide
DB00851,The metabolism of Dacarbazine can be decreased when combined with Interferon beta-1a.,Dacarbazine
DB01254,The metabolism of Dasatinib can be decreased when combined with Interferon beta-1a.,Dasatinib
DB08910,The metabolism of Pomalidomide can be decreased when combined with Interferon beta-1a.,Pomalidomide
DB09256,The metabolism of Tegafur can be decreased when combined with Interferon beta-1a.,Tegafur
DB13874,The metabolism of Enasidenib can be decreased when combined with Interferon beta-1a.,Enasidenib
DB00675,The metabolism of Tamoxifen can be decreased when combined with Interferon beta-1a.,Tamoxifen
DB10317,The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Interferon beta-1a.,Rubella virus vaccine
DB10343,The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Interferon beta-1a.,Bacillus calmette-guerin substrain tice live antigen
DB10804,The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Interferon beta-1a.,Bacillus calmette-guerin substrain connaught live antigen
DB10805,The therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Interferon beta-1a.,Yellow Fever Vaccine
DB11003,The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Interferon beta-1a.,Anthrax vaccine
DB11050,The therapeutic efficacy of Typhoid Vaccine Live can be decreased when used in combination with Interferon beta-1a.,Typhoid Vaccine Live
DB12386,The therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Interferon beta-1a.,Bacillus calmette-guerin substrain danish 1331 live antigen
DB12768,The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Interferon beta-1a.,BCG vaccine
DB14409,The therapeutic efficacy of Human adenovirus e serotype 4 strain cl-68578 antigen can be decreased when used in combination with Interferon beta-1a.,Human adenovirus e serotype 4 strain cl-68578 antigen
DB14443,The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Interferon beta-1a.,Vibrio cholerae CVD 103-HgR strain live antigen
DB14685,The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Interferon beta-1a.,Adenovirus type 7 vaccine live
DB10318,The therapeutic efficacy of Varicella Zoster Vaccine (Live/attenuated) can be decreased when used in combination with Interferon beta-1a.,Varicella Zoster Vaccine (Live/attenuated)
DB00268,The risk or severity of adverse effects can be increased when Interferon beta-1a is combined with Ropinirole.,Ropinirole
DB00552,The therapeutic efficacy of Pentostatin can be decreased when used in combination with Pegademase.,Pentostatin
DB00008,The therapeutic efficacy of Pegademase can be decreased when used in combination with Peginterferon alfa-2a.,Peginterferon alfa-2a
DB00019,The therapeutic efficacy of Pegademase can be decreased when used in combination with Pegfilgrastim.,Pegfilgrastim
DB00022,The therapeutic efficacy of Pegademase can be decreased when used in combination with Peginterferon alfa-2b.,Peginterferon alfa-2b
DB00059,The therapeutic efficacy of Pegademase can be decreased when used in combination with Pegaspargase.,Pegaspargase
DB00082,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pegademase.,Pegvisomant
DB01839,The therapeutic efficacy of Propylene glycol can be decreased when used in combination with Pegademase.,Propylene glycol
DB03394,The therapeutic efficacy of Heptaethylene glycol can be decreased when used in combination with Pegademase.,Heptaethylene glycol
DB04895,The therapeutic efficacy of Pegaptanib can be decreased when used in combination with Pegademase.,Pegaptanib
DB05202,The therapeutic efficacy of Egaptivon pegol can be decreased when used in combination with Pegademase.,Egaptivon pegol
DB05321,The therapeutic efficacy of PEG-uricase can be decreased when used in combination with Pegademase.,PEG-uricase
DB05860,The therapeutic efficacy of Peginterferon alfacon-1 can be decreased when used in combination with Pegademase.,Peginterferon alfacon-1
DB06022,The therapeutic efficacy of GlycoPEG-GCSF can be decreased when used in combination with Pegademase.,GlycoPEG-GCSF
DB06293,The therapeutic efficacy of Pegnivacogin can be decreased when used in combination with Pegademase.,Pegnivacogin
DB06325,The therapeutic efficacy of Pegpleranib can be decreased when used in combination with Pegademase.,Pegpleranib
DB06611,The therapeutic efficacy of Pegsunercept can be decreased when used in combination with Pegademase.,Pegsunercept
DB06811,The therapeutic efficacy of Polidocanol can be decreased when used in combination with Pegademase.,Polidocanol
DB08894,The therapeutic efficacy of Peginesatide can be decreased when used in combination with Pegademase.,Peginesatide
DB08904,The therapeutic efficacy of Certolizumab pegol can be decreased when used in combination with Pegademase.,Certolizumab pegol
DB09107,The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Pegademase.,Methoxy polyethylene glycol-epoetin beta
DB09122,The therapeutic efficacy of Peginterferon beta-1a can be decreased when used in combination with Pegademase.,Peginterferon beta-1a
DB09208,The therapeutic efficacy of Pegloticase can be decreased when used in combination with Pegademase.,Pegloticase
DB09287,The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pegademase.,Polyethylene glycol
DB09329,"The therapeutic efficacy of Antihemophilic Factor (Recombinant), PEGylated can be decreased when used in combination with Pegademase.","Antihemophilic Factor (Recombinant), PEGylated"
DB11077,The therapeutic efficacy of Polyethylene glycol 400 can be decreased when used in combination with Pegademase.,Polyethylene glycol 400
DB11567,The therapeutic efficacy of Insulin peglispro can be decreased when used in combination with Pegademase.,Insulin peglispro
DB11661,The therapeutic efficacy of Eptacog alfa pegol (activated) can be decreased when used in combination with Pegademase.,Eptacog alfa pegol (activated)
DB11707,The therapeutic efficacy of Olaptesed Pegol can be decreased when used in combination with Pegademase.,Olaptesed Pegol
DB12258,The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Pegademase.,Abicipar Pegol
DB12578,The therapeutic efficacy of Lexaptepid Pegol can be decreased when used in combination with Pegademase.,Lexaptepid Pegol
DB12814,The therapeutic efficacy of Cepeginterferon alfa-2B can be decreased when used in combination with Pegademase.,Cepeginterferon alfa-2B
DB12839,The therapeutic efficacy of Pegvaliase can be decreased when used in combination with Pegademase.,Pegvaliase
DB12842,The therapeutic efficacy of Pegamotecan can be decreased when used in combination with Pegademase.,Pegamotecan
DB13200,The therapeutic efficacy of Lipegfilgrastim can be decreased when used in combination with Pegademase.,Lipegfilgrastim
DB13933,The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Pegademase.,Nonacog beta pegol
DB14700,The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Pegademase.,Damoctocog alfa pegol
DB14712,The therapeutic efficacy of Elapegademase can be decreased when used in combination with Pegademase.,Elapegademase
DB06605,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Apixaban.,Apixaban
DB01254,Dasatinib may increase the anticoagulant activities of Eptifibatide.,Dasatinib
DB01586,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Ursodeoxycholic acid.,Ursodeoxycholic acid
DB02123,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Glycochenodeoxycholic Acid.,Glycochenodeoxycholic Acid
DB02659,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Cholic Acid.,Cholic Acid
DB02691,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Glycocholic acid.,Glycocholic acid
DB03619,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Deoxycholic acid.,Deoxycholic acid
DB04348,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Taurocholic acid.,Taurocholic acid
DB05990,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Obeticholic acid.,Obeticholic acid
DB06777,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Chenodeoxycholic acid.,Chenodeoxycholic acid
DB08833,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Taurochenodeoxycholic acid.,Taurochenodeoxycholic acid
DB08834,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Tauroursodeoxycholic acid.,Tauroursodeoxycholic acid
DB08857,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Bamet-UD2.,Bamet-UD2
DB11622,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Dehydrocholic acid.,Dehydrocholic acid
DB11789,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Hyodeoxycholic Acid.,Hyodeoxycholic Acid
DB01296,Glucosamine may increase the antiplatelet activities of Eptifibatide.,Glucosamine
DB00078,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Ibritumomab tiuxetan.,Ibritumomab tiuxetan
DB09053,The risk or severity of adverse effects can be increased when Ibrutinib is combined with Eptifibatide.,Ibrutinib
DB08935,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Obinutuzumab.,Obinutuzumab
DB00806,Pentoxifylline may increase the antiplatelet activities of Eptifibatide.,Pentoxifylline
DB06228,Eptifibatide may increase the anticoagulant activities of Rivaroxaban.,Rivaroxaban
DB00932,Tipranavir may increase the antiplatelet activities of Eptifibatide.,Tipranavir
DB00013,Eptifibatide may increase the anticoagulant activities of Urokinase.,Urokinase
DB00163,Vitamin E may increase the antiplatelet activities of Eptifibatide.,Vitamin E
DB00686,The risk or severity of adverse effects can be increased when Pentosan polysulfate is combined with Eptifibatide.,Pentosan polysulfate
DB09211,Limaprost may increase the antiplatelet activities of Eptifibatide.,Limaprost
DB11133,Omega-3 fatty acids may increase the antiplatelet activities of Eptifibatide.,Omega-3 fatty acids
DB00081,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Tositumomab.,Tositumomab
DB00001,The risk or severity of bleeding can be increased when Eptifibatide is combined with Lepirudin.,Lepirudin
DB00006,The risk or severity of bleeding can be increased when Eptifibatide is combined with Bivalirudin.,Bivalirudin
DB00009,The risk or severity of bleeding can be increased when Eptifibatide is combined with Alteplase.,Alteplase
DB00015,The risk or severity of bleeding can be increased when Eptifibatide is combined with Reteplase.,Reteplase
DB00029,The risk or severity of bleeding can be increased when Eptifibatide is combined with Anistreplase.,Anistreplase
DB00031,The risk or severity of bleeding can be increased when Eptifibatide is combined with Tenecteplase.,Tenecteplase
DB00054,The risk or severity of bleeding can be increased when Eptifibatide is combined with Abciximab.,Abciximab
DB00055,The risk or severity of bleeding can be increased when Eptifibatide is combined with Drotrecogin alfa.,Drotrecogin alfa
DB00086,The risk or severity of bleeding can be increased when Eptifibatide is combined with Streptokinase.,Streptokinase
DB00266,The risk or severity of bleeding can be increased when Eptifibatide is combined with Dicoumarol.,Dicoumarol
DB00278,The risk or severity of bleeding can be increased when Eptifibatide is combined with Argatroban.,Argatroban
DB00407,The risk or severity of bleeding can be increased when Eptifibatide is combined with Ardeparin.,Ardeparin
DB00498,The risk or severity of bleeding can be increased when Eptifibatide is combined with Phenindione.,Phenindione
DB00569,The risk or severity of bleeding can be increased when Eptifibatide is combined with Fondaparinux.,Fondaparinux
DB00682,The risk or severity of bleeding can be increased when Eptifibatide is combined with Warfarin.,Warfarin
DB00946,The risk or severity of bleeding can be increased when Eptifibatide is combined with Phenprocoumon.,Phenprocoumon
DB00975,The risk or severity of bleeding can be increased when Eptifibatide is combined with Dipyridamole.,Dipyridamole
DB01088,The risk or severity of bleeding can be increased when Eptifibatide is combined with Iloprost.,Iloprost
DB01109,The risk or severity of bleeding can be increased when Eptifibatide is combined with Heparin.,Heparin
DB01225,The risk or severity of bleeding can be increased when Eptifibatide is combined with Enoxaparin.,Enoxaparin
DB01240,The risk or severity of bleeding can be increased when Eptifibatide is combined with Epoprostenol.,Epoprostenol
DB01418,The risk or severity of bleeding can be increased when Eptifibatide is combined with Acenocoumarol.,Acenocoumarol
DB03410,The risk or severity of bleeding can be increased when Eptifibatide is combined with 4-hydroxycoumarin.,4-hydroxycoumarin
DB04665,The risk or severity of bleeding can be increased when Eptifibatide is combined with Coumarin.,Coumarin
DB04898,The risk or severity of bleeding can be increased when Eptifibatide is combined with Ximelagatran.,Ximelagatran
DB04925,The risk or severity of bleeding can be increased when Eptifibatide is combined with Desmoteplase.,Desmoteplase
DB04932,The risk or severity of bleeding can be increased when Eptifibatide is combined with Defibrotide.,Defibrotide
DB05099,The risk or severity of bleeding can be increased when Eptifibatide is combined with Ancrod.,Ancrod
DB05229,The risk or severity of bleeding can be increased when Eptifibatide is combined with Beraprost.,Beraprost
DB05254,The risk or severity of bleeding can be increased when Eptifibatide is combined with Fibrinolysin.,Fibrinolysin
DB06209,The risk or severity of bleeding can be increased when Eptifibatide is combined with Prasugrel.,Prasugrel
DB06271,The risk or severity of bleeding can be increased when Eptifibatide is combined with Sulodexide.,Sulodexide
DB06294,The risk or severity of bleeding can be increased when Eptifibatide is combined with Semuloparin.,Semuloparin
DB06406,The risk or severity of bleeding can be increased when Eptifibatide is combined with Idraparinux.,Idraparinux
DB06441,The risk or severity of bleeding can be increased when Eptifibatide is combined with Cangrelor.,Cangrelor
DB06543,The risk or severity of bleeding can be increased when Eptifibatide is combined with Astaxanthin.,Astaxanthin
DB06635,The risk or severity of bleeding can be increased when Eptifibatide is combined with Otamixaban.,Otamixaban
DB06679,The risk or severity of bleeding can be increased when Eptifibatide is combined with Amediplase.,Amediplase
DB06754,The risk or severity of bleeding can be increased when Eptifibatide is combined with Danaparoid.,Danaparoid
DB06779,The risk or severity of bleeding can be increased when Eptifibatide is combined with Dalteparin.,Dalteparin
DB06822,The risk or severity of bleeding can be increased when Eptifibatide is combined with Tinzaparin.,Tinzaparin
DB07767,The risk or severity of bleeding can be increased when Eptifibatide is combined with Ferulic acid.,Ferulic acid
DB08496,The risk or severity of bleeding can be increased when Eptifibatide is combined with (R)-warfarin.,(R)-warfarin
DB08794,The risk or severity of bleeding can be increased when Eptifibatide is combined with Ethyl biscoumacetate.,Ethyl biscoumacetate
DB08813,The risk or severity of bleeding can be increased when Eptifibatide is combined with Nadroparin.,Nadroparin
DB08814,The risk or severity of bleeding can be increased when Eptifibatide is combined with Triflusal.,Triflusal
DB08816,The risk or severity of bleeding can be increased when Eptifibatide is combined with Ticagrelor.,Ticagrelor
DB08994,The risk or severity of bleeding can be increased when Eptifibatide is combined with Ditazole.,Ditazole
DB09030,The risk or severity of bleeding can be increased when Eptifibatide is combined with Vorapaxar.,Vorapaxar
DB09075,The risk or severity of bleeding can be increased when Eptifibatide is combined with Edoxaban.,Edoxaban
DB09125,The risk or severity of bleeding can be increased when Eptifibatide is combined with Potassium citrate.,Potassium citrate
DB09154,The risk or severity of bleeding can be increased when Eptifibatide is combined with Sodium citrate.,Sodium citrate
DB09255,The risk or severity of bleeding can be increased when Eptifibatide is combined with Dextran.,Dextran
DB09258,The risk or severity of bleeding can be increased when Eptifibatide is combined with Bemiparin.,Bemiparin
DB09259,The risk or severity of bleeding can be increased when Eptifibatide is combined with Reviparin.,Reviparin
DB09260,The risk or severity of bleeding can be increased when Eptifibatide is combined with Parnaparin.,Parnaparin
DB09261,The risk or severity of bleeding can be increased when Eptifibatide is combined with Certoparin.,Certoparin
DB11095,The risk or severity of bleeding can be increased when Eptifibatide is combined with Desirudin.,Desirudin
DB11154,The risk or severity of bleeding can be increased when Eptifibatide is combined with Zinc citrate.,Zinc citrate
DB11166,The risk or severity of bleeding can be increased when Eptifibatide is combined with Antithrombin Alfa.,Antithrombin Alfa
DB11312,The risk or severity of bleeding can be increased when Eptifibatide is combined with Protein C.,Protein C
DB11598,The risk or severity of bleeding can be increased when Eptifibatide is combined with Antithrombin III human.,Antithrombin III human
DB11984,The risk or severity of bleeding can be increased when Eptifibatide is combined with Letaxaban.,Letaxaban
DB12289,The risk or severity of bleeding can be increased when Eptifibatide is combined with Darexaban.,Darexaban
DB12364,The risk or severity of bleeding can be increased when Eptifibatide is combined with Betrixaban.,Betrixaban
DB12598,The risk or severity of bleeding can be increased when Eptifibatide is combined with Nafamostat.,Nafamostat
DB12726,The risk or severity of bleeding can be increased when Eptifibatide is combined with Monteplase.,Monteplase
DB12831,The risk or severity of bleeding can be increased when Eptifibatide is combined with Gabexate.,Gabexate
DB13136,The risk or severity of bleeding can be increased when Eptifibatide is combined with Fluindione.,Fluindione
DB13149,The risk or severity of bleeding can be increased when Eptifibatide is combined with Protein S human.,Protein S human
DB13199,The risk or severity of bleeding can be increased when Eptifibatide is combined with Brinase.,Brinase
DB13275,The risk or severity of bleeding can be increased when Eptifibatide is combined with Clorindione.,Clorindione
DB13347,The risk or severity of bleeding can be increased when Eptifibatide is combined with Diphenadione.,Diphenadione
DB13451,The risk or severity of bleeding can be increased when Eptifibatide is combined with Tioclomarol.,Tioclomarol
DB13616,The risk or severity of bleeding can be increased when Eptifibatide is combined with Melagatran.,Melagatran
DB13646,The risk or severity of bleeding can be increased when Eptifibatide is combined with Saruplase.,Saruplase
DB14055,The risk or severity of bleeding can be increased when Eptifibatide is combined with (S)-Warfarin.,(S)-Warfarin
DB14094,The risk or severity of bleeding can be increased when Eptifibatide is combined with Tocopherylquinone.,Tocopherylquinone
DB14598,The risk or severity of bleeding can be increased when Eptifibatide is combined with Edetate calcium disodium anhydrous.,Edetate calcium disodium anhydrous
DB14726,The risk or severity of bleeding can be increased when Eptifibatide is combined with Dabigatran.,Dabigatran
DB00374,Treprostinil may increase the antiplatelet activities of Eptifibatide.,Treprostinil
DB00208,Eptifibatide may increase the antiplatelet activities of Ticlopidine.,Ticlopidine
DB00758,Eptifibatide may increase the antiplatelet activities of Clopidogrel.,Clopidogrel
DB00775,Eptifibatide may increase the antiplatelet activities of Tirofiban.,Tirofiban
DB01138,Eptifibatide may increase the antiplatelet activities of Sulfinpyrazone.,Sulfinpyrazone
DB01166,Eptifibatide may increase the antiplatelet activities of Cilostazol.,Cilostazol
DB01207,Eptifibatide may increase the antiplatelet activities of Ridogrel.,Ridogrel
DB01236,Eptifibatide may increase the antiplatelet activities of Sevoflurane.,Sevoflurane
DB02709,Eptifibatide may increase the antiplatelet activities of Resveratrol.,Resveratrol
DB04905,Eptifibatide may increase the antiplatelet activities of Tesmilifene.,Tesmilifene
DB05266,Eptifibatide may increase the antiplatelet activities of Ibudilast.,Ibudilast
DB05767,Eptifibatide may increase the antiplatelet activities of Andrographolide.,Andrographolide
DB06081,Eptifibatide may increase the antiplatelet activities of Caplacizumab.,Caplacizumab
DB07615,Eptifibatide may increase the antiplatelet activities of Tranilast.,Tranilast
DB08887,Eptifibatide may increase the antiplatelet activities of Icosapent ethyl.,Icosapent ethyl
DB09283,Eptifibatide may increase the antiplatelet activities of Trapidil.,Trapidil
DB12092,Eptifibatide may increase the antiplatelet activities of Naftopidil.,Naftopidil
DB12163,Eptifibatide may increase the antiplatelet activities of Sarpogrelate.,Sarpogrelate
DB12321,Eptifibatide may increase the antiplatelet activities of Ifetroban.,Ifetroban
DB12465,Eptifibatide may increase the antiplatelet activities of Ketanserin.,Ketanserin
DB12749,Eptifibatide may increase the antiplatelet activities of Butylphthalide.,Butylphthalide
DB12771,Eptifibatide may increase the antiplatelet activities of Hydroxytyrosol.,Hydroxytyrosol
DB13036,Eptifibatide may increase the antiplatelet activities of Ramatroban.,Ramatroban
DB13327,Eptifibatide may increase the antiplatelet activities of Picotamide.,Picotamide
DB13367,Eptifibatide may increase the antiplatelet activities of Cloricromen.,Cloricromen
DB13400,Eptifibatide may increase the antiplatelet activities of Linsidomine.,Linsidomine
DB13510,Eptifibatide may increase the antiplatelet activities of Buflomedil.,Buflomedil
DB13929,Eptifibatide may increase the antiplatelet activities of Relcovaptan.,Relcovaptan
DB00261,Eptifibatide may increase the antiplatelet activities of Anagrelide.,Anagrelide
DB00233,The risk or severity of bleeding can be increased when Eptifibatide is combined with Aminosalicylic acid.,Aminosalicylic acid
DB01294,The risk or severity of bleeding can be increased when Eptifibatide is combined with Bismuth subsalicylate.,Bismuth subsalicylate
DB06251,The risk or severity of bleeding can be increased when Eptifibatide is combined with Dersalazine.,Dersalazine
DB06807,The risk or severity of bleeding can be increased when Eptifibatide is combined with Phenyl aminosalicylate.,Phenyl aminosalicylate
DB09543,The risk or severity of bleeding can be increased when Eptifibatide is combined with Methyl salicylate.,Methyl salicylate
DB13509,The risk or severity of bleeding can be increased when Eptifibatide is combined with Aloxiprin.,Aloxiprin
DB14006,The risk or severity of bleeding can be increased when Eptifibatide is combined with Choline salicylate.,Choline salicylate
DB14026,The risk or severity of bleeding can be increased when Eptifibatide is combined with Thiosalicylic acid.,Thiosalicylic acid
DB06695,Eptifibatide may increase the anticoagulant activities of Dabigatran etexilate.,Dabigatran etexilate
DB00008,The risk or severity of bleeding can be increased when Eptifibatide is combined with Peginterferon alfa-2a.,Peginterferon alfa-2a
DB00011,The risk or severity of bleeding can be increased when Eptifibatide is combined with Interferon alfa-n1.,Interferon alfa-n1
DB00018,The risk or severity of bleeding can be increased when Eptifibatide is combined with Interferon alfa-n3.,Interferon alfa-n3
DB00022,The risk or severity of bleeding can be increased when Eptifibatide is combined with Peginterferon alfa-2b.,Peginterferon alfa-2b
DB00033,The risk or severity of bleeding can be increased when Eptifibatide is combined with Interferon gamma-1b.,Interferon gamma-1b
DB00034,"The risk or severity of bleeding can be increased when Eptifibatide is combined with Interferon alfa-2a, Recombinant.","Interferon alfa-2a, Recombinant"
DB00041,The risk or severity of bleeding can be increased when Eptifibatide is combined with Aldesleukin.,Aldesleukin
DB00056,The risk or severity of bleeding can be increased when Eptifibatide is combined with Gemtuzumab ozogamicin.,Gemtuzumab ozogamicin
DB00068,The risk or severity of bleeding can be increased when Eptifibatide is combined with Interferon beta-1b.,Interferon beta-1b
DB00069,The risk or severity of bleeding can be increased when Eptifibatide is combined with Interferon alfacon-1.,Interferon alfacon-1
DB00073,The risk or severity of bleeding can be increased when Eptifibatide is combined with Rituximab.,Rituximab
DB00087,The risk or severity of bleeding can be increased when Eptifibatide is combined with Alemtuzumab.,Alemtuzumab
DB00105,The risk or severity of bleeding can be increased when Eptifibatide is combined with Interferon alfa-2b.,Interferon alfa-2b
DB00120,The risk or severity of bleeding can be increased when Eptifibatide is combined with Phenylalanine.,Phenylalanine
DB00188,The risk or severity of bleeding can be increased when Eptifibatide is combined with Bortezomib.,Bortezomib
DB00242,The risk or severity of bleeding can be increased when Eptifibatide is combined with Cladribine.,Cladribine
DB00262,The risk or severity of bleeding can be increased when Eptifibatide is combined with Carmustine.,Carmustine
DB00276,The risk or severity of bleeding can be increased when Eptifibatide is combined with Amsacrine.,Amsacrine
DB00291,The risk or severity of bleeding can be increased when Eptifibatide is combined with Chlorambucil.,Chlorambucil
DB00293,The risk or severity of bleeding can be increased when Eptifibatide is combined with Raltitrexed.,Raltitrexed
DB00305,The risk or severity of bleeding can be increased when Eptifibatide is combined with Mitomycin.,Mitomycin
DB00307,The risk or severity of bleeding can be increased when Eptifibatide is combined with Bexarotene.,Bexarotene
DB00309,The risk or severity of bleeding can be increased when Eptifibatide is combined with Vindesine.,Vindesine
DB00322,The risk or severity of bleeding can be increased when Eptifibatide is combined with Floxuridine.,Floxuridine
DB00352,The risk or severity of bleeding can be increased when Eptifibatide is combined with Tioguanine.,Tioguanine
DB00361,The risk or severity of bleeding can be increased when Eptifibatide is combined with Vinorelbine.,Vinorelbine
DB00380,The risk or severity of bleeding can be increased when Eptifibatide is combined with Dexrazoxane.,Dexrazoxane
DB00398,The risk or severity of bleeding can be increased when Eptifibatide is combined with Sorafenib.,Sorafenib
DB00428,The risk or severity of bleeding can be increased when Eptifibatide is combined with Streptozocin.,Streptozocin
DB00441,The risk or severity of bleeding can be increased when Eptifibatide is combined with Gemcitabine.,Gemcitabine
DB00444,The risk or severity of bleeding can be increased when Eptifibatide is combined with Teniposide.,Teniposide
DB00445,The risk or severity of bleeding can be increased when Eptifibatide is combined with Epirubicin.,Epirubicin
DB00446,The risk or severity of bleeding can be increased when Eptifibatide is combined with Chloramphenicol.,Chloramphenicol
DB00480,The risk or severity of bleeding can be increased when Eptifibatide is combined with Lenalidomide.,Lenalidomide
DB00488,The risk or severity of bleeding can be increased when Eptifibatide is combined with Altretamine.,Altretamine
DB00495,The risk or severity of bleeding can be increased when Eptifibatide is combined with Zidovudine.,Zidovudine
DB00515,The risk or severity of bleeding can be increased when Eptifibatide is combined with Cisplatin.,Cisplatin
DB00526,The risk or severity of bleeding can be increased when Eptifibatide is combined with Oxaliplatin.,Oxaliplatin
DB00531,The risk or severity of bleeding can be increased when Eptifibatide is combined with Cyclophosphamide.,Cyclophosphamide
DB00544,The risk or severity of bleeding can be increased when Eptifibatide is combined with Fluorouracil.,Fluorouracil
DB00550,The risk or severity of bleeding can be increased when Eptifibatide is combined with Propylthiouracil.,Propylthiouracil
DB00552,The risk or severity of bleeding can be increased when Eptifibatide is combined with Pentostatin.,Pentostatin
DB00563,The risk or severity of bleeding can be increased when Eptifibatide is combined with Methotrexate.,Methotrexate
DB00564,The risk or severity of bleeding can be increased when Eptifibatide is combined with Carbamazepine.,Carbamazepine
DB00570,The risk or severity of bleeding can be increased when Eptifibatide is combined with Vinblastine.,Vinblastine
DB00619,The risk or severity of bleeding can be increased when Eptifibatide is combined with Imatinib.,Imatinib
DB00631,The risk or severity of bleeding can be increased when Eptifibatide is combined with Clofarabine.,Clofarabine
DB00642,The risk or severity of bleeding can be increased when Eptifibatide is combined with Pemetrexed.,Pemetrexed
DB00694,The risk or severity of bleeding can be increased when Eptifibatide is combined with Daunorubicin.,Daunorubicin
DB00762,The risk or severity of bleeding can be increased when Eptifibatide is combined with Irinotecan.,Irinotecan
DB00763,The risk or severity of bleeding can be increased when Eptifibatide is combined with Methimazole.,Methimazole
DB00773,The risk or severity of bleeding can be increased when Eptifibatide is combined with Etoposide.,Etoposide
DB00851,The risk or severity of bleeding can be increased when Eptifibatide is combined with Dacarbazine.,Dacarbazine
DB00853,The risk or severity of bleeding can be increased when Eptifibatide is combined with Temozolomide.,Temozolomide
DB00859,The risk or severity of bleeding can be increased when Eptifibatide is combined with Penicillamine.,Penicillamine
DB00864,The risk or severity of bleeding can be increased when Eptifibatide is combined with Tacrolimus.,Tacrolimus
DB00877,The risk or severity of bleeding can be increased when Eptifibatide is combined with Sirolimus.,Sirolimus
DB00888,The risk or severity of bleeding can be increased when Eptifibatide is combined with Mechlorethamine.,Mechlorethamine
DB00928,The risk or severity of bleeding can be increased when Eptifibatide is combined with Azacitidine.,Azacitidine
DB00958,The risk or severity of bleeding can be increased when Eptifibatide is combined with Carboplatin.,Carboplatin
DB00970,The risk or severity of bleeding can be increased when Eptifibatide is combined with Dactinomycin.,Dactinomycin
DB00987,The risk or severity of bleeding can be increased when Eptifibatide is combined with Cytarabine.,Cytarabine
DB00997,The risk or severity of bleeding can be increased when Eptifibatide is combined with Doxorubicin.,Doxorubicin
DB01005,The risk or severity of bleeding can be increased when Eptifibatide is combined with Hydroxyurea.,Hydroxyurea
DB01008,The risk or severity of bleeding can be increased when Eptifibatide is combined with Busulfan.,Busulfan
DB01030,The risk or severity of bleeding can be increased when Eptifibatide is combined with Topotecan.,Topotecan
DB01033,The risk or severity of bleeding can be increased when Eptifibatide is combined with Mercaptopurine.,Mercaptopurine
DB01041,The risk or severity of bleeding can be increased when Eptifibatide is combined with Thalidomide.,Thalidomide
DB01042,The risk or severity of bleeding can be increased when Eptifibatide is combined with Melphalan.,Melphalan
DB01073,The risk or severity of bleeding can be increased when Eptifibatide is combined with Fludarabine.,Fludarabine
DB01099,The risk or severity of bleeding can be increased when Eptifibatide is combined with Flucytosine.,Flucytosine
DB01101,The risk or severity of bleeding can be increased when Eptifibatide is combined with Capecitabine.,Capecitabine
DB01169,The risk or severity of bleeding can be increased when Eptifibatide is combined with Arsenic trioxide.,Arsenic trioxide
DB01177,The risk or severity of bleeding can be increased when Eptifibatide is combined with Idarubicin.,Idarubicin
DB01181,The risk or severity of bleeding can be increased when Eptifibatide is combined with Ifosfamide.,Ifosfamide
DB01204,The risk or severity of bleeding can be increased when Eptifibatide is combined with Mitoxantrone.,Mitoxantrone
DB01206,The risk or severity of bleeding can be increased when Eptifibatide is combined with Lomustine.,Lomustine
DB01229,The risk or severity of bleeding can be increased when Eptifibatide is combined with Paclitaxel.,Paclitaxel
DB01248,The risk or severity of bleeding can be increased when Eptifibatide is combined with Docetaxel.,Docetaxel
DB01262,The risk or severity of bleeding can be increased when Eptifibatide is combined with Decitabine.,Decitabine
DB01280,The risk or severity of bleeding can be increased when Eptifibatide is combined with Nelarabine.,Nelarabine
DB01590,The risk or severity of bleeding can be increased when Eptifibatide is combined with Everolimus.,Everolimus
DB02546,The risk or severity of bleeding can be increased when Eptifibatide is combined with Vorinostat.,Vorinostat
DB04572,The risk or severity of bleeding can be increased when Eptifibatide is combined with Thiotepa.,Thiotepa
DB04845,The risk or severity of bleeding can be increased when Eptifibatide is combined with Ixabepilone.,Ixabepilone
DB04868,The risk or severity of bleeding can be increased when Eptifibatide is combined with Nilotinib.,Nilotinib
DB05015,The risk or severity of bleeding can be increased when Eptifibatide is combined with Belinostat.,Belinostat
DB05109,The risk or severity of bleeding can be increased when Eptifibatide is combined with Trabectedin.,Trabectedin
DB05258,The risk or severity of bleeding can be increased when Eptifibatide is combined with Interferon alfa.,Interferon alfa
DB05472,The risk or severity of bleeding can be increased when Eptifibatide is combined with omega interferon.,omega interferon
DB05773,The risk or severity of bleeding can be increased when Eptifibatide is combined with Trastuzumab emtansine.,Trastuzumab emtansine
DB06287,The risk or severity of bleeding can be increased when Eptifibatide is combined with Temsirolimus.,Temsirolimus
DB06616,The risk or severity of bleeding can be increased when Eptifibatide is combined with Bosutinib.,Bosutinib
DB06769,The risk or severity of bleeding can be increased when Eptifibatide is combined with Bendamustine.,Bendamustine
DB06772,The risk or severity of bleeding can be increased when Eptifibatide is combined with Cabazitaxel.,Cabazitaxel
DB08871,The risk or severity of bleeding can be increased when Eptifibatide is combined with Eribulin.,Eribulin
DB08877,The risk or severity of bleeding can be increased when Eptifibatide is combined with Ruxolitinib.,Ruxolitinib
DB08889,The risk or severity of bleeding can be increased when Eptifibatide is combined with Carfilzomib.,Carfilzomib
DB08895,The risk or severity of bleeding can be increased when Eptifibatide is combined with Tofacitinib.,Tofacitinib
DB08901,The risk or severity of bleeding can be increased when Eptifibatide is combined with Ponatinib.,Ponatinib
DB08910,The risk or severity of bleeding can be increased when Eptifibatide is combined with Pomalidomide.,Pomalidomide
DB09042,The risk or severity of bleeding can be increased when Eptifibatide is combined with Tedizolid phosphate.,Tedizolid phosphate
DB09052,The risk or severity of bleeding can be increased when Eptifibatide is combined with Blinatumomab.,Blinatumomab
DB09073,The risk or severity of bleeding can be increased when Eptifibatide is combined with Palbociclib.,Palbociclib
DB09074,The risk or severity of bleeding can be increased when Eptifibatide is combined with Olaparib.,Olaparib
DB09077,The risk or severity of bleeding can be increased when Eptifibatide is combined with Dinutuximab.,Dinutuximab
DB09122,The risk or severity of bleeding can be increased when Eptifibatide is combined with Peginterferon beta-1a.,Peginterferon beta-1a
DB12814,The risk or severity of bleeding can be increased when Eptifibatide is combined with Cepeginterferon alfa-2B.,Cepeginterferon alfa-2B
DB00176,The risk or severity of hemorrhage can be increased when Fluvoxamine is combined with Eptifibatide.,Fluvoxamine
DB00215,The risk or severity of hemorrhage can be increased when Citalopram is combined with Eptifibatide.,Citalopram
DB00472,The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Eptifibatide.,Fluoxetine
DB00715,The risk or severity of hemorrhage can be increased when Paroxetine is combined with Eptifibatide.,Paroxetine
DB01149,The risk or severity of hemorrhage can be increased when Nefazodone is combined with Eptifibatide.,Nefazodone
DB04832,The risk or severity of hemorrhage can be increased when Zimelidine is combined with Eptifibatide.,Zimelidine
DB04884,The risk or severity of hemorrhage can be increased when Dapoxetine is combined with Eptifibatide.,Dapoxetine
DB06731,The risk or severity of hemorrhage can be increased when Seproxetine is combined with Eptifibatide.,Seproxetine
DB08953,The risk or severity of hemorrhage can be increased when Indalpine is combined with Eptifibatide.,Indalpine
DB12693,The risk or severity of hemorrhage can be increased when Ritanserin is combined with Eptifibatide.,Ritanserin
DB13233,The risk or severity of hemorrhage can be increased when Alaproclate is combined with Eptifibatide.,Alaproclate
DB00285,Venlafaxine may increase the antiplatelet activities of Eptifibatide.,Venlafaxine
DB00476,Duloxetine may increase the antiplatelet activities of Eptifibatide.,Duloxetine
DB01105,Sibutramine may increase the antiplatelet activities of Eptifibatide.,Sibutramine
DB04896,Milnacipran may increase the antiplatelet activities of Eptifibatide.,Milnacipran
DB06700,Desvenlafaxine may increase the antiplatelet activities of Eptifibatide.,Desvenlafaxine
DB08918,Levomilnacipran may increase the antiplatelet activities of Eptifibatide.,Levomilnacipran
DB00182,The risk or severity of bleeding and hemorrhage can be increased when Amphetamine is combined with Eptifibatide.,Amphetamine
DB00601,The risk or severity of bleeding and hemorrhage can be increased when Linezolid is combined with Eptifibatide.,Linezolid
DB00614,The risk or severity of bleeding and hemorrhage can be increased when Furazolidone is combined with Eptifibatide.,Furazolidone
DB00721,The risk or severity of bleeding and hemorrhage can be increased when Procaine is combined with Eptifibatide.,Procaine
DB00752,The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Eptifibatide.,Tranylcypromine
DB00780,The risk or severity of bleeding and hemorrhage can be increased when Phenelzine is combined with Eptifibatide.,Phenelzine
DB00805,The risk or severity of bleeding and hemorrhage can be increased when Minaprine is combined with Eptifibatide.,Minaprine
DB01037,The risk or severity of bleeding and hemorrhage can be increased when Selegiline is combined with Eptifibatide.,Selegiline
DB01168,The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Eptifibatide.,Procarbazine
DB01171,The risk or severity of bleeding and hemorrhage can be increased when Moclobemide is combined with Eptifibatide.,Moclobemide
DB01247,The risk or severity of bleeding and hemorrhage can be increased when Isocarboxazid is combined with Eptifibatide.,Isocarboxazid
DB01367,The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Eptifibatide.,Rasagiline
DB01626,The risk or severity of bleeding and hemorrhage can be increased when Pargyline is combined with Eptifibatide.,Pargyline
DB04017,The risk or severity of bleeding and hemorrhage can be increased when Clorgiline is combined with Eptifibatide.,Clorgiline
DB04818,The risk or severity of bleeding and hemorrhage can be increased when Iproniazid is combined with Eptifibatide.,Iproniazid
DB04820,The risk or severity of bleeding and hemorrhage can be increased when Nialamide is combined with Eptifibatide.,Nialamide
DB06654,The risk or severity of bleeding and hemorrhage can be increased when Safinamide is combined with Eptifibatide.,Safinamide
DB08550,"The risk or severity of bleeding and hemorrhage can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Eptifibatide.","7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline"
DB09241,The risk or severity of bleeding and hemorrhage can be increased when Methylene blue is combined with Eptifibatide.,Methylene blue
DB09243,The risk or severity of bleeding and hemorrhage can be increased when Hydracarbazine is combined with Eptifibatide.,Hydracarbazine
DB09244,The risk or severity of bleeding and hemorrhage can be increased when Pirlindole is combined with Eptifibatide.,Pirlindole
DB09245,The risk or severity of bleeding and hemorrhage can be increased when Toloxatone is combined with Eptifibatide.,Toloxatone
DB09246,The risk or severity of bleeding and hemorrhage can be increased when Benmoxin is combined with Eptifibatide.,Benmoxin
DB09248,The risk or severity of bleeding and hemorrhage can be increased when Mebanazine is combined with Eptifibatide.,Mebanazine
DB09249,The risk or severity of bleeding and hemorrhage can be increased when Octamoxin is combined with Eptifibatide.,Octamoxin
DB09250,The risk or severity of bleeding and hemorrhage can be increased when Pheniprazine is combined with Eptifibatide.,Pheniprazine
DB09251,The risk or severity of bleeding and hemorrhage can be increased when Phenoxypropazine is combined with Eptifibatide.,Phenoxypropazine
DB09252,The risk or severity of bleeding and hemorrhage can be increased when Pivhydrazine is combined with Eptifibatide.,Pivhydrazine
DB09253,The risk or severity of bleeding and hemorrhage can be increased when Safrazine is combined with Eptifibatide.,Safrazine
DB09254,The risk or severity of bleeding and hemorrhage can be increased when Caroxazone is combined with Eptifibatide.,Caroxazone
DB13875,The risk or severity of bleeding and hemorrhage can be increased when Harmaline is combined with Eptifibatide.,Harmaline
DB13876,The risk or severity of bleeding and hemorrhage can be increased when Brofaromine is combined with Eptifibatide.,Brofaromine
DB09539,The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Eptifibatide.,Omega-3-acid ethyl esters
DB00945,Acetylsalicylic acid may increase the antiplatelet activities of Eptifibatide.,Acetylsalicylic acid
DB00159,The risk or severity of bleeding can be increased when Icosapent is combined with Eptifibatide.,Icosapent
DB00244,The risk or severity of bleeding can be increased when Mesalazine is combined with Eptifibatide.,Mesalazine
DB00328,The risk or severity of bleeding can be increased when Indomethacin is combined with Eptifibatide.,Indomethacin
DB00461,The risk or severity of bleeding can be increased when Nabumetone is combined with Eptifibatide.,Nabumetone
DB00465,The risk or severity of bleeding can be increased when Ketorolac is combined with Eptifibatide.,Ketorolac
DB00469,The risk or severity of bleeding can be increased when Tenoxicam is combined with Eptifibatide.,Tenoxicam
DB00482,The risk or severity of bleeding can be increased when Celecoxib is combined with Eptifibatide.,Celecoxib
DB00500,The risk or severity of bleeding can be increased when Tolmetin is combined with Eptifibatide.,Tolmetin
DB00533,The risk or severity of bleeding can be increased when Rofecoxib is combined with Eptifibatide.,Rofecoxib
DB00554,The risk or severity of bleeding can be increased when Piroxicam is combined with Eptifibatide.,Piroxicam
DB00573,The risk or severity of bleeding can be increased when Fenoprofen is combined with Eptifibatide.,Fenoprofen
DB00580,The risk or severity of bleeding can be increased when Valdecoxib is combined with Eptifibatide.,Valdecoxib
DB00586,The risk or severity of bleeding can be increased when Diclofenac is combined with Eptifibatide.,Diclofenac
DB00605,The risk or severity of bleeding can be increased when Sulindac is combined with Eptifibatide.,Sulindac
DB00712,The risk or severity of bleeding can be increased when Flurbiprofen is combined with Eptifibatide.,Flurbiprofen
DB00749,The risk or severity of bleeding can be increased when Etodolac is combined with Eptifibatide.,Etodolac
DB00784,The risk or severity of bleeding can be increased when Mefenamic acid is combined with Eptifibatide.,Mefenamic acid
DB00788,The risk or severity of bleeding can be increased when Naproxen is combined with Eptifibatide.,Naproxen
DB00795,The risk or severity of bleeding can be increased when Sulfasalazine is combined with Eptifibatide.,Sulfasalazine
DB00812,The risk or severity of bleeding can be increased when Phenylbutazone is combined with Eptifibatide.,Phenylbutazone
DB00814,The risk or severity of bleeding can be increased when Meloxicam is combined with Eptifibatide.,Meloxicam
DB00821,The risk or severity of bleeding can be increased when Carprofen is combined with Eptifibatide.,Carprofen
DB00861,The risk or severity of bleeding can be increased when Diflunisal is combined with Eptifibatide.,Diflunisal
DB00936,The risk or severity of bleeding can be increased when Salicylic acid is combined with Eptifibatide.,Salicylic acid
DB00939,The risk or severity of bleeding can be increased when Meclofenamic acid is combined with Eptifibatide.,Meclofenamic acid
DB00991,The risk or severity of bleeding can be increased when Oxaprozin is combined with Eptifibatide.,Oxaprozin
DB01009,The risk or severity of bleeding can be increased when Ketoprofen is combined with Eptifibatide.,Ketoprofen
DB01014,The risk or severity of bleeding can be increased when Balsalazide is combined with Eptifibatide.,Balsalazide
DB01050,The risk or severity of bleeding can be increased when Ibuprofen is combined with Eptifibatide.,Ibuprofen
DB01250,The risk or severity of bleeding can be increased when Olsalazine is combined with Eptifibatide.,Olsalazine
DB01283,The risk or severity of bleeding can be increased when Lumiracoxib is combined with Eptifibatide.,Lumiracoxib
DB01397,The risk or severity of bleeding can be increased when Magnesium salicylate is combined with Eptifibatide.,Magnesium salicylate
DB01399,The risk or severity of bleeding can be increased when Salsalate is combined with Eptifibatide.,Salsalate
DB01401,The risk or severity of bleeding can be increased when Choline magnesium trisalicylate is combined with Eptifibatide.,Choline magnesium trisalicylate
DB01419,The risk or severity of bleeding can be increased when Antrafenine is combined with Eptifibatide.,Antrafenine
DB01424,The risk or severity of bleeding can be increased when Aminophenazone is combined with Eptifibatide.,Aminophenazone
DB01435,The risk or severity of bleeding can be increased when Antipyrine is combined with Eptifibatide.,Antipyrine
DB01600,The risk or severity of bleeding can be increased when Tiaprofenic acid is combined with Eptifibatide.,Tiaprofenic acid
DB01628,The risk or severity of bleeding can be increased when Etoricoxib is combined with Eptifibatide.,Etoricoxib
DB02224,The risk or severity of bleeding can be increased when Taxifolin is combined with Eptifibatide.,Taxifolin
DB03585,The risk or severity of bleeding can be increased when Oxyphenbutazone is combined with Eptifibatide.,Oxyphenbutazone
DB04552,The risk or severity of bleeding can be increased when Niflumic acid is combined with Eptifibatide.,Niflumic acid
DB04725,The risk or severity of bleeding can be increased when Licofelone is combined with Eptifibatide.,Licofelone
DB04743,The risk or severity of bleeding can be increased when Nimesulide is combined with Eptifibatide.,Nimesulide
DB04812,The risk or severity of bleeding can be increased when Benoxaprofen is combined with Eptifibatide.,Benoxaprofen
DB04817,The risk or severity of bleeding can be increased when Metamizole is combined with Eptifibatide.,Metamizole
DB04828,The risk or severity of bleeding can be increased when Zomepirac is combined with Eptifibatide.,Zomepirac
DB05095,The risk or severity of bleeding can be increased when Cimicoxib is combined with Eptifibatide.,Cimicoxib
DB06725,The risk or severity of bleeding can be increased when Lornoxicam is combined with Eptifibatide.,Lornoxicam
DB06736,The risk or severity of bleeding can be increased when Aceclofenac is combined with Eptifibatide.,Aceclofenac
DB06737,The risk or severity of bleeding can be increased when Zaltoprofen is combined with Eptifibatide.,Zaltoprofen
DB07402,The risk or severity of bleeding can be increased when Azapropazone is combined with Eptifibatide.,Azapropazone
DB07477,The risk or severity of bleeding can be increased when Felbinac is combined with Eptifibatide.,Felbinac
DB08439,The risk or severity of bleeding can be increased when Parecoxib is combined with Eptifibatide.,Parecoxib
DB08797,The risk or severity of bleeding can be increased when Salicylamide is combined with Eptifibatide.,Salicylamide
DB08940,The risk or severity of bleeding can be increased when Kebuzone is combined with Eptifibatide.,Kebuzone
DB08942,The risk or severity of bleeding can be increased when Isoxicam is combined with Eptifibatide.,Isoxicam
DB08951,The risk or severity of bleeding can be increased when Indoprofen is combined with Eptifibatide.,Indoprofen
DB08955,The risk or severity of bleeding can be increased when Ibuproxam is combined with Eptifibatide.,Ibuproxam
DB08976,The risk or severity of bleeding can be increased when Floctafenine is combined with Eptifibatide.,Floctafenine
DB08981,The risk or severity of bleeding can be increased when Fenbufen is combined with Eptifibatide.,Fenbufen
DB08984,The risk or severity of bleeding can be increased when Etofenamate is combined with Eptifibatide.,Etofenamate
DB08991,The risk or severity of bleeding can be increased when Epirizole is combined with Eptifibatide.,Epirizole
DB09084,The risk or severity of bleeding can be increased when Benzydamine is combined with Eptifibatide.,Benzydamine
DB09212,The risk or severity of bleeding can be increased when Loxoprofen is combined with Eptifibatide.,Loxoprofen
DB09213,The risk or severity of bleeding can be increased when Dexibuprofen is combined with Eptifibatide.,Dexibuprofen
DB09214,The risk or severity of bleeding can be increased when Dexketoprofen is combined with Eptifibatide.,Dexketoprofen
DB09215,The risk or severity of bleeding can be increased when Droxicam is combined with Eptifibatide.,Droxicam
DB09216,The risk or severity of bleeding can be increased when Tolfenamic acid is combined with Eptifibatide.,Tolfenamic acid
DB09217,The risk or severity of bleeding can be increased when Firocoxib is combined with Eptifibatide.,Firocoxib
DB09218,The risk or severity of bleeding can be increased when Clonixin is combined with Eptifibatide.,Clonixin
DB09285,The risk or severity of bleeding can be increased when Morniflumate is combined with Eptifibatide.,Morniflumate
DB09288,The risk or severity of bleeding can be increased when Propacetamol is combined with Eptifibatide.,Propacetamol
DB09295,The risk or severity of bleeding can be increased when Talniflumate is combined with Eptifibatide.,Talniflumate
DB11455,The risk or severity of bleeding can be increased when Robenacoxib is combined with Eptifibatide.,Robenacoxib
DB11466,The risk or severity of bleeding can be increased when Tepoxalin is combined with Eptifibatide.,Tepoxalin
DB11518,The risk or severity of bleeding can be increased when Flunixin is combined with Eptifibatide.,Flunixin
DB12399,The risk or severity of bleeding can be increased when Polmacoxib is combined with Eptifibatide.,Polmacoxib
DB12445,The risk or severity of bleeding can be increased when Nitroaspirin is combined with Eptifibatide.,Nitroaspirin
DB12480,The risk or severity of bleeding can be increased when Betulinic Acid is combined with Eptifibatide.,Betulinic Acid
DB12545,The risk or severity of bleeding can be increased when Indobufen is combined with Eptifibatide.,Indobufen
DB12610,The risk or severity of bleeding can be increased when Ebselen is combined with Eptifibatide.,Ebselen
DB13001,The risk or severity of bleeding can be increased when Tinoridine is combined with Eptifibatide.,Tinoridine
DB13167,The risk or severity of bleeding can be increased when Alclofenac is combined with Eptifibatide.,Alclofenac
DB13217,The risk or severity of bleeding can be increased when Fentiazac is combined with Eptifibatide.,Fentiazac
DB13232,The risk or severity of bleeding can be increased when Suxibuzone is combined with Eptifibatide.,Suxibuzone
DB13286,The risk or severity of bleeding can be increased when Bumadizone is combined with Eptifibatide.,Bumadizone
DB13314,The risk or severity of bleeding can be increased when Alminoprofen is combined with Eptifibatide.,Alminoprofen
DB13317,The risk or severity of bleeding can be increased when Flunoxaprofen is combined with Eptifibatide.,Flunoxaprofen
DB13364,The risk or severity of bleeding can be increased when Feprazone is combined with Eptifibatide.,Feprazone
DB13371,The risk or severity of bleeding can be increased when Difenpiramide is combined with Eptifibatide.,Difenpiramide
DB13407,The risk or severity of bleeding can be increased when Nifenazone is combined with Eptifibatide.,Nifenazone
DB13432,The risk or severity of bleeding can be increased when Lonazolac is combined with Eptifibatide.,Lonazolac
DB13481,The risk or severity of bleeding can be increased when Tenidap is combined with Eptifibatide.,Tenidap
DB13501,The risk or severity of bleeding can be increased when Bendazac is combined with Eptifibatide.,Bendazac
DB13514,The risk or severity of bleeding can be increased when Pranoprofen is combined with Eptifibatide.,Pranoprofen
DB13524,The risk or severity of bleeding can be increased when Propyphenazone is combined with Eptifibatide.,Propyphenazone
DB13527,The risk or severity of bleeding can be increased when Proglumetacin is combined with Eptifibatide.,Proglumetacin
DB13538,The risk or severity of bleeding can be increased when Guacetisal is combined with Eptifibatide.,Guacetisal
DB13544,The risk or severity of bleeding can be increased when Ethenzamide is combined with Eptifibatide.,Ethenzamide
DB13612,The risk or severity of bleeding can be increased when Carbaspirin calcium is combined with Eptifibatide.,Carbaspirin calcium
DB13629,The risk or severity of bleeding can be increased when Mofebutazone is combined with Eptifibatide.,Mofebutazone
DB13649,The risk or severity of bleeding can be increased when Proquazone is combined with Eptifibatide.,Proquazone
DB13657,The risk or severity of bleeding can be increased when Benorilate is combined with Eptifibatide.,Benorilate
DB13722,The risk or severity of bleeding can be increased when Pirprofen is combined with Eptifibatide.,Pirprofen
DB13783,The risk or severity of bleeding can be increased when Acemetacin is combined with Eptifibatide.,Acemetacin
DB13860,The risk or severity of bleeding can be increased when Imidazole salicylate is combined with Eptifibatide.,Imidazole salicylate
DB14059,The risk or severity of bleeding can be increased when SC-236 is combined with Eptifibatide.,SC-236
DB14060,The risk or severity of bleeding can be increased when NS-398 is combined with Eptifibatide.,NS-398
DB14938,The risk or severity of bleeding can be increased when Flurbiprofen axetil is combined with Eptifibatide.,Flurbiprofen axetil
DB00656,The risk or severity of bleeding can be increased when Trazodone is combined with Eptifibatide.,Trazodone
DB01175,The risk or severity of bleeding can be increased when Escitalopram is combined with Eptifibatide.,Escitalopram
DB01104,The risk or severity of bleeding can be increased when Sertraline is combined with Eptifibatide.,Sertraline
DB01281,The risk or severity of infection can be increased when Infliximab is combined with Abatacept.,Abatacept
DB00026,The risk or severity of adverse effects can be increased when Infliximab is combined with Anakinra.,Anakinra
DB06168,The risk or severity of infection and neutropenia can be increased when Infliximab is combined with Canakinumab.,Canakinumab
DB08904,The risk or severity of infection can be increased when Infliximab is combined with Certolizumab pegol.,Certolizumab pegol
DB06643,The risk or severity of adverse effects can be increased when Denosumab is combined with Infliximab.,Denosumab
DB00005,Etanercept may increase the immunosuppressive activities of Infliximab.,Etanercept
DB00008,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Infliximab.,Peginterferon alfa-2a
DB00011,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Infliximab.,Interferon alfa-n1
DB00018,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Infliximab.,Interferon alfa-n3
DB00022,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Infliximab.,Peginterferon alfa-2b
DB00033,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Infliximab.,Interferon gamma-1b
DB00034,"The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Infliximab.","Interferon alfa-2a, Recombinant"
DB00041,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Infliximab.,Aldesleukin
DB00056,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Infliximab.,Gemtuzumab ozogamicin
DB00059,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Infliximab.,Pegaspargase
DB00068,The risk or severity of adverse effects can be increased when Infliximab is combined with Interferon beta-1b.,Interferon beta-1b
DB00069,The risk or severity of adverse effects can be increased when Infliximab is combined with Interferon alfacon-1.,Interferon alfacon-1
DB00073,The risk or severity of adverse effects can be increased when Infliximab is combined with Rituximab.,Rituximab
DB00074,The risk or severity of adverse effects can be increased when Infliximab is combined with Basiliximab.,Basiliximab
DB00075,The risk or severity of adverse effects can be increased when Infliximab is combined with Muromonab.,Muromonab
DB00078,The risk or severity of adverse effects can be increased when Infliximab is combined with Ibritumomab tiuxetan.,Ibritumomab tiuxetan
DB00081,The risk or severity of adverse effects can be increased when Infliximab is combined with Tositumomab.,Tositumomab
DB00087,The risk or severity of adverse effects can be increased when Infliximab is combined with Alemtuzumab.,Alemtuzumab
DB00092,The risk or severity of adverse effects can be increased when Infliximab is combined with Alefacept.,Alefacept
DB00095,The risk or severity of adverse effects can be increased when Infliximab is combined with Efalizumab.,Efalizumab
DB00098,The risk or severity of adverse effects can be increased when Infliximab is combined with Antithymocyte immunoglobulin (rabbit).,Antithymocyte immunoglobulin (rabbit)
DB00105,The risk or severity of adverse effects can be increased when Infliximab is combined with Interferon alfa-2b.,Interferon alfa-2b
DB00111,The risk or severity of adverse effects can be increased when Infliximab is combined with Daclizumab.,Daclizumab
DB00112,The risk or severity of adverse effects can be increased when Infliximab is combined with Bevacizumab.,Bevacizumab
DB00120,The risk or severity of adverse effects can be increased when Infliximab is combined with Phenylalanine.,Phenylalanine
DB00242,The risk or severity of adverse effects can be increased when Infliximab is combined with Cladribine.,Cladribine
DB00276,The risk or severity of adverse effects can be increased when Infliximab is combined with Amsacrine.,Amsacrine
DB00290,The risk or severity of adverse effects can be increased when Infliximab is combined with Bleomycin.,Bleomycin
DB00291,The risk or severity of adverse effects can be increased when Infliximab is combined with Chlorambucil.,Chlorambucil
DB00293,The risk or severity of adverse effects can be increased when Infliximab is combined with Raltitrexed.,Raltitrexed
DB00305,The risk or severity of adverse effects can be increased when Infliximab is combined with Mitomycin.,Mitomycin
DB00322,The risk or severity of adverse effects can be increased when Infliximab is combined with Floxuridine.,Floxuridine
DB00352,The risk or severity of adverse effects can be increased when Infliximab is combined with Tioguanine.,Tioguanine
DB00380,The risk or severity of adverse effects can be increased when Infliximab is combined with Dexrazoxane.,Dexrazoxane
DB00428,The risk or severity of adverse effects can be increased when Infliximab is combined with Streptozocin.,Streptozocin
DB00432,The risk or severity of adverse effects can be increased when Infliximab is combined with Trifluridine.,Trifluridine
DB00441,The risk or severity of adverse effects can be increased when Infliximab is combined with Gemcitabine.,Gemcitabine
DB00445,The risk or severity of adverse effects can be increased when Infliximab is combined with Epirubicin.,Epirubicin
DB00446,The risk or severity of adverse effects can be increased when Infliximab is combined with Chloramphenicol.,Chloramphenicol
DB00480,The risk or severity of adverse effects can be increased when Infliximab is combined with Lenalidomide.,Lenalidomide
DB00488,The risk or severity of adverse effects can be increased when Infliximab is combined with Altretamine.,Altretamine
DB00515,The risk or severity of adverse effects can be increased when Infliximab is combined with Cisplatin.,Cisplatin
DB00526,The risk or severity of adverse effects can be increased when Infliximab is combined with Oxaliplatin.,Oxaliplatin
DB00550,The risk or severity of adverse effects can be increased when Infliximab is combined with Propylthiouracil.,Propylthiouracil
DB00552,The risk or severity of adverse effects can be increased when Infliximab is combined with Pentostatin.,Pentostatin
DB00601,The risk or severity of adverse effects can be increased when Infliximab is combined with Linezolid.,Linezolid
DB00631,The risk or severity of adverse effects can be increased when Infliximab is combined with Clofarabine.,Clofarabine
DB00763,The risk or severity of adverse effects can be increased when Infliximab is combined with Methimazole.,Methimazole
DB00795,The risk or severity of adverse effects can be increased when Infliximab is combined with Sulfasalazine.,Sulfasalazine
DB00853,The risk or severity of adverse effects can be increased when Infliximab is combined with Temozolomide.,Temozolomide
DB00859,The risk or severity of adverse effects can be increased when Infliximab is combined with Penicillamine.,Penicillamine
DB00888,The risk or severity of adverse effects can be increased when Infliximab is combined with Mechlorethamine.,Mechlorethamine
DB00928,The risk or severity of adverse effects can be increased when Infliximab is combined with Azacitidine.,Azacitidine
DB00958,The risk or severity of adverse effects can be increased when Infliximab is combined with Carboplatin.,Carboplatin
DB00970,The risk or severity of adverse effects can be increased when Infliximab is combined with Dactinomycin.,Dactinomycin
DB01005,The risk or severity of adverse effects can be increased when Infliximab is combined with Hydroxyurea.,Hydroxyurea
DB01024,The risk or severity of adverse effects can be increased when Infliximab is combined with Mycophenolic acid.,Mycophenolic acid
DB01030,The risk or severity of adverse effects can be increased when Infliximab is combined with Topotecan.,Topotecan
DB01033,The risk or severity of adverse effects can be increased when Infliximab is combined with Mercaptopurine.,Mercaptopurine
DB01042,The risk or severity of adverse effects can be increased when Infliximab is combined with Melphalan.,Melphalan
DB01073,The risk or severity of adverse effects can be increased when Infliximab is combined with Fludarabine.,Fludarabine
DB01099,The risk or severity of adverse effects can be increased when Infliximab is combined with Flucytosine.,Flucytosine
DB01168,The risk or severity of adverse effects can be increased when Infliximab is combined with Procarbazine.,Procarbazine
DB01169,The risk or severity of adverse effects can be increased when Infliximab is combined with Arsenic trioxide.,Arsenic trioxide
DB01204,The risk or severity of adverse effects can be increased when Infliximab is combined with Mitoxantrone.,Mitoxantrone
DB01206,The risk or severity of adverse effects can be increased when Infliximab is combined with Lomustine.,Lomustine
DB01257,The risk or severity of adverse effects can be increased when Infliximab is combined with Eculizumab.,Eculizumab
DB01262,The risk or severity of adverse effects can be increased when Infliximab is combined with Decitabine.,Decitabine
DB01280,The risk or severity of adverse effects can be increased when Infliximab is combined with Nelarabine.,Nelarabine
DB01423,The risk or severity of adverse effects can be increased when Infliximab is combined with Stepronin.,Stepronin
DB01816,The risk or severity of adverse effects can be increased when Infliximab is combined with Castanospermine.,Castanospermine
DB02546,The risk or severity of adverse effects can be increased when Infliximab is combined with Vorinostat.,Vorinostat
DB02806,The risk or severity of adverse effects can be increased when Infliximab is combined with 2-Methoxyethanol.,2-Methoxyethanol
DB03523,The risk or severity of adverse effects can be increased when Infliximab is combined with Brequinar.,Brequinar
DB04956,The risk or severity of adverse effects can be increased when Infliximab is combined with Afelimomab.,Afelimomab
DB05258,The risk or severity of adverse effects can be increased when Infliximab is combined with Interferon alfa.,Interferon alfa
DB05259,The risk or severity of adverse effects can be increased when Infliximab is combined with Glatiramer.,Glatiramer
DB05260,The risk or severity of adverse effects can be increased when Infliximab is combined with Gallium nitrate.,Gallium nitrate
DB05459,The risk or severity of adverse effects can be increased when Infliximab is combined with Briakinumab.,Briakinumab
DB05472,The risk or severity of adverse effects can be increased when Infliximab is combined with omega interferon.,omega interferon
DB06612,The risk or severity of adverse effects can be increased when Infliximab is combined with Mepolizumab.,Mepolizumab
DB06662,The risk or severity of adverse effects can be increased when Infliximab is combined with Abetimus.,Abetimus
DB06674,The risk or severity of adverse effects can be increased when Infliximab is combined with Golimumab.,Golimumab
DB06681,The risk or severity of adverse effects can be increased when Infliximab is combined with Belatacept.,Belatacept
DB06813,The risk or severity of adverse effects can be increased when Infliximab is combined with Pralatrexate.,Pralatrexate
DB08059,The risk or severity of adverse effects can be increased when Infliximab is combined with Wortmannin.,Wortmannin
DB08871,The risk or severity of adverse effects can be increased when Infliximab is combined with Eribulin.,Eribulin
DB08879,The risk or severity of adverse effects can be increased when Infliximab is combined with Belimumab.,Belimumab
DB08880,The risk or severity of adverse effects can be increased when Infliximab is combined with Teriflunomide.,Teriflunomide
DB08889,The risk or severity of adverse effects can be increased when Infliximab is combined with Carfilzomib.,Carfilzomib
DB08908,The risk or severity of adverse effects can be increased when Infliximab is combined with Dimethyl fumarate.,Dimethyl fumarate
DB08935,The risk or severity of adverse effects can be increased when Infliximab is combined with Obinutuzumab.,Obinutuzumab
DB09029,The risk or severity of adverse effects can be increased when Infliximab is combined with Secukinumab.,Secukinumab
DB09036,The risk or severity of adverse effects can be increased when Infliximab is combined with Siltuximab.,Siltuximab
DB09052,The risk or severity of adverse effects can be increased when Infliximab is combined with Blinatumomab.,Blinatumomab
DB09077,The risk or severity of adverse effects can be increased when Infliximab is combined with Dinutuximab.,Dinutuximab
DB09091,The risk or severity of adverse effects can be increased when Infliximab is combined with Tixocortol.,Tixocortol
DB09122,The risk or severity of adverse effects can be increased when Infliximab is combined with Peginterferon beta-1a.,Peginterferon beta-1a
DB09312,The risk or severity of adverse effects can be increased when Infliximab is combined with Antilymphocyte immunoglobulin (horse).,Antilymphocyte immunoglobulin (horse)
DB11466,The risk or severity of adverse effects can be increased when Infliximab is combined with Tepoxalin.,Tepoxalin
DB11569,The risk or severity of adverse effects can be increased when Infliximab is combined with Ixekizumab.,Ixekizumab
DB11580,The risk or severity of adverse effects can be increased when Infliximab is combined with Ravulizumab.,Ravulizumab
DB11616,The risk or severity of adverse effects can be increased when Infliximab is combined with Pirarubicin.,Pirarubicin
DB11693,The risk or severity of adverse effects can be increased when Infliximab is combined with Voclosporin.,Voclosporin
DB11708,The risk or severity of adverse effects can be increased when Infliximab is combined with Peficitinib.,Peficitinib
DB11767,The risk or severity of adverse effects can be increased when Infliximab is combined with Sarilumab.,Sarilumab
DB11776,The risk or severity of adverse effects can be increased when Infliximab is combined with Brodalumab.,Brodalumab
DB11803,The risk or severity of adverse effects can be increased when Infliximab is combined with Sirukumab.,Sirukumab
DB11834,The risk or severity of adverse effects can be increased when Infliximab is combined with Guselkumab.,Guselkumab
DB12025,The risk or severity of adverse effects can be increased when Infliximab is combined with Triptolide.,Triptolide
DB12612,The risk or severity of adverse effects can be increased when Infliximab is combined with Ozanimod.,Ozanimod
DB12617,The risk or severity of adverse effects can be increased when Infliximab is combined with Mizoribine.,Mizoribine
DB12692,The risk or severity of adverse effects can be increased when Infliximab is combined with Gusperimus.,Gusperimus
DB12814,The risk or severity of adverse effects can be increased when Infliximab is combined with Cepeginterferon alfa-2B.,Cepeginterferon alfa-2B
DB12902,The risk or severity of adverse effects can be increased when Infliximab is combined with Trofosfamide.,Trofosfamide
DB12947,The risk or severity of adverse effects can be increased when Infliximab is combined with Doxifluridine.,Doxifluridine
DB12991,The risk or severity of adverse effects can be increased when Infliximab is combined with Deoxyspergualin.,Deoxyspergualin
DB12996,The risk or severity of adverse effects can be increased when Infliximab is combined with Acteoside.,Acteoside
DB13003,The risk or severity of adverse effects can be increased when Infliximab is combined with Cortivazol.,Cortivazol
DB13014,The risk or severity of adverse effects can be increased when Infliximab is combined with Hypericin.,Hypericin
DB13068,The risk or severity of adverse effects can be increased when Infliximab is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.,9-(N-methyl-L-isoleucine)-cyclosporin A
DB13223,The risk or severity of adverse effects can be increased when Infliximab is combined with Fluocortin.,Fluocortin
DB13241,The risk or severity of adverse effects can be increased when Infliximab is combined with Begelomab.,Begelomab
DB13491,The risk or severity of adverse effects can be increased when Infliximab is combined with Fluperolone.,Fluperolone
DB13664,The risk or severity of adverse effects can be increased when Infliximab is combined with Formocortal.,Formocortal
DB13728,The risk or severity of adverse effects can be increased when Infliximab is combined with Halometasone.,Halometasone
DB13843,The risk or severity of adverse effects can be increased when Infliximab is combined with Cloprednol.,Cloprednol
DB13856,The risk or severity of adverse effects can be increased when Infliximab is combined with Fluclorolone.,Fluclorolone
DB14219,The risk or severity of adverse effects can be increased when Infliximab is combined with Monomethyl fumarate.,Monomethyl fumarate
DB14724,The risk or severity of adverse effects can be increased when Infliximab is combined with Emapalumab.,Emapalumab
DB14762,The risk or severity of adverse effects can be increased when Infliximab is combined with Risankizumab.,Risankizumab
DB14919,The risk or severity of adverse effects can be increased when Infliximab is combined with Rozanolixizumab.,Rozanolixizumab
DB15253,The risk or severity of adverse effects can be increased when Infliximab is combined with Bleselumab.,Bleselumab
DB00180,The risk or severity of adverse effects can be increased when Infliximab is combined with Flunisolide.,Flunisolide
DB00394,The risk or severity of adverse effects can be increased when Infliximab is combined with Beclomethasone dipropionate.,Beclomethasone dipropionate
DB00443,The risk or severity of adverse effects can be increased when Infliximab is combined with Betamethasone.,Betamethasone
DB00591,The risk or severity of adverse effects can be increased when Infliximab is combined with Fluocinolone acetonide.,Fluocinolone acetonide
DB00635,The risk or severity of adverse effects can be increased when Infliximab is combined with Prednisone.,Prednisone
DB00687,The risk or severity of adverse effects can be increased when Infliximab is combined with Fludrocortisone.,Fludrocortisone
DB00764,The risk or severity of adverse effects can be increased when Infliximab is combined with Mometasone.,Mometasone
DB00860,The risk or severity of adverse effects can be increased when Infliximab is combined with Prednisolone.,Prednisolone
DB00959,The risk or severity of adverse effects can be increased when Infliximab is combined with Methylprednisolone.,Methylprednisolone
DB01196,The risk or severity of adverse effects can be increased when Infliximab is combined with Estramustine.,Estramustine
DB01285,The risk or severity of adverse effects can be increased when Infliximab is combined with Corticotropin.,Corticotropin
DB01380,The risk or severity of adverse effects can be increased when Infliximab is combined with Cortisone acetate.,Cortisone acetate
DB01384,The risk or severity of adverse effects can be increased when Infliximab is combined with Paramethasone.,Paramethasone
DB01611,The risk or severity of adverse effects can be increased when Infliximab is combined with Hydroxychloroquine.,Hydroxychloroquine
DB04630,The risk or severity of adverse effects can be increased when Infliximab is combined with Aldosterone.,Aldosterone
DB08970,The risk or severity of adverse effects can be increased when Infliximab is combined with Fluprednidene.,Fluprednidene
DB08971,The risk or severity of adverse effects can be increased when Infliximab is combined with Fluocortolone.,Fluocortolone
DB09082,The risk or severity of adverse effects can be increased when Infliximab is combined with Vilanterol.,Vilanterol
DB09378,The risk or severity of adverse effects can be increased when Infliximab is combined with Fluprednisolone.,Fluprednisolone
DB09383,The risk or severity of adverse effects can be increased when Infliximab is combined with Meprednisone.,Meprednisone
DB11487,The risk or severity of adverse effects can be increased when Infliximab is combined with Dexamethasone isonicotinate.,Dexamethasone isonicotinate
DB11529,The risk or severity of adverse effects can be increased when Infliximab is combined with Melengestrol.,Melengestrol
DB11750,The risk or severity of adverse effects can be increased when Infliximab is combined with Clobetasol.,Clobetasol
DB11817,The risk or severity of adverse effects can be increased when Infliximab is combined with Baricitinib.,Baricitinib
DB11921,The risk or severity of adverse effects can be increased when Infliximab is combined with Deflazacort.,Deflazacort
DB13208,The risk or severity of adverse effects can be increased when Infliximab is combined with Prednylidene.,Prednylidene
DB14066,The risk or severity of adverse effects can be increased when Infliximab is combined with Tetrandrine.,Tetrandrine
DB14512,The risk or severity of adverse effects can be increased when Infliximab is combined with Mometasone furoate.,Mometasone furoate
DB14545,The risk or severity of adverse effects can be increased when Infliximab is combined with Hydrocortisone succinate.,Hydrocortisone succinate
DB01222,The risk or severity of adverse effects can be increased when Infliximab is combined with Budesonide.,Budesonide
DB01394,The risk or severity of adverse effects can be increased when Infliximab is combined with Colchicine.,Colchicine
DB00108,The risk or severity of adverse effects can be increased when Infliximab is combined with Natalizumab.,Natalizumab
DB00337,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Infliximab.,Pimecrolimus
DB06372,The risk or severity of adverse effects can be increased when Infliximab is combined with Rilonacept.,Rilonacept
DB01656,Infliximab may increase the immunosuppressive activities of Roflumilast.,Roflumilast
DB06688,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Infliximab.,Sipuleucel-T
DB06273,Tocilizumab may increase the immunosuppressive activities of Infliximab.,Tocilizumab
DB08895,The risk or severity of adverse effects can be increased when Infliximab is combined with Tofacitinib.,Tofacitinib
DB09033,The risk or severity of infection can be increased when Infliximab is combined with Vedolizumab.,Vedolizumab
DB00051,Adalimumab may increase the immunosuppressive activities of Infliximab.,Adalimumab
DB01015,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Infliximab.,Sulfamethoxazole
DB00269,Chlorotrianisene may increase the thrombogenic activities of Infliximab.,Chlorotrianisene
DB00655,Estrone may increase the thrombogenic activities of Infliximab.,Estrone
DB00890,Dienestrol may increase the thrombogenic activities of Infliximab.,Dienestrol
DB04573,Estriol may increase the thrombogenic activities of Infliximab.,Estriol
DB04575,Quinestrol may increase the thrombogenic activities of Infliximab.,Quinestrol
DB07931,Hexestrol may increase the thrombogenic activities of Infliximab.,Hexestrol
DB09070,Tibolone may increase the thrombogenic activities of Infliximab.,Tibolone
DB09369,Polyestradiol phosphate may increase the thrombogenic activities of Infliximab.,Polyestradiol phosphate
DB11478,Zeranol may increase the thrombogenic activities of Infliximab.,Zeranol
DB11674,Equol may increase the thrombogenic activities of Infliximab.,Equol
DB12487,Promestriene may increase the thrombogenic activities of Infliximab.,Promestriene
DB13143,Methallenestril may increase the thrombogenic activities of Infliximab.,Methallenestril
DB13386,Epimestrol may increase the thrombogenic activities of Infliximab.,Epimestrol
DB13418,Moxestrol may increase the thrombogenic activities of Infliximab.,Moxestrol
DB15334,Biochanin A may increase the thrombogenic activities of Infliximab.,Biochanin A
DB15335,Formononetin may increase the thrombogenic activities of Infliximab.,Formononetin
DB09317,"Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Infliximab.","Synthetic Conjugated Estrogens, A"
DB09318,"Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Infliximab.","Synthetic Conjugated Estrogens, B"
DB09381,Esterified estrogens may increase the thrombogenic activities of Infliximab.,Esterified estrogens
DB01097,The risk or severity of adverse effects can be increased when Infliximab is combined with Leflunomide.,Leflunomide
DB00072,Trastuzumab may increase the neutropenic activities of Infliximab.,Trastuzumab
DB08868,Infliximab may increase the immunosuppressive activities of Fingolimod.,Fingolimod
DB00864,Tacrolimus may increase the immunosuppressive activities of Infliximab.,Tacrolimus
DB04914,The therapeutic efficacy of G17DT can be decreased when used in combination with Infliximab.,G17DT
DB05144,The therapeutic efficacy of PEV3A can be decreased when used in combination with Infliximab.,PEV3A
DB05325,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Infliximab.,INGN 225
DB05374,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Infliximab.,Rindopepimut
DB05440,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Infliximab.,SRP 299
DB05942,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Infliximab.,GI-5005
DB06400,The therapeutic efficacy of Vitespen can be decreased when used in combination with Infliximab.,Vitespen
DB06584,The therapeutic efficacy of TG4010 can be decreased when used in combination with Infliximab.,TG4010
DB09057,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Infliximab.,Anthrax immune globulin human
DB10062,"The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Infliximab.","Rabies virus inactivated antigen, B"
DB10076,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Infliximab.,Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen
DB10276,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Infliximab.,Rotavirus vaccine
DB10283,"The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Infliximab.","Rabies virus inactivated antigen, A"
DB10342,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Infliximab.,Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen
DB10583,The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Infliximab.,Clostridium tetani toxoid antigen (formaldehyde inactivated)
DB10584,The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Infliximab.,Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
DB10600,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Infliximab.,Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated)
DB10769,The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Infliximab.,Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)
DB10794,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Infliximab.,Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated)
DB10803,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Infliximab.,Typhoid Vi polysaccharide vaccine
DB10989,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Infliximab.,Hepatitis A Vaccine
DB10990,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Infliximab.,Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
DB11038,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Infliximab.,Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated)
DB11040,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Infliximab.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated)
DB11041,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Infliximab.,Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)
DB11044,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Infliximab.,Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated)
DB11603,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Infliximab.,Human rabies virus immune globulin
DB11627,The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Infliximab.,Hepatitis B Vaccine (Recombinant)
DB12568,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Infliximab.,Tecemotide
DB14022,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Infliximab.,Typhoid vaccine
DB14384,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Infliximab.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated)
DB14385,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Infliximab.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)
DB14394,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Infliximab.,Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen
DB14445,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Infliximab.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated)
DB14449,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Infliximab.,Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen
DB14619,The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Infliximab.,Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated)
DB14620,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Infliximab.,Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated)
DB14711,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Infliximab.,Vaccinia virus strain new york city board of health live antigen
DB15274,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Infliximab.,Pertussis vaccine
DB15461,The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Infliximab.,Yersinia pestis 195/p antigen (formaldehyde inactivated)
DB13924,The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Infliximab.,Varicella Zoster Vaccine (Recombinant)
DB15483,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Infliximab.,Modified vaccinia ankara
DB11988,Ocrelizumab may increase the immunosuppressive activities of Infliximab.,Ocrelizumab
DB10317,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Infliximab.,Rubella virus vaccine
DB10318,The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Infliximab.,Varicella Zoster Vaccine (Live/attenuated)
DB10343,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Infliximab.,Bacillus calmette-guerin substrain tice live antigen
DB10804,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Infliximab.,Bacillus calmette-guerin substrain connaught live antigen
DB10805,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Infliximab.,Yellow Fever Vaccine
DB11003,The risk or severity of infection can be increased when Anthrax vaccine is combined with Infliximab.,Anthrax vaccine
DB11050,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Infliximab.,Typhoid Vaccine Live
DB12386,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Infliximab.,Bacillus calmette-guerin substrain danish 1331 live antigen
DB12768,The risk or severity of infection can be increased when BCG vaccine is combined with Infliximab.,BCG vaccine
DB14409,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Infliximab.,Human adenovirus e serotype 4 strain cl-68578 antigen
DB14443,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Infliximab.,Vibrio cholerae CVD 103-HgR strain live antigen
DB14685,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Infliximab.,Adenovirus type 7 vaccine live
DB00002,The risk or severity of adverse effects can be increased when Cetuximab is combined with Infliximab.,Cetuximab
DB00028,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Infliximab.,Human immunoglobulin G
DB00043,The risk or severity of adverse effects can be increased when Omalizumab is combined with Infliximab.,Omalizumab
DB00054,The risk or severity of adverse effects can be increased when Abciximab is combined with Infliximab.,Abciximab
DB00057,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Infliximab.,Indium In-111 satumomab pendetide
DB00076,The risk or severity of adverse effects can be increased when Infliximab is combined with Digoxin Immune Fab (Ovine).,Digoxin Immune Fab (Ovine)
DB00089,The risk or severity of adverse effects can be increased when Infliximab is combined with Capromab pendetide.,Capromab pendetide
DB00110,The risk or severity of adverse effects can be increased when Infliximab is combined with Palivizumab.,Palivizumab
DB00113,The risk or severity of adverse effects can be increased when Infliximab is combined with Technetium Tc-99m arcitumomab.,Technetium Tc-99m arcitumomab
DB01269,The risk or severity of adverse effects can be increased when Infliximab is combined with Panitumumab.,Panitumumab
DB01270,The risk or severity of adverse effects can be increased when Infliximab is combined with Ranibizumab.,Ranibizumab
DB04901,The risk or severity of adverse effects can be increased when Infliximab is combined with Galiximab.,Galiximab
DB04949,The risk or severity of adverse effects can be increased when Infliximab is combined with Pexelizumab.,Pexelizumab
DB04958,The risk or severity of adverse effects can be increased when Infliximab is combined with Epratuzumab.,Epratuzumab
DB04962,The risk or severity of adverse effects can be increased when Infliximab is combined with Bectumomab.,Bectumomab
DB04964,The risk or severity of adverse effects can be increased when Infliximab is combined with Oregovomab.,Oregovomab
DB04988,The risk or severity of adverse effects can be increased when Infliximab is combined with IGN311.,IGN311
DB05006,The risk or severity of adverse effects can be increased when Infliximab is combined with Adecatumumab.,Adecatumumab
DB05097,The risk or severity of adverse effects can be increased when Infliximab is combined with Labetuzumab.,Labetuzumab
DB05101,The risk or severity of adverse effects can be increased when Infliximab is combined with Matuzumab.,Matuzumab
DB05111,The risk or severity of adverse effects can be increased when Infliximab is combined with Fontolizumab.,Fontolizumab
DB05136,The risk or severity of adverse effects can be increased when Infliximab is combined with Bavituximab.,Bavituximab
DB05139,The risk or severity of adverse effects can be increased when Infliximab is combined with CR002.,CR002
DB05209,The risk or severity of adverse effects can be increased when Infliximab is combined with Rozrolimupab.,Rozrolimupab
DB05304,The risk or severity of adverse effects can be increased when Infliximab is combined with Girentuximab.,Girentuximab
DB05336,The risk or severity of adverse effects can be increased when Infliximab is combined with Obiltoxaximab.,Obiltoxaximab
DB05405,The risk or severity of adverse effects can be increased when Infliximab is combined with XTL-001.,XTL-001
DB05437,The risk or severity of adverse effects can be increased when Infliximab is combined with NAV 1800.,NAV 1800
DB05496,The risk or severity of adverse effects can be increased when Infliximab is combined with Otelixizumab.,Otelixizumab
DB05545,The risk or severity of adverse effects can be increased when Infliximab is combined with AMG 108.,AMG 108
DB05550,The risk or severity of adverse effects can be increased when Infliximab is combined with Iratumumab.,Iratumumab
DB05555,The risk or severity of adverse effects can be increased when Infliximab is combined with Enokizumab.,Enokizumab
DB05578,The risk or severity of adverse effects can be increased when Infliximab is combined with Ramucirumab.,Ramucirumab
DB05595,The risk or severity of adverse effects can be increased when Infliximab is combined with Farletuzumab.,Farletuzumab
DB05656,The risk or severity of adverse effects can be increased when Infliximab is combined with Veltuzumab.,Veltuzumab
DB05793,The risk or severity of adverse effects can be increased when Infliximab is combined with PRO-542.,PRO-542
DB05797,The risk or severity of adverse effects can be increased when Infliximab is combined with TNX-901.,TNX-901
DB05889,The risk or severity of adverse effects can be increased when Infliximab is combined with Inotuzumab ozogamicin.,Inotuzumab ozogamicin
DB05892,The risk or severity of adverse effects can be increased when Infliximab is combined with RI 624.,RI 624
DB05915,The risk or severity of adverse effects can be increased when Infliximab is combined with MYO-029.,MYO-029
DB05916,The risk or severity of adverse effects can be increased when Infliximab is combined with CT-011.,CT-011
DB05941,The risk or severity of adverse effects can be increased when Infliximab is combined with Leronlimab.,Leronlimab
DB05996,The risk or severity of adverse effects can be increased when Infliximab is combined with Glembatumumab vedotin.,Glembatumumab vedotin
DB06043,The risk or severity of adverse effects can be increased when Infliximab is combined with Olaratumab.,Olaratumab
DB06049,The risk or severity of adverse effects can be increased when Infliximab is combined with IPH 2101.,IPH 2101
DB06050,The risk or severity of adverse effects can be increased when Infliximab is combined with TB-402.,TB-402
DB06081,The risk or severity of adverse effects can be increased when Infliximab is combined with Caplacizumab.,Caplacizumab
DB06101,The risk or severity of adverse effects can be increased when Infliximab is combined with IMC-1C11.,IMC-1C11
DB06116,The risk or severity of adverse effects can be increased when Infliximab is combined with Eldelumab.,Eldelumab
DB06162,The risk or severity of adverse effects can be increased when Infliximab is combined with Lumiliximab.,Lumiliximab
DB06186,The risk or severity of adverse effects can be increased when Infliximab is combined with Ipilimumab.,Ipilimumab
DB06192,The risk or severity of adverse effects can be increased when Infliximab is combined with Nimotuzumab.,Nimotuzumab
DB06241,The risk or severity of adverse effects can be increased when Infliximab is combined with Clenoliximab.,Clenoliximab
DB06304,The risk or severity of adverse effects can be increased when Infliximab is combined with BIIB015.,BIIB015
DB06305,The risk or severity of adverse effects can be increased when Infliximab is combined with Sonepcizumab.,Sonepcizumab
DB06310,The risk or severity of adverse effects can be increased when Infliximab is combined with Motavizumab.,Motavizumab
DB06317,The risk or severity of adverse effects can be increased when Infliximab is combined with Elotuzumab.,Elotuzumab
DB06318,The risk or severity of adverse effects can be increased when Infliximab is combined with AVE9633.,AVE9633
DB06322,The risk or severity of adverse effects can be increased when Infliximab is combined with Carotuximab.,Carotuximab
DB06324,The risk or severity of adverse effects can be increased when Infliximab is combined with XmAb 2513.,XmAb 2513
DB06342,The risk or severity of adverse effects can be increased when Infliximab is combined with Coltuximab ravtansine.,Coltuximab ravtansine
DB06343,The risk or severity of adverse effects can be increased when Infliximab is combined with Teprotumumab.,Teprotumumab
DB06360,The risk or severity of adverse effects can be increased when Infliximab is combined with Lucatumumab.,Lucatumumab
DB06366,The risk or severity of adverse effects can be increased when Infliximab is combined with Pertuzumab.,Pertuzumab
DB06371,The risk or severity of adverse effects can be increased when Infliximab is combined with Siplizumab.,Siplizumab
DB06467,The risk or severity of adverse effects can be increased when Infliximab is combined with Apolizumab.,Apolizumab
DB06474,The risk or severity of adverse effects can be increased when Infliximab is combined with Sibrotuzumab.,Sibrotuzumab
DB06550,The risk or severity of adverse effects can be increased when Infliximab is combined with Bivatuzumab.,Bivatuzumab
DB06557,The risk or severity of adverse effects can be increased when Infliximab is combined with Lerdelimumab.,Lerdelimumab
DB06599,The risk or severity of adverse effects can be increased when Infliximab is combined with Lexatumumab.,Lexatumumab
DB06602,The risk or severity of adverse effects can be increased when Infliximab is combined with Reslizumab.,Reslizumab
DB06606,The risk or severity of adverse effects can be increased when Infliximab is combined with Teplizumab.,Teplizumab
DB06607,The risk or severity of adverse effects can be increased when Infliximab is combined with Catumaxomab.,Catumaxomab
DB06647,The risk or severity of adverse effects can be increased when Infliximab is combined with Volociximab.,Volociximab
DB06650,The risk or severity of adverse effects can be increased when Infliximab is combined with Ofatumumab.,Ofatumumab
DB08902,The risk or severity of adverse effects can be increased when Infliximab is combined with Raxibacumab.,Raxibacumab
DB09035,The risk or severity of adverse effects can be increased when Infliximab is combined with Nivolumab.,Nivolumab
DB09037,The risk or severity of adverse effects can be increased when Infliximab is combined with Pembrolizumab.,Pembrolizumab
DB09045,The risk or severity of adverse effects can be increased when Infliximab is combined with Dulaglutide.,Dulaglutide
DB09105,The risk or severity of adverse effects can be increased when Infliximab is combined with Asfotase alfa.,Asfotase alfa
DB09264,The risk or severity of adverse effects can be increased when Infliximab is combined with Idarucizumab.,Idarucizumab
DB09302,The risk or severity of adverse effects can be increased when Infliximab is combined with Alirocumab.,Alirocumab
DB09303,The risk or severity of adverse effects can be increased when Infliximab is combined with Evolocumab.,Evolocumab
DB09331,The risk or severity of adverse effects can be increased when Infliximab is combined with Daratumumab.,Daratumumab
DB09559,The risk or severity of adverse effects can be increased when Infliximab is combined with Necitumumab.,Necitumumab
DB11595,The risk or severity of adverse effects can be increased when Infliximab is combined with Atezolizumab.,Atezolizumab
DB11604,The risk or severity of adverse effects can be increased when Infliximab is combined with Tetanus Immune Globulin.,Tetanus Immune Globulin
DB11608,The risk or severity of adverse effects can be increased when Infliximab is combined with Eftrenonacog alfa.,Eftrenonacog alfa
DB11621,The risk or severity of adverse effects can be increased when Infliximab is combined with Human Varicella-Zoster Immune Globulin.,Human Varicella-Zoster Immune Globulin
DB11646,The risk or severity of adverse effects can be increased when Infliximab is combined with Conatumumab.,Conatumumab
DB11657,The risk or severity of adverse effects can be increased when Infliximab is combined with Tabalumab.,Tabalumab
DB11680,The risk or severity of adverse effects can be increased when Infliximab is combined with Ficlatuzumab.,Ficlatuzumab
DB11685,The risk or severity of adverse effects can be increased when Infliximab is combined with Figitumumab.,Figitumumab
DB11714,The risk or severity of adverse effects can be increased when Infliximab is combined with Durvalumab.,Durvalumab
DB11715,The risk or severity of adverse effects can be increased when Infliximab is combined with Bapineuzumab.,Bapineuzumab
DB11731,The risk or severity of adverse effects can be increased when Infliximab is combined with Depatuxizumab mafodotin.,Depatuxizumab mafodotin
DB11746,The risk or severity of adverse effects can be increased when Infliximab is combined with Onartuzumab.,Onartuzumab
DB11756,The risk or severity of adverse effects can be increased when Infliximab is combined with Solanezumab.,Solanezumab
DB11771,The risk or severity of adverse effects can be increased when Infliximab is combined with Tremelimumab.,Tremelimumab
DB11826,The risk or severity of adverse effects can be increased when Infliximab is combined with Lampalizumab.,Lampalizumab
DB11840,The risk or severity of adverse effects can be increased when Infliximab is combined with Dalotuzumab.,Dalotuzumab
DB11849,The risk or severity of adverse effects can be increased when Infliximab is combined with Emibetuzumab.,Emibetuzumab
DB11850,The risk or severity of adverse effects can be increased when Infliximab is combined with Ublituximab.,Ublituximab
DB11856,The risk or severity of adverse effects can be increased when Infliximab is combined with Ligelizumab.,Ligelizumab
DB11857,The risk or severity of adverse effects can be increased when Infliximab is combined with Seribantumab.,Seribantumab
DB11862,The risk or severity of adverse effects can be increased when Infliximab is combined with Landogrozumab.,Landogrozumab
DB11866,The risk or severity of adverse effects can be increased when Infliximab is combined with Romosozumab.,Romosozumab
DB11884,The risk or severity of adverse effects can be increased when Infliximab is combined with Vadastuximab Talirine.,Vadastuximab Talirine
DB11914,The risk or severity of adverse effects can be increased when Infliximab is combined with Lebrikizumab.,Lebrikizumab
DB11930,The risk or severity of adverse effects can be increased when Infliximab is combined with Varlilumab.,Varlilumab
DB11945,The risk or severity of adverse effects can be increased when Infliximab is combined with Avelumab.,Avelumab
DB11959,The risk or severity of adverse effects can be increased when Infliximab is combined with Crenezumab.,Crenezumab
DB11972,The risk or severity of adverse effects can be increased when Infliximab is combined with Rilotumumab.,Rilotumumab
DB11976,The risk or severity of adverse effects can be increased when Infliximab is combined with Anifrolumab.,Anifrolumab
DB12023,The risk or severity of adverse effects can be increased when Infliximab is combined with Benralizumab.,Benralizumab
DB12034,The risk or severity of adverse effects can be increased when Infliximab is combined with Gantenerumab.,Gantenerumab
DB12053,The risk or severity of adverse effects can be increased when Infliximab is combined with Visilizumab.,Visilizumab
DB12077,The risk or severity of adverse effects can be increased when Infliximab is combined with Urelumab.,Urelumab
DB12089,The risk or severity of adverse effects can be increased when Infliximab is combined with Lorvotuzumab mertansine.,Lorvotuzumab mertansine
DB12090,The risk or severity of adverse effects can be increased when Infliximab is combined with Patritumab.,Patritumab
DB12102,The risk or severity of adverse effects can be increased when Infliximab is combined with Fulranumab.,Fulranumab
DB12104,The risk or severity of adverse effects can be increased when Infliximab is combined with Tarextumab.,Tarextumab
DB12118,The risk or severity of adverse effects can be increased when Infliximab is combined with Sotatercept.,Sotatercept
DB12119,The risk or severity of adverse effects can be increased when Infliximab is combined with Gevokizumab.,Gevokizumab
DB12142,The risk or severity of adverse effects can be increased when Infliximab is combined with Duligotuzumab.,Duligotuzumab
DB12152,The risk or severity of adverse effects can be increased when Infliximab is combined with Simtuzumab.,Simtuzumab
DB12157,The risk or severity of adverse effects can be increased when Infliximab is combined with Fasinumab.,Fasinumab
DB12159,The risk or severity of adverse effects can be increased when Infliximab is combined with Dupilumab.,Dupilumab
DB12169,The risk or severity of adverse effects can be increased when Infliximab is combined with Tralokinumab.,Tralokinumab
DB12189,The risk or severity of adverse effects can be increased when Infliximab is combined with Etrolizumab.,Etrolizumab
DB12202,The risk or severity of adverse effects can be increased when Infliximab is combined with Zalutumumab.,Zalutumumab
DB12205,The risk or severity of adverse effects can be increased when Infliximab is combined with Ganitumab.,Ganitumab
DB12213,The risk or severity of adverse effects can be increased when Infliximab is combined with Etaracizumab.,Etaracizumab
DB12246,The risk or severity of adverse effects can be increased when Infliximab is combined with Inclacumab.,Inclacumab
DB12250,The risk or severity of adverse effects can be increased when Infliximab is combined with Cixutumumab.,Cixutumumab
DB12261,The risk or severity of adverse effects can be increased when Infliximab is combined with Ascrinvacumab.,Ascrinvacumab
DB12274,The risk or severity of adverse effects can be increased when Infliximab is combined with Aducanumab.,Aducanumab
DB12281,The risk or severity of adverse effects can be increased when Infliximab is combined with Luspatercept.,Luspatercept
DB12296,The risk or severity of adverse effects can be increased when Infliximab is combined with GS-5745.,GS-5745
DB12317,The risk or severity of adverse effects can be increased when Infliximab is combined with Vanucizumab.,Vanucizumab
DB12331,The risk or severity of adverse effects can be increased when Infliximab is combined with Labetuzumab govitecan.,Labetuzumab govitecan
DB12335,The risk or severity of adverse effects can be increased when Infliximab is combined with Tanezumab.,Tanezumab
DB12342,The risk or severity of adverse effects can be increased when Infliximab is combined with Ensituximab.,Ensituximab
DB12344,The risk or severity of adverse effects can be increased when Infliximab is combined with Fezakinumab.,Fezakinumab
DB12363,The risk or severity of adverse effects can be increased when Infliximab is combined with Dusigitumab.,Dusigitumab
DB12396,The risk or severity of adverse effects can be increased when Infliximab is combined with Fresolimumab.,Fresolimumab
DB12413,The risk or severity of adverse effects can be increased when Infliximab is combined with Indusatumab vedotin.,Indusatumab vedotin
DB12456,The risk or severity of adverse effects can be increased when Infliximab is combined with Bococizumab.,Bococizumab
DB12489,The risk or severity of adverse effects can be increased when Infliximab is combined with Mirvetuximab Soravtansine.,Mirvetuximab Soravtansine
DB12498,The risk or severity of adverse effects can be increased when Infliximab is combined with Mogamulizumab.,Mogamulizumab
DB12520,The risk or severity of adverse effects can be increased when Infliximab is combined with Plozalizumab.,Plozalizumab
DB12534,The risk or severity of adverse effects can be increased when Infliximab is combined with Mavrilimumab.,Mavrilimumab
DB12560,The risk or severity of adverse effects can be increased when Infliximab is combined with Blosozumab.,Blosozumab
DB12584,The risk or severity of adverse effects can be increased when Infliximab is combined with Bimagrumab.,Bimagrumab
DB12589,The risk or severity of adverse effects can be increased when Infliximab is combined with Dacetuzumab.,Dacetuzumab
DB12609,The risk or severity of adverse effects can be increased when Infliximab is combined with Tovetumab.,Tovetumab
DB12683,The risk or severity of adverse effects can be increased when Infliximab is combined with Lumretuzumab.,Lumretuzumab
DB12698,The risk or severity of adverse effects can be increased when Infliximab is combined with Ibalizumab.,Ibalizumab
DB12701,The risk or severity of adverse effects can be increased when Infliximab is combined with Intetumumab.,Intetumumab
DB12718,The risk or severity of adverse effects can be increased when Infliximab is combined with Carlumab.,Carlumab
DB12734,The risk or severity of adverse effects can be increased when Infliximab is combined with Demcizumab.,Demcizumab
DB12773,The risk or severity of adverse effects can be increased when Infliximab is combined with Sifalimumab.,Sifalimumab
DB12775,The risk or severity of adverse effects can be increased when Infliximab is combined with Abituzumab.,Abituzumab
DB12797,The risk or severity of adverse effects can be increased when Infliximab is combined with Ecromeximab.,Ecromeximab
DB12807,The risk or severity of adverse effects can be increased when Infliximab is combined with Naptumomab Estafenatox.,Naptumomab Estafenatox
DB12815,The risk or severity of adverse effects can be increased when Infliximab is combined with Crotedumab.,Crotedumab
DB12820,The risk or severity of adverse effects can be increased when Infliximab is combined with Concizumab.,Concizumab
DB12826,The risk or severity of adverse effects can be increased when Infliximab is combined with Depatuxizumab.,Depatuxizumab
DB12844,The risk or severity of adverse effects can be increased when Infliximab is combined with Rontalizumab.,Rontalizumab
DB12845,The risk or severity of adverse effects can be increased when Infliximab is combined with Amatuximab.,Amatuximab
DB12849,The risk or severity of adverse effects can be increased when Infliximab is combined with Clazakizumab.,Clazakizumab
DB12891,The risk or severity of adverse effects can be increased when Infliximab is combined with Ozanezumab.,Ozanezumab
DB12893,The risk or severity of adverse effects can be increased when Infliximab is combined with Sacituzumab govitecan.,Sacituzumab govitecan
DB12917,The risk or severity of adverse effects can be increased when Infliximab is combined with Bimekizumab.,Bimekizumab
DB12943,The risk or severity of adverse effects can be increased when Infliximab is combined with Milatuzumab.,Milatuzumab
DB12976,The risk or severity of adverse effects can be increased when Infliximab is combined with Robatumumab.,Robatumumab
DB13017,The risk or severity of adverse effects can be increased when Infliximab is combined with Rovalpituzumab Tesirine.,Rovalpituzumab Tesirine
DB13037,The risk or severity of adverse effects can be increased when Infliximab is combined with Namilumab.,Namilumab
DB13045,The risk or severity of adverse effects can be increased when Infliximab is combined with Racotumomab.,Racotumomab
DB13073,The risk or severity of adverse effects can be increased when Infliximab is combined with Tregalizumab.,Tregalizumab
DB13127,The risk or severity of adverse effects can be increased when Infliximab is combined with Olokizumab.,Olokizumab
DB13140,The risk or severity of adverse effects can be increased when Infliximab is combined with Bezlotoxumab.,Bezlotoxumab
DB13375,The risk or severity of adverse effects can be increased when Infliximab is combined with Edrecolomab.,Edrecolomab
DB13535,The risk or severity of adverse effects can be increased when Infliximab is combined with Nebacumab.,Nebacumab
DB13886,The risk or severity of adverse effects can be increased when Infliximab is combined with Human cytomegalovirus immune globulin.,Human cytomegalovirus immune globulin
DB13923,The risk or severity of adverse effects can be increased when Infliximab is combined with Emicizumab.,Emicizumab
DB13976,The risk or severity of adverse effects can be increased when Infliximab is combined with Sulesomab.,Sulesomab
DB13979,The risk or severity of adverse effects can be increased when Infliximab is combined with Besilesomab.,Besilesomab
DB14012,The risk or severity of adverse effects can be increased when Infliximab is combined with Burosumab.,Burosumab
DB14039,The risk or severity of adverse effects can be increased when Infliximab is combined with Erenumab.,Erenumab
DB14040,The risk or severity of adverse effects can be increased when Infliximab is combined with Eptinezumab.,Eptinezumab
DB14041,The risk or severity of adverse effects can be increased when Infliximab is combined with Fremanezumab.,Fremanezumab
DB14042,The risk or severity of adverse effects can be increased when Infliximab is combined with Galcanezumab.,Galcanezumab
DB14211,The risk or severity of adverse effects can be increased when Infliximab is combined with Fanolesomab.,Fanolesomab
DB14580,The risk or severity of adverse effects can be increased when Infliximab is combined with Lecanemab.,Lecanemab
DB14597,The risk or severity of adverse effects can be increased when Infliximab is combined with Lanadelumab.,Lanadelumab
DB14707,The risk or severity of adverse effects can be increased when Infliximab is combined with Cemiplimab.,Cemiplimab
DB14776,The risk or severity of adverse effects can be increased when Infliximab is combined with Camrelizumab.,Camrelizumab
DB14778,The risk or severity of adverse effects can be increased when Infliximab is combined with Setrusumab.,Setrusumab
DB14784,The risk or severity of adverse effects can be increased when Infliximab is combined with Gancotamab.,Gancotamab
DB14809,The risk or severity of adverse effects can be increased when Infliximab is combined with Anetumab ravtansine.,Anetumab ravtansine
DB14811,The risk or severity of adverse effects can be increased when Infliximab is combined with Isatuximab.,Isatuximab
DB14824,The risk or severity of adverse effects can be increased when Infliximab is combined with Icrucumab.,Icrucumab
DB14843,The risk or severity of adverse effects can be increased when Infliximab is combined with Codrituzumab.,Codrituzumab
DB14864,The risk or severity of adverse effects can be increased when Infliximab is combined with Brolucizumab.,Brolucizumab
DB14871,The risk or severity of adverse effects can be increased when Infliximab is combined with Xentuzumab.,Xentuzumab
DB14877,The risk or severity of adverse effects can be increased when Infliximab is combined with Lintuzumab.,Lintuzumab
DB14891,The risk or severity of adverse effects can be increased when Infliximab is combined with Vobarilizumab.,Vobarilizumab
DB14897,The risk or severity of adverse effects can be increased when Infliximab is combined with Parsatuzumab.,Parsatuzumab
DB14905,The risk or severity of adverse effects can be increased when Infliximab is combined with Emactuzumab.,Emactuzumab
DB14907,The risk or severity of adverse effects can be increased when Infliximab is combined with Bevacizumab zirconium Zr-89.,Bevacizumab zirconium Zr-89
DB14908,The risk or severity of adverse effects can be increased when Infliximab is combined with Refanezumab.,Refanezumab
DB14947,The risk or severity of adverse effects can be increased when Infliximab is combined with Bermekimab.,Bermekimab
DB14952,The risk or severity of adverse effects can be increased when Infliximab is combined with Pamrevlumab.,Pamrevlumab
DB14959,The risk or severity of adverse effects can be increased when Infliximab is combined with Opicinumab.,Opicinumab
DB14962,The risk or severity of adverse effects can be increased when Infliximab is combined with Trastuzumab deruxtecan.,Trastuzumab deruxtecan
DB14967,The risk or severity of adverse effects can be increased when Infliximab is combined with Margetuximab.,Margetuximab
DB14988,The risk or severity of adverse effects can be increased when Infliximab is combined with Dalantercept.,Dalantercept
DB14997,The risk or severity of adverse effects can be increased when Infliximab is combined with Pateclizumab.,Pateclizumab
DB15014,The risk or severity of adverse effects can be increased when Infliximab is combined with Gremubamab.,Gremubamab
DB15022,The risk or severity of adverse effects can be increased when Infliximab is combined with Apomab.,Apomab
DB15044,The risk or severity of adverse effects can be increased when Infliximab is combined with Tafasitamab.,Tafasitamab
DB15045,The risk or severity of adverse effects can be increased when Infliximab is combined with Ipafricept.,Ipafricept
DB15076,The risk or severity of adverse effects can be increased when Infliximab is combined with Abrilumab.,Abrilumab
DB15089,The risk or severity of adverse effects can be increased when Infliximab is combined with Frovocimab.,Frovocimab
DB15090,The risk or severity of adverse effects can be increased when Infliximab is combined with Tezepelumab.,Tezepelumab
DB15101,The risk or severity of adverse effects can be increased when Infliximab is combined with Tigatuzumab.,Tigatuzumab
DB15104,The risk or severity of adverse effects can be increased when Infliximab is combined with Telisotuzumab vedotin.,Telisotuzumab vedotin
DB15113,The risk or severity of adverse effects can be increased when Infliximab is combined with Utomilumab.,Utomilumab
DB15118,The risk or severity of adverse effects can be increased when Infliximab is combined with Zolbetuximab.,Zolbetuximab
DB15135,The risk or severity of adverse effects can be increased when Infliximab is combined with Ponezumab.,Ponezumab
DB15160,The risk or severity of adverse effects can be increased when Infliximab is combined with Asunercept.,Asunercept
DB15172,The risk or severity of adverse effects can be increased when Infliximab is combined with Suvratoxumab.,Suvratoxumab
DB15225,The risk or severity of adverse effects can be increased when Infliximab is combined with Mitazalimab.,Mitazalimab
DB15252,The risk or severity of adverse effects can be increased when Infliximab is combined with Nemolizumab.,Nemolizumab
DB15277,The risk or severity of adverse effects can be increased when Infliximab is combined with Gedivumab.,Gedivumab
DB15336,The risk or severity of adverse effects can be increased when Infliximab is combined with Valanafusp alfa.,Valanafusp alfa
DB15349,The risk or severity of adverse effects can be increased when Infliximab is combined with Sofituzumab vedotin.,Sofituzumab vedotin
DB15354,The risk or severity of adverse effects can be increased when Infliximab is combined with Evinacumab.,Evinacumab
DB15363,The risk or severity of adverse effects can be increased when Infliximab is combined with Istiratumab.,Istiratumab
DB15383,The risk or severity of adverse effects can be increased when Infliximab is combined with Pidilizumab.,Pidilizumab
DB15397,The risk or severity of adverse effects can be increased when Infliximab is combined with GMA-161.,GMA-161
DB15409,The risk or severity of adverse effects can be increased when Infliximab is combined with Ladiratuzumab vedotin.,Ladiratuzumab vedotin
DB15415,The risk or severity of adverse effects can be increased when Infliximab is combined with Tomaralimab.,Tomaralimab
DB15428,The risk or severity of adverse effects can be increased when Infliximab is combined with Vesencumab.,Vesencumab
DB15432,The risk or severity of adverse effects can be increased when Infliximab is combined with Pinatuzumab vedotin.,Pinatuzumab vedotin
DB15441,The risk or severity of adverse effects can be increased when Infliximab is combined with Lulizumab pegol.,Lulizumab pegol
DB15443,The risk or severity of adverse effects can be increased when Infliximab is combined with Lorukafusp alfa.,Lorukafusp alfa
DB15453,The risk or severity of adverse effects can be increased when Infliximab is combined with Naratuximab emtansine.,Naratuximab emtansine
DB14004,The risk or severity of adverse effects can be increased when Infliximab is combined with Tildrakizumab.,Tildrakizumab
DB05679,The risk or severity of adverse effects can be increased when Infliximab is combined with Ustekinumab.,Ustekinumab
DB12240,The risk or severity of adverse effects can be increased when Infliximab is combined with Polatuzumab vedotin.,Polatuzumab vedotin
DB15559,The risk or severity of adverse effects can be increased when Infliximab is combined with Zenocutuzumab.,Zenocutuzumab
DB00052,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Infliximab.",Somatotropin
DB00080,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Daptomycin.",Daptomycin
DB00175,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Pravastatin.",Pravastatin
DB00181,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Baclofen.",Baclofen
DB00282,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Pamidronic acid.",Pamidronic acid
DB00389,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Carbimazole.",Carbimazole
DB00537,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Ciprofloxacin.",Ciprofloxacin
DB00585,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Nizatidine.",Nizatidine
DB00627,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Niacin.",Niacin
DB00630,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Alendronic acid.",Alendronic acid
DB00649,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Stavudine.",Stavudine
DB00666,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Nafarelin.",Nafarelin
DB00681,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Amphotericin B.",Amphotericin B
DB00704,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Naltrexone.",Naltrexone
DB00709,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Lamivudine.",Lamivudine
DB00710,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Ibandronate.",Ibandronate
DB00876,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Eprosartan.",Eprosartan
DB00884,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Risedronic acid.",Risedronic acid
DB00887,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Bumetanide.",Bumetanide
DB00951,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Isoniazid.",Isoniazid
DB00968,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Methyldopa.",Methyldopa
DB01004,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Ganciclovir.",Ganciclovir
DB01017,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Minocycline.",Minocycline
DB01059,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Norfloxacin.",Norfloxacin
DB01088,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Iloprost.",Iloprost
DB01165,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Ofloxacin.",Ofloxacin
DB06693,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Mevastatin.",Mevastatin
DB06817,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Raltegravir.",Raltegravir
DB08983,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Etofibrate.",Etofibrate
DB09055,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Acipimox.",Acipimox
DB09064,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Ciprofibrate.",Ciprofibrate
DB09270,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Ubidecarenone.",Ubidecarenone
DB12554,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Mebeverine.",Mebeverine
DB13393,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Emetine.",Emetine
DB13433,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Simfibrate.",Simfibrate
DB13460,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Ronifibrate.",Ronifibrate
DB13780,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Aluminium clofibrate.",Aluminium clofibrate
DB13849,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Clofibride.",Clofibride
DB13873,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Fenofibric acid.",Fenofibric acid
DB00007,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Infliximab.",Leuprolide
DB00358,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Mefloquine.",Mefloquine
DB00501,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Cimetidine.",Cimetidine
DB00584,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Enalapril.",Enalapril
DB00602,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Ivermectin.",Ivermectin
DB00636,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Clofibrate.",Clofibrate
DB00982,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Isotretinoin.",Isotretinoin
DB01197,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Captopril.",Captopril
DB01241,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Gemfibrozil.",Gemfibrozil
DB01393,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Bezafibrate.",Bezafibrate
DB00201,The metabolism of Caffeine can be increased when combined with Infliximab.,Caffeine
DB00176,The metabolism of Fluvoxamine can be increased when combined with Infliximab.,Fluvoxamine
DB00195,The metabolism of Betaxolol can be increased when combined with Infliximab.,Betaxolol
DB00261,The metabolism of Anagrelide can be increased when combined with Infliximab.,Anagrelide
DB00262,The metabolism of Carmustine can be increased when combined with Infliximab.,Carmustine
DB00268,The metabolism of Ropinirole can be increased when combined with Infliximab.,Ropinirole
DB00280,The metabolism of Disopyramide can be increased when combined with Infliximab.,Disopyramide
DB00286,The metabolism of Conjugated estrogens can be increased when combined with Infliximab.,Conjugated estrogens
DB00296,The metabolism of Ropivacaine can be increased when combined with Infliximab.,Ropivacaine
DB00315,The metabolism of Zolmitriptan can be increased when combined with Infliximab.,Zolmitriptan
DB00316,The metabolism of Acetaminophen can be increased when combined with Infliximab.,Acetaminophen
DB00334,The metabolism of Olanzapine can be increased when combined with Infliximab.,Olanzapine
DB00356,The metabolism of Chlorzoxazone can be increased when combined with Infliximab.,Chlorzoxazone
DB00365,The metabolism of Grepafloxacin can be increased when combined with Infliximab.,Grepafloxacin
DB00370,The metabolism of Mirtazapine can be increased when combined with Infliximab.,Mirtazapine
DB00379,The metabolism of Mexiletine can be increased when combined with Infliximab.,Mexiletine
DB00382,The metabolism of Tacrine can be increased when combined with Infliximab.,Tacrine
DB00384,The metabolism of Triamterene can be increased when combined with Infliximab.,Triamterene
DB00442,The metabolism of Entecavir can be increased when combined with Infliximab.,Entecavir
DB00477,The metabolism of Chlorpromazine can be increased when combined with Infliximab.,Chlorpromazine
DB00518,The metabolism of Albendazole can be increased when combined with Infliximab.,Albendazole
DB00544,The metabolism of Fluorouracil can be increased when combined with Infliximab.,Fluorouracil
DB00629,The metabolism of Guanabenz can be increased when combined with Infliximab.,Guanabenz
DB00642,The metabolism of Pemetrexed can be increased when combined with Infliximab.,Pemetrexed
DB00730,The metabolism of Thiabendazole can be increased when combined with Infliximab.,Thiabendazole
DB00740,The metabolism of Riluzole can be increased when combined with Infliximab.,Riluzole
DB00787,The metabolism of Acyclovir can be increased when combined with Infliximab.,Acyclovir
DB00806,The metabolism of Pentoxifylline can be increased when combined with Infliximab.,Pentoxifylline
DB00831,The metabolism of Trifluoperazine can be increased when combined with Infliximab.,Trifluoperazine
DB00863,The metabolism of Ranitidine can be increased when combined with Infliximab.,Ranitidine
DB00898,The metabolism of Ethanol can be increased when combined with Infliximab.,Ethanol
DB00934,The metabolism of Maprotiline can be increased when combined with Infliximab.,Maprotiline
DB00978,The metabolism of Lomefloxacin can be increased when combined with Infliximab.,Lomefloxacin
DB00993,The metabolism of Azathioprine can be increased when combined with Infliximab.,Azathioprine
DB00998,The metabolism of Frovatriptan can be increased when combined with Infliximab.,Frovatriptan
DB01002,The metabolism of Levobupivacaine can be increased when combined with Infliximab.,Levobupivacaine
DB01012,The metabolism of Cinacalcet can be increased when combined with Infliximab.,Cinacalcet
DB01056,The metabolism of Tocainide can be increased when combined with Infliximab.,Tocainide
DB01087,The metabolism of Primaquine can be increased when combined with Infliximab.,Primaquine
DB01094,The metabolism of Hesperetin can be increased when combined with Infliximab.,Hesperetin
DB01182,The metabolism of Propafenone can be increased when combined with Infliximab.,Propafenone
DB01191,The metabolism of Dexfenfluramine can be increased when combined with Infliximab.,Dexfenfluramine
DB01303,The metabolism of Oxtriphylline can be increased when combined with Infliximab.,Oxtriphylline
DB01367,The metabolism of Rasagiline can be increased when combined with Infliximab.,Rasagiline
DB01405,The metabolism of Temafloxacin can be increased when combined with Infliximab.,Temafloxacin
DB01412,The metabolism of Theobromine can be increased when combined with Infliximab.,Theobromine
DB01482,The metabolism of Fenethylline can be increased when combined with Infliximab.,Fenethylline
DB01558,The metabolism of Bromazepam can be increased when combined with Infliximab.,Bromazepam
DB01623,The metabolism of Thiothixene can be increased when combined with Infliximab.,Thiothixene
DB01645,The metabolism of Genistein can be increased when combined with Infliximab.,Genistein
DB01667,The metabolism of 8-azaguanine can be increased when combined with Infliximab.,8-azaguanine
DB02134,The metabolism of Xanthine can be increased when combined with Infliximab.,Xanthine
DB02489,The metabolism of 9-Methylguanine can be increased when combined with Infliximab.,9-Methylguanine
DB02568,The metabolism of Peldesine can be increased when combined with Infliximab.,Peldesine
DB02709,The metabolism of Resveratrol can be increased when combined with Infliximab.,Resveratrol
DB04076,The metabolism of Hypoxanthine can be increased when combined with Infliximab.,Hypoxanthine
DB04356,The metabolism of 9-Deazaguanine can be increased when combined with Infliximab.,9-Deazaguanine
DB04871,The metabolism of Lorcaserin can be increased when combined with Infliximab.,Lorcaserin
DB04948,The metabolism of Lofexidine can be increased when combined with Infliximab.,Lofexidine
DB04951,The metabolism of Pirfenidone can be increased when combined with Infliximab.,Pirfenidone
DB06148,The metabolism of Mianserin can be increased when combined with Infliximab.,Mianserin
DB06210,The metabolism of Eltrombopag can be increased when combined with Infliximab.,Eltrombopag
DB06216,The metabolism of Asenapine can be increased when combined with Infliximab.,Asenapine
DB06235,The metabolism of Vadimezan can be increased when combined with Infliximab.,Vadimezan
DB06479,The metabolism of Propentofylline can be increased when combined with Infliximab.,Propentofylline
DB06594,The metabolism of Agomelatine can be increased when combined with Infliximab.,Agomelatine
DB06769,The metabolism of Bendamustine can be increased when combined with Infliximab.,Bendamustine
DB06770,The metabolism of Benzyl alcohol can be increased when combined with Infliximab.,Benzyl alcohol
DB06774,The metabolism of Capsaicin can be increased when combined with Infliximab.,Capsaicin
DB08496,The metabolism of (R)-warfarin can be increased when combined with Infliximab.,(R)-warfarin
DB09071,The metabolism of Tasimelteon can be increased when combined with Infliximab.,Tasimelteon
DB09118,The metabolism of Stiripentol can be increased when combined with Infliximab.,Stiripentol
DB09225,The metabolism of Zotepine can be increased when combined with Infliximab.,Zotepine
DB09273,The metabolism of Doxofylline can be increased when combined with Infliximab.,Doxofylline
DB09290,The metabolism of Ramosetron can be increased when combined with Infliximab.,Ramosetron
DB11919,The metabolism of 6-O-benzylguanine can be increased when combined with Infliximab.,6-O-benzylguanine
DB11967,The metabolism of Binimetinib can be increased when combined with Infliximab.,Binimetinib
DB12026,The metabolism of Voxilaprevir can be increased when combined with Infliximab.,Voxilaprevir
DB12245,The metabolism of Triclabendazole can be increased when combined with Infliximab.,Triclabendazole
DB12332,The metabolism of Rucaparib can be increased when combined with Infliximab.,Rucaparib
DB12406,The metabolism of Lisofylline can be increased when combined with Infliximab.,Lisofylline
DB12531,The metabolism of Lobucavir can be increased when combined with Infliximab.,Lobucavir
DB12926,The metabolism of Cafedrine can be increased when combined with Infliximab.,Cafedrine
DB12927,The metabolism of Theodrenaline can be increased when combined with Infliximab.,Theodrenaline
DB12945,The metabolism of Dihydralazine can be increased when combined with Infliximab.,Dihydralazine
DB13203,The metabolism of Bamifylline can be increased when combined with Infliximab.,Bamifylline
DB13449,The metabolism of Proxyphylline can be increased when combined with Infliximab.,Proxyphylline
DB13573,The metabolism of Acefylline can be increased when combined with Infliximab.,Acefylline
DB13592,The metabolism of Etamiphylline can be increased when combined with Infliximab.,Etamiphylline
DB13634,The metabolism of Pentifylline can be increased when combined with Infliximab.,Pentifylline
DB13812,The metabolism of Bufylline can be increased when combined with Infliximab.,Bufylline
DB14018,The metabolism of Bromotheophylline can be increased when combined with Infliximab.,Bromotheophylline
DB14132,The metabolism of 8-chlorotheophylline can be increased when combined with Infliximab.,8-chlorotheophylline
DB11757,The metabolism of Istradefylline can be increased when combined with Infliximab.,Istradefylline
DB04889,The metabolism of Bicifadine can be increased when combined with Infliximab.,Bicifadine
DB05708,The metabolism of GTS-21 can be increased when combined with Infliximab.,GTS-21
DB00977,The metabolism of Infliximab can be increased when combined with Ethinylestradiol.,Ethinylestradiol
DB00425,The metabolism of Zolpidem can be increased when combined with Infliximab.,Zolpidem
DB00458,The metabolism of Imipramine can be increased when combined with Infliximab.,Imipramine
DB00532,The metabolism of Mephenytoin can be increased when combined with Infliximab.,Mephenytoin
DB00540,The metabolism of Nortriptyline can be increased when combined with Infliximab.,Nortriptyline
DB00575,The metabolism of Clonidine can be increased when combined with Infliximab.,Clonidine
DB00924,The metabolism of Cyclobenzaprine can be increased when combined with Infliximab.,Cyclobenzaprine
DB01242,The metabolism of Clomipramine can be increased when combined with Infliximab.,Clomipramine
DB11689,The metabolism of Selumetinib can be increased when combined with Infliximab.,Selumetinib
DB00277,The metabolism of Theophylline can be increased when combined with Infliximab.,Theophylline
DB00564,The metabolism of Carbamazepine can be increased when combined with Infliximab.,Carbamazepine
DB00682,The metabolism of Warfarin can be increased when combined with Infliximab.,Warfarin
DB00697,The metabolism of Tizanidine can be increased when combined with Infliximab.,Tizanidine
DB01100,The metabolism of Pimozide can be increased when combined with Infliximab.,Pimozide
DB01223,The metabolism of Aminophylline can be increased when combined with Infliximab.,Aminophylline
DB01418,The metabolism of Acenocoumarol can be increased when combined with Infliximab.,Acenocoumarol
DB09256,The metabolism of Tegafur can be increased when combined with Infliximab.,Tegafur
DB00851,The metabolism of Dacarbazine can be increased when combined with Infliximab.,Dacarbazine
DB08910,The metabolism of Pomalidomide can be increased when combined with Infliximab.,Pomalidomide
DB00238,The metabolism of Nevirapine can be increased when combined with Infliximab.,Nevirapine
DB00690,The metabolism of Flurazepam can be increased when combined with Infliximab.,Flurazepam
DB00916,The metabolism of Metronidazole can be increased when combined with Infliximab.,Metronidazole
DB00983,The metabolism of Formoterol can be increased when combined with Infliximab.,Formoterol
DB01006,The metabolism of Letrozole can be increased when combined with Infliximab.,Letrozole
DB01028,The metabolism of Methoxyflurane can be increased when combined with Infliximab.,Methoxyflurane
DB01159,The metabolism of Halothane can be increased when combined with Infliximab.,Halothane
DB01236,The metabolism of Sevoflurane can be increased when combined with Infliximab.,Sevoflurane
DB01274,The metabolism of Arformoterol can be increased when combined with Infliximab.,Arformoterol
DB01544,The metabolism of Flunitrazepam can be increased when combined with Infliximab.,Flunitrazepam
DB06292,The metabolism of Dapagliflozin can be increased when combined with Infliximab.,Dapagliflozin
DB06470,The metabolism of Clomethiazole can be increased when combined with Infliximab.,Clomethiazole
DB09068,The metabolism of Vortioxetine can be increased when combined with Infliximab.,Vortioxetine
DB09327,The metabolism of Tegafur-uracil can be increased when combined with Infliximab.,Tegafur-uracil
DB11586,The metabolism of Asunaprevir can be increased when combined with Infliximab.,Asunaprevir
DB04977,The metabolism of Plitidepsin can be increased when combined with Infliximab.,Plitidepsin
DB06119,The metabolism of Cenobamate can be increased when combined with Infliximab.,Cenobamate
DB00193,The metabolism of Tramadol can be increased when combined with Infliximab.,Tramadol
DB00333,The metabolism of Methadone can be increased when combined with Infliximab.,Methadone
DB00349,The metabolism of Clobazam can be increased when combined with Infliximab.,Clobazam
DB00625,The metabolism of Efavirenz can be increased when combined with Infliximab.,Efavirenz
DB00753,The metabolism of Isoflurane can be increased when combined with Infliximab.,Isoflurane
DB00835,The metabolism of Brompheniramine can be increased when combined with Infliximab.,Brompheniramine
DB00836,The metabolism of Loperamide can be increased when combined with Infliximab.,Loperamide
DB00849,The metabolism of Methylphenobarbital can be increased when combined with Infliximab.,Methylphenobarbital
DB00865,The metabolism of Benzphetamine can be increased when combined with Infliximab.,Benzphetamine
DB01069,The metabolism of Promethazine can be increased when combined with Infliximab.,Promethazine
DB01074,The metabolism of Perhexiline can be increased when combined with Infliximab.,Perhexiline
DB01221,The metabolism of Ketamine can be increased when combined with Infliximab.,Ketamine
DB01466,The metabolism of Ethylmorphine can be increased when combined with Infliximab.,Ethylmorphine
DB01559,The metabolism of Clotiazepam can be increased when combined with Infliximab.,Clotiazepam
DB04938,The metabolism of Ospemifene can be increased when combined with Infliximab.,Ospemifene
DB04975,The metabolism of Banoxantrone can be increased when combined with Infliximab.,Banoxantrone
DB05541,The metabolism of Brivaracetam can be increased when combined with Infliximab.,Brivaracetam
DB06176,The metabolism of Romidepsin can be increased when combined with Infliximab.,Romidepsin
DB06209,The metabolism of Prasugrel can be increased when combined with Infliximab.,Prasugrel
DB06697,The metabolism of Artemether can be increased when combined with Infliximab.,Artemether
DB06710,The metabolism of Methyltestosterone can be increased when combined with Infliximab.,Methyltestosterone
DB06738,The metabolism of Ketobemidone can be increased when combined with Infliximab.,Ketobemidone
DB06739,The metabolism of Seratrodast can be increased when combined with Infliximab.,Seratrodast
DB11613,The metabolism of Velpatasvir can be increased when combined with Infliximab.,Velpatasvir
DB13132,The metabolism of Artemisinin can be increased when combined with Infliximab.,Artemisinin
DB13943,The metabolism of Testosterone cypionate can be increased when combined with Infliximab.,Testosterone cypionate
DB13944,The metabolism of Testosterone enanthate can be increased when combined with Infliximab.,Testosterone enanthate
DB13946,The metabolism of Testosterone undecanoate can be increased when combined with Infliximab.,Testosterone undecanoate
DB01156,The metabolism of Bupropion can be increased when combined with Infliximab.,Bupropion
DB00956,The metabolism of Hydrocodone can be increased when combined with Infliximab.,Hydrocodone
DB14975,The metabolism of Voxelotor can be increased when combined with Infliximab.,Voxelotor
DB11837,The metabolism of Osilodrostat can be increased when combined with Infliximab.,Osilodrostat
DB13384,The metabolism of Melitracen can be increased when combined with Infliximab.,Melitracen
DB13411,The metabolism of Lofepramine can be increased when combined with Infliximab.,Lofepramine
DB00714,The metabolism of Apomorphine can be increased when combined with Infliximab.,Apomorphine
DB09167,The metabolism of Dosulepin can be increased when combined with Infliximab.,Dosulepin
DB00213,The metabolism of Pantoprazole can be increased when combined with Infliximab.,Pantoprazole
DB00215,The metabolism of Citalopram can be increased when combined with Infliximab.,Citalopram
DB00312,The metabolism of Pentobarbital can be increased when combined with Infliximab.,Pentobarbital
DB00338,The metabolism of Omeprazole can be increased when combined with Infliximab.,Omeprazole
DB00347,The metabolism of Trimethadione can be increased when combined with Infliximab.,Trimethadione
DB00395,The metabolism of Carisoprodol can be increased when combined with Infliximab.,Carisoprodol
DB00448,The metabolism of Lansoprazole can be increased when combined with Infliximab.,Lansoprazole
DB00474,The metabolism of Methohexital can be increased when combined with Infliximab.,Methohexital
DB00582,The metabolism of Voriconazole can be increased when combined with Infliximab.,Voriconazole
DB00679,The metabolism of Thioridazine can be increased when combined with Infliximab.,Thioridazine
DB00736,The metabolism of Esomeprazole can be increased when combined with Infliximab.,Esomeprazole
DB00794,The metabolism of Primidone can be increased when combined with Infliximab.,Primidone
DB00909,The metabolism of Zonisamide can be increased when combined with Infliximab.,Zonisamide
DB01129,The metabolism of Rabeprazole can be increased when combined with Infliximab.,Rabeprazole
DB01131,The metabolism of Proguanil can be increased when combined with Infliximab.,Proguanil
DB01175,The metabolism of Escitalopram can be increased when combined with Infliximab.,Escitalopram
DB01259,The metabolism of Lapatinib can be increased when combined with Infliximab.,Lapatinib
DB01323,The metabolism of St. John's Wort can be increased when combined with Infliximab.,St. John's Wort
DB01355,The metabolism of Hexobarbital can be increased when combined with Infliximab.,Hexobarbital
DB01483,The metabolism of Barbital can be increased when combined with Infliximab.,Barbital
DB05246,The metabolism of Methsuximide can be increased when combined with Infliximab.,Methsuximide
DB05351,The metabolism of Dexlansoprazole can be increased when combined with Infliximab.,Dexlansoprazole
DB06218,The metabolism of Lacosamide can be increased when combined with Infliximab.,Lacosamide
DB06414,The metabolism of Etravirine can be increased when combined with Infliximab.,Etravirine
DB06605,The metabolism of Apixaban can be increased when combined with Infliximab.,Apixaban
DB09166,The metabolism of Etizolam can be increased when combined with Infliximab.,Etizolam
DB12130,The metabolism of Lorlatinib can be increased when combined with Infliximab.,Lorlatinib
DB12474,The metabolism of Lynestrenol can be increased when combined with Infliximab.,Lynestrenol
DB13762,The metabolism of Dexrabeprazole can be increased when combined with Infliximab.,Dexrabeprazole
DB14055,The metabolism of (S)-Warfarin can be increased when combined with Infliximab.,(S)-Warfarin
DB00715,The metabolism of Paroxetine can be increased when combined with Infliximab.,Paroxetine
DB12500,The metabolism of Fedratinib can be increased when combined with Infliximab.,Fedratinib
DB04861,The metabolism of Nebivolol can be increased when combined with Infliximab.,Nebivolol
DB06684,The metabolism of Vilazodone can be increased when combined with Infliximab.,Vilazodone
DB01104,The metabolism of Sertraline can be increased when combined with Infliximab.,Sertraline
DB11823,The metabolism of Esketamine can be increased when combined with Infliximab.,Esketamine
DB00252,The metabolism of Phenytoin can be increased when combined with Infliximab.,Phenytoin
DB00599,The metabolism of Thiopental can be increased when combined with Infliximab.,Thiopental
DB01174,The metabolism of Phenobarbital can be increased when combined with Infliximab.,Phenobarbital
DB01320,The metabolism of Fosphenytoin can be increased when combined with Infliximab.,Fosphenytoin
DB00613,The metabolism of Amodiaquine can be increased when combined with Infliximab.,Amodiaquine
DB00799,The metabolism of Tazarotene can be increased when combined with Infliximab.,Tazarotene
DB05229,The metabolism of Beraprost can be increased when combined with Infliximab.,Beraprost
DB06510,The metabolism of Muraglitazar can be increased when combined with Infliximab.,Muraglitazar
DB09296,The metabolism of Ombitasvir can be increased when combined with Infliximab.,Ombitasvir
DB01217,The metabolism of Anastrozole can be increased when combined with Infliximab.,Anastrozole
DB00255,The metabolism of Infliximab can be increased when combined with Diethylstilbestrol.,Diethylstilbestrol
DB00295,The metabolism of Morphine can be increased when combined with Infliximab.,Morphine
DB00359,The metabolism of Sulfadiazine can be increased when combined with Infliximab.,Sulfadiazine
DB00402,The metabolism of Eszopiclone can be increased when combined with Infliximab.,Eszopiclone
DB00622,The metabolism of Nicardipine can be increased when combined with Infliximab.,Nicardipine
DB00912,The metabolism of Repaglinide can be increased when combined with Infliximab.,Repaglinide
DB01261,The metabolism of Sitagliptin can be increased when combined with Infliximab.,Sitagliptin
DB06670,The metabolism of Odanacatib can be increased when combined with Infliximab.,Odanacatib
DB08502,The metabolism of Capravirine can be increased when combined with Infliximab.,Capravirine
DB08931,The metabolism of Riociguat can be increased when combined with Infliximab.,Riociguat
DB09198,The metabolism of Lobeglitazone can be increased when combined with Infliximab.,Lobeglitazone
DB09199,The metabolism of Netoglitazone can be increased when combined with Infliximab.,Netoglitazone
DB09200,The metabolism of Rivoglitazone can be increased when combined with Infliximab.,Rivoglitazone
DB09201,The metabolism of Ciglitazone can be increased when combined with Infliximab.,Ciglitazone
DB11362,The metabolism of Selexipag can be increased when combined with Infliximab.,Selexipag
DB11901,The metabolism of Apalutamide can be increased when combined with Infliximab.,Apalutamide
DB11978,The metabolism of Glasdegib can be increased when combined with Infliximab.,Glasdegib
DB12781,The metabolism of Balaglitazone can be increased when combined with Infliximab.,Balaglitazone
DB01132,The metabolism of Pioglitazone can be increased when combined with Infliximab.,Pioglitazone
DB11652,The metabolism of Tucatinib can be increased when combined with Infliximab.,Tucatinib
DB00946,The metabolism of Phenprocoumon can be increased when combined with Infliximab.,Phenprocoumon
DB01229,The metabolism of Paclitaxel can be increased when combined with Infliximab.,Paclitaxel
DB00177,The metabolism of Valsartan can be increased when combined with Infliximab.,Valsartan
DB00184,The metabolism of Nicotine can be increased when combined with Infliximab.,Nicotine
DB00197,The metabolism of Troglitazone can be increased when combined with Infliximab.,Troglitazone
DB00214,The metabolism of Torasemide can be increased when combined with Infliximab.,Torasemide
DB00222,The metabolism of Glimepiride can be increased when combined with Infliximab.,Glimepiride
DB00285,The metabolism of Venlafaxine can be increased when combined with Infliximab.,Venlafaxine
DB00304,The metabolism of Desogestrel can be increased when combined with Infliximab.,Desogestrel
DB00307,The metabolism of Bexarotene can be increased when combined with Infliximab.,Bexarotene
DB00327,The metabolism of Hydromorphone can be increased when combined with Infliximab.,Hydromorphone
DB00328,The metabolism of Indomethacin can be increased when combined with Infliximab.,Indomethacin
DB00343,The metabolism of Diltiazem can be increased when combined with Infliximab.,Diltiazem
DB00374,The metabolism of Treprostinil can be increased when combined with Infliximab.,Treprostinil
DB00412,The metabolism of Rosiglitazone can be increased when combined with Infliximab.,Rosiglitazone
DB00414,The metabolism of Acetohexamide can be increased when combined with Infliximab.,Acetohexamide
DB00420,The metabolism of Promazine can be increased when combined with Infliximab.,Promazine
DB00440,The metabolism of Trimethoprim can be increased when combined with Infliximab.,Trimethoprim
DB00461,The metabolism of Nabumetone can be increased when combined with Infliximab.,Nabumetone
DB00468,The metabolism of Quinine can be increased when combined with Infliximab.,Quinine
DB00469,The metabolism of Tenoxicam can be increased when combined with Infliximab.,Tenoxicam
DB00471,The metabolism of Montelukast can be increased when combined with Infliximab.,Montelukast
DB00472,The metabolism of Fluoxetine can be increased when combined with Infliximab.,Fluoxetine
DB00476,The metabolism of Duloxetine can be increased when combined with Infliximab.,Duloxetine
DB00482,The metabolism of Celecoxib can be increased when combined with Infliximab.,Celecoxib
DB00495,The metabolism of Zidovudine can be increased when combined with Infliximab.,Zidovudine
DB00502,The metabolism of Haloperidol can be increased when combined with Infliximab.,Haloperidol
DB00531,The metabolism of Cyclophosphamide can be increased when combined with Infliximab.,Cyclophosphamide
DB00533,The metabolism of Rofecoxib can be increased when combined with Infliximab.,Rofecoxib
DB00549,The metabolism of Zafirlukast can be increased when combined with Infliximab.,Zafirlukast
DB00554,The metabolism of Piroxicam can be increased when combined with Infliximab.,Piroxicam
DB00559,The metabolism of Bosentan can be increased when combined with Infliximab.,Bosentan
DB00568,The metabolism of Cinnarizine can be increased when combined with Infliximab.,Cinnarizine
DB00580,The metabolism of Valdecoxib can be increased when combined with Infliximab.,Valdecoxib
DB00586,The metabolism of Diclofenac can be increased when combined with Infliximab.,Diclofenac
DB00617,The metabolism of Paramethadione can be increased when combined with Infliximab.,Paramethadione
DB00661,The metabolism of Verapamil can be increased when combined with Infliximab.,Verapamil
DB00672,The metabolism of Chlorpropamide can be increased when combined with Infliximab.,Chlorpropamide
DB00678,The metabolism of Losartan can be increased when combined with Infliximab.,Losartan
DB00701,The metabolism of Amprenavir can be increased when combined with Infliximab.,Amprenavir
DB00712,The metabolism of Flurbiprofen can be increased when combined with Infliximab.,Flurbiprofen
DB00731,The metabolism of Nateglinide can be increased when combined with Infliximab.,Nateglinide
DB00744,The metabolism of Zileuton can be increased when combined with Infliximab.,Zileuton
DB00749,The metabolism of Etodolac can be increased when combined with Infliximab.,Etodolac
DB00755,The metabolism of Tretinoin can be increased when combined with Infliximab.,Tretinoin
DB00758,The metabolism of Clopidogrel can be increased when combined with Infliximab.,Clopidogrel
DB00783,The metabolism of Estradiol can be increased when combined with Infliximab.,Estradiol
DB00784,The metabolism of Mefenamic acid can be increased when combined with Infliximab.,Mefenamic acid
DB00788,The metabolism of Naproxen can be increased when combined with Infliximab.,Naproxen
DB00796,The metabolism of Candesartan cilexetil can be increased when combined with Infliximab.,Candesartan cilexetil
DB00812,The metabolism of Phenylbutazone can be increased when combined with Infliximab.,Phenylbutazone
DB00814,The metabolism of Meloxicam can be increased when combined with Infliximab.,Meloxicam
DB00818,The metabolism of Propofol can be increased when combined with Infliximab.,Propofol
DB00839,The metabolism of Tolazamide can be increased when combined with Infliximab.,Tolazamide
DB00843,The metabolism of Donepezil can be increased when combined with Infliximab.,Donepezil
DB00857,The metabolism of Terbinafine can be increased when combined with Infliximab.,Terbinafine
DB00904,The metabolism of Ondansetron can be increased when combined with Infliximab.,Ondansetron
DB00921,The metabolism of Buprenorphine can be increased when combined with Infliximab.,Buprenorphine
DB00936,The metabolism of Salicylic acid can be increased when combined with Infliximab.,Salicylic acid
DB00945,The metabolism of Acetylsalicylic acid can be increased when combined with Infliximab.,Acetylsalicylic acid
DB00969,The metabolism of Alosetron can be increased when combined with Infliximab.,Alosetron
DB00972,The metabolism of Azelastine can be increased when combined with Infliximab.,Azelastine
DB00980,The metabolism of Ramelteon can be increased when combined with Infliximab.,Ramelteon
DB01016,The metabolism of Glyburide can be increased when combined with Infliximab.,Glyburide
DB01029,The metabolism of Irbesartan can be increased when combined with Infliximab.,Irbesartan
DB01036,The metabolism of Tolterodine can be increased when combined with Infliximab.,Tolterodine
DB01037,The metabolism of Selegiline can be increased when combined with Infliximab.,Selegiline
DB01041,The metabolism of Thalidomide can be increased when combined with Infliximab.,Thalidomide
DB01050,The metabolism of Ibuprofen can be increased when combined with Infliximab.,Ibuprofen
DB01065,The metabolism of Melatonin can be increased when combined with Infliximab.,Melatonin
DB01067,The metabolism of Glipizide can be increased when combined with Infliximab.,Glipizide
DB01072,The metabolism of Atazanavir can be increased when combined with Infliximab.,Atazanavir
DB01075,The metabolism of Diphenhydramine can be increased when combined with Infliximab.,Diphenhydramine
DB01095,The metabolism of Fluvastatin can be increased when combined with Infliximab.,Fluvastatin
DB01098,The metabolism of Rosuvastatin can be increased when combined with Infliximab.,Rosuvastatin
DB01120,The metabolism of Gliclazide can be increased when combined with Infliximab.,Gliclazide
DB01124,The metabolism of Tolbutamide can be increased when combined with Infliximab.,Tolbutamide
DB01136,The metabolism of Carvedilol can be increased when combined with Infliximab.,Carvedilol
DB01154,The metabolism of Thiamylal can be increased when combined with Infliximab.,Thiamylal
DB01171,The metabolism of Moclobemide can be increased when combined with Infliximab.,Moclobemide
DB01177,The metabolism of Idarubicin can be increased when combined with Infliximab.,Idarubicin
DB01198,The metabolism of Zopiclone can be increased when combined with Infliximab.,Zopiclone
DB01251,The metabolism of Gliquidone can be increased when combined with Infliximab.,Gliquidone
DB01283,The metabolism of Lumiracoxib can be increased when combined with Infliximab.,Lumiracoxib
DB01289,The metabolism of Glisoxepide can be increased when combined with Infliximab.,Glisoxepide
DB01357,The metabolism of Mestranol can be increased when combined with Infliximab.,Mestranol
DB01424,The metabolism of Aminophenazone can be increased when combined with Infliximab.,Aminophenazone
DB01435,The metabolism of Antipyrine can be increased when combined with Infliximab.,Antipyrine
DB01589,The metabolism of Quazepam can be increased when combined with Infliximab.,Quazepam
DB01628,The metabolism of Etoricoxib can be increased when combined with Infliximab.,Etoricoxib
DB03756,The metabolism of Doconexent can be increased when combined with Infliximab.,Doconexent
DB03783,The metabolism of Phenacetin can be increased when combined with Infliximab.,Phenacetin
DB04557,The metabolism of Arachidonic Acid can be increased when combined with Infliximab.,Arachidonic Acid
DB04574,The metabolism of Estrone sulfate can be increased when combined with Infliximab.,Estrone sulfate
DB04665,The metabolism of Coumarin can be increased when combined with Infliximab.,Coumarin
DB04725,The metabolism of Licofelone can be increased when combined with Infliximab.,Licofelone
DB04841,The metabolism of Flunarizine can be increased when combined with Infliximab.,Flunarizine
DB04898,The metabolism of Ximelagatran can be increased when combined with Infliximab.,Ximelagatran
DB06204,The metabolism of Tapentadol can be increased when combined with Infliximab.,Tapentadol
DB06268,The metabolism of Sitaxentan can be increased when combined with Infliximab.,Sitaxentan
DB06370,The metabolism of Indisulam can be increased when combined with Infliximab.,Indisulam
DB06652,The metabolism of Vicriviroc can be increased when combined with Infliximab.,Vicriviroc
DB06725,The metabolism of Lornoxicam can be increased when combined with Infliximab.,Lornoxicam
DB06737,The metabolism of Zaltoprofen can be increased when combined with Infliximab.,Zaltoprofen
DB06803,The metabolism of Niclosamide can be increased when combined with Infliximab.,Niclosamide
DB07615,The metabolism of Tranilast can be increased when combined with Infliximab.,Tranilast
DB08439,The metabolism of Parecoxib can be increased when combined with Infliximab.,Parecoxib
DB08828,The metabolism of Vismodegib can be increased when combined with Infliximab.,Vismodegib
DB08860,The metabolism of Pitavastatin can be increased when combined with Infliximab.,Pitavastatin
DB08875,The metabolism of Cabozantinib can be increased when combined with Infliximab.,Cabozantinib
DB08899,The metabolism of Enzalutamide can be increased when combined with Infliximab.,Enzalutamide
DB08962,The metabolism of Glibornuride can be increased when combined with Infliximab.,Glibornuride
DB09048,The metabolism of Netupitant can be increased when combined with Infliximab.,Netupitant
DB09061,The metabolism of Cannabidiol can be increased when combined with Infliximab.,Cannabidiol
DB09080,The metabolism of Olodaterol can be increased when combined with Infliximab.,Olodaterol
DB09288,The metabolism of Propacetamol can be increased when combined with Infliximab.,Propacetamol
DB11560,The metabolism of Lesinurad can be increased when combined with Infliximab.,Lesinurad
DB11614,The metabolism of Rupatadine can be increased when combined with Infliximab.,Rupatadine
DB13406,The metabolism of Carbutamide can be increased when combined with Infliximab.,Carbutamide
DB13675,The metabolism of Metahexamide can be increased when combined with Infliximab.,Metahexamide
DB13919,The metabolism of Candesartan can be increased when combined with Infliximab.,Candesartan
DB13941,The metabolism of Piperaquine can be increased when combined with Infliximab.,Piperaquine
DB13952,The metabolism of Estradiol acetate can be increased when combined with Infliximab.,Estradiol acetate
DB13953,The metabolism of Estradiol benzoate can be increased when combined with Infliximab.,Estradiol benzoate
DB13954,The metabolism of Estradiol cypionate can be increased when combined with Infliximab.,Estradiol cypionate
DB13955,The metabolism of Estradiol dienanthate can be increased when combined with Infliximab.,Estradiol dienanthate
DB13956,The metabolism of Estradiol valerate can be increased when combined with Infliximab.,Estradiol valerate
DB14009,The metabolism of Medical Cannabis can be increased when combined with Infliximab.,Medical Cannabis
DB14011,The metabolism of Nabiximols can be increased when combined with Infliximab.,Nabiximols
DB00829,The metabolism of Diazepam can be increased when combined with Infliximab.,Diazepam
DB00514,The metabolism of Dextromethorphan can be increased when combined with Infliximab.,Dextromethorphan
DB00470,The metabolism of Dronabinol can be increased when combined with Infliximab.,Dronabinol
DB09213,The metabolism of Dexibuprofen can be increased when combined with Infliximab.,Dexibuprofen
DB00465,The metabolism of Ketorolac can be increased when combined with Infliximab.,Ketorolac
DB15233,The metabolism of Avapritinib can be increased when combined with Infliximab.,Avapritinib
DB00321,The metabolism of Amitriptyline can be increased when combined with Infliximab.,Amitriptyline
DB01142,The metabolism of Doxepin can be increased when combined with Infliximab.,Doxepin
DB00216,The metabolism of Eletriptan can be increased when combined with Infliximab.,Eletriptan
DB00404,The metabolism of Alprazolam can be increased when combined with Infliximab.,Alprazolam
DB00726,The metabolism of Trimipramine can be increased when combined with Infliximab.,Trimipramine
DB01101,The metabolism of Capecitabine can be increased when combined with Infliximab.,Capecitabine
DB00266,The metabolism of Dicoumarol can be increased when combined with Infliximab.,Dicoumarol
DB00313,The metabolism of Valproic acid can be increased when combined with Infliximab.,Valproic acid
DB00908,The metabolism of Quinidine can be increased when combined with Infliximab.,Quinidine
DB13136,The metabolism of Fluindione can be increased when combined with Infliximab.,Fluindione
DB01224,The metabolism of Quetiapine can be increased when combined with Infliximab.,Quetiapine
DB00182,The metabolism of Amphetamine can be increased when combined with Infliximab.,Amphetamine
DB00187,The metabolism of Esmolol can be increased when combined with Infliximab.,Esmolol
DB00245,The metabolism of Benzatropine can be increased when combined with Infliximab.,Benzatropine
DB00289,The metabolism of Atomoxetine can be increased when combined with Infliximab.,Atomoxetine
DB00335,The metabolism of Atenolol can be increased when combined with Infliximab.,Atenolol
DB00373,The metabolism of Timolol can be increased when combined with Infliximab.,Timolol
DB00409,The metabolism of Remoxipride can be increased when combined with Infliximab.,Remoxipride
DB00592,The metabolism of Piperazine can be increased when combined with Infliximab.,Piperazine
DB00699,The metabolism of Nicergoline can be increased when combined with Infliximab.,Nicergoline
DB00737,The metabolism of Meclizine can be increased when combined with Infliximab.,Meclizine
DB00805,The metabolism of Minaprine can be increased when combined with Infliximab.,Minaprine
DB00866,The metabolism of Alprenolol can be increased when combined with Infliximab.,Alprenolol
DB00914,The metabolism of Phenformin can be increased when combined with Infliximab.,Phenformin
DB00933,The metabolism of Mesoridazine can be increased when combined with Infliximab.,Mesoridazine
DB00960,The metabolism of Pindolol can be increased when combined with Infliximab.,Pindolol
DB01071,The metabolism of Mequitazine can be increased when combined with Infliximab.,Mequitazine
DB01079,The metabolism of Tegaserod can be increased when combined with Infliximab.,Tegaserod
DB01193,The metabolism of Acebutolol can be increased when combined with Infliximab.,Acebutolol
DB01203,The metabolism of Nadolol can be increased when combined with Infliximab.,Nadolol
DB01228,The metabolism of Encainide can be increased when combined with Infliximab.,Encainide
DB01233,The metabolism of Metoclopramide can be increased when combined with Infliximab.,Metoclopramide
DB01255,The metabolism of Lisdexamfetamine can be increased when combined with Infliximab.,Lisdexamfetamine
DB01295,The metabolism of Bevantolol can be increased when combined with Infliximab.,Bevantolol
DB01297,The metabolism of Practolol can be increased when combined with Infliximab.,Practolol
DB01359,The metabolism of Penbutolol can be increased when combined with Infliximab.,Penbutolol
DB01403,The metabolism of Methotrimeprazine can be increased when combined with Infliximab.,Methotrimeprazine
DB01429,The metabolism of Aprindine can be increased when combined with Infliximab.,Aprindine
DB01454,The metabolism of Midomafetamine can be increased when combined with Infliximab.,Midomafetamine
DB01472,The metabolism of 4-Methoxyamphetamine can be increased when combined with Infliximab.,4-Methoxyamphetamine
DB01576,The metabolism of Dextroamphetamine can be increased when combined with Infliximab.,Dextroamphetamine
DB01577,The metabolism of Metamfetamine can be increased when combined with Infliximab.,Metamfetamine
DB01580,The metabolism of Oxprenolol can be increased when combined with Infliximab.,Oxprenolol
DB04840,The metabolism of Debrisoquine can be increased when combined with Infliximab.,Debrisoquine
DB04844,The metabolism of Tetrabenazine can be increased when combined with Infliximab.,Tetrabenazine
DB04846,The metabolism of Celiprolol can be increased when combined with Infliximab.,Celiprolol
DB06217,The metabolism of Vernakalant can be increased when combined with Infliximab.,Vernakalant
DB06506,The metabolism of Repinotan can be increased when combined with Infliximab.,Repinotan
DB06608,The metabolism of Tafenoquine can be increased when combined with Infliximab.,Tafenoquine
DB06678,The metabolism of Esmirtazapine can be increased when combined with Infliximab.,Esmirtazapine
DB06726,The metabolism of Bufuralol can be increased when combined with Infliximab.,Bufuralol
DB06727,The metabolism of Sparteine can be increased when combined with Infliximab.,Sparteine
DB06735,The metabolism of Enclomiphene can be increased when combined with Infliximab.,Enclomiphene
DB08807,The metabolism of Bopindolol can be increased when combined with Infliximab.,Bopindolol
DB08808,The metabolism of Bupranolol can be increased when combined with Infliximab.,Bupranolol
DB08952,The metabolism of Indenolol can be increased when combined with Infliximab.,Indenolol
DB09013,The metabolism of Befunolol can be increased when combined with Infliximab.,Befunolol
DB09076,The metabolism of Umeclidinium can be increased when combined with Infliximab.,Umeclidinium
DB09204,The metabolism of Arotinolol can be increased when combined with Infliximab.,Arotinolol
DB09351,The metabolism of Levobetaxolol can be increased when combined with Infliximab.,Levobetaxolol
DB11770,The metabolism of Talinolol can be increased when combined with Infliximab.,Talinolol
DB11785,The metabolism of Anisodamine can be increased when combined with Infliximab.,Anisodamine
DB11855,The metabolism of Revefenacin can be increased when combined with Infliximab.,Revefenacin
DB11979,The metabolism of Elagolix can be increased when combined with Infliximab.,Elagolix
DB12070,The metabolism of Letermovir can be increased when combined with Infliximab.,Letermovir
DB12212,The metabolism of Landiolol can be increased when combined with Infliximab.,Landiolol
DB12752,The metabolism of Bucindolol can be increased when combined with Infliximab.,Bucindolol
DB13443,The metabolism of Esatenolol can be increased when combined with Infliximab.,Esatenolol
DB13508,The metabolism of Cloranolol can be increased when combined with Infliximab.,Cloranolol
DB13530,The metabolism of Mepindolol can be increased when combined with Infliximab.,Mepindolol
DB13679,The metabolism of Dexchlorpheniramine can be increased when combined with Infliximab.,Dexchlorpheniramine
DB13757,The metabolism of Epanolol can be increased when combined with Infliximab.,Epanolol
DB13775,The metabolism of Tertatolol can be increased when combined with Infliximab.,Tertatolol
DB00850,The metabolism of Perphenazine can be increased when combined with Infliximab.,Perphenazine
DB09173,The metabolism of Butyrfentanyl can be increased when combined with Infliximab.,Butyrfentanyl
DB00281,The metabolism of Lidocaine can be increased when combined with Infliximab.,Lidocaine
DB00598,The metabolism of Labetalol can be increased when combined with Infliximab.,Labetalol
DB14010,"The metabolism of 5-methoxy-N,N-dimethyltryptamine can be increased when combined with Infliximab.","5-methoxy-N,N-dimethyltryptamine"
DB01410,The metabolism of Ciclesonide can be increased when combined with Infliximab.,Ciclesonide
DB00918,The metabolism of Almotriptan can be increased when combined with Infliximab.,Almotriptan
DB08918,The metabolism of Levomilnacipran can be increased when combined with Infliximab.,Levomilnacipran
DB08922,The metabolism of Perospirone can be increased when combined with Infliximab.,Perospirone
DB09183,The metabolism of Dasabuvir can be increased when combined with Infliximab.,Dasabuvir
DB02703,The metabolism of Fusidic acid can be increased when combined with Infliximab.,Fusidic acid
DB13293,The metabolism of Ipecac can be increased when combined with Infliximab.,Ipecac
DB00185,The metabolism of Cevimeline can be increased when combined with Infliximab.,Cevimeline
DB00243,The metabolism of Ranolazine can be increased when combined with Infliximab.,Ranolazine
DB00297,The metabolism of Bupivacaine can be increased when combined with Infliximab.,Bupivacaine
DB00318,The metabolism of Codeine can be increased when combined with Infliximab.,Codeine
DB00377,The metabolism of Palonosetron can be increased when combined with Infliximab.,Palonosetron
DB00589,The metabolism of Lisuride can be increased when combined with Infliximab.,Lisuride
DB00647,The metabolism of Dextropropoxyphene can be increased when combined with Infliximab.,Dextropropoxyphene
DB00674,The metabolism of Galantamine can be increased when combined with Infliximab.,Galantamine
DB00705,The metabolism of Delavirdine can be increased when combined with Infliximab.,Delavirdine
DB00706,The metabolism of Tamsulosin can be increased when combined with Infliximab.,Tamsulosin
DB00757,The metabolism of Dolasetron can be increased when combined with Infliximab.,Dolasetron
DB01149,The metabolism of Nefazodone can be increased when combined with Infliximab.,Nefazodone
DB01192,The metabolism of Oxymorphone can be increased when combined with Infliximab.,Oxymorphone
DB01244,The metabolism of Bepridil can be increased when combined with Infliximab.,Bepridil
DB01392,The metabolism of Yohimbine can be increased when combined with Infliximab.,Yohimbine
DB01409,The metabolism of Tiotropium can be increased when combined with Infliximab.,Tiotropium
DB01551,The metabolism of Dihydrocodeine can be increased when combined with Infliximab.,Dihydrocodeine
DB01591,The metabolism of Solifenacin can be increased when combined with Infliximab.,Solifenacin
DB01621,The metabolism of Pipotiazine can be increased when combined with Infliximab.,Pipotiazine
DB04829,The metabolism of Lysergic acid diethylamide can be increased when combined with Infliximab.,Lysergic acid diethylamide
DB04884,The metabolism of Dapoxetine can be increased when combined with Infliximab.,Dapoxetine
DB04905,The metabolism of Tesmilifene can be increased when combined with Infliximab.,Tesmilifene
DB04920,The metabolism of Clevidipine can be increased when combined with Infliximab.,Clevidipine
DB05271,The metabolism of Rotigotine can be increased when combined with Infliximab.,Rotigotine
DB06016,The metabolism of Cariprazine can be increased when combined with Infliximab.,Cariprazine
DB06144,The metabolism of Sertindole can be increased when combined with Infliximab.,Sertindole
DB06203,The metabolism of Alogliptin can be increased when combined with Infliximab.,Alogliptin
DB06702,The metabolism of Fesoterodine can be increased when combined with Infliximab.,Fesoterodine
DB08893,The metabolism of Mirabegron can be increased when combined with Infliximab.,Mirabegron
DB09128,The metabolism of Brexpiprazole can be increased when combined with Infliximab.,Brexpiprazole
DB09195,The metabolism of Lorpiprazole can be increased when combined with Infliximab.,Lorpiprazole
DB09555,The metabolism of Dexchlorpheniramine maleate can be increased when combined with Infliximab.,Dexchlorpheniramine maleate
DB11130,The metabolism of Opium can be increased when combined with Infliximab.,Opium
DB11642,The metabolism of Pitolisant can be increased when combined with Infliximab.,Pitolisant
DB00344,The metabolism of Protriptyline can be increased when combined with Infliximab.,Protriptyline
DB00496,The metabolism of Darifenacin can be increased when combined with Infliximab.,Darifenacin
DB00543,The metabolism of Amoxapine can be increased when combined with Infliximab.,Amoxapine
DB00932,The metabolism of Tipranavir can be increased when combined with Infliximab.,Tipranavir
DB09039,The metabolism of Eliglustat can be increased when combined with Infliximab.,Eliglustat
DB12930,The metabolism of Opipramol can be increased when combined with Infliximab.,Opipramol
DB00489,The metabolism of Sotalol can be increased when combined with Infliximab.,Sotalol
DB01035,The metabolism of Procainamide can be increased when combined with Infliximab.,Procainamide
DB01195,The metabolism of Flecainide can be increased when combined with Infliximab.,Flecainide
DB00228,The metabolism of Enflurane can be increased when combined with Infliximab.,Enflurane
DB06712,The metabolism of Nilvadipine can be increased when combined with Infliximab.,Nilvadipine
DB06728,The metabolism of Aniline can be increased when combined with Infliximab.,Aniline
DB00949,The metabolism of Felbamate can be increased when combined with Infliximab.,Felbamate
DB00593,The metabolism of Ethosuximide can be increased when combined with Infliximab.,Ethosuximide
DB00186,The metabolism of Lorazepam can be increased when combined with Infliximab.,Lorazepam
DB00191,The metabolism of Phentermine can be increased when combined with Infliximab.,Phentermine
DB00207,The metabolism of Azithromycin can be increased when combined with Infliximab.,Azithromycin
DB00208,The metabolism of Ticlopidine can be increased when combined with Infliximab.,Ticlopidine
DB00264,The metabolism of Metoprolol can be increased when combined with Infliximab.,Metoprolol
DB00426,The metabolism of Famciclovir can be increased when combined with Infliximab.,Famciclovir
DB00433,The metabolism of Prochlorperazine can be increased when combined with Infliximab.,Prochlorperazine
DB00567,The metabolism of Cephalexin can be increased when combined with Infliximab.,Cephalexin
DB00590,The metabolism of Doxazosin can be increased when combined with Infliximab.,Doxazosin
DB01039,The metabolism of Fenofibrate can be increased when combined with Infliximab.,Fenofibrate
DB01395,The metabolism of Drospirenone can be increased when combined with Infliximab.,Drospirenone
DB01411,The metabolism of Pranlukast can be increased when combined with Infliximab.,Pranlukast
DB01431,The metabolism of Allylestrenol can be increased when combined with Infliximab.,Allylestrenol
DB01624,The metabolism of Zuclopenthixol can be increased when combined with Infliximab.,Zuclopenthixol
DB06201,The metabolism of Rufinamide can be increased when combined with Infliximab.,Rufinamide
DB06480,The metabolism of Prucalopride can be increased when combined with Infliximab.,Prucalopride
DB08882,The metabolism of Linagliptin can be increased when combined with Infliximab.,Linagliptin
DB09030,The metabolism of Vorapaxar can be increased when combined with Infliximab.,Vorapaxar
DB09034,The metabolism of Suvorexant can be increased when combined with Infliximab.,Suvorexant
DB09079,The metabolism of Nintedanib can be increased when combined with Infliximab.,Nintedanib
DB09299,The metabolism of Tenofovir alafenamide can be increased when combined with Infliximab.,Tenofovir alafenamide
DB09330,The metabolism of Osimertinib can be increased when combined with Infliximab.,Osimertinib
DB11094,The metabolism of Vitamin D can be increased when combined with Infliximab.,Vitamin D
DB11273,The metabolism of Dihydroergocornine can be increased when combined with Infliximab.,Dihydroergocornine
DB11730,The metabolism of Ribociclib can be increased when combined with Infliximab.,Ribociclib
DB11952,The metabolism of Duvelisib can be increased when combined with Infliximab.,Duvelisib
DB12141,The metabolism of Gilteritinib can be increased when combined with Infliximab.,Gilteritinib
DB12515,The metabolism of 9-aminocamptothecin can be increased when combined with Infliximab.,9-aminocamptothecin
DB12952,The metabolism of Methylprednisone can be increased when combined with Infliximab.,Methylprednisone
DB13345,The metabolism of Dihydroergocristine can be increased when combined with Infliximab.,Dihydroergocristine
DB13385,The metabolism of Dihydroergocryptine can be increased when combined with Infliximab.,Dihydroergocryptine
DB14126,The metabolism of Tenofovir can be increased when combined with Infliximab.,Tenofovir
DB15444,The metabolism of Elexacaftor can be increased when combined with Infliximab.,Elexacaftor
DB06717,The metabolism of Fosaprepitant can be increased when combined with Infliximab.,Fosaprepitant
DB12825,The metabolism of Lefamulin can be increased when combined with Infliximab.,Lefamulin
DB12887,The metabolism of Tazemetostat can be increased when combined with Infliximab.,Tazemetostat
DB00454,The metabolism of Meperidine can be increased when combined with Infliximab.,Meperidine
DB01151,The metabolism of Desipramine can be increased when combined with Infliximab.,Desipramine
DB12371,The metabolism of Siponimod can be increased when combined with Infliximab.,Siponimod
DB00247,The metabolism of Methysergide can be increased when combined with Infliximab.,Methysergide
DB08827,The metabolism of Lomitapide can be increased when combined with Infliximab.,Lomitapide
DB11742,The metabolism of Ebastine can be increased when combined with Infliximab.,Ebastine
DB05015,The metabolism of Belinostat can be increased when combined with Infliximab.,Belinostat
DB01118,The metabolism of Amiodarone can be increased when combined with Infliximab.,Amiodarone
DB00675,The metabolism of Tamoxifen can be increased when combined with Infliximab.,Tamoxifen
DB00204,The metabolism of Dofetilide can be increased when combined with Infliximab.,Dofetilide
DB00342,The metabolism of Terfenadine can be increased when combined with Infliximab.,Terfenadine
DB00451,The metabolism of Levothyroxine can be increased when combined with Infliximab.,Levothyroxine
DB00604,The metabolism of Cisapride can be increased when combined with Infliximab.,Cisapride
DB00877,The metabolism of Sirolimus can be increased when combined with Infliximab.,Sirolimus
DB01008,The metabolism of Busulfan can be increased when combined with Infliximab.,Busulfan
DB01254,The metabolism of Dasatinib can be increased when combined with Infliximab.,Dasatinib
DB01396,The metabolism of Digitoxin can be increased when combined with Infliximab.,Digitoxin
DB01590,The metabolism of Everolimus can be increased when combined with Infliximab.,Everolimus
DB03410,The metabolism of 4-hydroxycoumarin can be increased when combined with Infliximab.,4-hydroxycoumarin
DB04855,The metabolism of Dronedarone can be increased when combined with Infliximab.,Dronedarone
DB06287,The metabolism of Temsirolimus can be increased when combined with Infliximab.,Temsirolimus
DB09053,The metabolism of Ibrutinib can be increased when combined with Infliximab.,Ibrutinib
DB09289,The metabolism of Tianeptine can be increased when combined with Infliximab.,Tianeptine
DB11633,The metabolism of Isavuconazole can be increased when combined with Infliximab.,Isavuconazole
DB13275,The metabolism of Clorindione can be increased when combined with Infliximab.,Clorindione
DB00398,The metabolism of Sorafenib can be increased when combined with Infliximab.,Sorafenib
DB00444,The metabolism of Teniposide can be increased when combined with Infliximab.,Teniposide
DB00530,The metabolism of Erlotinib can be increased when combined with Infliximab.,Erlotinib
DB00541,The metabolism of Vincristine can be increased when combined with Infliximab.,Vincristine
DB00619,The metabolism of Imatinib can be increased when combined with Infliximab.,Imatinib
DB00773,The metabolism of Etoposide can be increased when combined with Infliximab.,Etoposide
DB01248,The metabolism of Docetaxel can be increased when combined with Infliximab.,Docetaxel
DB01268,The metabolism of Sunitinib can be increased when combined with Infliximab.,Sunitinib
DB06626,The metabolism of Axitinib can be increased when combined with Infliximab.,Axitinib
DB08865,The metabolism of Crizotinib can be increased when combined with Infliximab.,Crizotinib
DB08901,The metabolism of Ponatinib can be increased when combined with Infliximab.,Ponatinib
DB12483,The metabolism of Copanlisib can be increased when combined with Infliximab.,Copanlisib
DB00188,The metabolism of Bortezomib can be increased when combined with Infliximab.,Bortezomib
DB00363,The metabolism of Clozapine can be increased when combined with Infliximab.,Clozapine
DB01181,The metabolism of Ifosfamide can be increased when combined with Infliximab.,Ifosfamide
DB05109,The metabolism of Trabectedin can be increased when combined with Infliximab.,Trabectedin
DB12147,The metabolism of Erdafitinib can be increased when combined with Infliximab.,Erdafitinib
DB13874,The metabolism of Enasidenib can be increased when combined with Infliximab.,Enasidenib
DB06589,The metabolism of Pazopanib can be increased when combined with Infliximab.,Pazopanib
DB05239,The metabolism of Cobimetinib can be increased when combined with Infliximab.,Cobimetinib
DB09063,The metabolism of Ceritinib can be increased when combined with Infliximab.,Ceritinib
DB11963,The metabolism of Dacomitinib can be increased when combined with Infliximab.,Dacomitinib
DB12015,The metabolism of Alpelisib can be increased when combined with Infliximab.,Alpelisib
DB00309,The metabolism of Vindesine can be increased when combined with Infliximab.,Vindesine
DB00361,The metabolism of Vinorelbine can be increased when combined with Infliximab.,Vinorelbine
DB00570,The metabolism of Vinblastine can be increased when combined with Infliximab.,Vinblastine
DB00694,The metabolism of Daunorubicin can be increased when combined with Infliximab.,Daunorubicin
DB00987,The metabolism of Cytarabine can be increased when combined with Infliximab.,Cytarabine
DB00997,The metabolism of Doxorubicin can be increased when combined with Infliximab.,Doxorubicin
DB01108,The metabolism of Trilostane can be increased when combined with Infliximab.,Trilostane
DB04572,The metabolism of Thiotepa can be increased when combined with Infliximab.,Thiotepa
DB04845,The metabolism of Ixabepilone can be increased when combined with Infliximab.,Ixabepilone
DB04868,The metabolism of Nilotinib can be increased when combined with Infliximab.,Nilotinib
DB06603,The metabolism of Panobinostat can be increased when combined with Infliximab.,Panobinostat
DB06616,The metabolism of Bosutinib can be increased when combined with Infliximab.,Bosutinib
DB08870,The metabolism of Brentuximab vedotin can be increased when combined with Infliximab.,Brentuximab vedotin
DB08877,The metabolism of Ruxolitinib can be increased when combined with Infliximab.,Ruxolitinib
DB09073,The metabolism of Palbociclib can be increased when combined with Infliximab.,Palbociclib
DB08912,The metabolism of Dabrafenib can be increased when combined with Infliximab.,Dabrafenib
DB12267,The metabolism of Brigatinib can be increased when combined with Infliximab.,Brigatinib
DB11718,The metabolism of Encorafenib can be increased when combined with Infliximab.,Encorafenib
DB00563,The metabolism of Methotrexate can be increased when combined with Infliximab.,Methotrexate
DB05294,The metabolism of Vandetanib can be increased when combined with Infliximab.,Vandetanib
DB05812,The metabolism of Abiraterone can be increased when combined with Infliximab.,Abiraterone
DB08881,The metabolism of Vemurafenib can be increased when combined with Infliximab.,Vemurafenib
DB11363,The metabolism of Alectinib can be increased when combined with Infliximab.,Alectinib
DB11581,The metabolism of Venetoclax can be increased when combined with Infliximab.,Venetoclax
DB11641,The metabolism of Vinflunine can be increased when combined with Infliximab.,Vinflunine
DB11703,The metabolism of Acalabrutinib can be increased when combined with Infliximab.,Acalabrutinib
DB15035,The metabolism of Zanubrutinib can be increased when combined with Infliximab.,Zanubrutinib
DB00248,The metabolism of Cabergoline can be increased when combined with Infliximab.,Cabergoline
DB06595,The metabolism of Midostaurin can be increased when combined with Infliximab.,Midostaurin
DB09143,The metabolism of Sonidegib can be increased when combined with Infliximab.,Sonidegib
DB11828,The metabolism of Neratinib can be increased when combined with Infliximab.,Neratinib
DB11986,The metabolism of Entrectinib can be increased when combined with Infliximab.,Entrectinib
DB12978,The metabolism of Pexidartinib can be increased when combined with Infliximab.,Pexidartinib
DB14568,The metabolism of Ivosidenib can be increased when combined with Infliximab.,Ivosidenib
DB09054,The metabolism of Idelalisib can be increased when combined with Infliximab.,Idelalisib
DB09570,The metabolism of Ixazomib can be increased when combined with Infliximab.,Ixazomib
DB00199,The metabolism of Erythromycin can be increased when combined with Infliximab.,Erythromycin
DB00246,The metabolism of Ziprasidone can be increased when combined with Infliximab.,Ziprasidone
DB00439,The metabolism of Cerivastatin can be increased when combined with Infliximab.,Cerivastatin
DB00499,The metabolism of Flutamide can be increased when combined with Infliximab.,Flutamide
DB00503,The metabolism of Ritonavir can be increased when combined with Infliximab.,Ritonavir
DB00528,The metabolism of Lercanidipine can be increased when combined with Infliximab.,Lercanidipine
DB00571,The metabolism of Propranolol can be increased when combined with Infliximab.,Propranolol
DB00588,The metabolism of Fluticasone propionate can be increased when combined with Infliximab.,Fluticasone propionate
DB00608,The metabolism of Chloroquine can be increased when combined with Infliximab.,Chloroquine
DB00688,The metabolism of Mycophenolate mofetil can be increased when combined with Infliximab.,Mycophenolate mofetil
DB00717,The metabolism of Norethisterone can be increased when combined with Infliximab.,Norethisterone
DB00738,The metabolism of Pentamidine can be increased when combined with Infliximab.,Pentamidine
DB00741,The metabolism of Hydrocortisone can be increased when combined with Infliximab.,Hydrocortisone
DB00762,The metabolism of Irinotecan can be increased when combined with Infliximab.,Irinotecan
DB00822,The metabolism of Disulfiram can be increased when combined with Infliximab.,Disulfiram
DB00834,The metabolism of Mifepristone can be increased when combined with Infliximab.,Mifepristone
DB00938,The metabolism of Salmeterol can be increased when combined with Infliximab.,Salmeterol
DB00962,The metabolism of Zaleplon can be increased when combined with Infliximab.,Zaleplon
DB00976,The metabolism of Telithromycin can be increased when combined with Infliximab.,Telithromycin
DB01054,The metabolism of Nitrendipine can be increased when combined with Infliximab.,Nitrendipine
DB01058,The metabolism of Praziquantel can be increased when combined with Infliximab.,Praziquantel
DB01062,The metabolism of Oxybutynin can be increased when combined with Infliximab.,Oxybutynin
DB01076,The metabolism of Atorvastatin can be increased when combined with Infliximab.,Atorvastatin
DB01103,The metabolism of Quinacrine can be increased when combined with Infliximab.,Quinacrine
DB01115,The metabolism of Nifedipine can be increased when combined with Infliximab.,Nifedipine
DB01126,The metabolism of Dutasteride can be increased when combined with Infliximab.,Dutasteride
DB01166,The metabolism of Cilostazol can be increased when combined with Infliximab.,Cilostazol
DB01184,The metabolism of Domperidone can be increased when combined with Infliximab.,Domperidone
DB01211,The metabolism of Clarithromycin can be increased when combined with Infliximab.,Clarithromycin
DB01216,The metabolism of Finasteride can be increased when combined with Infliximab.,Finasteride
DB01218,The metabolism of Halofantrine can be increased when combined with Infliximab.,Halofantrine
DB05521,The metabolism of Telaprevir can be increased when combined with Infliximab.,Telaprevir
DB05773,The metabolism of Trastuzumab emtansine can be increased when combined with Infliximab.,Trastuzumab emtansine
DB06267,The metabolism of Udenafil can be increased when combined with Infliximab.,Udenafil
DB06335,The metabolism of Saxagliptin can be increased when combined with Infliximab.,Saxagliptin
DB06403,The metabolism of Ambrisentan can be increased when combined with Infliximab.,Ambrisentan
DB06419,The metabolism of Cethromycin can be increased when combined with Infliximab.,Cethromycin
DB06772,The metabolism of Cabazitaxel can be increased when combined with Infliximab.,Cabazitaxel
DB06789,The metabolism of Hydroxyprogesterone caproate can be increased when combined with Infliximab.,Hydroxyprogesterone caproate
DB08820,The metabolism of Ivacaftor can be increased when combined with Infliximab.,Ivacaftor
DB08873,The metabolism of Boceprevir can be increased when combined with Infliximab.,Boceprevir
DB08883,The metabolism of Perampanel can be increased when combined with Infliximab.,Perampanel
DB08906,The metabolism of Fluticasone furoate can be increased when combined with Infliximab.,Fluticasone furoate
DB09065,The metabolism of Cobicistat can be increased when combined with Infliximab.,Cobicistat
DB09074,The metabolism of Olaparib can be increased when combined with Infliximab.,Olaparib
DB09102,The metabolism of Daclatasvir can be increased when combined with Infliximab.,Daclatasvir
DB09231,The metabolism of Benidipine can be increased when combined with Infliximab.,Benidipine
DB09297,The metabolism of Paritaprevir can be increased when combined with Infliximab.,Paritaprevir
DB11574,The metabolism of Elbasvir can be increased when combined with Infliximab.,Elbasvir
DB11712,The metabolism of Tezacaftor can be increased when combined with Infliximab.,Tezacaftor
DB11737,The metabolism of Icotinib can be increased when combined with Infliximab.,Icotinib
DB12301,The metabolism of Doravirine can be increased when combined with Infliximab.,Doravirine
DB13867,The metabolism of Fluticasone can be increased when combined with Infliximab.,Fluticasone
DB14538,The metabolism of Hydrocortisone aceponate can be increased when combined with Infliximab.,Hydrocortisone aceponate
DB14539,The metabolism of Hydrocortisone acetate can be increased when combined with Infliximab.,Hydrocortisone acetate
DB14541,The metabolism of Hydrocortisone cypionate can be increased when combined with Infliximab.,Hydrocortisone cypionate
DB14542,The metabolism of Hydrocortisone phosphate can be increased when combined with Infliximab.,Hydrocortisone phosphate
DB00396,The metabolism of Progesterone can be increased when combined with Infliximab.,Progesterone
DB04856,The metabolism of Dexloxiglumide can be increased when combined with Infliximab.,Dexloxiglumide
DB04957,The metabolism of Azimilide can be increased when combined with Infliximab.,Azimilide
DB00250,The metabolism of Dapsone can be increased when combined with Infliximab.,Dapsone
DB00317,The metabolism of Gefitinib can be increased when combined with Infliximab.,Gefitinib
DB00367,The metabolism of Levonorgestrel can be increased when combined with Infliximab.,Levonorgestrel
DB00497,The metabolism of Oxycodone can be increased when combined with Infliximab.,Oxycodone
DB00620,The metabolism of Triamcinolone can be increased when combined with Infliximab.,Triamcinolone
DB00624,The metabolism of Testosterone can be increased when combined with Infliximab.,Testosterone
DB00656,The metabolism of Trazodone can be increased when combined with Infliximab.,Trazodone
DB00734,The metabolism of Risperidone can be increased when combined with Infliximab.,Risperidone
DB01114,The metabolism of Chlorpheniramine can be increased when combined with Infliximab.,Chlorpheniramine
DB01238,The metabolism of Aripiprazole can be increased when combined with Infliximab.,Aripiprazole
DB01267,The metabolism of Paliperidone can be increased when combined with Infliximab.,Paliperidone
DB04946,The metabolism of Iloperidone can be increased when combined with Infliximab.,Iloperidone
DB11915,The metabolism of Valbenazine can be increased when combined with Infliximab.,Valbenazine
DB12161,The metabolism of Deutetrabenazine can be increased when combined with Infliximab.,Deutetrabenazine
DB14185,The metabolism of Aripiprazole lauroxil can be increased when combined with Infliximab.,Aripiprazole lauroxil
DB01234,The metabolism of Dexamethasone can be increased when combined with Infliximab.,Dexamethasone
DB09237,The metabolism of Levamlodipine can be increased when combined with Infliximab.,Levamlodipine
DB11951,The metabolism of Lemborexant can be increased when combined with Infliximab.,Lemborexant
DB00557,The metabolism of Hydroxyzine can be increased when combined with Infliximab.,Hydroxyzine
DB00203,The metabolism of Sildenafil can be increased when combined with Infliximab.,Sildenafil
DB00227,The metabolism of Lovastatin can be increased when combined with Infliximab.,Lovastatin
DB00490,The metabolism of Buspirone can be increased when combined with Infliximab.,Buspirone
DB00641,The metabolism of Simvastatin can be increased when combined with Infliximab.,Simvastatin
DB00673,The metabolism of Aprepitant can be increased when combined with Infliximab.,Aprepitant
DB00820,The metabolism of Tadalafil can be increased when combined with Infliximab.,Tadalafil
DB00862,The metabolism of Vardenafil can be increased when combined with Infliximab.,Vardenafil
DB01190,The metabolism of Clindamycin can be increased when combined with Infliximab.,Clindamycin
DB00224,The metabolism of Indinavir can be increased when combined with Infliximab.,Indinavir
DB00401,The metabolism of Nisoldipine can be increased when combined with Infliximab.,Nisoldipine
DB00637,The metabolism of Astemizole can be increased when combined with Infliximab.,Astemizole
DB00683,The metabolism of Midazolam can be increased when combined with Infliximab.,Midazolam
DB00700,The metabolism of Eplerenone can be increased when combined with Infliximab.,Eplerenone
DB00802,The metabolism of Alfentanil can be increased when combined with Infliximab.,Alfentanil
DB00813,The metabolism of Fentanyl can be increased when combined with Infliximab.,Fentanyl
DB00897,The metabolism of Triazolam can be increased when combined with Infliximab.,Triazolam
DB01023,The metabolism of Felodipine can be increased when combined with Infliximab.,Felodipine
DB01227,The metabolism of Levacetylmethadol can be increased when combined with Infliximab.,Levacetylmethadol
DB01232,The metabolism of Saquinavir can be increased when combined with Infliximab.,Saquinavir
DB06228,The metabolism of Rivaroxaban can be increased when combined with Infliximab.,Rivaroxaban
DB05804,The metabolism of Prasterone sulfate can be increased when combined with Infliximab.,Prasterone sulfate
DB00091,Infliximab may increase the immunosuppressive activities of Cyclosporine.,Cyclosporine
DB05676,The therapeutic efficacy of Apremilast can be decreased when used in combination with Infliximab.,Apremilast
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Infliximab.","Ebola Zaire vaccine (live, attenuated)"
DB14513,The serum concentration of Magnesium can be decreased when it is combined with Infliximab.,Magnesium
DB01601,The serum concentration of Infliximab can be increased when it is combined with Lopinavir.,Lopinavir
DB12530,The risk or severity of infection can be increased when Infliximab is combined with Inebilizumab.,Inebilizumab
DB00176,The therapeutic efficacy of Follitropin can be decreased when used in combination with Fluvoxamine.,Fluvoxamine
DB00215,The therapeutic efficacy of Follitropin can be decreased when used in combination with Citalopram.,Citalopram
DB00472,The therapeutic efficacy of Follitropin can be decreased when used in combination with Fluoxetine.,Fluoxetine
DB00476,The therapeutic efficacy of Follitropin can be decreased when used in combination with Duloxetine.,Duloxetine
DB00656,The therapeutic efficacy of Follitropin can be decreased when used in combination with Trazodone.,Trazodone
DB00715,The therapeutic efficacy of Follitropin can be decreased when used in combination with Paroxetine.,Paroxetine
DB01104,The therapeutic efficacy of Follitropin can be decreased when used in combination with Sertraline.,Sertraline
DB01105,The therapeutic efficacy of Follitropin can be decreased when used in combination with Sibutramine.,Sibutramine
DB01149,The therapeutic efficacy of Follitropin can be decreased when used in combination with Nefazodone.,Nefazodone
DB01175,The therapeutic efficacy of Follitropin can be decreased when used in combination with Escitalopram.,Escitalopram
DB04832,The therapeutic efficacy of Follitropin can be decreased when used in combination with Zimelidine.,Zimelidine
DB04884,The therapeutic efficacy of Follitropin can be decreased when used in combination with Dapoxetine.,Dapoxetine
DB04896,The therapeutic efficacy of Follitropin can be decreased when used in combination with Milnacipran.,Milnacipran
DB06700,The therapeutic efficacy of Follitropin can be decreased when used in combination with Desvenlafaxine.,Desvenlafaxine
DB06731,The therapeutic efficacy of Follitropin can be decreased when used in combination with Seproxetine.,Seproxetine
DB08918,The therapeutic efficacy of Follitropin can be decreased when used in combination with Levomilnacipran.,Levomilnacipran
DB08953,The therapeutic efficacy of Follitropin can be decreased when used in combination with Indalpine.,Indalpine
DB12693,The therapeutic efficacy of Follitropin can be decreased when used in combination with Ritanserin.,Ritanserin
DB13233,The therapeutic efficacy of Follitropin can be decreased when used in combination with Alaproclate.,Alaproclate
DB00182,The risk or severity of adverse effects can be increased when Amphetamine is combined with Follitropin.,Amphetamine
DB00191,The risk or severity of adverse effects can be increased when Phentermine is combined with Follitropin.,Phentermine
DB00211,The risk or severity of adverse effects can be increased when Midodrine is combined with Follitropin.,Midodrine
DB00368,The risk or severity of adverse effects can be increased when Norepinephrine is combined with Follitropin.,Norepinephrine
DB00388,The risk or severity of adverse effects can be increased when Phenylephrine is combined with Follitropin.,Phenylephrine
DB00397,The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Follitropin.,Phenylpropanolamine
DB00610,The risk or severity of adverse effects can be increased when Metaraminol is combined with Follitropin.,Metaraminol
DB00668,The risk or severity of adverse effects can be increased when Epinephrine is combined with Follitropin.,Epinephrine
DB00723,The risk or severity of adverse effects can be increased when Methoxamine is combined with Follitropin.,Methoxamine
DB00816,The risk or severity of adverse effects can be increased when Orciprenaline is combined with Follitropin.,Orciprenaline
DB00830,The risk or severity of adverse effects can be increased when Phenmetrazine is combined with Follitropin.,Phenmetrazine
DB00841,The risk or severity of adverse effects can be increased when Dobutamine is combined with Follitropin.,Dobutamine
DB00852,The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Follitropin.,Pseudoephedrine
DB00865,The risk or severity of adverse effects can be increased when Benzphetamine is combined with Follitropin.,Benzphetamine
DB00867,The risk or severity of adverse effects can be increased when Ritodrine is combined with Follitropin.,Ritodrine
DB00871,The risk or severity of adverse effects can be increased when Terbutaline is combined with Follitropin.,Terbutaline
DB00935,The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Follitropin.,Oxymetazoline
DB00937,The risk or severity of adverse effects can be increased when Diethylpropion is combined with Follitropin.,Diethylpropion
DB00988,The risk or severity of adverse effects can be increased when Dopamine is combined with Follitropin.,Dopamine
DB01064,The risk or severity of adverse effects can be increased when Isoprenaline is combined with Follitropin.,Isoprenaline
DB01255,The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Follitropin.,Lisdexamfetamine
DB01288,The risk or severity of adverse effects can be increased when Fenoterol is combined with Follitropin.,Fenoterol
DB01364,The risk or severity of adverse effects can be increased when Ephedrine is combined with Follitropin.,Ephedrine
DB01365,The risk or severity of adverse effects can be increased when Mephentermine is combined with Follitropin.,Mephentermine
DB01366,The risk or severity of adverse effects can be increased when Procaterol is combined with Follitropin.,Procaterol
DB01407,The risk or severity of adverse effects can be increased when Clenbuterol is combined with Follitropin.,Clenbuterol
DB01442,The risk or severity of adverse effects can be increased when MMDA is combined with Follitropin.,MMDA
DB01454,The risk or severity of adverse effects can be increased when Midomafetamine is combined with Follitropin.,Midomafetamine
DB01467,"The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Follitropin.","2,5-Dimethoxy-4-ethylamphetamine"
DB01484,"The risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Follitropin.","4-Bromo-2,5-dimethoxyamphetamine"
DB01509,The risk or severity of adverse effects can be increased when Tenamfetamine is combined with Follitropin.,Tenamfetamine
DB01556,The risk or severity of adverse effects can be increased when Chlorphentermine is combined with Follitropin.,Chlorphentermine
DB01566,The risk or severity of adverse effects can be increased when Methylenedioxyethamphetamine is combined with Follitropin.,Methylenedioxyethamphetamine
DB01576,The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with Follitropin.,Dextroamphetamine
DB01577,The risk or severity of adverse effects can be increased when Metamfetamine is combined with Follitropin.,Metamfetamine
DB06152,The risk or severity of adverse effects can be increased when Nylidrin is combined with Follitropin.,Nylidrin
DB06764,The risk or severity of adverse effects can be increased when Tetryzoline is combined with Follitropin.,Tetryzoline
DB08841,The risk or severity of adverse effects can be increased when Tyramine is combined with Follitropin.,Tyramine
DB08941,The risk or severity of adverse effects can be increased when Isoxsuprine is combined with Follitropin.,Isoxsuprine
DB08985,The risk or severity of adverse effects can be increased when Etilefrine is combined with Follitropin.,Etilefrine
DB09203,The risk or severity of adverse effects can be increased when Synephrine is combined with Follitropin.,Synephrine
DB09480,The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Follitropin.,Iofetamine I-123
DB11124,The risk or severity of adverse effects can be increased when Racepinephrine is combined with Follitropin.,Racepinephrine
DB12080,The risk or severity of adverse effects can be increased when Ritobegron is combined with Follitropin.,Ritobegron
DB13064,The risk or severity of adverse effects can be increased when Tramazoline is combined with Follitropin.,Tramazoline
DB13108,The risk or severity of adverse effects can be increased when Mephedrone is combined with Follitropin.,Mephedrone
DB13341,The risk or severity of adverse effects can be increased when Fenozolone is combined with Follitropin.,Fenozolone
DB13624,The risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Follitropin.,Methoxyphenamine
DB13692,The risk or severity of adverse effects can be increased when Tretoquinol is combined with Follitropin.,Tretoquinol
DB13703,The risk or severity of adverse effects can be increased when Gepefrine is combined with Follitropin.,Gepefrine
DB13777,The risk or severity of adverse effects can be increased when Prenalterol is combined with Follitropin.,Prenalterol
DB13852,The risk or severity of adverse effects can be increased when Mefenorex is combined with Follitropin.,Mefenorex
DB13940,"The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Follitropin.","2,5-Dimethoxy-4-ethylthioamphetamine"
DB00598,The risk or severity of adverse effects can be increased when Labetalol is combined with Follitropin.,Labetalol
DB01193,The risk or severity of adverse effects can be increased when Acebutolol is combined with Follitropin.,Acebutolol
DB04846,The risk or severity of adverse effects can be increased when Celiprolol is combined with Follitropin.,Celiprolol
DB12752,The risk or severity of adverse effects can be increased when Bucindolol is combined with Follitropin.,Bucindolol
DB13757,The risk or severity of adverse effects can be increased when Epanolol is combined with Follitropin.,Epanolol
DB00317,The therapeutic efficacy of Follitropin can be decreased when used in combination with Gefitinib.,Gefitinib
DB00398,The therapeutic efficacy of Follitropin can be decreased when used in combination with Sorafenib.,Sorafenib
DB00530,The therapeutic efficacy of Follitropin can be decreased when used in combination with Erlotinib.,Erlotinib
DB00619,The therapeutic efficacy of Follitropin can be decreased when used in combination with Imatinib.,Imatinib
DB01254,The therapeutic efficacy of Follitropin can be decreased when used in combination with Dasatinib.,Dasatinib
DB01259,The therapeutic efficacy of Follitropin can be decreased when used in combination with Lapatinib.,Lapatinib
DB01268,The therapeutic efficacy of Follitropin can be decreased when used in combination with Sunitinib.,Sunitinib
DB01645,The therapeutic efficacy of Follitropin can be decreased when used in combination with Genistein.,Genistein
DB02058,The therapeutic efficacy of Follitropin can be decreased when used in combination with 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone.,3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone
DB02424,The therapeutic efficacy of Follitropin can be decreased when used in combination with Geldanamycin.,Geldanamycin
DB02567,The therapeutic efficacy of Follitropin can be decreased when used in combination with PD173955.,PD173955
DB03758,The therapeutic efficacy of Follitropin can be decreased when used in combination with Radicicol.,Radicicol
DB04849,The therapeutic efficacy of Follitropin can be decreased when used in combination with Cediranib.,Cediranib
DB04868,The therapeutic efficacy of Follitropin can be decreased when used in combination with Nilotinib.,Nilotinib
DB04879,The therapeutic efficacy of Follitropin can be decreased when used in combination with Vatalanib.,Vatalanib
DB05294,The therapeutic efficacy of Follitropin can be decreased when used in combination with Vandetanib.,Vandetanib
DB05424,The therapeutic efficacy of Follitropin can be decreased when used in combination with Canertinib.,Canertinib
DB05465,The therapeutic efficacy of Follitropin can be decreased when used in combination with Tandutinib.,Tandutinib
DB05575,The therapeutic efficacy of Follitropin can be decreased when used in combination with Motesanib.,Motesanib
DB05928,The therapeutic efficacy of Follitropin can be decreased when used in combination with Dovitinib.,Dovitinib
DB06302,The therapeutic efficacy of Follitropin can be decreased when used in combination with Glesatinib.,Glesatinib
DB06469,The therapeutic efficacy of Follitropin can be decreased when used in combination with Lestaurtinib.,Lestaurtinib
DB06589,The therapeutic efficacy of Follitropin can be decreased when used in combination with Pazopanib.,Pazopanib
DB06595,The therapeutic efficacy of Follitropin can be decreased when used in combination with Midostaurin.,Midostaurin
DB06616,The therapeutic efficacy of Follitropin can be decreased when used in combination with Bosutinib.,Bosutinib
DB06626,The therapeutic efficacy of Follitropin can be decreased when used in combination with Axitinib.,Axitinib
DB08399,The therapeutic efficacy of Follitropin can be decreased when used in combination with Piceatannol.,Piceatannol
DB08865,The therapeutic efficacy of Follitropin can be decreased when used in combination with Crizotinib.,Crizotinib
DB08875,The therapeutic efficacy of Follitropin can be decreased when used in combination with Cabozantinib.,Cabozantinib
DB08877,The therapeutic efficacy of Follitropin can be decreased when used in combination with Ruxolitinib.,Ruxolitinib
DB08881,The therapeutic efficacy of Follitropin can be decreased when used in combination with Vemurafenib.,Vemurafenib
DB08896,The therapeutic efficacy of Follitropin can be decreased when used in combination with Regorafenib.,Regorafenib
DB08901,The therapeutic efficacy of Follitropin can be decreased when used in combination with Ponatinib.,Ponatinib
DB08916,The therapeutic efficacy of Follitropin can be decreased when used in combination with Afatinib.,Afatinib
DB09053,The therapeutic efficacy of Follitropin can be decreased when used in combination with Ibrutinib.,Ibrutinib
DB09063,The therapeutic efficacy of Follitropin can be decreased when used in combination with Ceritinib.,Ceritinib
DB09078,The therapeutic efficacy of Follitropin can be decreased when used in combination with Lenvatinib.,Lenvatinib
DB09079,The therapeutic efficacy of Follitropin can be decreased when used in combination with Nintedanib.,Nintedanib
DB09330,The therapeutic efficacy of Follitropin can be decreased when used in combination with Osimertinib.,Osimertinib
DB11363,The therapeutic efficacy of Follitropin can be decreased when used in combination with Alectinib.,Alectinib
DB11689,The therapeutic efficacy of Follitropin can be decreased when used in combination with Selumetinib.,Selumetinib
DB11697,The therapeutic efficacy of Follitropin can be decreased when used in combination with Pacritinib.,Pacritinib
DB11703,The therapeutic efficacy of Follitropin can be decreased when used in combination with Acalabrutinib.,Acalabrutinib
DB11737,The therapeutic efficacy of Follitropin can be decreased when used in combination with Icotinib.,Icotinib
DB11805,The therapeutic efficacy of Follitropin can be decreased when used in combination with Saracatinib.,Saracatinib
DB11828,The therapeutic efficacy of Follitropin can be decreased when used in combination with Neratinib.,Neratinib
DB11832,The therapeutic efficacy of Follitropin can be decreased when used in combination with Crenolanib.,Crenolanib
DB11904,The therapeutic efficacy of Follitropin can be decreased when used in combination with Flumatinib.,Flumatinib
DB11963,The therapeutic efficacy of Follitropin can be decreased when used in combination with Dacomitinib.,Dacomitinib
DB11973,The therapeutic efficacy of Follitropin can be decreased when used in combination with Tesevatinib.,Tesevatinib
DB11986,The therapeutic efficacy of Follitropin can be decreased when used in combination with Entrectinib.,Entrectinib
DB12010,The therapeutic efficacy of Follitropin can be decreased when used in combination with Fostamatinib.,Fostamatinib
DB12048,The therapeutic efficacy of Follitropin can be decreased when used in combination with Savolitinib.,Savolitinib
DB12141,The therapeutic efficacy of Follitropin can be decreased when used in combination with Gilteritinib.,Gilteritinib
DB12147,The therapeutic efficacy of Follitropin can be decreased when used in combination with Erdafitinib.,Erdafitinib
DB12267,The therapeutic efficacy of Follitropin can be decreased when used in combination with Brigatinib.,Brigatinib
DB12307,The therapeutic efficacy of Follitropin can be decreased when used in combination with Foretinib.,Foretinib
DB12323,The therapeutic efficacy of Follitropin can be decreased when used in combination with Radotinib.,Radotinib
DB14723,The therapeutic efficacy of Follitropin can be decreased when used in combination with Larotrectinib.,Larotrectinib
DB12978,The therapeutic efficacy of Follitropin can be decreased when used in combination with Pexidartinib.,Pexidartinib
DB12500,The therapeutic efficacy of Follitropin can be decreased when used in combination with Fedratinib.,Fedratinib
DB11652,The therapeutic efficacy of Follitropin can be decreased when used in combination with Tucatinib.,Tucatinib
DB11791,The therapeutic efficacy of Follitropin can be decreased when used in combination with Capmatinib.,Capmatinib
DB15685,The therapeutic efficacy of Follitropin can be decreased when used in combination with Selpercatinib.,Selpercatinib
DB05258,The therapeutic efficacy of Follitropin can be decreased when used in combination with Interferon alfa.,Interferon alfa
DB00041,The therapeutic efficacy of Follitropin can be decreased when used in combination with Aldesleukin.,Aldesleukin
DB00227,The therapeutic efficacy of Follitropin can be decreased when used in combination with Lovastatin.,Lovastatin
DB00609,The therapeutic efficacy of Follitropin can be decreased when used in combination with Ethionamide.,Ethionamide
DB00829,The therapeutic efficacy of Follitropin can be decreased when used in combination with Diazepam.,Diazepam
DB00850,The therapeutic efficacy of Follitropin can be decreased when used in combination with Perphenazine.,Perphenazine
DB01233,The therapeutic efficacy of Follitropin can be decreased when used in combination with Metoclopramide.,Metoclopramide
DB14651,The therapeutic efficacy of Follitropin can be decreased when used in combination with Perphenazine enanthate.,Perphenazine enanthate
DB00233,The therapeutic efficacy of Follitropin can be decreased when used in combination with Aminosalicylic acid.,Aminosalicylic acid
DB11085,The therapeutic efficacy of Follitropin can be decreased when used in combination with Resorcinol.,Resorcinol
DB00222,The therapeutic efficacy of Glimepiride can be decreased when used in combination with Follitropin.,Glimepiride
DB00414,The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Follitropin.,Acetohexamide
DB00672,The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Follitropin.,Chlorpropamide
DB00839,The therapeutic efficacy of Tolazamide can be decreased when used in combination with Follitropin.,Tolazamide
DB01016,The therapeutic efficacy of Glyburide can be decreased when used in combination with Follitropin.,Glyburide
DB01067,The therapeutic efficacy of Glipizide can be decreased when used in combination with Follitropin.,Glipizide
DB01120,The therapeutic efficacy of Gliclazide can be decreased when used in combination with Follitropin.,Gliclazide
DB01124,The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Follitropin.,Tolbutamide
DB01251,The therapeutic efficacy of Gliquidone can be decreased when used in combination with Follitropin.,Gliquidone
DB01289,The therapeutic efficacy of Glisoxepide can be decreased when used in combination with Follitropin.,Glisoxepide
DB08962,The therapeutic efficacy of Glibornuride can be decreased when used in combination with Follitropin.,Glibornuride
DB13406,The therapeutic efficacy of Carbutamide can be decreased when used in combination with Follitropin.,Carbutamide
DB13675,The therapeutic efficacy of Metahexamide can be decreased when used in combination with Follitropin.,Metahexamide
DB00540,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Nortriptyline.,Nortriptyline
DB00321,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Amitriptyline.,Amitriptyline
DB00344,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Protriptyline.,Protriptyline
DB00458,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Imipramine.,Imipramine
DB00543,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Amoxapine.,Amoxapine
DB00726,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Trimipramine.,Trimipramine
DB01142,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Doxepin.,Doxepin
DB01151,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Desipramine.,Desipramine
DB01242,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Clomipramine.,Clomipramine
DB04836,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Amineptine.,Amineptine
DB08996,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Dimetacrine.,Dimetacrine
DB09016,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Butriptyline.,Butriptyline
DB09167,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Dosulepin.,Dosulepin
DB09289,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Tianeptine.,Tianeptine
DB09307,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Oxaprotiline.,Oxaprotiline
DB12930,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Opipramol.,Opipramol
DB13114,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Amitriptylinoxide.,Amitriptylinoxide
DB13225,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Dibenzepin.,Dibenzepin
DB13246,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Quinupramine.,Quinupramine
DB13384,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Melitracen.,Melitracen
DB13411,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Lofepramine.,Lofepramine
DB13496,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Iprindole.,Iprindole
DB13782,The risk or severity of Cardiac Arrhythmia can be increased when Follitropin is combined with Imipramine oxide.,Imipramine oxide
DB13967,The risk or severity of hypotension can be increased when Patent Blue is combined with Vasopressin.,Patent Blue
DB00564,The risk or severity of water intoxication can be increased when Carbamazepine is combined with Vasopressin.,Carbamazepine
DB00368,The risk or severity of adverse effects can be increased when Norepinephrine is combined with Vasopressin.,Norepinephrine
DB01356,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Lithium cation.,Lithium cation
DB14507,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Lithium citrate.,Lithium citrate
DB14509,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Lithium carbonate.,Lithium carbonate
DB14506,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Lithium hydroxide.,Lithium hydroxide
DB00407,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Ardeparin.,Ardeparin
DB01109,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Heparin.,Heparin
DB01225,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Enoxaparin.,Enoxaparin
DB06271,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Sulodexide.,Sulodexide
DB06294,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Semuloparin.,Semuloparin
DB06754,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Danaparoid.,Danaparoid
DB06779,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Dalteparin.,Dalteparin
DB06822,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Tinzaparin.,Tinzaparin
DB08813,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Nadroparin.,Nadroparin
DB09258,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Bemiparin.,Bemiparin
DB09259,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Reviparin.,Reviparin
DB09260,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Parnaparin.,Parnaparin
DB09261,The therapeutic efficacy of Vasopressin can be decreased when used in combination with Certoparin.,Certoparin
DB00024,Thyrotropin alfa may increase the vasoconstricting activities of Vasopressin.,Thyrotropin alfa
DB00279,Liothyronine may increase the vasoconstricting activities of Vasopressin.,Liothyronine
DB00451,Levothyroxine may increase the vasoconstricting activities of Vasopressin.,Levothyroxine
DB01583,Liotrix may increase the vasoconstricting activities of Vasopressin.,Liotrix
DB03604,Tiratricol may increase the vasoconstricting activities of Vasopressin.,Tiratricol
DB09100,"Thyroid, porcine may increase the vasoconstricting activities of Vasopressin.","Thyroid, porcine"
DB00281,The risk or severity of hypertension can be increased when Vasopressin is combined with Lidocaine.,Lidocaine
DB06643,The risk or severity of adverse effects can be increased when Denosumab is combined with Interferon beta-1b.,Denosumab
DB00005,The risk or severity of adverse effects can be increased when Etanercept is combined with Interferon beta-1b.,Etanercept
DB00008,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Interferon beta-1b.,Peginterferon alfa-2a
DB00011,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Interferon beta-1b.,Interferon alfa-n1
DB00018,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Interferon beta-1b.,Interferon alfa-n3
DB00022,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Interferon beta-1b.,Peginterferon alfa-2b
DB00026,The risk or severity of adverse effects can be increased when Anakinra is combined with Interferon beta-1b.,Anakinra
DB00033,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Interferon beta-1b.,Interferon gamma-1b
DB00034,"The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Interferon beta-1b.","Interferon alfa-2a, Recombinant"
DB00041,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Interferon beta-1b.,Aldesleukin
DB00051,The risk or severity of adverse effects can be increased when Adalimumab is combined with Interferon beta-1b.,Adalimumab
DB00056,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Interferon beta-1b.,Gemtuzumab ozogamicin
DB00059,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Interferon beta-1b.,Pegaspargase
DB00065,The risk or severity of adverse effects can be increased when Infliximab is combined with Interferon beta-1b.,Infliximab
DB00069,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Interferon alfacon-1.,Interferon alfacon-1
DB00073,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Rituximab.,Rituximab
DB00074,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Basiliximab.,Basiliximab
DB00075,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Muromonab.,Muromonab
DB00078,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ibritumomab tiuxetan.,Ibritumomab tiuxetan
DB00081,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Tositumomab.,Tositumomab
DB00087,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Alemtuzumab.,Alemtuzumab
DB00092,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Alefacept.,Alefacept
DB00095,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Efalizumab.,Efalizumab
DB00098,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Antithymocyte immunoglobulin (rabbit).,Antithymocyte immunoglobulin (rabbit)
DB00105,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Interferon alfa-2b.,Interferon alfa-2b
DB00111,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Daclizumab.,Daclizumab
DB00112,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Bevacizumab.,Bevacizumab
DB00120,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Phenylalanine.,Phenylalanine
DB00180,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Flunisolide.,Flunisolide
DB00188,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Bortezomib.,Bortezomib
DB00242,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Cladribine.,Cladribine
DB00262,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Carmustine.,Carmustine
DB00276,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Amsacrine.,Amsacrine
DB00290,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Bleomycin.,Bleomycin
DB00291,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Chlorambucil.,Chlorambucil
DB00293,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Raltitrexed.,Raltitrexed
DB00305,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Mitomycin.,Mitomycin
DB00307,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Bexarotene.,Bexarotene
DB00309,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Vindesine.,Vindesine
DB00322,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Floxuridine.,Floxuridine
DB00328,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Indomethacin.,Indomethacin
DB00352,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Tioguanine.,Tioguanine
DB00361,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Vinorelbine.,Vinorelbine
DB00380,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Dexrazoxane.,Dexrazoxane
DB00394,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Beclomethasone dipropionate.,Beclomethasone dipropionate
DB00398,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Sorafenib.,Sorafenib
DB00428,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Streptozocin.,Streptozocin
DB00432,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Trifluridine.,Trifluridine
DB00441,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Gemcitabine.,Gemcitabine
DB00443,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Betamethasone.,Betamethasone
DB00444,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Teniposide.,Teniposide
DB00445,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Epirubicin.,Epirubicin
DB00446,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Chloramphenicol.,Chloramphenicol
DB00480,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Lenalidomide.,Lenalidomide
DB00488,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Altretamine.,Altretamine
DB00495,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Zidovudine.,Zidovudine
DB00515,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Cisplatin.,Cisplatin
DB00526,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Oxaliplatin.,Oxaliplatin
DB00531,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Cyclophosphamide.,Cyclophosphamide
DB00541,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Vincristine.,Vincristine
DB00544,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fluorouracil.,Fluorouracil
DB00550,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Propylthiouracil.,Propylthiouracil
DB00552,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Pentostatin.,Pentostatin
DB00563,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Methotrexate.,Methotrexate
DB00564,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Carbamazepine.,Carbamazepine
DB00570,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Vinblastine.,Vinblastine
DB00588,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fluticasone propionate.,Fluticasone propionate
DB00591,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fluocinolone acetonide.,Fluocinolone acetonide
DB00601,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Linezolid.,Linezolid
DB00619,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Imatinib.,Imatinib
DB00620,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Triamcinolone.,Triamcinolone
DB00631,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Clofarabine.,Clofarabine
DB00635,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Prednisone.,Prednisone
DB00642,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Pemetrexed.,Pemetrexed
DB00687,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fludrocortisone.,Fludrocortisone
DB00688,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Mycophenolate mofetil.,Mycophenolate mofetil
DB00694,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Daunorubicin.,Daunorubicin
DB00755,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Tretinoin.,Tretinoin
DB00762,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Irinotecan.,Irinotecan
DB00763,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Methimazole.,Methimazole
DB00764,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Mometasone.,Mometasone
DB00773,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Etoposide.,Etoposide
DB00795,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Sulfasalazine.,Sulfasalazine
DB00851,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Dacarbazine.,Dacarbazine
DB00853,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Temozolomide.,Temozolomide
DB00859,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Penicillamine.,Penicillamine
DB00860,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Prednisolone.,Prednisolone
DB00877,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Sirolimus.,Sirolimus
DB00888,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Mechlorethamine.,Mechlorethamine
DB00928,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Azacitidine.,Azacitidine
DB00958,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Carboplatin.,Carboplatin
DB00959,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Methylprednisolone.,Methylprednisolone
DB00970,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Dactinomycin.,Dactinomycin
DB00987,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Cytarabine.,Cytarabine
DB00993,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Azathioprine.,Azathioprine
DB00997,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Doxorubicin.,Doxorubicin
DB01005,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Hydroxyurea.,Hydroxyurea
DB01008,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Busulfan.,Busulfan
DB01024,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Mycophenolic acid.,Mycophenolic acid
DB01030,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Topotecan.,Topotecan
DB01033,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Mercaptopurine.,Mercaptopurine
DB01041,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Thalidomide.,Thalidomide
DB01042,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Melphalan.,Melphalan
DB01073,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fludarabine.,Fludarabine
DB01099,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Flucytosine.,Flucytosine
DB01101,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Capecitabine.,Capecitabine
DB01108,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Trilostane.,Trilostane
DB01168,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Procarbazine.,Procarbazine
DB01169,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Arsenic trioxide.,Arsenic trioxide
DB01177,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Idarubicin.,Idarubicin
DB01181,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ifosfamide.,Ifosfamide
DB01196,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Estramustine.,Estramustine
DB01204,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Mitoxantrone.,Mitoxantrone
DB01206,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Lomustine.,Lomustine
DB01222,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Budesonide.,Budesonide
DB01229,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Paclitaxel.,Paclitaxel
DB01234,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Dexamethasone.,Dexamethasone
DB01248,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Docetaxel.,Docetaxel
DB01254,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Dasatinib.,Dasatinib
DB01257,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Eculizumab.,Eculizumab
DB01262,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Decitabine.,Decitabine
DB01268,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Sunitinib.,Sunitinib
DB01280,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Nelarabine.,Nelarabine
DB01281,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Abatacept.,Abatacept
DB01285,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Corticotropin.,Corticotropin
DB01380,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Cortisone acetate.,Cortisone acetate
DB01384,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Paramethasone.,Paramethasone
DB01394,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Colchicine.,Colchicine
DB01410,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ciclesonide.,Ciclesonide
DB01423,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Stepronin.,Stepronin
DB01590,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Everolimus.,Everolimus
DB01611,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Hydroxychloroquine.,Hydroxychloroquine
DB01816,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Castanospermine.,Castanospermine
DB02546,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Vorinostat.,Vorinostat
DB02806,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with 2-Methoxyethanol.,2-Methoxyethanol
DB03523,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Brequinar.,Brequinar
DB04572,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Thiotepa.,Thiotepa
DB04630,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Aldosterone.,Aldosterone
DB04845,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ixabepilone.,Ixabepilone
DB04868,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Nilotinib.,Nilotinib
DB04951,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Pirfenidone.,Pirfenidone
DB04956,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Afelimomab.,Afelimomab
DB05015,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Belinostat.,Belinostat
DB05109,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Trabectedin.,Trabectedin
DB05258,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Interferon alfa.,Interferon alfa
DB05259,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Glatiramer.,Glatiramer
DB05260,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Gallium nitrate.,Gallium nitrate
DB05459,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Briakinumab.,Briakinumab
DB05472,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with omega interferon.,omega interferon
DB05676,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Apremilast.,Apremilast
DB05773,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Trastuzumab emtansine.,Trastuzumab emtansine
DB06168,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Canakinumab.,Canakinumab
DB06273,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Tocilizumab.,Tocilizumab
DB06287,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Temsirolimus.,Temsirolimus
DB06372,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Rilonacept.,Rilonacept
DB06589,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Pazopanib.,Pazopanib
DB06603,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Panobinostat.,Panobinostat
DB06612,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Mepolizumab.,Mepolizumab
DB06616,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Bosutinib.,Bosutinib
DB06662,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Abetimus.,Abetimus
DB06674,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Golimumab.,Golimumab
DB06681,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Belatacept.,Belatacept
DB06769,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Bendamustine.,Bendamustine
DB06772,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Cabazitaxel.,Cabazitaxel
DB06813,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Pralatrexate.,Pralatrexate
DB08059,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Wortmannin.,Wortmannin
DB08870,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Brentuximab vedotin.,Brentuximab vedotin
DB08871,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Eribulin.,Eribulin
DB08877,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ruxolitinib.,Ruxolitinib
DB08879,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Belimumab.,Belimumab
DB08880,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Teriflunomide.,Teriflunomide
DB08889,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Carfilzomib.,Carfilzomib
DB08901,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ponatinib.,Ponatinib
DB08904,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Certolizumab pegol.,Certolizumab pegol
DB08906,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fluticasone furoate.,Fluticasone furoate
DB08908,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Dimethyl fumarate.,Dimethyl fumarate
DB08910,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Pomalidomide.,Pomalidomide
DB08935,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Obinutuzumab.,Obinutuzumab
DB08970,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fluprednidene.,Fluprednidene
DB08971,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fluocortolone.,Fluocortolone
DB09029,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Secukinumab.,Secukinumab
DB09033,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Vedolizumab.,Vedolizumab
DB09036,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Siltuximab.,Siltuximab
DB09052,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Blinatumomab.,Blinatumomab
DB09053,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ibrutinib.,Ibrutinib
DB09054,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Idelalisib.,Idelalisib
DB09073,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Palbociclib.,Palbociclib
DB09074,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Olaparib.,Olaparib
DB09077,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Dinutuximab.,Dinutuximab
DB09082,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Vilanterol.,Vilanterol
DB09091,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Tixocortol.,Tixocortol
DB09122,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Peginterferon beta-1a.,Peginterferon beta-1a
DB09312,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Antilymphocyte immunoglobulin (horse).,Antilymphocyte immunoglobulin (horse)
DB09378,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fluprednisolone.,Fluprednisolone
DB09383,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Meprednisone.,Meprednisone
DB11466,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Tepoxalin.,Tepoxalin
DB11487,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Dexamethasone isonicotinate.,Dexamethasone isonicotinate
DB11529,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Melengestrol.,Melengestrol
DB11569,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ixekizumab.,Ixekizumab
DB11580,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ravulizumab.,Ravulizumab
DB11616,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Pirarubicin.,Pirarubicin
DB11693,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Voclosporin.,Voclosporin
DB11708,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Peficitinib.,Peficitinib
DB11750,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Clobetasol.,Clobetasol
DB11767,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Sarilumab.,Sarilumab
DB11776,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Brodalumab.,Brodalumab
DB11803,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Sirukumab.,Sirukumab
DB11817,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Baricitinib.,Baricitinib
DB11834,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Guselkumab.,Guselkumab
DB11921,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Deflazacort.,Deflazacort
DB11988,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ocrelizumab.,Ocrelizumab
DB12025,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Triptolide.,Triptolide
DB12371,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Siponimod.,Siponimod
DB12612,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ozanimod.,Ozanimod
DB12617,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Mizoribine.,Mizoribine
DB12692,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Gusperimus.,Gusperimus
DB12814,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Cepeginterferon alfa-2B.,Cepeginterferon alfa-2B
DB12902,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Trofosfamide.,Trofosfamide
DB12947,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Doxifluridine.,Doxifluridine
DB12991,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Deoxyspergualin.,Deoxyspergualin
DB12996,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Acteoside.,Acteoside
DB13003,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Cortivazol.,Cortivazol
DB13014,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Hypericin.,Hypericin
DB13068,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.,9-(N-methyl-L-isoleucine)-cyclosporin A
DB13208,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Prednylidene.,Prednylidene
DB13223,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fluocortin.,Fluocortin
DB13241,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Begelomab.,Begelomab
DB13491,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fluperolone.,Fluperolone
DB13664,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Formocortal.,Formocortal
DB13728,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Halometasone.,Halometasone
DB13843,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Cloprednol.,Cloprednol
DB13856,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fluclorolone.,Fluclorolone
DB13867,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fluticasone.,Fluticasone
DB14066,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Tetrandrine.,Tetrandrine
DB14219,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Monomethyl fumarate.,Monomethyl fumarate
DB14512,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Mometasone furoate.,Mometasone furoate
DB14538,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Hydrocortisone aceponate.,Hydrocortisone aceponate
DB14539,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Hydrocortisone acetate.,Hydrocortisone acetate
DB14545,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Hydrocortisone succinate.,Hydrocortisone succinate
DB14724,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Emapalumab.,Emapalumab
DB14762,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Risankizumab.,Risankizumab
DB14919,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Rozanolixizumab.,Rozanolixizumab
DB15253,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Bleselumab.,Bleselumab
DB00108,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Natalizumab.,Natalizumab
DB00337,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Interferon beta-1b.,Pimecrolimus
DB01656,Roflumilast may increase the immunosuppressive activities of Interferon beta-1b.,Roflumilast
DB06688,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Interferon beta-1b.,Sipuleucel-T
DB00363,The risk or severity of neutropenia can be increased when Interferon beta-1b is combined with Clozapine.,Clozapine
DB00315,The metabolism of Zolmitriptan can be decreased when combined with Interferon beta-1b.,Zolmitriptan
DB01015,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Interferon beta-1b.,Sulfamethoxazole
DB01097,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Leflunomide.,Leflunomide
DB08895,Interferon beta-1b may increase the immunosuppressive activities of Tofacitinib.,Tofacitinib
DB00072,Trastuzumab may increase the neutropenic activities of Interferon beta-1b.,Trastuzumab
DB08868,Interferon beta-1b may increase the immunosuppressive activities of Fingolimod.,Fingolimod
DB00864,Tacrolimus may increase the immunosuppressive activities of Interferon beta-1b.,Tacrolimus
DB00201,The metabolism of Caffeine can be decreased when combined with Interferon beta-1b.,Caffeine
DB00651,The metabolism of Dyphylline can be decreased when combined with Interferon beta-1b.,Dyphylline
DB00806,The metabolism of Pentoxifylline can be decreased when combined with Interferon beta-1b.,Pentoxifylline
DB01303,The metabolism of Oxtriphylline can be decreased when combined with Interferon beta-1b.,Oxtriphylline
DB01412,The metabolism of Theobromine can be decreased when combined with Interferon beta-1b.,Theobromine
DB01482,The metabolism of Fenethylline can be decreased when combined with Interferon beta-1b.,Fenethylline
DB01667,The metabolism of 8-azaguanine can be decreased when combined with Interferon beta-1b.,8-azaguanine
DB01978,"The metabolism of 7,9-Dimethylguanine can be decreased when combined with Interferon beta-1b.","7,9-Dimethylguanine"
DB02134,The metabolism of Xanthine can be decreased when combined with Interferon beta-1b.,Xanthine
DB02245,The metabolism of 7-Deazaguanine can be decreased when combined with Interferon beta-1b.,7-Deazaguanine
DB02377,The metabolism of Guanine can be decreased when combined with Interferon beta-1b.,Guanine
DB02489,The metabolism of 9-Methylguanine can be decreased when combined with Interferon beta-1b.,9-Methylguanine
DB02568,The metabolism of Peldesine can be decreased when combined with Interferon beta-1b.,Peldesine
DB04076,The metabolism of Hypoxanthine can be decreased when combined with Interferon beta-1b.,Hypoxanthine
DB04356,The metabolism of 9-Deazaguanine can be decreased when combined with Interferon beta-1b.,9-Deazaguanine
DB06479,The metabolism of Propentofylline can be decreased when combined with Interferon beta-1b.,Propentofylline
DB06575,The metabolism of Valomaciclovir can be decreased when combined with Interferon beta-1b.,Valomaciclovir
DB07954,The metabolism of 3-isobutyl-1-methyl-7H-xanthine can be decreased when combined with Interferon beta-1b.,3-isobutyl-1-methyl-7H-xanthine
DB08844,The metabolism of Uric acid can be decreased when combined with Interferon beta-1b.,Uric acid
DB09273,The metabolism of Doxofylline can be decreased when combined with Interferon beta-1b.,Doxofylline
DB11919,The metabolism of 6-O-benzylguanine can be decreased when combined with Interferon beta-1b.,6-O-benzylguanine
DB12406,The metabolism of Lisofylline can be decreased when combined with Interferon beta-1b.,Lisofylline
DB12531,The metabolism of Lobucavir can be decreased when combined with Interferon beta-1b.,Lobucavir
DB12926,The metabolism of Cafedrine can be decreased when combined with Interferon beta-1b.,Cafedrine
DB12927,The metabolism of Theodrenaline can be decreased when combined with Interferon beta-1b.,Theodrenaline
DB13203,The metabolism of Bamifylline can be decreased when combined with Interferon beta-1b.,Bamifylline
DB13449,The metabolism of Proxyphylline can be decreased when combined with Interferon beta-1b.,Proxyphylline
DB13573,The metabolism of Acefylline can be decreased when combined with Interferon beta-1b.,Acefylline
DB13592,The metabolism of Etamiphylline can be decreased when combined with Interferon beta-1b.,Etamiphylline
DB13634,The metabolism of Pentifylline can be decreased when combined with Interferon beta-1b.,Pentifylline
DB13812,The metabolism of Bufylline can be decreased when combined with Interferon beta-1b.,Bufylline
DB14018,The metabolism of Bromotheophylline can be decreased when combined with Interferon beta-1b.,Bromotheophylline
DB14029,The metabolism of Furafylline can be decreased when combined with Interferon beta-1b.,Furafylline
DB14132,The metabolism of 8-chlorotheophylline can be decreased when combined with Interferon beta-1b.,8-chlorotheophylline
DB15122,The metabolism of PCS-499 can be decreased when combined with Interferon beta-1b.,PCS-499
DB04914,The therapeutic efficacy of G17DT can be decreased when used in combination with Interferon beta-1b.,G17DT
DB05144,The therapeutic efficacy of PEV3A can be decreased when used in combination with Interferon beta-1b.,PEV3A
DB05325,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Interferon beta-1b.,INGN 225
DB05374,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Interferon beta-1b.,Rindopepimut
DB05440,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Interferon beta-1b.,SRP 299
DB05942,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Interferon beta-1b.,GI-5005
DB06400,The therapeutic efficacy of Vitespen can be decreased when used in combination with Interferon beta-1b.,Vitespen
DB06584,The therapeutic efficacy of TG4010 can be decreased when used in combination with Interferon beta-1b.,TG4010
DB09057,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Interferon beta-1b.,Anthrax immune globulin human
DB10062,"The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Interferon beta-1b.","Rabies virus inactivated antigen, B"
DB10076,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Interferon beta-1b.,Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen
DB10276,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Interferon beta-1b.,Rotavirus vaccine
DB10283,"The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Interferon beta-1b.","Rabies virus inactivated antigen, A"
DB10342,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Interferon beta-1b.,Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen
DB10583,The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon beta-1b.,Clostridium tetani toxoid antigen (formaldehyde inactivated)
DB10584,The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon beta-1b.,Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
DB10600,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Interferon beta-1b.,Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated)
DB10769,The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon beta-1b.,Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)
DB10794,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon beta-1b.,Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated)
DB10803,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Interferon beta-1b.,Typhoid Vi polysaccharide vaccine
DB10989,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Interferon beta-1b.,Hepatitis A Vaccine
DB10990,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Interferon beta-1b.,Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
DB11038,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Interferon beta-1b.,Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated)
DB11040,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Interferon beta-1b.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated)
DB11041,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Interferon beta-1b.,Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)
DB11044,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Interferon beta-1b.,Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated)
DB11603,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Interferon beta-1b.,Human rabies virus immune globulin
DB11627,The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Interferon beta-1b.,Hepatitis B Vaccine (Recombinant)
DB12568,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Interferon beta-1b.,Tecemotide
DB14022,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Interferon beta-1b.,Typhoid vaccine
DB14384,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon beta-1b.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated)
DB14385,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon beta-1b.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)
DB14394,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Interferon beta-1b.,Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen
DB14445,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon beta-1b.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated)
DB14449,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Interferon beta-1b.,Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen
DB14619,The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Interferon beta-1b.,Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated)
DB14620,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Interferon beta-1b.,Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated)
DB14711,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Interferon beta-1b.,Vaccinia virus strain new york city board of health live antigen
DB15274,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Interferon beta-1b.,Pertussis vaccine
DB15461,The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon beta-1b.,Yersinia pestis 195/p antigen (formaldehyde inactivated)
DB13924,The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Interferon beta-1b.,Varicella Zoster Vaccine (Recombinant)
DB15483,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Interferon beta-1b.,Modified vaccinia ankara
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Interferon beta-1b.","Ebola Zaire vaccine (live, attenuated)"
DB00054,The risk or severity of bleeding can be increased when Abciximab is combined with Interferon beta-1b.,Abciximab
DB00063,The risk or severity of bleeding can be increased when Eptifibatide is combined with Interferon beta-1b.,Eptifibatide
DB00208,The risk or severity of bleeding can be increased when Ticlopidine is combined with Interferon beta-1b.,Ticlopidine
DB00775,The risk or severity of bleeding can be increased when Tirofiban is combined with Interferon beta-1b.,Tirofiban
DB00945,The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Interferon beta-1b.,Acetylsalicylic acid
DB00975,The risk or severity of bleeding can be increased when Dipyridamole is combined with Interferon beta-1b.,Dipyridamole
DB01088,The risk or severity of bleeding can be increased when Iloprost is combined with Interferon beta-1b.,Iloprost
DB01138,The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Interferon beta-1b.,Sulfinpyrazone
DB01207,The risk or severity of bleeding can be increased when Ridogrel is combined with Interferon beta-1b.,Ridogrel
DB01236,The risk or severity of bleeding can be increased when Sevoflurane is combined with Interferon beta-1b.,Sevoflurane
DB01240,The risk or severity of bleeding can be increased when Epoprostenol is combined with Interferon beta-1b.,Epoprostenol
DB04743,The risk or severity of bleeding can be increased when Nimesulide is combined with Interferon beta-1b.,Nimesulide
DB04905,The risk or severity of bleeding can be increased when Tesmilifene is combined with Interferon beta-1b.,Tesmilifene
DB04932,The risk or severity of bleeding can be increased when Defibrotide is combined with Interferon beta-1b.,Defibrotide
DB05229,The risk or severity of bleeding can be increased when Beraprost is combined with Interferon beta-1b.,Beraprost
DB05266,The risk or severity of bleeding can be increased when Ibudilast is combined with Interferon beta-1b.,Ibudilast
DB05767,The risk or severity of bleeding can be increased when Andrographolide is combined with Interferon beta-1b.,Andrographolide
DB06081,The risk or severity of bleeding can be increased when Caplacizumab is combined with Interferon beta-1b.,Caplacizumab
DB06209,The risk or severity of bleeding can be increased when Prasugrel is combined with Interferon beta-1b.,Prasugrel
DB06441,The risk or severity of bleeding can be increased when Cangrelor is combined with Interferon beta-1b.,Cangrelor
DB07615,The risk or severity of bleeding can be increased when Tranilast is combined with Interferon beta-1b.,Tranilast
DB08814,The risk or severity of bleeding can be increased when Triflusal is combined with Interferon beta-1b.,Triflusal
DB08816,The risk or severity of bleeding can be increased when Ticagrelor is combined with Interferon beta-1b.,Ticagrelor
DB08887,The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Interferon beta-1b.,Icosapent ethyl
DB09030,The risk or severity of bleeding can be increased when Vorapaxar is combined with Interferon beta-1b.,Vorapaxar
DB09283,The risk or severity of bleeding can be increased when Trapidil is combined with Interferon beta-1b.,Trapidil
DB12092,The risk or severity of bleeding can be increased when Naftopidil is combined with Interferon beta-1b.,Naftopidil
DB12163,The risk or severity of bleeding can be increased when Sarpogrelate is combined with Interferon beta-1b.,Sarpogrelate
DB12321,The risk or severity of bleeding can be increased when Ifetroban is combined with Interferon beta-1b.,Ifetroban
DB12445,The risk or severity of bleeding can be increased when Nitroaspirin is combined with Interferon beta-1b.,Nitroaspirin
DB12465,The risk or severity of bleeding can be increased when Ketanserin is combined with Interferon beta-1b.,Ketanserin
DB12545,The risk or severity of bleeding can be increased when Indobufen is combined with Interferon beta-1b.,Indobufen
DB12749,The risk or severity of bleeding can be increased when Butylphthalide is combined with Interferon beta-1b.,Butylphthalide
DB12771,The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Interferon beta-1b.,Hydroxytyrosol
DB13036,The risk or severity of bleeding can be increased when Ramatroban is combined with Interferon beta-1b.,Ramatroban
DB13327,The risk or severity of bleeding can be increased when Picotamide is combined with Interferon beta-1b.,Picotamide
DB13367,The risk or severity of bleeding can be increased when Cloricromen is combined with Interferon beta-1b.,Cloricromen
DB13400,The risk or severity of bleeding can be increased when Linsidomine is combined with Interferon beta-1b.,Linsidomine
DB13510,The risk or severity of bleeding can be increased when Buflomedil is combined with Interferon beta-1b.,Buflomedil
DB13929,The risk or severity of bleeding can be increased when Relcovaptan is combined with Interferon beta-1b.,Relcovaptan
DB13200,Interferon beta-1b may increase the myelosuppressive activities of Lipegfilgrastim.,Lipegfilgrastim
DB10317,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Interferon beta-1b.,Rubella virus vaccine
DB10318,The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Interferon beta-1b.,Varicella Zoster Vaccine (Live/attenuated)
DB10343,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Interferon beta-1b.,Bacillus calmette-guerin substrain tice live antigen
DB10804,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Interferon beta-1b.,Bacillus calmette-guerin substrain connaught live antigen
DB10805,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Interferon beta-1b.,Yellow Fever Vaccine
DB11003,The risk or severity of infection can be increased when Anthrax vaccine is combined with Interferon beta-1b.,Anthrax vaccine
DB11050,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Interferon beta-1b.,Typhoid Vaccine Live
DB12386,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Interferon beta-1b.,Bacillus calmette-guerin substrain danish 1331 live antigen
DB12768,The risk or severity of infection can be increased when BCG vaccine is combined with Interferon beta-1b.,BCG vaccine
DB14409,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Interferon beta-1b.,Human adenovirus e serotype 4 strain cl-68578 antigen
DB14443,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Interferon beta-1b.,Vibrio cholerae CVD 103-HgR strain live antigen
DB14685,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Interferon beta-1b.,Adenovirus type 7 vaccine live
DB00039,The therapeutic efficacy of Palifermin can be decreased when used in combination with Interferon beta-1b.,Palifermin
DB00176,The metabolism of Fluvoxamine can be decreased when combined with Interferon beta-1b.,Fluvoxamine
DB00184,The metabolism of Nicotine can be decreased when combined with Interferon beta-1b.,Nicotine
DB00195,The metabolism of Betaxolol can be decreased when combined with Interferon beta-1b.,Betaxolol
DB00261,The metabolism of Anagrelide can be decreased when combined with Interferon beta-1b.,Anagrelide
DB00280,The metabolism of Disopyramide can be decreased when combined with Interferon beta-1b.,Disopyramide
DB00281,The metabolism of Lidocaine can be decreased when combined with Interferon beta-1b.,Lidocaine
DB00286,The metabolism of Conjugated estrogens can be decreased when combined with Interferon beta-1b.,Conjugated estrogens
DB00296,The metabolism of Ropivacaine can be decreased when combined with Interferon beta-1b.,Ropivacaine
DB00316,The metabolism of Acetaminophen can be decreased when combined with Interferon beta-1b.,Acetaminophen
DB00334,The metabolism of Olanzapine can be decreased when combined with Interferon beta-1b.,Olanzapine
DB00356,The metabolism of Chlorzoxazone can be decreased when combined with Interferon beta-1b.,Chlorzoxazone
DB00365,The metabolism of Grepafloxacin can be decreased when combined with Interferon beta-1b.,Grepafloxacin
DB00370,The metabolism of Mirtazapine can be decreased when combined with Interferon beta-1b.,Mirtazapine
DB00379,The metabolism of Mexiletine can be decreased when combined with Interferon beta-1b.,Mexiletine
DB00382,The metabolism of Tacrine can be decreased when combined with Interferon beta-1b.,Tacrine
DB00384,The metabolism of Triamterene can be decreased when combined with Interferon beta-1b.,Triamterene
DB00420,The metabolism of Promazine can be decreased when combined with Interferon beta-1b.,Promazine
DB00425,The metabolism of Zolpidem can be decreased when combined with Interferon beta-1b.,Zolpidem
DB00442,The metabolism of Entecavir can be decreased when combined with Interferon beta-1b.,Entecavir
DB00461,The metabolism of Nabumetone can be decreased when combined with Interferon beta-1b.,Nabumetone
DB00468,The metabolism of Quinine can be decreased when combined with Interferon beta-1b.,Quinine
DB00472,The metabolism of Fluoxetine can be decreased when combined with Interferon beta-1b.,Fluoxetine
DB00476,The metabolism of Duloxetine can be decreased when combined with Interferon beta-1b.,Duloxetine
DB00477,The metabolism of Chlorpromazine can be decreased when combined with Interferon beta-1b.,Chlorpromazine
DB00499,The metabolism of Flutamide can be decreased when combined with Interferon beta-1b.,Flutamide
DB00502,The metabolism of Haloperidol can be decreased when combined with Interferon beta-1b.,Haloperidol
DB00518,The metabolism of Albendazole can be decreased when combined with Interferon beta-1b.,Albendazole
DB00533,The metabolism of Rofecoxib can be decreased when combined with Interferon beta-1b.,Rofecoxib
DB00568,The metabolism of Cinnarizine can be decreased when combined with Interferon beta-1b.,Cinnarizine
DB00571,The metabolism of Propranolol can be decreased when combined with Interferon beta-1b.,Propranolol
DB00586,The metabolism of Diclofenac can be decreased when combined with Interferon beta-1b.,Diclofenac
DB00629,The metabolism of Guanabenz can be decreased when combined with Interferon beta-1b.,Guanabenz
DB00661,The metabolism of Verapamil can be decreased when combined with Interferon beta-1b.,Verapamil
DB00715,The metabolism of Paroxetine can be decreased when combined with Interferon beta-1b.,Paroxetine
DB00730,The metabolism of Thiabendazole can be decreased when combined with Interferon beta-1b.,Thiabendazole
DB00740,The metabolism of Riluzole can be decreased when combined with Interferon beta-1b.,Riluzole
DB00744,The metabolism of Zileuton can be decreased when combined with Interferon beta-1b.,Zileuton
DB00758,The metabolism of Clopidogrel can be decreased when combined with Interferon beta-1b.,Clopidogrel
DB00783,The metabolism of Estradiol can be decreased when combined with Interferon beta-1b.,Estradiol
DB00787,The metabolism of Acyclovir can be decreased when combined with Interferon beta-1b.,Acyclovir
DB00788,The metabolism of Naproxen can be decreased when combined with Interferon beta-1b.,Naproxen
DB00831,The metabolism of Trifluoperazine can be decreased when combined with Interferon beta-1b.,Trifluoperazine
DB00850,The metabolism of Perphenazine can be decreased when combined with Interferon beta-1b.,Perphenazine
DB00857,The metabolism of Terbinafine can be decreased when combined with Interferon beta-1b.,Terbinafine
DB00863,The metabolism of Ranitidine can be decreased when combined with Interferon beta-1b.,Ranitidine
DB00898,The metabolism of Ethanol can be decreased when combined with Interferon beta-1b.,Ethanol
DB00934,The metabolism of Maprotiline can be decreased when combined with Interferon beta-1b.,Maprotiline
DB00969,The metabolism of Alosetron can be decreased when combined with Interferon beta-1b.,Alosetron
DB00978,The metabolism of Lomefloxacin can be decreased when combined with Interferon beta-1b.,Lomefloxacin
DB00980,The metabolism of Ramelteon can be decreased when combined with Interferon beta-1b.,Ramelteon
DB00998,The metabolism of Frovatriptan can be decreased when combined with Interferon beta-1b.,Frovatriptan
DB01002,The metabolism of Levobupivacaine can be decreased when combined with Interferon beta-1b.,Levobupivacaine
DB01012,The metabolism of Cinacalcet can be decreased when combined with Interferon beta-1b.,Cinacalcet
DB01037,The metabolism of Selegiline can be decreased when combined with Interferon beta-1b.,Selegiline
DB01056,The metabolism of Tocainide can be decreased when combined with Interferon beta-1b.,Tocainide
DB01058,The metabolism of Praziquantel can be decreased when combined with Interferon beta-1b.,Praziquantel
DB01065,The metabolism of Melatonin can be decreased when combined with Interferon beta-1b.,Melatonin
DB01087,The metabolism of Primaquine can be decreased when combined with Interferon beta-1b.,Primaquine
DB01094,The metabolism of Hesperetin can be decreased when combined with Interferon beta-1b.,Hesperetin
DB01115,The metabolism of Nifedipine can be decreased when combined with Interferon beta-1b.,Nifedipine
DB01136,The metabolism of Carvedilol can be decreased when combined with Interferon beta-1b.,Carvedilol
DB01166,The metabolism of Cilostazol can be decreased when combined with Interferon beta-1b.,Cilostazol
DB01182,The metabolism of Propafenone can be decreased when combined with Interferon beta-1b.,Propafenone
DB01184,The metabolism of Domperidone can be decreased when combined with Interferon beta-1b.,Domperidone
DB01191,The metabolism of Dexfenfluramine can be decreased when combined with Interferon beta-1b.,Dexfenfluramine
DB01367,The metabolism of Rasagiline can be decreased when combined with Interferon beta-1b.,Rasagiline
DB01405,The metabolism of Temafloxacin can be decreased when combined with Interferon beta-1b.,Temafloxacin
DB01424,The metabolism of Aminophenazone can be decreased when combined with Interferon beta-1b.,Aminophenazone
DB01435,The metabolism of Antipyrine can be decreased when combined with Interferon beta-1b.,Antipyrine
DB01558,The metabolism of Bromazepam can be decreased when combined with Interferon beta-1b.,Bromazepam
DB01623,The metabolism of Thiothixene can be decreased when combined with Interferon beta-1b.,Thiothixene
DB01628,The metabolism of Etoricoxib can be decreased when combined with Interferon beta-1b.,Etoricoxib
DB01645,The metabolism of Genistein can be decreased when combined with Interferon beta-1b.,Genistein
DB02709,The metabolism of Resveratrol can be decreased when combined with Interferon beta-1b.,Resveratrol
DB03783,The metabolism of Phenacetin can be decreased when combined with Interferon beta-1b.,Phenacetin
DB04574,The metabolism of Estrone sulfate can be decreased when combined with Interferon beta-1b.,Estrone sulfate
DB04841,The metabolism of Flunarizine can be decreased when combined with Interferon beta-1b.,Flunarizine
DB04871,The metabolism of Lorcaserin can be decreased when combined with Interferon beta-1b.,Lorcaserin
DB04948,The metabolism of Lofexidine can be decreased when combined with Interferon beta-1b.,Lofexidine
DB06148,The metabolism of Mianserin can be decreased when combined with Interferon beta-1b.,Mianserin
DB06210,The metabolism of Eltrombopag can be decreased when combined with Interferon beta-1b.,Eltrombopag
DB06216,The metabolism of Asenapine can be decreased when combined with Interferon beta-1b.,Asenapine
DB06235,The metabolism of Vadimezan can be decreased when combined with Interferon beta-1b.,Vadimezan
DB06292,The metabolism of Dapagliflozin can be decreased when combined with Interferon beta-1b.,Dapagliflozin
DB06594,The metabolism of Agomelatine can be decreased when combined with Interferon beta-1b.,Agomelatine
DB06626,The metabolism of Axitinib can be decreased when combined with Interferon beta-1b.,Axitinib
DB06770,The metabolism of Benzyl alcohol can be decreased when combined with Interferon beta-1b.,Benzyl alcohol
DB06774,The metabolism of Capsaicin can be decreased when combined with Interferon beta-1b.,Capsaicin
DB08496,The metabolism of (R)-warfarin can be decreased when combined with Interferon beta-1b.,(R)-warfarin
DB08883,The metabolism of Perampanel can be decreased when combined with Interferon beta-1b.,Perampanel
DB09071,The metabolism of Tasimelteon can be decreased when combined with Interferon beta-1b.,Tasimelteon
DB09118,The metabolism of Stiripentol can be decreased when combined with Interferon beta-1b.,Stiripentol
DB09225,The metabolism of Zotepine can be decreased when combined with Interferon beta-1b.,Zotepine
DB09288,The metabolism of Propacetamol can be decreased when combined with Interferon beta-1b.,Propacetamol
DB09290,The metabolism of Ramosetron can be decreased when combined with Interferon beta-1b.,Ramosetron
DB11967,The metabolism of Binimetinib can be decreased when combined with Interferon beta-1b.,Binimetinib
DB12026,The metabolism of Voxilaprevir can be decreased when combined with Interferon beta-1b.,Voxilaprevir
DB12245,The metabolism of Triclabendazole can be decreased when combined with Interferon beta-1b.,Triclabendazole
DB12332,The metabolism of Rucaparib can be decreased when combined with Interferon beta-1b.,Rucaparib
DB12945,The metabolism of Dihydralazine can be decreased when combined with Interferon beta-1b.,Dihydralazine
DB13952,The metabolism of Estradiol acetate can be decreased when combined with Interferon beta-1b.,Estradiol acetate
DB13953,The metabolism of Estradiol benzoate can be decreased when combined with Interferon beta-1b.,Estradiol benzoate
DB13954,The metabolism of Estradiol cypionate can be decreased when combined with Interferon beta-1b.,Estradiol cypionate
DB13955,The metabolism of Estradiol dienanthate can be decreased when combined with Interferon beta-1b.,Estradiol dienanthate
DB13956,The metabolism of Estradiol valerate can be decreased when combined with Interferon beta-1b.,Estradiol valerate
DB11757,The metabolism of Istradefylline can be decreased when combined with Interferon beta-1b.,Istradefylline
DB00972,The metabolism of Azelastine can be decreased when combined with Interferon beta-1b.,Azelastine
DB00625,The metabolism of Efavirenz can be decreased when combined with Interferon beta-1b.,Efavirenz
DB01233,The metabolism of Metoclopramide can be decreased when combined with Interferon beta-1b.,Metoclopramide
DB04889,The metabolism of Bicifadine can be decreased when combined with Interferon beta-1b.,Bicifadine
DB05708,The metabolism of GTS-21 can be decreased when combined with Interferon beta-1b.,GTS-21
DB01195,The metabolism of Flecainide can be decreased when combined with Interferon beta-1b.,Flecainide
DB00977,The metabolism of Ethinylestradiol can be decreased when combined with Interferon beta-1b.,Ethinylestradiol
DB00321,The metabolism of Amitriptyline can be decreased when combined with Interferon beta-1b.,Amitriptyline
DB00458,The metabolism of Imipramine can be decreased when combined with Interferon beta-1b.,Imipramine
DB01142,The metabolism of Doxepin can be decreased when combined with Interferon beta-1b.,Doxepin
DB00532,The metabolism of Mephenytoin can be decreased when combined with Interferon beta-1b.,Mephenytoin
DB00540,The metabolism of Nortriptyline can be decreased when combined with Interferon beta-1b.,Nortriptyline
DB00575,The metabolism of Clonidine can be decreased when combined with Interferon beta-1b.,Clonidine
DB00924,The metabolism of Cyclobenzaprine can be decreased when combined with Interferon beta-1b.,Cyclobenzaprine
DB01151,The metabolism of Desipramine can be decreased when combined with Interferon beta-1b.,Desipramine
DB01242,The metabolism of Clomipramine can be decreased when combined with Interferon beta-1b.,Clomipramine
DB11689,The metabolism of Selumetinib can be decreased when combined with Interferon beta-1b.,Selumetinib
DB00277,The metabolism of Theophylline can be decreased when combined with Interferon beta-1b.,Theophylline
DB00682,The metabolism of Warfarin can be decreased when combined with Interferon beta-1b.,Warfarin
DB00697,The metabolism of Tizanidine can be decreased when combined with Interferon beta-1b.,Tizanidine
DB01100,The metabolism of Pimozide can be decreased when combined with Interferon beta-1b.,Pimozide
DB01223,The metabolism of Aminophylline can be decreased when combined with Interferon beta-1b.,Aminophylline
DB01418,The metabolism of Acenocoumarol can be decreased when combined with Interferon beta-1b.,Acenocoumarol
DB00530,The metabolism of Erlotinib can be decreased when combined with Interferon beta-1b.,Erlotinib
DB09256,The metabolism of Tegafur can be decreased when combined with Interferon beta-1b.,Tegafur
DB13874,The metabolism of Enasidenib can be decreased when combined with Interferon beta-1b.,Enasidenib
DB00675,The metabolism of Tamoxifen can be decreased when combined with Interferon beta-1b.,Tamoxifen
DB00001,The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon beta-1b.,Lepirudin
DB00006,The risk or severity of bleeding can be increased when Bivalirudin is combined with Interferon beta-1b.,Bivalirudin
DB00009,The risk or severity of bleeding can be increased when Alteplase is combined with Interferon beta-1b.,Alteplase
DB00013,The risk or severity of bleeding can be increased when Urokinase is combined with Interferon beta-1b.,Urokinase
DB00015,The risk or severity of bleeding can be increased when Reteplase is combined with Interferon beta-1b.,Reteplase
DB00029,The risk or severity of bleeding can be increased when Anistreplase is combined with Interferon beta-1b.,Anistreplase
DB00031,The risk or severity of bleeding can be increased when Tenecteplase is combined with Interferon beta-1b.,Tenecteplase
DB00055,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Interferon beta-1b.,Drotrecogin alfa
DB00086,The risk or severity of bleeding can be increased when Streptokinase is combined with Interferon beta-1b.,Streptokinase
DB00266,The risk or severity of bleeding can be increased when Dicoumarol is combined with Interferon beta-1b.,Dicoumarol
DB00278,The risk or severity of bleeding can be increased when Argatroban is combined with Interferon beta-1b.,Argatroban
DB00407,The risk or severity of bleeding can be increased when Ardeparin is combined with Interferon beta-1b.,Ardeparin
DB00498,The risk or severity of bleeding can be increased when Phenindione is combined with Interferon beta-1b.,Phenindione
DB00569,The risk or severity of bleeding can be increased when Fondaparinux is combined with Interferon beta-1b.,Fondaparinux
DB00686,The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Interferon beta-1b.,Pentosan polysulfate
DB00946,The risk or severity of bleeding can be increased when Phenprocoumon is combined with Interferon beta-1b.,Phenprocoumon
DB01109,The risk or severity of bleeding can be increased when Heparin is combined with Interferon beta-1b.,Heparin
DB01225,The risk or severity of bleeding can be increased when Enoxaparin is combined with Interferon beta-1b.,Enoxaparin
DB03410,The risk or severity of bleeding can be increased when 4-hydroxycoumarin is combined with Interferon beta-1b.,4-hydroxycoumarin
DB04665,The risk or severity of bleeding can be increased when Coumarin is combined with Interferon beta-1b.,Coumarin
DB04898,The risk or severity of bleeding can be increased when Ximelagatran is combined with Interferon beta-1b.,Ximelagatran
DB04925,The risk or severity of bleeding can be increased when Desmoteplase is combined with Interferon beta-1b.,Desmoteplase
DB05099,The risk or severity of bleeding can be increased when Ancrod is combined with Interferon beta-1b.,Ancrod
DB05254,The risk or severity of bleeding can be increased when Fibrinolysin is combined with Interferon beta-1b.,Fibrinolysin
DB06228,The risk or severity of bleeding can be increased when Rivaroxaban is combined with Interferon beta-1b.,Rivaroxaban
DB06271,The risk or severity of bleeding can be increased when Sulodexide is combined with Interferon beta-1b.,Sulodexide
DB06294,The risk or severity of bleeding can be increased when Semuloparin is combined with Interferon beta-1b.,Semuloparin
DB06406,The risk or severity of bleeding can be increased when Idraparinux is combined with Interferon beta-1b.,Idraparinux
DB06543,The risk or severity of bleeding can be increased when Astaxanthin is combined with Interferon beta-1b.,Astaxanthin
DB06605,The risk or severity of bleeding can be increased when Apixaban is combined with Interferon beta-1b.,Apixaban
DB06635,The risk or severity of bleeding can be increased when Otamixaban is combined with Interferon beta-1b.,Otamixaban
DB06679,The risk or severity of bleeding can be increased when Amediplase is combined with Interferon beta-1b.,Amediplase
DB06695,The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Interferon beta-1b.,Dabigatran etexilate
DB06754,The risk or severity of bleeding can be increased when Danaparoid is combined with Interferon beta-1b.,Danaparoid
DB06779,The risk or severity of bleeding can be increased when Dalteparin is combined with Interferon beta-1b.,Dalteparin
DB06822,The risk or severity of bleeding can be increased when Tinzaparin is combined with Interferon beta-1b.,Tinzaparin
DB07767,The risk or severity of bleeding can be increased when Ferulic acid is combined with Interferon beta-1b.,Ferulic acid
DB08794,The risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Interferon beta-1b.,Ethyl biscoumacetate
DB08813,The risk or severity of bleeding can be increased when Nadroparin is combined with Interferon beta-1b.,Nadroparin
DB08994,The risk or severity of bleeding can be increased when Ditazole is combined with Interferon beta-1b.,Ditazole
DB09075,The risk or severity of bleeding can be increased when Edoxaban is combined with Interferon beta-1b.,Edoxaban
DB09125,The risk or severity of bleeding can be increased when Potassium citrate is combined with Interferon beta-1b.,Potassium citrate
DB09154,The risk or severity of bleeding can be increased when Sodium citrate is combined with Interferon beta-1b.,Sodium citrate
DB09255,The risk or severity of bleeding can be increased when Dextran is combined with Interferon beta-1b.,Dextran
DB09258,The risk or severity of bleeding can be increased when Bemiparin is combined with Interferon beta-1b.,Bemiparin
DB09259,The risk or severity of bleeding can be increased when Reviparin is combined with Interferon beta-1b.,Reviparin
DB09260,The risk or severity of bleeding can be increased when Parnaparin is combined with Interferon beta-1b.,Parnaparin
DB09261,The risk or severity of bleeding can be increased when Certoparin is combined with Interferon beta-1b.,Certoparin
DB11095,The risk or severity of bleeding can be increased when Desirudin is combined with Interferon beta-1b.,Desirudin
DB11154,The risk or severity of bleeding can be increased when Zinc citrate is combined with Interferon beta-1b.,Zinc citrate
DB11166,The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Interferon beta-1b.,Antithrombin Alfa
DB11312,The risk or severity of bleeding can be increased when Protein C is combined with Interferon beta-1b.,Protein C
DB11598,The risk or severity of bleeding can be increased when Antithrombin III human is combined with Interferon beta-1b.,Antithrombin III human
DB11984,The risk or severity of bleeding can be increased when Letaxaban is combined with Interferon beta-1b.,Letaxaban
DB12289,The risk or severity of bleeding can be increased when Darexaban is combined with Interferon beta-1b.,Darexaban
DB12364,The risk or severity of bleeding can be increased when Betrixaban is combined with Interferon beta-1b.,Betrixaban
DB12598,The risk or severity of bleeding can be increased when Nafamostat is combined with Interferon beta-1b.,Nafamostat
DB12726,The risk or severity of bleeding can be increased when Monteplase is combined with Interferon beta-1b.,Monteplase
DB12831,The risk or severity of bleeding can be increased when Gabexate is combined with Interferon beta-1b.,Gabexate
DB13136,The risk or severity of bleeding can be increased when Fluindione is combined with Interferon beta-1b.,Fluindione
DB13149,The risk or severity of bleeding can be increased when Protein S human is combined with Interferon beta-1b.,Protein S human
DB13199,The risk or severity of bleeding can be increased when Brinase is combined with Interferon beta-1b.,Brinase
DB13275,The risk or severity of bleeding can be increased when Clorindione is combined with Interferon beta-1b.,Clorindione
DB13347,The risk or severity of bleeding can be increased when Diphenadione is combined with Interferon beta-1b.,Diphenadione
DB13451,The risk or severity of bleeding can be increased when Tioclomarol is combined with Interferon beta-1b.,Tioclomarol
DB13616,The risk or severity of bleeding can be increased when Melagatran is combined with Interferon beta-1b.,Melagatran
DB13646,The risk or severity of bleeding can be increased when Saruplase is combined with Interferon beta-1b.,Saruplase
DB14055,The risk or severity of bleeding can be increased when (S)-Warfarin is combined with Interferon beta-1b.,(S)-Warfarin
DB14094,The risk or severity of bleeding can be increased when Tocopherylquinone is combined with Interferon beta-1b.,Tocopherylquinone
DB14598,The risk or severity of bleeding can be increased when Edetate calcium disodium anhydrous is combined with Interferon beta-1b.,Edetate calcium disodium anhydrous
DB14726,The risk or severity of bleeding can be increased when Dabigatran is combined with Interferon beta-1b.,Dabigatran
DB00232,The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Interferon beta-1b.,Methyclothiazide
DB00436,The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Interferon beta-1b.,Bendroflumethiazide
DB00562,The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Interferon beta-1b.,Benzthiazide
DB00606,The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Interferon beta-1b.,Cyclothiazide
DB00774,The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Interferon beta-1b.,Hydroflumethiazide
DB00880,The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Interferon beta-1b.,Chlorothiazide
DB00999,The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Interferon beta-1b.,Hydrochlorothiazide
DB01021,The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Interferon beta-1b.,Trichlormethiazide
DB01324,The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Interferon beta-1b.,Polythiazide
DB13430,The risk or severity of neutropenia and thrombocytopenia can be increased when Mebutizide is combined with Interferon beta-1b.,Mebutizide
DB13532,The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Interferon beta-1b.,Cyclopenthiazide
DB09042,The risk or severity of myelosuppression can be increased when Interferon beta-1b is combined with Tedizolid phosphate.,Tedizolid phosphate
DB00091,Interferon beta-1b may increase the immunosuppressive activities of Cyclosporine.,Cyclosporine
DB00268,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ropinirole.,Ropinirole
DB00115,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Interferon beta-1b.,Cyanocobalamin
DB00437,The risk or severity of adverse effects can be increased when Allopurinol is combined with Interferon beta-1b.,Allopurinol
DB14513,The serum concentration of Magnesium can be decreased when it is combined with Interferon beta-1b.,Magnesium
DB01601,The serum concentration of Interferon beta-1b can be increased when it is combined with Lopinavir.,Lopinavir
DB12530,The risk or severity of infection can be increased when Interferon beta-1b is combined with Inebilizumab.,Inebilizumab
DB06643,The risk or severity of adverse effects can be increased when Denosumab is combined with Interferon alfacon-1.,Denosumab
DB00005,The risk or severity of adverse effects can be increased when Etanercept is combined with Interferon alfacon-1.,Etanercept
DB00008,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Interferon alfacon-1.,Peginterferon alfa-2a
DB00011,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Interferon alfacon-1.,Interferon alfa-n1
DB00018,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Interferon alfacon-1.,Interferon alfa-n3
DB00022,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Interferon alfacon-1.,Peginterferon alfa-2b
DB00026,The risk or severity of adverse effects can be increased when Anakinra is combined with Interferon alfacon-1.,Anakinra
DB00033,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Interferon alfacon-1.,Interferon gamma-1b
DB00034,"The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Interferon alfacon-1.","Interferon alfa-2a, Recombinant"
DB00051,The risk or severity of adverse effects can be increased when Adalimumab is combined with Interferon alfacon-1.,Adalimumab
DB00056,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Interferon alfacon-1.,Gemtuzumab ozogamicin
DB00059,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Interferon alfacon-1.,Pegaspargase
DB00065,The risk or severity of adverse effects can be increased when Infliximab is combined with Interferon alfacon-1.,Infliximab
DB00068,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Interferon alfacon-1.,Interferon beta-1b
DB00073,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Rituximab.,Rituximab
DB00074,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Basiliximab.,Basiliximab
DB00075,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Muromonab.,Muromonab
DB00078,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ibritumomab tiuxetan.,Ibritumomab tiuxetan
DB00081,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Tositumomab.,Tositumomab
DB00087,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Alemtuzumab.,Alemtuzumab
DB00092,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Alefacept.,Alefacept
DB00095,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Efalizumab.,Efalizumab
DB00098,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Antithymocyte immunoglobulin (rabbit).,Antithymocyte immunoglobulin (rabbit)
DB00105,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Interferon alfa-2b.,Interferon alfa-2b
DB00111,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Daclizumab.,Daclizumab
DB00112,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Bevacizumab.,Bevacizumab
DB00120,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Phenylalanine.,Phenylalanine
DB00180,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Flunisolide.,Flunisolide
DB00188,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Bortezomib.,Bortezomib
DB00242,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Cladribine.,Cladribine
DB00262,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Carmustine.,Carmustine
DB00276,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Amsacrine.,Amsacrine
DB00290,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Bleomycin.,Bleomycin
DB00291,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Chlorambucil.,Chlorambucil
DB00293,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Raltitrexed.,Raltitrexed
DB00305,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Mitomycin.,Mitomycin
DB00307,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Bexarotene.,Bexarotene
DB00309,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Vindesine.,Vindesine
DB00322,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Floxuridine.,Floxuridine
DB00328,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Indomethacin.,Indomethacin
DB00352,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Tioguanine.,Tioguanine
DB00361,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Vinorelbine.,Vinorelbine
DB00380,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Dexrazoxane.,Dexrazoxane
DB00394,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Beclomethasone dipropionate.,Beclomethasone dipropionate
DB00398,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Sorafenib.,Sorafenib
DB00428,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Streptozocin.,Streptozocin
DB00432,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Trifluridine.,Trifluridine
DB00441,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Gemcitabine.,Gemcitabine
DB00443,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Betamethasone.,Betamethasone
DB00444,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Teniposide.,Teniposide
DB00445,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Epirubicin.,Epirubicin
DB00446,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Chloramphenicol.,Chloramphenicol
DB00480,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Lenalidomide.,Lenalidomide
DB00488,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Altretamine.,Altretamine
DB00495,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Zidovudine.,Zidovudine
DB00515,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Cisplatin.,Cisplatin
DB00526,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Oxaliplatin.,Oxaliplatin
DB00531,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Cyclophosphamide.,Cyclophosphamide
DB00541,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Vincristine.,Vincristine
DB00544,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fluorouracil.,Fluorouracil
DB00550,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Propylthiouracil.,Propylthiouracil
DB00552,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Pentostatin.,Pentostatin
DB00563,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Methotrexate.,Methotrexate
DB00564,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Carbamazepine.,Carbamazepine
DB00570,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Vinblastine.,Vinblastine
DB00588,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fluticasone propionate.,Fluticasone propionate
DB00591,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fluocinolone acetonide.,Fluocinolone acetonide
DB00601,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Linezolid.,Linezolid
DB00619,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Imatinib.,Imatinib
DB00620,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Triamcinolone.,Triamcinolone
DB00631,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Clofarabine.,Clofarabine
DB00635,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Prednisone.,Prednisone
DB00642,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Pemetrexed.,Pemetrexed
DB00687,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fludrocortisone.,Fludrocortisone
DB00688,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Mycophenolate mofetil.,Mycophenolate mofetil
DB00694,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Daunorubicin.,Daunorubicin
DB00755,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Tretinoin.,Tretinoin
DB00762,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Irinotecan.,Irinotecan
DB00763,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Methimazole.,Methimazole
DB00764,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Mometasone.,Mometasone
DB00773,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Etoposide.,Etoposide
DB00795,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Sulfasalazine.,Sulfasalazine
DB00851,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Dacarbazine.,Dacarbazine
DB00853,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Temozolomide.,Temozolomide
DB00859,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Penicillamine.,Penicillamine
DB00860,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Prednisolone.,Prednisolone
DB00877,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Sirolimus.,Sirolimus
DB00888,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Mechlorethamine.,Mechlorethamine
DB00928,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Azacitidine.,Azacitidine
DB00958,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Carboplatin.,Carboplatin
DB00959,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Methylprednisolone.,Methylprednisolone
DB00970,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Dactinomycin.,Dactinomycin
DB00987,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Cytarabine.,Cytarabine
DB00993,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Azathioprine.,Azathioprine
DB00997,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Doxorubicin.,Doxorubicin
DB01005,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Hydroxyurea.,Hydroxyurea
DB01008,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Busulfan.,Busulfan
DB01024,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Mycophenolic acid.,Mycophenolic acid
DB01030,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Topotecan.,Topotecan
DB01033,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Mercaptopurine.,Mercaptopurine
DB01041,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Thalidomide.,Thalidomide
DB01042,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Melphalan.,Melphalan
DB01073,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fludarabine.,Fludarabine
DB01099,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Flucytosine.,Flucytosine
DB01101,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Capecitabine.,Capecitabine
DB01108,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Trilostane.,Trilostane
DB01168,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Procarbazine.,Procarbazine
DB01169,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Arsenic trioxide.,Arsenic trioxide
DB01177,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Idarubicin.,Idarubicin
DB01181,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ifosfamide.,Ifosfamide
DB01196,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Estramustine.,Estramustine
DB01204,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Mitoxantrone.,Mitoxantrone
DB01206,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Lomustine.,Lomustine
DB01222,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Budesonide.,Budesonide
DB01229,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Paclitaxel.,Paclitaxel
DB01234,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Dexamethasone.,Dexamethasone
DB01248,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Docetaxel.,Docetaxel
DB01254,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Dasatinib.,Dasatinib
DB01257,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Eculizumab.,Eculizumab
DB01262,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Decitabine.,Decitabine
DB01268,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Sunitinib.,Sunitinib
DB01280,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Nelarabine.,Nelarabine
DB01281,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Abatacept.,Abatacept
DB01285,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Corticotropin.,Corticotropin
DB01380,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Cortisone acetate.,Cortisone acetate
DB01384,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Paramethasone.,Paramethasone
DB01394,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Colchicine.,Colchicine
DB01410,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ciclesonide.,Ciclesonide
DB01423,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Stepronin.,Stepronin
DB01590,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Everolimus.,Everolimus
DB01611,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Hydroxychloroquine.,Hydroxychloroquine
DB01816,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Castanospermine.,Castanospermine
DB02546,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Vorinostat.,Vorinostat
DB02806,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with 2-Methoxyethanol.,2-Methoxyethanol
DB03523,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Brequinar.,Brequinar
DB04572,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Thiotepa.,Thiotepa
DB04630,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Aldosterone.,Aldosterone
DB04845,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ixabepilone.,Ixabepilone
DB04868,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Nilotinib.,Nilotinib
DB04951,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Pirfenidone.,Pirfenidone
DB04956,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Afelimomab.,Afelimomab
DB05015,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Belinostat.,Belinostat
DB05109,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Trabectedin.,Trabectedin
DB05258,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Interferon alfa.,Interferon alfa
DB05259,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Glatiramer.,Glatiramer
DB05260,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Gallium nitrate.,Gallium nitrate
DB05459,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Briakinumab.,Briakinumab
DB05472,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with omega interferon.,omega interferon
DB05676,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Apremilast.,Apremilast
DB05773,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Trastuzumab emtansine.,Trastuzumab emtansine
DB06168,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Canakinumab.,Canakinumab
DB06273,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Tocilizumab.,Tocilizumab
DB06287,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Temsirolimus.,Temsirolimus
DB06372,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Rilonacept.,Rilonacept
DB06589,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Pazopanib.,Pazopanib
DB06603,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Panobinostat.,Panobinostat
DB06612,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Mepolizumab.,Mepolizumab
DB06616,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Bosutinib.,Bosutinib
DB06662,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Abetimus.,Abetimus
DB06674,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Golimumab.,Golimumab
DB06681,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Belatacept.,Belatacept
DB06769,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Bendamustine.,Bendamustine
DB06772,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Cabazitaxel.,Cabazitaxel
DB06813,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Pralatrexate.,Pralatrexate
DB08059,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Wortmannin.,Wortmannin
DB08870,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Brentuximab vedotin.,Brentuximab vedotin
DB08871,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Eribulin.,Eribulin
DB08877,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ruxolitinib.,Ruxolitinib
DB08879,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Belimumab.,Belimumab
DB08880,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Teriflunomide.,Teriflunomide
DB08889,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Carfilzomib.,Carfilzomib
DB08901,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ponatinib.,Ponatinib
DB08904,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Certolizumab pegol.,Certolizumab pegol
DB08906,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fluticasone furoate.,Fluticasone furoate
DB08908,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Dimethyl fumarate.,Dimethyl fumarate
DB08910,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Pomalidomide.,Pomalidomide
DB08935,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Obinutuzumab.,Obinutuzumab
DB08970,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fluprednidene.,Fluprednidene
DB08971,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fluocortolone.,Fluocortolone
DB09029,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Secukinumab.,Secukinumab
DB09033,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Vedolizumab.,Vedolizumab
DB09036,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Siltuximab.,Siltuximab
DB09052,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Blinatumomab.,Blinatumomab
DB09053,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ibrutinib.,Ibrutinib
DB09054,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Idelalisib.,Idelalisib
DB09073,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Palbociclib.,Palbociclib
DB09074,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Olaparib.,Olaparib
DB09077,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Dinutuximab.,Dinutuximab
DB09082,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Vilanterol.,Vilanterol
DB09091,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Tixocortol.,Tixocortol
DB09122,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Peginterferon beta-1a.,Peginterferon beta-1a
DB09312,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Antilymphocyte immunoglobulin (horse).,Antilymphocyte immunoglobulin (horse)
DB09378,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fluprednisolone.,Fluprednisolone
DB09383,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Meprednisone.,Meprednisone
DB11466,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Tepoxalin.,Tepoxalin
DB11487,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Dexamethasone isonicotinate.,Dexamethasone isonicotinate
DB11529,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Melengestrol.,Melengestrol
DB11569,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ixekizumab.,Ixekizumab
DB11580,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ravulizumab.,Ravulizumab
DB11616,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Pirarubicin.,Pirarubicin
DB11693,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Voclosporin.,Voclosporin
DB11708,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Peficitinib.,Peficitinib
DB11750,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Clobetasol.,Clobetasol
DB11767,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Sarilumab.,Sarilumab
DB11776,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Brodalumab.,Brodalumab
DB11803,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Sirukumab.,Sirukumab
DB11817,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Baricitinib.,Baricitinib
DB11834,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Guselkumab.,Guselkumab
DB11921,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Deflazacort.,Deflazacort
DB11988,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ocrelizumab.,Ocrelizumab
DB12025,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Triptolide.,Triptolide
DB12371,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Siponimod.,Siponimod
DB12612,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ozanimod.,Ozanimod
DB12617,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Mizoribine.,Mizoribine
DB12692,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Gusperimus.,Gusperimus
DB12814,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Cepeginterferon alfa-2B.,Cepeginterferon alfa-2B
DB12902,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Trofosfamide.,Trofosfamide
DB12947,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Doxifluridine.,Doxifluridine
DB12991,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Deoxyspergualin.,Deoxyspergualin
DB12996,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Acteoside.,Acteoside
DB13003,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Cortivazol.,Cortivazol
DB13014,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Hypericin.,Hypericin
DB13068,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.,9-(N-methyl-L-isoleucine)-cyclosporin A
DB13208,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Prednylidene.,Prednylidene
DB13223,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fluocortin.,Fluocortin
DB13241,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Begelomab.,Begelomab
DB13491,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fluperolone.,Fluperolone
DB13664,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Formocortal.,Formocortal
DB13728,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Halometasone.,Halometasone
DB13843,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Cloprednol.,Cloprednol
DB13856,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fluclorolone.,Fluclorolone
DB13867,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fluticasone.,Fluticasone
DB14066,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Tetrandrine.,Tetrandrine
DB14219,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Monomethyl fumarate.,Monomethyl fumarate
DB14512,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Mometasone furoate.,Mometasone furoate
DB14538,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Hydrocortisone aceponate.,Hydrocortisone aceponate
DB14539,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Hydrocortisone acetate.,Hydrocortisone acetate
DB14545,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Hydrocortisone succinate.,Hydrocortisone succinate
DB14724,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Emapalumab.,Emapalumab
DB14762,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Risankizumab.,Risankizumab
DB14919,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Rozanolixizumab.,Rozanolixizumab
DB15253,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Bleselumab.,Bleselumab
DB00108,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Natalizumab.,Natalizumab
DB00337,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Interferon alfacon-1.,Pimecrolimus
DB01656,Roflumilast may increase the immunosuppressive activities of Interferon alfacon-1.,Roflumilast
DB06688,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Interferon alfacon-1.,Sipuleucel-T
DB00041,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Aldesleukin.,Aldesleukin
DB00363,The risk or severity of neutropenia can be increased when Interferon alfacon-1 is combined with Clozapine.,Clozapine
DB00333,The serum concentration of Methadone can be increased when it is combined with Interferon alfacon-1.,Methadone
DB00811,The risk or severity of anemia can be increased when Interferon alfacon-1 is combined with Ribavirin.,Ribavirin
DB00315,The metabolism of Zolmitriptan can be decreased when combined with Interferon alfacon-1.,Zolmitriptan
DB01015,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Interferon alfacon-1.,Sulfamethoxazole
DB01265,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Telbivudine.,Telbivudine
DB01097,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Leflunomide.,Leflunomide
DB08895,Interferon alfacon-1 may increase the immunosuppressive activities of Tofacitinib.,Tofacitinib
DB00072,Trastuzumab may increase the neutropenic activities of Interferon alfacon-1.,Trastuzumab
DB08868,Interferon alfacon-1 may increase the immunosuppressive activities of Fingolimod.,Fingolimod
DB00864,Tacrolimus may increase the immunosuppressive activities of Interferon alfacon-1.,Tacrolimus
DB00201,The metabolism of Caffeine can be decreased when combined with Interferon alfacon-1.,Caffeine
DB00651,The metabolism of Dyphylline can be decreased when combined with Interferon alfacon-1.,Dyphylline
DB00806,The metabolism of Pentoxifylline can be decreased when combined with Interferon alfacon-1.,Pentoxifylline
DB01303,The metabolism of Oxtriphylline can be decreased when combined with Interferon alfacon-1.,Oxtriphylline
DB01412,The metabolism of Theobromine can be decreased when combined with Interferon alfacon-1.,Theobromine
DB01482,The metabolism of Fenethylline can be decreased when combined with Interferon alfacon-1.,Fenethylline
DB01667,The metabolism of 8-azaguanine can be decreased when combined with Interferon alfacon-1.,8-azaguanine
DB01978,"The metabolism of 7,9-Dimethylguanine can be decreased when combined with Interferon alfacon-1.","7,9-Dimethylguanine"
DB02134,The metabolism of Xanthine can be decreased when combined with Interferon alfacon-1.,Xanthine
DB02245,The metabolism of 7-Deazaguanine can be decreased when combined with Interferon alfacon-1.,7-Deazaguanine
DB02377,The metabolism of Guanine can be decreased when combined with Interferon alfacon-1.,Guanine
DB02489,The metabolism of 9-Methylguanine can be decreased when combined with Interferon alfacon-1.,9-Methylguanine
DB02568,The metabolism of Peldesine can be decreased when combined with Interferon alfacon-1.,Peldesine
DB04076,The metabolism of Hypoxanthine can be decreased when combined with Interferon alfacon-1.,Hypoxanthine
DB04356,The metabolism of 9-Deazaguanine can be decreased when combined with Interferon alfacon-1.,9-Deazaguanine
DB06479,The metabolism of Propentofylline can be decreased when combined with Interferon alfacon-1.,Propentofylline
DB06575,The metabolism of Valomaciclovir can be decreased when combined with Interferon alfacon-1.,Valomaciclovir
DB07954,The metabolism of 3-isobutyl-1-methyl-7H-xanthine can be decreased when combined with Interferon alfacon-1.,3-isobutyl-1-methyl-7H-xanthine
DB08844,The metabolism of Uric acid can be decreased when combined with Interferon alfacon-1.,Uric acid
DB09273,The metabolism of Doxofylline can be decreased when combined with Interferon alfacon-1.,Doxofylline
DB11919,The metabolism of 6-O-benzylguanine can be decreased when combined with Interferon alfacon-1.,6-O-benzylguanine
DB12406,The metabolism of Lisofylline can be decreased when combined with Interferon alfacon-1.,Lisofylline
DB12531,The metabolism of Lobucavir can be decreased when combined with Interferon alfacon-1.,Lobucavir
DB12926,The metabolism of Cafedrine can be decreased when combined with Interferon alfacon-1.,Cafedrine
DB12927,The metabolism of Theodrenaline can be decreased when combined with Interferon alfacon-1.,Theodrenaline
DB13203,The metabolism of Bamifylline can be decreased when combined with Interferon alfacon-1.,Bamifylline
DB13449,The metabolism of Proxyphylline can be decreased when combined with Interferon alfacon-1.,Proxyphylline
DB13573,The metabolism of Acefylline can be decreased when combined with Interferon alfacon-1.,Acefylline
DB13592,The metabolism of Etamiphylline can be decreased when combined with Interferon alfacon-1.,Etamiphylline
DB13634,The metabolism of Pentifylline can be decreased when combined with Interferon alfacon-1.,Pentifylline
DB13812,The metabolism of Bufylline can be decreased when combined with Interferon alfacon-1.,Bufylline
DB14018,The metabolism of Bromotheophylline can be decreased when combined with Interferon alfacon-1.,Bromotheophylline
DB14029,The metabolism of Furafylline can be decreased when combined with Interferon alfacon-1.,Furafylline
DB14132,The metabolism of 8-chlorotheophylline can be decreased when combined with Interferon alfacon-1.,8-chlorotheophylline
DB15122,The metabolism of PCS-499 can be decreased when combined with Interferon alfacon-1.,PCS-499
DB04914,The therapeutic efficacy of G17DT can be decreased when used in combination with Interferon alfacon-1.,G17DT
DB05144,The therapeutic efficacy of PEV3A can be decreased when used in combination with Interferon alfacon-1.,PEV3A
DB05325,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Interferon alfacon-1.,INGN 225
DB05374,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Interferon alfacon-1.,Rindopepimut
DB05440,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Interferon alfacon-1.,SRP 299
DB05942,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Interferon alfacon-1.,GI-5005
DB06400,The therapeutic efficacy of Vitespen can be decreased when used in combination with Interferon alfacon-1.,Vitespen
DB06584,The therapeutic efficacy of TG4010 can be decreased when used in combination with Interferon alfacon-1.,TG4010
DB09057,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Interferon alfacon-1.,Anthrax immune globulin human
DB10062,"The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Interferon alfacon-1.","Rabies virus inactivated antigen, B"
DB10076,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Interferon alfacon-1.,Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen
DB10276,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Interferon alfacon-1.,Rotavirus vaccine
DB10283,"The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Interferon alfacon-1.","Rabies virus inactivated antigen, A"
DB10342,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Interferon alfacon-1.,Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen
DB10583,The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfacon-1.,Clostridium tetani toxoid antigen (formaldehyde inactivated)
DB10584,The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfacon-1.,Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
DB10600,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfacon-1.,Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated)
DB10769,The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfacon-1.,Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)
DB10794,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfacon-1.,Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated)
DB10803,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Interferon alfacon-1.,Typhoid Vi polysaccharide vaccine
DB10989,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Interferon alfacon-1.,Hepatitis A Vaccine
DB10990,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Interferon alfacon-1.,Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
DB11038,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfacon-1.,Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated)
DB11040,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfacon-1.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated)
DB11041,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfacon-1.,Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)
DB11044,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfacon-1.,Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated)
DB11603,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Interferon alfacon-1.,Human rabies virus immune globulin
DB11627,The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Interferon alfacon-1.,Hepatitis B Vaccine (Recombinant)
DB12568,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Interferon alfacon-1.,Tecemotide
DB14022,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Interferon alfacon-1.,Typhoid vaccine
DB14384,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfacon-1.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated)
DB14385,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfacon-1.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)
DB14394,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Interferon alfacon-1.,Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen
DB14445,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfacon-1.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated)
DB14449,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Interferon alfacon-1.,Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen
DB14619,The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfacon-1.,Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated)
DB14620,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfacon-1.,Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated)
DB14711,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Interferon alfacon-1.,Vaccinia virus strain new york city board of health live antigen
DB15274,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Interferon alfacon-1.,Pertussis vaccine
DB15461,The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfacon-1.,Yersinia pestis 195/p antigen (formaldehyde inactivated)
DB13924,The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Interferon alfacon-1.,Varicella Zoster Vaccine (Recombinant)
DB15483,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Interferon alfacon-1.,Modified vaccinia ankara
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Interferon alfacon-1.","Ebola Zaire vaccine (live, attenuated)"
DB00054,The risk or severity of bleeding can be increased when Abciximab is combined with Interferon alfacon-1.,Abciximab
DB00063,The risk or severity of bleeding can be increased when Eptifibatide is combined with Interferon alfacon-1.,Eptifibatide
DB00208,The risk or severity of bleeding can be increased when Ticlopidine is combined with Interferon alfacon-1.,Ticlopidine
DB00775,The risk or severity of bleeding can be increased when Tirofiban is combined with Interferon alfacon-1.,Tirofiban
DB00945,The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Interferon alfacon-1.,Acetylsalicylic acid
DB00975,The risk or severity of bleeding can be increased when Dipyridamole is combined with Interferon alfacon-1.,Dipyridamole
DB01088,The risk or severity of bleeding can be increased when Iloprost is combined with Interferon alfacon-1.,Iloprost
DB01138,The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Interferon alfacon-1.,Sulfinpyrazone
DB01207,The risk or severity of bleeding can be increased when Ridogrel is combined with Interferon alfacon-1.,Ridogrel
DB01236,The risk or severity of bleeding can be increased when Sevoflurane is combined with Interferon alfacon-1.,Sevoflurane
DB01240,The risk or severity of bleeding can be increased when Epoprostenol is combined with Interferon alfacon-1.,Epoprostenol
DB04743,The risk or severity of bleeding can be increased when Nimesulide is combined with Interferon alfacon-1.,Nimesulide
DB04905,The risk or severity of bleeding can be increased when Tesmilifene is combined with Interferon alfacon-1.,Tesmilifene
DB04932,The risk or severity of bleeding can be increased when Defibrotide is combined with Interferon alfacon-1.,Defibrotide
DB05229,The risk or severity of bleeding can be increased when Beraprost is combined with Interferon alfacon-1.,Beraprost
DB05266,The risk or severity of bleeding can be increased when Ibudilast is combined with Interferon alfacon-1.,Ibudilast
DB05767,The risk or severity of bleeding can be increased when Andrographolide is combined with Interferon alfacon-1.,Andrographolide
DB06081,The risk or severity of bleeding can be increased when Caplacizumab is combined with Interferon alfacon-1.,Caplacizumab
DB06209,The risk or severity of bleeding can be increased when Prasugrel is combined with Interferon alfacon-1.,Prasugrel
DB06441,The risk or severity of bleeding can be increased when Cangrelor is combined with Interferon alfacon-1.,Cangrelor
DB07615,The risk or severity of bleeding can be increased when Tranilast is combined with Interferon alfacon-1.,Tranilast
DB08814,The risk or severity of bleeding can be increased when Triflusal is combined with Interferon alfacon-1.,Triflusal
DB08816,The risk or severity of bleeding can be increased when Ticagrelor is combined with Interferon alfacon-1.,Ticagrelor
DB08887,The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Interferon alfacon-1.,Icosapent ethyl
DB09030,The risk or severity of bleeding can be increased when Vorapaxar is combined with Interferon alfacon-1.,Vorapaxar
DB09283,The risk or severity of bleeding can be increased when Trapidil is combined with Interferon alfacon-1.,Trapidil
DB12092,The risk or severity of bleeding can be increased when Naftopidil is combined with Interferon alfacon-1.,Naftopidil
DB12163,The risk or severity of bleeding can be increased when Sarpogrelate is combined with Interferon alfacon-1.,Sarpogrelate
DB12321,The risk or severity of bleeding can be increased when Ifetroban is combined with Interferon alfacon-1.,Ifetroban
DB12445,The risk or severity of bleeding can be increased when Nitroaspirin is combined with Interferon alfacon-1.,Nitroaspirin
DB12465,The risk or severity of bleeding can be increased when Ketanserin is combined with Interferon alfacon-1.,Ketanserin
DB12545,The risk or severity of bleeding can be increased when Indobufen is combined with Interferon alfacon-1.,Indobufen
DB12749,The risk or severity of bleeding can be increased when Butylphthalide is combined with Interferon alfacon-1.,Butylphthalide
DB12771,The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Interferon alfacon-1.,Hydroxytyrosol
DB13036,The risk or severity of bleeding can be increased when Ramatroban is combined with Interferon alfacon-1.,Ramatroban
DB13327,The risk or severity of bleeding can be increased when Picotamide is combined with Interferon alfacon-1.,Picotamide
DB13367,The risk or severity of bleeding can be increased when Cloricromen is combined with Interferon alfacon-1.,Cloricromen
DB13400,The risk or severity of bleeding can be increased when Linsidomine is combined with Interferon alfacon-1.,Linsidomine
DB13510,The risk or severity of bleeding can be increased when Buflomedil is combined with Interferon alfacon-1.,Buflomedil
DB13929,The risk or severity of bleeding can be increased when Relcovaptan is combined with Interferon alfacon-1.,Relcovaptan
DB13200,Interferon alfacon-1 may increase the myelosuppressive activities of Lipegfilgrastim.,Lipegfilgrastim
DB10318,The risk or severity of infection can be increased when Interferon alfacon-1 is combined with Varicella Zoster Vaccine (Live/attenuated).,Varicella Zoster Vaccine (Live/attenuated)
DB10317,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Interferon alfacon-1.,Rubella virus vaccine
DB10343,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Interferon alfacon-1.,Bacillus calmette-guerin substrain tice live antigen
DB10804,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Interferon alfacon-1.,Bacillus calmette-guerin substrain connaught live antigen
DB10805,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Interferon alfacon-1.,Yellow Fever Vaccine
DB11003,The risk or severity of infection can be increased when Anthrax vaccine is combined with Interferon alfacon-1.,Anthrax vaccine
DB11050,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Interferon alfacon-1.,Typhoid Vaccine Live
DB12386,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Interferon alfacon-1.,Bacillus calmette-guerin substrain danish 1331 live antigen
DB12768,The risk or severity of infection can be increased when BCG vaccine is combined with Interferon alfacon-1.,BCG vaccine
DB14409,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Interferon alfacon-1.,Human adenovirus e serotype 4 strain cl-68578 antigen
DB14443,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Interferon alfacon-1.,Vibrio cholerae CVD 103-HgR strain live antigen
DB14685,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Interferon alfacon-1.,Adenovirus type 7 vaccine live
DB00039,The therapeutic efficacy of Palifermin can be decreased when used in combination with Interferon alfacon-1.,Palifermin
DB00176,The metabolism of Fluvoxamine can be decreased when combined with Interferon alfacon-1.,Fluvoxamine
DB00184,The metabolism of Nicotine can be decreased when combined with Interferon alfacon-1.,Nicotine
DB00195,The metabolism of Betaxolol can be decreased when combined with Interferon alfacon-1.,Betaxolol
DB00261,The metabolism of Anagrelide can be decreased when combined with Interferon alfacon-1.,Anagrelide
DB00280,The metabolism of Disopyramide can be decreased when combined with Interferon alfacon-1.,Disopyramide
DB00281,The metabolism of Lidocaine can be decreased when combined with Interferon alfacon-1.,Lidocaine
DB00286,The metabolism of Conjugated estrogens can be decreased when combined with Interferon alfacon-1.,Conjugated estrogens
DB00296,The metabolism of Ropivacaine can be decreased when combined with Interferon alfacon-1.,Ropivacaine
DB00316,The metabolism of Acetaminophen can be decreased when combined with Interferon alfacon-1.,Acetaminophen
DB00334,The metabolism of Olanzapine can be decreased when combined with Interferon alfacon-1.,Olanzapine
DB00356,The metabolism of Chlorzoxazone can be decreased when combined with Interferon alfacon-1.,Chlorzoxazone
DB00365,The metabolism of Grepafloxacin can be decreased when combined with Interferon alfacon-1.,Grepafloxacin
DB00370,The metabolism of Mirtazapine can be decreased when combined with Interferon alfacon-1.,Mirtazapine
DB00379,The metabolism of Mexiletine can be decreased when combined with Interferon alfacon-1.,Mexiletine
DB00382,The metabolism of Tacrine can be decreased when combined with Interferon alfacon-1.,Tacrine
DB00384,The metabolism of Triamterene can be decreased when combined with Interferon alfacon-1.,Triamterene
DB00420,The metabolism of Promazine can be decreased when combined with Interferon alfacon-1.,Promazine
DB00425,The metabolism of Zolpidem can be decreased when combined with Interferon alfacon-1.,Zolpidem
DB00442,The metabolism of Entecavir can be decreased when combined with Interferon alfacon-1.,Entecavir
DB00461,The metabolism of Nabumetone can be decreased when combined with Interferon alfacon-1.,Nabumetone
DB00468,The metabolism of Quinine can be decreased when combined with Interferon alfacon-1.,Quinine
DB00472,The metabolism of Fluoxetine can be decreased when combined with Interferon alfacon-1.,Fluoxetine
DB00476,The metabolism of Duloxetine can be decreased when combined with Interferon alfacon-1.,Duloxetine
DB00477,The metabolism of Chlorpromazine can be decreased when combined with Interferon alfacon-1.,Chlorpromazine
DB00499,The metabolism of Flutamide can be decreased when combined with Interferon alfacon-1.,Flutamide
DB00502,The metabolism of Haloperidol can be decreased when combined with Interferon alfacon-1.,Haloperidol
DB00518,The metabolism of Albendazole can be decreased when combined with Interferon alfacon-1.,Albendazole
DB00533,The metabolism of Rofecoxib can be decreased when combined with Interferon alfacon-1.,Rofecoxib
DB00568,The metabolism of Cinnarizine can be decreased when combined with Interferon alfacon-1.,Cinnarizine
DB00571,The metabolism of Propranolol can be decreased when combined with Interferon alfacon-1.,Propranolol
DB00586,The metabolism of Diclofenac can be decreased when combined with Interferon alfacon-1.,Diclofenac
DB00629,The metabolism of Guanabenz can be decreased when combined with Interferon alfacon-1.,Guanabenz
DB00661,The metabolism of Verapamil can be decreased when combined with Interferon alfacon-1.,Verapamil
DB00715,The metabolism of Paroxetine can be decreased when combined with Interferon alfacon-1.,Paroxetine
DB00730,The metabolism of Thiabendazole can be decreased when combined with Interferon alfacon-1.,Thiabendazole
DB00740,The metabolism of Riluzole can be decreased when combined with Interferon alfacon-1.,Riluzole
DB00744,The metabolism of Zileuton can be decreased when combined with Interferon alfacon-1.,Zileuton
DB00758,The metabolism of Clopidogrel can be decreased when combined with Interferon alfacon-1.,Clopidogrel
DB00783,The metabolism of Estradiol can be decreased when combined with Interferon alfacon-1.,Estradiol
DB00787,The metabolism of Acyclovir can be decreased when combined with Interferon alfacon-1.,Acyclovir
DB00788,The metabolism of Naproxen can be decreased when combined with Interferon alfacon-1.,Naproxen
DB00831,The metabolism of Trifluoperazine can be decreased when combined with Interferon alfacon-1.,Trifluoperazine
DB00850,The metabolism of Perphenazine can be decreased when combined with Interferon alfacon-1.,Perphenazine
DB00857,The metabolism of Terbinafine can be decreased when combined with Interferon alfacon-1.,Terbinafine
DB00863,The metabolism of Ranitidine can be decreased when combined with Interferon alfacon-1.,Ranitidine
DB00898,The metabolism of Ethanol can be decreased when combined with Interferon alfacon-1.,Ethanol
DB00934,The metabolism of Maprotiline can be decreased when combined with Interferon alfacon-1.,Maprotiline
DB00969,The metabolism of Alosetron can be decreased when combined with Interferon alfacon-1.,Alosetron
DB00978,The metabolism of Lomefloxacin can be decreased when combined with Interferon alfacon-1.,Lomefloxacin
DB00980,The metabolism of Ramelteon can be decreased when combined with Interferon alfacon-1.,Ramelteon
DB00998,The metabolism of Frovatriptan can be decreased when combined with Interferon alfacon-1.,Frovatriptan
DB01002,The metabolism of Levobupivacaine can be decreased when combined with Interferon alfacon-1.,Levobupivacaine
DB01012,The metabolism of Cinacalcet can be decreased when combined with Interferon alfacon-1.,Cinacalcet
DB01037,The metabolism of Selegiline can be decreased when combined with Interferon alfacon-1.,Selegiline
DB01056,The metabolism of Tocainide can be decreased when combined with Interferon alfacon-1.,Tocainide
DB01058,The metabolism of Praziquantel can be decreased when combined with Interferon alfacon-1.,Praziquantel
DB01065,The metabolism of Melatonin can be decreased when combined with Interferon alfacon-1.,Melatonin
DB01087,The metabolism of Primaquine can be decreased when combined with Interferon alfacon-1.,Primaquine
DB01094,The metabolism of Hesperetin can be decreased when combined with Interferon alfacon-1.,Hesperetin
DB01115,The metabolism of Nifedipine can be decreased when combined with Interferon alfacon-1.,Nifedipine
DB01136,The metabolism of Carvedilol can be decreased when combined with Interferon alfacon-1.,Carvedilol
DB01166,The metabolism of Cilostazol can be decreased when combined with Interferon alfacon-1.,Cilostazol
DB01182,The metabolism of Propafenone can be decreased when combined with Interferon alfacon-1.,Propafenone
DB01184,The metabolism of Domperidone can be decreased when combined with Interferon alfacon-1.,Domperidone
DB01191,The metabolism of Dexfenfluramine can be decreased when combined with Interferon alfacon-1.,Dexfenfluramine
DB01367,The metabolism of Rasagiline can be decreased when combined with Interferon alfacon-1.,Rasagiline
DB01405,The metabolism of Temafloxacin can be decreased when combined with Interferon alfacon-1.,Temafloxacin
DB01424,The metabolism of Aminophenazone can be decreased when combined with Interferon alfacon-1.,Aminophenazone
DB01435,The metabolism of Antipyrine can be decreased when combined with Interferon alfacon-1.,Antipyrine
DB01558,The metabolism of Bromazepam can be decreased when combined with Interferon alfacon-1.,Bromazepam
DB01623,The metabolism of Thiothixene can be decreased when combined with Interferon alfacon-1.,Thiothixene
DB01628,The metabolism of Etoricoxib can be decreased when combined with Interferon alfacon-1.,Etoricoxib
DB01645,The metabolism of Genistein can be decreased when combined with Interferon alfacon-1.,Genistein
DB02709,The metabolism of Resveratrol can be decreased when combined with Interferon alfacon-1.,Resveratrol
DB03783,The metabolism of Phenacetin can be decreased when combined with Interferon alfacon-1.,Phenacetin
DB04574,The metabolism of Estrone sulfate can be decreased when combined with Interferon alfacon-1.,Estrone sulfate
DB04841,The metabolism of Flunarizine can be decreased when combined with Interferon alfacon-1.,Flunarizine
DB04871,The metabolism of Lorcaserin can be decreased when combined with Interferon alfacon-1.,Lorcaserin
DB04948,The metabolism of Lofexidine can be decreased when combined with Interferon alfacon-1.,Lofexidine
DB06148,The metabolism of Mianserin can be decreased when combined with Interferon alfacon-1.,Mianserin
DB06210,The metabolism of Eltrombopag can be decreased when combined with Interferon alfacon-1.,Eltrombopag
DB06216,The metabolism of Asenapine can be decreased when combined with Interferon alfacon-1.,Asenapine
DB06235,The metabolism of Vadimezan can be decreased when combined with Interferon alfacon-1.,Vadimezan
DB06292,The metabolism of Dapagliflozin can be decreased when combined with Interferon alfacon-1.,Dapagliflozin
DB06594,The metabolism of Agomelatine can be decreased when combined with Interferon alfacon-1.,Agomelatine
DB06626,The metabolism of Axitinib can be decreased when combined with Interferon alfacon-1.,Axitinib
DB06770,The metabolism of Benzyl alcohol can be decreased when combined with Interferon alfacon-1.,Benzyl alcohol
DB06774,The metabolism of Capsaicin can be decreased when combined with Interferon alfacon-1.,Capsaicin
DB08496,The metabolism of (R)-warfarin can be decreased when combined with Interferon alfacon-1.,(R)-warfarin
DB08883,The metabolism of Perampanel can be decreased when combined with Interferon alfacon-1.,Perampanel
DB09071,The metabolism of Tasimelteon can be decreased when combined with Interferon alfacon-1.,Tasimelteon
DB09118,The metabolism of Stiripentol can be decreased when combined with Interferon alfacon-1.,Stiripentol
DB09225,The metabolism of Zotepine can be decreased when combined with Interferon alfacon-1.,Zotepine
DB09288,The metabolism of Propacetamol can be decreased when combined with Interferon alfacon-1.,Propacetamol
DB09290,The metabolism of Ramosetron can be decreased when combined with Interferon alfacon-1.,Ramosetron
DB11967,The metabolism of Binimetinib can be decreased when combined with Interferon alfacon-1.,Binimetinib
DB12026,The metabolism of Voxilaprevir can be decreased when combined with Interferon alfacon-1.,Voxilaprevir
DB12245,The metabolism of Triclabendazole can be decreased when combined with Interferon alfacon-1.,Triclabendazole
DB12332,The metabolism of Rucaparib can be decreased when combined with Interferon alfacon-1.,Rucaparib
DB12945,The metabolism of Dihydralazine can be decreased when combined with Interferon alfacon-1.,Dihydralazine
DB13952,The metabolism of Estradiol acetate can be decreased when combined with Interferon alfacon-1.,Estradiol acetate
DB13953,The metabolism of Estradiol benzoate can be decreased when combined with Interferon alfacon-1.,Estradiol benzoate
DB13954,The metabolism of Estradiol cypionate can be decreased when combined with Interferon alfacon-1.,Estradiol cypionate
DB13955,The metabolism of Estradiol dienanthate can be decreased when combined with Interferon alfacon-1.,Estradiol dienanthate
DB13956,The metabolism of Estradiol valerate can be decreased when combined with Interferon alfacon-1.,Estradiol valerate
DB11757,The metabolism of Istradefylline can be decreased when combined with Interferon alfacon-1.,Istradefylline
DB00972,The metabolism of Azelastine can be decreased when combined with Interferon alfacon-1.,Azelastine
DB00625,The metabolism of Efavirenz can be decreased when combined with Interferon alfacon-1.,Efavirenz
DB01233,The metabolism of Metoclopramide can be decreased when combined with Interferon alfacon-1.,Metoclopramide
DB04889,The metabolism of Bicifadine can be decreased when combined with Interferon alfacon-1.,Bicifadine
DB05708,The metabolism of GTS-21 can be decreased when combined with Interferon alfacon-1.,GTS-21
DB01195,The metabolism of Flecainide can be decreased when combined with Interferon alfacon-1.,Flecainide
DB00977,The metabolism of Ethinylestradiol can be decreased when combined with Interferon alfacon-1.,Ethinylestradiol
DB00321,The metabolism of Amitriptyline can be decreased when combined with Interferon alfacon-1.,Amitriptyline
DB00458,The metabolism of Imipramine can be decreased when combined with Interferon alfacon-1.,Imipramine
DB01142,The metabolism of Doxepin can be decreased when combined with Interferon alfacon-1.,Doxepin
DB00532,The metabolism of Mephenytoin can be decreased when combined with Interferon alfacon-1.,Mephenytoin
DB00540,The metabolism of Nortriptyline can be decreased when combined with Interferon alfacon-1.,Nortriptyline
DB00575,The metabolism of Clonidine can be decreased when combined with Interferon alfacon-1.,Clonidine
DB00924,The metabolism of Cyclobenzaprine can be decreased when combined with Interferon alfacon-1.,Cyclobenzaprine
DB01151,The metabolism of Desipramine can be decreased when combined with Interferon alfacon-1.,Desipramine
DB01242,The metabolism of Clomipramine can be decreased when combined with Interferon alfacon-1.,Clomipramine
DB11689,The metabolism of Selumetinib can be decreased when combined with Interferon alfacon-1.,Selumetinib
DB00277,The metabolism of Theophylline can be decreased when combined with Interferon alfacon-1.,Theophylline
DB00682,The metabolism of Warfarin can be decreased when combined with Interferon alfacon-1.,Warfarin
DB00697,The metabolism of Tizanidine can be decreased when combined with Interferon alfacon-1.,Tizanidine
DB01100,The metabolism of Pimozide can be decreased when combined with Interferon alfacon-1.,Pimozide
DB01223,The metabolism of Aminophylline can be decreased when combined with Interferon alfacon-1.,Aminophylline
DB01418,The metabolism of Acenocoumarol can be decreased when combined with Interferon alfacon-1.,Acenocoumarol
DB00530,The metabolism of Erlotinib can be decreased when combined with Interferon alfacon-1.,Erlotinib
DB09256,The metabolism of Tegafur can be decreased when combined with Interferon alfacon-1.,Tegafur
DB13874,The metabolism of Enasidenib can be decreased when combined with Interferon alfacon-1.,Enasidenib
DB00675,The metabolism of Tamoxifen can be decreased when combined with Interferon alfacon-1.,Tamoxifen
DB00001,The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon alfacon-1.,Lepirudin
DB00006,The risk or severity of bleeding can be increased when Bivalirudin is combined with Interferon alfacon-1.,Bivalirudin
DB00009,The risk or severity of bleeding can be increased when Alteplase is combined with Interferon alfacon-1.,Alteplase
DB00013,The risk or severity of bleeding can be increased when Urokinase is combined with Interferon alfacon-1.,Urokinase
DB00015,The risk or severity of bleeding can be increased when Reteplase is combined with Interferon alfacon-1.,Reteplase
DB00029,The risk or severity of bleeding can be increased when Anistreplase is combined with Interferon alfacon-1.,Anistreplase
DB00031,The risk or severity of bleeding can be increased when Tenecteplase is combined with Interferon alfacon-1.,Tenecteplase
DB00055,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Interferon alfacon-1.,Drotrecogin alfa
DB00086,The risk or severity of bleeding can be increased when Streptokinase is combined with Interferon alfacon-1.,Streptokinase
DB00266,The risk or severity of bleeding can be increased when Dicoumarol is combined with Interferon alfacon-1.,Dicoumarol
DB00278,The risk or severity of bleeding can be increased when Argatroban is combined with Interferon alfacon-1.,Argatroban
DB00407,The risk or severity of bleeding can be increased when Ardeparin is combined with Interferon alfacon-1.,Ardeparin
DB00498,The risk or severity of bleeding can be increased when Phenindione is combined with Interferon alfacon-1.,Phenindione
DB00569,The risk or severity of bleeding can be increased when Fondaparinux is combined with Interferon alfacon-1.,Fondaparinux
DB00686,The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Interferon alfacon-1.,Pentosan polysulfate
DB00946,The risk or severity of bleeding can be increased when Phenprocoumon is combined with Interferon alfacon-1.,Phenprocoumon
DB01109,The risk or severity of bleeding can be increased when Heparin is combined with Interferon alfacon-1.,Heparin
DB01225,The risk or severity of bleeding can be increased when Enoxaparin is combined with Interferon alfacon-1.,Enoxaparin
DB03410,The risk or severity of bleeding can be increased when 4-hydroxycoumarin is combined with Interferon alfacon-1.,4-hydroxycoumarin
DB04665,The risk or severity of bleeding can be increased when Coumarin is combined with Interferon alfacon-1.,Coumarin
DB04898,The risk or severity of bleeding can be increased when Ximelagatran is combined with Interferon alfacon-1.,Ximelagatran
DB04925,The risk or severity of bleeding can be increased when Desmoteplase is combined with Interferon alfacon-1.,Desmoteplase
DB05099,The risk or severity of bleeding can be increased when Ancrod is combined with Interferon alfacon-1.,Ancrod
DB05254,The risk or severity of bleeding can be increased when Fibrinolysin is combined with Interferon alfacon-1.,Fibrinolysin
DB06228,The risk or severity of bleeding can be increased when Rivaroxaban is combined with Interferon alfacon-1.,Rivaroxaban
DB06271,The risk or severity of bleeding can be increased when Sulodexide is combined with Interferon alfacon-1.,Sulodexide
DB06294,The risk or severity of bleeding can be increased when Semuloparin is combined with Interferon alfacon-1.,Semuloparin
DB06406,The risk or severity of bleeding can be increased when Idraparinux is combined with Interferon alfacon-1.,Idraparinux
DB06543,The risk or severity of bleeding can be increased when Astaxanthin is combined with Interferon alfacon-1.,Astaxanthin
DB06605,The risk or severity of bleeding can be increased when Apixaban is combined with Interferon alfacon-1.,Apixaban
DB06635,The risk or severity of bleeding can be increased when Otamixaban is combined with Interferon alfacon-1.,Otamixaban
DB06679,The risk or severity of bleeding can be increased when Amediplase is combined with Interferon alfacon-1.,Amediplase
DB06695,The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Interferon alfacon-1.,Dabigatran etexilate
DB06754,The risk or severity of bleeding can be increased when Danaparoid is combined with Interferon alfacon-1.,Danaparoid
DB06779,The risk or severity of bleeding can be increased when Dalteparin is combined with Interferon alfacon-1.,Dalteparin
DB06822,The risk or severity of bleeding can be increased when Tinzaparin is combined with Interferon alfacon-1.,Tinzaparin
DB07767,The risk or severity of bleeding can be increased when Ferulic acid is combined with Interferon alfacon-1.,Ferulic acid
DB08794,The risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Interferon alfacon-1.,Ethyl biscoumacetate
DB08813,The risk or severity of bleeding can be increased when Nadroparin is combined with Interferon alfacon-1.,Nadroparin
DB08994,The risk or severity of bleeding can be increased when Ditazole is combined with Interferon alfacon-1.,Ditazole
DB09075,The risk or severity of bleeding can be increased when Edoxaban is combined with Interferon alfacon-1.,Edoxaban
DB09125,The risk or severity of bleeding can be increased when Potassium citrate is combined with Interferon alfacon-1.,Potassium citrate
DB09154,The risk or severity of bleeding can be increased when Sodium citrate is combined with Interferon alfacon-1.,Sodium citrate
DB09255,The risk or severity of bleeding can be increased when Dextran is combined with Interferon alfacon-1.,Dextran
DB09258,The risk or severity of bleeding can be increased when Bemiparin is combined with Interferon alfacon-1.,Bemiparin
DB09259,The risk or severity of bleeding can be increased when Reviparin is combined with Interferon alfacon-1.,Reviparin
DB09260,The risk or severity of bleeding can be increased when Parnaparin is combined with Interferon alfacon-1.,Parnaparin
DB09261,The risk or severity of bleeding can be increased when Certoparin is combined with Interferon alfacon-1.,Certoparin
DB11095,The risk or severity of bleeding can be increased when Desirudin is combined with Interferon alfacon-1.,Desirudin
DB11154,The risk or severity of bleeding can be increased when Zinc citrate is combined with Interferon alfacon-1.,Zinc citrate
DB11166,The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Interferon alfacon-1.,Antithrombin Alfa
DB11312,The risk or severity of bleeding can be increased when Protein C is combined with Interferon alfacon-1.,Protein C
DB11598,The risk or severity of bleeding can be increased when Antithrombin III human is combined with Interferon alfacon-1.,Antithrombin III human
DB11984,The risk or severity of bleeding can be increased when Letaxaban is combined with Interferon alfacon-1.,Letaxaban
DB12289,The risk or severity of bleeding can be increased when Darexaban is combined with Interferon alfacon-1.,Darexaban
DB12364,The risk or severity of bleeding can be increased when Betrixaban is combined with Interferon alfacon-1.,Betrixaban
DB12598,The risk or severity of bleeding can be increased when Nafamostat is combined with Interferon alfacon-1.,Nafamostat
DB12726,The risk or severity of bleeding can be increased when Monteplase is combined with Interferon alfacon-1.,Monteplase
DB12831,The risk or severity of bleeding can be increased when Gabexate is combined with Interferon alfacon-1.,Gabexate
DB13136,The risk or severity of bleeding can be increased when Fluindione is combined with Interferon alfacon-1.,Fluindione
DB13149,The risk or severity of bleeding can be increased when Protein S human is combined with Interferon alfacon-1.,Protein S human
DB13199,The risk or severity of bleeding can be increased when Brinase is combined with Interferon alfacon-1.,Brinase
DB13275,The risk or severity of bleeding can be increased when Clorindione is combined with Interferon alfacon-1.,Clorindione
DB13347,The risk or severity of bleeding can be increased when Diphenadione is combined with Interferon alfacon-1.,Diphenadione
DB13451,The risk or severity of bleeding can be increased when Tioclomarol is combined with Interferon alfacon-1.,Tioclomarol
DB13616,The risk or severity of bleeding can be increased when Melagatran is combined with Interferon alfacon-1.,Melagatran
DB13646,The risk or severity of bleeding can be increased when Saruplase is combined with Interferon alfacon-1.,Saruplase
DB14055,The risk or severity of bleeding can be increased when (S)-Warfarin is combined with Interferon alfacon-1.,(S)-Warfarin
DB14094,The risk or severity of bleeding can be increased when Tocopherylquinone is combined with Interferon alfacon-1.,Tocopherylquinone
DB14598,The risk or severity of bleeding can be increased when Edetate calcium disodium anhydrous is combined with Interferon alfacon-1.,Edetate calcium disodium anhydrous
DB14726,The risk or severity of bleeding can be increased when Dabigatran is combined with Interferon alfacon-1.,Dabigatran
DB00232,The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Interferon alfacon-1.,Methyclothiazide
DB00436,The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Interferon alfacon-1.,Bendroflumethiazide
DB00562,The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Interferon alfacon-1.,Benzthiazide
DB00606,The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Interferon alfacon-1.,Cyclothiazide
DB00774,The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Interferon alfacon-1.,Hydroflumethiazide
DB00880,The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Interferon alfacon-1.,Chlorothiazide
DB00999,The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Interferon alfacon-1.,Hydrochlorothiazide
DB01021,The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Interferon alfacon-1.,Trichlormethiazide
DB01324,The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Interferon alfacon-1.,Polythiazide
DB13430,The risk or severity of neutropenia and thrombocytopenia can be increased when Mebutizide is combined with Interferon alfacon-1.,Mebutizide
DB13532,The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Interferon alfacon-1.,Cyclopenthiazide
DB09042,The risk or severity of myelosuppression can be increased when Interferon alfacon-1 is combined with Tedizolid phosphate.,Tedizolid phosphate
DB00091,Interferon alfacon-1 may increase the immunosuppressive activities of Cyclosporine.,Cyclosporine
DB00268,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ropinirole.,Ropinirole
DB00115,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Interferon alfacon-1.,Cyanocobalamin
DB00437,The risk or severity of adverse effects can be increased when Allopurinol is combined with Interferon alfacon-1.,Allopurinol
DB14513,The serum concentration of Magnesium can be decreased when it is combined with Interferon alfacon-1.,Magnesium
DB01601,The serum concentration of Interferon alfacon-1 can be increased when it is combined with Lopinavir.,Lopinavir
DB12530,The risk or severity of infection can be increased when Interferon alfacon-1 is combined with Inebilizumab.,Inebilizumab
DB00988,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Dopamine.,Dopamine
DB00443,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Betamethasone.,Betamethasone
DB00591,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Fluocinolone acetonide.,Fluocinolone acetonide
DB00620,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Triamcinolone.,Triamcinolone
DB00741,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Hydrocortisone.,Hydrocortisone
DB00959,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Methylprednisolone.,Methylprednisolone
DB01108,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Trilostane.,Trilostane
DB01234,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Dexamethasone.,Dexamethasone
DB01285,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Corticotropin.,Corticotropin
DB01380,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Cortisone acetate.,Cortisone acetate
DB01384,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Paramethasone.,Paramethasone
DB04630,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Aldosterone.,Aldosterone
DB08970,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Fluprednidene.,Fluprednidene
DB08971,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Fluocortolone.,Fluocortolone
DB09378,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Fluprednisolone.,Fluprednisolone
DB09383,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Meprednisone.,Meprednisone
DB11487,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Dexamethasone isonicotinate.,Dexamethasone isonicotinate
DB11529,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Melengestrol.,Melengestrol
DB11750,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Clobetasol.,Clobetasol
DB13003,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Cortivazol.,Cortivazol
DB13208,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Prednylidene.,Prednylidene
DB13223,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Fluocortin.,Fluocortin
DB13491,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Fluperolone.,Fluperolone
DB13664,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Formocortal.,Formocortal
DB13728,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Halometasone.,Halometasone
DB13843,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Cloprednol.,Cloprednol
DB13856,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Fluclorolone.,Fluclorolone
DB13867,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Fluticasone.,Fluticasone
DB14538,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Hydrocortisone aceponate.,Hydrocortisone aceponate
DB14545,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Hydrocortisone succinate.,Hydrocortisone succinate
DB00873,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Loteprednol.,Loteprednol
DB14633,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Prednisolone hemisuccinate.,Prednisolone hemisuccinate
DB14634,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Fluprednidene acetate.,Fluprednidene acetate
DB14643,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Methylprednisolone aceponate.,Methylprednisolone aceponate
DB14644,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Methylprednisolone hemisuccinate.,Methylprednisolone hemisuccinate
DB14646,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Prednisone acetate.,Prednisone acetate
DB14652,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Clocortolone acetate.,Clocortolone acetate
DB14659,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Melengestrol acetate.,Melengestrol acetate
DB14669,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Betamethasone phosphate.,Betamethasone phosphate
DB14681,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Cortisone.,Cortisone
DB00764,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Mometasone.,Mometasone
DB00936,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Salicylic acid.,Salicylic acid
DB06251,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Dersalazine.,Dersalazine
DB06807,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Phenyl aminosalicylate.,Phenyl aminosalicylate
DB12445,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Nitroaspirin.,Nitroaspirin
DB13509,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Aloxiprin.,Aloxiprin
DB13538,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Guacetisal.,Guacetisal
DB13612,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Carbaspirin calcium.,Carbaspirin calcium
DB14026,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Thiosalicylic acid.,Thiosalicylic acid
DB00281,Hyaluronidase (ovine) can cause an increase in the absorption of Lidocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.,Lidocaine
DB00297,Hyaluronidase (ovine) can cause an increase in the absorption of Bupivacaine resulting in an increased serum concentration and potentially a worsening of adverse effects.,Bupivacaine
DB00527,Hyaluronidase (ovine) can cause an increase in the absorption of Cinchocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.,Cinchocaine
DB00645,Hyaluronidase (ovine) can cause an increase in the absorption of Dyclonine resulting in an increased serum concentration and potentially a worsening of adverse effects.,Dyclonine
DB00750,Hyaluronidase (ovine) can cause an increase in the absorption of Prilocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.,Prilocaine
DB00807,Hyaluronidase (ovine) can cause an increase in the absorption of Proparacaine resulting in an increased serum concentration and potentially a worsening of adverse effects.,Proparacaine
DB00892,Hyaluronidase (ovine) can cause an increase in the absorption of Oxybuprocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.,Oxybuprocaine
DB00961,Hyaluronidase (ovine) can cause an increase in the absorption of Mepivacaine resulting in an increased serum concentration and potentially a worsening of adverse effects.,Mepivacaine
DB01002,Hyaluronidase (ovine) can cause an increase in the absorption of Levobupivacaine resulting in an increased serum concentration and potentially a worsening of adverse effects.,Levobupivacaine
DB01086,Hyaluronidase (ovine) can cause an increase in the absorption of Benzocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.,Benzocaine
DB05232,Hyaluronidase (ovine) can cause an increase in the absorption of Tetrodotoxin resulting in an increased serum concentration and potentially a worsening of adverse effects.,Tetrodotoxin
DB06770,Hyaluronidase (ovine) can cause an increase in the absorption of Benzyl alcohol resulting in an increased serum concentration and potentially a worsening of adverse effects.,Benzyl alcohol
DB08987,Hyaluronidase (ovine) can cause an increase in the absorption of Etidocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.,Etidocaine
DB09009,Hyaluronidase (ovine) can cause an increase in the absorption of Articaine resulting in an increased serum concentration and potentially a worsening of adverse effects.,Articaine
DB09085,Hyaluronidase (ovine) can cause an increase in the absorption of Tetracaine resulting in an increased serum concentration and potentially a worsening of adverse effects.,Tetracaine
DB09342,Hyaluronidase (ovine) can cause an increase in the absorption of Propoxycaine resulting in an increased serum concentration and potentially a worsening of adverse effects.,Propoxycaine
DB11148,Hyaluronidase (ovine) can cause an increase in the absorption of Butamben resulting in an increased serum concentration and potentially a worsening of adverse effects.,Butamben
DB11502,Hyaluronidase (ovine) can cause an increase in the absorption of Butacaine resulting in an increased serum concentration and potentially a worsening of adverse effects.,Butacaine
DB13328,Hyaluronidase (ovine) can cause an increase in the absorption of Butanilicaine resulting in an increased serum concentration and potentially a worsening of adverse effects.,Butanilicaine
DB13578,Hyaluronidase (ovine) can cause an increase in the absorption of Metabutethamine resulting in an increased serum concentration and potentially a worsening of adverse effects.,Metabutethamine
DB13683,Hyaluronidase (ovine) can cause an increase in the absorption of Quinisocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.,Quinisocaine
DB00245,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Benzatropine.,Benzatropine
DB00246,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Ziprasidone.,Ziprasidone
DB00341,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Cetirizine.,Cetirizine
DB00354,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Buclizine.,Buclizine
DB00420,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Promazine.,Promazine
DB00458,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Imipramine.,Imipramine
DB00477,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Chlorpromazine.,Chlorpromazine
DB00501,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Cimetidine.,Cimetidine
DB00557,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Hydroxyzine.,Hydroxyzine
DB00568,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Cinnarizine.,Cinnarizine
DB00734,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Risperidone.,Risperidone
DB00767,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Benzquinamide.,Benzquinamide
DB00777,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Propiomazine.,Propiomazine
DB00835,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Brompheniramine.,Brompheniramine
DB00863,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Ranitidine.,Ranitidine
DB00902,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Methdilazine.,Methdilazine
DB00927,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Famotidine.,Famotidine
DB00940,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Methantheline.,Methantheline
DB00972,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Azelastine.,Azelastine
DB00985,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Dimenhydrinate.,Dimenhydrinate
DB01069,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Promethazine.,Promethazine
DB01071,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Mequitazine.,Mequitazine
DB01075,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Diphenhydramine.,Diphenhydramine
DB01114,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Chlorpheniramine.,Chlorpheniramine
DB01173,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Orphenadrine.,Orphenadrine
DB01176,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Cyclizine.,Cyclizine
DB01238,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Aripiprazole.,Aripiprazole
DB01239,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Chlorprothixene.,Chlorprothixene
DB01403,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Methotrimeprazine.,Methotrimeprazine
DB01615,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Aceprometazine.,Aceprometazine
DB01619,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Phenindamine.,Phenindamine
DB01624,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Zuclopenthixol.,Zuclopenthixol
DB03255,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Phenol.,Phenol
DB04819,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Methapyrilene.,Methapyrilene
DB06148,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Mianserin.,Mianserin
DB06678,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Esmirtazapine.,Esmirtazapine
DB08800,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Chloropyramine.,Chloropyramine
DB08801,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Dimetindene.,Dimetindene
DB08802,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Isothipendyl.,Isothipendyl
DB08805,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Metiamide.,Metiamide
DB08806,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Roxatidine acetate.,Roxatidine acetate
DB08967,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Dimetotiazine.,Dimetotiazine
DB09007,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Chlorphenoxamine.,Chlorphenoxamine
DB09016,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Butriptyline.,Butriptyline
DB09167,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Dosulepin.,Dosulepin
DB11742,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Ebastine.,Ebastine
DB12523,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Mizolastine.,Mizolastine
DB12770,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Lafutidine.,Lafutidine
DB12806,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with GSK-1004723.,GSK-1004723
DB12877,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Oxatomide.,Oxatomide
DB12884,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Lavoltidine.,Lavoltidine
DB13466,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Deptropine.,Deptropine
DB13489,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Bamipine.,Bamipine
DB13711,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Tritoqualine.,Tritoqualine
DB13713,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Quifenadine.,Quifenadine
DB13760,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Niperotidine.,Niperotidine
DB14185,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Aripiprazole lauroxil.,Aripiprazole lauroxil
DB15120,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with GSK-239512.,GSK-239512
DB15192,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with ABT-288.,ABT-288
DB00334,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Olanzapine.,Olanzapine
DB00217,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Bethanidine.,Bethanidine
DB00292,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Etomidate.,Etomidate
DB00368,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Norepinephrine.,Norepinephrine
DB00388,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Phenylephrine.,Phenylephrine
DB00575,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Clonidine.,Clonidine
DB00610,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Metaraminol.,Metaraminol
DB00633,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Dexmedetomidine.,Dexmedetomidine
DB00668,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Epinephrine.,Epinephrine
DB00723,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Methoxamine.,Methoxamine
DB00841,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Dobutamine.,Dobutamine
DB00968,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Methyldopa.,Methyldopa
DB01253,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Ergometrine.,Ergometrine
DB01364,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Ephedrine.,Ephedrine
DB01365,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Mephentermine.,Mephentermine
DB01472,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with 4-Methoxyamphetamine.,4-Methoxyamphetamine
DB01537,"The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with 4-Bromo-2,5-dimethoxyphenethylamine.","4-Bromo-2,5-dimethoxyphenethylamine"
DB06764,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Tetryzoline.,Tetryzoline
DB08925,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Adrafinil.,Adrafinil
DB08985,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Etilefrine.,Etilefrine
DB09202,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Cirazoline.,Cirazoline
DB09203,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Synephrine.,Synephrine
DB09242,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Moxonidine.,Moxonidine
DB11373,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Amitraz.,Amitraz
DB11428,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Medetomidine.,Medetomidine
DB11477,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Xylazine.,Xylazine
DB11543,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Romifidine.,Romifidine
DB11556,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Detomidine.,Detomidine
DB11738,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Rilmenidine.,Rilmenidine
DB13251,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Octopamine.,Octopamine
DB13378,The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Norfenefrine.,Norfenefrine
DB00255,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Diethylstilbestrol.,Diethylstilbestrol
DB00269,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Chlorotrianisene.,Chlorotrianisene
DB00286,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Conjugated estrogens.,Conjugated estrogens
DB00783,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Estradiol.,Estradiol
DB00977,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Ethinylestradiol.,Ethinylestradiol
DB01357,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Mestranol.,Mestranol
DB04573,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Estriol.,Estriol
DB04574,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Estrone sulfate.,Estrone sulfate
DB04575,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Quinestrol.,Quinestrol
DB07931,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Hexestrol.,Hexestrol
DB09070,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Tibolone.,Tibolone
DB09317,"The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Synthetic Conjugated Estrogens, A.","Synthetic Conjugated Estrogens, A"
DB09318,"The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Synthetic Conjugated Estrogens, B.","Synthetic Conjugated Estrogens, B"
DB09369,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Polyestradiol phosphate.,Polyestradiol phosphate
DB09381,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Esterified estrogens.,Esterified estrogens
DB11478,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Zeranol.,Zeranol
DB11674,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Equol.,Equol
DB12487,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Promestriene.,Promestriene
DB13143,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Methallenestril.,Methallenestril
DB13386,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Epimestrol.,Epimestrol
DB13418,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Moxestrol.,Moxestrol
DB13952,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Estradiol acetate.,Estradiol acetate
DB13953,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Estradiol benzoate.,Estradiol benzoate
DB13954,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Estradiol cypionate.,Estradiol cypionate
DB13956,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Estradiol valerate.,Estradiol valerate
DB15334,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Biochanin A.,Biochanin A
DB15335,The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Formononetin.,Formononetin
DB00186,The therapeutic efficacy of Lorazepam can be decreased when used in combination with Hyaluronidase (ovine).,Lorazepam
DB00546,The therapeutic efficacy of Adinazolam can be decreased when used in combination with Hyaluronidase (ovine).,Adinazolam
DB00683,The therapeutic efficacy of Midazolam can be decreased when used in combination with Hyaluronidase (ovine).,Midazolam
DB00801,The therapeutic efficacy of Halazepam can be decreased when used in combination with Hyaluronidase (ovine).,Halazepam
DB00829,The therapeutic efficacy of Diazepam can be decreased when used in combination with Hyaluronidase (ovine).,Diazepam
DB01489,The therapeutic efficacy of Camazepam can be decreased when used in combination with Hyaluronidase (ovine).,Camazepam
DB01511,The therapeutic efficacy of Delorazepam can be decreased when used in combination with Hyaluronidase (ovine).,Delorazepam
DB01544,The therapeutic efficacy of Flunitrazepam can be decreased when used in combination with Hyaluronidase (ovine).,Flunitrazepam
DB01545,The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with Hyaluronidase (ovine).,Ethyl loflazepate
DB01553,The therapeutic efficacy of Cloxazolam can be decreased when used in combination with Hyaluronidase (ovine).,Cloxazolam
DB01559,The therapeutic efficacy of Clotiazepam can be decreased when used in combination with Hyaluronidase (ovine).,Clotiazepam
DB01567,The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Hyaluronidase (ovine).,Fludiazepam
DB01588,The therapeutic efficacy of Prazepam can be decreased when used in combination with Hyaluronidase (ovine).,Prazepam
DB01594,The therapeutic efficacy of Cinolazepam can be decreased when used in combination with Hyaluronidase (ovine).,Cinolazepam
DB09017,The therapeutic efficacy of Brotizolam can be decreased when used in combination with Hyaluronidase (ovine).,Brotizolam
DB09166,The therapeutic efficacy of Etizolam can be decreased when used in combination with Hyaluronidase (ovine).,Etizolam
DB12537,The therapeutic efficacy of Benzodiazepine can be decreased when used in combination with Hyaluronidase (ovine).,Benzodiazepine
DB13335,The therapeutic efficacy of Pinazepam can be decreased when used in combination with Hyaluronidase (ovine).,Pinazepam
DB13437,The therapeutic efficacy of Medazepam can be decreased when used in combination with Hyaluronidase (ovine).,Medazepam
DB13643,The therapeutic efficacy of Loprazolam can be decreased when used in combination with Hyaluronidase (ovine).,Loprazolam
DB13837,The therapeutic efficacy of Doxefazepam can be decreased when used in combination with Hyaluronidase (ovine).,Doxefazepam
DB13872,The therapeutic efficacy of Lormetazepam can be decreased when used in combination with Hyaluronidase (ovine).,Lormetazepam
DB14028,The therapeutic efficacy of Nordazepam can be decreased when used in combination with Hyaluronidase (ovine).,Nordazepam
DB14672,The therapeutic efficacy of Oxazepam acetate can be decreased when used in combination with Hyaluronidase (ovine).,Oxazepam acetate
DB14715,The therapeutic efficacy of Cinazepam can be decreased when used in combination with Hyaluronidase (ovine).,Cinazepam
DB14719,The therapeutic efficacy of Bentazepam can be decreased when used in combination with Hyaluronidase (ovine).,Bentazepam
DB00695,The therapeutic efficacy of Furosemide can be decreased when used in combination with Hyaluronidase (ovine).,Furosemide
DB00252,The therapeutic efficacy of Phenytoin can be decreased when used in combination with Hyaluronidase (ovine).,Phenytoin
DB01320,The therapeutic efficacy of Fosphenytoin can be decreased when used in combination with Hyaluronidase (ovine).,Fosphenytoin
DB06655,Liraglutide may increase the hypoglycemic activities of Insulin pork.,Liraglutide
DB09046,Metreleptin may increase the hypoglycemic activities of Insulin pork.,Metreleptin
DB00082,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin pork.,Pegvisomant
DB01132,The risk or severity of adverse effects can be increased when Pioglitazone is combined with Insulin pork.,Pioglitazone
DB01278,Pramlintide may increase the hypoglycemic activities of Insulin pork.,Pramlintide
DB00412,The risk or severity of congestive heart failure can be increased when Insulin pork is combined with Rosiglitazone.,Rosiglitazone
DB00166,The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Insulin pork.,Lipoic acid
DB00974,Edetic acid may increase the hypoglycemic activities of Insulin pork.,Edetic acid
DB00187,Esmolol may increase the hypoglycemic activities of Insulin pork.,Esmolol
DB00218,The therapeutic efficacy of Insulin pork can be increased when used in combination with Moxifloxacin.,Moxifloxacin
DB00365,The therapeutic efficacy of Insulin pork can be increased when used in combination with Grepafloxacin.,Grepafloxacin
DB00467,The therapeutic efficacy of Insulin pork can be increased when used in combination with Enoxacin.,Enoxacin
DB00487,The therapeutic efficacy of Insulin pork can be increased when used in combination with Pefloxacin.,Pefloxacin
DB00537,The therapeutic efficacy of Insulin pork can be increased when used in combination with Ciprofloxacin.,Ciprofloxacin
DB00685,The therapeutic efficacy of Insulin pork can be increased when used in combination with Trovafloxacin.,Trovafloxacin
DB00779,The therapeutic efficacy of Insulin pork can be increased when used in combination with Nalidixic acid.,Nalidixic acid
DB00817,The therapeutic efficacy of Insulin pork can be increased when used in combination with Rosoxacin.,Rosoxacin
DB00827,The therapeutic efficacy of Insulin pork can be increased when used in combination with Cinoxacin.,Cinoxacin
DB00978,The therapeutic efficacy of Insulin pork can be increased when used in combination with Lomefloxacin.,Lomefloxacin
DB01044,The therapeutic efficacy of Insulin pork can be increased when used in combination with Gatifloxacin.,Gatifloxacin
DB01059,The therapeutic efficacy of Insulin pork can be increased when used in combination with Norfloxacin.,Norfloxacin
DB01137,The therapeutic efficacy of Insulin pork can be increased when used in combination with Levofloxacin.,Levofloxacin
DB01155,The therapeutic efficacy of Insulin pork can be increased when used in combination with Gemifloxacin.,Gemifloxacin
DB01165,The therapeutic efficacy of Insulin pork can be increased when used in combination with Ofloxacin.,Ofloxacin
DB01208,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sparfloxacin.,Sparfloxacin
DB01405,The therapeutic efficacy of Insulin pork can be increased when used in combination with Temafloxacin.,Temafloxacin
DB04576,The therapeutic efficacy of Insulin pork can be increased when used in combination with Fleroxacin.,Fleroxacin
DB05488,The therapeutic efficacy of Insulin pork can be increased when used in combination with Technetium Tc-99m ciprofloxacin.,Technetium Tc-99m ciprofloxacin
DB06160,The therapeutic efficacy of Insulin pork can be increased when used in combination with Garenoxacin.,Garenoxacin
DB06600,The therapeutic efficacy of Insulin pork can be increased when used in combination with Nemonoxacin.,Nemonoxacin
DB08972,The therapeutic efficacy of Insulin pork can be increased when used in combination with Flumequine.,Flumequine
DB11404,The therapeutic efficacy of Insulin pork can be increased when used in combination with Enrofloxacin.,Enrofloxacin
DB11443,The therapeutic efficacy of Insulin pork can be increased when used in combination with Orbifloxacin.,Orbifloxacin
DB11491,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sarafloxacin.,Sarafloxacin
DB11511,The therapeutic efficacy of Insulin pork can be increased when used in combination with Difloxacin.,Difloxacin
DB11774,The therapeutic efficacy of Insulin pork can be increased when used in combination with Pazufloxacin.,Pazufloxacin
DB11892,The therapeutic efficacy of Insulin pork can be increased when used in combination with Prulifloxacin.,Prulifloxacin
DB11943,The therapeutic efficacy of Insulin pork can be increased when used in combination with Delafloxacin.,Delafloxacin
DB13261,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sitafloxacin.,Sitafloxacin
DB13627,The therapeutic efficacy of Insulin pork can be increased when used in combination with Oxolinic acid.,Oxolinic acid
DB13772,The therapeutic efficacy of Insulin pork can be increased when used in combination with Rufloxacin.,Rufloxacin
DB13823,The therapeutic efficacy of Insulin pork can be increased when used in combination with Pipemidic acid.,Pipemidic acid
DB00232,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Methyclothiazide.,Methyclothiazide
DB00310,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Chlorthalidone.,Chlorthalidone
DB00436,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Bendroflumethiazide.,Bendroflumethiazide
DB00524,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Metolazone.,Metolazone
DB00562,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Benzthiazide.,Benzthiazide
DB00774,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Hydroflumethiazide.,Hydroflumethiazide
DB00808,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Indapamide.,Indapamide
DB00880,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Chlorothiazide.,Chlorothiazide
DB00999,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Hydrochlorothiazide.,Hydrochlorothiazide
DB01021,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Trichlormethiazide.,Trichlormethiazide
DB01324,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Polythiazide.,Polythiazide
DB01325,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Quinethazone.,Quinethazone
DB13532,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Cyclopenthiazide.,Cyclopenthiazide
DB13989,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Epitizide.,Epitizide
DB00344,Protriptyline may decrease the hypoglycemic activities of Insulin pork.,Protriptyline
DB00543,Amoxapine may decrease the hypoglycemic activities of Insulin pork.,Amoxapine
DB00726,Trimipramine may decrease the hypoglycemic activities of Insulin pork.,Trimipramine
DB04836,Amineptine may decrease the hypoglycemic activities of Insulin pork.,Amineptine
DB08996,Dimetacrine may decrease the hypoglycemic activities of Insulin pork.,Dimetacrine
DB09016,Butriptyline may decrease the hypoglycemic activities of Insulin pork.,Butriptyline
DB09167,Dosulepin may decrease the hypoglycemic activities of Insulin pork.,Dosulepin
DB09289,Tianeptine may decrease the hypoglycemic activities of Insulin pork.,Tianeptine
DB09307,Oxaprotiline may decrease the hypoglycemic activities of Insulin pork.,Oxaprotiline
DB12930,Opipramol may decrease the hypoglycemic activities of Insulin pork.,Opipramol
DB13114,Amitriptylinoxide may decrease the hypoglycemic activities of Insulin pork.,Amitriptylinoxide
DB13225,Dibenzepin may decrease the hypoglycemic activities of Insulin pork.,Dibenzepin
DB13246,Quinupramine may decrease the hypoglycemic activities of Insulin pork.,Quinupramine
DB13384,Melitracen may decrease the hypoglycemic activities of Insulin pork.,Melitracen
DB13411,Lofepramine may decrease the hypoglycemic activities of Insulin pork.,Lofepramine
DB13496,Iprindole may decrease the hypoglycemic activities of Insulin pork.,Iprindole
DB13782,Imipramine oxide may decrease the hypoglycemic activities of Insulin pork.,Imipramine oxide
DB06292,Dapagliflozin may increase the hypoglycemic activities of Insulin pork.,Dapagliflozin
DB08907,Canagliflozin may increase the hypoglycemic activities of Insulin pork.,Canagliflozin
DB00007,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Leuprolide.,Leuprolide
DB00014,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Goserelin.,Goserelin
DB00104,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Octreotide.,Octreotide
DB00220,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Nelfinavir.,Nelfinavir
DB00224,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Indinavir.,Indinavir
DB00246,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Ziprasidone.,Ziprasidone
DB00294,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Etonogestrel.,Etonogestrel
DB00304,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Desogestrel.,Desogestrel
DB00334,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Olanzapine.,Olanzapine
DB00351,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Megestrol acetate.,Megestrol acetate
DB00363,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Clozapine.,Clozapine
DB00367,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Levonorgestrel.,Levonorgestrel
DB00396,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Progesterone.,Progesterone
DB00477,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Chlorpromazine.,Chlorpromazine
DB00502,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Haloperidol.,Haloperidol
DB00503,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Ritonavir.,Ritonavir
DB00592,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Piperazine.,Piperazine
DB00603,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Medroxyprogesterone acetate.,Medroxyprogesterone acetate
DB00627,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Niacin.,Niacin
DB00668,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Epinephrine.,Epinephrine
DB00717,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Norethisterone.,Norethisterone
DB00734,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Risperidone.,Risperidone
DB00738,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Pentamidine.,Pentamidine
DB00823,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Ethynodiol diacetate.,Ethynodiol diacetate
DB00852,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Pseudoephedrine.,Pseudoephedrine
DB00864,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Tacrolimus.,Tacrolimus
DB00877,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Sirolimus.,Sirolimus
DB00903,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Etacrynic acid.,Etacrynic acid
DB00932,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Tipranavir.,Tipranavir
DB00957,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Norgestimate.,Norgestimate
DB00977,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Ethinylestradiol.,Ethinylestradiol
DB01072,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Atazanavir.,Atazanavir
DB01169,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Arsenic trioxide.,Arsenic trioxide
DB01224,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Quetiapine.,Quetiapine
DB01232,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Saquinavir.,Saquinavir
DB01238,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Aripiprazole.,Aripiprazole
DB01267,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Paliperidone.,Paliperidone
DB01319,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Fosamprenavir.,Fosamprenavir
DB01323,The therapeutic efficacy of Insulin pork can be decreased when used in combination with St. John's Wort.,St. John's Wort
DB01357,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Mestranol.,Mestranol
DB01363,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Ephedra sinica root.,Ephedra sinica root
DB01395,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Drospirenone.,Drospirenone
DB01403,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Methotrimeprazine.,Methotrimeprazine
DB01406,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Danazol.,Danazol
DB01590,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Everolimus.,Everolimus
DB01601,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Lopinavir.,Lopinavir
DB01621,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Pipotiazine.,Pipotiazine
DB02546,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Vorinostat.,Vorinostat
DB04574,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Estrone sulfate.,Estrone sulfate
DB04839,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Cyproterone acetate.,Cyproterone acetate
DB04868,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Nilotinib.,Nilotinib
DB04946,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Iloperidone.,Iloperidone
DB06216,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Asenapine.,Asenapine
DB06287,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Temsirolimus.,Temsirolimus
DB06663,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Pasireotide.,Pasireotide
DB06719,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Buserelin.,Buserelin
DB06788,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Histrelin.,Histrelin
DB06789,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Hydroxyprogesterone caproate.,Hydroxyprogesterone caproate
DB06791,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Lanreotide.,Lanreotide
DB06825,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Triptorelin.,Triptorelin
DB08815,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Lurasidone.,Lurasidone
DB08912,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Dabrafenib.,Dabrafenib
DB09009,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Articaine.,Articaine
DB09063,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Ceritinib.,Ceritinib
DB09123,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Dienogest.,Dienogest
DB09128,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Brexpiprazole.,Brexpiprazole
DB06343,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Teprotumumab.,Teprotumumab
DB00621,Oxandrolone may increase the hypoglycemic activities of Insulin pork.,Oxandrolone
DB00624,Testosterone may increase the hypoglycemic activities of Insulin pork.,Testosterone
DB00984,Nandrolone phenpropionate may increase the hypoglycemic activities of Insulin pork.,Nandrolone phenpropionate
DB01185,Fluoxymesterone may increase the hypoglycemic activities of Insulin pork.,Fluoxymesterone
DB01420,Testosterone propionate may increase the hypoglycemic activities of Insulin pork.,Testosterone propionate
DB02901,Stanolone may increase the hypoglycemic activities of Insulin pork.,Stanolone
DB06412,Oxymetholone may increase the hypoglycemic activities of Insulin pork.,Oxymetholone
DB06710,Methyltestosterone may increase the hypoglycemic activities of Insulin pork.,Methyltestosterone
DB06718,Stanozolol may increase the hypoglycemic activities of Insulin pork.,Stanozolol
DB08804,Nandrolone decanoate may increase the hypoglycemic activities of Insulin pork.,Nandrolone decanoate
DB12461,GLPG-0492 may increase the hypoglycemic activities of Insulin pork.,GLPG-0492
DB13169,Nandrolone may increase the hypoglycemic activities of Insulin pork.,Nandrolone
DB13587,Mesterolone may increase the hypoglycemic activities of Insulin pork.,Mesterolone
DB13943,Testosterone cypionate may increase the hypoglycemic activities of Insulin pork.,Testosterone cypionate
DB13944,Testosterone enanthate may increase the hypoglycemic activities of Insulin pork.,Testosterone enanthate
DB00215,The risk or severity of hypoglycemia can be increased when Citalopram is combined with Insulin pork.,Citalopram
DB00230,The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Insulin pork.,Pregabalin
DB00285,The risk or severity of hypoglycemia can be increased when Venlafaxine is combined with Insulin pork.,Venlafaxine
DB00328,The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Insulin pork.,Indomethacin
DB01104,The risk or severity of hypoglycemia can be increased when Sertraline is combined with Insulin pork.,Sertraline
DB01149,The risk or severity of hypoglycemia can be increased when Nefazodone is combined with Insulin pork.,Nefazodone
DB01175,The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Insulin pork.,Escitalopram
DB04832,The risk or severity of hypoglycemia can be increased when Zimelidine is combined with Insulin pork.,Zimelidine
DB04884,The risk or severity of hypoglycemia can be increased when Dapoxetine is combined with Insulin pork.,Dapoxetine
DB04896,The risk or severity of hypoglycemia can be increased when Milnacipran is combined with Insulin pork.,Milnacipran
DB06700,The risk or severity of hypoglycemia can be increased when Desvenlafaxine is combined with Insulin pork.,Desvenlafaxine
DB08918,The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Insulin pork.,Levomilnacipran
DB08953,The risk or severity of hypoglycemia can be increased when Indalpine is combined with Insulin pork.,Indalpine
DB09270,The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Insulin pork.,Ubidecarenone
DB12693,The risk or severity of hypoglycemia can be increased when Ritanserin is combined with Insulin pork.,Ritanserin
DB13233,The risk or severity of hypoglycemia can be increased when Alaproclate is combined with Insulin pork.,Alaproclate
DB13358,The risk or severity of hypoglycemia can be increased when Cibenzoline is combined with Insulin pork.,Cibenzoline
DB14025,The risk or severity of hypoglycemia can be increased when Clinafloxacin is combined with Insulin pork.,Clinafloxacin
DB00233,Aminosalicylic acid may increase the hypoglycemic activities of Insulin pork.,Aminosalicylic acid
DB00244,Mesalazine may increase the hypoglycemic activities of Insulin pork.,Mesalazine
DB00795,Sulfasalazine may increase the hypoglycemic activities of Insulin pork.,Sulfasalazine
DB00861,Diflunisal may increase the hypoglycemic activities of Insulin pork.,Diflunisal
DB00936,Salicylic acid may increase the hypoglycemic activities of Insulin pork.,Salicylic acid
DB01014,Balsalazide may increase the hypoglycemic activities of Insulin pork.,Balsalazide
DB01250,Olsalazine may increase the hypoglycemic activities of Insulin pork.,Olsalazine
DB01294,Bismuth subsalicylate may increase the hypoglycemic activities of Insulin pork.,Bismuth subsalicylate
DB06251,Dersalazine may increase the hypoglycemic activities of Insulin pork.,Dersalazine
DB06807,Phenyl aminosalicylate may increase the hypoglycemic activities of Insulin pork.,Phenyl aminosalicylate
DB09543,Methyl salicylate may increase the hypoglycemic activities of Insulin pork.,Methyl salicylate
DB11079,Trolamine salicylate may increase the hypoglycemic activities of Insulin pork.,Trolamine salicylate
DB12445,Nitroaspirin may increase the hypoglycemic activities of Insulin pork.,Nitroaspirin
DB13509,Aloxiprin may increase the hypoglycemic activities of Insulin pork.,Aloxiprin
DB13538,Guacetisal may increase the hypoglycemic activities of Insulin pork.,Guacetisal
DB13612,Carbaspirin calcium may increase the hypoglycemic activities of Insulin pork.,Carbaspirin calcium
DB14006,Choline salicylate may increase the hypoglycemic activities of Insulin pork.,Choline salicylate
DB14026,Thiosalicylic acid may increase the hypoglycemic activities of Insulin pork.,Thiosalicylic acid
DB01261,Sitagliptin may increase the hypoglycemic activities of Insulin pork.,Sitagliptin
DB04876,Vildagliptin may increase the hypoglycemic activities of Insulin pork.,Vildagliptin
DB06011,AMG-222 may increase the hypoglycemic activities of Insulin pork.,AMG-222
DB06127,Bisegliptin may increase the hypoglycemic activities of Insulin pork.,Bisegliptin
DB06203,Alogliptin may increase the hypoglycemic activities of Insulin pork.,Alogliptin
DB06335,Saxagliptin may increase the hypoglycemic activities of Insulin pork.,Saxagliptin
DB08382,Gosogliptin may increase the hypoglycemic activities of Insulin pork.,Gosogliptin
DB08882,Linagliptin may increase the hypoglycemic activities of Insulin pork.,Linagliptin
DB11723,Dutogliptin may increase the hypoglycemic activities of Insulin pork.,Dutogliptin
DB11950,Teneligliptin may increase the hypoglycemic activities of Insulin pork.,Teneligliptin
DB11992,Omarigliptin may increase the hypoglycemic activities of Insulin pork.,Omarigliptin
DB12268,Carmegliptin may increase the hypoglycemic activities of Insulin pork.,Carmegliptin
DB12412,Gemigliptin may increase the hypoglycemic activities of Insulin pork.,Gemigliptin
DB12417,Anagliptin may increase the hypoglycemic activities of Insulin pork.,Anagliptin
DB12625,Evogliptin may increase the hypoglycemic activities of Insulin pork.,Evogliptin
DB01276,Exenatide may increase the hypoglycemic activities of Insulin pork.,Exenatide
DB09043,Albiglutide may increase the hypoglycemic activities of Insulin pork.,Albiglutide
DB09045,Dulaglutide may increase the hypoglycemic activities of Insulin pork.,Dulaglutide
DB09265,Lixisenatide may increase the hypoglycemic activities of Insulin pork.,Lixisenatide
DB13928,Semaglutide may increase the hypoglycemic activities of Insulin pork.,Semaglutide
DB14027,Taspoglutide may increase the hypoglycemic activities of Insulin pork.,Taspoglutide
DB00752,Tranylcypromine may increase the hypoglycemic activities of Insulin pork.,Tranylcypromine
DB00780,Phenelzine may increase the hypoglycemic activities of Insulin pork.,Phenelzine
DB01171,Moclobemide may increase the hypoglycemic activities of Insulin pork.,Moclobemide
DB01247,Isocarboxazid may increase the hypoglycemic activities of Insulin pork.,Isocarboxazid
DB01626,Pargyline may increase the hypoglycemic activities of Insulin pork.,Pargyline
DB00805,Minaprine may increase the hypoglycemic activities of Insulin pork.,Minaprine
DB04818,Iproniazid may increase the hypoglycemic activities of Insulin pork.,Iproniazid
DB04820,Nialamide may increase the hypoglycemic activities of Insulin pork.,Nialamide
DB09244,Pirlindole may increase the hypoglycemic activities of Insulin pork.,Pirlindole
DB09245,Toloxatone may increase the hypoglycemic activities of Insulin pork.,Toloxatone
DB09243,Hydracarbazine may increase the hypoglycemic activities of Insulin pork.,Hydracarbazine
DB09241,Methylene blue may increase the hypoglycemic activities of Insulin pork.,Methylene blue
DB09246,Benmoxin may increase the hypoglycemic activities of Insulin pork.,Benmoxin
DB09248,Mebanazine may increase the hypoglycemic activities of Insulin pork.,Mebanazine
DB09249,Octamoxin may increase the hypoglycemic activities of Insulin pork.,Octamoxin
DB09250,Pheniprazine may increase the hypoglycemic activities of Insulin pork.,Pheniprazine
DB09251,Phenoxypropazine may increase the hypoglycemic activities of Insulin pork.,Phenoxypropazine
DB09252,Pivhydrazine may increase the hypoglycemic activities of Insulin pork.,Pivhydrazine
DB09253,Safrazine may increase the hypoglycemic activities of Insulin pork.,Safrazine
DB09254,Caroxazone may increase the hypoglycemic activities of Insulin pork.,Caroxazone
DB00614,Furazolidone may increase the hypoglycemic activities of Insulin pork.,Furazolidone
DB08550,"7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Insulin pork.","7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline"
DB13875,Harmaline may increase the hypoglycemic activities of Insulin pork.,Harmaline
DB13876,Brofaromine may increase the hypoglycemic activities of Insulin pork.,Brofaromine
DB00721,Procaine may increase the hypoglycemic activities of Insulin pork.,Procaine
DB00182,Amphetamine may increase the hypoglycemic activities of Insulin pork.,Amphetamine
DB01168,Procarbazine may increase the hypoglycemic activities of Insulin pork.,Procarbazine
DB00601,Linezolid may increase the hypoglycemic activities of Insulin pork.,Linezolid
DB06654,Safinamide may increase the hypoglycemic activities of Insulin pork.,Safinamide
DB04017,Clorgiline may increase the hypoglycemic activities of Insulin pork.,Clorgiline
DB11827,The therapeutic efficacy of Insulin pork can be increased when used in combination with Ertugliflozin.,Ertugliflozin
DB00203,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sildenafil.,Sildenafil
DB00214,The therapeutic efficacy of Insulin pork can be increased when used in combination with Torasemide.,Torasemide
DB00263,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfisoxazole.,Sulfisoxazole
DB00311,The therapeutic efficacy of Insulin pork can be increased when used in combination with Ethoxzolamide.,Ethoxzolamide
DB00359,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfadiazine.,Sulfadiazine
DB00482,The therapeutic efficacy of Insulin pork can be increased when used in combination with Celecoxib.,Celecoxib
DB00559,The therapeutic efficacy of Insulin pork can be increased when used in combination with Bosentan.,Bosentan
DB00576,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfamethizole.,Sulfamethizole
DB00606,The therapeutic efficacy of Insulin pork can be increased when used in combination with Cyclothiazide.,Cyclothiazide
DB00664,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfametopyrazine.,Sulfametopyrazine
DB00669,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sumatriptan.,Sumatriptan
DB00695,The therapeutic efficacy of Insulin pork can be increased when used in combination with Furosemide.,Furosemide
DB00706,The therapeutic efficacy of Insulin pork can be increased when used in combination with Tamsulosin.,Tamsulosin
DB00819,The therapeutic efficacy of Insulin pork can be increased when used in combination with Acetazolamide.,Acetazolamide
DB00887,The therapeutic efficacy of Insulin pork can be increased when used in combination with Bumetanide.,Bumetanide
DB00891,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfapyridine.,Sulfapyridine
DB00909,The therapeutic efficacy of Insulin pork can be increased when used in combination with Zonisamide.,Zonisamide
DB01015,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfamethoxazole.,Sulfamethoxazole
DB01032,The therapeutic efficacy of Insulin pork can be increased when used in combination with Probenecid.,Probenecid
DB01098,The therapeutic efficacy of Insulin pork can be increased when used in combination with Rosuvastatin.,Rosuvastatin
DB01119,The therapeutic efficacy of Insulin pork can be increased when used in combination with Diazoxide.,Diazoxide
DB01144,The therapeutic efficacy of Insulin pork can be increased when used in combination with Diclofenamide.,Diclofenamide
DB01264,The therapeutic efficacy of Insulin pork can be increased when used in combination with Darunavir.,Darunavir
DB01298,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfacytine.,Sulfacytine
DB01299,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfadoxine.,Sulfadoxine
DB01382,The therapeutic efficacy of Insulin pork can be increased when used in combination with Glymidine.,Glymidine
DB01581,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfamerazine.,Sulfamerazine
DB01582,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfamethazine.,Sulfamethazine
DB02925,The therapeutic efficacy of Insulin pork can be increased when used in combination with Piretanide.,Piretanide
DB04707,The therapeutic efficacy of Insulin pork can be increased when used in combination with Hydroxyfasudil.,Hydroxyfasudil
DB06150,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfadimethoxine.,Sulfadimethoxine
DB06290,The therapeutic efficacy of Insulin pork can be increased when used in combination with Simeprevir.,Simeprevir
DB06729,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfaphenazole.,Sulfaphenazole
DB06821,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfameter.,Sulfameter
DB07996,The therapeutic efficacy of Insulin pork can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline.,5-(2-methylpiperazine-1-sulfonyl)isoquinoline
DB08162,The therapeutic efficacy of Insulin pork can be increased when used in combination with Fasudil.,Fasudil
DB08798,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfamoxole.,Sulfamoxole
DB08881,The therapeutic efficacy of Insulin pork can be increased when used in combination with Vemurafenib.,Vemurafenib
DB08961,The therapeutic efficacy of Insulin pork can be increased when used in combination with Azosemide.,Azosemide
DB11389,The therapeutic efficacy of Insulin pork can be increased when used in combination with Clorsulon.,Clorsulon
DB11461,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfachlorpyridazine.,Sulfachlorpyridazine
DB11462,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfaethoxypyridazine.,Sulfaethoxypyridazine
DB11463,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfanitran.,Sulfanitran
DB11464,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfaquinoxaline.,Sulfaquinoxaline
DB12051,The therapeutic efficacy of Insulin pork can be increased when used in combination with Setrobuvir.,Setrobuvir
DB12921,The therapeutic efficacy of Insulin pork can be increased when used in combination with Chlorsulfaquinoxaline.,Chlorsulfaquinoxaline
DB13214,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfadicramide.,Sulfadicramide
DB13248,The therapeutic efficacy of Insulin pork can be increased when used in combination with Phthalylsulfathiazole.,Phthalylsulfathiazole
DB13283,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfaisodimidine.,Sulfaisodimidine
DB13284,The therapeutic efficacy of Insulin pork can be increased when used in combination with Meticrane.,Meticrane
DB13320,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfaperin.,Sulfaperin
DB13405,The therapeutic efficacy of Insulin pork can be increased when used in combination with Mefruside.,Mefruside
DB13430,The therapeutic efficacy of Insulin pork can be increased when used in combination with Mebutizide.,Mebutizide
DB13485,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfametomidine.,Sulfametomidine
DB13547,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfatolamide.,Sulfatolamide
DB13556,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfamazone.,Sulfamazone
DB13580,The therapeutic efficacy of Insulin pork can be increased when used in combination with Succinylsulfathiazole.,Succinylsulfathiazole
DB13617,The therapeutic efficacy of Insulin pork can be increased when used in combination with Clorexolone.,Clorexolone
DB13663,The therapeutic efficacy of Insulin pork can be increased when used in combination with Clofenamide.,Clofenamide
DB13699,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfathiourea.,Sulfathiourea
DB13708,The therapeutic efficacy of Insulin pork can be increased when used in combination with Fenquizone.,Fenquizone
DB13726,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfaguanidine.,Sulfaguanidine
DB13773,The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfamethoxypyridazine.,Sulfamethoxypyridazine
DB13792,The therapeutic efficacy of Insulin pork can be increased when used in combination with Clopamide.,Clopamide
DB13803,The therapeutic efficacy of Insulin pork can be increased when used in combination with Xipamide.,Xipamide
DB14033,The therapeutic efficacy of Insulin pork can be increased when used in combination with Acetyl sulfisoxazole.,Acetyl sulfisoxazole
DB14708,The therapeutic efficacy of Insulin pork can be increased when used in combination with Tosylchloramide.,Tosylchloramide
DB00703,The therapeutic efficacy of Insulin pork can be increased when used in combination with Methazolamide.,Methazolamide
DB06370,The therapeutic efficacy of Insulin pork can be increased when used in combination with Indisulam.,Indisulam
DB00176,The metabolism of Fluvoxamine can be increased when combined with Insulin pork.,Fluvoxamine
DB00184,The metabolism of Nicotine can be increased when combined with Insulin pork.,Nicotine
DB00188,The metabolism of Bortezomib can be increased when combined with Insulin pork.,Bortezomib
DB00201,The metabolism of Caffeine can be increased when combined with Insulin pork.,Caffeine
DB00261,The metabolism of Anagrelide can be increased when combined with Insulin pork.,Anagrelide
DB00262,The metabolism of Carmustine can be increased when combined with Insulin pork.,Carmustine
DB00281,The metabolism of Lidocaine can be increased when combined with Insulin pork.,Lidocaine
DB00286,The metabolism of Conjugated estrogens can be increased when combined with Insulin pork.,Conjugated estrogens
DB00296,The metabolism of Ropivacaine can be increased when combined with Insulin pork.,Ropivacaine
DB00315,The metabolism of Zolmitriptan can be increased when combined with Insulin pork.,Zolmitriptan
DB00316,The metabolism of Acetaminophen can be increased when combined with Insulin pork.,Acetaminophen
DB00356,The metabolism of Chlorzoxazone can be increased when combined with Insulin pork.,Chlorzoxazone
DB00370,The metabolism of Mirtazapine can be increased when combined with Insulin pork.,Mirtazapine
DB00379,The metabolism of Mexiletine can be increased when combined with Insulin pork.,Mexiletine
DB00382,The metabolism of Tacrine can be increased when combined with Insulin pork.,Tacrine
DB00384,The metabolism of Triamterene can be increased when combined with Insulin pork.,Triamterene
DB00420,The metabolism of Promazine can be increased when combined with Insulin pork.,Promazine
DB00425,The metabolism of Zolpidem can be increased when combined with Insulin pork.,Zolpidem
DB00442,The metabolism of Entecavir can be increased when combined with Insulin pork.,Entecavir
DB00461,The metabolism of Nabumetone can be increased when combined with Insulin pork.,Nabumetone
DB00472,The metabolism of Fluoxetine can be increased when combined with Insulin pork.,Fluoxetine
DB00476,The metabolism of Duloxetine can be increased when combined with Insulin pork.,Duloxetine
DB00499,The metabolism of Flutamide can be increased when combined with Insulin pork.,Flutamide
DB00518,The metabolism of Albendazole can be increased when combined with Insulin pork.,Albendazole
DB00533,The metabolism of Rofecoxib can be increased when combined with Insulin pork.,Rofecoxib
DB00544,The metabolism of Fluorouracil can be increased when combined with Insulin pork.,Fluorouracil
DB00568,The metabolism of Cinnarizine can be increased when combined with Insulin pork.,Cinnarizine
DB00586,The metabolism of Diclofenac can be increased when combined with Insulin pork.,Diclofenac
DB00619,The metabolism of Imatinib can be increased when combined with Insulin pork.,Imatinib
DB00629,The metabolism of Guanabenz can be increased when combined with Insulin pork.,Guanabenz
DB00642,The metabolism of Pemetrexed can be increased when combined with Insulin pork.,Pemetrexed
DB00661,The metabolism of Verapamil can be increased when combined with Insulin pork.,Verapamil
DB00715,The metabolism of Paroxetine can be increased when combined with Insulin pork.,Paroxetine
DB00730,The metabolism of Thiabendazole can be increased when combined with Insulin pork.,Thiabendazole
DB00740,The metabolism of Riluzole can be increased when combined with Insulin pork.,Riluzole
DB00744,The metabolism of Zileuton can be increased when combined with Insulin pork.,Zileuton
DB00758,The metabolism of Clopidogrel can be increased when combined with Insulin pork.,Clopidogrel
DB00787,The metabolism of Acyclovir can be increased when combined with Insulin pork.,Acyclovir
DB00788,The metabolism of Naproxen can be increased when combined with Insulin pork.,Naproxen
DB00806,The metabolism of Pentoxifylline can be increased when combined with Insulin pork.,Pentoxifylline
DB00831,The metabolism of Trifluoperazine can be increased when combined with Insulin pork.,Trifluoperazine
DB00850,The metabolism of Perphenazine can be increased when combined with Insulin pork.,Perphenazine
DB00857,The metabolism of Terbinafine can be increased when combined with Insulin pork.,Terbinafine
DB00863,The metabolism of Ranitidine can be increased when combined with Insulin pork.,Ranitidine
DB00898,The metabolism of Ethanol can be increased when combined with Insulin pork.,Ethanol
DB00934,The metabolism of Maprotiline can be increased when combined with Insulin pork.,Maprotiline
DB00969,The metabolism of Alosetron can be increased when combined with Insulin pork.,Alosetron
DB00980,The metabolism of Ramelteon can be increased when combined with Insulin pork.,Ramelteon
DB00993,The metabolism of Azathioprine can be increased when combined with Insulin pork.,Azathioprine
DB00998,The metabolism of Frovatriptan can be increased when combined with Insulin pork.,Frovatriptan
DB01002,The metabolism of Levobupivacaine can be increased when combined with Insulin pork.,Levobupivacaine
DB01012,The metabolism of Cinacalcet can be increased when combined with Insulin pork.,Cinacalcet
DB01037,The metabolism of Selegiline can be increased when combined with Insulin pork.,Selegiline
DB01056,The metabolism of Tocainide can be increased when combined with Insulin pork.,Tocainide
DB01058,The metabolism of Praziquantel can be increased when combined with Insulin pork.,Praziquantel
DB01065,The metabolism of Melatonin can be increased when combined with Insulin pork.,Melatonin
DB01087,The metabolism of Primaquine can be increased when combined with Insulin pork.,Primaquine
DB01094,The metabolism of Hesperetin can be increased when combined with Insulin pork.,Hesperetin
DB01097,The metabolism of Leflunomide can be increased when combined with Insulin pork.,Leflunomide
DB01166,The metabolism of Cilostazol can be increased when combined with Insulin pork.,Cilostazol
DB01184,The metabolism of Domperidone can be increased when combined with Insulin pork.,Domperidone
DB01191,The metabolism of Dexfenfluramine can be increased when combined with Insulin pork.,Dexfenfluramine
DB01303,The metabolism of Oxtriphylline can be increased when combined with Insulin pork.,Oxtriphylline
DB01367,The metabolism of Rasagiline can be increased when combined with Insulin pork.,Rasagiline
DB01412,The metabolism of Theobromine can be increased when combined with Insulin pork.,Theobromine
DB01424,The metabolism of Aminophenazone can be increased when combined with Insulin pork.,Aminophenazone
DB01435,The metabolism of Antipyrine can be increased when combined with Insulin pork.,Antipyrine
DB01482,The metabolism of Fenethylline can be increased when combined with Insulin pork.,Fenethylline
DB01558,The metabolism of Bromazepam can be increased when combined with Insulin pork.,Bromazepam
DB01623,The metabolism of Thiothixene can be increased when combined with Insulin pork.,Thiothixene
DB01628,The metabolism of Etoricoxib can be increased when combined with Insulin pork.,Etoricoxib
DB01645,The metabolism of Genistein can be increased when combined with Insulin pork.,Genistein
DB01667,The metabolism of 8-azaguanine can be increased when combined with Insulin pork.,8-azaguanine
DB02134,The metabolism of Xanthine can be increased when combined with Insulin pork.,Xanthine
DB02489,The metabolism of 9-Methylguanine can be increased when combined with Insulin pork.,9-Methylguanine
DB02568,The metabolism of Peldesine can be increased when combined with Insulin pork.,Peldesine
DB02709,The metabolism of Resveratrol can be increased when combined with Insulin pork.,Resveratrol
DB03783,The metabolism of Phenacetin can be increased when combined with Insulin pork.,Phenacetin
DB04076,The metabolism of Hypoxanthine can be increased when combined with Insulin pork.,Hypoxanthine
DB04356,The metabolism of 9-Deazaguanine can be increased when combined with Insulin pork.,9-Deazaguanine
DB04841,The metabolism of Flunarizine can be increased when combined with Insulin pork.,Flunarizine
DB04871,The metabolism of Lorcaserin can be increased when combined with Insulin pork.,Lorcaserin
DB04948,The metabolism of Lofexidine can be increased when combined with Insulin pork.,Lofexidine
DB04951,The metabolism of Pirfenidone can be increased when combined with Insulin pork.,Pirfenidone
DB05676,The metabolism of Apremilast can be increased when combined with Insulin pork.,Apremilast
DB06148,The metabolism of Mianserin can be increased when combined with Insulin pork.,Mianserin
DB06210,The metabolism of Eltrombopag can be increased when combined with Insulin pork.,Eltrombopag
DB06235,The metabolism of Vadimezan can be increased when combined with Insulin pork.,Vadimezan
DB06479,The metabolism of Propentofylline can be increased when combined with Insulin pork.,Propentofylline
DB06589,The metabolism of Pazopanib can be increased when combined with Insulin pork.,Pazopanib
DB06594,The metabolism of Agomelatine can be increased when combined with Insulin pork.,Agomelatine
DB06626,The metabolism of Axitinib can be increased when combined with Insulin pork.,Axitinib
DB06769,The metabolism of Bendamustine can be increased when combined with Insulin pork.,Bendamustine
DB06770,The metabolism of Benzyl alcohol can be increased when combined with Insulin pork.,Benzyl alcohol
DB06774,The metabolism of Capsaicin can be increased when combined with Insulin pork.,Capsaicin
DB08496,The metabolism of (R)-warfarin can be increased when combined with Insulin pork.,(R)-warfarin
DB08883,The metabolism of Perampanel can be increased when combined with Insulin pork.,Perampanel
DB09071,The metabolism of Tasimelteon can be increased when combined with Insulin pork.,Tasimelteon
DB09118,The metabolism of Stiripentol can be increased when combined with Insulin pork.,Stiripentol
DB09225,The metabolism of Zotepine can be increased when combined with Insulin pork.,Zotepine
DB09273,The metabolism of Doxofylline can be increased when combined with Insulin pork.,Doxofylline
DB09288,The metabolism of Propacetamol can be increased when combined with Insulin pork.,Propacetamol
DB09290,The metabolism of Ramosetron can be increased when combined with Insulin pork.,Ramosetron
DB11919,The metabolism of 6-O-benzylguanine can be increased when combined with Insulin pork.,6-O-benzylguanine
DB11967,The metabolism of Binimetinib can be increased when combined with Insulin pork.,Binimetinib
DB12026,The metabolism of Voxilaprevir can be increased when combined with Insulin pork.,Voxilaprevir
DB12245,The metabolism of Triclabendazole can be increased when combined with Insulin pork.,Triclabendazole
DB12332,The metabolism of Rucaparib can be increased when combined with Insulin pork.,Rucaparib
DB12406,The metabolism of Lisofylline can be increased when combined with Insulin pork.,Lisofylline
DB12531,The metabolism of Lobucavir can be increased when combined with Insulin pork.,Lobucavir
DB12926,The metabolism of Cafedrine can be increased when combined with Insulin pork.,Cafedrine
DB12927,The metabolism of Theodrenaline can be increased when combined with Insulin pork.,Theodrenaline
DB12945,The metabolism of Dihydralazine can be increased when combined with Insulin pork.,Dihydralazine
DB13203,The metabolism of Bamifylline can be increased when combined with Insulin pork.,Bamifylline
DB13449,The metabolism of Proxyphylline can be increased when combined with Insulin pork.,Proxyphylline
DB13573,The metabolism of Acefylline can be increased when combined with Insulin pork.,Acefylline
DB13592,The metabolism of Etamiphylline can be increased when combined with Insulin pork.,Etamiphylline
DB13634,The metabolism of Pentifylline can be increased when combined with Insulin pork.,Pentifylline
DB13812,The metabolism of Bufylline can be increased when combined with Insulin pork.,Bufylline
DB13952,The metabolism of Estradiol acetate can be increased when combined with Insulin pork.,Estradiol acetate
DB13953,The metabolism of Estradiol benzoate can be increased when combined with Insulin pork.,Estradiol benzoate
DB13954,The metabolism of Estradiol cypionate can be increased when combined with Insulin pork.,Estradiol cypionate
DB13955,The metabolism of Estradiol dienanthate can be increased when combined with Insulin pork.,Estradiol dienanthate
DB13956,The metabolism of Estradiol valerate can be increased when combined with Insulin pork.,Estradiol valerate
DB14018,The metabolism of Bromotheophylline can be increased when combined with Insulin pork.,Bromotheophylline
DB14132,The metabolism of 8-chlorotheophylline can be increased when combined with Insulin pork.,8-chlorotheophylline
DB01115,The metabolism of Nifedipine can be increased when combined with Insulin pork.,Nifedipine
DB11757,The metabolism of Istradefylline can be increased when combined with Insulin pork.,Istradefylline
DB00972,The metabolism of Azelastine can be increased when combined with Insulin pork.,Azelastine
DB00625,The metabolism of Efavirenz can be increased when combined with Insulin pork.,Efavirenz
DB04889,The metabolism of Bicifadine can be increased when combined with Insulin pork.,Bicifadine
DB05708,The metabolism of GTS-21 can be increased when combined with Insulin pork.,GTS-21
DB01195,The metabolism of Flecainide can be increased when combined with Insulin pork.,Flecainide
DB00783,The metabolism of Estradiol can be increased when combined with Insulin pork.,Estradiol
DB00321,The metabolism of Amitriptyline can be increased when combined with Insulin pork.,Amitriptyline
DB00458,The metabolism of Imipramine can be increased when combined with Insulin pork.,Imipramine
DB01142,The metabolism of Doxepin can be increased when combined with Insulin pork.,Doxepin
DB00532,The metabolism of Mephenytoin can be increased when combined with Insulin pork.,Mephenytoin
DB00540,The metabolism of Nortriptyline can be increased when combined with Insulin pork.,Nortriptyline
DB00575,The metabolism of Clonidine can be increased when combined with Insulin pork.,Clonidine
DB00924,The metabolism of Cyclobenzaprine can be increased when combined with Insulin pork.,Cyclobenzaprine
DB01151,The metabolism of Desipramine can be increased when combined with Insulin pork.,Desipramine
DB01242,The metabolism of Clomipramine can be increased when combined with Insulin pork.,Clomipramine
DB11689,The metabolism of Selumetinib can be increased when combined with Insulin pork.,Selumetinib
DB00277,The metabolism of Theophylline can be increased when combined with Insulin pork.,Theophylline
DB00398,The metabolism of Sorafenib can be increased when combined with Insulin pork.,Sorafenib
DB00530,The metabolism of Erlotinib can be increased when combined with Insulin pork.,Erlotinib
DB00564,The metabolism of Carbamazepine can be increased when combined with Insulin pork.,Carbamazepine
DB00682,The metabolism of Warfarin can be increased when combined with Insulin pork.,Warfarin
DB00697,The metabolism of Tizanidine can be increased when combined with Insulin pork.,Tizanidine
DB00773,The metabolism of Etoposide can be increased when combined with Insulin pork.,Etoposide
DB00851,The metabolism of Dacarbazine can be increased when combined with Insulin pork.,Dacarbazine
DB01100,The metabolism of Pimozide can be increased when combined with Insulin pork.,Pimozide
DB01223,The metabolism of Aminophylline can be increased when combined with Insulin pork.,Aminophylline
DB01254,The metabolism of Dasatinib can be increased when combined with Insulin pork.,Dasatinib
DB01418,The metabolism of Acenocoumarol can be increased when combined with Insulin pork.,Acenocoumarol
DB08910,The metabolism of Pomalidomide can be increased when combined with Insulin pork.,Pomalidomide
DB09256,The metabolism of Tegafur can be increased when combined with Insulin pork.,Tegafur
DB13874,The metabolism of Enasidenib can be increased when combined with Insulin pork.,Enasidenib
DB00675,The metabolism of Tamoxifen can be increased when combined with Insulin pork.,Tamoxifen
DB00030,The risk or severity of hypoglycemia can be increased when Insulin human is combined with Insulin pork.,Insulin human
DB00046,The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Insulin pork.,Insulin lispro
DB00047,The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Insulin pork.,Insulin glargine
DB00197,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Troglitazone.,Troglitazone
DB00222,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Glimepiride.,Glimepiride
DB00280,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Disopyramide.,Disopyramide
DB00284,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Acarbose.,Acarbose
DB00414,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Acetohexamide.,Acetohexamide
DB00468,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Quinine.,Quinine
DB00491,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Miglitol.,Miglitol
DB00672,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Chlorpropamide.,Chlorpropamide
DB00731,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Nateglinide.,Nateglinide
DB00834,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Mifepristone.,Mifepristone
DB00839,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Tolazamide.,Tolazamide
DB00912,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Repaglinide.,Repaglinide
DB00914,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Phenformin.,Phenformin
DB01016,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Glyburide.,Glyburide
DB01067,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Glipizide.,Glipizide
DB01120,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Gliclazide.,Gliclazide
DB01124,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Tolbutamide.,Tolbutamide
DB01200,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Bromocriptine.,Bromocriptine
DB01251,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Gliquidone.,Gliquidone
DB01252,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Mitiglinide.,Mitiglinide
DB01268,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Sunitinib.,Sunitinib
DB01277,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Mecasermin.,Mecasermin
DB01289,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Glisoxepide.,Glisoxepide
DB01306,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Insulin aspart.,Insulin aspart
DB01307,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Insulin detemir.,Insulin detemir
DB01309,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Insulin glulisine.,Insulin glulisine
DB01700,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with AICA ribonucleotide.,AICA ribonucleotide
DB04830,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Buformin.,Buformin
DB04878,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Voglibose.,Voglibose
DB05115,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with NN344.,NN344
DB05819,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with NBI-6024.,NBI-6024
DB08962,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Glibornuride.,Glibornuride
DB09022,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Benfluorex.,Benfluorex
DB09198,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Lobeglitazone.,Lobeglitazone
DB09199,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Netoglitazone.,Netoglitazone
DB09200,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Rivoglitazone.,Rivoglitazone
DB09201,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Ciglitazone.,Ciglitazone
DB09456,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Insulin beef.,Insulin beef
DB09564,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Insulin degludec.,Insulin degludec
DB11567,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Insulin peglispro.,Insulin peglispro
DB11568,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Insulin tregopil.,Insulin tregopil
DB11698,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Ipragliflozin.,Ipragliflozin
DB11780,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Allicin.,Allicin
DB11824,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Tofogliflozin.,Tofogliflozin
DB11898,"The risk or severity of hypoglycemia can be increased when Insulin pork is combined with 2,4-thiazolidinedione.","2,4-thiazolidinedione"
DB12713,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Sotagliflozin.,Sotagliflozin
DB12781,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Balaglitazone.,Balaglitazone
DB12935,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Remogliflozin etabonate.,Remogliflozin etabonate
DB13406,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Carbutamide.,Carbutamide
DB13446,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Guar gum.,Guar gum
DB13675,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Metahexamide.,Metahexamide
DB14035,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Englitazone.,Englitazone
DB15171,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Tirzepatide.,Tirzepatide
DB15217,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Gastric inhibitory polypeptide.,Gastric inhibitory polypeptide
DB09038,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Empagliflozin.,Empagliflozin
DB00270,The risk or severity of hypoglycemia can be increased when Isradipine is combined with Insulin pork.,Isradipine
DB00343,The risk or severity of hypoglycemia can be increased when Diltiazem is combined with Insulin pork.,Diltiazem
DB00347,The risk or severity of hypoglycemia can be increased when Trimethadione is combined with Insulin pork.,Trimethadione
DB00381,The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Insulin pork.,Amlodipine
DB00393,The risk or severity of hypoglycemia can be increased when Nimodipine is combined with Insulin pork.,Nimodipine
DB00401,The risk or severity of hypoglycemia can be increased when Nisoldipine is combined with Insulin pork.,Nisoldipine
DB00528,The risk or severity of hypoglycemia can be increased when Lercanidipine is combined with Insulin pork.,Lercanidipine
DB00555,The risk or severity of hypoglycemia can be increased when Lamotrigine is combined with Insulin pork.,Lamotrigine
DB00593,The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Insulin pork.,Ethosuximide
DB00622,The risk or severity of hypoglycemia can be increased when Nicardipine is combined with Insulin pork.,Nicardipine
DB00653,The risk or severity of hypoglycemia can be increased when Magnesium sulfate is combined with Insulin pork.,Magnesium sulfate
DB00836,The risk or severity of hypoglycemia can be increased when Loperamide is combined with Insulin pork.,Loperamide
DB01054,The risk or severity of hypoglycemia can be increased when Nitrendipine is combined with Insulin pork.,Nitrendipine
DB01074,The risk or severity of hypoglycemia can be increased when Perhexiline is combined with Insulin pork.,Perhexiline
DB01244,The risk or severity of hypoglycemia can be increased when Bepridil is combined with Insulin pork.,Bepridil
DB01388,The risk or severity of hypoglycemia can be increased when Mibefradil is combined with Insulin pork.,Mibefradil
DB04743,The risk or severity of hypoglycemia can be increased when Nimesulide is combined with Insulin pork.,Nimesulide
DB04825,The risk or severity of hypoglycemia can be increased when Prenylamine is combined with Insulin pork.,Prenylamine
DB04838,The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Insulin pork.,Cyclandelate
DB04842,The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Insulin pork.,Fluspirilene
DB04920,The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Insulin pork.,Clevidipine
DB05246,The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Insulin pork.,Methsuximide
DB05885,The risk or severity of hypoglycemia can be increased when Seletracetam is combined with Insulin pork.,Seletracetam
DB06152,The risk or severity of hypoglycemia can be increased when Nylidrin is combined with Insulin pork.,Nylidrin
DB06283,The risk or severity of hypoglycemia can be increased when Ziconotide is combined with Insulin pork.,Ziconotide
DB06446,The risk or severity of hypoglycemia can be increased when Dotarizine is combined with Insulin pork.,Dotarizine
DB06694,The risk or severity of hypoglycemia can be increased when Xylometazoline is combined with Insulin pork.,Xylometazoline
DB06712,The risk or severity of hypoglycemia can be increased when Nilvadipine is combined with Insulin pork.,Nilvadipine
DB07615,The risk or severity of hypoglycemia can be increased when Tranilast is combined with Insulin pork.,Tranilast
DB08838,The risk or severity of hypoglycemia can be increased when Agmatine is combined with Insulin pork.,Agmatine
DB08980,The risk or severity of hypoglycemia can be increased when Fendiline is combined with Insulin pork.,Fendiline
DB08992,The risk or severity of hypoglycemia can be increased when Eperisone is combined with Insulin pork.,Eperisone
DB09089,The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Insulin pork.,Trimebutine
DB09090,The risk or severity of hypoglycemia can be increased when Pinaverium is combined with Insulin pork.,Pinaverium
DB09216,The risk or severity of hypoglycemia can be increased when Tolfenamic acid is combined with Insulin pork.,Tolfenamic acid
DB09227,The risk or severity of hypoglycemia can be increased when Barnidipine is combined with Insulin pork.,Barnidipine
DB09229,The risk or severity of hypoglycemia can be increased when Aranidipine is combined with Insulin pork.,Aranidipine
DB09230,The risk or severity of hypoglycemia can be increased when Azelnidipine is combined with Insulin pork.,Azelnidipine
DB09231,The risk or severity of hypoglycemia can be increased when Benidipine is combined with Insulin pork.,Benidipine
DB09232,The risk or severity of hypoglycemia can be increased when Cilnidipine is combined with Insulin pork.,Cilnidipine
DB09234,The risk or severity of hypoglycemia can be increased when Darodipine is combined with Insulin pork.,Darodipine
DB09235,The risk or severity of hypoglycemia can be increased when Efonidipine is combined with Insulin pork.,Efonidipine
DB09236,The risk or severity of hypoglycemia can be increased when Lacidipine is combined with Insulin pork.,Lacidipine
DB09238,The risk or severity of hypoglycemia can be increased when Manidipine is combined with Insulin pork.,Manidipine
DB09239,The risk or severity of hypoglycemia can be increased when Niguldipine is combined with Insulin pork.,Niguldipine
DB09240,The risk or severity of hypoglycemia can be increased when Niludipine is combined with Insulin pork.,Niludipine
DB11960,The risk or severity of hypoglycemia can be increased when Carboxyamidotriazole is combined with Insulin pork.,Carboxyamidotriazole
DB12092,The risk or severity of hypoglycemia can be increased when Naftopidil is combined with Insulin pork.,Naftopidil
DB12093,The risk or severity of hypoglycemia can be increased when Tetrahydropalmatine is combined with Insulin pork.,Tetrahydropalmatine
DB12131,The risk or severity of hypoglycemia can be increased when Vinpocetine is combined with Insulin pork.,Vinpocetine
DB12923,The risk or severity of hypoglycemia can be increased when Gallopamil is combined with Insulin pork.,Gallopamil
DB13488,The risk or severity of hypoglycemia can be increased when Bencyclane is combined with Insulin pork.,Bencyclane
DB13500,The risk or severity of hypoglycemia can be increased when Otilonium is combined with Insulin pork.,Otilonium
DB13725,The risk or severity of hypoglycemia can be increased when Terodiline is combined with Insulin pork.,Terodiline
DB13766,The risk or severity of hypoglycemia can be increased when Lidoflazine is combined with Insulin pork.,Lidoflazine
DB13791,The risk or severity of hypoglycemia can be increased when Penfluridol is combined with Insulin pork.,Penfluridol
DB13835,The risk or severity of hypoglycemia can be increased when Caroverine is combined with Insulin pork.,Caroverine
DB13950,The risk or severity of hypoglycemia can be increased when WIN 55212-2 is combined with Insulin pork.,WIN 55212-2
DB13961,The risk or severity of hypoglycemia can be increased when Fish oil is combined with Insulin pork.,Fish oil
DB14063,The risk or severity of hypoglycemia can be increased when Dexverapamil is combined with Insulin pork.,Dexverapamil
DB14064,The risk or severity of hypoglycemia can be increased when Emopamil is combined with Insulin pork.,Emopamil
DB14065,The risk or severity of hypoglycemia can be increased when Lomerizine is combined with Insulin pork.,Lomerizine
DB14066,The risk or severity of hypoglycemia can be increased when Tetrandrine is combined with Insulin pork.,Tetrandrine
DB14068,The risk or severity of hypoglycemia can be increased when Dexniguldipine is combined with Insulin pork.,Dexniguldipine
DB01023,The risk or severity of hypoglycemia can be increased when Felodipine is combined with Insulin pork.,Felodipine
DB01118,The risk or severity of hypoglycemia can be increased when Amiodarone is combined with Insulin pork.,Amiodarone
DB00191,The therapeutic efficacy of Insulin pork can be increased when used in combination with Phentermine.,Phentermine
DB00268,The metabolism of Ropinirole can be increased when combined with Insulin pork.,Ropinirole
DB13074,The therapeutic efficacy of Macimorelin can be decreased when used in combination with Insulin pork.,Macimorelin
DB00279,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Liothyronine.,Liothyronine
DB00331,The risk or severity of adverse effects can be increased when Insulin pork is combined with Metformin.,Metformin
DB00542,The risk or severity of hypoglycemia can be increased when Benazepril is combined with Insulin pork.,Benazepril
DB13946,The risk or severity of adverse effects can be increased when Testosterone undecanoate is combined with Insulin pork.,Testosterone undecanoate
DB00945,The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Insulin pork.,Acetylsalicylic acid
DB00181,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Baclofen.,Baclofen
DB00489,The risk or severity of hypoglycemia can be increased when Sotalol is combined with Insulin pork.,Sotalol
DB00196,The risk or severity of hypoglycemia can be increased when Insulin pork is combined with Fluconazole.,Fluconazole
DB00040,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Glucagon.,Glucagon
DB00264,The therapeutic efficacy of Insulin pork can be increased when used in combination with Metoprolol.,Metoprolol
DB00335,The therapeutic efficacy of Insulin pork can be increased when used in combination with Atenolol.,Atenolol
DB00373,The therapeutic efficacy of Insulin pork can be increased when used in combination with Timolol.,Timolol
DB00598,The therapeutic efficacy of Insulin pork can be increased when used in combination with Labetalol.,Labetalol
DB00612,The therapeutic efficacy of Insulin pork can be increased when used in combination with Bisoprolol.,Bisoprolol
DB00866,The therapeutic efficacy of Insulin pork can be increased when used in combination with Alprenolol.,Alprenolol
DB00960,The therapeutic efficacy of Insulin pork can be increased when used in combination with Pindolol.,Pindolol
DB01193,The therapeutic efficacy of Insulin pork can be increased when used in combination with Acebutolol.,Acebutolol
DB01203,The therapeutic efficacy of Insulin pork can be increased when used in combination with Nadolol.,Nadolol
DB01295,The therapeutic efficacy of Insulin pork can be increased when used in combination with Bevantolol.,Bevantolol
DB01297,The therapeutic efficacy of Insulin pork can be increased when used in combination with Practolol.,Practolol
DB01359,The therapeutic efficacy of Insulin pork can be increased when used in combination with Penbutolol.,Penbutolol
DB01580,The therapeutic efficacy of Insulin pork can be increased when used in combination with Oxprenolol.,Oxprenolol
DB03322,The therapeutic efficacy of Insulin pork can be increased when used in combination with Dexpropranolol.,Dexpropranolol
DB04846,The therapeutic efficacy of Insulin pork can be increased when used in combination with Celiprolol.,Celiprolol
DB04861,The therapeutic efficacy of Insulin pork can be increased when used in combination with Nebivolol.,Nebivolol
DB06726,The therapeutic efficacy of Insulin pork can be increased when used in combination with Bufuralol.,Bufuralol
DB08807,The therapeutic efficacy of Insulin pork can be increased when used in combination with Bopindolol.,Bopindolol
DB08808,The therapeutic efficacy of Insulin pork can be increased when used in combination with Bupranolol.,Bupranolol
DB08952,The therapeutic efficacy of Insulin pork can be increased when used in combination with Indenolol.,Indenolol
DB09013,The therapeutic efficacy of Insulin pork can be increased when used in combination with Befunolol.,Befunolol
DB09204,The therapeutic efficacy of Insulin pork can be increased when used in combination with Arotinolol.,Arotinolol
DB09351,The therapeutic efficacy of Insulin pork can be increased when used in combination with Levobetaxolol.,Levobetaxolol
DB11770,The therapeutic efficacy of Insulin pork can be increased when used in combination with Talinolol.,Talinolol
DB11785,The therapeutic efficacy of Insulin pork can be increased when used in combination with Anisodamine.,Anisodamine
DB12212,The therapeutic efficacy of Insulin pork can be increased when used in combination with Landiolol.,Landiolol
DB12752,The therapeutic efficacy of Insulin pork can be increased when used in combination with Bucindolol.,Bucindolol
DB13443,The therapeutic efficacy of Insulin pork can be increased when used in combination with Esatenolol.,Esatenolol
DB13508,The therapeutic efficacy of Insulin pork can be increased when used in combination with Cloranolol.,Cloranolol
DB13530,The therapeutic efficacy of Insulin pork can be increased when used in combination with Mepindolol.,Mepindolol
DB13757,The therapeutic efficacy of Insulin pork can be increased when used in combination with Epanolol.,Epanolol
DB13775,The therapeutic efficacy of Insulin pork can be increased when used in combination with Tertatolol.,Tertatolol
DB00195,The therapeutic efficacy of Betaxolol can be increased when used in combination with Insulin pork.,Betaxolol
DB00571,The therapeutic efficacy of Propranolol can be increased when used in combination with Insulin pork.,Propranolol
DB01136,The therapeutic efficacy of Carvedilol can be increased when used in combination with Insulin pork.,Carvedilol
DB01182,The therapeutic efficacy of Propafenone can be increased when used in combination with Insulin pork.,Propafenone
DB01611,The therapeutic efficacy of Insulin pork can be increased when used in combination with Hydroxychloroquine.,Hydroxychloroquine
DB01233,The therapeutic efficacy of Metoclopramide can be increased when used in combination with Insulin pork.,Metoclopramide
DB00394,The risk or severity of hyperglycemia can be increased when Beclomethasone dipropionate is combined with Insulin pork.,Beclomethasone dipropionate
DB00443,The risk or severity of hyperglycemia can be increased when Betamethasone is combined with Insulin pork.,Betamethasone
DB00620,The risk or severity of hyperglycemia can be increased when Triamcinolone is combined with Insulin pork.,Triamcinolone
DB00635,The risk or severity of hyperglycemia can be increased when Prednisone is combined with Insulin pork.,Prednisone
DB00687,The risk or severity of hyperglycemia can be increased when Fludrocortisone is combined with Insulin pork.,Fludrocortisone
DB00741,The risk or severity of hyperglycemia can be increased when Hydrocortisone is combined with Insulin pork.,Hydrocortisone
DB00764,The risk or severity of hyperglycemia can be increased when Mometasone is combined with Insulin pork.,Mometasone
DB00860,The risk or severity of hyperglycemia can be increased when Prednisolone is combined with Insulin pork.,Prednisolone
DB00959,The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Insulin pork.,Methylprednisolone
DB01234,The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Insulin pork.,Dexamethasone
DB01285,The risk or severity of hyperglycemia can be increased when Corticotropin is combined with Insulin pork.,Corticotropin
DB01380,The risk or severity of hyperglycemia can be increased when Cortisone acetate is combined with Insulin pork.,Cortisone acetate
DB01384,The risk or severity of hyperglycemia can be increased when Paramethasone is combined with Insulin pork.,Paramethasone
DB01410,The risk or severity of hyperglycemia can be increased when Ciclesonide is combined with Insulin pork.,Ciclesonide
DB08906,The risk or severity of hyperglycemia can be increased when Fluticasone furoate is combined with Insulin pork.,Fluticasone furoate
DB08970,The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Insulin pork.,Fluprednidene
DB08971,The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Insulin pork.,Fluocortolone
DB09383,The risk or severity of hyperglycemia can be increased when Meprednisone is combined with Insulin pork.,Meprednisone
DB11487,The risk or severity of hyperglycemia can be increased when Dexamethasone isonicotinate is combined with Insulin pork.,Dexamethasone isonicotinate
DB11750,The risk or severity of hyperglycemia can be increased when Clobetasol is combined with Insulin pork.,Clobetasol
DB11921,The risk or severity of hyperglycemia can be increased when Deflazacort is combined with Insulin pork.,Deflazacort
DB13003,The risk or severity of hyperglycemia can be increased when Cortivazol is combined with Insulin pork.,Cortivazol
DB13208,The risk or severity of hyperglycemia can be increased when Prednylidene is combined with Insulin pork.,Prednylidene
DB13843,The risk or severity of hyperglycemia can be increased when Cloprednol is combined with Insulin pork.,Cloprednol
DB13867,The risk or severity of hyperglycemia can be increased when Fluticasone is combined with Insulin pork.,Fluticasone
DB14512,The risk or severity of hyperglycemia can be increased when Mometasone furoate is combined with Insulin pork.,Mometasone furoate
DB00180,The risk or severity of hyperglycemia can be increased when Flunisolide is combined with Insulin pork.,Flunisolide
DB01108,The risk or severity of hyperglycemia can be increased when Trilostane is combined with Insulin pork.,Trilostane
DB01222,The risk or severity of hyperglycemia can be increased when Budesonide is combined with Insulin pork.,Budesonide
DB04630,The risk or severity of hyperglycemia can be increased when Aldosterone is combined with Insulin pork.,Aldosterone
DB09378,The risk or severity of hyperglycemia can be increased when Fluprednisolone is combined with Insulin pork.,Fluprednisolone
DB11529,The risk or severity of hyperglycemia can be increased when Melengestrol is combined with Insulin pork.,Melengestrol
DB14681,The risk or severity of hyperglycemia can be increased when Cortisone is combined with Insulin pork.,Cortisone
DB00223,The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Insulin pork.,Diflorasone
DB00240,The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Insulin pork.,Alclometasone
DB00253,The risk or severity of hyperglycemia can be increased when Medrysone is combined with Insulin pork.,Medrysone
DB00288,The risk or severity of hyperglycemia can be increased when Amcinonide is combined with Insulin pork.,Amcinonide
DB00324,The risk or severity of hyperglycemia can be increased when Fluorometholone is combined with Insulin pork.,Fluorometholone
DB00547,The risk or severity of hyperglycemia can be increased when Desoximetasone is combined with Insulin pork.,Desoximetasone
DB00588,The risk or severity of hyperglycemia can be increased when Fluticasone propionate is combined with Insulin pork.,Fluticasone propionate
DB00591,The risk or severity of hyperglycemia can be increased when Fluocinolone acetonide is combined with Insulin pork.,Fluocinolone acetonide
DB00596,The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Insulin pork.,Ulobetasol
DB00663,The risk or severity of hyperglycemia can be increased when Flumethasone is combined with Insulin pork.,Flumethasone
DB00838,The risk or severity of hyperglycemia can be increased when Clocortolone is combined with Insulin pork.,Clocortolone
DB00846,The risk or severity of hyperglycemia can be increased when Flurandrenolide is combined with Insulin pork.,Flurandrenolide
DB14596,The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Insulin pork.,Loteprednol etabonate
DB00896,The risk or severity of hyperglycemia can be increased when Rimexolone is combined with Insulin pork.,Rimexolone
DB01013,The risk or severity of hyperglycemia can be increased when Clobetasol propionate is combined with Insulin pork.,Clobetasol propionate
DB01047,The risk or severity of hyperglycemia can be increased when Fluocinonide is combined with Insulin pork.,Fluocinonide
DB01130,The risk or severity of hyperglycemia can be increased when Prednicarbate is combined with Insulin pork.,Prednicarbate
DB01260,The risk or severity of hyperglycemia can be increased when Desonide is combined with Insulin pork.,Desonide
DB06781,The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Insulin pork.,Difluprednate
DB06786,The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Insulin pork.,Halcinonide
DB09091,The risk or severity of hyperglycemia can be increased when Tixocortol is combined with Insulin pork.,Tixocortol
DB09095,The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Insulin pork.,Difluocortolone
DB13158,The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Insulin pork.,Clobetasone
DB13223,The risk or severity of hyperglycemia can be increased when Fluocortin is combined with Insulin pork.,Fluocortin
DB13491,The risk or severity of hyperglycemia can be increased when Fluperolone is combined with Insulin pork.,Fluperolone
DB13664,The risk or severity of hyperglycemia can be increased when Formocortal is combined with Insulin pork.,Formocortal
DB13728,The risk or severity of hyperglycemia can be increased when Halometasone is combined with Insulin pork.,Halometasone
DB13856,The risk or severity of hyperglycemia can be increased when Fluclorolone is combined with Insulin pork.,Fluclorolone
DB14538,The risk or severity of hyperglycemia can be increased when Hydrocortisone aceponate is combined with Insulin pork.,Hydrocortisone aceponate
DB14539,The risk or severity of hyperglycemia can be increased when Hydrocortisone acetate is combined with Insulin pork.,Hydrocortisone acetate
DB14540,The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Insulin pork.,Hydrocortisone butyrate
DB14541,The risk or severity of hyperglycemia can be increased when Hydrocortisone cypionate is combined with Insulin pork.,Hydrocortisone cypionate
DB14543,The risk or severity of hyperglycemia can be increased when Hydrocortisone probutate is combined with Insulin pork.,Hydrocortisone probutate
DB14544,The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Insulin pork.,Hydrocortisone valerate
DB14545,The risk or severity of hyperglycemia can be increased when Hydrocortisone succinate is combined with Insulin pork.,Hydrocortisone succinate
DB00873,The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Insulin pork.,Loteprednol
DB14631,The risk or severity of hyperglycemia can be increased when Prednisolone phosphate is combined with Insulin pork.,Prednisolone phosphate
DB14633,The risk or severity of hyperglycemia can be increased when Prednisolone hemisuccinate is combined with Insulin pork.,Prednisolone hemisuccinate
DB14634,The risk or severity of hyperglycemia can be increased when Fluprednidene acetate is combined with Insulin pork.,Fluprednidene acetate
DB14643,The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Insulin pork.,Methylprednisolone aceponate
DB14644,The risk or severity of hyperglycemia can be increased when Methylprednisolone hemisuccinate is combined with Insulin pork.,Methylprednisolone hemisuccinate
DB14646,The risk or severity of hyperglycemia can be increased when Prednisone acetate is combined with Insulin pork.,Prednisone acetate
DB14652,The risk or severity of hyperglycemia can be increased when Clocortolone acetate is combined with Insulin pork.,Clocortolone acetate
DB14659,The risk or severity of hyperglycemia can be increased when Melengestrol acetate is combined with Insulin pork.,Melengestrol acetate
DB14669,The risk or severity of hyperglycemia can be increased when Betamethasone phosphate is combined with Insulin pork.,Betamethasone phosphate
DB15566,The risk or severity of hyperglycemia can be increased when Prednisolone acetate is combined with Insulin pork.,Prednisolone acetate
DB00451,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Levothyroxine.,Levothyroxine
DB00024,Thyrotropin alfa may decrease the hypoglycemic activities of Insulin pork.,Thyrotropin alfa
DB01583,Liotrix may decrease the hypoglycemic activities of Insulin pork.,Liotrix
DB03604,Tiratricol may decrease the hypoglycemic activities of Insulin pork.,Tiratricol
DB09100,"Thyroid, porcine may decrease the hypoglycemic activities of Insulin pork.","Thyroid, porcine"
DB06643,The risk or severity of adverse effects can be increased when Denosumab is combined with Trastuzumab.,Denosumab
DB00108,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Natalizumab.,Natalizumab
DB00337,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Trastuzumab.,Pimecrolimus
DB01656,Roflumilast may increase the immunosuppressive activities of Trastuzumab.,Roflumilast
DB06688,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Trastuzumab.,Sipuleucel-T
DB00012,The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Trastuzumab.,Darbepoetin alfa
DB00016,The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Trastuzumab.,Erythropoietin
DB08894,The risk or severity of Thrombosis can be increased when Peginesatide is combined with Trastuzumab.,Peginesatide
DB09107,The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Trastuzumab.,Methoxy polyethylene glycol-epoetin beta
DB01015,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Trastuzumab.,Sulfamethoxazole
DB01229,The serum concentration of Paclitaxel can be decreased when it is combined with Trastuzumab.,Paclitaxel
DB00255,Diethylstilbestrol may increase the thrombogenic activities of Trastuzumab.,Diethylstilbestrol
DB00269,Chlorotrianisene may increase the thrombogenic activities of Trastuzumab.,Chlorotrianisene
DB00286,Conjugated estrogens may increase the thrombogenic activities of Trastuzumab.,Conjugated estrogens
DB00655,Estrone may increase the thrombogenic activities of Trastuzumab.,Estrone
DB00783,Estradiol may increase the thrombogenic activities of Trastuzumab.,Estradiol
DB00890,Dienestrol may increase the thrombogenic activities of Trastuzumab.,Dienestrol
DB00977,Ethinylestradiol may increase the thrombogenic activities of Trastuzumab.,Ethinylestradiol
DB01357,Mestranol may increase the thrombogenic activities of Trastuzumab.,Mestranol
DB04573,Estriol may increase the thrombogenic activities of Trastuzumab.,Estriol
DB04574,Estrone sulfate may increase the thrombogenic activities of Trastuzumab.,Estrone sulfate
DB04575,Quinestrol may increase the thrombogenic activities of Trastuzumab.,Quinestrol
DB07931,Hexestrol may increase the thrombogenic activities of Trastuzumab.,Hexestrol
DB09070,Tibolone may increase the thrombogenic activities of Trastuzumab.,Tibolone
DB09317,"Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Trastuzumab.","Synthetic Conjugated Estrogens, A"
DB09318,"Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Trastuzumab.","Synthetic Conjugated Estrogens, B"
DB09369,Polyestradiol phosphate may increase the thrombogenic activities of Trastuzumab.,Polyestradiol phosphate
DB09381,Esterified estrogens may increase the thrombogenic activities of Trastuzumab.,Esterified estrogens
DB11478,Zeranol may increase the thrombogenic activities of Trastuzumab.,Zeranol
DB11674,Equol may increase the thrombogenic activities of Trastuzumab.,Equol
DB12487,Promestriene may increase the thrombogenic activities of Trastuzumab.,Promestriene
DB13143,Methallenestril may increase the thrombogenic activities of Trastuzumab.,Methallenestril
DB13386,Epimestrol may increase the thrombogenic activities of Trastuzumab.,Epimestrol
DB13418,Moxestrol may increase the thrombogenic activities of Trastuzumab.,Moxestrol
DB13952,Estradiol acetate may increase the thrombogenic activities of Trastuzumab.,Estradiol acetate
DB13953,Estradiol benzoate may increase the thrombogenic activities of Trastuzumab.,Estradiol benzoate
DB13954,Estradiol cypionate may increase the thrombogenic activities of Trastuzumab.,Estradiol cypionate
DB13956,Estradiol valerate may increase the thrombogenic activities of Trastuzumab.,Estradiol valerate
DB15334,Biochanin A may increase the thrombogenic activities of Trastuzumab.,Biochanin A
DB15335,Formononetin may increase the thrombogenic activities of Trastuzumab.,Formononetin
DB01097,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Leflunomide.,Leflunomide
DB08895,Trastuzumab may increase the immunosuppressive activities of Tofacitinib.,Tofacitinib
DB00005,Trastuzumab may increase the neutropenic activities of Etanercept.,Etanercept
DB00074,Trastuzumab may increase the neutropenic activities of Basiliximab.,Basiliximab
DB00075,Trastuzumab may increase the neutropenic activities of Muromonab.,Muromonab
DB00111,Trastuzumab may increase the neutropenic activities of Daclizumab.,Daclizumab
DB00242,Trastuzumab may increase the neutropenic activities of Cladribine.,Cladribine
DB00688,Trastuzumab may increase the neutropenic activities of Mycophenolate mofetil.,Mycophenolate mofetil
DB00877,Trastuzumab may increase the neutropenic activities of Sirolimus.,Sirolimus
DB00993,Trastuzumab may increase the neutropenic activities of Azathioprine.,Azathioprine
DB01024,Trastuzumab may increase the neutropenic activities of Mycophenolic acid.,Mycophenolic acid
DB01041,Trastuzumab may increase the neutropenic activities of Thalidomide.,Thalidomide
DB01281,Trastuzumab may increase the neutropenic activities of Abatacept.,Abatacept
DB01590,Trastuzumab may increase the neutropenic activities of Everolimus.,Everolimus
DB06681,Trastuzumab may increase the neutropenic activities of Belatacept.,Belatacept
DB08879,Trastuzumab may increase the neutropenic activities of Belimumab.,Belimumab
DB08880,Trastuzumab may increase the neutropenic activities of Teriflunomide.,Teriflunomide
DB08904,Trastuzumab may increase the neutropenic activities of Certolizumab pegol.,Certolizumab pegol
DB06168,Trastuzumab may increase the neutropenic activities of Canakinumab.,Canakinumab
DB09033,Trastuzumab may increase the neutropenic activities of Vedolizumab.,Vedolizumab
DB09036,Trastuzumab may increase the neutropenic activities of Siltuximab.,Siltuximab
DB12692,Trastuzumab may increase the neutropenic activities of Gusperimus.,Gusperimus
DB11693,Trastuzumab may increase the neutropenic activities of Voclosporin.,Voclosporin
DB09312,Trastuzumab may increase the neutropenic activities of Antilymphocyte immunoglobulin (horse).,Antilymphocyte immunoglobulin (horse)
DB06612,Trastuzumab may increase the neutropenic activities of Mepolizumab.,Mepolizumab
DB00441,Trastuzumab may increase the neutropenic activities of Gemcitabine.,Gemcitabine
DB00531,Trastuzumab may increase the neutropenic activities of Cyclophosphamide.,Cyclophosphamide
DB00544,Trastuzumab may increase the neutropenic activities of Fluorouracil.,Fluorouracil
DB00563,Trastuzumab may increase the neutropenic activities of Methotrexate.,Methotrexate
DB00620,Trastuzumab may increase the neutropenic activities of Triamcinolone.,Triamcinolone
DB00987,Trastuzumab may increase the neutropenic activities of Cytarabine.,Cytarabine
DB01008,Trastuzumab may increase the neutropenic activities of Busulfan.,Busulfan
DB01033,Trastuzumab may increase the neutropenic activities of Mercaptopurine.,Mercaptopurine
DB01042,Trastuzumab may increase the neutropenic activities of Melphalan.,Melphalan
DB01073,Trastuzumab may increase the neutropenic activities of Fludarabine.,Fludarabine
DB04572,Trastuzumab may increase the neutropenic activities of Thiotepa.,Thiotepa
DB05259,Trastuzumab may increase the neutropenic activities of Glatiramer.,Glatiramer
DB00026,Trastuzumab may increase the neutropenic activities of Anakinra.,Anakinra
DB00051,Trastuzumab may increase the neutropenic activities of Adalimumab.,Adalimumab
DB00065,Trastuzumab may increase the neutropenic activities of Infliximab.,Infliximab
DB00087,Trastuzumab may increase the neutropenic activities of Alemtuzumab.,Alemtuzumab
DB00098,Trastuzumab may increase the neutropenic activities of Antithymocyte immunoglobulin (rabbit).,Antithymocyte immunoglobulin (rabbit)
DB00480,Trastuzumab may increase the neutropenic activities of Lenalidomide.,Lenalidomide
DB01257,Trastuzumab may increase the neutropenic activities of Eculizumab.,Eculizumab
DB06273,Trastuzumab may increase the neutropenic activities of Tocilizumab.,Tocilizumab
DB06372,Trastuzumab may increase the neutropenic activities of Rilonacept.,Rilonacept
DB06674,Trastuzumab may increase the neutropenic activities of Golimumab.,Golimumab
DB08910,Trastuzumab may increase the neutropenic activities of Pomalidomide.,Pomalidomide
DB09029,Trastuzumab may increase the neutropenic activities of Secukinumab.,Secukinumab
DB00056,Trastuzumab may increase the neutropenic activities of Gemtuzumab ozogamicin.,Gemtuzumab ozogamicin
DB00059,Trastuzumab may increase the neutropenic activities of Pegaspargase.,Pegaspargase
DB00073,Trastuzumab may increase the neutropenic activities of Rituximab.,Rituximab
DB00078,Trastuzumab may increase the neutropenic activities of Ibritumomab tiuxetan.,Ibritumomab tiuxetan
DB00081,Trastuzumab may increase the neutropenic activities of Tositumomab.,Tositumomab
DB00120,Trastuzumab may increase the neutropenic activities of Phenylalanine.,Phenylalanine
DB00262,Trastuzumab may increase the neutropenic activities of Carmustine.,Carmustine
DB00276,Trastuzumab may increase the neutropenic activities of Amsacrine.,Amsacrine
DB00290,Trastuzumab may increase the neutropenic activities of Bleomycin.,Bleomycin
DB00291,Trastuzumab may increase the neutropenic activities of Chlorambucil.,Chlorambucil
DB00305,Trastuzumab may increase the neutropenic activities of Mitomycin.,Mitomycin
DB00309,Trastuzumab may increase the neutropenic activities of Vindesine.,Vindesine
DB00322,Trastuzumab may increase the neutropenic activities of Floxuridine.,Floxuridine
DB00352,Trastuzumab may increase the neutropenic activities of Tioguanine.,Tioguanine
DB00361,Trastuzumab may increase the neutropenic activities of Vinorelbine.,Vinorelbine
DB00398,Trastuzumab may increase the neutropenic activities of Sorafenib.,Sorafenib
DB00428,Trastuzumab may increase the neutropenic activities of Streptozocin.,Streptozocin
DB00443,Trastuzumab may increase the neutropenic activities of Betamethasone.,Betamethasone
DB00444,Trastuzumab may increase the neutropenic activities of Teniposide.,Teniposide
DB00488,Trastuzumab may increase the neutropenic activities of Altretamine.,Altretamine
DB00515,Trastuzumab may increase the neutropenic activities of Cisplatin.,Cisplatin
DB00526,Trastuzumab may increase the neutropenic activities of Oxaliplatin.,Oxaliplatin
DB00541,Trastuzumab may increase the neutropenic activities of Vincristine.,Vincristine
DB00552,Trastuzumab may increase the neutropenic activities of Pentostatin.,Pentostatin
DB00570,Trastuzumab may increase the neutropenic activities of Vinblastine.,Vinblastine
DB00619,Trastuzumab may increase the neutropenic activities of Imatinib.,Imatinib
DB00631,Trastuzumab may increase the neutropenic activities of Clofarabine.,Clofarabine
DB00635,Trastuzumab may increase the neutropenic activities of Prednisone.,Prednisone
DB00642,Trastuzumab may increase the neutropenic activities of Pemetrexed.,Pemetrexed
DB00687,Trastuzumab may increase the neutropenic activities of Fludrocortisone.,Fludrocortisone
DB00724,Trastuzumab may increase the neutropenic activities of Imiquimod.,Imiquimod
DB00741,Trastuzumab may increase the neutropenic activities of Hydrocortisone.,Hydrocortisone
DB00755,Trastuzumab may increase the neutropenic activities of Tretinoin.,Tretinoin
DB00762,Trastuzumab may increase the neutropenic activities of Irinotecan.,Irinotecan
DB00773,Trastuzumab may increase the neutropenic activities of Etoposide.,Etoposide
DB00851,Trastuzumab may increase the neutropenic activities of Dacarbazine.,Dacarbazine
DB00853,Trastuzumab may increase the neutropenic activities of Temozolomide.,Temozolomide
DB00860,Trastuzumab may increase the neutropenic activities of Prednisolone.,Prednisolone
DB00888,Trastuzumab may increase the neutropenic activities of Mechlorethamine.,Mechlorethamine
DB00928,Trastuzumab may increase the neutropenic activities of Azacitidine.,Azacitidine
DB00958,Trastuzumab may increase the neutropenic activities of Carboplatin.,Carboplatin
DB00959,Trastuzumab may increase the neutropenic activities of Methylprednisolone.,Methylprednisolone
DB00970,Trastuzumab may increase the neutropenic activities of Dactinomycin.,Dactinomycin
DB01005,Trastuzumab may increase the neutropenic activities of Hydroxyurea.,Hydroxyurea
DB01030,Trastuzumab may increase the neutropenic activities of Topotecan.,Topotecan
DB01101,Trastuzumab may increase the neutropenic activities of Capecitabine.,Capecitabine
DB01168,Trastuzumab may increase the neutropenic activities of Procarbazine.,Procarbazine
DB01181,Trastuzumab may increase the neutropenic activities of Ifosfamide.,Ifosfamide
DB01196,Trastuzumab may increase the neutropenic activities of Estramustine.,Estramustine
DB01204,Trastuzumab may increase the neutropenic activities of Mitoxantrone.,Mitoxantrone
DB01206,Trastuzumab may increase the neutropenic activities of Lomustine.,Lomustine
DB01222,Trastuzumab may increase the neutropenic activities of Budesonide.,Budesonide
DB01234,Trastuzumab may increase the neutropenic activities of Dexamethasone.,Dexamethasone
DB01248,Trastuzumab may increase the neutropenic activities of Docetaxel.,Docetaxel
DB01254,Trastuzumab may increase the neutropenic activities of Dasatinib.,Dasatinib
DB01268,Trastuzumab may increase the neutropenic activities of Sunitinib.,Sunitinib
DB01280,Trastuzumab may increase the neutropenic activities of Nelarabine.,Nelarabine
DB01285,Trastuzumab may increase the neutropenic activities of Corticotropin.,Corticotropin
DB01380,Trastuzumab may increase the neutropenic activities of Cortisone acetate.,Cortisone acetate
DB04868,Trastuzumab may increase the neutropenic activities of Nilotinib.,Nilotinib
DB05109,Trastuzumab may increase the neutropenic activities of Trabectedin.,Trabectedin
DB05773,Trastuzumab may increase the neutropenic activities of Trastuzumab emtansine.,Trastuzumab emtansine
DB06287,Trastuzumab may increase the neutropenic activities of Temsirolimus.,Temsirolimus
DB06589,Trastuzumab may increase the neutropenic activities of Pazopanib.,Pazopanib
DB06603,Trastuzumab may increase the neutropenic activities of Panobinostat.,Panobinostat
DB06772,Trastuzumab may increase the neutropenic activities of Cabazitaxel.,Cabazitaxel
DB06813,Trastuzumab may increase the neutropenic activities of Pralatrexate.,Pralatrexate
DB08870,Trastuzumab may increase the neutropenic activities of Brentuximab vedotin.,Brentuximab vedotin
DB08877,Trastuzumab may increase the neutropenic activities of Ruxolitinib.,Ruxolitinib
DB08935,Trastuzumab may increase the neutropenic activities of Obinutuzumab.,Obinutuzumab
DB09052,Trastuzumab may increase the neutropenic activities of Blinatumomab.,Blinatumomab
DB09053,Trastuzumab may increase the neutropenic activities of Ibrutinib.,Ibrutinib
DB09054,Trastuzumab may increase the neutropenic activities of Idelalisib.,Idelalisib
DB09073,Trastuzumab may increase the neutropenic activities of Palbociclib.,Palbociclib
DB09077,Trastuzumab may increase the neutropenic activities of Dinutuximab.,Dinutuximab
DB09082,Trastuzumab may increase the neutropenic activities of Vilanterol.,Vilanterol
DB01423,Trastuzumab may increase the neutropenic activities of Stepronin.,Stepronin
DB01816,Trastuzumab may increase the neutropenic activities of Castanospermine.,Castanospermine
DB02806,Trastuzumab may increase the neutropenic activities of 2-Methoxyethanol.,2-Methoxyethanol
DB05260,Trastuzumab may increase the neutropenic activities of Gallium nitrate.,Gallium nitrate
DB08908,Trastuzumab may increase the neutropenic activities of Dimethyl fumarate.,Dimethyl fumarate
DB11921,Trastuzumab may increase the neutropenic activities of Deflazacort.,Deflazacort
DB12025,Trastuzumab may increase the neutropenic activities of Triptolide.,Triptolide
DB12617,Trastuzumab may increase the neutropenic activities of Mizoribine.,Mizoribine
DB12902,Trastuzumab may increase the neutropenic activities of Trofosfamide.,Trofosfamide
DB12947,Trastuzumab may increase the neutropenic activities of Doxifluridine.,Doxifluridine
DB12991,Trastuzumab may increase the neutropenic activities of Deoxyspergualin.,Deoxyspergualin
DB12996,Trastuzumab may increase the neutropenic activities of Acteoside.,Acteoside
DB13014,Trastuzumab may increase the neutropenic activities of Hypericin.,Hypericin
DB00092,Trastuzumab may increase the neutropenic activities of Alefacept.,Alefacept
DB00095,Trastuzumab may increase the neutropenic activities of Efalizumab.,Efalizumab
DB04951,Trastuzumab may increase the neutropenic activities of Pirfenidone.,Pirfenidone
DB04956,Trastuzumab may increase the neutropenic activities of Afelimomab.,Afelimomab
DB05676,Trastuzumab may increase the neutropenic activities of Apremilast.,Apremilast
DB06662,Trastuzumab may increase the neutropenic activities of Abetimus.,Abetimus
DB11776,Trastuzumab may increase the neutropenic activities of Brodalumab.,Brodalumab
DB13241,Trastuzumab may increase the neutropenic activities of Begelomab.,Begelomab
DB08059,Trastuzumab may increase the neutropenic activities of Wortmannin.,Wortmannin
DB13068,Trastuzumab may increase the neutropenic activities of 9-(N-methyl-L-isoleucine)-cyclosporin A.,9-(N-methyl-L-isoleucine)-cyclosporin A
DB00008,Trastuzumab may increase the neutropenic activities of Peginterferon alfa-2a.,Peginterferon alfa-2a
DB00018,Trastuzumab may increase the neutropenic activities of Interferon alfa-n3.,Interferon alfa-n3
DB00022,Trastuzumab may increase the neutropenic activities of Peginterferon alfa-2b.,Peginterferon alfa-2b
DB00041,Trastuzumab may increase the neutropenic activities of Aldesleukin.,Aldesleukin
DB00069,Trastuzumab may increase the neutropenic activities of Interferon alfacon-1.,Interferon alfacon-1
DB00112,Trastuzumab may increase the neutropenic activities of Bevacizumab.,Bevacizumab
DB00188,Trastuzumab may increase the neutropenic activities of Bortezomib.,Bortezomib
DB00293,Trastuzumab may increase the neutropenic activities of Raltitrexed.,Raltitrexed
DB00307,Trastuzumab may increase the neutropenic activities of Bexarotene.,Bexarotene
DB00380,Trastuzumab may increase the neutropenic activities of Dexrazoxane.,Dexrazoxane
DB00446,Trastuzumab may increase the neutropenic activities of Chloramphenicol.,Chloramphenicol
DB00495,Trastuzumab may increase the neutropenic activities of Zidovudine.,Zidovudine
DB00550,Trastuzumab may increase the neutropenic activities of Propylthiouracil.,Propylthiouracil
DB00564,Trastuzumab may increase the neutropenic activities of Carbamazepine.,Carbamazepine
DB00601,Trastuzumab may increase the neutropenic activities of Linezolid.,Linezolid
DB00763,Trastuzumab may increase the neutropenic activities of Methimazole.,Methimazole
DB01099,Trastuzumab may increase the neutropenic activities of Flucytosine.,Flucytosine
DB01169,Trastuzumab may increase the neutropenic activities of Arsenic trioxide.,Arsenic trioxide
DB01262,Trastuzumab may increase the neutropenic activities of Decitabine.,Decitabine
DB02546,Trastuzumab may increase the neutropenic activities of Vorinostat.,Vorinostat
DB04845,Trastuzumab may increase the neutropenic activities of Ixabepilone.,Ixabepilone
DB05015,Trastuzumab may increase the neutropenic activities of Belinostat.,Belinostat
DB06616,Trastuzumab may increase the neutropenic activities of Bosutinib.,Bosutinib
DB06769,Trastuzumab may increase the neutropenic activities of Bendamustine.,Bendamustine
DB08871,Trastuzumab may increase the neutropenic activities of Eribulin.,Eribulin
DB08889,Trastuzumab may increase the neutropenic activities of Carfilzomib.,Carfilzomib
DB08901,Trastuzumab may increase the neutropenic activities of Ponatinib.,Ponatinib
DB09074,Trastuzumab may increase the neutropenic activities of Olaparib.,Olaparib
DB11767,Trastuzumab may increase the neutropenic activities of Sarilumab.,Sarilumab
DB05459,Trastuzumab may increase the neutropenic activities of Briakinumab.,Briakinumab
DB11466,Trastuzumab may increase the neutropenic activities of Tepoxalin.,Tepoxalin
DB14066,Trastuzumab may increase the neutropenic activities of Tetrandrine.,Tetrandrine
DB00795,Trastuzumab may increase the neutropenic activities of Sulfasalazine.,Sulfasalazine
DB01611,Trastuzumab may increase the neutropenic activities of Hydroxychloroquine.,Hydroxychloroquine
DB00432,Trastuzumab may increase the neutropenic activities of Trifluridine.,Trifluridine
DB04630,Trastuzumab may increase the neutropenic activities of Aldosterone.,Aldosterone
DB01108,Trastuzumab may increase the neutropenic activities of Trilostane.,Trilostane
DB13208,Trastuzumab may increase the neutropenic activities of Prednylidene.,Prednylidene
DB01384,Trastuzumab may increase the neutropenic activities of Paramethasone.,Paramethasone
DB09383,Trastuzumab may increase the neutropenic activities of Meprednisone.,Meprednisone
DB11529,Trastuzumab may increase the neutropenic activities of Melengestrol.,Melengestrol
DB09378,Trastuzumab may increase the neutropenic activities of Fluprednisolone.,Fluprednisolone
DB00180,Trastuzumab may increase the neutropenic activities of Flunisolide.,Flunisolide
DB13003,Trastuzumab may increase the neutropenic activities of Cortivazol.,Cortivazol
DB13843,Trastuzumab may increase the neutropenic activities of Cloprednol.,Cloprednol
DB00240,Trastuzumab may increase the neutropenic activities of Alclometasone.,Alclometasone
DB00288,Trastuzumab may increase the neutropenic activities of Amcinonide.,Amcinonide
DB01410,Trastuzumab may increase the neutropenic activities of Ciclesonide.,Ciclesonide
DB11750,Trastuzumab may increase the neutropenic activities of Clobetasol.,Clobetasol
DB01013,Trastuzumab may increase the neutropenic activities of Clobetasol propionate.,Clobetasol propionate
DB13158,Trastuzumab may increase the neutropenic activities of Clobetasone.,Clobetasone
DB00838,Trastuzumab may increase the neutropenic activities of Clocortolone.,Clocortolone
DB01260,Trastuzumab may increase the neutropenic activities of Desonide.,Desonide
DB00547,Trastuzumab may increase the neutropenic activities of Desoximetasone.,Desoximetasone
DB11487,Trastuzumab may increase the neutropenic activities of Dexamethasone isonicotinate.,Dexamethasone isonicotinate
DB00223,Trastuzumab may increase the neutropenic activities of Diflorasone.,Diflorasone
DB09095,Trastuzumab may increase the neutropenic activities of Difluocortolone.,Difluocortolone
DB06781,Trastuzumab may increase the neutropenic activities of Difluprednate.,Difluprednate
DB13856,Trastuzumab may increase the neutropenic activities of Fluclorolone.,Fluclorolone
DB00663,Trastuzumab may increase the neutropenic activities of Flumethasone.,Flumethasone
DB00591,Trastuzumab may increase the neutropenic activities of Fluocinolone acetonide.,Fluocinolone acetonide
DB01047,Trastuzumab may increase the neutropenic activities of Fluocinonide.,Fluocinonide
DB13223,Trastuzumab may increase the neutropenic activities of Fluocortin.,Fluocortin
DB08971,Trastuzumab may increase the neutropenic activities of Fluocortolone.,Fluocortolone
DB00324,Trastuzumab may increase the neutropenic activities of Fluorometholone.,Fluorometholone
DB13491,Trastuzumab may increase the neutropenic activities of Fluperolone.,Fluperolone
DB08970,Trastuzumab may increase the neutropenic activities of Fluprednidene.,Fluprednidene
DB00846,Trastuzumab may increase the neutropenic activities of Flurandrenolide.,Flurandrenolide
DB13867,Trastuzumab may increase the neutropenic activities of Fluticasone.,Fluticasone
DB08906,Trastuzumab may increase the neutropenic activities of Fluticasone furoate.,Fluticasone furoate
DB00588,Trastuzumab may increase the neutropenic activities of Fluticasone propionate.,Fluticasone propionate
DB13664,Trastuzumab may increase the neutropenic activities of Formocortal.,Formocortal
DB06786,Trastuzumab may increase the neutropenic activities of Halcinonide.,Halcinonide
DB13728,Trastuzumab may increase the neutropenic activities of Halometasone.,Halometasone
DB14538,Trastuzumab may increase the neutropenic activities of Hydrocortisone aceponate.,Hydrocortisone aceponate
DB14539,Trastuzumab may increase the neutropenic activities of Hydrocortisone acetate.,Hydrocortisone acetate
DB14543,Trastuzumab may increase the neutropenic activities of Hydrocortisone probutate.,Hydrocortisone probutate
DB14540,Trastuzumab may increase the neutropenic activities of Hydrocortisone butyrate.,Hydrocortisone butyrate
DB14545,Trastuzumab may increase the neutropenic activities of Hydrocortisone succinate.,Hydrocortisone succinate
DB14544,Trastuzumab may increase the neutropenic activities of Hydrocortisone valerate.,Hydrocortisone valerate
DB14596,Trastuzumab may increase the neutropenic activities of Loteprednol etabonate.,Loteprednol etabonate
DB00253,Trastuzumab may increase the neutropenic activities of Medrysone.,Medrysone
DB00764,Trastuzumab may increase the neutropenic activities of Mometasone.,Mometasone
DB14512,Trastuzumab may increase the neutropenic activities of Mometasone furoate.,Mometasone furoate
DB01130,Trastuzumab may increase the neutropenic activities of Prednicarbate.,Prednicarbate
DB00896,Trastuzumab may increase the neutropenic activities of Rimexolone.,Rimexolone
DB09091,Trastuzumab may increase the neutropenic activities of Tixocortol.,Tixocortol
DB00596,Trastuzumab may increase the neutropenic activities of Ulobetasol.,Ulobetasol
DB01394,Trastuzumab may increase the neutropenic activities of Colchicine.,Colchicine
DB14219,Trastuzumab may increase the neutropenic activities of Monomethyl fumarate.,Monomethyl fumarate
DB00859,Trastuzumab may increase the neutropenic activities of Penicillamine.,Penicillamine
DB00328,Trastuzumab may increase the neutropenic activities of Indomethacin.,Indomethacin
DB03523,Trastuzumab may increase the neutropenic activities of Brequinar.,Brequinar
DB00033,Trastuzumab may increase the neutropenic activities of Interferon gamma-1b.,Interferon gamma-1b
DB05472,Trastuzumab may increase the neutropenic activities of omega interferon.,omega interferon
DB00011,Trastuzumab may increase the neutropenic activities of Interferon alfa-n1.,Interferon alfa-n1
DB09122,Trastuzumab may increase the neutropenic activities of Peginterferon beta-1a.,Peginterferon beta-1a
DB12814,Trastuzumab may increase the neutropenic activities of Cepeginterferon alfa-2B.,Cepeginterferon alfa-2B
DB00068,Trastuzumab may increase the neutropenic activities of Interferon beta-1b.,Interferon beta-1b
DB00034,"Trastuzumab may increase the neutropenic activities of Interferon alfa-2a, Recombinant.","Interferon alfa-2a, Recombinant"
DB05258,Trastuzumab may increase the neutropenic activities of Interferon alfa.,Interferon alfa
DB00105,Trastuzumab may increase the neutropenic activities of Interferon alfa-2b.,Interferon alfa-2b
DB11569,Trastuzumab may increase the neutropenic activities of Ixekizumab.,Ixekizumab
DB11803,Trastuzumab may increase the neutropenic activities of Sirukumab.,Sirukumab
DB11817,Trastuzumab may increase the neutropenic activities of Baricitinib.,Baricitinib
DB11834,Trastuzumab may increase the neutropenic activities of Guselkumab.,Guselkumab
DB12612,Trastuzumab may increase the neutropenic activities of Ozanimod.,Ozanimod
DB14724,Trastuzumab may increase the neutropenic activities of Emapalumab.,Emapalumab
DB12371,Trastuzumab may increase the neutropenic activities of Siponimod.,Siponimod
DB14762,Trastuzumab may increase the neutropenic activities of Risankizumab.,Risankizumab
DB15253,Trastuzumab may increase the neutropenic activities of Bleselumab.,Bleselumab
DB00394,Trastuzumab may increase the neutropenic activities of Beclomethasone dipropionate.,Beclomethasone dipropionate
DB11580,Trastuzumab may increase the neutropenic activities of Ravulizumab.,Ravulizumab
DB11708,Trastuzumab may increase the neutropenic activities of Peficitinib.,Peficitinib
DB14919,Trastuzumab may increase the neutropenic activities of Rozanolixizumab.,Rozanolixizumab
DB08868,Trastuzumab may increase the immunosuppressive activities of Fingolimod.,Fingolimod
DB00864,Tacrolimus may increase the immunosuppressive activities of Trastuzumab.,Tacrolimus
DB00390,Digoxin may decrease the cardiotoxic activities of Trastuzumab.,Digoxin
DB00511,Acetyldigitoxin may decrease the cardiotoxic activities of Trastuzumab.,Acetyldigitoxin
DB01078,Deslanoside may decrease the cardiotoxic activities of Trastuzumab.,Deslanoside
DB01092,Ouabain may decrease the cardiotoxic activities of Trastuzumab.,Ouabain
DB01396,Digitoxin may decrease the cardiotoxic activities of Trastuzumab.,Digitoxin
DB12843,Oleandrin may decrease the cardiotoxic activities of Trastuzumab.,Oleandrin
DB13240,Cymarin may decrease the cardiotoxic activities of Trastuzumab.,Cymarin
DB13307,Proscillaridin may decrease the cardiotoxic activities of Trastuzumab.,Proscillaridin
DB13401,Metildigoxin may decrease the cardiotoxic activities of Trastuzumab.,Metildigoxin
DB13467,Lanatoside C may decrease the cardiotoxic activities of Trastuzumab.,Lanatoside C
DB13537,Gitoformate may decrease the cardiotoxic activities of Trastuzumab.,Gitoformate
DB13691,Acetyldigoxin may decrease the cardiotoxic activities of Trastuzumab.,Acetyldigoxin
DB13756,Peruvoside may decrease the cardiotoxic activities of Trastuzumab.,Peruvoside
DB00675,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Tamoxifen.,Tamoxifen
DB01217,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Anastrozole.,Anastrozole
DB06171,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Paclitaxel trevatide.,Paclitaxel trevatide
DB13809,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Paclitaxel poliglumex.,Paclitaxel poliglumex
DB04914,The therapeutic efficacy of G17DT can be decreased when used in combination with Trastuzumab.,G17DT
DB05144,The therapeutic efficacy of PEV3A can be decreased when used in combination with Trastuzumab.,PEV3A
DB05325,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Trastuzumab.,INGN 225
DB05374,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Trastuzumab.,Rindopepimut
DB05440,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Trastuzumab.,SRP 299
DB05942,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Trastuzumab.,GI-5005
DB06400,The therapeutic efficacy of Vitespen can be decreased when used in combination with Trastuzumab.,Vitespen
DB06584,The therapeutic efficacy of TG4010 can be decreased when used in combination with Trastuzumab.,TG4010
DB09057,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Trastuzumab.,Anthrax immune globulin human
DB10062,"The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Trastuzumab.","Rabies virus inactivated antigen, B"
DB10076,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Trastuzumab.,Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen
DB10276,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Trastuzumab.,Rotavirus vaccine
DB10283,"The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Trastuzumab.","Rabies virus inactivated antigen, A"
DB10342,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Trastuzumab.,Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen
DB10583,The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Trastuzumab.,Clostridium tetani toxoid antigen (formaldehyde inactivated)
DB10584,The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Trastuzumab.,Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
DB10600,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Trastuzumab.,Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated)
DB10769,The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Trastuzumab.,Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)
DB10794,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Trastuzumab.,Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated)
DB10803,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Trastuzumab.,Typhoid Vi polysaccharide vaccine
DB10989,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Trastuzumab.,Hepatitis A Vaccine
DB10990,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Trastuzumab.,Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
DB11038,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Trastuzumab.,Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated)
DB11040,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Trastuzumab.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated)
DB11041,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Trastuzumab.,Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)
DB11044,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Trastuzumab.,Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated)
DB11603,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Trastuzumab.,Human rabies virus immune globulin
DB11627,The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Trastuzumab.,Hepatitis B Vaccine (Recombinant)
DB12568,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Trastuzumab.,Tecemotide
DB14022,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Trastuzumab.,Typhoid vaccine
DB14384,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Trastuzumab.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated)
DB14385,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Trastuzumab.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)
DB14394,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Trastuzumab.,Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen
DB14445,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Trastuzumab.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated)
DB14449,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Trastuzumab.,Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen
DB14619,The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Trastuzumab.,Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated)
DB14620,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Trastuzumab.,Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated)
DB14711,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Trastuzumab.,Vaccinia virus strain new york city board of health live antigen
DB15274,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Trastuzumab.,Pertussis vaccine
DB15461,The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Trastuzumab.,Yersinia pestis 195/p antigen (formaldehyde inactivated)
DB13924,The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Trastuzumab.,Varicella Zoster Vaccine (Recombinant)
DB15483,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Trastuzumab.,Modified vaccinia ankara
DB11988,Ocrelizumab may increase the immunosuppressive activities of Trastuzumab.,Ocrelizumab
DB10317,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Trastuzumab.,Rubella virus vaccine
DB10318,The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Trastuzumab.,Varicella Zoster Vaccine (Live/attenuated)
DB10343,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Trastuzumab.,Bacillus calmette-guerin substrain tice live antigen
DB10804,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Trastuzumab.,Bacillus calmette-guerin substrain connaught live antigen
DB10805,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Trastuzumab.,Yellow Fever Vaccine
DB11003,The risk or severity of infection can be increased when Anthrax vaccine is combined with Trastuzumab.,Anthrax vaccine
DB11050,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Trastuzumab.,Typhoid Vaccine Live
DB12386,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Trastuzumab.,Bacillus calmette-guerin substrain danish 1331 live antigen
DB12768,The risk or severity of infection can be increased when BCG vaccine is combined with Trastuzumab.,BCG vaccine
DB14409,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Trastuzumab.,Human adenovirus e serotype 4 strain cl-68578 antigen
DB14443,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Trastuzumab.,Vibrio cholerae CVD 103-HgR strain live antigen
DB14685,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Trastuzumab.,Adenovirus type 7 vaccine live
DB00002,The risk or severity of adverse effects can be increased when Cetuximab is combined with Trastuzumab.,Cetuximab
DB00028,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Trastuzumab.,Human immunoglobulin G
DB00043,The risk or severity of adverse effects can be increased when Omalizumab is combined with Trastuzumab.,Omalizumab
DB00054,The risk or severity of adverse effects can be increased when Abciximab is combined with Trastuzumab.,Abciximab
DB00057,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Trastuzumab.,Indium In-111 satumomab pendetide
DB00076,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Digoxin Immune Fab (Ovine).,Digoxin Immune Fab (Ovine)
DB00089,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Capromab pendetide.,Capromab pendetide
DB00110,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Palivizumab.,Palivizumab
DB00113,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Technetium Tc-99m arcitumomab.,Technetium Tc-99m arcitumomab
DB01269,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Panitumumab.,Panitumumab
DB01270,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ranibizumab.,Ranibizumab
DB04901,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Galiximab.,Galiximab
DB04949,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Pexelizumab.,Pexelizumab
DB04958,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Epratuzumab.,Epratuzumab
DB04962,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Bectumomab.,Bectumomab
DB04964,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Oregovomab.,Oregovomab
DB04988,The risk or severity of adverse effects can be increased when Trastuzumab is combined with IGN311.,IGN311
DB05006,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Adecatumumab.,Adecatumumab
DB05097,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Labetuzumab.,Labetuzumab
DB05101,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Matuzumab.,Matuzumab
DB05111,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Fontolizumab.,Fontolizumab
DB05136,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Bavituximab.,Bavituximab
DB05139,The risk or severity of adverse effects can be increased when Trastuzumab is combined with CR002.,CR002
DB05209,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Rozrolimupab.,Rozrolimupab
DB05304,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Girentuximab.,Girentuximab
DB05336,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Obiltoxaximab.,Obiltoxaximab
DB05405,The risk or severity of adverse effects can be increased when Trastuzumab is combined with XTL-001.,XTL-001
DB05437,The risk or severity of adverse effects can be increased when Trastuzumab is combined with NAV 1800.,NAV 1800
DB05496,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Otelixizumab.,Otelixizumab
DB05545,The risk or severity of adverse effects can be increased when Trastuzumab is combined with AMG 108.,AMG 108
DB05550,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Iratumumab.,Iratumumab
DB05555,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Enokizumab.,Enokizumab
DB05578,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ramucirumab.,Ramucirumab
DB05595,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Farletuzumab.,Farletuzumab
DB05656,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Veltuzumab.,Veltuzumab
DB05793,The risk or severity of adverse effects can be increased when Trastuzumab is combined with PRO-542.,PRO-542
DB05797,The risk or severity of adverse effects can be increased when Trastuzumab is combined with TNX-901.,TNX-901
DB05889,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Inotuzumab ozogamicin.,Inotuzumab ozogamicin
DB05892,The risk or severity of adverse effects can be increased when Trastuzumab is combined with RI 624.,RI 624
DB05915,The risk or severity of adverse effects can be increased when Trastuzumab is combined with MYO-029.,MYO-029
DB05916,The risk or severity of adverse effects can be increased when Trastuzumab is combined with CT-011.,CT-011
DB05941,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Leronlimab.,Leronlimab
DB05996,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Glembatumumab vedotin.,Glembatumumab vedotin
DB06043,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Olaratumab.,Olaratumab
DB06049,The risk or severity of adverse effects can be increased when Trastuzumab is combined with IPH 2101.,IPH 2101
DB06050,The risk or severity of adverse effects can be increased when Trastuzumab is combined with TB-402.,TB-402
DB06081,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Caplacizumab.,Caplacizumab
DB06101,The risk or severity of adverse effects can be increased when Trastuzumab is combined with IMC-1C11.,IMC-1C11
DB06116,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Eldelumab.,Eldelumab
DB06162,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Lumiliximab.,Lumiliximab
DB06186,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ipilimumab.,Ipilimumab
DB06192,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Nimotuzumab.,Nimotuzumab
DB06241,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Clenoliximab.,Clenoliximab
DB06304,The risk or severity of adverse effects can be increased when Trastuzumab is combined with BIIB015.,BIIB015
DB06305,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Sonepcizumab.,Sonepcizumab
DB06310,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Motavizumab.,Motavizumab
DB06317,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Elotuzumab.,Elotuzumab
DB06318,The risk or severity of adverse effects can be increased when Trastuzumab is combined with AVE9633.,AVE9633
DB06322,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Carotuximab.,Carotuximab
DB06324,The risk or severity of adverse effects can be increased when Trastuzumab is combined with XmAb 2513.,XmAb 2513
DB06342,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Coltuximab ravtansine.,Coltuximab ravtansine
DB06343,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Teprotumumab.,Teprotumumab
DB06360,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Lucatumumab.,Lucatumumab
DB06366,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Pertuzumab.,Pertuzumab
DB06371,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Siplizumab.,Siplizumab
DB06467,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Apolizumab.,Apolizumab
DB06474,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Sibrotuzumab.,Sibrotuzumab
DB06550,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Bivatuzumab.,Bivatuzumab
DB06557,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Lerdelimumab.,Lerdelimumab
DB06599,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Lexatumumab.,Lexatumumab
DB06602,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Reslizumab.,Reslizumab
DB06606,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Teplizumab.,Teplizumab
DB06607,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Catumaxomab.,Catumaxomab
DB06647,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Volociximab.,Volociximab
DB06650,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ofatumumab.,Ofatumumab
DB08902,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Raxibacumab.,Raxibacumab
DB09035,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Nivolumab.,Nivolumab
DB09037,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Pembrolizumab.,Pembrolizumab
DB09045,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Dulaglutide.,Dulaglutide
DB09105,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Asfotase alfa.,Asfotase alfa
DB09264,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Idarucizumab.,Idarucizumab
DB09302,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Alirocumab.,Alirocumab
DB09303,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Evolocumab.,Evolocumab
DB09331,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Daratumumab.,Daratumumab
DB09559,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Necitumumab.,Necitumumab
DB11595,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Atezolizumab.,Atezolizumab
DB11604,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tetanus Immune Globulin.,Tetanus Immune Globulin
DB11608,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Eftrenonacog alfa.,Eftrenonacog alfa
DB11621,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Human Varicella-Zoster Immune Globulin.,Human Varicella-Zoster Immune Globulin
DB11646,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Conatumumab.,Conatumumab
DB11657,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tabalumab.,Tabalumab
DB11680,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ficlatuzumab.,Ficlatuzumab
DB11685,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Figitumumab.,Figitumumab
DB11714,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Durvalumab.,Durvalumab
DB11715,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Bapineuzumab.,Bapineuzumab
DB11731,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Depatuxizumab mafodotin.,Depatuxizumab mafodotin
DB11746,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Onartuzumab.,Onartuzumab
DB11756,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Solanezumab.,Solanezumab
DB11771,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tremelimumab.,Tremelimumab
DB11826,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Lampalizumab.,Lampalizumab
DB11840,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Dalotuzumab.,Dalotuzumab
DB11849,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Emibetuzumab.,Emibetuzumab
DB11850,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ublituximab.,Ublituximab
DB11856,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ligelizumab.,Ligelizumab
DB11857,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Seribantumab.,Seribantumab
DB11862,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Landogrozumab.,Landogrozumab
DB11866,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Romosozumab.,Romosozumab
DB11884,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Vadastuximab Talirine.,Vadastuximab Talirine
DB11914,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Lebrikizumab.,Lebrikizumab
DB11930,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Varlilumab.,Varlilumab
DB11945,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Avelumab.,Avelumab
DB11959,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Crenezumab.,Crenezumab
DB11972,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Rilotumumab.,Rilotumumab
DB11976,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Anifrolumab.,Anifrolumab
DB12023,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Benralizumab.,Benralizumab
DB12034,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Gantenerumab.,Gantenerumab
DB12053,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Visilizumab.,Visilizumab
DB12077,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Urelumab.,Urelumab
DB12089,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Lorvotuzumab mertansine.,Lorvotuzumab mertansine
DB12090,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Patritumab.,Patritumab
DB12102,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Fulranumab.,Fulranumab
DB12104,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tarextumab.,Tarextumab
DB12118,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Sotatercept.,Sotatercept
DB12119,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Gevokizumab.,Gevokizumab
DB12142,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Duligotuzumab.,Duligotuzumab
DB12152,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Simtuzumab.,Simtuzumab
DB12157,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Fasinumab.,Fasinumab
DB12159,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Dupilumab.,Dupilumab
DB12169,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tralokinumab.,Tralokinumab
DB12189,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Etrolizumab.,Etrolizumab
DB12202,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Zalutumumab.,Zalutumumab
DB12205,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ganitumab.,Ganitumab
DB12213,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Etaracizumab.,Etaracizumab
DB12240,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Polatuzumab vedotin.,Polatuzumab vedotin
DB12246,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Inclacumab.,Inclacumab
DB12250,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Cixutumumab.,Cixutumumab
DB12261,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ascrinvacumab.,Ascrinvacumab
DB12274,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Aducanumab.,Aducanumab
DB12281,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Luspatercept.,Luspatercept
DB12296,The risk or severity of adverse effects can be increased when Trastuzumab is combined with GS-5745.,GS-5745
DB12317,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Vanucizumab.,Vanucizumab
DB12331,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Labetuzumab govitecan.,Labetuzumab govitecan
DB12335,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tanezumab.,Tanezumab
DB12342,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ensituximab.,Ensituximab
DB12344,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Fezakinumab.,Fezakinumab
DB12363,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Dusigitumab.,Dusigitumab
DB12396,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Fresolimumab.,Fresolimumab
DB12413,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Indusatumab vedotin.,Indusatumab vedotin
DB12456,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Bococizumab.,Bococizumab
DB12489,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Mirvetuximab Soravtansine.,Mirvetuximab Soravtansine
DB12498,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Mogamulizumab.,Mogamulizumab
DB12520,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Plozalizumab.,Plozalizumab
DB12534,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Mavrilimumab.,Mavrilimumab
DB12560,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Blosozumab.,Blosozumab
DB12584,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Bimagrumab.,Bimagrumab
DB12589,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Dacetuzumab.,Dacetuzumab
DB12609,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tovetumab.,Tovetumab
DB12683,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Lumretuzumab.,Lumretuzumab
DB12698,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ibalizumab.,Ibalizumab
DB12701,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Intetumumab.,Intetumumab
DB12718,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Carlumab.,Carlumab
DB12734,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Demcizumab.,Demcizumab
DB12773,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Sifalimumab.,Sifalimumab
DB12775,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Abituzumab.,Abituzumab
DB12797,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ecromeximab.,Ecromeximab
DB12807,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Naptumomab Estafenatox.,Naptumomab Estafenatox
DB12815,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Crotedumab.,Crotedumab
DB12820,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Concizumab.,Concizumab
DB12826,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Depatuxizumab.,Depatuxizumab
DB12844,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Rontalizumab.,Rontalizumab
DB12845,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Amatuximab.,Amatuximab
DB12849,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Clazakizumab.,Clazakizumab
DB12891,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ozanezumab.,Ozanezumab
DB12893,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Sacituzumab govitecan.,Sacituzumab govitecan
DB12917,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Bimekizumab.,Bimekizumab
DB12943,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Milatuzumab.,Milatuzumab
DB12976,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Robatumumab.,Robatumumab
DB13017,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Rovalpituzumab Tesirine.,Rovalpituzumab Tesirine
DB13037,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Namilumab.,Namilumab
DB13045,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Racotumomab.,Racotumomab
DB13073,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tregalizumab.,Tregalizumab
DB13127,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Olokizumab.,Olokizumab
DB13140,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Bezlotoxumab.,Bezlotoxumab
DB13375,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Edrecolomab.,Edrecolomab
DB13535,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Nebacumab.,Nebacumab
DB13886,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Human cytomegalovirus immune globulin.,Human cytomegalovirus immune globulin
DB13923,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Emicizumab.,Emicizumab
DB13976,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Sulesomab.,Sulesomab
DB13979,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Besilesomab.,Besilesomab
DB14012,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Burosumab.,Burosumab
DB14039,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Erenumab.,Erenumab
DB14040,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Eptinezumab.,Eptinezumab
DB14041,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Fremanezumab.,Fremanezumab
DB14042,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Galcanezumab.,Galcanezumab
DB14211,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Fanolesomab.,Fanolesomab
DB14580,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Lecanemab.,Lecanemab
DB14597,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Lanadelumab.,Lanadelumab
DB14707,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Cemiplimab.,Cemiplimab
DB14776,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Camrelizumab.,Camrelizumab
DB14778,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Setrusumab.,Setrusumab
DB14809,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Anetumab ravtansine.,Anetumab ravtansine
DB14811,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Isatuximab.,Isatuximab
DB14824,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Icrucumab.,Icrucumab
DB14843,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Codrituzumab.,Codrituzumab
DB14864,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Brolucizumab.,Brolucizumab
DB14871,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Xentuzumab.,Xentuzumab
DB14877,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Lintuzumab.,Lintuzumab
DB14891,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Vobarilizumab.,Vobarilizumab
DB14897,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Parsatuzumab.,Parsatuzumab
DB14905,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Emactuzumab.,Emactuzumab
DB14907,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Bevacizumab zirconium Zr-89.,Bevacizumab zirconium Zr-89
DB14908,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Refanezumab.,Refanezumab
DB14947,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Bermekimab.,Bermekimab
DB14952,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Pamrevlumab.,Pamrevlumab
DB14959,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Opicinumab.,Opicinumab
DB14962,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Trastuzumab deruxtecan.,Trastuzumab deruxtecan
DB14967,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Margetuximab.,Margetuximab
DB14988,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Dalantercept.,Dalantercept
DB14997,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Pateclizumab.,Pateclizumab
DB15014,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Gremubamab.,Gremubamab
DB15022,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Apomab.,Apomab
DB15044,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tafasitamab.,Tafasitamab
DB15045,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ipafricept.,Ipafricept
DB15076,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Abrilumab.,Abrilumab
DB15089,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Frovocimab.,Frovocimab
DB15090,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tezepelumab.,Tezepelumab
DB15101,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tigatuzumab.,Tigatuzumab
DB15104,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Telisotuzumab vedotin.,Telisotuzumab vedotin
DB15113,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Utomilumab.,Utomilumab
DB15118,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Zolbetuximab.,Zolbetuximab
DB15135,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ponezumab.,Ponezumab
DB15160,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Asunercept.,Asunercept
DB15172,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Suvratoxumab.,Suvratoxumab
DB15225,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Mitazalimab.,Mitazalimab
DB15252,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Nemolizumab.,Nemolizumab
DB15277,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Gedivumab.,Gedivumab
DB15336,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Valanafusp alfa.,Valanafusp alfa
DB15349,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Sofituzumab vedotin.,Sofituzumab vedotin
DB15354,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Evinacumab.,Evinacumab
DB15363,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Istiratumab.,Istiratumab
DB15383,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Pidilizumab.,Pidilizumab
DB15397,The risk or severity of adverse effects can be increased when Trastuzumab is combined with GMA-161.,GMA-161
DB15409,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ladiratuzumab vedotin.,Ladiratuzumab vedotin
DB15415,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tomaralimab.,Tomaralimab
DB15428,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Vesencumab.,Vesencumab
DB15432,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Pinatuzumab vedotin.,Pinatuzumab vedotin
DB15441,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Lulizumab pegol.,Lulizumab pegol
DB15443,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Lorukafusp alfa.,Lorukafusp alfa
DB15453,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Naratuximab emtansine.,Naratuximab emtansine
DB14004,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tildrakizumab.,Tildrakizumab
DB05679,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ustekinumab.,Ustekinumab
DB15559,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Zenocutuzumab.,Zenocutuzumab
DB00091,Trastuzumab may increase the immunosuppressive activities of Cyclosporine.,Cyclosporine
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Trastuzumab.","Ebola Zaire vaccine (live, attenuated)"
DB14513,The serum concentration of Magnesium can be decreased when it is combined with Trastuzumab.,Magnesium
DB01601,The serum concentration of Trastuzumab can be increased when it is combined with Lopinavir.,Lopinavir
DB00445,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Epirubicin.,Epirubicin
DB00694,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Daunorubicin.,Daunorubicin
DB00997,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Doxorubicin.,Doxorubicin
DB01177,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Idarubicin.,Idarubicin
DB11616,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Pirarubicin.,Pirarubicin
DB06013,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Aldoxorubicin.,Aldoxorubicin
DB14784,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Gancotamab.,Gancotamab
DB00385,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Valrubicin.,Valrubicin
DB04978,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with SP1049C.,SP1049C
DB06071,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with DTS-201.,DTS-201
DB06420,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Annamycin.,Annamycin
DB06810,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Plicamycin.,Plicamycin
DB11617,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Aclarubicin.,Aclarubicin
DB11618,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Zorubicin.,Zorubicin
DB12410,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Sabarubicin.,Sabarubicin
DB12755,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Zoptarelin doxorubicin.,Zoptarelin doxorubicin
DB13103,The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with GPX-150.,GPX-150
DB12530,The risk or severity of infection can be increased when Trastuzumab is combined with Inebilizumab.,Inebilizumab
DB06643,The risk or severity of adverse effects can be increased when Denosumab is combined with Rituximab.,Denosumab
DB00005,The risk or severity of adverse effects can be increased when Etanercept is combined with Rituximab.,Etanercept
DB00008,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Rituximab.,Peginterferon alfa-2a
DB00011,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Rituximab.,Interferon alfa-n1
DB00018,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Rituximab.,Interferon alfa-n3
DB00022,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Rituximab.,Peginterferon alfa-2b
DB00026,The risk or severity of adverse effects can be increased when Anakinra is combined with Rituximab.,Anakinra
DB00033,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Rituximab.,Interferon gamma-1b
DB00034,"The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Rituximab.","Interferon alfa-2a, Recombinant"
DB00041,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Rituximab.,Aldesleukin
DB00051,The risk or severity of adverse effects can be increased when Adalimumab is combined with Rituximab.,Adalimumab
DB00056,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Rituximab.,Gemtuzumab ozogamicin
DB00059,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Rituximab.,Pegaspargase
DB00065,The risk or severity of adverse effects can be increased when Infliximab is combined with Rituximab.,Infliximab
DB00068,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Rituximab.,Interferon beta-1b
DB00069,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Rituximab.,Interferon alfacon-1
DB00074,The risk or severity of adverse effects can be increased when Rituximab is combined with Basiliximab.,Basiliximab
DB00075,The risk or severity of adverse effects can be increased when Rituximab is combined with Muromonab.,Muromonab
DB00078,The risk or severity of adverse effects can be increased when Rituximab is combined with Ibritumomab tiuxetan.,Ibritumomab tiuxetan
DB00081,The risk or severity of adverse effects can be increased when Rituximab is combined with Tositumomab.,Tositumomab
DB00087,The risk or severity of adverse effects can be increased when Rituximab is combined with Alemtuzumab.,Alemtuzumab
DB00092,The risk or severity of adverse effects can be increased when Rituximab is combined with Alefacept.,Alefacept
DB00095,The risk or severity of adverse effects can be increased when Rituximab is combined with Efalizumab.,Efalizumab
DB00098,The risk or severity of adverse effects can be increased when Rituximab is combined with Antithymocyte immunoglobulin (rabbit).,Antithymocyte immunoglobulin (rabbit)
DB00105,The risk or severity of adverse effects can be increased when Rituximab is combined with Interferon alfa-2b.,Interferon alfa-2b
DB00111,The risk or severity of adverse effects can be increased when Rituximab is combined with Daclizumab.,Daclizumab
DB00112,The risk or severity of adverse effects can be increased when Rituximab is combined with Bevacizumab.,Bevacizumab
DB00120,The risk or severity of adverse effects can be increased when Rituximab is combined with Phenylalanine.,Phenylalanine
DB00180,The risk or severity of adverse effects can be increased when Rituximab is combined with Flunisolide.,Flunisolide
DB00188,The risk or severity of adverse effects can be increased when Rituximab is combined with Bortezomib.,Bortezomib
DB00242,The risk or severity of adverse effects can be increased when Rituximab is combined with Cladribine.,Cladribine
DB00262,The risk or severity of adverse effects can be increased when Rituximab is combined with Carmustine.,Carmustine
DB00276,The risk or severity of adverse effects can be increased when Rituximab is combined with Amsacrine.,Amsacrine
DB00290,The risk or severity of adverse effects can be increased when Rituximab is combined with Bleomycin.,Bleomycin
DB00291,The risk or severity of adverse effects can be increased when Rituximab is combined with Chlorambucil.,Chlorambucil
DB00293,The risk or severity of adverse effects can be increased when Rituximab is combined with Raltitrexed.,Raltitrexed
DB00305,The risk or severity of adverse effects can be increased when Rituximab is combined with Mitomycin.,Mitomycin
DB00307,The risk or severity of adverse effects can be increased when Rituximab is combined with Bexarotene.,Bexarotene
DB00309,The risk or severity of adverse effects can be increased when Rituximab is combined with Vindesine.,Vindesine
DB00322,The risk or severity of adverse effects can be increased when Rituximab is combined with Floxuridine.,Floxuridine
DB00328,The risk or severity of adverse effects can be increased when Rituximab is combined with Indomethacin.,Indomethacin
DB00352,The risk or severity of adverse effects can be increased when Rituximab is combined with Tioguanine.,Tioguanine
DB00361,The risk or severity of adverse effects can be increased when Rituximab is combined with Vinorelbine.,Vinorelbine
DB00380,The risk or severity of adverse effects can be increased when Rituximab is combined with Dexrazoxane.,Dexrazoxane
DB00394,The risk or severity of adverse effects can be increased when Rituximab is combined with Beclomethasone dipropionate.,Beclomethasone dipropionate
DB00398,The risk or severity of adverse effects can be increased when Rituximab is combined with Sorafenib.,Sorafenib
DB00428,The risk or severity of adverse effects can be increased when Rituximab is combined with Streptozocin.,Streptozocin
DB00432,The risk or severity of adverse effects can be increased when Rituximab is combined with Trifluridine.,Trifluridine
DB00441,The risk or severity of adverse effects can be increased when Rituximab is combined with Gemcitabine.,Gemcitabine
DB00443,The risk or severity of adverse effects can be increased when Rituximab is combined with Betamethasone.,Betamethasone
DB00444,The risk or severity of adverse effects can be increased when Rituximab is combined with Teniposide.,Teniposide
DB00445,The risk or severity of adverse effects can be increased when Rituximab is combined with Epirubicin.,Epirubicin
DB00446,The risk or severity of adverse effects can be increased when Rituximab is combined with Chloramphenicol.,Chloramphenicol
DB00480,The risk or severity of adverse effects can be increased when Rituximab is combined with Lenalidomide.,Lenalidomide
DB00488,The risk or severity of adverse effects can be increased when Rituximab is combined with Altretamine.,Altretamine
DB00495,The risk or severity of adverse effects can be increased when Rituximab is combined with Zidovudine.,Zidovudine
DB00526,The risk or severity of adverse effects can be increased when Rituximab is combined with Oxaliplatin.,Oxaliplatin
DB00531,The risk or severity of adverse effects can be increased when Rituximab is combined with Cyclophosphamide.,Cyclophosphamide
DB00541,The risk or severity of adverse effects can be increased when Rituximab is combined with Vincristine.,Vincristine
DB00544,The risk or severity of adverse effects can be increased when Rituximab is combined with Fluorouracil.,Fluorouracil
DB00550,The risk or severity of adverse effects can be increased when Rituximab is combined with Propylthiouracil.,Propylthiouracil
DB00552,The risk or severity of adverse effects can be increased when Rituximab is combined with Pentostatin.,Pentostatin
DB00563,The risk or severity of adverse effects can be increased when Rituximab is combined with Methotrexate.,Methotrexate
DB00564,The risk or severity of adverse effects can be increased when Rituximab is combined with Carbamazepine.,Carbamazepine
DB00570,The risk or severity of adverse effects can be increased when Rituximab is combined with Vinblastine.,Vinblastine
DB00588,The risk or severity of adverse effects can be increased when Rituximab is combined with Fluticasone propionate.,Fluticasone propionate
DB00591,The risk or severity of adverse effects can be increased when Rituximab is combined with Fluocinolone acetonide.,Fluocinolone acetonide
DB00601,The risk or severity of adverse effects can be increased when Rituximab is combined with Linezolid.,Linezolid
DB00619,The risk or severity of adverse effects can be increased when Rituximab is combined with Imatinib.,Imatinib
DB00620,The risk or severity of adverse effects can be increased when Rituximab is combined with Triamcinolone.,Triamcinolone
DB00631,The risk or severity of adverse effects can be increased when Rituximab is combined with Clofarabine.,Clofarabine
DB00635,The risk or severity of adverse effects can be increased when Rituximab is combined with Prednisone.,Prednisone
DB00642,The risk or severity of adverse effects can be increased when Rituximab is combined with Pemetrexed.,Pemetrexed
DB00687,The risk or severity of adverse effects can be increased when Rituximab is combined with Fludrocortisone.,Fludrocortisone
DB00688,The risk or severity of adverse effects can be increased when Rituximab is combined with Mycophenolate mofetil.,Mycophenolate mofetil
DB00694,The risk or severity of adverse effects can be increased when Rituximab is combined with Daunorubicin.,Daunorubicin
DB00755,The risk or severity of adverse effects can be increased when Rituximab is combined with Tretinoin.,Tretinoin
DB00762,The risk or severity of adverse effects can be increased when Rituximab is combined with Irinotecan.,Irinotecan
DB00763,The risk or severity of adverse effects can be increased when Rituximab is combined with Methimazole.,Methimazole
DB00764,The risk or severity of adverse effects can be increased when Rituximab is combined with Mometasone.,Mometasone
DB00773,The risk or severity of adverse effects can be increased when Rituximab is combined with Etoposide.,Etoposide
DB00795,The risk or severity of adverse effects can be increased when Rituximab is combined with Sulfasalazine.,Sulfasalazine
DB00851,The risk or severity of adverse effects can be increased when Rituximab is combined with Dacarbazine.,Dacarbazine
DB00853,The risk or severity of adverse effects can be increased when Rituximab is combined with Temozolomide.,Temozolomide
DB00859,The risk or severity of adverse effects can be increased when Rituximab is combined with Penicillamine.,Penicillamine
DB00860,The risk or severity of adverse effects can be increased when Rituximab is combined with Prednisolone.,Prednisolone
DB00877,The risk or severity of adverse effects can be increased when Rituximab is combined with Sirolimus.,Sirolimus
DB00888,The risk or severity of adverse effects can be increased when Rituximab is combined with Mechlorethamine.,Mechlorethamine
DB00928,The risk or severity of adverse effects can be increased when Rituximab is combined with Azacitidine.,Azacitidine
DB00958,The risk or severity of adverse effects can be increased when Rituximab is combined with Carboplatin.,Carboplatin
DB00959,The risk or severity of adverse effects can be increased when Rituximab is combined with Methylprednisolone.,Methylprednisolone
DB00970,The risk or severity of adverse effects can be increased when Rituximab is combined with Dactinomycin.,Dactinomycin
DB00987,The risk or severity of adverse effects can be increased when Rituximab is combined with Cytarabine.,Cytarabine
DB00993,The risk or severity of adverse effects can be increased when Rituximab is combined with Azathioprine.,Azathioprine
DB00997,The risk or severity of adverse effects can be increased when Rituximab is combined with Doxorubicin.,Doxorubicin
DB01005,The risk or severity of adverse effects can be increased when Rituximab is combined with Hydroxyurea.,Hydroxyurea
DB01008,The risk or severity of adverse effects can be increased when Rituximab is combined with Busulfan.,Busulfan
DB01024,The risk or severity of adverse effects can be increased when Rituximab is combined with Mycophenolic acid.,Mycophenolic acid
DB01030,The risk or severity of adverse effects can be increased when Rituximab is combined with Topotecan.,Topotecan
DB01033,The risk or severity of adverse effects can be increased when Rituximab is combined with Mercaptopurine.,Mercaptopurine
DB01041,The risk or severity of adverse effects can be increased when Rituximab is combined with Thalidomide.,Thalidomide
DB01042,The risk or severity of adverse effects can be increased when Rituximab is combined with Melphalan.,Melphalan
DB01073,The risk or severity of adverse effects can be increased when Rituximab is combined with Fludarabine.,Fludarabine
DB01099,The risk or severity of adverse effects can be increased when Rituximab is combined with Flucytosine.,Flucytosine
DB01101,The risk or severity of adverse effects can be increased when Rituximab is combined with Capecitabine.,Capecitabine
DB01108,The risk or severity of adverse effects can be increased when Rituximab is combined with Trilostane.,Trilostane
DB01168,The risk or severity of adverse effects can be increased when Rituximab is combined with Procarbazine.,Procarbazine
DB01169,The risk or severity of adverse effects can be increased when Rituximab is combined with Arsenic trioxide.,Arsenic trioxide
DB01177,The risk or severity of adverse effects can be increased when Rituximab is combined with Idarubicin.,Idarubicin
DB01181,The risk or severity of adverse effects can be increased when Rituximab is combined with Ifosfamide.,Ifosfamide
DB01196,The risk or severity of adverse effects can be increased when Rituximab is combined with Estramustine.,Estramustine
DB01204,The risk or severity of adverse effects can be increased when Rituximab is combined with Mitoxantrone.,Mitoxantrone
DB01206,The risk or severity of adverse effects can be increased when Rituximab is combined with Lomustine.,Lomustine
DB01222,The risk or severity of adverse effects can be increased when Rituximab is combined with Budesonide.,Budesonide
DB01229,The risk or severity of adverse effects can be increased when Rituximab is combined with Paclitaxel.,Paclitaxel
DB01234,The risk or severity of adverse effects can be increased when Rituximab is combined with Dexamethasone.,Dexamethasone
DB01248,The risk or severity of adverse effects can be increased when Rituximab is combined with Docetaxel.,Docetaxel
DB01254,The risk or severity of adverse effects can be increased when Rituximab is combined with Dasatinib.,Dasatinib
DB01257,The risk or severity of adverse effects can be increased when Rituximab is combined with Eculizumab.,Eculizumab
DB01262,The risk or severity of adverse effects can be increased when Rituximab is combined with Decitabine.,Decitabine
DB01268,The risk or severity of adverse effects can be increased when Rituximab is combined with Sunitinib.,Sunitinib
DB01280,The risk or severity of adverse effects can be increased when Rituximab is combined with Nelarabine.,Nelarabine
DB01285,The risk or severity of adverse effects can be increased when Rituximab is combined with Corticotropin.,Corticotropin
DB01380,The risk or severity of adverse effects can be increased when Rituximab is combined with Cortisone acetate.,Cortisone acetate
DB01384,The risk or severity of adverse effects can be increased when Rituximab is combined with Paramethasone.,Paramethasone
DB01394,The risk or severity of adverse effects can be increased when Rituximab is combined with Colchicine.,Colchicine
DB01410,The risk or severity of adverse effects can be increased when Rituximab is combined with Ciclesonide.,Ciclesonide
DB01423,The risk or severity of adverse effects can be increased when Rituximab is combined with Stepronin.,Stepronin
DB01590,The risk or severity of adverse effects can be increased when Rituximab is combined with Everolimus.,Everolimus
DB01611,The risk or severity of adverse effects can be increased when Rituximab is combined with Hydroxychloroquine.,Hydroxychloroquine
DB01816,The risk or severity of adverse effects can be increased when Rituximab is combined with Castanospermine.,Castanospermine
DB02546,The risk or severity of adverse effects can be increased when Rituximab is combined with Vorinostat.,Vorinostat
DB02806,The risk or severity of adverse effects can be increased when Rituximab is combined with 2-Methoxyethanol.,2-Methoxyethanol
DB03523,The risk or severity of adverse effects can be increased when Rituximab is combined with Brequinar.,Brequinar
DB04572,The risk or severity of adverse effects can be increased when Rituximab is combined with Thiotepa.,Thiotepa
DB04630,The risk or severity of adverse effects can be increased when Rituximab is combined with Aldosterone.,Aldosterone
DB04845,The risk or severity of adverse effects can be increased when Rituximab is combined with Ixabepilone.,Ixabepilone
DB04868,The risk or severity of adverse effects can be increased when Rituximab is combined with Nilotinib.,Nilotinib
DB04951,The risk or severity of adverse effects can be increased when Rituximab is combined with Pirfenidone.,Pirfenidone
DB04956,The risk or severity of adverse effects can be increased when Rituximab is combined with Afelimomab.,Afelimomab
DB05015,The risk or severity of adverse effects can be increased when Rituximab is combined with Belinostat.,Belinostat
DB05109,The risk or severity of adverse effects can be increased when Rituximab is combined with Trabectedin.,Trabectedin
DB05258,The risk or severity of adverse effects can be increased when Rituximab is combined with Interferon alfa.,Interferon alfa
DB05259,The risk or severity of adverse effects can be increased when Rituximab is combined with Glatiramer.,Glatiramer
DB05260,The risk or severity of adverse effects can be increased when Rituximab is combined with Gallium nitrate.,Gallium nitrate
DB05459,The risk or severity of adverse effects can be increased when Rituximab is combined with Briakinumab.,Briakinumab
DB05472,The risk or severity of adverse effects can be increased when Rituximab is combined with omega interferon.,omega interferon
DB05773,The risk or severity of adverse effects can be increased when Rituximab is combined with Trastuzumab emtansine.,Trastuzumab emtansine
DB06168,The risk or severity of adverse effects can be increased when Rituximab is combined with Canakinumab.,Canakinumab
DB06273,The risk or severity of adverse effects can be increased when Rituximab is combined with Tocilizumab.,Tocilizumab
DB06287,The risk or severity of adverse effects can be increased when Rituximab is combined with Temsirolimus.,Temsirolimus
DB06372,The risk or severity of adverse effects can be increased when Rituximab is combined with Rilonacept.,Rilonacept
DB06589,The risk or severity of adverse effects can be increased when Rituximab is combined with Pazopanib.,Pazopanib
DB06603,The risk or severity of adverse effects can be increased when Rituximab is combined with Panobinostat.,Panobinostat
DB06612,The risk or severity of adverse effects can be increased when Rituximab is combined with Mepolizumab.,Mepolizumab
DB06616,The risk or severity of adverse effects can be increased when Rituximab is combined with Bosutinib.,Bosutinib
DB06662,The risk or severity of adverse effects can be increased when Rituximab is combined with Abetimus.,Abetimus
DB06674,The risk or severity of adverse effects can be increased when Rituximab is combined with Golimumab.,Golimumab
DB06681,The risk or severity of adverse effects can be increased when Rituximab is combined with Belatacept.,Belatacept
DB06769,The risk or severity of adverse effects can be increased when Rituximab is combined with Bendamustine.,Bendamustine
DB06772,The risk or severity of adverse effects can be increased when Rituximab is combined with Cabazitaxel.,Cabazitaxel
DB06813,The risk or severity of adverse effects can be increased when Rituximab is combined with Pralatrexate.,Pralatrexate
DB08059,The risk or severity of adverse effects can be increased when Rituximab is combined with Wortmannin.,Wortmannin
DB08870,The risk or severity of adverse effects can be increased when Rituximab is combined with Brentuximab vedotin.,Brentuximab vedotin
DB08871,The risk or severity of adverse effects can be increased when Rituximab is combined with Eribulin.,Eribulin
DB08877,The risk or severity of adverse effects can be increased when Rituximab is combined with Ruxolitinib.,Ruxolitinib
DB08879,The risk or severity of adverse effects can be increased when Rituximab is combined with Belimumab.,Belimumab
DB08880,The risk or severity of adverse effects can be increased when Rituximab is combined with Teriflunomide.,Teriflunomide
DB08889,The risk or severity of adverse effects can be increased when Rituximab is combined with Carfilzomib.,Carfilzomib
DB08901,The risk or severity of adverse effects can be increased when Rituximab is combined with Ponatinib.,Ponatinib
DB08906,The risk or severity of adverse effects can be increased when Rituximab is combined with Fluticasone furoate.,Fluticasone furoate
DB08908,The risk or severity of adverse effects can be increased when Rituximab is combined with Dimethyl fumarate.,Dimethyl fumarate
DB08910,The risk or severity of adverse effects can be increased when Rituximab is combined with Pomalidomide.,Pomalidomide
DB08935,The risk or severity of adverse effects can be increased when Rituximab is combined with Obinutuzumab.,Obinutuzumab
DB08970,The risk or severity of adverse effects can be increased when Rituximab is combined with Fluprednidene.,Fluprednidene
DB08971,The risk or severity of adverse effects can be increased when Rituximab is combined with Fluocortolone.,Fluocortolone
DB09029,The risk or severity of adverse effects can be increased when Rituximab is combined with Secukinumab.,Secukinumab
DB09033,The risk or severity of adverse effects can be increased when Rituximab is combined with Vedolizumab.,Vedolizumab
DB09036,The risk or severity of adverse effects can be increased when Rituximab is combined with Siltuximab.,Siltuximab
DB09052,The risk or severity of adverse effects can be increased when Rituximab is combined with Blinatumomab.,Blinatumomab
DB09053,The risk or severity of adverse effects can be increased when Rituximab is combined with Ibrutinib.,Ibrutinib
DB09054,The risk or severity of adverse effects can be increased when Rituximab is combined with Idelalisib.,Idelalisib
DB09073,The risk or severity of adverse effects can be increased when Rituximab is combined with Palbociclib.,Palbociclib
DB09074,The risk or severity of adverse effects can be increased when Rituximab is combined with Olaparib.,Olaparib
DB09077,The risk or severity of adverse effects can be increased when Rituximab is combined with Dinutuximab.,Dinutuximab
DB09082,The risk or severity of adverse effects can be increased when Rituximab is combined with Vilanterol.,Vilanterol
DB09091,The risk or severity of adverse effects can be increased when Rituximab is combined with Tixocortol.,Tixocortol
DB09122,The risk or severity of adverse effects can be increased when Rituximab is combined with Peginterferon beta-1a.,Peginterferon beta-1a
DB09312,The risk or severity of adverse effects can be increased when Rituximab is combined with Antilymphocyte immunoglobulin (horse).,Antilymphocyte immunoglobulin (horse)
DB09378,The risk or severity of adverse effects can be increased when Rituximab is combined with Fluprednisolone.,Fluprednisolone
DB09383,The risk or severity of adverse effects can be increased when Rituximab is combined with Meprednisone.,Meprednisone
DB11466,The risk or severity of adverse effects can be increased when Rituximab is combined with Tepoxalin.,Tepoxalin
DB11487,The risk or severity of adverse effects can be increased when Rituximab is combined with Dexamethasone isonicotinate.,Dexamethasone isonicotinate
DB11529,The risk or severity of adverse effects can be increased when Rituximab is combined with Melengestrol.,Melengestrol
DB11569,The risk or severity of adverse effects can be increased when Rituximab is combined with Ixekizumab.,Ixekizumab
DB11580,The risk or severity of adverse effects can be increased when Rituximab is combined with Ravulizumab.,Ravulizumab
DB11616,The risk or severity of adverse effects can be increased when Rituximab is combined with Pirarubicin.,Pirarubicin
DB11693,The risk or severity of adverse effects can be increased when Rituximab is combined with Voclosporin.,Voclosporin
DB11708,The risk or severity of adverse effects can be increased when Rituximab is combined with Peficitinib.,Peficitinib
DB11750,The risk or severity of adverse effects can be increased when Rituximab is combined with Clobetasol.,Clobetasol
DB11767,The risk or severity of adverse effects can be increased when Rituximab is combined with Sarilumab.,Sarilumab
DB11776,The risk or severity of adverse effects can be increased when Rituximab is combined with Brodalumab.,Brodalumab
DB11803,The risk or severity of adverse effects can be increased when Rituximab is combined with Sirukumab.,Sirukumab
DB11817,The risk or severity of adverse effects can be increased when Rituximab is combined with Baricitinib.,Baricitinib
DB11834,The risk or severity of adverse effects can be increased when Rituximab is combined with Guselkumab.,Guselkumab
DB11921,The risk or severity of adverse effects can be increased when Rituximab is combined with Deflazacort.,Deflazacort
DB12025,The risk or severity of adverse effects can be increased when Rituximab is combined with Triptolide.,Triptolide
DB12371,The risk or severity of adverse effects can be increased when Rituximab is combined with Siponimod.,Siponimod
DB12612,The risk or severity of adverse effects can be increased when Rituximab is combined with Ozanimod.,Ozanimod
DB12617,The risk or severity of adverse effects can be increased when Rituximab is combined with Mizoribine.,Mizoribine
DB12692,The risk or severity of adverse effects can be increased when Rituximab is combined with Gusperimus.,Gusperimus
DB12814,The risk or severity of adverse effects can be increased when Rituximab is combined with Cepeginterferon alfa-2B.,Cepeginterferon alfa-2B
DB12902,The risk or severity of adverse effects can be increased when Rituximab is combined with Trofosfamide.,Trofosfamide
DB12947,The risk or severity of adverse effects can be increased when Rituximab is combined with Doxifluridine.,Doxifluridine
DB12991,The risk or severity of adverse effects can be increased when Rituximab is combined with Deoxyspergualin.,Deoxyspergualin
DB12996,The risk or severity of adverse effects can be increased when Rituximab is combined with Acteoside.,Acteoside
DB13003,The risk or severity of adverse effects can be increased when Rituximab is combined with Cortivazol.,Cortivazol
DB13014,The risk or severity of adverse effects can be increased when Rituximab is combined with Hypericin.,Hypericin
DB13068,The risk or severity of adverse effects can be increased when Rituximab is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.,9-(N-methyl-L-isoleucine)-cyclosporin A
DB13208,The risk or severity of adverse effects can be increased when Rituximab is combined with Prednylidene.,Prednylidene
DB13223,The risk or severity of adverse effects can be increased when Rituximab is combined with Fluocortin.,Fluocortin
DB13241,The risk or severity of adverse effects can be increased when Rituximab is combined with Begelomab.,Begelomab
DB13491,The risk or severity of adverse effects can be increased when Rituximab is combined with Fluperolone.,Fluperolone
DB13664,The risk or severity of adverse effects can be increased when Rituximab is combined with Formocortal.,Formocortal
DB13728,The risk or severity of adverse effects can be increased when Rituximab is combined with Halometasone.,Halometasone
DB13843,The risk or severity of adverse effects can be increased when Rituximab is combined with Cloprednol.,Cloprednol
DB13856,The risk or severity of adverse effects can be increased when Rituximab is combined with Fluclorolone.,Fluclorolone
DB13867,The risk or severity of adverse effects can be increased when Rituximab is combined with Fluticasone.,Fluticasone
DB14066,The risk or severity of adverse effects can be increased when Rituximab is combined with Tetrandrine.,Tetrandrine
DB14219,The risk or severity of adverse effects can be increased when Rituximab is combined with Monomethyl fumarate.,Monomethyl fumarate
DB14512,The risk or severity of adverse effects can be increased when Rituximab is combined with Mometasone furoate.,Mometasone furoate
DB14538,The risk or severity of adverse effects can be increased when Rituximab is combined with Hydrocortisone aceponate.,Hydrocortisone aceponate
DB14539,The risk or severity of adverse effects can be increased when Rituximab is combined with Hydrocortisone acetate.,Hydrocortisone acetate
DB14545,The risk or severity of adverse effects can be increased when Rituximab is combined with Hydrocortisone succinate.,Hydrocortisone succinate
DB14724,The risk or severity of adverse effects can be increased when Rituximab is combined with Emapalumab.,Emapalumab
DB14762,The risk or severity of adverse effects can be increased when Rituximab is combined with Risankizumab.,Risankizumab
DB14919,The risk or severity of adverse effects can be increased when Rituximab is combined with Rozanolixizumab.,Rozanolixizumab
DB15253,The risk or severity of adverse effects can be increased when Rituximab is combined with Bleselumab.,Bleselumab
DB00108,The risk or severity of adverse effects can be increased when Rituximab is combined with Natalizumab.,Natalizumab
DB00337,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Rituximab.,Pimecrolimus
DB01656,Roflumilast may increase the immunosuppressive activities of Rituximab.,Roflumilast
DB06688,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Rituximab.,Sipuleucel-T
DB00363,The risk or severity of neutropenia can be increased when Rituximab is combined with Clozapine.,Clozapine
DB00012,The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Rituximab.,Darbepoetin alfa
DB00016,The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Rituximab.,Erythropoietin
DB08894,The risk or severity of Thrombosis can be increased when Peginesatide is combined with Rituximab.,Peginesatide
DB09107,The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Rituximab.,Methoxy polyethylene glycol-epoetin beta
DB01281,Rituximab may increase the immunosuppressive activities of Abatacept.,Abatacept
DB08904,Rituximab may increase the immunosuppressive activities of Certolizumab pegol.,Certolizumab pegol
DB08895,Rituximab may increase the immunosuppressive activities of Tofacitinib.,Tofacitinib
DB00177,Valsartan may increase the hypotensive activities of Rituximab.,Valsartan
DB00178,Ramipril may increase the hypotensive activities of Rituximab.,Ramipril
DB00187,Esmolol may increase the hypotensive activities of Rituximab.,Esmolol
DB00195,Betaxolol may increase the hypotensive activities of Rituximab.,Betaxolol
DB00206,Reserpine may increase the hypotensive activities of Rituximab.,Reserpine
DB00212,Remikiren may increase the hypotensive activities of Rituximab.,Remikiren
DB00214,Torasemide may increase the hypotensive activities of Rituximab.,Torasemide
DB00217,Bethanidine may increase the hypotensive activities of Rituximab.,Bethanidine
DB00226,Guanadrel may increase the hypotensive activities of Rituximab.,Guanadrel
DB00264,Metoprolol may increase the hypotensive activities of Rituximab.,Metoprolol
DB00270,Isradipine may increase the hypotensive activities of Rituximab.,Isradipine
DB00275,Olmesartan may increase the hypotensive activities of Rituximab.,Olmesartan
DB00310,Chlorthalidone may increase the hypotensive activities of Rituximab.,Chlorthalidone
DB00325,Nitroprusside may increase the hypotensive activities of Rituximab.,Nitroprusside
DB00335,Atenolol may increase the hypotensive activities of Rituximab.,Atenolol
DB00343,Diltiazem may increase the hypotensive activities of Rituximab.,Diltiazem
DB00350,Minoxidil may increase the hypotensive activities of Rituximab.,Minoxidil
DB00373,Timolol may increase the hypotensive activities of Rituximab.,Timolol
DB00374,Treprostinil may increase the hypotensive activities of Rituximab.,Treprostinil
DB00381,Amlodipine may increase the hypotensive activities of Rituximab.,Amlodipine
DB00393,Nimodipine may increase the hypotensive activities of Rituximab.,Nimodipine
DB00401,Nisoldipine may increase the hypotensive activities of Rituximab.,Nisoldipine
DB00436,Bendroflumethiazide may increase the hypotensive activities of Rituximab.,Bendroflumethiazide
DB00457,Prazosin may increase the hypotensive activities of Rituximab.,Prazosin
DB00492,Fosinopril may increase the hypotensive activities of Rituximab.,Fosinopril
DB00519,Trandolapril may increase the hypotensive activities of Rituximab.,Trandolapril
DB00524,Metolazone may increase the hypotensive activities of Rituximab.,Metolazone
DB00528,Lercanidipine may increase the hypotensive activities of Rituximab.,Lercanidipine
DB00542,Benazepril may increase the hypotensive activities of Rituximab.,Benazepril
DB00559,Bosentan may increase the hypotensive activities of Rituximab.,Bosentan
DB00571,Propranolol may increase the hypotensive activities of Rituximab.,Propranolol
DB00575,Clonidine may increase the hypotensive activities of Rituximab.,Clonidine
DB00584,Enalapril may increase the hypotensive activities of Rituximab.,Enalapril
DB00590,Doxazosin may increase the hypotensive activities of Rituximab.,Doxazosin
DB00598,Labetalol may increase the hypotensive activities of Rituximab.,Labetalol
DB00606,Cyclothiazide may increase the hypotensive activities of Rituximab.,Cyclothiazide
DB00612,Bisoprolol may increase the hypotensive activities of Rituximab.,Bisoprolol
DB00616,Candoxatril may increase the hypotensive activities of Rituximab.,Candoxatril
DB00622,Nicardipine may increase the hypotensive activities of Rituximab.,Nicardipine
DB00629,Guanabenz may increase the hypotensive activities of Rituximab.,Guanabenz
DB00657,Mecamylamine may increase the hypotensive activities of Rituximab.,Mecamylamine
DB00678,Losartan may increase the hypotensive activities of Rituximab.,Losartan
DB00691,Moexipril may increase the hypotensive activities of Rituximab.,Moexipril
DB00692,Phentolamine may increase the hypotensive activities of Rituximab.,Phentolamine
DB00700,Eplerenone may increase the hypotensive activities of Rituximab.,Eplerenone
DB00722,Lisinopril may increase the hypotensive activities of Rituximab.,Lisinopril
DB00727,Nitroglycerin may increase the hypotensive activities of Rituximab.,Nitroglycerin
DB00765,Metyrosine may increase the hypotensive activities of Rituximab.,Metyrosine
DB00774,Hydroflumethiazide may increase the hypotensive activities of Rituximab.,Hydroflumethiazide
DB00785,Cryptenamine may increase the hypotensive activities of Rituximab.,Cryptenamine
DB00790,Perindopril may increase the hypotensive activities of Rituximab.,Perindopril
DB00796,Candesartan cilexetil may increase the hypotensive activities of Rituximab.,Candesartan cilexetil
DB00797,Tolazoline may increase the hypotensive activities of Rituximab.,Tolazoline
DB00800,Fenoldopam may increase the hypotensive activities of Rituximab.,Fenoldopam
DB00808,Indapamide may increase the hypotensive activities of Rituximab.,Indapamide
DB00820,Tadalafil may increase the hypotensive activities of Rituximab.,Tadalafil
DB00866,Alprenolol may increase the hypotensive activities of Rituximab.,Alprenolol
DB00876,Eprosartan may increase the hypotensive activities of Rituximab.,Eprosartan
DB00880,Chlorothiazide may increase the hypotensive activities of Rituximab.,Chlorothiazide
DB00881,Quinapril may increase the hypotensive activities of Rituximab.,Quinapril
DB00886,Omapatrilat may increase the hypotensive activities of Rituximab.,Omapatrilat
DB00925,Phenoxybenzamine may increase the hypotensive activities of Rituximab.,Phenoxybenzamine
DB00960,Pindolol may increase the hypotensive activities of Rituximab.,Pindolol
DB00966,Telmisartan may increase the hypotensive activities of Rituximab.,Telmisartan
DB00968,Methyldopa may increase the hypotensive activities of Rituximab.,Methyldopa
DB00999,Hydrochlorothiazide may increase the hypotensive activities of Rituximab.,Hydrochlorothiazide
DB01018,Guanfacine may increase the hypotensive activities of Rituximab.,Guanfacine
DB01021,Trichlormethiazide may increase the hypotensive activities of Rituximab.,Trichlormethiazide
DB01023,Felodipine may increase the hypotensive activities of Rituximab.,Felodipine
DB01029,Irbesartan may increase the hypotensive activities of Rituximab.,Irbesartan
DB01054,Nitrendipine may increase the hypotensive activities of Rituximab.,Nitrendipine
DB01089,Deserpidine may increase the hypotensive activities of Rituximab.,Deserpidine
DB01090,Pentolinium may increase the hypotensive activities of Rituximab.,Pentolinium
DB01116,Trimethaphan may increase the hypotensive activities of Rituximab.,Trimethaphan
DB01119,Diazoxide may increase the hypotensive activities of Rituximab.,Diazoxide
DB01136,Carvedilol may increase the hypotensive activities of Rituximab.,Carvedilol
DB01158,Bretylium may increase the hypotensive activities of Rituximab.,Bretylium
DB01162,Terazosin may increase the hypotensive activities of Rituximab.,Terazosin
DB01170,Guanethidine may increase the hypotensive activities of Rituximab.,Guanethidine
DB01180,Rescinnamine may increase the hypotensive activities of Rituximab.,Rescinnamine
DB01193,Acebutolol may increase the hypotensive activities of Rituximab.,Acebutolol
DB01197,Captopril may increase the hypotensive activities of Rituximab.,Captopril
DB01203,Nadolol may increase the hypotensive activities of Rituximab.,Nadolol
DB01240,Epoprostenol may increase the hypotensive activities of Rituximab.,Epoprostenol
DB01244,Bepridil may increase the hypotensive activities of Rituximab.,Bepridil
DB01275,Hydralazine may increase the hypotensive activities of Rituximab.,Hydralazine
DB01295,Bevantolol may increase the hypotensive activities of Rituximab.,Bevantolol
DB01297,Practolol may increase the hypotensive activities of Rituximab.,Practolol
DB01324,Polythiazide may increase the hypotensive activities of Rituximab.,Polythiazide
DB01340,Cilazapril may increase the hypotensive activities of Rituximab.,Cilazapril
DB01347,Saprisartan may increase the hypotensive activities of Rituximab.,Saprisartan
DB01348,Spirapril may increase the hypotensive activities of Rituximab.,Spirapril
DB01359,Penbutolol may increase the hypotensive activities of Rituximab.,Penbutolol
DB01388,Mibefradil may increase the hypotensive activities of Rituximab.,Mibefradil
DB01580,Oxprenolol may increase the hypotensive activities of Rituximab.,Oxprenolol
DB01626,Pargyline may increase the hypotensive activities of Rituximab.,Pargyline
DB03322,Dexpropranolol may increase the hypotensive activities of Rituximab.,Dexpropranolol
DB04831,Tienilic acid may increase the hypotensive activities of Rituximab.,Tienilic acid
DB04840,Debrisoquine may increase the hypotensive activities of Rituximab.,Debrisoquine
DB04846,Celiprolol may increase the hypotensive activities of Rituximab.,Celiprolol
DB04861,Nebivolol may increase the hypotensive activities of Rituximab.,Nebivolol
DB04948,Lofexidine may increase the hypotensive activities of Rituximab.,Lofexidine
DB06268,Sitaxentan may increase the hypotensive activities of Rituximab.,Sitaxentan
DB06403,Ambrisentan may increase the hypotensive activities of Rituximab.,Ambrisentan
DB06445,Diethylnorspermine may increase the hypotensive activities of Rituximab.,Diethylnorspermine
DB06712,Nilvadipine may increase the hypotensive activities of Rituximab.,Nilvadipine
DB06762,Pinacidil may increase the hypotensive activities of Rituximab.,Pinacidil
DB07767,Ferulic acid may increase the hypotensive activities of Rituximab.,Ferulic acid
DB08808,Bupranolol may increase the hypotensive activities of Rituximab.,Bupranolol
DB08836,Temocapril may increase the hypotensive activities of Rituximab.,Temocapril
DB08931,Riociguat may increase the hypotensive activities of Rituximab.,Riociguat
DB08932,Macitentan may increase the hypotensive activities of Rituximab.,Macitentan
DB08950,Indoramin may increase the hypotensive activities of Rituximab.,Indoramin
DB08952,Indenolol may increase the hypotensive activities of Rituximab.,Indenolol
DB08960,Hexamethonium may increase the hypotensive activities of Rituximab.,Hexamethonium
DB09026,Aliskiren may increase the hypotensive activities of Rituximab.,Aliskiren
DB09206,Trimazosin may increase the hypotensive activities of Rituximab.,Trimazosin
DB09220,Nicorandil may increase the hypotensive activities of Rituximab.,Nicorandil
DB09235,Efonidipine may increase the hypotensive activities of Rituximab.,Efonidipine
DB09236,Lacidipine may increase the hypotensive activities of Rituximab.,Lacidipine
DB09238,Manidipine may increase the hypotensive activities of Rituximab.,Manidipine
DB09239,Niguldipine may increase the hypotensive activities of Rituximab.,Niguldipine
DB09242,Moxonidine may increase the hypotensive activities of Rituximab.,Moxonidine
DB09363,Rauwolfia serpentina root may increase the hypotensive activities of Rituximab.,Rauwolfia serpentina root
DB09477,Enalaprilat may increase the hypotensive activities of Rituximab.,Enalaprilat
DB11362,Selexipag may increase the hypotensive activities of Rituximab.,Selexipag
DB11720,Angiotensin 1-7 may increase the hypotensive activities of Rituximab.,Angiotensin 1-7
DB11738,Rilmenidine may increase the hypotensive activities of Rituximab.,Rilmenidine
DB11770,Talinolol may increase the hypotensive activities of Rituximab.,Talinolol
DB11783,Imidapril may increase the hypotensive activities of Rituximab.,Imidapril
DB12054,BQ-123 may increase the hypotensive activities of Rituximab.,BQ-123
DB12092,Naftopidil may increase the hypotensive activities of Rituximab.,Naftopidil
DB12093,Tetrahydropalmatine may increase the hypotensive activities of Rituximab.,Tetrahydropalmatine
DB12212,Landiolol may increase the hypotensive activities of Rituximab.,Landiolol
DB12465,Ketanserin may increase the hypotensive activities of Rituximab.,Ketanserin
DB12661,Urapidil may increase the hypotensive activities of Rituximab.,Urapidil
DB12766,Cicletanine may increase the hypotensive activities of Rituximab.,Cicletanine
DB12945,Dihydralazine may increase the hypotensive activities of Rituximab.,Dihydralazine
DB13166,Zofenopril may increase the hypotensive activities of Rituximab.,Zofenopril
DB13211,Guanoxan may increase the hypotensive activities of Rituximab.,Guanoxan
DB13312,Delapril may increase the hypotensive activities of Rituximab.,Delapril
DB13374,Vincamine may increase the hypotensive activities of Rituximab.,Vincamine
DB13400,Linsidomine may increase the hypotensive activities of Rituximab.,Linsidomine
DB13410,Guanoxabenz may increase the hypotensive activities of Rituximab.,Guanoxabenz
DB13429,Tolonidine may increase the hypotensive activities of Rituximab.,Tolonidine
DB13435,Endralazine may increase the hypotensive activities of Rituximab.,Endralazine
DB13443,Esatenolol may increase the hypotensive activities of Rituximab.,Esatenolol
DB13452,Cadralazine may increase the hypotensive activities of Rituximab.,Cadralazine
DB13508,Cloranolol may increase the hypotensive activities of Rituximab.,Cloranolol
DB13532,Cyclopenthiazide may increase the hypotensive activities of Rituximab.,Cyclopenthiazide
DB13575,Bietaserpine may increase the hypotensive activities of Rituximab.,Bietaserpine
DB13604,Guanazodine may increase the hypotensive activities of Rituximab.,Guanazodine
DB13631,Methoserpidine may increase the hypotensive activities of Rituximab.,Methoserpidine
DB13757,Epanolol may increase the hypotensive activities of Rituximab.,Epanolol
DB13779,Guanoclor may increase the hypotensive activities of Rituximab.,Guanoclor
DB13801,Muzolimine may increase the hypotensive activities of Rituximab.,Muzolimine
DB13803,Xipamide may increase the hypotensive activities of Rituximab.,Xipamide
DB13919,Candesartan may increase the hypotensive activities of Rituximab.,Candesartan
DB14068,Dexniguldipine may increase the hypotensive activities of Rituximab.,Dexniguldipine
DB14094,Tocopherylquinone may increase the hypotensive activities of Rituximab.,Tocopherylquinone
DB14125,Benazeprilat may increase the hypotensive activities of Rituximab.,Benazeprilat
DB14207,Fosinoprilat may increase the hypotensive activities of Rituximab.,Fosinoprilat
DB14208,Ramiprilat may increase the hypotensive activities of Rituximab.,Ramiprilat
DB14213,Perindoprilat may increase the hypotensive activities of Rituximab.,Perindoprilat
DB14217,Quinaprilat may increase the hypotensive activities of Rituximab.,Quinaprilat
DB00695,Furosemide may increase the hypotensive activities of Rituximab.,Furosemide
DB01015,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Rituximab.,Sulfamethoxazole
DB00255,Diethylstilbestrol may increase the thrombogenic activities of Rituximab.,Diethylstilbestrol
DB00269,Chlorotrianisene may increase the thrombogenic activities of Rituximab.,Chlorotrianisene
DB00286,Conjugated estrogens may increase the thrombogenic activities of Rituximab.,Conjugated estrogens
DB00655,Estrone may increase the thrombogenic activities of Rituximab.,Estrone
DB00783,Estradiol may increase the thrombogenic activities of Rituximab.,Estradiol
DB00890,Dienestrol may increase the thrombogenic activities of Rituximab.,Dienestrol
DB00977,Ethinylestradiol may increase the thrombogenic activities of Rituximab.,Ethinylestradiol
DB01357,Mestranol may increase the thrombogenic activities of Rituximab.,Mestranol
DB04573,Estriol may increase the thrombogenic activities of Rituximab.,Estriol
DB04574,Estrone sulfate may increase the thrombogenic activities of Rituximab.,Estrone sulfate
DB04575,Quinestrol may increase the thrombogenic activities of Rituximab.,Quinestrol
DB07931,Hexestrol may increase the thrombogenic activities of Rituximab.,Hexestrol
DB09070,Tibolone may increase the thrombogenic activities of Rituximab.,Tibolone
DB09317,"Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Rituximab.","Synthetic Conjugated Estrogens, A"
DB09318,"Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Rituximab.","Synthetic Conjugated Estrogens, B"
DB09369,Polyestradiol phosphate may increase the thrombogenic activities of Rituximab.,Polyestradiol phosphate
DB09381,Esterified estrogens may increase the thrombogenic activities of Rituximab.,Esterified estrogens
DB11478,Zeranol may increase the thrombogenic activities of Rituximab.,Zeranol
DB11674,Equol may increase the thrombogenic activities of Rituximab.,Equol
DB12487,Promestriene may increase the thrombogenic activities of Rituximab.,Promestriene
DB13143,Methallenestril may increase the thrombogenic activities of Rituximab.,Methallenestril
DB13386,Epimestrol may increase the thrombogenic activities of Rituximab.,Epimestrol
DB13418,Moxestrol may increase the thrombogenic activities of Rituximab.,Moxestrol
DB13952,Estradiol acetate may increase the thrombogenic activities of Rituximab.,Estradiol acetate
DB13953,Estradiol benzoate may increase the thrombogenic activities of Rituximab.,Estradiol benzoate
DB13954,Estradiol cypionate may increase the thrombogenic activities of Rituximab.,Estradiol cypionate
DB13956,Estradiol valerate may increase the thrombogenic activities of Rituximab.,Estradiol valerate
DB15334,Biochanin A may increase the thrombogenic activities of Rituximab.,Biochanin A
DB15335,Formononetin may increase the thrombogenic activities of Rituximab.,Formononetin
DB01097,The risk or severity of adverse effects can be increased when Rituximab is combined with Leflunomide.,Leflunomide
DB00072,Trastuzumab may increase the neutropenic activities of Rituximab.,Trastuzumab
DB08868,Rituximab may increase the immunosuppressive activities of Fingolimod.,Fingolimod
DB00864,Tacrolimus may increase the immunosuppressive activities of Rituximab.,Tacrolimus
DB04914,The therapeutic efficacy of G17DT can be decreased when used in combination with Rituximab.,G17DT
DB05144,The therapeutic efficacy of PEV3A can be decreased when used in combination with Rituximab.,PEV3A
DB05325,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Rituximab.,INGN 225
DB05374,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Rituximab.,Rindopepimut
DB05440,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Rituximab.,SRP 299
DB05942,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Rituximab.,GI-5005
DB06400,The therapeutic efficacy of Vitespen can be decreased when used in combination with Rituximab.,Vitespen
DB06584,The therapeutic efficacy of TG4010 can be decreased when used in combination with Rituximab.,TG4010
DB09057,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Rituximab.,Anthrax immune globulin human
DB10062,"The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Rituximab.","Rabies virus inactivated antigen, B"
DB10076,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Rituximab.,Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen
DB10276,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Rituximab.,Rotavirus vaccine
DB10283,"The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Rituximab.","Rabies virus inactivated antigen, A"
DB10342,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Rituximab.,Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen
DB10583,The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Rituximab.,Clostridium tetani toxoid antigen (formaldehyde inactivated)
DB10584,The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Rituximab.,Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
DB10600,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Rituximab.,Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated)
DB10769,The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Rituximab.,Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)
DB10794,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Rituximab.,Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated)
DB10803,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Rituximab.,Typhoid Vi polysaccharide vaccine
DB10989,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Rituximab.,Hepatitis A Vaccine
DB10990,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Rituximab.,Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
DB11038,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Rituximab.,Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated)
DB11040,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Rituximab.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated)
DB11041,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Rituximab.,Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)
DB11044,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Rituximab.,Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated)
DB11603,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Rituximab.,Human rabies virus immune globulin
DB11627,The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Rituximab.,Hepatitis B Vaccine (Recombinant)
DB12568,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Rituximab.,Tecemotide
DB14022,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Rituximab.,Typhoid vaccine
DB14384,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Rituximab.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated)
DB14385,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Rituximab.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)
DB14394,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Rituximab.,Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen
DB14445,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Rituximab.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated)
DB14449,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Rituximab.,Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen
DB14619,The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Rituximab.,Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated)
DB14620,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Rituximab.,Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated)
DB14711,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Rituximab.,Vaccinia virus strain new york city board of health live antigen
DB15274,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Rituximab.,Pertussis vaccine
DB15461,The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Rituximab.,Yersinia pestis 195/p antigen (formaldehyde inactivated)
DB13924,The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Rituximab.,Varicella Zoster Vaccine (Recombinant)
DB15483,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Rituximab.,Modified vaccinia ankara
DB00063,The risk or severity of bleeding can be increased when Eptifibatide is combined with Rituximab.,Eptifibatide
DB00208,The risk or severity of bleeding can be increased when Ticlopidine is combined with Rituximab.,Ticlopidine
DB00261,The risk or severity of bleeding can be increased when Anagrelide is combined with Rituximab.,Anagrelide
DB00758,The risk or severity of bleeding can be increased when Clopidogrel is combined with Rituximab.,Clopidogrel
DB00775,The risk or severity of bleeding can be increased when Tirofiban is combined with Rituximab.,Tirofiban
DB00806,The risk or severity of bleeding can be increased when Pentoxifylline is combined with Rituximab.,Pentoxifylline
DB00945,The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Rituximab.,Acetylsalicylic acid
DB00975,The risk or severity of bleeding can be increased when Dipyridamole is combined with Rituximab.,Dipyridamole
DB01088,The risk or severity of bleeding can be increased when Iloprost is combined with Rituximab.,Iloprost
DB01138,The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Rituximab.,Sulfinpyrazone
DB01166,The risk or severity of bleeding can be increased when Cilostazol is combined with Rituximab.,Cilostazol
DB01207,The risk or severity of bleeding can be increased when Ridogrel is combined with Rituximab.,Ridogrel
DB01236,The risk or severity of bleeding can be increased when Sevoflurane is combined with Rituximab.,Sevoflurane
DB02709,The risk or severity of bleeding can be increased when Resveratrol is combined with Rituximab.,Resveratrol
DB04743,The risk or severity of bleeding can be increased when Nimesulide is combined with Rituximab.,Nimesulide
DB04905,The risk or severity of bleeding can be increased when Tesmilifene is combined with Rituximab.,Tesmilifene
DB04932,The risk or severity of bleeding can be increased when Defibrotide is combined with Rituximab.,Defibrotide
DB05229,The risk or severity of bleeding can be increased when Beraprost is combined with Rituximab.,Beraprost
DB05266,The risk or severity of bleeding can be increased when Ibudilast is combined with Rituximab.,Ibudilast
DB05767,The risk or severity of bleeding can be increased when Andrographolide is combined with Rituximab.,Andrographolide
DB06209,The risk or severity of bleeding can be increased when Prasugrel is combined with Rituximab.,Prasugrel
DB06441,The risk or severity of bleeding can be increased when Cangrelor is combined with Rituximab.,Cangrelor
DB07615,The risk or severity of bleeding can be increased when Tranilast is combined with Rituximab.,Tranilast
DB08814,The risk or severity of bleeding can be increased when Triflusal is combined with Rituximab.,Triflusal
DB08816,The risk or severity of bleeding can be increased when Ticagrelor is combined with Rituximab.,Ticagrelor
DB08887,The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Rituximab.,Icosapent ethyl
DB09030,The risk or severity of bleeding can be increased when Vorapaxar is combined with Rituximab.,Vorapaxar
DB09283,The risk or severity of bleeding can be increased when Trapidil is combined with Rituximab.,Trapidil
DB12163,The risk or severity of bleeding can be increased when Sarpogrelate is combined with Rituximab.,Sarpogrelate
DB12321,The risk or severity of bleeding can be increased when Ifetroban is combined with Rituximab.,Ifetroban
DB12445,The risk or severity of bleeding can be increased when Nitroaspirin is combined with Rituximab.,Nitroaspirin
DB12545,The risk or severity of bleeding can be increased when Indobufen is combined with Rituximab.,Indobufen
DB12749,The risk or severity of bleeding can be increased when Butylphthalide is combined with Rituximab.,Butylphthalide
DB12771,The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Rituximab.,Hydroxytyrosol
DB13036,The risk or severity of bleeding can be increased when Ramatroban is combined with Rituximab.,Ramatroban
DB13327,The risk or severity of bleeding can be increased when Picotamide is combined with Rituximab.,Picotamide
DB13367,The risk or severity of bleeding can be increased when Cloricromen is combined with Rituximab.,Cloricromen
DB13510,The risk or severity of bleeding can be increased when Buflomedil is combined with Rituximab.,Buflomedil
DB13929,The risk or severity of bleeding can be increased when Relcovaptan is combined with Rituximab.,Relcovaptan
DB11988,Ocrelizumab may increase the immunosuppressive activities of Rituximab.,Ocrelizumab
DB13200,Rituximab may increase the myelosuppressive activities of Lipegfilgrastim.,Lipegfilgrastim
DB10317,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Rituximab.,Rubella virus vaccine
DB10318,The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Rituximab.,Varicella Zoster Vaccine (Live/attenuated)
DB10343,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Rituximab.,Bacillus calmette-guerin substrain tice live antigen
DB10804,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Rituximab.,Bacillus calmette-guerin substrain connaught live antigen
DB10805,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Rituximab.,Yellow Fever Vaccine
DB11003,The risk or severity of infection can be increased when Anthrax vaccine is combined with Rituximab.,Anthrax vaccine
DB11050,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Rituximab.,Typhoid Vaccine Live
DB12386,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Rituximab.,Bacillus calmette-guerin substrain danish 1331 live antigen
DB12768,The risk or severity of infection can be increased when BCG vaccine is combined with Rituximab.,BCG vaccine
DB14409,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Rituximab.,Human adenovirus e serotype 4 strain cl-68578 antigen
DB14443,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Rituximab.,Vibrio cholerae CVD 103-HgR strain live antigen
DB14685,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Rituximab.,Adenovirus type 7 vaccine live
DB00002,The risk or severity of adverse effects can be increased when Cetuximab is combined with Rituximab.,Cetuximab
DB00028,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Rituximab.,Human immunoglobulin G
DB00043,The risk or severity of adverse effects can be increased when Omalizumab is combined with Rituximab.,Omalizumab
DB00054,The risk or severity of adverse effects can be increased when Abciximab is combined with Rituximab.,Abciximab
DB00057,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Rituximab.,Indium In-111 satumomab pendetide
DB00076,The risk or severity of adverse effects can be increased when Rituximab is combined with Digoxin Immune Fab (Ovine).,Digoxin Immune Fab (Ovine)
DB00089,The risk or severity of adverse effects can be increased when Rituximab is combined with Capromab pendetide.,Capromab pendetide
DB00110,The risk or severity of adverse effects can be increased when Rituximab is combined with Palivizumab.,Palivizumab
DB00113,The risk or severity of adverse effects can be increased when Rituximab is combined with Technetium Tc-99m arcitumomab.,Technetium Tc-99m arcitumomab
DB01269,The risk or severity of adverse effects can be increased when Rituximab is combined with Panitumumab.,Panitumumab
DB01270,The risk or severity of adverse effects can be increased when Rituximab is combined with Ranibizumab.,Ranibizumab
DB04901,The risk or severity of adverse effects can be increased when Rituximab is combined with Galiximab.,Galiximab
DB04949,The risk or severity of adverse effects can be increased when Rituximab is combined with Pexelizumab.,Pexelizumab
DB04958,The risk or severity of adverse effects can be increased when Rituximab is combined with Epratuzumab.,Epratuzumab
DB04962,The risk or severity of adverse effects can be increased when Rituximab is combined with Bectumomab.,Bectumomab
DB04964,The risk or severity of adverse effects can be increased when Rituximab is combined with Oregovomab.,Oregovomab
DB04988,The risk or severity of adverse effects can be increased when Rituximab is combined with IGN311.,IGN311
DB05006,The risk or severity of adverse effects can be increased when Rituximab is combined with Adecatumumab.,Adecatumumab
DB05097,The risk or severity of adverse effects can be increased when Rituximab is combined with Labetuzumab.,Labetuzumab
DB05101,The risk or severity of adverse effects can be increased when Rituximab is combined with Matuzumab.,Matuzumab
DB05111,The risk or severity of adverse effects can be increased when Rituximab is combined with Fontolizumab.,Fontolizumab
DB05136,The risk or severity of adverse effects can be increased when Rituximab is combined with Bavituximab.,Bavituximab
DB05139,The risk or severity of adverse effects can be increased when Rituximab is combined with CR002.,CR002
DB05209,The risk or severity of adverse effects can be increased when Rituximab is combined with Rozrolimupab.,Rozrolimupab
DB05304,The risk or severity of adverse effects can be increased when Rituximab is combined with Girentuximab.,Girentuximab
DB05336,The risk or severity of adverse effects can be increased when Rituximab is combined with Obiltoxaximab.,Obiltoxaximab
DB05405,The risk or severity of adverse effects can be increased when Rituximab is combined with XTL-001.,XTL-001
DB05437,The risk or severity of adverse effects can be increased when Rituximab is combined with NAV 1800.,NAV 1800
DB05496,The risk or severity of adverse effects can be increased when Rituximab is combined with Otelixizumab.,Otelixizumab
DB05545,The risk or severity of adverse effects can be increased when Rituximab is combined with AMG 108.,AMG 108
DB05550,The risk or severity of adverse effects can be increased when Rituximab is combined with Iratumumab.,Iratumumab
DB05555,The risk or severity of adverse effects can be increased when Rituximab is combined with Enokizumab.,Enokizumab
DB05578,The risk or severity of adverse effects can be increased when Rituximab is combined with Ramucirumab.,Ramucirumab
DB05595,The risk or severity of adverse effects can be increased when Rituximab is combined with Farletuzumab.,Farletuzumab
DB05656,The risk or severity of adverse effects can be increased when Rituximab is combined with Veltuzumab.,Veltuzumab
DB05793,The risk or severity of adverse effects can be increased when Rituximab is combined with PRO-542.,PRO-542
DB05797,The risk or severity of adverse effects can be increased when Rituximab is combined with TNX-901.,TNX-901
DB05889,The risk or severity of adverse effects can be increased when Rituximab is combined with Inotuzumab ozogamicin.,Inotuzumab ozogamicin
DB05892,The risk or severity of adverse effects can be increased when Rituximab is combined with RI 624.,RI 624
DB05915,The risk or severity of adverse effects can be increased when Rituximab is combined with MYO-029.,MYO-029
DB05916,The risk or severity of adverse effects can be increased when Rituximab is combined with CT-011.,CT-011
DB05941,The risk or severity of adverse effects can be increased when Rituximab is combined with Leronlimab.,Leronlimab
DB05996,The risk or severity of adverse effects can be increased when Rituximab is combined with Glembatumumab vedotin.,Glembatumumab vedotin
DB06043,The risk or severity of adverse effects can be increased when Rituximab is combined with Olaratumab.,Olaratumab
DB06049,The risk or severity of adverse effects can be increased when Rituximab is combined with IPH 2101.,IPH 2101
DB06050,The risk or severity of adverse effects can be increased when Rituximab is combined with TB-402.,TB-402
DB06081,The risk or severity of adverse effects can be increased when Rituximab is combined with Caplacizumab.,Caplacizumab
DB06101,The risk or severity of adverse effects can be increased when Rituximab is combined with IMC-1C11.,IMC-1C11
DB06116,The risk or severity of adverse effects can be increased when Rituximab is combined with Eldelumab.,Eldelumab
DB06162,The risk or severity of adverse effects can be increased when Rituximab is combined with Lumiliximab.,Lumiliximab
DB06186,The risk or severity of adverse effects can be increased when Rituximab is combined with Ipilimumab.,Ipilimumab
DB06192,The risk or severity of adverse effects can be increased when Rituximab is combined with Nimotuzumab.,Nimotuzumab
DB06241,The risk or severity of adverse effects can be increased when Rituximab is combined with Clenoliximab.,Clenoliximab
DB06304,The risk or severity of adverse effects can be increased when Rituximab is combined with BIIB015.,BIIB015
DB06305,The risk or severity of adverse effects can be increased when Rituximab is combined with Sonepcizumab.,Sonepcizumab
DB06310,The risk or severity of adverse effects can be increased when Rituximab is combined with Motavizumab.,Motavizumab
DB06317,The risk or severity of adverse effects can be increased when Rituximab is combined with Elotuzumab.,Elotuzumab
DB06318,The risk or severity of adverse effects can be increased when Rituximab is combined with AVE9633.,AVE9633
DB06322,The risk or severity of adverse effects can be increased when Rituximab is combined with Carotuximab.,Carotuximab
DB06324,The risk or severity of adverse effects can be increased when Rituximab is combined with XmAb 2513.,XmAb 2513
DB06342,The risk or severity of adverse effects can be increased when Rituximab is combined with Coltuximab ravtansine.,Coltuximab ravtansine
DB06343,The risk or severity of adverse effects can be increased when Rituximab is combined with Teprotumumab.,Teprotumumab
DB06360,The risk or severity of adverse effects can be increased when Rituximab is combined with Lucatumumab.,Lucatumumab
DB06366,The risk or severity of adverse effects can be increased when Rituximab is combined with Pertuzumab.,Pertuzumab
DB06371,The risk or severity of adverse effects can be increased when Rituximab is combined with Siplizumab.,Siplizumab
DB06467,The risk or severity of adverse effects can be increased when Rituximab is combined with Apolizumab.,Apolizumab
DB06474,The risk or severity of adverse effects can be increased when Rituximab is combined with Sibrotuzumab.,Sibrotuzumab
DB06550,The risk or severity of adverse effects can be increased when Rituximab is combined with Bivatuzumab.,Bivatuzumab
DB06557,The risk or severity of adverse effects can be increased when Rituximab is combined with Lerdelimumab.,Lerdelimumab
DB06599,The risk or severity of adverse effects can be increased when Rituximab is combined with Lexatumumab.,Lexatumumab
DB06602,The risk or severity of adverse effects can be increased when Rituximab is combined with Reslizumab.,Reslizumab
DB06606,The risk or severity of adverse effects can be increased when Rituximab is combined with Teplizumab.,Teplizumab
DB06607,The risk or severity of adverse effects can be increased when Rituximab is combined with Catumaxomab.,Catumaxomab
DB06647,The risk or severity of adverse effects can be increased when Rituximab is combined with Volociximab.,Volociximab
DB06650,The risk or severity of adverse effects can be increased when Rituximab is combined with Ofatumumab.,Ofatumumab
DB08902,The risk or severity of adverse effects can be increased when Rituximab is combined with Raxibacumab.,Raxibacumab
DB09035,The risk or severity of adverse effects can be increased when Rituximab is combined with Nivolumab.,Nivolumab
DB09037,The risk or severity of adverse effects can be increased when Rituximab is combined with Pembrolizumab.,Pembrolizumab
DB09045,The risk or severity of adverse effects can be increased when Rituximab is combined with Dulaglutide.,Dulaglutide
DB09105,The risk or severity of adverse effects can be increased when Rituximab is combined with Asfotase alfa.,Asfotase alfa
DB09264,The risk or severity of adverse effects can be increased when Rituximab is combined with Idarucizumab.,Idarucizumab
DB09302,The risk or severity of adverse effects can be increased when Rituximab is combined with Alirocumab.,Alirocumab
DB09303,The risk or severity of adverse effects can be increased when Rituximab is combined with Evolocumab.,Evolocumab
DB09331,The risk or severity of adverse effects can be increased when Rituximab is combined with Daratumumab.,Daratumumab
DB09559,The risk or severity of adverse effects can be increased when Rituximab is combined with Necitumumab.,Necitumumab
DB11595,The risk or severity of adverse effects can be increased when Rituximab is combined with Atezolizumab.,Atezolizumab
DB11604,The risk or severity of adverse effects can be increased when Rituximab is combined with Tetanus Immune Globulin.,Tetanus Immune Globulin
DB11608,The risk or severity of adverse effects can be increased when Rituximab is combined with Eftrenonacog alfa.,Eftrenonacog alfa
DB11621,The risk or severity of adverse effects can be increased when Rituximab is combined with Human Varicella-Zoster Immune Globulin.,Human Varicella-Zoster Immune Globulin
DB11646,The risk or severity of adverse effects can be increased when Rituximab is combined with Conatumumab.,Conatumumab
DB11657,The risk or severity of adverse effects can be increased when Rituximab is combined with Tabalumab.,Tabalumab
DB11680,The risk or severity of adverse effects can be increased when Rituximab is combined with Ficlatuzumab.,Ficlatuzumab
DB11685,The risk or severity of adverse effects can be increased when Rituximab is combined with Figitumumab.,Figitumumab
DB11714,The risk or severity of adverse effects can be increased when Rituximab is combined with Durvalumab.,Durvalumab
DB11715,The risk or severity of adverse effects can be increased when Rituximab is combined with Bapineuzumab.,Bapineuzumab
DB11731,The risk or severity of adverse effects can be increased when Rituximab is combined with Depatuxizumab mafodotin.,Depatuxizumab mafodotin
DB11746,The risk or severity of adverse effects can be increased when Rituximab is combined with Onartuzumab.,Onartuzumab
DB11756,The risk or severity of adverse effects can be increased when Rituximab is combined with Solanezumab.,Solanezumab
DB11771,The risk or severity of adverse effects can be increased when Rituximab is combined with Tremelimumab.,Tremelimumab
DB11826,The risk or severity of adverse effects can be increased when Rituximab is combined with Lampalizumab.,Lampalizumab
DB11840,The risk or severity of adverse effects can be increased when Rituximab is combined with Dalotuzumab.,Dalotuzumab
DB11849,The risk or severity of adverse effects can be increased when Rituximab is combined with Emibetuzumab.,Emibetuzumab
DB11850,The risk or severity of adverse effects can be increased when Rituximab is combined with Ublituximab.,Ublituximab
DB11856,The risk or severity of adverse effects can be increased when Rituximab is combined with Ligelizumab.,Ligelizumab
DB11857,The risk or severity of adverse effects can be increased when Rituximab is combined with Seribantumab.,Seribantumab
DB11862,The risk or severity of adverse effects can be increased when Rituximab is combined with Landogrozumab.,Landogrozumab
DB11866,The risk or severity of adverse effects can be increased when Rituximab is combined with Romosozumab.,Romosozumab
DB11884,The risk or severity of adverse effects can be increased when Rituximab is combined with Vadastuximab Talirine.,Vadastuximab Talirine
DB11914,The risk or severity of adverse effects can be increased when Rituximab is combined with Lebrikizumab.,Lebrikizumab
DB11930,The risk or severity of adverse effects can be increased when Rituximab is combined with Varlilumab.,Varlilumab
DB11945,The risk or severity of adverse effects can be increased when Rituximab is combined with Avelumab.,Avelumab
DB11959,The risk or severity of adverse effects can be increased when Rituximab is combined with Crenezumab.,Crenezumab
DB11972,The risk or severity of adverse effects can be increased when Rituximab is combined with Rilotumumab.,Rilotumumab
DB11976,The risk or severity of adverse effects can be increased when Rituximab is combined with Anifrolumab.,Anifrolumab
DB12023,The risk or severity of adverse effects can be increased when Rituximab is combined with Benralizumab.,Benralizumab
DB12034,The risk or severity of adverse effects can be increased when Rituximab is combined with Gantenerumab.,Gantenerumab
DB12053,The risk or severity of adverse effects can be increased when Rituximab is combined with Visilizumab.,Visilizumab
DB12077,The risk or severity of adverse effects can be increased when Rituximab is combined with Urelumab.,Urelumab
DB12089,The risk or severity of adverse effects can be increased when Rituximab is combined with Lorvotuzumab mertansine.,Lorvotuzumab mertansine
DB12090,The risk or severity of adverse effects can be increased when Rituximab is combined with Patritumab.,Patritumab
DB12102,The risk or severity of adverse effects can be increased when Rituximab is combined with Fulranumab.,Fulranumab
DB12104,The risk or severity of adverse effects can be increased when Rituximab is combined with Tarextumab.,Tarextumab
DB12118,The risk or severity of adverse effects can be increased when Rituximab is combined with Sotatercept.,Sotatercept
DB12119,The risk or severity of adverse effects can be increased when Rituximab is combined with Gevokizumab.,Gevokizumab
DB12142,The risk or severity of adverse effects can be increased when Rituximab is combined with Duligotuzumab.,Duligotuzumab
DB12152,The risk or severity of adverse effects can be increased when Rituximab is combined with Simtuzumab.,Simtuzumab
DB12157,The risk or severity of adverse effects can be increased when Rituximab is combined with Fasinumab.,Fasinumab
DB12159,The risk or severity of adverse effects can be increased when Rituximab is combined with Dupilumab.,Dupilumab
DB12169,The risk or severity of adverse effects can be increased when Rituximab is combined with Tralokinumab.,Tralokinumab
DB12189,The risk or severity of adverse effects can be increased when Rituximab is combined with Etrolizumab.,Etrolizumab
DB12202,The risk or severity of adverse effects can be increased when Rituximab is combined with Zalutumumab.,Zalutumumab
DB12205,The risk or severity of adverse effects can be increased when Rituximab is combined with Ganitumab.,Ganitumab
DB12213,The risk or severity of adverse effects can be increased when Rituximab is combined with Etaracizumab.,Etaracizumab
DB12240,The risk or severity of adverse effects can be increased when Rituximab is combined with Polatuzumab vedotin.,Polatuzumab vedotin
DB12246,The risk or severity of adverse effects can be increased when Rituximab is combined with Inclacumab.,Inclacumab
DB12250,The risk or severity of adverse effects can be increased when Rituximab is combined with Cixutumumab.,Cixutumumab
DB12261,The risk or severity of adverse effects can be increased when Rituximab is combined with Ascrinvacumab.,Ascrinvacumab
DB12274,The risk or severity of adverse effects can be increased when Rituximab is combined with Aducanumab.,Aducanumab
DB12281,The risk or severity of adverse effects can be increased when Rituximab is combined with Luspatercept.,Luspatercept
DB12296,The risk or severity of adverse effects can be increased when Rituximab is combined with GS-5745.,GS-5745
DB12317,The risk or severity of adverse effects can be increased when Rituximab is combined with Vanucizumab.,Vanucizumab
DB12331,The risk or severity of adverse effects can be increased when Rituximab is combined with Labetuzumab govitecan.,Labetuzumab govitecan
DB12335,The risk or severity of adverse effects can be increased when Rituximab is combined with Tanezumab.,Tanezumab
DB12342,The risk or severity of adverse effects can be increased when Rituximab is combined with Ensituximab.,Ensituximab
DB12344,The risk or severity of adverse effects can be increased when Rituximab is combined with Fezakinumab.,Fezakinumab
DB12363,The risk or severity of adverse effects can be increased when Rituximab is combined with Dusigitumab.,Dusigitumab
DB12396,The risk or severity of adverse effects can be increased when Rituximab is combined with Fresolimumab.,Fresolimumab
DB12413,The risk or severity of adverse effects can be increased when Rituximab is combined with Indusatumab vedotin.,Indusatumab vedotin
DB12456,The risk or severity of adverse effects can be increased when Rituximab is combined with Bococizumab.,Bococizumab
DB12489,The risk or severity of adverse effects can be increased when Rituximab is combined with Mirvetuximab Soravtansine.,Mirvetuximab Soravtansine
DB12498,The risk or severity of adverse effects can be increased when Rituximab is combined with Mogamulizumab.,Mogamulizumab
DB12520,The risk or severity of adverse effects can be increased when Rituximab is combined with Plozalizumab.,Plozalizumab
DB12534,The risk or severity of adverse effects can be increased when Rituximab is combined with Mavrilimumab.,Mavrilimumab
DB12560,The risk or severity of adverse effects can be increased when Rituximab is combined with Blosozumab.,Blosozumab
DB12584,The risk or severity of adverse effects can be increased when Rituximab is combined with Bimagrumab.,Bimagrumab
DB12589,The risk or severity of adverse effects can be increased when Rituximab is combined with Dacetuzumab.,Dacetuzumab
DB12609,The risk or severity of adverse effects can be increased when Rituximab is combined with Tovetumab.,Tovetumab
DB12683,The risk or severity of adverse effects can be increased when Rituximab is combined with Lumretuzumab.,Lumretuzumab
DB12698,The risk or severity of adverse effects can be increased when Rituximab is combined with Ibalizumab.,Ibalizumab
DB12701,The risk or severity of adverse effects can be increased when Rituximab is combined with Intetumumab.,Intetumumab
DB12718,The risk or severity of adverse effects can be increased when Rituximab is combined with Carlumab.,Carlumab
DB12734,The risk or severity of adverse effects can be increased when Rituximab is combined with Demcizumab.,Demcizumab
DB12773,The risk or severity of adverse effects can be increased when Rituximab is combined with Sifalimumab.,Sifalimumab
DB12775,The risk or severity of adverse effects can be increased when Rituximab is combined with Abituzumab.,Abituzumab
DB12797,The risk or severity of adverse effects can be increased when Rituximab is combined with Ecromeximab.,Ecromeximab
DB12807,The risk or severity of adverse effects can be increased when Rituximab is combined with Naptumomab Estafenatox.,Naptumomab Estafenatox
DB12815,The risk or severity of adverse effects can be increased when Rituximab is combined with Crotedumab.,Crotedumab
DB12820,The risk or severity of adverse effects can be increased when Rituximab is combined with Concizumab.,Concizumab
DB12826,The risk or severity of adverse effects can be increased when Rituximab is combined with Depatuxizumab.,Depatuxizumab
DB12844,The risk or severity of adverse effects can be increased when Rituximab is combined with Rontalizumab.,Rontalizumab
DB12845,The risk or severity of adverse effects can be increased when Rituximab is combined with Amatuximab.,Amatuximab
DB12849,The risk or severity of adverse effects can be increased when Rituximab is combined with Clazakizumab.,Clazakizumab
DB12891,The risk or severity of adverse effects can be increased when Rituximab is combined with Ozanezumab.,Ozanezumab
DB12893,The risk or severity of adverse effects can be increased when Rituximab is combined with Sacituzumab govitecan.,Sacituzumab govitecan
DB12917,The risk or severity of adverse effects can be increased when Rituximab is combined with Bimekizumab.,Bimekizumab
DB12943,The risk or severity of adverse effects can be increased when Rituximab is combined with Milatuzumab.,Milatuzumab
DB12976,The risk or severity of adverse effects can be increased when Rituximab is combined with Robatumumab.,Robatumumab
DB13017,The risk or severity of adverse effects can be increased when Rituximab is combined with Rovalpituzumab Tesirine.,Rovalpituzumab Tesirine
DB13037,The risk or severity of adverse effects can be increased when Rituximab is combined with Namilumab.,Namilumab
DB13045,The risk or severity of adverse effects can be increased when Rituximab is combined with Racotumomab.,Racotumomab
DB13073,The risk or severity of adverse effects can be increased when Rituximab is combined with Tregalizumab.,Tregalizumab
DB13127,The risk or severity of adverse effects can be increased when Rituximab is combined with Olokizumab.,Olokizumab
DB13140,The risk or severity of adverse effects can be increased when Rituximab is combined with Bezlotoxumab.,Bezlotoxumab
DB13375,The risk or severity of adverse effects can be increased when Rituximab is combined with Edrecolomab.,Edrecolomab
DB13535,The risk or severity of adverse effects can be increased when Rituximab is combined with Nebacumab.,Nebacumab
DB13886,The risk or severity of adverse effects can be increased when Rituximab is combined with Human cytomegalovirus immune globulin.,Human cytomegalovirus immune globulin
DB13923,The risk or severity of adverse effects can be increased when Rituximab is combined with Emicizumab.,Emicizumab
DB13976,The risk or severity of adverse effects can be increased when Rituximab is combined with Sulesomab.,Sulesomab
DB13979,The risk or severity of adverse effects can be increased when Rituximab is combined with Besilesomab.,Besilesomab
DB14012,The risk or severity of adverse effects can be increased when Rituximab is combined with Burosumab.,Burosumab
DB14039,The risk or severity of adverse effects can be increased when Rituximab is combined with Erenumab.,Erenumab
DB14040,The risk or severity of adverse effects can be increased when Rituximab is combined with Eptinezumab.,Eptinezumab
DB14041,The risk or severity of adverse effects can be increased when Rituximab is combined with Fremanezumab.,Fremanezumab
DB14042,The risk or severity of adverse effects can be increased when Rituximab is combined with Galcanezumab.,Galcanezumab
DB14211,The risk or severity of adverse effects can be increased when Rituximab is combined with Fanolesomab.,Fanolesomab
DB14580,The risk or severity of adverse effects can be increased when Rituximab is combined with Lecanemab.,Lecanemab
DB14597,The risk or severity of adverse effects can be increased when Rituximab is combined with Lanadelumab.,Lanadelumab
DB14707,The risk or severity of adverse effects can be increased when Rituximab is combined with Cemiplimab.,Cemiplimab
DB14776,The risk or severity of adverse effects can be increased when Rituximab is combined with Camrelizumab.,Camrelizumab
DB14778,The risk or severity of adverse effects can be increased when Rituximab is combined with Setrusumab.,Setrusumab
DB14784,The risk or severity of adverse effects can be increased when Rituximab is combined with Gancotamab.,Gancotamab
DB14809,The risk or severity of adverse effects can be increased when Rituximab is combined with Anetumab ravtansine.,Anetumab ravtansine
DB14811,The risk or severity of adverse effects can be increased when Rituximab is combined with Isatuximab.,Isatuximab
DB14824,The risk or severity of adverse effects can be increased when Rituximab is combined with Icrucumab.,Icrucumab
DB14843,The risk or severity of adverse effects can be increased when Rituximab is combined with Codrituzumab.,Codrituzumab
DB14864,The risk or severity of adverse effects can be increased when Rituximab is combined with Brolucizumab.,Brolucizumab
DB14871,The risk or severity of adverse effects can be increased when Rituximab is combined with Xentuzumab.,Xentuzumab
DB14877,The risk or severity of adverse effects can be increased when Rituximab is combined with Lintuzumab.,Lintuzumab
DB14891,The risk or severity of adverse effects can be increased when Rituximab is combined with Vobarilizumab.,Vobarilizumab
DB14897,The risk or severity of adverse effects can be increased when Rituximab is combined with Parsatuzumab.,Parsatuzumab
DB14905,The risk or severity of adverse effects can be increased when Rituximab is combined with Emactuzumab.,Emactuzumab
DB14907,The risk or severity of adverse effects can be increased when Rituximab is combined with Bevacizumab zirconium Zr-89.,Bevacizumab zirconium Zr-89
DB14908,The risk or severity of adverse effects can be increased when Rituximab is combined with Refanezumab.,Refanezumab
DB14947,The risk or severity of adverse effects can be increased when Rituximab is combined with Bermekimab.,Bermekimab
DB14952,The risk or severity of adverse effects can be increased when Rituximab is combined with Pamrevlumab.,Pamrevlumab
DB14959,The risk or severity of adverse effects can be increased when Rituximab is combined with Opicinumab.,Opicinumab
DB14962,The risk or severity of adverse effects can be increased when Rituximab is combined with Trastuzumab deruxtecan.,Trastuzumab deruxtecan
DB14967,The risk or severity of adverse effects can be increased when Rituximab is combined with Margetuximab.,Margetuximab
DB14988,The risk or severity of adverse effects can be increased when Rituximab is combined with Dalantercept.,Dalantercept
DB14997,The risk or severity of adverse effects can be increased when Rituximab is combined with Pateclizumab.,Pateclizumab
DB15014,The risk or severity of adverse effects can be increased when Rituximab is combined with Gremubamab.,Gremubamab
DB15022,The risk or severity of adverse effects can be increased when Rituximab is combined with Apomab.,Apomab
DB15044,The risk or severity of adverse effects can be increased when Rituximab is combined with Tafasitamab.,Tafasitamab
DB15045,The risk or severity of adverse effects can be increased when Rituximab is combined with Ipafricept.,Ipafricept
DB15076,The risk or severity of adverse effects can be increased when Rituximab is combined with Abrilumab.,Abrilumab
DB15089,The risk or severity of adverse effects can be increased when Rituximab is combined with Frovocimab.,Frovocimab
DB15090,The risk or severity of adverse effects can be increased when Rituximab is combined with Tezepelumab.,Tezepelumab
DB15101,The risk or severity of adverse effects can be increased when Rituximab is combined with Tigatuzumab.,Tigatuzumab
DB15104,The risk or severity of adverse effects can be increased when Rituximab is combined with Telisotuzumab vedotin.,Telisotuzumab vedotin
DB15113,The risk or severity of adverse effects can be increased when Rituximab is combined with Utomilumab.,Utomilumab
DB15118,The risk or severity of adverse effects can be increased when Rituximab is combined with Zolbetuximab.,Zolbetuximab
DB15135,The risk or severity of adverse effects can be increased when Rituximab is combined with Ponezumab.,Ponezumab
DB15160,The risk or severity of adverse effects can be increased when Rituximab is combined with Asunercept.,Asunercept
DB15172,The risk or severity of adverse effects can be increased when Rituximab is combined with Suvratoxumab.,Suvratoxumab
DB15225,The risk or severity of adverse effects can be increased when Rituximab is combined with Mitazalimab.,Mitazalimab
DB15252,The risk or severity of adverse effects can be increased when Rituximab is combined with Nemolizumab.,Nemolizumab
DB15277,The risk or severity of adverse effects can be increased when Rituximab is combined with Gedivumab.,Gedivumab
DB15336,The risk or severity of adverse effects can be increased when Rituximab is combined with Valanafusp alfa.,Valanafusp alfa
DB15349,The risk or severity of adverse effects can be increased when Rituximab is combined with Sofituzumab vedotin.,Sofituzumab vedotin
DB15354,The risk or severity of adverse effects can be increased when Rituximab is combined with Evinacumab.,Evinacumab
DB15363,The risk or severity of adverse effects can be increased when Rituximab is combined with Istiratumab.,Istiratumab
DB15383,The risk or severity of adverse effects can be increased when Rituximab is combined with Pidilizumab.,Pidilizumab
DB15397,The risk or severity of adverse effects can be increased when Rituximab is combined with GMA-161.,GMA-161
DB15409,The risk or severity of adverse effects can be increased when Rituximab is combined with Ladiratuzumab vedotin.,Ladiratuzumab vedotin
DB15415,The risk or severity of adverse effects can be increased when Rituximab is combined with Tomaralimab.,Tomaralimab
DB15428,The risk or severity of adverse effects can be increased when Rituximab is combined with Vesencumab.,Vesencumab
DB15432,The risk or severity of adverse effects can be increased when Rituximab is combined with Pinatuzumab vedotin.,Pinatuzumab vedotin
DB15441,The risk or severity of adverse effects can be increased when Rituximab is combined with Lulizumab pegol.,Lulizumab pegol
DB15443,The risk or severity of adverse effects can be increased when Rituximab is combined with Lorukafusp alfa.,Lorukafusp alfa
DB15453,The risk or severity of adverse effects can be increased when Rituximab is combined with Naratuximab emtansine.,Naratuximab emtansine
DB14004,The risk or severity of adverse effects can be increased when Rituximab is combined with Tildrakizumab.,Tildrakizumab
DB05679,The risk or severity of adverse effects can be increased when Rituximab is combined with Ustekinumab.,Ustekinumab
DB15559,The risk or severity of adverse effects can be increased when Rituximab is combined with Zenocutuzumab.,Zenocutuzumab
DB00039,The therapeutic efficacy of Palifermin can be decreased when used in combination with Rituximab.,Palifermin
DB00001,The risk or severity of bleeding can be increased when Lepirudin is combined with Rituximab.,Lepirudin
DB00006,The risk or severity of bleeding can be increased when Bivalirudin is combined with Rituximab.,Bivalirudin
DB00009,The risk or severity of bleeding can be increased when Alteplase is combined with Rituximab.,Alteplase
DB00013,The risk or severity of bleeding can be increased when Urokinase is combined with Rituximab.,Urokinase
DB00015,The risk or severity of bleeding can be increased when Reteplase is combined with Rituximab.,Reteplase
DB00029,The risk or severity of bleeding can be increased when Anistreplase is combined with Rituximab.,Anistreplase
DB00031,The risk or severity of bleeding can be increased when Tenecteplase is combined with Rituximab.,Tenecteplase
DB00055,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Rituximab.,Drotrecogin alfa
DB00086,The risk or severity of bleeding can be increased when Streptokinase is combined with Rituximab.,Streptokinase
DB00266,The risk or severity of bleeding can be increased when Dicoumarol is combined with Rituximab.,Dicoumarol
DB00278,The risk or severity of bleeding can be increased when Argatroban is combined with Rituximab.,Argatroban
DB00407,The risk or severity of bleeding can be increased when Ardeparin is combined with Rituximab.,Ardeparin
DB00498,The risk or severity of bleeding can be increased when Phenindione is combined with Rituximab.,Phenindione
DB00569,The risk or severity of bleeding can be increased when Fondaparinux is combined with Rituximab.,Fondaparinux
DB00682,The risk or severity of bleeding can be increased when Warfarin is combined with Rituximab.,Warfarin
DB00686,The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Rituximab.,Pentosan polysulfate
DB00946,The risk or severity of bleeding can be increased when Phenprocoumon is combined with Rituximab.,Phenprocoumon
DB01109,The risk or severity of bleeding can be increased when Heparin is combined with Rituximab.,Heparin
DB01225,The risk or severity of bleeding can be increased when Enoxaparin is combined with Rituximab.,Enoxaparin
DB01418,The risk or severity of bleeding can be increased when Acenocoumarol is combined with Rituximab.,Acenocoumarol
DB03410,The risk or severity of bleeding can be increased when 4-hydroxycoumarin is combined with Rituximab.,4-hydroxycoumarin
DB04665,The risk or severity of bleeding can be increased when Coumarin is combined with Rituximab.,Coumarin
DB04898,The risk or severity of bleeding can be increased when Ximelagatran is combined with Rituximab.,Ximelagatran
DB04925,The risk or severity of bleeding can be increased when Desmoteplase is combined with Rituximab.,Desmoteplase
DB05099,The risk or severity of bleeding can be increased when Ancrod is combined with Rituximab.,Ancrod
DB05254,The risk or severity of bleeding can be increased when Fibrinolysin is combined with Rituximab.,Fibrinolysin
DB06228,The risk or severity of bleeding can be increased when Rivaroxaban is combined with Rituximab.,Rivaroxaban
DB06271,The risk or severity of bleeding can be increased when Sulodexide is combined with Rituximab.,Sulodexide
DB06294,The risk or severity of bleeding can be increased when Semuloparin is combined with Rituximab.,Semuloparin
DB06406,The risk or severity of bleeding can be increased when Idraparinux is combined with Rituximab.,Idraparinux
DB06543,The risk or severity of bleeding can be increased when Astaxanthin is combined with Rituximab.,Astaxanthin
DB06605,The risk or severity of bleeding can be increased when Apixaban is combined with Rituximab.,Apixaban
DB06635,The risk or severity of bleeding can be increased when Otamixaban is combined with Rituximab.,Otamixaban
DB06679,The risk or severity of bleeding can be increased when Amediplase is combined with Rituximab.,Amediplase
DB06695,The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Rituximab.,Dabigatran etexilate
DB06754,The risk or severity of bleeding can be increased when Danaparoid is combined with Rituximab.,Danaparoid
DB06779,The risk or severity of bleeding can be increased when Dalteparin is combined with Rituximab.,Dalteparin
DB06822,The risk or severity of bleeding can be increased when Tinzaparin is combined with Rituximab.,Tinzaparin
DB08496,The risk or severity of bleeding can be increased when (R)-warfarin is combined with Rituximab.,(R)-warfarin
DB08794,The risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Rituximab.,Ethyl biscoumacetate
DB08813,The risk or severity of bleeding can be increased when Nadroparin is combined with Rituximab.,Nadroparin
DB08994,The risk or severity of bleeding can be increased when Ditazole is combined with Rituximab.,Ditazole
DB09075,The risk or severity of bleeding can be increased when Edoxaban is combined with Rituximab.,Edoxaban
DB09125,The risk or severity of bleeding can be increased when Potassium citrate is combined with Rituximab.,Potassium citrate
DB09154,The risk or severity of bleeding can be increased when Sodium citrate is combined with Rituximab.,Sodium citrate
DB09255,The risk or severity of bleeding can be increased when Dextran is combined with Rituximab.,Dextran
DB09258,The risk or severity of bleeding can be increased when Bemiparin is combined with Rituximab.,Bemiparin
DB09259,The risk or severity of bleeding can be increased when Reviparin is combined with Rituximab.,Reviparin
DB09260,The risk or severity of bleeding can be increased when Parnaparin is combined with Rituximab.,Parnaparin
DB09261,The risk or severity of bleeding can be increased when Certoparin is combined with Rituximab.,Certoparin
DB11095,The risk or severity of bleeding can be increased when Desirudin is combined with Rituximab.,Desirudin
DB11154,The risk or severity of bleeding can be increased when Zinc citrate is combined with Rituximab.,Zinc citrate
DB11166,The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Rituximab.,Antithrombin Alfa
DB11312,The risk or severity of bleeding can be increased when Protein C is combined with Rituximab.,Protein C
DB11598,The risk or severity of bleeding can be increased when Antithrombin III human is combined with Rituximab.,Antithrombin III human
DB11984,The risk or severity of bleeding can be increased when Letaxaban is combined with Rituximab.,Letaxaban
DB12289,The risk or severity of bleeding can be increased when Darexaban is combined with Rituximab.,Darexaban
DB12364,The risk or severity of bleeding can be increased when Betrixaban is combined with Rituximab.,Betrixaban
DB12598,The risk or severity of bleeding can be increased when Nafamostat is combined with Rituximab.,Nafamostat
DB12726,The risk or severity of bleeding can be increased when Monteplase is combined with Rituximab.,Monteplase
DB12831,The risk or severity of bleeding can be increased when Gabexate is combined with Rituximab.,Gabexate
DB13136,The risk or severity of bleeding can be increased when Fluindione is combined with Rituximab.,Fluindione
DB13149,The risk or severity of bleeding can be increased when Protein S human is combined with Rituximab.,Protein S human
DB13199,The risk or severity of bleeding can be increased when Brinase is combined with Rituximab.,Brinase
DB13275,The risk or severity of bleeding can be increased when Clorindione is combined with Rituximab.,Clorindione
DB13347,The risk or severity of bleeding can be increased when Diphenadione is combined with Rituximab.,Diphenadione
DB13451,The risk or severity of bleeding can be increased when Tioclomarol is combined with Rituximab.,Tioclomarol
DB13616,The risk or severity of bleeding can be increased when Melagatran is combined with Rituximab.,Melagatran
DB13646,The risk or severity of bleeding can be increased when Saruplase is combined with Rituximab.,Saruplase
DB14055,The risk or severity of bleeding can be increased when (S)-Warfarin is combined with Rituximab.,(S)-Warfarin
DB14598,The risk or severity of bleeding can be increased when Edetate calcium disodium anhydrous is combined with Rituximab.,Edetate calcium disodium anhydrous
DB14726,The risk or severity of bleeding can be increased when Dabigatran is combined with Rituximab.,Dabigatran
DB00232,The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Rituximab.,Methyclothiazide
DB00562,The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Rituximab.,Benzthiazide
DB13430,The risk or severity of neutropenia and thrombocytopenia can be increased when Mebutizide is combined with Rituximab.,Mebutizide
DB00515,Rituximab may increase the nephrotoxic activities of Cisplatin.,Cisplatin
DB09042,The risk or severity of myelosuppression can be increased when Rituximab is combined with Tedizolid phosphate.,Tedizolid phosphate
DB00091,Rituximab may increase the immunosuppressive activities of Cyclosporine.,Cyclosporine
DB00115,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Rituximab.,Cyanocobalamin
DB00437,The risk or severity of adverse effects can be increased when Allopurinol is combined with Rituximab.,Allopurinol
DB05676,The therapeutic efficacy of Apremilast can be decreased when used in combination with Rituximab.,Apremilast
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Rituximab.","Ebola Zaire vaccine (live, attenuated)"
DB14513,The serum concentration of Magnesium can be decreased when it is combined with Rituximab.,Magnesium
DB01601,The serum concentration of Rituximab can be increased when it is combined with Lopinavir.,Lopinavir
DB12530,The risk or severity of infection can be increased when Rituximab is combined with Inebilizumab.,Inebilizumab
DB06643,The risk or severity of adverse effects can be increased when Denosumab is combined with Basiliximab.,Denosumab
DB00005,The risk or severity of adverse effects can be increased when Etanercept is combined with Basiliximab.,Etanercept
DB00008,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Basiliximab.,Peginterferon alfa-2a
DB00011,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Basiliximab.,Interferon alfa-n1
DB00018,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Basiliximab.,Interferon alfa-n3
DB00022,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Basiliximab.,Peginterferon alfa-2b
DB00026,The risk or severity of adverse effects can be increased when Anakinra is combined with Basiliximab.,Anakinra
DB00033,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Basiliximab.,Interferon gamma-1b
DB00034,"The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Basiliximab.","Interferon alfa-2a, Recombinant"
DB00041,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Basiliximab.,Aldesleukin
DB00051,The risk or severity of adverse effects can be increased when Adalimumab is combined with Basiliximab.,Adalimumab
DB00056,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Basiliximab.,Gemtuzumab ozogamicin
DB00059,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Basiliximab.,Pegaspargase
DB00065,The risk or severity of adverse effects can be increased when Infliximab is combined with Basiliximab.,Infliximab
DB00068,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Basiliximab.,Interferon beta-1b
DB00069,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Basiliximab.,Interferon alfacon-1
DB00073,The risk or severity of adverse effects can be increased when Rituximab is combined with Basiliximab.,Rituximab
DB00075,The risk or severity of adverse effects can be increased when Basiliximab is combined with Muromonab.,Muromonab
DB00078,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ibritumomab tiuxetan.,Ibritumomab tiuxetan
DB00081,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tositumomab.,Tositumomab
DB00087,The risk or severity of adverse effects can be increased when Basiliximab is combined with Alemtuzumab.,Alemtuzumab
DB00092,The risk or severity of adverse effects can be increased when Basiliximab is combined with Alefacept.,Alefacept
DB00095,The risk or severity of adverse effects can be increased when Basiliximab is combined with Efalizumab.,Efalizumab
DB00098,The risk or severity of adverse effects can be increased when Basiliximab is combined with Antithymocyte immunoglobulin (rabbit).,Antithymocyte immunoglobulin (rabbit)
DB00105,The risk or severity of adverse effects can be increased when Basiliximab is combined with Interferon alfa-2b.,Interferon alfa-2b
DB00111,The risk or severity of adverse effects can be increased when Basiliximab is combined with Daclizumab.,Daclizumab
DB00112,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bevacizumab.,Bevacizumab
DB00120,The risk or severity of adverse effects can be increased when Basiliximab is combined with Phenylalanine.,Phenylalanine
DB00180,The risk or severity of adverse effects can be increased when Basiliximab is combined with Flunisolide.,Flunisolide
DB00188,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bortezomib.,Bortezomib
DB00242,The risk or severity of adverse effects can be increased when Basiliximab is combined with Cladribine.,Cladribine
DB00262,The risk or severity of adverse effects can be increased when Basiliximab is combined with Carmustine.,Carmustine
DB00276,The risk or severity of adverse effects can be increased when Basiliximab is combined with Amsacrine.,Amsacrine
DB00290,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bleomycin.,Bleomycin
DB00291,The risk or severity of adverse effects can be increased when Basiliximab is combined with Chlorambucil.,Chlorambucil
DB00293,The risk or severity of adverse effects can be increased when Basiliximab is combined with Raltitrexed.,Raltitrexed
DB00305,The risk or severity of adverse effects can be increased when Basiliximab is combined with Mitomycin.,Mitomycin
DB00307,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bexarotene.,Bexarotene
DB00309,The risk or severity of adverse effects can be increased when Basiliximab is combined with Vindesine.,Vindesine
DB00322,The risk or severity of adverse effects can be increased when Basiliximab is combined with Floxuridine.,Floxuridine
DB00328,The risk or severity of adverse effects can be increased when Basiliximab is combined with Indomethacin.,Indomethacin
DB00352,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tioguanine.,Tioguanine
DB00361,The risk or severity of adverse effects can be increased when Basiliximab is combined with Vinorelbine.,Vinorelbine
DB00380,The risk or severity of adverse effects can be increased when Basiliximab is combined with Dexrazoxane.,Dexrazoxane
DB00394,The risk or severity of adverse effects can be increased when Basiliximab is combined with Beclomethasone dipropionate.,Beclomethasone dipropionate
DB00398,The risk or severity of adverse effects can be increased when Basiliximab is combined with Sorafenib.,Sorafenib
DB00428,The risk or severity of adverse effects can be increased when Basiliximab is combined with Streptozocin.,Streptozocin
DB00432,The risk or severity of adverse effects can be increased when Basiliximab is combined with Trifluridine.,Trifluridine
DB00441,The risk or severity of adverse effects can be increased when Basiliximab is combined with Gemcitabine.,Gemcitabine
DB00443,The risk or severity of adverse effects can be increased when Basiliximab is combined with Betamethasone.,Betamethasone
DB00444,The risk or severity of adverse effects can be increased when Basiliximab is combined with Teniposide.,Teniposide
DB00445,The risk or severity of adverse effects can be increased when Basiliximab is combined with Epirubicin.,Epirubicin
DB00446,The risk or severity of adverse effects can be increased when Basiliximab is combined with Chloramphenicol.,Chloramphenicol
DB00480,The risk or severity of adverse effects can be increased when Basiliximab is combined with Lenalidomide.,Lenalidomide
DB00488,The risk or severity of adverse effects can be increased when Basiliximab is combined with Altretamine.,Altretamine
DB00495,The risk or severity of adverse effects can be increased when Basiliximab is combined with Zidovudine.,Zidovudine
DB00515,The risk or severity of adverse effects can be increased when Basiliximab is combined with Cisplatin.,Cisplatin
DB00526,The risk or severity of adverse effects can be increased when Basiliximab is combined with Oxaliplatin.,Oxaliplatin
DB00531,The risk or severity of adverse effects can be increased when Basiliximab is combined with Cyclophosphamide.,Cyclophosphamide
DB00541,The risk or severity of adverse effects can be increased when Basiliximab is combined with Vincristine.,Vincristine
DB00544,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fluorouracil.,Fluorouracil
DB00550,The risk or severity of adverse effects can be increased when Basiliximab is combined with Propylthiouracil.,Propylthiouracil
DB00552,The risk or severity of adverse effects can be increased when Basiliximab is combined with Pentostatin.,Pentostatin
DB00563,The risk or severity of adverse effects can be increased when Basiliximab is combined with Methotrexate.,Methotrexate
DB00564,The risk or severity of adverse effects can be increased when Basiliximab is combined with Carbamazepine.,Carbamazepine
DB00570,The risk or severity of adverse effects can be increased when Basiliximab is combined with Vinblastine.,Vinblastine
DB00588,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fluticasone propionate.,Fluticasone propionate
DB00591,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fluocinolone acetonide.,Fluocinolone acetonide
DB00601,The risk or severity of adverse effects can be increased when Basiliximab is combined with Linezolid.,Linezolid
DB00619,The risk or severity of adverse effects can be increased when Basiliximab is combined with Imatinib.,Imatinib
DB00620,The risk or severity of adverse effects can be increased when Basiliximab is combined with Triamcinolone.,Triamcinolone
DB00631,The risk or severity of adverse effects can be increased when Basiliximab is combined with Clofarabine.,Clofarabine
DB00635,The risk or severity of adverse effects can be increased when Basiliximab is combined with Prednisone.,Prednisone
DB00642,The risk or severity of adverse effects can be increased when Basiliximab is combined with Pemetrexed.,Pemetrexed
DB00687,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fludrocortisone.,Fludrocortisone
DB00688,The risk or severity of adverse effects can be increased when Basiliximab is combined with Mycophenolate mofetil.,Mycophenolate mofetil
DB00694,The risk or severity of adverse effects can be increased when Basiliximab is combined with Daunorubicin.,Daunorubicin
DB00755,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tretinoin.,Tretinoin
DB00762,The risk or severity of adverse effects can be increased when Basiliximab is combined with Irinotecan.,Irinotecan
DB00763,The risk or severity of adverse effects can be increased when Basiliximab is combined with Methimazole.,Methimazole
DB00764,The risk or severity of adverse effects can be increased when Basiliximab is combined with Mometasone.,Mometasone
DB00773,The risk or severity of adverse effects can be increased when Basiliximab is combined with Etoposide.,Etoposide
DB00795,The risk or severity of adverse effects can be increased when Basiliximab is combined with Sulfasalazine.,Sulfasalazine
DB00851,The risk or severity of adverse effects can be increased when Basiliximab is combined with Dacarbazine.,Dacarbazine
DB00853,The risk or severity of adverse effects can be increased when Basiliximab is combined with Temozolomide.,Temozolomide
DB00859,The risk or severity of adverse effects can be increased when Basiliximab is combined with Penicillamine.,Penicillamine
DB00860,The risk or severity of adverse effects can be increased when Basiliximab is combined with Prednisolone.,Prednisolone
DB00877,The risk or severity of adverse effects can be increased when Basiliximab is combined with Sirolimus.,Sirolimus
DB00888,The risk or severity of adverse effects can be increased when Basiliximab is combined with Mechlorethamine.,Mechlorethamine
DB00928,The risk or severity of adverse effects can be increased when Basiliximab is combined with Azacitidine.,Azacitidine
DB00958,The risk or severity of adverse effects can be increased when Basiliximab is combined with Carboplatin.,Carboplatin
DB00959,The risk or severity of adverse effects can be increased when Basiliximab is combined with Methylprednisolone.,Methylprednisolone
DB00970,The risk or severity of adverse effects can be increased when Basiliximab is combined with Dactinomycin.,Dactinomycin
DB00987,The risk or severity of adverse effects can be increased when Basiliximab is combined with Cytarabine.,Cytarabine
DB00993,The risk or severity of adverse effects can be increased when Basiliximab is combined with Azathioprine.,Azathioprine
DB00997,The risk or severity of adverse effects can be increased when Basiliximab is combined with Doxorubicin.,Doxorubicin
DB01005,The risk or severity of adverse effects can be increased when Basiliximab is combined with Hydroxyurea.,Hydroxyurea
DB01008,The risk or severity of adverse effects can be increased when Basiliximab is combined with Busulfan.,Busulfan
DB01024,The risk or severity of adverse effects can be increased when Basiliximab is combined with Mycophenolic acid.,Mycophenolic acid
DB01030,The risk or severity of adverse effects can be increased when Basiliximab is combined with Topotecan.,Topotecan
DB01033,The risk or severity of adverse effects can be increased when Basiliximab is combined with Mercaptopurine.,Mercaptopurine
DB01041,The risk or severity of adverse effects can be increased when Basiliximab is combined with Thalidomide.,Thalidomide
DB01042,The risk or severity of adverse effects can be increased when Basiliximab is combined with Melphalan.,Melphalan
DB01073,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fludarabine.,Fludarabine
DB01099,The risk or severity of adverse effects can be increased when Basiliximab is combined with Flucytosine.,Flucytosine
DB01101,The risk or severity of adverse effects can be increased when Basiliximab is combined with Capecitabine.,Capecitabine
DB01108,The risk or severity of adverse effects can be increased when Basiliximab is combined with Trilostane.,Trilostane
DB01168,The risk or severity of adverse effects can be increased when Basiliximab is combined with Procarbazine.,Procarbazine
DB01169,The risk or severity of adverse effects can be increased when Basiliximab is combined with Arsenic trioxide.,Arsenic trioxide
DB01177,The risk or severity of adverse effects can be increased when Basiliximab is combined with Idarubicin.,Idarubicin
DB01181,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ifosfamide.,Ifosfamide
DB01196,The risk or severity of adverse effects can be increased when Basiliximab is combined with Estramustine.,Estramustine
DB01204,The risk or severity of adverse effects can be increased when Basiliximab is combined with Mitoxantrone.,Mitoxantrone
DB01206,The risk or severity of adverse effects can be increased when Basiliximab is combined with Lomustine.,Lomustine
DB01222,The risk or severity of adverse effects can be increased when Basiliximab is combined with Budesonide.,Budesonide
DB01229,The risk or severity of adverse effects can be increased when Basiliximab is combined with Paclitaxel.,Paclitaxel
DB01234,The risk or severity of adverse effects can be increased when Basiliximab is combined with Dexamethasone.,Dexamethasone
DB01248,The risk or severity of adverse effects can be increased when Basiliximab is combined with Docetaxel.,Docetaxel
DB01254,The risk or severity of adverse effects can be increased when Basiliximab is combined with Dasatinib.,Dasatinib
DB01257,The risk or severity of adverse effects can be increased when Basiliximab is combined with Eculizumab.,Eculizumab
DB01262,The risk or severity of adverse effects can be increased when Basiliximab is combined with Decitabine.,Decitabine
DB01268,The risk or severity of adverse effects can be increased when Basiliximab is combined with Sunitinib.,Sunitinib
DB01280,The risk or severity of adverse effects can be increased when Basiliximab is combined with Nelarabine.,Nelarabine
DB01281,The risk or severity of adverse effects can be increased when Basiliximab is combined with Abatacept.,Abatacept
DB01285,The risk or severity of adverse effects can be increased when Basiliximab is combined with Corticotropin.,Corticotropin
DB01380,The risk or severity of adverse effects can be increased when Basiliximab is combined with Cortisone acetate.,Cortisone acetate
DB01384,The risk or severity of adverse effects can be increased when Basiliximab is combined with Paramethasone.,Paramethasone
DB01394,The risk or severity of adverse effects can be increased when Basiliximab is combined with Colchicine.,Colchicine
DB01410,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ciclesonide.,Ciclesonide
DB01423,The risk or severity of adverse effects can be increased when Basiliximab is combined with Stepronin.,Stepronin
DB01590,The risk or severity of adverse effects can be increased when Basiliximab is combined with Everolimus.,Everolimus
DB01611,The risk or severity of adverse effects can be increased when Basiliximab is combined with Hydroxychloroquine.,Hydroxychloroquine
DB01816,The risk or severity of adverse effects can be increased when Basiliximab is combined with Castanospermine.,Castanospermine
DB02546,The risk or severity of adverse effects can be increased when Basiliximab is combined with Vorinostat.,Vorinostat
DB02806,The risk or severity of adverse effects can be increased when Basiliximab is combined with 2-Methoxyethanol.,2-Methoxyethanol
DB03523,The risk or severity of adverse effects can be increased when Basiliximab is combined with Brequinar.,Brequinar
DB04572,The risk or severity of adverse effects can be increased when Basiliximab is combined with Thiotepa.,Thiotepa
DB04630,The risk or severity of adverse effects can be increased when Basiliximab is combined with Aldosterone.,Aldosterone
DB04845,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ixabepilone.,Ixabepilone
DB04868,The risk or severity of adverse effects can be increased when Basiliximab is combined with Nilotinib.,Nilotinib
DB04951,The risk or severity of adverse effects can be increased when Basiliximab is combined with Pirfenidone.,Pirfenidone
DB04956,The risk or severity of adverse effects can be increased when Basiliximab is combined with Afelimomab.,Afelimomab
DB05015,The risk or severity of adverse effects can be increased when Basiliximab is combined with Belinostat.,Belinostat
DB05109,The risk or severity of adverse effects can be increased when Basiliximab is combined with Trabectedin.,Trabectedin
DB05258,The risk or severity of adverse effects can be increased when Basiliximab is combined with Interferon alfa.,Interferon alfa
DB05259,The risk or severity of adverse effects can be increased when Basiliximab is combined with Glatiramer.,Glatiramer
DB05260,The risk or severity of adverse effects can be increased when Basiliximab is combined with Gallium nitrate.,Gallium nitrate
DB05459,The risk or severity of adverse effects can be increased when Basiliximab is combined with Briakinumab.,Briakinumab
DB05472,The risk or severity of adverse effects can be increased when Basiliximab is combined with omega interferon.,omega interferon
DB05676,The risk or severity of adverse effects can be increased when Basiliximab is combined with Apremilast.,Apremilast
DB05773,The risk or severity of adverse effects can be increased when Basiliximab is combined with Trastuzumab emtansine.,Trastuzumab emtansine
DB06168,The risk or severity of adverse effects can be increased when Basiliximab is combined with Canakinumab.,Canakinumab
DB06273,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tocilizumab.,Tocilizumab
DB06287,The risk or severity of adverse effects can be increased when Basiliximab is combined with Temsirolimus.,Temsirolimus
DB06372,The risk or severity of adverse effects can be increased when Basiliximab is combined with Rilonacept.,Rilonacept
DB06589,The risk or severity of adverse effects can be increased when Basiliximab is combined with Pazopanib.,Pazopanib
DB06603,The risk or severity of adverse effects can be increased when Basiliximab is combined with Panobinostat.,Panobinostat
DB06612,The risk or severity of adverse effects can be increased when Basiliximab is combined with Mepolizumab.,Mepolizumab
DB06616,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bosutinib.,Bosutinib
DB06662,The risk or severity of adverse effects can be increased when Basiliximab is combined with Abetimus.,Abetimus
DB06674,The risk or severity of adverse effects can be increased when Basiliximab is combined with Golimumab.,Golimumab
DB06681,The risk or severity of adverse effects can be increased when Basiliximab is combined with Belatacept.,Belatacept
DB06769,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bendamustine.,Bendamustine
DB06772,The risk or severity of adverse effects can be increased when Basiliximab is combined with Cabazitaxel.,Cabazitaxel
DB06813,The risk or severity of adverse effects can be increased when Basiliximab is combined with Pralatrexate.,Pralatrexate
DB08059,The risk or severity of adverse effects can be increased when Basiliximab is combined with Wortmannin.,Wortmannin
DB08870,The risk or severity of adverse effects can be increased when Basiliximab is combined with Brentuximab vedotin.,Brentuximab vedotin
DB08871,The risk or severity of adverse effects can be increased when Basiliximab is combined with Eribulin.,Eribulin
DB08877,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ruxolitinib.,Ruxolitinib
DB08879,The risk or severity of adverse effects can be increased when Basiliximab is combined with Belimumab.,Belimumab
DB08880,The risk or severity of adverse effects can be increased when Basiliximab is combined with Teriflunomide.,Teriflunomide
DB08889,The risk or severity of adverse effects can be increased when Basiliximab is combined with Carfilzomib.,Carfilzomib
DB08901,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ponatinib.,Ponatinib
DB08904,The risk or severity of adverse effects can be increased when Basiliximab is combined with Certolizumab pegol.,Certolizumab pegol
DB08906,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fluticasone furoate.,Fluticasone furoate
DB08908,The risk or severity of adverse effects can be increased when Basiliximab is combined with Dimethyl fumarate.,Dimethyl fumarate
DB08910,The risk or severity of adverse effects can be increased when Basiliximab is combined with Pomalidomide.,Pomalidomide
DB08935,The risk or severity of adverse effects can be increased when Basiliximab is combined with Obinutuzumab.,Obinutuzumab
DB08970,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fluprednidene.,Fluprednidene
DB08971,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fluocortolone.,Fluocortolone
DB09029,The risk or severity of adverse effects can be increased when Basiliximab is combined with Secukinumab.,Secukinumab
DB09033,The risk or severity of adverse effects can be increased when Basiliximab is combined with Vedolizumab.,Vedolizumab
DB09036,The risk or severity of adverse effects can be increased when Basiliximab is combined with Siltuximab.,Siltuximab
DB09052,The risk or severity of adverse effects can be increased when Basiliximab is combined with Blinatumomab.,Blinatumomab
DB09053,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ibrutinib.,Ibrutinib
DB09054,The risk or severity of adverse effects can be increased when Basiliximab is combined with Idelalisib.,Idelalisib
DB09073,The risk or severity of adverse effects can be increased when Basiliximab is combined with Palbociclib.,Palbociclib
DB09074,The risk or severity of adverse effects can be increased when Basiliximab is combined with Olaparib.,Olaparib
DB09077,The risk or severity of adverse effects can be increased when Basiliximab is combined with Dinutuximab.,Dinutuximab
DB09082,The risk or severity of adverse effects can be increased when Basiliximab is combined with Vilanterol.,Vilanterol
DB09091,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tixocortol.,Tixocortol
DB09122,The risk or severity of adverse effects can be increased when Basiliximab is combined with Peginterferon beta-1a.,Peginterferon beta-1a
DB09312,The risk or severity of adverse effects can be increased when Basiliximab is combined with Antilymphocyte immunoglobulin (horse).,Antilymphocyte immunoglobulin (horse)
DB09378,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fluprednisolone.,Fluprednisolone
DB09383,The risk or severity of adverse effects can be increased when Basiliximab is combined with Meprednisone.,Meprednisone
DB11466,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tepoxalin.,Tepoxalin
DB11487,The risk or severity of adverse effects can be increased when Basiliximab is combined with Dexamethasone isonicotinate.,Dexamethasone isonicotinate
DB11529,The risk or severity of adverse effects can be increased when Basiliximab is combined with Melengestrol.,Melengestrol
DB11569,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ixekizumab.,Ixekizumab
DB11580,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ravulizumab.,Ravulizumab
DB11616,The risk or severity of adverse effects can be increased when Basiliximab is combined with Pirarubicin.,Pirarubicin
DB11693,The risk or severity of adverse effects can be increased when Basiliximab is combined with Voclosporin.,Voclosporin
DB11708,The risk or severity of adverse effects can be increased when Basiliximab is combined with Peficitinib.,Peficitinib
DB11750,The risk or severity of adverse effects can be increased when Basiliximab is combined with Clobetasol.,Clobetasol
DB11767,The risk or severity of adverse effects can be increased when Basiliximab is combined with Sarilumab.,Sarilumab
DB11776,The risk or severity of adverse effects can be increased when Basiliximab is combined with Brodalumab.,Brodalumab
DB11803,The risk or severity of adverse effects can be increased when Basiliximab is combined with Sirukumab.,Sirukumab
DB11817,The risk or severity of adverse effects can be increased when Basiliximab is combined with Baricitinib.,Baricitinib
DB11834,The risk or severity of adverse effects can be increased when Basiliximab is combined with Guselkumab.,Guselkumab
DB11921,The risk or severity of adverse effects can be increased when Basiliximab is combined with Deflazacort.,Deflazacort
DB12025,The risk or severity of adverse effects can be increased when Basiliximab is combined with Triptolide.,Triptolide
DB12371,The risk or severity of adverse effects can be increased when Basiliximab is combined with Siponimod.,Siponimod
DB12612,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ozanimod.,Ozanimod
DB12617,The risk or severity of adverse effects can be increased when Basiliximab is combined with Mizoribine.,Mizoribine
DB12692,The risk or severity of adverse effects can be increased when Basiliximab is combined with Gusperimus.,Gusperimus
DB12814,The risk or severity of adverse effects can be increased when Basiliximab is combined with Cepeginterferon alfa-2B.,Cepeginterferon alfa-2B
DB12902,The risk or severity of adverse effects can be increased when Basiliximab is combined with Trofosfamide.,Trofosfamide
DB12947,The risk or severity of adverse effects can be increased when Basiliximab is combined with Doxifluridine.,Doxifluridine
DB12991,The risk or severity of adverse effects can be increased when Basiliximab is combined with Deoxyspergualin.,Deoxyspergualin
DB12996,The risk or severity of adverse effects can be increased when Basiliximab is combined with Acteoside.,Acteoside
DB13003,The risk or severity of adverse effects can be increased when Basiliximab is combined with Cortivazol.,Cortivazol
DB13014,The risk or severity of adverse effects can be increased when Basiliximab is combined with Hypericin.,Hypericin
DB13068,The risk or severity of adverse effects can be increased when Basiliximab is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.,9-(N-methyl-L-isoleucine)-cyclosporin A
DB13208,The risk or severity of adverse effects can be increased when Basiliximab is combined with Prednylidene.,Prednylidene
DB13223,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fluocortin.,Fluocortin
DB13241,The risk or severity of adverse effects can be increased when Basiliximab is combined with Begelomab.,Begelomab
DB13491,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fluperolone.,Fluperolone
DB13664,The risk or severity of adverse effects can be increased when Basiliximab is combined with Formocortal.,Formocortal
DB13728,The risk or severity of adverse effects can be increased when Basiliximab is combined with Halometasone.,Halometasone
DB13843,The risk or severity of adverse effects can be increased when Basiliximab is combined with Cloprednol.,Cloprednol
DB13856,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fluclorolone.,Fluclorolone
DB13867,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fluticasone.,Fluticasone
DB14066,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tetrandrine.,Tetrandrine
DB14219,The risk or severity of adverse effects can be increased when Basiliximab is combined with Monomethyl fumarate.,Monomethyl fumarate
DB14512,The risk or severity of adverse effects can be increased when Basiliximab is combined with Mometasone furoate.,Mometasone furoate
DB14538,The risk or severity of adverse effects can be increased when Basiliximab is combined with Hydrocortisone aceponate.,Hydrocortisone aceponate
DB14539,The risk or severity of adverse effects can be increased when Basiliximab is combined with Hydrocortisone acetate.,Hydrocortisone acetate
DB14545,The risk or severity of adverse effects can be increased when Basiliximab is combined with Hydrocortisone succinate.,Hydrocortisone succinate
DB14724,The risk or severity of adverse effects can be increased when Basiliximab is combined with Emapalumab.,Emapalumab
DB14762,The risk or severity of adverse effects can be increased when Basiliximab is combined with Risankizumab.,Risankizumab
DB14919,The risk or severity of adverse effects can be increased when Basiliximab is combined with Rozanolixizumab.,Rozanolixizumab
DB15253,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bleselumab.,Bleselumab
DB00108,The risk or severity of adverse effects can be increased when Basiliximab is combined with Natalizumab.,Natalizumab
DB00337,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Basiliximab.,Pimecrolimus
DB01656,Roflumilast may increase the immunosuppressive activities of Basiliximab.,Roflumilast
DB06688,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Basiliximab.,Sipuleucel-T
DB01015,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Basiliximab.,Sulfamethoxazole
DB00255,Diethylstilbestrol may increase the thrombogenic activities of Basiliximab.,Diethylstilbestrol
DB00269,Chlorotrianisene may increase the thrombogenic activities of Basiliximab.,Chlorotrianisene
DB00286,Conjugated estrogens may increase the thrombogenic activities of Basiliximab.,Conjugated estrogens
DB00655,Estrone may increase the thrombogenic activities of Basiliximab.,Estrone
DB00783,Estradiol may increase the thrombogenic activities of Basiliximab.,Estradiol
DB00890,Dienestrol may increase the thrombogenic activities of Basiliximab.,Dienestrol
DB00977,Ethinylestradiol may increase the thrombogenic activities of Basiliximab.,Ethinylestradiol
DB01357,Mestranol may increase the thrombogenic activities of Basiliximab.,Mestranol
DB04573,Estriol may increase the thrombogenic activities of Basiliximab.,Estriol
DB04574,Estrone sulfate may increase the thrombogenic activities of Basiliximab.,Estrone sulfate
DB04575,Quinestrol may increase the thrombogenic activities of Basiliximab.,Quinestrol
DB07931,Hexestrol may increase the thrombogenic activities of Basiliximab.,Hexestrol
DB09070,Tibolone may increase the thrombogenic activities of Basiliximab.,Tibolone
DB09317,"Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Basiliximab.","Synthetic Conjugated Estrogens, A"
DB09318,"Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Basiliximab.","Synthetic Conjugated Estrogens, B"
DB09369,Polyestradiol phosphate may increase the thrombogenic activities of Basiliximab.,Polyestradiol phosphate
DB09381,Esterified estrogens may increase the thrombogenic activities of Basiliximab.,Esterified estrogens
DB11478,Zeranol may increase the thrombogenic activities of Basiliximab.,Zeranol
DB11674,Equol may increase the thrombogenic activities of Basiliximab.,Equol
DB12487,Promestriene may increase the thrombogenic activities of Basiliximab.,Promestriene
DB13143,Methallenestril may increase the thrombogenic activities of Basiliximab.,Methallenestril
DB13386,Epimestrol may increase the thrombogenic activities of Basiliximab.,Epimestrol
DB13418,Moxestrol may increase the thrombogenic activities of Basiliximab.,Moxestrol
DB13952,Estradiol acetate may increase the thrombogenic activities of Basiliximab.,Estradiol acetate
DB13953,Estradiol benzoate may increase the thrombogenic activities of Basiliximab.,Estradiol benzoate
DB13954,Estradiol cypionate may increase the thrombogenic activities of Basiliximab.,Estradiol cypionate
DB13956,Estradiol valerate may increase the thrombogenic activities of Basiliximab.,Estradiol valerate
DB15334,Biochanin A may increase the thrombogenic activities of Basiliximab.,Biochanin A
DB15335,Formononetin may increase the thrombogenic activities of Basiliximab.,Formononetin
DB01097,The risk or severity of adverse effects can be increased when Basiliximab is combined with Leflunomide.,Leflunomide
DB08895,Basiliximab may increase the immunosuppressive activities of Tofacitinib.,Tofacitinib
DB00072,Trastuzumab may increase the neutropenic activities of Basiliximab.,Trastuzumab
DB08868,Basiliximab may increase the immunosuppressive activities of Fingolimod.,Fingolimod
DB00864,Tacrolimus may increase the immunosuppressive activities of Basiliximab.,Tacrolimus
DB04914,The therapeutic efficacy of G17DT can be decreased when used in combination with Basiliximab.,G17DT
DB05144,The therapeutic efficacy of PEV3A can be decreased when used in combination with Basiliximab.,PEV3A
DB05325,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Basiliximab.,INGN 225
DB05374,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Basiliximab.,Rindopepimut
DB05440,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Basiliximab.,SRP 299
DB05942,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Basiliximab.,GI-5005
DB06400,The therapeutic efficacy of Vitespen can be decreased when used in combination with Basiliximab.,Vitespen
DB06584,The therapeutic efficacy of TG4010 can be decreased when used in combination with Basiliximab.,TG4010
DB09057,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Basiliximab.,Anthrax immune globulin human
DB10062,"The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Basiliximab.","Rabies virus inactivated antigen, B"
DB10076,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Basiliximab.,Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen
DB10276,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Basiliximab.,Rotavirus vaccine
DB10283,"The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Basiliximab.","Rabies virus inactivated antigen, A"
DB10342,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Basiliximab.,Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen
DB10583,The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Basiliximab.,Clostridium tetani toxoid antigen (formaldehyde inactivated)
DB10584,The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Basiliximab.,Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
DB10600,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Basiliximab.,Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated)
DB10769,The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Basiliximab.,Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)
DB10794,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Basiliximab.,Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated)
DB10803,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Basiliximab.,Typhoid Vi polysaccharide vaccine
DB10989,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Basiliximab.,Hepatitis A Vaccine
DB10990,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Basiliximab.,Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
DB11038,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Basiliximab.,Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated)
DB11040,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Basiliximab.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated)
DB11041,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Basiliximab.,Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)
DB11044,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Basiliximab.,Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated)
DB11603,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Basiliximab.,Human rabies virus immune globulin
DB11627,The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Basiliximab.,Hepatitis B Vaccine (Recombinant)
DB12568,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Basiliximab.,Tecemotide
DB14022,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Basiliximab.,Typhoid vaccine
DB14384,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Basiliximab.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated)
DB14385,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Basiliximab.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)
DB14394,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Basiliximab.,Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen
DB14445,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Basiliximab.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated)
DB14449,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Basiliximab.,Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen
DB14619,The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Basiliximab.,Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated)
DB14620,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Basiliximab.,Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated)
DB14711,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Basiliximab.,Vaccinia virus strain new york city board of health live antigen
DB15274,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Basiliximab.,Pertussis vaccine
DB15461,The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Basiliximab.,Yersinia pestis 195/p antigen (formaldehyde inactivated)
DB13924,The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Basiliximab.,Varicella Zoster Vaccine (Recombinant)
DB15483,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Basiliximab.,Modified vaccinia ankara
DB11988,Ocrelizumab may increase the immunosuppressive activities of Basiliximab.,Ocrelizumab
DB10317,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Basiliximab.,Rubella virus vaccine
DB10318,The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Basiliximab.,Varicella Zoster Vaccine (Live/attenuated)
DB10343,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Basiliximab.,Bacillus calmette-guerin substrain tice live antigen
DB10804,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Basiliximab.,Bacillus calmette-guerin substrain connaught live antigen
DB10805,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Basiliximab.,Yellow Fever Vaccine
DB11003,The risk or severity of infection can be increased when Anthrax vaccine is combined with Basiliximab.,Anthrax vaccine
DB11050,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Basiliximab.,Typhoid Vaccine Live
DB12386,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Basiliximab.,Bacillus calmette-guerin substrain danish 1331 live antigen
DB12768,The risk or severity of infection can be increased when BCG vaccine is combined with Basiliximab.,BCG vaccine
DB14409,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Basiliximab.,Human adenovirus e serotype 4 strain cl-68578 antigen
DB14443,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Basiliximab.,Vibrio cholerae CVD 103-HgR strain live antigen
DB14685,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Basiliximab.,Adenovirus type 7 vaccine live
DB00002,The risk or severity of adverse effects can be increased when Cetuximab is combined with Basiliximab.,Cetuximab
DB00028,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Basiliximab.,Human immunoglobulin G
DB00043,The risk or severity of adverse effects can be increased when Omalizumab is combined with Basiliximab.,Omalizumab
DB00054,The risk or severity of adverse effects can be increased when Abciximab is combined with Basiliximab.,Abciximab
DB00057,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Basiliximab.,Indium In-111 satumomab pendetide
DB00076,The risk or severity of adverse effects can be increased when Basiliximab is combined with Digoxin Immune Fab (Ovine).,Digoxin Immune Fab (Ovine)
DB00089,The risk or severity of adverse effects can be increased when Basiliximab is combined with Capromab pendetide.,Capromab pendetide
DB00110,The risk or severity of adverse effects can be increased when Basiliximab is combined with Palivizumab.,Palivizumab
DB00113,The risk or severity of adverse effects can be increased when Basiliximab is combined with Technetium Tc-99m arcitumomab.,Technetium Tc-99m arcitumomab
DB01269,The risk or severity of adverse effects can be increased when Basiliximab is combined with Panitumumab.,Panitumumab
DB01270,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ranibizumab.,Ranibizumab
DB04901,The risk or severity of adverse effects can be increased when Basiliximab is combined with Galiximab.,Galiximab
DB04949,The risk or severity of adverse effects can be increased when Basiliximab is combined with Pexelizumab.,Pexelizumab
DB04958,The risk or severity of adverse effects can be increased when Basiliximab is combined with Epratuzumab.,Epratuzumab
DB04962,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bectumomab.,Bectumomab
DB04964,The risk or severity of adverse effects can be increased when Basiliximab is combined with Oregovomab.,Oregovomab
DB04988,The risk or severity of adverse effects can be increased when Basiliximab is combined with IGN311.,IGN311
DB05006,The risk or severity of adverse effects can be increased when Basiliximab is combined with Adecatumumab.,Adecatumumab
DB05097,The risk or severity of adverse effects can be increased when Basiliximab is combined with Labetuzumab.,Labetuzumab
DB05101,The risk or severity of adverse effects can be increased when Basiliximab is combined with Matuzumab.,Matuzumab
DB05111,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fontolizumab.,Fontolizumab
DB05136,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bavituximab.,Bavituximab
DB05139,The risk or severity of adverse effects can be increased when Basiliximab is combined with CR002.,CR002
DB05209,The risk or severity of adverse effects can be increased when Basiliximab is combined with Rozrolimupab.,Rozrolimupab
DB05304,The risk or severity of adverse effects can be increased when Basiliximab is combined with Girentuximab.,Girentuximab
DB05336,The risk or severity of adverse effects can be increased when Basiliximab is combined with Obiltoxaximab.,Obiltoxaximab
DB05405,The risk or severity of adverse effects can be increased when Basiliximab is combined with XTL-001.,XTL-001
DB05437,The risk or severity of adverse effects can be increased when Basiliximab is combined with NAV 1800.,NAV 1800
DB05496,The risk or severity of adverse effects can be increased when Basiliximab is combined with Otelixizumab.,Otelixizumab
DB05545,The risk or severity of adverse effects can be increased when Basiliximab is combined with AMG 108.,AMG 108
DB05550,The risk or severity of adverse effects can be increased when Basiliximab is combined with Iratumumab.,Iratumumab
DB05555,The risk or severity of adverse effects can be increased when Basiliximab is combined with Enokizumab.,Enokizumab
DB05578,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ramucirumab.,Ramucirumab
DB05595,The risk or severity of adverse effects can be increased when Basiliximab is combined with Farletuzumab.,Farletuzumab
DB05656,The risk or severity of adverse effects can be increased when Basiliximab is combined with Veltuzumab.,Veltuzumab
DB05793,The risk or severity of adverse effects can be increased when Basiliximab is combined with PRO-542.,PRO-542
DB05797,The risk or severity of adverse effects can be increased when Basiliximab is combined with TNX-901.,TNX-901
DB05889,The risk or severity of adverse effects can be increased when Basiliximab is combined with Inotuzumab ozogamicin.,Inotuzumab ozogamicin
DB05892,The risk or severity of adverse effects can be increased when Basiliximab is combined with RI 624.,RI 624
DB05915,The risk or severity of adverse effects can be increased when Basiliximab is combined with MYO-029.,MYO-029
DB05916,The risk or severity of adverse effects can be increased when Basiliximab is combined with CT-011.,CT-011
DB05941,The risk or severity of adverse effects can be increased when Basiliximab is combined with Leronlimab.,Leronlimab
DB05996,The risk or severity of adverse effects can be increased when Basiliximab is combined with Glembatumumab vedotin.,Glembatumumab vedotin
DB06043,The risk or severity of adverse effects can be increased when Basiliximab is combined with Olaratumab.,Olaratumab
DB06049,The risk or severity of adverse effects can be increased when Basiliximab is combined with IPH 2101.,IPH 2101
DB06050,The risk or severity of adverse effects can be increased when Basiliximab is combined with TB-402.,TB-402
DB06081,The risk or severity of adverse effects can be increased when Basiliximab is combined with Caplacizumab.,Caplacizumab
DB06101,The risk or severity of adverse effects can be increased when Basiliximab is combined with IMC-1C11.,IMC-1C11
DB06116,The risk or severity of adverse effects can be increased when Basiliximab is combined with Eldelumab.,Eldelumab
DB06162,The risk or severity of adverse effects can be increased when Basiliximab is combined with Lumiliximab.,Lumiliximab
DB06186,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ipilimumab.,Ipilimumab
DB06192,The risk or severity of adverse effects can be increased when Basiliximab is combined with Nimotuzumab.,Nimotuzumab
DB06241,The risk or severity of adverse effects can be increased when Basiliximab is combined with Clenoliximab.,Clenoliximab
DB06304,The risk or severity of adverse effects can be increased when Basiliximab is combined with BIIB015.,BIIB015
DB06305,The risk or severity of adverse effects can be increased when Basiliximab is combined with Sonepcizumab.,Sonepcizumab
DB06310,The risk or severity of adverse effects can be increased when Basiliximab is combined with Motavizumab.,Motavizumab
DB06317,The risk or severity of adverse effects can be increased when Basiliximab is combined with Elotuzumab.,Elotuzumab
DB06318,The risk or severity of adverse effects can be increased when Basiliximab is combined with AVE9633.,AVE9633
DB06322,The risk or severity of adverse effects can be increased when Basiliximab is combined with Carotuximab.,Carotuximab
DB06324,The risk or severity of adverse effects can be increased when Basiliximab is combined with XmAb 2513.,XmAb 2513
DB06342,The risk or severity of adverse effects can be increased when Basiliximab is combined with Coltuximab ravtansine.,Coltuximab ravtansine
DB06343,The risk or severity of adverse effects can be increased when Basiliximab is combined with Teprotumumab.,Teprotumumab
DB06360,The risk or severity of adverse effects can be increased when Basiliximab is combined with Lucatumumab.,Lucatumumab
DB06366,The risk or severity of adverse effects can be increased when Basiliximab is combined with Pertuzumab.,Pertuzumab
DB06371,The risk or severity of adverse effects can be increased when Basiliximab is combined with Siplizumab.,Siplizumab
DB06467,The risk or severity of adverse effects can be increased when Basiliximab is combined with Apolizumab.,Apolizumab
DB06474,The risk or severity of adverse effects can be increased when Basiliximab is combined with Sibrotuzumab.,Sibrotuzumab
DB06550,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bivatuzumab.,Bivatuzumab
DB06557,The risk or severity of adverse effects can be increased when Basiliximab is combined with Lerdelimumab.,Lerdelimumab
DB06599,The risk or severity of adverse effects can be increased when Basiliximab is combined with Lexatumumab.,Lexatumumab
DB06602,The risk or severity of adverse effects can be increased when Basiliximab is combined with Reslizumab.,Reslizumab
DB06606,The risk or severity of adverse effects can be increased when Basiliximab is combined with Teplizumab.,Teplizumab
DB06607,The risk or severity of adverse effects can be increased when Basiliximab is combined with Catumaxomab.,Catumaxomab
DB06647,The risk or severity of adverse effects can be increased when Basiliximab is combined with Volociximab.,Volociximab
DB06650,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ofatumumab.,Ofatumumab
DB08902,The risk or severity of adverse effects can be increased when Basiliximab is combined with Raxibacumab.,Raxibacumab
DB09035,The risk or severity of adverse effects can be increased when Basiliximab is combined with Nivolumab.,Nivolumab
DB09037,The risk or severity of adverse effects can be increased when Basiliximab is combined with Pembrolizumab.,Pembrolizumab
DB09045,The risk or severity of adverse effects can be increased when Basiliximab is combined with Dulaglutide.,Dulaglutide
DB09105,The risk or severity of adverse effects can be increased when Basiliximab is combined with Asfotase alfa.,Asfotase alfa
DB09264,The risk or severity of adverse effects can be increased when Basiliximab is combined with Idarucizumab.,Idarucizumab
DB09302,The risk or severity of adverse effects can be increased when Basiliximab is combined with Alirocumab.,Alirocumab
DB09303,The risk or severity of adverse effects can be increased when Basiliximab is combined with Evolocumab.,Evolocumab
DB09331,The risk or severity of adverse effects can be increased when Basiliximab is combined with Daratumumab.,Daratumumab
DB09559,The risk or severity of adverse effects can be increased when Basiliximab is combined with Necitumumab.,Necitumumab
DB11595,The risk or severity of adverse effects can be increased when Basiliximab is combined with Atezolizumab.,Atezolizumab
DB11604,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tetanus Immune Globulin.,Tetanus Immune Globulin
DB11608,The risk or severity of adverse effects can be increased when Basiliximab is combined with Eftrenonacog alfa.,Eftrenonacog alfa
DB11621,The risk or severity of adverse effects can be increased when Basiliximab is combined with Human Varicella-Zoster Immune Globulin.,Human Varicella-Zoster Immune Globulin
DB11646,The risk or severity of adverse effects can be increased when Basiliximab is combined with Conatumumab.,Conatumumab
DB11657,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tabalumab.,Tabalumab
DB11680,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ficlatuzumab.,Ficlatuzumab
DB11685,The risk or severity of adverse effects can be increased when Basiliximab is combined with Figitumumab.,Figitumumab
DB11714,The risk or severity of adverse effects can be increased when Basiliximab is combined with Durvalumab.,Durvalumab
DB11715,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bapineuzumab.,Bapineuzumab
DB11731,The risk or severity of adverse effects can be increased when Basiliximab is combined with Depatuxizumab mafodotin.,Depatuxizumab mafodotin
DB11746,The risk or severity of adverse effects can be increased when Basiliximab is combined with Onartuzumab.,Onartuzumab
DB11756,The risk or severity of adverse effects can be increased when Basiliximab is combined with Solanezumab.,Solanezumab
DB11771,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tremelimumab.,Tremelimumab
DB11826,The risk or severity of adverse effects can be increased when Basiliximab is combined with Lampalizumab.,Lampalizumab
DB11840,The risk or severity of adverse effects can be increased when Basiliximab is combined with Dalotuzumab.,Dalotuzumab
DB11849,The risk or severity of adverse effects can be increased when Basiliximab is combined with Emibetuzumab.,Emibetuzumab
DB11850,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ublituximab.,Ublituximab
DB11856,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ligelizumab.,Ligelizumab
DB11857,The risk or severity of adverse effects can be increased when Basiliximab is combined with Seribantumab.,Seribantumab
DB11862,The risk or severity of adverse effects can be increased when Basiliximab is combined with Landogrozumab.,Landogrozumab
DB11866,The risk or severity of adverse effects can be increased when Basiliximab is combined with Romosozumab.,Romosozumab
DB11884,The risk or severity of adverse effects can be increased when Basiliximab is combined with Vadastuximab Talirine.,Vadastuximab Talirine
DB11914,The risk or severity of adverse effects can be increased when Basiliximab is combined with Lebrikizumab.,Lebrikizumab
DB11930,The risk or severity of adverse effects can be increased when Basiliximab is combined with Varlilumab.,Varlilumab
DB11945,The risk or severity of adverse effects can be increased when Basiliximab is combined with Avelumab.,Avelumab
DB11959,The risk or severity of adverse effects can be increased when Basiliximab is combined with Crenezumab.,Crenezumab
DB11972,The risk or severity of adverse effects can be increased when Basiliximab is combined with Rilotumumab.,Rilotumumab
DB11976,The risk or severity of adverse effects can be increased when Basiliximab is combined with Anifrolumab.,Anifrolumab
DB12023,The risk or severity of adverse effects can be increased when Basiliximab is combined with Benralizumab.,Benralizumab
DB12034,The risk or severity of adverse effects can be increased when Basiliximab is combined with Gantenerumab.,Gantenerumab
DB12053,The risk or severity of adverse effects can be increased when Basiliximab is combined with Visilizumab.,Visilizumab
DB12077,The risk or severity of adverse effects can be increased when Basiliximab is combined with Urelumab.,Urelumab
DB12089,The risk or severity of adverse effects can be increased when Basiliximab is combined with Lorvotuzumab mertansine.,Lorvotuzumab mertansine
DB12090,The risk or severity of adverse effects can be increased when Basiliximab is combined with Patritumab.,Patritumab
DB12102,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fulranumab.,Fulranumab
DB12104,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tarextumab.,Tarextumab
DB12118,The risk or severity of adverse effects can be increased when Basiliximab is combined with Sotatercept.,Sotatercept
DB12119,The risk or severity of adverse effects can be increased when Basiliximab is combined with Gevokizumab.,Gevokizumab
DB12142,The risk or severity of adverse effects can be increased when Basiliximab is combined with Duligotuzumab.,Duligotuzumab
DB12152,The risk or severity of adverse effects can be increased when Basiliximab is combined with Simtuzumab.,Simtuzumab
DB12157,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fasinumab.,Fasinumab
DB12159,The risk or severity of adverse effects can be increased when Basiliximab is combined with Dupilumab.,Dupilumab
DB12169,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tralokinumab.,Tralokinumab
DB12189,The risk or severity of adverse effects can be increased when Basiliximab is combined with Etrolizumab.,Etrolizumab
DB12202,The risk or severity of adverse effects can be increased when Basiliximab is combined with Zalutumumab.,Zalutumumab
DB12205,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ganitumab.,Ganitumab
DB12213,The risk or severity of adverse effects can be increased when Basiliximab is combined with Etaracizumab.,Etaracizumab
DB12240,The risk or severity of adverse effects can be increased when Basiliximab is combined with Polatuzumab vedotin.,Polatuzumab vedotin
DB12246,The risk or severity of adverse effects can be increased when Basiliximab is combined with Inclacumab.,Inclacumab
DB12250,The risk or severity of adverse effects can be increased when Basiliximab is combined with Cixutumumab.,Cixutumumab
DB12261,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ascrinvacumab.,Ascrinvacumab
DB12274,The risk or severity of adverse effects can be increased when Basiliximab is combined with Aducanumab.,Aducanumab
DB12281,The risk or severity of adverse effects can be increased when Basiliximab is combined with Luspatercept.,Luspatercept
DB12296,The risk or severity of adverse effects can be increased when Basiliximab is combined with GS-5745.,GS-5745
DB12317,The risk or severity of adverse effects can be increased when Basiliximab is combined with Vanucizumab.,Vanucizumab
DB12331,The risk or severity of adverse effects can be increased when Basiliximab is combined with Labetuzumab govitecan.,Labetuzumab govitecan
DB12335,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tanezumab.,Tanezumab
DB12342,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ensituximab.,Ensituximab
DB12344,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fezakinumab.,Fezakinumab
DB12363,The risk or severity of adverse effects can be increased when Basiliximab is combined with Dusigitumab.,Dusigitumab
DB12396,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fresolimumab.,Fresolimumab
DB12413,The risk or severity of adverse effects can be increased when Basiliximab is combined with Indusatumab vedotin.,Indusatumab vedotin
DB12456,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bococizumab.,Bococizumab
DB12489,The risk or severity of adverse effects can be increased when Basiliximab is combined with Mirvetuximab Soravtansine.,Mirvetuximab Soravtansine
DB12498,The risk or severity of adverse effects can be increased when Basiliximab is combined with Mogamulizumab.,Mogamulizumab
DB12520,The risk or severity of adverse effects can be increased when Basiliximab is combined with Plozalizumab.,Plozalizumab
DB12534,The risk or severity of adverse effects can be increased when Basiliximab is combined with Mavrilimumab.,Mavrilimumab
DB12560,The risk or severity of adverse effects can be increased when Basiliximab is combined with Blosozumab.,Blosozumab
DB12584,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bimagrumab.,Bimagrumab
DB12589,The risk or severity of adverse effects can be increased when Basiliximab is combined with Dacetuzumab.,Dacetuzumab
DB12609,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tovetumab.,Tovetumab
DB12683,The risk or severity of adverse effects can be increased when Basiliximab is combined with Lumretuzumab.,Lumretuzumab
DB12698,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ibalizumab.,Ibalizumab
DB12701,The risk or severity of adverse effects can be increased when Basiliximab is combined with Intetumumab.,Intetumumab
DB12718,The risk or severity of adverse effects can be increased when Basiliximab is combined with Carlumab.,Carlumab
DB12734,The risk or severity of adverse effects can be increased when Basiliximab is combined with Demcizumab.,Demcizumab
DB12773,The risk or severity of adverse effects can be increased when Basiliximab is combined with Sifalimumab.,Sifalimumab
DB12775,The risk or severity of adverse effects can be increased when Basiliximab is combined with Abituzumab.,Abituzumab
DB12797,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ecromeximab.,Ecromeximab
DB12807,The risk or severity of adverse effects can be increased when Basiliximab is combined with Naptumomab Estafenatox.,Naptumomab Estafenatox
DB12815,The risk or severity of adverse effects can be increased when Basiliximab is combined with Crotedumab.,Crotedumab
DB12820,The risk or severity of adverse effects can be increased when Basiliximab is combined with Concizumab.,Concizumab
DB12826,The risk or severity of adverse effects can be increased when Basiliximab is combined with Depatuxizumab.,Depatuxizumab
DB12844,The risk or severity of adverse effects can be increased when Basiliximab is combined with Rontalizumab.,Rontalizumab
DB12845,The risk or severity of adverse effects can be increased when Basiliximab is combined with Amatuximab.,Amatuximab
DB12849,The risk or severity of adverse effects can be increased when Basiliximab is combined with Clazakizumab.,Clazakizumab
DB12891,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ozanezumab.,Ozanezumab
DB12893,The risk or severity of adverse effects can be increased when Basiliximab is combined with Sacituzumab govitecan.,Sacituzumab govitecan
DB12917,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bimekizumab.,Bimekizumab
DB12943,The risk or severity of adverse effects can be increased when Basiliximab is combined with Milatuzumab.,Milatuzumab
DB12976,The risk or severity of adverse effects can be increased when Basiliximab is combined with Robatumumab.,Robatumumab
DB13017,The risk or severity of adverse effects can be increased when Basiliximab is combined with Rovalpituzumab Tesirine.,Rovalpituzumab Tesirine
DB13037,The risk or severity of adverse effects can be increased when Basiliximab is combined with Namilumab.,Namilumab
DB13045,The risk or severity of adverse effects can be increased when Basiliximab is combined with Racotumomab.,Racotumomab
DB13073,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tregalizumab.,Tregalizumab
DB13127,The risk or severity of adverse effects can be increased when Basiliximab is combined with Olokizumab.,Olokizumab
DB13140,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bezlotoxumab.,Bezlotoxumab
DB13375,The risk or severity of adverse effects can be increased when Basiliximab is combined with Edrecolomab.,Edrecolomab
DB13535,The risk or severity of adverse effects can be increased when Basiliximab is combined with Nebacumab.,Nebacumab
DB13886,The risk or severity of adverse effects can be increased when Basiliximab is combined with Human cytomegalovirus immune globulin.,Human cytomegalovirus immune globulin
DB13923,The risk or severity of adverse effects can be increased when Basiliximab is combined with Emicizumab.,Emicizumab
DB13976,The risk or severity of adverse effects can be increased when Basiliximab is combined with Sulesomab.,Sulesomab
DB13979,The risk or severity of adverse effects can be increased when Basiliximab is combined with Besilesomab.,Besilesomab
DB14012,The risk or severity of adverse effects can be increased when Basiliximab is combined with Burosumab.,Burosumab
DB14039,The risk or severity of adverse effects can be increased when Basiliximab is combined with Erenumab.,Erenumab
DB14040,The risk or severity of adverse effects can be increased when Basiliximab is combined with Eptinezumab.,Eptinezumab
DB14041,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fremanezumab.,Fremanezumab
DB14042,The risk or severity of adverse effects can be increased when Basiliximab is combined with Galcanezumab.,Galcanezumab
DB14211,The risk or severity of adverse effects can be increased when Basiliximab is combined with Fanolesomab.,Fanolesomab
DB14580,The risk or severity of adverse effects can be increased when Basiliximab is combined with Lecanemab.,Lecanemab
DB14597,The risk or severity of adverse effects can be increased when Basiliximab is combined with Lanadelumab.,Lanadelumab
DB14707,The risk or severity of adverse effects can be increased when Basiliximab is combined with Cemiplimab.,Cemiplimab
DB14776,The risk or severity of adverse effects can be increased when Basiliximab is combined with Camrelizumab.,Camrelizumab
DB14778,The risk or severity of adverse effects can be increased when Basiliximab is combined with Setrusumab.,Setrusumab
DB14784,The risk or severity of adverse effects can be increased when Basiliximab is combined with Gancotamab.,Gancotamab
DB14809,The risk or severity of adverse effects can be increased when Basiliximab is combined with Anetumab ravtansine.,Anetumab ravtansine
DB14811,The risk or severity of adverse effects can be increased when Basiliximab is combined with Isatuximab.,Isatuximab
DB14824,The risk or severity of adverse effects can be increased when Basiliximab is combined with Icrucumab.,Icrucumab
DB14843,The risk or severity of adverse effects can be increased when Basiliximab is combined with Codrituzumab.,Codrituzumab
DB14864,The risk or severity of adverse effects can be increased when Basiliximab is combined with Brolucizumab.,Brolucizumab
DB14871,The risk or severity of adverse effects can be increased when Basiliximab is combined with Xentuzumab.,Xentuzumab
DB14877,The risk or severity of adverse effects can be increased when Basiliximab is combined with Lintuzumab.,Lintuzumab
DB14891,The risk or severity of adverse effects can be increased when Basiliximab is combined with Vobarilizumab.,Vobarilizumab
DB14897,The risk or severity of adverse effects can be increased when Basiliximab is combined with Parsatuzumab.,Parsatuzumab
DB14905,The risk or severity of adverse effects can be increased when Basiliximab is combined with Emactuzumab.,Emactuzumab
DB14907,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bevacizumab zirconium Zr-89.,Bevacizumab zirconium Zr-89
DB14908,The risk or severity of adverse effects can be increased when Basiliximab is combined with Refanezumab.,Refanezumab
DB14947,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bermekimab.,Bermekimab
DB14952,The risk or severity of adverse effects can be increased when Basiliximab is combined with Pamrevlumab.,Pamrevlumab
DB14959,The risk or severity of adverse effects can be increased when Basiliximab is combined with Opicinumab.,Opicinumab
DB14962,The risk or severity of adverse effects can be increased when Basiliximab is combined with Trastuzumab deruxtecan.,Trastuzumab deruxtecan
DB14967,The risk or severity of adverse effects can be increased when Basiliximab is combined with Margetuximab.,Margetuximab
DB14988,The risk or severity of adverse effects can be increased when Basiliximab is combined with Dalantercept.,Dalantercept
DB14997,The risk or severity of adverse effects can be increased when Basiliximab is combined with Pateclizumab.,Pateclizumab
DB15014,The risk or severity of adverse effects can be increased when Basiliximab is combined with Gremubamab.,Gremubamab
DB15022,The risk or severity of adverse effects can be increased when Basiliximab is combined with Apomab.,Apomab
DB15044,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tafasitamab.,Tafasitamab
DB15045,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ipafricept.,Ipafricept
DB15076,The risk or severity of adverse effects can be increased when Basiliximab is combined with Abrilumab.,Abrilumab
DB15089,The risk or severity of adverse effects can be increased when Basiliximab is combined with Frovocimab.,Frovocimab
DB15090,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tezepelumab.,Tezepelumab
DB15101,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tigatuzumab.,Tigatuzumab
DB15104,The risk or severity of adverse effects can be increased when Basiliximab is combined with Telisotuzumab vedotin.,Telisotuzumab vedotin
DB15113,The risk or severity of adverse effects can be increased when Basiliximab is combined with Utomilumab.,Utomilumab
DB15118,The risk or severity of adverse effects can be increased when Basiliximab is combined with Zolbetuximab.,Zolbetuximab
DB15135,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ponezumab.,Ponezumab
DB15160,The risk or severity of adverse effects can be increased when Basiliximab is combined with Asunercept.,Asunercept
DB15172,The risk or severity of adverse effects can be increased when Basiliximab is combined with Suvratoxumab.,Suvratoxumab
DB15225,The risk or severity of adverse effects can be increased when Basiliximab is combined with Mitazalimab.,Mitazalimab
DB15252,The risk or severity of adverse effects can be increased when Basiliximab is combined with Nemolizumab.,Nemolizumab
DB15277,The risk or severity of adverse effects can be increased when Basiliximab is combined with Gedivumab.,Gedivumab
DB15336,The risk or severity of adverse effects can be increased when Basiliximab is combined with Valanafusp alfa.,Valanafusp alfa
DB15349,The risk or severity of adverse effects can be increased when Basiliximab is combined with Sofituzumab vedotin.,Sofituzumab vedotin
DB15354,The risk or severity of adverse effects can be increased when Basiliximab is combined with Evinacumab.,Evinacumab
DB15363,The risk or severity of adverse effects can be increased when Basiliximab is combined with Istiratumab.,Istiratumab
DB15383,The risk or severity of adverse effects can be increased when Basiliximab is combined with Pidilizumab.,Pidilizumab
DB15397,The risk or severity of adverse effects can be increased when Basiliximab is combined with GMA-161.,GMA-161
DB15409,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ladiratuzumab vedotin.,Ladiratuzumab vedotin
DB15415,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tomaralimab.,Tomaralimab
DB15428,The risk or severity of adverse effects can be increased when Basiliximab is combined with Vesencumab.,Vesencumab
DB15432,The risk or severity of adverse effects can be increased when Basiliximab is combined with Pinatuzumab vedotin.,Pinatuzumab vedotin
DB15441,The risk or severity of adverse effects can be increased when Basiliximab is combined with Lulizumab pegol.,Lulizumab pegol
DB15443,The risk or severity of adverse effects can be increased when Basiliximab is combined with Lorukafusp alfa.,Lorukafusp alfa
DB15453,The risk or severity of adverse effects can be increased when Basiliximab is combined with Naratuximab emtansine.,Naratuximab emtansine
DB14004,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tildrakizumab.,Tildrakizumab
DB05679,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ustekinumab.,Ustekinumab
DB15559,The risk or severity of adverse effects can be increased when Basiliximab is combined with Zenocutuzumab.,Zenocutuzumab
DB00091,Basiliximab may increase the immunosuppressive activities of Cyclosporine.,Cyclosporine
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Basiliximab.","Ebola Zaire vaccine (live, attenuated)"
DB14513,The serum concentration of Magnesium can be decreased when it is combined with Basiliximab.,Magnesium
DB01601,The serum concentration of Basiliximab can be increased when it is combined with Lopinavir.,Lopinavir
DB12530,The risk or severity of infection can be increased when Basiliximab is combined with Inebilizumab.,Inebilizumab
DB06643,The risk or severity of adverse effects can be increased when Denosumab is combined with Muromonab.,Denosumab
DB00005,The risk or severity of adverse effects can be increased when Etanercept is combined with Muromonab.,Etanercept
DB00008,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Muromonab.,Peginterferon alfa-2a
DB00011,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Muromonab.,Interferon alfa-n1
DB00018,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Muromonab.,Interferon alfa-n3
DB00022,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Muromonab.,Peginterferon alfa-2b
DB00026,The risk or severity of adverse effects can be increased when Anakinra is combined with Muromonab.,Anakinra
DB00033,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Muromonab.,Interferon gamma-1b
DB00034,"The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Muromonab.","Interferon alfa-2a, Recombinant"
DB00041,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Muromonab.,Aldesleukin
DB00051,The risk or severity of adverse effects can be increased when Adalimumab is combined with Muromonab.,Adalimumab
DB00056,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Muromonab.,Gemtuzumab ozogamicin
DB00059,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Muromonab.,Pegaspargase
DB00065,The risk or severity of adverse effects can be increased when Infliximab is combined with Muromonab.,Infliximab
DB00068,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Muromonab.,Interferon beta-1b
DB00069,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Muromonab.,Interferon alfacon-1
DB00073,The risk or severity of adverse effects can be increased when Rituximab is combined with Muromonab.,Rituximab
DB00074,The risk or severity of adverse effects can be increased when Basiliximab is combined with Muromonab.,Basiliximab
DB00078,The risk or severity of adverse effects can be increased when Muromonab is combined with Ibritumomab tiuxetan.,Ibritumomab tiuxetan
DB00081,The risk or severity of adverse effects can be increased when Muromonab is combined with Tositumomab.,Tositumomab
DB00087,The risk or severity of adverse effects can be increased when Muromonab is combined with Alemtuzumab.,Alemtuzumab
DB00092,The risk or severity of adverse effects can be increased when Muromonab is combined with Alefacept.,Alefacept
DB00095,The risk or severity of adverse effects can be increased when Muromonab is combined with Efalizumab.,Efalizumab
DB00098,The risk or severity of adverse effects can be increased when Muromonab is combined with Antithymocyte immunoglobulin (rabbit).,Antithymocyte immunoglobulin (rabbit)
DB00105,The risk or severity of adverse effects can be increased when Muromonab is combined with Interferon alfa-2b.,Interferon alfa-2b
DB00111,The risk or severity of adverse effects can be increased when Muromonab is combined with Daclizumab.,Daclizumab
DB00112,The risk or severity of adverse effects can be increased when Muromonab is combined with Bevacizumab.,Bevacizumab
DB00120,The risk or severity of adverse effects can be increased when Muromonab is combined with Phenylalanine.,Phenylalanine
DB00180,The risk or severity of adverse effects can be increased when Muromonab is combined with Flunisolide.,Flunisolide
DB00188,The risk or severity of adverse effects can be increased when Muromonab is combined with Bortezomib.,Bortezomib
DB00242,The risk or severity of adverse effects can be increased when Muromonab is combined with Cladribine.,Cladribine
DB00262,The risk or severity of adverse effects can be increased when Muromonab is combined with Carmustine.,Carmustine
DB00276,The risk or severity of adverse effects can be increased when Muromonab is combined with Amsacrine.,Amsacrine
DB00290,The risk or severity of adverse effects can be increased when Muromonab is combined with Bleomycin.,Bleomycin
DB00291,The risk or severity of adverse effects can be increased when Muromonab is combined with Chlorambucil.,Chlorambucil
DB00293,The risk or severity of adverse effects can be increased when Muromonab is combined with Raltitrexed.,Raltitrexed
DB00305,The risk or severity of adverse effects can be increased when Muromonab is combined with Mitomycin.,Mitomycin
DB00307,The risk or severity of adverse effects can be increased when Muromonab is combined with Bexarotene.,Bexarotene
DB00309,The risk or severity of adverse effects can be increased when Muromonab is combined with Vindesine.,Vindesine
DB00322,The risk or severity of adverse effects can be increased when Muromonab is combined with Floxuridine.,Floxuridine
DB00328,The risk or severity of adverse effects can be increased when Muromonab is combined with Indomethacin.,Indomethacin
DB00352,The risk or severity of adverse effects can be increased when Muromonab is combined with Tioguanine.,Tioguanine
DB00361,The risk or severity of adverse effects can be increased when Muromonab is combined with Vinorelbine.,Vinorelbine
DB00380,The risk or severity of adverse effects can be increased when Muromonab is combined with Dexrazoxane.,Dexrazoxane
DB00394,The risk or severity of adverse effects can be increased when Muromonab is combined with Beclomethasone dipropionate.,Beclomethasone dipropionate
DB00398,The risk or severity of adverse effects can be increased when Muromonab is combined with Sorafenib.,Sorafenib
DB00428,The risk or severity of adverse effects can be increased when Muromonab is combined with Streptozocin.,Streptozocin
DB00432,The risk or severity of adverse effects can be increased when Muromonab is combined with Trifluridine.,Trifluridine
DB00441,The risk or severity of adverse effects can be increased when Muromonab is combined with Gemcitabine.,Gemcitabine
DB00443,The risk or severity of adverse effects can be increased when Muromonab is combined with Betamethasone.,Betamethasone
DB00444,The risk or severity of adverse effects can be increased when Muromonab is combined with Teniposide.,Teniposide
DB00445,The risk or severity of adverse effects can be increased when Muromonab is combined with Epirubicin.,Epirubicin
DB00446,The risk or severity of adverse effects can be increased when Muromonab is combined with Chloramphenicol.,Chloramphenicol
DB00480,The risk or severity of adverse effects can be increased when Muromonab is combined with Lenalidomide.,Lenalidomide
DB00488,The risk or severity of adverse effects can be increased when Muromonab is combined with Altretamine.,Altretamine
DB00495,The risk or severity of adverse effects can be increased when Muromonab is combined with Zidovudine.,Zidovudine
DB00515,The risk or severity of adverse effects can be increased when Muromonab is combined with Cisplatin.,Cisplatin
DB00526,The risk or severity of adverse effects can be increased when Muromonab is combined with Oxaliplatin.,Oxaliplatin
DB00531,The risk or severity of adverse effects can be increased when Muromonab is combined with Cyclophosphamide.,Cyclophosphamide
DB00541,The risk or severity of adverse effects can be increased when Muromonab is combined with Vincristine.,Vincristine
DB00544,The risk or severity of adverse effects can be increased when Muromonab is combined with Fluorouracil.,Fluorouracil
DB00550,The risk or severity of adverse effects can be increased when Muromonab is combined with Propylthiouracil.,Propylthiouracil
DB00552,The risk or severity of adverse effects can be increased when Muromonab is combined with Pentostatin.,Pentostatin
DB00563,The risk or severity of adverse effects can be increased when Muromonab is combined with Methotrexate.,Methotrexate
DB00564,The risk or severity of adverse effects can be increased when Muromonab is combined with Carbamazepine.,Carbamazepine
DB00570,The risk or severity of adverse effects can be increased when Muromonab is combined with Vinblastine.,Vinblastine
DB00588,The risk or severity of adverse effects can be increased when Muromonab is combined with Fluticasone propionate.,Fluticasone propionate
DB00591,The risk or severity of adverse effects can be increased when Muromonab is combined with Fluocinolone acetonide.,Fluocinolone acetonide
DB00601,The risk or severity of adverse effects can be increased when Muromonab is combined with Linezolid.,Linezolid
DB00619,The risk or severity of adverse effects can be increased when Muromonab is combined with Imatinib.,Imatinib
DB00620,The risk or severity of adverse effects can be increased when Muromonab is combined with Triamcinolone.,Triamcinolone
DB00631,The risk or severity of adverse effects can be increased when Muromonab is combined with Clofarabine.,Clofarabine
DB00635,The risk or severity of adverse effects can be increased when Muromonab is combined with Prednisone.,Prednisone
DB00642,The risk or severity of adverse effects can be increased when Muromonab is combined with Pemetrexed.,Pemetrexed
DB00687,The risk or severity of adverse effects can be increased when Muromonab is combined with Fludrocortisone.,Fludrocortisone
DB00688,The risk or severity of adverse effects can be increased when Muromonab is combined with Mycophenolate mofetil.,Mycophenolate mofetil
DB00694,The risk or severity of adverse effects can be increased when Muromonab is combined with Daunorubicin.,Daunorubicin
DB00755,The risk or severity of adverse effects can be increased when Muromonab is combined with Tretinoin.,Tretinoin
DB00762,The risk or severity of adverse effects can be increased when Muromonab is combined with Irinotecan.,Irinotecan
DB00763,The risk or severity of adverse effects can be increased when Muromonab is combined with Methimazole.,Methimazole
DB00764,The risk or severity of adverse effects can be increased when Muromonab is combined with Mometasone.,Mometasone
DB00773,The risk or severity of adverse effects can be increased when Muromonab is combined with Etoposide.,Etoposide
DB00795,The risk or severity of adverse effects can be increased when Muromonab is combined with Sulfasalazine.,Sulfasalazine
DB00851,The risk or severity of adverse effects can be increased when Muromonab is combined with Dacarbazine.,Dacarbazine
DB00853,The risk or severity of adverse effects can be increased when Muromonab is combined with Temozolomide.,Temozolomide
DB00859,The risk or severity of adverse effects can be increased when Muromonab is combined with Penicillamine.,Penicillamine
DB00860,The risk or severity of adverse effects can be increased when Muromonab is combined with Prednisolone.,Prednisolone
DB00877,The risk or severity of adverse effects can be increased when Muromonab is combined with Sirolimus.,Sirolimus
DB00888,The risk or severity of adverse effects can be increased when Muromonab is combined with Mechlorethamine.,Mechlorethamine
DB00928,The risk or severity of adverse effects can be increased when Muromonab is combined with Azacitidine.,Azacitidine
DB00958,The risk or severity of adverse effects can be increased when Muromonab is combined with Carboplatin.,Carboplatin
DB00959,The risk or severity of adverse effects can be increased when Muromonab is combined with Methylprednisolone.,Methylprednisolone
DB00970,The risk or severity of adverse effects can be increased when Muromonab is combined with Dactinomycin.,Dactinomycin
DB00987,The risk or severity of adverse effects can be increased when Muromonab is combined with Cytarabine.,Cytarabine
DB00993,The risk or severity of adverse effects can be increased when Muromonab is combined with Azathioprine.,Azathioprine
DB00997,The risk or severity of adverse effects can be increased when Muromonab is combined with Doxorubicin.,Doxorubicin
DB01005,The risk or severity of adverse effects can be increased when Muromonab is combined with Hydroxyurea.,Hydroxyurea
DB01008,The risk or severity of adverse effects can be increased when Muromonab is combined with Busulfan.,Busulfan
DB01024,The risk or severity of adverse effects can be increased when Muromonab is combined with Mycophenolic acid.,Mycophenolic acid
DB01030,The risk or severity of adverse effects can be increased when Muromonab is combined with Topotecan.,Topotecan
DB01033,The risk or severity of adverse effects can be increased when Muromonab is combined with Mercaptopurine.,Mercaptopurine
DB01041,The risk or severity of adverse effects can be increased when Muromonab is combined with Thalidomide.,Thalidomide
DB01042,The risk or severity of adverse effects can be increased when Muromonab is combined with Melphalan.,Melphalan
DB01073,The risk or severity of adverse effects can be increased when Muromonab is combined with Fludarabine.,Fludarabine
DB01099,The risk or severity of adverse effects can be increased when Muromonab is combined with Flucytosine.,Flucytosine
DB01101,The risk or severity of adverse effects can be increased when Muromonab is combined with Capecitabine.,Capecitabine
DB01108,The risk or severity of adverse effects can be increased when Muromonab is combined with Trilostane.,Trilostane
DB01168,The risk or severity of adverse effects can be increased when Muromonab is combined with Procarbazine.,Procarbazine
DB01169,The risk or severity of adverse effects can be increased when Muromonab is combined with Arsenic trioxide.,Arsenic trioxide
DB01177,The risk or severity of adverse effects can be increased when Muromonab is combined with Idarubicin.,Idarubicin
DB01181,The risk or severity of adverse effects can be increased when Muromonab is combined with Ifosfamide.,Ifosfamide
DB01196,The risk or severity of adverse effects can be increased when Muromonab is combined with Estramustine.,Estramustine
DB01204,The risk or severity of adverse effects can be increased when Muromonab is combined with Mitoxantrone.,Mitoxantrone
DB01206,The risk or severity of adverse effects can be increased when Muromonab is combined with Lomustine.,Lomustine
DB01222,The risk or severity of adverse effects can be increased when Muromonab is combined with Budesonide.,Budesonide
DB01229,The risk or severity of adverse effects can be increased when Muromonab is combined with Paclitaxel.,Paclitaxel
DB01234,The risk or severity of adverse effects can be increased when Muromonab is combined with Dexamethasone.,Dexamethasone
DB01248,The risk or severity of adverse effects can be increased when Muromonab is combined with Docetaxel.,Docetaxel
DB01254,The risk or severity of adverse effects can be increased when Muromonab is combined with Dasatinib.,Dasatinib
DB01257,The risk or severity of adverse effects can be increased when Muromonab is combined with Eculizumab.,Eculizumab
DB01262,The risk or severity of adverse effects can be increased when Muromonab is combined with Decitabine.,Decitabine
DB01268,The risk or severity of adverse effects can be increased when Muromonab is combined with Sunitinib.,Sunitinib
DB01280,The risk or severity of adverse effects can be increased when Muromonab is combined with Nelarabine.,Nelarabine
DB01281,The risk or severity of adverse effects can be increased when Muromonab is combined with Abatacept.,Abatacept
DB01285,The risk or severity of adverse effects can be increased when Muromonab is combined with Corticotropin.,Corticotropin
DB01380,The risk or severity of adverse effects can be increased when Muromonab is combined with Cortisone acetate.,Cortisone acetate
DB01384,The risk or severity of adverse effects can be increased when Muromonab is combined with Paramethasone.,Paramethasone
DB01394,The risk or severity of adverse effects can be increased when Muromonab is combined with Colchicine.,Colchicine
DB01410,The risk or severity of adverse effects can be increased when Muromonab is combined with Ciclesonide.,Ciclesonide
DB01423,The risk or severity of adverse effects can be increased when Muromonab is combined with Stepronin.,Stepronin
DB01590,The risk or severity of adverse effects can be increased when Muromonab is combined with Everolimus.,Everolimus
DB01611,The risk or severity of adverse effects can be increased when Muromonab is combined with Hydroxychloroquine.,Hydroxychloroquine
DB01816,The risk or severity of adverse effects can be increased when Muromonab is combined with Castanospermine.,Castanospermine
DB02546,The risk or severity of adverse effects can be increased when Muromonab is combined with Vorinostat.,Vorinostat
DB02806,The risk or severity of adverse effects can be increased when Muromonab is combined with 2-Methoxyethanol.,2-Methoxyethanol
DB03523,The risk or severity of adverse effects can be increased when Muromonab is combined with Brequinar.,Brequinar
DB04572,The risk or severity of adverse effects can be increased when Muromonab is combined with Thiotepa.,Thiotepa
DB04630,The risk or severity of adverse effects can be increased when Muromonab is combined with Aldosterone.,Aldosterone
DB04845,The risk or severity of adverse effects can be increased when Muromonab is combined with Ixabepilone.,Ixabepilone
DB04868,The risk or severity of adverse effects can be increased when Muromonab is combined with Nilotinib.,Nilotinib
DB04951,The risk or severity of adverse effects can be increased when Muromonab is combined with Pirfenidone.,Pirfenidone
DB04956,The risk or severity of adverse effects can be increased when Muromonab is combined with Afelimomab.,Afelimomab
DB05015,The risk or severity of adverse effects can be increased when Muromonab is combined with Belinostat.,Belinostat
DB05109,The risk or severity of adverse effects can be increased when Muromonab is combined with Trabectedin.,Trabectedin
DB05258,The risk or severity of adverse effects can be increased when Muromonab is combined with Interferon alfa.,Interferon alfa
DB05259,The risk or severity of adverse effects can be increased when Muromonab is combined with Glatiramer.,Glatiramer
DB05260,The risk or severity of adverse effects can be increased when Muromonab is combined with Gallium nitrate.,Gallium nitrate
DB05459,The risk or severity of adverse effects can be increased when Muromonab is combined with Briakinumab.,Briakinumab
DB05472,The risk or severity of adverse effects can be increased when Muromonab is combined with omega interferon.,omega interferon
DB05676,The risk or severity of adverse effects can be increased when Muromonab is combined with Apremilast.,Apremilast
DB05773,The risk or severity of adverse effects can be increased when Muromonab is combined with Trastuzumab emtansine.,Trastuzumab emtansine
DB06168,The risk or severity of adverse effects can be increased when Muromonab is combined with Canakinumab.,Canakinumab
DB06273,The risk or severity of adverse effects can be increased when Muromonab is combined with Tocilizumab.,Tocilizumab
DB06287,The risk or severity of adverse effects can be increased when Muromonab is combined with Temsirolimus.,Temsirolimus
DB06372,The risk or severity of adverse effects can be increased when Muromonab is combined with Rilonacept.,Rilonacept
DB06589,The risk or severity of adverse effects can be increased when Muromonab is combined with Pazopanib.,Pazopanib
DB06603,The risk or severity of adverse effects can be increased when Muromonab is combined with Panobinostat.,Panobinostat
DB06612,The risk or severity of adverse effects can be increased when Muromonab is combined with Mepolizumab.,Mepolizumab
DB06616,The risk or severity of adverse effects can be increased when Muromonab is combined with Bosutinib.,Bosutinib
DB06662,The risk or severity of adverse effects can be increased when Muromonab is combined with Abetimus.,Abetimus
DB06674,The risk or severity of adverse effects can be increased when Muromonab is combined with Golimumab.,Golimumab
DB06681,The risk or severity of adverse effects can be increased when Muromonab is combined with Belatacept.,Belatacept
DB06769,The risk or severity of adverse effects can be increased when Muromonab is combined with Bendamustine.,Bendamustine
DB06772,The risk or severity of adverse effects can be increased when Muromonab is combined with Cabazitaxel.,Cabazitaxel
DB06813,The risk or severity of adverse effects can be increased when Muromonab is combined with Pralatrexate.,Pralatrexate
DB08059,The risk or severity of adverse effects can be increased when Muromonab is combined with Wortmannin.,Wortmannin
DB08870,The risk or severity of adverse effects can be increased when Muromonab is combined with Brentuximab vedotin.,Brentuximab vedotin
DB08871,The risk or severity of adverse effects can be increased when Muromonab is combined with Eribulin.,Eribulin
DB08877,The risk or severity of adverse effects can be increased when Muromonab is combined with Ruxolitinib.,Ruxolitinib
DB08879,The risk or severity of adverse effects can be increased when Muromonab is combined with Belimumab.,Belimumab
DB08880,The risk or severity of adverse effects can be increased when Muromonab is combined with Teriflunomide.,Teriflunomide
DB08889,The risk or severity of adverse effects can be increased when Muromonab is combined with Carfilzomib.,Carfilzomib
DB08901,The risk or severity of adverse effects can be increased when Muromonab is combined with Ponatinib.,Ponatinib
DB08904,The risk or severity of adverse effects can be increased when Muromonab is combined with Certolizumab pegol.,Certolizumab pegol
DB08906,The risk or severity of adverse effects can be increased when Muromonab is combined with Fluticasone furoate.,Fluticasone furoate
DB08908,The risk or severity of adverse effects can be increased when Muromonab is combined with Dimethyl fumarate.,Dimethyl fumarate
DB08910,The risk or severity of adverse effects can be increased when Muromonab is combined with Pomalidomide.,Pomalidomide
DB08935,The risk or severity of adverse effects can be increased when Muromonab is combined with Obinutuzumab.,Obinutuzumab
DB08970,The risk or severity of adverse effects can be increased when Muromonab is combined with Fluprednidene.,Fluprednidene
DB08971,The risk or severity of adverse effects can be increased when Muromonab is combined with Fluocortolone.,Fluocortolone
DB09029,The risk or severity of adverse effects can be increased when Muromonab is combined with Secukinumab.,Secukinumab
DB09033,The risk or severity of adverse effects can be increased when Muromonab is combined with Vedolizumab.,Vedolizumab
DB09036,The risk or severity of adverse effects can be increased when Muromonab is combined with Siltuximab.,Siltuximab
DB09052,The risk or severity of adverse effects can be increased when Muromonab is combined with Blinatumomab.,Blinatumomab
DB09053,The risk or severity of adverse effects can be increased when Muromonab is combined with Ibrutinib.,Ibrutinib
DB09054,The risk or severity of adverse effects can be increased when Muromonab is combined with Idelalisib.,Idelalisib
DB09073,The risk or severity of adverse effects can be increased when Muromonab is combined with Palbociclib.,Palbociclib
DB09074,The risk or severity of adverse effects can be increased when Muromonab is combined with Olaparib.,Olaparib
DB09077,The risk or severity of adverse effects can be increased when Muromonab is combined with Dinutuximab.,Dinutuximab
DB09082,The risk or severity of adverse effects can be increased when Muromonab is combined with Vilanterol.,Vilanterol
DB09091,The risk or severity of adverse effects can be increased when Muromonab is combined with Tixocortol.,Tixocortol
DB09122,The risk or severity of adverse effects can be increased when Muromonab is combined with Peginterferon beta-1a.,Peginterferon beta-1a
DB09312,The risk or severity of adverse effects can be increased when Muromonab is combined with Antilymphocyte immunoglobulin (horse).,Antilymphocyte immunoglobulin (horse)
DB09378,The risk or severity of adverse effects can be increased when Muromonab is combined with Fluprednisolone.,Fluprednisolone
DB09383,The risk or severity of adverse effects can be increased when Muromonab is combined with Meprednisone.,Meprednisone
DB11466,The risk or severity of adverse effects can be increased when Muromonab is combined with Tepoxalin.,Tepoxalin
DB11487,The risk or severity of adverse effects can be increased when Muromonab is combined with Dexamethasone isonicotinate.,Dexamethasone isonicotinate
DB11529,The risk or severity of adverse effects can be increased when Muromonab is combined with Melengestrol.,Melengestrol
DB11569,The risk or severity of adverse effects can be increased when Muromonab is combined with Ixekizumab.,Ixekizumab
DB11580,The risk or severity of adverse effects can be increased when Muromonab is combined with Ravulizumab.,Ravulizumab
DB11616,The risk or severity of adverse effects can be increased when Muromonab is combined with Pirarubicin.,Pirarubicin
DB11693,The risk or severity of adverse effects can be increased when Muromonab is combined with Voclosporin.,Voclosporin
DB11708,The risk or severity of adverse effects can be increased when Muromonab is combined with Peficitinib.,Peficitinib
DB11750,The risk or severity of adverse effects can be increased when Muromonab is combined with Clobetasol.,Clobetasol
DB11767,The risk or severity of adverse effects can be increased when Muromonab is combined with Sarilumab.,Sarilumab
DB11776,The risk or severity of adverse effects can be increased when Muromonab is combined with Brodalumab.,Brodalumab
DB11803,The risk or severity of adverse effects can be increased when Muromonab is combined with Sirukumab.,Sirukumab
DB11817,The risk or severity of adverse effects can be increased when Muromonab is combined with Baricitinib.,Baricitinib
DB11834,The risk or severity of adverse effects can be increased when Muromonab is combined with Guselkumab.,Guselkumab
DB11921,The risk or severity of adverse effects can be increased when Muromonab is combined with Deflazacort.,Deflazacort
DB12025,The risk or severity of adverse effects can be increased when Muromonab is combined with Triptolide.,Triptolide
DB12371,The risk or severity of adverse effects can be increased when Muromonab is combined with Siponimod.,Siponimod
DB12612,The risk or severity of adverse effects can be increased when Muromonab is combined with Ozanimod.,Ozanimod
DB12617,The risk or severity of adverse effects can be increased when Muromonab is combined with Mizoribine.,Mizoribine
DB12692,The risk or severity of adverse effects can be increased when Muromonab is combined with Gusperimus.,Gusperimus
DB12814,The risk or severity of adverse effects can be increased when Muromonab is combined with Cepeginterferon alfa-2B.,Cepeginterferon alfa-2B
DB12902,The risk or severity of adverse effects can be increased when Muromonab is combined with Trofosfamide.,Trofosfamide
DB12947,The risk or severity of adverse effects can be increased when Muromonab is combined with Doxifluridine.,Doxifluridine
DB12991,The risk or severity of adverse effects can be increased when Muromonab is combined with Deoxyspergualin.,Deoxyspergualin
DB12996,The risk or severity of adverse effects can be increased when Muromonab is combined with Acteoside.,Acteoside
DB13003,The risk or severity of adverse effects can be increased when Muromonab is combined with Cortivazol.,Cortivazol
DB13014,The risk or severity of adverse effects can be increased when Muromonab is combined with Hypericin.,Hypericin
DB13068,The risk or severity of adverse effects can be increased when Muromonab is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.,9-(N-methyl-L-isoleucine)-cyclosporin A
DB13208,The risk or severity of adverse effects can be increased when Muromonab is combined with Prednylidene.,Prednylidene
DB13223,The risk or severity of adverse effects can be increased when Muromonab is combined with Fluocortin.,Fluocortin
DB13241,The risk or severity of adverse effects can be increased when Muromonab is combined with Begelomab.,Begelomab
DB13491,The risk or severity of adverse effects can be increased when Muromonab is combined with Fluperolone.,Fluperolone
DB13664,The risk or severity of adverse effects can be increased when Muromonab is combined with Formocortal.,Formocortal
DB13728,The risk or severity of adverse effects can be increased when Muromonab is combined with Halometasone.,Halometasone
DB13843,The risk or severity of adverse effects can be increased when Muromonab is combined with Cloprednol.,Cloprednol
DB13856,The risk or severity of adverse effects can be increased when Muromonab is combined with Fluclorolone.,Fluclorolone
DB13867,The risk or severity of adverse effects can be increased when Muromonab is combined with Fluticasone.,Fluticasone
DB14066,The risk or severity of adverse effects can be increased when Muromonab is combined with Tetrandrine.,Tetrandrine
DB14219,The risk or severity of adverse effects can be increased when Muromonab is combined with Monomethyl fumarate.,Monomethyl fumarate
DB14512,The risk or severity of adverse effects can be increased when Muromonab is combined with Mometasone furoate.,Mometasone furoate
DB14538,The risk or severity of adverse effects can be increased when Muromonab is combined with Hydrocortisone aceponate.,Hydrocortisone aceponate
DB14539,The risk or severity of adverse effects can be increased when Muromonab is combined with Hydrocortisone acetate.,Hydrocortisone acetate
DB14545,The risk or severity of adverse effects can be increased when Muromonab is combined with Hydrocortisone succinate.,Hydrocortisone succinate
DB14724,The risk or severity of adverse effects can be increased when Muromonab is combined with Emapalumab.,Emapalumab
DB14762,The risk or severity of adverse effects can be increased when Muromonab is combined with Risankizumab.,Risankizumab
DB14919,The risk or severity of adverse effects can be increased when Muromonab is combined with Rozanolixizumab.,Rozanolixizumab
DB15253,The risk or severity of adverse effects can be increased when Muromonab is combined with Bleselumab.,Bleselumab
DB00108,The risk or severity of adverse effects can be increased when Muromonab is combined with Natalizumab.,Natalizumab
DB00337,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Muromonab.,Pimecrolimus
DB01656,Roflumilast may increase the immunosuppressive activities of Muromonab.,Roflumilast
DB06688,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Muromonab.,Sipuleucel-T
DB01015,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Muromonab.,Sulfamethoxazole
DB00255,Diethylstilbestrol may increase the thrombogenic activities of Muromonab.,Diethylstilbestrol
DB00269,Chlorotrianisene may increase the thrombogenic activities of Muromonab.,Chlorotrianisene
DB00286,Conjugated estrogens may increase the thrombogenic activities of Muromonab.,Conjugated estrogens
DB00655,Estrone may increase the thrombogenic activities of Muromonab.,Estrone
DB00783,Estradiol may increase the thrombogenic activities of Muromonab.,Estradiol
DB00890,Dienestrol may increase the thrombogenic activities of Muromonab.,Dienestrol
DB00977,Ethinylestradiol may increase the thrombogenic activities of Muromonab.,Ethinylestradiol
DB01357,Mestranol may increase the thrombogenic activities of Muromonab.,Mestranol
DB04573,Estriol may increase the thrombogenic activities of Muromonab.,Estriol
DB04574,Estrone sulfate may increase the thrombogenic activities of Muromonab.,Estrone sulfate
DB04575,Quinestrol may increase the thrombogenic activities of Muromonab.,Quinestrol
DB07931,Hexestrol may increase the thrombogenic activities of Muromonab.,Hexestrol
DB09070,Tibolone may increase the thrombogenic activities of Muromonab.,Tibolone
DB09317,"Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Muromonab.","Synthetic Conjugated Estrogens, A"
DB09318,"Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Muromonab.","Synthetic Conjugated Estrogens, B"
DB09369,Polyestradiol phosphate may increase the thrombogenic activities of Muromonab.,Polyestradiol phosphate
DB09381,Esterified estrogens may increase the thrombogenic activities of Muromonab.,Esterified estrogens
DB11478,Zeranol may increase the thrombogenic activities of Muromonab.,Zeranol
DB11674,Equol may increase the thrombogenic activities of Muromonab.,Equol
DB12487,Promestriene may increase the thrombogenic activities of Muromonab.,Promestriene
DB13143,Methallenestril may increase the thrombogenic activities of Muromonab.,Methallenestril
DB13386,Epimestrol may increase the thrombogenic activities of Muromonab.,Epimestrol
DB13418,Moxestrol may increase the thrombogenic activities of Muromonab.,Moxestrol
DB13952,Estradiol acetate may increase the thrombogenic activities of Muromonab.,Estradiol acetate
DB13953,Estradiol benzoate may increase the thrombogenic activities of Muromonab.,Estradiol benzoate
DB13954,Estradiol cypionate may increase the thrombogenic activities of Muromonab.,Estradiol cypionate
DB13956,Estradiol valerate may increase the thrombogenic activities of Muromonab.,Estradiol valerate
DB15334,Biochanin A may increase the thrombogenic activities of Muromonab.,Biochanin A
DB15335,Formononetin may increase the thrombogenic activities of Muromonab.,Formononetin
DB01097,The risk or severity of adverse effects can be increased when Muromonab is combined with Leflunomide.,Leflunomide
DB08895,Muromonab may increase the immunosuppressive activities of Tofacitinib.,Tofacitinib
DB00072,Trastuzumab may increase the neutropenic activities of Muromonab.,Trastuzumab
DB08868,Muromonab may increase the immunosuppressive activities of Fingolimod.,Fingolimod
DB00864,Tacrolimus may increase the immunosuppressive activities of Muromonab.,Tacrolimus
DB04914,The therapeutic efficacy of G17DT can be decreased when used in combination with Muromonab.,G17DT
DB05144,The therapeutic efficacy of PEV3A can be decreased when used in combination with Muromonab.,PEV3A
DB05325,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Muromonab.,INGN 225
DB05374,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Muromonab.,Rindopepimut
DB05440,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Muromonab.,SRP 299
DB05942,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Muromonab.,GI-5005
DB06400,The therapeutic efficacy of Vitespen can be decreased when used in combination with Muromonab.,Vitespen
DB06584,The therapeutic efficacy of TG4010 can be decreased when used in combination with Muromonab.,TG4010
DB09057,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Muromonab.,Anthrax immune globulin human
DB10062,"The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Muromonab.","Rabies virus inactivated antigen, B"
DB10076,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Muromonab.,Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen
DB10276,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Muromonab.,Rotavirus vaccine
DB10283,"The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Muromonab.","Rabies virus inactivated antigen, A"
DB10342,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Muromonab.,Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen
DB10583,The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Muromonab.,Clostridium tetani toxoid antigen (formaldehyde inactivated)
DB10584,The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Muromonab.,Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
DB10600,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Muromonab.,Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated)
DB10769,The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Muromonab.,Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)
DB10794,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Muromonab.,Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated)
DB10803,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Muromonab.,Typhoid Vi polysaccharide vaccine
DB10989,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Muromonab.,Hepatitis A Vaccine
DB10990,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Muromonab.,Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
DB11038,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Muromonab.,Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated)
DB11040,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Muromonab.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated)
DB11041,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Muromonab.,Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)
DB11044,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Muromonab.,Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated)
DB11603,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Muromonab.,Human rabies virus immune globulin
DB11627,The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Muromonab.,Hepatitis B Vaccine (Recombinant)
DB12568,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Muromonab.,Tecemotide
DB14022,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Muromonab.,Typhoid vaccine
DB14384,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Muromonab.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated)
DB14385,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Muromonab.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)
DB14394,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Muromonab.,Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen
DB14445,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Muromonab.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated)
DB14449,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Muromonab.,Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen
DB14619,The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Muromonab.,Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated)
DB14620,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Muromonab.,Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated)
DB14711,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Muromonab.,Vaccinia virus strain new york city board of health live antigen
DB15274,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Muromonab.,Pertussis vaccine
DB15461,The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Muromonab.,Yersinia pestis 195/p antigen (formaldehyde inactivated)
DB13924,The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Muromonab.,Varicella Zoster Vaccine (Recombinant)
DB15483,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Muromonab.,Modified vaccinia ankara
DB11988,Ocrelizumab may increase the immunosuppressive activities of Muromonab.,Ocrelizumab
DB10317,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Muromonab.,Rubella virus vaccine
DB10318,The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Muromonab.,Varicella Zoster Vaccine (Live/attenuated)
DB10343,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Muromonab.,Bacillus calmette-guerin substrain tice live antigen
DB10804,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Muromonab.,Bacillus calmette-guerin substrain connaught live antigen
DB10805,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Muromonab.,Yellow Fever Vaccine
DB11003,The risk or severity of infection can be increased when Anthrax vaccine is combined with Muromonab.,Anthrax vaccine
DB11050,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Muromonab.,Typhoid Vaccine Live
DB12386,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Muromonab.,Bacillus calmette-guerin substrain danish 1331 live antigen
DB12768,The risk or severity of infection can be increased when BCG vaccine is combined with Muromonab.,BCG vaccine
DB14409,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Muromonab.,Human adenovirus e serotype 4 strain cl-68578 antigen
DB14443,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Muromonab.,Vibrio cholerae CVD 103-HgR strain live antigen
DB14685,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Muromonab.,Adenovirus type 7 vaccine live
DB00002,The risk or severity of adverse effects can be increased when Cetuximab is combined with Muromonab.,Cetuximab
DB00028,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Muromonab.,Human immunoglobulin G
DB00043,The risk or severity of adverse effects can be increased when Omalizumab is combined with Muromonab.,Omalizumab
DB00054,The risk or severity of adverse effects can be increased when Abciximab is combined with Muromonab.,Abciximab
DB00057,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Muromonab.,Indium In-111 satumomab pendetide
DB00076,The risk or severity of adverse effects can be increased when Muromonab is combined with Digoxin Immune Fab (Ovine).,Digoxin Immune Fab (Ovine)
DB00089,The risk or severity of adverse effects can be increased when Muromonab is combined with Capromab pendetide.,Capromab pendetide
DB00110,The risk or severity of adverse effects can be increased when Muromonab is combined with Palivizumab.,Palivizumab
DB00113,The risk or severity of adverse effects can be increased when Muromonab is combined with Technetium Tc-99m arcitumomab.,Technetium Tc-99m arcitumomab
DB01269,The risk or severity of adverse effects can be increased when Muromonab is combined with Panitumumab.,Panitumumab
DB01270,The risk or severity of adverse effects can be increased when Muromonab is combined with Ranibizumab.,Ranibizumab
DB04901,The risk or severity of adverse effects can be increased when Muromonab is combined with Galiximab.,Galiximab
DB04949,The risk or severity of adverse effects can be increased when Muromonab is combined with Pexelizumab.,Pexelizumab
DB04958,The risk or severity of adverse effects can be increased when Muromonab is combined with Epratuzumab.,Epratuzumab
DB04962,The risk or severity of adverse effects can be increased when Muromonab is combined with Bectumomab.,Bectumomab
DB04964,The risk or severity of adverse effects can be increased when Muromonab is combined with Oregovomab.,Oregovomab
DB04988,The risk or severity of adverse effects can be increased when Muromonab is combined with IGN311.,IGN311
DB05006,The risk or severity of adverse effects can be increased when Muromonab is combined with Adecatumumab.,Adecatumumab
DB05097,The risk or severity of adverse effects can be increased when Muromonab is combined with Labetuzumab.,Labetuzumab
DB05101,The risk or severity of adverse effects can be increased when Muromonab is combined with Matuzumab.,Matuzumab
DB05111,The risk or severity of adverse effects can be increased when Muromonab is combined with Fontolizumab.,Fontolizumab
DB05136,The risk or severity of adverse effects can be increased when Muromonab is combined with Bavituximab.,Bavituximab
DB05139,The risk or severity of adverse effects can be increased when Muromonab is combined with CR002.,CR002
DB05209,The risk or severity of adverse effects can be increased when Muromonab is combined with Rozrolimupab.,Rozrolimupab
DB05304,The risk or severity of adverse effects can be increased when Muromonab is combined with Girentuximab.,Girentuximab
DB05336,The risk or severity of adverse effects can be increased when Muromonab is combined with Obiltoxaximab.,Obiltoxaximab
DB05405,The risk or severity of adverse effects can be increased when Muromonab is combined with XTL-001.,XTL-001
DB05437,The risk or severity of adverse effects can be increased when Muromonab is combined with NAV 1800.,NAV 1800
DB05496,The risk or severity of adverse effects can be increased when Muromonab is combined with Otelixizumab.,Otelixizumab
DB05545,The risk or severity of adverse effects can be increased when Muromonab is combined with AMG 108.,AMG 108
DB05550,The risk or severity of adverse effects can be increased when Muromonab is combined with Iratumumab.,Iratumumab
DB05555,The risk or severity of adverse effects can be increased when Muromonab is combined with Enokizumab.,Enokizumab
DB05578,The risk or severity of adverse effects can be increased when Muromonab is combined with Ramucirumab.,Ramucirumab
DB05595,The risk or severity of adverse effects can be increased when Muromonab is combined with Farletuzumab.,Farletuzumab
DB05656,The risk or severity of adverse effects can be increased when Muromonab is combined with Veltuzumab.,Veltuzumab
DB05793,The risk or severity of adverse effects can be increased when Muromonab is combined with PRO-542.,PRO-542
DB05797,The risk or severity of adverse effects can be increased when Muromonab is combined with TNX-901.,TNX-901
DB05889,The risk or severity of adverse effects can be increased when Muromonab is combined with Inotuzumab ozogamicin.,Inotuzumab ozogamicin
DB05892,The risk or severity of adverse effects can be increased when Muromonab is combined with RI 624.,RI 624
DB05915,The risk or severity of adverse effects can be increased when Muromonab is combined with MYO-029.,MYO-029
DB05916,The risk or severity of adverse effects can be increased when Muromonab is combined with CT-011.,CT-011
DB05941,The risk or severity of adverse effects can be increased when Muromonab is combined with Leronlimab.,Leronlimab
DB05996,The risk or severity of adverse effects can be increased when Muromonab is combined with Glembatumumab vedotin.,Glembatumumab vedotin
DB06043,The risk or severity of adverse effects can be increased when Muromonab is combined with Olaratumab.,Olaratumab
DB06049,The risk or severity of adverse effects can be increased when Muromonab is combined with IPH 2101.,IPH 2101
DB06050,The risk or severity of adverse effects can be increased when Muromonab is combined with TB-402.,TB-402
DB06081,The risk or severity of adverse effects can be increased when Muromonab is combined with Caplacizumab.,Caplacizumab
DB06101,The risk or severity of adverse effects can be increased when Muromonab is combined with IMC-1C11.,IMC-1C11
DB06116,The risk or severity of adverse effects can be increased when Muromonab is combined with Eldelumab.,Eldelumab
DB06162,The risk or severity of adverse effects can be increased when Muromonab is combined with Lumiliximab.,Lumiliximab
DB06186,The risk or severity of adverse effects can be increased when Muromonab is combined with Ipilimumab.,Ipilimumab
DB06192,The risk or severity of adverse effects can be increased when Muromonab is combined with Nimotuzumab.,Nimotuzumab
DB06241,The risk or severity of adverse effects can be increased when Muromonab is combined with Clenoliximab.,Clenoliximab
DB06304,The risk or severity of adverse effects can be increased when Muromonab is combined with BIIB015.,BIIB015
DB06305,The risk or severity of adverse effects can be increased when Muromonab is combined with Sonepcizumab.,Sonepcizumab
DB06310,The risk or severity of adverse effects can be increased when Muromonab is combined with Motavizumab.,Motavizumab
DB06317,The risk or severity of adverse effects can be increased when Muromonab is combined with Elotuzumab.,Elotuzumab
DB06318,The risk or severity of adverse effects can be increased when Muromonab is combined with AVE9633.,AVE9633
DB06322,The risk or severity of adverse effects can be increased when Muromonab is combined with Carotuximab.,Carotuximab
DB06324,The risk or severity of adverse effects can be increased when Muromonab is combined with XmAb 2513.,XmAb 2513
DB06342,The risk or severity of adverse effects can be increased when Muromonab is combined with Coltuximab ravtansine.,Coltuximab ravtansine
DB06343,The risk or severity of adverse effects can be increased when Muromonab is combined with Teprotumumab.,Teprotumumab
DB06360,The risk or severity of adverse effects can be increased when Muromonab is combined with Lucatumumab.,Lucatumumab
DB06366,The risk or severity of adverse effects can be increased when Muromonab is combined with Pertuzumab.,Pertuzumab
DB06371,The risk or severity of adverse effects can be increased when Muromonab is combined with Siplizumab.,Siplizumab
DB06467,The risk or severity of adverse effects can be increased when Muromonab is combined with Apolizumab.,Apolizumab
DB06474,The risk or severity of adverse effects can be increased when Muromonab is combined with Sibrotuzumab.,Sibrotuzumab
DB06550,The risk or severity of adverse effects can be increased when Muromonab is combined with Bivatuzumab.,Bivatuzumab
DB06557,The risk or severity of adverse effects can be increased when Muromonab is combined with Lerdelimumab.,Lerdelimumab
DB06599,The risk or severity of adverse effects can be increased when Muromonab is combined with Lexatumumab.,Lexatumumab
DB06602,The risk or severity of adverse effects can be increased when Muromonab is combined with Reslizumab.,Reslizumab
DB06606,The risk or severity of adverse effects can be increased when Muromonab is combined with Teplizumab.,Teplizumab
DB06607,The risk or severity of adverse effects can be increased when Muromonab is combined with Catumaxomab.,Catumaxomab
DB06647,The risk or severity of adverse effects can be increased when Muromonab is combined with Volociximab.,Volociximab
DB06650,The risk or severity of adverse effects can be increased when Muromonab is combined with Ofatumumab.,Ofatumumab
DB08902,The risk or severity of adverse effects can be increased when Muromonab is combined with Raxibacumab.,Raxibacumab
DB09035,The risk or severity of adverse effects can be increased when Muromonab is combined with Nivolumab.,Nivolumab
DB09037,The risk or severity of adverse effects can be increased when Muromonab is combined with Pembrolizumab.,Pembrolizumab
DB09045,The risk or severity of adverse effects can be increased when Muromonab is combined with Dulaglutide.,Dulaglutide
DB09105,The risk or severity of adverse effects can be increased when Muromonab is combined with Asfotase alfa.,Asfotase alfa
DB09264,The risk or severity of adverse effects can be increased when Muromonab is combined with Idarucizumab.,Idarucizumab
DB09302,The risk or severity of adverse effects can be increased when Muromonab is combined with Alirocumab.,Alirocumab
DB09303,The risk or severity of adverse effects can be increased when Muromonab is combined with Evolocumab.,Evolocumab
DB09331,The risk or severity of adverse effects can be increased when Muromonab is combined with Daratumumab.,Daratumumab
DB09559,The risk or severity of adverse effects can be increased when Muromonab is combined with Necitumumab.,Necitumumab
DB11595,The risk or severity of adverse effects can be increased when Muromonab is combined with Atezolizumab.,Atezolizumab
DB11604,The risk or severity of adverse effects can be increased when Muromonab is combined with Tetanus Immune Globulin.,Tetanus Immune Globulin
DB11608,The risk or severity of adverse effects can be increased when Muromonab is combined with Eftrenonacog alfa.,Eftrenonacog alfa
DB11621,The risk or severity of adverse effects can be increased when Muromonab is combined with Human Varicella-Zoster Immune Globulin.,Human Varicella-Zoster Immune Globulin
DB11646,The risk or severity of adverse effects can be increased when Muromonab is combined with Conatumumab.,Conatumumab
DB11657,The risk or severity of adverse effects can be increased when Muromonab is combined with Tabalumab.,Tabalumab
DB11680,The risk or severity of adverse effects can be increased when Muromonab is combined with Ficlatuzumab.,Ficlatuzumab
DB11685,The risk or severity of adverse effects can be increased when Muromonab is combined with Figitumumab.,Figitumumab
DB11714,The risk or severity of adverse effects can be increased when Muromonab is combined with Durvalumab.,Durvalumab
DB11715,The risk or severity of adverse effects can be increased when Muromonab is combined with Bapineuzumab.,Bapineuzumab
DB11731,The risk or severity of adverse effects can be increased when Muromonab is combined with Depatuxizumab mafodotin.,Depatuxizumab mafodotin
DB11746,The risk or severity of adverse effects can be increased when Muromonab is combined with Onartuzumab.,Onartuzumab
DB11756,The risk or severity of adverse effects can be increased when Muromonab is combined with Solanezumab.,Solanezumab
DB11771,The risk or severity of adverse effects can be increased when Muromonab is combined with Tremelimumab.,Tremelimumab
DB11826,The risk or severity of adverse effects can be increased when Muromonab is combined with Lampalizumab.,Lampalizumab
DB11840,The risk or severity of adverse effects can be increased when Muromonab is combined with Dalotuzumab.,Dalotuzumab
DB11849,The risk or severity of adverse effects can be increased when Muromonab is combined with Emibetuzumab.,Emibetuzumab
DB11850,The risk or severity of adverse effects can be increased when Muromonab is combined with Ublituximab.,Ublituximab
DB11856,The risk or severity of adverse effects can be increased when Muromonab is combined with Ligelizumab.,Ligelizumab
DB11857,The risk or severity of adverse effects can be increased when Muromonab is combined with Seribantumab.,Seribantumab
DB11862,The risk or severity of adverse effects can be increased when Muromonab is combined with Landogrozumab.,Landogrozumab
DB11866,The risk or severity of adverse effects can be increased when Muromonab is combined with Romosozumab.,Romosozumab
DB11884,The risk or severity of adverse effects can be increased when Muromonab is combined with Vadastuximab Talirine.,Vadastuximab Talirine
DB11914,The risk or severity of adverse effects can be increased when Muromonab is combined with Lebrikizumab.,Lebrikizumab
DB11930,The risk or severity of adverse effects can be increased when Muromonab is combined with Varlilumab.,Varlilumab
DB11945,The risk or severity of adverse effects can be increased when Muromonab is combined with Avelumab.,Avelumab
DB11959,The risk or severity of adverse effects can be increased when Muromonab is combined with Crenezumab.,Crenezumab
DB11972,The risk or severity of adverse effects can be increased when Muromonab is combined with Rilotumumab.,Rilotumumab
DB11976,The risk or severity of adverse effects can be increased when Muromonab is combined with Anifrolumab.,Anifrolumab
DB12023,The risk or severity of adverse effects can be increased when Muromonab is combined with Benralizumab.,Benralizumab
DB12034,The risk or severity of adverse effects can be increased when Muromonab is combined with Gantenerumab.,Gantenerumab
DB12053,The risk or severity of adverse effects can be increased when Muromonab is combined with Visilizumab.,Visilizumab
DB12077,The risk or severity of adverse effects can be increased when Muromonab is combined with Urelumab.,Urelumab
DB12089,The risk or severity of adverse effects can be increased when Muromonab is combined with Lorvotuzumab mertansine.,Lorvotuzumab mertansine
DB12090,The risk or severity of adverse effects can be increased when Muromonab is combined with Patritumab.,Patritumab
DB12102,The risk or severity of adverse effects can be increased when Muromonab is combined with Fulranumab.,Fulranumab
DB12104,The risk or severity of adverse effects can be increased when Muromonab is combined with Tarextumab.,Tarextumab
DB12118,The risk or severity of adverse effects can be increased when Muromonab is combined with Sotatercept.,Sotatercept
DB12119,The risk or severity of adverse effects can be increased when Muromonab is combined with Gevokizumab.,Gevokizumab
DB12142,The risk or severity of adverse effects can be increased when Muromonab is combined with Duligotuzumab.,Duligotuzumab
DB12152,The risk or severity of adverse effects can be increased when Muromonab is combined with Simtuzumab.,Simtuzumab
DB12157,The risk or severity of adverse effects can be increased when Muromonab is combined with Fasinumab.,Fasinumab
DB12159,The risk or severity of adverse effects can be increased when Muromonab is combined with Dupilumab.,Dupilumab
DB12169,The risk or severity of adverse effects can be increased when Muromonab is combined with Tralokinumab.,Tralokinumab
DB12189,The risk or severity of adverse effects can be increased when Muromonab is combined with Etrolizumab.,Etrolizumab
DB12202,The risk or severity of adverse effects can be increased when Muromonab is combined with Zalutumumab.,Zalutumumab
DB12205,The risk or severity of adverse effects can be increased when Muromonab is combined with Ganitumab.,Ganitumab
DB12213,The risk or severity of adverse effects can be increased when Muromonab is combined with Etaracizumab.,Etaracizumab
DB12240,The risk or severity of adverse effects can be increased when Muromonab is combined with Polatuzumab vedotin.,Polatuzumab vedotin
DB12246,The risk or severity of adverse effects can be increased when Muromonab is combined with Inclacumab.,Inclacumab
DB12250,The risk or severity of adverse effects can be increased when Muromonab is combined with Cixutumumab.,Cixutumumab
DB12261,The risk or severity of adverse effects can be increased when Muromonab is combined with Ascrinvacumab.,Ascrinvacumab
DB12274,The risk or severity of adverse effects can be increased when Muromonab is combined with Aducanumab.,Aducanumab
DB12281,The risk or severity of adverse effects can be increased when Muromonab is combined with Luspatercept.,Luspatercept
DB12296,The risk or severity of adverse effects can be increased when Muromonab is combined with GS-5745.,GS-5745
DB12317,The risk or severity of adverse effects can be increased when Muromonab is combined with Vanucizumab.,Vanucizumab
DB12331,The risk or severity of adverse effects can be increased when Muromonab is combined with Labetuzumab govitecan.,Labetuzumab govitecan
DB12335,The risk or severity of adverse effects can be increased when Muromonab is combined with Tanezumab.,Tanezumab
DB12342,The risk or severity of adverse effects can be increased when Muromonab is combined with Ensituximab.,Ensituximab
DB12344,The risk or severity of adverse effects can be increased when Muromonab is combined with Fezakinumab.,Fezakinumab
DB12363,The risk or severity of adverse effects can be increased when Muromonab is combined with Dusigitumab.,Dusigitumab
DB12396,The risk or severity of adverse effects can be increased when Muromonab is combined with Fresolimumab.,Fresolimumab
DB12413,The risk or severity of adverse effects can be increased when Muromonab is combined with Indusatumab vedotin.,Indusatumab vedotin
DB12456,The risk or severity of adverse effects can be increased when Muromonab is combined with Bococizumab.,Bococizumab
DB12489,The risk or severity of adverse effects can be increased when Muromonab is combined with Mirvetuximab Soravtansine.,Mirvetuximab Soravtansine
DB12498,The risk or severity of adverse effects can be increased when Muromonab is combined with Mogamulizumab.,Mogamulizumab
DB12520,The risk or severity of adverse effects can be increased when Muromonab is combined with Plozalizumab.,Plozalizumab
DB12534,The risk or severity of adverse effects can be increased when Muromonab is combined with Mavrilimumab.,Mavrilimumab
DB12560,The risk or severity of adverse effects can be increased when Muromonab is combined with Blosozumab.,Blosozumab
DB12584,The risk or severity of adverse effects can be increased when Muromonab is combined with Bimagrumab.,Bimagrumab
DB12589,The risk or severity of adverse effects can be increased when Muromonab is combined with Dacetuzumab.,Dacetuzumab
DB12609,The risk or severity of adverse effects can be increased when Muromonab is combined with Tovetumab.,Tovetumab
DB12683,The risk or severity of adverse effects can be increased when Muromonab is combined with Lumretuzumab.,Lumretuzumab
DB12698,The risk or severity of adverse effects can be increased when Muromonab is combined with Ibalizumab.,Ibalizumab
DB12701,The risk or severity of adverse effects can be increased when Muromonab is combined with Intetumumab.,Intetumumab
DB12718,The risk or severity of adverse effects can be increased when Muromonab is combined with Carlumab.,Carlumab
DB12734,The risk or severity of adverse effects can be increased when Muromonab is combined with Demcizumab.,Demcizumab
DB12773,The risk or severity of adverse effects can be increased when Muromonab is combined with Sifalimumab.,Sifalimumab
DB12775,The risk or severity of adverse effects can be increased when Muromonab is combined with Abituzumab.,Abituzumab
DB12797,The risk or severity of adverse effects can be increased when Muromonab is combined with Ecromeximab.,Ecromeximab
DB12807,The risk or severity of adverse effects can be increased when Muromonab is combined with Naptumomab Estafenatox.,Naptumomab Estafenatox
DB12815,The risk or severity of adverse effects can be increased when Muromonab is combined with Crotedumab.,Crotedumab
DB12820,The risk or severity of adverse effects can be increased when Muromonab is combined with Concizumab.,Concizumab
DB12826,The risk or severity of adverse effects can be increased when Muromonab is combined with Depatuxizumab.,Depatuxizumab
DB12844,The risk or severity of adverse effects can be increased when Muromonab is combined with Rontalizumab.,Rontalizumab
DB12845,The risk or severity of adverse effects can be increased when Muromonab is combined with Amatuximab.,Amatuximab
DB12849,The risk or severity of adverse effects can be increased when Muromonab is combined with Clazakizumab.,Clazakizumab
DB12891,The risk or severity of adverse effects can be increased when Muromonab is combined with Ozanezumab.,Ozanezumab
DB12893,The risk or severity of adverse effects can be increased when Muromonab is combined with Sacituzumab govitecan.,Sacituzumab govitecan
DB12917,The risk or severity of adverse effects can be increased when Muromonab is combined with Bimekizumab.,Bimekizumab
DB12943,The risk or severity of adverse effects can be increased when Muromonab is combined with Milatuzumab.,Milatuzumab
DB12976,The risk or severity of adverse effects can be increased when Muromonab is combined with Robatumumab.,Robatumumab
DB13017,The risk or severity of adverse effects can be increased when Muromonab is combined with Rovalpituzumab Tesirine.,Rovalpituzumab Tesirine
DB13037,The risk or severity of adverse effects can be increased when Muromonab is combined with Namilumab.,Namilumab
DB13045,The risk or severity of adverse effects can be increased when Muromonab is combined with Racotumomab.,Racotumomab
DB13073,The risk or severity of adverse effects can be increased when Muromonab is combined with Tregalizumab.,Tregalizumab
DB13127,The risk or severity of adverse effects can be increased when Muromonab is combined with Olokizumab.,Olokizumab
DB13140,The risk or severity of adverse effects can be increased when Muromonab is combined with Bezlotoxumab.,Bezlotoxumab
DB13375,The risk or severity of adverse effects can be increased when Muromonab is combined with Edrecolomab.,Edrecolomab
DB13535,The risk or severity of adverse effects can be increased when Muromonab is combined with Nebacumab.,Nebacumab
DB13886,The risk or severity of adverse effects can be increased when Muromonab is combined with Human cytomegalovirus immune globulin.,Human cytomegalovirus immune globulin
DB13923,The risk or severity of adverse effects can be increased when Muromonab is combined with Emicizumab.,Emicizumab
DB13976,The risk or severity of adverse effects can be increased when Muromonab is combined with Sulesomab.,Sulesomab
DB13979,The risk or severity of adverse effects can be increased when Muromonab is combined with Besilesomab.,Besilesomab
DB14012,The risk or severity of adverse effects can be increased when Muromonab is combined with Burosumab.,Burosumab
DB14039,The risk or severity of adverse effects can be increased when Muromonab is combined with Erenumab.,Erenumab
DB14040,The risk or severity of adverse effects can be increased when Muromonab is combined with Eptinezumab.,Eptinezumab
DB14041,The risk or severity of adverse effects can be increased when Muromonab is combined with Fremanezumab.,Fremanezumab
DB14042,The risk or severity of adverse effects can be increased when Muromonab is combined with Galcanezumab.,Galcanezumab
DB14211,The risk or severity of adverse effects can be increased when Muromonab is combined with Fanolesomab.,Fanolesomab
DB14580,The risk or severity of adverse effects can be increased when Muromonab is combined with Lecanemab.,Lecanemab
DB14597,The risk or severity of adverse effects can be increased when Muromonab is combined with Lanadelumab.,Lanadelumab
DB14707,The risk or severity of adverse effects can be increased when Muromonab is combined with Cemiplimab.,Cemiplimab
DB14776,The risk or severity of adverse effects can be increased when Muromonab is combined with Camrelizumab.,Camrelizumab
DB14778,The risk or severity of adverse effects can be increased when Muromonab is combined with Setrusumab.,Setrusumab
DB14784,The risk or severity of adverse effects can be increased when Muromonab is combined with Gancotamab.,Gancotamab
DB14809,The risk or severity of adverse effects can be increased when Muromonab is combined with Anetumab ravtansine.,Anetumab ravtansine
DB14811,The risk or severity of adverse effects can be increased when Muromonab is combined with Isatuximab.,Isatuximab
DB14824,The risk or severity of adverse effects can be increased when Muromonab is combined with Icrucumab.,Icrucumab
DB14843,The risk or severity of adverse effects can be increased when Muromonab is combined with Codrituzumab.,Codrituzumab
DB14864,The risk or severity of adverse effects can be increased when Muromonab is combined with Brolucizumab.,Brolucizumab
DB14871,The risk or severity of adverse effects can be increased when Muromonab is combined with Xentuzumab.,Xentuzumab
DB14877,The risk or severity of adverse effects can be increased when Muromonab is combined with Lintuzumab.,Lintuzumab
DB14891,The risk or severity of adverse effects can be increased when Muromonab is combined with Vobarilizumab.,Vobarilizumab
DB14897,The risk or severity of adverse effects can be increased when Muromonab is combined with Parsatuzumab.,Parsatuzumab
DB14905,The risk or severity of adverse effects can be increased when Muromonab is combined with Emactuzumab.,Emactuzumab
DB14907,The risk or severity of adverse effects can be increased when Muromonab is combined with Bevacizumab zirconium Zr-89.,Bevacizumab zirconium Zr-89
DB14908,The risk or severity of adverse effects can be increased when Muromonab is combined with Refanezumab.,Refanezumab
DB14947,The risk or severity of adverse effects can be increased when Muromonab is combined with Bermekimab.,Bermekimab
DB14952,The risk or severity of adverse effects can be increased when Muromonab is combined with Pamrevlumab.,Pamrevlumab
DB14959,The risk or severity of adverse effects can be increased when Muromonab is combined with Opicinumab.,Opicinumab
DB14962,The risk or severity of adverse effects can be increased when Muromonab is combined with Trastuzumab deruxtecan.,Trastuzumab deruxtecan
DB14967,The risk or severity of adverse effects can be increased when Muromonab is combined with Margetuximab.,Margetuximab
DB14988,The risk or severity of adverse effects can be increased when Muromonab is combined with Dalantercept.,Dalantercept
DB14997,The risk or severity of adverse effects can be increased when Muromonab is combined with Pateclizumab.,Pateclizumab
DB15014,The risk or severity of adverse effects can be increased when Muromonab is combined with Gremubamab.,Gremubamab
DB15022,The risk or severity of adverse effects can be increased when Muromonab is combined with Apomab.,Apomab
DB15044,The risk or severity of adverse effects can be increased when Muromonab is combined with Tafasitamab.,Tafasitamab
DB15045,The risk or severity of adverse effects can be increased when Muromonab is combined with Ipafricept.,Ipafricept
DB15076,The risk or severity of adverse effects can be increased when Muromonab is combined with Abrilumab.,Abrilumab
DB15089,The risk or severity of adverse effects can be increased when Muromonab is combined with Frovocimab.,Frovocimab
DB15090,The risk or severity of adverse effects can be increased when Muromonab is combined with Tezepelumab.,Tezepelumab
DB15101,The risk or severity of adverse effects can be increased when Muromonab is combined with Tigatuzumab.,Tigatuzumab
DB15104,The risk or severity of adverse effects can be increased when Muromonab is combined with Telisotuzumab vedotin.,Telisotuzumab vedotin
DB15113,The risk or severity of adverse effects can be increased when Muromonab is combined with Utomilumab.,Utomilumab
DB15118,The risk or severity of adverse effects can be increased when Muromonab is combined with Zolbetuximab.,Zolbetuximab
DB15135,The risk or severity of adverse effects can be increased when Muromonab is combined with Ponezumab.,Ponezumab
DB15160,The risk or severity of adverse effects can be increased when Muromonab is combined with Asunercept.,Asunercept
DB15172,The risk or severity of adverse effects can be increased when Muromonab is combined with Suvratoxumab.,Suvratoxumab
DB15225,The risk or severity of adverse effects can be increased when Muromonab is combined with Mitazalimab.,Mitazalimab
DB15252,The risk or severity of adverse effects can be increased when Muromonab is combined with Nemolizumab.,Nemolizumab
DB15277,The risk or severity of adverse effects can be increased when Muromonab is combined with Gedivumab.,Gedivumab
DB15336,The risk or severity of adverse effects can be increased when Muromonab is combined with Valanafusp alfa.,Valanafusp alfa
DB15349,The risk or severity of adverse effects can be increased when Muromonab is combined with Sofituzumab vedotin.,Sofituzumab vedotin
DB15354,The risk or severity of adverse effects can be increased when Muromonab is combined with Evinacumab.,Evinacumab
DB15363,The risk or severity of adverse effects can be increased when Muromonab is combined with Istiratumab.,Istiratumab
DB15383,The risk or severity of adverse effects can be increased when Muromonab is combined with Pidilizumab.,Pidilizumab
DB15397,The risk or severity of adverse effects can be increased when Muromonab is combined with GMA-161.,GMA-161
DB15409,The risk or severity of adverse effects can be increased when Muromonab is combined with Ladiratuzumab vedotin.,Ladiratuzumab vedotin
DB15415,The risk or severity of adverse effects can be increased when Muromonab is combined with Tomaralimab.,Tomaralimab
DB15428,The risk or severity of adverse effects can be increased when Muromonab is combined with Vesencumab.,Vesencumab
DB15432,The risk or severity of adverse effects can be increased when Muromonab is combined with Pinatuzumab vedotin.,Pinatuzumab vedotin
DB15441,The risk or severity of adverse effects can be increased when Muromonab is combined with Lulizumab pegol.,Lulizumab pegol
DB15443,The risk or severity of adverse effects can be increased when Muromonab is combined with Lorukafusp alfa.,Lorukafusp alfa
DB15453,The risk or severity of adverse effects can be increased when Muromonab is combined with Naratuximab emtansine.,Naratuximab emtansine
DB14004,The risk or severity of adverse effects can be increased when Muromonab is combined with Tildrakizumab.,Tildrakizumab
DB05679,The risk or severity of adverse effects can be increased when Muromonab is combined with Ustekinumab.,Ustekinumab
DB15559,The risk or severity of adverse effects can be increased when Muromonab is combined with Zenocutuzumab.,Zenocutuzumab
DB00091,Muromonab may increase the immunosuppressive activities of Cyclosporine.,Cyclosporine
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Muromonab.","Ebola Zaire vaccine (live, attenuated)"
DB14513,The serum concentration of Magnesium can be decreased when it is combined with Muromonab.,Magnesium
DB01601,The serum concentration of Muromonab can be increased when it is combined with Lopinavir.,Lopinavir
DB12530,The risk or severity of infection can be increased when Muromonab is combined with Inebilizumab.,Inebilizumab
DB00255,Diethylstilbestrol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Diethylstilbestrol
DB00269,Chlorotrianisene may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Chlorotrianisene
DB00286,Conjugated estrogens may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Conjugated estrogens
DB00655,Estrone may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Estrone
DB00783,Estradiol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Estradiol
DB00890,Dienestrol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Dienestrol
DB00977,Ethinylestradiol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Ethinylestradiol
DB01357,Mestranol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Mestranol
DB04573,Estriol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Estriol
DB04574,Estrone sulfate may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Estrone sulfate
DB04575,Quinestrol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Quinestrol
DB07931,Hexestrol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Hexestrol
DB09070,Tibolone may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Tibolone
DB09317,"Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).","Synthetic Conjugated Estrogens, A"
DB09318,"Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).","Synthetic Conjugated Estrogens, B"
DB09369,Polyestradiol phosphate may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Polyestradiol phosphate
DB09381,Esterified estrogens may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Esterified estrogens
DB11478,Zeranol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Zeranol
DB11674,Equol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Equol
DB12487,Promestriene may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Promestriene
DB13143,Methallenestril may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Methallenestril
DB13386,Epimestrol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Epimestrol
DB13418,Moxestrol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Moxestrol
DB13952,Estradiol acetate may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Estradiol acetate
DB13953,Estradiol benzoate may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Estradiol benzoate
DB13954,Estradiol cypionate may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Estradiol cypionate
DB13956,Estradiol valerate may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Estradiol valerate
DB15334,Biochanin A may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Biochanin A
DB15335,Formononetin may increase the thrombogenic activities of Digoxin Immune Fab (Ovine).,Formononetin
DB00002,The risk or severity of adverse effects can be increased when Cetuximab is combined with Digoxin Immune Fab (Ovine).,Cetuximab
DB00028,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Digoxin Immune Fab (Ovine).,Human immunoglobulin G
DB00043,The risk or severity of adverse effects can be increased when Omalizumab is combined with Digoxin Immune Fab (Ovine).,Omalizumab
DB00051,The risk or severity of adverse effects can be increased when Adalimumab is combined with Digoxin Immune Fab (Ovine).,Adalimumab
DB00054,The risk or severity of adverse effects can be increased when Abciximab is combined with Digoxin Immune Fab (Ovine).,Abciximab
DB00056,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Digoxin Immune Fab (Ovine).,Gemtuzumab ozogamicin
DB00057,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Digoxin Immune Fab (Ovine).,Indium In-111 satumomab pendetide
DB00065,The risk or severity of adverse effects can be increased when Infliximab is combined with Digoxin Immune Fab (Ovine).,Infliximab
DB00072,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Digoxin Immune Fab (Ovine).,Trastuzumab
DB00073,The risk or severity of adverse effects can be increased when Rituximab is combined with Digoxin Immune Fab (Ovine).,Rituximab
DB00074,The risk or severity of adverse effects can be increased when Basiliximab is combined with Digoxin Immune Fab (Ovine).,Basiliximab
DB00075,The risk or severity of adverse effects can be increased when Muromonab is combined with Digoxin Immune Fab (Ovine).,Muromonab
DB00078,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ibritumomab tiuxetan.,Ibritumomab tiuxetan
DB00081,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tositumomab.,Tositumomab
DB00087,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Alemtuzumab.,Alemtuzumab
DB00089,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Capromab pendetide.,Capromab pendetide
DB00095,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Efalizumab.,Efalizumab
DB00098,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Antithymocyte immunoglobulin (rabbit).,Antithymocyte immunoglobulin (rabbit)
DB00108,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Natalizumab.,Natalizumab
DB00110,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Palivizumab.,Palivizumab
DB00111,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Daclizumab.,Daclizumab
DB00112,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bevacizumab.,Bevacizumab
DB00113,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Technetium Tc-99m arcitumomab.,Technetium Tc-99m arcitumomab
DB01257,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Eculizumab.,Eculizumab
DB01269,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Panitumumab.,Panitumumab
DB01270,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ranibizumab.,Ranibizumab
DB04901,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Galiximab.,Galiximab
DB04949,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Pexelizumab.,Pexelizumab
DB04956,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Afelimomab.,Afelimomab
DB04958,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Epratuzumab.,Epratuzumab
DB04962,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bectumomab.,Bectumomab
DB04964,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Oregovomab.,Oregovomab
DB04988,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with IGN311.,IGN311
DB05006,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Adecatumumab.,Adecatumumab
DB05097,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Labetuzumab.,Labetuzumab
DB05101,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Matuzumab.,Matuzumab
DB05111,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Fontolizumab.,Fontolizumab
DB05136,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bavituximab.,Bavituximab
DB05139,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with CR002.,CR002
DB05209,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Rozrolimupab.,Rozrolimupab
DB05304,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Girentuximab.,Girentuximab
DB05336,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Obiltoxaximab.,Obiltoxaximab
DB05405,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with XTL-001.,XTL-001
DB05437,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with NAV 1800.,NAV 1800
DB05459,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Briakinumab.,Briakinumab
DB05496,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Otelixizumab.,Otelixizumab
DB05545,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with AMG 108.,AMG 108
DB05550,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Iratumumab.,Iratumumab
DB05555,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Enokizumab.,Enokizumab
DB05578,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ramucirumab.,Ramucirumab
DB05595,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Farletuzumab.,Farletuzumab
DB05656,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Veltuzumab.,Veltuzumab
DB05679,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ustekinumab.,Ustekinumab
DB05773,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Trastuzumab emtansine.,Trastuzumab emtansine
DB05793,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with PRO-542.,PRO-542
DB05797,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with TNX-901.,TNX-901
DB05889,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Inotuzumab ozogamicin.,Inotuzumab ozogamicin
DB05892,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with RI 624.,RI 624
DB05915,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with MYO-029.,MYO-029
DB05916,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with CT-011.,CT-011
DB05941,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Leronlimab.,Leronlimab
DB05996,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Glembatumumab vedotin.,Glembatumumab vedotin
DB06043,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Olaratumab.,Olaratumab
DB06049,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with IPH 2101.,IPH 2101
DB06050,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with TB-402.,TB-402
DB06081,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Caplacizumab.,Caplacizumab
DB06101,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with IMC-1C11.,IMC-1C11
DB06116,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Eldelumab.,Eldelumab
DB06162,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Lumiliximab.,Lumiliximab
DB06168,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Canakinumab.,Canakinumab
DB06186,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ipilimumab.,Ipilimumab
DB06192,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Nimotuzumab.,Nimotuzumab
DB06241,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Clenoliximab.,Clenoliximab
DB06273,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tocilizumab.,Tocilizumab
DB06304,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with BIIB015.,BIIB015
DB06305,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Sonepcizumab.,Sonepcizumab
DB06310,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Motavizumab.,Motavizumab
DB06317,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Elotuzumab.,Elotuzumab
DB06318,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with AVE9633.,AVE9633
DB06322,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Carotuximab.,Carotuximab
DB06324,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with XmAb 2513.,XmAb 2513
DB06342,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Coltuximab ravtansine.,Coltuximab ravtansine
DB06343,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Teprotumumab.,Teprotumumab
DB06360,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Lucatumumab.,Lucatumumab
DB06366,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Pertuzumab.,Pertuzumab
DB06371,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Siplizumab.,Siplizumab
DB06467,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Apolizumab.,Apolizumab
DB06474,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Sibrotuzumab.,Sibrotuzumab
DB06550,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bivatuzumab.,Bivatuzumab
DB06557,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Lerdelimumab.,Lerdelimumab
DB06599,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Lexatumumab.,Lexatumumab
DB06602,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Reslizumab.,Reslizumab
DB06606,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Teplizumab.,Teplizumab
DB06607,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Catumaxomab.,Catumaxomab
DB06612,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Mepolizumab.,Mepolizumab
DB06643,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Denosumab.,Denosumab
DB06647,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Volociximab.,Volociximab
DB06650,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ofatumumab.,Ofatumumab
DB06674,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Golimumab.,Golimumab
DB08870,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Brentuximab vedotin.,Brentuximab vedotin
DB08879,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Belimumab.,Belimumab
DB08902,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Raxibacumab.,Raxibacumab
DB08904,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Certolizumab pegol.,Certolizumab pegol
DB08935,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Obinutuzumab.,Obinutuzumab
DB09029,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Secukinumab.,Secukinumab
DB09033,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Vedolizumab.,Vedolizumab
DB09035,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Nivolumab.,Nivolumab
DB09036,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Siltuximab.,Siltuximab
DB09037,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Pembrolizumab.,Pembrolizumab
DB09045,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Dulaglutide.,Dulaglutide
DB09052,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Blinatumomab.,Blinatumomab
DB09057,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Anthrax immune globulin human.,Anthrax immune globulin human
DB09077,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Dinutuximab.,Dinutuximab
DB09105,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Asfotase alfa.,Asfotase alfa
DB09264,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Idarucizumab.,Idarucizumab
DB09302,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Alirocumab.,Alirocumab
DB09303,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Evolocumab.,Evolocumab
DB09312,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Antilymphocyte immunoglobulin (horse).,Antilymphocyte immunoglobulin (horse)
DB09331,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Daratumumab.,Daratumumab
DB09559,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Necitumumab.,Necitumumab
DB11569,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ixekizumab.,Ixekizumab
DB11580,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ravulizumab.,Ravulizumab
DB11595,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Atezolizumab.,Atezolizumab
DB11604,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tetanus Immune Globulin.,Tetanus Immune Globulin
DB11608,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Eftrenonacog alfa.,Eftrenonacog alfa
DB11621,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Human Varicella-Zoster Immune Globulin.,Human Varicella-Zoster Immune Globulin
DB11646,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Conatumumab.,Conatumumab
DB11657,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tabalumab.,Tabalumab
DB11680,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ficlatuzumab.,Ficlatuzumab
DB11685,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Figitumumab.,Figitumumab
DB11714,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Durvalumab.,Durvalumab
DB11715,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bapineuzumab.,Bapineuzumab
DB11731,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Depatuxizumab mafodotin.,Depatuxizumab mafodotin
DB11746,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Onartuzumab.,Onartuzumab
DB11756,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Solanezumab.,Solanezumab
DB11767,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Sarilumab.,Sarilumab
DB11771,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tremelimumab.,Tremelimumab
DB11776,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Brodalumab.,Brodalumab
DB11803,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Sirukumab.,Sirukumab
DB11826,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Lampalizumab.,Lampalizumab
DB11834,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Guselkumab.,Guselkumab
DB11840,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Dalotuzumab.,Dalotuzumab
DB11849,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Emibetuzumab.,Emibetuzumab
DB11850,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ublituximab.,Ublituximab
DB11856,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ligelizumab.,Ligelizumab
DB11857,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Seribantumab.,Seribantumab
DB11862,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Landogrozumab.,Landogrozumab
DB11866,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Romosozumab.,Romosozumab
DB11884,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Vadastuximab Talirine.,Vadastuximab Talirine
DB11914,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Lebrikizumab.,Lebrikizumab
DB11930,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Varlilumab.,Varlilumab
DB11945,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Avelumab.,Avelumab
DB11959,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Crenezumab.,Crenezumab
DB11972,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Rilotumumab.,Rilotumumab
DB11976,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Anifrolumab.,Anifrolumab
DB11988,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ocrelizumab.,Ocrelizumab
DB12023,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Benralizumab.,Benralizumab
DB12034,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Gantenerumab.,Gantenerumab
DB12053,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Visilizumab.,Visilizumab
DB12077,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Urelumab.,Urelumab
DB12089,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Lorvotuzumab mertansine.,Lorvotuzumab mertansine
DB12090,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Patritumab.,Patritumab
DB12102,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Fulranumab.,Fulranumab
DB12104,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tarextumab.,Tarextumab
DB12118,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Sotatercept.,Sotatercept
DB12119,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Gevokizumab.,Gevokizumab
DB12142,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Duligotuzumab.,Duligotuzumab
DB12152,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Simtuzumab.,Simtuzumab
DB12157,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Fasinumab.,Fasinumab
DB12159,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Dupilumab.,Dupilumab
DB12169,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tralokinumab.,Tralokinumab
DB12189,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Etrolizumab.,Etrolizumab
DB12202,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Zalutumumab.,Zalutumumab
DB12205,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ganitumab.,Ganitumab
DB12213,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Etaracizumab.,Etaracizumab
DB12240,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Polatuzumab vedotin.,Polatuzumab vedotin
DB12246,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Inclacumab.,Inclacumab
DB12250,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Cixutumumab.,Cixutumumab
DB12261,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ascrinvacumab.,Ascrinvacumab
DB12274,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Aducanumab.,Aducanumab
DB12281,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Luspatercept.,Luspatercept
DB12296,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with GS-5745.,GS-5745
DB12317,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Vanucizumab.,Vanucizumab
DB12331,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Labetuzumab govitecan.,Labetuzumab govitecan
DB12335,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tanezumab.,Tanezumab
DB12342,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ensituximab.,Ensituximab
DB12344,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Fezakinumab.,Fezakinumab
DB12363,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Dusigitumab.,Dusigitumab
DB12396,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Fresolimumab.,Fresolimumab
DB12413,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Indusatumab vedotin.,Indusatumab vedotin
DB12456,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bococizumab.,Bococizumab
DB12489,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Mirvetuximab Soravtansine.,Mirvetuximab Soravtansine
DB12498,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Mogamulizumab.,Mogamulizumab
DB12520,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Plozalizumab.,Plozalizumab
DB12530,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Inebilizumab.,Inebilizumab
DB12534,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Mavrilimumab.,Mavrilimumab
DB12560,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Blosozumab.,Blosozumab
DB12584,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bimagrumab.,Bimagrumab
DB12589,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Dacetuzumab.,Dacetuzumab
DB12609,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tovetumab.,Tovetumab
DB12683,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Lumretuzumab.,Lumretuzumab
DB12698,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ibalizumab.,Ibalizumab
DB12701,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Intetumumab.,Intetumumab
DB12718,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Carlumab.,Carlumab
DB12734,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Demcizumab.,Demcizumab
DB12773,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Sifalimumab.,Sifalimumab
DB12775,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Abituzumab.,Abituzumab
DB12797,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ecromeximab.,Ecromeximab
DB12807,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Naptumomab Estafenatox.,Naptumomab Estafenatox
DB12815,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Crotedumab.,Crotedumab
DB12820,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Concizumab.,Concizumab
DB12826,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Depatuxizumab.,Depatuxizumab
DB12844,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Rontalizumab.,Rontalizumab
DB12845,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Amatuximab.,Amatuximab
DB12849,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Clazakizumab.,Clazakizumab
DB12891,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ozanezumab.,Ozanezumab
DB12893,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Sacituzumab govitecan.,Sacituzumab govitecan
DB12917,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bimekizumab.,Bimekizumab
DB12943,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Milatuzumab.,Milatuzumab
DB12976,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Robatumumab.,Robatumumab
DB13017,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Rovalpituzumab Tesirine.,Rovalpituzumab Tesirine
DB13037,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Namilumab.,Namilumab
DB13045,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Racotumomab.,Racotumomab
DB13073,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tregalizumab.,Tregalizumab
DB13127,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Olokizumab.,Olokizumab
DB13140,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bezlotoxumab.,Bezlotoxumab
DB13375,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Edrecolomab.,Edrecolomab
DB13535,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Nebacumab.,Nebacumab
DB13886,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Human cytomegalovirus immune globulin.,Human cytomegalovirus immune globulin
DB13923,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Emicizumab.,Emicizumab
DB13976,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Sulesomab.,Sulesomab
DB13979,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Besilesomab.,Besilesomab
DB14004,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tildrakizumab.,Tildrakizumab
DB14012,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Burosumab.,Burosumab
DB14039,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Erenumab.,Erenumab
DB14040,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Eptinezumab.,Eptinezumab
DB14041,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Fremanezumab.,Fremanezumab
DB14042,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Galcanezumab.,Galcanezumab
DB14211,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Fanolesomab.,Fanolesomab
DB14580,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Lecanemab.,Lecanemab
DB14597,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Lanadelumab.,Lanadelumab
DB14707,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Cemiplimab.,Cemiplimab
DB14724,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Emapalumab.,Emapalumab
DB14762,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Risankizumab.,Risankizumab
DB14776,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Camrelizumab.,Camrelizumab
DB14778,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Setrusumab.,Setrusumab
DB14784,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Gancotamab.,Gancotamab
DB14809,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Anetumab ravtansine.,Anetumab ravtansine
DB14811,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Isatuximab.,Isatuximab
DB14824,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Icrucumab.,Icrucumab
DB14843,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Codrituzumab.,Codrituzumab
DB14864,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Brolucizumab.,Brolucizumab
DB14871,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Xentuzumab.,Xentuzumab
DB14877,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Lintuzumab.,Lintuzumab
DB14891,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Vobarilizumab.,Vobarilizumab
DB14897,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Parsatuzumab.,Parsatuzumab
DB14905,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Emactuzumab.,Emactuzumab
DB14907,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bevacizumab zirconium Zr-89.,Bevacizumab zirconium Zr-89
DB14908,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Refanezumab.,Refanezumab
DB14919,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Rozanolixizumab.,Rozanolixizumab
DB14947,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bermekimab.,Bermekimab
DB14952,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Pamrevlumab.,Pamrevlumab
DB14959,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Opicinumab.,Opicinumab
DB14962,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Trastuzumab deruxtecan.,Trastuzumab deruxtecan
DB14967,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Margetuximab.,Margetuximab
DB14988,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Dalantercept.,Dalantercept
DB14997,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Pateclizumab.,Pateclizumab
DB15014,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Gremubamab.,Gremubamab
DB15022,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Apomab.,Apomab
DB15044,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tafasitamab.,Tafasitamab
DB15045,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ipafricept.,Ipafricept
DB15076,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Abrilumab.,Abrilumab
DB15089,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Frovocimab.,Frovocimab
DB15090,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tezepelumab.,Tezepelumab
DB15101,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tigatuzumab.,Tigatuzumab
DB15104,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Telisotuzumab vedotin.,Telisotuzumab vedotin
DB15113,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Utomilumab.,Utomilumab
DB15118,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Zolbetuximab.,Zolbetuximab
DB15135,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ponezumab.,Ponezumab
DB15160,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Asunercept.,Asunercept
DB15172,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Suvratoxumab.,Suvratoxumab
DB15225,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Mitazalimab.,Mitazalimab
DB15252,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Nemolizumab.,Nemolizumab
DB15253,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bleselumab.,Bleselumab
DB15277,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Gedivumab.,Gedivumab
DB15336,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Valanafusp alfa.,Valanafusp alfa
DB15349,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Sofituzumab vedotin.,Sofituzumab vedotin
DB15354,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Evinacumab.,Evinacumab
DB15363,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Istiratumab.,Istiratumab
DB15383,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Pidilizumab.,Pidilizumab
DB15397,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with GMA-161.,GMA-161
DB15409,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ladiratuzumab vedotin.,Ladiratuzumab vedotin
DB15415,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tomaralimab.,Tomaralimab
DB15428,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Vesencumab.,Vesencumab
DB15432,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Pinatuzumab vedotin.,Pinatuzumab vedotin
DB15441,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Lulizumab pegol.,Lulizumab pegol
DB15443,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Lorukafusp alfa.,Lorukafusp alfa
DB15453,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Naratuximab emtansine.,Naratuximab emtansine
DB15559,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Zenocutuzumab.,Zenocutuzumab
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Digoxin Immune Fab (Ovine).","Ebola Zaire vaccine (live, attenuated)"
DB06643,The risk or severity of adverse effects can be increased when Denosumab is combined with Ibritumomab tiuxetan.,Denosumab
DB00005,The risk or severity of adverse effects can be increased when Etanercept is combined with Ibritumomab tiuxetan.,Etanercept
DB00008,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ibritumomab tiuxetan.,Peginterferon alfa-2a
DB00011,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Ibritumomab tiuxetan.,Interferon alfa-n1
DB00018,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Ibritumomab tiuxetan.,Interferon alfa-n3
DB00022,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ibritumomab tiuxetan.,Peginterferon alfa-2b
DB00026,The risk or severity of adverse effects can be increased when Anakinra is combined with Ibritumomab tiuxetan.,Anakinra
DB00033,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Ibritumomab tiuxetan.,Interferon gamma-1b
DB00034,"The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Ibritumomab tiuxetan.","Interferon alfa-2a, Recombinant"
DB00041,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Ibritumomab tiuxetan.,Aldesleukin
DB00051,The risk or severity of adverse effects can be increased when Adalimumab is combined with Ibritumomab tiuxetan.,Adalimumab
DB00056,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ibritumomab tiuxetan.,Gemtuzumab ozogamicin
DB00059,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ibritumomab tiuxetan.,Pegaspargase
DB00065,The risk or severity of adverse effects can be increased when Infliximab is combined with Ibritumomab tiuxetan.,Infliximab
DB00068,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ibritumomab tiuxetan.,Interferon beta-1b
DB00069,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ibritumomab tiuxetan.,Interferon alfacon-1
DB00073,The risk or severity of adverse effects can be increased when Rituximab is combined with Ibritumomab tiuxetan.,Rituximab
DB00074,The risk or severity of adverse effects can be increased when Basiliximab is combined with Ibritumomab tiuxetan.,Basiliximab
DB00075,The risk or severity of adverse effects can be increased when Muromonab is combined with Ibritumomab tiuxetan.,Muromonab
DB00081,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tositumomab.,Tositumomab
DB00087,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Alemtuzumab.,Alemtuzumab
DB00092,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Alefacept.,Alefacept
DB00095,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Efalizumab.,Efalizumab
DB00098,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Antithymocyte immunoglobulin (rabbit).,Antithymocyte immunoglobulin (rabbit)
DB00105,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Interferon alfa-2b.,Interferon alfa-2b
DB00111,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Daclizumab.,Daclizumab
DB00112,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bevacizumab.,Bevacizumab
DB00120,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Phenylalanine.,Phenylalanine
DB00180,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Flunisolide.,Flunisolide
DB00188,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bortezomib.,Bortezomib
DB00242,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cladribine.,Cladribine
DB00262,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Carmustine.,Carmustine
DB00276,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Amsacrine.,Amsacrine
DB00290,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bleomycin.,Bleomycin
DB00291,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Chlorambucil.,Chlorambucil
DB00293,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Raltitrexed.,Raltitrexed
DB00305,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mitomycin.,Mitomycin
DB00307,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bexarotene.,Bexarotene
DB00309,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vindesine.,Vindesine
DB00322,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Floxuridine.,Floxuridine
DB00328,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Indomethacin.,Indomethacin
DB00352,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tioguanine.,Tioguanine
DB00361,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vinorelbine.,Vinorelbine
DB00380,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dexrazoxane.,Dexrazoxane
DB00394,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Beclomethasone dipropionate.,Beclomethasone dipropionate
DB00398,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sorafenib.,Sorafenib
DB00428,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Streptozocin.,Streptozocin
DB00432,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Trifluridine.,Trifluridine
DB00441,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Gemcitabine.,Gemcitabine
DB00443,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Betamethasone.,Betamethasone
DB00444,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Teniposide.,Teniposide
DB00445,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Epirubicin.,Epirubicin
DB00446,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Chloramphenicol.,Chloramphenicol
DB00480,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lenalidomide.,Lenalidomide
DB00488,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Altretamine.,Altretamine
DB00495,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Zidovudine.,Zidovudine
DB00515,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cisplatin.,Cisplatin
DB00526,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Oxaliplatin.,Oxaliplatin
DB00531,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cyclophosphamide.,Cyclophosphamide
DB00541,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vincristine.,Vincristine
DB00544,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluorouracil.,Fluorouracil
DB00550,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Propylthiouracil.,Propylthiouracil
DB00552,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pentostatin.,Pentostatin
DB00563,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Methotrexate.,Methotrexate
DB00564,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Carbamazepine.,Carbamazepine
DB00570,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vinblastine.,Vinblastine
DB00588,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluticasone propionate.,Fluticasone propionate
DB00591,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluocinolone acetonide.,Fluocinolone acetonide
DB00601,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Linezolid.,Linezolid
DB00619,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Imatinib.,Imatinib
DB00620,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Triamcinolone.,Triamcinolone
DB00631,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Clofarabine.,Clofarabine
DB00635,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Prednisone.,Prednisone
DB00642,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pemetrexed.,Pemetrexed
DB00687,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fludrocortisone.,Fludrocortisone
DB00688,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mycophenolate mofetil.,Mycophenolate mofetil
DB00694,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Daunorubicin.,Daunorubicin
DB00755,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tretinoin.,Tretinoin
DB00762,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Irinotecan.,Irinotecan
DB00763,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Methimazole.,Methimazole
DB00764,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mometasone.,Mometasone
DB00773,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Etoposide.,Etoposide
DB00795,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sulfasalazine.,Sulfasalazine
DB00851,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dacarbazine.,Dacarbazine
DB00853,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Temozolomide.,Temozolomide
DB00859,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Penicillamine.,Penicillamine
DB00860,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Prednisolone.,Prednisolone
DB00877,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sirolimus.,Sirolimus
DB00888,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mechlorethamine.,Mechlorethamine
DB00928,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Azacitidine.,Azacitidine
DB00958,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Carboplatin.,Carboplatin
DB00959,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Methylprednisolone.,Methylprednisolone
DB00970,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dactinomycin.,Dactinomycin
DB00987,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cytarabine.,Cytarabine
DB00993,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Azathioprine.,Azathioprine
DB00997,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Doxorubicin.,Doxorubicin
DB01005,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Hydroxyurea.,Hydroxyurea
DB01008,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Busulfan.,Busulfan
DB01024,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mycophenolic acid.,Mycophenolic acid
DB01030,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Topotecan.,Topotecan
DB01033,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mercaptopurine.,Mercaptopurine
DB01041,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Thalidomide.,Thalidomide
DB01042,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Melphalan.,Melphalan
DB01073,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fludarabine.,Fludarabine
DB01099,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Flucytosine.,Flucytosine
DB01101,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Capecitabine.,Capecitabine
DB01108,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Trilostane.,Trilostane
DB01168,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Procarbazine.,Procarbazine
DB01169,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Arsenic trioxide.,Arsenic trioxide
DB01177,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Idarubicin.,Idarubicin
DB01181,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ifosfamide.,Ifosfamide
DB01196,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Estramustine.,Estramustine
DB01204,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mitoxantrone.,Mitoxantrone
DB01206,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lomustine.,Lomustine
DB01222,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Budesonide.,Budesonide
DB01229,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Paclitaxel.,Paclitaxel
DB01234,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dexamethasone.,Dexamethasone
DB01248,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Docetaxel.,Docetaxel
DB01254,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dasatinib.,Dasatinib
DB01257,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Eculizumab.,Eculizumab
DB01262,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Decitabine.,Decitabine
DB01268,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sunitinib.,Sunitinib
DB01280,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Nelarabine.,Nelarabine
DB01281,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Abatacept.,Abatacept
DB01285,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Corticotropin.,Corticotropin
DB01380,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cortisone acetate.,Cortisone acetate
DB01384,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Paramethasone.,Paramethasone
DB01394,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Colchicine.,Colchicine
DB01410,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ciclesonide.,Ciclesonide
DB01423,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Stepronin.,Stepronin
DB01590,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Everolimus.,Everolimus
DB01611,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Hydroxychloroquine.,Hydroxychloroquine
DB01816,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Castanospermine.,Castanospermine
DB02546,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vorinostat.,Vorinostat
DB02806,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with 2-Methoxyethanol.,2-Methoxyethanol
DB03523,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Brequinar.,Brequinar
DB04572,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Thiotepa.,Thiotepa
DB04630,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Aldosterone.,Aldosterone
DB04845,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ixabepilone.,Ixabepilone
DB04868,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Nilotinib.,Nilotinib
DB04951,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pirfenidone.,Pirfenidone
DB04956,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Afelimomab.,Afelimomab
DB05015,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Belinostat.,Belinostat
DB05109,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Trabectedin.,Trabectedin
DB05258,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Interferon alfa.,Interferon alfa
DB05259,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Glatiramer.,Glatiramer
DB05260,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Gallium nitrate.,Gallium nitrate
DB05459,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Briakinumab.,Briakinumab
DB05472,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with omega interferon.,omega interferon
DB05676,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Apremilast.,Apremilast
DB05773,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Trastuzumab emtansine.,Trastuzumab emtansine
DB06168,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Canakinumab.,Canakinumab
DB06273,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tocilizumab.,Tocilizumab
DB06287,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Temsirolimus.,Temsirolimus
DB06372,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Rilonacept.,Rilonacept
DB06589,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pazopanib.,Pazopanib
DB06603,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Panobinostat.,Panobinostat
DB06612,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mepolizumab.,Mepolizumab
DB06616,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bosutinib.,Bosutinib
DB06662,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Abetimus.,Abetimus
DB06674,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Golimumab.,Golimumab
DB06681,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Belatacept.,Belatacept
DB06769,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bendamustine.,Bendamustine
DB06772,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cabazitaxel.,Cabazitaxel
DB06813,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pralatrexate.,Pralatrexate
DB08059,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Wortmannin.,Wortmannin
DB08870,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Brentuximab vedotin.,Brentuximab vedotin
DB08871,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Eribulin.,Eribulin
DB08877,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ruxolitinib.,Ruxolitinib
DB08879,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Belimumab.,Belimumab
DB08880,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Teriflunomide.,Teriflunomide
DB08889,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Carfilzomib.,Carfilzomib
DB08901,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ponatinib.,Ponatinib
DB08904,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Certolizumab pegol.,Certolizumab pegol
DB08906,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluticasone furoate.,Fluticasone furoate
DB08908,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dimethyl fumarate.,Dimethyl fumarate
DB08910,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pomalidomide.,Pomalidomide
DB08935,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Obinutuzumab.,Obinutuzumab
DB08970,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluprednidene.,Fluprednidene
DB08971,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluocortolone.,Fluocortolone
DB09029,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Secukinumab.,Secukinumab
DB09033,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vedolizumab.,Vedolizumab
DB09036,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Siltuximab.,Siltuximab
DB09052,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Blinatumomab.,Blinatumomab
DB09053,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ibrutinib.,Ibrutinib
DB09054,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Idelalisib.,Idelalisib
DB09073,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Palbociclib.,Palbociclib
DB09074,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Olaparib.,Olaparib
DB09077,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dinutuximab.,Dinutuximab
DB09082,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vilanterol.,Vilanterol
DB09091,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tixocortol.,Tixocortol
DB09122,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Peginterferon beta-1a.,Peginterferon beta-1a
DB09312,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Antilymphocyte immunoglobulin (horse).,Antilymphocyte immunoglobulin (horse)
DB09378,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluprednisolone.,Fluprednisolone
DB09383,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Meprednisone.,Meprednisone
DB11466,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tepoxalin.,Tepoxalin
DB11487,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dexamethasone isonicotinate.,Dexamethasone isonicotinate
DB11529,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Melengestrol.,Melengestrol
DB11569,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ixekizumab.,Ixekizumab
DB11580,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ravulizumab.,Ravulizumab
DB11616,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pirarubicin.,Pirarubicin
DB11693,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Voclosporin.,Voclosporin
DB11708,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Peficitinib.,Peficitinib
DB11750,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Clobetasol.,Clobetasol
DB11767,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sarilumab.,Sarilumab
DB11776,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Brodalumab.,Brodalumab
DB11803,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sirukumab.,Sirukumab
DB11817,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Baricitinib.,Baricitinib
DB11834,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Guselkumab.,Guselkumab
DB11921,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Deflazacort.,Deflazacort
DB12025,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Triptolide.,Triptolide
DB12371,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Siponimod.,Siponimod
DB12612,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ozanimod.,Ozanimod
DB12617,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mizoribine.,Mizoribine
DB12692,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Gusperimus.,Gusperimus
DB12814,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cepeginterferon alfa-2B.,Cepeginterferon alfa-2B
DB12902,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Trofosfamide.,Trofosfamide
DB12947,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Doxifluridine.,Doxifluridine
DB12991,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Deoxyspergualin.,Deoxyspergualin
DB12996,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Acteoside.,Acteoside
DB13003,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cortivazol.,Cortivazol
DB13014,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Hypericin.,Hypericin
DB13068,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.,9-(N-methyl-L-isoleucine)-cyclosporin A
DB13208,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Prednylidene.,Prednylidene
DB13223,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluocortin.,Fluocortin
DB13241,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Begelomab.,Begelomab
DB13491,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluperolone.,Fluperolone
DB13664,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Formocortal.,Formocortal
DB13728,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Halometasone.,Halometasone
DB13843,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cloprednol.,Cloprednol
DB13856,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluclorolone.,Fluclorolone
DB13867,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluticasone.,Fluticasone
DB14066,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tetrandrine.,Tetrandrine
DB14219,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Monomethyl fumarate.,Monomethyl fumarate
DB14512,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mometasone furoate.,Mometasone furoate
DB14538,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Hydrocortisone aceponate.,Hydrocortisone aceponate
DB14539,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Hydrocortisone acetate.,Hydrocortisone acetate
DB14545,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Hydrocortisone succinate.,Hydrocortisone succinate
DB14724,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Emapalumab.,Emapalumab
DB14762,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Risankizumab.,Risankizumab
DB14919,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Rozanolixizumab.,Rozanolixizumab
DB15253,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bleselumab.,Bleselumab
DB00108,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Natalizumab.,Natalizumab
DB00337,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ibritumomab tiuxetan.,Pimecrolimus
DB01656,Roflumilast may increase the immunosuppressive activities of Ibritumomab tiuxetan.,Roflumilast
DB06688,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Ibritumomab tiuxetan.,Sipuleucel-T
DB00363,The risk or severity of neutropenia can be increased when Ibritumomab tiuxetan is combined with Clozapine.,Clozapine
DB00054,The risk or severity of adverse effects can be increased when Abciximab is combined with Ibritumomab tiuxetan.,Abciximab
DB00063,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Ibritumomab tiuxetan.,Eptifibatide
DB00208,The risk or severity of adverse effects can be increased when Ticlopidine is combined with Ibritumomab tiuxetan.,Ticlopidine
DB00261,The risk or severity of adverse effects can be increased when Anagrelide is combined with Ibritumomab tiuxetan.,Anagrelide
DB00758,The risk or severity of adverse effects can be increased when Clopidogrel is combined with Ibritumomab tiuxetan.,Clopidogrel
DB00775,The risk or severity of adverse effects can be increased when Tirofiban is combined with Ibritumomab tiuxetan.,Tirofiban
DB00806,The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Ibritumomab tiuxetan.,Pentoxifylline
DB00945,The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Ibritumomab tiuxetan.,Acetylsalicylic acid
DB00975,The risk or severity of adverse effects can be increased when Dipyridamole is combined with Ibritumomab tiuxetan.,Dipyridamole
DB01088,The risk or severity of adverse effects can be increased when Iloprost is combined with Ibritumomab tiuxetan.,Iloprost
DB01138,The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Ibritumomab tiuxetan.,Sulfinpyrazone
DB01166,The risk or severity of adverse effects can be increased when Cilostazol is combined with Ibritumomab tiuxetan.,Cilostazol
DB01207,The risk or severity of adverse effects can be increased when Ridogrel is combined with Ibritumomab tiuxetan.,Ridogrel
DB01236,The risk or severity of adverse effects can be increased when Sevoflurane is combined with Ibritumomab tiuxetan.,Sevoflurane
DB01240,The risk or severity of adverse effects can be increased when Epoprostenol is combined with Ibritumomab tiuxetan.,Epoprostenol
DB02709,The risk or severity of adverse effects can be increased when Resveratrol is combined with Ibritumomab tiuxetan.,Resveratrol
DB04743,The risk or severity of adverse effects can be increased when Nimesulide is combined with Ibritumomab tiuxetan.,Nimesulide
DB04905,The risk or severity of adverse effects can be increased when Tesmilifene is combined with Ibritumomab tiuxetan.,Tesmilifene
DB04932,The risk or severity of adverse effects can be increased when Defibrotide is combined with Ibritumomab tiuxetan.,Defibrotide
DB05229,The risk or severity of adverse effects can be increased when Beraprost is combined with Ibritumomab tiuxetan.,Beraprost
DB05266,The risk or severity of adverse effects can be increased when Ibudilast is combined with Ibritumomab tiuxetan.,Ibudilast
DB05767,The risk or severity of adverse effects can be increased when Andrographolide is combined with Ibritumomab tiuxetan.,Andrographolide
DB06081,The risk or severity of adverse effects can be increased when Caplacizumab is combined with Ibritumomab tiuxetan.,Caplacizumab
DB06209,The risk or severity of adverse effects can be increased when Prasugrel is combined with Ibritumomab tiuxetan.,Prasugrel
DB06441,The risk or severity of adverse effects can be increased when Cangrelor is combined with Ibritumomab tiuxetan.,Cangrelor
DB07615,The risk or severity of adverse effects can be increased when Tranilast is combined with Ibritumomab tiuxetan.,Tranilast
DB08814,The risk or severity of adverse effects can be increased when Triflusal is combined with Ibritumomab tiuxetan.,Triflusal
DB08816,The risk or severity of adverse effects can be increased when Ticagrelor is combined with Ibritumomab tiuxetan.,Ticagrelor
DB08887,The risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Ibritumomab tiuxetan.,Icosapent ethyl
DB09030,The risk or severity of adverse effects can be increased when Vorapaxar is combined with Ibritumomab tiuxetan.,Vorapaxar
DB09283,The risk or severity of adverse effects can be increased when Trapidil is combined with Ibritumomab tiuxetan.,Trapidil
DB12092,The risk or severity of adverse effects can be increased when Naftopidil is combined with Ibritumomab tiuxetan.,Naftopidil
DB12163,The risk or severity of adverse effects can be increased when Sarpogrelate is combined with Ibritumomab tiuxetan.,Sarpogrelate
DB12321,The risk or severity of adverse effects can be increased when Ifetroban is combined with Ibritumomab tiuxetan.,Ifetroban
DB12445,The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Ibritumomab tiuxetan.,Nitroaspirin
DB12465,The risk or severity of adverse effects can be increased when Ketanserin is combined with Ibritumomab tiuxetan.,Ketanserin
DB12545,The risk or severity of adverse effects can be increased when Indobufen is combined with Ibritumomab tiuxetan.,Indobufen
DB12749,The risk or severity of adverse effects can be increased when Butylphthalide is combined with Ibritumomab tiuxetan.,Butylphthalide
DB12771,The risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Ibritumomab tiuxetan.,Hydroxytyrosol
DB13036,The risk or severity of adverse effects can be increased when Ramatroban is combined with Ibritumomab tiuxetan.,Ramatroban
DB13327,The risk or severity of adverse effects can be increased when Picotamide is combined with Ibritumomab tiuxetan.,Picotamide
DB13367,The risk or severity of adverse effects can be increased when Cloricromen is combined with Ibritumomab tiuxetan.,Cloricromen
DB13400,The risk or severity of adverse effects can be increased when Linsidomine is combined with Ibritumomab tiuxetan.,Linsidomine
DB13510,The risk or severity of adverse effects can be increased when Buflomedil is combined with Ibritumomab tiuxetan.,Buflomedil
DB13929,The risk or severity of adverse effects can be increased when Relcovaptan is combined with Ibritumomab tiuxetan.,Relcovaptan
DB01015,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Ibritumomab tiuxetan.,Sulfamethoxazole
DB00255,Diethylstilbestrol may increase the thrombogenic activities of Ibritumomab tiuxetan.,Diethylstilbestrol
DB00269,Chlorotrianisene may increase the thrombogenic activities of Ibritumomab tiuxetan.,Chlorotrianisene
DB00286,Conjugated estrogens may increase the thrombogenic activities of Ibritumomab tiuxetan.,Conjugated estrogens
DB00655,Estrone may increase the thrombogenic activities of Ibritumomab tiuxetan.,Estrone
DB00783,Estradiol may increase the thrombogenic activities of Ibritumomab tiuxetan.,Estradiol
DB00890,Dienestrol may increase the thrombogenic activities of Ibritumomab tiuxetan.,Dienestrol
DB00977,Ethinylestradiol may increase the thrombogenic activities of Ibritumomab tiuxetan.,Ethinylestradiol
DB01357,Mestranol may increase the thrombogenic activities of Ibritumomab tiuxetan.,Mestranol
DB04573,Estriol may increase the thrombogenic activities of Ibritumomab tiuxetan.,Estriol
DB04574,Estrone sulfate may increase the thrombogenic activities of Ibritumomab tiuxetan.,Estrone sulfate
DB04575,Quinestrol may increase the thrombogenic activities of Ibritumomab tiuxetan.,Quinestrol
DB07931,Hexestrol may increase the thrombogenic activities of Ibritumomab tiuxetan.,Hexestrol
DB09070,Tibolone may increase the thrombogenic activities of Ibritumomab tiuxetan.,Tibolone
DB09317,"Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Ibritumomab tiuxetan.","Synthetic Conjugated Estrogens, A"
DB09318,"Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Ibritumomab tiuxetan.","Synthetic Conjugated Estrogens, B"
DB09369,Polyestradiol phosphate may increase the thrombogenic activities of Ibritumomab tiuxetan.,Polyestradiol phosphate
DB09381,Esterified estrogens may increase the thrombogenic activities of Ibritumomab tiuxetan.,Esterified estrogens
DB11478,Zeranol may increase the thrombogenic activities of Ibritumomab tiuxetan.,Zeranol
DB11674,Equol may increase the thrombogenic activities of Ibritumomab tiuxetan.,Equol
DB12487,Promestriene may increase the thrombogenic activities of Ibritumomab tiuxetan.,Promestriene
DB13143,Methallenestril may increase the thrombogenic activities of Ibritumomab tiuxetan.,Methallenestril
DB13386,Epimestrol may increase the thrombogenic activities of Ibritumomab tiuxetan.,Epimestrol
DB13418,Moxestrol may increase the thrombogenic activities of Ibritumomab tiuxetan.,Moxestrol
DB13952,Estradiol acetate may increase the thrombogenic activities of Ibritumomab tiuxetan.,Estradiol acetate
DB13953,Estradiol benzoate may increase the thrombogenic activities of Ibritumomab tiuxetan.,Estradiol benzoate
DB13954,Estradiol cypionate may increase the thrombogenic activities of Ibritumomab tiuxetan.,Estradiol cypionate
DB13956,Estradiol valerate may increase the thrombogenic activities of Ibritumomab tiuxetan.,Estradiol valerate
DB15334,Biochanin A may increase the thrombogenic activities of Ibritumomab tiuxetan.,Biochanin A
DB15335,Formononetin may increase the thrombogenic activities of Ibritumomab tiuxetan.,Formononetin
DB01097,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Leflunomide.,Leflunomide
DB08895,Ibritumomab tiuxetan may increase the immunosuppressive activities of Tofacitinib.,Tofacitinib
DB00072,Trastuzumab may increase the neutropenic activities of Ibritumomab tiuxetan.,Trastuzumab
DB08868,Ibritumomab tiuxetan may increase the immunosuppressive activities of Fingolimod.,Fingolimod
DB00864,Tacrolimus may increase the immunosuppressive activities of Ibritumomab tiuxetan.,Tacrolimus
DB04914,The therapeutic efficacy of G17DT can be decreased when used in combination with Ibritumomab tiuxetan.,G17DT
DB05144,The therapeutic efficacy of PEV3A can be decreased when used in combination with Ibritumomab tiuxetan.,PEV3A
DB05325,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Ibritumomab tiuxetan.,INGN 225
DB05374,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Ibritumomab tiuxetan.,Rindopepimut
DB05440,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Ibritumomab tiuxetan.,SRP 299
DB05942,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Ibritumomab tiuxetan.,GI-5005
DB06400,The therapeutic efficacy of Vitespen can be decreased when used in combination with Ibritumomab tiuxetan.,Vitespen
DB06584,The therapeutic efficacy of TG4010 can be decreased when used in combination with Ibritumomab tiuxetan.,TG4010
DB09057,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Ibritumomab tiuxetan.,Anthrax immune globulin human
DB10062,"The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Ibritumomab tiuxetan.","Rabies virus inactivated antigen, B"
DB10076,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Ibritumomab tiuxetan.,Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen
DB10276,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Ibritumomab tiuxetan.,Rotavirus vaccine
DB10283,"The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Ibritumomab tiuxetan.","Rabies virus inactivated antigen, A"
DB10342,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Ibritumomab tiuxetan.,Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen
DB10583,The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.,Clostridium tetani toxoid antigen (formaldehyde inactivated)
DB10584,The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.,Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
DB10600,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.,Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated)
DB10769,The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.,Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)
DB10794,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.,Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated)
DB10803,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Ibritumomab tiuxetan.,Typhoid Vi polysaccharide vaccine
DB10989,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Ibritumomab tiuxetan.,Hepatitis A Vaccine
DB10990,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Ibritumomab tiuxetan.,Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
DB11038,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.,Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated)
DB11040,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated)
DB11041,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.,Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)
DB11044,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.,Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated)
DB11603,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Ibritumomab tiuxetan.,Human rabies virus immune globulin
DB11627,The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Ibritumomab tiuxetan.,Hepatitis B Vaccine (Recombinant)
DB12568,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Ibritumomab tiuxetan.,Tecemotide
DB14022,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Ibritumomab tiuxetan.,Typhoid vaccine
DB14384,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated)
DB14385,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)
DB14394,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Ibritumomab tiuxetan.,Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen
DB14445,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated)
DB14449,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Ibritumomab tiuxetan.,Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen
DB14619,The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.,Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated)
DB14620,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.,Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated)
DB14711,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Ibritumomab tiuxetan.,Vaccinia virus strain new york city board of health live antigen
DB15274,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Ibritumomab tiuxetan.,Pertussis vaccine
DB15461,The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.,Yersinia pestis 195/p antigen (formaldehyde inactivated)
DB13924,The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Ibritumomab tiuxetan.,Varicella Zoster Vaccine (Recombinant)
DB15483,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Ibritumomab tiuxetan.,Modified vaccinia ankara
DB00266,The risk or severity of adverse effects can be increased when Dicoumarol is combined with Ibritumomab tiuxetan.,Dicoumarol
DB00407,The risk or severity of adverse effects can be increased when Ardeparin is combined with Ibritumomab tiuxetan.,Ardeparin
DB00498,The risk or severity of adverse effects can be increased when Phenindione is combined with Ibritumomab tiuxetan.,Phenindione
DB00682,The risk or severity of adverse effects can be increased when Warfarin is combined with Ibritumomab tiuxetan.,Warfarin
DB00686,The risk or severity of adverse effects can be increased when Pentosan polysulfate is combined with Ibritumomab tiuxetan.,Pentosan polysulfate
DB00946,The risk or severity of adverse effects can be increased when Phenprocoumon is combined with Ibritumomab tiuxetan.,Phenprocoumon
DB01418,The risk or severity of adverse effects can be increased when Acenocoumarol is combined with Ibritumomab tiuxetan.,Acenocoumarol
DB03410,The risk or severity of adverse effects can be increased when 4-hydroxycoumarin is combined with Ibritumomab tiuxetan.,4-hydroxycoumarin
DB04665,The risk or severity of adverse effects can be increased when Coumarin is combined with Ibritumomab tiuxetan.,Coumarin
DB04898,The risk or severity of adverse effects can be increased when Ximelagatran is combined with Ibritumomab tiuxetan.,Ximelagatran
DB04925,The risk or severity of adverse effects can be increased when Desmoteplase is combined with Ibritumomab tiuxetan.,Desmoteplase
DB05254,The risk or severity of adverse effects can be increased when Fibrinolysin is combined with Ibritumomab tiuxetan.,Fibrinolysin
DB06228,The risk or severity of adverse effects can be increased when Rivaroxaban is combined with Ibritumomab tiuxetan.,Rivaroxaban
DB06271,The risk or severity of adverse effects can be increased when Sulodexide is combined with Ibritumomab tiuxetan.,Sulodexide
DB06294,The risk or severity of adverse effects can be increased when Semuloparin is combined with Ibritumomab tiuxetan.,Semuloparin
DB06406,The risk or severity of adverse effects can be increased when Idraparinux is combined with Ibritumomab tiuxetan.,Idraparinux
DB06543,The risk or severity of adverse effects can be increased when Astaxanthin is combined with Ibritumomab tiuxetan.,Astaxanthin
DB06605,The risk or severity of adverse effects can be increased when Apixaban is combined with Ibritumomab tiuxetan.,Apixaban
DB06635,The risk or severity of adverse effects can be increased when Otamixaban is combined with Ibritumomab tiuxetan.,Otamixaban
DB06679,The risk or severity of adverse effects can be increased when Amediplase is combined with Ibritumomab tiuxetan.,Amediplase
DB06695,The risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Ibritumomab tiuxetan.,Dabigatran etexilate
DB07767,The risk or severity of adverse effects can be increased when Ferulic acid is combined with Ibritumomab tiuxetan.,Ferulic acid
DB08496,The risk or severity of adverse effects can be increased when (R)-warfarin is combined with Ibritumomab tiuxetan.,(R)-warfarin
DB08794,The risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Ibritumomab tiuxetan.,Ethyl biscoumacetate
DB08994,The risk or severity of adverse effects can be increased when Ditazole is combined with Ibritumomab tiuxetan.,Ditazole
DB09075,The risk or severity of adverse effects can be increased when Edoxaban is combined with Ibritumomab tiuxetan.,Edoxaban
DB09125,The risk or severity of adverse effects can be increased when Potassium citrate is combined with Ibritumomab tiuxetan.,Potassium citrate
DB09154,The risk or severity of adverse effects can be increased when Sodium citrate is combined with Ibritumomab tiuxetan.,Sodium citrate
DB09258,The risk or severity of adverse effects can be increased when Bemiparin is combined with Ibritumomab tiuxetan.,Bemiparin
DB09259,The risk or severity of adverse effects can be increased when Reviparin is combined with Ibritumomab tiuxetan.,Reviparin
DB09260,The risk or severity of adverse effects can be increased when Parnaparin is combined with Ibritumomab tiuxetan.,Parnaparin
DB09261,The risk or severity of adverse effects can be increased when Certoparin is combined with Ibritumomab tiuxetan.,Certoparin
DB11154,The risk or severity of adverse effects can be increased when Zinc citrate is combined with Ibritumomab tiuxetan.,Zinc citrate
DB11984,The risk or severity of adverse effects can be increased when Letaxaban is combined with Ibritumomab tiuxetan.,Letaxaban
DB12289,The risk or severity of adverse effects can be increased when Darexaban is combined with Ibritumomab tiuxetan.,Darexaban
DB12364,The risk or severity of adverse effects can be increased when Betrixaban is combined with Ibritumomab tiuxetan.,Betrixaban
DB12598,The risk or severity of adverse effects can be increased when Nafamostat is combined with Ibritumomab tiuxetan.,Nafamostat
DB12726,The risk or severity of adverse effects can be increased when Monteplase is combined with Ibritumomab tiuxetan.,Monteplase
DB12831,The risk or severity of adverse effects can be increased when Gabexate is combined with Ibritumomab tiuxetan.,Gabexate
DB13136,The risk or severity of adverse effects can be increased when Fluindione is combined with Ibritumomab tiuxetan.,Fluindione
DB13199,The risk or severity of adverse effects can be increased when Brinase is combined with Ibritumomab tiuxetan.,Brinase
DB13275,The risk or severity of adverse effects can be increased when Clorindione is combined with Ibritumomab tiuxetan.,Clorindione
DB13347,The risk or severity of adverse effects can be increased when Diphenadione is combined with Ibritumomab tiuxetan.,Diphenadione
DB13451,The risk or severity of adverse effects can be increased when Tioclomarol is combined with Ibritumomab tiuxetan.,Tioclomarol
DB13616,The risk or severity of adverse effects can be increased when Melagatran is combined with Ibritumomab tiuxetan.,Melagatran
DB13646,The risk or severity of adverse effects can be increased when Saruplase is combined with Ibritumomab tiuxetan.,Saruplase
DB14055,The risk or severity of adverse effects can be increased when (S)-Warfarin is combined with Ibritumomab tiuxetan.,(S)-Warfarin
DB14094,The risk or severity of adverse effects can be increased when Tocopherylquinone is combined with Ibritumomab tiuxetan.,Tocopherylquinone
DB14726,The risk or severity of adverse effects can be increased when Dabigatran is combined with Ibritumomab tiuxetan.,Dabigatran
DB11988,Ocrelizumab may increase the immunosuppressive activities of Ibritumomab tiuxetan.,Ocrelizumab
DB13200,Ibritumomab tiuxetan may increase the myelosuppressive activities of Lipegfilgrastim.,Lipegfilgrastim
DB10317,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Ibritumomab tiuxetan.,Rubella virus vaccine
DB10318,The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Ibritumomab tiuxetan.,Varicella Zoster Vaccine (Live/attenuated)
DB10343,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Ibritumomab tiuxetan.,Bacillus calmette-guerin substrain tice live antigen
DB10804,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Ibritumomab tiuxetan.,Bacillus calmette-guerin substrain connaught live antigen
DB10805,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Ibritumomab tiuxetan.,Yellow Fever Vaccine
DB11003,The risk or severity of infection can be increased when Anthrax vaccine is combined with Ibritumomab tiuxetan.,Anthrax vaccine
DB11050,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Ibritumomab tiuxetan.,Typhoid Vaccine Live
DB12386,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Ibritumomab tiuxetan.,Bacillus calmette-guerin substrain danish 1331 live antigen
DB12768,The risk or severity of infection can be increased when BCG vaccine is combined with Ibritumomab tiuxetan.,BCG vaccine
DB14409,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Ibritumomab tiuxetan.,Human adenovirus e serotype 4 strain cl-68578 antigen
DB14443,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Ibritumomab tiuxetan.,Vibrio cholerae CVD 103-HgR strain live antigen
DB14685,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Ibritumomab tiuxetan.,Adenovirus type 7 vaccine live
DB00002,The risk or severity of adverse effects can be increased when Cetuximab is combined with Ibritumomab tiuxetan.,Cetuximab
DB00028,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ibritumomab tiuxetan.,Human immunoglobulin G
DB00043,The risk or severity of adverse effects can be increased when Omalizumab is combined with Ibritumomab tiuxetan.,Omalizumab
DB00057,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ibritumomab tiuxetan.,Indium In-111 satumomab pendetide
DB00076,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ibritumomab tiuxetan.,Digoxin Immune Fab (Ovine)
DB00089,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Capromab pendetide.,Capromab pendetide
DB00110,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Palivizumab.,Palivizumab
DB00113,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Technetium Tc-99m arcitumomab.,Technetium Tc-99m arcitumomab
DB01269,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Panitumumab.,Panitumumab
DB01270,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ranibizumab.,Ranibizumab
DB04901,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Galiximab.,Galiximab
DB04949,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pexelizumab.,Pexelizumab
DB04958,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Epratuzumab.,Epratuzumab
DB04962,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bectumomab.,Bectumomab
DB04964,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Oregovomab.,Oregovomab
DB04988,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with IGN311.,IGN311
DB05006,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Adecatumumab.,Adecatumumab
DB05097,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Labetuzumab.,Labetuzumab
DB05101,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Matuzumab.,Matuzumab
DB05111,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fontolizumab.,Fontolizumab
DB05136,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bavituximab.,Bavituximab
DB05139,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with CR002.,CR002
DB05209,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Rozrolimupab.,Rozrolimupab
DB05304,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Girentuximab.,Girentuximab
DB05336,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Obiltoxaximab.,Obiltoxaximab
DB05405,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with XTL-001.,XTL-001
DB05437,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with NAV 1800.,NAV 1800
DB05496,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Otelixizumab.,Otelixizumab
DB05545,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with AMG 108.,AMG 108
DB05550,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Iratumumab.,Iratumumab
DB05555,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Enokizumab.,Enokizumab
DB05578,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ramucirumab.,Ramucirumab
DB05595,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Farletuzumab.,Farletuzumab
DB05656,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Veltuzumab.,Veltuzumab
DB05793,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with PRO-542.,PRO-542
DB05797,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with TNX-901.,TNX-901
DB05889,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Inotuzumab ozogamicin.,Inotuzumab ozogamicin
DB05892,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with RI 624.,RI 624
DB05915,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with MYO-029.,MYO-029
DB05916,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with CT-011.,CT-011
DB05941,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Leronlimab.,Leronlimab
DB05996,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Glembatumumab vedotin.,Glembatumumab vedotin
DB06043,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Olaratumab.,Olaratumab
DB06049,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with IPH 2101.,IPH 2101
DB06050,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with TB-402.,TB-402
DB06101,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with IMC-1C11.,IMC-1C11
DB06116,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Eldelumab.,Eldelumab
DB06162,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lumiliximab.,Lumiliximab
DB06186,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ipilimumab.,Ipilimumab
DB06192,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Nimotuzumab.,Nimotuzumab
DB06241,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Clenoliximab.,Clenoliximab
DB06304,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with BIIB015.,BIIB015
DB06305,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sonepcizumab.,Sonepcizumab
DB06310,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Motavizumab.,Motavizumab
DB06317,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Elotuzumab.,Elotuzumab
DB06318,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with AVE9633.,AVE9633
DB06322,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Carotuximab.,Carotuximab
DB06324,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with XmAb 2513.,XmAb 2513
DB06342,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Coltuximab ravtansine.,Coltuximab ravtansine
DB06343,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Teprotumumab.,Teprotumumab
DB06360,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lucatumumab.,Lucatumumab
DB06366,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pertuzumab.,Pertuzumab
DB06371,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Siplizumab.,Siplizumab
DB06467,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Apolizumab.,Apolizumab
DB06474,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sibrotuzumab.,Sibrotuzumab
DB06550,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bivatuzumab.,Bivatuzumab
DB06557,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lerdelimumab.,Lerdelimumab
DB06599,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lexatumumab.,Lexatumumab
DB06602,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Reslizumab.,Reslizumab
DB06606,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Teplizumab.,Teplizumab
DB06607,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Catumaxomab.,Catumaxomab
DB06647,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Volociximab.,Volociximab
DB06650,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ofatumumab.,Ofatumumab
DB08902,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Raxibacumab.,Raxibacumab
DB09035,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Nivolumab.,Nivolumab
DB09037,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pembrolizumab.,Pembrolizumab
DB09045,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dulaglutide.,Dulaglutide
DB09105,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Asfotase alfa.,Asfotase alfa
DB09264,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Idarucizumab.,Idarucizumab
DB09302,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Alirocumab.,Alirocumab
DB09303,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Evolocumab.,Evolocumab
DB09331,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Daratumumab.,Daratumumab
DB09559,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Necitumumab.,Necitumumab
DB11595,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Atezolizumab.,Atezolizumab
DB11604,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tetanus Immune Globulin.,Tetanus Immune Globulin
DB11608,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Eftrenonacog alfa.,Eftrenonacog alfa
DB11621,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Human Varicella-Zoster Immune Globulin.,Human Varicella-Zoster Immune Globulin
DB11646,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Conatumumab.,Conatumumab
DB11657,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tabalumab.,Tabalumab
DB11680,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ficlatuzumab.,Ficlatuzumab
DB11685,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Figitumumab.,Figitumumab
DB11714,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Durvalumab.,Durvalumab
DB11715,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bapineuzumab.,Bapineuzumab
DB11731,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Depatuxizumab mafodotin.,Depatuxizumab mafodotin
DB11746,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Onartuzumab.,Onartuzumab
DB11756,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Solanezumab.,Solanezumab
DB11771,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tremelimumab.,Tremelimumab
DB11826,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lampalizumab.,Lampalizumab
DB11840,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dalotuzumab.,Dalotuzumab
DB11849,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Emibetuzumab.,Emibetuzumab
DB11850,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ublituximab.,Ublituximab
DB11856,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ligelizumab.,Ligelizumab
DB11857,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Seribantumab.,Seribantumab
DB11862,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Landogrozumab.,Landogrozumab
DB11866,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Romosozumab.,Romosozumab
DB11884,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vadastuximab Talirine.,Vadastuximab Talirine
DB11914,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lebrikizumab.,Lebrikizumab
DB11930,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Varlilumab.,Varlilumab
DB11945,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Avelumab.,Avelumab
DB11959,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Crenezumab.,Crenezumab
DB11972,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Rilotumumab.,Rilotumumab
DB11976,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Anifrolumab.,Anifrolumab
DB12023,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Benralizumab.,Benralizumab
DB12034,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Gantenerumab.,Gantenerumab
DB12053,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Visilizumab.,Visilizumab
DB12077,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Urelumab.,Urelumab
DB12089,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lorvotuzumab mertansine.,Lorvotuzumab mertansine
DB12090,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Patritumab.,Patritumab
DB12102,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fulranumab.,Fulranumab
DB12104,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tarextumab.,Tarextumab
DB12118,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sotatercept.,Sotatercept
DB12119,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Gevokizumab.,Gevokizumab
DB12142,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Duligotuzumab.,Duligotuzumab
DB12152,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Simtuzumab.,Simtuzumab
DB12157,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fasinumab.,Fasinumab
DB12159,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dupilumab.,Dupilumab
DB12169,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tralokinumab.,Tralokinumab
DB12189,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Etrolizumab.,Etrolizumab
DB12202,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Zalutumumab.,Zalutumumab
DB12205,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ganitumab.,Ganitumab
DB12213,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Etaracizumab.,Etaracizumab
DB12240,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Polatuzumab vedotin.,Polatuzumab vedotin
DB12246,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Inclacumab.,Inclacumab
DB12250,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cixutumumab.,Cixutumumab
DB12261,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ascrinvacumab.,Ascrinvacumab
DB12274,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Aducanumab.,Aducanumab
DB12281,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Luspatercept.,Luspatercept
DB12296,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with GS-5745.,GS-5745
DB12317,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vanucizumab.,Vanucizumab
DB12331,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Labetuzumab govitecan.,Labetuzumab govitecan
DB12335,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tanezumab.,Tanezumab
DB12342,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ensituximab.,Ensituximab
DB12344,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fezakinumab.,Fezakinumab
DB12363,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dusigitumab.,Dusigitumab
DB12396,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fresolimumab.,Fresolimumab
DB12413,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Indusatumab vedotin.,Indusatumab vedotin
DB12456,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bococizumab.,Bococizumab
DB12489,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mirvetuximab Soravtansine.,Mirvetuximab Soravtansine
DB12498,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mogamulizumab.,Mogamulizumab
DB12520,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Plozalizumab.,Plozalizumab
DB12534,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mavrilimumab.,Mavrilimumab
DB12560,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Blosozumab.,Blosozumab
DB12584,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bimagrumab.,Bimagrumab
DB12589,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dacetuzumab.,Dacetuzumab
DB12609,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tovetumab.,Tovetumab
DB12683,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lumretuzumab.,Lumretuzumab
DB12698,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ibalizumab.,Ibalizumab
DB12701,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Intetumumab.,Intetumumab
DB12718,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Carlumab.,Carlumab
DB12734,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Demcizumab.,Demcizumab
DB12773,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sifalimumab.,Sifalimumab
DB12775,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Abituzumab.,Abituzumab
DB12797,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ecromeximab.,Ecromeximab
DB12807,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Naptumomab Estafenatox.,Naptumomab Estafenatox
DB12815,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Crotedumab.,Crotedumab
DB12820,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Concizumab.,Concizumab
DB12826,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Depatuxizumab.,Depatuxizumab
DB12844,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Rontalizumab.,Rontalizumab
DB12845,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Amatuximab.,Amatuximab
DB12849,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Clazakizumab.,Clazakizumab
DB12891,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ozanezumab.,Ozanezumab
DB12893,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sacituzumab govitecan.,Sacituzumab govitecan
DB12917,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bimekizumab.,Bimekizumab
DB12943,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Milatuzumab.,Milatuzumab
DB12976,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Robatumumab.,Robatumumab
DB13017,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Rovalpituzumab Tesirine.,Rovalpituzumab Tesirine
DB13037,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Namilumab.,Namilumab
DB13045,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Racotumomab.,Racotumomab
DB13073,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tregalizumab.,Tregalizumab
DB13127,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Olokizumab.,Olokizumab
DB13140,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bezlotoxumab.,Bezlotoxumab
DB13375,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Edrecolomab.,Edrecolomab
DB13535,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Nebacumab.,Nebacumab
DB13886,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Human cytomegalovirus immune globulin.,Human cytomegalovirus immune globulin
DB13923,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Emicizumab.,Emicizumab
DB13976,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sulesomab.,Sulesomab
DB13979,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Besilesomab.,Besilesomab
DB14012,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Burosumab.,Burosumab
DB14039,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Erenumab.,Erenumab
DB14040,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Eptinezumab.,Eptinezumab
DB14041,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fremanezumab.,Fremanezumab
DB14042,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Galcanezumab.,Galcanezumab
DB14211,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fanolesomab.,Fanolesomab
DB14580,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lecanemab.,Lecanemab
DB14597,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lanadelumab.,Lanadelumab
DB14707,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cemiplimab.,Cemiplimab
DB14776,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Camrelizumab.,Camrelizumab
DB14778,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Setrusumab.,Setrusumab
DB14784,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Gancotamab.,Gancotamab
DB14809,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Anetumab ravtansine.,Anetumab ravtansine
DB14811,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Isatuximab.,Isatuximab
DB14824,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Icrucumab.,Icrucumab
DB14843,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Codrituzumab.,Codrituzumab
DB14864,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Brolucizumab.,Brolucizumab
DB14871,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Xentuzumab.,Xentuzumab
DB14877,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lintuzumab.,Lintuzumab
DB14891,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vobarilizumab.,Vobarilizumab
DB14897,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Parsatuzumab.,Parsatuzumab
DB14905,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Emactuzumab.,Emactuzumab
DB14907,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bevacizumab zirconium Zr-89.,Bevacizumab zirconium Zr-89
DB14908,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Refanezumab.,Refanezumab
DB14947,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bermekimab.,Bermekimab
DB14952,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pamrevlumab.,Pamrevlumab
DB14959,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Opicinumab.,Opicinumab
DB14962,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Trastuzumab deruxtecan.,Trastuzumab deruxtecan
DB14967,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Margetuximab.,Margetuximab
DB14988,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dalantercept.,Dalantercept
DB14997,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pateclizumab.,Pateclizumab
DB15014,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Gremubamab.,Gremubamab
DB15022,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Apomab.,Apomab
DB15044,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tafasitamab.,Tafasitamab
DB15045,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ipafricept.,Ipafricept
DB15076,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Abrilumab.,Abrilumab
DB15089,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Frovocimab.,Frovocimab
DB15090,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tezepelumab.,Tezepelumab
DB15101,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tigatuzumab.,Tigatuzumab
DB15104,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Telisotuzumab vedotin.,Telisotuzumab vedotin
DB15113,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Utomilumab.,Utomilumab
DB15118,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Zolbetuximab.,Zolbetuximab
DB15135,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ponezumab.,Ponezumab
DB15160,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Asunercept.,Asunercept
DB15172,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Suvratoxumab.,Suvratoxumab
DB15225,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mitazalimab.,Mitazalimab
DB15252,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Nemolizumab.,Nemolizumab
DB15277,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Gedivumab.,Gedivumab
DB15336,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Valanafusp alfa.,Valanafusp alfa
DB15349,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sofituzumab vedotin.,Sofituzumab vedotin
DB15354,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Evinacumab.,Evinacumab
DB15363,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Istiratumab.,Istiratumab
DB15383,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pidilizumab.,Pidilizumab
DB15397,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with GMA-161.,GMA-161
DB15409,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ladiratuzumab vedotin.,Ladiratuzumab vedotin
DB15415,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tomaralimab.,Tomaralimab
DB15428,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vesencumab.,Vesencumab
DB15432,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pinatuzumab vedotin.,Pinatuzumab vedotin
DB15441,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lulizumab pegol.,Lulizumab pegol
DB15443,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lorukafusp alfa.,Lorukafusp alfa
DB15453,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Naratuximab emtansine.,Naratuximab emtansine
DB14004,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tildrakizumab.,Tildrakizumab
DB05679,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ustekinumab.,Ustekinumab
DB15559,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Zenocutuzumab.,Zenocutuzumab
DB00039,The therapeutic efficacy of Palifermin can be decreased when used in combination with Ibritumomab tiuxetan.,Palifermin
DB00001,The risk or severity of bleeding can be increased when Lepirudin is combined with Ibritumomab tiuxetan.,Lepirudin
DB00006,The risk or severity of bleeding can be increased when Bivalirudin is combined with Ibritumomab tiuxetan.,Bivalirudin
DB00009,The risk or severity of bleeding can be increased when Alteplase is combined with Ibritumomab tiuxetan.,Alteplase
DB00013,The risk or severity of bleeding can be increased when Urokinase is combined with Ibritumomab tiuxetan.,Urokinase
DB00015,The risk or severity of bleeding can be increased when Reteplase is combined with Ibritumomab tiuxetan.,Reteplase
DB00029,The risk or severity of bleeding can be increased when Anistreplase is combined with Ibritumomab tiuxetan.,Anistreplase
DB00031,The risk or severity of bleeding can be increased when Tenecteplase is combined with Ibritumomab tiuxetan.,Tenecteplase
DB00055,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Ibritumomab tiuxetan.,Drotrecogin alfa
DB00086,The risk or severity of bleeding can be increased when Streptokinase is combined with Ibritumomab tiuxetan.,Streptokinase
DB00278,The risk or severity of bleeding can be increased when Argatroban is combined with Ibritumomab tiuxetan.,Argatroban
DB00569,The risk or severity of bleeding can be increased when Fondaparinux is combined with Ibritumomab tiuxetan.,Fondaparinux
DB01109,The risk or severity of bleeding can be increased when Heparin is combined with Ibritumomab tiuxetan.,Heparin
DB01225,The risk or severity of bleeding can be increased when Enoxaparin is combined with Ibritumomab tiuxetan.,Enoxaparin
DB05099,The risk or severity of bleeding can be increased when Ancrod is combined with Ibritumomab tiuxetan.,Ancrod
DB06754,The risk or severity of bleeding can be increased when Danaparoid is combined with Ibritumomab tiuxetan.,Danaparoid
DB06779,The risk or severity of bleeding can be increased when Dalteparin is combined with Ibritumomab tiuxetan.,Dalteparin
DB06822,The risk or severity of bleeding can be increased when Tinzaparin is combined with Ibritumomab tiuxetan.,Tinzaparin
DB08813,The risk or severity of bleeding can be increased when Nadroparin is combined with Ibritumomab tiuxetan.,Nadroparin
DB09255,The risk or severity of bleeding can be increased when Dextran is combined with Ibritumomab tiuxetan.,Dextran
DB11095,The risk or severity of bleeding can be increased when Desirudin is combined with Ibritumomab tiuxetan.,Desirudin
DB11166,The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Ibritumomab tiuxetan.,Antithrombin Alfa
DB11312,The risk or severity of bleeding can be increased when Protein C is combined with Ibritumomab tiuxetan.,Protein C
DB11598,The risk or severity of bleeding can be increased when Antithrombin III human is combined with Ibritumomab tiuxetan.,Antithrombin III human
DB13149,The risk or severity of bleeding can be increased when Protein S human is combined with Ibritumomab tiuxetan.,Protein S human
DB14598,The risk or severity of bleeding can be increased when Edetate calcium disodium anhydrous is combined with Ibritumomab tiuxetan.,Edetate calcium disodium anhydrous
DB00232,The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Ibritumomab tiuxetan.,Methyclothiazide
DB00436,The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Ibritumomab tiuxetan.,Bendroflumethiazide
DB00562,The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Ibritumomab tiuxetan.,Benzthiazide
DB00606,The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Ibritumomab tiuxetan.,Cyclothiazide
DB00774,The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Ibritumomab tiuxetan.,Hydroflumethiazide
DB00880,The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Ibritumomab tiuxetan.,Chlorothiazide
DB00999,The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Ibritumomab tiuxetan.,Hydrochlorothiazide
DB01021,The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Ibritumomab tiuxetan.,Trichlormethiazide
DB01324,The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Ibritumomab tiuxetan.,Polythiazide
DB13430,The risk or severity of neutropenia and thrombocytopenia can be increased when Mebutizide is combined with Ibritumomab tiuxetan.,Mebutizide
DB13532,The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Ibritumomab tiuxetan.,Cyclopenthiazide
DB09042,The risk or severity of myelosuppression can be increased when Ibritumomab tiuxetan is combined with Tedizolid phosphate.,Tedizolid phosphate
DB00091,Ibritumomab tiuxetan may increase the immunosuppressive activities of Cyclosporine.,Cyclosporine
DB00115,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Ibritumomab tiuxetan.,Cyanocobalamin
DB00437,The risk or severity of adverse effects can be increased when Allopurinol is combined with Ibritumomab tiuxetan.,Allopurinol
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Ibritumomab tiuxetan.","Ebola Zaire vaccine (live, attenuated)"
DB14513,The serum concentration of Magnesium can be decreased when it is combined with Ibritumomab tiuxetan.,Magnesium
DB01601,The serum concentration of Ibritumomab tiuxetan can be increased when it is combined with Lopinavir.,Lopinavir
DB12530,The risk or severity of infection can be increased when Ibritumomab tiuxetan is combined with Inebilizumab.,Inebilizumab
DB00175,The risk or severity of myopathy can be increased when Pravastatin is combined with Daptomycin.,Pravastatin
DB00227,The risk or severity of myopathy can be increased when Lovastatin is combined with Daptomycin.,Lovastatin
DB00439,The risk or severity of myopathy can be increased when Cerivastatin is combined with Daptomycin.,Cerivastatin
DB00641,The risk or severity of myopathy can be increased when Simvastatin is combined with Daptomycin.,Simvastatin
DB01076,The risk or severity of myopathy can be increased when Atorvastatin is combined with Daptomycin.,Atorvastatin
DB01095,The risk or severity of myopathy can be increased when Fluvastatin is combined with Daptomycin.,Fluvastatin
DB01098,The risk or severity of myopathy can be increased when Rosuvastatin is combined with Daptomycin.,Rosuvastatin
DB06693,The risk or severity of myopathy can be increased when Mevastatin is combined with Daptomycin.,Mevastatin
DB08860,The risk or severity of myopathy can be increased when Pitavastatin is combined with Daptomycin.,Pitavastatin
DB12768,The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Daptomycin.,BCG vaccine
DB14022,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Daptomycin.,Typhoid vaccine
DB00091,Cyclosporine may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cyclosporine
DB00159,Icosapent may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Icosapent
DB00229,Cefotiam may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefotiam
DB00244,Mesalazine may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Mesalazine
DB00267,Cefmenoxime may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefmenoxime
DB00274,Cefmetazole may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefmetazole
DB00282,Pamidronic acid may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Pamidronic acid
DB00300,Tenofovir disoproxil may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Tenofovir disoproxil
DB00328,Indomethacin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Indomethacin
DB00369,Cidofovir may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cidofovir
DB00384,Triamterene may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Triamterene
DB00430,Cefpiramide may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefpiramide
DB00438,Ceftazidime may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Ceftazidime
DB00447,Loracarbef may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Loracarbef
DB00456,Cefalotin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefalotin
DB00461,Nabumetone may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Nabumetone
DB00465,Ketorolac may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Ketorolac
DB00469,Tenoxicam may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Tenoxicam
DB00482,Celecoxib may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Celecoxib
DB00493,Cefotaxime may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefotaxime
DB00500,Tolmetin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Tolmetin
DB00529,Foscarnet may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Foscarnet
DB00533,Rofecoxib may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Rofecoxib
DB00554,Piroxicam may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Piroxicam
DB00563,Methotrexate may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Methotrexate
DB00567,Cephalexin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cephalexin
DB00573,Fenoprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Fenoprofen
DB00577,Valaciclovir may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Valaciclovir
DB00580,Valdecoxib may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Valdecoxib
DB00586,Diclofenac may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Diclofenac
DB00605,Sulindac may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Sulindac
DB00626,Bacitracin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Bacitracin
DB00681,Amphotericin B may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Amphotericin B
DB00689,Cephaloglycin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cephaloglycin
DB00712,Flurbiprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Flurbiprofen
DB00718,Adefovir dipivoxil may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Adefovir dipivoxil
DB00738,Pentamidine may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Pentamidine
DB00742,Mannitol may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Mannitol
DB00749,Etodolac may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Etodolac
DB00784,Mefenamic acid may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Mefenamic acid
DB00787,Acyclovir may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Acyclovir
DB00788,Naproxen may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Naproxen
DB00795,Sulfasalazine may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Sulfasalazine
DB00812,Phenylbutazone may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Phenylbutazone
DB00814,Meloxicam may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Meloxicam
DB00821,Carprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Carprofen
DB00833,Cefaclor may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefaclor
DB00861,Diflunisal may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Diflunisal
DB00864,Tacrolimus may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Tacrolimus
DB00903,Etacrynic acid may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Etacrynic acid
DB00923,Ceforanide may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Ceforanide
DB00936,Salicylic acid may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Salicylic acid
DB00939,Meclofenamic acid may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Meclofenamic acid
DB00945,Acetylsalicylic acid may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Acetylsalicylic acid
DB00958,Carboplatin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Carboplatin
DB00991,Oxaprozin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Oxaprozin
DB00999,Hydrochlorothiazide may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Hydrochlorothiazide
DB01009,Ketoprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Ketoprofen
DB01014,Balsalazide may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Balsalazide
DB01050,Ibuprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Ibuprofen
DB01066,Cefditoren may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefditoren
DB01072,Atazanavir may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Atazanavir
DB01111,Colistimethate may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Colistimethate
DB01112,Cefuroxime may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefuroxime
DB01139,Cefapirin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefapirin
DB01140,Cefadroxil may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefadroxil
DB01150,Cefprozil may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefprozil
DB01212,Ceftriaxone may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Ceftriaxone
DB01250,Olsalazine may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Olsalazine
DB01283,Lumiracoxib may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Lumiracoxib
DB01326,Cefamandole may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefamandole
DB01327,Cefazolin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefazolin
DB01328,Cefonicid may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefonicid
DB01329,Cefoperazone may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefoperazone
DB01330,Cefotetan may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefotetan
DB01331,Cefoxitin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefoxitin
DB01332,Ceftizoxime may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Ceftizoxime
DB01333,Cefradine may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefradine
DB01397,Magnesium salicylate may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Magnesium salicylate
DB01399,Salsalate may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Salsalate
DB01401,Choline magnesium trisalicylate may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Choline magnesium trisalicylate
DB01413,Cefepime may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefepime
DB01414,Cefacetrile may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefacetrile
DB01415,Ceftibuten may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Ceftibuten
DB01416,Cefpodoxime may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefpodoxime
DB01419,Antrafenine may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Antrafenine
DB01424,Aminophenazone may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Aminophenazone
DB01435,Antipyrine may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Antipyrine
DB01600,Tiaprofenic acid may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Tiaprofenic acid
DB01601,Lopinavir may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Lopinavir
DB01628,Etoricoxib may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Etoricoxib
DB02247,Hydrolyzed Cephalothin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Hydrolyzed Cephalothin
DB03450,Cephalothin Group may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cephalothin Group
DB03585,Oxyphenbutazone may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Oxyphenbutazone
DB04552,Niflumic acid may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Niflumic acid
DB04570,Latamoxef may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Latamoxef
DB04743,Nimesulide may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Nimesulide
DB04812,Benoxaprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Benoxaprofen
DB04817,Metamizole may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Metamizole
DB04828,Zomepirac may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Zomepirac
DB04918,Ceftobiprole may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Ceftobiprole
DB05095,Cimicoxib may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cimicoxib
DB06590,Ceftaroline fosamil may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Ceftaroline fosamil
DB06725,Lornoxicam may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Lornoxicam
DB06736,Aceclofenac may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Aceclofenac
DB06737,Zaltoprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Zaltoprofen
DB07402,Azapropazone may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Azapropazone
DB07477,Felbinac may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Felbinac
DB08439,Parecoxib may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Parecoxib
DB08797,Salicylamide may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Salicylamide
DB08940,Kebuzone may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Kebuzone
DB08942,Isoxicam may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Isoxicam
DB08951,Indoprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Indoprofen
DB08955,Ibuproxam may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Ibuproxam
DB08976,Floctafenine may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Floctafenine
DB08981,Fenbufen may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Fenbufen
DB08984,Etofenamate may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Etofenamate
DB08991,Epirizole may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Epirizole
DB09008,Cefaloridine may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefaloridine
DB09062,Cefminox may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefminox
DB09084,Benzydamine may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Benzydamine
DB09212,Loxoprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Loxoprofen
DB09213,Dexibuprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Dexibuprofen
DB09214,Dexketoprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Dexketoprofen
DB09215,Droxicam may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Droxicam
DB09216,Tolfenamic acid may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Tolfenamic acid
DB09217,Firocoxib may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Firocoxib
DB09218,Clonixin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Clonixin
DB09285,Morniflumate may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Morniflumate
DB09288,Propacetamol may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Propacetamol
DB09295,Talniflumate may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Talniflumate
DB09299,Tenofovir alafenamide may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Tenofovir alafenamide
DB11367,Cefroxadine may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefroxadine
DB11455,Robenacoxib may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Robenacoxib
DB11466,Tepoxalin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Tepoxalin
DB11518,Flunixin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Flunixin
DB11935,Flomoxef may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Flomoxef
DB12151,Brincidofovir may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Brincidofovir
DB12445,Nitroaspirin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Nitroaspirin
DB12545,Indobufen may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Indobufen
DB13001,Tinoridine may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Tinoridine
DB13167,Alclofenac may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Alclofenac
DB13217,Fentiazac may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Fentiazac
DB13232,Suxibuzone may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Suxibuzone
DB13266,Cefatrizine may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefatrizine
DB13286,Bumadizone may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Bumadizone
DB13314,Alminoprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Alminoprofen
DB13317,Flunoxaprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Flunoxaprofen
DB13364,Feprazone may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Feprazone
DB13371,Difenpiramide may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Difenpiramide
DB13407,Nifenazone may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Nifenazone
DB13432,Lonazolac may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Lonazolac
DB13461,Cefcapene may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefcapene
DB13470,Cefodizime may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefodizime
DB13481,Tenidap may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Tenidap
DB13499,Cefsulodin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefsulodin
DB13501,Bendazac may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Bendazac
DB13504,Cefetamet may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefetamet
DB13514,Pranoprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Pranoprofen
DB13524,Propyphenazone may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Propyphenazone
DB13527,Proglumetacin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Proglumetacin
DB13538,Guacetisal may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Guacetisal
DB13544,Ethenzamide may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Ethenzamide
DB13612,Carbaspirin calcium may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Carbaspirin calcium
DB13629,Mofebutazone may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Mofebutazone
DB13638,Cefbuperazone may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefbuperazone
DB13649,Proquazone may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Proquazone
DB13657,Benorilate may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Benorilate
DB13667,Cefozopran may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefozopran
DB13682,Cefpirome may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefpirome
DB13722,Pirprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Pirprofen
DB13778,Cefazedone may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Cefazedone
DB13783,Acemetacin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Acemetacin
DB13821,Ceftezole may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Ceftezole
DB13860,Imidazole salicylate may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Imidazole salicylate
DB13868,Adefovir may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Adefovir
DB14059,SC-236 may decrease the excretion rate of Daptomycin which could result in a higher serum level.,SC-236
DB14060,NS-398 may decrease the excretion rate of Daptomycin which could result in a higher serum level.,NS-398
DB14126,Tenofovir may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Tenofovir
DB14713,Inotersen may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Inotersen
DB01438,Phenazopyridine may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Phenazopyridine
DB15066,Givosiran may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Givosiran
DB01356,Lithium cation may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Lithium cation
DB14507,Lithium citrate may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Lithium citrate
DB00014,Goserelin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Goserelin
DB00017,Salmon calcitonin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Salmon calcitonin
DB00035,Desmopressin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Desmopressin
DB00041,Aldesleukin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Aldesleukin
DB00081,Daptomycin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Tositumomab
DB00115,Daptomycin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cyanocobalamin
DB00158,Daptomycin may decrease the excretion rate of Folic acid which could result in a higher serum level.,Folic acid
DB00165,Daptomycin may decrease the excretion rate of Pyridoxine which could result in a higher serum level.,Pyridoxine
DB00176,Daptomycin may decrease the excretion rate of Fluvoxamine which could result in a higher serum level.,Fluvoxamine
DB00182,Daptomycin may decrease the excretion rate of Amphetamine which could result in a higher serum level.,Amphetamine
DB00185,Daptomycin may decrease the excretion rate of Cevimeline which could result in a higher serum level.,Cevimeline
DB00186,Daptomycin may decrease the excretion rate of Lorazepam which could result in a higher serum level.,Lorazepam
DB00190,Daptomycin may decrease the excretion rate of Carbidopa which could result in a higher serum level.,Carbidopa
DB00193,Daptomycin may decrease the excretion rate of Tramadol which could result in a higher serum level.,Tramadol
DB00196,Daptomycin may decrease the excretion rate of Fluconazole which could result in a higher serum level.,Fluconazole
DB00198,Daptomycin may decrease the excretion rate of Oseltamivir which could result in a higher serum level.,Oseltamivir
DB00200,Daptomycin may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level.,Hydroxocobalamin
DB00206,Daptomycin may decrease the excretion rate of Reserpine which could result in a higher serum level.,Reserpine
DB00208,Daptomycin may decrease the excretion rate of Ticlopidine which could result in a higher serum level.,Ticlopidine
DB00213,Daptomycin may decrease the excretion rate of Pantoprazole which could result in a higher serum level.,Pantoprazole
DB00225,Daptomycin may decrease the excretion rate of Gadodiamide which could result in a higher serum level.,Gadodiamide
DB00230,Daptomycin may decrease the excretion rate of Pregabalin which could result in a higher serum level.,Pregabalin
DB00231,Daptomycin may decrease the excretion rate of Temazepam which could result in a higher serum level.,Temazepam
DB00235,Daptomycin may decrease the excretion rate of Milrinone which could result in a higher serum level.,Milrinone
DB00237,Daptomycin may decrease the excretion rate of Butabarbital which could result in a higher serum level.,Butabarbital
DB00243,Daptomycin may decrease the excretion rate of Ranolazine which could result in a higher serum level.,Ranolazine
DB00245,Daptomycin may decrease the excretion rate of Benzatropine which could result in a higher serum level.,Benzatropine
DB00254,Daptomycin may decrease the excretion rate of Doxycycline which could result in a higher serum level.,Doxycycline
DB00262,Daptomycin may decrease the excretion rate of Carmustine which could result in a higher serum level.,Carmustine
DB00264,Daptomycin may decrease the excretion rate of Metoprolol which could result in a higher serum level.,Metoprolol
DB00270,Daptomycin may decrease the excretion rate of Isradipine which could result in a higher serum level.,Isradipine
DB00271,Daptomycin may decrease the excretion rate of Diatrizoate which could result in a higher serum level.,Diatrizoate
DB00273,Daptomycin may decrease the excretion rate of Topiramate which could result in a higher serum level.,Topiramate
DB00279,Daptomycin may decrease the excretion rate of Liothyronine which could result in a higher serum level.,Liothyronine
DB00280,Daptomycin may decrease the excretion rate of Disopyramide which could result in a higher serum level.,Disopyramide
DB00284,Daptomycin may decrease the excretion rate of Acarbose which could result in a higher serum level.,Acarbose
DB00285,Daptomycin may decrease the excretion rate of Venlafaxine which could result in a higher serum level.,Venlafaxine
DB00286,Daptomycin may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level.,Conjugated estrogens
DB00289,Daptomycin may decrease the excretion rate of Atomoxetine which could result in a higher serum level.,Atomoxetine
DB00290,Daptomycin may decrease the excretion rate of Bleomycin which could result in a higher serum level.,Bleomycin
DB00292,Daptomycin may decrease the excretion rate of Etomidate which could result in a higher serum level.,Etomidate
DB00294,Daptomycin may decrease the excretion rate of Etonogestrel which could result in a higher serum level.,Etonogestrel
DB00296,Daptomycin may decrease the excretion rate of Ropivacaine which could result in a higher serum level.,Ropivacaine
DB00303,Daptomycin may decrease the excretion rate of Ertapenem which could result in a higher serum level.,Ertapenem
DB00308,Daptomycin may decrease the excretion rate of Ibutilide which could result in a higher serum level.,Ibutilide
DB00312,Daptomycin may decrease the excretion rate of Pentobarbital which could result in a higher serum level.,Pentobarbital
DB00316,Daptomycin may decrease the excretion rate of Acetaminophen which could result in a higher serum level.,Acetaminophen
DB00319,Daptomycin may decrease the excretion rate of Piperacillin which could result in a higher serum level.,Piperacillin
DB00322,Daptomycin may decrease the excretion rate of Floxuridine which could result in a higher serum level.,Floxuridine
DB00323,Daptomycin may decrease the excretion rate of Tolcapone which could result in a higher serum level.,Tolcapone
DB00325,Daptomycin may decrease the excretion rate of Nitroprusside which could result in a higher serum level.,Nitroprusside
DB00327,Daptomycin may decrease the excretion rate of Hydromorphone which could result in a higher serum level.,Hydromorphone
DB00330,Daptomycin may decrease the excretion rate of Ethambutol which could result in a higher serum level.,Ethambutol
DB00331,Daptomycin may decrease the excretion rate of Metformin which could result in a higher serum level.,Metformin
DB00333,Daptomycin may decrease the excretion rate of Methadone which could result in a higher serum level.,Methadone
DB00339,Daptomycin may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.,Pyrazinamide
DB00341,Daptomycin may decrease the excretion rate of Cetirizine which could result in a higher serum level.,Cetirizine
DB00349,Daptomycin may decrease the excretion rate of Clobazam which could result in a higher serum level.,Clobazam
DB00351,Daptomycin may decrease the excretion rate of Megestrol acetate which could result in a higher serum level.,Megestrol acetate
DB00355,Daptomycin may decrease the excretion rate of Aztreonam which could result in a higher serum level.,Aztreonam
DB00356,Daptomycin may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level.,Chlorzoxazone
DB00359,Daptomycin may decrease the excretion rate of Sulfadiazine which could result in a higher serum level.,Sulfadiazine
DB00363,Daptomycin may decrease the excretion rate of Clozapine which could result in a higher serum level.,Clozapine
DB00364,Daptomycin may decrease the excretion rate of Sucralfate which could result in a higher serum level.,Sucralfate
DB00372,Daptomycin may decrease the excretion rate of Thiethylperazine which could result in a higher serum level.,Thiethylperazine
DB00373,Daptomycin may decrease the excretion rate of Timolol which could result in a higher serum level.,Timolol
DB00377,Daptomycin may decrease the excretion rate of Palonosetron which could result in a higher serum level.,Palonosetron
DB00380,Daptomycin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.,Dexrazoxane
DB00398,Daptomycin may decrease the excretion rate of Sorafenib which could result in a higher serum level.,Sorafenib
DB00401,Daptomycin may decrease the excretion rate of Nisoldipine which could result in a higher serum level.,Nisoldipine
DB00402,Daptomycin may decrease the excretion rate of Eszopiclone which could result in a higher serum level.,Eszopiclone
DB00404,Daptomycin may decrease the excretion rate of Alprazolam which could result in a higher serum level.,Alprazolam
DB00412,Daptomycin may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.,Rosiglitazone
DB00413,Daptomycin may decrease the excretion rate of Pramipexole which could result in a higher serum level.,Pramipexole
DB00415,Daptomycin may decrease the excretion rate of Ampicillin which could result in a higher serum level.,Ampicillin
DB00418,Daptomycin may decrease the excretion rate of Secobarbital which could result in a higher serum level.,Secobarbital
DB00422,Daptomycin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.,Methylphenidate
DB00432,Daptomycin may decrease the excretion rate of Trifluridine which could result in a higher serum level.,Trifluridine
DB00435,Daptomycin may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.,Nitric Oxide
DB00437,Daptomycin may decrease the excretion rate of Allopurinol which could result in a higher serum level.,Allopurinol
DB00441,Daptomycin may decrease the excretion rate of Gemcitabine which could result in a higher serum level.,Gemcitabine
DB00476,Daptomycin may decrease the excretion rate of Duloxetine which could result in a higher serum level.,Duloxetine
DB00477,Daptomycin may decrease the excretion rate of Chlorpromazine which could result in a higher serum level.,Chlorpromazine
DB00480,Daptomycin may decrease the excretion rate of Lenalidomide which could result in a higher serum level.,Lenalidomide
DB00490,Daptomycin may decrease the excretion rate of Buspirone which could result in a higher serum level.,Buspirone
DB00492,Daptomycin may decrease the excretion rate of Fosinopril which could result in a higher serum level.,Fosinopril
DB00499,Daptomycin may decrease the excretion rate of Flutamide which could result in a higher serum level.,Flutamide
DB00502,Daptomycin may decrease the excretion rate of Haloperidol which could result in a higher serum level.,Haloperidol
DB00535,Daptomycin may decrease the excretion rate of Cefdinir which could result in a higher serum level.,Cefdinir
DB00548,Daptomycin may decrease the excretion rate of Azelaic acid which could result in a higher serum level.,Azelaic acid
DB00553,Daptomycin may decrease the excretion rate of Methoxsalen which could result in a higher serum level.,Methoxsalen
DB00555,Daptomycin may decrease the excretion rate of Lamotrigine which could result in a higher serum level.,Lamotrigine
DB00558,Daptomycin may decrease the excretion rate of Zanamivir which could result in a higher serum level.,Zanamivir
DB00569,Daptomycin may decrease the excretion rate of Fondaparinux which could result in a higher serum level.,Fondaparinux
DB00571,Daptomycin may decrease the excretion rate of Propranolol which could result in a higher serum level.,Propranolol
DB00583,Daptomycin may decrease the excretion rate of Levocarnitine which could result in a higher serum level.,Levocarnitine
DB00591,Daptomycin may decrease the excretion rate of Fluocinolone acetonide which could result in a higher serum level.,Fluocinolone acetonide
DB00597,Daptomycin may decrease the excretion rate of Gadoteridol which could result in a higher serum level.,Gadoteridol
DB00598,Daptomycin may decrease the excretion rate of Labetalol which could result in a higher serum level.,Labetalol
DB00603,Daptomycin may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.,Medroxyprogesterone acetate
DB00612,Daptomycin may decrease the excretion rate of Bisoprolol which could result in a higher serum level.,Bisoprolol
DB00624,Daptomycin may decrease the excretion rate of Testosterone which could result in a higher serum level.,Testosterone
DB00628,Daptomycin may decrease the excretion rate of Clorazepic acid which could result in a higher serum level.,Clorazepic acid
DB00631,Daptomycin may decrease the excretion rate of Clofarabine which could result in a higher serum level.,Clofarabine
DB00633,Daptomycin may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level.,Dexmedetomidine
DB00635,Daptomycin may decrease the excretion rate of Prednisone which could result in a higher serum level.,Prednisone
DB00651,Daptomycin may decrease the excretion rate of Dyphylline which could result in a higher serum level.,Dyphylline
DB00657,Daptomycin may decrease the excretion rate of Mecamylamine which could result in a higher serum level.,Mecamylamine
DB00660,Daptomycin may decrease the excretion rate of Metaxalone which could result in a higher serum level.,Metaxalone
DB00661,Daptomycin may decrease the excretion rate of Verapamil which could result in a higher serum level.,Verapamil
DB00665,Daptomycin may decrease the excretion rate of Nilutamide which could result in a higher serum level.,Nilutamide
DB00669,Daptomycin may decrease the excretion rate of Sumatriptan which could result in a higher serum level.,Sumatriptan
DB00672,Daptomycin may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.,Chlorpropamide
DB00683,Daptomycin may decrease the excretion rate of Midazolam which could result in a higher serum level.,Midazolam
DB00690,Daptomycin may decrease the excretion rate of Flurazepam which could result in a higher serum level.,Flurazepam
DB00692,Daptomycin may decrease the excretion rate of Phentolamine which could result in a higher serum level.,Phentolamine
DB00698,Daptomycin may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.,Nitrofurantoin
DB00706,Daptomycin may decrease the excretion rate of Tamsulosin which could result in a higher serum level.,Tamsulosin
DB00713,Daptomycin may decrease the excretion rate of Oxacillin which could result in a higher serum level.,Oxacillin
DB00716,Daptomycin may decrease the excretion rate of Nedocromil which could result in a higher serum level.,Nedocromil
DB00722,Daptomycin may decrease the excretion rate of Lisinopril which could result in a higher serum level.,Lisinopril
DB00730,Daptomycin may decrease the excretion rate of Thiabendazole which could result in a higher serum level.,Thiabendazole
DB00731,Daptomycin may decrease the excretion rate of Nateglinide which could result in a higher serum level.,Nateglinide
DB00733,Daptomycin may decrease the excretion rate of Pralidoxime which could result in a higher serum level.,Pralidoxime
DB00743,Daptomycin may decrease the excretion rate of Gadobenic acid which could result in a higher serum level.,Gadobenic acid
DB00759,Daptomycin may decrease the excretion rate of Tetracycline which could result in a higher serum level.,Tetracycline
DB00760,Daptomycin may decrease the excretion rate of Meropenem which could result in a higher serum level.,Meropenem
DB00761,Daptomycin may decrease the excretion rate of Potassium chloride which could result in a higher serum level.,Potassium chloride
DB00763,Daptomycin may decrease the excretion rate of Methimazole which could result in a higher serum level.,Methimazole
DB00775,Daptomycin may decrease the excretion rate of Tirofiban which could result in a higher serum level.,Tirofiban
DB00780,Daptomycin may decrease the excretion rate of Phenelzine which could result in a higher serum level.,Phenelzine
DB00782,Daptomycin may decrease the excretion rate of Propantheline which could result in a higher serum level.,Propantheline
DB00783,Daptomycin may decrease the excretion rate of Estradiol which could result in a higher serum level.,Estradiol
DB00789,Daptomycin may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level.,Gadopentetic acid
DB00790,Daptomycin may decrease the excretion rate of Perindopril which could result in a higher serum level.,Perindopril
DB00800,Daptomycin may decrease the excretion rate of Fenoldopam which could result in a higher serum level.,Fenoldopam
DB00804,Daptomycin may decrease the excretion rate of Dicyclomine which could result in a higher serum level.,Dicyclomine
DB00806,Daptomycin may decrease the excretion rate of Pentoxifylline which could result in a higher serum level.,Pentoxifylline
DB00811,Daptomycin may decrease the excretion rate of Ribavirin which could result in a higher serum level.,Ribavirin
DB00820,Daptomycin may decrease the excretion rate of Tadalafil which could result in a higher serum level.,Tadalafil
DB00828,Daptomycin may decrease the excretion rate of Fosfomycin which could result in a higher serum level.,Fosfomycin
DB00829,Daptomycin may decrease the excretion rate of Diazepam which could result in a higher serum level.,Diazepam
DB00839,Daptomycin may decrease the excretion rate of Tolazamide which could result in a higher serum level.,Tolazamide
DB00841,Daptomycin may decrease the excretion rate of Dobutamine which could result in a higher serum level.,Dobutamine
DB00842,Daptomycin may decrease the excretion rate of Oxazepam which could result in a higher serum level.,Oxazepam
DB00851,Daptomycin may decrease the excretion rate of Dacarbazine which could result in a higher serum level.,Dacarbazine
DB00853,Daptomycin may decrease the excretion rate of Temozolomide which could result in a higher serum level.,Temozolomide
DB00871,Daptomycin may decrease the excretion rate of Terbutaline which could result in a higher serum level.,Terbutaline
DB00894,Daptomycin may decrease the excretion rate of Testolactone which could result in a higher serum level.,Testolactone
DB00900,Daptomycin may decrease the excretion rate of Didanosine which could result in a higher serum level.,Didanosine
DB00911,Daptomycin may decrease the excretion rate of Tinidazole which could result in a higher serum level.,Tinidazole
DB00915,Daptomycin may decrease the excretion rate of Amantadine which could result in a higher serum level.,Amantadine
DB00918,Daptomycin may decrease the excretion rate of Almotriptan which could result in a higher serum level.,Almotriptan
DB00928,Daptomycin may decrease the excretion rate of Azacitidine which could result in a higher serum level.,Azacitidine
DB00934,Daptomycin may decrease the excretion rate of Maprotiline which could result in a higher serum level.,Maprotiline
DB00953,Daptomycin may decrease the excretion rate of Rizatriptan which could result in a higher serum level.,Rizatriptan
DB00960,Daptomycin may decrease the excretion rate of Pindolol which could result in a higher serum level.,Pindolol
DB00961,Daptomycin may decrease the excretion rate of Mepivacaine which could result in a higher serum level.,Mepivacaine
DB00962,Daptomycin may decrease the excretion rate of Zaleplon which could result in a higher serum level.,Zaleplon
DB00980,Daptomycin may decrease the excretion rate of Ramelteon which could result in a higher serum level.,Ramelteon
DB00988,Daptomycin may decrease the excretion rate of Dopamine which could result in a higher serum level.,Dopamine
DB00993,Daptomycin may decrease the excretion rate of Azathioprine which could result in a higher serum level.,Azathioprine
DB00995,Daptomycin may decrease the excretion rate of Auranofin which could result in a higher serum level.,Auranofin
DB01001,Daptomycin may decrease the excretion rate of Salbutamol which could result in a higher serum level.,Salbutamol
DB01002,Daptomycin may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.,Levobupivacaine
DB01010,Daptomycin may decrease the excretion rate of Edrophonium which could result in a higher serum level.,Edrophonium
DB01011,Daptomycin may decrease the excretion rate of Metyrapone which could result in a higher serum level.,Metyrapone
DB01018,Daptomycin may decrease the excretion rate of Guanfacine which could result in a higher serum level.,Guanfacine
DB01020,Daptomycin may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.,Isosorbide mononitrate
DB01022,Daptomycin may decrease the excretion rate of Phylloquinone which could result in a higher serum level.,Phylloquinone
DB01024,Daptomycin may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.,Mycophenolic acid
DB01030,Daptomycin may decrease the excretion rate of Topotecan which could result in a higher serum level.,Topotecan
DB01032,Daptomycin may decrease the excretion rate of Probenecid which could result in a higher serum level.,Probenecid
DB01036,Daptomycin may decrease the excretion rate of Tolterodine which could result in a higher serum level.,Tolterodine
DB01043,Daptomycin may decrease the excretion rate of Memantine which could result in a higher serum level.,Memantine
DB01046,Daptomycin may decrease the excretion rate of Lubiprostone which could result in a higher serum level.,Lubiprostone
DB01048,Daptomycin may decrease the excretion rate of Abacavir which could result in a higher serum level.,Abacavir
DB01060,Daptomycin may decrease the excretion rate of Amoxicillin which could result in a higher serum level.,Amoxicillin
DB01067,Daptomycin may decrease the excretion rate of Glipizide which could result in a higher serum level.,Glipizide
DB01068,Daptomycin may decrease the excretion rate of Clonazepam which could result in a higher serum level.,Clonazepam
DB01069,Daptomycin may decrease the excretion rate of Promethazine which could result in a higher serum level.,Promethazine
DB01093,Daptomycin may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.,Dimethyl sulfoxide
DB01099,Daptomycin may decrease the excretion rate of Flucytosine which could result in a higher serum level.,Flucytosine
DB01101,Daptomycin may decrease the excretion rate of Capecitabine which could result in a higher serum level.,Capecitabine
DB01105,Daptomycin may decrease the excretion rate of Sibutramine which could result in a higher serum level.,Sibutramine
DB01115,Daptomycin may decrease the excretion rate of Nifedipine which could result in a higher serum level.,Nifedipine
DB01124,Daptomycin may decrease the excretion rate of Tolbutamide which could result in a higher serum level.,Tolbutamide
DB01129,Daptomycin may decrease the excretion rate of Rabeprazole which could result in a higher serum level.,Rabeprazole
DB01133,Daptomycin may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.,Tiludronic acid
DB01135,Daptomycin may decrease the excretion rate of Doxacurium which could result in a higher serum level.,Doxacurium
DB01137,Daptomycin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.,Levofloxacin
DB01148,Daptomycin may decrease the excretion rate of Flavoxate which could result in a higher serum level.,Flavoxate
DB01149,Daptomycin may decrease the excretion rate of Nefazodone which could result in a higher serum level.,Nefazodone
DB01156,Daptomycin may decrease the excretion rate of Bupropion which could result in a higher serum level.,Bupropion
DB01157,Daptomycin may decrease the excretion rate of Trimetrexate which could result in a higher serum level.,Trimetrexate
DB01166,Daptomycin may decrease the excretion rate of Cilostazol which could result in a higher serum level.,Cilostazol
DB01169,Daptomycin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.,Arsenic trioxide
DB01170,Daptomycin may decrease the excretion rate of Guanethidine which could result in a higher serum level.,Guanethidine
DB01181,Daptomycin may decrease the excretion rate of Ifosfamide which could result in a higher serum level.,Ifosfamide
DB01183,Daptomycin may decrease the excretion rate of Naloxone which could result in a higher serum level.,Naloxone
DB01203,Daptomycin may decrease the excretion rate of Nadolol which could result in a higher serum level.,Nadolol
DB01205,Daptomycin may decrease the excretion rate of Flumazenil which could result in a higher serum level.,Flumazenil
DB01213,Daptomycin may decrease the excretion rate of Fomepizole which could result in a higher serum level.,Fomepizole
DB01215,Daptomycin may decrease the excretion rate of Estazolam which could result in a higher serum level.,Estazolam
DB01221,Daptomycin may decrease the excretion rate of Ketamine which could result in a higher serum level.,Ketamine
DB01222,Daptomycin may decrease the excretion rate of Budesonide which could result in a higher serum level.,Budesonide
DB01224,Daptomycin may decrease the excretion rate of Quetiapine which could result in a higher serum level.,Quetiapine
DB01240,Daptomycin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.,Epoprostenol
DB01249,Daptomycin may decrease the excretion rate of Iodixanol which could result in a higher serum level.,Iodixanol
DB01261,Daptomycin may decrease the excretion rate of Sitagliptin which could result in a higher serum level.,Sitagliptin
DB01267,Daptomycin may decrease the excretion rate of Paliperidone which could result in a higher serum level.,Paliperidone
DB01273,Daptomycin may decrease the excretion rate of Varenicline which could result in a higher serum level.,Varenicline
DB01274,Daptomycin may decrease the excretion rate of Arformoterol which could result in a higher serum level.,Arformoterol
DB01275,Daptomycin may decrease the excretion rate of Hydralazine which could result in a higher serum level.,Hydralazine
DB01359,Daptomycin may decrease the excretion rate of Penbutolol which could result in a higher serum level.,Penbutolol
DB01367,Daptomycin may decrease the excretion rate of Rasagiline which could result in a higher serum level.,Rasagiline
DB01409,Daptomycin may decrease the excretion rate of Tiotropium which could result in a higher serum level.,Tiotropium
DB01420,Daptomycin may decrease the excretion rate of Testosterone propionate which could result in a higher serum level.,Testosterone propionate
DB01427,Daptomycin may decrease the excretion rate of Amrinone which could result in a higher serum level.,Amrinone
DB01428,Daptomycin may decrease the excretion rate of Oxybenzone which could result in a higher serum level.,Oxybenzone
DB01431,Daptomycin may decrease the excretion rate of Allylestrenol which could result in a higher serum level.,Allylestrenol
DB01550,Daptomycin may decrease the excretion rate of Fenproporex which could result in a higher serum level.,Fenproporex
DB01558,Daptomycin may decrease the excretion rate of Bromazepam which could result in a higher serum level.,Bromazepam
DB01563,Daptomycin may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.,Chloral hydrate
DB01577,Daptomycin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.,Metamfetamine
DB01587,Daptomycin may decrease the excretion rate of Ketazolam which could result in a higher serum level.,Ketazolam
DB01610,Daptomycin may decrease the excretion rate of Valganciclovir which could result in a higher serum level.,Valganciclovir
DB01638,Daptomycin may decrease the excretion rate of Sorbitol which could result in a higher serum level.,Sorbitol
DB01656,Daptomycin may decrease the excretion rate of Roflumilast which could result in a higher serum level.,Roflumilast
DB01685,Daptomycin may decrease the excretion rate of Topiroxostat which could result in a higher serum level.,Topiroxostat
DB04574,Daptomycin may decrease the excretion rate of Estrone sulfate which could result in a higher serum level.,Estrone sulfate
DB04871,Daptomycin may decrease the excretion rate of Lorcaserin which could result in a higher serum level.,Lorcaserin
DB04895,Daptomycin may decrease the excretion rate of Pegaptanib which could result in a higher serum level.,Pegaptanib
DB04896,Daptomycin may decrease the excretion rate of Milnacipran which could result in a higher serum level.,Milnacipran
DB04920,Daptomycin may decrease the excretion rate of Clevidipine which could result in a higher serum level.,Clevidipine
DB04948,Daptomycin may decrease the excretion rate of Lofexidine which could result in a higher serum level.,Lofexidine
DB04953,Daptomycin may decrease the excretion rate of Ezogabine which could result in a higher serum level.,Ezogabine
DB05018,Daptomycin may decrease the excretion rate of Migalastat which could result in a higher serum level.,Migalastat
DB05541,Daptomycin may decrease the excretion rate of Brivaracetam which could result in a higher serum level.,Brivaracetam
DB05676,Daptomycin may decrease the excretion rate of Apremilast which could result in a higher serum level.,Apremilast
DB06154,Daptomycin may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.,Pentaerythritol tetranitrate
DB06186,Daptomycin may decrease the excretion rate of Ipilimumab which could result in a higher serum level.,Ipilimumab
DB06196,Daptomycin may decrease the excretion rate of Icatibant which could result in a higher serum level.,Icatibant
DB06203,Daptomycin may decrease the excretion rate of Alogliptin which could result in a higher serum level.,Alogliptin
DB06209,Daptomycin may decrease the excretion rate of Prasugrel which could result in a higher serum level.,Prasugrel
DB06211,Daptomycin may decrease the excretion rate of Doripenem which could result in a higher serum level.,Doripenem
DB06228,Daptomycin may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.,Rivaroxaban
DB06230,Daptomycin may decrease the excretion rate of Nalmefene which could result in a higher serum level.,Nalmefene
DB06262,Daptomycin may decrease the excretion rate of Droxidopa which could result in a higher serum level.,Droxidopa
DB06282,Daptomycin may decrease the excretion rate of Levocetirizine which could result in a higher serum level.,Levocetirizine
DB06335,Daptomycin may decrease the excretion rate of Saxagliptin which could result in a higher serum level.,Saxagliptin
DB06402,Daptomycin may decrease the excretion rate of Telavancin which could result in a higher serum level.,Telavancin
DB06480,Daptomycin may decrease the excretion rate of Prucalopride which could result in a higher serum level.,Prucalopride
DB06623,Daptomycin may decrease the excretion rate of Flupirtine which could result in a higher serum level.,Flupirtine
DB06637,Daptomycin may decrease the excretion rate of Dalfampridine which could result in a higher serum level.,Dalfampridine
DB06695,Daptomycin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.,Dabigatran etexilate
DB06700,Daptomycin may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level.,Desvenlafaxine
DB06702,Daptomycin may decrease the excretion rate of Fesoterodine which could result in a higher serum level.,Fesoterodine
DB06705,Daptomycin may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.,Gadofosveset trisodium
DB06710,Daptomycin may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.,Methyltestosterone
DB06767,Daptomycin may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.,Ammonium chloride
DB06782,Daptomycin may decrease the excretion rate of Dimercaprol which could result in a higher serum level.,Dimercaprol
DB06796,Daptomycin may decrease the excretion rate of Mangafodipir which could result in a higher serum level.,Mangafodipir
DB06800,Daptomycin may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.,Methylnaltrexone
DB06809,Daptomycin may decrease the excretion rate of Plerixafor which could result in a higher serum level.,Plerixafor
DB06813,Daptomycin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.,Pralatrexate
DB06823,Daptomycin may decrease the excretion rate of Tiopronin which could result in a higher serum level.,Tiopronin
DB06824,Daptomycin may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.,Triethylenetetramine
DB08824,Daptomycin may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.,Ioflupane I-123
DB08826,Daptomycin may decrease the excretion rate of Deferiprone which could result in a higher serum level.,Deferiprone
DB08840,Daptomycin may decrease the excretion rate of N-methylnicotinamide which could result in a higher serum level.,N-methylnicotinamide
DB08872,Daptomycin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.,Gabapentin enacarbil
DB08877,Daptomycin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.,Ruxolitinib
DB08893,Daptomycin may decrease the excretion rate of Mirabegron which could result in a higher serum level.,Mirabegron
DB08894,Daptomycin may decrease the excretion rate of Peginesatide which could result in a higher serum level.,Peginesatide
DB08897,Daptomycin may decrease the excretion rate of Aclidinium which could result in a higher serum level.,Aclidinium
DB08899,Daptomycin may decrease the excretion rate of Enzalutamide which could result in a higher serum level.,Enzalutamide
DB08900,Daptomycin may decrease the excretion rate of Teduglutide which could result in a higher serum level.,Teduglutide
DB08904,Daptomycin may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.,Certolizumab pegol
DB08905,Daptomycin may decrease the excretion rate of Formestane which could result in a higher serum level.,Formestane
DB08909,Daptomycin may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.,Glycerol phenylbutyrate
DB08910,Daptomycin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.,Pomalidomide
DB08911,Daptomycin may decrease the excretion rate of Trametinib which could result in a higher serum level.,Trametinib
DB08918,Daptomycin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.,Levomilnacipran
DB08932,Daptomycin may decrease the excretion rate of Macitentan which could result in a higher serum level.,Macitentan
DB08934,Daptomycin may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.,Sofosbuvir
DB08964,Daptomycin may decrease the excretion rate of Gemeprost which could result in a higher serum level.,Gemeprost
DB09027,Daptomycin may decrease the excretion rate of Ledipasvir which could result in a higher serum level.,Ledipasvir
DB09050,Daptomycin may decrease the excretion rate of Ceftolozane which could result in a higher serum level.,Ceftolozane
DB09066,Daptomycin may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level.,Corifollitropin alfa
DB09068,Daptomycin may decrease the excretion rate of Vortioxetine which could result in a higher serum level.,Vortioxetine
DB09071,Daptomycin may decrease the excretion rate of Tasimelteon which could result in a higher serum level.,Tasimelteon
DB09075,Daptomycin may decrease the excretion rate of Edoxaban which could result in a higher serum level.,Edoxaban
DB09081,Daptomycin may decrease the excretion rate of Idebenone which could result in a higher serum level.,Idebenone
DB09082,Daptomycin may decrease the excretion rate of Vilanterol which could result in a higher serum level.,Vilanterol
DB09089,Daptomycin may decrease the excretion rate of Trimebutine which could result in a higher serum level.,Trimebutine
DB09091,Daptomycin may decrease the excretion rate of Tixocortol which could result in a higher serum level.,Tixocortol
DB09103,Daptomycin may decrease the excretion rate of Ancestim which could result in a higher serum level.,Ancestim
DB09104,Daptomycin may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.,Magnesium hydroxide
DB09106,Daptomycin may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.,Hydroxyethyl Starch
DB09111,Daptomycin may decrease the excretion rate of Pentastarch which could result in a higher serum level.,Pentastarch
DB09118,Daptomycin may decrease the excretion rate of Stiripentol which could result in a higher serum level.,Stiripentol
DB09121,Daptomycin may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.,Aurothioglucose
DB09123,Daptomycin may decrease the excretion rate of Dienogest which could result in a higher serum level.,Dienogest
DB09129,Daptomycin may decrease the excretion rate of Chromic chloride which could result in a higher serum level.,Chromic chloride
DB09132,Daptomycin may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.,Gadoteric acid
DB09133,Daptomycin may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.,Iothalamic acid
DB09134,Daptomycin may decrease the excretion rate of Ioversol which could result in a higher serum level.,Ioversol
DB09135,Daptomycin may decrease the excretion rate of Ioxilan which could result in a higher serum level.,Ioxilan
DB09136,Daptomycin may decrease the excretion rate of Isosulfan blue which could result in a higher serum level.,Isosulfan blue
DB09137,Daptomycin may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level.,Technetium Tc-99m mebrofenin
DB09139,Daptomycin may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level.,Technetium Tc-99m oxidronate
DB09148,Daptomycin may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.,Florbetaben (18F)
DB09149,Daptomycin may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.,Florbetapir (18F)
DB09156,Daptomycin may decrease the excretion rate of Iopromide which could result in a higher serum level.,Iopromide
DB09163,Daptomycin may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.,Technetium Tc-99m exametazime
DB09165,Daptomycin may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.,Technetium Tc-99m pyrophosphate
DB09185,Daptomycin may decrease the excretion rate of Viloxazine which could result in a higher serum level.,Viloxazine
DB09194,Daptomycin may decrease the excretion rate of Etoperidone which could result in a higher serum level.,Etoperidone
DB09195,Daptomycin may decrease the excretion rate of Lorpiprazole which could result in a higher serum level.,Lorpiprazole
DB09204,Daptomycin may decrease the excretion rate of Arotinolol which could result in a higher serum level.,Arotinolol
DB09205,Daptomycin may decrease the excretion rate of Moxisylyte which could result in a higher serum level.,Moxisylyte
DB09209,Daptomycin may decrease the excretion rate of Pholcodine which could result in a higher serum level.,Pholcodine
DB09210,Daptomycin may decrease the excretion rate of Piracetam which could result in a higher serum level.,Piracetam
DB09219,Daptomycin may decrease the excretion rate of Bisoxatin which could result in a higher serum level.,Bisoxatin
DB09220,Daptomycin may decrease the excretion rate of Nicorandil which could result in a higher serum level.,Nicorandil
DB09223,Daptomycin may decrease the excretion rate of Blonanserin which could result in a higher serum level.,Blonanserin
DB09224,Daptomycin may decrease the excretion rate of Melperone which could result in a higher serum level.,Melperone
DB09241,Daptomycin may decrease the excretion rate of Methylene blue which could result in a higher serum level.,Methylene blue
DB09244,Daptomycin may decrease the excretion rate of Pirlindole which could result in a higher serum level.,Pirlindole
DB09245,Daptomycin may decrease the excretion rate of Toloxatone which could result in a higher serum level.,Toloxatone
DB09255,Daptomycin may decrease the excretion rate of Dextran which could result in a higher serum level.,Dextran
DB09256,Daptomycin may decrease the excretion rate of Tegafur which could result in a higher serum level.,Tegafur
DB09257,Daptomycin may decrease the excretion rate of Gimeracil which could result in a higher serum level.,Gimeracil
DB09262,Daptomycin may decrease the excretion rate of Imidafenacin which could result in a higher serum level.,Imidafenacin
DB09264,Daptomycin may decrease the excretion rate of Idarucizumab which could result in a higher serum level.,Idarucizumab
DB09265,Daptomycin may decrease the excretion rate of Lixisenatide which could result in a higher serum level.,Lixisenatide
DB09268,Daptomycin may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level.,Picosulfuric acid
DB09276,Daptomycin may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.,Sodium aurothiomalate
DB09277,Daptomycin may decrease the excretion rate of Choline C 11 which could result in a higher serum level.,Choline C 11
DB09281,Daptomycin may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.,Magnesium trisilicate
DB09292,Daptomycin may decrease the excretion rate of Sacubitril which could result in a higher serum level.,Sacubitril
DB09301,Daptomycin may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.,Chondroitin sulfate
DB09317,"Daptomycin may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level.","Synthetic Conjugated Estrogens, A"
DB09318,"Daptomycin may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level.","Synthetic Conjugated Estrogens, B"
DB09320,Daptomycin may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.,Procaine benzylpenicillin
DB09324,Daptomycin may decrease the excretion rate of Sulbactam which could result in a higher serum level.,Sulbactam
DB09325,Daptomycin may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.,Sodium fluoride
DB09329,"Daptomycin may decrease the excretion rate of Antihemophilic Factor (Recombinant), PEGylated which could result in a higher serum level.","Antihemophilic Factor (Recombinant), PEGylated"
DB09344,Daptomycin may decrease the excretion rate of Invert sugar which could result in a higher serum level.,Invert sugar
DB09357,Daptomycin may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.,Dexpanthenol
DB09394,Daptomycin may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.,Phosphoric acid
DB09395,Daptomycin may decrease the excretion rate of Sodium acetate which could result in a higher serum level.,Sodium acetate
DB09407,Daptomycin may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.,Magnesium chloride
DB09418,Daptomycin may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.,Potassium perchlorate
DB09472,Daptomycin may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.,Sodium sulfate
DB09477,Daptomycin may decrease the excretion rate of Enalaprilat which could result in a higher serum level.,Enalaprilat
DB09481,Daptomycin may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.,Magnesium carbonate
DB09488,Daptomycin may decrease the excretion rate of Acrivastine which could result in a higher serum level.,Acrivastine
DB09496,Daptomycin may decrease the excretion rate of Octinoxate which could result in a higher serum level.,Octinoxate
DB09502,Daptomycin may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.,Fludeoxyglucose (18F)
DB09546,Daptomycin may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.,Iobenguane sulfate I-123
DB09570,Daptomycin may decrease the excretion rate of Ixazomib which could result in a higher serum level.,Ixazomib
DB11077,Daptomycin may decrease the excretion rate of Polyethylene glycol 400 which could result in a higher serum level.,Polyethylene glycol 400
DB11090,Daptomycin may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.,Potassium nitrate
DB11098,Daptomycin may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level.,Potassium bicarbonate
DB11102,Daptomycin may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.,N-acetyltyrosine
DB11114,Daptomycin may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.,Eucalyptus oil
DB11127,Daptomycin may decrease the excretion rate of Selenious acid which could result in a higher serum level.,Selenious acid
DB11130,Daptomycin may decrease the excretion rate of Opium which could result in a higher serum level.,Opium
DB11135,Daptomycin may decrease the excretion rate of Selenium which could result in a higher serum level.,Selenium
DB11136,Daptomycin may decrease the excretion rate of Chromium which could result in a higher serum level.,Chromium
DB11145,Daptomycin may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.,Oxyquinoline
DB11156,Daptomycin may decrease the excretion rate of Pyrantel which could result in a higher serum level.,Pyrantel
DB11164,Daptomycin may decrease the excretion rate of Bicisate which could result in a higher serum level.,Bicisate
DB11251,Daptomycin may decrease the excretion rate of Tocopherol which could result in a higher serum level.,Tocopherol
DB11278,Daptomycin may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level.,DL-Methylephedrine
DB11328,Daptomycin may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.,Tetradecyl hydrogen sulfate (ester)
DB11338,Daptomycin may decrease the excretion rate of Clove oil which could result in a higher serum level.,Clove oil
DB11358,Daptomycin may decrease the excretion rate of Evening primrose oil which could result in a higher serum level.,Evening primrose oil
DB11364,Daptomycin may decrease the excretion rate of Pidotimod which could result in a higher serum level.,Pidotimod
DB11560,Daptomycin may decrease the excretion rate of Lesinurad which could result in a higher serum level.,Lesinurad
DB11577,Daptomycin may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.,Indigotindisulfonic acid
DB11587,Daptomycin may decrease the excretion rate of Etafedrine which could result in a higher serum level.,Etafedrine
DB11598,Daptomycin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.,Antithrombin III human
DB11642,Daptomycin may decrease the excretion rate of Pitolisant which could result in a higher serum level.,Pitolisant
DB11691,Daptomycin may decrease the excretion rate of Naldemedine which could result in a higher serum level.,Naldemedine
DB11699,Daptomycin may decrease the excretion rate of Tropisetron which could result in a higher serum level.,Tropisetron
DB11817,Daptomycin may decrease the excretion rate of Baricitinib which could result in a higher serum level.,Baricitinib
DB11901,Daptomycin may decrease the excretion rate of Apalutamide which could result in a higher serum level.,Apalutamide
DB11915,Daptomycin may decrease the excretion rate of Valbenazine which could result in a higher serum level.,Valbenazine
DB11943,Daptomycin may decrease the excretion rate of Delafloxacin which could result in a higher serum level.,Delafloxacin
DB11989,Daptomycin may decrease the excretion rate of Benznidazole which could result in a higher serum level.,Benznidazole
DB12007,Daptomycin may decrease the excretion rate of Isoflavone which could result in a higher serum level.,Isoflavone
DB12107,Daptomycin may decrease the excretion rate of Vaborbactam which could result in a higher serum level.,Vaborbactam
DB12161,Daptomycin may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.,Deutetrabenazine
DB12278,Daptomycin may decrease the excretion rate of Propiverine which could result in a higher serum level.,Propiverine
DB12783,Daptomycin may decrease the excretion rate of Benserazide which could result in a higher serum level.,Benserazide
DB13025,Daptomycin may decrease the excretion rate of Tiapride which could result in a higher serum level.,Tiapride
DB13139,Daptomycin may decrease the excretion rate of Levosalbutamol which could result in a higher serum level.,Levosalbutamol
DB13156,Daptomycin may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.,Inosine pranobex
DB13178,Daptomycin may decrease the excretion rate of Inositol which could result in a higher serum level.,Inositol
DB13185,Daptomycin may decrease the excretion rate of Oxabolone cipionate which could result in a higher serum level.,Oxabolone cipionate
DB13191,Daptomycin may decrease the excretion rate of Phosphocreatine which could result in a higher serum level.,Phosphocreatine
DB13269,Daptomycin may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.,Dichlorobenzyl alcohol
DB13595,Daptomycin may decrease the excretion rate of Almasilate which could result in a higher serum level.,Almasilate
DB13884,Daptomycin may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.,Albutrepenonacog alfa
DB13909,Daptomycin may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level.,Bismuth subgallate
DB13943,Daptomycin may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level.,Testosterone cypionate
DB13944,Daptomycin may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level.,Testosterone enanthate
DB13946,Daptomycin may decrease the excretion rate of Testosterone undecanoate which could result in a higher serum level.,Testosterone undecanoate
DB13952,Daptomycin may decrease the excretion rate of Estradiol acetate which could result in a higher serum level.,Estradiol acetate
DB13954,Daptomycin may decrease the excretion rate of Estradiol cypionate which could result in a higher serum level.,Estradiol cypionate
DB13955,Daptomycin may decrease the excretion rate of Estradiol dienanthate which could result in a higher serum level.,Estradiol dienanthate
DB13956,Daptomycin may decrease the excretion rate of Estradiol valerate which could result in a higher serum level.,Estradiol valerate
DB13967,Daptomycin may decrease the excretion rate of Patent Blue which could result in a higher serum level.,Patent Blue
DB14006,Daptomycin may decrease the excretion rate of Choline salicylate which could result in a higher serum level.,Choline salicylate
DB14007,Daptomycin may decrease the excretion rate of Pentetic acid which could result in a higher serum level.,Pentetic acid
DB14498,Daptomycin may decrease the excretion rate of Potassium acetate which could result in a higher serum level.,Potassium acetate
DB14499,Daptomycin may decrease the excretion rate of Potassium sulfate which could result in a higher serum level.,Potassium sulfate
DB14526,Daptomycin may decrease the excretion rate of Chromic citrate which could result in a higher serum level.,Chromic citrate
DB14527,Daptomycin may decrease the excretion rate of Chromic nitrate which could result in a higher serum level.,Chromic nitrate
DB14528,Daptomycin may decrease the excretion rate of Chromium gluconate which could result in a higher serum level.,Chromium gluconate
DB14529,Daptomycin may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level.,Chromium nicotinate
DB14530,Daptomycin may decrease the excretion rate of Chromous sulfate which could result in a higher serum level.,Chromous sulfate
DB14754,Daptomycin may decrease the excretion rate of Solriamfetol which could result in a higher serum level.,Solriamfetol
DB06815,Daptomycin may decrease the excretion rate of Pyrithione which could result in a higher serum level.,Pyrithione
DB11121,Daptomycin may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.,Chloroxylenol
DB11085,Daptomycin may decrease the excretion rate of Resorcinol which could result in a higher serum level.,Resorcinol
DB15593,Daptomycin may decrease the excretion rate of Golodirsen which could result in a higher serum level.,Golodirsen
DB00321,Daptomycin may decrease the excretion rate of Amitriptyline which could result in a higher serum level.,Amitriptyline
DB00458,Daptomycin may decrease the excretion rate of Imipramine which could result in a higher serum level.,Imipramine
DB01142,Daptomycin may decrease the excretion rate of Doxepin which could result in a higher serum level.,Doxepin
DB00318,Daptomycin may decrease the excretion rate of Codeine which could result in a higher serum level.,Codeine
DB00454,Daptomycin may decrease the excretion rate of Meperidine which could result in a higher serum level.,Meperidine
DB00813,Daptomycin may decrease the excretion rate of Fentanyl which could result in a higher serum level.,Fentanyl
DB00879,Daptomycin may decrease the excretion rate of Emtricitabine which could result in a higher serum level.,Emtricitabine
DB01151,Daptomycin may decrease the excretion rate of Desipramine which could result in a higher serum level.,Desipramine
DB01242,Daptomycin may decrease the excretion rate of Clomipramine which could result in a higher serum level.,Clomipramine
DB08996,Daptomycin may decrease the excretion rate of Dimetacrine which could result in a higher serum level.,Dimetacrine
DB14506,Daptomycin may decrease the excretion rate of Lithium hydroxide which could result in a higher serum level.,Lithium hydroxide
DB00452,Framycetin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Framycetin
DB00479,Amikacin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Amikacin
DB00684,Tobramycin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Tobramycin
DB00798,Gentamicin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Gentamicin
DB00955,Netilmicin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Netilmicin
DB00994,Neomycin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Neomycin
DB01082,Streptomycin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Streptomycin
DB01172,Kanamycin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Kanamycin
DB01421,Paromomycin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Paromomycin
DB03615,Ribostamycin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Ribostamycin
DB04263,Geneticin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Geneticin
DB04626,Apramycin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Apramycin
DB04729,Gentamicin C1a may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Gentamicin C1a
DB04808,Neamine may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Neamine
DB06696,Arbekacin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Arbekacin
DB08437,Puromycin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Puromycin
DB11512,Dihydrostreptomycin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Dihydrostreptomycin
DB11520,Hygromycin B may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Hygromycin B
DB12604,Sisomicin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Sisomicin
DB13270,Dibekacin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Dibekacin
DB13274,Micronomicin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Micronomicin
DB13540,Isepamicin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Isepamicin
DB13673,Bekanamycin may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Bekanamycin
DB00552,Daptomycin may decrease the excretion rate of Pentostatin which could result in a higher serum level.,Pentostatin
DB13145,Daptomycin may decrease the excretion rate of Nedaplatin which could result in a higher serum level.,Nedaplatin
DB00314,Daptomycin may decrease the excretion rate of Capreomycin which could result in a higher serum level.,Capreomycin
DB00390,Daptomycin may decrease the excretion rate of Digoxin which could result in a higher serum level.,Digoxin
DB00512,Daptomycin may decrease the excretion rate of Vancomycin which could result in a higher serum level.,Vancomycin
DB00515,Daptomycin may decrease the excretion rate of Cisplatin which could result in a higher serum level.,Cisplatin
DB00564,Daptomycin may decrease the excretion rate of Carbamazepine which could result in a higher serum level.,Carbamazepine
DB00642,Daptomycin may decrease the excretion rate of Pemetrexed which could result in a higher serum level.,Pemetrexed
DB00682,Daptomycin may decrease the excretion rate of Warfarin which could result in a higher serum level.,Warfarin
DB00908,Daptomycin may decrease the excretion rate of Quinidine which could result in a higher serum level.,Quinidine
DB00982,Daptomycin may decrease the excretion rate of Isotretinoin which could result in a higher serum level.,Isotretinoin
DB01035,Daptomycin may decrease the excretion rate of Procainamide which could result in a higher serum level.,Procainamide
DB12615,Daptomycin may decrease the excretion rate of Plazomicin which could result in a higher serum level.,Plazomicin
DB14509,Daptomycin may decrease the excretion rate of Lithium carbonate which could result in a higher serum level.,Lithium carbonate
DB00524,Daptomycin may increase the excretion rate of Metolazone which could result in a lower serum level and potentially a reduction in efficacy.,Metolazone
DB00695,Daptomycin may increase the excretion rate of Furosemide which could result in a lower serum level and potentially a reduction in efficacy.,Furosemide
DB00808,Daptomycin may increase the excretion rate of Indapamide which could result in a lower serum level and potentially a reduction in efficacy.,Indapamide
DB00909,Daptomycin may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.,Zonisamide
DB08907,Daptomycin may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.,Canagliflozin
DB09338,Daptomycin may increase the excretion rate of Mersalyl which could result in a lower serum level and potentially a reduction in efficacy.,Mersalyl
DB00214,Torasemide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Torasemide
DB00232,Methyclothiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Methyclothiazide
DB00310,Chlorthalidone may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Chlorthalidone
DB00311,Ethoxzolamide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Ethoxzolamide
DB00421,Spironolactone may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Spironolactone
DB00436,Bendroflumethiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Bendroflumethiazide
DB00562,Benzthiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Benzthiazide
DB00594,Amiloride may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Amiloride
DB00606,Cyclothiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Cyclothiazide
DB00700,Eplerenone may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Eplerenone
DB00703,Methazolamide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Methazolamide
DB00774,Hydroflumethiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Hydroflumethiazide
DB00819,Acetazolamide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Acetazolamide
DB00872,Conivaptan may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Conivaptan
DB00880,Chlorothiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Chlorothiazide
DB01021,Trichlormethiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Trichlormethiazide
DB01119,Diazoxide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Diazoxide
DB01144,Diclofenamide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Diclofenamide
DB01324,Polythiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Polythiazide
DB01325,Quinethazone may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Quinethazone
DB01395,Drospirenone may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Drospirenone
DB01412,Theobromine may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Theobromine
DB02925,Piretanide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Piretanide
DB04831,Tienilic acid may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Tienilic acid
DB05034,Ularitide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Ularitide
DB06212,Tolvaptan may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Tolvaptan
DB06292,Dapagliflozin may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Dapagliflozin
DB06370,Indisulam may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Indisulam
DB08961,Azosemide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Azosemide
DB09015,Canrenoic acid may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Canrenoic acid
DB09125,Potassium citrate may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Potassium citrate
DB09235,Efonidipine may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Efonidipine
DB09401,Isosorbide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Isosorbide
DB11827,Ertugliflozin may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Ertugliflozin
DB12221,Canrenone may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Canrenone
DB12670,Rolofylline may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Rolofylline
DB12704,Spiradoline may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Spiradoline
DB12766,Cicletanine may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Cicletanine
DB13284,Meticrane may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Meticrane
DB13316,Ibopamine may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Ibopamine
DB13405,Mefruside may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Mefruside
DB13430,Mebutizide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Mebutizide
DB13532,Cyclopenthiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Cyclopenthiazide
DB13617,Clorexolone may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Clorexolone
DB13663,Clofenamide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Clofenamide
DB13708,Fenquizone may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Fenquizone
DB13792,Clopamide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Clopamide
DB13801,Muzolimine may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Muzolimine
DB13803,Xipamide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Xipamide
DB13989,Epitizide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Epitizide
DB14018,Bromotheophylline may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Bromotheophylline
DB14500,Potassium may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.,Potassium
DB00266,The risk or severity of bleeding can be increased when Daptomycin is combined with Dicoumarol.,Dicoumarol
DB00498,The risk or severity of bleeding can be increased when Daptomycin is combined with Phenindione.,Phenindione
DB00946,The risk or severity of bleeding can be increased when Daptomycin is combined with Phenprocoumon.,Phenprocoumon
DB01418,The risk or severity of bleeding can be increased when Daptomycin is combined with Acenocoumarol.,Acenocoumarol
DB03410,The risk or severity of bleeding can be increased when Daptomycin is combined with 4-hydroxycoumarin.,4-hydroxycoumarin
DB04665,The risk or severity of bleeding can be increased when Daptomycin is combined with Coumarin.,Coumarin
DB08496,The risk or severity of bleeding can be increased when Daptomycin is combined with (R)-warfarin.,(R)-warfarin
DB08794,The risk or severity of bleeding can be increased when Daptomycin is combined with Ethyl biscoumacetate.,Ethyl biscoumacetate
DB13136,The risk or severity of bleeding can be increased when Daptomycin is combined with Fluindione.,Fluindione
DB13275,The risk or severity of bleeding can be increased when Daptomycin is combined with Clorindione.,Clorindione
DB13347,The risk or severity of bleeding can be increased when Daptomycin is combined with Diphenadione.,Diphenadione
DB13451,The risk or severity of bleeding can be increased when Daptomycin is combined with Tioclomarol.,Tioclomarol
DB14055,The risk or severity of bleeding can be increased when Daptomycin is combined with (S)-Warfarin.,(S)-Warfarin
DB00007,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Daptomycin.",Leuprolide
DB00052,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Daptomycin.",Somatotropin
DB00065,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Daptomycin.",Infliximab
DB00181,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Baclofen.",Baclofen
DB00203,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Sildenafil.",Sildenafil
DB00224,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Indinavir.",Indinavir
DB00242,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Cladribine.",Cladribine
DB00252,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Phenytoin.",Phenytoin
DB00358,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Mefloquine.",Mefloquine
DB00382,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Tacrine.",Tacrine
DB00389,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Carbimazole.",Carbimazole
DB00440,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Trimethoprim.",Trimethoprim
DB00443,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Betamethasone.",Betamethasone
DB00471,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Montelukast.",Montelukast
DB00495,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Zidovudine.",Zidovudine
DB00501,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Cimetidine.",Cimetidine
DB00503,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ritonavir.",Ritonavir
DB00528,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Lercanidipine.",Lercanidipine
DB00537,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ciprofloxacin.",Ciprofloxacin
DB00541,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Vincristine.",Vincristine
DB00550,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Propylthiouracil.",Propylthiouracil
DB00584,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Enalapril.",Enalapril
DB00585,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Nizatidine.",Nizatidine
DB00602,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ivermectin.",Ivermectin
DB00608,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Chloroquine.",Chloroquine
DB00620,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Triamcinolone.",Triamcinolone
DB00627,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Niacin.",Niacin
DB00630,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Alendronic acid.",Alendronic acid
DB00636,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Clofibrate.",Clofibrate
DB00649,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Stavudine.",Stavudine
DB00666,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Nafarelin.",Nafarelin
DB00688,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Mycophenolate mofetil.",Mycophenolate mofetil
DB00704,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Naltrexone.",Naltrexone
DB00709,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Lamivudine.",Lamivudine
DB00710,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ibandronate.",Ibandronate
DB00818,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Propofol.",Propofol
DB00857,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Terbinafine.",Terbinafine
DB00859,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Penicillamine.",Penicillamine
DB00863,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ranitidine.",Ranitidine
DB00876,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Eprosartan.",Eprosartan
DB00884,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Risedronic acid.",Risedronic acid
DB00887,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Bumetanide.",Bumetanide
DB00897,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Triazolam.",Triazolam
DB00898,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ethanol.",Ethanol
DB00938,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Salmeterol.",Salmeterol
DB00951,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Isoniazid.",Isoniazid
DB00968,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Methyldopa.",Methyldopa
DB00987,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Cytarabine.",Cytarabine
DB01004,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ganciclovir.",Ganciclovir
DB01006,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Letrozole.",Letrozole
DB01015,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Sulfamethoxazole.",Sulfamethoxazole
DB01017,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Minocycline.",Minocycline
DB01039,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Fenofibrate.",Fenofibrate
DB01059,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Norfloxacin.",Norfloxacin
DB01088,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Iloprost.",Iloprost
DB01097,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Leflunomide.",Leflunomide
DB01118,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Amiodarone.",Amiodarone
DB01165,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ofloxacin.",Ofloxacin
DB01168,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Procarbazine.",Procarbazine
DB01197,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Captopril.",Captopril
DB01229,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Paclitaxel.",Paclitaxel
DB01232,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Saquinavir.",Saquinavir
DB01233,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Metoclopramide.",Metoclopramide
DB01234,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Dexamethasone.",Dexamethasone
DB01241,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Gemfibrozil.",Gemfibrozil
DB01248,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Docetaxel.",Docetaxel
DB01393,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Bezafibrate.",Bezafibrate
DB01394,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Colchicine.",Colchicine
DB02703,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Fusidic acid.",Fusidic acid
DB05109,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Trabectedin.",Trabectedin
DB06817,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Raltegravir.",Raltegravir
DB08983,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Etofibrate.",Etofibrate
DB09055,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Acipimox.",Acipimox
DB09064,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ciprofibrate.",Ciprofibrate
DB09270,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ubidecarenone.",Ubidecarenone
DB09289,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Tianeptine.",Tianeptine
DB12554,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Mebeverine.",Mebeverine
DB13293,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ipecac.",Ipecac
DB13393,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Emetine.",Emetine
DB13433,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Simfibrate.",Simfibrate
DB13460,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ronifibrate.",Ronifibrate
DB13780,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Aluminium clofibrate.",Aluminium clofibrate
DB13849,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Clofibride.",Clofibride
DB13873,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Fenofibric acid.",Fenofibric acid
DB14443,The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Daptomycin.,Vibrio cholerae CVD 103-HgR strain live antigen
DB06643,The risk or severity of adverse effects can be increased when Denosumab is combined with Tositumomab.,Denosumab
DB00005,The risk or severity of adverse effects can be increased when Etanercept is combined with Tositumomab.,Etanercept
DB00008,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Tositumomab.,Peginterferon alfa-2a
DB00011,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Tositumomab.,Interferon alfa-n1
DB00018,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Tositumomab.,Interferon alfa-n3
DB00022,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Tositumomab.,Peginterferon alfa-2b
DB00026,The risk or severity of adverse effects can be increased when Anakinra is combined with Tositumomab.,Anakinra
DB00033,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Tositumomab.,Interferon gamma-1b
DB00034,"The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Tositumomab.","Interferon alfa-2a, Recombinant"
DB00041,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Tositumomab.,Aldesleukin
DB00051,The risk or severity of adverse effects can be increased when Adalimumab is combined with Tositumomab.,Adalimumab
DB00056,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tositumomab.,Gemtuzumab ozogamicin
DB00059,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Tositumomab.,Pegaspargase
DB00065,The risk or severity of adverse effects can be increased when Infliximab is combined with Tositumomab.,Infliximab
DB00068,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Tositumomab.,Interferon beta-1b
DB00069,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Tositumomab.,Interferon alfacon-1
DB00073,The risk or severity of adverse effects can be increased when Rituximab is combined with Tositumomab.,Rituximab
DB00074,The risk or severity of adverse effects can be increased when Basiliximab is combined with Tositumomab.,Basiliximab
DB00075,The risk or severity of adverse effects can be increased when Muromonab is combined with Tositumomab.,Muromonab
DB00078,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tositumomab.,Ibritumomab tiuxetan
DB00087,The risk or severity of adverse effects can be increased when Tositumomab is combined with Alemtuzumab.,Alemtuzumab
DB00092,The risk or severity of adverse effects can be increased when Tositumomab is combined with Alefacept.,Alefacept
DB00095,The risk or severity of adverse effects can be increased when Tositumomab is combined with Efalizumab.,Efalizumab
DB00098,The risk or severity of adverse effects can be increased when Tositumomab is combined with Antithymocyte immunoglobulin (rabbit).,Antithymocyte immunoglobulin (rabbit)
DB00105,The risk or severity of adverse effects can be increased when Tositumomab is combined with Interferon alfa-2b.,Interferon alfa-2b
DB00111,The risk or severity of adverse effects can be increased when Tositumomab is combined with Daclizumab.,Daclizumab
DB00112,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bevacizumab.,Bevacizumab
DB00120,The risk or severity of adverse effects can be increased when Tositumomab is combined with Phenylalanine.,Phenylalanine
DB00180,The risk or severity of adverse effects can be increased when Tositumomab is combined with Flunisolide.,Flunisolide
DB00188,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bortezomib.,Bortezomib
DB00242,The risk or severity of adverse effects can be increased when Tositumomab is combined with Cladribine.,Cladribine
DB00262,The risk or severity of adverse effects can be increased when Tositumomab is combined with Carmustine.,Carmustine
DB00276,The risk or severity of adverse effects can be increased when Tositumomab is combined with Amsacrine.,Amsacrine
DB00290,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bleomycin.,Bleomycin
DB00291,The risk or severity of adverse effects can be increased when Tositumomab is combined with Chlorambucil.,Chlorambucil
DB00293,The risk or severity of adverse effects can be increased when Tositumomab is combined with Raltitrexed.,Raltitrexed
DB00305,The risk or severity of adverse effects can be increased when Tositumomab is combined with Mitomycin.,Mitomycin
DB00307,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bexarotene.,Bexarotene
DB00309,The risk or severity of adverse effects can be increased when Tositumomab is combined with Vindesine.,Vindesine
DB00322,The risk or severity of adverse effects can be increased when Tositumomab is combined with Floxuridine.,Floxuridine
DB00328,The risk or severity of adverse effects can be increased when Tositumomab is combined with Indomethacin.,Indomethacin
DB00352,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tioguanine.,Tioguanine
DB00361,The risk or severity of adverse effects can be increased when Tositumomab is combined with Vinorelbine.,Vinorelbine
DB00380,The risk or severity of adverse effects can be increased when Tositumomab is combined with Dexrazoxane.,Dexrazoxane
DB00394,The risk or severity of adverse effects can be increased when Tositumomab is combined with Beclomethasone dipropionate.,Beclomethasone dipropionate
DB00398,The risk or severity of adverse effects can be increased when Tositumomab is combined with Sorafenib.,Sorafenib
DB00428,The risk or severity of adverse effects can be increased when Tositumomab is combined with Streptozocin.,Streptozocin
DB00432,The risk or severity of adverse effects can be increased when Tositumomab is combined with Trifluridine.,Trifluridine
DB00441,The risk or severity of adverse effects can be increased when Tositumomab is combined with Gemcitabine.,Gemcitabine
DB00443,The risk or severity of adverse effects can be increased when Tositumomab is combined with Betamethasone.,Betamethasone
DB00444,The risk or severity of adverse effects can be increased when Tositumomab is combined with Teniposide.,Teniposide
DB00445,The risk or severity of adverse effects can be increased when Tositumomab is combined with Epirubicin.,Epirubicin
DB00446,The risk or severity of adverse effects can be increased when Tositumomab is combined with Chloramphenicol.,Chloramphenicol
DB00480,The risk or severity of adverse effects can be increased when Tositumomab is combined with Lenalidomide.,Lenalidomide
DB00488,The risk or severity of adverse effects can be increased when Tositumomab is combined with Altretamine.,Altretamine
DB00495,The risk or severity of adverse effects can be increased when Tositumomab is combined with Zidovudine.,Zidovudine
DB00515,The risk or severity of adverse effects can be increased when Tositumomab is combined with Cisplatin.,Cisplatin
DB00526,The risk or severity of adverse effects can be increased when Tositumomab is combined with Oxaliplatin.,Oxaliplatin
DB00531,The risk or severity of adverse effects can be increased when Tositumomab is combined with Cyclophosphamide.,Cyclophosphamide
DB00541,The risk or severity of adverse effects can be increased when Tositumomab is combined with Vincristine.,Vincristine
DB00544,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fluorouracil.,Fluorouracil
DB00550,The risk or severity of adverse effects can be increased when Tositumomab is combined with Propylthiouracil.,Propylthiouracil
DB00552,The risk or severity of adverse effects can be increased when Tositumomab is combined with Pentostatin.,Pentostatin
DB00563,The risk or severity of adverse effects can be increased when Tositumomab is combined with Methotrexate.,Methotrexate
DB00564,The risk or severity of adverse effects can be increased when Tositumomab is combined with Carbamazepine.,Carbamazepine
DB00570,The risk or severity of adverse effects can be increased when Tositumomab is combined with Vinblastine.,Vinblastine
DB00588,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fluticasone propionate.,Fluticasone propionate
DB00591,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fluocinolone acetonide.,Fluocinolone acetonide
DB00601,The risk or severity of adverse effects can be increased when Tositumomab is combined with Linezolid.,Linezolid
DB00619,The risk or severity of adverse effects can be increased when Tositumomab is combined with Imatinib.,Imatinib
DB00620,The risk or severity of adverse effects can be increased when Tositumomab is combined with Triamcinolone.,Triamcinolone
DB00631,The risk or severity of adverse effects can be increased when Tositumomab is combined with Clofarabine.,Clofarabine
DB00635,The risk or severity of adverse effects can be increased when Tositumomab is combined with Prednisone.,Prednisone
DB00642,The risk or severity of adverse effects can be increased when Tositumomab is combined with Pemetrexed.,Pemetrexed
DB00687,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fludrocortisone.,Fludrocortisone
DB00688,The risk or severity of adverse effects can be increased when Tositumomab is combined with Mycophenolate mofetil.,Mycophenolate mofetil
DB00694,The risk or severity of adverse effects can be increased when Tositumomab is combined with Daunorubicin.,Daunorubicin
DB00755,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tretinoin.,Tretinoin
DB00762,The risk or severity of adverse effects can be increased when Tositumomab is combined with Irinotecan.,Irinotecan
DB00763,The risk or severity of adverse effects can be increased when Tositumomab is combined with Methimazole.,Methimazole
DB00764,The risk or severity of adverse effects can be increased when Tositumomab is combined with Mometasone.,Mometasone
DB00773,The risk or severity of adverse effects can be increased when Tositumomab is combined with Etoposide.,Etoposide
DB00795,The risk or severity of adverse effects can be increased when Tositumomab is combined with Sulfasalazine.,Sulfasalazine
DB00851,The risk or severity of adverse effects can be increased when Tositumomab is combined with Dacarbazine.,Dacarbazine
DB00853,The risk or severity of adverse effects can be increased when Tositumomab is combined with Temozolomide.,Temozolomide
DB00859,The risk or severity of adverse effects can be increased when Tositumomab is combined with Penicillamine.,Penicillamine
DB00860,The risk or severity of adverse effects can be increased when Tositumomab is combined with Prednisolone.,Prednisolone
DB00877,The risk or severity of adverse effects can be increased when Tositumomab is combined with Sirolimus.,Sirolimus
DB00888,The risk or severity of adverse effects can be increased when Tositumomab is combined with Mechlorethamine.,Mechlorethamine
DB00928,The risk or severity of adverse effects can be increased when Tositumomab is combined with Azacitidine.,Azacitidine
DB00958,The risk or severity of adverse effects can be increased when Tositumomab is combined with Carboplatin.,Carboplatin
DB00959,The risk or severity of adverse effects can be increased when Tositumomab is combined with Methylprednisolone.,Methylprednisolone
DB00970,The risk or severity of adverse effects can be increased when Tositumomab is combined with Dactinomycin.,Dactinomycin
DB00987,The risk or severity of adverse effects can be increased when Tositumomab is combined with Cytarabine.,Cytarabine
DB00993,The risk or severity of adverse effects can be increased when Tositumomab is combined with Azathioprine.,Azathioprine
DB00997,The risk or severity of adverse effects can be increased when Tositumomab is combined with Doxorubicin.,Doxorubicin
DB01005,The risk or severity of adverse effects can be increased when Tositumomab is combined with Hydroxyurea.,Hydroxyurea
DB01008,The risk or severity of adverse effects can be increased when Tositumomab is combined with Busulfan.,Busulfan
DB01024,The risk or severity of adverse effects can be increased when Tositumomab is combined with Mycophenolic acid.,Mycophenolic acid
DB01030,The risk or severity of adverse effects can be increased when Tositumomab is combined with Topotecan.,Topotecan
DB01033,The risk or severity of adverse effects can be increased when Tositumomab is combined with Mercaptopurine.,Mercaptopurine
DB01041,The risk or severity of adverse effects can be increased when Tositumomab is combined with Thalidomide.,Thalidomide
DB01042,The risk or severity of adverse effects can be increased when Tositumomab is combined with Melphalan.,Melphalan
DB01073,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fludarabine.,Fludarabine
DB01099,The risk or severity of adverse effects can be increased when Tositumomab is combined with Flucytosine.,Flucytosine
DB01101,The risk or severity of adverse effects can be increased when Tositumomab is combined with Capecitabine.,Capecitabine
DB01108,The risk or severity of adverse effects can be increased when Tositumomab is combined with Trilostane.,Trilostane
DB01168,The risk or severity of adverse effects can be increased when Tositumomab is combined with Procarbazine.,Procarbazine
DB01169,The risk or severity of adverse effects can be increased when Tositumomab is combined with Arsenic trioxide.,Arsenic trioxide
DB01177,The risk or severity of adverse effects can be increased when Tositumomab is combined with Idarubicin.,Idarubicin
DB01181,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ifosfamide.,Ifosfamide
DB01196,The risk or severity of adverse effects can be increased when Tositumomab is combined with Estramustine.,Estramustine
DB01204,The risk or severity of adverse effects can be increased when Tositumomab is combined with Mitoxantrone.,Mitoxantrone
DB01206,The risk or severity of adverse effects can be increased when Tositumomab is combined with Lomustine.,Lomustine
DB01222,The risk or severity of adverse effects can be increased when Tositumomab is combined with Budesonide.,Budesonide
DB01229,The risk or severity of adverse effects can be increased when Tositumomab is combined with Paclitaxel.,Paclitaxel
DB01234,The risk or severity of adverse effects can be increased when Tositumomab is combined with Dexamethasone.,Dexamethasone
DB01248,The risk or severity of adverse effects can be increased when Tositumomab is combined with Docetaxel.,Docetaxel
DB01254,The risk or severity of adverse effects can be increased when Tositumomab is combined with Dasatinib.,Dasatinib
DB01257,The risk or severity of adverse effects can be increased when Tositumomab is combined with Eculizumab.,Eculizumab
DB01262,The risk or severity of adverse effects can be increased when Tositumomab is combined with Decitabine.,Decitabine
DB01268,The risk or severity of adverse effects can be increased when Tositumomab is combined with Sunitinib.,Sunitinib
DB01280,The risk or severity of adverse effects can be increased when Tositumomab is combined with Nelarabine.,Nelarabine
DB01281,The risk or severity of adverse effects can be increased when Tositumomab is combined with Abatacept.,Abatacept
DB01285,The risk or severity of adverse effects can be increased when Tositumomab is combined with Corticotropin.,Corticotropin
DB01380,The risk or severity of adverse effects can be increased when Tositumomab is combined with Cortisone acetate.,Cortisone acetate
DB01384,The risk or severity of adverse effects can be increased when Tositumomab is combined with Paramethasone.,Paramethasone
DB01394,The risk or severity of adverse effects can be increased when Tositumomab is combined with Colchicine.,Colchicine
DB01410,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ciclesonide.,Ciclesonide
DB01423,The risk or severity of adverse effects can be increased when Tositumomab is combined with Stepronin.,Stepronin
DB01590,The risk or severity of adverse effects can be increased when Tositumomab is combined with Everolimus.,Everolimus
DB01611,The risk or severity of adverse effects can be increased when Tositumomab is combined with Hydroxychloroquine.,Hydroxychloroquine
DB01816,The risk or severity of adverse effects can be increased when Tositumomab is combined with Castanospermine.,Castanospermine
DB02546,The risk or severity of adverse effects can be increased when Tositumomab is combined with Vorinostat.,Vorinostat
DB02806,The risk or severity of adverse effects can be increased when Tositumomab is combined with 2-Methoxyethanol.,2-Methoxyethanol
DB03523,The risk or severity of adverse effects can be increased when Tositumomab is combined with Brequinar.,Brequinar
DB04572,The risk or severity of adverse effects can be increased when Tositumomab is combined with Thiotepa.,Thiotepa
DB04630,The risk or severity of adverse effects can be increased when Tositumomab is combined with Aldosterone.,Aldosterone
DB04845,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ixabepilone.,Ixabepilone
DB04868,The risk or severity of adverse effects can be increased when Tositumomab is combined with Nilotinib.,Nilotinib
DB04951,The risk or severity of adverse effects can be increased when Tositumomab is combined with Pirfenidone.,Pirfenidone
DB04956,The risk or severity of adverse effects can be increased when Tositumomab is combined with Afelimomab.,Afelimomab
DB05015,The risk or severity of adverse effects can be increased when Tositumomab is combined with Belinostat.,Belinostat
DB05109,The risk or severity of adverse effects can be increased when Tositumomab is combined with Trabectedin.,Trabectedin
DB05258,The risk or severity of adverse effects can be increased when Tositumomab is combined with Interferon alfa.,Interferon alfa
DB05259,The risk or severity of adverse effects can be increased when Tositumomab is combined with Glatiramer.,Glatiramer
DB05260,The risk or severity of adverse effects can be increased when Tositumomab is combined with Gallium nitrate.,Gallium nitrate
DB05459,The risk or severity of adverse effects can be increased when Tositumomab is combined with Briakinumab.,Briakinumab
DB05472,The risk or severity of adverse effects can be increased when Tositumomab is combined with omega interferon.,omega interferon
DB05676,The risk or severity of adverse effects can be increased when Tositumomab is combined with Apremilast.,Apremilast
DB05773,The risk or severity of adverse effects can be increased when Tositumomab is combined with Trastuzumab emtansine.,Trastuzumab emtansine
DB06168,The risk or severity of adverse effects can be increased when Tositumomab is combined with Canakinumab.,Canakinumab
DB06273,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tocilizumab.,Tocilizumab
DB06287,The risk or severity of adverse effects can be increased when Tositumomab is combined with Temsirolimus.,Temsirolimus
DB06372,The risk or severity of adverse effects can be increased when Tositumomab is combined with Rilonacept.,Rilonacept
DB06589,The risk or severity of adverse effects can be increased when Tositumomab is combined with Pazopanib.,Pazopanib
DB06603,The risk or severity of adverse effects can be increased when Tositumomab is combined with Panobinostat.,Panobinostat
DB06612,The risk or severity of adverse effects can be increased when Tositumomab is combined with Mepolizumab.,Mepolizumab
DB06616,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bosutinib.,Bosutinib
DB06662,The risk or severity of adverse effects can be increased when Tositumomab is combined with Abetimus.,Abetimus
DB06674,The risk or severity of adverse effects can be increased when Tositumomab is combined with Golimumab.,Golimumab
DB06681,The risk or severity of adverse effects can be increased when Tositumomab is combined with Belatacept.,Belatacept
DB06769,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bendamustine.,Bendamustine
DB06772,The risk or severity of adverse effects can be increased when Tositumomab is combined with Cabazitaxel.,Cabazitaxel
DB06813,The risk or severity of adverse effects can be increased when Tositumomab is combined with Pralatrexate.,Pralatrexate
DB08059,The risk or severity of adverse effects can be increased when Tositumomab is combined with Wortmannin.,Wortmannin
DB08870,The risk or severity of adverse effects can be increased when Tositumomab is combined with Brentuximab vedotin.,Brentuximab vedotin
DB08871,The risk or severity of adverse effects can be increased when Tositumomab is combined with Eribulin.,Eribulin
DB08877,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ruxolitinib.,Ruxolitinib
DB08879,The risk or severity of adverse effects can be increased when Tositumomab is combined with Belimumab.,Belimumab
DB08880,The risk or severity of adverse effects can be increased when Tositumomab is combined with Teriflunomide.,Teriflunomide
DB08889,The risk or severity of adverse effects can be increased when Tositumomab is combined with Carfilzomib.,Carfilzomib
DB08901,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ponatinib.,Ponatinib
DB08904,The risk or severity of adverse effects can be increased when Tositumomab is combined with Certolizumab pegol.,Certolizumab pegol
DB08906,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fluticasone furoate.,Fluticasone furoate
DB08908,The risk or severity of adverse effects can be increased when Tositumomab is combined with Dimethyl fumarate.,Dimethyl fumarate
DB08910,The risk or severity of adverse effects can be increased when Tositumomab is combined with Pomalidomide.,Pomalidomide
DB08935,The risk or severity of adverse effects can be increased when Tositumomab is combined with Obinutuzumab.,Obinutuzumab
DB08970,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fluprednidene.,Fluprednidene
DB08971,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fluocortolone.,Fluocortolone
DB09029,The risk or severity of adverse effects can be increased when Tositumomab is combined with Secukinumab.,Secukinumab
DB09033,The risk or severity of adverse effects can be increased when Tositumomab is combined with Vedolizumab.,Vedolizumab
DB09036,The risk or severity of adverse effects can be increased when Tositumomab is combined with Siltuximab.,Siltuximab
DB09052,The risk or severity of adverse effects can be increased when Tositumomab is combined with Blinatumomab.,Blinatumomab
DB09053,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ibrutinib.,Ibrutinib
DB09054,The risk or severity of adverse effects can be increased when Tositumomab is combined with Idelalisib.,Idelalisib
DB09073,The risk or severity of adverse effects can be increased when Tositumomab is combined with Palbociclib.,Palbociclib
DB09074,The risk or severity of adverse effects can be increased when Tositumomab is combined with Olaparib.,Olaparib
DB09077,The risk or severity of adverse effects can be increased when Tositumomab is combined with Dinutuximab.,Dinutuximab
DB09082,The risk or severity of adverse effects can be increased when Tositumomab is combined with Vilanterol.,Vilanterol
DB09091,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tixocortol.,Tixocortol
DB09122,The risk or severity of adverse effects can be increased when Tositumomab is combined with Peginterferon beta-1a.,Peginterferon beta-1a
DB09312,The risk or severity of adverse effects can be increased when Tositumomab is combined with Antilymphocyte immunoglobulin (horse).,Antilymphocyte immunoglobulin (horse)
DB09378,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fluprednisolone.,Fluprednisolone
DB09383,The risk or severity of adverse effects can be increased when Tositumomab is combined with Meprednisone.,Meprednisone
DB11466,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tepoxalin.,Tepoxalin
DB11487,The risk or severity of adverse effects can be increased when Tositumomab is combined with Dexamethasone isonicotinate.,Dexamethasone isonicotinate
DB11529,The risk or severity of adverse effects can be increased when Tositumomab is combined with Melengestrol.,Melengestrol
DB11569,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ixekizumab.,Ixekizumab
DB11580,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ravulizumab.,Ravulizumab
DB11616,The risk or severity of adverse effects can be increased when Tositumomab is combined with Pirarubicin.,Pirarubicin
DB11693,The risk or severity of adverse effects can be increased when Tositumomab is combined with Voclosporin.,Voclosporin
DB11708,The risk or severity of adverse effects can be increased when Tositumomab is combined with Peficitinib.,Peficitinib
DB11750,The risk or severity of adverse effects can be increased when Tositumomab is combined with Clobetasol.,Clobetasol
DB11767,The risk or severity of adverse effects can be increased when Tositumomab is combined with Sarilumab.,Sarilumab
DB11776,The risk or severity of adverse effects can be increased when Tositumomab is combined with Brodalumab.,Brodalumab
DB11803,The risk or severity of adverse effects can be increased when Tositumomab is combined with Sirukumab.,Sirukumab
DB11817,The risk or severity of adverse effects can be increased when Tositumomab is combined with Baricitinib.,Baricitinib
DB11834,The risk or severity of adverse effects can be increased when Tositumomab is combined with Guselkumab.,Guselkumab
DB11921,The risk or severity of adverse effects can be increased when Tositumomab is combined with Deflazacort.,Deflazacort
DB12025,The risk or severity of adverse effects can be increased when Tositumomab is combined with Triptolide.,Triptolide
DB12371,The risk or severity of adverse effects can be increased when Tositumomab is combined with Siponimod.,Siponimod
DB12612,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ozanimod.,Ozanimod
DB12617,The risk or severity of adverse effects can be increased when Tositumomab is combined with Mizoribine.,Mizoribine
DB12692,The risk or severity of adverse effects can be increased when Tositumomab is combined with Gusperimus.,Gusperimus
DB12814,The risk or severity of adverse effects can be increased when Tositumomab is combined with Cepeginterferon alfa-2B.,Cepeginterferon alfa-2B
DB12902,The risk or severity of adverse effects can be increased when Tositumomab is combined with Trofosfamide.,Trofosfamide
DB12947,The risk or severity of adverse effects can be increased when Tositumomab is combined with Doxifluridine.,Doxifluridine
DB12991,The risk or severity of adverse effects can be increased when Tositumomab is combined with Deoxyspergualin.,Deoxyspergualin
DB12996,The risk or severity of adverse effects can be increased when Tositumomab is combined with Acteoside.,Acteoside
DB13003,The risk or severity of adverse effects can be increased when Tositumomab is combined with Cortivazol.,Cortivazol
DB13014,The risk or severity of adverse effects can be increased when Tositumomab is combined with Hypericin.,Hypericin
DB13068,The risk or severity of adverse effects can be increased when Tositumomab is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.,9-(N-methyl-L-isoleucine)-cyclosporin A
DB13208,The risk or severity of adverse effects can be increased when Tositumomab is combined with Prednylidene.,Prednylidene
DB13223,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fluocortin.,Fluocortin
DB13241,The risk or severity of adverse effects can be increased when Tositumomab is combined with Begelomab.,Begelomab
DB13491,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fluperolone.,Fluperolone
DB13664,The risk or severity of adverse effects can be increased when Tositumomab is combined with Formocortal.,Formocortal
DB13728,The risk or severity of adverse effects can be increased when Tositumomab is combined with Halometasone.,Halometasone
DB13843,The risk or severity of adverse effects can be increased when Tositumomab is combined with Cloprednol.,Cloprednol
DB13856,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fluclorolone.,Fluclorolone
DB13867,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fluticasone.,Fluticasone
DB14066,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tetrandrine.,Tetrandrine
DB14219,The risk or severity of adverse effects can be increased when Tositumomab is combined with Monomethyl fumarate.,Monomethyl fumarate
DB14512,The risk or severity of adverse effects can be increased when Tositumomab is combined with Mometasone furoate.,Mometasone furoate
DB14538,The risk or severity of adverse effects can be increased when Tositumomab is combined with Hydrocortisone aceponate.,Hydrocortisone aceponate
DB14539,The risk or severity of adverse effects can be increased when Tositumomab is combined with Hydrocortisone acetate.,Hydrocortisone acetate
DB14545,The risk or severity of adverse effects can be increased when Tositumomab is combined with Hydrocortisone succinate.,Hydrocortisone succinate
DB14724,The risk or severity of adverse effects can be increased when Tositumomab is combined with Emapalumab.,Emapalumab
DB14762,The risk or severity of adverse effects can be increased when Tositumomab is combined with Risankizumab.,Risankizumab
DB14919,The risk or severity of adverse effects can be increased when Tositumomab is combined with Rozanolixizumab.,Rozanolixizumab
DB15253,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bleselumab.,Bleselumab
DB00108,The risk or severity of adverse effects can be increased when Tositumomab is combined with Natalizumab.,Natalizumab
DB00337,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tositumomab.,Pimecrolimus
DB01656,Roflumilast may increase the immunosuppressive activities of Tositumomab.,Roflumilast
DB06688,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Tositumomab.,Sipuleucel-T
DB00363,The risk or severity of neutropenia can be increased when Tositumomab is combined with Clozapine.,Clozapine
DB08894,The risk or severity of Thrombosis can be increased when Tositumomab is combined with Peginesatide.,Peginesatide
DB00012,The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tositumomab.,Darbepoetin alfa
DB00016,The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Tositumomab.,Erythropoietin
DB09107,The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tositumomab.,Methoxy polyethylene glycol-epoetin beta
DB01015,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Tositumomab.,Sulfamethoxazole
DB00255,Diethylstilbestrol may increase the thrombogenic activities of Tositumomab.,Diethylstilbestrol
DB00269,Chlorotrianisene may increase the thrombogenic activities of Tositumomab.,Chlorotrianisene
DB00655,Estrone may increase the thrombogenic activities of Tositumomab.,Estrone
DB00890,Dienestrol may increase the thrombogenic activities of Tositumomab.,Dienestrol
DB00977,Ethinylestradiol may increase the thrombogenic activities of Tositumomab.,Ethinylestradiol
DB01357,Mestranol may increase the thrombogenic activities of Tositumomab.,Mestranol
DB04573,Estriol may increase the thrombogenic activities of Tositumomab.,Estriol
DB04575,Quinestrol may increase the thrombogenic activities of Tositumomab.,Quinestrol
DB07931,Hexestrol may increase the thrombogenic activities of Tositumomab.,Hexestrol
DB09070,Tibolone may increase the thrombogenic activities of Tositumomab.,Tibolone
DB09369,Polyestradiol phosphate may increase the thrombogenic activities of Tositumomab.,Polyestradiol phosphate
DB09381,Esterified estrogens may increase the thrombogenic activities of Tositumomab.,Esterified estrogens
DB11478,Zeranol may increase the thrombogenic activities of Tositumomab.,Zeranol
DB11674,Equol may increase the thrombogenic activities of Tositumomab.,Equol
DB12487,Promestriene may increase the thrombogenic activities of Tositumomab.,Promestriene
DB13143,Methallenestril may increase the thrombogenic activities of Tositumomab.,Methallenestril
DB13386,Epimestrol may increase the thrombogenic activities of Tositumomab.,Epimestrol
DB13418,Moxestrol may increase the thrombogenic activities of Tositumomab.,Moxestrol
DB13953,Estradiol benzoate may increase the thrombogenic activities of Tositumomab.,Estradiol benzoate
DB15334,Biochanin A may increase the thrombogenic activities of Tositumomab.,Biochanin A
DB15335,Formononetin may increase the thrombogenic activities of Tositumomab.,Formononetin
DB01097,The risk or severity of adverse effects can be increased when Tositumomab is combined with Leflunomide.,Leflunomide
DB08895,Tositumomab may increase the immunosuppressive activities of Tofacitinib.,Tofacitinib
DB00072,Trastuzumab may increase the neutropenic activities of Tositumomab.,Trastuzumab
DB08868,Tositumomab may increase the immunosuppressive activities of Fingolimod.,Fingolimod
DB00864,Tacrolimus may increase the immunosuppressive activities of Tositumomab.,Tacrolimus
DB00001,The risk or severity of bleeding and hemorrhage can be increased when Lepirudin is combined with Tositumomab.,Lepirudin
DB00006,The risk or severity of bleeding and hemorrhage can be increased when Bivalirudin is combined with Tositumomab.,Bivalirudin
DB00009,The risk or severity of bleeding and hemorrhage can be increased when Alteplase is combined with Tositumomab.,Alteplase
DB00013,The risk or severity of bleeding and hemorrhage can be increased when Urokinase is combined with Tositumomab.,Urokinase
DB00015,The risk or severity of bleeding and hemorrhage can be increased when Reteplase is combined with Tositumomab.,Reteplase
DB00029,The risk or severity of bleeding and hemorrhage can be increased when Anistreplase is combined with Tositumomab.,Anistreplase
DB00031,The risk or severity of bleeding and hemorrhage can be increased when Tenecteplase is combined with Tositumomab.,Tenecteplase
DB00055,The risk or severity of bleeding and hemorrhage can be increased when Drotrecogin alfa is combined with Tositumomab.,Drotrecogin alfa
DB00086,The risk or severity of bleeding and hemorrhage can be increased when Streptokinase is combined with Tositumomab.,Streptokinase
DB00266,The risk or severity of bleeding and hemorrhage can be increased when Dicoumarol is combined with Tositumomab.,Dicoumarol
DB00278,The risk or severity of bleeding and hemorrhage can be increased when Argatroban is combined with Tositumomab.,Argatroban
DB00407,The risk or severity of bleeding and hemorrhage can be increased when Ardeparin is combined with Tositumomab.,Ardeparin
DB00498,The risk or severity of bleeding and hemorrhage can be increased when Phenindione is combined with Tositumomab.,Phenindione
DB00569,The risk or severity of bleeding and hemorrhage can be increased when Fondaparinux is combined with Tositumomab.,Fondaparinux
DB00682,The risk or severity of bleeding and hemorrhage can be increased when Warfarin is combined with Tositumomab.,Warfarin
DB00686,The risk or severity of bleeding and hemorrhage can be increased when Pentosan polysulfate is combined with Tositumomab.,Pentosan polysulfate
DB00946,The risk or severity of bleeding and hemorrhage can be increased when Phenprocoumon is combined with Tositumomab.,Phenprocoumon
DB01109,The risk or severity of bleeding and hemorrhage can be increased when Heparin is combined with Tositumomab.,Heparin
DB01225,The risk or severity of bleeding and hemorrhage can be increased when Enoxaparin is combined with Tositumomab.,Enoxaparin
DB01418,The risk or severity of bleeding and hemorrhage can be increased when Acenocoumarol is combined with Tositumomab.,Acenocoumarol
DB03410,The risk or severity of bleeding and hemorrhage can be increased when 4-hydroxycoumarin is combined with Tositumomab.,4-hydroxycoumarin
DB04665,The risk or severity of bleeding and hemorrhage can be increased when Coumarin is combined with Tositumomab.,Coumarin
DB04898,The risk or severity of bleeding and hemorrhage can be increased when Ximelagatran is combined with Tositumomab.,Ximelagatran
DB04925,The risk or severity of bleeding and hemorrhage can be increased when Desmoteplase is combined with Tositumomab.,Desmoteplase
DB05099,The risk or severity of bleeding and hemorrhage can be increased when Ancrod is combined with Tositumomab.,Ancrod
DB05254,The risk or severity of bleeding and hemorrhage can be increased when Fibrinolysin is combined with Tositumomab.,Fibrinolysin
DB06228,The risk or severity of bleeding and hemorrhage can be increased when Rivaroxaban is combined with Tositumomab.,Rivaroxaban
DB06271,The risk or severity of bleeding and hemorrhage can be increased when Sulodexide is combined with Tositumomab.,Sulodexide
DB06294,The risk or severity of bleeding and hemorrhage can be increased when Semuloparin is combined with Tositumomab.,Semuloparin
DB06406,The risk or severity of bleeding and hemorrhage can be increased when Idraparinux is combined with Tositumomab.,Idraparinux
DB06543,The risk or severity of bleeding and hemorrhage can be increased when Astaxanthin is combined with Tositumomab.,Astaxanthin
DB06605,The risk or severity of bleeding and hemorrhage can be increased when Apixaban is combined with Tositumomab.,Apixaban
DB06635,The risk or severity of bleeding and hemorrhage can be increased when Otamixaban is combined with Tositumomab.,Otamixaban
DB06679,The risk or severity of bleeding and hemorrhage can be increased when Amediplase is combined with Tositumomab.,Amediplase
DB06695,The risk or severity of bleeding and hemorrhage can be increased when Dabigatran etexilate is combined with Tositumomab.,Dabigatran etexilate
DB06754,The risk or severity of bleeding and hemorrhage can be increased when Danaparoid is combined with Tositumomab.,Danaparoid
DB06779,The risk or severity of bleeding and hemorrhage can be increased when Dalteparin is combined with Tositumomab.,Dalteparin
DB06822,The risk or severity of bleeding and hemorrhage can be increased when Tinzaparin is combined with Tositumomab.,Tinzaparin
DB07767,The risk or severity of bleeding and hemorrhage can be increased when Ferulic acid is combined with Tositumomab.,Ferulic acid
DB08496,The risk or severity of bleeding and hemorrhage can be increased when (R)-warfarin is combined with Tositumomab.,(R)-warfarin
DB08794,The risk or severity of bleeding and hemorrhage can be increased when Ethyl biscoumacetate is combined with Tositumomab.,Ethyl biscoumacetate
DB08813,The risk or severity of bleeding and hemorrhage can be increased when Nadroparin is combined with Tositumomab.,Nadroparin
DB08994,The risk or severity of bleeding and hemorrhage can be increased when Ditazole is combined with Tositumomab.,Ditazole
DB09075,The risk or severity of bleeding and hemorrhage can be increased when Edoxaban is combined with Tositumomab.,Edoxaban
DB09125,The risk or severity of bleeding and hemorrhage can be increased when Potassium citrate is combined with Tositumomab.,Potassium citrate
DB09154,The risk or severity of bleeding and hemorrhage can be increased when Sodium citrate is combined with Tositumomab.,Sodium citrate
DB09255,The risk or severity of bleeding and hemorrhage can be increased when Dextran is combined with Tositumomab.,Dextran
DB09258,The risk or severity of bleeding and hemorrhage can be increased when Bemiparin is combined with Tositumomab.,Bemiparin
DB09259,The risk or severity of bleeding and hemorrhage can be increased when Reviparin is combined with Tositumomab.,Reviparin
DB09260,The risk or severity of bleeding and hemorrhage can be increased when Parnaparin is combined with Tositumomab.,Parnaparin
DB09261,The risk or severity of bleeding and hemorrhage can be increased when Certoparin is combined with Tositumomab.,Certoparin
DB11095,The risk or severity of bleeding and hemorrhage can be increased when Desirudin is combined with Tositumomab.,Desirudin
DB11154,The risk or severity of bleeding and hemorrhage can be increased when Zinc citrate is combined with Tositumomab.,Zinc citrate
DB11166,The risk or severity of bleeding and hemorrhage can be increased when Antithrombin Alfa is combined with Tositumomab.,Antithrombin Alfa
DB11312,The risk or severity of bleeding and hemorrhage can be increased when Protein C is combined with Tositumomab.,Protein C
DB11598,The risk or severity of bleeding and hemorrhage can be increased when Antithrombin III human is combined with Tositumomab.,Antithrombin III human
DB11984,The risk or severity of bleeding and hemorrhage can be increased when Letaxaban is combined with Tositumomab.,Letaxaban
DB12289,The risk or severity of bleeding and hemorrhage can be increased when Darexaban is combined with Tositumomab.,Darexaban
DB12364,The risk or severity of bleeding and hemorrhage can be increased when Betrixaban is combined with Tositumomab.,Betrixaban
DB12598,The risk or severity of bleeding and hemorrhage can be increased when Nafamostat is combined with Tositumomab.,Nafamostat
DB12726,The risk or severity of bleeding and hemorrhage can be increased when Monteplase is combined with Tositumomab.,Monteplase
DB12831,The risk or severity of bleeding and hemorrhage can be increased when Gabexate is combined with Tositumomab.,Gabexate
DB13136,The risk or severity of bleeding and hemorrhage can be increased when Fluindione is combined with Tositumomab.,Fluindione
DB13149,The risk or severity of bleeding and hemorrhage can be increased when Protein S human is combined with Tositumomab.,Protein S human
DB13199,The risk or severity of bleeding and hemorrhage can be increased when Brinase is combined with Tositumomab.,Brinase
DB13275,The risk or severity of bleeding and hemorrhage can be increased when Clorindione is combined with Tositumomab.,Clorindione
DB13347,The risk or severity of bleeding and hemorrhage can be increased when Diphenadione is combined with Tositumomab.,Diphenadione
DB13451,The risk or severity of bleeding and hemorrhage can be increased when Tioclomarol is combined with Tositumomab.,Tioclomarol
DB13616,The risk or severity of bleeding and hemorrhage can be increased when Melagatran is combined with Tositumomab.,Melagatran
DB13646,The risk or severity of bleeding and hemorrhage can be increased when Saruplase is combined with Tositumomab.,Saruplase
DB14055,The risk or severity of bleeding and hemorrhage can be increased when (S)-Warfarin is combined with Tositumomab.,(S)-Warfarin
DB14094,The risk or severity of bleeding and hemorrhage can be increased when Tocopherylquinone is combined with Tositumomab.,Tocopherylquinone
DB14598,The risk or severity of bleeding and hemorrhage can be increased when Edetate calcium disodium anhydrous is combined with Tositumomab.,Edetate calcium disodium anhydrous
DB14726,The risk or severity of bleeding and hemorrhage can be increased when Dabigatran is combined with Tositumomab.,Dabigatran
DB00054,The risk or severity of adverse effects can be increased when Abciximab is combined with Tositumomab.,Abciximab
DB00063,The risk or severity of adverse effects can be increased when Eptifibatide is combined with Tositumomab.,Eptifibatide
DB00208,The risk or severity of adverse effects can be increased when Ticlopidine is combined with Tositumomab.,Ticlopidine
DB00261,The risk or severity of adverse effects can be increased when Anagrelide is combined with Tositumomab.,Anagrelide
DB00758,The risk or severity of adverse effects can be increased when Clopidogrel is combined with Tositumomab.,Clopidogrel
DB00775,The risk or severity of adverse effects can be increased when Tirofiban is combined with Tositumomab.,Tirofiban
DB00806,The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Tositumomab.,Pentoxifylline
DB00945,The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Tositumomab.,Acetylsalicylic acid
DB00975,The risk or severity of adverse effects can be increased when Dipyridamole is combined with Tositumomab.,Dipyridamole
DB01088,The risk or severity of adverse effects can be increased when Iloprost is combined with Tositumomab.,Iloprost
DB01138,The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Tositumomab.,Sulfinpyrazone
DB01166,The risk or severity of adverse effects can be increased when Cilostazol is combined with Tositumomab.,Cilostazol
DB01207,The risk or severity of adverse effects can be increased when Ridogrel is combined with Tositumomab.,Ridogrel
DB01236,The risk or severity of adverse effects can be increased when Sevoflurane is combined with Tositumomab.,Sevoflurane
DB01240,The risk or severity of adverse effects can be increased when Epoprostenol is combined with Tositumomab.,Epoprostenol
DB02709,The risk or severity of adverse effects can be increased when Resveratrol is combined with Tositumomab.,Resveratrol
DB04743,The risk or severity of adverse effects can be increased when Nimesulide is combined with Tositumomab.,Nimesulide
DB04905,The risk or severity of adverse effects can be increased when Tesmilifene is combined with Tositumomab.,Tesmilifene
DB04932,The risk or severity of adverse effects can be increased when Defibrotide is combined with Tositumomab.,Defibrotide
DB05229,The risk or severity of adverse effects can be increased when Beraprost is combined with Tositumomab.,Beraprost
DB05266,The risk or severity of adverse effects can be increased when Ibudilast is combined with Tositumomab.,Ibudilast
DB05767,The risk or severity of adverse effects can be increased when Andrographolide is combined with Tositumomab.,Andrographolide
DB06081,The risk or severity of adverse effects can be increased when Caplacizumab is combined with Tositumomab.,Caplacizumab
DB06209,The risk or severity of adverse effects can be increased when Prasugrel is combined with Tositumomab.,Prasugrel
DB06441,The risk or severity of adverse effects can be increased when Cangrelor is combined with Tositumomab.,Cangrelor
DB07615,The risk or severity of adverse effects can be increased when Tranilast is combined with Tositumomab.,Tranilast
DB08814,The risk or severity of adverse effects can be increased when Triflusal is combined with Tositumomab.,Triflusal
DB08816,The risk or severity of adverse effects can be increased when Ticagrelor is combined with Tositumomab.,Ticagrelor
DB08887,The risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Tositumomab.,Icosapent ethyl
DB09030,The risk or severity of adverse effects can be increased when Vorapaxar is combined with Tositumomab.,Vorapaxar
DB09283,The risk or severity of adverse effects can be increased when Trapidil is combined with Tositumomab.,Trapidil
DB12092,The risk or severity of adverse effects can be increased when Naftopidil is combined with Tositumomab.,Naftopidil
DB12163,The risk or severity of adverse effects can be increased when Sarpogrelate is combined with Tositumomab.,Sarpogrelate
DB12321,The risk or severity of adverse effects can be increased when Ifetroban is combined with Tositumomab.,Ifetroban
DB12445,The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Tositumomab.,Nitroaspirin
DB12465,The risk or severity of adverse effects can be increased when Ketanserin is combined with Tositumomab.,Ketanserin
DB12545,The risk or severity of adverse effects can be increased when Indobufen is combined with Tositumomab.,Indobufen
DB12749,The risk or severity of adverse effects can be increased when Butylphthalide is combined with Tositumomab.,Butylphthalide
DB12771,The risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Tositumomab.,Hydroxytyrosol
DB13036,The risk or severity of adverse effects can be increased when Ramatroban is combined with Tositumomab.,Ramatroban
DB13327,The risk or severity of adverse effects can be increased when Picotamide is combined with Tositumomab.,Picotamide
DB13367,The risk or severity of adverse effects can be increased when Cloricromen is combined with Tositumomab.,Cloricromen
DB13400,The risk or severity of adverse effects can be increased when Linsidomine is combined with Tositumomab.,Linsidomine
DB13510,The risk or severity of adverse effects can be increased when Buflomedil is combined with Tositumomab.,Buflomedil
DB13929,The risk or severity of adverse effects can be increased when Relcovaptan is combined with Tositumomab.,Relcovaptan
DB04914,The therapeutic efficacy of G17DT can be decreased when used in combination with Tositumomab.,G17DT
DB05144,The therapeutic efficacy of PEV3A can be decreased when used in combination with Tositumomab.,PEV3A
DB05325,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Tositumomab.,INGN 225
DB05374,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Tositumomab.,Rindopepimut
DB05440,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Tositumomab.,SRP 299
DB05942,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Tositumomab.,GI-5005
DB06400,The therapeutic efficacy of Vitespen can be decreased when used in combination with Tositumomab.,Vitespen
DB06584,The therapeutic efficacy of TG4010 can be decreased when used in combination with Tositumomab.,TG4010
DB09057,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Tositumomab.,Anthrax immune globulin human
DB10062,"The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Tositumomab.","Rabies virus inactivated antigen, B"
DB10076,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Tositumomab.,Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen
DB10276,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Tositumomab.,Rotavirus vaccine
DB10283,"The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Tositumomab.","Rabies virus inactivated antigen, A"
DB10342,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Tositumomab.,Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen
DB10583,The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Tositumomab.,Clostridium tetani toxoid antigen (formaldehyde inactivated)
DB10584,The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Tositumomab.,Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
DB10600,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Tositumomab.,Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated)
DB10769,The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Tositumomab.,Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)
DB10794,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Tositumomab.,Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated)
DB10803,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Tositumomab.,Typhoid Vi polysaccharide vaccine
DB10989,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Tositumomab.,Hepatitis A Vaccine
DB10990,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Tositumomab.,Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
DB11038,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Tositumomab.,Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated)
DB11040,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Tositumomab.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated)
DB11041,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Tositumomab.,Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)
DB11044,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Tositumomab.,Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated)
DB11603,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Tositumomab.,Human rabies virus immune globulin
DB11627,The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Tositumomab.,Hepatitis B Vaccine (Recombinant)
DB12568,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Tositumomab.,Tecemotide
DB14022,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Tositumomab.,Typhoid vaccine
DB14384,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Tositumomab.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated)
DB14385,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Tositumomab.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)
DB14394,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Tositumomab.,Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen
DB14445,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Tositumomab.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated)
DB14449,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Tositumomab.,Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen
DB14619,The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Tositumomab.,Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated)
DB14620,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Tositumomab.,Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated)
DB14711,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Tositumomab.,Vaccinia virus strain new york city board of health live antigen
DB15274,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Tositumomab.,Pertussis vaccine
DB15461,The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Tositumomab.,Yersinia pestis 195/p antigen (formaldehyde inactivated)
DB13924,The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Tositumomab.,Varicella Zoster Vaccine (Recombinant)
DB15483,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Tositumomab.,Modified vaccinia ankara
DB11988,Ocrelizumab may increase the immunosuppressive activities of Tositumomab.,Ocrelizumab
DB13200,Tositumomab may increase the myelosuppressive activities of Lipegfilgrastim.,Lipegfilgrastim
DB10317,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Tositumomab.,Rubella virus vaccine
DB10318,The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Tositumomab.,Varicella Zoster Vaccine (Live/attenuated)
DB10343,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Tositumomab.,Bacillus calmette-guerin substrain tice live antigen
DB10804,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Tositumomab.,Bacillus calmette-guerin substrain connaught live antigen
DB10805,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Tositumomab.,Yellow Fever Vaccine
DB11003,The risk or severity of infection can be increased when Anthrax vaccine is combined with Tositumomab.,Anthrax vaccine
DB11050,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Tositumomab.,Typhoid Vaccine Live
DB12386,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Tositumomab.,Bacillus calmette-guerin substrain danish 1331 live antigen
DB12768,The risk or severity of infection can be increased when BCG vaccine is combined with Tositumomab.,BCG vaccine
DB14409,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Tositumomab.,Human adenovirus e serotype 4 strain cl-68578 antigen
DB14443,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Tositumomab.,Vibrio cholerae CVD 103-HgR strain live antigen
DB14685,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Tositumomab.,Adenovirus type 7 vaccine live
DB00002,The risk or severity of adverse effects can be increased when Cetuximab is combined with Tositumomab.,Cetuximab
DB00028,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tositumomab.,Human immunoglobulin G
DB00043,The risk or severity of adverse effects can be increased when Omalizumab is combined with Tositumomab.,Omalizumab
DB00057,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tositumomab.,Indium In-111 satumomab pendetide
DB00076,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tositumomab.,Digoxin Immune Fab (Ovine)
DB00089,The risk or severity of adverse effects can be increased when Tositumomab is combined with Capromab pendetide.,Capromab pendetide
DB00110,The risk or severity of adverse effects can be increased when Tositumomab is combined with Palivizumab.,Palivizumab
DB00113,The risk or severity of adverse effects can be increased when Tositumomab is combined with Technetium Tc-99m arcitumomab.,Technetium Tc-99m arcitumomab
DB01269,The risk or severity of adverse effects can be increased when Tositumomab is combined with Panitumumab.,Panitumumab
DB01270,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ranibizumab.,Ranibizumab
DB04901,The risk or severity of adverse effects can be increased when Tositumomab is combined with Galiximab.,Galiximab
DB04949,The risk or severity of adverse effects can be increased when Tositumomab is combined with Pexelizumab.,Pexelizumab
DB04958,The risk or severity of adverse effects can be increased when Tositumomab is combined with Epratuzumab.,Epratuzumab
DB04962,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bectumomab.,Bectumomab
DB04964,The risk or severity of adverse effects can be increased when Tositumomab is combined with Oregovomab.,Oregovomab
DB04988,The risk or severity of adverse effects can be increased when Tositumomab is combined with IGN311.,IGN311
DB05006,The risk or severity of adverse effects can be increased when Tositumomab is combined with Adecatumumab.,Adecatumumab
DB05097,The risk or severity of adverse effects can be increased when Tositumomab is combined with Labetuzumab.,Labetuzumab
DB05101,The risk or severity of adverse effects can be increased when Tositumomab is combined with Matuzumab.,Matuzumab
DB05111,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fontolizumab.,Fontolizumab
DB05136,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bavituximab.,Bavituximab
DB05139,The risk or severity of adverse effects can be increased when Tositumomab is combined with CR002.,CR002
DB05209,The risk or severity of adverse effects can be increased when Tositumomab is combined with Rozrolimupab.,Rozrolimupab
DB05304,The risk or severity of adverse effects can be increased when Tositumomab is combined with Girentuximab.,Girentuximab
DB05336,The risk or severity of adverse effects can be increased when Tositumomab is combined with Obiltoxaximab.,Obiltoxaximab
DB05405,The risk or severity of adverse effects can be increased when Tositumomab is combined with XTL-001.,XTL-001
DB05437,The risk or severity of adverse effects can be increased when Tositumomab is combined with NAV 1800.,NAV 1800
DB05496,The risk or severity of adverse effects can be increased when Tositumomab is combined with Otelixizumab.,Otelixizumab
DB05545,The risk or severity of adverse effects can be increased when Tositumomab is combined with AMG 108.,AMG 108
DB05550,The risk or severity of adverse effects can be increased when Tositumomab is combined with Iratumumab.,Iratumumab
DB05555,The risk or severity of adverse effects can be increased when Tositumomab is combined with Enokizumab.,Enokizumab
DB05578,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ramucirumab.,Ramucirumab
DB05595,The risk or severity of adverse effects can be increased when Tositumomab is combined with Farletuzumab.,Farletuzumab
DB05656,The risk or severity of adverse effects can be increased when Tositumomab is combined with Veltuzumab.,Veltuzumab
DB05793,The risk or severity of adverse effects can be increased when Tositumomab is combined with PRO-542.,PRO-542
DB05797,The risk or severity of adverse effects can be increased when Tositumomab is combined with TNX-901.,TNX-901
DB05889,The risk or severity of adverse effects can be increased when Tositumomab is combined with Inotuzumab ozogamicin.,Inotuzumab ozogamicin
DB05892,The risk or severity of adverse effects can be increased when Tositumomab is combined with RI 624.,RI 624
DB05915,The risk or severity of adverse effects can be increased when Tositumomab is combined with MYO-029.,MYO-029
DB05916,The risk or severity of adverse effects can be increased when Tositumomab is combined with CT-011.,CT-011
DB05941,The risk or severity of adverse effects can be increased when Tositumomab is combined with Leronlimab.,Leronlimab
DB05996,The risk or severity of adverse effects can be increased when Tositumomab is combined with Glembatumumab vedotin.,Glembatumumab vedotin
DB06043,The risk or severity of adverse effects can be increased when Tositumomab is combined with Olaratumab.,Olaratumab
DB06049,The risk or severity of adverse effects can be increased when Tositumomab is combined with IPH 2101.,IPH 2101
DB06050,The risk or severity of adverse effects can be increased when Tositumomab is combined with TB-402.,TB-402
DB06101,The risk or severity of adverse effects can be increased when Tositumomab is combined with IMC-1C11.,IMC-1C11
DB06116,The risk or severity of adverse effects can be increased when Tositumomab is combined with Eldelumab.,Eldelumab
DB06162,The risk or severity of adverse effects can be increased when Tositumomab is combined with Lumiliximab.,Lumiliximab
DB06192,The risk or severity of adverse effects can be increased when Tositumomab is combined with Nimotuzumab.,Nimotuzumab
DB06241,The risk or severity of adverse effects can be increased when Tositumomab is combined with Clenoliximab.,Clenoliximab
DB06304,The risk or severity of adverse effects can be increased when Tositumomab is combined with BIIB015.,BIIB015
DB06305,The risk or severity of adverse effects can be increased when Tositumomab is combined with Sonepcizumab.,Sonepcizumab
DB06310,The risk or severity of adverse effects can be increased when Tositumomab is combined with Motavizumab.,Motavizumab
DB06317,The risk or severity of adverse effects can be increased when Tositumomab is combined with Elotuzumab.,Elotuzumab
DB06318,The risk or severity of adverse effects can be increased when Tositumomab is combined with AVE9633.,AVE9633
DB06322,The risk or severity of adverse effects can be increased when Tositumomab is combined with Carotuximab.,Carotuximab
DB06324,The risk or severity of adverse effects can be increased when Tositumomab is combined with XmAb 2513.,XmAb 2513
DB06342,The risk or severity of adverse effects can be increased when Tositumomab is combined with Coltuximab ravtansine.,Coltuximab ravtansine
DB06343,The risk or severity of adverse effects can be increased when Tositumomab is combined with Teprotumumab.,Teprotumumab
DB06360,The risk or severity of adverse effects can be increased when Tositumomab is combined with Lucatumumab.,Lucatumumab
DB06366,The risk or severity of adverse effects can be increased when Tositumomab is combined with Pertuzumab.,Pertuzumab
DB06371,The risk or severity of adverse effects can be increased when Tositumomab is combined with Siplizumab.,Siplizumab
DB06467,The risk or severity of adverse effects can be increased when Tositumomab is combined with Apolizumab.,Apolizumab
DB06474,The risk or severity of adverse effects can be increased when Tositumomab is combined with Sibrotuzumab.,Sibrotuzumab
DB06550,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bivatuzumab.,Bivatuzumab
DB06557,The risk or severity of adverse effects can be increased when Tositumomab is combined with Lerdelimumab.,Lerdelimumab
DB06599,The risk or severity of adverse effects can be increased when Tositumomab is combined with Lexatumumab.,Lexatumumab
DB06602,The risk or severity of adverse effects can be increased when Tositumomab is combined with Reslizumab.,Reslizumab
DB06606,The risk or severity of adverse effects can be increased when Tositumomab is combined with Teplizumab.,Teplizumab
DB06607,The risk or severity of adverse effects can be increased when Tositumomab is combined with Catumaxomab.,Catumaxomab
DB06647,The risk or severity of adverse effects can be increased when Tositumomab is combined with Volociximab.,Volociximab
DB06650,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ofatumumab.,Ofatumumab
DB08902,The risk or severity of adverse effects can be increased when Tositumomab is combined with Raxibacumab.,Raxibacumab
DB09035,The risk or severity of adverse effects can be increased when Tositumomab is combined with Nivolumab.,Nivolumab
DB09037,The risk or severity of adverse effects can be increased when Tositumomab is combined with Pembrolizumab.,Pembrolizumab
DB09045,The risk or severity of adverse effects can be increased when Tositumomab is combined with Dulaglutide.,Dulaglutide
DB09105,The risk or severity of adverse effects can be increased when Tositumomab is combined with Asfotase alfa.,Asfotase alfa
DB09302,The risk or severity of adverse effects can be increased when Tositumomab is combined with Alirocumab.,Alirocumab
DB09303,The risk or severity of adverse effects can be increased when Tositumomab is combined with Evolocumab.,Evolocumab
DB09331,The risk or severity of adverse effects can be increased when Tositumomab is combined with Daratumumab.,Daratumumab
DB09559,The risk or severity of adverse effects can be increased when Tositumomab is combined with Necitumumab.,Necitumumab
DB11595,The risk or severity of adverse effects can be increased when Tositumomab is combined with Atezolizumab.,Atezolizumab
DB11604,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tetanus Immune Globulin.,Tetanus Immune Globulin
DB11608,The risk or severity of adverse effects can be increased when Tositumomab is combined with Eftrenonacog alfa.,Eftrenonacog alfa
DB11621,The risk or severity of adverse effects can be increased when Tositumomab is combined with Human Varicella-Zoster Immune Globulin.,Human Varicella-Zoster Immune Globulin
DB11646,The risk or severity of adverse effects can be increased when Tositumomab is combined with Conatumumab.,Conatumumab
DB11657,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tabalumab.,Tabalumab
DB11680,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ficlatuzumab.,Ficlatuzumab
DB11685,The risk or severity of adverse effects can be increased when Tositumomab is combined with Figitumumab.,Figitumumab
DB11714,The risk or severity of adverse effects can be increased when Tositumomab is combined with Durvalumab.,Durvalumab
DB11715,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bapineuzumab.,Bapineuzumab
DB11731,The risk or severity of adverse effects can be increased when Tositumomab is combined with Depatuxizumab mafodotin.,Depatuxizumab mafodotin
DB11746,The risk or severity of adverse effects can be increased when Tositumomab is combined with Onartuzumab.,Onartuzumab
DB11756,The risk or severity of adverse effects can be increased when Tositumomab is combined with Solanezumab.,Solanezumab
DB11771,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tremelimumab.,Tremelimumab
DB11826,The risk or severity of adverse effects can be increased when Tositumomab is combined with Lampalizumab.,Lampalizumab
DB11840,The risk or severity of adverse effects can be increased when Tositumomab is combined with Dalotuzumab.,Dalotuzumab
DB11849,The risk or severity of adverse effects can be increased when Tositumomab is combined with Emibetuzumab.,Emibetuzumab
DB11850,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ublituximab.,Ublituximab
DB11856,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ligelizumab.,Ligelizumab
DB11857,The risk or severity of adverse effects can be increased when Tositumomab is combined with Seribantumab.,Seribantumab
DB11862,The risk or severity of adverse effects can be increased when Tositumomab is combined with Landogrozumab.,Landogrozumab
DB11866,The risk or severity of adverse effects can be increased when Tositumomab is combined with Romosozumab.,Romosozumab
DB11884,The risk or severity of adverse effects can be increased when Tositumomab is combined with Vadastuximab Talirine.,Vadastuximab Talirine
DB11914,The risk or severity of adverse effects can be increased when Tositumomab is combined with Lebrikizumab.,Lebrikizumab
DB11930,The risk or severity of adverse effects can be increased when Tositumomab is combined with Varlilumab.,Varlilumab
DB11945,The risk or severity of adverse effects can be increased when Tositumomab is combined with Avelumab.,Avelumab
DB11959,The risk or severity of adverse effects can be increased when Tositumomab is combined with Crenezumab.,Crenezumab
DB11972,The risk or severity of adverse effects can be increased when Tositumomab is combined with Rilotumumab.,Rilotumumab
DB11976,The risk or severity of adverse effects can be increased when Tositumomab is combined with Anifrolumab.,Anifrolumab
DB12023,The risk or severity of adverse effects can be increased when Tositumomab is combined with Benralizumab.,Benralizumab
DB12034,The risk or severity of adverse effects can be increased when Tositumomab is combined with Gantenerumab.,Gantenerumab
DB12053,The risk or severity of adverse effects can be increased when Tositumomab is combined with Visilizumab.,Visilizumab
DB12077,The risk or severity of adverse effects can be increased when Tositumomab is combined with Urelumab.,Urelumab
DB12089,The risk or severity of adverse effects can be increased when Tositumomab is combined with Lorvotuzumab mertansine.,Lorvotuzumab mertansine
DB12090,The risk or severity of adverse effects can be increased when Tositumomab is combined with Patritumab.,Patritumab
DB12102,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fulranumab.,Fulranumab
DB12104,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tarextumab.,Tarextumab
DB12118,The risk or severity of adverse effects can be increased when Tositumomab is combined with Sotatercept.,Sotatercept
DB12119,The risk or severity of adverse effects can be increased when Tositumomab is combined with Gevokizumab.,Gevokizumab
DB12142,The risk or severity of adverse effects can be increased when Tositumomab is combined with Duligotuzumab.,Duligotuzumab
DB12152,The risk or severity of adverse effects can be increased when Tositumomab is combined with Simtuzumab.,Simtuzumab
DB12157,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fasinumab.,Fasinumab
DB12159,The risk or severity of adverse effects can be increased when Tositumomab is combined with Dupilumab.,Dupilumab
DB12169,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tralokinumab.,Tralokinumab
DB12189,The risk or severity of adverse effects can be increased when Tositumomab is combined with Etrolizumab.,Etrolizumab
DB12202,The risk or severity of adverse effects can be increased when Tositumomab is combined with Zalutumumab.,Zalutumumab
DB12205,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ganitumab.,Ganitumab
DB12213,The risk or severity of adverse effects can be increased when Tositumomab is combined with Etaracizumab.,Etaracizumab
DB12240,The risk or severity of adverse effects can be increased when Tositumomab is combined with Polatuzumab vedotin.,Polatuzumab vedotin
DB12246,The risk or severity of adverse effects can be increased when Tositumomab is combined with Inclacumab.,Inclacumab
DB12250,The risk or severity of adverse effects can be increased when Tositumomab is combined with Cixutumumab.,Cixutumumab
DB12261,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ascrinvacumab.,Ascrinvacumab
DB12274,The risk or severity of adverse effects can be increased when Tositumomab is combined with Aducanumab.,Aducanumab
DB12281,The risk or severity of adverse effects can be increased when Tositumomab is combined with Luspatercept.,Luspatercept
DB12296,The risk or severity of adverse effects can be increased when Tositumomab is combined with GS-5745.,GS-5745
DB12317,The risk or severity of adverse effects can be increased when Tositumomab is combined with Vanucizumab.,Vanucizumab
DB12331,The risk or severity of adverse effects can be increased when Tositumomab is combined with Labetuzumab govitecan.,Labetuzumab govitecan
DB12335,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tanezumab.,Tanezumab
DB12342,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ensituximab.,Ensituximab
DB12344,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fezakinumab.,Fezakinumab
DB12363,The risk or severity of adverse effects can be increased when Tositumomab is combined with Dusigitumab.,Dusigitumab
DB12396,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fresolimumab.,Fresolimumab
DB12413,The risk or severity of adverse effects can be increased when Tositumomab is combined with Indusatumab vedotin.,Indusatumab vedotin
DB12456,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bococizumab.,Bococizumab
DB12489,The risk or severity of adverse effects can be increased when Tositumomab is combined with Mirvetuximab Soravtansine.,Mirvetuximab Soravtansine
DB12498,The risk or severity of adverse effects can be increased when Tositumomab is combined with Mogamulizumab.,Mogamulizumab
DB12520,The risk or severity of adverse effects can be increased when Tositumomab is combined with Plozalizumab.,Plozalizumab
DB12534,The risk or severity of adverse effects can be increased when Tositumomab is combined with Mavrilimumab.,Mavrilimumab
DB12560,The risk or severity of adverse effects can be increased when Tositumomab is combined with Blosozumab.,Blosozumab
DB12584,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bimagrumab.,Bimagrumab
DB12589,The risk or severity of adverse effects can be increased when Tositumomab is combined with Dacetuzumab.,Dacetuzumab
DB12609,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tovetumab.,Tovetumab
DB12683,The risk or severity of adverse effects can be increased when Tositumomab is combined with Lumretuzumab.,Lumretuzumab
DB12698,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ibalizumab.,Ibalizumab
DB12701,The risk or severity of adverse effects can be increased when Tositumomab is combined with Intetumumab.,Intetumumab
DB12718,The risk or severity of adverse effects can be increased when Tositumomab is combined with Carlumab.,Carlumab
DB12734,The risk or severity of adverse effects can be increased when Tositumomab is combined with Demcizumab.,Demcizumab
DB12773,The risk or severity of adverse effects can be increased when Tositumomab is combined with Sifalimumab.,Sifalimumab
DB12775,The risk or severity of adverse effects can be increased when Tositumomab is combined with Abituzumab.,Abituzumab
DB12797,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ecromeximab.,Ecromeximab
DB12807,The risk or severity of adverse effects can be increased when Tositumomab is combined with Naptumomab Estafenatox.,Naptumomab Estafenatox
DB12815,The risk or severity of adverse effects can be increased when Tositumomab is combined with Crotedumab.,Crotedumab
DB12820,The risk or severity of adverse effects can be increased when Tositumomab is combined with Concizumab.,Concizumab
DB12826,The risk or severity of adverse effects can be increased when Tositumomab is combined with Depatuxizumab.,Depatuxizumab
DB12844,The risk or severity of adverse effects can be increased when Tositumomab is combined with Rontalizumab.,Rontalizumab
DB12845,The risk or severity of adverse effects can be increased when Tositumomab is combined with Amatuximab.,Amatuximab
DB12849,The risk or severity of adverse effects can be increased when Tositumomab is combined with Clazakizumab.,Clazakizumab
DB12891,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ozanezumab.,Ozanezumab
DB12893,The risk or severity of adverse effects can be increased when Tositumomab is combined with Sacituzumab govitecan.,Sacituzumab govitecan
DB12917,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bimekizumab.,Bimekizumab
DB12943,The risk or severity of adverse effects can be increased when Tositumomab is combined with Milatuzumab.,Milatuzumab
DB12976,The risk or severity of adverse effects can be increased when Tositumomab is combined with Robatumumab.,Robatumumab
DB13017,The risk or severity of adverse effects can be increased when Tositumomab is combined with Rovalpituzumab Tesirine.,Rovalpituzumab Tesirine
DB13037,The risk or severity of adverse effects can be increased when Tositumomab is combined with Namilumab.,Namilumab
DB13045,The risk or severity of adverse effects can be increased when Tositumomab is combined with Racotumomab.,Racotumomab
DB13073,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tregalizumab.,Tregalizumab
DB13127,The risk or severity of adverse effects can be increased when Tositumomab is combined with Olokizumab.,Olokizumab
DB13140,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bezlotoxumab.,Bezlotoxumab
DB13375,The risk or severity of adverse effects can be increased when Tositumomab is combined with Edrecolomab.,Edrecolomab
DB13535,The risk or severity of adverse effects can be increased when Tositumomab is combined with Nebacumab.,Nebacumab
DB13886,The risk or severity of adverse effects can be increased when Tositumomab is combined with Human cytomegalovirus immune globulin.,Human cytomegalovirus immune globulin
DB13923,The risk or severity of adverse effects can be increased when Tositumomab is combined with Emicizumab.,Emicizumab
DB13976,The risk or severity of adverse effects can be increased when Tositumomab is combined with Sulesomab.,Sulesomab
DB13979,The risk or severity of adverse effects can be increased when Tositumomab is combined with Besilesomab.,Besilesomab
DB14012,The risk or severity of adverse effects can be increased when Tositumomab is combined with Burosumab.,Burosumab
DB14039,The risk or severity of adverse effects can be increased when Tositumomab is combined with Erenumab.,Erenumab
DB14040,The risk or severity of adverse effects can be increased when Tositumomab is combined with Eptinezumab.,Eptinezumab
DB14041,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fremanezumab.,Fremanezumab
DB14042,The risk or severity of adverse effects can be increased when Tositumomab is combined with Galcanezumab.,Galcanezumab
DB14211,The risk or severity of adverse effects can be increased when Tositumomab is combined with Fanolesomab.,Fanolesomab
DB14580,The risk or severity of adverse effects can be increased when Tositumomab is combined with Lecanemab.,Lecanemab
DB14597,The risk or severity of adverse effects can be increased when Tositumomab is combined with Lanadelumab.,Lanadelumab
DB14707,The risk or severity of adverse effects can be increased when Tositumomab is combined with Cemiplimab.,Cemiplimab
DB14776,The risk or severity of adverse effects can be increased when Tositumomab is combined with Camrelizumab.,Camrelizumab
DB14778,The risk or severity of adverse effects can be increased when Tositumomab is combined with Setrusumab.,Setrusumab
DB14784,The risk or severity of adverse effects can be increased when Tositumomab is combined with Gancotamab.,Gancotamab
DB14809,The risk or severity of adverse effects can be increased when Tositumomab is combined with Anetumab ravtansine.,Anetumab ravtansine
DB14811,The risk or severity of adverse effects can be increased when Tositumomab is combined with Isatuximab.,Isatuximab
DB14824,The risk or severity of adverse effects can be increased when Tositumomab is combined with Icrucumab.,Icrucumab
DB14843,The risk or severity of adverse effects can be increased when Tositumomab is combined with Codrituzumab.,Codrituzumab
DB14864,The risk or severity of adverse effects can be increased when Tositumomab is combined with Brolucizumab.,Brolucizumab
DB14871,The risk or severity of adverse effects can be increased when Tositumomab is combined with Xentuzumab.,Xentuzumab
DB14877,The risk or severity of adverse effects can be increased when Tositumomab is combined with Lintuzumab.,Lintuzumab
DB14891,The risk or severity of adverse effects can be increased when Tositumomab is combined with Vobarilizumab.,Vobarilizumab
DB14897,The risk or severity of adverse effects can be increased when Tositumomab is combined with Parsatuzumab.,Parsatuzumab
DB14905,The risk or severity of adverse effects can be increased when Tositumomab is combined with Emactuzumab.,Emactuzumab
DB14907,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bevacizumab zirconium Zr-89.,Bevacizumab zirconium Zr-89
DB14908,The risk or severity of adverse effects can be increased when Tositumomab is combined with Refanezumab.,Refanezumab
DB14947,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bermekimab.,Bermekimab
DB14952,The risk or severity of adverse effects can be increased when Tositumomab is combined with Pamrevlumab.,Pamrevlumab
DB14959,The risk or severity of adverse effects can be increased when Tositumomab is combined with Opicinumab.,Opicinumab
DB14962,The risk or severity of adverse effects can be increased when Tositumomab is combined with Trastuzumab deruxtecan.,Trastuzumab deruxtecan
DB14967,The risk or severity of adverse effects can be increased when Tositumomab is combined with Margetuximab.,Margetuximab
DB14988,The risk or severity of adverse effects can be increased when Tositumomab is combined with Dalantercept.,Dalantercept
DB14997,The risk or severity of adverse effects can be increased when Tositumomab is combined with Pateclizumab.,Pateclizumab
DB15014,The risk or severity of adverse effects can be increased when Tositumomab is combined with Gremubamab.,Gremubamab
DB15022,The risk or severity of adverse effects can be increased when Tositumomab is combined with Apomab.,Apomab
DB15044,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tafasitamab.,Tafasitamab
DB15045,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ipafricept.,Ipafricept
DB15076,The risk or severity of adverse effects can be increased when Tositumomab is combined with Abrilumab.,Abrilumab
DB15089,The risk or severity of adverse effects can be increased when Tositumomab is combined with Frovocimab.,Frovocimab
DB15090,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tezepelumab.,Tezepelumab
DB15101,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tigatuzumab.,Tigatuzumab
DB15104,The risk or severity of adverse effects can be increased when Tositumomab is combined with Telisotuzumab vedotin.,Telisotuzumab vedotin
DB15113,The risk or severity of adverse effects can be increased when Tositumomab is combined with Utomilumab.,Utomilumab
DB15118,The risk or severity of adverse effects can be increased when Tositumomab is combined with Zolbetuximab.,Zolbetuximab
DB15135,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ponezumab.,Ponezumab
DB15160,The risk or severity of adverse effects can be increased when Tositumomab is combined with Asunercept.,Asunercept
DB15172,The risk or severity of adverse effects can be increased when Tositumomab is combined with Suvratoxumab.,Suvratoxumab
DB15225,The risk or severity of adverse effects can be increased when Tositumomab is combined with Mitazalimab.,Mitazalimab
DB15252,The risk or severity of adverse effects can be increased when Tositumomab is combined with Nemolizumab.,Nemolizumab
DB15277,The risk or severity of adverse effects can be increased when Tositumomab is combined with Gedivumab.,Gedivumab
DB15336,The risk or severity of adverse effects can be increased when Tositumomab is combined with Valanafusp alfa.,Valanafusp alfa
DB15349,The risk or severity of adverse effects can be increased when Tositumomab is combined with Sofituzumab vedotin.,Sofituzumab vedotin
DB15354,The risk or severity of adverse effects can be increased when Tositumomab is combined with Evinacumab.,Evinacumab
DB15363,The risk or severity of adverse effects can be increased when Tositumomab is combined with Istiratumab.,Istiratumab
DB15383,The risk or severity of adverse effects can be increased when Tositumomab is combined with Pidilizumab.,Pidilizumab
DB15397,The risk or severity of adverse effects can be increased when Tositumomab is combined with GMA-161.,GMA-161
DB15409,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ladiratuzumab vedotin.,Ladiratuzumab vedotin
DB15415,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tomaralimab.,Tomaralimab
DB15428,The risk or severity of adverse effects can be increased when Tositumomab is combined with Vesencumab.,Vesencumab
DB15432,The risk or severity of adverse effects can be increased when Tositumomab is combined with Pinatuzumab vedotin.,Pinatuzumab vedotin
DB15441,The risk or severity of adverse effects can be increased when Tositumomab is combined with Lulizumab pegol.,Lulizumab pegol
DB15443,The risk or severity of adverse effects can be increased when Tositumomab is combined with Lorukafusp alfa.,Lorukafusp alfa
DB15453,The risk or severity of adverse effects can be increased when Tositumomab is combined with Naratuximab emtansine.,Naratuximab emtansine
DB14004,The risk or severity of adverse effects can be increased when Tositumomab is combined with Tildrakizumab.,Tildrakizumab
DB05679,The risk or severity of adverse effects can be increased when Tositumomab is combined with Ustekinumab.,Ustekinumab
DB15559,The risk or severity of adverse effects can be increased when Tositumomab is combined with Zenocutuzumab.,Zenocutuzumab
DB00039,The therapeutic efficacy of Palifermin can be decreased when used in combination with Tositumomab.,Palifermin
DB00159,Icosapent may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Icosapent
DB00229,Cefotiam may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefotiam
DB00244,Mesalazine may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Mesalazine
DB00267,Cefmenoxime may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefmenoxime
DB00274,Cefmetazole may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefmetazole
DB00282,Pamidronic acid may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Pamidronic acid
DB00300,Tenofovir disoproxil may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Tenofovir disoproxil
DB00369,Cidofovir may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cidofovir
DB00384,Triamterene may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Triamterene
DB00430,Cefpiramide may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefpiramide
DB00438,Ceftazidime may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Ceftazidime
DB00447,Loracarbef may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Loracarbef
DB00456,Cefalotin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefalotin
DB00461,Nabumetone may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Nabumetone
DB00465,Ketorolac may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Ketorolac
DB00469,Tenoxicam may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Tenoxicam
DB00482,Celecoxib may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Celecoxib
DB00493,Cefotaxime may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefotaxime
DB00500,Tolmetin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Tolmetin
DB00529,Foscarnet may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Foscarnet
DB00533,Rofecoxib may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Rofecoxib
DB00554,Piroxicam may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Piroxicam
DB00567,Cephalexin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cephalexin
DB00573,Fenoprofen may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Fenoprofen
DB00577,Valaciclovir may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Valaciclovir
DB00580,Valdecoxib may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Valdecoxib
DB00586,Diclofenac may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Diclofenac
DB00605,Sulindac may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Sulindac
DB00626,Bacitracin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Bacitracin
DB00681,Amphotericin B may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Amphotericin B
DB00689,Cephaloglycin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cephaloglycin
DB00712,Flurbiprofen may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Flurbiprofen
DB00718,Adefovir dipivoxil may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Adefovir dipivoxil
DB00738,Pentamidine may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Pentamidine
DB00742,Mannitol may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Mannitol
DB00749,Etodolac may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Etodolac
DB00784,Mefenamic acid may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Mefenamic acid
DB00787,Acyclovir may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Acyclovir
DB00788,Naproxen may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Naproxen
DB00812,Phenylbutazone may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Phenylbutazone
DB00814,Meloxicam may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Meloxicam
DB00821,Carprofen may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Carprofen
DB00833,Cefaclor may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefaclor
DB00861,Diflunisal may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Diflunisal
DB00903,Etacrynic acid may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Etacrynic acid
DB00923,Ceforanide may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Ceforanide
DB00936,Salicylic acid may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Salicylic acid
DB00939,Meclofenamic acid may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Meclofenamic acid
DB00991,Oxaprozin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Oxaprozin
DB00999,Hydrochlorothiazide may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Hydrochlorothiazide
DB01009,Ketoprofen may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Ketoprofen
DB01014,Balsalazide may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Balsalazide
DB01050,Ibuprofen may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Ibuprofen
DB01066,Cefditoren may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefditoren
DB01072,Atazanavir may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Atazanavir
DB01111,Colistimethate may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Colistimethate
DB01112,Cefuroxime may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefuroxime
DB01139,Cefapirin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefapirin
DB01140,Cefadroxil may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefadroxil
DB01150,Cefprozil may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefprozil
DB01212,Ceftriaxone may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Ceftriaxone
DB01250,Olsalazine may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Olsalazine
DB01283,Lumiracoxib may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Lumiracoxib
DB01326,Cefamandole may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefamandole
DB01327,Cefazolin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefazolin
DB01328,Cefonicid may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefonicid
DB01329,Cefoperazone may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefoperazone
DB01330,Cefotetan may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefotetan
DB01331,Cefoxitin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefoxitin
DB01332,Ceftizoxime may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Ceftizoxime
DB01333,Cefradine may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefradine
DB01397,Magnesium salicylate may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Magnesium salicylate
DB01399,Salsalate may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Salsalate
DB01401,Choline magnesium trisalicylate may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Choline magnesium trisalicylate
DB01413,Cefepime may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefepime
DB01414,Cefacetrile may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefacetrile
DB01415,Ceftibuten may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Ceftibuten
DB01416,Cefpodoxime may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefpodoxime
DB01419,Antrafenine may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Antrafenine
DB01424,Aminophenazone may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Aminophenazone
DB01435,Antipyrine may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Antipyrine
DB01600,Tiaprofenic acid may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Tiaprofenic acid
DB01628,Etoricoxib may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Etoricoxib
DB02247,Hydrolyzed Cephalothin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Hydrolyzed Cephalothin
DB03450,Cephalothin Group may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cephalothin Group
DB03585,Oxyphenbutazone may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Oxyphenbutazone
DB04552,Niflumic acid may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Niflumic acid
DB04570,Latamoxef may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Latamoxef
DB04812,Benoxaprofen may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Benoxaprofen
DB04817,Metamizole may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Metamizole
DB04828,Zomepirac may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Zomepirac
DB04918,Ceftobiprole may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Ceftobiprole
DB05095,Cimicoxib may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cimicoxib
DB06590,Ceftaroline fosamil may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Ceftaroline fosamil
DB06725,Lornoxicam may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Lornoxicam
DB06736,Aceclofenac may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Aceclofenac
DB06737,Zaltoprofen may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Zaltoprofen
DB07402,Azapropazone may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Azapropazone
DB07477,Felbinac may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Felbinac
DB08439,Parecoxib may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Parecoxib
DB08797,Salicylamide may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Salicylamide
DB08940,Kebuzone may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Kebuzone
DB08942,Isoxicam may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Isoxicam
DB08951,Indoprofen may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Indoprofen
DB08955,Ibuproxam may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Ibuproxam
DB08976,Floctafenine may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Floctafenine
DB08981,Fenbufen may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Fenbufen
DB08984,Etofenamate may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Etofenamate
DB08991,Epirizole may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Epirizole
DB09008,Cefaloridine may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefaloridine
DB09062,Cefminox may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefminox
DB09084,Benzydamine may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Benzydamine
DB09212,Loxoprofen may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Loxoprofen
DB09213,Dexibuprofen may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Dexibuprofen
DB09214,Dexketoprofen may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Dexketoprofen
DB09215,Droxicam may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Droxicam
DB09216,Tolfenamic acid may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Tolfenamic acid
DB09217,Firocoxib may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Firocoxib
DB09218,Clonixin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Clonixin
DB09285,Morniflumate may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Morniflumate
DB09288,Propacetamol may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Propacetamol
DB09295,Talniflumate may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Talniflumate
DB09299,Tenofovir alafenamide may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Tenofovir alafenamide
DB11367,Cefroxadine may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefroxadine
DB11455,Robenacoxib may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Robenacoxib
DB11518,Flunixin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Flunixin
DB11935,Flomoxef may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Flomoxef
DB12151,Brincidofovir may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Brincidofovir
DB13001,Tinoridine may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Tinoridine
DB13167,Alclofenac may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Alclofenac
DB13217,Fentiazac may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Fentiazac
DB13232,Suxibuzone may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Suxibuzone
DB13266,Cefatrizine may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefatrizine
DB13286,Bumadizone may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Bumadizone
DB13314,Alminoprofen may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Alminoprofen
DB13317,Flunoxaprofen may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Flunoxaprofen
DB13364,Feprazone may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Feprazone
DB13371,Difenpiramide may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Difenpiramide
DB13407,Nifenazone may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Nifenazone
DB13432,Lonazolac may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Lonazolac
DB13461,Cefcapene may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefcapene
DB13470,Cefodizime may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefodizime
DB13481,Tenidap may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Tenidap
DB13499,Cefsulodin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefsulodin
DB13501,Bendazac may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Bendazac
DB13504,Cefetamet may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefetamet
DB13514,Pranoprofen may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Pranoprofen
DB13524,Propyphenazone may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Propyphenazone
DB13527,Proglumetacin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Proglumetacin
DB13538,Guacetisal may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Guacetisal
DB13544,Ethenzamide may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Ethenzamide
DB13612,Carbaspirin calcium may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Carbaspirin calcium
DB13629,Mofebutazone may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Mofebutazone
DB13638,Cefbuperazone may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefbuperazone
DB13649,Proquazone may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Proquazone
DB13657,Benorilate may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Benorilate
DB13667,Cefozopran may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefozopran
DB13682,Cefpirome may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefpirome
DB13722,Pirprofen may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Pirprofen
DB13778,Cefazedone may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Cefazedone
DB13783,Acemetacin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Acemetacin
DB13821,Ceftezole may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Ceftezole
DB13860,Imidazole salicylate may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Imidazole salicylate
DB13868,Adefovir may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Adefovir
DB14059,SC-236 may decrease the excretion rate of Tositumomab which could result in a higher serum level.,SC-236
DB14060,NS-398 may decrease the excretion rate of Tositumomab which could result in a higher serum level.,NS-398
DB14126,Tenofovir may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Tenofovir
DB14713,Inotersen may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Inotersen
DB01438,Phenazopyridine may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Phenazopyridine
DB15066,Givosiran may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Givosiran
DB01356,Lithium cation may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Lithium cation
DB14507,Lithium citrate may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Lithium citrate
DB00007,Leuprolide may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Leuprolide
DB00014,Goserelin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Goserelin
DB00017,Salmon calcitonin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Salmon calcitonin
DB00035,Desmopressin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Desmopressin
DB00080,Daptomycin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Daptomycin
DB00158,Tositumomab may decrease the excretion rate of Folic acid which could result in a higher serum level.,Folic acid
DB00165,Tositumomab may decrease the excretion rate of Pyridoxine which could result in a higher serum level.,Pyridoxine
DB00176,Tositumomab may decrease the excretion rate of Fluvoxamine which could result in a higher serum level.,Fluvoxamine
DB00181,Tositumomab may decrease the excretion rate of Baclofen which could result in a higher serum level.,Baclofen
DB00182,Tositumomab may decrease the excretion rate of Amphetamine which could result in a higher serum level.,Amphetamine
DB00185,Tositumomab may decrease the excretion rate of Cevimeline which could result in a higher serum level.,Cevimeline
DB00186,Tositumomab may decrease the excretion rate of Lorazepam which could result in a higher serum level.,Lorazepam
DB00190,Tositumomab may decrease the excretion rate of Carbidopa which could result in a higher serum level.,Carbidopa
DB00193,Tositumomab may decrease the excretion rate of Tramadol which could result in a higher serum level.,Tramadol
DB00196,Tositumomab may decrease the excretion rate of Fluconazole which could result in a higher serum level.,Fluconazole
DB00198,Tositumomab may decrease the excretion rate of Oseltamivir which could result in a higher serum level.,Oseltamivir
DB00200,Tositumomab may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level.,Hydroxocobalamin
DB00206,Tositumomab may decrease the excretion rate of Reserpine which could result in a higher serum level.,Reserpine
DB00213,Tositumomab may decrease the excretion rate of Pantoprazole which could result in a higher serum level.,Pantoprazole
DB00225,Tositumomab may decrease the excretion rate of Gadodiamide which could result in a higher serum level.,Gadodiamide
DB00230,Tositumomab may decrease the excretion rate of Pregabalin which could result in a higher serum level.,Pregabalin
DB00231,Tositumomab may decrease the excretion rate of Temazepam which could result in a higher serum level.,Temazepam
DB00235,Tositumomab may decrease the excretion rate of Milrinone which could result in a higher serum level.,Milrinone
DB00237,Tositumomab may decrease the excretion rate of Butabarbital which could result in a higher serum level.,Butabarbital
DB00243,Tositumomab may decrease the excretion rate of Ranolazine which could result in a higher serum level.,Ranolazine
DB00245,Tositumomab may decrease the excretion rate of Benzatropine which could result in a higher serum level.,Benzatropine
DB00254,Tositumomab may decrease the excretion rate of Doxycycline which could result in a higher serum level.,Doxycycline
DB00264,Tositumomab may decrease the excretion rate of Metoprolol which could result in a higher serum level.,Metoprolol
DB00270,Tositumomab may decrease the excretion rate of Isradipine which could result in a higher serum level.,Isradipine
DB00271,Tositumomab may decrease the excretion rate of Diatrizoate which could result in a higher serum level.,Diatrizoate
DB00273,Tositumomab may decrease the excretion rate of Topiramate which could result in a higher serum level.,Topiramate
DB00279,Tositumomab may decrease the excretion rate of Liothyronine which could result in a higher serum level.,Liothyronine
DB00280,Tositumomab may decrease the excretion rate of Disopyramide which could result in a higher serum level.,Disopyramide
DB00284,Tositumomab may decrease the excretion rate of Acarbose which could result in a higher serum level.,Acarbose
DB00285,Tositumomab may decrease the excretion rate of Venlafaxine which could result in a higher serum level.,Venlafaxine
DB00286,Tositumomab may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level.,Conjugated estrogens
DB00289,Tositumomab may decrease the excretion rate of Atomoxetine which could result in a higher serum level.,Atomoxetine
DB00292,Tositumomab may decrease the excretion rate of Etomidate which could result in a higher serum level.,Etomidate
DB00294,Tositumomab may decrease the excretion rate of Etonogestrel which could result in a higher serum level.,Etonogestrel
DB00296,Tositumomab may decrease the excretion rate of Ropivacaine which could result in a higher serum level.,Ropivacaine
DB00303,Tositumomab may decrease the excretion rate of Ertapenem which could result in a higher serum level.,Ertapenem
DB00308,Tositumomab may decrease the excretion rate of Ibutilide which could result in a higher serum level.,Ibutilide
DB00312,Tositumomab may decrease the excretion rate of Pentobarbital which could result in a higher serum level.,Pentobarbital
DB00316,Tositumomab may decrease the excretion rate of Acetaminophen which could result in a higher serum level.,Acetaminophen
DB00319,Tositumomab may decrease the excretion rate of Piperacillin which could result in a higher serum level.,Piperacillin
DB00323,Tositumomab may decrease the excretion rate of Tolcapone which could result in a higher serum level.,Tolcapone
DB00325,Tositumomab may decrease the excretion rate of Nitroprusside which could result in a higher serum level.,Nitroprusside
DB00327,Tositumomab may decrease the excretion rate of Hydromorphone which could result in a higher serum level.,Hydromorphone
DB00330,Tositumomab may decrease the excretion rate of Ethambutol which could result in a higher serum level.,Ethambutol
DB00331,Tositumomab may decrease the excretion rate of Metformin which could result in a higher serum level.,Metformin
DB00333,Tositumomab may decrease the excretion rate of Methadone which could result in a higher serum level.,Methadone
DB00339,Tositumomab may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.,Pyrazinamide
DB00341,Tositumomab may decrease the excretion rate of Cetirizine which could result in a higher serum level.,Cetirizine
DB00349,Tositumomab may decrease the excretion rate of Clobazam which could result in a higher serum level.,Clobazam
DB00351,Tositumomab may decrease the excretion rate of Megestrol acetate which could result in a higher serum level.,Megestrol acetate
DB00355,Tositumomab may decrease the excretion rate of Aztreonam which could result in a higher serum level.,Aztreonam
DB00356,Tositumomab may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level.,Chlorzoxazone
DB00359,Tositumomab may decrease the excretion rate of Sulfadiazine which could result in a higher serum level.,Sulfadiazine
DB00364,Tositumomab may decrease the excretion rate of Sucralfate which could result in a higher serum level.,Sucralfate
DB00372,Tositumomab may decrease the excretion rate of Thiethylperazine which could result in a higher serum level.,Thiethylperazine
DB00373,Tositumomab may decrease the excretion rate of Timolol which could result in a higher serum level.,Timolol
DB00377,Tositumomab may decrease the excretion rate of Palonosetron which could result in a higher serum level.,Palonosetron
DB00401,Tositumomab may decrease the excretion rate of Nisoldipine which could result in a higher serum level.,Nisoldipine
DB00402,Tositumomab may decrease the excretion rate of Eszopiclone which could result in a higher serum level.,Eszopiclone
DB00404,Tositumomab may decrease the excretion rate of Alprazolam which could result in a higher serum level.,Alprazolam
DB00412,Tositumomab may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.,Rosiglitazone
DB00413,Tositumomab may decrease the excretion rate of Pramipexole which could result in a higher serum level.,Pramipexole
DB00415,Tositumomab may decrease the excretion rate of Ampicillin which could result in a higher serum level.,Ampicillin
DB00418,Tositumomab may decrease the excretion rate of Secobarbital which could result in a higher serum level.,Secobarbital
DB00422,Tositumomab may decrease the excretion rate of Methylphenidate which could result in a higher serum level.,Methylphenidate
DB00435,Tositumomab may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.,Nitric Oxide
DB00440,Tositumomab may decrease the excretion rate of Trimethoprim which could result in a higher serum level.,Trimethoprim
DB00476,Tositumomab may decrease the excretion rate of Duloxetine which could result in a higher serum level.,Duloxetine
DB00477,Tositumomab may decrease the excretion rate of Chlorpromazine which could result in a higher serum level.,Chlorpromazine
DB00490,Tositumomab may decrease the excretion rate of Buspirone which could result in a higher serum level.,Buspirone
DB00492,Tositumomab may decrease the excretion rate of Fosinopril which could result in a higher serum level.,Fosinopril
DB00499,Tositumomab may decrease the excretion rate of Flutamide which could result in a higher serum level.,Flutamide
DB00502,Tositumomab may decrease the excretion rate of Haloperidol which could result in a higher serum level.,Haloperidol
DB00535,Tositumomab may decrease the excretion rate of Cefdinir which could result in a higher serum level.,Cefdinir
DB00537,Tositumomab may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.,Ciprofloxacin
DB00548,Tositumomab may decrease the excretion rate of Azelaic acid which could result in a higher serum level.,Azelaic acid
DB00553,Tositumomab may decrease the excretion rate of Methoxsalen which could result in a higher serum level.,Methoxsalen
DB00555,Tositumomab may decrease the excretion rate of Lamotrigine which could result in a higher serum level.,Lamotrigine
DB00558,Tositumomab may decrease the excretion rate of Zanamivir which could result in a higher serum level.,Zanamivir
DB00571,Tositumomab may decrease the excretion rate of Propranolol which could result in a higher serum level.,Propranolol
DB00583,Tositumomab may decrease the excretion rate of Levocarnitine which could result in a higher serum level.,Levocarnitine
DB00597,Tositumomab may decrease the excretion rate of Gadoteridol which could result in a higher serum level.,Gadoteridol
DB00598,Tositumomab may decrease the excretion rate of Labetalol which could result in a higher serum level.,Labetalol
DB00603,Tositumomab may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.,Medroxyprogesterone acetate
DB00608,Tositumomab may decrease the excretion rate of Chloroquine which could result in a higher serum level.,Chloroquine
DB00612,Tositumomab may decrease the excretion rate of Bisoprolol which could result in a higher serum level.,Bisoprolol
DB00624,Tositumomab may decrease the excretion rate of Testosterone which could result in a higher serum level.,Testosterone
DB00628,Tositumomab may decrease the excretion rate of Clorazepic acid which could result in a higher serum level.,Clorazepic acid
DB00633,Tositumomab may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level.,Dexmedetomidine
DB00651,Tositumomab may decrease the excretion rate of Dyphylline which could result in a higher serum level.,Dyphylline
DB00657,Tositumomab may decrease the excretion rate of Mecamylamine which could result in a higher serum level.,Mecamylamine
DB00660,Tositumomab may decrease the excretion rate of Metaxalone which could result in a higher serum level.,Metaxalone
DB00661,Tositumomab may decrease the excretion rate of Verapamil which could result in a higher serum level.,Verapamil
DB00665,Tositumomab may decrease the excretion rate of Nilutamide which could result in a higher serum level.,Nilutamide
DB00669,Tositumomab may decrease the excretion rate of Sumatriptan which could result in a higher serum level.,Sumatriptan
DB00672,Tositumomab may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.,Chlorpropamide
DB00683,Tositumomab may decrease the excretion rate of Midazolam which could result in a higher serum level.,Midazolam
DB00690,Tositumomab may decrease the excretion rate of Flurazepam which could result in a higher serum level.,Flurazepam
DB00692,Tositumomab may decrease the excretion rate of Phentolamine which could result in a higher serum level.,Phentolamine
DB00698,Tositumomab may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.,Nitrofurantoin
DB00706,Tositumomab may decrease the excretion rate of Tamsulosin which could result in a higher serum level.,Tamsulosin
DB00709,Tositumomab may decrease the excretion rate of Lamivudine which could result in a higher serum level.,Lamivudine
DB00713,Tositumomab may decrease the excretion rate of Oxacillin which could result in a higher serum level.,Oxacillin
DB00716,Tositumomab may decrease the excretion rate of Nedocromil which could result in a higher serum level.,Nedocromil
DB00722,Tositumomab may decrease the excretion rate of Lisinopril which could result in a higher serum level.,Lisinopril
DB00730,Tositumomab may decrease the excretion rate of Thiabendazole which could result in a higher serum level.,Thiabendazole
DB00731,Tositumomab may decrease the excretion rate of Nateglinide which could result in a higher serum level.,Nateglinide
DB00733,Tositumomab may decrease the excretion rate of Pralidoxime which could result in a higher serum level.,Pralidoxime
DB00743,Tositumomab may decrease the excretion rate of Gadobenic acid which could result in a higher serum level.,Gadobenic acid
DB00759,Tositumomab may decrease the excretion rate of Tetracycline which could result in a higher serum level.,Tetracycline
DB00760,Tositumomab may decrease the excretion rate of Meropenem which could result in a higher serum level.,Meropenem
DB00761,Tositumomab may decrease the excretion rate of Potassium chloride which could result in a higher serum level.,Potassium chloride
DB00780,Tositumomab may decrease the excretion rate of Phenelzine which could result in a higher serum level.,Phenelzine
DB00782,Tositumomab may decrease the excretion rate of Propantheline which could result in a higher serum level.,Propantheline
DB00783,Tositumomab may decrease the excretion rate of Estradiol which could result in a higher serum level.,Estradiol
DB00789,Tositumomab may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level.,Gadopentetic acid
DB00790,Tositumomab may decrease the excretion rate of Perindopril which could result in a higher serum level.,Perindopril
DB00800,Tositumomab may decrease the excretion rate of Fenoldopam which could result in a higher serum level.,Fenoldopam
DB00804,Tositumomab may decrease the excretion rate of Dicyclomine which could result in a higher serum level.,Dicyclomine
DB00811,Tositumomab may decrease the excretion rate of Ribavirin which could result in a higher serum level.,Ribavirin
DB00820,Tositumomab may decrease the excretion rate of Tadalafil which could result in a higher serum level.,Tadalafil
DB00828,Tositumomab may decrease the excretion rate of Fosfomycin which could result in a higher serum level.,Fosfomycin
DB00829,Tositumomab may decrease the excretion rate of Diazepam which could result in a higher serum level.,Diazepam
DB00839,Tositumomab may decrease the excretion rate of Tolazamide which could result in a higher serum level.,Tolazamide
DB00841,Tositumomab may decrease the excretion rate of Dobutamine which could result in a higher serum level.,Dobutamine
DB00842,Tositumomab may decrease the excretion rate of Oxazepam which could result in a higher serum level.,Oxazepam
DB00863,Tositumomab may decrease the excretion rate of Ranitidine which could result in a higher serum level.,Ranitidine
DB00871,Tositumomab may decrease the excretion rate of Terbutaline which could result in a higher serum level.,Terbutaline
DB00894,Tositumomab may decrease the excretion rate of Testolactone which could result in a higher serum level.,Testolactone
DB00897,Tositumomab may decrease the excretion rate of Triazolam which could result in a higher serum level.,Triazolam
DB00900,Tositumomab may decrease the excretion rate of Didanosine which could result in a higher serum level.,Didanosine
DB00911,Tositumomab may decrease the excretion rate of Tinidazole which could result in a higher serum level.,Tinidazole
DB00915,Tositumomab may decrease the excretion rate of Amantadine which could result in a higher serum level.,Amantadine
DB00918,Tositumomab may decrease the excretion rate of Almotriptan which could result in a higher serum level.,Almotriptan
DB00934,Tositumomab may decrease the excretion rate of Maprotiline which could result in a higher serum level.,Maprotiline
DB00951,Tositumomab may decrease the excretion rate of Isoniazid which could result in a higher serum level.,Isoniazid
DB00953,Tositumomab may decrease the excretion rate of Rizatriptan which could result in a higher serum level.,Rizatriptan
DB00960,Tositumomab may decrease the excretion rate of Pindolol which could result in a higher serum level.,Pindolol
DB00961,Tositumomab may decrease the excretion rate of Mepivacaine which could result in a higher serum level.,Mepivacaine
DB00962,Tositumomab may decrease the excretion rate of Zaleplon which could result in a higher serum level.,Zaleplon
DB00968,Tositumomab may decrease the excretion rate of Methyldopa which could result in a higher serum level.,Methyldopa
DB00980,Tositumomab may decrease the excretion rate of Ramelteon which could result in a higher serum level.,Ramelteon
DB00988,Tositumomab may decrease the excretion rate of Dopamine which could result in a higher serum level.,Dopamine
DB00995,Tositumomab may decrease the excretion rate of Auranofin which could result in a higher serum level.,Auranofin
DB01001,Tositumomab may decrease the excretion rate of Salbutamol which could result in a higher serum level.,Salbutamol
DB01002,Tositumomab may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.,Levobupivacaine
DB01004,Tositumomab may decrease the excretion rate of Ganciclovir which could result in a higher serum level.,Ganciclovir
DB01010,Tositumomab may decrease the excretion rate of Edrophonium which could result in a higher serum level.,Edrophonium
DB01011,Tositumomab may decrease the excretion rate of Metyrapone which could result in a higher serum level.,Metyrapone
DB01018,Tositumomab may decrease the excretion rate of Guanfacine which could result in a higher serum level.,Guanfacine
DB01020,Tositumomab may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.,Isosorbide mononitrate
DB01022,Tositumomab may decrease the excretion rate of Phylloquinone which could result in a higher serum level.,Phylloquinone
DB01032,Tositumomab may decrease the excretion rate of Probenecid which could result in a higher serum level.,Probenecid
DB01036,Tositumomab may decrease the excretion rate of Tolterodine which could result in a higher serum level.,Tolterodine
DB01039,Tositumomab may decrease the excretion rate of Fenofibrate which could result in a higher serum level.,Fenofibrate
DB01043,Tositumomab may decrease the excretion rate of Memantine which could result in a higher serum level.,Memantine
DB01046,Tositumomab may decrease the excretion rate of Lubiprostone which could result in a higher serum level.,Lubiprostone
DB01048,Tositumomab may decrease the excretion rate of Abacavir which could result in a higher serum level.,Abacavir
DB01060,Tositumomab may decrease the excretion rate of Amoxicillin which could result in a higher serum level.,Amoxicillin
DB01067,Tositumomab may decrease the excretion rate of Glipizide which could result in a higher serum level.,Glipizide
DB01068,Tositumomab may decrease the excretion rate of Clonazepam which could result in a higher serum level.,Clonazepam
DB01069,Tositumomab may decrease the excretion rate of Promethazine which could result in a higher serum level.,Promethazine
DB01093,Tositumomab may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.,Dimethyl sulfoxide
DB01105,Tositumomab may decrease the excretion rate of Sibutramine which could result in a higher serum level.,Sibutramine
DB01115,Tositumomab may decrease the excretion rate of Nifedipine which could result in a higher serum level.,Nifedipine
DB01124,Tositumomab may decrease the excretion rate of Tolbutamide which could result in a higher serum level.,Tolbutamide
DB01129,Tositumomab may decrease the excretion rate of Rabeprazole which could result in a higher serum level.,Rabeprazole
DB01133,Tositumomab may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.,Tiludronic acid
DB01135,Tositumomab may decrease the excretion rate of Doxacurium which could result in a higher serum level.,Doxacurium
DB01137,Tositumomab may decrease the excretion rate of Levofloxacin which could result in a higher serum level.,Levofloxacin
DB01148,Tositumomab may decrease the excretion rate of Flavoxate which could result in a higher serum level.,Flavoxate
DB01149,Tositumomab may decrease the excretion rate of Nefazodone which could result in a higher serum level.,Nefazodone
DB01156,Tositumomab may decrease the excretion rate of Bupropion which could result in a higher serum level.,Bupropion
DB01157,Tositumomab may decrease the excretion rate of Trimetrexate which could result in a higher serum level.,Trimetrexate
DB01170,Tositumomab may decrease the excretion rate of Guanethidine which could result in a higher serum level.,Guanethidine
DB01183,Tositumomab may decrease the excretion rate of Naloxone which could result in a higher serum level.,Naloxone
DB01203,Tositumomab may decrease the excretion rate of Nadolol which could result in a higher serum level.,Nadolol
DB01205,Tositumomab may decrease the excretion rate of Flumazenil which could result in a higher serum level.,Flumazenil
DB01213,Tositumomab may decrease the excretion rate of Fomepizole which could result in a higher serum level.,Fomepizole
DB01215,Tositumomab may decrease the excretion rate of Estazolam which could result in a higher serum level.,Estazolam
DB01221,Tositumomab may decrease the excretion rate of Ketamine which could result in a higher serum level.,Ketamine
DB01224,Tositumomab may decrease the excretion rate of Quetiapine which could result in a higher serum level.,Quetiapine
DB01233,Tositumomab may decrease the excretion rate of Metoclopramide which could result in a higher serum level.,Metoclopramide
DB01241,Tositumomab may decrease the excretion rate of Gemfibrozil which could result in a higher serum level.,Gemfibrozil
DB01249,Tositumomab may decrease the excretion rate of Iodixanol which could result in a higher serum level.,Iodixanol
DB01261,Tositumomab may decrease the excretion rate of Sitagliptin which could result in a higher serum level.,Sitagliptin
DB01267,Tositumomab may decrease the excretion rate of Paliperidone which could result in a higher serum level.,Paliperidone
DB01273,Tositumomab may decrease the excretion rate of Varenicline which could result in a higher serum level.,Varenicline
DB01274,Tositumomab may decrease the excretion rate of Arformoterol which could result in a higher serum level.,Arformoterol
DB01275,Tositumomab may decrease the excretion rate of Hydralazine which could result in a higher serum level.,Hydralazine
DB01359,Tositumomab may decrease the excretion rate of Penbutolol which could result in a higher serum level.,Penbutolol
DB01367,Tositumomab may decrease the excretion rate of Rasagiline which could result in a higher serum level.,Rasagiline
DB01409,Tositumomab may decrease the excretion rate of Tiotropium which could result in a higher serum level.,Tiotropium
DB01420,Tositumomab may decrease the excretion rate of Testosterone propionate which could result in a higher serum level.,Testosterone propionate
DB01427,Tositumomab may decrease the excretion rate of Amrinone which could result in a higher serum level.,Amrinone
DB01428,Tositumomab may decrease the excretion rate of Oxybenzone which could result in a higher serum level.,Oxybenzone
DB01431,Tositumomab may decrease the excretion rate of Allylestrenol which could result in a higher serum level.,Allylestrenol
DB01550,Tositumomab may decrease the excretion rate of Fenproporex which could result in a higher serum level.,Fenproporex
DB01558,Tositumomab may decrease the excretion rate of Bromazepam which could result in a higher serum level.,Bromazepam
DB01563,Tositumomab may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.,Chloral hydrate
DB01577,Tositumomab may decrease the excretion rate of Metamfetamine which could result in a higher serum level.,Metamfetamine
DB01587,Tositumomab may decrease the excretion rate of Ketazolam which could result in a higher serum level.,Ketazolam
DB01610,Tositumomab may decrease the excretion rate of Valganciclovir which could result in a higher serum level.,Valganciclovir
DB01638,Tositumomab may decrease the excretion rate of Sorbitol which could result in a higher serum level.,Sorbitol
DB01685,Tositumomab may decrease the excretion rate of Topiroxostat which could result in a higher serum level.,Topiroxostat
DB04574,Tositumomab may decrease the excretion rate of Estrone sulfate which could result in a higher serum level.,Estrone sulfate
DB04871,Tositumomab may decrease the excretion rate of Lorcaserin which could result in a higher serum level.,Lorcaserin
DB04895,Tositumomab may decrease the excretion rate of Pegaptanib which could result in a higher serum level.,Pegaptanib
DB04896,Tositumomab may decrease the excretion rate of Milnacipran which could result in a higher serum level.,Milnacipran
DB04920,Tositumomab may decrease the excretion rate of Clevidipine which could result in a higher serum level.,Clevidipine
DB04948,Tositumomab may decrease the excretion rate of Lofexidine which could result in a higher serum level.,Lofexidine
DB04953,Tositumomab may decrease the excretion rate of Ezogabine which could result in a higher serum level.,Ezogabine
DB05018,Tositumomab may decrease the excretion rate of Migalastat which could result in a higher serum level.,Migalastat
DB05541,Tositumomab may decrease the excretion rate of Brivaracetam which could result in a higher serum level.,Brivaracetam
DB06154,Tositumomab may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.,Pentaerythritol tetranitrate
DB06186,Tositumomab may decrease the excretion rate of Ipilimumab which could result in a higher serum level.,Ipilimumab
DB06196,Tositumomab may decrease the excretion rate of Icatibant which could result in a higher serum level.,Icatibant
DB06203,Tositumomab may decrease the excretion rate of Alogliptin which could result in a higher serum level.,Alogliptin
DB06211,Tositumomab may decrease the excretion rate of Doripenem which could result in a higher serum level.,Doripenem
DB06230,Tositumomab may decrease the excretion rate of Nalmefene which could result in a higher serum level.,Nalmefene
DB06262,Tositumomab may decrease the excretion rate of Droxidopa which could result in a higher serum level.,Droxidopa
DB06282,Tositumomab may decrease the excretion rate of Levocetirizine which could result in a higher serum level.,Levocetirizine
DB06335,Tositumomab may decrease the excretion rate of Saxagliptin which could result in a higher serum level.,Saxagliptin
DB06402,Tositumomab may decrease the excretion rate of Telavancin which could result in a higher serum level.,Telavancin
DB06480,Tositumomab may decrease the excretion rate of Prucalopride which could result in a higher serum level.,Prucalopride
DB06623,Tositumomab may decrease the excretion rate of Flupirtine which could result in a higher serum level.,Flupirtine
DB06637,Tositumomab may decrease the excretion rate of Dalfampridine which could result in a higher serum level.,Dalfampridine
DB06700,Tositumomab may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level.,Desvenlafaxine
DB06702,Tositumomab may decrease the excretion rate of Fesoterodine which could result in a higher serum level.,Fesoterodine
DB06705,Tositumomab may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.,Gadofosveset trisodium
DB06710,Tositumomab may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.,Methyltestosterone
DB06767,Tositumomab may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.,Ammonium chloride
DB06782,Tositumomab may decrease the excretion rate of Dimercaprol which could result in a higher serum level.,Dimercaprol
DB06796,Tositumomab may decrease the excretion rate of Mangafodipir which could result in a higher serum level.,Mangafodipir
DB06800,Tositumomab may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.,Methylnaltrexone
DB06809,Tositumomab may decrease the excretion rate of Plerixafor which could result in a higher serum level.,Plerixafor
DB06823,Tositumomab may decrease the excretion rate of Tiopronin which could result in a higher serum level.,Tiopronin
DB06824,Tositumomab may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.,Triethylenetetramine
DB08824,Tositumomab may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.,Ioflupane I-123
DB08826,Tositumomab may decrease the excretion rate of Deferiprone which could result in a higher serum level.,Deferiprone
DB08840,Tositumomab may decrease the excretion rate of N-methylnicotinamide which could result in a higher serum level.,N-methylnicotinamide
DB08872,Tositumomab may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.,Gabapentin enacarbil
DB08893,Tositumomab may decrease the excretion rate of Mirabegron which could result in a higher serum level.,Mirabegron
DB08897,Tositumomab may decrease the excretion rate of Aclidinium which could result in a higher serum level.,Aclidinium
DB08899,Tositumomab may decrease the excretion rate of Enzalutamide which could result in a higher serum level.,Enzalutamide
DB08900,Tositumomab may decrease the excretion rate of Teduglutide which could result in a higher serum level.,Teduglutide
DB08905,Tositumomab may decrease the excretion rate of Formestane which could result in a higher serum level.,Formestane
DB08909,Tositumomab may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.,Glycerol phenylbutyrate
DB08911,Tositumomab may decrease the excretion rate of Trametinib which could result in a higher serum level.,Trametinib
DB08918,Tositumomab may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.,Levomilnacipran
DB08932,Tositumomab may decrease the excretion rate of Macitentan which could result in a higher serum level.,Macitentan
DB08934,Tositumomab may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.,Sofosbuvir
DB08964,Tositumomab may decrease the excretion rate of Gemeprost which could result in a higher serum level.,Gemeprost
DB09027,Tositumomab may decrease the excretion rate of Ledipasvir which could result in a higher serum level.,Ledipasvir
DB09050,Tositumomab may decrease the excretion rate of Ceftolozane which could result in a higher serum level.,Ceftolozane
DB09066,Tositumomab may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level.,Corifollitropin alfa
DB09068,Tositumomab may decrease the excretion rate of Vortioxetine which could result in a higher serum level.,Vortioxetine
DB09071,Tositumomab may decrease the excretion rate of Tasimelteon which could result in a higher serum level.,Tasimelteon
DB09081,Tositumomab may decrease the excretion rate of Idebenone which could result in a higher serum level.,Idebenone
DB09089,Tositumomab may decrease the excretion rate of Trimebutine which could result in a higher serum level.,Trimebutine
DB09103,Tositumomab may decrease the excretion rate of Ancestim which could result in a higher serum level.,Ancestim
DB09104,Tositumomab may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.,Magnesium hydroxide
DB09106,Tositumomab may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.,Hydroxyethyl Starch
DB09111,Tositumomab may decrease the excretion rate of Pentastarch which could result in a higher serum level.,Pentastarch
DB09118,Tositumomab may decrease the excretion rate of Stiripentol which could result in a higher serum level.,Stiripentol
DB09121,Tositumomab may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.,Aurothioglucose
DB09123,Tositumomab may decrease the excretion rate of Dienogest which could result in a higher serum level.,Dienogest
DB09129,Tositumomab may decrease the excretion rate of Chromic chloride which could result in a higher serum level.,Chromic chloride
DB09132,Tositumomab may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.,Gadoteric acid
DB09133,Tositumomab may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.,Iothalamic acid
DB09134,Tositumomab may decrease the excretion rate of Ioversol which could result in a higher serum level.,Ioversol
DB09135,Tositumomab may decrease the excretion rate of Ioxilan which could result in a higher serum level.,Ioxilan
DB09136,Tositumomab may decrease the excretion rate of Isosulfan blue which could result in a higher serum level.,Isosulfan blue
DB09137,Tositumomab may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level.,Technetium Tc-99m mebrofenin
DB09139,Tositumomab may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level.,Technetium Tc-99m oxidronate
DB09148,Tositumomab may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.,Florbetaben (18F)
DB09149,Tositumomab may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.,Florbetapir (18F)
DB09156,Tositumomab may decrease the excretion rate of Iopromide which could result in a higher serum level.,Iopromide
DB09163,Tositumomab may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.,Technetium Tc-99m exametazime
DB09165,Tositumomab may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.,Technetium Tc-99m pyrophosphate
DB09185,Tositumomab may decrease the excretion rate of Viloxazine which could result in a higher serum level.,Viloxazine
DB09194,Tositumomab may decrease the excretion rate of Etoperidone which could result in a higher serum level.,Etoperidone
DB09195,Tositumomab may decrease the excretion rate of Lorpiprazole which could result in a higher serum level.,Lorpiprazole
DB09204,Tositumomab may decrease the excretion rate of Arotinolol which could result in a higher serum level.,Arotinolol
DB09205,Tositumomab may decrease the excretion rate of Moxisylyte which could result in a higher serum level.,Moxisylyte
DB09209,Tositumomab may decrease the excretion rate of Pholcodine which could result in a higher serum level.,Pholcodine
DB09210,Tositumomab may decrease the excretion rate of Piracetam which could result in a higher serum level.,Piracetam
DB09219,Tositumomab may decrease the excretion rate of Bisoxatin which could result in a higher serum level.,Bisoxatin
DB09220,Tositumomab may decrease the excretion rate of Nicorandil which could result in a higher serum level.,Nicorandil
DB09223,Tositumomab may decrease the excretion rate of Blonanserin which could result in a higher serum level.,Blonanserin
DB09224,Tositumomab may decrease the excretion rate of Melperone which could result in a higher serum level.,Melperone
DB09241,Tositumomab may decrease the excretion rate of Methylene blue which could result in a higher serum level.,Methylene blue
DB09244,Tositumomab may decrease the excretion rate of Pirlindole which could result in a higher serum level.,Pirlindole
DB09245,Tositumomab may decrease the excretion rate of Toloxatone which could result in a higher serum level.,Toloxatone
DB09256,Tositumomab may decrease the excretion rate of Tegafur which could result in a higher serum level.,Tegafur
DB09257,Tositumomab may decrease the excretion rate of Gimeracil which could result in a higher serum level.,Gimeracil
DB09262,Tositumomab may decrease the excretion rate of Imidafenacin which could result in a higher serum level.,Imidafenacin
DB09264,Tositumomab may decrease the excretion rate of Idarucizumab which could result in a higher serum level.,Idarucizumab
DB09265,Tositumomab may decrease the excretion rate of Lixisenatide which could result in a higher serum level.,Lixisenatide
DB09268,Tositumomab may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level.,Picosulfuric acid
DB09276,Tositumomab may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.,Sodium aurothiomalate
DB09277,Tositumomab may decrease the excretion rate of Choline C 11 which could result in a higher serum level.,Choline C 11
DB09281,Tositumomab may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.,Magnesium trisilicate
DB09292,Tositumomab may decrease the excretion rate of Sacubitril which could result in a higher serum level.,Sacubitril
DB09301,Tositumomab may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.,Chondroitin sulfate
DB09317,"Tositumomab may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level.","Synthetic Conjugated Estrogens, A"
DB09318,"Tositumomab may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level.","Synthetic Conjugated Estrogens, B"
DB09320,Tositumomab may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.,Procaine benzylpenicillin
DB09324,Tositumomab may decrease the excretion rate of Sulbactam which could result in a higher serum level.,Sulbactam
DB09325,Tositumomab may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.,Sodium fluoride
DB09329,"Tositumomab may decrease the excretion rate of Antihemophilic Factor (Recombinant), PEGylated which could result in a higher serum level.","Antihemophilic Factor (Recombinant), PEGylated"
DB09344,Tositumomab may decrease the excretion rate of Invert sugar which could result in a higher serum level.,Invert sugar
DB09357,Tositumomab may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.,Dexpanthenol
DB09394,Tositumomab may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.,Phosphoric acid
DB09395,Tositumomab may decrease the excretion rate of Sodium acetate which could result in a higher serum level.,Sodium acetate
DB09407,Tositumomab may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.,Magnesium chloride
DB09418,Tositumomab may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.,Potassium perchlorate
DB09472,Tositumomab may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.,Sodium sulfate
DB09477,Tositumomab may decrease the excretion rate of Enalaprilat which could result in a higher serum level.,Enalaprilat
DB09481,Tositumomab may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.,Magnesium carbonate
DB09488,Tositumomab may decrease the excretion rate of Acrivastine which could result in a higher serum level.,Acrivastine
DB09496,Tositumomab may decrease the excretion rate of Octinoxate which could result in a higher serum level.,Octinoxate
DB09502,Tositumomab may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.,Fludeoxyglucose (18F)
DB09546,Tositumomab may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.,Iobenguane sulfate I-123
DB09570,Tositumomab may decrease the excretion rate of Ixazomib which could result in a higher serum level.,Ixazomib
DB11077,Tositumomab may decrease the excretion rate of Polyethylene glycol 400 which could result in a higher serum level.,Polyethylene glycol 400
DB11090,Tositumomab may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.,Potassium nitrate
DB11098,Tositumomab may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level.,Potassium bicarbonate
DB11102,Tositumomab may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.,N-acetyltyrosine
DB11114,Tositumomab may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.,Eucalyptus oil
DB11127,Tositumomab may decrease the excretion rate of Selenious acid which could result in a higher serum level.,Selenious acid
DB11130,Tositumomab may decrease the excretion rate of Opium which could result in a higher serum level.,Opium
DB11135,Tositumomab may decrease the excretion rate of Selenium which could result in a higher serum level.,Selenium
DB11136,Tositumomab may decrease the excretion rate of Chromium which could result in a higher serum level.,Chromium
DB11145,Tositumomab may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.,Oxyquinoline
DB11156,Tositumomab may decrease the excretion rate of Pyrantel which could result in a higher serum level.,Pyrantel
DB11164,Tositumomab may decrease the excretion rate of Bicisate which could result in a higher serum level.,Bicisate
DB11251,Tositumomab may decrease the excretion rate of Tocopherol which could result in a higher serum level.,Tocopherol
DB11278,Tositumomab may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level.,DL-Methylephedrine
DB11328,Tositumomab may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.,Tetradecyl hydrogen sulfate (ester)
DB11338,Tositumomab may decrease the excretion rate of Clove oil which could result in a higher serum level.,Clove oil
DB11358,Tositumomab may decrease the excretion rate of Evening primrose oil which could result in a higher serum level.,Evening primrose oil
DB11364,Tositumomab may decrease the excretion rate of Pidotimod which could result in a higher serum level.,Pidotimod
DB11560,Tositumomab may decrease the excretion rate of Lesinurad which could result in a higher serum level.,Lesinurad
DB11577,Tositumomab may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.,Indigotindisulfonic acid
DB11587,Tositumomab may decrease the excretion rate of Etafedrine which could result in a higher serum level.,Etafedrine
DB11642,Tositumomab may decrease the excretion rate of Pitolisant which could result in a higher serum level.,Pitolisant
DB11691,Tositumomab may decrease the excretion rate of Naldemedine which could result in a higher serum level.,Naldemedine
DB11699,Tositumomab may decrease the excretion rate of Tropisetron which could result in a higher serum level.,Tropisetron
DB11901,Tositumomab may decrease the excretion rate of Apalutamide which could result in a higher serum level.,Apalutamide
DB11915,Tositumomab may decrease the excretion rate of Valbenazine which could result in a higher serum level.,Valbenazine
DB11943,Tositumomab may decrease the excretion rate of Delafloxacin which could result in a higher serum level.,Delafloxacin
DB11989,Tositumomab may decrease the excretion rate of Benznidazole which could result in a higher serum level.,Benznidazole
DB12007,Tositumomab may decrease the excretion rate of Isoflavone which could result in a higher serum level.,Isoflavone
DB12107,Tositumomab may decrease the excretion rate of Vaborbactam which could result in a higher serum level.,Vaborbactam
DB12161,Tositumomab may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.,Deutetrabenazine
DB12278,Tositumomab may decrease the excretion rate of Propiverine which could result in a higher serum level.,Propiverine
DB12783,Tositumomab may decrease the excretion rate of Benserazide which could result in a higher serum level.,Benserazide
DB13025,Tositumomab may decrease the excretion rate of Tiapride which could result in a higher serum level.,Tiapride
DB13139,Tositumomab may decrease the excretion rate of Levosalbutamol which could result in a higher serum level.,Levosalbutamol
DB13156,Tositumomab may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.,Inosine pranobex
DB13178,Tositumomab may decrease the excretion rate of Inositol which could result in a higher serum level.,Inositol
DB13185,Tositumomab may decrease the excretion rate of Oxabolone cipionate which could result in a higher serum level.,Oxabolone cipionate
DB13191,Tositumomab may decrease the excretion rate of Phosphocreatine which could result in a higher serum level.,Phosphocreatine
DB13269,Tositumomab may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.,Dichlorobenzyl alcohol
DB13293,Tositumomab may decrease the excretion rate of Ipecac which could result in a higher serum level.,Ipecac
DB13595,Tositumomab may decrease the excretion rate of Almasilate which could result in a higher serum level.,Almasilate
DB13873,Tositumomab may decrease the excretion rate of Fenofibric acid which could result in a higher serum level.,Fenofibric acid
DB13884,Tositumomab may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.,Albutrepenonacog alfa
DB13909,Tositumomab may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level.,Bismuth subgallate
DB13943,Tositumomab may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level.,Testosterone cypionate
DB13944,Tositumomab may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level.,Testosterone enanthate
DB13946,Tositumomab may decrease the excretion rate of Testosterone undecanoate which could result in a higher serum level.,Testosterone undecanoate
DB13952,Tositumomab may decrease the excretion rate of Estradiol acetate which could result in a higher serum level.,Estradiol acetate
DB13954,Tositumomab may decrease the excretion rate of Estradiol cypionate which could result in a higher serum level.,Estradiol cypionate
DB13955,Tositumomab may decrease the excretion rate of Estradiol dienanthate which could result in a higher serum level.,Estradiol dienanthate
DB13956,Tositumomab may decrease the excretion rate of Estradiol valerate which could result in a higher serum level.,Estradiol valerate
DB13967,Tositumomab may decrease the excretion rate of Patent Blue which could result in a higher serum level.,Patent Blue
DB14006,Tositumomab may decrease the excretion rate of Choline salicylate which could result in a higher serum level.,Choline salicylate
DB14007,Tositumomab may decrease the excretion rate of Pentetic acid which could result in a higher serum level.,Pentetic acid
DB14498,Tositumomab may decrease the excretion rate of Potassium acetate which could result in a higher serum level.,Potassium acetate
DB14499,Tositumomab may decrease the excretion rate of Potassium sulfate which could result in a higher serum level.,Potassium sulfate
DB14526,Tositumomab may decrease the excretion rate of Chromic citrate which could result in a higher serum level.,Chromic citrate
DB14527,Tositumomab may decrease the excretion rate of Chromic nitrate which could result in a higher serum level.,Chromic nitrate
DB14528,Tositumomab may decrease the excretion rate of Chromium gluconate which could result in a higher serum level.,Chromium gluconate
DB14529,Tositumomab may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level.,Chromium nicotinate
DB14530,Tositumomab may decrease the excretion rate of Chromous sulfate which could result in a higher serum level.,Chromous sulfate
DB14754,Tositumomab may decrease the excretion rate of Solriamfetol which could result in a higher serum level.,Solriamfetol
DB06815,Tositumomab may decrease the excretion rate of Pyrithione which could result in a higher serum level.,Pyrithione
DB11121,Tositumomab may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.,Chloroxylenol
DB11085,Tositumomab may decrease the excretion rate of Resorcinol which could result in a higher serum level.,Resorcinol
DB00501,Tositumomab may decrease the excretion rate of Cimetidine which could result in a higher serum level.,Cimetidine
DB15593,Tositumomab may decrease the excretion rate of Golodirsen which could result in a higher serum level.,Golodirsen
DB00321,Tositumomab may decrease the excretion rate of Amitriptyline which could result in a higher serum level.,Amitriptyline
DB00458,Tositumomab may decrease the excretion rate of Imipramine which could result in a higher serum level.,Imipramine
DB01142,Tositumomab may decrease the excretion rate of Doxepin which could result in a higher serum level.,Doxepin
DB00318,Tositumomab may decrease the excretion rate of Codeine which could result in a higher serum level.,Codeine
DB00454,Tositumomab may decrease the excretion rate of Meperidine which could result in a higher serum level.,Meperidine
DB00813,Tositumomab may decrease the excretion rate of Fentanyl which could result in a higher serum level.,Fentanyl
DB00879,Tositumomab may decrease the excretion rate of Emtricitabine which could result in a higher serum level.,Emtricitabine
DB01151,Tositumomab may decrease the excretion rate of Desipramine which could result in a higher serum level.,Desipramine
DB01242,Tositumomab may decrease the excretion rate of Clomipramine which could result in a higher serum level.,Clomipramine
DB08996,Tositumomab may decrease the excretion rate of Dimetacrine which could result in a higher serum level.,Dimetacrine
DB14506,Tositumomab may decrease the excretion rate of Lithium hydroxide which could result in a higher serum level.,Lithium hydroxide
DB00452,Framycetin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Framycetin
DB00479,Amikacin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Amikacin
DB00684,Tobramycin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Tobramycin
DB00798,Gentamicin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Gentamicin
DB00955,Netilmicin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Netilmicin
DB00994,Neomycin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Neomycin
DB01082,Streptomycin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Streptomycin
DB01172,Kanamycin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Kanamycin
DB01421,Paromomycin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Paromomycin
DB03615,Ribostamycin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Ribostamycin
DB04263,Geneticin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Geneticin
DB04626,Apramycin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Apramycin
DB04729,Gentamicin C1a may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Gentamicin C1a
DB04808,Neamine may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Neamine
DB06696,Arbekacin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Arbekacin
DB08437,Puromycin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Puromycin
DB11512,Dihydrostreptomycin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Dihydrostreptomycin
DB11520,Hygromycin B may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Hygromycin B
DB12604,Sisomicin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Sisomicin
DB13270,Dibekacin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Dibekacin
DB13274,Micronomicin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Micronomicin
DB13540,Isepamicin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Isepamicin
DB13673,Bekanamycin may decrease the excretion rate of Tositumomab which could result in a higher serum level.,Bekanamycin
DB13145,Tositumomab may decrease the excretion rate of Nedaplatin which could result in a higher serum level.,Nedaplatin
DB00314,Tositumomab may decrease the excretion rate of Capreomycin which could result in a higher serum level.,Capreomycin
DB00390,Tositumomab may decrease the excretion rate of Digoxin which could result in a higher serum level.,Digoxin
DB00512,Tositumomab may decrease the excretion rate of Vancomycin which could result in a higher serum level.,Vancomycin
DB00908,Tositumomab may decrease the excretion rate of Quinidine which could result in a higher serum level.,Quinidine
DB00982,Tositumomab may decrease the excretion rate of Isotretinoin which could result in a higher serum level.,Isotretinoin
DB01035,Tositumomab may decrease the excretion rate of Procainamide which could result in a higher serum level.,Procainamide
DB12615,Tositumomab may decrease the excretion rate of Plazomicin which could result in a higher serum level.,Plazomicin
DB14509,Tositumomab may decrease the excretion rate of Lithium carbonate which could result in a higher serum level.,Lithium carbonate
DB00232,Methyclothiazide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Methyclothiazide
DB00436,Bendroflumethiazide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Bendroflumethiazide
DB00562,Benzthiazide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Benzthiazide
DB00606,Cyclothiazide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Cyclothiazide
DB00774,Hydroflumethiazide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Hydroflumethiazide
DB00880,Chlorothiazide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Chlorothiazide
DB01021,Trichlormethiazide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Trichlormethiazide
DB01119,Diazoxide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Diazoxide
DB01324,Polythiazide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Polythiazide
DB13430,Mebutizide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Mebutizide
DB13532,Cyclopenthiazide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Cyclopenthiazide
DB00524,Tositumomab may increase the excretion rate of Metolazone which could result in a lower serum level and potentially a reduction in efficacy.,Metolazone
DB00695,Tositumomab may increase the excretion rate of Furosemide which could result in a lower serum level and potentially a reduction in efficacy.,Furosemide
DB00808,Tositumomab may increase the excretion rate of Indapamide which could result in a lower serum level and potentially a reduction in efficacy.,Indapamide
DB00887,Tositumomab may increase the excretion rate of Bumetanide which could result in a lower serum level and potentially a reduction in efficacy.,Bumetanide
DB00909,Tositumomab may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.,Zonisamide
DB08907,Tositumomab may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.,Canagliflozin
DB09338,Tositumomab may increase the excretion rate of Mersalyl which could result in a lower serum level and potentially a reduction in efficacy.,Mersalyl
DB00214,Torasemide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Torasemide
DB00310,Chlorthalidone may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Chlorthalidone
DB00311,Ethoxzolamide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Ethoxzolamide
DB00421,Spironolactone may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Spironolactone
DB00594,Amiloride may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Amiloride
DB00700,Eplerenone may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Eplerenone
DB00703,Methazolamide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Methazolamide
DB00819,Acetazolamide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Acetazolamide
DB00872,Conivaptan may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Conivaptan
DB01144,Diclofenamide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Diclofenamide
DB01325,Quinethazone may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Quinethazone
DB01395,Drospirenone may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Drospirenone
DB01412,Theobromine may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Theobromine
DB02925,Piretanide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Piretanide
DB04831,Tienilic acid may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Tienilic acid
DB05034,Ularitide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Ularitide
DB06212,Tolvaptan may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Tolvaptan
DB06292,Dapagliflozin may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Dapagliflozin
DB06370,Indisulam may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Indisulam
DB08961,Azosemide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Azosemide
DB09015,Canrenoic acid may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Canrenoic acid
DB09235,Efonidipine may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Efonidipine
DB09401,Isosorbide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Isosorbide
DB11827,Ertugliflozin may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Ertugliflozin
DB12221,Canrenone may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Canrenone
DB12670,Rolofylline may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Rolofylline
DB12704,Spiradoline may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Spiradoline
DB12766,Cicletanine may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Cicletanine
DB13284,Meticrane may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Meticrane
DB13316,Ibopamine may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Ibopamine
DB13405,Mefruside may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Mefruside
DB13617,Clorexolone may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Clorexolone
DB13663,Clofenamide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Clofenamide
DB13708,Fenquizone may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Fenquizone
DB13792,Clopamide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Clopamide
DB13801,Muzolimine may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Muzolimine
DB13803,Xipamide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Xipamide
DB13989,Epitizide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Epitizide
DB14018,Bromotheophylline may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Bromotheophylline
DB14500,Potassium may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy.,Potassium
DB09042,The risk or severity of myelosuppression can be increased when Tositumomab is combined with Tedizolid phosphate.,Tedizolid phosphate
DB00091,Tositumomab may increase the immunosuppressive activities of Cyclosporine.,Cyclosporine
DB00115,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Tositumomab.,Cyanocobalamin
DB00437,The risk or severity of adverse effects can be increased when Allopurinol is combined with Tositumomab.,Allopurinol
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Tositumomab.","Ebola Zaire vaccine (live, attenuated)"
DB14513,The serum concentration of Magnesium can be decreased when it is combined with Tositumomab.,Magnesium
DB01601,The serum concentration of Tositumomab can be increased when it is combined with Lopinavir.,Lopinavir
DB12530,The risk or severity of infection can be increased when Tositumomab is combined with Inebilizumab.,Inebilizumab
DB00030,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin human.,Insulin human
DB00046,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin lispro.,Insulin lispro
DB00047,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin glargine.,Insulin glargine
DB00071,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin pork.,Insulin pork
DB00197,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Troglitazone.,Troglitazone
DB00222,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Glimepiride.,Glimepiride
DB00263,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Sulfisoxazole.,Sulfisoxazole
DB00280,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Disopyramide.,Disopyramide
DB00284,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Acarbose.,Acarbose
DB00331,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Metformin.,Metformin
DB00359,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Sulfadiazine.,Sulfadiazine
DB00412,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Rosiglitazone.,Rosiglitazone
DB00414,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Acetohexamide.,Acetohexamide
DB00468,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Quinine.,Quinine
DB00491,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Miglitol.,Miglitol
DB00672,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Chlorpropamide.,Chlorpropamide
DB00731,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Nateglinide.,Nateglinide
DB00738,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Pentamidine.,Pentamidine
DB00834,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Mifepristone.,Mifepristone
DB00839,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Tolazamide.,Tolazamide
DB00912,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Repaglinide.,Repaglinide
DB00914,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Phenformin.,Phenformin
DB01015,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Sulfamethoxazole.,Sulfamethoxazole
DB01016,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Glyburide.,Glyburide
DB01067,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Glipizide.,Glipizide
DB01120,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Gliclazide.,Gliclazide
DB01124,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Tolbutamide.,Tolbutamide
DB01132,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Pioglitazone.,Pioglitazone
DB01200,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Bromocriptine.,Bromocriptine
DB01251,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Gliquidone.,Gliquidone
DB01252,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Mitiglinide.,Mitiglinide
DB01261,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Sitagliptin.,Sitagliptin
DB01268,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Sunitinib.,Sunitinib
DB01276,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Exenatide.,Exenatide
DB01277,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Mecasermin.,Mecasermin
DB01278,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Pramlintide.,Pramlintide
DB01289,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Glisoxepide.,Glisoxepide
DB01306,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin aspart.,Insulin aspart
DB01307,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin detemir.,Insulin detemir
DB01309,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin glulisine.,Insulin glulisine
DB01382,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Glymidine.,Glymidine
DB01700,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with AICA ribonucleotide.,AICA ribonucleotide
DB04830,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Buformin.,Buformin
DB04876,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Vildagliptin.,Vildagliptin
DB04878,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Voglibose.,Voglibose
DB05115,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with NN344.,NN344
DB05819,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with NBI-6024.,NBI-6024
DB06011,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with AMG-222.,AMG-222
DB06127,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Bisegliptin.,Bisegliptin
DB06203,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Alogliptin.,Alogliptin
DB06292,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Dapagliflozin.,Dapagliflozin
DB06335,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Saxagliptin.,Saxagliptin
DB06655,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Liraglutide.,Liraglutide
DB08382,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Gosogliptin.,Gosogliptin
DB08882,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Linagliptin.,Linagliptin
DB08907,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Canagliflozin.,Canagliflozin
DB08962,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Glibornuride.,Glibornuride
DB09022,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Benfluorex.,Benfluorex
DB09038,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Empagliflozin.,Empagliflozin
DB09043,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Albiglutide.,Albiglutide
DB09045,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Dulaglutide.,Dulaglutide
DB09198,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Lobeglitazone.,Lobeglitazone
DB09199,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Netoglitazone.,Netoglitazone
DB09200,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Rivoglitazone.,Rivoglitazone
DB09201,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Ciglitazone.,Ciglitazone
DB09265,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Lixisenatide.,Lixisenatide
DB09456,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin beef.,Insulin beef
DB09564,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin degludec.,Insulin degludec
DB11567,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin peglispro.,Insulin peglispro
DB11568,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin tregopil.,Insulin tregopil
DB11698,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Ipragliflozin.,Ipragliflozin
DB11723,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Dutogliptin.,Dutogliptin
DB11780,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Allicin.,Allicin
DB11824,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Tofogliflozin.,Tofogliflozin
DB11827,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Ertugliflozin.,Ertugliflozin
DB11898,"The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with 2,4-thiazolidinedione.","2,4-thiazolidinedione"
DB11950,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Teneligliptin.,Teneligliptin
DB11992,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Omarigliptin.,Omarigliptin
DB12268,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Carmegliptin.,Carmegliptin
DB12412,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Gemigliptin.,Gemigliptin
DB12417,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Anagliptin.,Anagliptin
DB12625,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Evogliptin.,Evogliptin
DB12713,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Sotagliflozin.,Sotagliflozin
DB12781,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Balaglitazone.,Balaglitazone
DB12935,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Remogliflozin etabonate.,Remogliflozin etabonate
DB13406,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Carbutamide.,Carbutamide
DB13446,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Guar gum.,Guar gum
DB13675,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Metahexamide.,Metahexamide
DB13928,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Semaglutide.,Semaglutide
DB14027,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Taspoglutide.,Taspoglutide
DB14035,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Englitazone.,Englitazone
DB15171,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Tirzepatide.,Tirzepatide
DB15217,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Gastric inhibitory polypeptide.,Gastric inhibitory polypeptide
DB00104,The risk or severity of increased transaminases can be increased when Octreotide is combined with Pegvisomant.,Octreotide
DB04894,The risk or severity of increased transaminases can be increased when Vapreotide is combined with Pegvisomant.,Vapreotide
DB06663,The risk or severity of increased transaminases can be increased when Pasireotide is combined with Pegvisomant.,Pasireotide
DB06791,The risk or severity of increased transaminases can be increased when Lanreotide is combined with Pegvisomant.,Lanreotide
DB09099,The risk or severity of increased transaminases can be increased when Somatostatin is combined with Pegvisomant.,Somatostatin
DB01238,The metabolism of Aripiprazole can be increased when combined with Pegvisomant.,Aripiprazole
DB14185,The metabolism of Aripiprazole lauroxil can be increased when combined with Pegvisomant.,Aripiprazole lauroxil
DB00295,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Morphine.,Morphine
DB00318,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Codeine.,Codeine
DB00327,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Hydromorphone.,Hydromorphone
DB00333,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Methadone.,Methadone
DB00454,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Meperidine.,Meperidine
DB00497,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Oxycodone.,Oxycodone
DB00611,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Butorphanol.,Butorphanol
DB00647,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dextropropoxyphene.,Dextropropoxyphene
DB00652,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pentazocine.,Pentazocine
DB00704,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Naltrexone.,Naltrexone
DB00708,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Sufentanil.,Sufentanil
DB00802,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Alfentanil.,Alfentanil
DB00813,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fentanyl.,Fentanyl
DB00844,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Nalbuphine.,Nalbuphine
DB00854,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Levorphanol.,Levorphanol
DB00899,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Remifentanil.,Remifentanil
DB00921,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Buprenorphine.,Buprenorphine
DB01081,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Diphenoxylate.,Diphenoxylate
DB01192,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Oxymorphone.,Oxymorphone
DB01209,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dezocine.,Dezocine
DB01227,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Levacetylmethadol.,Levacetylmethadol
DB01433,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Methadyl acetate.,Methadyl acetate
DB01450,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dihydroetorphine.,Dihydroetorphine
DB01452,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Diamorphine.,Diamorphine
DB01459,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Bezitramide.,Bezitramide
DB01466,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Ethylmorphine.,Ethylmorphine
DB01497,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Etorphine.,Etorphine
DB01529,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dextromoramide.,Dextromoramide
DB01531,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Desomorphine.,Desomorphine
DB01535,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Carfentanil.,Carfentanil
DB01551,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dihydrocodeine.,Dihydrocodeine
DB01555,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Alphacetylmethadol.,Alphacetylmethadol
DB01565,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dihydromorphine.,Dihydromorphine
DB06204,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Tapentadol.,Tapentadol
DB06738,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Ketobemidone.,Ketobemidone
DB08861,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with DPDPE.,DPDPE
DB09174,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Lofentanil.,Lofentanil
DB09272,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Eluxadoline.,Eluxadoline
DB11130,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Opium.,Opium
DB11609,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Normethadone.,Normethadone
DB12492,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Piritramide.,Piritramide
DB13160,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Alphaprodine.,Alphaprodine
DB13454,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Nicomorphine.,Nicomorphine
DB13478,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Meptazinol.,Meptazinol
DB13605,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Phenoperidine.,Phenoperidine
DB13606,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Phenazocine.,Phenazocine
DB13787,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Tilidine.,Tilidine
DB15360,"The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Carfentanil, C-11.","Carfentanil, C-11"
DB15465,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Benzhydrocodone.,Benzhydrocodone
DB00956,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Hydrocodone.,Hydrocodone
DB00975,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dipyridamole.,Dipyridamole
DB01364,Pegvisomant may increase the neuromuscular blocking activities of Ephedrine.,Ephedrine
DB01408,Pegvisomant may increase the neuromuscular blocking activities of Bambuterol.,Bambuterol
DB05875,"Pegvisomant may increase the neuromuscular blocking activities of Sar9, Met (O2)11-Substance P.","Sar9, Met (O2)11-Substance P"
DB09205,Pegvisomant may increase the neuromuscular blocking activities of Moxisylyte.,Moxisylyte
DB00721,Pegvisomant may increase the neuromuscular blocking activities of Procaine.,Procaine
DB00907,Pegvisomant may increase the neuromuscular blocking activities of Cocaine.,Cocaine
DB01116,Pegvisomant may increase the neuromuscular blocking activities of Trimethaphan.,Trimethaphan
DB01135,Pegvisomant may increase the neuromuscular blocking activities of Doxacurium.,Doxacurium
DB01161,Pegvisomant may increase the neuromuscular blocking activities of Chloroprocaine.,Chloroprocaine
DB01199,Pegvisomant may increase the neuromuscular blocking activities of Tubocurarine.,Tubocurarine
DB08897,Pegvisomant may increase the neuromuscular blocking activities of Aclidinium.,Aclidinium
DB09288,Pegvisomant may increase the neuromuscular blocking activities of Propacetamol.,Propacetamol
DB04250,Pegvisomant may increase the neuromuscular blocking activities of Butyrylthiocholine.,Butyrylthiocholine
DB00762,Pegvisomant may increase the neuromuscular blocking activities of Irinotecan.,Irinotecan
DB04920,Pegvisomant may increase the neuromuscular blocking activities of Clevidipine.,Clevidipine
DB08893,Pegvisomant may increase the neuromuscular blocking activities of Mirabegron.,Mirabegron
DB01181,The metabolism of Ifosfamide can be increased when combined with Pegvisomant.,Ifosfamide
DB08883,The metabolism of Perampanel can be increased when combined with Pegvisomant.,Perampanel
DB00682,The metabolism of Warfarin can be increased when combined with Pegvisomant.,Warfarin
DB01418,The metabolism of Acenocoumarol can be increased when combined with Pegvisomant.,Acenocoumarol
DB08496,The metabolism of (R)-warfarin can be increased when combined with Pegvisomant.,(R)-warfarin
DB08735,"The metabolism of R,S-Warfarin alcohol can be increased when combined with Pegvisomant.","R,S-Warfarin alcohol"
DB08736,"The metabolism of S,R-Warfarin alcohol can be increased when combined with Pegvisomant.","S,R-Warfarin alcohol"
DB14055,The metabolism of (S)-Warfarin can be increased when combined with Pegvisomant.,(S)-Warfarin
DB00202,The metabolism of Succinylcholine can be decreased when combined with Pegvisomant.,Succinylcholine
DB00008,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Peginterferon alfa-2a.,Peginterferon alfa-2a
DB00019,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pegfilgrastim.,Pegfilgrastim
DB00022,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Peginterferon alfa-2b.,Peginterferon alfa-2b
DB00059,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pegaspargase.,Pegaspargase
DB00061,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pegademase.,Pegademase
DB01839,The therapeutic efficacy of Propylene glycol can be decreased when used in combination with Pegvisomant.,Propylene glycol
DB03394,The therapeutic efficacy of Heptaethylene glycol can be decreased when used in combination with Pegvisomant.,Heptaethylene glycol
DB04895,The therapeutic efficacy of Pegaptanib can be decreased when used in combination with Pegvisomant.,Pegaptanib
DB05202,The therapeutic efficacy of Egaptivon pegol can be decreased when used in combination with Pegvisomant.,Egaptivon pegol
DB05321,The therapeutic efficacy of PEG-uricase can be decreased when used in combination with Pegvisomant.,PEG-uricase
DB05860,The therapeutic efficacy of Peginterferon alfacon-1 can be decreased when used in combination with Pegvisomant.,Peginterferon alfacon-1
DB06022,The therapeutic efficacy of GlycoPEG-GCSF can be decreased when used in combination with Pegvisomant.,GlycoPEG-GCSF
DB06293,The therapeutic efficacy of Pegnivacogin can be decreased when used in combination with Pegvisomant.,Pegnivacogin
DB06325,The therapeutic efficacy of Pegpleranib can be decreased when used in combination with Pegvisomant.,Pegpleranib
DB06611,The therapeutic efficacy of Pegsunercept can be decreased when used in combination with Pegvisomant.,Pegsunercept
DB06811,The therapeutic efficacy of Polidocanol can be decreased when used in combination with Pegvisomant.,Polidocanol
DB08894,The therapeutic efficacy of Peginesatide can be decreased when used in combination with Pegvisomant.,Peginesatide
DB08904,The therapeutic efficacy of Certolizumab pegol can be decreased when used in combination with Pegvisomant.,Certolizumab pegol
DB09107,The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Pegvisomant.,Methoxy polyethylene glycol-epoetin beta
DB09122,The therapeutic efficacy of Peginterferon beta-1a can be decreased when used in combination with Pegvisomant.,Peginterferon beta-1a
DB09208,The therapeutic efficacy of Pegloticase can be decreased when used in combination with Pegvisomant.,Pegloticase
DB09287,The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pegvisomant.,Polyethylene glycol
DB09329,"The therapeutic efficacy of Antihemophilic Factor (Recombinant), PEGylated can be decreased when used in combination with Pegvisomant.","Antihemophilic Factor (Recombinant), PEGylated"
DB11077,The therapeutic efficacy of Polyethylene glycol 400 can be decreased when used in combination with Pegvisomant.,Polyethylene glycol 400
DB11661,The therapeutic efficacy of Eptacog alfa pegol (activated) can be decreased when used in combination with Pegvisomant.,Eptacog alfa pegol (activated)
DB11707,The therapeutic efficacy of Olaptesed Pegol can be decreased when used in combination with Pegvisomant.,Olaptesed Pegol
DB12258,The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Pegvisomant.,Abicipar Pegol
DB12578,The therapeutic efficacy of Lexaptepid Pegol can be decreased when used in combination with Pegvisomant.,Lexaptepid Pegol
DB12814,The therapeutic efficacy of Cepeginterferon alfa-2B can be decreased when used in combination with Pegvisomant.,Cepeginterferon alfa-2B
DB12839,The therapeutic efficacy of Pegvaliase can be decreased when used in combination with Pegvisomant.,Pegvaliase
DB12842,The therapeutic efficacy of Pegamotecan can be decreased when used in combination with Pegvisomant.,Pegamotecan
DB13200,The therapeutic efficacy of Lipegfilgrastim can be decreased when used in combination with Pegvisomant.,Lipegfilgrastim
DB13933,The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Pegvisomant.,Nonacog beta pegol
DB14700,The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Pegvisomant.,Damoctocog alfa pegol
DB14712,The therapeutic efficacy of Elapegademase can be decreased when used in combination with Pegvisomant.,Elapegademase
DB00530,The serum concentration of Erlotinib can be decreased when it is combined with Pegvisomant.,Erlotinib
DB00209,The therapeutic efficacy of Trospium can be decreased when used in combination with Pegvisomant.,Trospium
DB00219,The therapeutic efficacy of Oxyphenonium can be decreased when used in combination with Pegvisomant.,Oxyphenonium
DB00237,The therapeutic efficacy of Butabarbital can be decreased when used in combination with Pegvisomant.,Butabarbital
DB00241,The therapeutic efficacy of Butalbital can be decreased when used in combination with Pegvisomant.,Butalbital
DB00245,The therapeutic efficacy of Benzatropine can be decreased when used in combination with Pegvisomant.,Benzatropine
DB00306,The therapeutic efficacy of Talbutal can be decreased when used in combination with Pegvisomant.,Talbutal
DB00312,The therapeutic efficacy of Pentobarbital can be decreased when used in combination with Pegvisomant.,Pentobarbital
DB00332,The therapeutic efficacy of Ipratropium can be decreased when used in combination with Pegvisomant.,Ipratropium
DB00334,The therapeutic efficacy of Olanzapine can be decreased when used in combination with Pegvisomant.,Olanzapine
DB00340,The therapeutic efficacy of Metixene can be decreased when used in combination with Pegvisomant.,Metixene
DB00354,The therapeutic efficacy of Buclizine can be decreased when used in combination with Pegvisomant.,Buclizine
DB00366,The therapeutic efficacy of Doxylamine can be decreased when used in combination with Pegvisomant.,Doxylamine
DB00376,The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Pegvisomant.,Trihexyphenidyl
DB00383,The therapeutic efficacy of Oxyphencyclimine can be decreased when used in combination with Pegvisomant.,Oxyphencyclimine
DB00387,The therapeutic efficacy of Procyclidine can be decreased when used in combination with Pegvisomant.,Procyclidine
DB00392,The therapeutic efficacy of Profenamine can be decreased when used in combination with Pegvisomant.,Profenamine
DB00418,The therapeutic efficacy of Secobarbital can be decreased when used in combination with Pegvisomant.,Secobarbital
DB00420,The therapeutic efficacy of Promazine can be decreased when used in combination with Pegvisomant.,Promazine
DB00424,The therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Pegvisomant.,Hyoscyamine
DB00434,The therapeutic efficacy of Cyproheptadine can be decreased when used in combination with Pegvisomant.,Cyproheptadine
DB00462,The therapeutic efficacy of Methscopolamine bromide can be decreased when used in combination with Pegvisomant.,Methscopolamine bromide
DB00463,The therapeutic efficacy of Metharbital can be decreased when used in combination with Pegvisomant.,Metharbital
DB00472,The therapeutic efficacy of Fluoxetine can be decreased when used in combination with Pegvisomant.,Fluoxetine
DB00505,The therapeutic efficacy of Tridihexethyl can be decreased when used in combination with Pegvisomant.,Tridihexethyl
DB00508,The therapeutic efficacy of Triflupromazine can be decreased when used in combination with Pegvisomant.,Triflupromazine
DB00514,The therapeutic efficacy of Dextromethorphan can be decreased when used in combination with Pegvisomant.,Dextromethorphan
DB00517,The therapeutic efficacy of Anisotropine methylbromide can be decreased when used in combination with Pegvisomant.,Anisotropine methylbromide
DB00543,The therapeutic efficacy of Amoxapine can be decreased when used in combination with Pegvisomant.,Amoxapine
DB00555,The therapeutic efficacy of Lamotrigine can be decreased when used in combination with Pegvisomant.,Lamotrigine
DB00572,The therapeutic efficacy of Atropine can be decreased when used in combination with Pegvisomant.,Atropine
DB00599,The therapeutic efficacy of Thiopental can be decreased when used in combination with Pegvisomant.,Thiopental
DB00622,The therapeutic efficacy of Nicardipine can be decreased when used in combination with Pegvisomant.,Nicardipine
DB00657,The therapeutic efficacy of Mecamylamine can be decreased when used in combination with Pegvisomant.,Mecamylamine
DB00670,The therapeutic efficacy of Pirenzepine can be decreased when used in combination with Pegvisomant.,Pirenzepine
DB00715,The therapeutic efficacy of Paroxetine can be decreased when used in combination with Pegvisomant.,Paroxetine
DB00725,The therapeutic efficacy of Homatropine methylbromide can be decreased when used in combination with Pegvisomant.,Homatropine methylbromide
DB00747,The therapeutic efficacy of Scopolamine can be decreased when used in combination with Pegvisomant.,Scopolamine
DB00753,The therapeutic efficacy of Isoflurane can be decreased when used in combination with Pegvisomant.,Isoflurane
DB00767,The therapeutic efficacy of Benzquinamide can be decreased when used in combination with Pegvisomant.,Benzquinamide
DB00771,The therapeutic efficacy of Clidinium can be decreased when used in combination with Pegvisomant.,Clidinium
DB00777,The therapeutic efficacy of Propiomazine can be decreased when used in combination with Pegvisomant.,Propiomazine
DB00782,The therapeutic efficacy of Propantheline can be decreased when used in combination with Pegvisomant.,Propantheline
DB00794,The therapeutic efficacy of Primidone can be decreased when used in combination with Pegvisomant.,Primidone
DB00804,The therapeutic efficacy of Dicyclomine can be decreased when used in combination with Pegvisomant.,Dicyclomine
DB00810,The therapeutic efficacy of Biperiden can be decreased when used in combination with Pegvisomant.,Biperiden
DB00835,The therapeutic efficacy of Brompheniramine can be decreased when used in combination with Pegvisomant.,Brompheniramine
DB00849,The therapeutic efficacy of Methylphenobarbital can be decreased when used in combination with Pegvisomant.,Methylphenobarbital
DB00875,The therapeutic efficacy of Flupentixol can be decreased when used in combination with Pegvisomant.,Flupentixol
DB00915,The therapeutic efficacy of Amantadine can be decreased when used in combination with Pegvisomant.,Amantadine
DB00934,The therapeutic efficacy of Maprotiline can be decreased when used in combination with Pegvisomant.,Maprotiline
DB00940,The therapeutic efficacy of Methantheline can be decreased when used in combination with Pegvisomant.,Methantheline
DB00941,The therapeutic efficacy of Hexafluronium can be decreased when used in combination with Pegvisomant.,Hexafluronium
DB00942,The therapeutic efficacy of Cycrimine can be decreased when used in combination with Pegvisomant.,Cycrimine
DB00967,The therapeutic efficacy of Desloratadine can be decreased when used in combination with Pegvisomant.,Desloratadine
DB00986,The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Pegvisomant.,Glycopyrronium
DB01036,The therapeutic efficacy of Tolterodine can be decreased when used in combination with Pegvisomant.,Tolterodine
DB01062,The therapeutic efficacy of Oxybutynin can be decreased when used in combination with Pegvisomant.,Oxybutynin
DB01069,The therapeutic efficacy of Promethazine can be decreased when used in combination with Pegvisomant.,Promethazine
DB01075,The therapeutic efficacy of Diphenhydramine can be decreased when used in combination with Pegvisomant.,Diphenhydramine
DB01090,The therapeutic efficacy of Pentolinium can be decreased when used in combination with Pegvisomant.,Pentolinium
DB01148,The therapeutic efficacy of Flavoxate can be decreased when used in combination with Pegvisomant.,Flavoxate
DB01173,The therapeutic efficacy of Orphenadrine can be decreased when used in combination with Pegvisomant.,Orphenadrine
DB01175,The therapeutic efficacy of Escitalopram can be decreased when used in combination with Pegvisomant.,Escitalopram
DB01231,The therapeutic efficacy of Diphenidol can be decreased when used in combination with Pegvisomant.,Diphenidol
DB01239,The therapeutic efficacy of Chlorprothixene can be decreased when used in combination with Pegvisomant.,Chlorprothixene
DB01288,The therapeutic efficacy of Fenoterol can be decreased when used in combination with Pegvisomant.,Fenoterol
DB01351,The therapeutic efficacy of Amobarbital can be decreased when used in combination with Pegvisomant.,Amobarbital
DB01352,The therapeutic efficacy of Aprobarbital can be decreased when used in combination with Pegvisomant.,Aprobarbital
DB01353,The therapeutic efficacy of Butobarbital can be decreased when used in combination with Pegvisomant.,Butobarbital
DB01354,The therapeutic efficacy of Heptabarbital can be decreased when used in combination with Pegvisomant.,Heptabarbital
DB01355,The therapeutic efficacy of Hexobarbital can be decreased when used in combination with Pegvisomant.,Hexobarbital
DB01403,The therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Pegvisomant.,Methotrimeprazine
DB01409,The therapeutic efficacy of Tiotropium can be decreased when used in combination with Pegvisomant.,Tiotropium
DB01483,The therapeutic efficacy of Barbital can be decreased when used in combination with Pegvisomant.,Barbital
DB01496,"The therapeutic efficacy of Dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1H,5H)-pyrimidinedione can be decreased when used in combination with Pegvisomant.","Dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1H,5H)-pyrimidinedione"
DB01591,The therapeutic efficacy of Solifenacin can be decreased when used in combination with Pegvisomant.,Solifenacin
DB01625,The therapeutic efficacy of Isopropamide can be decreased when used in combination with Pegvisomant.,Isopropamide
DB04843,The therapeutic efficacy of Mepenzolate can be decreased when used in combination with Pegvisomant.,Mepenzolate
DB05710,The therapeutic efficacy of Gantacurium can be decreased when used in combination with Pegvisomant.,Gantacurium
DB06153,The therapeutic efficacy of Pizotifen can be decreased when used in combination with Pegvisomant.,Pizotifen
DB06702,The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Pegvisomant.,Fesoterodine
DB06787,The therapeutic efficacy of Hexocyclium can be decreased when used in combination with Pegvisomant.,Hexocyclium
DB08801,The therapeutic efficacy of Dimetindene can be decreased when used in combination with Pegvisomant.,Dimetindene
DB08838,The therapeutic efficacy of Agmatine can be decreased when used in combination with Pegvisomant.,Agmatine
DB08960,The therapeutic efficacy of Hexamethonium can be decreased when used in combination with Pegvisomant.,Hexamethonium
DB08997,The therapeutic efficacy of Dexetimide can be decreased when used in combination with Pegvisomant.,Dexetimide
DB09007,The therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Pegvisomant.,Chlorphenoxamine
DB09023,The therapeutic efficacy of Benactyzine can be decreased when used in combination with Pegvisomant.,Benactyzine
DB09076,The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Pegvisomant.,Umeclidinium
DB09089,The therapeutic efficacy of Trimebutine can be decreased when used in combination with Pegvisomant.,Trimebutine
DB09167,The therapeutic efficacy of Dosulepin can be decreased when used in combination with Pegvisomant.,Dosulepin
DB09262,The therapeutic efficacy of Imidafenacin can be decreased when used in combination with Pegvisomant.,Imidafenacin
DB09300,The therapeutic efficacy of Butylscopolamine can be decreased when used in combination with Pegvisomant.,Butylscopolamine
DB11235,The therapeutic efficacy of Thonzylamine can be decreased when used in combination with Pegvisomant.,Thonzylamine
DB11315,The therapeutic efficacy of Methscopolamine can be decreased when used in combination with Pegvisomant.,Methscopolamine
DB11855,The therapeutic efficacy of Revefenacin can be decreased when used in combination with Pegvisomant.,Revefenacin
DB12086,The therapeutic efficacy of Oxitropium can be decreased when used in combination with Pegvisomant.,Oxitropium
DB12278,The therapeutic efficacy of Propiverine can be decreased when used in combination with Pegvisomant.,Propiverine
DB12526,The therapeutic efficacy of Batefenterol can be decreased when used in combination with Pegvisomant.,Batefenterol
DB12554,The therapeutic efficacy of Mebeverine can be decreased when used in combination with Pegvisomant.,Mebeverine
DB13252,The therapeutic efficacy of Tropatepine can be decreased when used in combination with Pegvisomant.,Tropatepine
DB13254,The therapeutic efficacy of Prifinium can be decreased when used in combination with Pegvisomant.,Prifinium
DB13351,The therapeutic efficacy of Piperidolate can be decreased when used in combination with Pegvisomant.,Piperidolate
DB13369,The therapeutic efficacy of Benzilone can be decreased when used in combination with Pegvisomant.,Benzilone
DB13380,The therapeutic efficacy of Difemerine can be decreased when used in combination with Pegvisomant.,Difemerine
DB13413,The therapeutic efficacy of Phenglutarimide can be decreased when used in combination with Pegvisomant.,Phenglutarimide
DB13448,The therapeutic efficacy of Mazaticol can be decreased when used in combination with Pegvisomant.,Mazaticol
DB13468,The therapeutic efficacy of Etybenzatropine can be decreased when used in combination with Pegvisomant.,Etybenzatropine
DB13500,The therapeutic efficacy of Otilonium can be decreased when used in combination with Pegvisomant.,Otilonium
DB13505,The therapeutic efficacy of Emepronium can be decreased when used in combination with Pegvisomant.,Emepronium
DB13507,The therapeutic efficacy of Poldine can be decreased when used in combination with Pegvisomant.,Poldine
DB13542,The therapeutic efficacy of Bevonium can be decreased when used in combination with Pegvisomant.,Bevonium
DB13581,The therapeutic efficacy of Rociverine can be decreased when used in combination with Pegvisomant.,Rociverine
DB13619,The therapeutic efficacy of Bornaprine can be decreased when used in combination with Pegvisomant.,Bornaprine
DB13636,The therapeutic efficacy of Etanautine can be decreased when used in combination with Pegvisomant.,Etanautine
DB13666,The therapeutic efficacy of Tiemonium iodide can be decreased when used in combination with Pegvisomant.,Tiemonium iodide
DB13678,The therapeutic efficacy of Dihexyverine can be decreased when used in combination with Pegvisomant.,Dihexyverine
DB13695,The therapeutic efficacy of Penthienate can be decreased when used in combination with Pegvisomant.,Penthienate
DB13720,The therapeutic efficacy of Diphemanil can be decreased when used in combination with Pegvisomant.,Diphemanil
DB13738,The therapeutic efficacy of Camylofin can be decreased when used in combination with Pegvisomant.,Camylofin
DB13759,The therapeutic efficacy of Fenpiverinium can be decreased when used in combination with Pegvisomant.,Fenpiverinium
DB13769,The therapeutic efficacy of Emetonium iodide can be decreased when used in combination with Pegvisomant.,Emetonium iodide
DB13844,The therapeutic efficacy of Pipenzolate can be decreased when used in combination with Pegvisomant.,Pipenzolate
DB13850,The therapeutic efficacy of Timepidium can be decreased when used in combination with Pegvisomant.,Timepidium
DB01224,The therapeutic efficacy of Quetiapine can be decreased when used in combination with Pegvisomant.,Quetiapine
DB00321,The therapeutic efficacy of Amitriptyline can be decreased when used in combination with Pegvisomant.,Amitriptyline
DB01142,The therapeutic efficacy of Doxepin can be decreased when used in combination with Pegvisomant.,Doxepin
DB00496,The therapeutic efficacy of Darifenacin can be decreased when used in combination with Pegvisomant.,Darifenacin
DB00540,The therapeutic efficacy of Nortriptyline can be decreased when used in combination with Pegvisomant.,Nortriptyline
DB00187,Pegvisomant may increase the bradycardic activities of Esmolol.,Esmolol
DB00195,Pegvisomant may increase the bradycardic activities of Betaxolol.,Betaxolol
DB00335,Pegvisomant may increase the bradycardic activities of Atenolol.,Atenolol
DB00373,Pegvisomant may increase the bradycardic activities of Timolol.,Timolol
DB00489,Pegvisomant may increase the bradycardic activities of Sotalol.,Sotalol
DB00598,Pegvisomant may increase the bradycardic activities of Labetalol.,Labetalol
DB00866,Pegvisomant may increase the bradycardic activities of Alprenolol.,Alprenolol
DB00960,Pegvisomant may increase the bradycardic activities of Pindolol.,Pindolol
DB01193,Pegvisomant may increase the bradycardic activities of Acebutolol.,Acebutolol
DB01203,Pegvisomant may increase the bradycardic activities of Nadolol.,Nadolol
DB01295,Pegvisomant may increase the bradycardic activities of Bevantolol.,Bevantolol
DB01297,Pegvisomant may increase the bradycardic activities of Practolol.,Practolol
DB01359,Pegvisomant may increase the bradycardic activities of Penbutolol.,Penbutolol
DB01580,Pegvisomant may increase the bradycardic activities of Oxprenolol.,Oxprenolol
DB03322,Pegvisomant may increase the bradycardic activities of Dexpropranolol.,Dexpropranolol
DB04846,Pegvisomant may increase the bradycardic activities of Celiprolol.,Celiprolol
DB06726,Pegvisomant may increase the bradycardic activities of Bufuralol.,Bufuralol
DB08807,Pegvisomant may increase the bradycardic activities of Bopindolol.,Bopindolol
DB08808,Pegvisomant may increase the bradycardic activities of Bupranolol.,Bupranolol
DB08952,Pegvisomant may increase the bradycardic activities of Indenolol.,Indenolol
DB09013,Pegvisomant may increase the bradycardic activities of Befunolol.,Befunolol
DB09204,Pegvisomant may increase the bradycardic activities of Arotinolol.,Arotinolol
DB09351,Pegvisomant may increase the bradycardic activities of Levobetaxolol.,Levobetaxolol
DB11770,Pegvisomant may increase the bradycardic activities of Talinolol.,Talinolol
DB11785,Pegvisomant may increase the bradycardic activities of Anisodamine.,Anisodamine
DB12212,Pegvisomant may increase the bradycardic activities of Landiolol.,Landiolol
DB12752,Pegvisomant may increase the bradycardic activities of Bucindolol.,Bucindolol
DB13443,Pegvisomant may increase the bradycardic activities of Esatenolol.,Esatenolol
DB13508,Pegvisomant may increase the bradycardic activities of Cloranolol.,Cloranolol
DB13530,Pegvisomant may increase the bradycardic activities of Mepindolol.,Mepindolol
DB13757,Pegvisomant may increase the bradycardic activities of Epanolol.,Epanolol
DB13775,Pegvisomant may increase the bradycardic activities of Tertatolol.,Tertatolol
DB00571,Pegvisomant may increase the bradycardic activities of Propranolol.,Propranolol
DB00612,Pegvisomant may increase the bradycardic activities of Bisoprolol.,Bisoprolol
DB01136,Pegvisomant may increase the bradycardic activities of Carvedilol.,Carvedilol
DB01182,Pegvisomant may increase the bradycardic activities of Propafenone.,Propafenone
DB04861,Pegvisomant may increase the bradycardic activities of Nebivolol.,Nebivolol
DB00411,The risk or severity of adverse effects can be increased when Pegvisomant is combined with Carbamoylcholine.,Carbamoylcholine
DB01019,The risk or severity of adverse effects can be increased when Pegvisomant is combined with Bethanechol.,Bethanechol
DB01085,The risk or severity of adverse effects can be increased when Pegvisomant is combined with Pilocarpine.,Pilocarpine
DB01273,The risk or severity of adverse effects can be increased when Pegvisomant is combined with Varenicline.,Varenicline
DB03128,The risk or severity of adverse effects can be increased when Pegvisomant is combined with Acetylcholine.,Acetylcholine
DB04365,The risk or severity of adverse effects can be increased when Pegvisomant is combined with Arecoline.,Arecoline
DB05137,The risk or severity of adverse effects can be increased when Pegvisomant is combined with Lobeline.,Lobeline
DB05152,The risk or severity of adverse effects can be increased when Pegvisomant is combined with NGX267.,NGX267
DB05708,The risk or severity of adverse effects can be increased when Pegvisomant is combined with GTS-21.,GTS-21
DB06709,The risk or severity of adverse effects can be increased when Pegvisomant is combined with Methacholine.,Methacholine
DB07720,The risk or severity of adverse effects can be increased when Pegvisomant is combined with Epibatidine.,Epibatidine
DB15357,The risk or severity of adverse effects can be increased when Pegvisomant is combined with Xanomeline.,Xanomeline
DB00184,The risk or severity of adverse effects can be increased when Pegvisomant is combined with Nicotine.,Nicotine
DB00185,The risk or severity of adverse effects can be increased when Pegvisomant is combined with Cevimeline.,Cevimeline
DB00166,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Lipoic acid.,Lipoic acid
DB00328,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Indomethacin.,Indomethacin
DB01044,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Gatifloxacin.,Gatifloxacin
DB04832,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Zimelidine.,Zimelidine
DB09270,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Ubidecarenone.,Ubidecarenone
DB12693,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Ritanserin.,Ritanserin
DB13233,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Alaproclate.,Alaproclate
DB13358,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Cibenzoline.,Cibenzoline
DB14025,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Clinafloxacin.,Clinafloxacin
DB00176,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Fluvoxamine.,Fluvoxamine
DB00215,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Citalopram.,Citalopram
DB00230,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Pregabalin.,Pregabalin
DB00285,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Venlafaxine.,Venlafaxine
DB01104,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Sertraline.,Sertraline
DB01149,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Nefazodone.,Nefazodone
DB04884,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Dapoxetine.,Dapoxetine
DB06700,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Desvenlafaxine.,Desvenlafaxine
DB08953,The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Indalpine.,Indalpine
DB09091,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Tixocortol.,Tixocortol
DB13003,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Cortivazol.,Cortivazol
DB13223,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fluocortin.,Fluocortin
DB13491,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fluperolone.,Fluperolone
DB13664,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Formocortal.,Formocortal
DB13728,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Halometasone.,Halometasone
DB13843,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Cloprednol.,Cloprednol
DB13856,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fluclorolone.,Fluclorolone
DB00873,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Loteprednol.,Loteprednol
DB14631,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Prednisolone phosphate.,Prednisolone phosphate
DB14633,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Prednisolone hemisuccinate.,Prednisolone hemisuccinate
DB14634,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fluprednidene acetate.,Fluprednidene acetate
DB14643,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Methylprednisolone aceponate.,Methylprednisolone aceponate
DB14644,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Methylprednisolone hemisuccinate.,Methylprednisolone hemisuccinate
DB14646,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Prednisone acetate.,Prednisone acetate
DB14652,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Clocortolone acetate.,Clocortolone acetate
DB14659,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Melengestrol acetate.,Melengestrol acetate
DB14669,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Betamethasone phosphate.,Betamethasone phosphate
DB14681,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Cortisone.,Cortisone
DB00180,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Flunisolide.,Flunisolide
DB00394,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Beclomethasone dipropionate.,Beclomethasone dipropionate
DB00443,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Betamethasone.,Betamethasone
DB00588,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fluticasone propionate.,Fluticasone propionate
DB00591,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fluocinolone acetonide.,Fluocinolone acetonide
DB00620,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Triamcinolone.,Triamcinolone
DB00635,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Prednisone.,Prednisone
DB00687,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fludrocortisone.,Fludrocortisone
DB00741,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Hydrocortisone.,Hydrocortisone
DB00764,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Mometasone.,Mometasone
DB00860,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Prednisolone.,Prednisolone
DB00959,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Methylprednisolone.,Methylprednisolone
DB01108,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Trilostane.,Trilostane
DB01234,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dexamethasone.,Dexamethasone
DB01285,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Corticotropin.,Corticotropin
DB01380,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Cortisone acetate.,Cortisone acetate
DB01384,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Paramethasone.,Paramethasone
DB01410,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Ciclesonide.,Ciclesonide
DB04630,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Aldosterone.,Aldosterone
DB08906,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fluticasone furoate.,Fluticasone furoate
DB08970,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fluprednidene.,Fluprednidene
DB08971,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fluocortolone.,Fluocortolone
DB09378,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fluprednisolone.,Fluprednisolone
DB09383,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Meprednisone.,Meprednisone
DB11487,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dexamethasone isonicotinate.,Dexamethasone isonicotinate
DB11529,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Melengestrol.,Melengestrol
DB11750,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Clobetasol.,Clobetasol
DB11921,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Deflazacort.,Deflazacort
DB13208,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Prednylidene.,Prednylidene
DB13867,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fluticasone.,Fluticasone
DB14512,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Mometasone furoate.,Mometasone furoate
DB14538,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Hydrocortisone aceponate.,Hydrocortisone aceponate
DB14539,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Hydrocortisone acetate.,Hydrocortisone acetate
DB14541,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Hydrocortisone cypionate.,Hydrocortisone cypionate
DB14545,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Hydrocortisone succinate.,Hydrocortisone succinate
DB01222,The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Budesonide.,Budesonide
DB00416,Pegvisomant may decrease the neuromuscular blocking activities of Metocurine iodide.,Metocurine iodide
DB00483,Pegvisomant may decrease the neuromuscular blocking activities of Gallamine triethiodide.,Gallamine triethiodide
DB00565,Pegvisomant may decrease the neuromuscular blocking activities of Cisatracurium.,Cisatracurium
DB00728,Pegvisomant may decrease the neuromuscular blocking activities of Rocuronium.,Rocuronium
DB00732,Pegvisomant may decrease the neuromuscular blocking activities of Atracurium besylate.,Atracurium besylate
DB01226,Pegvisomant may decrease the neuromuscular blocking activities of Mivacurium.,Mivacurium
DB01336,Pegvisomant may decrease the neuromuscular blocking activities of Metocurine.,Metocurine
DB01337,Pegvisomant may decrease the neuromuscular blocking activities of Pancuronium.,Pancuronium
DB01338,Pegvisomant may decrease the neuromuscular blocking activities of Pipecuronium.,Pipecuronium
DB01339,Pegvisomant may decrease the neuromuscular blocking activities of Vecuronium.,Vecuronium
DB04834,Pegvisomant may decrease the neuromuscular blocking activities of Rapacuronium.,Rapacuronium
DB13295,Pegvisomant may decrease the neuromuscular blocking activities of Atracurium.,Atracurium
DB13584,Pegvisomant may decrease the neuromuscular blocking activities of Gallamine.,Gallamine
DB13648,Pegvisomant may decrease the neuromuscular blocking activities of Alcuronium.,Alcuronium
DB14583,The metabolism of Segesterone acetate can be increased when combined with Pegvisomant.,Segesterone acetate
DB00255,The metabolism of Diethylstilbestrol can be increased when combined with Pegvisomant.,Diethylstilbestrol
DB00294,The metabolism of Etonogestrel can be increased when combined with Pegvisomant.,Etonogestrel
DB00304,The metabolism of Desogestrel can be increased when combined with Pegvisomant.,Desogestrel
DB00351,The metabolism of Megestrol acetate can be increased when combined with Pegvisomant.,Megestrol acetate
DB00367,The metabolism of Levonorgestrel can be increased when combined with Pegvisomant.,Levonorgestrel
DB00396,The metabolism of Progesterone can be increased when combined with Pegvisomant.,Progesterone
DB00603,The metabolism of Medroxyprogesterone acetate can be increased when combined with Pegvisomant.,Medroxyprogesterone acetate
DB00717,The metabolism of Norethisterone can be increased when combined with Pegvisomant.,Norethisterone
DB00783,The metabolism of Estradiol can be increased when combined with Pegvisomant.,Estradiol
DB00823,The metabolism of Ethynodiol diacetate can be increased when combined with Pegvisomant.,Ethynodiol diacetate
DB00957,The metabolism of Norgestimate can be increased when combined with Pegvisomant.,Norgestimate
DB00977,The metabolism of Ethinylestradiol can be increased when combined with Pegvisomant.,Ethinylestradiol
DB01357,The metabolism of Mestranol can be increased when combined with Pegvisomant.,Mestranol
DB01395,The metabolism of Drospirenone can be increased when combined with Pegvisomant.,Drospirenone
DB04066,The metabolism of p-Coumaric acid can be increased when combined with Pegvisomant.,p-Coumaric acid
DB04574,The metabolism of Estrone sulfate can be increased when combined with Pegvisomant.,Estrone sulfate
DB04682,The metabolism of Octylphenoxy polyethoxyethanol can be increased when combined with Pegvisomant.,Octylphenoxy polyethoxyethanol
DB04839,The metabolism of Cyproterone acetate can be increased when combined with Pegvisomant.,Cyproterone acetate
DB05830,The metabolism of Trestolone can be increased when combined with Pegvisomant.,Trestolone
DB06266,The metabolism of Lonidamine can be increased when combined with Pegvisomant.,Lonidamine
DB06713,The metabolism of Norelgestromin can be increased when combined with Pegvisomant.,Norelgestromin
DB06730,The metabolism of Gestodene can be increased when combined with Pegvisomant.,Gestodene
DB06789,The metabolism of Hydroxyprogesterone caproate can be increased when combined with Pegvisomant.,Hydroxyprogesterone caproate
DB09123,The metabolism of Dienogest can be increased when combined with Pegvisomant.,Dienogest
DB09371,The metabolism of Norethynodrel can be increased when combined with Pegvisomant.,Norethynodrel
DB09389,The metabolism of Norgestrel can be increased when combined with Pegvisomant.,Norgestrel
DB09401,The metabolism of Isosorbide can be increased when combined with Pegvisomant.,Isosorbide
DB11507,The metabolism of Cloprostenol can be increased when combined with Pegvisomant.,Cloprostenol
DB11619,The metabolism of Gestrinone can be increased when combined with Pegvisomant.,Gestrinone
DB11636,The metabolism of Nomegestrol can be increased when combined with Pegvisomant.,Nomegestrol
DB12025,The metabolism of Triptolide can be increased when combined with Pegvisomant.,Triptolide
DB12474,The metabolism of Lynestrenol can be increased when combined with Pegvisomant.,Lynestrenol
DB13044,The metabolism of Gossypol can be increased when combined with Pegvisomant.,Gossypol
DB13310,The metabolism of Ormeloxifene can be increased when combined with Pegvisomant.,Ormeloxifene
DB13528,The metabolism of Chlormadinone can be increased when combined with Pegvisomant.,Chlormadinone
DB13563,The metabolism of Norgestrienone can be increased when combined with Pegvisomant.,Norgestrienone
DB13685,The metabolism of Quingestanol can be increased when combined with Pegvisomant.,Quingestanol
DB13857,The metabolism of Demegestone can be increased when combined with Pegvisomant.,Demegestone
DB13866,The metabolism of Etynodiol can be increased when combined with Pegvisomant.,Etynodiol
DB13944,The metabolism of Testosterone enanthate can be increased when combined with Pegvisomant.,Testosterone enanthate
DB13953,The metabolism of Estradiol benzoate can be increased when combined with Pegvisomant.,Estradiol benzoate
DB13954,The metabolism of Estradiol cypionate can be increased when combined with Pegvisomant.,Estradiol cypionate
DB13956,The metabolism of Estradiol valerate can be increased when combined with Pegvisomant.,Estradiol valerate
DB13981,The metabolism of Nomegestrol acetate can be increased when combined with Pegvisomant.,Nomegestrol acetate
DB14678,The metabolism of Norethindrone enanthate can be increased when combined with Pegvisomant.,Norethindrone enanthate
DB08867,The metabolism of Ulipristal can be increased when combined with Pegvisomant.,Ulipristal
DB00246,The metabolism of Ziprasidone can be increased when combined with Pegvisomant.,Ziprasidone
DB00477,The metabolism of Chlorpromazine can be increased when combined with Pegvisomant.,Chlorpromazine
DB01151,The metabolism of Desipramine can be increased when combined with Pegvisomant.,Desipramine
DB00186,The metabolism of Lorazepam can be increased when combined with Pegvisomant.,Lorazepam
DB00191,The metabolism of Phentermine can be increased when combined with Pegvisomant.,Phentermine
DB00207,The metabolism of Azithromycin can be increased when combined with Pegvisomant.,Azithromycin
DB00208,The metabolism of Ticlopidine can be increased when combined with Pegvisomant.,Ticlopidine
DB00264,The metabolism of Metoprolol can be increased when combined with Pegvisomant.,Metoprolol
DB00426,The metabolism of Famciclovir can be increased when combined with Pegvisomant.,Famciclovir
DB00433,The metabolism of Prochlorperazine can be increased when combined with Pegvisomant.,Prochlorperazine
DB00476,The metabolism of Duloxetine can be increased when combined with Pegvisomant.,Duloxetine
DB00518,The metabolism of Albendazole can be increased when combined with Pegvisomant.,Albendazole
DB00567,The metabolism of Cephalexin can be increased when combined with Pegvisomant.,Cephalexin
DB00590,The metabolism of Doxazosin can be increased when combined with Pegvisomant.,Doxazosin
DB01039,The metabolism of Fenofibrate can be increased when combined with Pegvisomant.,Fenofibrate
DB01072,The metabolism of Atazanavir can be increased when combined with Pegvisomant.,Atazanavir
DB01323,The metabolism of St. John's Wort can be increased when combined with Pegvisomant.,St. John's Wort
DB01411,The metabolism of Pranlukast can be increased when combined with Pegvisomant.,Pranlukast
DB01431,The metabolism of Allylestrenol can be increased when combined with Pegvisomant.,Allylestrenol
DB01624,The metabolism of Zuclopenthixol can be increased when combined with Pegvisomant.,Zuclopenthixol
DB01656,The metabolism of Roflumilast can be increased when combined with Pegvisomant.,Roflumilast
DB06201,The metabolism of Rufinamide can be increased when combined with Pegvisomant.,Rufinamide
DB06218,The metabolism of Lacosamide can be increased when combined with Pegvisomant.,Lacosamide
DB06480,The metabolism of Prucalopride can be increased when combined with Pegvisomant.,Prucalopride
DB09030,The metabolism of Vorapaxar can be increased when combined with Pegvisomant.,Vorapaxar
DB09034,The metabolism of Suvorexant can be increased when combined with Pegvisomant.,Suvorexant
DB09048,The metabolism of Netupitant can be increased when combined with Pegvisomant.,Netupitant
DB09071,The metabolism of Tasimelteon can be increased when combined with Pegvisomant.,Tasimelteon
DB09079,The metabolism of Nintedanib can be increased when combined with Pegvisomant.,Nintedanib
DB09299,The metabolism of Tenofovir alafenamide can be increased when combined with Pegvisomant.,Tenofovir alafenamide
DB09330,The metabolism of Osimertinib can be increased when combined with Pegvisomant.,Osimertinib
DB11094,The metabolism of Vitamin D can be increased when combined with Pegvisomant.,Vitamin D
DB11273,The metabolism of Dihydroergocornine can be increased when combined with Pegvisomant.,Dihydroergocornine
DB11730,The metabolism of Ribociclib can be increased when combined with Pegvisomant.,Ribociclib
DB11952,The metabolism of Duvelisib can be increased when combined with Pegvisomant.,Duvelisib
DB12141,The metabolism of Gilteritinib can be increased when combined with Pegvisomant.,Gilteritinib
DB12515,The metabolism of 9-aminocamptothecin can be increased when combined with Pegvisomant.,9-aminocamptothecin
DB12952,The metabolism of Methylprednisone can be increased when combined with Pegvisomant.,Methylprednisone
DB13345,The metabolism of Dihydroergocristine can be increased when combined with Pegvisomant.,Dihydroergocristine
DB13385,The metabolism of Dihydroergocryptine can be increased when combined with Pegvisomant.,Dihydroergocryptine
DB14009,The metabolism of Medical Cannabis can be increased when combined with Pegvisomant.,Medical Cannabis
DB14126,The metabolism of Tenofovir can be increased when combined with Pegvisomant.,Tenofovir
DB01098,The metabolism of Rosuvastatin can be increased when combined with Pegvisomant.,Rosuvastatin
DB00549,The metabolism of Zafirlukast can be increased when combined with Pegvisomant.,Zafirlukast
DB15444,The metabolism of Elexacaftor can be increased when combined with Pegvisomant.,Elexacaftor
DB12887,The metabolism of Tazemetostat can be increased when combined with Pegvisomant.,Tazemetostat
DB06717,The metabolism of Fosaprepitant can be increased when combined with Pegvisomant.,Fosaprepitant
DB12825,The metabolism of Lefamulin can be increased when combined with Pegvisomant.,Lefamulin
DB00247,The metabolism of Methysergide can be increased when combined with Pegvisomant.,Methysergide
DB00637,The metabolism of Astemizole can be increased when combined with Pegvisomant.,Astemizole
DB08827,The metabolism of Lomitapide can be increased when combined with Pegvisomant.,Lomitapide
DB11742,The metabolism of Ebastine can be increased when combined with Pegvisomant.,Ebastine
DB12371,The metabolism of Siponimod can be increased when combined with Pegvisomant.,Siponimod
DB00363,The metabolism of Clozapine can be increased when combined with Pegvisomant.,Clozapine
DB00091,The metabolism of Cyclosporine can be increased when combined with Pegvisomant.,Cyclosporine
DB00204,The metabolism of Dofetilide can be increased when combined with Pegvisomant.,Dofetilide
DB00277,The metabolism of Theophylline can be increased when combined with Pegvisomant.,Theophylline
DB00342,The metabolism of Terfenadine can be increased when combined with Pegvisomant.,Terfenadine
DB00451,The metabolism of Levothyroxine can be increased when combined with Pegvisomant.,Levothyroxine
DB00564,The metabolism of Carbamazepine can be increased when combined with Pegvisomant.,Carbamazepine
DB00604,The metabolism of Cisapride can be increased when combined with Pegvisomant.,Cisapride
DB00864,The metabolism of Tacrolimus can be increased when combined with Pegvisomant.,Tacrolimus
DB00877,The metabolism of Sirolimus can be increased when combined with Pegvisomant.,Sirolimus
DB00908,The metabolism of Quinidine can be increased when combined with Pegvisomant.,Quinidine
DB00946,The metabolism of Phenprocoumon can be increased when combined with Pegvisomant.,Phenprocoumon
DB01008,The metabolism of Busulfan can be increased when combined with Pegvisomant.,Busulfan
DB01100,The metabolism of Pimozide can be increased when combined with Pegvisomant.,Pimozide
DB01118,The metabolism of Amiodarone can be increased when combined with Pegvisomant.,Amiodarone
DB01223,The metabolism of Aminophylline can be increased when combined with Pegvisomant.,Aminophylline
DB01229,The metabolism of Paclitaxel can be increased when combined with Pegvisomant.,Paclitaxel
DB01254,The metabolism of Dasatinib can be increased when combined with Pegvisomant.,Dasatinib
DB01320,The metabolism of Fosphenytoin can be increased when combined with Pegvisomant.,Fosphenytoin
DB01396,The metabolism of Digitoxin can be increased when combined with Pegvisomant.,Digitoxin
DB01590,The metabolism of Everolimus can be increased when combined with Pegvisomant.,Everolimus
DB03410,The metabolism of 4-hydroxycoumarin can be increased when combined with Pegvisomant.,4-hydroxycoumarin
DB04855,The metabolism of Dronedarone can be increased when combined with Pegvisomant.,Dronedarone
DB06287,The metabolism of Temsirolimus can be increased when combined with Pegvisomant.,Temsirolimus
DB09053,The metabolism of Ibrutinib can be increased when combined with Pegvisomant.,Ibrutinib
DB09289,The metabolism of Tianeptine can be increased when combined with Pegvisomant.,Tianeptine
DB11633,The metabolism of Isavuconazole can be increased when combined with Pegvisomant.,Isavuconazole
DB13136,The metabolism of Fluindione can be increased when combined with Pegvisomant.,Fluindione
DB13275,The metabolism of Clorindione can be increased when combined with Pegvisomant.,Clorindione
DB05239,The metabolism of Cobimetinib can be increased when combined with Pegvisomant.,Cobimetinib
DB09054,The metabolism of Idelalisib can be increased when combined with Pegvisomant.,Idelalisib
DB09063,The metabolism of Ceritinib can be increased when combined with Pegvisomant.,Ceritinib
DB11963,The metabolism of Dacomitinib can be increased when combined with Pegvisomant.,Dacomitinib
DB12015,The metabolism of Alpelisib can be increased when combined with Pegvisomant.,Alpelisib
DB00563,The metabolism of Methotrexate can be increased when combined with Pegvisomant.,Methotrexate
DB00361,The metabolism of Vinorelbine can be increased when combined with Pegvisomant.,Vinorelbine
DB00541,The metabolism of Vincristine can be increased when combined with Pegvisomant.,Vincristine
DB00570,The metabolism of Vinblastine can be increased when combined with Pegvisomant.,Vinblastine
DB00694,The metabolism of Daunorubicin can be increased when combined with Pegvisomant.,Daunorubicin
DB00987,The metabolism of Cytarabine can be increased when combined with Pegvisomant.,Cytarabine
DB00997,The metabolism of Doxorubicin can be increased when combined with Pegvisomant.,Doxorubicin
DB01248,The metabolism of Docetaxel can be increased when combined with Pegvisomant.,Docetaxel
DB04572,The metabolism of Thiotepa can be increased when combined with Pegvisomant.,Thiotepa
DB05109,The metabolism of Trabectedin can be increased when combined with Pegvisomant.,Trabectedin
DB05294,The metabolism of Vandetanib can be increased when combined with Pegvisomant.,Vandetanib
DB05812,The metabolism of Abiraterone can be increased when combined with Pegvisomant.,Abiraterone
DB08881,The metabolism of Vemurafenib can be increased when combined with Pegvisomant.,Vemurafenib
DB11363,The metabolism of Alectinib can be increased when combined with Pegvisomant.,Alectinib
DB11581,The metabolism of Venetoclax can be increased when combined with Pegvisomant.,Venetoclax
DB11641,The metabolism of Vinflunine can be increased when combined with Pegvisomant.,Vinflunine
DB11703,The metabolism of Acalabrutinib can be increased when combined with Pegvisomant.,Acalabrutinib
DB13874,The metabolism of Enasidenib can be increased when combined with Pegvisomant.,Enasidenib
DB15035,The metabolism of Zanubrutinib can be increased when combined with Pegvisomant.,Zanubrutinib
DB00188,The metabolism of Bortezomib can be increased when combined with Pegvisomant.,Bortezomib
DB00248,The metabolism of Cabergoline can be increased when combined with Pegvisomant.,Cabergoline
DB00309,The metabolism of Vindesine can be increased when combined with Pegvisomant.,Vindesine
DB00398,The metabolism of Sorafenib can be increased when combined with Pegvisomant.,Sorafenib
DB00444,The metabolism of Teniposide can be increased when combined with Pegvisomant.,Teniposide
DB00619,The metabolism of Imatinib can be increased when combined with Pegvisomant.,Imatinib
DB00675,The metabolism of Tamoxifen can be increased when combined with Pegvisomant.,Tamoxifen
DB00773,The metabolism of Etoposide can be increased when combined with Pegvisomant.,Etoposide
DB04845,The metabolism of Ixabepilone can be increased when combined with Pegvisomant.,Ixabepilone
DB04868,The metabolism of Nilotinib can be increased when combined with Pegvisomant.,Nilotinib
DB05015,The metabolism of Belinostat can be increased when combined with Pegvisomant.,Belinostat
DB06589,The metabolism of Pazopanib can be increased when combined with Pegvisomant.,Pazopanib
DB06595,The metabolism of Midostaurin can be increased when combined with Pegvisomant.,Midostaurin
DB06603,The metabolism of Panobinostat can be increased when combined with Pegvisomant.,Panobinostat
DB06616,The metabolism of Bosutinib can be increased when combined with Pegvisomant.,Bosutinib
DB06626,The metabolism of Axitinib can be increased when combined with Pegvisomant.,Axitinib
DB08865,The metabolism of Crizotinib can be increased when combined with Pegvisomant.,Crizotinib
DB08870,The metabolism of Brentuximab vedotin can be increased when combined with Pegvisomant.,Brentuximab vedotin
DB08877,The metabolism of Ruxolitinib can be increased when combined with Pegvisomant.,Ruxolitinib
DB08901,The metabolism of Ponatinib can be increased when combined with Pegvisomant.,Ponatinib
DB08912,The metabolism of Dabrafenib can be increased when combined with Pegvisomant.,Dabrafenib
DB09073,The metabolism of Palbociclib can be increased when combined with Pegvisomant.,Palbociclib
DB09143,The metabolism of Sonidegib can be increased when combined with Pegvisomant.,Sonidegib
DB09570,The metabolism of Ixazomib can be increased when combined with Pegvisomant.,Ixazomib
DB11718,The metabolism of Encorafenib can be increased when combined with Pegvisomant.,Encorafenib
DB11828,The metabolism of Neratinib can be increased when combined with Pegvisomant.,Neratinib
DB12147,The metabolism of Erdafitinib can be increased when combined with Pegvisomant.,Erdafitinib
DB12267,The metabolism of Brigatinib can be increased when combined with Pegvisomant.,Brigatinib
DB12483,The metabolism of Copanlisib can be increased when combined with Pegvisomant.,Copanlisib
DB12978,The metabolism of Pexidartinib can be increased when combined with Pegvisomant.,Pexidartinib
DB14568,The metabolism of Ivosidenib can be increased when combined with Pegvisomant.,Ivosidenib
DB04896,The metabolism of Milnacipran can be increased when combined with Pegvisomant.,Milnacipran
DB08918,The metabolism of Levomilnacipran can be increased when combined with Pegvisomant.,Levomilnacipran
DB01256,The metabolism of Retapamulin can be increased when combined with Pegvisomant.,Retapamulin
DB11640,The risk or severity of adverse effects can be increased when Pegvisomant is combined with Amifampridine.,Amifampridine
DB00381,The metabolism of Amlodipine can be increased when combined with Pegvisomant.,Amlodipine
DB01068,The metabolism of Clonazepam can be increased when combined with Pegvisomant.,Clonazepam
DB00425,The metabolism of Zolpidem can be increased when combined with Pegvisomant.,Zolpidem
DB00402,The serum concentration of Eszopiclone can be decreased when it is combined with Pegvisomant.,Eszopiclone
DB01174,The metabolism of Phenobarbital can be decreased when combined with Pegvisomant.,Phenobarbital
DB00818,The metabolism of Propofol can be decreased when combined with Pegvisomant.,Propofol
DB00252,The metabolism of Phenytoin can be decreased when combined with Pegvisomant.,Phenytoin
DB00281,The metabolism of Lidocaine can be decreased when combined with Pegvisomant.,Lidocaine
DB00338,The metabolism of Omeprazole can be decreased when combined with Pegvisomant.,Omeprazole
DB00349,The metabolism of Clobazam can be decreased when combined with Pegvisomant.,Clobazam
DB00448,The metabolism of Lansoprazole can be decreased when combined with Pegvisomant.,Lansoprazole
DB00531,The metabolism of Cyclophosphamide can be decreased when combined with Pegvisomant.,Cyclophosphamide
DB00586,The metabolism of Diclofenac can be decreased when combined with Pegvisomant.,Diclofenac
DB00755,The metabolism of Tretinoin can be decreased when combined with Pegvisomant.,Tretinoin
DB01424,The metabolism of Aminophenazone can be decreased when combined with Pegvisomant.,Aminophenazone
DB01435,The metabolism of Antipyrine can be decreased when combined with Pegvisomant.,Antipyrine
DB01559,The metabolism of Clotiazepam can be decreased when combined with Pegvisomant.,Clotiazepam
DB09166,The metabolism of Etizolam can be decreased when combined with Pegvisomant.,Etizolam
DB11757,The metabolism of Istradefylline can be decreased when combined with Pegvisomant.,Istradefylline
DB00458,The metabolism of Imipramine can be decreased when combined with Pegvisomant.,Imipramine
DB11986,The metabolism of Entrectinib can be increased when combined with Pegvisomant.,Entrectinib
DB11951,The serum concentration of Lemborexant can be decreased when it is combined with Pegvisomant.,Lemborexant
DB06077,The serum concentration of Lumateperone can be decreased when it is combined with Pegvisomant.,Lumateperone
DB00243,The metabolism of Ranolazine can be increased when combined with Pegvisomant.,Ranolazine
DB00193,The metabolism of Pegvisomant can be increased when combined with Tramadol.,Tramadol
DB01190,The metabolism of Clindamycin can be increased when combined with Pegvisomant.,Clindamycin
DB12457,The metabolism of Rimegepant can be increased when combined with Pegvisomant.,Rimegepant
DB11791,The serum concentration of Capmatinib can be decreased when it is combined with Pegvisomant.,Capmatinib
DB15685,The serum concentration of Selpercatinib can be decreased when it is combined with Pegvisomant.,Selpercatinib
DB00921,Botulinum toxin type A may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.,Buprenorphine
DB00366,Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Botulinum toxin type A.,Doxylamine
DB00470,Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Botulinum toxin type A.,Dronabinol
DB00450,Droperidol may increase the central nervous system depressant (CNS depressant) activities of Botulinum toxin type A.,Droperidol
DB00956,Botulinum toxin type A may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.,Hydrocodone
DB00557,Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Botulinum toxin type A.,Hydroxyzine
DB00653,The therapeutic efficacy of Botulinum toxin type A can be increased when used in combination with Magnesium sulfate.,Magnesium sulfate
DB00765,Botulinum toxin type A may increase the sedative activities of Metyrosine.,Metyrosine
DB01017,Minocycline may increase the central nervous system depressant (CNS depressant) activities of Botulinum toxin type A.,Minocycline
DB00370,Botulinum toxin type A may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.,Mirtazapine
DB00486,Nabilone may increase the central nervous system depressant (CNS depressant) activities of Botulinum toxin type A.,Nabilone
DB09117,Botulinum toxin type A may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.,Paraldehyde
DB08883,Perampanel may increase the central nervous system depressant (CNS depressant) activities of Botulinum toxin type A.,Perampanel
DB00413,Botulinum toxin type A may increase the sedative activities of Pramipexole.,Pramipexole
DB00268,Botulinum toxin type A may increase the sedative activities of Ropinirole.,Ropinirole
DB05271,Botulinum toxin type A may increase the sedative activities of Rotigotine.,Rotigotine
DB06201,The risk or severity of adverse effects can be increased when Rufinamide is combined with Botulinum toxin type A.,Rufinamide
DB09072,Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Botulinum toxin type A.,Sodium oxybate
DB09034,Botulinum toxin type A may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.,Suvorexant
DB06204,Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Botulinum toxin type A.,Tapentadol
DB01041,Botulinum toxin type A may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.,Thalidomide
DB00425,Botulinum toxin type A may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.,Zolpidem
DB00202,The therapeutic efficacy of Succinylcholine can be increased when used in combination with Botulinum toxin type A.,Succinylcholine
DB01245,The therapeutic efficacy of Decamethonium can be increased when used in combination with Botulinum toxin type A.,Decamethonium
DB11156,The therapeutic efficacy of Pyrantel can be increased when used in combination with Botulinum toxin type A.,Pyrantel
DB12989,The therapeutic efficacy of Neosaxitoxin can be increased when used in combination with Botulinum toxin type A.,Neosaxitoxin
DB00333,The risk or severity of adverse effects can be increased when Methadone is combined with Botulinum toxin type A.,Methadone
DB00193,The risk or severity of adverse effects can be increased when Tramadol is combined with Botulinum toxin type A.,Tramadol
DB00209,The risk or severity of adverse effects can be increased when Trospium is combined with Botulinum toxin type A.,Trospium
DB00219,The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Botulinum toxin type A.,Oxyphenonium
DB00237,The risk or severity of adverse effects can be increased when Butabarbital is combined with Botulinum toxin type A.,Butabarbital
DB00241,The risk or severity of adverse effects can be increased when Butalbital is combined with Botulinum toxin type A.,Butalbital
DB00245,The risk or severity of adverse effects can be increased when Benzatropine is combined with Botulinum toxin type A.,Benzatropine
DB00246,The risk or severity of adverse effects can be increased when Ziprasidone is combined with Botulinum toxin type A.,Ziprasidone
DB00280,The risk or severity of adverse effects can be increased when Disopyramide is combined with Botulinum toxin type A.,Disopyramide
DB00306,The risk or severity of adverse effects can be increased when Talbutal is combined with Botulinum toxin type A.,Talbutal
DB00312,The risk or severity of adverse effects can be increased when Pentobarbital is combined with Botulinum toxin type A.,Pentobarbital
DB00321,The risk or severity of adverse effects can be increased when Amitriptyline is combined with Botulinum toxin type A.,Amitriptyline
DB00332,The risk or severity of adverse effects can be increased when Ipratropium is combined with Botulinum toxin type A.,Ipratropium
DB00334,The risk or severity of adverse effects can be increased when Olanzapine is combined with Botulinum toxin type A.,Olanzapine
DB00340,The risk or severity of adverse effects can be increased when Metixene is combined with Botulinum toxin type A.,Metixene
DB00342,The risk or severity of adverse effects can be increased when Terfenadine is combined with Botulinum toxin type A.,Terfenadine
DB00354,The risk or severity of adverse effects can be increased when Buclizine is combined with Botulinum toxin type A.,Buclizine
DB00363,The risk or severity of adverse effects can be increased when Clozapine is combined with Botulinum toxin type A.,Clozapine
DB00376,The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Botulinum toxin type A.,Trihexyphenidyl
DB00383,The risk or severity of adverse effects can be increased when Oxyphencyclimine is combined with Botulinum toxin type A.,Oxyphencyclimine
DB00387,The risk or severity of adverse effects can be increased when Procyclidine is combined with Botulinum toxin type A.,Procyclidine
DB00392,The risk or severity of adverse effects can be increased when Profenamine is combined with Botulinum toxin type A.,Profenamine
DB00416,The risk or severity of adverse effects can be increased when Metocurine iodide is combined with Botulinum toxin type A.,Metocurine iodide
DB00418,The risk or severity of adverse effects can be increased when Secobarbital is combined with Botulinum toxin type A.,Secobarbital
DB00420,The risk or severity of adverse effects can be increased when Promazine is combined with Botulinum toxin type A.,Promazine
DB00424,The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Botulinum toxin type A.,Hyoscyamine
DB00434,The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Botulinum toxin type A.,Cyproheptadine
DB00458,The risk or severity of adverse effects can be increased when Imipramine is combined with Botulinum toxin type A.,Imipramine
DB00462,The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Botulinum toxin type A.,Methscopolamine bromide
DB00463,The risk or severity of adverse effects can be increased when Metharbital is combined with Botulinum toxin type A.,Metharbital
DB00472,The risk or severity of adverse effects can be increased when Fluoxetine is combined with Botulinum toxin type A.,Fluoxetine
DB00477,The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Botulinum toxin type A.,Chlorpromazine
DB00483,The risk or severity of adverse effects can be increased when Gallamine triethiodide is combined with Botulinum toxin type A.,Gallamine triethiodide
DB00496,The risk or severity of adverse effects can be increased when Darifenacin is combined with Botulinum toxin type A.,Darifenacin
DB00505,The risk or severity of adverse effects can be increased when Tridihexethyl is combined with Botulinum toxin type A.,Tridihexethyl
DB00508,The risk or severity of adverse effects can be increased when Triflupromazine is combined with Botulinum toxin type A.,Triflupromazine
DB00514,The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Botulinum toxin type A.,Dextromethorphan
DB00517,The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Botulinum toxin type A.,Anisotropine methylbromide
DB00540,The risk or severity of adverse effects can be increased when Nortriptyline is combined with Botulinum toxin type A.,Nortriptyline
DB00543,The risk or severity of adverse effects can be increased when Amoxapine is combined with Botulinum toxin type A.,Amoxapine
DB00555,The risk or severity of adverse effects can be increased when Lamotrigine is combined with Botulinum toxin type A.,Lamotrigine
DB00565,The risk or severity of adverse effects can be increased when Cisatracurium is combined with Botulinum toxin type A.,Cisatracurium
DB00572,The risk or severity of adverse effects can be increased when Atropine is combined with Botulinum toxin type A.,Atropine
DB00599,The risk or severity of adverse effects can be increased when Thiopental is combined with Botulinum toxin type A.,Thiopental
DB00622,The risk or severity of adverse effects can be increased when Nicardipine is combined with Botulinum toxin type A.,Nicardipine
DB00657,The risk or severity of adverse effects can be increased when Mecamylamine is combined with Botulinum toxin type A.,Mecamylamine
DB00670,The risk or severity of adverse effects can be increased when Pirenzepine is combined with Botulinum toxin type A.,Pirenzepine
DB00715,The risk or severity of adverse effects can be increased when Paroxetine is combined with Botulinum toxin type A.,Paroxetine
DB00721,The risk or severity of adverse effects can be increased when Procaine is combined with Botulinum toxin type A.,Procaine
DB00725,The risk or severity of adverse effects can be increased when Homatropine methylbromide is combined with Botulinum toxin type A.,Homatropine methylbromide
DB00728,The risk or severity of adverse effects can be increased when Rocuronium is combined with Botulinum toxin type A.,Rocuronium
DB00732,The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Botulinum toxin type A.,Atracurium besylate
DB00747,The risk or severity of adverse effects can be increased when Scopolamine is combined with Botulinum toxin type A.,Scopolamine
DB00753,The risk or severity of adverse effects can be increased when Isoflurane is combined with Botulinum toxin type A.,Isoflurane
DB00767,The risk or severity of adverse effects can be increased when Benzquinamide is combined with Botulinum toxin type A.,Benzquinamide
DB00771,The risk or severity of adverse effects can be increased when Clidinium is combined with Botulinum toxin type A.,Clidinium
DB00777,The risk or severity of adverse effects can be increased when Propiomazine is combined with Botulinum toxin type A.,Propiomazine
DB00782,The risk or severity of adverse effects can be increased when Propantheline is combined with Botulinum toxin type A.,Propantheline
DB00794,The risk or severity of adverse effects can be increased when Primidone is combined with Botulinum toxin type A.,Primidone
DB00804,The risk or severity of adverse effects can be increased when Dicyclomine is combined with Botulinum toxin type A.,Dicyclomine
DB00810,The risk or severity of adverse effects can be increased when Biperiden is combined with Botulinum toxin type A.,Biperiden
DB00835,The risk or severity of adverse effects can be increased when Brompheniramine is combined with Botulinum toxin type A.,Brompheniramine
DB00849,The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Botulinum toxin type A.,Methylphenobarbital
DB00875,The risk or severity of adverse effects can be increased when Flupentixol is combined with Botulinum toxin type A.,Flupentixol
DB00907,The risk or severity of adverse effects can be increased when Cocaine is combined with Botulinum toxin type A.,Cocaine
DB00908,The risk or severity of adverse effects can be increased when Quinidine is combined with Botulinum toxin type A.,Quinidine
DB00915,The risk or severity of adverse effects can be increased when Amantadine is combined with Botulinum toxin type A.,Amantadine
DB00934,The risk or severity of adverse effects can be increased when Maprotiline is combined with Botulinum toxin type A.,Maprotiline
DB00940,The risk or severity of adverse effects can be increased when Methantheline is combined with Botulinum toxin type A.,Methantheline
DB00941,The risk or severity of adverse effects can be increased when Hexafluronium is combined with Botulinum toxin type A.,Hexafluronium
DB00942,The risk or severity of adverse effects can be increased when Cycrimine is combined with Botulinum toxin type A.,Cycrimine
DB00967,The risk or severity of adverse effects can be increased when Desloratadine is combined with Botulinum toxin type A.,Desloratadine
DB00986,The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Botulinum toxin type A.,Glycopyrronium
DB01036,The risk or severity of adverse effects can be increased when Tolterodine is combined with Botulinum toxin type A.,Tolterodine
DB01062,The risk or severity of adverse effects can be increased when Oxybutynin is combined with Botulinum toxin type A.,Oxybutynin
DB01069,The risk or severity of adverse effects can be increased when Promethazine is combined with Botulinum toxin type A.,Promethazine
DB01075,The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Botulinum toxin type A.,Diphenhydramine
DB01090,The risk or severity of adverse effects can be increased when Pentolinium is combined with Botulinum toxin type A.,Pentolinium
DB01116,The risk or severity of adverse effects can be increased when Trimethaphan is combined with Botulinum toxin type A.,Trimethaphan
DB01135,The risk or severity of adverse effects can be increased when Doxacurium is combined with Botulinum toxin type A.,Doxacurium
DB01142,The risk or severity of adverse effects can be increased when Doxepin is combined with Botulinum toxin type A.,Doxepin
DB01148,The risk or severity of adverse effects can be increased when Flavoxate is combined with Botulinum toxin type A.,Flavoxate
DB01151,The risk or severity of adverse effects can be increased when Desipramine is combined with Botulinum toxin type A.,Desipramine
DB01161,The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Botulinum toxin type A.,Chloroprocaine
DB01173,The risk or severity of adverse effects can be increased when Orphenadrine is combined with Botulinum toxin type A.,Orphenadrine
DB01174,The risk or severity of adverse effects can be increased when Phenobarbital is combined with Botulinum toxin type A.,Phenobarbital
DB01175,The risk or severity of adverse effects can be increased when Escitalopram is combined with Botulinum toxin type A.,Escitalopram
DB01199,The risk or severity of adverse effects can be increased when Tubocurarine is combined with Botulinum toxin type A.,Tubocurarine
DB01224,The risk or severity of adverse effects can be increased when Quetiapine is combined with Botulinum toxin type A.,Quetiapine
DB01226,The risk or severity of adverse effects can be increased when Mivacurium is combined with Botulinum toxin type A.,Mivacurium
DB01227,The risk or severity of adverse effects can be increased when Levacetylmethadol is combined with Botulinum toxin type A.,Levacetylmethadol
DB01231,The risk or severity of adverse effects can be increased when Diphenidol is combined with Botulinum toxin type A.,Diphenidol
DB01238,The risk or severity of adverse effects can be increased when Aripiprazole is combined with Botulinum toxin type A.,Aripiprazole
DB01239,The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Botulinum toxin type A.,Chlorprothixene
DB01288,The risk or severity of adverse effects can be increased when Fenoterol is combined with Botulinum toxin type A.,Fenoterol
DB01336,The risk or severity of adverse effects can be increased when Metocurine is combined with Botulinum toxin type A.,Metocurine
DB01337,The risk or severity of adverse effects can be increased when Pancuronium is combined with Botulinum toxin type A.,Pancuronium
DB01338,The risk or severity of adverse effects can be increased when Pipecuronium is combined with Botulinum toxin type A.,Pipecuronium
DB01339,The risk or severity of adverse effects can be increased when Vecuronium is combined with Botulinum toxin type A.,Vecuronium
DB01351,The risk or severity of adverse effects can be increased when Amobarbital is combined with Botulinum toxin type A.,Amobarbital
DB01352,The risk or severity of adverse effects can be increased when Aprobarbital is combined with Botulinum toxin type A.,Aprobarbital
DB01353,The risk or severity of adverse effects can be increased when Butobarbital is combined with Botulinum toxin type A.,Butobarbital
DB01354,The risk or severity of adverse effects can be increased when Heptabarbital is combined with Botulinum toxin type A.,Heptabarbital
DB01355,The risk or severity of adverse effects can be increased when Hexobarbital is combined with Botulinum toxin type A.,Hexobarbital
DB01403,The risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Botulinum toxin type A.,Methotrimeprazine
DB01409,The risk or severity of adverse effects can be increased when Tiotropium is combined with Botulinum toxin type A.,Tiotropium
DB01483,The risk or severity of adverse effects can be increased when Barbital is combined with Botulinum toxin type A.,Barbital
DB01496,"The risk or severity of adverse effects can be increased when Dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1H,5H)-pyrimidinedione is combined with Botulinum toxin type A.","Dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1H,5H)-pyrimidinedione"
DB01591,The risk or severity of adverse effects can be increased when Solifenacin is combined with Botulinum toxin type A.,Solifenacin
DB01625,The risk or severity of adverse effects can be increased when Isopropamide is combined with Botulinum toxin type A.,Isopropamide
DB04834,The risk or severity of adverse effects can be increased when Rapacuronium is combined with Botulinum toxin type A.,Rapacuronium
DB04843,The risk or severity of adverse effects can be increased when Mepenzolate is combined with Botulinum toxin type A.,Mepenzolate
DB05710,The risk or severity of adverse effects can be increased when Gantacurium is combined with Botulinum toxin type A.,Gantacurium
DB06153,The risk or severity of adverse effects can be increased when Pizotifen is combined with Botulinum toxin type A.,Pizotifen
DB06702,The risk or severity of adverse effects can be increased when Fesoterodine is combined with Botulinum toxin type A.,Fesoterodine
DB06787,The risk or severity of adverse effects can be increased when Hexocyclium is combined with Botulinum toxin type A.,Hexocyclium
DB08801,The risk or severity of adverse effects can be increased when Dimetindene is combined with Botulinum toxin type A.,Dimetindene
DB08838,The risk or severity of adverse effects can be increased when Agmatine is combined with Botulinum toxin type A.,Agmatine
DB08897,The risk or severity of adverse effects can be increased when Aclidinium is combined with Botulinum toxin type A.,Aclidinium
DB08960,The risk or severity of adverse effects can be increased when Hexamethonium is combined with Botulinum toxin type A.,Hexamethonium
DB08997,The risk or severity of adverse effects can be increased when Dexetimide is combined with Botulinum toxin type A.,Dexetimide
DB09007,The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Botulinum toxin type A.,Chlorphenoxamine
DB09023,The risk or severity of adverse effects can be increased when Benactyzine is combined with Botulinum toxin type A.,Benactyzine
DB09076,The risk or severity of adverse effects can be increased when Umeclidinium is combined with Botulinum toxin type A.,Umeclidinium
DB09089,The risk or severity of adverse effects can be increased when Trimebutine is combined with Botulinum toxin type A.,Trimebutine
DB09167,The risk or severity of adverse effects can be increased when Dosulepin is combined with Botulinum toxin type A.,Dosulepin
DB09262,The risk or severity of adverse effects can be increased when Imidafenacin is combined with Botulinum toxin type A.,Imidafenacin
DB09300,The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Botulinum toxin type A.,Butylscopolamine
DB11235,The risk or severity of adverse effects can be increased when Thonzylamine is combined with Botulinum toxin type A.,Thonzylamine
DB11315,The risk or severity of adverse effects can be increased when Methscopolamine is combined with Botulinum toxin type A.,Methscopolamine
DB11855,The risk or severity of adverse effects can be increased when Revefenacin is combined with Botulinum toxin type A.,Revefenacin
DB12086,The risk or severity of adverse effects can be increased when Oxitropium is combined with Botulinum toxin type A.,Oxitropium
DB12278,The risk or severity of adverse effects can be increased when Propiverine is combined with Botulinum toxin type A.,Propiverine
DB12526,The risk or severity of adverse effects can be increased when Batefenterol is combined with Botulinum toxin type A.,Batefenterol
DB12554,The risk or severity of adverse effects can be increased when Mebeverine is combined with Botulinum toxin type A.,Mebeverine
DB13252,The risk or severity of adverse effects can be increased when Tropatepine is combined with Botulinum toxin type A.,Tropatepine
DB13254,The risk or severity of adverse effects can be increased when Prifinium is combined with Botulinum toxin type A.,Prifinium
DB13295,The risk or severity of adverse effects can be increased when Atracurium is combined with Botulinum toxin type A.,Atracurium
DB13351,The risk or severity of adverse effects can be increased when Piperidolate is combined with Botulinum toxin type A.,Piperidolate
DB13369,The risk or severity of adverse effects can be increased when Benzilone is combined with Botulinum toxin type A.,Benzilone
DB13380,The risk or severity of adverse effects can be increased when Difemerine is combined with Botulinum toxin type A.,Difemerine
DB13413,The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Botulinum toxin type A.,Phenglutarimide
DB13448,The risk or severity of adverse effects can be increased when Mazaticol is combined with Botulinum toxin type A.,Mazaticol
DB13468,The risk or severity of adverse effects can be increased when Etybenzatropine is combined with Botulinum toxin type A.,Etybenzatropine
DB13500,The risk or severity of adverse effects can be increased when Otilonium is combined with Botulinum toxin type A.,Otilonium
DB13505,The risk or severity of adverse effects can be increased when Emepronium is combined with Botulinum toxin type A.,Emepronium
DB13507,The risk or severity of adverse effects can be increased when Poldine is combined with Botulinum toxin type A.,Poldine
DB13542,The risk or severity of adverse effects can be increased when Bevonium is combined with Botulinum toxin type A.,Bevonium
DB13581,The risk or severity of adverse effects can be increased when Rociverine is combined with Botulinum toxin type A.,Rociverine
DB13584,The risk or severity of adverse effects can be increased when Gallamine is combined with Botulinum toxin type A.,Gallamine
DB13619,The risk or severity of adverse effects can be increased when Bornaprine is combined with Botulinum toxin type A.,Bornaprine
DB13636,The risk or severity of adverse effects can be increased when Etanautine is combined with Botulinum toxin type A.,Etanautine
DB13648,The risk or severity of adverse effects can be increased when Alcuronium is combined with Botulinum toxin type A.,Alcuronium
DB13666,The risk or severity of adverse effects can be increased when Tiemonium iodide is combined with Botulinum toxin type A.,Tiemonium iodide
DB13678,The risk or severity of adverse effects can be increased when Dihexyverine is combined with Botulinum toxin type A.,Dihexyverine
DB13695,The risk or severity of adverse effects can be increased when Penthienate is combined with Botulinum toxin type A.,Penthienate
DB13720,The risk or severity of adverse effects can be increased when Diphemanil is combined with Botulinum toxin type A.,Diphemanil
DB13738,The risk or severity of adverse effects can be increased when Camylofin is combined with Botulinum toxin type A.,Camylofin
DB13759,The risk or severity of adverse effects can be increased when Fenpiverinium is combined with Botulinum toxin type A.,Fenpiverinium
DB13769,The risk or severity of adverse effects can be increased when Emetonium iodide is combined with Botulinum toxin type A.,Emetonium iodide
DB13844,The risk or severity of adverse effects can be increased when Pipenzolate is combined with Botulinum toxin type A.,Pipenzolate
DB13850,The risk or severity of adverse effects can be increased when Timepidium is combined with Botulinum toxin type A.,Timepidium
DB00898,Botulinum toxin type A may increase the central nervous system depressant (CNS depressant) activities of Ethanol.,Ethanol
DB00972,Botulinum toxin type A may increase the central nervous system depressant (CNS depressant) activities of Azelastine.,Azelastine
DB00484,Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Botulinum toxin type A.,Brimonidine
DB00176,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Fluvoxamine.,Fluvoxamine
DB00215,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Citalopram.,Citalopram
DB00476,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Duloxetine.,Duloxetine
DB00656,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Trazodone.,Trazodone
DB01104,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Sertraline.,Sertraline
DB01105,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Sibutramine.,Sibutramine
DB01149,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Nefazodone.,Nefazodone
DB04832,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Zimelidine.,Zimelidine
DB04884,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dapoxetine.,Dapoxetine
DB04896,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Milnacipran.,Milnacipran
DB06700,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Desvenlafaxine.,Desvenlafaxine
DB06731,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Seproxetine.,Seproxetine
DB08918,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Levomilnacipran.,Levomilnacipran
DB08953,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Indalpine.,Indalpine
DB12693,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ritanserin.,Ritanserin
DB13233,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Alaproclate.,Alaproclate
DB01198,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Zopiclone.,Zopiclone
DB00150,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tryptophan.,Tryptophan
DB00181,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Baclofen.,Baclofen
DB00182,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Amphetamine.,Amphetamine
DB00186,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lorazepam.,Lorazepam
DB00189,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ethchlorvynol.,Ethchlorvynol
DB00206,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Reserpine.,Reserpine
DB00216,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Eletriptan.,Eletriptan
DB00228,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Enflurane.,Enflurane
DB00231,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Temazepam.,Temazepam
DB00234,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Reboxetine.,Reboxetine
DB00247,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Methysergide.,Methysergide
DB00248,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cabergoline.,Cabergoline
DB00252,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Phenytoin.,Phenytoin
DB00273,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Topiramate.,Topiramate
DB00283,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Clemastine.,Clemastine
DB00285,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Venlafaxine.,Venlafaxine
DB00289,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Atomoxetine.,Atomoxetine
DB00292,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Etomidate.,Etomidate
DB00295,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Morphine.,Morphine
DB00313,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Valproic acid.,Valproic acid
DB00315,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Zolmitriptan.,Zolmitriptan
DB00318,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Codeine.,Codeine
DB00320,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dihydroergotamine.,Dihydroergotamine
DB00323,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tolcapone.,Tolcapone
DB00327,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Hydromorphone.,Hydromorphone
DB00341,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cetirizine.,Cetirizine
DB00344,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Protriptyline.,Protriptyline
DB00347,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Trimethadione.,Trimethadione
DB00349,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Clobazam.,Clobazam
DB00356,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Chlorzoxazone.,Chlorzoxazone
DB00371,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Meprobamate.,Meprobamate
DB00372,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Thiethylperazine.,Thiethylperazine
DB00377,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Palonosetron.,Palonosetron
DB00391,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Sulpiride.,Sulpiride
DB00404,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Alprazolam.,Alprazolam
DB00405,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dexbrompheniramine.,Dexbrompheniramine
DB00408,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Loxapine.,Loxapine
DB00409,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Remoxipride.,Remoxipride
DB00423,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Methocarbamol.,Methocarbamol
DB00427,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Triprolidine.,Triprolidine
DB00433,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Prochlorperazine.,Prochlorperazine
DB00454,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Meperidine.,Meperidine
DB00474,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Methohexital.,Methohexital
DB00475,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Chlordiazepoxide.,Chlordiazepoxide
DB00494,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Entacapone.,Entacapone
DB00497,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Oxycodone.,Oxycodone
DB00532,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Mephenytoin.,Mephenytoin
DB00546,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Adinazolam.,Adinazolam
DB00564,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Carbamazepine.,Carbamazepine
DB00574,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Fenfluramine.,Fenfluramine
DB00579,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Mazindol.,Mazindol
DB00588,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Fluticasone propionate.,Fluticasone propionate
DB00589,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lisuride.,Lisuride
DB00593,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ethosuximide.,Ethosuximide
DB00601,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Linezolid.,Linezolid
DB00604,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cisapride.,Cisapride
DB00611,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Butorphanol.,Butorphanol
DB00614,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Furazolidone.,Furazolidone
DB00617,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Paramethadione.,Paramethadione
DB00623,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Fluphenazine.,Fluphenazine
DB00625,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Efavirenz.,Efavirenz
DB00628,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Clorazepic acid.,Clorazepic acid
DB00633,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dexmedetomidine.,Dexmedetomidine
DB00645,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dyclonine.,Dyclonine
DB00647,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dextropropoxyphene.,Dextropropoxyphene
DB00652,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pentazocine.,Pentazocine
DB00660,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Metaxalone.,Metaxalone
DB00662,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Trimethobenzamide.,Trimethobenzamide
DB00669,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Sumatriptan.,Sumatriptan
DB00679,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Thioridazine.,Thioridazine
DB00680,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Moricizine.,Moricizine
DB00683,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Midazolam.,Midazolam
DB00690,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Flurazepam.,Flurazepam
DB00696,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ergotamine.,Ergotamine
DB00697,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tizanidine.,Tizanidine
DB00708,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Sufentanil.,Sufentanil
DB00714,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Apomorphine.,Apomorphine
DB00726,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Trimipramine.,Trimipramine
DB00734,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Risperidone.,Risperidone
DB00737,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Meclizine.,Meclizine
DB00740,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Riluzole.,Riluzole
DB00748,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Carbinoxamine.,Carbinoxamine
DB00752,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tranylcypromine.,Tranylcypromine
DB00754,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ethotoin.,Ethotoin
DB00757,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dolasetron.,Dolasetron
DB00776,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Oxcarbazepine.,Oxcarbazepine
DB00780,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Phenelzine.,Phenelzine
DB00801,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Halazepam.,Halazepam
DB00802,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Alfentanil.,Alfentanil
DB00805,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Minaprine.,Minaprine
DB00813,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Fentanyl.,Fentanyl
DB00818,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Propofol.,Propofol
DB00819,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Acetazolamide.,Acetazolamide
DB00829,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Diazepam.,Diazepam
DB00831,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Trifluoperazine.,Trifluoperazine
DB00832,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Phensuximide.,Phensuximide
DB00837,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Progabide.,Progabide
DB00842,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Oxazepam.,Oxazepam
DB00843,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Donepezil.,Donepezil
DB00844,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Nalbuphine.,Nalbuphine
DB00850,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Perphenazine.,Perphenazine
DB00854,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Levorphanol.,Levorphanol
DB00865,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Benzphetamine.,Benzphetamine
DB00866,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Alprenolol.,Alprenolol
DB00889,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Granisetron.,Granisetron
DB00897,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Triazolam.,Triazolam
DB00899,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Remifentanil.,Remifentanil
DB00904,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ondansetron.,Ondansetron
DB00906,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tiagabine.,Tiagabine
DB00909,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Zonisamide.,Zonisamide
DB00918,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Almotriptan.,Almotriptan
DB00933,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Mesoridazine.,Mesoridazine
DB00937,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Diethylpropion.,Diethylpropion
DB00949,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Felbamate.,Felbamate
DB00952,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Naratriptan.,Naratriptan
DB00953,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Rizatriptan.,Rizatriptan
DB00960,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pindolol.,Pindolol
DB00962,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Zaleplon.,Zaleplon
DB00969,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Alosetron.,Alosetron
DB00980,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ramelteon.,Ramelteon
DB00985,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dimenhydrinate.,Dimenhydrinate
DB00996,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Gabapentin.,Gabapentin
DB00998,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Frovatriptan.,Frovatriptan
DB01018,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Guanfacine.,Guanfacine
DB01028,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Methoxyflurane.,Methoxyflurane
DB01037,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Selegiline.,Selegiline
DB01049,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ergoloid mesylate.,Ergoloid mesylate
DB01063,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Acetophenazine.,Acetophenazine
DB01065,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Melatonin.,Melatonin
DB01068,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Clonazepam.,Clonazepam
DB01080,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Vigabatrin.,Vigabatrin
DB01081,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Diphenoxylate.,Diphenoxylate
DB01100,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pimozide.,Pimozide
DB01107,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Methyprylon.,Methyprylon
DB01114,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Chlorpheniramine.,Chlorpheniramine
DB01121,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Phenacemide.,Phenacemide
DB01154,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Thiamylal.,Thiamylal
DB01156,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Bupropion.,Bupropion
DB01159,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Halothane.,Halothane
DB01168,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Procarbazine.,Procarbazine
DB01171,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Moclobemide.,Moclobemide
DB01176,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cyclizine.,Cyclizine
DB01178,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Chlormezanone.,Chlormezanone
DB01186,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pergolide.,Pergolide
DB01189,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Desflurane.,Desflurane
DB01192,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Oxymorphone.,Oxymorphone
DB01200,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Bromocriptine.,Bromocriptine
DB01202,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Levetiracetam.,Levetiracetam
DB01209,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dezocine.,Dezocine
DB01215,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Estazolam.,Estazolam
DB01221,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ketamine.,Ketamine
DB01235,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Levodopa.,Levodopa
DB01236,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Sevoflurane.,Sevoflurane
DB01242,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Clomipramine.,Clomipramine
DB01246,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Alimemazine.,Alimemazine
DB01247,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Isocarboxazid.,Isocarboxazid
DB01253,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ergometrine.,Ergometrine
DB01267,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Paliperidone.,Paliperidone
DB01320,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Fosphenytoin.,Fosphenytoin
DB01323,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with St. John's Wort.,St. John's Wort
DB01356,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lithium cation.,Lithium cation
DB01359,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Penbutolol.,Penbutolol
DB01367,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Rasagiline.,Rasagiline
DB01392,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Yohimbine.,Yohimbine
DB01433,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Methadyl acetate.,Methadyl acetate
DB01437,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Glutethimide.,Glutethimide
DB01440,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with gamma-Hydroxybutyric acid.,gamma-Hydroxybutyric acid
DB01442,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with MMDA.,MMDA
DB01445,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Bufotenine.,Bufotenine
DB01450,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dihydroetorphine.,Dihydroetorphine
DB01452,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Diamorphine.,Diamorphine
DB01454,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Midomafetamine.,Midomafetamine
DB01463,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Fencamfamin.,Fencamfamin
DB01466,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ethylmorphine.,Ethylmorphine
DB01472,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with 4-Methoxyamphetamine.,4-Methoxyamphetamine
DB01484,"The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with 4-Bromo-2,5-dimethoxyamphetamine.","4-Bromo-2,5-dimethoxyamphetamine"
DB01488,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dimethyltryptamine.,Dimethyltryptamine
DB01489,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Camazepam.,Camazepam
DB01495,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dichloralphenazone.,Dichloralphenazone
DB01497,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Etorphine.,Etorphine
DB01501,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Difenoxin.,Difenoxin
DB01509,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tenamfetamine.,Tenamfetamine
DB01511,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Delorazepam.,Delorazepam
DB01529,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dextromoramide.,Dextromoramide
DB01531,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Desomorphine.,Desomorphine
DB01534,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Chlorhexadol.,Chlorhexadol
DB01535,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Carfentanil.,Carfentanil
DB01544,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Flunitrazepam.,Flunitrazepam
DB01545,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ethyl loflazepate.,Ethyl loflazepate
DB01547,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Drotebanol.,Drotebanol
DB01551,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dihydrocodeine.,Dihydrocodeine
DB01553,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cloxazolam.,Cloxazolam
DB01555,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Alphacetylmethadol.,Alphacetylmethadol
DB01558,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Bromazepam.,Bromazepam
DB01559,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Clotiazepam.,Clotiazepam
DB01560,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cathinone.,Cathinone
DB01563,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Chloral hydrate.,Chloral hydrate
DB01565,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dihydromorphine.,Dihydromorphine
DB01567,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Fludiazepam.,Fludiazepam
DB01577,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Metamfetamine.,Metamfetamine
DB01580,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Oxprenolol.,Oxprenolol
DB01587,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ketazolam.,Ketazolam
DB01588,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Prazepam.,Prazepam
DB01589,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Quazepam.,Quazepam
DB01594,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cinolazepam.,Cinolazepam
DB01595,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Nitrazepam.,Nitrazepam
DB01608,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Periciazine.,Periciazine
DB01614,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Acepromazine.,Acepromazine
DB01615,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Aceprometazine.,Aceprometazine
DB01616,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Alverine.,Alverine
DB01618,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Molindone.,Molindone
DB01621,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pipotiazine.,Pipotiazine
DB01622,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Thioproperazine.,Thioproperazine
DB01623,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Thiothixene.,Thiothixene
DB01624,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Zuclopenthixol.,Zuclopenthixol
DB01626,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pargyline.,Pargyline
DB01954,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Rolipram.,Rolipram
DB02207,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with 7-Nitroindazole.,7-Nitroindazole
DB02234,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with S-Ethylisothiourea.,S-Ethylisothiourea
DB02852,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Domoic Acid.,Domoic Acid
DB02959,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Oxitriptan.,Oxitriptan
DB03575,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Phencyclidine.,Phencyclidine
DB04017,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Clorgiline.,Clorgiline
DB04165,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Valpromide.,Valpromide
DB04325,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Phenethylamine.,Phenethylamine
DB04599,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Aniracetam.,Aniracetam
DB04818,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Iproniazid.,Iproniazid
DB04819,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Methapyrilene.,Methapyrilene
DB04820,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Nialamide.,Nialamide
DB04821,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Nomifensine.,Nomifensine
DB04827,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Urethane.,Urethane
DB04829,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lysergic acid diethylamide.,Lysergic acid diethylamide
DB04833,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Methaqualone.,Methaqualone
DB04836,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Amineptine.,Amineptine
DB04841,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Flunarizine.,Flunarizine
DB04842,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Fluspirilene.,Fluspirilene
DB04871,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lorcaserin.,Lorcaserin
DB04872,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Osanetant.,Osanetant
DB04885,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cilansetron.,Cilansetron
DB04888,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Bifeprunox.,Bifeprunox
DB04903,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pagoclone.,Pagoclone
DB04908,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Flibanserin.,Flibanserin
DB04917,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Renzapride.,Renzapride
DB04946,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Iloperidone.,Iloperidone
DB04953,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ezogabine.,Ezogabine
DB05227,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with APD791.,APD791
DB05232,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tetrodotoxin.,Tetrodotoxin
DB05246,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Methsuximide.,Methsuximide
DB05316,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pimavanserin.,Pimavanserin
DB05541,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Brivaracetam.,Brivaracetam
DB05542,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Naronapride.,Naronapride
DB05562,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Naluzotan.,Naluzotan
DB05607,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with PRX-08066.,PRX-08066
DB05687,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with BL-1020.,BL-1020
DB06016,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cariprazine.,Cariprazine
DB06077,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lumateperone.,Lumateperone
DB06109,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with YKP-1358.,YKP-1358
DB06144,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Sertindole.,Sertindole
DB06148,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Mianserin.,Mianserin
DB06216,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Asenapine.,Asenapine
DB06218,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lacosamide.,Lacosamide
DB06264,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tolperisone.,Tolperisone
DB06282,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Levocetirizine.,Levocetirizine
DB06283,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ziconotide.,Ziconotide
DB06288,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Amisulpride.,Amisulpride
DB06446,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dotarizine.,Dotarizine
DB06458,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Remacemide.,Remacemide
DB06470,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Clomethiazole.,Clomethiazole
DB06512,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Deramciclane.,Deramciclane
DB06527,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tramiprosate.,Tramiprosate
DB06529,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ocinaplon.,Ocinaplon
DB06554,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Gaboxadol.,Gaboxadol
DB06579,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Adipiplon.,Adipiplon
DB06582,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dextofisopam.,Dextofisopam
DB06594,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Agomelatine.,Agomelatine
DB06654,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Safinamide.,Safinamide
DB06660,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Saredutant.,Saredutant
DB06678,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Esmirtazapine.,Esmirtazapine
DB06684,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Vilazodone.,Vilazodone
DB06690,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Nitrous oxide.,Nitrous oxide
DB06691,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Mepyramine.,Mepyramine
DB06701,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dexmethylphenidate.,Dexmethylphenidate
DB06716,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Fospropofol.,Fospropofol
DB06738,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ketobemidone.,Ketobemidone
DB06753,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Triclofos.,Triclofos
DB06770,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Benzyl alcohol.,Benzyl alcohol
DB06797,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Mebutamate.,Mebutamate
DB08059,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Wortmannin.,Wortmannin
DB08329,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Sulthiame.,Sulthiame
DB08550,"The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.","7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline"
DB08810,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cinitapride.,Cinitapride
DB08811,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tofisopam.,Tofisopam
DB08815,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lurasidone.,Lurasidone
DB08839,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Serotonin.,Serotonin
DB08861,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with DPDPE.,DPDPE
DB08872,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Gabapentin enacarbil.,Gabapentin enacarbil
DB08892,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Arbaclofen Placarbil.,Arbaclofen Placarbil
DB08910,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pomalidomide.,Pomalidomide
DB08922,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Perospirone.,Perospirone
DB08927,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Amperozide.,Amperozide
DB08954,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ifenprodil.,Ifenprodil
DB08986,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Etifoxine.,Etifoxine
DB08992,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Eperisone.,Eperisone
DB08996,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dimetacrine.,Dimetacrine
DB09000,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cyamemazine.,Cyamemazine
DB09001,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Barbexaclone.,Barbexaclone
DB09011,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Beclamide.,Beclamide
DB09014,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Captodiame.,Captodiame
DB09016,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Butriptyline.,Butriptyline
DB09017,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Brotizolam.,Brotizolam
DB09021,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Benzoctamine.,Benzoctamine
DB09068,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Vortioxetine.,Vortioxetine
DB09071,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tasimelteon.,Tasimelteon
DB09118,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Stiripentol.,Stiripentol
DB09119,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Eslicarbazepine acetate.,Eslicarbazepine acetate
DB09128,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Brexpiprazole.,Brexpiprazole
DB09166,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Etizolam.,Etizolam
DB09174,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lofentanil.,Lofentanil
DB09184,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Edivoxetine.,Edivoxetine
DB09185,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Viloxazine.,Viloxazine
DB09186,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Nisoxetine.,Nisoxetine
DB09187,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lortalamine.,Lortalamine
DB09190,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Talopram.,Talopram
DB09194,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Etoperidone.,Etoperidone
DB09223,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Blonanserin.,Blonanserin
DB09224,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Melperone.,Melperone
DB09225,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Zotepine.,Zotepine
DB09226,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Brilaroxazine.,Brilaroxazine
DB09241,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Methylene blue.,Methylene blue
DB09243,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Hydracarbazine.,Hydracarbazine
DB09244,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pirlindole.,Pirlindole
DB09245,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Toloxatone.,Toloxatone
DB09246,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Benmoxin.,Benmoxin
DB09247,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Iproclozide.,Iproclozide
DB09248,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Mebanazine.,Mebanazine
DB09249,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Octamoxin.,Octamoxin
DB09250,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pheniprazine.,Pheniprazine
DB09251,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Phenoxypropazine.,Phenoxypropazine
DB09252,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pivhydrazine.,Pivhydrazine
DB09253,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Safrazine.,Safrazine
DB09254,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Caroxazone.,Caroxazone
DB09286,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pipamperone.,Pipamperone
DB09289,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tianeptine.,Tianeptine
DB09290,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ramosetron.,Ramosetron
DB09307,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Oxaprotiline.,Oxaprotiline
DB11130,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Opium.,Opium
DB11371,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Alfaxalone.,Alfaxalone
DB11376,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Azaperone.,Azaperone
DB11400,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Doramectin.,Doramectin
DB11428,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Medetomidine.,Medetomidine
DB11477,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Xylazine.,Xylazine
DB11540,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Propiopromazine.,Propiopromazine
DB11543,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Romifidine.,Romifidine
DB11549,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tiletamine.,Tiletamine
DB11552,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tricaine.,Tricaine
DB11555,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Zolazepam.,Zolazepam
DB11556,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Detomidine.,Detomidine
DB11582,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Thiocolchicoside.,Thiocolchicoside
DB11609,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Normethadone.,Normethadone
DB11664,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Psilocybin.,Psilocybin
DB11675,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Mosapride.,Mosapride
DB11686,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Iferanserin.,Iferanserin
DB11699,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tropisetron.,Tropisetron
DB11755,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tetrahydrocannabivarin.,Tetrahydrocannabivarin
DB11859,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Brexanolone.,Brexanolone
DB11868,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Etiracetam.,Etiracetam
DB11889,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lanicemine.,Lanicemine
DB11957,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Idalopirdine.,Idalopirdine
DB12071,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Vabicaserin.,Vabicaserin
DB12093,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tetrahydropalmatine.,Tetrahydropalmatine
DB12105,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Imagabalin.,Imagabalin
DB12110,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with m-Chlorophenylpiperazine.,m-Chlorophenylpiperazine
DB12111,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with MK-212.,MK-212
DB12131,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Vinpocetine.,Vinpocetine
DB12163,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Sarpogrelate.,Sarpogrelate
DB12177,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Eplivanserin.,Eplivanserin
DB12184,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Gepirone.,Gepirone
DB12229,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cerlapirdine.,Cerlapirdine
DB12273,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ecopipam.,Ecopipam
DB12308,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Eltanolone.,Eltanolone
DB12327,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Salvinorin A.,Salvinorin A
DB12338,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Carisbamate.,Carisbamate
DB12361,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Piclozotan.,Piclozotan
DB12395,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Esreboxetine.,Esreboxetine
DB12401,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Bromperidol.,Bromperidol
DB12427,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Orvepitant.,Orvepitant
DB12465,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ketanserin.,Ketanserin
DB12492,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Piritramide.,Piritramide
DB12518,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Raclopride.,Raclopride
DB12537,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Benzodiazepine.,Benzodiazepine
DB12576,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with AZD-3043.,AZD-3043
DB12590,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Indiplon.,Indiplon
DB12661,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Urapidil.,Urapidil
DB12710,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Perazine.,Perazine
DB12725,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with TD-8954.,TD-8954
DB12833,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tandospirone.,Tandospirone
DB12867,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Benperidol.,Benperidol
DB12883,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Eltoprazine.,Eltoprazine
DB12930,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Opipramol.,Opipramol
DB12951,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pivagabine.,Pivagabine
DB12958,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Prothipendyl.,Prothipendyl
DB13014,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Hypericin.,Hypericin
DB13025,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tiapride.,Tiapride
DB13082,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Nefiracetam.,Nefiracetam
DB13099,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Valnoctamide.,Valnoctamide
DB13114,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Amitriptylinoxide.,Amitriptylinoxide
DB13160,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Alphaprodine.,Alphaprodine
DB13213,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Butaperazine.,Butaperazine
DB13219,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Medifoxamine.,Medifoxamine
DB13221,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Apronalide.,Apronalide
DB13225,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dibenzepin.,Dibenzepin
DB13234,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Propanidid.,Propanidid
DB13246,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Quinupramine.,Quinupramine
DB13253,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Proxibarbal.,Proxibarbal
DB13256,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Clothiapine.,Clothiapine
DB13273,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Sultopride.,Sultopride
DB13303,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Febarbamate.,Febarbamate
DB13323,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Trichloroethylene.,Trichloroethylene
DB13324,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tetrazepam.,Tetrazepam
DB13331,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pyrithyldione.,Pyrithyldione
DB13335,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pinazepam.,Pinazepam
DB13352,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Deanol.,Deanol
DB13354,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Phenprobamate.,Phenprobamate
DB13357,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Styramate.,Styramate
DB13362,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pheneturide.,Pheneturide
DB13370,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Bromisoval.,Bromisoval
DB13377,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Vinbarbital.,Vinbarbital
DB13382,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Chlorproethazine.,Chlorproethazine
DB13384,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Melitracen.,Melitracen
DB13396,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Neocitrullamon.,Neocitrullamon
DB13402,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Acetylglycinamide chloral hydrate.,Acetylglycinamide chloral hydrate
DB13403,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Oxypertine.,Oxypertine
DB13411,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lofepramine.,Lofepramine
DB13414,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Fenyramidol.,Fenyramidol
DB13420,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Thiazinam.,Thiazinam
DB13437,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Medazepam.,Medazepam
DB13455,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Phenibut.,Phenibut
DB13457,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Oxaflozane.,Oxaflozane
DB13478,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Meptazinol.,Meptazinol
DB13496,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Iprindole.,Iprindole
DB13520,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Metergoline.,Metergoline
DB13522,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Mebicar.,Mebicar
DB13523,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Veralipride.,Veralipride
DB13534,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Gedocarnil.,Gedocarnil
DB13541,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Iprazochrome.,Iprazochrome
DB13550,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Bifemelane.,Bifemelane
DB13552,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Trifluperidol.,Trifluperidol
DB13554,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Moperone.,Moperone
DB13557,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Thiopropazate.,Thiopropazate
DB13572,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Emylcamate.,Emylcamate
DB13577,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Allobarbital.,Allobarbital
DB13588,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Naftidrofuryl.,Naftidrofuryl
DB13598,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Diethyl ether.,Diethyl ether
DB13601,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Oxiracetam.,Oxiracetam
DB13605,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Phenoperidine.,Phenoperidine
DB13606,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Phenazocine.,Phenazocine
DB13623,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Fabomotizole.,Fabomotizole
DB13642,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pridinol.,Pridinol
DB13643,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Loprazolam.,Loprazolam
DB13662,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Hexapropymate.,Hexapropymate
DB13665,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Fluanisone.,Fluanisone
DB13676,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Mosapramine.,Mosapramine
DB13687,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Niaprazine.,Niaprazine
DB13690,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Vinyl ether.,Vinyl ether
DB13733,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Methylpentynol.,Methylpentynol
DB13737,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cyclobarbital.,Cyclobarbital
DB13745,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Fazadinium bromide.,Fazadinium bromide
DB13754,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Mephenoxalone.,Mephenoxalone
DB13770,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Vinylbital.,Vinylbital
DB13782,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Imipramine oxide.,Imipramine oxide
DB13784,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Dixyrazine.,Dixyrazine
DB13787,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tilidine.,Tilidine
DB13791,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Penfluridol.,Penfluridol
DB13799,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Ethadione.,Ethadione
DB13805,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Reposal.,Reposal
DB13817,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Carbromal.,Carbromal
DB13837,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Doxefazepam.,Doxefazepam
DB13841,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Clopenthixol.,Clopenthixol
DB13872,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lormetazepam.,Lormetazepam
DB13875,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Harmaline.,Harmaline
DB13876,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Brofaromine.,Brofaromine
DB13940,"The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.","2,5-Dimethoxy-4-ethylthioamphetamine"
DB13948,"The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine.","N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine"
DB13984,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cyclopropane.,Cyclopropane
DB13993,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with MRK-409.,MRK-409
DB14010,"The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with 5-methoxy-N,N-dimethyltryptamine.","5-methoxy-N,N-dimethyltryptamine"
DB14028,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Nordazepam.,Nordazepam
DB14050,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cannabidivarin.,Cannabidivarin
DB14185,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Aripiprazole lauroxil.,Aripiprazole lauroxil
DB14509,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lithium carbonate.,Lithium carbonate
DB14575,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Eslicarbazepine.,Eslicarbazepine
DB14651,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Perphenazine enanthate.,Perphenazine enanthate
DB14672,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Oxazepam acetate.,Oxazepam acetate
DB14715,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cinazepam.,Cinazepam
DB14718,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Pyrazolam.,Pyrazolam
DB14719,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Bentazepam.,Bentazepam
DB14754,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Solriamfetol.,Solriamfetol
DB15203,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with JNJ-26489112.,JNJ-26489112
DB15360,"The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Carfentanil, C-11.","Carfentanil, C-11"
DB11951,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lemborexant.,Lemborexant
DB00230,The therapeutic efficacy of Botulinum toxin type A can be increased when used in combination with Pregabalin.,Pregabalin
DB04948,The therapeutic efficacy of Botulinum toxin type A can be increased when used in combination with Lofexidine.,Lofexidine
DB00042,The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Botulinum toxin type A.,Botulinum Toxin Type B
DB00184,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Nicotine.,Nicotine
DB08837,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Tetraethylammonium.,Tetraethylammonium
DB08999,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Cyclopentamine.,Cyclopentamine
DB00091,The risk or severity of adverse effects can be increased when Cyclosporine is combined with Botulinum toxin type A.,Cyclosporine
DB00254,The risk or severity of adverse effects can be increased when Doxycycline is combined with Botulinum toxin type A.,Doxycycline
DB00256,The risk or severity of adverse effects can be increased when Lymecycline is combined with Botulinum toxin type A.,Lymecycline
DB00314,The risk or severity of adverse effects can be increased when Capreomycin is combined with Botulinum toxin type A.,Capreomycin
DB00319,The risk or severity of adverse effects can be increased when Piperacillin is combined with Botulinum toxin type A.,Piperacillin
DB00452,The risk or severity of adverse effects can be increased when Framycetin is combined with Botulinum toxin type A.,Framycetin
DB00453,The risk or severity of adverse effects can be increased when Clomocycline is combined with Botulinum toxin type A.,Clomocycline
DB00468,The risk or severity of adverse effects can be increased when Quinine is combined with Botulinum toxin type A.,Quinine
DB00512,The risk or severity of adverse effects can be increased when Vancomycin is combined with Botulinum toxin type A.,Vancomycin
DB00560,The risk or severity of adverse effects can be increased when Tigecycline is combined with Botulinum toxin type A.,Tigecycline
DB00595,The risk or severity of adverse effects can be increased when Oxytetracycline is combined with Botulinum toxin type A.,Oxytetracycline
DB00608,The risk or severity of adverse effects can be increased when Chloroquine is combined with Botulinum toxin type A.,Chloroquine
DB00618,The risk or severity of adverse effects can be increased when Demeclocycline is combined with Botulinum toxin type A.,Demeclocycline
DB00684,The risk or severity of adverse effects can be increased when Tobramycin is combined with Botulinum toxin type A.,Tobramycin
DB00759,The risk or severity of adverse effects can be increased when Tetracycline is combined with Botulinum toxin type A.,Tetracycline
DB00798,The risk or severity of adverse effects can be increased when Gentamicin is combined with Botulinum toxin type A.,Gentamicin
DB00903,The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Botulinum toxin type A.,Etacrynic acid
DB00931,The risk or severity of adverse effects can be increased when Metacycline is combined with Botulinum toxin type A.,Metacycline
DB00955,The risk or severity of adverse effects can be increased when Netilmicin is combined with Botulinum toxin type A.,Netilmicin
DB00994,The risk or severity of adverse effects can be increased when Neomycin is combined with Botulinum toxin type A.,Neomycin
DB01035,The risk or severity of adverse effects can be increased when Procainamide is combined with Botulinum toxin type A.,Procainamide
DB01082,The risk or severity of adverse effects can be increased when Streptomycin is combined with Botulinum toxin type A.,Streptomycin
DB01111,The risk or severity of adverse effects can be increased when Colistimethate is combined with Botulinum toxin type A.,Colistimethate
DB01172,The risk or severity of adverse effects can be increased when Kanamycin is combined with Botulinum toxin type A.,Kanamycin
DB01190,The risk or severity of adverse effects can be increased when Clindamycin is combined with Botulinum toxin type A.,Clindamycin
DB01219,The risk or severity of adverse effects can be increased when Dantrolene is combined with Botulinum toxin type A.,Dantrolene
DB01301,The risk or severity of adverse effects can be increased when Rolitetracycline is combined with Botulinum toxin type A.,Rolitetracycline
DB01377,The risk or severity of adverse effects can be increased when Magnesium oxide is combined with Botulinum toxin type A.,Magnesium oxide
DB01378,The risk or severity of adverse effects can be increased when Magnesium cation is combined with Botulinum toxin type A.,Magnesium cation
DB01421,The risk or severity of adverse effects can be increased when Paromomycin is combined with Botulinum toxin type A.,Paromomycin
DB01627,The risk or severity of adverse effects can be increased when Lincomycin is combined with Botulinum toxin type A.,Lincomycin
DB03615,The risk or severity of adverse effects can be increased when Ribostamycin is combined with Botulinum toxin type A.,Ribostamycin
DB04263,The risk or severity of adverse effects can be increased when Geneticin is combined with Botulinum toxin type A.,Geneticin
DB04626,The risk or severity of adverse effects can be increased when Apramycin is combined with Botulinum toxin type A.,Apramycin
DB04729,The risk or severity of adverse effects can be increased when Gentamicin C1a is combined with Botulinum toxin type A.,Gentamicin C1a
DB04808,The risk or severity of adverse effects can be increased when Neamine is combined with Botulinum toxin type A.,Neamine
DB06696,The risk or severity of adverse effects can be increased when Arbekacin is combined with Botulinum toxin type A.,Arbekacin
DB06827,The risk or severity of adverse effects can be increased when Viomycin is combined with Botulinum toxin type A.,Viomycin
DB08437,The risk or severity of adverse effects can be increased when Puromycin is combined with Botulinum toxin type A.,Puromycin
DB09104,The risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Botulinum toxin type A.,Magnesium hydroxide
DB09281,The risk or severity of adverse effects can be increased when Magnesium trisilicate is combined with Botulinum toxin type A.,Magnesium trisilicate
DB09407,The risk or severity of adverse effects can be increased when Magnesium chloride is combined with Botulinum toxin type A.,Magnesium chloride
DB09409,The risk or severity of adverse effects can be increased when Magnesium acetate tetrahydrate is combined with Botulinum toxin type A.,Magnesium acetate tetrahydrate
DB09481,The risk or severity of adverse effects can be increased when Magnesium carbonate is combined with Botulinum toxin type A.,Magnesium carbonate
DB11110,The risk or severity of adverse effects can be increased when Magnesium citrate is combined with Botulinum toxin type A.,Magnesium citrate
DB11189,The risk or severity of adverse effects can be increased when Magnesium glycinate is combined with Botulinum toxin type A.,Magnesium glycinate
DB11230,The risk or severity of adverse effects can be increased when Magnesium Aluminum Silicate is combined with Botulinum toxin type A.,Magnesium Aluminum Silicate
DB11512,The risk or severity of adverse effects can be increased when Dihydrostreptomycin is combined with Botulinum toxin type A.,Dihydrostreptomycin
DB11520,The risk or severity of adverse effects can be increased when Hygromycin B is combined with Botulinum toxin type A.,Hygromycin B
DB12604,The risk or severity of adverse effects can be increased when Sisomicin is combined with Botulinum toxin type A.,Sisomicin
DB12615,The risk or severity of adverse effects can be increased when Plazomicin is combined with Botulinum toxin type A.,Plazomicin
DB13249,The risk or severity of adverse effects can be increased when Magnesium silicate is combined with Botulinum toxin type A.,Magnesium silicate
DB13264,The risk or severity of adverse effects can be increased when Penimepicycline is combined with Botulinum toxin type A.,Penimepicycline
DB13270,The risk or severity of adverse effects can be increased when Dibekacin is combined with Botulinum toxin type A.,Dibekacin
DB13274,The risk or severity of adverse effects can be increased when Micronomicin is combined with Botulinum toxin type A.,Micronomicin
DB13359,The risk or severity of adverse effects can be increased when Magnesium aspartate is combined with Botulinum toxin type A.,Magnesium aspartate
DB13540,The risk or severity of adverse effects can be increased when Isepamicin is combined with Botulinum toxin type A.,Isepamicin
DB13673,The risk or severity of adverse effects can be increased when Bekanamycin is combined with Botulinum toxin type A.,Bekanamycin
DB13749,The risk or severity of adverse effects can be increased when Magnesium gluconate is combined with Botulinum toxin type A.,Magnesium gluconate
DB13786,The risk or severity of adverse effects can be increased when Magnesium orotate is combined with Botulinum toxin type A.,Magnesium orotate
DB13862,The risk or severity of adverse effects can be increased when Magnesium phosphate is combined with Botulinum toxin type A.,Magnesium phosphate
DB13996,The risk or severity of adverse effects can be increased when Magnesium acetate is combined with Botulinum toxin type A.,Magnesium acetate
DB05077,The risk or severity of adverse effects can be increased when SLV319 is combined with Botulinum toxin type A.,SLV319
DB06155,The risk or severity of adverse effects can be increased when Rimonabant is combined with Botulinum toxin type A.,Rimonabant
DB06624,The risk or severity of adverse effects can be increased when Taranabant is combined with Botulinum toxin type A.,Taranabant
DB09061,The risk or severity of adverse effects can be increased when Cannabidiol is combined with Botulinum toxin type A.,Cannabidiol
DB11903,The risk or severity of adverse effects can be increased when GW842166 is combined with Botulinum toxin type A.,GW842166
DB12193,The risk or severity of adverse effects can be increased when Ajulemic acid is combined with Botulinum toxin type A.,Ajulemic acid
DB12649,The risk or severity of adverse effects can be increased when Ibipinabant is combined with Botulinum toxin type A.,Ibipinabant
DB13070,The risk or severity of adverse effects can be increased when Surinabant is combined with Botulinum toxin type A.,Surinabant
DB13950,The risk or severity of adverse effects can be increased when WIN 55212-2 is combined with Botulinum toxin type A.,WIN 55212-2
DB14011,The risk or severity of adverse effects can be increased when Nabiximols is combined with Botulinum toxin type A.,Nabiximols
DB14043,The risk or severity of adverse effects can be increased when Palmidrol is combined with Botulinum toxin type A.,Palmidrol
DB14737,The risk or severity of adverse effects can be increased when Cannabinol is combined with Botulinum toxin type A.,Cannabinol
DB11823,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Esketamine.,Esketamine
DB00395,The risk or severity of adverse effects can be increased when Carisoprodol is combined with Botulinum toxin type A.,Carisoprodol
DB00704,The risk or severity of respiratory depression can be increased when Naltrexone is combined with Botulinum toxin type A.,Naltrexone
DB01459,The risk or severity of respiratory depression can be increased when Bezitramide is combined with Botulinum toxin type A.,Bezitramide
DB09272,The risk or severity of respiratory depression can be increased when Eluxadoline is combined with Botulinum toxin type A.,Eluxadoline
DB13454,The risk or severity of respiratory depression can be increased when Nicomorphine is combined with Botulinum toxin type A.,Nicomorphine
DB15465,The risk or severity of respiratory depression can be increased when Benzhydrocodone is combined with Botulinum toxin type A.,Benzhydrocodone
DB00402,The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Eszopiclone.,Eszopiclone
DB00575,The risk or severity of sedation can be increased when Clonidine is combined with Botulinum toxin type A.,Clonidine
DB00924,The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Cyclobenzaprine.,Cyclobenzaprine
DB01233,The risk or severity of sedation can be increased when Metoclopramide is combined with Botulinum toxin type A.,Metoclopramide
DB11732,The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Lasmiditan.,Lasmiditan
DB14513,Magnesium can cause a decrease in the absorption of Botulinum toxin type A resulting in a reduced serum concentration and potentially a decrease in efficacy.,Magnesium
DB00502,The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Haloperidol.,Haloperidol
DB00325,Pancrelipase can cause a decrease in the absorption of Nitroprusside resulting in a reduced serum concentration and potentially a decrease in efficacy.,Nitroprusside
DB06783,Pancrelipase can cause a decrease in the absorption of Prussian blue resulting in a reduced serum concentration and potentially a decrease in efficacy.,Prussian blue
DB09146,Pancrelipase can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.,Iron sucrose
DB09501,Pancrelipase can cause a decrease in the absorption of Ferric ammonium citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.,Ferric ammonium citrate
DB09507,Pancrelipase can cause a decrease in the absorption of Ferumoxsil resulting in a reduced serum concentration and potentially a decrease in efficacy.,Ferumoxsil
DB09508,Pancrelipase can cause a decrease in the absorption of Ferumoxides resulting in a reduced serum concentration and potentially a decrease in efficacy.,Ferumoxides
DB11171,Pancrelipase can cause a decrease in the absorption of Ferric sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.,Ferric sulfate
DB11210,Pancrelipase can cause a decrease in the absorption of Ferrous bisglycinate resulting in a reduced serum concentration and potentially a decrease in efficacy.,Ferrous bisglycinate
DB11417,Pancrelipase can cause a decrease in the absorption of Gleptoferron resulting in a reduced serum concentration and potentially a decrease in efficacy.,Gleptoferron
DB11576,Pancrelipase can cause a decrease in the absorption of Ferric oxide resulting in a reduced serum concentration and potentially a decrease in efficacy.,Ferric oxide
DB12208,Pancrelipase can cause a decrease in the absorption of Iron isomaltoside 1000 resulting in a reduced serum concentration and potentially a decrease in efficacy.,Iron isomaltoside 1000
DB12821,Pancrelipase can cause a decrease in the absorption of Perflubutane resulting in a reduced serum concentration and potentially a decrease in efficacy.,Perflubutane
DB13257,Pancrelipase can cause a decrease in the absorption of Ferrous sulfate anhydrous resulting in a reduced serum concentration and potentially a decrease in efficacy.,Ferrous sulfate anhydrous
DB13381,Pancrelipase can cause a decrease in the absorption of Sodium feredetate resulting in a reduced serum concentration and potentially a decrease in efficacy.,Sodium feredetate
DB13423,Pancrelipase can cause a decrease in the absorption of Ferric hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.,Ferric hydroxide
DB13569,Pancrelipase can cause a decrease in the absorption of Ferrous chloride resulting in a reduced serum concentration and potentially a decrease in efficacy.,Ferrous chloride
DB13949,Pancrelipase can cause a decrease in the absorption of Ferric cation resulting in a reduced serum concentration and potentially a decrease in efficacy.,Ferric cation
DB14488,Pancrelipase can cause a decrease in the absorption of Ferrous gluconate resulting in a reduced serum concentration and potentially a decrease in efficacy.,Ferrous gluconate
DB14489,Pancrelipase can cause a decrease in the absorption of Ferrous succinate resulting in a reduced serum concentration and potentially a decrease in efficacy.,Ferrous succinate
DB14491,Pancrelipase can cause a decrease in the absorption of Ferrous fumarate resulting in a reduced serum concentration and potentially a decrease in efficacy.,Ferrous fumarate
DB14520,Pancrelipase can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.,Tetraferric tricitrate decahydrate
DB14695,Pancrelipase can cause a decrease in the absorption of Ferric oxyhydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.,Ferric oxyhydroxide
DB15598,Pancrelipase can cause a decrease in the absorption of Ferric maltol resulting in a reduced serum concentration and potentially a decrease in efficacy.,Ferric maltol
DB06605,Apixaban may increase the anticoagulant activities of Streptokinase.,Apixaban
DB06695,Dabigatran etexilate may increase the anticoagulant activities of Streptokinase.,Dabigatran etexilate
DB01254,The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Streptokinase.,Dasatinib
DB01609,The risk or severity of gastrointestinal bleeding can be increased when Streptokinase is combined with Deferasirox.,Deferasirox
DB01586,The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Ursodeoxycholic acid.,Ursodeoxycholic acid
DB02123,The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Glycochenodeoxycholic Acid.,Glycochenodeoxycholic Acid
DB02659,The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Cholic Acid.,Cholic Acid
DB02691,The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Glycocholic acid.,Glycocholic acid
DB03619,The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Deoxycholic acid.,Deoxycholic acid
DB04348,The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Taurocholic acid.,Taurocholic acid
DB05990,The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Obeticholic acid.,Obeticholic acid
DB06777,The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Chenodeoxycholic acid.,Chenodeoxycholic acid
DB08833,The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Taurochenodeoxycholic acid.,Taurochenodeoxycholic acid
DB08834,The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Tauroursodeoxycholic acid.,Tauroursodeoxycholic acid
DB08857,The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Bamet-UD2.,Bamet-UD2
DB11622,The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Dehydrocholic acid.,Dehydrocholic acid
DB11789,The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Hyodeoxycholic Acid.,Hyodeoxycholic Acid
DB09075,The risk or severity of bleeding can be increased when Edoxaban is combined with Streptokinase.,Edoxaban
DB09053,The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Streptokinase.,Ibrutinib
DB08935,The risk or severity of bleeding and hemorrhage can be increased when Streptokinase is combined with Obinutuzumab.,Obinutuzumab
DB06228,Streptokinase may increase the anticoagulant activities of Rivaroxaban.,Rivaroxaban
DB06206,The risk or severity of bleeding and hemorrhage can be increased when Streptokinase is combined with Sugammadex.,Sugammadex
DB09070,Tibolone may increase the anticoagulant activities of Streptokinase.,Tibolone
DB00932,The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Streptokinase.,Tipranavir
DB00013,Urokinase may increase the anticoagulant activities of Streptokinase.,Urokinase
DB00163,Vitamin E may increase the anticoagulant activities of Streptokinase.,Vitamin E
DB09030,The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Streptokinase.,Vorapaxar
DB06692,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Aprotinin.,Aprotinin
DB00476,The risk or severity of orthostatic hypotension and syncope can be increased when Streptokinase is combined with Duloxetine.,Duloxetine
DB01235,The risk or severity of hypotension and orthostatic hypotension can be increased when Streptokinase is combined with Levodopa.,Levodopa
DB00734,Streptokinase may increase the hypotensive activities of Risperidone.,Risperidone
DB01381,The therapeutic efficacy of Streptokinase can be increased when used in combination with Ginkgo biloba.,Ginkgo biloba
DB01181,The risk or severity of bleeding can be increased when Ifosfamide is combined with Streptokinase.,Ifosfamide
DB00468,The therapeutic efficacy of Streptokinase can be increased when used in combination with Quinine.,Quinine
DB00908,The therapeutic efficacy of Streptokinase can be increased when used in combination with Quinidine.,Quinidine
DB00675,The risk or severity of bleeding can be increased when Tamoxifen is combined with Streptokinase.,Tamoxifen
DB00539,The risk or severity of bleeding can be increased when Toremifene is combined with Streptokinase.,Toremifene
DB00407,Streptokinase may increase the anticoagulant activities of Ardeparin.,Ardeparin
DB01109,Streptokinase may increase the anticoagulant activities of Heparin.,Heparin
DB01225,Streptokinase may increase the anticoagulant activities of Enoxaparin.,Enoxaparin
DB06271,Streptokinase may increase the anticoagulant activities of Sulodexide.,Sulodexide
DB06294,Streptokinase may increase the anticoagulant activities of Semuloparin.,Semuloparin
DB06754,Streptokinase may increase the anticoagulant activities of Danaparoid.,Danaparoid
DB06779,Streptokinase may increase the anticoagulant activities of Dalteparin.,Dalteparin
DB06822,Streptokinase may increase the anticoagulant activities of Tinzaparin.,Tinzaparin
DB08813,Streptokinase may increase the anticoagulant activities of Nadroparin.,Nadroparin
DB09258,Streptokinase may increase the anticoagulant activities of Bemiparin.,Bemiparin
DB09259,Streptokinase may increase the anticoagulant activities of Reviparin.,Reviparin
DB09260,Streptokinase may increase the anticoagulant activities of Parnaparin.,Parnaparin
DB09261,Streptokinase may increase the anticoagulant activities of Certoparin.,Certoparin
DB00806,The therapeutic efficacy of Streptokinase can be increased when used in combination with Pentoxifylline.,Pentoxifylline
DB00686,Pentosan polysulfate may increase the anticoagulant activities of Streptokinase.,Pentosan polysulfate
DB00583,The therapeutic efficacy of Streptokinase can be increased when used in combination with Levocarnitine.,Levocarnitine
DB01238,Aripiprazole may increase the hypotensive activities of Streptokinase.,Aripiprazole
DB14185,Aripiprazole lauroxil may increase the hypotensive activities of Streptokinase.,Aripiprazole lauroxil
DB09220,Nicorandil may increase the hypotensive activities of Streptokinase.,Nicorandil
DB00255,Diethylstilbestrol may decrease the anticoagulant activities of Streptokinase.,Diethylstilbestrol
DB00269,Chlorotrianisene may decrease the anticoagulant activities of Streptokinase.,Chlorotrianisene
DB00286,Conjugated estrogens may decrease the anticoagulant activities of Streptokinase.,Conjugated estrogens
DB00783,Estradiol may decrease the anticoagulant activities of Streptokinase.,Estradiol
DB00977,Ethinylestradiol may decrease the anticoagulant activities of Streptokinase.,Ethinylestradiol
DB01357,Mestranol may decrease the anticoagulant activities of Streptokinase.,Mestranol
DB04573,Estriol may decrease the anticoagulant activities of Streptokinase.,Estriol
DB04574,Estrone sulfate may decrease the anticoagulant activities of Streptokinase.,Estrone sulfate
DB04575,Quinestrol may decrease the anticoagulant activities of Streptokinase.,Quinestrol
DB07931,Hexestrol may decrease the anticoagulant activities of Streptokinase.,Hexestrol
DB09317,"Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Streptokinase.","Synthetic Conjugated Estrogens, A"
DB09318,"Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Streptokinase.","Synthetic Conjugated Estrogens, B"
DB09369,Polyestradiol phosphate may decrease the anticoagulant activities of Streptokinase.,Polyestradiol phosphate
DB09381,Esterified estrogens may decrease the anticoagulant activities of Streptokinase.,Esterified estrogens
DB11478,Zeranol may decrease the anticoagulant activities of Streptokinase.,Zeranol
DB11674,Equol may decrease the anticoagulant activities of Streptokinase.,Equol
DB12487,Promestriene may decrease the anticoagulant activities of Streptokinase.,Promestriene
DB13143,Methallenestril may decrease the anticoagulant activities of Streptokinase.,Methallenestril
DB13386,Epimestrol may decrease the anticoagulant activities of Streptokinase.,Epimestrol
DB13418,Moxestrol may decrease the anticoagulant activities of Streptokinase.,Moxestrol
DB13952,Estradiol acetate may decrease the anticoagulant activities of Streptokinase.,Estradiol acetate
DB13953,Estradiol benzoate may decrease the anticoagulant activities of Streptokinase.,Estradiol benzoate
DB13954,Estradiol cypionate may decrease the anticoagulant activities of Streptokinase.,Estradiol cypionate
DB13956,Estradiol valerate may decrease the anticoagulant activities of Streptokinase.,Estradiol valerate
DB15334,Biochanin A may decrease the anticoagulant activities of Streptokinase.,Biochanin A
DB15335,Formononetin may decrease the anticoagulant activities of Streptokinase.,Formononetin
DB00159,The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Streptokinase.,Icosapent
DB00244,The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Streptokinase.,Mesalazine
DB00328,The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Streptokinase.,Indomethacin
DB00461,The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Streptokinase.,Nabumetone
DB00465,The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Streptokinase.,Ketorolac
DB00469,The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Streptokinase.,Tenoxicam
DB00482,The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Streptokinase.,Celecoxib
DB00500,The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Streptokinase.,Tolmetin
DB00533,The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Streptokinase.,Rofecoxib
DB00554,The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Streptokinase.,Piroxicam
DB00573,The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Streptokinase.,Fenoprofen
DB00580,The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Streptokinase.,Valdecoxib
DB00586,The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Streptokinase.,Diclofenac
DB00605,The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Streptokinase.,Sulindac
DB00712,The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Streptokinase.,Flurbiprofen
DB00749,The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Streptokinase.,Etodolac
DB00784,The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Streptokinase.,Mefenamic acid
DB00788,The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Streptokinase.,Naproxen
DB00795,The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Streptokinase.,Sulfasalazine
DB00812,The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Streptokinase.,Phenylbutazone
DB00814,The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Streptokinase.,Meloxicam
DB00821,The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Streptokinase.,Carprofen
DB00861,The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Streptokinase.,Diflunisal
DB00936,The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Streptokinase.,Salicylic acid
DB00939,The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Streptokinase.,Meclofenamic acid
DB00991,The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Streptokinase.,Oxaprozin
DB01009,The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Streptokinase.,Ketoprofen
DB01014,The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Streptokinase.,Balsalazide
DB01250,The risk or severity of bleeding and hemorrhage can be increased when Olsalazine is combined with Streptokinase.,Olsalazine
DB01283,The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Streptokinase.,Lumiracoxib
DB01397,The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Streptokinase.,Magnesium salicylate
DB01399,The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Streptokinase.,Salsalate
DB01401,The risk or severity of bleeding and hemorrhage can be increased when Choline magnesium trisalicylate is combined with Streptokinase.,Choline magnesium trisalicylate
DB01419,The risk or severity of bleeding and hemorrhage can be increased when Antrafenine is combined with Streptokinase.,Antrafenine
DB01424,The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Streptokinase.,Aminophenazone
DB01435,The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Streptokinase.,Antipyrine
DB01600,The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Streptokinase.,Tiaprofenic acid
DB01628,The risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Streptokinase.,Etoricoxib
DB02224,The risk or severity of bleeding and hemorrhage can be increased when Taxifolin is combined with Streptokinase.,Taxifolin
DB03585,The risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with Streptokinase.,Oxyphenbutazone
DB04552,The risk or severity of bleeding and hemorrhage can be increased when Niflumic acid is combined with Streptokinase.,Niflumic acid
DB04725,The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Streptokinase.,Licofelone
DB04812,The risk or severity of bleeding and hemorrhage can be increased when Benoxaprofen is combined with Streptokinase.,Benoxaprofen
DB04817,The risk or severity of bleeding and hemorrhage can be increased when Metamizole is combined with Streptokinase.,Metamizole
DB04828,The risk or severity of bleeding and hemorrhage can be increased when Zomepirac is combined with Streptokinase.,Zomepirac
DB05095,The risk or severity of bleeding and hemorrhage can be increased when Cimicoxib is combined with Streptokinase.,Cimicoxib
DB06725,The risk or severity of bleeding and hemorrhage can be increased when Lornoxicam is combined with Streptokinase.,Lornoxicam
DB06736,The risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Streptokinase.,Aceclofenac
DB06737,The risk or severity of bleeding and hemorrhage can be increased when Zaltoprofen is combined with Streptokinase.,Zaltoprofen
DB07402,The risk or severity of bleeding and hemorrhage can be increased when Azapropazone is combined with Streptokinase.,Azapropazone
DB07477,The risk or severity of bleeding and hemorrhage can be increased when Felbinac is combined with Streptokinase.,Felbinac
DB08439,The risk or severity of bleeding and hemorrhage can be increased when Parecoxib is combined with Streptokinase.,Parecoxib
DB08797,The risk or severity of bleeding and hemorrhage can be increased when Salicylamide is combined with Streptokinase.,Salicylamide
DB08940,The risk or severity of bleeding and hemorrhage can be increased when Kebuzone is combined with Streptokinase.,Kebuzone
DB08942,The risk or severity of bleeding and hemorrhage can be increased when Isoxicam is combined with Streptokinase.,Isoxicam
DB08951,The risk or severity of bleeding and hemorrhage can be increased when Indoprofen is combined with Streptokinase.,Indoprofen
DB08955,The risk or severity of bleeding and hemorrhage can be increased when Ibuproxam is combined with Streptokinase.,Ibuproxam
DB08976,The risk or severity of bleeding and hemorrhage can be increased when Floctafenine is combined with Streptokinase.,Floctafenine
DB08981,The risk or severity of bleeding and hemorrhage can be increased when Fenbufen is combined with Streptokinase.,Fenbufen
DB08984,The risk or severity of bleeding and hemorrhage can be increased when Etofenamate is combined with Streptokinase.,Etofenamate
DB08991,The risk or severity of bleeding and hemorrhage can be increased when Epirizole is combined with Streptokinase.,Epirizole
DB09084,The risk or severity of bleeding and hemorrhage can be increased when Benzydamine is combined with Streptokinase.,Benzydamine
DB09212,The risk or severity of bleeding and hemorrhage can be increased when Loxoprofen is combined with Streptokinase.,Loxoprofen
DB09214,The risk or severity of bleeding and hemorrhage can be increased when Dexketoprofen is combined with Streptokinase.,Dexketoprofen
DB09215,The risk or severity of bleeding and hemorrhage can be increased when Droxicam is combined with Streptokinase.,Droxicam
DB09216,The risk or severity of bleeding and hemorrhage can be increased when Tolfenamic acid is combined with Streptokinase.,Tolfenamic acid
DB09217,The risk or severity of bleeding and hemorrhage can be increased when Firocoxib is combined with Streptokinase.,Firocoxib
DB09218,The risk or severity of bleeding and hemorrhage can be increased when Clonixin is combined with Streptokinase.,Clonixin
DB09285,The risk or severity of bleeding and hemorrhage can be increased when Morniflumate is combined with Streptokinase.,Morniflumate
DB09288,The risk or severity of bleeding and hemorrhage can be increased when Propacetamol is combined with Streptokinase.,Propacetamol
DB09295,The risk or severity of bleeding and hemorrhage can be increased when Talniflumate is combined with Streptokinase.,Talniflumate
DB11455,The risk or severity of bleeding and hemorrhage can be increased when Robenacoxib is combined with Streptokinase.,Robenacoxib
DB11466,The risk or severity of bleeding and hemorrhage can be increased when Tepoxalin is combined with Streptokinase.,Tepoxalin
DB11518,The risk or severity of bleeding and hemorrhage can be increased when Flunixin is combined with Streptokinase.,Flunixin
DB12399,The risk or severity of bleeding and hemorrhage can be increased when Polmacoxib is combined with Streptokinase.,Polmacoxib
DB12480,The risk or severity of bleeding and hemorrhage can be increased when Betulinic Acid is combined with Streptokinase.,Betulinic Acid
DB12610,The risk or severity of bleeding and hemorrhage can be increased when Ebselen is combined with Streptokinase.,Ebselen
DB13001,The risk or severity of bleeding and hemorrhage can be increased when Tinoridine is combined with Streptokinase.,Tinoridine
DB13167,The risk or severity of bleeding and hemorrhage can be increased when Alclofenac is combined with Streptokinase.,Alclofenac
DB13217,The risk or severity of bleeding and hemorrhage can be increased when Fentiazac is combined with Streptokinase.,Fentiazac
DB13232,The risk or severity of bleeding and hemorrhage can be increased when Suxibuzone is combined with Streptokinase.,Suxibuzone
DB13286,The risk or severity of bleeding and hemorrhage can be increased when Bumadizone is combined with Streptokinase.,Bumadizone
DB13314,The risk or severity of bleeding and hemorrhage can be increased when Alminoprofen is combined with Streptokinase.,Alminoprofen
DB13317,The risk or severity of bleeding and hemorrhage can be increased when Flunoxaprofen is combined with Streptokinase.,Flunoxaprofen
DB13364,The risk or severity of bleeding and hemorrhage can be increased when Feprazone is combined with Streptokinase.,Feprazone
DB13371,The risk or severity of bleeding and hemorrhage can be increased when Difenpiramide is combined with Streptokinase.,Difenpiramide
DB13407,The risk or severity of bleeding and hemorrhage can be increased when Nifenazone is combined with Streptokinase.,Nifenazone
DB13432,The risk or severity of bleeding and hemorrhage can be increased when Lonazolac is combined with Streptokinase.,Lonazolac
DB13481,The risk or severity of bleeding and hemorrhage can be increased when Tenidap is combined with Streptokinase.,Tenidap
DB13501,The risk or severity of bleeding and hemorrhage can be increased when Bendazac is combined with Streptokinase.,Bendazac
DB13514,The risk or severity of bleeding and hemorrhage can be increased when Pranoprofen is combined with Streptokinase.,Pranoprofen
DB13524,The risk or severity of bleeding and hemorrhage can be increased when Propyphenazone is combined with Streptokinase.,Propyphenazone
DB13527,The risk or severity of bleeding and hemorrhage can be increased when Proglumetacin is combined with Streptokinase.,Proglumetacin
DB13538,The risk or severity of bleeding and hemorrhage can be increased when Guacetisal is combined with Streptokinase.,Guacetisal
DB13544,The risk or severity of bleeding and hemorrhage can be increased when Ethenzamide is combined with Streptokinase.,Ethenzamide
DB13612,The risk or severity of bleeding and hemorrhage can be increased when Carbaspirin calcium is combined with Streptokinase.,Carbaspirin calcium
DB13629,The risk or severity of bleeding and hemorrhage can be increased when Mofebutazone is combined with Streptokinase.,Mofebutazone
DB13649,The risk or severity of bleeding and hemorrhage can be increased when Proquazone is combined with Streptokinase.,Proquazone
DB13657,The risk or severity of bleeding and hemorrhage can be increased when Benorilate is combined with Streptokinase.,Benorilate
DB13722,The risk or severity of bleeding and hemorrhage can be increased when Pirprofen is combined with Streptokinase.,Pirprofen
DB13860,The risk or severity of bleeding and hemorrhage can be increased when Imidazole salicylate is combined with Streptokinase.,Imidazole salicylate
DB14059,The risk or severity of bleeding and hemorrhage can be increased when SC-236 is combined with Streptokinase.,SC-236
DB14060,The risk or severity of bleeding and hemorrhage can be increased when NS-398 is combined with Streptokinase.,NS-398
DB14938,The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen axetil is combined with Streptokinase.,Flurbiprofen axetil
DB04865,The risk or severity of bleeding can be increased when Streptokinase is combined with Omacetaxine mepesuccinate.,Omacetaxine mepesuccinate
DB11133,Omega-3 fatty acids may increase the anticoagulant activities of Streptokinase.,Omega-3 fatty acids
DB00081,The risk or severity of bleeding and hemorrhage can be increased when Streptokinase is combined with Tositumomab.,Tositumomab
DB09211,The risk or severity of adverse effects can be increased when Limaprost is combined with Streptokinase.,Limaprost
DB00048,The risk or severity of adverse effects can be increased when Streptokinase is combined with Collagenase clostridium histolyticum.,Collagenase clostridium histolyticum
DB00389,Carbimazole may increase the anticoagulant activities of Streptokinase.,Carbimazole
DB00550,Propylthiouracil may increase the anticoagulant activities of Streptokinase.,Propylthiouracil
DB00763,Methimazole may increase the anticoagulant activities of Streptokinase.,Methimazole
DB03374,"3,5-Diiodotyrosine may increase the anticoagulant activities of Streptokinase.","3,5-Diiodotyrosine"
DB06715,Potassium Iodide may increase the anticoagulant activities of Streptokinase.,Potassium Iodide
DB07637,Dibromotyrosine may increase the anticoagulant activities of Streptokinase.,Dibromotyrosine
DB09418,Potassium perchlorate may increase the anticoagulant activities of Streptokinase.,Potassium perchlorate
DB13644,Methylthiouracil may increase the anticoagulant activities of Streptokinase.,Methylthiouracil
DB13804,Benzylthiouracil may increase the anticoagulant activities of Streptokinase.,Benzylthiouracil
DB00834,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Mifepristone.,Mifepristone
DB04066,The therapeutic efficacy of Streptokinase can be decreased when used in combination with p-Coumaric acid.,p-Coumaric acid
DB04682,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Octylphenoxy polyethoxyethanol.,Octylphenoxy polyethoxyethanol
DB05830,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Trestolone.,Trestolone
DB06266,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Lonidamine.,Lonidamine
DB08867,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Ulipristal.,Ulipristal
DB09401,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Isosorbide.,Isosorbide
DB11507,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cloprostenol.,Cloprostenol
DB12025,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Triptolide.,Triptolide
DB13044,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Gossypol.,Gossypol
DB13310,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Ormeloxifene.,Ormeloxifene
DB00182,Amphetamine may increase the orthostatic hypotensive activities of Streptokinase.,Amphetamine
DB00601,Linezolid may increase the orthostatic hypotensive activities of Streptokinase.,Linezolid
DB00614,Furazolidone may increase the orthostatic hypotensive activities of Streptokinase.,Furazolidone
DB00721,Procaine may increase the orthostatic hypotensive activities of Streptokinase.,Procaine
DB00752,Tranylcypromine may increase the orthostatic hypotensive activities of Streptokinase.,Tranylcypromine
DB00780,Phenelzine may increase the orthostatic hypotensive activities of Streptokinase.,Phenelzine
DB00805,Minaprine may increase the orthostatic hypotensive activities of Streptokinase.,Minaprine
DB01037,Selegiline may increase the orthostatic hypotensive activities of Streptokinase.,Selegiline
DB01168,Procarbazine may increase the orthostatic hypotensive activities of Streptokinase.,Procarbazine
DB01171,Moclobemide may increase the orthostatic hypotensive activities of Streptokinase.,Moclobemide
DB01247,Isocarboxazid may increase the orthostatic hypotensive activities of Streptokinase.,Isocarboxazid
DB01367,Rasagiline may increase the orthostatic hypotensive activities of Streptokinase.,Rasagiline
DB01626,Pargyline may increase the orthostatic hypotensive activities of Streptokinase.,Pargyline
DB04017,Clorgiline may increase the orthostatic hypotensive activities of Streptokinase.,Clorgiline
DB04818,Iproniazid may increase the orthostatic hypotensive activities of Streptokinase.,Iproniazid
DB04820,Nialamide may increase the orthostatic hypotensive activities of Streptokinase.,Nialamide
DB06654,Safinamide may increase the orthostatic hypotensive activities of Streptokinase.,Safinamide
DB08550,"7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the orthostatic hypotensive activities of Streptokinase.","7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline"
DB09241,Methylene blue may increase the orthostatic hypotensive activities of Streptokinase.,Methylene blue
DB09243,Hydracarbazine may increase the orthostatic hypotensive activities of Streptokinase.,Hydracarbazine
DB09244,Pirlindole may increase the orthostatic hypotensive activities of Streptokinase.,Pirlindole
DB09245,Toloxatone may increase the orthostatic hypotensive activities of Streptokinase.,Toloxatone
DB09246,Benmoxin may increase the orthostatic hypotensive activities of Streptokinase.,Benmoxin
DB09248,Mebanazine may increase the orthostatic hypotensive activities of Streptokinase.,Mebanazine
DB09249,Octamoxin may increase the orthostatic hypotensive activities of Streptokinase.,Octamoxin
DB09250,Pheniprazine may increase the orthostatic hypotensive activities of Streptokinase.,Pheniprazine
DB09251,Phenoxypropazine may increase the orthostatic hypotensive activities of Streptokinase.,Phenoxypropazine
DB09252,Pivhydrazine may increase the orthostatic hypotensive activities of Streptokinase.,Pivhydrazine
DB09253,Safrazine may increase the orthostatic hypotensive activities of Streptokinase.,Safrazine
DB09254,Caroxazone may increase the orthostatic hypotensive activities of Streptokinase.,Caroxazone
DB13875,Harmaline may increase the orthostatic hypotensive activities of Streptokinase.,Harmaline
DB13876,Brofaromine may increase the orthostatic hypotensive activities of Streptokinase.,Brofaromine
DB00294,Etonogestrel may decrease the anticoagulant activities of Streptokinase.,Etonogestrel
DB00304,Desogestrel may decrease the anticoagulant activities of Streptokinase.,Desogestrel
DB00351,Megestrol acetate may decrease the anticoagulant activities of Streptokinase.,Megestrol acetate
DB00367,Levonorgestrel may decrease the anticoagulant activities of Streptokinase.,Levonorgestrel
DB00378,Dydrogesterone may decrease the anticoagulant activities of Streptokinase.,Dydrogesterone
DB00396,Progesterone may decrease the anticoagulant activities of Streptokinase.,Progesterone
DB00603,Medroxyprogesterone acetate may decrease the anticoagulant activities of Streptokinase.,Medroxyprogesterone acetate
DB00717,Norethisterone may decrease the anticoagulant activities of Streptokinase.,Norethisterone
DB00823,Ethynodiol diacetate may decrease the anticoagulant activities of Streptokinase.,Ethynodiol diacetate
DB00957,Norgestimate may decrease the anticoagulant activities of Streptokinase.,Norgestimate
DB01395,Drospirenone may decrease the anticoagulant activities of Streptokinase.,Drospirenone
DB01431,Allylestrenol may decrease the anticoagulant activities of Streptokinase.,Allylestrenol
DB04839,Cyproterone acetate may decrease the anticoagulant activities of Streptokinase.,Cyproterone acetate
DB06713,Norelgestromin may decrease the anticoagulant activities of Streptokinase.,Norelgestromin
DB06730,Gestodene may decrease the anticoagulant activities of Streptokinase.,Gestodene
DB06789,Hydroxyprogesterone caproate may decrease the anticoagulant activities of Streptokinase.,Hydroxyprogesterone caproate
DB09123,Dienogest may decrease the anticoagulant activities of Streptokinase.,Dienogest
DB09124,Medrogestone may decrease the anticoagulant activities of Streptokinase.,Medrogestone
DB09371,Norethynodrel may decrease the anticoagulant activities of Streptokinase.,Norethynodrel
DB09389,Norgestrel may decrease the anticoagulant activities of Streptokinase.,Norgestrel
DB11372,Altrenogest may decrease the anticoagulant activities of Streptokinase.,Altrenogest
DB11619,Gestrinone may decrease the anticoagulant activities of Streptokinase.,Gestrinone
DB11636,Nomegestrol may decrease the anticoagulant activities of Streptokinase.,Nomegestrol
DB12474,Lynestrenol may decrease the anticoagulant activities of Streptokinase.,Lynestrenol
DB13230,Gestonorone may decrease the anticoagulant activities of Streptokinase.,Gestonorone
DB13528,Chlormadinone may decrease the anticoagulant activities of Streptokinase.,Chlormadinone
DB13533,Methylestrenolone may decrease the anticoagulant activities of Streptokinase.,Methylestrenolone
DB13563,Norgestrienone may decrease the anticoagulant activities of Streptokinase.,Norgestrienone
DB13602,Promegestone may decrease the anticoagulant activities of Streptokinase.,Promegestone
DB13685,Quingestanol may decrease the anticoagulant activities of Streptokinase.,Quingestanol
DB13857,Demegestone may decrease the anticoagulant activities of Streptokinase.,Demegestone
DB13866,Etynodiol may decrease the anticoagulant activities of Streptokinase.,Etynodiol
DB13981,Nomegestrol acetate may decrease the anticoagulant activities of Streptokinase.,Nomegestrol acetate
DB14570,Hydroxyprogesterone may decrease the anticoagulant activities of Streptokinase.,Hydroxyprogesterone
DB14678,Norethindrone enanthate may decrease the anticoagulant activities of Streptokinase.,Norethindrone enanthate
DB14679,Quingestanol acetate may decrease the anticoagulant activities of Streptokinase.,Quingestanol acetate
DB00233,The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Streptokinase.,Aminosalicylic acid
DB01294,The risk or severity of bleeding can be increased when Bismuth subsalicylate is combined with Streptokinase.,Bismuth subsalicylate
DB06251,The risk or severity of bleeding can be increased when Dersalazine is combined with Streptokinase.,Dersalazine
DB06807,The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Streptokinase.,Phenyl aminosalicylate
DB09543,The risk or severity of bleeding can be increased when Methyl salicylate is combined with Streptokinase.,Methyl salicylate
DB11079,The risk or severity of bleeding can be increased when Trolamine salicylate is combined with Streptokinase.,Trolamine salicylate
DB13509,The risk or severity of bleeding can be increased when Aloxiprin is combined with Streptokinase.,Aloxiprin
DB14006,The risk or severity of bleeding can be increased when Choline salicylate is combined with Streptokinase.,Choline salicylate
DB14026,The risk or severity of bleeding can be increased when Thiosalicylic acid is combined with Streptokinase.,Thiosalicylic acid
DB00241,Butalbital may increase the hypotensive activities of Streptokinase.,Butalbital
DB00312,Pentobarbital may increase the hypotensive activities of Streptokinase.,Pentobarbital
DB00418,Secobarbital may increase the hypotensive activities of Streptokinase.,Secobarbital
DB00474,Methohexital may increase the hypotensive activities of Streptokinase.,Methohexital
DB00599,Thiopental may increase the hypotensive activities of Streptokinase.,Thiopental
DB00794,Primidone may increase the hypotensive activities of Streptokinase.,Primidone
DB00849,Methylphenobarbital may increase the hypotensive activities of Streptokinase.,Methylphenobarbital
DB01154,Thiamylal may increase the hypotensive activities of Streptokinase.,Thiamylal
DB01174,Phenobarbital may increase the hypotensive activities of Streptokinase.,Phenobarbital
DB01351,Amobarbital may increase the hypotensive activities of Streptokinase.,Amobarbital
DB01355,Hexobarbital may increase the hypotensive activities of Streptokinase.,Hexobarbital
DB01483,Barbital may increase the hypotensive activities of Streptokinase.,Barbital
DB09001,Barbexaclone may increase the hypotensive activities of Streptokinase.,Barbexaclone
DB00237,Butabarbital may increase the hypotensive activities of Streptokinase.,Butabarbital
DB00054,The risk or severity of bleeding can be increased when Abciximab is combined with Streptokinase.,Abciximab
DB00063,The risk or severity of bleeding can be increased when Eptifibatide is combined with Streptokinase.,Eptifibatide
DB00208,The risk or severity of bleeding can be increased when Ticlopidine is combined with Streptokinase.,Ticlopidine
DB00261,The risk or severity of bleeding can be increased when Anagrelide is combined with Streptokinase.,Anagrelide
DB00758,The risk or severity of bleeding can be increased when Clopidogrel is combined with Streptokinase.,Clopidogrel
DB00775,The risk or severity of bleeding can be increased when Tirofiban is combined with Streptokinase.,Tirofiban
DB00975,The risk or severity of bleeding can be increased when Dipyridamole is combined with Streptokinase.,Dipyridamole
DB01088,The risk or severity of bleeding can be increased when Iloprost is combined with Streptokinase.,Iloprost
DB01138,The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Streptokinase.,Sulfinpyrazone
DB01166,The risk or severity of bleeding can be increased when Cilostazol is combined with Streptokinase.,Cilostazol
DB01207,The risk or severity of bleeding can be increased when Ridogrel is combined with Streptokinase.,Ridogrel
DB01236,The risk or severity of bleeding can be increased when Sevoflurane is combined with Streptokinase.,Sevoflurane
DB01240,The risk or severity of bleeding can be increased when Epoprostenol is combined with Streptokinase.,Epoprostenol
DB02709,The risk or severity of bleeding can be increased when Resveratrol is combined with Streptokinase.,Resveratrol
DB04743,The risk or severity of bleeding can be increased when Nimesulide is combined with Streptokinase.,Nimesulide
DB04905,The risk or severity of bleeding can be increased when Tesmilifene is combined with Streptokinase.,Tesmilifene
DB04932,The risk or severity of bleeding can be increased when Defibrotide is combined with Streptokinase.,Defibrotide
DB05229,The risk or severity of bleeding can be increased when Beraprost is combined with Streptokinase.,Beraprost
DB05266,The risk or severity of bleeding can be increased when Ibudilast is combined with Streptokinase.,Ibudilast
DB05767,The risk or severity of bleeding can be increased when Andrographolide is combined with Streptokinase.,Andrographolide
DB06081,The risk or severity of bleeding can be increased when Caplacizumab is combined with Streptokinase.,Caplacizumab
DB06209,The risk or severity of bleeding can be increased when Prasugrel is combined with Streptokinase.,Prasugrel
DB06441,The risk or severity of bleeding can be increased when Cangrelor is combined with Streptokinase.,Cangrelor
DB07615,The risk or severity of bleeding can be increased when Tranilast is combined with Streptokinase.,Tranilast
DB08814,The risk or severity of bleeding can be increased when Triflusal is combined with Streptokinase.,Triflusal
DB08816,The risk or severity of bleeding can be increased when Ticagrelor is combined with Streptokinase.,Ticagrelor
DB08887,The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Streptokinase.,Icosapent ethyl
DB09283,The risk or severity of bleeding can be increased when Trapidil is combined with Streptokinase.,Trapidil
DB12092,The risk or severity of bleeding can be increased when Naftopidil is combined with Streptokinase.,Naftopidil
DB12163,The risk or severity of bleeding can be increased when Sarpogrelate is combined with Streptokinase.,Sarpogrelate
DB12321,The risk or severity of bleeding can be increased when Ifetroban is combined with Streptokinase.,Ifetroban
DB12445,The risk or severity of bleeding can be increased when Nitroaspirin is combined with Streptokinase.,Nitroaspirin
DB12465,The risk or severity of bleeding can be increased when Ketanserin is combined with Streptokinase.,Ketanserin
DB12545,The risk or severity of bleeding can be increased when Indobufen is combined with Streptokinase.,Indobufen
DB12749,The risk or severity of bleeding can be increased when Butylphthalide is combined with Streptokinase.,Butylphthalide
DB12771,The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Streptokinase.,Hydroxytyrosol
DB13036,The risk or severity of bleeding can be increased when Ramatroban is combined with Streptokinase.,Ramatroban
DB13327,The risk or severity of bleeding can be increased when Picotamide is combined with Streptokinase.,Picotamide
DB13367,The risk or severity of bleeding can be increased when Cloricromen is combined with Streptokinase.,Cloricromen
DB13400,The risk or severity of bleeding can be increased when Linsidomine is combined with Streptokinase.,Linsidomine
DB13510,The risk or severity of bleeding can be increased when Buflomedil is combined with Streptokinase.,Buflomedil
DB13929,The risk or severity of bleeding can be increased when Relcovaptan is combined with Streptokinase.,Relcovaptan
DB00374,The risk or severity of adverse effects can be increased when Streptokinase is combined with Treprostinil.,Treprostinil
DB00041,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Streptokinase.,Aldesleukin
DB00232,The risk or severity of adverse effects can be increased when Streptokinase is combined with Methyclothiazide.,Methyclothiazide
DB00268,The risk or severity of adverse effects can be increased when Streptokinase is combined with Ropinirole.,Ropinirole
DB00295,The risk or severity of adverse effects can be increased when Streptokinase is combined with Morphine.,Morphine
DB00296,The risk or severity of adverse effects can be increased when Streptokinase is combined with Ropivacaine.,Ropivacaine
DB00297,The risk or severity of adverse effects can be increased when Streptokinase is combined with Bupivacaine.,Bupivacaine
DB00323,The risk or severity of adverse effects can be increased when Streptokinase is combined with Tolcapone.,Tolcapone
DB00334,The risk or severity of adverse effects can be increased when Streptokinase is combined with Olanzapine.,Olanzapine
DB00363,The risk or severity of adverse effects can be increased when Streptokinase is combined with Clozapine.,Clozapine
DB00384,The risk or severity of adverse effects can be increased when Streptokinase is combined with Triamterene.,Triamterene
DB00413,The risk or severity of adverse effects can be increased when Streptokinase is combined with Pramipexole.,Pramipexole
DB00421,The risk or severity of adverse effects can be increased when Streptokinase is combined with Spironolactone.,Spironolactone
DB00435,The risk or severity of adverse effects can be increased when Streptokinase is combined with Nitric Oxide.,Nitric Oxide
DB00458,The risk or severity of adverse effects can be increased when Streptokinase is combined with Imipramine.,Imipramine
DB00477,The risk or severity of adverse effects can be increased when Streptokinase is combined with Chlorpromazine.,Chlorpromazine
DB00486,The risk or severity of adverse effects can be increased when Streptokinase is combined with Nabilone.,Nabilone
DB00489,The risk or severity of adverse effects can be increased when Streptokinase is combined with Sotalol.,Sotalol
DB00594,The risk or severity of adverse effects can be increased when Streptokinase is combined with Amiloride.,Amiloride
DB00631,The risk or severity of adverse effects can be increased when Streptokinase is combined with Clofarabine.,Clofarabine
DB00633,The risk or severity of adverse effects can be increased when Streptokinase is combined with Dexmedetomidine.,Dexmedetomidine
DB00661,The risk or severity of adverse effects can be increased when Streptokinase is combined with Verapamil.,Verapamil
DB00679,The risk or severity of adverse effects can be increased when Streptokinase is combined with Thioridazine.,Thioridazine
DB00681,The risk or severity of adverse effects can be increased when Streptokinase is combined with Amphotericin B.,Amphotericin B
DB00695,The risk or severity of adverse effects can be increased when Streptokinase is combined with Furosemide.,Furosemide
DB00697,The risk or severity of adverse effects can be increased when Streptokinase is combined with Tizanidine.,Tizanidine
DB00703,The risk or severity of adverse effects can be increased when Streptokinase is combined with Methazolamide.,Methazolamide
DB00706,The risk or severity of adverse effects can be increased when Streptokinase is combined with Tamsulosin.,Tamsulosin
DB00708,The risk or severity of adverse effects can be increased when Streptokinase is combined with Sufentanil.,Sufentanil
DB00714,The risk or severity of adverse effects can be increased when Streptokinase is combined with Apomorphine.,Apomorphine
DB00742,The risk or severity of adverse effects can be increased when Streptokinase is combined with Mannitol.,Mannitol
DB00753,The risk or severity of adverse effects can be increased when Streptokinase is combined with Isoflurane.,Isoflurane
DB00755,The risk or severity of adverse effects can be increased when Streptokinase is combined with Tretinoin.,Tretinoin
DB00818,The risk or severity of adverse effects can be increased when Streptokinase is combined with Propofol.,Propofol
DB00872,The risk or severity of adverse effects can be increased when Streptokinase is combined with Conivaptan.,Conivaptan
DB00883,The risk or severity of adverse effects can be increased when Streptokinase is combined with Isosorbide dinitrate.,Isosorbide dinitrate
DB00887,The risk or severity of adverse effects can be increased when Streptokinase is combined with Bumetanide.,Bumetanide
DB00899,The risk or severity of adverse effects can be increased when Streptokinase is combined with Remifentanil.,Remifentanil
DB00903,The risk or severity of adverse effects can be increased when Streptokinase is combined with Etacrynic acid.,Etacrynic acid
DB00922,The risk or severity of adverse effects can be increased when Streptokinase is combined with Levosimendan.,Levosimendan
DB01002,The risk or severity of adverse effects can be increased when Streptokinase is combined with Levobupivacaine.,Levobupivacaine
DB01020,The risk or severity of adverse effects can be increased when Streptokinase is combined with Isosorbide mononitrate.,Isosorbide mononitrate
DB01041,The risk or severity of adverse effects can be increased when Streptokinase is combined with Thalidomide.,Thalidomide
DB01113,The risk or severity of adverse effects can be increased when Streptokinase is combined with Papaverine.,Papaverine
DB01118,The risk or severity of adverse effects can be increased when Streptokinase is combined with Amiodarone.,Amiodarone
DB01143,The risk or severity of adverse effects can be increased when Streptokinase is combined with Amifostine.,Amifostine
DB01144,The risk or severity of adverse effects can be increased when Streptokinase is combined with Diclofenamide.,Diclofenamide
DB01159,The risk or severity of adverse effects can be increased when Streptokinase is combined with Halothane.,Halothane
DB01169,The risk or severity of adverse effects can be increased when Streptokinase is combined with Arsenic trioxide.,Arsenic trioxide
DB01189,The risk or severity of adverse effects can be increased when Streptokinase is combined with Desflurane.,Desflurane
DB01200,The risk or severity of adverse effects can be increased when Streptokinase is combined with Bromocriptine.,Bromocriptine
DB01224,The risk or severity of adverse effects can be increased when Streptokinase is combined with Quetiapine.,Quetiapine
DB01229,The risk or severity of adverse effects can be increased when Streptokinase is combined with Paclitaxel.,Paclitaxel
DB01242,The risk or severity of adverse effects can be increased when Streptokinase is combined with Clomipramine.,Clomipramine
DB01282,The risk or severity of adverse effects can be increased when Streptokinase is combined with Carbetocin.,Carbetocin
DB01612,The risk or severity of adverse effects can be increased when Streptokinase is combined with Amyl Nitrite.,Amyl Nitrite
DB04899,The risk or severity of adverse effects can be increased when Streptokinase is combined with Nesiritide.,Nesiritide
DB04920,The risk or severity of adverse effects can be increased when Streptokinase is combined with Clevidipine.,Clevidipine
DB05271,The risk or severity of adverse effects can be increased when Streptokinase is combined with Rotigotine.,Rotigotine
DB06292,The risk or severity of adverse effects can be increased when Streptokinase is combined with Dapagliflozin.,Dapagliflozin
DB08907,The risk or severity of adverse effects can be increased when Streptokinase is combined with Canagliflozin.,Canagliflozin
DB08941,The risk or severity of adverse effects can be increased when Streptokinase is combined with Isoxsuprine.,Isoxsuprine
DB09038,The risk or severity of adverse effects can be increased when Streptokinase is combined with Empagliflozin.,Empagliflozin
DB09077,The risk or severity of adverse effects can be increased when Streptokinase is combined with Dinutuximab.,Dinutuximab
DB09112,The risk or severity of adverse effects can be increased when Streptokinase is combined with Nitrous acid.,Nitrous acid
DB09204,The risk or severity of adverse effects can be increased when Streptokinase is combined with Arotinolol.,Arotinolol
DB09227,The risk or severity of adverse effects can be increased when Streptokinase is combined with Barnidipine.,Barnidipine
DB09232,The risk or severity of adverse effects can be increased when Streptokinase is combined with Cilnidipine.,Cilnidipine
DB09279,The risk or severity of adverse effects can be increased when Streptokinase is combined with Fimasartan.,Fimasartan
DB09286,The risk or severity of adverse effects can be increased when Streptokinase is combined with Pipamperone.,Pipamperone
DB00187,The risk or severity of adverse effects can be increased when Streptokinase is combined with Esmolol.,Esmolol
DB00195,The risk or severity of adverse effects can be increased when Streptokinase is combined with Betaxolol.,Betaxolol
DB00206,The risk or severity of adverse effects can be increased when Streptokinase is combined with Reserpine.,Reserpine
DB00214,The risk or severity of adverse effects can be increased when Streptokinase is combined with Torasemide.,Torasemide
DB00264,The risk or severity of adverse effects can be increased when Streptokinase is combined with Metoprolol.,Metoprolol
DB00270,The risk or severity of adverse effects can be increased when Streptokinase is combined with Isradipine.,Isradipine
DB00275,The risk or severity of adverse effects can be increased when Streptokinase is combined with Olmesartan.,Olmesartan
DB00310,The risk or severity of adverse effects can be increased when Streptokinase is combined with Chlorthalidone.,Chlorthalidone
DB00325,The risk or severity of adverse effects can be increased when Streptokinase is combined with Nitroprusside.,Nitroprusside
DB00335,The risk or severity of adverse effects can be increased when Streptokinase is combined with Atenolol.,Atenolol
DB00343,The risk or severity of adverse effects can be increased when Streptokinase is combined with Diltiazem.,Diltiazem
DB00350,The risk or severity of adverse effects can be increased when Streptokinase is combined with Minoxidil.,Minoxidil
DB00373,The risk or severity of adverse effects can be increased when Streptokinase is combined with Timolol.,Timolol
DB00381,The risk or severity of adverse effects can be increased when Streptokinase is combined with Amlodipine.,Amlodipine
DB00393,The risk or severity of adverse effects can be increased when Streptokinase is combined with Nimodipine.,Nimodipine
DB00401,The risk or severity of adverse effects can be increased when Streptokinase is combined with Nisoldipine.,Nisoldipine
DB00436,The risk or severity of adverse effects can be increased when Streptokinase is combined with Bendroflumethiazide.,Bendroflumethiazide
DB00457,The risk or severity of adverse effects can be increased when Streptokinase is combined with Prazosin.,Prazosin
DB00524,The risk or severity of adverse effects can be increased when Streptokinase is combined with Metolazone.,Metolazone
DB00528,The risk or severity of adverse effects can be increased when Streptokinase is combined with Lercanidipine.,Lercanidipine
DB00571,The risk or severity of adverse effects can be increased when Streptokinase is combined with Propranolol.,Propranolol
DB00575,The risk or severity of adverse effects can be increased when Streptokinase is combined with Clonidine.,Clonidine
DB00590,The risk or severity of adverse effects can be increased when Streptokinase is combined with Doxazosin.,Doxazosin
DB00598,The risk or severity of adverse effects can be increased when Streptokinase is combined with Labetalol.,Labetalol
DB00612,The risk or severity of adverse effects can be increased when Streptokinase is combined with Bisoprolol.,Bisoprolol
DB00622,The risk or severity of adverse effects can be increased when Streptokinase is combined with Nicardipine.,Nicardipine
DB00657,The risk or severity of adverse effects can be increased when Streptokinase is combined with Mecamylamine.,Mecamylamine
DB00692,The risk or severity of adverse effects can be increased when Streptokinase is combined with Phentolamine.,Phentolamine
DB00700,The risk or severity of adverse effects can be increased when Streptokinase is combined with Eplerenone.,Eplerenone
DB00727,The risk or severity of adverse effects can be increased when Streptokinase is combined with Nitroglycerin.,Nitroglycerin
DB00774,The risk or severity of adverse effects can be increased when Streptokinase is combined with Hydroflumethiazide.,Hydroflumethiazide
DB00796,The risk or severity of adverse effects can be increased when Streptokinase is combined with Candesartan cilexetil.,Candesartan cilexetil
DB00797,The risk or severity of adverse effects can be increased when Streptokinase is combined with Tolazoline.,Tolazoline
DB00800,The risk or severity of adverse effects can be increased when Streptokinase is combined with Fenoldopam.,Fenoldopam
DB00808,The risk or severity of adverse effects can be increased when Streptokinase is combined with Indapamide.,Indapamide
DB00880,The risk or severity of adverse effects can be increased when Streptokinase is combined with Chlorothiazide.,Chlorothiazide
DB00925,The risk or severity of adverse effects can be increased when Streptokinase is combined with Phenoxybenzamine.,Phenoxybenzamine
DB00960,The risk or severity of adverse effects can be increased when Streptokinase is combined with Pindolol.,Pindolol
DB00968,The risk or severity of adverse effects can be increased when Streptokinase is combined with Methyldopa.,Methyldopa
DB00999,The risk or severity of adverse effects can be increased when Streptokinase is combined with Hydrochlorothiazide.,Hydrochlorothiazide
DB01018,The risk or severity of adverse effects can be increased when Streptokinase is combined with Guanfacine.,Guanfacine
DB01023,The risk or severity of adverse effects can be increased when Streptokinase is combined with Felodipine.,Felodipine
DB01029,The risk or severity of adverse effects can be increased when Streptokinase is combined with Irbesartan.,Irbesartan
DB01054,The risk or severity of adverse effects can be increased when Streptokinase is combined with Nitrendipine.,Nitrendipine
DB01119,The risk or severity of adverse effects can be increased when Streptokinase is combined with Diazoxide.,Diazoxide
DB01136,The risk or severity of adverse effects can be increased when Streptokinase is combined with Carvedilol.,Carvedilol
DB01158,The risk or severity of adverse effects can be increased when Streptokinase is combined with Bretylium.,Bretylium
DB01162,The risk or severity of adverse effects can be increased when Streptokinase is combined with Terazosin.,Terazosin
DB01193,The risk or severity of adverse effects can be increased when Streptokinase is combined with Acebutolol.,Acebutolol
DB01203,The risk or severity of adverse effects can be increased when Streptokinase is combined with Nadolol.,Nadolol
DB01244,The risk or severity of adverse effects can be increased when Streptokinase is combined with Bepridil.,Bepridil
DB01275,The risk or severity of adverse effects can be increased when Streptokinase is combined with Hydralazine.,Hydralazine
DB01359,The risk or severity of adverse effects can be increased when Streptokinase is combined with Penbutolol.,Penbutolol
DB01580,The risk or severity of adverse effects can be increased when Streptokinase is combined with Oxprenolol.,Oxprenolol
DB04861,The risk or severity of adverse effects can be increased when Streptokinase is combined with Nebivolol.,Nebivolol
DB04948,The risk or severity of adverse effects can be increased when Streptokinase is combined with Lofexidine.,Lofexidine
DB06712,The risk or severity of adverse effects can be increased when Streptokinase is combined with Nilvadipine.,Nilvadipine
DB08931,The risk or severity of adverse effects can be increased when Streptokinase is combined with Riociguat.,Riociguat
DB08950,The risk or severity of adverse effects can be increased when Streptokinase is combined with Indoramin.,Indoramin
DB09026,The risk or severity of adverse effects can be increased when Streptokinase is combined with Aliskiren.,Aliskiren
DB09235,The risk or severity of adverse effects can be increased when Streptokinase is combined with Efonidipine.,Efonidipine
DB09242,The risk or severity of adverse effects can be increased when Streptokinase is combined with Moxonidine.,Moxonidine
DB01115,The risk or severity of adverse effects can be increased when Streptokinase is combined with Nifedipine.,Nifedipine
DB03404,Hemin may increase the anticoagulant activities of Streptokinase.,Hemin
DB13783,The risk or severity of bleeding and hemorrhage can be increased when Acemetacin is combined with Streptokinase.,Acemetacin
DB09236,Streptokinase may increase the hypotensive activities of Lacidipine.,Lacidipine
DB00898,Ethanol may increase the hypotensive activities of Streptokinase.,Ethanol
DB00624,Testosterone may increase the anticoagulant activities of Streptokinase.,Testosterone
DB01420,Testosterone propionate may increase the anticoagulant activities of Streptokinase.,Testosterone propionate
DB01481,1-Testosterone may increase the anticoagulant activities of Streptokinase.,1-Testosterone
DB01485,4-Hydroxytestosterone may increase the anticoagulant activities of Streptokinase.,4-Hydroxytestosterone
DB01510,Dehydrochloromethyltestosterone may increase the anticoagulant activities of Streptokinase.,Dehydrochloromethyltestosterone
DB01541,Boldenone may increase the anticoagulant activities of Streptokinase.,Boldenone
DB01543,18-methyl-19-nortestosterone may increase the anticoagulant activities of Streptokinase.,18-methyl-19-nortestosterone
DB01564,Calusterone may increase the anticoagulant activities of Streptokinase.,Calusterone
DB01569,Formebolone may increase the anticoagulant activities of Streptokinase.,Formebolone
DB01572,Methyl-1-testosterone may increase the anticoagulant activities of Streptokinase.,Methyl-1-testosterone
DB02901,Stanolone may increase the anticoagulant activities of Streptokinase.,Stanolone
DB07447,5beta-dihydrotestosterone may increase the anticoagulant activities of Streptokinase.,5beta-dihydrotestosterone
DB08619,Testosterone succinate may increase the anticoagulant activities of Streptokinase.,Testosterone succinate
DB11429,Mibolerone may increase the anticoagulant activities of Streptokinase.,Mibolerone
DB13943,Testosterone cypionate may increase the anticoagulant activities of Streptokinase.,Testosterone cypionate
DB13944,Testosterone enanthate may increase the anticoagulant activities of Streptokinase.,Testosterone enanthate
DB13946,Testosterone undecanoate may increase the anticoagulant activities of Streptokinase.,Testosterone undecanoate
DB13947,Testosterone enantate benzilic acid hydrazone may increase the anticoagulant activities of Streptokinase.,Testosterone enantate benzilic acid hydrazone
DB13951,Stanolone acetate may increase the anticoagulant activities of Streptokinase.,Stanolone acetate
DB13958,Trestolone acetate may increase the anticoagulant activities of Streptokinase.,Trestolone acetate
DB14093,"(1,2,6,7-3H)Testosterone may increase the anticoagulant activities of Streptokinase.","(1,2,6,7-3H)Testosterone"
DB14655,Drostanolone propionate may increase the anticoagulant activities of Streptokinase.,Drostanolone propionate
DB11051,The risk or severity of adverse effects can be increased when Streptokinase is combined with Azficel-T.,Azficel-T
DB09568,The therapeutic efficacy of Streptokinase can be increased when used in combination with Omega-3-carboxylic acids.,Omega-3-carboxylic acids
DB00258,The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Streptokinase.,Calcium acetate
DB01164,The therapeutic efficacy of Calcium chloride can be decreased when used in combination with Streptokinase.,Calcium chloride
DB01373,The therapeutic efficacy of Calcium can be decreased when used in combination with Streptokinase.,Calcium
DB11126,The therapeutic efficacy of Calcium gluconate can be decreased when used in combination with Streptokinase.,Calcium gluconate
DB11608,The therapeutic efficacy of Eftrenonacog alfa can be decreased when used in combination with Streptokinase.,Eftrenonacog alfa
DB13884,The therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Streptokinase.,Albutrepenonacog alfa
DB13923,The therapeutic efficacy of Emicizumab can be decreased when used in combination with Streptokinase.,Emicizumab
DB14738,The therapeutic efficacy of Turoctocog alfa pegol can be decreased when used in combination with Streptokinase.,Turoctocog alfa pegol
DB00025,"The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Streptokinase.","Antihemophilic factor, human recombinant"
DB00036,The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Streptokinase.,Coagulation factor VIIa Recombinant Human
DB00100,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Streptokinase.,Coagulation Factor IX (Recombinant)
DB01783,The therapeutic efficacy of Pantothenic acid can be decreased when used in combination with Streptokinase.,Pantothenic acid
DB01942,The therapeutic efficacy of Formic acid can be decreased when used in combination with Streptokinase.,Formic acid
DB02261,The therapeutic efficacy of Platelet Activating Factor can be decreased when used in combination with Streptokinase.,Platelet Activating Factor
DB06724,The therapeutic efficacy of Calcium carbonate can be decreased when used in combination with Streptokinase.,Calcium carbonate
DB09109,The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Streptokinase.,Turoctocog alfa
DB09222,The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Streptokinase.,Fibrinogen human
DB09310,The therapeutic efficacy of Catridecacog can be decreased when used in combination with Streptokinase.,Catridecacog
DB09329,"The therapeutic efficacy of Antihemophilic Factor (Recombinant), PEGylated can be decreased when used in combination with Streptokinase.","Antihemophilic Factor (Recombinant), PEGylated"
DB11093,The therapeutic efficacy of Calcium citrate can be decreased when used in combination with Streptokinase.,Calcium citrate
DB11168,The therapeutic efficacy of Calcium threonate can be decreased when used in combination with Streptokinase.,Calcium threonate
DB11311,The therapeutic efficacy of Prothrombin can be decreased when used in combination with Streptokinase.,Prothrombin
DB11330,The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Streptokinase.,Factor IX Complex (Human)
DB11348,The therapeutic efficacy of Calcium Phosphate can be decreased when used in combination with Streptokinase.,Calcium Phosphate
DB11606,The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Streptokinase.,Susoctocog alfa
DB11668,The therapeutic efficacy of Rusalatide acetate can be decreased when used in combination with Streptokinase.,Rusalatide acetate
DB12409,The therapeutic efficacy of Vatreptacog alfa can be decreased when used in combination with Streptokinase.,Vatreptacog alfa
DB12909,The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Streptokinase.,Factor XIII (human)
DB13133,The therapeutic efficacy of Von Willebrand Factor Human can be decreased when used in combination with Streptokinase.,Von Willebrand Factor Human
DB13148,The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Streptokinase.,Coagulation factor X human
DB13150,The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Streptokinase.,Coagulation factor VII human
DB13151,The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Streptokinase.,Anti-inhibitor coagulant complex
DB13152,The therapeutic efficacy of Coagulation Factor IX Human can be decreased when used in combination with Streptokinase.,Coagulation Factor IX Human
DB13192,The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Streptokinase.,Antihemophilic factor human
DB13197,The therapeutic efficacy of Kallidinogenase can be decreased when used in combination with Streptokinase.,Kallidinogenase
DB13201,The therapeutic efficacy of Trenonacog alfa can be decreased when used in combination with Streptokinase.,Trenonacog alfa
DB13933,The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Streptokinase.,Nonacog beta pegol
DB13999,The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Streptokinase.,Moroctocog alfa
DB14473,The therapeutic efficacy of Beroctocog alfa can be decreased when used in combination with Streptokinase.,Beroctocog alfa
DB14562,The therapeutic efficacy of Andexanet alfa can be decreased when used in combination with Streptokinase.,Andexanet alfa
DB14577,The therapeutic efficacy of Calcium cation can be decreased when used in combination with Streptokinase.,Calcium cation
DB14700,The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Streptokinase.,Damoctocog alfa pegol
DB00176,The risk or severity of hemorrhage can be increased when Fluvoxamine is combined with Streptokinase.,Fluvoxamine
DB00215,The risk or severity of hemorrhage can be increased when Citalopram is combined with Streptokinase.,Citalopram
DB00472,The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Streptokinase.,Fluoxetine
DB00715,The risk or severity of hemorrhage can be increased when Paroxetine is combined with Streptokinase.,Paroxetine
DB01149,The risk or severity of hemorrhage can be increased when Nefazodone is combined with Streptokinase.,Nefazodone
DB04832,The risk or severity of hemorrhage can be increased when Zimelidine is combined with Streptokinase.,Zimelidine
DB04884,The risk or severity of hemorrhage can be increased when Dapoxetine is combined with Streptokinase.,Dapoxetine
DB06731,The risk or severity of hemorrhage can be increased when Seproxetine is combined with Streptokinase.,Seproxetine
DB08953,The risk or severity of hemorrhage can be increased when Indalpine is combined with Streptokinase.,Indalpine
DB12693,The risk or severity of hemorrhage can be increased when Ritanserin is combined with Streptokinase.,Ritanserin
DB13233,The risk or severity of hemorrhage can be increased when Alaproclate is combined with Streptokinase.,Alaproclate
DB01105,The risk or severity of hemorrhage can be increased when Sibutramine is combined with Streptokinase.,Sibutramine
DB04896,The risk or severity of hemorrhage can be increased when Milnacipran is combined with Streptokinase.,Milnacipran
DB06700,The risk or severity of hemorrhage can be increased when Desvenlafaxine is combined with Streptokinase.,Desvenlafaxine
DB08918,The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Streptokinase.,Levomilnacipran
DB00285,Venlafaxine may increase the antiplatelet activities of Streptokinase.,Venlafaxine
DB00006,The risk or severity of bleeding can be increased when Bivalirudin is combined with Streptokinase.,Bivalirudin
DB00266,The risk or severity of bleeding can be increased when Dicoumarol is combined with Streptokinase.,Dicoumarol
DB00278,The risk or severity of bleeding can be increased when Argatroban is combined with Streptokinase.,Argatroban
DB00498,The risk or severity of bleeding can be increased when Phenindione is combined with Streptokinase.,Phenindione
DB00569,The risk or severity of bleeding can be increased when Fondaparinux is combined with Streptokinase.,Fondaparinux
DB00682,The risk or severity of bleeding can be increased when Warfarin is combined with Streptokinase.,Warfarin
DB00946,The risk or severity of bleeding can be increased when Phenprocoumon is combined with Streptokinase.,Phenprocoumon
DB00974,The risk or severity of bleeding can be increased when Edetic acid is combined with Streptokinase.,Edetic acid
DB01418,The risk or severity of bleeding can be increased when Acenocoumarol is combined with Streptokinase.,Acenocoumarol
DB04898,The risk or severity of bleeding can be increased when Ximelagatran is combined with Streptokinase.,Ximelagatran
DB05099,The risk or severity of bleeding can be increased when Ancrod is combined with Streptokinase.,Ancrod
DB06406,The risk or severity of bleeding can be increased when Idraparinux is combined with Streptokinase.,Idraparinux
DB06635,The risk or severity of bleeding can be increased when Otamixaban is combined with Streptokinase.,Otamixaban
DB07767,The risk or severity of bleeding can be increased when Ferulic acid is combined with Streptokinase.,Ferulic acid
DB08794,The risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Streptokinase.,Ethyl biscoumacetate
DB09255,The risk or severity of bleeding can be increased when Dextran is combined with Streptokinase.,Dextran
DB11095,The risk or severity of bleeding can be increased when Desirudin is combined with Streptokinase.,Desirudin
DB11268,The risk or severity of bleeding can be increased when Protocatechualdehyde is combined with Streptokinase.,Protocatechualdehyde
DB11312,The risk or severity of bleeding can be increased when Protein C is combined with Streptokinase.,Protein C
DB11598,The risk or severity of bleeding can be increased when Antithrombin III human is combined with Streptokinase.,Antithrombin III human
DB11984,The risk or severity of bleeding can be increased when Letaxaban is combined with Streptokinase.,Letaxaban
DB12289,The risk or severity of bleeding can be increased when Darexaban is combined with Streptokinase.,Darexaban
DB12598,The risk or severity of bleeding can be increased when Nafamostat is combined with Streptokinase.,Nafamostat
DB12831,The risk or severity of bleeding can be increased when Gabexate is combined with Streptokinase.,Gabexate
DB13124,The risk or severity of bleeding can be increased when Troxerutin is combined with Streptokinase.,Troxerutin
DB13136,The risk or severity of bleeding can be increased when Fluindione is combined with Streptokinase.,Fluindione
DB13149,The risk or severity of bleeding can be increased when Protein S human is combined with Streptokinase.,Protein S human
DB13616,The risk or severity of bleeding can be increased when Melagatran is combined with Streptokinase.,Melagatran
DB09125,The risk or severity of bleeding can be increased when Potassium citrate is combined with Streptokinase.,Potassium citrate
DB09154,The risk or severity of bleeding can be increased when Sodium citrate is combined with Streptokinase.,Sodium citrate
DB00031,The risk or severity of bleeding can be increased when Tenecteplase is combined with Streptokinase.,Tenecteplase
DB00055,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Streptokinase.,Drotrecogin alfa
DB13199,The risk or severity of bleeding can be increased when Brinase is combined with Streptokinase.,Brinase
DB13646,The risk or severity of bleeding can be increased when Saruplase is combined with Streptokinase.,Saruplase
DB04925,The risk or severity of bleeding can be increased when Streptokinase is combined with Desmoteplase.,Desmoteplase
DB05254,The risk or severity of bleeding can be increased when Streptokinase is combined with Fibrinolysin.,Fibrinolysin
DB06543,The risk or severity of bleeding can be increased when Streptokinase is combined with Astaxanthin.,Astaxanthin
DB08994,The risk or severity of bleeding can be increased when Streptokinase is combined with Ditazole.,Ditazole
DB13275,The risk or severity of bleeding can be increased when Streptokinase is combined with Clorindione.,Clorindione
DB13347,The risk or severity of bleeding can be increased when Streptokinase is combined with Diphenadione.,Diphenadione
DB13451,The risk or severity of bleeding can be increased when Streptokinase is combined with Tioclomarol.,Tioclomarol
DB00001,The risk or severity of bleeding can be increased when Streptokinase is combined with Lepirudin.,Lepirudin
DB00009,The risk or severity of bleeding can be increased when Streptokinase is combined with Alteplase.,Alteplase
DB00015,The risk or severity of bleeding can be increased when Streptokinase is combined with Reteplase.,Reteplase
DB00029,The risk or severity of bleeding can be increased when Streptokinase is combined with Anistreplase.,Anistreplase
DB14094,The risk or severity of bleeding can be increased when Streptokinase is combined with Tocopherylquinone.,Tocopherylquinone
DB06679,The risk or severity of bleeding can be increased when Streptokinase is combined with Amediplase.,Amediplase
DB03410,The risk or severity of bleeding can be increased when Streptokinase is combined with 4-hydroxycoumarin.,4-hydroxycoumarin
DB08496,The risk or severity of bleeding can be increased when Streptokinase is combined with (R)-warfarin.,(R)-warfarin
DB14055,The risk or severity of bleeding can be increased when Streptokinase is combined with (S)-Warfarin.,(S)-Warfarin
DB12364,The risk or severity of bleeding can be increased when Streptokinase is combined with Betrixaban.,Betrixaban
DB14598,The risk or severity of bleeding can be increased when Streptokinase is combined with Edetate calcium disodium anhydrous.,Edetate calcium disodium anhydrous
DB11154,The risk or severity of bleeding can be increased when Streptokinase is combined with Zinc citrate.,Zinc citrate
DB11166,The risk or severity of bleeding can be increased when Streptokinase is combined with Antithrombin Alfa.,Antithrombin Alfa
DB04665,The risk or severity of bleeding can be increased when Streptokinase is combined with Coumarin.,Coumarin
DB14726,The risk or severity of bleeding can be increased when Streptokinase is combined with Dabigatran.,Dabigatran
DB12726,The risk or severity of bleeding can be increased when Streptokinase is combined with Monteplase.,Monteplase
DB00177,The risk or severity of angioedema can be increased when Streptokinase is combined with Valsartan.,Valsartan
DB00178,The risk or severity of angioedema can be increased when Streptokinase is combined with Ramipril.,Ramipril
DB00230,The risk or severity of angioedema can be increased when Streptokinase is combined with Pregabalin.,Pregabalin
DB00492,The risk or severity of angioedema can be increased when Streptokinase is combined with Fosinopril.,Fosinopril
DB00519,The risk or severity of angioedema can be increased when Streptokinase is combined with Trandolapril.,Trandolapril
DB00542,The risk or severity of angioedema can be increased when Streptokinase is combined with Benazepril.,Benazepril
DB00584,The risk or severity of angioedema can be increased when Streptokinase is combined with Enalapril.,Enalapril
DB00678,The risk or severity of angioedema can be increased when Streptokinase is combined with Losartan.,Losartan
DB00691,The risk or severity of angioedema can be increased when Streptokinase is combined with Moexipril.,Moexipril
DB00722,The risk or severity of angioedema can be increased when Streptokinase is combined with Lisinopril.,Lisinopril
DB00790,The risk or severity of angioedema can be increased when Streptokinase is combined with Perindopril.,Perindopril
DB00876,The risk or severity of angioedema can be increased when Streptokinase is combined with Eprosartan.,Eprosartan
DB00877,The risk or severity of angioedema can be increased when Streptokinase is combined with Sirolimus.,Sirolimus
DB00881,The risk or severity of angioedema can be increased when Streptokinase is combined with Quinapril.,Quinapril
DB00886,The risk or severity of angioedema can be increased when Streptokinase is combined with Omapatrilat.,Omapatrilat
DB00966,The risk or severity of angioedema can be increased when Streptokinase is combined with Telmisartan.,Telmisartan
DB01050,The risk or severity of angioedema can be increased when Streptokinase is combined with Ibuprofen.,Ibuprofen
DB01180,The risk or severity of angioedema can be increased when Streptokinase is combined with Rescinnamine.,Rescinnamine
DB01197,The risk or severity of angioedema can be increased when Streptokinase is combined with Captopril.,Captopril
DB01261,The risk or severity of angioedema can be increased when Streptokinase is combined with Sitagliptin.,Sitagliptin
DB01340,The risk or severity of angioedema can be increased when Streptokinase is combined with Cilazapril.,Cilazapril
DB01342,The risk or severity of angioedema can be increased when Streptokinase is combined with Forasartan.,Forasartan
DB01347,The risk or severity of angioedema can be increased when Streptokinase is combined with Saprisartan.,Saprisartan
DB01348,The risk or severity of angioedema can be increased when Streptokinase is combined with Spirapril.,Spirapril
DB04876,The risk or severity of angioedema can be increased when Streptokinase is combined with Vildagliptin.,Vildagliptin
DB06011,The risk or severity of angioedema can be increased when Streptokinase is combined with AMG-222.,AMG-222
DB06127,The risk or severity of angioedema can be increased when Streptokinase is combined with Bisegliptin.,Bisegliptin
DB06196,The risk or severity of angioedema can be increased when Streptokinase is combined with Icatibant.,Icatibant
DB06203,The risk or severity of angioedema can be increased when Streptokinase is combined with Alogliptin.,Alogliptin
DB06245,The risk or severity of angioedema can be increased when Streptokinase is combined with Lanoteplase.,Lanoteplase
DB06287,The risk or severity of angioedema can be increased when Streptokinase is combined with Temsirolimus.,Temsirolimus
DB06335,The risk or severity of angioedema can be increased when Streptokinase is combined with Saxagliptin.,Saxagliptin
DB08382,The risk or severity of angioedema can be increased when Streptokinase is combined with Gosogliptin.,Gosogliptin
DB08822,The risk or severity of angioedema can be increased when Streptokinase is combined with Azilsartan medoxomil.,Azilsartan medoxomil
DB08836,The risk or severity of angioedema can be increased when Streptokinase is combined with Temocapril.,Temocapril
DB08882,The risk or severity of angioedema can be increased when Streptokinase is combined with Linagliptin.,Linagliptin
DB09292,The risk or severity of angioedema can be increased when Streptokinase is combined with Sacubitril.,Sacubitril
DB09477,The risk or severity of angioedema can be increased when Streptokinase is combined with Enalaprilat.,Enalaprilat
DB11723,The risk or severity of angioedema can be increased when Streptokinase is combined with Dutogliptin.,Dutogliptin
DB11783,The risk or severity of angioedema can be increased when Streptokinase is combined with Imidapril.,Imidapril
DB11950,The risk or severity of angioedema can be increased when Streptokinase is combined with Teneligliptin.,Teneligliptin
DB11992,The risk or severity of angioedema can be increased when Streptokinase is combined with Omarigliptin.,Omarigliptin
DB12268,The risk or severity of angioedema can be increased when Streptokinase is combined with Carmegliptin.,Carmegliptin
DB12412,The risk or severity of angioedema can be increased when Streptokinase is combined with Gemigliptin.,Gemigliptin
DB12417,The risk or severity of angioedema can be increased when Streptokinase is combined with Anagliptin.,Anagliptin
DB12625,The risk or severity of angioedema can be increased when Streptokinase is combined with Evogliptin.,Evogliptin
DB13166,The risk or severity of angioedema can be increased when Streptokinase is combined with Zofenopril.,Zofenopril
DB13312,The risk or severity of angioedema can be increased when Streptokinase is combined with Delapril.,Delapril
DB14125,The risk or severity of angioedema can be increased when Streptokinase is combined with Benazeprilat.,Benazeprilat
DB14207,The risk or severity of angioedema can be increased when Streptokinase is combined with Fosinoprilat.,Fosinoprilat
DB14208,The risk or severity of angioedema can be increased when Streptokinase is combined with Ramiprilat.,Ramiprilat
DB14209,The risk or severity of angioedema can be increased when Streptokinase is combined with Trandolaprilat.,Trandolaprilat
DB14210,The risk or severity of angioedema can be increased when Streptokinase is combined with Moexiprilat.,Moexiprilat
DB14213,The risk or severity of angioedema can be increased when Streptokinase is combined with Perindoprilat.,Perindoprilat
DB14217,The risk or severity of angioedema can be increased when Streptokinase is combined with Quinaprilat.,Quinaprilat
DB14231,The risk or severity of angioedema can be increased when Streptokinase is combined with Quinoline Yellow WS.,Quinoline Yellow WS
DB00203,The risk or severity of hemorrhage can be increased when Streptokinase is combined with Sildenafil.,Sildenafil
DB00008,The risk or severity of bleeding can be increased when Streptokinase is combined with Peginterferon alfa-2a.,Peginterferon alfa-2a
DB00011,The risk or severity of bleeding can be increased when Streptokinase is combined with Interferon alfa-n1.,Interferon alfa-n1
DB00018,The risk or severity of bleeding can be increased when Streptokinase is combined with Interferon alfa-n3.,Interferon alfa-n3
DB00022,The risk or severity of bleeding can be increased when Streptokinase is combined with Peginterferon alfa-2b.,Peginterferon alfa-2b
DB00033,The risk or severity of bleeding can be increased when Streptokinase is combined with Interferon gamma-1b.,Interferon gamma-1b
DB00034,"The risk or severity of bleeding can be increased when Streptokinase is combined with Interferon alfa-2a, Recombinant.","Interferon alfa-2a, Recombinant"
DB00056,The risk or severity of bleeding can be increased when Streptokinase is combined with Gemtuzumab ozogamicin.,Gemtuzumab ozogamicin
DB00068,The risk or severity of bleeding can be increased when Streptokinase is combined with Interferon beta-1b.,Interferon beta-1b
DB00069,The risk or severity of bleeding can be increased when Streptokinase is combined with Interferon alfacon-1.,Interferon alfacon-1
DB00073,The risk or severity of bleeding can be increased when Streptokinase is combined with Rituximab.,Rituximab
DB00078,The risk or severity of bleeding can be increased when Streptokinase is combined with Ibritumomab tiuxetan.,Ibritumomab tiuxetan
DB00087,The risk or severity of bleeding can be increased when Streptokinase is combined with Alemtuzumab.,Alemtuzumab
DB00105,The risk or severity of bleeding can be increased when Streptokinase is combined with Interferon alfa-2b.,Interferon alfa-2b
DB00120,The risk or severity of bleeding can be increased when Streptokinase is combined with Phenylalanine.,Phenylalanine
DB00242,The risk or severity of bleeding can be increased when Streptokinase is combined with Cladribine.,Cladribine
DB00262,The risk or severity of bleeding can be increased when Streptokinase is combined with Carmustine.,Carmustine
DB00276,The risk or severity of bleeding can be increased when Streptokinase is combined with Amsacrine.,Amsacrine
DB00291,The risk or severity of bleeding can be increased when Streptokinase is combined with Chlorambucil.,Chlorambucil
DB00293,The risk or severity of bleeding can be increased when Streptokinase is combined with Raltitrexed.,Raltitrexed
DB00305,The risk or severity of bleeding can be increased when Streptokinase is combined with Mitomycin.,Mitomycin
DB00307,The risk or severity of bleeding can be increased when Streptokinase is combined with Bexarotene.,Bexarotene
DB00309,The risk or severity of bleeding can be increased when Streptokinase is combined with Vindesine.,Vindesine
DB00322,The risk or severity of bleeding can be increased when Streptokinase is combined with Floxuridine.,Floxuridine
DB00352,The risk or severity of bleeding can be increased when Streptokinase is combined with Tioguanine.,Tioguanine
DB00361,The risk or severity of bleeding can be increased when Streptokinase is combined with Vinorelbine.,Vinorelbine
DB00380,The risk or severity of bleeding can be increased when Streptokinase is combined with Dexrazoxane.,Dexrazoxane
DB00398,The risk or severity of bleeding can be increased when Streptokinase is combined with Sorafenib.,Sorafenib
DB00428,The risk or severity of bleeding can be increased when Streptokinase is combined with Streptozocin.,Streptozocin
DB00441,The risk or severity of bleeding can be increased when Streptokinase is combined with Gemcitabine.,Gemcitabine
DB00444,The risk or severity of bleeding can be increased when Streptokinase is combined with Teniposide.,Teniposide
DB00445,The risk or severity of bleeding can be increased when Streptokinase is combined with Epirubicin.,Epirubicin
DB00446,The risk or severity of bleeding can be increased when Streptokinase is combined with Chloramphenicol.,Chloramphenicol
DB00480,The risk or severity of bleeding can be increased when Streptokinase is combined with Lenalidomide.,Lenalidomide
DB00488,The risk or severity of bleeding can be increased when Streptokinase is combined with Altretamine.,Altretamine
DB00495,The risk or severity of bleeding can be increased when Streptokinase is combined with Zidovudine.,Zidovudine
DB00515,The risk or severity of bleeding can be increased when Streptokinase is combined with Cisplatin.,Cisplatin
DB00526,The risk or severity of bleeding can be increased when Streptokinase is combined with Oxaliplatin.,Oxaliplatin
DB00531,The risk or severity of bleeding can be increased when Streptokinase is combined with Cyclophosphamide.,Cyclophosphamide
DB00544,The risk or severity of bleeding can be increased when Streptokinase is combined with Fluorouracil.,Fluorouracil
DB00552,The risk or severity of bleeding can be increased when Streptokinase is combined with Pentostatin.,Pentostatin
DB00563,The risk or severity of bleeding can be increased when Streptokinase is combined with Methotrexate.,Methotrexate
DB00564,The risk or severity of bleeding can be increased when Streptokinase is combined with Carbamazepine.,Carbamazepine
DB00570,The risk or severity of bleeding can be increased when Streptokinase is combined with Vinblastine.,Vinblastine
DB00619,The risk or severity of bleeding can be increased when Streptokinase is combined with Imatinib.,Imatinib
DB00642,The risk or severity of bleeding can be increased when Streptokinase is combined with Pemetrexed.,Pemetrexed
DB00694,The risk or severity of bleeding can be increased when Streptokinase is combined with Daunorubicin.,Daunorubicin
DB00762,The risk or severity of bleeding can be increased when Streptokinase is combined with Irinotecan.,Irinotecan
DB00773,The risk or severity of bleeding can be increased when Streptokinase is combined with Etoposide.,Etoposide
DB00851,The risk or severity of bleeding can be increased when Streptokinase is combined with Dacarbazine.,Dacarbazine
DB00853,The risk or severity of bleeding can be increased when Streptokinase is combined with Temozolomide.,Temozolomide
DB00859,The risk or severity of bleeding can be increased when Streptokinase is combined with Penicillamine.,Penicillamine
DB00864,The risk or severity of bleeding can be increased when Streptokinase is combined with Tacrolimus.,Tacrolimus
DB00888,The risk or severity of bleeding can be increased when Streptokinase is combined with Mechlorethamine.,Mechlorethamine
DB00928,The risk or severity of bleeding can be increased when Streptokinase is combined with Azacitidine.,Azacitidine
DB00958,The risk or severity of bleeding can be increased when Streptokinase is combined with Carboplatin.,Carboplatin
DB00970,The risk or severity of bleeding can be increased when Streptokinase is combined with Dactinomycin.,Dactinomycin
DB00987,The risk or severity of bleeding can be increased when Streptokinase is combined with Cytarabine.,Cytarabine
DB00997,The risk or severity of bleeding can be increased when Streptokinase is combined with Doxorubicin.,Doxorubicin
DB01005,The risk or severity of bleeding can be increased when Streptokinase is combined with Hydroxyurea.,Hydroxyurea
DB01008,The risk or severity of bleeding can be increased when Streptokinase is combined with Busulfan.,Busulfan
DB01030,The risk or severity of bleeding can be increased when Streptokinase is combined with Topotecan.,Topotecan
DB01033,The risk or severity of bleeding can be increased when Streptokinase is combined with Mercaptopurine.,Mercaptopurine
DB01042,The risk or severity of bleeding can be increased when Streptokinase is combined with Melphalan.,Melphalan
DB01073,The risk or severity of bleeding can be increased when Streptokinase is combined with Fludarabine.,Fludarabine
DB01099,The risk or severity of bleeding can be increased when Streptokinase is combined with Flucytosine.,Flucytosine
DB01101,The risk or severity of bleeding can be increased when Streptokinase is combined with Capecitabine.,Capecitabine
DB01177,The risk or severity of bleeding can be increased when Streptokinase is combined with Idarubicin.,Idarubicin
DB01204,The risk or severity of bleeding can be increased when Streptokinase is combined with Mitoxantrone.,Mitoxantrone
DB01206,The risk or severity of bleeding can be increased when Streptokinase is combined with Lomustine.,Lomustine
DB01248,The risk or severity of bleeding can be increased when Streptokinase is combined with Docetaxel.,Docetaxel
DB01262,The risk or severity of bleeding can be increased when Streptokinase is combined with Decitabine.,Decitabine
DB01280,The risk or severity of bleeding can be increased when Streptokinase is combined with Nelarabine.,Nelarabine
DB01590,The risk or severity of bleeding can be increased when Streptokinase is combined with Everolimus.,Everolimus
DB02546,The risk or severity of bleeding can be increased when Streptokinase is combined with Vorinostat.,Vorinostat
DB04572,The risk or severity of bleeding can be increased when Streptokinase is combined with Thiotepa.,Thiotepa
DB04845,The risk or severity of bleeding can be increased when Streptokinase is combined with Ixabepilone.,Ixabepilone
DB04868,The risk or severity of bleeding can be increased when Streptokinase is combined with Nilotinib.,Nilotinib
DB05015,The risk or severity of bleeding can be increased when Streptokinase is combined with Belinostat.,Belinostat
DB05109,The risk or severity of bleeding can be increased when Streptokinase is combined with Trabectedin.,Trabectedin
DB05258,The risk or severity of bleeding can be increased when Streptokinase is combined with Interferon alfa.,Interferon alfa
DB05472,The risk or severity of bleeding can be increased when Streptokinase is combined with omega interferon.,omega interferon
DB05773,The risk or severity of bleeding can be increased when Streptokinase is combined with Trastuzumab emtansine.,Trastuzumab emtansine
DB06616,The risk or severity of bleeding can be increased when Streptokinase is combined with Bosutinib.,Bosutinib
DB06769,The risk or severity of bleeding can be increased when Streptokinase is combined with Bendamustine.,Bendamustine
DB06772,The risk or severity of bleeding can be increased when Streptokinase is combined with Cabazitaxel.,Cabazitaxel
DB08871,The risk or severity of bleeding can be increased when Streptokinase is combined with Eribulin.,Eribulin
DB08877,The risk or severity of bleeding can be increased when Streptokinase is combined with Ruxolitinib.,Ruxolitinib
DB08889,The risk or severity of bleeding can be increased when Streptokinase is combined with Carfilzomib.,Carfilzomib
DB08895,The risk or severity of bleeding can be increased when Streptokinase is combined with Tofacitinib.,Tofacitinib
DB08901,The risk or severity of bleeding can be increased when Streptokinase is combined with Ponatinib.,Ponatinib
DB08910,The risk or severity of bleeding can be increased when Streptokinase is combined with Pomalidomide.,Pomalidomide
DB09042,The risk or severity of bleeding can be increased when Streptokinase is combined with Tedizolid phosphate.,Tedizolid phosphate
DB09052,The risk or severity of bleeding can be increased when Streptokinase is combined with Blinatumomab.,Blinatumomab
DB09073,The risk or severity of bleeding can be increased when Streptokinase is combined with Palbociclib.,Palbociclib
DB09074,The risk or severity of bleeding can be increased when Streptokinase is combined with Olaparib.,Olaparib
DB09122,The risk or severity of bleeding can be increased when Streptokinase is combined with Peginterferon beta-1a.,Peginterferon beta-1a
DB12814,The risk or severity of bleeding can be increased when Streptokinase is combined with Cepeginterferon alfa-2B.,Cepeginterferon alfa-2B
DB00188,The risk or severity of bleeding can be increased when Streptokinase is combined with Bortezomib.,Bortezomib
DB00229,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefotiam.,Cefotiam
DB00267,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefmenoxime.,Cefmenoxime
DB00274,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefmetazole.,Cefmetazole
DB00430,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefpiramide.,Cefpiramide
DB00438,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Ceftazidime.,Ceftazidime
DB00447,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Loracarbef.,Loracarbef
DB00456,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefalotin.,Cefalotin
DB00493,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefotaxime.,Cefotaxime
DB00535,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefdinir.,Cefdinir
DB00567,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cephalexin.,Cephalexin
DB00671,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefixime.,Cefixime
DB00689,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cephaloglycin.,Cephaloglycin
DB00833,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefaclor.,Cefaclor
DB00923,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Ceforanide.,Ceforanide
DB01066,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefditoren.,Cefditoren
DB01112,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefuroxime.,Cefuroxime
DB01139,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefapirin.,Cefapirin
DB01140,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefadroxil.,Cefadroxil
DB01150,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefprozil.,Cefprozil
DB01212,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Ceftriaxone.,Ceftriaxone
DB01326,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefamandole.,Cefamandole
DB01327,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefazolin.,Cefazolin
DB01328,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefonicid.,Cefonicid
DB01329,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefoperazone.,Cefoperazone
DB01330,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefotetan.,Cefotetan
DB01331,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefoxitin.,Cefoxitin
DB01332,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Ceftizoxime.,Ceftizoxime
DB01333,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefradine.,Cefradine
DB01413,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefepime.,Cefepime
DB01414,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefacetrile.,Cefacetrile
DB01415,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Ceftibuten.,Ceftibuten
DB01416,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefpodoxime.,Cefpodoxime
DB04570,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Latamoxef.,Latamoxef
DB04918,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Ceftobiprole.,Ceftobiprole
DB06590,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Ceftaroline fosamil.,Ceftaroline fosamil
DB09008,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefaloridine.,Cefaloridine
DB09050,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Ceftolozane.,Ceftolozane
DB09062,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefminox.,Cefminox
DB11367,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefroxadine.,Cefroxadine
DB11935,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Flomoxef.,Flomoxef
DB13266,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefatrizine.,Cefatrizine
DB13461,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefcapene.,Cefcapene
DB13470,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefodizime.,Cefodizime
DB13499,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefsulodin.,Cefsulodin
DB13504,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefetamet.,Cefetamet
DB13638,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefbuperazone.,Cefbuperazone
DB13667,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefozopran.,Cefozopran
DB13682,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefpirome.,Cefpirome
DB13778,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefazedone.,Cefazedone
DB13821,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Ceftezole.,Ceftezole
DB14725,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Cefamandole nafate.,Cefamandole nafate
DB00254,The risk or severity of bleeding can be increased when Doxycycline is combined with Streptokinase.,Doxycycline
DB00207,The risk or severity of adverse effects can be increased when Azithromycin is combined with Streptokinase.,Azithromycin
DB09539,The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Streptokinase.,Omega-3-acid ethyl esters
DB00212,Streptokinase may increase the hypotensive activities of Remikiren.,Remikiren
DB00217,Streptokinase may increase the hypotensive activities of Bethanidine.,Bethanidine
DB00226,Streptokinase may increase the hypotensive activities of Guanadrel.,Guanadrel
DB00559,Streptokinase may increase the hypotensive activities of Bosentan.,Bosentan
DB00606,Streptokinase may increase the hypotensive activities of Cyclothiazide.,Cyclothiazide
DB00616,Streptokinase may increase the hypotensive activities of Candoxatril.,Candoxatril
DB00629,Streptokinase may increase the hypotensive activities of Guanabenz.,Guanabenz
DB00765,Streptokinase may increase the hypotensive activities of Metyrosine.,Metyrosine
DB00785,Streptokinase may increase the hypotensive activities of Cryptenamine.,Cryptenamine
DB00820,Streptokinase may increase the hypotensive activities of Tadalafil.,Tadalafil
DB00866,Streptokinase may increase the hypotensive activities of Alprenolol.,Alprenolol
DB01021,Streptokinase may increase the hypotensive activities of Trichlormethiazide.,Trichlormethiazide
DB01089,Streptokinase may increase the hypotensive activities of Deserpidine.,Deserpidine
DB01090,Streptokinase may increase the hypotensive activities of Pentolinium.,Pentolinium
DB01116,Streptokinase may increase the hypotensive activities of Trimethaphan.,Trimethaphan
DB01170,Streptokinase may increase the hypotensive activities of Guanethidine.,Guanethidine
DB01295,Streptokinase may increase the hypotensive activities of Bevantolol.,Bevantolol
DB01297,Streptokinase may increase the hypotensive activities of Practolol.,Practolol
DB01324,Streptokinase may increase the hypotensive activities of Polythiazide.,Polythiazide
DB01388,Streptokinase may increase the hypotensive activities of Mibefradil.,Mibefradil
DB03322,Streptokinase may increase the hypotensive activities of Dexpropranolol.,Dexpropranolol
DB04831,Streptokinase may increase the hypotensive activities of Tienilic acid.,Tienilic acid
DB04840,Streptokinase may increase the hypotensive activities of Debrisoquine.,Debrisoquine
DB04846,Streptokinase may increase the hypotensive activities of Celiprolol.,Celiprolol
DB06268,Streptokinase may increase the hypotensive activities of Sitaxentan.,Sitaxentan
DB06403,Streptokinase may increase the hypotensive activities of Ambrisentan.,Ambrisentan
DB06445,Streptokinase may increase the hypotensive activities of Diethylnorspermine.,Diethylnorspermine
DB06762,Streptokinase may increase the hypotensive activities of Pinacidil.,Pinacidil
DB08808,Streptokinase may increase the hypotensive activities of Bupranolol.,Bupranolol
DB08932,Streptokinase may increase the hypotensive activities of Macitentan.,Macitentan
DB08952,Streptokinase may increase the hypotensive activities of Indenolol.,Indenolol
DB08960,Streptokinase may increase the hypotensive activities of Hexamethonium.,Hexamethonium
DB09206,Streptokinase may increase the hypotensive activities of Trimazosin.,Trimazosin
DB09238,Streptokinase may increase the hypotensive activities of Manidipine.,Manidipine
DB09239,Streptokinase may increase the hypotensive activities of Niguldipine.,Niguldipine
DB09363,Streptokinase may increase the hypotensive activities of Rauwolfia serpentina root.,Rauwolfia serpentina root
DB11362,Streptokinase may increase the hypotensive activities of Selexipag.,Selexipag
DB11720,Streptokinase may increase the hypotensive activities of Angiotensin 1-7.,Angiotensin 1-7
DB11738,Streptokinase may increase the hypotensive activities of Rilmenidine.,Rilmenidine
DB11770,Streptokinase may increase the hypotensive activities of Talinolol.,Talinolol
DB12054,Streptokinase may increase the hypotensive activities of BQ-123.,BQ-123
DB12093,Streptokinase may increase the hypotensive activities of Tetrahydropalmatine.,Tetrahydropalmatine
DB12212,Streptokinase may increase the hypotensive activities of Landiolol.,Landiolol
DB12661,Streptokinase may increase the hypotensive activities of Urapidil.,Urapidil
DB12766,Streptokinase may increase the hypotensive activities of Cicletanine.,Cicletanine
DB12945,Streptokinase may increase the hypotensive activities of Dihydralazine.,Dihydralazine
DB13211,Streptokinase may increase the hypotensive activities of Guanoxan.,Guanoxan
DB13374,Streptokinase may increase the hypotensive activities of Vincamine.,Vincamine
DB13410,Streptokinase may increase the hypotensive activities of Guanoxabenz.,Guanoxabenz
DB13429,Streptokinase may increase the hypotensive activities of Tolonidine.,Tolonidine
DB13435,Streptokinase may increase the hypotensive activities of Endralazine.,Endralazine
DB13443,Streptokinase may increase the hypotensive activities of Esatenolol.,Esatenolol
DB13452,Streptokinase may increase the hypotensive activities of Cadralazine.,Cadralazine
DB13508,Streptokinase may increase the hypotensive activities of Cloranolol.,Cloranolol
DB13532,Streptokinase may increase the hypotensive activities of Cyclopenthiazide.,Cyclopenthiazide
DB13575,Streptokinase may increase the hypotensive activities of Bietaserpine.,Bietaserpine
DB13604,Streptokinase may increase the hypotensive activities of Guanazodine.,Guanazodine
DB13631,Streptokinase may increase the hypotensive activities of Methoserpidine.,Methoserpidine
DB13757,Streptokinase may increase the hypotensive activities of Epanolol.,Epanolol
DB13779,Streptokinase may increase the hypotensive activities of Guanoclor.,Guanoclor
DB13801,Streptokinase may increase the hypotensive activities of Muzolimine.,Muzolimine
DB13803,Streptokinase may increase the hypotensive activities of Xipamide.,Xipamide
DB13919,Streptokinase may increase the hypotensive activities of Candesartan.,Candesartan
DB14068,Streptokinase may increase the hypotensive activities of Dexniguldipine.,Dexniguldipine
DB00945,Acetylsalicylic acid may increase the anticoagulant activities of Streptokinase.,Acetylsalicylic acid
DB01606,The risk or severity of bleeding can be increased when Tazobactam is combined with Streptokinase.,Tazobactam
DB00199,The risk or severity of bleeding can be increased when Erythromycin is combined with Streptokinase.,Erythromycin
DB00656,The risk or severity of bleeding can be increased when Trazodone is combined with Streptokinase.,Trazodone
DB00620,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Triamcinolone.,Triamcinolone
DB09079,The risk or severity of bleeding can be increased when Streptokinase is combined with Nintedanib.,Nintedanib
DB01175,The risk or severity of bleeding can be increased when Escitalopram is combined with Streptokinase.,Escitalopram
DB01104,The risk or severity of bleeding can be increased when Sertraline is combined with Streptokinase.,Sertraline
DB00562,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Benzthiazide.,Benzthiazide
DB13430,The therapeutic efficacy of Streptokinase can be decreased when used in combination with Mebutizide.,Mebutizide
DB06643,The risk or severity of adverse effects can be increased when Denosumab is combined with Alemtuzumab.,Denosumab
DB00005,The risk or severity of adverse effects can be increased when Etanercept is combined with Alemtuzumab.,Etanercept
DB00008,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Alemtuzumab.,Peginterferon alfa-2a
DB00011,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Alemtuzumab.,Interferon alfa-n1
DB00018,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Alemtuzumab.,Interferon alfa-n3
DB00022,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Alemtuzumab.,Peginterferon alfa-2b
DB00026,The risk or severity of adverse effects can be increased when Anakinra is combined with Alemtuzumab.,Anakinra
DB00033,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Alemtuzumab.,Interferon gamma-1b
DB00034,"The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Alemtuzumab.","Interferon alfa-2a, Recombinant"
DB00041,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Alemtuzumab.,Aldesleukin
DB00051,The risk or severity of adverse effects can be increased when Adalimumab is combined with Alemtuzumab.,Adalimumab
DB00056,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Alemtuzumab.,Gemtuzumab ozogamicin
DB00059,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Alemtuzumab.,Pegaspargase
DB00065,The risk or severity of adverse effects can be increased when Infliximab is combined with Alemtuzumab.,Infliximab
DB00068,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Alemtuzumab.,Interferon beta-1b
DB00069,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Alemtuzumab.,Interferon alfacon-1
DB00073,The risk or severity of adverse effects can be increased when Rituximab is combined with Alemtuzumab.,Rituximab
DB00074,The risk or severity of adverse effects can be increased when Basiliximab is combined with Alemtuzumab.,Basiliximab
DB00075,The risk or severity of adverse effects can be increased when Muromonab is combined with Alemtuzumab.,Muromonab
DB00078,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Alemtuzumab.,Ibritumomab tiuxetan
DB00081,The risk or severity of adverse effects can be increased when Tositumomab is combined with Alemtuzumab.,Tositumomab
DB00092,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Alefacept.,Alefacept
DB00095,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Efalizumab.,Efalizumab
DB00098,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Antithymocyte immunoglobulin (rabbit).,Antithymocyte immunoglobulin (rabbit)
DB00105,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Interferon alfa-2b.,Interferon alfa-2b
DB00111,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Daclizumab.,Daclizumab
DB00112,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bevacizumab.,Bevacizumab
DB00120,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Phenylalanine.,Phenylalanine
DB00180,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Flunisolide.,Flunisolide
DB00188,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bortezomib.,Bortezomib
DB00242,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cladribine.,Cladribine
DB00262,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Carmustine.,Carmustine
DB00276,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Amsacrine.,Amsacrine
DB00290,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bleomycin.,Bleomycin
DB00291,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Chlorambucil.,Chlorambucil
DB00293,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Raltitrexed.,Raltitrexed
DB00305,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mitomycin.,Mitomycin
DB00307,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bexarotene.,Bexarotene
DB00309,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Vindesine.,Vindesine
DB00322,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Floxuridine.,Floxuridine
DB00328,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Indomethacin.,Indomethacin
DB00352,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tioguanine.,Tioguanine
DB00361,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Vinorelbine.,Vinorelbine
DB00380,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dexrazoxane.,Dexrazoxane
DB00394,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Beclomethasone dipropionate.,Beclomethasone dipropionate
DB00398,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sorafenib.,Sorafenib
DB00428,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Streptozocin.,Streptozocin
DB00432,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Trifluridine.,Trifluridine
DB00441,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Gemcitabine.,Gemcitabine
DB00443,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Betamethasone.,Betamethasone
DB00444,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Teniposide.,Teniposide
DB00445,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Epirubicin.,Epirubicin
DB00446,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Chloramphenicol.,Chloramphenicol
DB00480,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lenalidomide.,Lenalidomide
DB00488,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Altretamine.,Altretamine
DB00495,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Zidovudine.,Zidovudine
DB00515,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cisplatin.,Cisplatin
DB00526,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Oxaliplatin.,Oxaliplatin
DB00531,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cyclophosphamide.,Cyclophosphamide
DB00541,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Vincristine.,Vincristine
DB00544,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fluorouracil.,Fluorouracil
DB00550,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Propylthiouracil.,Propylthiouracil
DB00552,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pentostatin.,Pentostatin
DB00563,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Methotrexate.,Methotrexate
DB00564,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Carbamazepine.,Carbamazepine
DB00570,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Vinblastine.,Vinblastine
DB00588,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fluticasone propionate.,Fluticasone propionate
DB00591,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fluocinolone acetonide.,Fluocinolone acetonide
DB00601,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Linezolid.,Linezolid
DB00619,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Imatinib.,Imatinib
DB00620,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Triamcinolone.,Triamcinolone
DB00631,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Clofarabine.,Clofarabine
DB00635,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Prednisone.,Prednisone
DB00642,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pemetrexed.,Pemetrexed
DB00687,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fludrocortisone.,Fludrocortisone
DB00688,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mycophenolate mofetil.,Mycophenolate mofetil
DB00694,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Daunorubicin.,Daunorubicin
DB00755,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tretinoin.,Tretinoin
DB00762,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Irinotecan.,Irinotecan
DB00763,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Methimazole.,Methimazole
DB00764,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mometasone.,Mometasone
DB00773,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Etoposide.,Etoposide
DB00795,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sulfasalazine.,Sulfasalazine
DB00851,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dacarbazine.,Dacarbazine
DB00853,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Temozolomide.,Temozolomide
DB00859,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Penicillamine.,Penicillamine
DB00860,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Prednisolone.,Prednisolone
DB00877,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sirolimus.,Sirolimus
DB00888,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mechlorethamine.,Mechlorethamine
DB00928,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Azacitidine.,Azacitidine
DB00958,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Carboplatin.,Carboplatin
DB00959,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Methylprednisolone.,Methylprednisolone
DB00970,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dactinomycin.,Dactinomycin
DB00987,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cytarabine.,Cytarabine
DB00993,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Azathioprine.,Azathioprine
DB00997,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Doxorubicin.,Doxorubicin
DB01005,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Hydroxyurea.,Hydroxyurea
DB01008,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Busulfan.,Busulfan
DB01024,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mycophenolic acid.,Mycophenolic acid
DB01030,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Topotecan.,Topotecan
DB01033,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mercaptopurine.,Mercaptopurine
DB01041,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Thalidomide.,Thalidomide
DB01042,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Melphalan.,Melphalan
DB01073,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fludarabine.,Fludarabine
DB01099,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Flucytosine.,Flucytosine
DB01101,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Capecitabine.,Capecitabine
DB01108,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Trilostane.,Trilostane
DB01168,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Procarbazine.,Procarbazine
DB01169,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Arsenic trioxide.,Arsenic trioxide
DB01177,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Idarubicin.,Idarubicin
DB01181,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ifosfamide.,Ifosfamide
DB01196,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Estramustine.,Estramustine
DB01204,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mitoxantrone.,Mitoxantrone
DB01206,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lomustine.,Lomustine
DB01222,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Budesonide.,Budesonide
DB01229,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Paclitaxel.,Paclitaxel
DB01234,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dexamethasone.,Dexamethasone
DB01248,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Docetaxel.,Docetaxel
DB01254,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dasatinib.,Dasatinib
DB01257,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Eculizumab.,Eculizumab
DB01262,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Decitabine.,Decitabine
DB01268,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sunitinib.,Sunitinib
DB01280,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Nelarabine.,Nelarabine
DB01281,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Abatacept.,Abatacept
DB01285,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Corticotropin.,Corticotropin
DB01380,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cortisone acetate.,Cortisone acetate
DB01384,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Paramethasone.,Paramethasone
DB01394,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Colchicine.,Colchicine
DB01410,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ciclesonide.,Ciclesonide
DB01423,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Stepronin.,Stepronin
DB01590,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Everolimus.,Everolimus
DB01611,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Hydroxychloroquine.,Hydroxychloroquine
DB01816,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Castanospermine.,Castanospermine
DB02546,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Vorinostat.,Vorinostat
DB02806,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with 2-Methoxyethanol.,2-Methoxyethanol
DB03523,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Brequinar.,Brequinar
DB04572,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Thiotepa.,Thiotepa
DB04630,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Aldosterone.,Aldosterone
DB04845,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ixabepilone.,Ixabepilone
DB04868,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Nilotinib.,Nilotinib
DB04951,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pirfenidone.,Pirfenidone
DB04956,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Afelimomab.,Afelimomab
DB05015,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Belinostat.,Belinostat
DB05109,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Trabectedin.,Trabectedin
DB05258,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Interferon alfa.,Interferon alfa
DB05259,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Glatiramer.,Glatiramer
DB05260,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Gallium nitrate.,Gallium nitrate
DB05459,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Briakinumab.,Briakinumab
DB05472,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with omega interferon.,omega interferon
DB05676,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Apremilast.,Apremilast
DB05773,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Trastuzumab emtansine.,Trastuzumab emtansine
DB06168,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Canakinumab.,Canakinumab
DB06273,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tocilizumab.,Tocilizumab
DB06287,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Temsirolimus.,Temsirolimus
DB06372,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Rilonacept.,Rilonacept
DB06589,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pazopanib.,Pazopanib
DB06603,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Panobinostat.,Panobinostat
DB06612,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mepolizumab.,Mepolizumab
DB06616,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bosutinib.,Bosutinib
DB06662,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Abetimus.,Abetimus
DB06674,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Golimumab.,Golimumab
DB06681,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Belatacept.,Belatacept
DB06769,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bendamustine.,Bendamustine
DB06772,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cabazitaxel.,Cabazitaxel
DB06813,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pralatrexate.,Pralatrexate
DB08059,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Wortmannin.,Wortmannin
DB08870,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Brentuximab vedotin.,Brentuximab vedotin
DB08871,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Eribulin.,Eribulin
DB08877,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ruxolitinib.,Ruxolitinib
DB08879,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Belimumab.,Belimumab
DB08880,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Teriflunomide.,Teriflunomide
DB08889,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Carfilzomib.,Carfilzomib
DB08901,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ponatinib.,Ponatinib
DB08904,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Certolizumab pegol.,Certolizumab pegol
DB08906,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fluticasone furoate.,Fluticasone furoate
DB08908,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dimethyl fumarate.,Dimethyl fumarate
DB08910,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pomalidomide.,Pomalidomide
DB08935,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Obinutuzumab.,Obinutuzumab
DB08970,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fluprednidene.,Fluprednidene
DB08971,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fluocortolone.,Fluocortolone
DB09029,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Secukinumab.,Secukinumab
DB09033,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Vedolizumab.,Vedolizumab
DB09036,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Siltuximab.,Siltuximab
DB09052,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Blinatumomab.,Blinatumomab
DB09053,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ibrutinib.,Ibrutinib
DB09054,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Idelalisib.,Idelalisib
DB09073,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Palbociclib.,Palbociclib
DB09074,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Olaparib.,Olaparib
DB09077,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dinutuximab.,Dinutuximab
DB09082,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Vilanterol.,Vilanterol
DB09091,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tixocortol.,Tixocortol
DB09122,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Peginterferon beta-1a.,Peginterferon beta-1a
DB09312,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Antilymphocyte immunoglobulin (horse).,Antilymphocyte immunoglobulin (horse)
DB09378,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fluprednisolone.,Fluprednisolone
DB09383,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Meprednisone.,Meprednisone
DB11466,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tepoxalin.,Tepoxalin
DB11487,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dexamethasone isonicotinate.,Dexamethasone isonicotinate
DB11529,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Melengestrol.,Melengestrol
DB11569,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ixekizumab.,Ixekizumab
DB11580,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ravulizumab.,Ravulizumab
DB11616,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pirarubicin.,Pirarubicin
DB11693,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Voclosporin.,Voclosporin
DB11708,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Peficitinib.,Peficitinib
DB11750,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Clobetasol.,Clobetasol
DB11767,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sarilumab.,Sarilumab
DB11776,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Brodalumab.,Brodalumab
DB11803,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sirukumab.,Sirukumab
DB11817,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Baricitinib.,Baricitinib
DB11834,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Guselkumab.,Guselkumab
DB11921,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Deflazacort.,Deflazacort
DB12025,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Triptolide.,Triptolide
DB12371,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Siponimod.,Siponimod
DB12612,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ozanimod.,Ozanimod
DB12617,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mizoribine.,Mizoribine
DB12692,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Gusperimus.,Gusperimus
DB12814,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cepeginterferon alfa-2B.,Cepeginterferon alfa-2B
DB12902,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Trofosfamide.,Trofosfamide
DB12947,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Doxifluridine.,Doxifluridine
DB12991,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Deoxyspergualin.,Deoxyspergualin
DB12996,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Acteoside.,Acteoside
DB13003,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cortivazol.,Cortivazol
DB13014,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Hypericin.,Hypericin
DB13068,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.,9-(N-methyl-L-isoleucine)-cyclosporin A
DB13208,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Prednylidene.,Prednylidene
DB13223,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fluocortin.,Fluocortin
DB13241,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Begelomab.,Begelomab
DB13491,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fluperolone.,Fluperolone
DB13664,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Formocortal.,Formocortal
DB13728,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Halometasone.,Halometasone
DB13843,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cloprednol.,Cloprednol
DB13856,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fluclorolone.,Fluclorolone
DB13867,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fluticasone.,Fluticasone
DB14066,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tetrandrine.,Tetrandrine
DB14219,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Monomethyl fumarate.,Monomethyl fumarate
DB14512,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mometasone furoate.,Mometasone furoate
DB14538,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Hydrocortisone aceponate.,Hydrocortisone aceponate
DB14539,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Hydrocortisone acetate.,Hydrocortisone acetate
DB14545,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Hydrocortisone succinate.,Hydrocortisone succinate
DB14724,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Emapalumab.,Emapalumab
DB14762,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Risankizumab.,Risankizumab
DB14919,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Rozanolixizumab.,Rozanolixizumab
DB15253,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bleselumab.,Bleselumab
DB00108,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Natalizumab.,Natalizumab
DB00337,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Alemtuzumab.,Pimecrolimus
DB01656,Roflumilast may increase the immunosuppressive activities of Alemtuzumab.,Roflumilast
DB06688,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Alemtuzumab.,Sipuleucel-T
DB00363,The risk or severity of neutropenia can be increased when Alemtuzumab is combined with Clozapine.,Clozapine
DB00012,The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Alemtuzumab.,Darbepoetin alfa
DB00016,The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Alemtuzumab.,Erythropoietin
DB08894,The risk or severity of Thrombosis can be increased when Peginesatide is combined with Alemtuzumab.,Peginesatide
DB09107,The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Alemtuzumab.,Methoxy polyethylene glycol-epoetin beta
DB01015,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Alemtuzumab.,Sulfamethoxazole
DB00255,Diethylstilbestrol may increase the thrombogenic activities of Alemtuzumab.,Diethylstilbestrol
DB00269,Chlorotrianisene may increase the thrombogenic activities of Alemtuzumab.,Chlorotrianisene
DB00286,Conjugated estrogens may increase the thrombogenic activities of Alemtuzumab.,Conjugated estrogens
DB00655,Estrone may increase the thrombogenic activities of Alemtuzumab.,Estrone
DB00783,Estradiol may increase the thrombogenic activities of Alemtuzumab.,Estradiol
DB00890,Dienestrol may increase the thrombogenic activities of Alemtuzumab.,Dienestrol
DB00977,Ethinylestradiol may increase the thrombogenic activities of Alemtuzumab.,Ethinylestradiol
DB01357,Mestranol may increase the thrombogenic activities of Alemtuzumab.,Mestranol
DB04573,Estriol may increase the thrombogenic activities of Alemtuzumab.,Estriol
DB04574,Estrone sulfate may increase the thrombogenic activities of Alemtuzumab.,Estrone sulfate
DB04575,Quinestrol may increase the thrombogenic activities of Alemtuzumab.,Quinestrol
DB07931,Hexestrol may increase the thrombogenic activities of Alemtuzumab.,Hexestrol
DB09070,Tibolone may increase the thrombogenic activities of Alemtuzumab.,Tibolone
DB09317,"Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Alemtuzumab.","Synthetic Conjugated Estrogens, A"
DB09318,"Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Alemtuzumab.","Synthetic Conjugated Estrogens, B"
DB09369,Polyestradiol phosphate may increase the thrombogenic activities of Alemtuzumab.,Polyestradiol phosphate
DB09381,Esterified estrogens may increase the thrombogenic activities of Alemtuzumab.,Esterified estrogens
DB11478,Zeranol may increase the thrombogenic activities of Alemtuzumab.,Zeranol
DB11674,Equol may increase the thrombogenic activities of Alemtuzumab.,Equol
DB12487,Promestriene may increase the thrombogenic activities of Alemtuzumab.,Promestriene
DB13143,Methallenestril may increase the thrombogenic activities of Alemtuzumab.,Methallenestril
DB13386,Epimestrol may increase the thrombogenic activities of Alemtuzumab.,Epimestrol
DB13418,Moxestrol may increase the thrombogenic activities of Alemtuzumab.,Moxestrol
DB13952,Estradiol acetate may increase the thrombogenic activities of Alemtuzumab.,Estradiol acetate
DB13953,Estradiol benzoate may increase the thrombogenic activities of Alemtuzumab.,Estradiol benzoate
DB13954,Estradiol cypionate may increase the thrombogenic activities of Alemtuzumab.,Estradiol cypionate
DB13956,Estradiol valerate may increase the thrombogenic activities of Alemtuzumab.,Estradiol valerate
DB15334,Biochanin A may increase the thrombogenic activities of Alemtuzumab.,Biochanin A
DB15335,Formononetin may increase the thrombogenic activities of Alemtuzumab.,Formononetin
DB01097,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Leflunomide.,Leflunomide
DB08895,Alemtuzumab may increase the immunosuppressive activities of Tofacitinib.,Tofacitinib
DB00072,Trastuzumab may increase the neutropenic activities of Alemtuzumab.,Trastuzumab
DB08868,Alemtuzumab may increase the immunosuppressive activities of Fingolimod.,Fingolimod
DB00864,Tacrolimus may increase the immunosuppressive activities of Alemtuzumab.,Tacrolimus
DB04914,The therapeutic efficacy of G17DT can be decreased when used in combination with Alemtuzumab.,G17DT
DB05144,The therapeutic efficacy of PEV3A can be decreased when used in combination with Alemtuzumab.,PEV3A
DB05325,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Alemtuzumab.,INGN 225
DB05374,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Alemtuzumab.,Rindopepimut
DB05440,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Alemtuzumab.,SRP 299
DB05942,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Alemtuzumab.,GI-5005
DB06400,The therapeutic efficacy of Vitespen can be decreased when used in combination with Alemtuzumab.,Vitespen
DB06584,The therapeutic efficacy of TG4010 can be decreased when used in combination with Alemtuzumab.,TG4010
DB09057,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Alemtuzumab.,Anthrax immune globulin human
DB10062,"The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Alemtuzumab.","Rabies virus inactivated antigen, B"
DB10076,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Alemtuzumab.,Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen
DB10276,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Alemtuzumab.,Rotavirus vaccine
DB10283,"The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Alemtuzumab.","Rabies virus inactivated antigen, A"
DB10342,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Alemtuzumab.,Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen
DB10583,The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Alemtuzumab.,Clostridium tetani toxoid antigen (formaldehyde inactivated)
DB10584,The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Alemtuzumab.,Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
DB10600,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Alemtuzumab.,Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated)
DB10769,The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Alemtuzumab.,Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)
DB10794,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Alemtuzumab.,Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated)
DB10803,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Alemtuzumab.,Typhoid Vi polysaccharide vaccine
DB10989,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Alemtuzumab.,Hepatitis A Vaccine
DB10990,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Alemtuzumab.,Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
DB11038,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Alemtuzumab.,Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated)
DB11040,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Alemtuzumab.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated)
DB11041,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Alemtuzumab.,Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)
DB11044,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Alemtuzumab.,Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated)
DB11603,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Alemtuzumab.,Human rabies virus immune globulin
DB11627,The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Alemtuzumab.,Hepatitis B Vaccine (Recombinant)
DB12568,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Alemtuzumab.,Tecemotide
DB14022,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Alemtuzumab.,Typhoid vaccine
DB14384,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Alemtuzumab.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated)
DB14385,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Alemtuzumab.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)
DB14394,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Alemtuzumab.,Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen
DB14445,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Alemtuzumab.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated)
DB14449,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Alemtuzumab.,Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen
DB14619,The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Alemtuzumab.,Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated)
DB14620,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Alemtuzumab.,Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated)
DB14711,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Alemtuzumab.,Vaccinia virus strain new york city board of health live antigen
DB15274,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Alemtuzumab.,Pertussis vaccine
DB15461,The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Alemtuzumab.,Yersinia pestis 195/p antigen (formaldehyde inactivated)
DB13924,The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Alemtuzumab.,Varicella Zoster Vaccine (Recombinant)
DB15483,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Alemtuzumab.,Modified vaccinia ankara
DB00063,The risk or severity of bleeding can be increased when Eptifibatide is combined with Alemtuzumab.,Eptifibatide
DB00208,The risk or severity of bleeding can be increased when Ticlopidine is combined with Alemtuzumab.,Ticlopidine
DB00261,The risk or severity of bleeding can be increased when Anagrelide is combined with Alemtuzumab.,Anagrelide
DB00758,The risk or severity of bleeding can be increased when Clopidogrel is combined with Alemtuzumab.,Clopidogrel
DB00775,The risk or severity of bleeding can be increased when Tirofiban is combined with Alemtuzumab.,Tirofiban
DB00806,The risk or severity of bleeding can be increased when Pentoxifylline is combined with Alemtuzumab.,Pentoxifylline
DB00945,The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Alemtuzumab.,Acetylsalicylic acid
DB00975,The risk or severity of bleeding can be increased when Dipyridamole is combined with Alemtuzumab.,Dipyridamole
DB01088,The risk or severity of bleeding can be increased when Iloprost is combined with Alemtuzumab.,Iloprost
DB01138,The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Alemtuzumab.,Sulfinpyrazone
DB01166,The risk or severity of bleeding can be increased when Cilostazol is combined with Alemtuzumab.,Cilostazol
DB01207,The risk or severity of bleeding can be increased when Ridogrel is combined with Alemtuzumab.,Ridogrel
DB01236,The risk or severity of bleeding can be increased when Sevoflurane is combined with Alemtuzumab.,Sevoflurane
DB01240,The risk or severity of bleeding can be increased when Epoprostenol is combined with Alemtuzumab.,Epoprostenol
DB02709,The risk or severity of bleeding can be increased when Resveratrol is combined with Alemtuzumab.,Resveratrol
DB04743,The risk or severity of bleeding can be increased when Nimesulide is combined with Alemtuzumab.,Nimesulide
DB04905,The risk or severity of bleeding can be increased when Tesmilifene is combined with Alemtuzumab.,Tesmilifene
DB04932,The risk or severity of bleeding can be increased when Defibrotide is combined with Alemtuzumab.,Defibrotide
DB05229,The risk or severity of bleeding can be increased when Beraprost is combined with Alemtuzumab.,Beraprost
DB05266,The risk or severity of bleeding can be increased when Ibudilast is combined with Alemtuzumab.,Ibudilast
DB05767,The risk or severity of bleeding can be increased when Andrographolide is combined with Alemtuzumab.,Andrographolide
DB06209,The risk or severity of bleeding can be increased when Prasugrel is combined with Alemtuzumab.,Prasugrel
DB06441,The risk or severity of bleeding can be increased when Cangrelor is combined with Alemtuzumab.,Cangrelor
DB07615,The risk or severity of bleeding can be increased when Tranilast is combined with Alemtuzumab.,Tranilast
DB08814,The risk or severity of bleeding can be increased when Triflusal is combined with Alemtuzumab.,Triflusal
DB08816,The risk or severity of bleeding can be increased when Ticagrelor is combined with Alemtuzumab.,Ticagrelor
DB08887,The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Alemtuzumab.,Icosapent ethyl
DB09030,The risk or severity of bleeding can be increased when Vorapaxar is combined with Alemtuzumab.,Vorapaxar
DB09283,The risk or severity of bleeding can be increased when Trapidil is combined with Alemtuzumab.,Trapidil
DB12092,The risk or severity of bleeding can be increased when Naftopidil is combined with Alemtuzumab.,Naftopidil
DB12163,The risk or severity of bleeding can be increased when Sarpogrelate is combined with Alemtuzumab.,Sarpogrelate
DB12321,The risk or severity of bleeding can be increased when Ifetroban is combined with Alemtuzumab.,Ifetroban
DB12445,The risk or severity of bleeding can be increased when Nitroaspirin is combined with Alemtuzumab.,Nitroaspirin
DB12465,The risk or severity of bleeding can be increased when Ketanserin is combined with Alemtuzumab.,Ketanserin
DB12545,The risk or severity of bleeding can be increased when Indobufen is combined with Alemtuzumab.,Indobufen
DB12749,The risk or severity of bleeding can be increased when Butylphthalide is combined with Alemtuzumab.,Butylphthalide
DB12771,The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Alemtuzumab.,Hydroxytyrosol
DB13036,The risk or severity of bleeding can be increased when Ramatroban is combined with Alemtuzumab.,Ramatroban
DB13327,The risk or severity of bleeding can be increased when Picotamide is combined with Alemtuzumab.,Picotamide
DB13367,The risk or severity of bleeding can be increased when Cloricromen is combined with Alemtuzumab.,Cloricromen
DB13400,The risk or severity of bleeding can be increased when Linsidomine is combined with Alemtuzumab.,Linsidomine
DB13510,The risk or severity of bleeding can be increased when Buflomedil is combined with Alemtuzumab.,Buflomedil
DB13929,The risk or severity of bleeding can be increased when Relcovaptan is combined with Alemtuzumab.,Relcovaptan
DB11988,Ocrelizumab may increase the immunosuppressive activities of Alemtuzumab.,Ocrelizumab
DB13200,Alemtuzumab may increase the myelosuppressive activities of Lipegfilgrastim.,Lipegfilgrastim
DB10317,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Alemtuzumab.,Rubella virus vaccine
DB10318,The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Alemtuzumab.,Varicella Zoster Vaccine (Live/attenuated)
DB10343,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Alemtuzumab.,Bacillus calmette-guerin substrain tice live antigen
DB10804,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Alemtuzumab.,Bacillus calmette-guerin substrain connaught live antigen
DB10805,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Alemtuzumab.,Yellow Fever Vaccine
DB11003,The risk or severity of infection can be increased when Anthrax vaccine is combined with Alemtuzumab.,Anthrax vaccine
DB11050,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Alemtuzumab.,Typhoid Vaccine Live
DB12386,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Alemtuzumab.,Bacillus calmette-guerin substrain danish 1331 live antigen
DB12768,The risk or severity of infection can be increased when BCG vaccine is combined with Alemtuzumab.,BCG vaccine
DB14409,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Alemtuzumab.,Human adenovirus e serotype 4 strain cl-68578 antigen
DB14443,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Alemtuzumab.,Vibrio cholerae CVD 103-HgR strain live antigen
DB14685,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Alemtuzumab.,Adenovirus type 7 vaccine live
DB00002,The risk or severity of adverse effects can be increased when Cetuximab is combined with Alemtuzumab.,Cetuximab
DB00028,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Alemtuzumab.,Human immunoglobulin G
DB00043,The risk or severity of adverse effects can be increased when Omalizumab is combined with Alemtuzumab.,Omalizumab
DB00054,The risk or severity of adverse effects can be increased when Abciximab is combined with Alemtuzumab.,Abciximab
DB00057,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Alemtuzumab.,Indium In-111 satumomab pendetide
DB00076,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Alemtuzumab.,Digoxin Immune Fab (Ovine)
DB00089,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Capromab pendetide.,Capromab pendetide
DB00110,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Palivizumab.,Palivizumab
DB00113,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Technetium Tc-99m arcitumomab.,Technetium Tc-99m arcitumomab
DB01269,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Panitumumab.,Panitumumab
DB01270,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ranibizumab.,Ranibizumab
DB04901,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Galiximab.,Galiximab
DB04949,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pexelizumab.,Pexelizumab
DB04958,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Epratuzumab.,Epratuzumab
DB04962,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bectumomab.,Bectumomab
DB04964,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Oregovomab.,Oregovomab
DB04988,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with IGN311.,IGN311
DB05006,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Adecatumumab.,Adecatumumab
DB05097,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Labetuzumab.,Labetuzumab
DB05101,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Matuzumab.,Matuzumab
DB05111,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fontolizumab.,Fontolizumab
DB05136,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bavituximab.,Bavituximab
DB05139,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with CR002.,CR002
DB05209,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Rozrolimupab.,Rozrolimupab
DB05304,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Girentuximab.,Girentuximab
DB05336,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Obiltoxaximab.,Obiltoxaximab
DB05405,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with XTL-001.,XTL-001
DB05437,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with NAV 1800.,NAV 1800
DB05496,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Otelixizumab.,Otelixizumab
DB05545,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with AMG 108.,AMG 108
DB05550,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Iratumumab.,Iratumumab
DB05555,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Enokizumab.,Enokizumab
DB05578,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ramucirumab.,Ramucirumab
DB05595,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Farletuzumab.,Farletuzumab
DB05656,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Veltuzumab.,Veltuzumab
DB05793,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with PRO-542.,PRO-542
DB05797,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with TNX-901.,TNX-901
DB05889,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Inotuzumab ozogamicin.,Inotuzumab ozogamicin
DB05892,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with RI 624.,RI 624
DB05915,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with MYO-029.,MYO-029
DB05916,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with CT-011.,CT-011
DB05941,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Leronlimab.,Leronlimab
DB05996,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Glembatumumab vedotin.,Glembatumumab vedotin
DB06043,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Olaratumab.,Olaratumab
DB06049,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with IPH 2101.,IPH 2101
DB06050,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with TB-402.,TB-402
DB06081,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Caplacizumab.,Caplacizumab
DB06101,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with IMC-1C11.,IMC-1C11
DB06116,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Eldelumab.,Eldelumab
DB06162,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lumiliximab.,Lumiliximab
DB06186,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ipilimumab.,Ipilimumab
DB06192,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Nimotuzumab.,Nimotuzumab
DB06241,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Clenoliximab.,Clenoliximab
DB06304,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with BIIB015.,BIIB015
DB06305,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sonepcizumab.,Sonepcizumab
DB06310,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Motavizumab.,Motavizumab
DB06317,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Elotuzumab.,Elotuzumab
DB06318,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with AVE9633.,AVE9633
DB06322,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Carotuximab.,Carotuximab
DB06324,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with XmAb 2513.,XmAb 2513
DB06342,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Coltuximab ravtansine.,Coltuximab ravtansine
DB06343,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Teprotumumab.,Teprotumumab
DB06360,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lucatumumab.,Lucatumumab
DB06366,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pertuzumab.,Pertuzumab
DB06371,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Siplizumab.,Siplizumab
DB06467,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Apolizumab.,Apolizumab
DB06474,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sibrotuzumab.,Sibrotuzumab
DB06550,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bivatuzumab.,Bivatuzumab
DB06557,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lerdelimumab.,Lerdelimumab
DB06599,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lexatumumab.,Lexatumumab
DB06602,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Reslizumab.,Reslizumab
DB06606,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Teplizumab.,Teplizumab
DB06607,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Catumaxomab.,Catumaxomab
DB06647,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Volociximab.,Volociximab
DB06650,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ofatumumab.,Ofatumumab
DB08902,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Raxibacumab.,Raxibacumab
DB09035,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Nivolumab.,Nivolumab
DB09037,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pembrolizumab.,Pembrolizumab
DB09045,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dulaglutide.,Dulaglutide
DB09105,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Asfotase alfa.,Asfotase alfa
DB09264,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Idarucizumab.,Idarucizumab
DB09302,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Alirocumab.,Alirocumab
DB09303,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Evolocumab.,Evolocumab
DB09331,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Daratumumab.,Daratumumab
DB09559,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Necitumumab.,Necitumumab
DB11595,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Atezolizumab.,Atezolizumab
DB11604,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tetanus Immune Globulin.,Tetanus Immune Globulin
DB11608,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Eftrenonacog alfa.,Eftrenonacog alfa
DB11621,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Human Varicella-Zoster Immune Globulin.,Human Varicella-Zoster Immune Globulin
DB11646,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Conatumumab.,Conatumumab
DB11657,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tabalumab.,Tabalumab
DB11680,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ficlatuzumab.,Ficlatuzumab
DB11685,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Figitumumab.,Figitumumab
DB11714,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Durvalumab.,Durvalumab
DB11715,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bapineuzumab.,Bapineuzumab
DB11731,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Depatuxizumab mafodotin.,Depatuxizumab mafodotin
DB11746,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Onartuzumab.,Onartuzumab
DB11756,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Solanezumab.,Solanezumab
DB11771,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tremelimumab.,Tremelimumab
DB11826,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lampalizumab.,Lampalizumab
DB11840,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dalotuzumab.,Dalotuzumab
DB11849,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Emibetuzumab.,Emibetuzumab
DB11850,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ublituximab.,Ublituximab
DB11856,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ligelizumab.,Ligelizumab
DB11857,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Seribantumab.,Seribantumab
DB11862,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Landogrozumab.,Landogrozumab
DB11866,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Romosozumab.,Romosozumab
DB11884,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Vadastuximab Talirine.,Vadastuximab Talirine
DB11914,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lebrikizumab.,Lebrikizumab
DB11930,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Varlilumab.,Varlilumab
DB11945,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Avelumab.,Avelumab
DB11959,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Crenezumab.,Crenezumab
DB11972,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Rilotumumab.,Rilotumumab
DB11976,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Anifrolumab.,Anifrolumab
DB12023,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Benralizumab.,Benralizumab
DB12034,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Gantenerumab.,Gantenerumab
DB12053,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Visilizumab.,Visilizumab
DB12077,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Urelumab.,Urelumab
DB12089,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lorvotuzumab mertansine.,Lorvotuzumab mertansine
DB12090,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Patritumab.,Patritumab
DB12102,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fulranumab.,Fulranumab
DB12104,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tarextumab.,Tarextumab
DB12118,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sotatercept.,Sotatercept
DB12119,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Gevokizumab.,Gevokizumab
DB12142,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Duligotuzumab.,Duligotuzumab
DB12152,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Simtuzumab.,Simtuzumab
DB12157,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fasinumab.,Fasinumab
DB12159,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dupilumab.,Dupilumab
DB12169,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tralokinumab.,Tralokinumab
DB12189,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Etrolizumab.,Etrolizumab
DB12202,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Zalutumumab.,Zalutumumab
DB12205,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ganitumab.,Ganitumab
DB12213,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Etaracizumab.,Etaracizumab
DB12240,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Polatuzumab vedotin.,Polatuzumab vedotin
DB12246,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Inclacumab.,Inclacumab
DB12250,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cixutumumab.,Cixutumumab
DB12261,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ascrinvacumab.,Ascrinvacumab
DB12274,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Aducanumab.,Aducanumab
DB12281,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Luspatercept.,Luspatercept
DB12296,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with GS-5745.,GS-5745
DB12317,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Vanucizumab.,Vanucizumab
DB12331,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Labetuzumab govitecan.,Labetuzumab govitecan
DB12335,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tanezumab.,Tanezumab
DB12342,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ensituximab.,Ensituximab
DB12344,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fezakinumab.,Fezakinumab
DB12363,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dusigitumab.,Dusigitumab
DB12396,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fresolimumab.,Fresolimumab
DB12413,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Indusatumab vedotin.,Indusatumab vedotin
DB12456,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bococizumab.,Bococizumab
DB12489,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mirvetuximab Soravtansine.,Mirvetuximab Soravtansine
DB12498,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mogamulizumab.,Mogamulizumab
DB12520,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Plozalizumab.,Plozalizumab
DB12534,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mavrilimumab.,Mavrilimumab
DB12560,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Blosozumab.,Blosozumab
DB12584,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bimagrumab.,Bimagrumab
DB12589,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dacetuzumab.,Dacetuzumab
DB12609,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tovetumab.,Tovetumab
DB12683,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lumretuzumab.,Lumretuzumab
DB12698,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ibalizumab.,Ibalizumab
DB12701,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Intetumumab.,Intetumumab
DB12718,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Carlumab.,Carlumab
DB12734,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Demcizumab.,Demcizumab
DB12773,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sifalimumab.,Sifalimumab
DB12775,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Abituzumab.,Abituzumab
DB12797,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ecromeximab.,Ecromeximab
DB12807,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Naptumomab Estafenatox.,Naptumomab Estafenatox
DB12815,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Crotedumab.,Crotedumab
DB12820,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Concizumab.,Concizumab
DB12826,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Depatuxizumab.,Depatuxizumab
DB12844,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Rontalizumab.,Rontalizumab
DB12845,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Amatuximab.,Amatuximab
DB12849,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Clazakizumab.,Clazakizumab
DB12891,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ozanezumab.,Ozanezumab
DB12893,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sacituzumab govitecan.,Sacituzumab govitecan
DB12917,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bimekizumab.,Bimekizumab
DB12943,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Milatuzumab.,Milatuzumab
DB12976,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Robatumumab.,Robatumumab
DB13017,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Rovalpituzumab Tesirine.,Rovalpituzumab Tesirine
DB13037,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Namilumab.,Namilumab
DB13045,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Racotumomab.,Racotumomab
DB13073,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tregalizumab.,Tregalizumab
DB13127,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Olokizumab.,Olokizumab
DB13140,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bezlotoxumab.,Bezlotoxumab
DB13375,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Edrecolomab.,Edrecolomab
DB13535,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Nebacumab.,Nebacumab
DB13886,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Human cytomegalovirus immune globulin.,Human cytomegalovirus immune globulin
DB13923,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Emicizumab.,Emicizumab
DB13976,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sulesomab.,Sulesomab
DB13979,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Besilesomab.,Besilesomab
DB14012,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Burosumab.,Burosumab
DB14039,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Erenumab.,Erenumab
DB14040,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Eptinezumab.,Eptinezumab
DB14041,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fremanezumab.,Fremanezumab
DB14042,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Galcanezumab.,Galcanezumab
DB14211,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fanolesomab.,Fanolesomab
DB14580,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lecanemab.,Lecanemab
DB14597,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lanadelumab.,Lanadelumab
DB14707,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cemiplimab.,Cemiplimab
DB14776,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Camrelizumab.,Camrelizumab
DB14778,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Setrusumab.,Setrusumab
DB14784,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Gancotamab.,Gancotamab
DB14809,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Anetumab ravtansine.,Anetumab ravtansine
DB14811,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Isatuximab.,Isatuximab
DB14824,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Icrucumab.,Icrucumab
DB14843,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Codrituzumab.,Codrituzumab
DB14864,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Brolucizumab.,Brolucizumab
DB14871,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Xentuzumab.,Xentuzumab
DB14877,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lintuzumab.,Lintuzumab
DB14891,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Vobarilizumab.,Vobarilizumab
DB14897,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Parsatuzumab.,Parsatuzumab
DB14905,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Emactuzumab.,Emactuzumab
DB14907,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bevacizumab zirconium Zr-89.,Bevacizumab zirconium Zr-89
DB14908,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Refanezumab.,Refanezumab
DB14947,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bermekimab.,Bermekimab
DB14952,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pamrevlumab.,Pamrevlumab
DB14959,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Opicinumab.,Opicinumab
DB14962,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Trastuzumab deruxtecan.,Trastuzumab deruxtecan
DB14967,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Margetuximab.,Margetuximab
DB14988,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dalantercept.,Dalantercept
DB14997,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pateclizumab.,Pateclizumab
DB15014,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Gremubamab.,Gremubamab
DB15022,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Apomab.,Apomab
DB15044,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tafasitamab.,Tafasitamab
DB15045,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ipafricept.,Ipafricept
DB15076,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Abrilumab.,Abrilumab
DB15089,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Frovocimab.,Frovocimab
DB15090,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tezepelumab.,Tezepelumab
DB15101,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tigatuzumab.,Tigatuzumab
DB15104,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Telisotuzumab vedotin.,Telisotuzumab vedotin
DB15113,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Utomilumab.,Utomilumab
DB15118,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Zolbetuximab.,Zolbetuximab
DB15135,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ponezumab.,Ponezumab
DB15160,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Asunercept.,Asunercept
DB15172,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Suvratoxumab.,Suvratoxumab
DB15225,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mitazalimab.,Mitazalimab
DB15252,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Nemolizumab.,Nemolizumab
DB15277,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Gedivumab.,Gedivumab
DB15336,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Valanafusp alfa.,Valanafusp alfa
DB15349,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sofituzumab vedotin.,Sofituzumab vedotin
DB15354,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Evinacumab.,Evinacumab
DB15363,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Istiratumab.,Istiratumab
DB15383,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pidilizumab.,Pidilizumab
DB15397,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with GMA-161.,GMA-161
DB15409,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ladiratuzumab vedotin.,Ladiratuzumab vedotin
DB15415,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tomaralimab.,Tomaralimab
DB15428,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Vesencumab.,Vesencumab
DB15432,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pinatuzumab vedotin.,Pinatuzumab vedotin
DB15441,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lulizumab pegol.,Lulizumab pegol
DB15443,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lorukafusp alfa.,Lorukafusp alfa
DB15453,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Naratuximab emtansine.,Naratuximab emtansine
DB14004,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tildrakizumab.,Tildrakizumab
DB05679,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ustekinumab.,Ustekinumab
DB15559,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Zenocutuzumab.,Zenocutuzumab
DB00039,The therapeutic efficacy of Palifermin can be decreased when used in combination with Alemtuzumab.,Palifermin
DB00001,The risk or severity of bleeding can be increased when Lepirudin is combined with Alemtuzumab.,Lepirudin
DB00006,The risk or severity of bleeding can be increased when Bivalirudin is combined with Alemtuzumab.,Bivalirudin
DB00009,The risk or severity of bleeding can be increased when Alteplase is combined with Alemtuzumab.,Alteplase
DB00013,The risk or severity of bleeding can be increased when Urokinase is combined with Alemtuzumab.,Urokinase
DB00015,The risk or severity of bleeding can be increased when Reteplase is combined with Alemtuzumab.,Reteplase
DB00029,The risk or severity of bleeding can be increased when Anistreplase is combined with Alemtuzumab.,Anistreplase
DB00031,The risk or severity of bleeding can be increased when Tenecteplase is combined with Alemtuzumab.,Tenecteplase
DB00055,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Alemtuzumab.,Drotrecogin alfa
DB00086,The risk or severity of bleeding can be increased when Streptokinase is combined with Alemtuzumab.,Streptokinase
DB00266,The risk or severity of bleeding can be increased when Dicoumarol is combined with Alemtuzumab.,Dicoumarol
DB00278,The risk or severity of bleeding can be increased when Argatroban is combined with Alemtuzumab.,Argatroban
DB00407,The risk or severity of bleeding can be increased when Ardeparin is combined with Alemtuzumab.,Ardeparin
DB00498,The risk or severity of bleeding can be increased when Phenindione is combined with Alemtuzumab.,Phenindione
DB00569,The risk or severity of bleeding can be increased when Fondaparinux is combined with Alemtuzumab.,Fondaparinux
DB00682,The risk or severity of bleeding can be increased when Warfarin is combined with Alemtuzumab.,Warfarin
DB00686,The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Alemtuzumab.,Pentosan polysulfate
DB00946,The risk or severity of bleeding can be increased when Phenprocoumon is combined with Alemtuzumab.,Phenprocoumon
DB01109,The risk or severity of bleeding can be increased when Heparin is combined with Alemtuzumab.,Heparin
DB01225,The risk or severity of bleeding can be increased when Enoxaparin is combined with Alemtuzumab.,Enoxaparin
DB01418,The risk or severity of bleeding can be increased when Acenocoumarol is combined with Alemtuzumab.,Acenocoumarol
DB03410,The risk or severity of bleeding can be increased when 4-hydroxycoumarin is combined with Alemtuzumab.,4-hydroxycoumarin
DB04665,The risk or severity of bleeding can be increased when Coumarin is combined with Alemtuzumab.,Coumarin
DB04898,The risk or severity of bleeding can be increased when Ximelagatran is combined with Alemtuzumab.,Ximelagatran
DB04925,The risk or severity of bleeding can be increased when Desmoteplase is combined with Alemtuzumab.,Desmoteplase
DB05099,The risk or severity of bleeding can be increased when Ancrod is combined with Alemtuzumab.,Ancrod
DB05254,The risk or severity of bleeding can be increased when Fibrinolysin is combined with Alemtuzumab.,Fibrinolysin
DB06228,The risk or severity of bleeding can be increased when Rivaroxaban is combined with Alemtuzumab.,Rivaroxaban
DB06271,The risk or severity of bleeding can be increased when Sulodexide is combined with Alemtuzumab.,Sulodexide
DB06294,The risk or severity of bleeding can be increased when Semuloparin is combined with Alemtuzumab.,Semuloparin
DB06406,The risk or severity of bleeding can be increased when Idraparinux is combined with Alemtuzumab.,Idraparinux
DB06543,The risk or severity of bleeding can be increased when Astaxanthin is combined with Alemtuzumab.,Astaxanthin
DB06605,The risk or severity of bleeding can be increased when Apixaban is combined with Alemtuzumab.,Apixaban
DB06635,The risk or severity of bleeding can be increased when Otamixaban is combined with Alemtuzumab.,Otamixaban
DB06679,The risk or severity of bleeding can be increased when Amediplase is combined with Alemtuzumab.,Amediplase
DB06695,The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Alemtuzumab.,Dabigatran etexilate
DB06754,The risk or severity of bleeding can be increased when Danaparoid is combined with Alemtuzumab.,Danaparoid
DB06779,The risk or severity of bleeding can be increased when Dalteparin is combined with Alemtuzumab.,Dalteparin
DB06822,The risk or severity of bleeding can be increased when Tinzaparin is combined with Alemtuzumab.,Tinzaparin
DB07767,The risk or severity of bleeding can be increased when Ferulic acid is combined with Alemtuzumab.,Ferulic acid
DB08496,The risk or severity of bleeding can be increased when (R)-warfarin is combined with Alemtuzumab.,(R)-warfarin
DB08794,The risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Alemtuzumab.,Ethyl biscoumacetate
DB08813,The risk or severity of bleeding can be increased when Nadroparin is combined with Alemtuzumab.,Nadroparin
DB08994,The risk or severity of bleeding can be increased when Ditazole is combined with Alemtuzumab.,Ditazole
DB09075,The risk or severity of bleeding can be increased when Edoxaban is combined with Alemtuzumab.,Edoxaban
DB09125,The risk or severity of bleeding can be increased when Potassium citrate is combined with Alemtuzumab.,Potassium citrate
DB09154,The risk or severity of bleeding can be increased when Sodium citrate is combined with Alemtuzumab.,Sodium citrate
DB09255,The risk or severity of bleeding can be increased when Dextran is combined with Alemtuzumab.,Dextran
DB09258,The risk or severity of bleeding can be increased when Bemiparin is combined with Alemtuzumab.,Bemiparin
DB09259,The risk or severity of bleeding can be increased when Reviparin is combined with Alemtuzumab.,Reviparin
DB09260,The risk or severity of bleeding can be increased when Parnaparin is combined with Alemtuzumab.,Parnaparin
DB09261,The risk or severity of bleeding can be increased when Certoparin is combined with Alemtuzumab.,Certoparin
DB11095,The risk or severity of bleeding can be increased when Desirudin is combined with Alemtuzumab.,Desirudin
DB11154,The risk or severity of bleeding can be increased when Zinc citrate is combined with Alemtuzumab.,Zinc citrate
DB11166,The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Alemtuzumab.,Antithrombin Alfa
DB11312,The risk or severity of bleeding can be increased when Protein C is combined with Alemtuzumab.,Protein C
DB11598,The risk or severity of bleeding can be increased when Antithrombin III human is combined with Alemtuzumab.,Antithrombin III human
DB11984,The risk or severity of bleeding can be increased when Letaxaban is combined with Alemtuzumab.,Letaxaban
DB12289,The risk or severity of bleeding can be increased when Darexaban is combined with Alemtuzumab.,Darexaban
DB12364,The risk or severity of bleeding can be increased when Betrixaban is combined with Alemtuzumab.,Betrixaban
DB12598,The risk or severity of bleeding can be increased when Nafamostat is combined with Alemtuzumab.,Nafamostat
DB12726,The risk or severity of bleeding can be increased when Monteplase is combined with Alemtuzumab.,Monteplase
DB12831,The risk or severity of bleeding can be increased when Gabexate is combined with Alemtuzumab.,Gabexate
DB13136,The risk or severity of bleeding can be increased when Fluindione is combined with Alemtuzumab.,Fluindione
DB13149,The risk or severity of bleeding can be increased when Protein S human is combined with Alemtuzumab.,Protein S human
DB13199,The risk or severity of bleeding can be increased when Brinase is combined with Alemtuzumab.,Brinase
DB13275,The risk or severity of bleeding can be increased when Clorindione is combined with Alemtuzumab.,Clorindione
DB13347,The risk or severity of bleeding can be increased when Diphenadione is combined with Alemtuzumab.,Diphenadione
DB13451,The risk or severity of bleeding can be increased when Tioclomarol is combined with Alemtuzumab.,Tioclomarol
DB13616,The risk or severity of bleeding can be increased when Melagatran is combined with Alemtuzumab.,Melagatran
DB13646,The risk or severity of bleeding can be increased when Saruplase is combined with Alemtuzumab.,Saruplase
DB14055,The risk or severity of bleeding can be increased when (S)-Warfarin is combined with Alemtuzumab.,(S)-Warfarin
DB14094,The risk or severity of bleeding can be increased when Tocopherylquinone is combined with Alemtuzumab.,Tocopherylquinone
DB14598,The risk or severity of bleeding can be increased when Edetate calcium disodium anhydrous is combined with Alemtuzumab.,Edetate calcium disodium anhydrous
DB14726,The risk or severity of bleeding can be increased when Dabigatran is combined with Alemtuzumab.,Dabigatran
DB00232,The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Alemtuzumab.,Methyclothiazide
DB00436,The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Alemtuzumab.,Bendroflumethiazide
DB00562,The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Alemtuzumab.,Benzthiazide
DB00606,The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Alemtuzumab.,Cyclothiazide
DB00774,The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Alemtuzumab.,Hydroflumethiazide
DB00880,The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Alemtuzumab.,Chlorothiazide
DB00999,The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Alemtuzumab.,Hydrochlorothiazide
DB01021,The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Alemtuzumab.,Trichlormethiazide
DB01324,The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Alemtuzumab.,Polythiazide
DB13430,The risk or severity of neutropenia and thrombocytopenia can be increased when Mebutizide is combined with Alemtuzumab.,Mebutizide
DB13532,The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Alemtuzumab.,Cyclopenthiazide
DB09042,The risk or severity of myelosuppression can be increased when Alemtuzumab is combined with Tedizolid phosphate.,Tedizolid phosphate
DB00091,Alemtuzumab may increase the immunosuppressive activities of Cyclosporine.,Cyclosporine
DB00115,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Alemtuzumab.,Cyanocobalamin
DB00437,The risk or severity of adverse effects can be increased when Allopurinol is combined with Alemtuzumab.,Allopurinol
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Alemtuzumab.","Ebola Zaire vaccine (live, attenuated)"
DB14513,The serum concentration of Magnesium can be decreased when it is combined with Alemtuzumab.,Magnesium
DB01601,The serum concentration of Alemtuzumab can be increased when it is combined with Lopinavir.,Lopinavir
DB12530,The risk or severity of infection can be increased when Alemtuzumab is combined with Inebilizumab.,Inebilizumab
DB00269,Chlorotrianisene may increase the thrombogenic activities of Capromab pendetide.,Chlorotrianisene
DB00286,Conjugated estrogens may increase the thrombogenic activities of Capromab pendetide.,Conjugated estrogens
DB00655,Estrone may increase the thrombogenic activities of Capromab pendetide.,Estrone
DB00890,Dienestrol may increase the thrombogenic activities of Capromab pendetide.,Dienestrol
DB04573,Estriol may increase the thrombogenic activities of Capromab pendetide.,Estriol
DB04575,Quinestrol may increase the thrombogenic activities of Capromab pendetide.,Quinestrol
DB07931,Hexestrol may increase the thrombogenic activities of Capromab pendetide.,Hexestrol
DB09070,Tibolone may increase the thrombogenic activities of Capromab pendetide.,Tibolone
DB09317,"Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Capromab pendetide.","Synthetic Conjugated Estrogens, A"
DB09318,"Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Capromab pendetide.","Synthetic Conjugated Estrogens, B"
DB09369,Polyestradiol phosphate may increase the thrombogenic activities of Capromab pendetide.,Polyestradiol phosphate
DB09381,Esterified estrogens may increase the thrombogenic activities of Capromab pendetide.,Esterified estrogens
DB11478,Zeranol may increase the thrombogenic activities of Capromab pendetide.,Zeranol
DB11674,Equol may increase the thrombogenic activities of Capromab pendetide.,Equol
DB12487,Promestriene may increase the thrombogenic activities of Capromab pendetide.,Promestriene
DB13143,Methallenestril may increase the thrombogenic activities of Capromab pendetide.,Methallenestril
DB13386,Epimestrol may increase the thrombogenic activities of Capromab pendetide.,Epimestrol
DB13418,Moxestrol may increase the thrombogenic activities of Capromab pendetide.,Moxestrol
DB13952,Estradiol acetate may increase the thrombogenic activities of Capromab pendetide.,Estradiol acetate
DB15334,Biochanin A may increase the thrombogenic activities of Capromab pendetide.,Biochanin A
DB15335,Formononetin may increase the thrombogenic activities of Capromab pendetide.,Formononetin
DB00255,Diethylstilbestrol may increase the thrombogenic activities of Capromab pendetide.,Diethylstilbestrol
DB00783,Estradiol may increase the thrombogenic activities of Capromab pendetide.,Estradiol
DB00977,Ethinylestradiol may increase the thrombogenic activities of Capromab pendetide.,Ethinylestradiol
DB01357,Mestranol may increase the thrombogenic activities of Capromab pendetide.,Mestranol
DB04574,Estrone sulfate may increase the thrombogenic activities of Capromab pendetide.,Estrone sulfate
DB13953,Estradiol benzoate may increase the thrombogenic activities of Capromab pendetide.,Estradiol benzoate
DB13954,Estradiol cypionate may increase the thrombogenic activities of Capromab pendetide.,Estradiol cypionate
DB13956,Estradiol valerate may increase the thrombogenic activities of Capromab pendetide.,Estradiol valerate
DB00007,Leuprolide may decrease effectiveness of Capromab pendetide as a diagnostic agent.,Leuprolide
DB00014,Goserelin may decrease effectiveness of Capromab pendetide as a diagnostic agent.,Goserelin
DB00644,Gonadorelin may decrease effectiveness of Capromab pendetide as a diagnostic agent.,Gonadorelin
DB00666,Nafarelin may decrease effectiveness of Capromab pendetide as a diagnostic agent.,Nafarelin
DB06719,Buserelin may decrease effectiveness of Capromab pendetide as a diagnostic agent.,Buserelin
DB06788,Histrelin may decrease effectiveness of Capromab pendetide as a diagnostic agent.,Histrelin
DB06825,Triptorelin may decrease effectiveness of Capromab pendetide as a diagnostic agent.,Triptorelin
DB11510,Deslorelin may decrease effectiveness of Capromab pendetide as a diagnostic agent.,Deslorelin
DB01406,Danazol may decrease effectiveness of Capromab pendetide as a diagnostic agent.,Danazol
DB11979,Elagolix may decrease effectiveness of Capromab pendetide as a diagnostic agent.,Elagolix
DB11619,Gestrinone may decrease effectiveness of Capromab pendetide as a diagnostic agent.,Gestrinone
DB00499,Flutamide may decrease effectiveness of Capromab pendetide as a diagnostic agent.,Flutamide
DB00665,Nilutamide may decrease effectiveness of Capromab pendetide as a diagnostic agent.,Nilutamide
DB01128,Bicalutamide may decrease effectiveness of Capromab pendetide as a diagnostic agent.,Bicalutamide
DB08899,Enzalutamide may decrease effectiveness of Capromab pendetide as a diagnostic agent.,Enzalutamide
DB11901,Apalutamide may decrease effectiveness of Capromab pendetide as a diagnostic agent.,Apalutamide
DB12941,Darolutamide may decrease effectiveness of Capromab pendetide as a diagnostic agent.,Darolutamide
DB04839,Cyproterone acetate may decrease effectiveness of Capromab pendetide as a diagnostic agent.,Cyproterone acetate
DB13528,Chlormadinone may decrease effectiveness of Capromab pendetide as a diagnostic agent.,Chlormadinone
DB00002,The risk or severity of adverse effects can be increased when Cetuximab is combined with Capromab pendetide.,Cetuximab
DB00028,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Capromab pendetide.,Human immunoglobulin G
DB00043,The risk or severity of adverse effects can be increased when Omalizumab is combined with Capromab pendetide.,Omalizumab
DB00051,The risk or severity of adverse effects can be increased when Adalimumab is combined with Capromab pendetide.,Adalimumab
DB00054,The risk or severity of adverse effects can be increased when Abciximab is combined with Capromab pendetide.,Abciximab
DB00056,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Capromab pendetide.,Gemtuzumab ozogamicin
DB00057,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Capromab pendetide.,Indium In-111 satumomab pendetide
DB00065,The risk or severity of adverse effects can be increased when Infliximab is combined with Capromab pendetide.,Infliximab
DB00072,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Capromab pendetide.,Trastuzumab
DB00073,The risk or severity of adverse effects can be increased when Rituximab is combined with Capromab pendetide.,Rituximab
DB00074,The risk or severity of adverse effects can be increased when Basiliximab is combined with Capromab pendetide.,Basiliximab
DB00075,The risk or severity of adverse effects can be increased when Muromonab is combined with Capromab pendetide.,Muromonab
DB00076,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Capromab pendetide.,Digoxin Immune Fab (Ovine)
DB00078,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Capromab pendetide.,Ibritumomab tiuxetan
DB00081,The risk or severity of adverse effects can be increased when Tositumomab is combined with Capromab pendetide.,Tositumomab
DB00087,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Capromab pendetide.,Alemtuzumab
DB00095,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Efalizumab.,Efalizumab
DB00098,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Antithymocyte immunoglobulin (rabbit).,Antithymocyte immunoglobulin (rabbit)
DB00108,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Natalizumab.,Natalizumab
DB00110,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Palivizumab.,Palivizumab
DB00111,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Daclizumab.,Daclizumab
DB00112,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bevacizumab.,Bevacizumab
DB00113,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Technetium Tc-99m arcitumomab.,Technetium Tc-99m arcitumomab
DB01257,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Eculizumab.,Eculizumab
DB01269,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Panitumumab.,Panitumumab
DB01270,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ranibizumab.,Ranibizumab
DB04901,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Galiximab.,Galiximab
DB04949,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Pexelizumab.,Pexelizumab
DB04956,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Afelimomab.,Afelimomab
DB04958,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Epratuzumab.,Epratuzumab
DB04962,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bectumomab.,Bectumomab
DB04964,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Oregovomab.,Oregovomab
DB04988,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with IGN311.,IGN311
DB05006,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Adecatumumab.,Adecatumumab
DB05097,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Labetuzumab.,Labetuzumab
DB05101,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Matuzumab.,Matuzumab
DB05111,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Fontolizumab.,Fontolizumab
DB05136,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bavituximab.,Bavituximab
DB05139,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with CR002.,CR002
DB05209,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Rozrolimupab.,Rozrolimupab
DB05304,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Girentuximab.,Girentuximab
DB05336,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Obiltoxaximab.,Obiltoxaximab
DB05405,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with XTL-001.,XTL-001
DB05437,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with NAV 1800.,NAV 1800
DB05459,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Briakinumab.,Briakinumab
DB05496,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Otelixizumab.,Otelixizumab
DB05545,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with AMG 108.,AMG 108
DB05550,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Iratumumab.,Iratumumab
DB05555,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Enokizumab.,Enokizumab
DB05578,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ramucirumab.,Ramucirumab
DB05595,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Farletuzumab.,Farletuzumab
DB05656,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Veltuzumab.,Veltuzumab
DB05679,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ustekinumab.,Ustekinumab
DB05773,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Trastuzumab emtansine.,Trastuzumab emtansine
DB05793,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with PRO-542.,PRO-542
DB05797,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with TNX-901.,TNX-901
DB05889,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Inotuzumab ozogamicin.,Inotuzumab ozogamicin
DB05892,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with RI 624.,RI 624
DB05915,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with MYO-029.,MYO-029
DB05916,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with CT-011.,CT-011
DB05941,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Leronlimab.,Leronlimab
DB05996,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Glembatumumab vedotin.,Glembatumumab vedotin
DB06043,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Olaratumab.,Olaratumab
DB06049,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with IPH 2101.,IPH 2101
DB06050,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with TB-402.,TB-402
DB06081,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Caplacizumab.,Caplacizumab
DB06101,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with IMC-1C11.,IMC-1C11
DB06116,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Eldelumab.,Eldelumab
DB06162,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Lumiliximab.,Lumiliximab
DB06168,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Canakinumab.,Canakinumab
DB06186,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ipilimumab.,Ipilimumab
DB06192,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Nimotuzumab.,Nimotuzumab
DB06241,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Clenoliximab.,Clenoliximab
DB06273,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tocilizumab.,Tocilizumab
DB06304,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with BIIB015.,BIIB015
DB06305,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Sonepcizumab.,Sonepcizumab
DB06310,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Motavizumab.,Motavizumab
DB06317,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Elotuzumab.,Elotuzumab
DB06318,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with AVE9633.,AVE9633
DB06322,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Carotuximab.,Carotuximab
DB06324,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with XmAb 2513.,XmAb 2513
DB06342,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Coltuximab ravtansine.,Coltuximab ravtansine
DB06343,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Teprotumumab.,Teprotumumab
DB06360,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Lucatumumab.,Lucatumumab
DB06366,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Pertuzumab.,Pertuzumab
DB06371,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Siplizumab.,Siplizumab
DB06467,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Apolizumab.,Apolizumab
DB06474,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Sibrotuzumab.,Sibrotuzumab
DB06550,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bivatuzumab.,Bivatuzumab
DB06557,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Lerdelimumab.,Lerdelimumab
DB06599,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Lexatumumab.,Lexatumumab
DB06602,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Reslizumab.,Reslizumab
DB06606,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Teplizumab.,Teplizumab
DB06607,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Catumaxomab.,Catumaxomab
DB06612,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Mepolizumab.,Mepolizumab
DB06643,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Denosumab.,Denosumab
DB06647,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Volociximab.,Volociximab
DB06650,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ofatumumab.,Ofatumumab
DB06674,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Golimumab.,Golimumab
DB08870,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Brentuximab vedotin.,Brentuximab vedotin
DB08879,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Belimumab.,Belimumab
DB08902,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Raxibacumab.,Raxibacumab
DB08904,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Certolizumab pegol.,Certolizumab pegol
DB08935,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Obinutuzumab.,Obinutuzumab
DB09029,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Secukinumab.,Secukinumab
DB09033,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Vedolizumab.,Vedolizumab
DB09035,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Nivolumab.,Nivolumab
DB09036,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Siltuximab.,Siltuximab
DB09037,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Pembrolizumab.,Pembrolizumab
DB09045,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Dulaglutide.,Dulaglutide
DB09052,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Blinatumomab.,Blinatumomab
DB09057,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Anthrax immune globulin human.,Anthrax immune globulin human
DB09077,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Dinutuximab.,Dinutuximab
DB09105,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Asfotase alfa.,Asfotase alfa
DB09264,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Idarucizumab.,Idarucizumab
DB09302,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Alirocumab.,Alirocumab
DB09303,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Evolocumab.,Evolocumab
DB09312,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Antilymphocyte immunoglobulin (horse).,Antilymphocyte immunoglobulin (horse)
DB09331,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Daratumumab.,Daratumumab
DB09559,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Necitumumab.,Necitumumab
DB11569,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ixekizumab.,Ixekizumab
DB11580,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ravulizumab.,Ravulizumab
DB11595,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Atezolizumab.,Atezolizumab
DB11604,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tetanus Immune Globulin.,Tetanus Immune Globulin
DB11608,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Eftrenonacog alfa.,Eftrenonacog alfa
DB11621,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Human Varicella-Zoster Immune Globulin.,Human Varicella-Zoster Immune Globulin
DB11646,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Conatumumab.,Conatumumab
DB11657,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tabalumab.,Tabalumab
DB11680,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ficlatuzumab.,Ficlatuzumab
DB11685,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Figitumumab.,Figitumumab
DB11714,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Durvalumab.,Durvalumab
DB11715,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bapineuzumab.,Bapineuzumab
DB11731,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Depatuxizumab mafodotin.,Depatuxizumab mafodotin
DB11746,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Onartuzumab.,Onartuzumab
DB11756,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Solanezumab.,Solanezumab
DB11767,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Sarilumab.,Sarilumab
DB11771,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tremelimumab.,Tremelimumab
DB11776,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Brodalumab.,Brodalumab
DB11803,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Sirukumab.,Sirukumab
DB11826,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Lampalizumab.,Lampalizumab
DB11834,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Guselkumab.,Guselkumab
DB11840,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Dalotuzumab.,Dalotuzumab
DB11849,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Emibetuzumab.,Emibetuzumab
DB11850,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ublituximab.,Ublituximab
DB11856,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ligelizumab.,Ligelizumab
DB11857,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Seribantumab.,Seribantumab
DB11862,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Landogrozumab.,Landogrozumab
DB11866,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Romosozumab.,Romosozumab
DB11884,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Vadastuximab Talirine.,Vadastuximab Talirine
DB11914,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Lebrikizumab.,Lebrikizumab
DB11930,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Varlilumab.,Varlilumab
DB11945,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Avelumab.,Avelumab
DB11959,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Crenezumab.,Crenezumab
DB11972,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Rilotumumab.,Rilotumumab
DB11976,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Anifrolumab.,Anifrolumab
DB11988,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ocrelizumab.,Ocrelizumab
DB12023,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Benralizumab.,Benralizumab
DB12034,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Gantenerumab.,Gantenerumab
DB12053,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Visilizumab.,Visilizumab
DB12077,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Urelumab.,Urelumab
DB12089,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Lorvotuzumab mertansine.,Lorvotuzumab mertansine
DB12090,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Patritumab.,Patritumab
DB12102,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Fulranumab.,Fulranumab
DB12104,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tarextumab.,Tarextumab
DB12118,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Sotatercept.,Sotatercept
DB12119,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Gevokizumab.,Gevokizumab
DB12142,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Duligotuzumab.,Duligotuzumab
DB12152,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Simtuzumab.,Simtuzumab
DB12157,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Fasinumab.,Fasinumab
DB12159,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Dupilumab.,Dupilumab
DB12169,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tralokinumab.,Tralokinumab
DB12189,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Etrolizumab.,Etrolizumab
DB12202,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Zalutumumab.,Zalutumumab
DB12205,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ganitumab.,Ganitumab
DB12213,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Etaracizumab.,Etaracizumab
DB12240,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Polatuzumab vedotin.,Polatuzumab vedotin
DB12246,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Inclacumab.,Inclacumab
DB12250,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Cixutumumab.,Cixutumumab
DB12261,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ascrinvacumab.,Ascrinvacumab
DB12274,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Aducanumab.,Aducanumab
DB12281,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Luspatercept.,Luspatercept
DB12296,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with GS-5745.,GS-5745
DB12317,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Vanucizumab.,Vanucizumab
DB12331,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Labetuzumab govitecan.,Labetuzumab govitecan
DB12335,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tanezumab.,Tanezumab
DB12342,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ensituximab.,Ensituximab
DB12344,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Fezakinumab.,Fezakinumab
DB12363,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Dusigitumab.,Dusigitumab
DB12396,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Fresolimumab.,Fresolimumab
DB12413,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Indusatumab vedotin.,Indusatumab vedotin
DB12456,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bococizumab.,Bococizumab
DB12489,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Mirvetuximab Soravtansine.,Mirvetuximab Soravtansine
DB12498,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Mogamulizumab.,Mogamulizumab
DB12520,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Plozalizumab.,Plozalizumab
DB12530,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Inebilizumab.,Inebilizumab
DB12534,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Mavrilimumab.,Mavrilimumab
DB12560,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Blosozumab.,Blosozumab
DB12584,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bimagrumab.,Bimagrumab
DB12589,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Dacetuzumab.,Dacetuzumab
DB12609,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tovetumab.,Tovetumab
DB12683,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Lumretuzumab.,Lumretuzumab
DB12698,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ibalizumab.,Ibalizumab
DB12701,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Intetumumab.,Intetumumab
DB12718,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Carlumab.,Carlumab
DB12734,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Demcizumab.,Demcizumab
DB12773,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Sifalimumab.,Sifalimumab
DB12775,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Abituzumab.,Abituzumab
DB12797,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ecromeximab.,Ecromeximab
DB12807,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Naptumomab Estafenatox.,Naptumomab Estafenatox
DB12815,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Crotedumab.,Crotedumab
DB12820,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Concizumab.,Concizumab
DB12826,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Depatuxizumab.,Depatuxizumab
DB12844,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Rontalizumab.,Rontalizumab
DB12845,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Amatuximab.,Amatuximab
DB12849,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Clazakizumab.,Clazakizumab
DB12891,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ozanezumab.,Ozanezumab
DB12893,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Sacituzumab govitecan.,Sacituzumab govitecan
DB12917,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bimekizumab.,Bimekizumab
DB12943,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Milatuzumab.,Milatuzumab
DB12976,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Robatumumab.,Robatumumab
DB13017,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Rovalpituzumab Tesirine.,Rovalpituzumab Tesirine
DB13037,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Namilumab.,Namilumab
DB13045,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Racotumomab.,Racotumomab
DB13073,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tregalizumab.,Tregalizumab
DB13127,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Olokizumab.,Olokizumab
DB13140,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bezlotoxumab.,Bezlotoxumab
DB13375,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Edrecolomab.,Edrecolomab
DB13535,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Nebacumab.,Nebacumab
DB13886,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Human cytomegalovirus immune globulin.,Human cytomegalovirus immune globulin
DB13923,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Emicizumab.,Emicizumab
DB13976,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Sulesomab.,Sulesomab
DB13979,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Besilesomab.,Besilesomab
DB14004,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tildrakizumab.,Tildrakizumab
DB14012,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Burosumab.,Burosumab
DB14039,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Erenumab.,Erenumab
DB14040,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Eptinezumab.,Eptinezumab
DB14041,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Fremanezumab.,Fremanezumab
DB14042,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Galcanezumab.,Galcanezumab
DB14211,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Fanolesomab.,Fanolesomab
DB14580,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Lecanemab.,Lecanemab
DB14597,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Lanadelumab.,Lanadelumab
DB14707,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Cemiplimab.,Cemiplimab
DB14724,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Emapalumab.,Emapalumab
DB14762,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Risankizumab.,Risankizumab
DB14776,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Camrelizumab.,Camrelizumab
DB14778,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Setrusumab.,Setrusumab
DB14784,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Gancotamab.,Gancotamab
DB14809,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Anetumab ravtansine.,Anetumab ravtansine
DB14811,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Isatuximab.,Isatuximab
DB14824,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Icrucumab.,Icrucumab
DB14843,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Codrituzumab.,Codrituzumab
DB14864,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Brolucizumab.,Brolucizumab
DB14871,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Xentuzumab.,Xentuzumab
DB14877,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Lintuzumab.,Lintuzumab
DB14891,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Vobarilizumab.,Vobarilizumab
DB14897,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Parsatuzumab.,Parsatuzumab
DB14905,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Emactuzumab.,Emactuzumab
DB14907,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bevacizumab zirconium Zr-89.,Bevacizumab zirconium Zr-89
DB14908,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Refanezumab.,Refanezumab
DB14919,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Rozanolixizumab.,Rozanolixizumab
DB14947,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bermekimab.,Bermekimab
DB14952,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Pamrevlumab.,Pamrevlumab
DB14959,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Opicinumab.,Opicinumab
DB14962,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Trastuzumab deruxtecan.,Trastuzumab deruxtecan
DB14967,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Margetuximab.,Margetuximab
DB14988,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Dalantercept.,Dalantercept
DB14997,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Pateclizumab.,Pateclizumab
DB15014,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Gremubamab.,Gremubamab
DB15022,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Apomab.,Apomab
DB15044,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tafasitamab.,Tafasitamab
DB15045,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ipafricept.,Ipafricept
DB15076,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Abrilumab.,Abrilumab
DB15089,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Frovocimab.,Frovocimab
DB15090,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tezepelumab.,Tezepelumab
DB15101,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tigatuzumab.,Tigatuzumab
DB15104,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Telisotuzumab vedotin.,Telisotuzumab vedotin
DB15113,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Utomilumab.,Utomilumab
DB15118,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Zolbetuximab.,Zolbetuximab
DB15135,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ponezumab.,Ponezumab
DB15160,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Asunercept.,Asunercept
DB15172,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Suvratoxumab.,Suvratoxumab
DB15225,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Mitazalimab.,Mitazalimab
DB15252,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Nemolizumab.,Nemolizumab
DB15253,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bleselumab.,Bleselumab
DB15277,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Gedivumab.,Gedivumab
DB15336,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Valanafusp alfa.,Valanafusp alfa
DB15349,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Sofituzumab vedotin.,Sofituzumab vedotin
DB15354,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Evinacumab.,Evinacumab
DB15363,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Istiratumab.,Istiratumab
DB15383,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Pidilizumab.,Pidilizumab
DB15397,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with GMA-161.,GMA-161
DB15409,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ladiratuzumab vedotin.,Ladiratuzumab vedotin
DB15415,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Tomaralimab.,Tomaralimab
DB15428,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Vesencumab.,Vesencumab
DB15432,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Pinatuzumab vedotin.,Pinatuzumab vedotin
DB15441,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Lulizumab pegol.,Lulizumab pegol
DB15443,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Lorukafusp alfa.,Lorukafusp alfa
DB15453,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Naratuximab emtansine.,Naratuximab emtansine
DB15559,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Zenocutuzumab.,Zenocutuzumab
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Capromab pendetide.","Ebola Zaire vaccine (live, attenuated)"
DB00337,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cyclosporine.,Pimecrolimus
DB01656,Roflumilast may increase the immunosuppressive activities of Cyclosporine.,Roflumilast
DB06688,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Cyclosporine.,Sipuleucel-T
DB00819,The serum concentration of Cyclosporine can be increased when it is combined with Acetazolamide.,Acetazolamide
DB00051,The serum concentration of Cyclosporine can be decreased when it is combined with Adalimumab.,Adalimumab
DB08916,The serum concentration of Cyclosporine can be increased when it is combined with Afatinib.,Afatinib
DB09026,The serum concentration of Aliskiren can be increased when it is combined with Cyclosporine.,Aliskiren
DB06403,The serum concentration of Ambrisentan can be increased when it is combined with Cyclosporine.,Ambrisentan
DB01118,The serum concentration of Cyclosporine can be increased when it is combined with Amiodarone.,Amiodarone
DB00681,Amphotericin B may increase the nephrotoxic activities of Cyclosporine.,Amphotericin B
DB01026,Ketoconazole may increase the nephrotoxic activities of Cyclosporine.,Ketoconazole
DB01076,The excretion of Atorvastatin can be decreased when combined with Cyclosporine.,Atorvastatin
DB08873,The serum concentration of Cyclosporine can be increased when it is combined with Boceprevir.,Boceprevir
DB00559,The serum concentration of Bosentan can be increased when it is combined with Cyclosporine.,Bosentan
DB01200,The serum concentration of Cyclosporine can be increased when it is combined with Bromocriptine.,Bromocriptine
DB00564,The serum concentration of Cyclosporine can be decreased when it is combined with Carbamazepine.,Carbamazepine
DB01136,The serum concentration of Cyclosporine can be increased when it is combined with Carvedilol.,Carvedilol
DB00520,The risk or severity of adverse effects can be increased when Cyclosporine is combined with Caspofungin.,Caspofungin
DB00446,The serum concentration of Cyclosporine can be increased when it is combined with Chloramphenicol.,Chloramphenicol
DB02123,Cyclosporine may decrease the excretion rate of Glycochenodeoxycholic Acid which could result in a higher serum level.,Glycochenodeoxycholic Acid
DB05804,Prasterone sulfate may decrease the excretion rate of Cyclosporine which could result in a higher serum level.,Prasterone sulfate
DB00222,Cyclosporine may decrease the excretion rate of Glimepiride which could result in a higher serum level.,Glimepiride
DB00572,Cyclosporine may decrease the excretion rate of Atropine which could result in a higher serum level.,Atropine
DB00693,Cyclosporine may decrease the excretion rate of Fluorescein which could result in a higher serum level.,Fluorescein
DB00698,Cyclosporine may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.,Nitrofurantoin
DB00833,Cyclosporine may decrease the excretion rate of Cefaclor which could result in a higher serum level.,Cefaclor
DB09374,Cyclosporine may decrease the excretion rate of Indocyanine green acid form which could result in a higher serum level.,Indocyanine green acid form
DB12319,Cyclosporine may decrease the excretion rate of Benzbromarone which could result in a higher serum level.,Benzbromarone
DB12712,Cyclosporine may decrease the excretion rate of Pilsicainide which could result in a higher serum level.,Pilsicainide
DB13751,Cyclosporine may decrease the excretion rate of Glycyrrhizic acid which could result in a higher serum level.,Glycyrrhizic acid
DB00412,Cyclosporine may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.,Rosiglitazone
DB02659,Cyclosporine may decrease the excretion rate of Cholic Acid which could result in a higher serum level.,Cholic Acid
DB04348,Cyclosporine may decrease the excretion rate of Taurocholic acid which could result in a higher serum level.,Taurocholic acid
DB00455,Cyclosporine may decrease the excretion rate of Loratadine which could result in a higher serum level.,Loratadine
DB00975,Cyclosporine may decrease the excretion rate of Dipyridamole which could result in a higher serum level.,Dipyridamole
DB00930,The serum concentration of Cyclosporine can be decreased when it is combined with Colesevelam.,Colesevelam
DB08865,The serum concentration of Cyclosporine can be increased when it is combined with Crizotinib.,Crizotinib
DB00531,The serum concentration of Cyclosporine can be decreased when it is combined with Cyclophosphamide.,Cyclophosphamide
DB00390,The serum concentration of Digoxin can be increased when it is combined with Cyclosporine.,Digoxin
DB13401,The serum concentration of Metildigoxin can be increased when it is combined with Cyclosporine.,Metildigoxin
DB13691,The serum concentration of Acetyldigoxin can be increased when it is combined with Cyclosporine.,Acetyldigoxin
DB04855,The serum concentration of Dronedarone can be increased when it is combined with Cyclosporine.,Dronedarone
DB09075,The serum concentration of Cyclosporine can be increased when it is combined with Edoxaban.,Edoxaban
DB00625,The serum concentration of Cyclosporine can be decreased when it is combined with Efavirenz.,Efavirenz
DB08899,The serum concentration of Cyclosporine can be decreased when it is combined with Enzalutamide.,Enzalutamide
DB00773,The serum concentration of Etoposide can be increased when it is combined with Cyclosporine.,Etoposide
DB01590,The serum concentration of Everolimus can be increased when it is combined with Cyclosporine.,Everolimus
DB00973,The serum concentration of Cyclosporine can be increased when it is combined with Ezetimibe.,Ezetimibe
DB00196,The serum concentration of Cyclosporine can be increased when it is combined with Fluconazole.,Fluconazole
DB01095,The serum concentration of Fluvastatin can be increased when it is combined with Cyclosporine.,Fluvastatin
DB00529,Foscarnet may increase the nephrotoxic activities of Cyclosporine.,Foscarnet
DB00252,The serum concentration of Cyclosporine can be decreased when it is combined with Phenytoin.,Phenytoin
DB01320,The serum concentration of Cyclosporine can be decreased when it is combined with Fosphenytoin.,Fosphenytoin
DB01016,The therapeutic efficacy of Glyburide can be decreased when used in combination with Cyclosporine.,Glyburide
DB00400,The serum concentration of Cyclosporine can be decreased when it is combined with Griseofulvin.,Griseofulvin
DB00619,The serum concentration of Cyclosporine can be increased when it is combined with Imatinib.,Imatinib
DB01598,Cyclosporine may increase the neurotoxic activities of Imipenem.,Imipenem
DB09027,The serum concentration of Cyclosporine can be increased when it is combined with Ledipasvir.,Ledipasvir
DB00227,The serum concentration of Lovastatin can be increased when it is combined with Cyclosporine.,Lovastatin
DB01042,Melphalan may increase the nephrotoxic activities of Cyclosporine.,Melphalan
DB00563,The serum concentration of Methotrexate can be increased when it is combined with Cyclosporine.,Methotrexate
DB00959,The serum concentration of Methylprednisolone can be increased when it is combined with Cyclosporine.,Methylprednisolone
DB01233,Metoclopramide can cause an increase in the absorption of Cyclosporine resulting in an increased serum concentration and potentially a worsening of adverse effects.,Metoclopramide
DB00834,The serum concentration of Cyclosporine can be increased when it is combined with Mifepristone.,Mifepristone
DB01204,The serum concentration of Mitoxantrone can be increased when it is combined with Cyclosporine.,Mitoxantrone
DB06413,The serum concentration of Cyclosporine can be decreased when it is combined with Armodafinil.,Armodafinil
DB00745,The serum concentration of Cyclosporine can be decreased when it is combined with Modafinil.,Modafinil
DB00607,The metabolism of Cyclosporine can be increased when combined with Nafcillin.,Nafcillin
DB01059,The metabolism of Cyclosporine can be decreased when combined with Norfloxacin.,Norfloxacin
DB00338,The serum concentration of Cyclosporine can be increased when it is combined with Omeprazole.,Omeprazole
DB00736,The serum concentration of Cyclosporine can be increased when it is combined with Esomeprazole.,Esomeprazole
DB01083,Orlistat can cause a decrease in the absorption of Cyclosporine resulting in a reduced serum concentration and potentially a decrease in efficacy.,Orlistat
DB08860,The serum concentration of Pitavastatin can be increased when it is combined with Cyclosporine.,Pitavastatin
DB00175,The serum concentration of Pravastatin can be increased when it is combined with Cyclosporine.,Pravastatin
DB06480,The serum concentration of Prucalopride can be increased when it is combined with Cyclosporine.,Prucalopride
DB00339,The serum concentration of Cyclosporine can be decreased when it is combined with Pyrazinamide.,Pyrazinamide
DB01369,The serum concentration of Cyclosporine can be increased when it is combined with Quinupristin.,Quinupristin
DB00243,The serum concentration of Cyclosporine can be increased when it is combined with Ranolazine.,Ranolazine
DB00912,The serum concentration of Repaglinide can be increased when it is combined with Cyclosporine.,Repaglinide
DB01220,The serum concentration of Rifaximin can be increased when it is combined with Cyclosporine.,Rifaximin
DB00503,The serum concentration of Cyclosporine can be increased when it is combined with Ritonavir.,Ritonavir
DB01098,The serum concentration of Rosuvastatin can be increased when it is combined with Cyclosporine.,Rosuvastatin
DB00658,The serum concentration of Cyclosporine can be decreased when it is combined with Sevelamer.,Sevelamer
DB06207,The serum concentration of Cyclosporine can be increased when it is combined with Silodosin.,Silodosin
DB06290,The serum concentration of Cyclosporine can be increased when it is combined with Simeprevir.,Simeprevir
DB00641,The serum concentration of Simvastatin can be increased when it is combined with Cyclosporine.,Simvastatin
DB06268,The risk or severity of adverse effects can be increased when Cyclosporine is combined with Sitaxentan.,Sitaxentan
DB01138,The serum concentration of Cyclosporine can be decreased when it is combined with Sulfinpyrazone.,Sulfinpyrazone
DB05521,The serum concentration of Cyclosporine can be increased when it is combined with Telaprevir.,Telaprevir
DB08816,The serum concentration of Ticagrelor can be increased when it is combined with Cyclosporine.,Ticagrelor
DB00163,The serum concentration of Cyclosporine can be decreased when it is combined with Vitamin E.,Vitamin E
DB00212,Cyclosporine may decrease the antihypertensive activities of Remikiren.,Remikiren
DB00226,Cyclosporine may decrease the antihypertensive activities of Guanadrel.,Guanadrel
DB00616,Cyclosporine may decrease the antihypertensive activities of Candoxatril.,Candoxatril
DB00727,Cyclosporine may decrease the antihypertensive activities of Nitroglycerin.,Nitroglycerin
DB00765,Cyclosporine may decrease the antihypertensive activities of Metyrosine.,Metyrosine
DB00785,Cyclosporine may decrease the antihypertensive activities of Cryptenamine.,Cryptenamine
DB01089,Cyclosporine may decrease the antihypertensive activities of Deserpidine.,Deserpidine
DB01158,Cyclosporine may decrease the antihypertensive activities of Bretylium.,Bretylium
DB03322,Cyclosporine may decrease the antihypertensive activities of Dexpropranolol.,Dexpropranolol
DB04831,Cyclosporine may decrease the antihypertensive activities of Tienilic acid.,Tienilic acid
DB06445,Cyclosporine may decrease the antihypertensive activities of Diethylnorspermine.,Diethylnorspermine
DB07767,Cyclosporine may decrease the antihypertensive activities of Ferulic acid.,Ferulic acid
DB09206,Cyclosporine may decrease the antihypertensive activities of Trimazosin.,Trimazosin
DB09363,Cyclosporine may decrease the antihypertensive activities of Rauwolfia serpentina root.,Rauwolfia serpentina root
DB11720,Cyclosporine may decrease the antihypertensive activities of Angiotensin 1-7.,Angiotensin 1-7
DB12054,Cyclosporine may decrease the antihypertensive activities of BQ-123.,BQ-123
DB12465,Cyclosporine may decrease the antihypertensive activities of Ketanserin.,Ketanserin
DB12766,Cyclosporine may decrease the antihypertensive activities of Cicletanine.,Cicletanine
DB12945,Cyclosporine may decrease the antihypertensive activities of Dihydralazine.,Dihydralazine
DB13211,Cyclosporine may decrease the antihypertensive activities of Guanoxan.,Guanoxan
DB13374,Cyclosporine may decrease the antihypertensive activities of Vincamine.,Vincamine
DB13400,Cyclosporine may decrease the antihypertensive activities of Linsidomine.,Linsidomine
DB13410,Cyclosporine may decrease the antihypertensive activities of Guanoxabenz.,Guanoxabenz
DB13429,Cyclosporine may decrease the antihypertensive activities of Tolonidine.,Tolonidine
DB13435,Cyclosporine may decrease the antihypertensive activities of Endralazine.,Endralazine
DB13452,Cyclosporine may decrease the antihypertensive activities of Cadralazine.,Cadralazine
DB13575,Cyclosporine may decrease the antihypertensive activities of Bietaserpine.,Bietaserpine
DB13604,Cyclosporine may decrease the antihypertensive activities of Guanazodine.,Guanazodine
DB13631,Cyclosporine may decrease the antihypertensive activities of Methoserpidine.,Methoserpidine
DB13779,Cyclosporine may decrease the antihypertensive activities of Guanoclor.,Guanoclor
DB13801,Cyclosporine may decrease the antihypertensive activities of Muzolimine.,Muzolimine
DB14094,Cyclosporine may decrease the antihypertensive activities of Tocopherylquinone.,Tocopherylquinone
DB06762,Cyclosporine may decrease the antihypertensive activities of Pinacidil.,Pinacidil
DB00374,Cyclosporine may decrease the antihypertensive activities of Treprostinil.,Treprostinil
DB00393,Cyclosporine may decrease the antihypertensive activities of Nimodipine.,Nimodipine
DB01162,Cyclosporine may decrease the antihypertensive activities of Terazosin.,Terazosin
DB01340,Cyclosporine may decrease the antihypertensive activities of Cilazapril.,Cilazapril
DB00381,Cyclosporine may decrease the antihypertensive activities of Amlodipine.,Amlodipine
DB09128,The metabolism of Brexpiprazole can be decreased when combined with Cyclosporine.,Brexpiprazole
DB09039,The metabolism of Eliglustat can be decreased when combined with Cyclosporine.,Eliglustat
DB04908,The metabolism of Cyclosporine can be decreased when combined with Flibanserin.,Flibanserin
DB09083,The metabolism of Cyclosporine can be decreased when combined with Ivabradine.,Ivabradine
DB08820,The metabolism of Cyclosporine can be decreased when combined with Ivacaftor.,Ivacaftor
DB08815,The metabolism of Lurasidone can be decreased when combined with Cyclosporine.,Lurasidone
DB09049,The metabolism of Naloxegol can be decreased when combined with Cyclosporine.,Naloxegol
DB09143,The metabolism of Cyclosporine can be decreased when combined with Sonidegib.,Sonidegib
DB06237,The metabolism of Avanafil can be decreased when combined with Cyclosporine.,Avanafil
DB00202,The therapeutic efficacy of Succinylcholine can be increased when used in combination with Cyclosporine.,Succinylcholine
DB00416,The therapeutic efficacy of Metocurine iodide can be increased when used in combination with Cyclosporine.,Metocurine iodide
DB00483,The therapeutic efficacy of Gallamine triethiodide can be increased when used in combination with Cyclosporine.,Gallamine triethiodide
DB00565,The therapeutic efficacy of Cisatracurium can be increased when used in combination with Cyclosporine.,Cisatracurium
DB00728,The therapeutic efficacy of Rocuronium can be increased when used in combination with Cyclosporine.,Rocuronium
DB00732,The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Cyclosporine.,Atracurium besylate
DB01135,The therapeutic efficacy of Doxacurium can be increased when used in combination with Cyclosporine.,Doxacurium
DB01226,The therapeutic efficacy of Mivacurium can be increased when used in combination with Cyclosporine.,Mivacurium
DB01245,The therapeutic efficacy of Decamethonium can be increased when used in combination with Cyclosporine.,Decamethonium
DB01336,The therapeutic efficacy of Metocurine can be increased when used in combination with Cyclosporine.,Metocurine
DB01337,The therapeutic efficacy of Pancuronium can be increased when used in combination with Cyclosporine.,Pancuronium
DB01338,The therapeutic efficacy of Pipecuronium can be increased when used in combination with Cyclosporine.,Pipecuronium
DB01339,The therapeutic efficacy of Vecuronium can be increased when used in combination with Cyclosporine.,Vecuronium
DB04834,The therapeutic efficacy of Rapacuronium can be increased when used in combination with Cyclosporine.,Rapacuronium
DB11156,The therapeutic efficacy of Pyrantel can be increased when used in combination with Cyclosporine.,Pyrantel
DB12989,The therapeutic efficacy of Neosaxitoxin can be increased when used in combination with Cyclosporine.,Neosaxitoxin
DB13295,The therapeutic efficacy of Atracurium can be increased when used in combination with Cyclosporine.,Atracurium
DB13584,The therapeutic efficacy of Gallamine can be increased when used in combination with Cyclosporine.,Gallamine
DB13648,The therapeutic efficacy of Alcuronium can be increased when used in combination with Cyclosporine.,Alcuronium
DB01199,The therapeutic efficacy of Tubocurarine can be increased when used in combination with Cyclosporine.,Tubocurarine
DB00211,The risk or severity of hypertension can be increased when Cyclosporine is combined with Midodrine.,Midodrine
DB00217,The risk or severity of hypertension can be increased when Cyclosporine is combined with Bethanidine.,Bethanidine
DB00221,The risk or severity of hypertension can be increased when Cyclosporine is combined with Isoetharine.,Isoetharine
DB00315,The risk or severity of hypertension can be increased when Cyclosporine is combined with Zolmitriptan.,Zolmitriptan
DB00368,The risk or severity of hypertension can be increased when Cyclosporine is combined with Norepinephrine.,Norepinephrine
DB00388,The risk or severity of hypertension can be increased when Cyclosporine is combined with Phenylephrine.,Phenylephrine
DB00397,The risk or severity of hypertension can be increased when Cyclosporine is combined with Phenylpropanolamine.,Phenylpropanolamine
DB00561,The risk or severity of hypertension can be increased when Cyclosporine is combined with Doxapram.,Doxapram
DB00610,The risk or severity of hypertension can be increased when Cyclosporine is combined with Metaraminol.,Metaraminol
DB00614,The risk or severity of hypertension can be increased when Cyclosporine is combined with Furazolidone.,Furazolidone
DB00629,The risk or severity of hypertension can be increased when Cyclosporine is combined with Guanabenz.,Guanabenz
DB00723,The risk or severity of hypertension can be increased when Cyclosporine is combined with Methoxamine.,Methoxamine
DB00753,The risk or severity of hypertension can be increased when Cyclosporine is combined with Isoflurane.,Isoflurane
DB00777,The risk or severity of hypertension can be increased when Cyclosporine is combined with Propiomazine.,Propiomazine
DB00797,The risk or severity of hypertension can be increased when Cyclosporine is combined with Tolazoline.,Tolazoline
DB00816,The risk or severity of hypertension can be increased when Cyclosporine is combined with Orciprenaline.,Orciprenaline
DB00830,The risk or severity of hypertension can be increased when Cyclosporine is combined with Phenmetrazine.,Phenmetrazine
DB00852,The risk or severity of hypertension can be increased when Cyclosporine is combined with Pseudoephedrine.,Pseudoephedrine
DB00867,The risk or severity of hypertension can be increased when Cyclosporine is combined with Ritodrine.,Ritodrine
DB00899,The risk or severity of hypertension can be increased when Cyclosporine is combined with Remifentanil.,Remifentanil
DB00901,The risk or severity of hypertension can be increased when Cyclosporine is combined with Bitolterol.,Bitolterol
DB00925,The risk or severity of hypertension can be increased when Cyclosporine is combined with Phenoxybenzamine.,Phenoxybenzamine
DB00935,The risk or severity of hypertension can be increased when Cyclosporine is combined with Oxymetazoline.,Oxymetazoline
DB00937,The risk or severity of hypertension can be increased when Cyclosporine is combined with Diethylpropion.,Diethylpropion
DB00952,The risk or severity of hypertension can be increased when Cyclosporine is combined with Naratriptan.,Naratriptan
DB00998,The risk or severity of hypertension can be increased when Cyclosporine is combined with Frovatriptan.,Frovatriptan
DB01064,The risk or severity of hypertension can be increased when Cyclosporine is combined with Isoprenaline.,Isoprenaline
DB01102,The risk or severity of hypertension can be increased when Cyclosporine is combined with Arbutamine.,Arbutamine
DB01189,The risk or severity of hypertension can be increased when Cyclosporine is combined with Desflurane.,Desflurane
DB01247,The risk or severity of hypertension can be increased when Cyclosporine is combined with Isocarboxazid.,Isocarboxazid
DB01288,The risk or severity of hypertension can be increased when Cyclosporine is combined with Fenoterol.,Fenoterol
DB01291,The risk or severity of hypertension can be increased when Cyclosporine is combined with Pirbuterol.,Pirbuterol
DB01363,The risk or severity of hypertension can be increased when Cyclosporine is combined with Ephedra sinica root.,Ephedra sinica root
DB01364,The risk or severity of hypertension can be increased when Cyclosporine is combined with Ephedrine.,Ephedrine
DB01365,The risk or severity of hypertension can be increased when Cyclosporine is combined with Mephentermine.,Mephentermine
DB01366,The risk or severity of hypertension can be increased when Cyclosporine is combined with Procaterol.,Procaterol
DB01407,The risk or severity of hypertension can be increased when Cyclosporine is combined with Clenbuterol.,Clenbuterol
DB01408,The risk or severity of hypertension can be increased when Cyclosporine is combined with Bambuterol.,Bambuterol
DB01442,The risk or severity of hypertension can be increased when Cyclosporine is combined with MMDA.,MMDA
DB01467,"The risk or severity of hypertension can be increased when Cyclosporine is combined with 2,5-Dimethoxy-4-ethylamphetamine.","2,5-Dimethoxy-4-ethylamphetamine"
DB01484,"The risk or severity of hypertension can be increased when Cyclosporine is combined with 4-Bromo-2,5-dimethoxyamphetamine.","4-Bromo-2,5-dimethoxyamphetamine"
DB01509,The risk or severity of hypertension can be increased when Cyclosporine is combined with Tenamfetamine.,Tenamfetamine
DB01556,The risk or severity of hypertension can be increased when Cyclosporine is combined with Chlorphentermine.,Chlorphentermine
DB01579,The risk or severity of hypertension can be increased when Cyclosporine is combined with Phendimetrazine.,Phendimetrazine
DB01626,The risk or severity of hypertension can be increased when Cyclosporine is combined with Pargyline.,Pargyline
DB02032,The risk or severity of hypertension can be increased when Cyclosporine is combined with Epicaptopril.,Epicaptopril
DB04017,The risk or severity of hypertension can be increased when Cyclosporine is combined with Clorgiline.,Clorgiline
DB04581,The risk or severity of hypertension can be increased when Cyclosporine is combined with 1-benzylimidazole.,1-benzylimidazole
DB04818,The risk or severity of hypertension can be increased when Cyclosporine is combined with Iproniazid.,Iproniazid
DB04820,The risk or severity of hypertension can be increased when Cyclosporine is combined with Nialamide.,Nialamide
DB05395,The risk or severity of hypertension can be increased when Cyclosporine is combined with Amibegron.,Amibegron
DB05562,The risk or severity of hypertension can be increased when Cyclosporine is combined with Naluzotan.,Naluzotan
DB06153,The risk or severity of hypertension can be increased when Cyclosporine is combined with Pizotifen.,Pizotifen
DB06190,The risk or severity of hypertension can be increased when Cyclosporine is combined with Solabegron.,Solabegron
DB06690,The risk or severity of hypertension can be increased when Cyclosporine is combined with Nitrous oxide.,Nitrous oxide
DB06694,The risk or severity of hypertension can be increased when Cyclosporine is combined with Xylometazoline.,Xylometazoline
DB06701,The risk or severity of hypertension can be increased when Cyclosporine is combined with Dexmethylphenidate.,Dexmethylphenidate
DB06706,The risk or severity of hypertension can be increased when Cyclosporine is combined with Isometheptene.,Isometheptene
DB06707,The risk or severity of hypertension can be increased when Cyclosporine is combined with Levonordefrin.,Levonordefrin
DB06711,The risk or severity of hypertension can be increased when Cyclosporine is combined with Naphazoline.,Naphazoline
DB06764,The risk or severity of hypertension can be increased when Cyclosporine is combined with Tetryzoline.,Tetryzoline
DB08810,The risk or severity of hypertension can be increased when Cyclosporine is combined with Cinitapride.,Cinitapride
DB08841,The risk or severity of hypertension can be increased when Cyclosporine is combined with Tyramine.,Tyramine
DB08925,The risk or severity of hypertension can be increased when Cyclosporine is combined with Adrafinil.,Adrafinil
DB08941,The risk or severity of hypertension can be increased when Cyclosporine is combined with Isoxsuprine.,Isoxsuprine
DB08950,The risk or severity of hypertension can be increased when Cyclosporine is combined with Indoramin.,Indoramin
DB08957,The risk or severity of hypertension can be increased when Cyclosporine is combined with Hexoprenaline.,Hexoprenaline
DB08985,The risk or severity of hypertension can be increased when Cyclosporine is combined with Etilefrine.,Etilefrine
DB09202,The risk or severity of hypertension can be increased when Cyclosporine is combined with Cirazoline.,Cirazoline
DB09203,The risk or severity of hypertension can be increased when Cyclosporine is combined with Synephrine.,Synephrine
DB09242,The risk or severity of hypertension can be increased when Cyclosporine is combined with Moxonidine.,Moxonidine
DB09243,The risk or severity of hypertension can be increased when Cyclosporine is combined with Hydracarbazine.,Hydracarbazine
DB09246,The risk or severity of hypertension can be increased when Cyclosporine is combined with Benmoxin.,Benmoxin
DB09248,The risk or severity of hypertension can be increased when Cyclosporine is combined with Mebanazine.,Mebanazine
DB09249,The risk or severity of hypertension can be increased when Cyclosporine is combined with Octamoxin.,Octamoxin
DB09250,The risk or severity of hypertension can be increased when Cyclosporine is combined with Pheniprazine.,Pheniprazine
DB09251,The risk or severity of hypertension can be increased when Cyclosporine is combined with Phenoxypropazine.,Phenoxypropazine
DB09252,The risk or severity of hypertension can be increased when Cyclosporine is combined with Pivhydrazine.,Pivhydrazine
DB09253,The risk or severity of hypertension can be increased when Cyclosporine is combined with Safrazine.,Safrazine
DB09254,The risk or severity of hypertension can be increased when Cyclosporine is combined with Caroxazone.,Caroxazone
DB09273,The risk or severity of hypertension can be increased when Cyclosporine is combined with Doxofylline.,Doxofylline
DB09480,The risk or severity of hypertension can be increased when Cyclosporine is combined with Iofetamine I-123.,Iofetamine I-123
DB11124,The risk or severity of hypertension can be increased when Cyclosporine is combined with Racepinephrine.,Racepinephrine
DB11373,The risk or severity of hypertension can be increased when Cyclosporine is combined with Amitraz.,Amitraz
DB11428,The risk or severity of hypertension can be increased when Cyclosporine is combined with Medetomidine.,Medetomidine
DB11477,The risk or severity of hypertension can be increased when Cyclosporine is combined with Xylazine.,Xylazine
DB11481,The risk or severity of hypertension can be increased when Cyclosporine is combined with Atipamezole.,Atipamezole
DB11541,The risk or severity of hypertension can be increased when Cyclosporine is combined with Ractopamine.,Ractopamine
DB11543,The risk or severity of hypertension can be increased when Cyclosporine is combined with Romifidine.,Romifidine
DB11556,The risk or severity of hypertension can be increased when Cyclosporine is combined with Detomidine.,Detomidine
DB11738,The risk or severity of hypertension can be increased when Cyclosporine is combined with Rilmenidine.,Rilmenidine
DB11755,The risk or severity of hypertension can be increased when Cyclosporine is combined with Tetrahydrocannabivarin.,Tetrahydrocannabivarin
DB11871,The risk or severity of hypertension can be increased when Cyclosporine is combined with PF-00610355.,PF-00610355
DB12080,The risk or severity of hypertension can be increased when Cyclosporine is combined with Ritobegron.,Ritobegron
DB12100,The risk or severity of hypertension can be increased when Cyclosporine is combined with Abediterol.,Abediterol
DB12248,The risk or severity of hypertension can be increased when Cyclosporine is combined with Tulobuterol.,Tulobuterol
DB12313,The risk or severity of hypertension can be increased when Cyclosporine is combined with Dopexamine.,Dopexamine
DB12361,The risk or severity of hypertension can be increased when Cyclosporine is combined with Piclozotan.,Piclozotan
DB12551,The risk or severity of hypertension can be increased when Cyclosporine is combined with Idazoxan.,Idazoxan
DB12661,The risk or severity of hypertension can be increased when Cyclosporine is combined with Urapidil.,Urapidil
DB12779,The risk or severity of hypertension can be increased when Cyclosporine is combined with Higenamine.,Higenamine
DB12846,The risk or severity of hypertension can be increased when Cyclosporine is combined with Reproterol.,Reproterol
DB12927,The risk or severity of hypertension can be increased when Cyclosporine is combined with Theodrenaline.,Theodrenaline
DB13064,The risk or severity of hypertension can be increased when Cyclosporine is combined with Tramazoline.,Tramazoline
DB13108,The risk or severity of hypertension can be increased when Cyclosporine is combined with Mephedrone.,Mephedrone
DB13251,The risk or severity of hypertension can be increased when Cyclosporine is combined with Octopamine.,Octopamine
DB13316,The risk or severity of hypertension can be increased when Cyclosporine is combined with Ibopamine.,Ibopamine
DB13323,The risk or severity of hypertension can be increased when Cyclosporine is combined with Trichloroethylene.,Trichloroethylene
DB13341,The risk or severity of hypertension can be increased when Cyclosporine is combined with Fenozolone.,Fenozolone
DB13378,The risk or severity of hypertension can be increased when Cyclosporine is combined with Norfenefrine.,Norfenefrine
DB13398,The risk or severity of hypertension can be increased when Cyclosporine is combined with Oxyfedrine.,Oxyfedrine
DB13453,The risk or severity of hypertension can be increased when Cyclosporine is combined with Xenon.,Xenon
DB13510,The risk or severity of hypertension can be increased when Cyclosporine is combined with Buflomedil.,Buflomedil
DB13520,The risk or severity of hypertension can be increased when Cyclosporine is combined with Metergoline.,Metergoline
DB13559,The risk or severity of hypertension can be increased when Cyclosporine is combined with Rimiterol.,Rimiterol
DB13624,The risk or severity of hypertension can be increased when Cyclosporine is combined with Methoxyphenamine.,Methoxyphenamine
DB13692,The risk or severity of hypertension can be increased when Cyclosporine is combined with Tretoquinol.,Tretoquinol
DB13703,The risk or severity of hypertension can be increased when Cyclosporine is combined with Gepefrine.,Gepefrine
DB13777,The risk or severity of hypertension can be increased when Cyclosporine is combined with Prenalterol.,Prenalterol
DB13781,The risk or severity of hypertension can be increased when Cyclosporine is combined with Xamoterol.,Xamoterol
DB13852,The risk or severity of hypertension can be increased when Cyclosporine is combined with Mefenorex.,Mefenorex
DB13875,The risk or severity of hypertension can be increased when Cyclosporine is combined with Harmaline.,Harmaline
DB13917,The risk or severity of hypertension can be increased when Cyclosporine is combined with Deoxyepinephrine.,Deoxyepinephrine
DB13940,"The risk or severity of hypertension can be increased when Cyclosporine is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.","2,5-Dimethoxy-4-ethylthioamphetamine"
DB14231,The risk or severity of hypertension can be increased when Cyclosporine is combined with Quinoline Yellow WS.,Quinoline Yellow WS
DB00708,The risk or severity of hypertension can be increased when Cyclosporine is combined with Sufentanil.,Sufentanil
DB00865,The risk or severity of hypertension can be increased when Cyclosporine is combined with Benzphetamine.,Benzphetamine
DB01049,The risk or severity of hypertension can be increased when Cyclosporine is combined with Ergoloid mesylate.,Ergoloid mesylate
DB01236,The risk or severity of hypertension can be increased when Cyclosporine is combined with Sevoflurane.,Sevoflurane
DB06216,The risk or severity of hypertension can be increased when Cyclosporine is combined with Asenapine.,Asenapine
DB13399,The risk or severity of hypertension can be increased when Cyclosporine is combined with Terguride.,Terguride
DB00831,The risk or severity of hypertension can be increased when Cyclosporine is combined with Trifluoperazine.,Trifluoperazine
DB00875,The risk or severity of hypertension can be increased when Cyclosporine is combined with Flupentixol.,Flupentixol
DB01159,The risk or severity of hypertension can be increased when Cyclosporine is combined with Halothane.,Halothane
DB01253,The risk or severity of hypertension can be increased when Cyclosporine is combined with Ergometrine.,Ergometrine
DB09080,The risk or severity of hypertension can be increased when Cyclosporine is combined with Olodaterol.,Olodaterol
DB13598,The risk or severity of hypertension can be increased when Cyclosporine is combined with Diethyl ether.,Diethyl ether
DB01186,The risk or severity of hypertension can be increased when Cyclosporine is combined with Pergolide.,Pergolide
DB15685,The risk or severity of hypertension can be increased when Cyclosporine is combined with Selpercatinib.,Selpercatinib
DB01166,The metabolism of Cilostazol can be decreased when combined with Cyclosporine.,Cilostazol
DB00813,The metabolism of Cyclosporine can be decreased when combined with Fentanyl.,Fentanyl
DB04946,The metabolism of Iloperidone can be decreased when combined with Cyclosporine.,Iloperidone
DB01256,The metabolism of Retapamulin can be decreased when combined with Cyclosporine.,Retapamulin
DB00862,The metabolism of Vardenafil can be decreased when combined with Cyclosporine.,Vardenafil
DB00402,The metabolism of Eszopiclone can be decreased when combined with Cyclosporine.,Eszopiclone
DB01198,The metabolism of Zopiclone can be decreased when combined with Cyclosporine.,Zopiclone
DB09046,The metabolism of Cyclosporine can be increased when combined with Metreleptin.,Metreleptin
DB00346,The metabolism of Alfuzosin can be decreased when combined with Cyclosporine.,Alfuzosin
DB00404,The metabolism of Alprazolam can be decreased when combined with Cyclosporine.,Alprazolam
DB00289,The metabolism of Atomoxetine can be decreased when combined with Cyclosporine.,Atomoxetine
DB00742,The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cyclosporine.,Mannitol
DB09299,Tenofovir alafenamide may increase the nephrotoxic activities of Cyclosporine.,Tenofovir alafenamide
DB14126,Tenofovir may increase the nephrotoxic activities of Cyclosporine.,Tenofovir
DB00300,Cyclosporine may increase the nephrotoxic activities of Tenofovir disoproxil.,Tenofovir disoproxil
DB00682,The serum concentration of Warfarin can be increased when it is combined with Cyclosporine.,Warfarin
DB01418,The serum concentration of Acenocoumarol can be increased when it is combined with Cyclosporine.,Acenocoumarol
DB08496,The serum concentration of (R)-warfarin can be increased when it is combined with Cyclosporine.,(R)-warfarin
DB08735,"The serum concentration of R,S-Warfarin alcohol can be increased when it is combined with Cyclosporine.","R,S-Warfarin alcohol"
DB08736,"The serum concentration of S,R-Warfarin alcohol can be increased when it is combined with Cyclosporine.","S,R-Warfarin alcohol"
DB14055,The serum concentration of (S)-Warfarin can be increased when it is combined with Cyclosporine.,(S)-Warfarin
DB00683,The serum concentration of Midazolam can be increased when it is combined with Cyclosporine.,Midazolam
DB01015,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Cyclosporine.,Sulfamethoxazole
DB00997,The serum concentration of Doxorubicin can be increased when it is combined with Cyclosporine.,Doxorubicin
DB09272,The serum concentration of Eluxadoline can be increased when it is combined with Cyclosporine.,Eluxadoline
DB00636,The risk or severity of renal failure can be increased when Cyclosporine is combined with Clofibrate.,Clofibrate
DB01039,The risk or severity of renal failure can be increased when Cyclosporine is combined with Fenofibrate.,Fenofibrate
DB01241,The risk or severity of renal failure can be increased when Cyclosporine is combined with Gemfibrozil.,Gemfibrozil
DB01393,The risk or severity of renal failure can be increased when Cyclosporine is combined with Bezafibrate.,Bezafibrate
DB08983,The risk or severity of renal failure can be increased when Cyclosporine is combined with Etofibrate.,Etofibrate
DB09064,The risk or severity of renal failure can be increased when Cyclosporine is combined with Ciprofibrate.,Ciprofibrate
DB13433,The risk or severity of renal failure can be increased when Cyclosporine is combined with Simfibrate.,Simfibrate
DB13460,The risk or severity of renal failure can be increased when Cyclosporine is combined with Ronifibrate.,Ronifibrate
DB13780,The risk or severity of renal failure can be increased when Cyclosporine is combined with Aluminium clofibrate.,Aluminium clofibrate
DB13849,The risk or severity of renal failure can be increased when Cyclosporine is combined with Clofibride.,Clofibride
DB13873,The risk or severity of renal failure can be increased when Cyclosporine is combined with Fenofibric acid.,Fenofibric acid
DB00350,The risk or severity of Hypertrichosis can be increased when Cyclosporine is combined with Minoxidil.,Minoxidil
DB00864,Tacrolimus may increase the nephrotoxic activities of Cyclosporine.,Tacrolimus
DB00104,The serum concentration of Cyclosporine can be decreased when it is combined with Octreotide.,Octreotide
DB04894,The serum concentration of Cyclosporine can be decreased when it is combined with Vapreotide.,Vapreotide
DB06663,The serum concentration of Cyclosporine can be decreased when it is combined with Pasireotide.,Pasireotide
DB06791,The serum concentration of Cyclosporine can be decreased when it is combined with Lanreotide.,Lanreotide
DB09099,The serum concentration of Cyclosporine can be decreased when it is combined with Somatostatin.,Somatostatin
DB00126,The serum concentration of Cyclosporine can be decreased when it is combined with Ascorbic acid.,Ascorbic acid
DB00177,The risk or severity of hyperkalemia can be increased when Valsartan is combined with Cyclosporine.,Valsartan
DB00275,The risk or severity of hyperkalemia can be increased when Olmesartan is combined with Cyclosporine.,Olmesartan
DB00678,The risk or severity of hyperkalemia can be increased when Losartan is combined with Cyclosporine.,Losartan
DB00796,The risk or severity of hyperkalemia can be increased when Candesartan cilexetil is combined with Cyclosporine.,Candesartan cilexetil
DB00876,The risk or severity of hyperkalemia can be increased when Eprosartan is combined with Cyclosporine.,Eprosartan
DB00966,The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Cyclosporine.,Telmisartan
DB01029,The risk or severity of hyperkalemia can be increased when Irbesartan is combined with Cyclosporine.,Irbesartan
DB01342,The risk or severity of hyperkalemia can be increased when Forasartan is combined with Cyclosporine.,Forasartan
DB01347,The risk or severity of hyperkalemia can be increased when Saprisartan is combined with Cyclosporine.,Saprisartan
DB01349,The risk or severity of hyperkalemia can be increased when Tasosartan is combined with Cyclosporine.,Tasosartan
DB06763,The risk or severity of hyperkalemia can be increased when Saralasin is combined with Cyclosporine.,Saralasin
DB08822,The risk or severity of hyperkalemia can be increased when Azilsartan medoxomil is combined with Cyclosporine.,Azilsartan medoxomil
DB09279,The risk or severity of hyperkalemia can be increased when Fimasartan is combined with Cyclosporine.,Fimasartan
DB13919,The risk or severity of hyperkalemia can be increased when Candesartan is combined with Cyclosporine.,Candesartan
DB00199,The metabolism of Cyclosporine can be decreased when combined with Erythromycin.,Erythromycin
DB00207,The metabolism of Cyclosporine can be decreased when combined with Azithromycin.,Azithromycin
DB00954,The metabolism of Cyclosporine can be decreased when combined with Dirithromycin.,Dirithromycin
DB00976,The metabolism of Cyclosporine can be decreased when combined with Telithromycin.,Telithromycin
DB01152,The metabolism of Cyclosporine can be decreased when combined with Candicidin.,Candicidin
DB01211,The metabolism of Cyclosporine can be decreased when combined with Clarithromycin.,Clarithromycin
DB01321,The metabolism of Cyclosporine can be decreased when combined with Josamycin.,Josamycin
DB01873,The metabolism of Cyclosporine can be decreased when combined with Epothilone D.,Epothilone D
DB03010,The metabolism of Cyclosporine can be decreased when combined with Patupilone.,Patupilone
DB04070,The metabolism of Cyclosporine can be decreased when combined with 6-Deoxyerythronolide B.,6-Deoxyerythronolide B
DB05903,The metabolism of Cyclosporine can be decreased when combined with KOS-1584.,KOS-1584
DB06233,The metabolism of Cyclosporine can be decreased when combined with Ridaforolimus.,Ridaforolimus
DB06318,The metabolism of Cyclosporine can be decreased when combined with AVE9633.,AVE9633
DB06342,The metabolism of Cyclosporine can be decreased when combined with Coltuximab ravtansine.,Coltuximab ravtansine
DB06419,The metabolism of Cyclosporine can be decreased when combined with Cethromycin.,Cethromycin
DB06587,The metabolism of Cyclosporine can be decreased when combined with Mitemcinal.,Mitemcinal
DB07348,The metabolism of Cyclosporine can be decreased when combined with Brefeldin A.,Brefeldin A
DB09308,The metabolism of Cyclosporine can be decreased when combined with Solithromycin.,Solithromycin
DB09309,The metabolism of Cyclosporine can be decreased when combined with Kitasamycin.,Kitasamycin
DB11383,The metabolism of Cyclosporine can be decreased when combined with Carbomycin.,Carbomycin
DB11400,The metabolism of Cyclosporine can be decreased when combined with Doramectin.,Doramectin
DB11405,The metabolism of Cyclosporine can be decreased when combined with Eprinomectin.,Eprinomectin
DB11442,The metabolism of Cyclosporine can be decreased when combined with Oleandomycin.,Oleandomycin
DB11459,The metabolism of Cyclosporine can be decreased when combined with Selamectin.,Selamectin
DB11470,The metabolism of Cyclosporine can be decreased when combined with Tildipirosin.,Tildipirosin
DB11471,The metabolism of Cyclosporine can be decreased when combined with Tilmicosin.,Tilmicosin
DB11475,The metabolism of Cyclosporine can be decreased when combined with Tylosin.,Tylosin
DB11554,The metabolism of Cyclosporine can be decreased when combined with Tylvalosin.,Tylvalosin
DB11752,The metabolism of Cyclosporine can be decreased when combined with Bryostatin 1.,Bryostatin 1
DB12089,The metabolism of Cyclosporine can be decreased when combined with Lorvotuzumab mertansine.,Lorvotuzumab mertansine
DB12266,The metabolism of Cyclosporine can be decreased when combined with Epofolate.,Epofolate
DB12391,The metabolism of Cyclosporine can be decreased when combined with Sagopilone.,Sagopilone
DB12489,The metabolism of Cyclosporine can be decreased when combined with Mirvetuximab Soravtansine.,Mirvetuximab Soravtansine
DB13179,The metabolism of Cyclosporine can be decreased when combined with Troleandomycin.,Troleandomycin
DB13287,The metabolism of Cyclosporine can be decreased when combined with Miocamycin.,Miocamycin
DB13338,The metabolism of Cyclosporine can be decreased when combined with Flurithromycin.,Flurithromycin
DB13409,The metabolism of Cyclosporine can be decreased when combined with Rokitamycin.,Rokitamycin
DB13456,The metabolism of Cyclosporine can be decreased when combined with Midecamycin.,Midecamycin
DB13633,The metabolism of Cyclosporine can be decreased when combined with Mepartricin.,Mepartricin
DB00903,The risk or severity of adverse effects can be increased when Cyclosporine is combined with Etacrynic acid.,Etacrynic acid
DB00241,The metabolism of Cyclosporine can be increased when combined with Butalbital.,Butalbital
DB00312,The metabolism of Cyclosporine can be increased when combined with Pentobarbital.,Pentobarbital
DB00418,The metabolism of Cyclosporine can be increased when combined with Secobarbital.,Secobarbital
DB00474,The metabolism of Cyclosporine can be increased when combined with Methohexital.,Methohexital
DB00599,The metabolism of Cyclosporine can be increased when combined with Thiopental.,Thiopental
DB00794,The metabolism of Cyclosporine can be increased when combined with Primidone.,Primidone
DB00849,The metabolism of Cyclosporine can be increased when combined with Methylphenobarbital.,Methylphenobarbital
DB01154,The metabolism of Cyclosporine can be increased when combined with Thiamylal.,Thiamylal
DB01174,The metabolism of Cyclosporine can be increased when combined with Phenobarbital.,Phenobarbital
DB01351,The metabolism of Cyclosporine can be increased when combined with Amobarbital.,Amobarbital
DB01355,The metabolism of Cyclosporine can be increased when combined with Hexobarbital.,Hexobarbital
DB01483,The metabolism of Cyclosporine can be increased when combined with Barbital.,Barbital
DB09001,The metabolism of Cyclosporine can be increased when combined with Barbexaclone.,Barbexaclone
DB00237,The metabolism of Butabarbital can be increased when combined with Cyclosporine.,Butabarbital
DB09280,The serum concentration of Cyclosporine can be decreased when it is combined with Lumacaftor.,Lumacaftor
DB00214,The risk or severity of renal failure can be increased when Cyclosporine is combined with Torasemide.,Torasemide
DB00887,The risk or severity of renal failure can be increased when Cyclosporine is combined with Bumetanide.,Bumetanide
DB02925,The risk or severity of renal failure can be increased when Cyclosporine is combined with Piretanide.,Piretanide
DB08961,The risk or severity of renal failure can be increased when Cyclosporine is combined with Azosemide.,Azosemide
DB00203,The risk or severity of renal failure can be increased when Sildenafil is combined with Cyclosporine.,Sildenafil
DB00232,The risk or severity of renal failure can be increased when Methyclothiazide is combined with Cyclosporine.,Methyclothiazide
DB00263,The risk or severity of renal failure can be increased when Sulfisoxazole is combined with Cyclosporine.,Sulfisoxazole
DB00310,The risk or severity of renal failure can be increased when Chlorthalidone is combined with Cyclosporine.,Chlorthalidone
DB00311,The risk or severity of renal failure can be increased when Ethoxzolamide is combined with Cyclosporine.,Ethoxzolamide
DB00359,The risk or severity of renal failure can be increased when Sulfadiazine is combined with Cyclosporine.,Sulfadiazine
DB00436,The risk or severity of renal failure can be increased when Bendroflumethiazide is combined with Cyclosporine.,Bendroflumethiazide
DB00524,The risk or severity of renal failure can be increased when Metolazone is combined with Cyclosporine.,Metolazone
DB00562,The risk or severity of renal failure can be increased when Benzthiazide is combined with Cyclosporine.,Benzthiazide
DB00576,The risk or severity of renal failure can be increased when Sulfamethizole is combined with Cyclosporine.,Sulfamethizole
DB00606,The risk or severity of renal failure can be increased when Cyclothiazide is combined with Cyclosporine.,Cyclothiazide
DB00664,The risk or severity of renal failure can be increased when Sulfametopyrazine is combined with Cyclosporine.,Sulfametopyrazine
DB00669,The risk or severity of renal failure can be increased when Sumatriptan is combined with Cyclosporine.,Sumatriptan
DB00706,The risk or severity of renal failure can be increased when Tamsulosin is combined with Cyclosporine.,Tamsulosin
DB00774,The risk or severity of renal failure can be increased when Hydroflumethiazide is combined with Cyclosporine.,Hydroflumethiazide
DB00808,The risk or severity of renal failure can be increased when Indapamide is combined with Cyclosporine.,Indapamide
DB00880,The risk or severity of renal failure can be increased when Chlorothiazide is combined with Cyclosporine.,Chlorothiazide
DB00891,The risk or severity of renal failure can be increased when Sulfapyridine is combined with Cyclosporine.,Sulfapyridine
DB00909,The risk or severity of renal failure can be increased when Zonisamide is combined with Cyclosporine.,Zonisamide
DB00999,The risk or severity of renal failure can be increased when Hydrochlorothiazide is combined with Cyclosporine.,Hydrochlorothiazide
DB01021,The risk or severity of renal failure can be increased when Trichlormethiazide is combined with Cyclosporine.,Trichlormethiazide
DB01032,The risk or severity of renal failure can be increased when Probenecid is combined with Cyclosporine.,Probenecid
DB01119,The risk or severity of renal failure can be increased when Diazoxide is combined with Cyclosporine.,Diazoxide
DB01144,The risk or severity of renal failure can be increased when Diclofenamide is combined with Cyclosporine.,Diclofenamide
DB01298,The risk or severity of renal failure can be increased when Sulfacytine is combined with Cyclosporine.,Sulfacytine
DB01299,The risk or severity of renal failure can be increased when Sulfadoxine is combined with Cyclosporine.,Sulfadoxine
DB01324,The risk or severity of renal failure can be increased when Polythiazide is combined with Cyclosporine.,Polythiazide
DB01325,The risk or severity of renal failure can be increased when Quinethazone is combined with Cyclosporine.,Quinethazone
DB01382,The risk or severity of renal failure can be increased when Glymidine is combined with Cyclosporine.,Glymidine
DB01581,The risk or severity of renal failure can be increased when Sulfamerazine is combined with Cyclosporine.,Sulfamerazine
DB01582,The risk or severity of renal failure can be increased when Sulfamethazine is combined with Cyclosporine.,Sulfamethazine
DB04707,The risk or severity of renal failure can be increased when Hydroxyfasudil is combined with Cyclosporine.,Hydroxyfasudil
DB06150,The risk or severity of renal failure can be increased when Sulfadimethoxine is combined with Cyclosporine.,Sulfadimethoxine
DB06729,The risk or severity of renal failure can be increased when Sulfaphenazole is combined with Cyclosporine.,Sulfaphenazole
DB06821,The risk or severity of renal failure can be increased when Sulfameter is combined with Cyclosporine.,Sulfameter
DB07996,The risk or severity of renal failure can be increased when 5-(2-methylpiperazine-1-sulfonyl)isoquinoline is combined with Cyclosporine.,5-(2-methylpiperazine-1-sulfonyl)isoquinoline
DB08162,The risk or severity of renal failure can be increased when Fasudil is combined with Cyclosporine.,Fasudil
DB08798,The risk or severity of renal failure can be increased when Sulfamoxole is combined with Cyclosporine.,Sulfamoxole
DB11389,The risk or severity of renal failure can be increased when Clorsulon is combined with Cyclosporine.,Clorsulon
DB11461,The risk or severity of renal failure can be increased when Sulfachlorpyridazine is combined with Cyclosporine.,Sulfachlorpyridazine
DB11462,The risk or severity of renal failure can be increased when Sulfaethoxypyridazine is combined with Cyclosporine.,Sulfaethoxypyridazine
DB11463,The risk or severity of renal failure can be increased when Sulfanitran is combined with Cyclosporine.,Sulfanitran
DB11464,The risk or severity of renal failure can be increased when Sulfaquinoxaline is combined with Cyclosporine.,Sulfaquinoxaline
DB12051,The risk or severity of renal failure can be increased when Setrobuvir is combined with Cyclosporine.,Setrobuvir
DB12921,The risk or severity of renal failure can be increased when Chlorsulfaquinoxaline is combined with Cyclosporine.,Chlorsulfaquinoxaline
DB13214,The risk or severity of renal failure can be increased when Sulfadicramide is combined with Cyclosporine.,Sulfadicramide
DB13248,The risk or severity of renal failure can be increased when Phthalylsulfathiazole is combined with Cyclosporine.,Phthalylsulfathiazole
DB13283,The risk or severity of renal failure can be increased when Sulfaisodimidine is combined with Cyclosporine.,Sulfaisodimidine
DB13284,The risk or severity of renal failure can be increased when Meticrane is combined with Cyclosporine.,Meticrane
DB13320,The risk or severity of renal failure can be increased when Sulfaperin is combined with Cyclosporine.,Sulfaperin
DB13405,The risk or severity of renal failure can be increased when Mefruside is combined with Cyclosporine.,Mefruside
DB13430,The risk or severity of renal failure can be increased when Mebutizide is combined with Cyclosporine.,Mebutizide
DB13485,The risk or severity of renal failure can be increased when Sulfametomidine is combined with Cyclosporine.,Sulfametomidine
DB13532,The risk or severity of renal failure can be increased when Cyclopenthiazide is combined with Cyclosporine.,Cyclopenthiazide
DB13547,The risk or severity of renal failure can be increased when Sulfatolamide is combined with Cyclosporine.,Sulfatolamide
DB13556,The risk or severity of renal failure can be increased when Sulfamazone is combined with Cyclosporine.,Sulfamazone
DB13580,The risk or severity of renal failure can be increased when Succinylsulfathiazole is combined with Cyclosporine.,Succinylsulfathiazole
DB13617,The risk or severity of renal failure can be increased when Clorexolone is combined with Cyclosporine.,Clorexolone
DB13663,The risk or severity of renal failure can be increased when Clofenamide is combined with Cyclosporine.,Clofenamide
DB13699,The risk or severity of renal failure can be increased when Sulfathiourea is combined with Cyclosporine.,Sulfathiourea
DB13708,The risk or severity of renal failure can be increased when Fenquizone is combined with Cyclosporine.,Fenquizone
DB13726,The risk or severity of renal failure can be increased when Sulfaguanidine is combined with Cyclosporine.,Sulfaguanidine
DB13773,The risk or severity of renal failure can be increased when Sulfamethoxypyridazine is combined with Cyclosporine.,Sulfamethoxypyridazine
DB13792,The risk or severity of renal failure can be increased when Clopamide is combined with Cyclosporine.,Clopamide
DB13803,The risk or severity of renal failure can be increased when Xipamide is combined with Cyclosporine.,Xipamide
DB14033,The risk or severity of renal failure can be increased when Acetyl sulfisoxazole is combined with Cyclosporine.,Acetyl sulfisoxazole
DB14708,The risk or severity of renal failure can be increased when Tosylchloramide is combined with Cyclosporine.,Tosylchloramide
DB06370,The risk or severity of renal failure can be increased when Cyclosporine is combined with Indisulam.,Indisulam
DB00703,The risk or severity of renal failure can be increased when Methazolamide is combined with Cyclosporine.,Methazolamide
DB00384,The risk or severity of hyperkalemia can be increased when Triamterene is combined with Cyclosporine.,Triamterene
DB00421,The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Cyclosporine.,Spironolactone
DB00594,The risk or severity of hyperkalemia can be increased when Amiloride is combined with Cyclosporine.,Amiloride
DB00700,The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Cyclosporine.,Eplerenone
DB09015,The risk or severity of hyperkalemia can be increased when Canrenoic acid is combined with Cyclosporine.,Canrenoic acid
DB12221,The risk or severity of hyperkalemia can be increased when Canrenone is combined with Cyclosporine.,Canrenone
DB00229,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefotiam.,Cefotiam
DB00267,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefmenoxime.,Cefmenoxime
DB00274,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefmetazole.,Cefmetazole
DB00430,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefpiramide.,Cefpiramide
DB00447,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Loracarbef.,Loracarbef
DB00456,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefalotin.,Cefalotin
DB00493,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefotaxime.,Cefotaxime
DB00626,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Bacitracin.,Bacitracin
DB00689,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cephaloglycin.,Cephaloglycin
DB00718,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Adefovir dipivoxil.,Adefovir dipivoxil
DB00923,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Ceforanide.,Ceforanide
DB01066,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefditoren.,Cefditoren
DB01111,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Colistimethate.,Colistimethate
DB01112,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefuroxime.,Cefuroxime
DB01139,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefapirin.,Cefapirin
DB01150,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefprozil.,Cefprozil
DB01326,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefamandole.,Cefamandole
DB01327,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefazolin.,Cefazolin
DB01328,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefonicid.,Cefonicid
DB01331,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefoxitin.,Cefoxitin
DB01332,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Ceftizoxime.,Ceftizoxime
DB01413,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefepime.,Cefepime
DB01414,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefacetrile.,Cefacetrile
DB01416,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefpodoxime.,Cefpodoxime
DB02247,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Hydrolyzed Cephalothin.,Hydrolyzed Cephalothin
DB03450,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cephalothin Group.,Cephalothin Group
DB04570,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Latamoxef.,Latamoxef
DB04918,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Ceftobiprole.,Ceftobiprole
DB06590,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Ceftaroline fosamil.,Ceftaroline fosamil
DB09008,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefaloridine.,Cefaloridine
DB09062,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefminox.,Cefminox
DB11935,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Flomoxef.,Flomoxef
DB13266,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefatrizine.,Cefatrizine
DB13461,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefcapene.,Cefcapene
DB13470,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefodizime.,Cefodizime
DB13499,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefsulodin.,Cefsulodin
DB13504,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefetamet.,Cefetamet
DB13638,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefbuperazone.,Cefbuperazone
DB13667,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefozopran.,Cefozopran
DB13682,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefpirome.,Cefpirome
DB13778,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefazedone.,Cefazedone
DB13821,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Ceftezole.,Ceftezole
DB13868,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Adefovir.,Adefovir
DB14713,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Inotersen.,Inotersen
DB01438,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Phenazopyridine.,Phenazopyridine
DB15066,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Givosiran.,Givosiran
DB01329,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefoperazone.,Cefoperazone
DB01356,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Lithium cation.,Lithium cation
DB14507,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Lithium citrate.,Lithium citrate
DB00621,The risk or severity of liver damage can be increased when Oxandrolone is combined with Cyclosporine.,Oxandrolone
DB00624,The risk or severity of liver damage can be increased when Testosterone is combined with Cyclosporine.,Testosterone
DB00984,The risk or severity of liver damage can be increased when Nandrolone phenpropionate is combined with Cyclosporine.,Nandrolone phenpropionate
DB01185,The risk or severity of liver damage can be increased when Fluoxymesterone is combined with Cyclosporine.,Fluoxymesterone
DB01406,The risk or severity of liver damage can be increased when Danazol is combined with Cyclosporine.,Danazol
DB01420,The risk or severity of liver damage can be increased when Testosterone propionate is combined with Cyclosporine.,Testosterone propionate
DB02901,The risk or severity of liver damage can be increased when Stanolone is combined with Cyclosporine.,Stanolone
DB06412,The risk or severity of liver damage can be increased when Oxymetholone is combined with Cyclosporine.,Oxymetholone
DB06710,The risk or severity of liver damage can be increased when Methyltestosterone is combined with Cyclosporine.,Methyltestosterone
DB06718,The risk or severity of liver damage can be increased when Stanozolol is combined with Cyclosporine.,Stanozolol
DB08804,The risk or severity of liver damage can be increased when Nandrolone decanoate is combined with Cyclosporine.,Nandrolone decanoate
DB12461,The risk or severity of liver damage can be increased when GLPG-0492 is combined with Cyclosporine.,GLPG-0492
DB13169,The risk or severity of liver damage can be increased when Nandrolone is combined with Cyclosporine.,Nandrolone
DB13587,The risk or severity of liver damage can be increased when Mesterolone is combined with Cyclosporine.,Mesterolone
DB13943,The risk or severity of liver damage can be increased when Testosterone cypionate is combined with Cyclosporine.,Testosterone cypionate
DB13944,The risk or severity of liver damage can be increased when Testosterone enanthate is combined with Cyclosporine.,Testosterone enanthate
DB14010,"The metabolism of 5-methoxy-N,N-dimethyltryptamine can be decreased when combined with Cyclosporine.","5-methoxy-N,N-dimethyltryptamine"
DB00318,The metabolism of Codeine can be decreased when combined with Cyclosporine.,Codeine
DB00454,The metabolism of Meperidine can be decreased when combined with Cyclosporine.,Meperidine
DB00458,The metabolism of Imipramine can be decreased when combined with Cyclosporine.,Imipramine
DB00908,The metabolism of Quinidine can be decreased when combined with Cyclosporine.,Quinidine
DB01035,The metabolism of Procainamide can be decreased when combined with Cyclosporine.,Procainamide
DB01151,The metabolism of Desipramine can be decreased when combined with Cyclosporine.,Desipramine
DB01242,The metabolism of Clomipramine can be decreased when combined with Cyclosporine.,Clomipramine
DB00238,The metabolism of Cyclosporine can be decreased when combined with Nevirapine.,Nevirapine
DB11586,The metabolism of Cyclosporine can be decreased when combined with Asunaprevir.,Asunaprevir
DB00497,The metabolism of Cyclosporine can be decreased when combined with Oxycodone.,Oxycodone
DB00514,The metabolism of Cyclosporine can be decreased when combined with Dextromethorphan.,Dextromethorphan
DB00731,The metabolism of Cyclosporine can be decreased when combined with Nateglinide.,Nateglinide
DB00738,The metabolism of Cyclosporine can be decreased when combined with Pentamidine.,Pentamidine
DB00904,The metabolism of Cyclosporine can be decreased when combined with Ondansetron.,Ondansetron
DB01114,The metabolism of Cyclosporine can be decreased when combined with Chlorpheniramine.,Chlorpheniramine
DB01184,The metabolism of Cyclosporine can be decreased when combined with Domperidone.,Domperidone
DB09068,The metabolism of Cyclosporine can be decreased when combined with Vortioxetine.,Vortioxetine
DB11915,The metabolism of Cyclosporine can be decreased when combined with Valbenazine.,Valbenazine
DB12161,The metabolism of Cyclosporine can be decreased when combined with Deutetrabenazine.,Deutetrabenazine
DB00176,The metabolism of Cyclosporine can be decreased when combined with Fluvoxamine.,Fluvoxamine
DB00281,The metabolism of Cyclosporine can be decreased when combined with Lidocaine.,Lidocaine
DB00285,The metabolism of Cyclosporine can be decreased when combined with Venlafaxine.,Venlafaxine
DB00316,The metabolism of Cyclosporine can be decreased when combined with Acetaminophen.,Acetaminophen
DB00317,The metabolism of Cyclosporine can be decreased when combined with Gefitinib.,Gefitinib
DB00333,The metabolism of Cyclosporine can be decreased when combined with Methadone.,Methadone
DB00342,The metabolism of Cyclosporine can be decreased when combined with Terfenadine.,Terfenadine
DB00343,The metabolism of Cyclosporine can be decreased when combined with Diltiazem.,Diltiazem
DB00344,The metabolism of Cyclosporine can be decreased when combined with Protriptyline.,Protriptyline
DB00468,The metabolism of Cyclosporine can be decreased when combined with Quinine.,Quinine
DB00472,The metabolism of Cyclosporine can be decreased when combined with Fluoxetine.,Fluoxetine
DB00476,The metabolism of Cyclosporine can be decreased when combined with Duloxetine.,Duloxetine
DB00477,The metabolism of Cyclosporine can be decreased when combined with Chlorpromazine.,Chlorpromazine
DB00490,The metabolism of Cyclosporine can be decreased when combined with Buspirone.,Buspirone
DB00543,The metabolism of Cyclosporine can be decreased when combined with Amoxapine.,Amoxapine
DB00590,The metabolism of Cyclosporine can be decreased when combined with Doxazosin.,Doxazosin
DB00637,The metabolism of Cyclosporine can be decreased when combined with Astemizole.,Astemizole
DB00715,The metabolism of Cyclosporine can be decreased when combined with Paroxetine.,Paroxetine
DB00836,The metabolism of Cyclosporine can be decreased when combined with Loperamide.,Loperamide
DB00921,The metabolism of Cyclosporine can be decreased when combined with Buprenorphine.,Buprenorphine
DB00932,The metabolism of Cyclosporine can be decreased when combined with Tipranavir.,Tipranavir
DB00972,The metabolism of Cyclosporine can be decreased when combined with Azelastine.,Azelastine
DB01037,The metabolism of Cyclosporine can be decreased when combined with Selegiline.,Selegiline
DB01069,The metabolism of Cyclosporine can be decreased when combined with Promethazine.,Promethazine
DB01100,The metabolism of Cyclosporine can be decreased when combined with Pimozide.,Pimozide
DB01104,The metabolism of Cyclosporine can be decreased when combined with Sertraline.,Sertraline
DB01182,The metabolism of Cyclosporine can be decreased when combined with Propafenone.,Propafenone
DB01244,The metabolism of Cyclosporine can be decreased when combined with Bepridil.,Bepridil
DB01392,The metabolism of Cyclosporine can be decreased when combined with Yohimbine.,Yohimbine
DB06770,The metabolism of Cyclosporine can be decreased when combined with Benzyl alcohol.,Benzyl alcohol
DB08893,The metabolism of Cyclosporine can be decreased when combined with Mirabegron.,Mirabegron
DB09048,The metabolism of Cyclosporine can be decreased when combined with Netupitant.,Netupitant
DB11963,The metabolism of Cyclosporine can be decreased when combined with Dacomitinib.,Dacomitinib
DB12070,The metabolism of Cyclosporine can be decreased when combined with Letermovir.,Letermovir
DB12332,The metabolism of Cyclosporine can be decreased when combined with Rucaparib.,Rucaparib
DB13874,The metabolism of Cyclosporine can be decreased when combined with Enasidenib.,Enasidenib
DB00216,The metabolism of Eletriptan can be decreased when combined with Cyclosporine.,Eletriptan
DB00277,The metabolism of Theophylline can be decreased when combined with Cyclosporine.,Theophylline
DB00496,The metabolism of Darifenacin can be decreased when combined with Cyclosporine.,Darifenacin
DB00540,The metabolism of Nortriptyline can be decreased when combined with Cyclosporine.,Nortriptyline
DB00575,The metabolism of Clonidine can be decreased when combined with Cyclosporine.,Clonidine
DB00726,The metabolism of Trimipramine can be decreased when combined with Cyclosporine.,Trimipramine
DB01142,The metabolism of Doxepin can be decreased when combined with Cyclosporine.,Doxepin
DB01224,The metabolism of Quetiapine can be decreased when combined with Cyclosporine.,Quetiapine
DB00363,The metabolism of Cyclosporine can be decreased when combined with Clozapine.,Clozapine
DB00396,The metabolism of Cyclosporine can be decreased when combined with Progesterone.,Progesterone
DB00675,The metabolism of Cyclosporine can be decreased when combined with Tamoxifen.,Tamoxifen
DB01115,The metabolism of Cyclosporine can be decreased when combined with Nifedipine.,Nifedipine
DB04905,The metabolism of Cyclosporine can be decreased when combined with Tesmilifene.,Tesmilifene
DB04920,The metabolism of Cyclosporine can be decreased when combined with Clevidipine.,Clevidipine
DB01149,The metabolism of Cyclosporine can be decreased when combined with Nefazodone.,Nefazodone
DB00705,The metabolism of Cyclosporine can be decreased when combined with Delavirdine.,Delavirdine
DB00215,The metabolism of Citalopram can be decreased when combined with Cyclosporine.,Citalopram
DB00335,The metabolism of Atenolol can be decreased when combined with Cyclosporine.,Atenolol
DB01193,The metabolism of Acebutolol can be decreased when combined with Cyclosporine.,Acebutolol
DB01203,The metabolism of Nadolol can be decreased when combined with Cyclosporine.,Nadolol
DB04840,The metabolism of Debrisoquine can be decreased when combined with Cyclosporine.,Debrisoquine
DB04846,The metabolism of Celiprolol can be decreased when combined with Cyclosporine.,Celiprolol
DB09076,The metabolism of Umeclidinium can be decreased when combined with Cyclosporine.,Umeclidinium
DB11770,The metabolism of Talinolol can be decreased when combined with Cyclosporine.,Talinolol
DB11979,The metabolism of Elagolix can be decreased when combined with Cyclosporine.,Elagolix
DB00182,The metabolism of Amphetamine can be decreased when combined with Cyclosporine.,Amphetamine
DB00245,The metabolism of Benzatropine can be decreased when combined with Cyclosporine.,Benzatropine
DB00598,The metabolism of Labetalol can be decreased when combined with Cyclosporine.,Labetalol
DB00934,The metabolism of Maprotiline can be decreased when combined with Cyclosporine.,Maprotiline
DB00960,The metabolism of Pindolol can be decreased when combined with Cyclosporine.,Pindolol
DB01274,The metabolism of Arformoterol can be decreased when combined with Cyclosporine.,Arformoterol
DB01359,The metabolism of Penbutolol can be decreased when combined with Cyclosporine.,Penbutolol
DB01577,The metabolism of Metamfetamine can be decreased when combined with Cyclosporine.,Metamfetamine
DB04948,The metabolism of Lofexidine can be decreased when combined with Cyclosporine.,Lofexidine
DB09204,The metabolism of Arotinolol can be decreased when combined with Cyclosporine.,Arotinolol
DB00532,The metabolism of Mephenytoin can be decreased when combined with Cyclosporine.,Mephenytoin
DB00983,The metabolism of Formoterol can be decreased when combined with Cyclosporine.,Formoterol
DB01075,The metabolism of Diphenhydramine can be decreased when combined with Cyclosporine.,Diphenhydramine
DB01171,The metabolism of Moclobemide can be decreased when combined with Cyclosporine.,Moclobemide
DB06204,The metabolism of Tapentadol can be decreased when combined with Cyclosporine.,Tapentadol
DB00530,The metabolism of Erlotinib can be decreased when combined with Cyclosporine.,Erlotinib
DB00187,The metabolism of Esmolol can be decreased when combined with Cyclosporine.,Esmolol
DB00195,The metabolism of Betaxolol can be decreased when combined with Cyclosporine.,Betaxolol
DB00334,The metabolism of Olanzapine can be decreased when combined with Cyclosporine.,Olanzapine
DB00409,The metabolism of Remoxipride can be decreased when combined with Cyclosporine.,Remoxipride
DB00489,The metabolism of Sotalol can be decreased when combined with Cyclosporine.,Sotalol
DB00592,The metabolism of Piperazine can be decreased when combined with Cyclosporine.,Piperazine
DB00679,The metabolism of Thioridazine can be decreased when combined with Cyclosporine.,Thioridazine
DB00699,The metabolism of Nicergoline can be decreased when combined with Cyclosporine.,Nicergoline
DB00737,The metabolism of Meclizine can be decreased when combined with Cyclosporine.,Meclizine
DB00805,The metabolism of Minaprine can be decreased when combined with Cyclosporine.,Minaprine
DB00866,The metabolism of Alprenolol can be decreased when combined with Cyclosporine.,Alprenolol
DB00914,The metabolism of Phenformin can be decreased when combined with Cyclosporine.,Phenformin
DB00933,The metabolism of Mesoridazine can be decreased when combined with Cyclosporine.,Mesoridazine
DB01071,The metabolism of Mequitazine can be decreased when combined with Cyclosporine.,Mequitazine
DB01079,The metabolism of Tegaserod can be decreased when combined with Cyclosporine.,Tegaserod
DB01191,The metabolism of Dexfenfluramine can be decreased when combined with Cyclosporine.,Dexfenfluramine
DB01195,The metabolism of Flecainide can be decreased when combined with Cyclosporine.,Flecainide
DB01228,The metabolism of Encainide can be decreased when combined with Cyclosporine.,Encainide
DB01255,The metabolism of Lisdexamfetamine can be decreased when combined with Cyclosporine.,Lisdexamfetamine
DB01295,The metabolism of Bevantolol can be decreased when combined with Cyclosporine.,Bevantolol
DB01297,The metabolism of Practolol can be decreased when combined with Cyclosporine.,Practolol
DB01403,The metabolism of Methotrimeprazine can be decreased when combined with Cyclosporine.,Methotrimeprazine
DB01429,The metabolism of Aprindine can be decreased when combined with Cyclosporine.,Aprindine
DB01454,The metabolism of Midomafetamine can be decreased when combined with Cyclosporine.,Midomafetamine
DB01472,The metabolism of 4-Methoxyamphetamine can be decreased when combined with Cyclosporine.,4-Methoxyamphetamine
DB01576,The metabolism of Dextroamphetamine can be decreased when combined with Cyclosporine.,Dextroamphetamine
DB01580,The metabolism of Oxprenolol can be decreased when combined with Cyclosporine.,Oxprenolol
DB04844,The metabolism of Tetrabenazine can be decreased when combined with Cyclosporine.,Tetrabenazine
DB06217,The metabolism of Vernakalant can be decreased when combined with Cyclosporine.,Vernakalant
DB06506,The metabolism of Repinotan can be decreased when combined with Cyclosporine.,Repinotan
DB06608,The metabolism of Tafenoquine can be decreased when combined with Cyclosporine.,Tafenoquine
DB06678,The metabolism of Esmirtazapine can be decreased when combined with Cyclosporine.,Esmirtazapine
DB06726,The metabolism of Bufuralol can be decreased when combined with Cyclosporine.,Bufuralol
DB06727,The metabolism of Sparteine can be decreased when combined with Cyclosporine.,Sparteine
DB06735,The metabolism of Enclomiphene can be decreased when combined with Cyclosporine.,Enclomiphene
DB08807,The metabolism of Bopindolol can be decreased when combined with Cyclosporine.,Bopindolol
DB08808,The metabolism of Bupranolol can be decreased when combined with Cyclosporine.,Bupranolol
DB08952,The metabolism of Indenolol can be decreased when combined with Cyclosporine.,Indenolol
DB09013,The metabolism of Befunolol can be decreased when combined with Cyclosporine.,Befunolol
DB09167,The metabolism of Dosulepin can be decreased when combined with Cyclosporine.,Dosulepin
DB09351,The metabolism of Levobetaxolol can be decreased when combined with Cyclosporine.,Levobetaxolol
DB11785,The metabolism of Anisodamine can be decreased when combined with Cyclosporine.,Anisodamine
DB12212,The metabolism of Landiolol can be decreased when combined with Cyclosporine.,Landiolol
DB12752,The metabolism of Bucindolol can be decreased when combined with Cyclosporine.,Bucindolol
DB12930,The metabolism of Opipramol can be decreased when combined with Cyclosporine.,Opipramol
DB13443,The metabolism of Esatenolol can be decreased when combined with Cyclosporine.,Esatenolol
DB13508,The metabolism of Cloranolol can be decreased when combined with Cyclosporine.,Cloranolol
DB13530,The metabolism of Mepindolol can be decreased when combined with Cyclosporine.,Mepindolol
DB13679,The metabolism of Dexchlorpheniramine can be decreased when combined with Cyclosporine.,Dexchlorpheniramine
DB13757,The metabolism of Epanolol can be decreased when combined with Cyclosporine.,Epanolol
DB13775,The metabolism of Tertatolol can be decreased when combined with Cyclosporine.,Tertatolol
DB08918,The metabolism of Levomilnacipran can be decreased when combined with Cyclosporine.,Levomilnacipran
DB00184,The metabolism of Cyclosporine can be decreased when combined with Nicotine.,Nicotine
DB00185,The metabolism of Cyclosporine can be decreased when combined with Cevimeline.,Cevimeline
DB00208,The metabolism of Cyclosporine can be decreased when combined with Ticlopidine.,Ticlopidine
DB00264,The metabolism of Cyclosporine can be decreased when combined with Metoprolol.,Metoprolol
DB00297,The metabolism of Cyclosporine can be decreased when combined with Bupivacaine.,Bupivacaine
DB00356,The metabolism of Cyclosporine can be decreased when combined with Chlorzoxazone.,Chlorzoxazone
DB00370,The metabolism of Cyclosporine can be decreased when combined with Mirtazapine.,Mirtazapine
DB00377,The metabolism of Cyclosporine can be decreased when combined with Palonosetron.,Palonosetron
DB00379,The metabolism of Cyclosporine can be decreased when combined with Mexiletine.,Mexiletine
DB00420,The metabolism of Cyclosporine can be decreased when combined with Promazine.,Promazine
DB00433,The metabolism of Cyclosporine can be decreased when combined with Prochlorperazine.,Prochlorperazine
DB00568,The metabolism of Cyclosporine can be decreased when combined with Cinnarizine.,Cinnarizine
DB00589,The metabolism of Cyclosporine can be decreased when combined with Lisuride.,Lisuride
DB00647,The metabolism of Cyclosporine can be decreased when combined with Dextropropoxyphene.,Dextropropoxyphene
DB00656,The metabolism of Cyclosporine can be decreased when combined with Trazodone.,Trazodone
DB00674,The metabolism of Cyclosporine can be decreased when combined with Galantamine.,Galantamine
DB00701,The metabolism of Cyclosporine can be decreased when combined with Amprenavir.,Amprenavir
DB00734,The metabolism of Cyclosporine can be decreased when combined with Risperidone.,Risperidone
DB00757,The metabolism of Cyclosporine can be decreased when combined with Dolasetron.,Dolasetron
DB00843,The metabolism of Cyclosporine can be decreased when combined with Donepezil.,Donepezil
DB00850,The metabolism of Cyclosporine can be decreased when combined with Perphenazine.,Perphenazine
DB00918,The metabolism of Cyclosporine can be decreased when combined with Almotriptan.,Almotriptan
DB01028,The metabolism of Cyclosporine can be decreased when combined with Methoxyflurane.,Methoxyflurane
DB01036,The metabolism of Cyclosporine can be decreased when combined with Tolterodine.,Tolterodine
DB01074,The metabolism of Cyclosporine can be decreased when combined with Perhexiline.,Perhexiline
DB01175,The metabolism of Cyclosporine can be decreased when combined with Escitalopram.,Escitalopram
DB01192,The metabolism of Cyclosporine can be decreased when combined with Oxymorphone.,Oxymorphone
DB01409,The metabolism of Cyclosporine can be decreased when combined with Tiotropium.,Tiotropium
DB01466,The metabolism of Cyclosporine can be decreased when combined with Ethylmorphine.,Ethylmorphine
DB01551,The metabolism of Cyclosporine can be decreased when combined with Dihydrocodeine.,Dihydrocodeine
DB01591,The metabolism of Cyclosporine can be decreased when combined with Solifenacin.,Solifenacin
DB01621,The metabolism of Cyclosporine can be decreased when combined with Pipotiazine.,Pipotiazine
DB01624,The metabolism of Cyclosporine can be decreased when combined with Zuclopenthixol.,Zuclopenthixol
DB02703,The metabolism of Cyclosporine can be decreased when combined with Fusidic acid.,Fusidic acid
DB03783,The metabolism of Cyclosporine can be decreased when combined with Phenacetin.,Phenacetin
DB04829,The metabolism of Cyclosporine can be decreased when combined with Lysergic acid diethylamide.,Lysergic acid diethylamide
DB04841,The metabolism of Cyclosporine can be decreased when combined with Flunarizine.,Flunarizine
DB04861,The metabolism of Cyclosporine can be decreased when combined with Nebivolol.,Nebivolol
DB04871,The metabolism of Cyclosporine can be decreased when combined with Lorcaserin.,Lorcaserin
DB04884,The metabolism of Cyclosporine can be decreased when combined with Dapoxetine.,Dapoxetine
DB05271,The metabolism of Cyclosporine can be decreased when combined with Rotigotine.,Rotigotine
DB06016,The metabolism of Cyclosporine can be decreased when combined with Cariprazine.,Cariprazine
DB06144,The metabolism of Cyclosporine can be decreased when combined with Sertindole.,Sertindole
DB06148,The metabolism of Cyclosporine can be decreased when combined with Mianserin.,Mianserin
DB06203,The metabolism of Cyclosporine can be decreased when combined with Alogliptin.,Alogliptin
DB06292,The metabolism of Cyclosporine can be decreased when combined with Dapagliflozin.,Dapagliflozin
DB06684,The metabolism of Cyclosporine can be decreased when combined with Vilazodone.,Vilazodone
DB06702,The metabolism of Cyclosporine can be decreased when combined with Fesoterodine.,Fesoterodine
DB08922,The metabolism of Cyclosporine can be decreased when combined with Perospirone.,Perospirone
DB09183,The metabolism of Cyclosporine can be decreased when combined with Dasabuvir.,Dasabuvir
DB09195,The metabolism of Cyclosporine can be decreased when combined with Lorpiprazole.,Lorpiprazole
DB09555,The metabolism of Cyclosporine can be decreased when combined with Dexchlorpheniramine maleate.,Dexchlorpheniramine maleate
DB11130,The metabolism of Cyclosporine can be decreased when combined with Opium.,Opium
DB11614,The metabolism of Cyclosporine can be decreased when combined with Rupatadine.,Rupatadine
DB11718,The metabolism of Cyclosporine can be decreased when combined with Encorafenib.,Encorafenib
DB12245,The metabolism of Cyclosporine can be decreased when combined with Triclabendazole.,Triclabendazole
DB13293,The metabolism of Cyclosporine can be decreased when combined with Ipecac.,Ipecac
DB09173,The metabolism of Butyrfentanyl can be decreased when combined with Cyclosporine.,Butyrfentanyl
DB11757,The metabolism of Istradefylline can be decreased when combined with Cyclosporine.,Istradefylline
DB04889,The metabolism of Bicifadine can be decreased when combined with Cyclosporine.,Bicifadine
DB01267,The metabolism of Cyclosporine can be decreased when combined with Paliperidone.,Paliperidone
DB00571,The metabolism of Cyclosporine can be decreased when combined with Propranolol.,Propranolol
DB00425,The metabolism of Zolpidem can be decreased when combined with Cyclosporine.,Zolpidem
DB00956,The metabolism of Hydrocodone can be decreased when combined with Cyclosporine.,Hydrocodone
DB00178,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Ramipril.,Ramipril
DB00407,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Ardeparin.,Ardeparin
DB00519,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Trandolapril.,Trandolapril
DB00542,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Benazepril.,Benazepril
DB00691,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Moexipril.,Moexipril
DB00881,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Quinapril.,Quinapril
DB00886,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Omapatrilat.,Omapatrilat
DB01109,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Heparin.,Heparin
DB01180,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Rescinnamine.,Rescinnamine
DB01225,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Enoxaparin.,Enoxaparin
DB01348,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Spirapril.,Spirapril
DB02968,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Penicillin G Acyl-Serine.,Penicillin G Acyl-Serine
DB06271,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Sulodexide.,Sulodexide
DB06754,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Danaparoid.,Danaparoid
DB06779,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Dalteparin.,Dalteparin
DB06822,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Tinzaparin.,Tinzaparin
DB08813,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Nadroparin.,Nadroparin
DB08836,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Temocapril.,Temocapril
DB09258,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Bemiparin.,Bemiparin
DB09259,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Reviparin.,Reviparin
DB09260,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Parnaparin.,Parnaparin
DB09261,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Certoparin.,Certoparin
DB11783,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Imidapril.,Imidapril
DB12097,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Mannitol busulfan.,Mannitol busulfan
DB13166,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Zofenopril.,Zofenopril
DB13312,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Delapril.,Delapril
DB14125,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Benazeprilat.,Benazeprilat
DB14207,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Fosinoprilat.,Fosinoprilat
DB14208,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Ramiprilat.,Ramiprilat
DB14213,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Perindoprilat.,Perindoprilat
DB14217,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Quinaprilat.,Quinaprilat
DB01219,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Dantrolene.,Dantrolene
DB09236,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Lacidipine.,Lacidipine
DB12092,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Naftopidil.,Naftopidil
DB12093,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Tetrahydropalmatine.,Tetrahydropalmatine
DB00825,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Levomenthol.,Levomenthol
DB04825,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Prenylamine.,Prenylamine
DB04838,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Cyclandelate.,Cyclandelate
DB04842,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Fluspirilene.,Fluspirilene
DB05885,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Seletracetam.,Seletracetam
DB06152,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Nylidrin.,Nylidrin
DB06446,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Dotarizine.,Dotarizine
DB08838,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Agmatine.,Agmatine
DB08980,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Fendiline.,Fendiline
DB08992,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Eperisone.,Eperisone
DB09090,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Pinaverium.,Pinaverium
DB09229,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Aranidipine.,Aranidipine
DB09230,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Azelnidipine.,Azelnidipine
DB09232,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Cilnidipine.,Cilnidipine
DB09234,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Darodipine.,Darodipine
DB09240,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Niludipine.,Niludipine
DB11960,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Carboxyamidotriazole.,Carboxyamidotriazole
DB13488,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Bencyclane.,Bencyclane
DB13500,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Otilonium.,Otilonium
DB13725,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Terodiline.,Terodiline
DB13766,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Lidoflazine.,Lidoflazine
DB13791,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Penfluridol.,Penfluridol
DB13835,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Caroverine.,Caroverine
DB13961,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Fish oil.,Fish oil
DB07615,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Tranilast.,Tranilast
DB12923,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Gallopamil.,Gallopamil
DB14063,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Dexverapamil.,Dexverapamil
DB14064,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Emopamil.,Emopamil
DB14065,The risk or severity of hyperkalemia can be increased when Cyclosporine is combined with Lomerizine.,Lomerizine
DB05239,The metabolism of Cyclosporine can be decreased when combined with Cobimetinib.,Cobimetinib
DB04914,The therapeutic efficacy of G17DT can be decreased when used in combination with Cyclosporine.,G17DT
DB05144,The therapeutic efficacy of PEV3A can be decreased when used in combination with Cyclosporine.,PEV3A
DB05325,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Cyclosporine.,INGN 225
DB05374,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Cyclosporine.,Rindopepimut
DB05440,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Cyclosporine.,SRP 299
DB05942,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Cyclosporine.,GI-5005
DB06400,The therapeutic efficacy of Vitespen can be decreased when used in combination with Cyclosporine.,Vitespen
DB06584,The therapeutic efficacy of TG4010 can be decreased when used in combination with Cyclosporine.,TG4010
DB09057,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Cyclosporine.,Anthrax immune globulin human
DB10062,"The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Cyclosporine.","Rabies virus inactivated antigen, B"
DB10076,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Cyclosporine.,Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen
DB10276,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Cyclosporine.,Rotavirus vaccine
DB10283,"The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Cyclosporine.","Rabies virus inactivated antigen, A"
DB10342,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Cyclosporine.,Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen
DB10583,The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cyclosporine.,Clostridium tetani toxoid antigen (formaldehyde inactivated)
DB10584,The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cyclosporine.,Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
DB10600,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Cyclosporine.,Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated)
DB10769,The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Cyclosporine.,Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)
DB10794,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Cyclosporine.,Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated)
DB10803,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Cyclosporine.,Typhoid Vi polysaccharide vaccine
DB10989,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Cyclosporine.,Hepatitis A Vaccine
DB10990,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Cyclosporine.,Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
DB11038,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Cyclosporine.,Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated)
DB11040,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Cyclosporine.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated)
DB11041,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Cyclosporine.,Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)
DB11044,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Cyclosporine.,Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated)
DB11603,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Cyclosporine.,Human rabies virus immune globulin
DB11627,The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Cyclosporine.,Hepatitis B Vaccine (Recombinant)
DB12568,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Cyclosporine.,Tecemotide
DB14022,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Cyclosporine.,Typhoid vaccine
DB14384,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Cyclosporine.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated)
DB14385,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Cyclosporine.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)
DB14394,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Cyclosporine.,Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen
DB14445,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Cyclosporine.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated)
DB14449,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Cyclosporine.,Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen
DB14619,The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Cyclosporine.,Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated)
DB14620,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Cyclosporine.,Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated)
DB14711,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Cyclosporine.,Vaccinia virus strain new york city board of health live antigen
DB15274,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Cyclosporine.,Pertussis vaccine
DB15461,The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Cyclosporine.,Yersinia pestis 195/p antigen (formaldehyde inactivated)
DB13924,The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Cyclosporine.,Varicella Zoster Vaccine (Recombinant)
DB15483,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Cyclosporine.,Modified vaccinia ankara
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Cyclosporine.","Ebola Zaire vaccine (live, attenuated)"
DB12364,The serum concentration of Cyclosporine can be increased when it is combined with Betrixaban.,Betrixaban
DB08881,The serum concentration of Cyclosporine can be increased when it is combined with Vemurafenib.,Vemurafenib
DB00159,The risk or severity of renal failure and hypertension can be increased when Icosapent is combined with Cyclosporine.,Icosapent
DB00244,The risk or severity of renal failure and hypertension can be increased when Mesalazine is combined with Cyclosporine.,Mesalazine
DB00461,The risk or severity of renal failure and hypertension can be increased when Nabumetone is combined with Cyclosporine.,Nabumetone
DB00465,The risk or severity of renal failure and hypertension can be increased when Ketorolac is combined with Cyclosporine.,Ketorolac
DB00469,The risk or severity of renal failure and hypertension can be increased when Tenoxicam is combined with Cyclosporine.,Tenoxicam
DB00482,The risk or severity of renal failure and hypertension can be increased when Celecoxib is combined with Cyclosporine.,Celecoxib
DB00500,The risk or severity of renal failure and hypertension can be increased when Tolmetin is combined with Cyclosporine.,Tolmetin
DB00533,The risk or severity of renal failure and hypertension can be increased when Rofecoxib is combined with Cyclosporine.,Rofecoxib
DB00554,The risk or severity of renal failure and hypertension can be increased when Piroxicam is combined with Cyclosporine.,Piroxicam
DB00573,The risk or severity of renal failure and hypertension can be increased when Fenoprofen is combined with Cyclosporine.,Fenoprofen
DB00580,The risk or severity of renal failure and hypertension can be increased when Valdecoxib is combined with Cyclosporine.,Valdecoxib
DB00605,The risk or severity of renal failure and hypertension can be increased when Sulindac is combined with Cyclosporine.,Sulindac
DB00712,The risk or severity of renal failure and hypertension can be increased when Flurbiprofen is combined with Cyclosporine.,Flurbiprofen
DB00749,The risk or severity of renal failure and hypertension can be increased when Etodolac is combined with Cyclosporine.,Etodolac
DB00784,The risk or severity of renal failure and hypertension can be increased when Mefenamic acid is combined with Cyclosporine.,Mefenamic acid
DB00788,The risk or severity of renal failure and hypertension can be increased when Naproxen is combined with Cyclosporine.,Naproxen
DB00812,The risk or severity of renal failure and hypertension can be increased when Phenylbutazone is combined with Cyclosporine.,Phenylbutazone
DB00814,The risk or severity of renal failure and hypertension can be increased when Meloxicam is combined with Cyclosporine.,Meloxicam
DB00821,The risk or severity of renal failure and hypertension can be increased when Carprofen is combined with Cyclosporine.,Carprofen
DB00861,The risk or severity of renal failure and hypertension can be increased when Diflunisal is combined with Cyclosporine.,Diflunisal
DB00936,The risk or severity of renal failure and hypertension can be increased when Salicylic acid is combined with Cyclosporine.,Salicylic acid
DB00939,The risk or severity of renal failure and hypertension can be increased when Meclofenamic acid is combined with Cyclosporine.,Meclofenamic acid
DB00945,The risk or severity of renal failure and hypertension can be increased when Acetylsalicylic acid is combined with Cyclosporine.,Acetylsalicylic acid
DB00991,The risk or severity of renal failure and hypertension can be increased when Oxaprozin is combined with Cyclosporine.,Oxaprozin
DB01009,The risk or severity of renal failure and hypertension can be increased when Ketoprofen is combined with Cyclosporine.,Ketoprofen
DB01014,The risk or severity of renal failure and hypertension can be increased when Balsalazide is combined with Cyclosporine.,Balsalazide
DB01050,The risk or severity of renal failure and hypertension can be increased when Ibuprofen is combined with Cyclosporine.,Ibuprofen
DB01250,The risk or severity of renal failure and hypertension can be increased when Olsalazine is combined with Cyclosporine.,Olsalazine
DB01283,The risk or severity of renal failure and hypertension can be increased when Lumiracoxib is combined with Cyclosporine.,Lumiracoxib
DB01397,The risk or severity of renal failure and hypertension can be increased when Magnesium salicylate is combined with Cyclosporine.,Magnesium salicylate
DB01399,The risk or severity of renal failure and hypertension can be increased when Salsalate is combined with Cyclosporine.,Salsalate
DB01401,The risk or severity of renal failure and hypertension can be increased when Choline magnesium trisalicylate is combined with Cyclosporine.,Choline magnesium trisalicylate
DB01419,The risk or severity of renal failure and hypertension can be increased when Antrafenine is combined with Cyclosporine.,Antrafenine
DB01424,The risk or severity of renal failure and hypertension can be increased when Aminophenazone is combined with Cyclosporine.,Aminophenazone
DB01435,The risk or severity of renal failure and hypertension can be increased when Antipyrine is combined with Cyclosporine.,Antipyrine
DB01600,The risk or severity of renal failure and hypertension can be increased when Tiaprofenic acid is combined with Cyclosporine.,Tiaprofenic acid
DB01628,The risk or severity of renal failure and hypertension can be increased when Etoricoxib is combined with Cyclosporine.,Etoricoxib
DB02224,The risk or severity of renal failure and hypertension can be increased when Taxifolin is combined with Cyclosporine.,Taxifolin
DB03585,The risk or severity of renal failure and hypertension can be increased when Oxyphenbutazone is combined with Cyclosporine.,Oxyphenbutazone
DB04552,The risk or severity of renal failure and hypertension can be increased when Niflumic acid is combined with Cyclosporine.,Niflumic acid
DB04725,The risk or severity of renal failure and hypertension can be increased when Licofelone is combined with Cyclosporine.,Licofelone
DB04743,The risk or severity of renal failure and hypertension can be increased when Nimesulide is combined with Cyclosporine.,Nimesulide
DB04812,The risk or severity of renal failure and hypertension can be increased when Benoxaprofen is combined with Cyclosporine.,Benoxaprofen
DB04817,The risk or severity of renal failure and hypertension can be increased when Metamizole is combined with Cyclosporine.,Metamizole
DB04828,The risk or severity of renal failure and hypertension can be increased when Zomepirac is combined with Cyclosporine.,Zomepirac
DB05095,The risk or severity of renal failure and hypertension can be increased when Cimicoxib is combined with Cyclosporine.,Cimicoxib
DB06725,The risk or severity of renal failure and hypertension can be increased when Lornoxicam is combined with Cyclosporine.,Lornoxicam
DB06736,The risk or severity of renal failure and hypertension can be increased when Aceclofenac is combined with Cyclosporine.,Aceclofenac
DB06737,The risk or severity of renal failure and hypertension can be increased when Zaltoprofen is combined with Cyclosporine.,Zaltoprofen
DB07402,The risk or severity of renal failure and hypertension can be increased when Azapropazone is combined with Cyclosporine.,Azapropazone
DB07477,The risk or severity of renal failure and hypertension can be increased when Felbinac is combined with Cyclosporine.,Felbinac
DB08439,The risk or severity of renal failure and hypertension can be increased when Parecoxib is combined with Cyclosporine.,Parecoxib
DB08797,The risk or severity of renal failure and hypertension can be increased when Salicylamide is combined with Cyclosporine.,Salicylamide
DB08940,The risk or severity of renal failure and hypertension can be increased when Kebuzone is combined with Cyclosporine.,Kebuzone
DB08942,The risk or severity of renal failure and hypertension can be increased when Isoxicam is combined with Cyclosporine.,Isoxicam
DB08951,The risk or severity of renal failure and hypertension can be increased when Indoprofen is combined with Cyclosporine.,Indoprofen
DB08955,The risk or severity of renal failure and hypertension can be increased when Ibuproxam is combined with Cyclosporine.,Ibuproxam
DB08976,The risk or severity of renal failure and hypertension can be increased when Floctafenine is combined with Cyclosporine.,Floctafenine
DB08981,The risk or severity of renal failure and hypertension can be increased when Fenbufen is combined with Cyclosporine.,Fenbufen
DB08984,The risk or severity of renal failure and hypertension can be increased when Etofenamate is combined with Cyclosporine.,Etofenamate
DB08991,The risk or severity of renal failure and hypertension can be increased when Epirizole is combined with Cyclosporine.,Epirizole
DB09084,The risk or severity of renal failure and hypertension can be increased when Benzydamine is combined with Cyclosporine.,Benzydamine
DB09212,The risk or severity of renal failure and hypertension can be increased when Loxoprofen is combined with Cyclosporine.,Loxoprofen
DB09213,The risk or severity of renal failure and hypertension can be increased when Dexibuprofen is combined with Cyclosporine.,Dexibuprofen
DB09214,The risk or severity of renal failure and hypertension can be increased when Dexketoprofen is combined with Cyclosporine.,Dexketoprofen
DB09215,The risk or severity of renal failure and hypertension can be increased when Droxicam is combined with Cyclosporine.,Droxicam
DB09216,The risk or severity of renal failure and hypertension can be increased when Tolfenamic acid is combined with Cyclosporine.,Tolfenamic acid
DB09217,The risk or severity of renal failure and hypertension can be increased when Firocoxib is combined with Cyclosporine.,Firocoxib
DB09218,The risk or severity of renal failure and hypertension can be increased when Clonixin is combined with Cyclosporine.,Clonixin
DB09285,The risk or severity of renal failure and hypertension can be increased when Morniflumate is combined with Cyclosporine.,Morniflumate
DB09288,The risk or severity of renal failure and hypertension can be increased when Propacetamol is combined with Cyclosporine.,Propacetamol
DB09295,The risk or severity of renal failure and hypertension can be increased when Talniflumate is combined with Cyclosporine.,Talniflumate
DB11455,The risk or severity of renal failure and hypertension can be increased when Robenacoxib is combined with Cyclosporine.,Robenacoxib
DB11518,The risk or severity of renal failure and hypertension can be increased when Flunixin is combined with Cyclosporine.,Flunixin
DB12399,The risk or severity of renal failure and hypertension can be increased when Polmacoxib is combined with Cyclosporine.,Polmacoxib
DB12445,The risk or severity of renal failure and hypertension can be increased when Nitroaspirin is combined with Cyclosporine.,Nitroaspirin
DB12480,The risk or severity of renal failure and hypertension can be increased when Betulinic Acid is combined with Cyclosporine.,Betulinic Acid
DB12545,The risk or severity of renal failure and hypertension can be increased when Indobufen is combined with Cyclosporine.,Indobufen
DB12610,The risk or severity of renal failure and hypertension can be increased when Ebselen is combined with Cyclosporine.,Ebselen
DB13001,The risk or severity of renal failure and hypertension can be increased when Tinoridine is combined with Cyclosporine.,Tinoridine
DB13167,The risk or severity of renal failure and hypertension can be increased when Alclofenac is combined with Cyclosporine.,Alclofenac
DB13217,The risk or severity of renal failure and hypertension can be increased when Fentiazac is combined with Cyclosporine.,Fentiazac
DB13232,The risk or severity of renal failure and hypertension can be increased when Suxibuzone is combined with Cyclosporine.,Suxibuzone
DB13286,The risk or severity of renal failure and hypertension can be increased when Bumadizone is combined with Cyclosporine.,Bumadizone
DB13314,The risk or severity of renal failure and hypertension can be increased when Alminoprofen is combined with Cyclosporine.,Alminoprofen
DB13317,The risk or severity of renal failure and hypertension can be increased when Flunoxaprofen is combined with Cyclosporine.,Flunoxaprofen
DB13364,The risk or severity of renal failure and hypertension can be increased when Feprazone is combined with Cyclosporine.,Feprazone
DB13371,The risk or severity of renal failure and hypertension can be increased when Difenpiramide is combined with Cyclosporine.,Difenpiramide
DB13407,The risk or severity of renal failure and hypertension can be increased when Nifenazone is combined with Cyclosporine.,Nifenazone
DB13432,The risk or severity of renal failure and hypertension can be increased when Lonazolac is combined with Cyclosporine.,Lonazolac
DB13481,The risk or severity of renal failure and hypertension can be increased when Tenidap is combined with Cyclosporine.,Tenidap
DB13501,The risk or severity of renal failure and hypertension can be increased when Bendazac is combined with Cyclosporine.,Bendazac
DB13514,The risk or severity of renal failure and hypertension can be increased when Pranoprofen is combined with Cyclosporine.,Pranoprofen
DB13524,The risk or severity of renal failure and hypertension can be increased when Propyphenazone is combined with Cyclosporine.,Propyphenazone
DB13527,The risk or severity of renal failure and hypertension can be increased when Proglumetacin is combined with Cyclosporine.,Proglumetacin
DB13538,The risk or severity of renal failure and hypertension can be increased when Guacetisal is combined with Cyclosporine.,Guacetisal
DB13544,The risk or severity of renal failure and hypertension can be increased when Ethenzamide is combined with Cyclosporine.,Ethenzamide
DB13612,The risk or severity of renal failure and hypertension can be increased when Carbaspirin calcium is combined with Cyclosporine.,Carbaspirin calcium
DB13629,The risk or severity of renal failure and hypertension can be increased when Mofebutazone is combined with Cyclosporine.,Mofebutazone
DB13649,The risk or severity of renal failure and hypertension can be increased when Proquazone is combined with Cyclosporine.,Proquazone
DB13657,The risk or severity of renal failure and hypertension can be increased when Benorilate is combined with Cyclosporine.,Benorilate
DB13722,The risk or severity of renal failure and hypertension can be increased when Pirprofen is combined with Cyclosporine.,Pirprofen
DB13783,The risk or severity of renal failure and hypertension can be increased when Acemetacin is combined with Cyclosporine.,Acemetacin
DB13860,The risk or severity of renal failure and hypertension can be increased when Imidazole salicylate is combined with Cyclosporine.,Imidazole salicylate
DB14059,The risk or severity of renal failure and hypertension can be increased when SC-236 is combined with Cyclosporine.,SC-236
DB14060,The risk or severity of renal failure and hypertension can be increased when NS-398 is combined with Cyclosporine.,NS-398
DB14938,The risk or severity of renal failure and hypertension can be increased when Flurbiprofen axetil is combined with Cyclosporine.,Flurbiprofen axetil
DB09227,The serum concentration of Barnidipine can be increased when it is combined with Cyclosporine.,Barnidipine
DB13615,The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Cyclosporine.,Mifamurtide
DB11901,The serum concentration of Cyclosporine can be decreased when it is combined with Apalutamide.,Apalutamide
DB11642,The serum concentration of Cyclosporine can be decreased when it is combined with Pitolisant.,Pitolisant
DB11633,The serum concentration of Cyclosporine can be increased when it is combined with Isavuconazole.,Isavuconazole
DB06636,The serum concentration of Cyclosporine can be increased when it is combined with Isavuconazonium.,Isavuconazonium
DB10317,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Cyclosporine.,Rubella virus vaccine
DB10318,The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Cyclosporine.,Varicella Zoster Vaccine (Live/attenuated)
DB10343,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Cyclosporine.,Bacillus calmette-guerin substrain tice live antigen
DB10804,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Cyclosporine.,Bacillus calmette-guerin substrain connaught live antigen
DB10805,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Cyclosporine.,Yellow Fever Vaccine
DB11003,The risk or severity of infection can be increased when Anthrax vaccine is combined with Cyclosporine.,Anthrax vaccine
DB11050,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Cyclosporine.,Typhoid Vaccine Live
DB12386,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Cyclosporine.,Bacillus calmette-guerin substrain danish 1331 live antigen
DB12768,The risk or severity of infection can be increased when BCG vaccine is combined with Cyclosporine.,BCG vaccine
DB14409,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Cyclosporine.,Human adenovirus e serotype 4 strain cl-68578 antigen
DB14443,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Cyclosporine.,Vibrio cholerae CVD 103-HgR strain live antigen
DB14685,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Cyclosporine.,Adenovirus type 7 vaccine live
DB00158,Cyclosporine may decrease the excretion rate of Folic acid which could result in a higher serum level.,Folic acid
DB00740,Cyclosporine may decrease the excretion rate of Riluzole which could result in a higher serum level.,Riluzole
DB03496,Cyclosporine may decrease the excretion rate of Alvocidib which could result in a higher serum level.,Alvocidib
DB08931,Cyclosporine may decrease the excretion rate of Riociguat which could result in a higher serum level.,Riociguat
DB12941,Cyclosporine may decrease the excretion rate of Darolutamide which could result in a higher serum level.,Darolutamide
DB00286,Cyclosporine may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level.,Conjugated estrogens
DB00457,Cyclosporine may decrease the excretion rate of Prazosin which could result in a higher serum level.,Prazosin
DB00709,Cyclosporine may decrease the excretion rate of Lamivudine which could result in a higher serum level.,Lamivudine
DB04690,Cyclosporine may decrease the excretion rate of Camptothecin which could result in a higher serum level.,Camptothecin
DB12001,Cyclosporine may decrease the excretion rate of Abemaciclib which could result in a higher serum level.,Abemaciclib
DB13125,Cyclosporine may decrease the excretion rate of Lusutrombopag which could result in a higher serum level.,Lusutrombopag
DB00612,The serum concentration of Bisoprolol can be increased when it is combined with Cyclosporine.,Bisoprolol
DB01238,The metabolism of Aripiprazole can be decreased when combined with Cyclosporine.,Aripiprazole
DB14185,The metabolism of Aripiprazole lauroxil can be decreased when combined with Cyclosporine.,Aripiprazole lauroxil
DB00256,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Lymecycline.,Lymecycline
DB00453,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Clomocycline.,Clomocycline
DB00560,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Tigecycline.,Tigecycline
DB00595,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Oxytetracycline.,Oxytetracycline
DB00618,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Demeclocycline.,Demeclocycline
DB00931,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Metacycline.,Metacycline
DB01301,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Rolitetracycline.,Rolitetracycline
DB01377,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium oxide.,Magnesium oxide
DB01378,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium cation.,Magnesium cation
DB01627,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Lincomycin.,Lincomycin
DB06827,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Viomycin.,Viomycin
DB09409,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium acetate tetrahydrate.,Magnesium acetate tetrahydrate
DB11110,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium citrate.,Magnesium citrate
DB11189,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium glycinate.,Magnesium glycinate
DB11230,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium Aluminum Silicate.,Magnesium Aluminum Silicate
DB13249,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium silicate.,Magnesium silicate
DB13264,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Penimepicycline.,Penimepicycline
DB13359,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium aspartate.,Magnesium aspartate
DB13749,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium gluconate.,Magnesium gluconate
DB13786,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium orotate.,Magnesium orotate
DB13862,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium phosphate.,Magnesium phosphate
DB13996,The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Magnesium acetate.,Magnesium acetate
DB00042,The risk or severity of adverse effects can be increased when Cyclosporine is combined with Botulinum Toxin Type B.,Botulinum Toxin Type B
DB00083,The risk or severity of adverse effects can be increased when Cyclosporine is combined with Botulinum toxin type A.,Botulinum toxin type A
DB00657,The risk or severity of adverse effects can be increased when Cyclosporine is combined with Mecamylamine.,Mecamylamine
DB01090,The risk or severity of adverse effects can be increased when Cyclosporine is combined with Pentolinium.,Pentolinium
DB01116,The risk or severity of adverse effects can be increased when Cyclosporine is combined with Trimethaphan.,Trimethaphan
DB08837,The risk or severity of adverse effects can be increased when Cyclosporine is combined with Tetraethylammonium.,Tetraethylammonium
DB08960,The risk or severity of adverse effects can be increased when Cyclosporine is combined with Hexamethonium.,Hexamethonium
DB08999,The risk or severity of adverse effects can be increased when Cyclosporine is combined with Cyclopentamine.,Cyclopentamine
DB00282,The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Pamidronic acid.,Pamidronic acid
DB00399,The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Zoledronic acid.,Zoledronic acid
DB00630,The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Alendronic acid.,Alendronic acid
DB00710,The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Ibandronate.,Ibandronate
DB00720,The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Clodronic acid.,Clodronic acid
DB00884,The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Risedronic acid.,Risedronic acid
DB01077,The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Etidronic acid.,Etidronic acid
DB01133,The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Tiludronic acid.,Tiludronic acid
DB06255,The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Incadronic acid.,Incadronic acid
DB06695,The serum concentration of Dabigatran etexilate can be increased when it is combined with Cyclosporine.,Dabigatran etexilate
DB00917,The excretion of Dinoprostone can be decreased when combined with Cyclosporine.,Dinoprostone
DB01053,The excretion of Benzylpenicillin can be decreased when combined with Cyclosporine.,Benzylpenicillin
DB01092,The excretion of Ouabain can be decreased when combined with Cyclosporine.,Ouabain
DB06199,The excretion of Atrasentan can be decreased when combined with Cyclosporine.,Atrasentan
DB06721,The excretion of Gimatecan can be decreased when combined with Cyclosporine.,Gimatecan
DB08862,The excretion of Cholecystokinin can be decreased when combined with Cyclosporine.,Cholecystokinin
DB08884,The excretion of Gadoxetic acid can be decreased when combined with Cyclosporine.,Gadoxetic acid
DB01583,The excretion of Liotrix can be decreased when combined with Cyclosporine.,Liotrix
DB01586,The risk or severity of liver damage can be increased when Cyclosporine is combined with Ursodeoxycholic acid.,Ursodeoxycholic acid
DB14057,The risk or severity of liver damage can be increased when Cyclosporine is combined with Valinomycin.,Valinomycin
DB00555,Cyclosporine may decrease the excretion rate of Lamotrigine which could result in a higher serum level.,Lamotrigine
DB00014,Cyclosporine may decrease the excretion rate of Goserelin which could result in a higher serum level.,Goserelin
DB00017,Cyclosporine may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.,Salmon calcitonin
DB00035,Cyclosporine may decrease the excretion rate of Desmopressin which could result in a higher serum level.,Desmopressin
DB00080,Cyclosporine may decrease the excretion rate of Daptomycin which could result in a higher serum level.,Daptomycin
DB00115,Cyclosporine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cyanocobalamin
DB00165,Cyclosporine may decrease the excretion rate of Pyridoxine which could result in a higher serum level.,Pyridoxine
DB00190,Cyclosporine may decrease the excretion rate of Carbidopa which could result in a higher serum level.,Carbidopa
DB00198,Cyclosporine may decrease the excretion rate of Oseltamivir which could result in a higher serum level.,Oseltamivir
DB00200,Cyclosporine may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level.,Hydroxocobalamin
DB00225,Cyclosporine may decrease the excretion rate of Gadodiamide which could result in a higher serum level.,Gadodiamide
DB00235,Cyclosporine may decrease the excretion rate of Milrinone which could result in a higher serum level.,Milrinone
DB00271,Cyclosporine may decrease the excretion rate of Diatrizoate which could result in a higher serum level.,Diatrizoate
DB00284,Cyclosporine may decrease the excretion rate of Acarbose which could result in a higher serum level.,Acarbose
DB00292,Cyclosporine may decrease the excretion rate of Etomidate which could result in a higher serum level.,Etomidate
DB00303,Cyclosporine may decrease the excretion rate of Ertapenem which could result in a higher serum level.,Ertapenem
DB00308,Cyclosporine may decrease the excretion rate of Ibutilide which could result in a higher serum level.,Ibutilide
DB00319,Cyclosporine may decrease the excretion rate of Piperacillin which could result in a higher serum level.,Piperacillin
DB00323,Cyclosporine may decrease the excretion rate of Tolcapone which could result in a higher serum level.,Tolcapone
DB00325,Cyclosporine may decrease the excretion rate of Nitroprusside which could result in a higher serum level.,Nitroprusside
DB00330,Cyclosporine may decrease the excretion rate of Ethambutol which could result in a higher serum level.,Ethambutol
DB00331,Cyclosporine may decrease the excretion rate of Metformin which could result in a higher serum level.,Metformin
DB00355,Cyclosporine may decrease the excretion rate of Aztreonam which could result in a higher serum level.,Aztreonam
DB00364,Cyclosporine may decrease the excretion rate of Sucralfate which could result in a higher serum level.,Sucralfate
DB00369,Cyclosporine may decrease the excretion rate of Cidofovir which could result in a higher serum level.,Cidofovir
DB00372,Cyclosporine may decrease the excretion rate of Thiethylperazine which could result in a higher serum level.,Thiethylperazine
DB00413,Cyclosporine may decrease the excretion rate of Pramipexole which could result in a higher serum level.,Pramipexole
DB00415,Cyclosporine may decrease the excretion rate of Ampicillin which could result in a higher serum level.,Ampicillin
DB00422,Cyclosporine may decrease the excretion rate of Methylphenidate which could result in a higher serum level.,Methylphenidate
DB00438,Cyclosporine may decrease the excretion rate of Ceftazidime which could result in a higher serum level.,Ceftazidime
DB00492,Cyclosporine may decrease the excretion rate of Fosinopril which could result in a higher serum level.,Fosinopril
DB00535,Cyclosporine may decrease the excretion rate of Cefdinir which could result in a higher serum level.,Cefdinir
DB00548,Cyclosporine may decrease the excretion rate of Azelaic acid which could result in a higher serum level.,Azelaic acid
DB00553,Cyclosporine may decrease the excretion rate of Methoxsalen which could result in a higher serum level.,Methoxsalen
DB00558,Cyclosporine may decrease the excretion rate of Zanamivir which could result in a higher serum level.,Zanamivir
DB00569,Cyclosporine may decrease the excretion rate of Fondaparinux which could result in a higher serum level.,Fondaparinux
DB00577,Cyclosporine may decrease the excretion rate of Valaciclovir which could result in a higher serum level.,Valaciclovir
DB00583,Cyclosporine may decrease the excretion rate of Levocarnitine which could result in a higher serum level.,Levocarnitine
DB00597,Cyclosporine may decrease the excretion rate of Gadoteridol which could result in a higher serum level.,Gadoteridol
DB00633,Cyclosporine may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level.,Dexmedetomidine
DB00651,Cyclosporine may decrease the excretion rate of Dyphylline which could result in a higher serum level.,Dyphylline
DB00660,Cyclosporine may decrease the excretion rate of Metaxalone which could result in a higher serum level.,Metaxalone
DB00665,Cyclosporine may decrease the excretion rate of Nilutamide which could result in a higher serum level.,Nilutamide
DB00672,Cyclosporine may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.,Chlorpropamide
DB00692,Cyclosporine may decrease the excretion rate of Phentolamine which could result in a higher serum level.,Phentolamine
DB00713,Cyclosporine may decrease the excretion rate of Oxacillin which could result in a higher serum level.,Oxacillin
DB00716,Cyclosporine may decrease the excretion rate of Nedocromil which could result in a higher serum level.,Nedocromil
DB00722,Cyclosporine may decrease the excretion rate of Lisinopril which could result in a higher serum level.,Lisinopril
DB00730,Cyclosporine may decrease the excretion rate of Thiabendazole which could result in a higher serum level.,Thiabendazole
DB00733,Cyclosporine may decrease the excretion rate of Pralidoxime which could result in a higher serum level.,Pralidoxime
DB00743,Cyclosporine may decrease the excretion rate of Gadobenic acid which could result in a higher serum level.,Gadobenic acid
DB00760,Cyclosporine may decrease the excretion rate of Meropenem which could result in a higher serum level.,Meropenem
DB00761,Cyclosporine may decrease the excretion rate of Potassium chloride which could result in a higher serum level.,Potassium chloride
DB00775,Cyclosporine may decrease the excretion rate of Tirofiban which could result in a higher serum level.,Tirofiban
DB00782,Cyclosporine may decrease the excretion rate of Propantheline which could result in a higher serum level.,Propantheline
DB00787,Cyclosporine may decrease the excretion rate of Acyclovir which could result in a higher serum level.,Acyclovir
DB00789,Cyclosporine may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level.,Gadopentetic acid
DB00790,Cyclosporine may decrease the excretion rate of Perindopril which could result in a higher serum level.,Perindopril
DB00800,Cyclosporine may decrease the excretion rate of Fenoldopam which could result in a higher serum level.,Fenoldopam
DB00804,Cyclosporine may decrease the excretion rate of Dicyclomine which could result in a higher serum level.,Dicyclomine
DB00806,Cyclosporine may decrease the excretion rate of Pentoxifylline which could result in a higher serum level.,Pentoxifylline
DB00811,Cyclosporine may decrease the excretion rate of Ribavirin which could result in a higher serum level.,Ribavirin
DB00828,Cyclosporine may decrease the excretion rate of Fosfomycin which could result in a higher serum level.,Fosfomycin
DB00839,Cyclosporine may decrease the excretion rate of Tolazamide which could result in a higher serum level.,Tolazamide
DB00841,Cyclosporine may decrease the excretion rate of Dobutamine which could result in a higher serum level.,Dobutamine
DB00871,Cyclosporine may decrease the excretion rate of Terbutaline which could result in a higher serum level.,Terbutaline
DB00894,Cyclosporine may decrease the excretion rate of Testolactone which could result in a higher serum level.,Testolactone
DB00900,Cyclosporine may decrease the excretion rate of Didanosine which could result in a higher serum level.,Didanosine
DB00915,Cyclosporine may decrease the excretion rate of Amantadine which could result in a higher serum level.,Amantadine
DB00953,Cyclosporine may decrease the excretion rate of Rizatriptan which could result in a higher serum level.,Rizatriptan
DB00961,Cyclosporine may decrease the excretion rate of Mepivacaine which could result in a higher serum level.,Mepivacaine
DB00968,Cyclosporine may decrease the excretion rate of Methyldopa which could result in a higher serum level.,Methyldopa
DB00988,Cyclosporine may decrease the excretion rate of Dopamine which could result in a higher serum level.,Dopamine
DB00995,Cyclosporine may decrease the excretion rate of Auranofin which could result in a higher serum level.,Auranofin
DB01004,Cyclosporine may decrease the excretion rate of Ganciclovir which could result in a higher serum level.,Ganciclovir
DB01010,Cyclosporine may decrease the excretion rate of Edrophonium which could result in a higher serum level.,Edrophonium
DB01022,Cyclosporine may decrease the excretion rate of Phylloquinone which could result in a higher serum level.,Phylloquinone
DB01043,Cyclosporine may decrease the excretion rate of Memantine which could result in a higher serum level.,Memantine
DB01046,Cyclosporine may decrease the excretion rate of Lubiprostone which could result in a higher serum level.,Lubiprostone
DB01048,Cyclosporine may decrease the excretion rate of Abacavir which could result in a higher serum level.,Abacavir
DB01060,Cyclosporine may decrease the excretion rate of Amoxicillin which could result in a higher serum level.,Amoxicillin
DB01124,Cyclosporine may decrease the excretion rate of Tolbutamide which could result in a higher serum level.,Tolbutamide
DB01140,Cyclosporine may decrease the excretion rate of Cefadroxil which could result in a higher serum level.,Cefadroxil
DB01148,Cyclosporine may decrease the excretion rate of Flavoxate which could result in a higher serum level.,Flavoxate
DB01157,Cyclosporine may decrease the excretion rate of Trimetrexate which could result in a higher serum level.,Trimetrexate
DB01205,Cyclosporine may decrease the excretion rate of Flumazenil which could result in a higher serum level.,Flumazenil
DB01213,Cyclosporine may decrease the excretion rate of Fomepizole which could result in a higher serum level.,Fomepizole
DB01240,Cyclosporine may decrease the excretion rate of Epoprostenol which could result in a higher serum level.,Epoprostenol
DB01249,Cyclosporine may decrease the excretion rate of Iodixanol which could result in a higher serum level.,Iodixanol
DB01273,Cyclosporine may decrease the excretion rate of Varenicline which could result in a higher serum level.,Varenicline
DB01330,Cyclosporine may decrease the excretion rate of Cefotetan which could result in a higher serum level.,Cefotetan
DB01367,Cyclosporine may decrease the excretion rate of Rasagiline which could result in a higher serum level.,Rasagiline
DB01415,Cyclosporine may decrease the excretion rate of Ceftibuten which could result in a higher serum level.,Ceftibuten
DB01427,Cyclosporine may decrease the excretion rate of Amrinone which could result in a higher serum level.,Amrinone
DB01428,Cyclosporine may decrease the excretion rate of Oxybenzone which could result in a higher serum level.,Oxybenzone
DB01550,Cyclosporine may decrease the excretion rate of Fenproporex which could result in a higher serum level.,Fenproporex
DB01563,Cyclosporine may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.,Chloral hydrate
DB01610,Cyclosporine may decrease the excretion rate of Valganciclovir which could result in a higher serum level.,Valganciclovir
DB01638,Cyclosporine may decrease the excretion rate of Sorbitol which could result in a higher serum level.,Sorbitol
DB04895,Cyclosporine may decrease the excretion rate of Pegaptanib which could result in a higher serum level.,Pegaptanib
DB04953,Cyclosporine may decrease the excretion rate of Ezogabine which could result in a higher serum level.,Ezogabine
DB05018,Cyclosporine may decrease the excretion rate of Migalastat which could result in a higher serum level.,Migalastat
DB06154,Cyclosporine may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.,Pentaerythritol tetranitrate
DB06186,Cyclosporine may decrease the excretion rate of Ipilimumab which could result in a higher serum level.,Ipilimumab
DB06196,Cyclosporine may decrease the excretion rate of Icatibant which could result in a higher serum level.,Icatibant
DB06209,Cyclosporine may decrease the excretion rate of Prasugrel which could result in a higher serum level.,Prasugrel
DB06211,Cyclosporine may decrease the excretion rate of Doripenem which could result in a higher serum level.,Doripenem
DB06230,Cyclosporine may decrease the excretion rate of Nalmefene which could result in a higher serum level.,Nalmefene
DB06262,Cyclosporine may decrease the excretion rate of Droxidopa which could result in a higher serum level.,Droxidopa
DB06402,Cyclosporine may decrease the excretion rate of Telavancin which could result in a higher serum level.,Telavancin
DB06623,Cyclosporine may decrease the excretion rate of Flupirtine which could result in a higher serum level.,Flupirtine
DB06705,Cyclosporine may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.,Gadofosveset trisodium
DB06767,Cyclosporine may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.,Ammonium chloride
DB06782,Cyclosporine may decrease the excretion rate of Dimercaprol which could result in a higher serum level.,Dimercaprol
DB06796,Cyclosporine may decrease the excretion rate of Mangafodipir which could result in a higher serum level.,Mangafodipir
DB06800,Cyclosporine may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.,Methylnaltrexone
DB06809,Cyclosporine may decrease the excretion rate of Plerixafor which could result in a higher serum level.,Plerixafor
DB06823,Cyclosporine may decrease the excretion rate of Tiopronin which could result in a higher serum level.,Tiopronin
DB06824,Cyclosporine may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.,Triethylenetetramine
DB08824,Cyclosporine may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.,Ioflupane I-123
DB08826,Cyclosporine may decrease the excretion rate of Deferiprone which could result in a higher serum level.,Deferiprone
DB08840,Cyclosporine may decrease the excretion rate of N-methylnicotinamide which could result in a higher serum level.,N-methylnicotinamide
DB08872,Cyclosporine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.,Gabapentin enacarbil
DB08894,Cyclosporine may decrease the excretion rate of Peginesatide which could result in a higher serum level.,Peginesatide
DB08897,Cyclosporine may decrease the excretion rate of Aclidinium which could result in a higher serum level.,Aclidinium
DB08900,Cyclosporine may decrease the excretion rate of Teduglutide which could result in a higher serum level.,Teduglutide
DB08964,Cyclosporine may decrease the excretion rate of Gemeprost which could result in a higher serum level.,Gemeprost
DB09050,Cyclosporine may decrease the excretion rate of Ceftolozane which could result in a higher serum level.,Ceftolozane
DB09066,Cyclosporine may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level.,Corifollitropin alfa
DB09081,Cyclosporine may decrease the excretion rate of Idebenone which could result in a higher serum level.,Idebenone
DB09103,Cyclosporine may decrease the excretion rate of Ancestim which could result in a higher serum level.,Ancestim
DB09104,Cyclosporine may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.,Magnesium hydroxide
DB09106,Cyclosporine may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.,Hydroxyethyl Starch
DB09111,Cyclosporine may decrease the excretion rate of Pentastarch which could result in a higher serum level.,Pentastarch
DB09121,Cyclosporine may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.,Aurothioglucose
DB09129,Cyclosporine may decrease the excretion rate of Chromic chloride which could result in a higher serum level.,Chromic chloride
DB09132,Cyclosporine may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.,Gadoteric acid
DB09133,Cyclosporine may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.,Iothalamic acid
DB09134,Cyclosporine may decrease the excretion rate of Ioversol which could result in a higher serum level.,Ioversol
DB09135,Cyclosporine may decrease the excretion rate of Ioxilan which could result in a higher serum level.,Ioxilan
DB09136,Cyclosporine may decrease the excretion rate of Isosulfan blue which could result in a higher serum level.,Isosulfan blue
DB09137,Cyclosporine may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level.,Technetium Tc-99m mebrofenin
DB09139,Cyclosporine may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level.,Technetium Tc-99m oxidronate
DB09148,Cyclosporine may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.,Florbetaben (18F)
DB09149,Cyclosporine may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.,Florbetapir (18F)
DB09156,Cyclosporine may decrease the excretion rate of Iopromide which could result in a higher serum level.,Iopromide
DB09163,Cyclosporine may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.,Technetium Tc-99m exametazime
DB09165,Cyclosporine may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.,Technetium Tc-99m pyrophosphate
DB09185,Cyclosporine may decrease the excretion rate of Viloxazine which could result in a higher serum level.,Viloxazine
DB09194,Cyclosporine may decrease the excretion rate of Etoperidone which could result in a higher serum level.,Etoperidone
DB09205,Cyclosporine may decrease the excretion rate of Moxisylyte which could result in a higher serum level.,Moxisylyte
DB09209,Cyclosporine may decrease the excretion rate of Pholcodine which could result in a higher serum level.,Pholcodine
DB09210,Cyclosporine may decrease the excretion rate of Piracetam which could result in a higher serum level.,Piracetam
DB09219,Cyclosporine may decrease the excretion rate of Bisoxatin which could result in a higher serum level.,Bisoxatin
DB09220,Cyclosporine may decrease the excretion rate of Nicorandil which could result in a higher serum level.,Nicorandil
DB09224,Cyclosporine may decrease the excretion rate of Melperone which could result in a higher serum level.,Melperone
DB09244,Cyclosporine may decrease the excretion rate of Pirlindole which could result in a higher serum level.,Pirlindole
DB09245,Cyclosporine may decrease the excretion rate of Toloxatone which could result in a higher serum level.,Toloxatone
DB09255,Cyclosporine may decrease the excretion rate of Dextran which could result in a higher serum level.,Dextran
DB09257,Cyclosporine may decrease the excretion rate of Gimeracil which could result in a higher serum level.,Gimeracil
DB09264,Cyclosporine may decrease the excretion rate of Idarucizumab which could result in a higher serum level.,Idarucizumab
DB09265,Cyclosporine may decrease the excretion rate of Lixisenatide which could result in a higher serum level.,Lixisenatide
DB09268,Cyclosporine may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level.,Picosulfuric acid
DB09276,Cyclosporine may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.,Sodium aurothiomalate
DB09277,Cyclosporine may decrease the excretion rate of Choline C 11 which could result in a higher serum level.,Choline C 11
DB09281,Cyclosporine may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.,Magnesium trisilicate
DB09292,Cyclosporine may decrease the excretion rate of Sacubitril which could result in a higher serum level.,Sacubitril
DB09301,Cyclosporine may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.,Chondroitin sulfate
DB09320,Cyclosporine may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.,Procaine benzylpenicillin
DB09324,Cyclosporine may decrease the excretion rate of Sulbactam which could result in a higher serum level.,Sulbactam
DB09325,Cyclosporine may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.,Sodium fluoride
DB09329,"Cyclosporine may decrease the excretion rate of Antihemophilic Factor (Recombinant), PEGylated which could result in a higher serum level.","Antihemophilic Factor (Recombinant), PEGylated"
DB09338,Cyclosporine may decrease the excretion rate of Mersalyl which could result in a higher serum level.,Mersalyl
DB09344,Cyclosporine may decrease the excretion rate of Invert sugar which could result in a higher serum level.,Invert sugar
DB09357,Cyclosporine may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.,Dexpanthenol
DB09394,Cyclosporine may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.,Phosphoric acid
DB09395,Cyclosporine may decrease the excretion rate of Sodium acetate which could result in a higher serum level.,Sodium acetate
DB09407,Cyclosporine may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.,Magnesium chloride
DB09418,Cyclosporine may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.,Potassium perchlorate
DB09472,Cyclosporine may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.,Sodium sulfate
DB09477,Cyclosporine may decrease the excretion rate of Enalaprilat which could result in a higher serum level.,Enalaprilat
DB09481,Cyclosporine may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.,Magnesium carbonate
DB09488,Cyclosporine may decrease the excretion rate of Acrivastine which could result in a higher serum level.,Acrivastine
DB09496,Cyclosporine may decrease the excretion rate of Octinoxate which could result in a higher serum level.,Octinoxate
DB09502,Cyclosporine may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.,Fludeoxyglucose (18F)
DB09546,Cyclosporine may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.,Iobenguane sulfate I-123
DB11077,Cyclosporine may decrease the excretion rate of Polyethylene glycol 400 which could result in a higher serum level.,Polyethylene glycol 400
DB11090,Cyclosporine may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.,Potassium nitrate
DB11098,Cyclosporine may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level.,Potassium bicarbonate
DB11102,Cyclosporine may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.,N-acetyltyrosine
DB11114,Cyclosporine may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.,Eucalyptus oil
DB11127,Cyclosporine may decrease the excretion rate of Selenious acid which could result in a higher serum level.,Selenious acid
DB11135,Cyclosporine may decrease the excretion rate of Selenium which could result in a higher serum level.,Selenium
DB11136,Cyclosporine may decrease the excretion rate of Chromium which could result in a higher serum level.,Chromium
DB11145,Cyclosporine may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.,Oxyquinoline
DB11164,Cyclosporine may decrease the excretion rate of Bicisate which could result in a higher serum level.,Bicisate
DB11278,Cyclosporine may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level.,DL-Methylephedrine
DB11328,Cyclosporine may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.,Tetradecyl hydrogen sulfate (ester)
DB11338,Cyclosporine may decrease the excretion rate of Clove oil which could result in a higher serum level.,Clove oil
DB11358,Cyclosporine may decrease the excretion rate of Evening primrose oil which could result in a higher serum level.,Evening primrose oil
DB11364,Cyclosporine may decrease the excretion rate of Pidotimod which could result in a higher serum level.,Pidotimod
DB11367,Cyclosporine may decrease the excretion rate of Cefroxadine which could result in a higher serum level.,Cefroxadine
DB11577,Cyclosporine may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.,Indigotindisulfonic acid
DB11587,Cyclosporine may decrease the excretion rate of Etafedrine which could result in a higher serum level.,Etafedrine
DB11598,Cyclosporine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.,Antithrombin III human
DB11691,Cyclosporine may decrease the excretion rate of Naldemedine which could result in a higher serum level.,Naldemedine
DB11699,Cyclosporine may decrease the excretion rate of Tropisetron which could result in a higher serum level.,Tropisetron
DB11989,Cyclosporine may decrease the excretion rate of Benznidazole which could result in a higher serum level.,Benznidazole
DB12007,Cyclosporine may decrease the excretion rate of Isoflavone which could result in a higher serum level.,Isoflavone
DB12107,Cyclosporine may decrease the excretion rate of Vaborbactam which could result in a higher serum level.,Vaborbactam
DB12151,Cyclosporine may decrease the excretion rate of Brincidofovir which could result in a higher serum level.,Brincidofovir
DB12783,Cyclosporine may decrease the excretion rate of Benserazide which could result in a higher serum level.,Benserazide
DB13025,Cyclosporine may decrease the excretion rate of Tiapride which could result in a higher serum level.,Tiapride
DB13156,Cyclosporine may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.,Inosine pranobex
DB13178,Cyclosporine may decrease the excretion rate of Inositol which could result in a higher serum level.,Inositol
DB13185,Cyclosporine may decrease the excretion rate of Oxabolone cipionate which could result in a higher serum level.,Oxabolone cipionate
DB13191,Cyclosporine may decrease the excretion rate of Phosphocreatine which could result in a higher serum level.,Phosphocreatine
DB13269,Cyclosporine may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.,Dichlorobenzyl alcohol
DB13595,Cyclosporine may decrease the excretion rate of Almasilate which could result in a higher serum level.,Almasilate
DB13884,Cyclosporine may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.,Albutrepenonacog alfa
DB13909,Cyclosporine may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level.,Bismuth subgallate
DB13967,Cyclosporine may decrease the excretion rate of Patent Blue which could result in a higher serum level.,Patent Blue
DB14006,Cyclosporine may decrease the excretion rate of Choline salicylate which could result in a higher serum level.,Choline salicylate
DB14007,Cyclosporine may decrease the excretion rate of Pentetic acid which could result in a higher serum level.,Pentetic acid
DB14498,Cyclosporine may decrease the excretion rate of Potassium acetate which could result in a higher serum level.,Potassium acetate
DB14499,Cyclosporine may decrease the excretion rate of Potassium sulfate which could result in a higher serum level.,Potassium sulfate
DB14526,Cyclosporine may decrease the excretion rate of Chromic citrate which could result in a higher serum level.,Chromic citrate
DB14527,Cyclosporine may decrease the excretion rate of Chromic nitrate which could result in a higher serum level.,Chromic nitrate
DB14528,Cyclosporine may decrease the excretion rate of Chromium gluconate which could result in a higher serum level.,Chromium gluconate
DB14529,Cyclosporine may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level.,Chromium nicotinate
DB14530,Cyclosporine may decrease the excretion rate of Chromous sulfate which could result in a higher serum level.,Chromous sulfate
DB06815,Cyclosporine may decrease the excretion rate of Pyrithione which could result in a higher serum level.,Pyrithione
DB11121,Cyclosporine may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.,Chloroxylenol
DB00842,Cyclosporine may decrease the excretion rate of Oxazepam which could result in a higher serum level.,Oxazepam
DB01020,Cyclosporine may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.,Isosorbide mononitrate
DB01067,Cyclosporine may decrease the excretion rate of Glipizide which could result in a higher serum level.,Glipizide
DB01558,Cyclosporine may decrease the excretion rate of Bromazepam which could result in a higher serum level.,Bromazepam
DB00231,Cyclosporine may decrease the excretion rate of Temazepam which could result in a higher serum level.,Temazepam
DB01170,Cyclosporine may decrease the excretion rate of Guanethidine which could result in a higher serum level.,Guanethidine
DB11085,Cyclosporine may decrease the excretion rate of Resorcinol which could result in a higher serum level.,Resorcinol
DB13139,Cyclosporine may decrease the excretion rate of Levosalbutamol which could result in a higher serum level.,Levosalbutamol
DB01018,Cyclosporine may decrease the excretion rate of Guanfacine which could result in a higher serum level.,Guanfacine
DB08932,Cyclosporine may decrease the excretion rate of Macitentan which could result in a higher serum level.,Macitentan
DB00294,Cyclosporine may decrease the excretion rate of Etonogestrel which could result in a higher serum level.,Etonogestrel
DB09123,Cyclosporine may decrease the excretion rate of Dienogest which could result in a higher serum level.,Dienogest
DB00007,Cyclosporine may decrease the excretion rate of Leuprolide which could result in a higher serum level.,Leuprolide
DB00280,Cyclosporine may decrease the excretion rate of Disopyramide which could result in a higher serum level.,Disopyramide
DB00296,Cyclosporine may decrease the excretion rate of Ropivacaine which could result in a higher serum level.,Ropivacaine
DB00628,Cyclosporine may decrease the excretion rate of Clorazepic acid which could result in a higher serum level.,Clorazepic acid
DB00911,Cyclosporine may decrease the excretion rate of Tinidazole which could result in a higher serum level.,Tinidazole
DB01001,Cyclosporine may decrease the excretion rate of Salbutamol which could result in a higher serum level.,Salbutamol
DB01002,Cyclosporine may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.,Levobupivacaine
DB01105,Cyclosporine may decrease the excretion rate of Sibutramine which could result in a higher serum level.,Sibutramine
DB01215,Cyclosporine may decrease the excretion rate of Estazolam which could result in a higher serum level.,Estazolam
DB06282,Cyclosporine may decrease the excretion rate of Levocetirizine which could result in a higher serum level.,Levocetirizine
DB09089,Cyclosporine may decrease the excretion rate of Trimebutine which could result in a higher serum level.,Trimebutine
DB09223,Cyclosporine may decrease the excretion rate of Blonanserin which could result in a higher serum level.,Blonanserin
DB09262,Cyclosporine may decrease the excretion rate of Imidafenacin which could result in a higher serum level.,Imidafenacin
DB09317,"Cyclosporine may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level.","Synthetic Conjugated Estrogens, A"
DB09318,"Cyclosporine may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level.","Synthetic Conjugated Estrogens, B"
DB11251,Cyclosporine may decrease the excretion rate of Tocopherol which could result in a higher serum level.,Tocopherol
DB12278,Cyclosporine may decrease the excretion rate of Propiverine which could result in a higher serum level.,Propiverine
DB15593,Cyclosporine may decrease the excretion rate of Golodirsen which could result in a higher serum level.,Golodirsen
DB00327,Cyclosporine may decrease the excretion rate of Hydromorphone which could result in a higher serum level.,Hydromorphone
DB00980,Cyclosporine may decrease the excretion rate of Ramelteon which could result in a higher serum level.,Ramelteon
DB04574,Cyclosporine may decrease the excretion rate of Estrone sulfate which could result in a higher serum level.,Estrone sulfate
DB00279,Cyclosporine may decrease the excretion rate of Liothyronine which could result in a higher serum level.,Liothyronine
DB00863,Cyclosporine may decrease the excretion rate of Ranitidine which could result in a higher serum level.,Ranitidine
DB00213,Cyclosporine may decrease the excretion rate of Pantoprazole which could result in a higher serum level.,Pantoprazole
DB00341,Cyclosporine may decrease the excretion rate of Cetirizine which could result in a higher serum level.,Cetirizine
DB00351,Cyclosporine may decrease the excretion rate of Megestrol acetate which could result in a higher serum level.,Megestrol acetate
DB00440,Cyclosporine may decrease the excretion rate of Trimethoprim which could result in a higher serum level.,Trimethoprim
DB00690,Cyclosporine may decrease the excretion rate of Flurazepam which could result in a higher serum level.,Flurazepam
DB01212,Cyclosporine may decrease the excretion rate of Ceftriaxone which could result in a higher serum level.,Ceftriaxone
DB08996,Cyclosporine may decrease the excretion rate of Dimetacrine which could result in a higher serum level.,Dimetacrine
DB00879,Cyclosporine may decrease the excretion rate of Emtricitabine which could result in a higher serum level.,Emtricitabine
DB14506,Cyclosporine may decrease the excretion rate of Lithium hydroxide which could result in a higher serum level.,Lithium hydroxide
DB00452,Cyclosporine may decrease the excretion rate of Framycetin which could result in a higher serum level.,Framycetin
DB00479,Cyclosporine may decrease the excretion rate of Amikacin which could result in a higher serum level.,Amikacin
DB00684,Cyclosporine may decrease the excretion rate of Tobramycin which could result in a higher serum level.,Tobramycin
DB00798,Cyclosporine may decrease the excretion rate of Gentamicin which could result in a higher serum level.,Gentamicin
DB00955,Cyclosporine may decrease the excretion rate of Netilmicin which could result in a higher serum level.,Netilmicin
DB01082,Cyclosporine may decrease the excretion rate of Streptomycin which could result in a higher serum level.,Streptomycin
DB01172,Cyclosporine may decrease the excretion rate of Kanamycin which could result in a higher serum level.,Kanamycin
DB01421,Cyclosporine may decrease the excretion rate of Paromomycin which could result in a higher serum level.,Paromomycin
DB03615,Cyclosporine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.,Ribostamycin
DB04263,Cyclosporine may decrease the excretion rate of Geneticin which could result in a higher serum level.,Geneticin
DB04626,Cyclosporine may decrease the excretion rate of Apramycin which could result in a higher serum level.,Apramycin
DB04729,Cyclosporine may decrease the excretion rate of Gentamicin C1a which could result in a higher serum level.,Gentamicin C1a
DB04808,Cyclosporine may decrease the excretion rate of Neamine which could result in a higher serum level.,Neamine
DB06696,Cyclosporine may decrease the excretion rate of Arbekacin which could result in a higher serum level.,Arbekacin
DB08437,Cyclosporine may decrease the excretion rate of Puromycin which could result in a higher serum level.,Puromycin
DB11512,Cyclosporine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.,Dihydrostreptomycin
DB11520,Cyclosporine may decrease the excretion rate of Hygromycin B which could result in a higher serum level.,Hygromycin B
DB12604,Cyclosporine may decrease the excretion rate of Sisomicin which could result in a higher serum level.,Sisomicin
DB13270,Cyclosporine may decrease the excretion rate of Dibekacin which could result in a higher serum level.,Dibekacin
DB13274,Cyclosporine may decrease the excretion rate of Micronomicin which could result in a higher serum level.,Micronomicin
DB13540,Cyclosporine may decrease the excretion rate of Isepamicin which could result in a higher serum level.,Isepamicin
DB13673,Cyclosporine may decrease the excretion rate of Bekanamycin which could result in a higher serum level.,Bekanamycin
DB00314,Cyclosporine may decrease the excretion rate of Capreomycin which could result in a higher serum level.,Capreomycin
DB00512,Cyclosporine may decrease the excretion rate of Vancomycin which could result in a higher serum level.,Vancomycin
DB00982,Cyclosporine may decrease the excretion rate of Isotretinoin which could result in a higher serum level.,Isotretinoin
DB12615,Cyclosporine may decrease the excretion rate of Plazomicin which could result in a higher serum level.,Plazomicin
DB14509,Cyclosporine may decrease the excretion rate of Lithium carbonate which could result in a higher serum level.,Lithium carbonate
DB13145,Cyclosporine may decrease the excretion rate of Nedaplatin which could result in a higher serum level.,Nedaplatin
DB00408,The serum concentration of Cyclosporine can be increased when it is combined with Loxapine.,Loxapine
DB00539,The serum concentration of Cyclosporine can be increased when it is combined with Toremifene.,Toremifene
DB00872,The serum concentration of Cyclosporine can be increased when it is combined with Conivaptan.,Conivaptan
DB01167,The serum concentration of Cyclosporine can be increased when it is combined with Itraconazole.,Itraconazole
DB01259,The serum concentration of Cyclosporine can be increased when it is combined with Lapatinib.,Lapatinib
DB01388,The serum concentration of Cyclosporine can be increased when it is combined with Mibefradil.,Mibefradil
DB04851,The serum concentration of Cyclosporine can be increased when it is combined with Biricodar.,Biricodar
DB04881,The serum concentration of Cyclosporine can be increased when it is combined with Elacridar.,Elacridar
DB05294,The serum concentration of Cyclosporine can be increased when it is combined with Vandetanib.,Vandetanib
DB06191,The serum concentration of Cyclosporine can be increased when it is combined with Zosuquidar.,Zosuquidar
DB06240,The serum concentration of Cyclosporine can be increased when it is combined with Tariquidar.,Tariquidar
DB08896,The serum concentration of Cyclosporine can be increased when it is combined with Regorafenib.,Regorafenib
DB08907,The serum concentration of Cyclosporine can be increased when it is combined with Canagliflozin.,Canagliflozin
DB09030,The serum concentration of Cyclosporine can be increased when it is combined with Vorapaxar.,Vorapaxar
DB09034,The serum concentration of Cyclosporine can be increased when it is combined with Suvorexant.,Suvorexant
DB09065,The serum concentration of Cyclosporine can be increased when it is combined with Cobicistat.,Cobicistat
DB09102,The serum concentration of Cyclosporine can be increased when it is combined with Daclatasvir.,Daclatasvir
DB09239,The serum concentration of Cyclosporine can be increased when it is combined with Niguldipine.,Niguldipine
DB09291,The serum concentration of Cyclosporine can be increased when it is combined with Rolapitant.,Rolapitant
DB11581,The serum concentration of Cyclosporine can be increased when it is combined with Venetoclax.,Venetoclax
DB11613,The serum concentration of Cyclosporine can be increased when it is combined with Velpatasvir.,Velpatasvir
DB11828,The serum concentration of Cyclosporine can be increased when it is combined with Neratinib.,Neratinib
DB11869,The serum concentration of Cyclosporine can be increased when it is combined with Valspodar.,Valspodar
DB11978,The serum concentration of Cyclosporine can be increased when it is combined with Glasdegib.,Glasdegib
DB12026,The serum concentration of Cyclosporine can be increased when it is combined with Voxilaprevir.,Voxilaprevir
DB12035,The serum concentration of Cyclosporine can be increased when it is combined with Sarecycline.,Sarecycline
DB12799,The serum concentration of Cyclosporine can be increased when it is combined with Laniquidar.,Laniquidar
DB13878,The serum concentration of Cyclosporine can be increased when it is combined with Pibrentasvir.,Pibrentasvir
DB13879,The serum concentration of Cyclosporine can be increased when it is combined with Glecaprevir.,Glecaprevir
DB14068,The serum concentration of Cyclosporine can be increased when it is combined with Dexniguldipine.,Dexniguldipine
DB14069,The serum concentration of Cyclosporine can be increased when it is combined with ONT-093.,ONT-093
DB14568,The serum concentration of Cyclosporine can be increased when it is combined with Ivosidenib.,Ivosidenib
DB12500,The serum concentration of Fedratinib can be increased when it is combined with Cyclosporine.,Fedratinib
DB08827,The serum concentration of Lomitapide can be increased when it is combined with Cyclosporine.,Lomitapide
DB08882,The serum concentration of Cyclosporine can be increased when it is combined with Linagliptin.,Linagliptin
DB11760,The serum concentration of Cyclosporine can be increased when it is combined with Talazoparib.,Talazoparib
DB00206,The serum concentration of Cyclosporine can be increased when it is combined with Reserpine.,Reserpine
DB12466,The serum concentration of Cyclosporine can be increased when it is combined with Favipiravir.,Favipiravir
DB11967,The serum concentration of Binimetinib can be increased when it is combined with Cyclosporine.,Binimetinib
DB14840,The serum concentration of Ripretinib can be increased when it is combined with Cyclosporine.,Ripretinib
DB09125,Cyclosporine may increase the hyperkalemic activities of Potassium citrate.,Potassium citrate
DB06715,Potassium Iodide may increase the hyperkalemic activities of Cyclosporine.,Potassium Iodide
DB09087,Potassium alum may increase the hyperkalemic activities of Cyclosporine.,Potassium alum
DB09413,Monopotassium phosphate may increase the hyperkalemic activities of Cyclosporine.,Monopotassium phosphate
DB09414,Dipotassium phosphate may increase the hyperkalemic activities of Cyclosporine.,Dipotassium phosphate
DB09449,"Sodium phosphate, monobasic may increase the hyperkalemic activities of Cyclosporine.","Sodium phosphate, monobasic"
DB09483,Potassium lactate may increase the hyperkalemic activities of Cyclosporine.,Potassium lactate
DB11107,Potassium bitartrate may increase the hyperkalemic activities of Cyclosporine.,Potassium bitartrate
DB11153,Potassium hydroxide may increase the hyperkalemic activities of Cyclosporine.,Potassium hydroxide
DB13620,Potassium gluconate may increase the hyperkalemic activities of Cyclosporine.,Potassium gluconate
DB13735,Potassium Guaiacolsulfonate may increase the hyperkalemic activities of Cyclosporine.,Potassium Guaiacolsulfonate
DB13831,Potassium permanganate may increase the hyperkalemic activities of Cyclosporine.,Potassium permanganate
DB13977,Potassium carbonate may increase the hyperkalemic activities of Cyclosporine.,Potassium carbonate
DB14492,Potassium triiodide may increase the hyperkalemic activities of Cyclosporine.,Potassium triiodide
DB14500,Potassium may increase the hyperkalemic activities of Cyclosporine.,Potassium
DB00155,The excretion of Citrulline can be decreased when combined with Cyclosporine.,Citrulline
DB00345,The excretion of Aminohippuric acid can be decreased when combined with Cyclosporine.,Aminohippuric acid
DB00770,The excretion of Alprostadil can be decreased when combined with Cyclosporine.,Alprostadil
DB00943,The excretion of Zalcitabine can be decreased when combined with Cyclosporine.,Zalcitabine
DB01606,The excretion of Tazobactam can be decreased when combined with Cyclosporine.,Tazobactam
DB02527,The excretion of Cyclic adenosine monophosphate can be decreased when combined with Cyclosporine.,Cyclic adenosine monophosphate
DB03553,The excretion of Glutaric Acid can be decreased when combined with Cyclosporine.,Glutaric Acid
DB08846,The excretion of Ellagic acid can be decreased when combined with Cyclosporine.,Ellagic acid
DB09298,The excretion of Silibinin can be decreased when combined with Cyclosporine.,Silibinin
DB12243,The excretion of Edaravone can be decreased when combined with Cyclosporine.,Edaravone
DB00052,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Cyclosporine.",Somatotropin
DB00389,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Carbimazole.",Carbimazole
DB00649,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Stavudine.",Stavudine
DB00666,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Nafarelin.",Nafarelin
DB00704,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Naltrexone.",Naltrexone
DB01017,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Minocycline.",Minocycline
DB01088,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Iloprost.",Iloprost
DB06693,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Mevastatin.",Mevastatin
DB06817,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Raltegravir.",Raltegravir
DB09055,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Acipimox.",Acipimox
DB12554,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Mebeverine.",Mebeverine
DB13393,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Emetine.",Emetine
DB01006,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Letrozole.",Letrozole
DB00584,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Enalapril.",Enalapril
DB01197,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Captopril.",Captopril
DB00382,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Tacrine.",Tacrine
DB00471,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Montelukast.",Montelukast
DB00585,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Nizatidine.",Nizatidine
DB09270,"The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Ubidecarenone.",Ubidecarenone
DB01045,The metabolism of Cyclosporine can be increased when combined with Rifampicin.,Rifampicin
DB01323,The metabolism of Cyclosporine can be increased when combined with St. John's Wort.,St. John's Wort
DB06595,The metabolism of Cyclosporine can be increased when combined with Midostaurin.,Midostaurin
DB11753,The metabolism of Cyclosporine can be increased when combined with Rifamycin.,Rifamycin
DB00648,The metabolism of Cyclosporine can be increased when combined with Mitotane.,Mitotane
DB06414,The metabolism of Cyclosporine can be increased when combined with Etravirine.,Etravirine
DB06442,The metabolism of Cyclosporine can be increased when combined with Avasimibe.,Avasimibe
DB08912,The metabolism of Cyclosporine can be increased when combined with Dabrafenib.,Dabrafenib
DB14240,The metabolism of Cyclosporine can be increased when combined with Echinacea.,Echinacea
DB00273,The metabolism of Cyclosporine can be increased when combined with Topiramate.,Topiramate
DB00615,The metabolism of Cyclosporine can be increased when combined with Rifabutin.,Rifabutin
DB00949,The metabolism of Cyclosporine can be increased when combined with Felbamate.,Felbamate
DB04911,The metabolism of Cyclosporine can be increased when combined with Oritavancin.,Oritavancin
DB06201,The metabolism of Cyclosporine can be increased when combined with Rufinamide.,Rufinamide
DB08909,The metabolism of Cyclosporine can be increased when combined with Glycerol phenylbutyrate.,Glycerol phenylbutyrate
DB09078,The metabolism of Cyclosporine can be increased when combined with Lenvatinib.,Lenvatinib
DB09119,The metabolism of Cyclosporine can be increased when combined with Eslicarbazepine acetate.,Eslicarbazepine acetate
DB11560,The metabolism of Lesinurad can be increased when combined with Cyclosporine.,Lesinurad
DB01645,The metabolism of Cyclosporine can be increased when combined with Genistein.,Genistein
DB00349,The metabolism of Cyclosporine can be increased when combined with Clobazam.,Clobazam
DB00082,The metabolism of Cyclosporine can be increased when combined with Pegvisomant.,Pegvisomant
DB06717,The metabolism of Fosaprepitant can be increased when combined with Cyclosporine.,Fosaprepitant
DB00136,The metabolism of Cyclosporine can be increased when combined with Calcitriol.,Calcitriol
DB00197,The metabolism of Cyclosporine can be increased when combined with Troglitazone.,Troglitazone
DB00301,The metabolism of Cyclosporine can be increased when combined with Flucloxacillin.,Flucloxacillin
DB00357,The metabolism of Cyclosporine can be increased when combined with Aminoglutethimide.,Aminoglutethimide
DB00439,The metabolism of Cyclosporine can be increased when combined with Cerivastatin.,Cerivastatin
DB00485,The metabolism of Cyclosporine can be increased when combined with Dicloxacillin.,Dicloxacillin
DB00603,The metabolism of Cyclosporine can be increased when combined with Medroxyprogesterone acetate.,Medroxyprogesterone acetate
DB00754,The metabolism of Cyclosporine can be increased when combined with Ethotoin.,Ethotoin
DB00769,The metabolism of Cyclosporine can be increased when combined with Hydrocortamate.,Hydrocortamate
DB00857,The metabolism of Cyclosporine can be increased when combined with Terbinafine.,Terbinafine
DB00898,The metabolism of Cyclosporine can be increased when combined with Ethanol.,Ethanol
DB00957,The metabolism of Cyclosporine can be increased when combined with Norgestimate.,Norgestimate
DB01011,The metabolism of Cyclosporine can be increased when combined with Metyrapone.,Metyrapone
DB01201,The metabolism of Cyclosporine can be increased when combined with Rifapentine.,Rifapentine
DB01221,The metabolism of Cyclosporine can be increased when combined with Ketamine.,Ketamine
DB01333,The metabolism of Cyclosporine can be increased when combined with Cefradine.,Cefradine
DB01352,The metabolism of Cyclosporine can be increased when combined with Aprobarbital.,Aprobarbital
DB01609,The metabolism of Cyclosporine can be increased when combined with Deferasirox.,Deferasirox
DB06708,The metabolism of Cyclosporine can be increased when combined with Lumefantrine.,Lumefantrine
DB06739,The metabolism of Cyclosporine can be increased when combined with Seratrodast.,Seratrodast
DB08905,The metabolism of Cyclosporine can be increased when combined with Formestane.,Formestane
DB08911,The metabolism of Cyclosporine can be increased when combined with Trametinib.,Trametinib
DB09330,The metabolism of Cyclosporine can be increased when combined with Osimertinib.,Osimertinib
DB12267,The metabolism of Cyclosporine can be increased when combined with Brigatinib.,Brigatinib
DB13952,The metabolism of Cyclosporine can be increased when combined with Estradiol acetate.,Estradiol acetate
DB13953,The metabolism of Cyclosporine can be increased when combined with Estradiol benzoate.,Estradiol benzoate
DB13954,The metabolism of Cyclosporine can be increased when combined with Estradiol cypionate.,Estradiol cypionate
DB13955,The metabolism of Cyclosporine can be increased when combined with Estradiol dienanthate.,Estradiol dienanthate
DB13956,The metabolism of Cyclosporine can be increased when combined with Estradiol valerate.,Estradiol valerate
DB08883,The metabolism of Perampanel can be increased when combined with Cyclosporine.,Perampanel
DB00776,The metabolism of Cyclosporine can be increased when combined with Oxcarbazepine.,Oxcarbazepine
DB14575,The metabolism of Cyclosporine can be increased when combined with Eslicarbazepine.,Eslicarbazepine
DB00448,The metabolism of Cyclosporine can be increased when combined with Lansoprazole.,Lansoprazole
DB00602,The metabolism of Ivermectin can be increased when combined with Cyclosporine.,Ivermectin
DB01183,The metabolism of Cyclosporine can be decreased when combined with Naloxone.,Naloxone
DB09118,The metabolism of Cyclosporine can be decreased when combined with Stiripentol.,Stiripentol
DB11779,The metabolism of Cyclosporine can be decreased when combined with Danoprevir.,Danoprevir
DB11730,The metabolism of Cyclosporine can be decreased when combined with Ribociclib.,Ribociclib
DB09101,The metabolism of Cyclosporine can be decreased when combined with Elvitegravir.,Elvitegravir
DB00696,The metabolism of Cyclosporine can be decreased when combined with Ergotamine.,Ergotamine
DB01263,The metabolism of Posaconazole can be decreased when combined with Cyclosporine.,Posaconazole
DB01072,The metabolism of Atazanavir can be decreased when combined with Cyclosporine.,Atazanavir
DB11712,The metabolism of Cyclosporine can be decreased when combined with Tezacaftor.,Tezacaftor
DB01396,The metabolism of Digitoxin can be decreased when combined with Cyclosporine.,Digitoxin
DB00951,The metabolism of Isoniazid can be decreased when combined with Cyclosporine.,Isoniazid
DB00582,The metabolism of Cyclosporine can be decreased when combined with Voriconazole.,Voriconazole
DB04896,The metabolism of Milnacipran can be decreased when combined with Cyclosporine.,Milnacipran
DB11641,The metabolism of Cyclosporine can be decreased when combined with Vinflunine.,Vinflunine
DB06712,The metabolism of Nilvadipine can be decreased when combined with Cyclosporine.,Nilvadipine
DB06700,The metabolism of Desvenlafaxine can be decreased when combined with Cyclosporine.,Desvenlafaxine
DB08953,The metabolism of Cyclosporine can be decreased when combined with Indalpine.,Indalpine
DB14019,The metabolism of Cyclosporine can be decreased when combined with Fosnetupitant.,Fosnetupitant
DB00204,The metabolism of Dofetilide can be decreased when combined with Cyclosporine.,Dofetilide
DB00451,The metabolism of Levothyroxine can be decreased when combined with Cyclosporine.,Levothyroxine
DB00946,The metabolism of Phenprocoumon can be decreased when combined with Cyclosporine.,Phenprocoumon
DB01223,The metabolism of Aminophylline can be decreased when combined with Cyclosporine.,Aminophylline
DB03410,The metabolism of 4-hydroxycoumarin can be decreased when combined with Cyclosporine.,4-hydroxycoumarin
DB09289,The metabolism of Tianeptine can be decreased when combined with Cyclosporine.,Tianeptine
DB13136,The metabolism of Fluindione can be decreased when combined with Cyclosporine.,Fluindione
DB13275,The metabolism of Clorindione can be decreased when combined with Cyclosporine.,Clorindione
DB00270,The metabolism of Cyclosporine can be decreased when combined with Isradipine.,Isradipine
DB00622,The metabolism of Cyclosporine can be decreased when combined with Nicardipine.,Nicardipine
DB01110,The metabolism of Cyclosporine can be decreased when combined with Miconazole.,Miconazole
DB01087,The metabolism of Cyclosporine can be decreased when combined with Primaquine.,Primaquine
DB04832,The metabolism of Cyclosporine can be decreased when combined with Zimelidine.,Zimelidine
DB05812,The metabolism of Abiraterone can be decreased when combined with Cyclosporine.,Abiraterone
DB11363,The metabolism of Alectinib can be decreased when combined with Cyclosporine.,Alectinib
DB09570,The metabolism of Ixazomib can be decreased when combined with Cyclosporine.,Ixazomib
DB12978,The metabolism of Pexidartinib can be decreased when combined with Cyclosporine.,Pexidartinib
DB00501,The metabolism of Cyclosporine can be decreased when combined with Cimetidine.,Cimetidine
DB01764,The metabolism of Cyclosporine can be decreased when combined with Dalfopristin.,Dalfopristin
DB04794,The metabolism of Cyclosporine can be decreased when combined with Bifonazole.,Bifonazole
DB09063,The metabolism of Cyclosporine can be decreased when combined with Ceritinib.,Ceritinib
DB13941,The metabolism of Piperaquine can be decreased when combined with Cyclosporine.,Piperaquine
DB09238,The metabolism of Manidipine can be decreased when combined with Cyclosporine.,Manidipine
DB04839,The metabolism of Cyproterone acetate can be decreased when combined with Cyclosporine.,Cyproterone acetate
DB00778,The metabolism of Cyclosporine can be decreased when combined with Roxithromycin.,Roxithromycin
DB01173,The metabolism of Cyclosporine can be decreased when combined with Orphenadrine.,Orphenadrine
DB00818,The metabolism of Cyclosporine can be decreased when combined with Propofol.,Propofol
DB01128,The metabolism of Cyclosporine can be decreased when combined with Bicalutamide.,Bicalutamide
DB05928,The metabolism of Cyclosporine can be decreased when combined with Dovitinib.,Dovitinib
DB11837,The metabolism of Cyclosporine can be decreased when combined with Osilodrostat.,Osilodrostat
DB08864,The metabolism of Cyclosporine can be decreased when combined with Rilpivirine.,Rilpivirine
DB01395,The metabolism of Cyclosporine can be decreased when combined with Drospirenone.,Drospirenone
DB00186,The metabolism of Cyclosporine can be decreased when combined with Lorazepam.,Lorazepam
DB00191,The metabolism of Cyclosporine can be decreased when combined with Phentermine.,Phentermine
DB00426,The metabolism of Cyclosporine can be decreased when combined with Famciclovir.,Famciclovir
DB00567,The metabolism of Cyclosporine can be decreased when combined with Cephalexin.,Cephalexin
DB01411,The metabolism of Cyclosporine can be decreased when combined with Pranlukast.,Pranlukast
DB01431,The metabolism of Cyclosporine can be decreased when combined with Allylestrenol.,Allylestrenol
DB06218,The metabolism of Cyclosporine can be decreased when combined with Lacosamide.,Lacosamide
DB09071,The metabolism of Cyclosporine can be decreased when combined with Tasimelteon.,Tasimelteon
DB09079,The metabolism of Cyclosporine can be decreased when combined with Nintedanib.,Nintedanib
DB11094,The metabolism of Cyclosporine can be decreased when combined with Vitamin D.,Vitamin D
DB11273,The metabolism of Cyclosporine can be decreased when combined with Dihydroergocornine.,Dihydroergocornine
DB11952,The metabolism of Cyclosporine can be decreased when combined with Duvelisib.,Duvelisib
DB12141,The metabolism of Cyclosporine can be decreased when combined with Gilteritinib.,Gilteritinib
DB12515,The metabolism of Cyclosporine can be decreased when combined with 9-aminocamptothecin.,9-aminocamptothecin
DB12952,The metabolism of Cyclosporine can be decreased when combined with Methylprednisone.,Methylprednisone
DB13345,The metabolism of Cyclosporine can be decreased when combined with Dihydroergocristine.,Dihydroergocristine
DB13385,The metabolism of Cyclosporine can be decreased when combined with Dihydroergocryptine.,Dihydroergocryptine
DB12887,The metabolism of Tazemetostat can be decreased when combined with Cyclosporine.,Tazemetostat
DB00518,The metabolism of Cyclosporine can be decreased when combined with Albendazole.,Albendazole
DB00247,The metabolism of Methysergide can be decreased when combined with Cyclosporine.,Methysergide
DB11742,The metabolism of Ebastine can be decreased when combined with Cyclosporine.,Ebastine
DB00220,The metabolism of Cyclosporine can be decreased when combined with Nelfinavir.,Nelfinavir
DB00673,The metabolism of Aprepitant can be decreased when combined with Cyclosporine.,Aprepitant
DB01232,The metabolism of Saquinavir can be decreased when combined with Cyclosporine.,Saquinavir
DB00780,The metabolism of Cyclosporine can be decreased when combined with Phenelzine.,Phenelzine
DB02520,The metabolism of Cyclosporine can be decreased when combined with Ditiocarb.,Ditiocarb
DB06731,The metabolism of Cyclosporine can be decreased when combined with Seproxetine.,Seproxetine
DB11574,The metabolism of Cyclosporine can be decreased when combined with Elbasvir.,Elbasvir
DB09241,The metabolism of Methylene blue can be decreased when combined with Cyclosporine.,Methylene blue
DB06654,The metabolism of Cyclosporine can be decreased when combined with Safinamide.,Safinamide
DB06730,The metabolism of Cyclosporine can be decreased when combined with Gestodene.,Gestodene
DB11703,The metabolism of Cyclosporine can be decreased when combined with Acalabrutinib.,Acalabrutinib
DB00224,The metabolism of Cyclosporine can be decreased when combined with Indinavir.,Indinavir
DB00250,The metabolism of Cyclosporine can be decreased when combined with Dapsone.,Dapsone
DB00499,The metabolism of Cyclosporine can be decreased when combined with Flutamide.,Flutamide
DB00758,The metabolism of Cyclosporine can be decreased when combined with Clopidogrel.,Clopidogrel
DB00822,The metabolism of Cyclosporine can be decreased when combined with Disulfiram.,Disulfiram
DB00962,The metabolism of Cyclosporine can be decreased when combined with Zaleplon.,Zaleplon
DB01058,The metabolism of Cyclosporine can be decreased when combined with Praziquantel.,Praziquantel
DB01126,The metabolism of Cyclosporine can be decreased when combined with Dutasteride.,Dutasteride
DB01216,The metabolism of Cyclosporine can be decreased when combined with Finasteride.,Finasteride
DB01218,The metabolism of Cyclosporine can be decreased when combined with Halofantrine.,Halofantrine
DB01227,The metabolism of Cyclosporine can be decreased when combined with Levacetylmethadol.,Levacetylmethadol
DB06176,The metabolism of Cyclosporine can be decreased when combined with Romidepsin.,Romidepsin
DB06267,The metabolism of Cyclosporine can be decreased when combined with Udenafil.,Udenafil
DB06335,The metabolism of Cyclosporine can be decreased when combined with Saxagliptin.,Saxagliptin
DB06605,The metabolism of Cyclosporine can be decreased when combined with Apixaban.,Apixaban
DB06626,The metabolism of Cyclosporine can be decreased when combined with Axitinib.,Axitinib
DB06652,The metabolism of Cyclosporine can be decreased when combined with Vicriviroc.,Vicriviroc
DB06789,The metabolism of Cyclosporine can be decreased when combined with Hydroxyprogesterone caproate.,Hydroxyprogesterone caproate
DB09256,The metabolism of Cyclosporine can be decreased when combined with Tegafur.,Tegafur
DB11737,The metabolism of Cyclosporine can be decreased when combined with Icotinib.,Icotinib
DB12130,The metabolism of Cyclosporine can be decreased when combined with Lorlatinib.,Lorlatinib
DB12301,The metabolism of Cyclosporine can be decreased when combined with Doravirine.,Doravirine
DB12483,The metabolism of Cyclosporine can be decreased when combined with Copanlisib.,Copanlisib
DB14542,The metabolism of Cyclosporine can be decreased when combined with Hydrocortisone phosphate.,Hydrocortisone phosphate
DB00604,The metabolism of Cisapride can be decreased when combined with Cyclosporine.,Cisapride
DB00820,The metabolism of Tadalafil can be decreased when combined with Cyclosporine.,Tadalafil
DB00897,The metabolism of Triazolam can be decreased when combined with Cyclosporine.,Triazolam
DB06228,The metabolism of Rivaroxaban can be decreased when combined with Cyclosporine.,Rivaroxaban
DB00783,The metabolism of Cyclosporine can be decreased when combined with Estradiol.,Estradiol
DB00246,The metabolism of Cyclosporine can be decreased when combined with Ziprasidone.,Ziprasidone
DB00717,The metabolism of Cyclosporine can be decreased when combined with Norethisterone.,Norethisterone
DB00829,The metabolism of Cyclosporine can be decreased when combined with Diazepam.,Diazepam
DB00977,The metabolism of Cyclosporine can be decreased when combined with Ethinylestradiol.,Ethinylestradiol
DB01062,The metabolism of Cyclosporine can be decreased when combined with Oxybutynin.,Oxybutynin
DB06697,The metabolism of Artemether can be decreased when combined with Cyclosporine.,Artemether
DB04856,The metabolism of Dexloxiglumide can be decreased when combined with Cyclosporine.,Dexloxiglumide
DB04957,The metabolism of Azimilide can be decreased when combined with Cyclosporine.,Azimilide
DB00367,The metabolism of Levonorgestrel can be decreased when combined with Cyclosporine.,Levonorgestrel
DB00528,The metabolism of Lercanidipine can be decreased when combined with Cyclosporine.,Lercanidipine
DB00938,The metabolism of Salmeterol can be decreased when combined with Cyclosporine.,Salmeterol
DB09061,The metabolism of Cannabidiol can be decreased when combined with Cyclosporine.,Cannabidiol
DB09231,The metabolism of Benidipine can be decreased when combined with Cyclosporine.,Benidipine
DB14011,The metabolism of Nabiximols can be decreased when combined with Cyclosporine.,Nabiximols
DB00557,The metabolism of Hydroxyzine can be decreased when combined with Cyclosporine.,Hydroxyzine
DB11951,The metabolism of Lemborexant can be decreased when combined with Cyclosporine.,Lemborexant
DB01190,The metabolism of Clindamycin can be decreased when combined with Cyclosporine.,Clindamycin
DB01054,The metabolism of Cyclosporine can be decreased when combined with Nitrendipine.,Nitrendipine
DB01103,The metabolism of Cyclosporine can be decreased when combined with Quinacrine.,Quinacrine
DB09297,The metabolism of Paritaprevir can be decreased when combined with Cyclosporine.,Paritaprevir
DB00401,The metabolism of Cyclosporine can be decreased when combined with Nisoldipine.,Nisoldipine
DB00802,The metabolism of Cyclosporine can be decreased when combined with Alfentanil.,Alfentanil
DB00714,The metabolism of Apomorphine can be decreased when combined with Cyclosporine.,Apomorphine
DB00260,Cyclosporine may increase the neurotoxic activities of Cycloserine.,Cycloserine
DB00391,Cyclosporine may increase the neurotoxic activities of Sulpiride.,Sulpiride
DB00450,Cyclosporine may increase the neurotoxic activities of Droperidol.,Droperidol
DB00680,Cyclosporine may increase the neurotoxic activities of Moricizine.,Moricizine
DB01063,Cyclosporine may increase the neurotoxic activities of Acetophenazine.,Acetophenazine
DB01294,Cyclosporine may increase the neurotoxic activities of Bismuth subsalicylate.,Bismuth subsalicylate
DB01608,Cyclosporine may increase the neurotoxic activities of Periciazine.,Periciazine
DB01614,Cyclosporine may increase the neurotoxic activities of Acepromazine.,Acepromazine
DB01615,Cyclosporine may increase the neurotoxic activities of Aceprometazine.,Aceprometazine
DB01618,Cyclosporine may increase the neurotoxic activities of Molindone.,Molindone
DB01622,Cyclosporine may increase the neurotoxic activities of Thioproperazine.,Thioproperazine
DB01623,Cyclosporine may increase the neurotoxic activities of Thiothixene.,Thiothixene
DB04836,Cyclosporine may increase the neurotoxic activities of Amineptine.,Amineptine
DB04872,Cyclosporine may increase the neurotoxic activities of Osanetant.,Osanetant
DB04888,Cyclosporine may increase the neurotoxic activities of Bifeprunox.,Bifeprunox
DB05316,Cyclosporine may increase the neurotoxic activities of Pimavanserin.,Pimavanserin
DB05687,Cyclosporine may increase the neurotoxic activities of BL-1020.,BL-1020
DB06288,Cyclosporine may increase the neurotoxic activities of Amisulpride.,Amisulpride
DB08927,Cyclosporine may increase the neurotoxic activities of Amperozide.,Amperozide
DB09000,Cyclosporine may increase the neurotoxic activities of Cyamemazine.,Cyamemazine
DB09016,Cyclosporine may increase the neurotoxic activities of Butriptyline.,Butriptyline
DB09154,Cyclosporine may increase the neurotoxic activities of Sodium citrate.,Sodium citrate
DB09226,Cyclosporine may increase the neurotoxic activities of Brilaroxazine.,Brilaroxazine
DB09275,Cyclosporine may increase the neurotoxic activities of Bismuth subcitrate potassium.,Bismuth subcitrate potassium
DB09286,Cyclosporine may increase the neurotoxic activities of Pipamperone.,Pipamperone
DB09307,Cyclosporine may increase the neurotoxic activities of Oxaprotiline.,Oxaprotiline
DB11281,Cyclosporine may increase the neurotoxic activities of Bismuth subcarbonate.,Bismuth subcarbonate
DB11376,Cyclosporine may increase the neurotoxic activities of Azaperone.,Azaperone
DB11537,Cyclosporine may increase the neurotoxic activities of Pirlimycin.,Pirlimycin
DB11540,Cyclosporine may increase the neurotoxic activities of Propiopromazine.,Propiopromazine
DB12273,Cyclosporine may increase the neurotoxic activities of Ecopipam.,Ecopipam
DB12518,Cyclosporine may increase the neurotoxic activities of Raclopride.,Raclopride
DB12693,Cyclosporine may increase the neurotoxic activities of Ritanserin.,Ritanserin
DB12710,Cyclosporine may increase the neurotoxic activities of Perazine.,Perazine
DB12867,Cyclosporine may increase the neurotoxic activities of Benperidol.,Benperidol
DB12958,Cyclosporine may increase the neurotoxic activities of Prothipendyl.,Prothipendyl
DB13114,Cyclosporine may increase the neurotoxic activities of Amitriptylinoxide.,Amitriptylinoxide
DB13209,Cyclosporine may increase the neurotoxic activities of Bismuth subnitrate.,Bismuth subnitrate
DB13213,Cyclosporine may increase the neurotoxic activities of Butaperazine.,Butaperazine
DB13225,Cyclosporine may increase the neurotoxic activities of Dibenzepin.,Dibenzepin
DB13246,Cyclosporine may increase the neurotoxic activities of Quinupramine.,Quinupramine
DB13256,Cyclosporine may increase the neurotoxic activities of Clothiapine.,Clothiapine
DB13273,Cyclosporine may increase the neurotoxic activities of Sultopride.,Sultopride
DB13382,Cyclosporine may increase the neurotoxic activities of Chlorproethazine.,Chlorproethazine
DB13384,Cyclosporine may increase the neurotoxic activities of Melitracen.,Melitracen
DB13403,Cyclosporine may increase the neurotoxic activities of Oxypertine.,Oxypertine
DB13411,Cyclosporine may increase the neurotoxic activities of Lofepramine.,Lofepramine
DB13420,Cyclosporine may increase the neurotoxic activities of Thiazinam.,Thiazinam
DB13496,Cyclosporine may increase the neurotoxic activities of Iprindole.,Iprindole
DB13523,Cyclosporine may increase the neurotoxic activities of Veralipride.,Veralipride
DB13552,Cyclosporine may increase the neurotoxic activities of Trifluperidol.,Trifluperidol
DB13554,Cyclosporine may increase the neurotoxic activities of Moperone.,Moperone
DB13557,Cyclosporine may increase the neurotoxic activities of Thiopropazate.,Thiopropazate
DB13665,Cyclosporine may increase the neurotoxic activities of Fluanisone.,Fluanisone
DB13676,Cyclosporine may increase the neurotoxic activities of Mosapramine.,Mosapramine
DB13782,Cyclosporine may increase the neurotoxic activities of Imipramine oxide.,Imipramine oxide
DB13784,Cyclosporine may increase the neurotoxic activities of Dixyrazine.,Dixyrazine
DB13841,Cyclosporine may increase the neurotoxic activities of Clopenthixol.,Clopenthixol
DB13910,Cyclosporine may increase the neurotoxic activities of Valproate bismuth.,Valproate bismuth
DB14651,Cyclosporine may increase the neurotoxic activities of Perphenazine enanthate.,Perphenazine enanthate
DB01246,Cyclosporine may increase the neurotoxic activities of Alimemazine.,Alimemazine
DB09225,Cyclosporine may increase the neurotoxic activities of Zotepine.,Zotepine
DB00508,Cyclosporine may increase the neurotoxic activities of Triflupromazine.,Triflupromazine
DB00623,Cyclosporine may increase the neurotoxic activities of Fluphenazine.,Fluphenazine
DB01239,Cyclosporine may increase the neurotoxic activities of Chlorprothixene.,Chlorprothixene
DB12401,Cyclosporine may increase the neurotoxic activities of Bromperidol.,Bromperidol
DB00924,Cyclosporine may increase the neurotoxic activities of Cyclobenzaprine.,Cyclobenzaprine
DB01597,The excretion of Cyclosporine can be increased when combined with Cilastatin.,Cilastatin
DB00653,The therapeutic efficacy of Magnesium sulfate can be decreased when used in combination with Cyclosporine.,Magnesium sulfate
DB00463,The therapeutic efficacy of Metharbital can be decreased when used in combination with Cyclosporine.,Metharbital
DB00697,The therapeutic efficacy of Tizanidine can be decreased when used in combination with Cyclosporine.,Tizanidine
DB00832,The therapeutic efficacy of Phensuximide can be decreased when used in combination with Cyclosporine.,Phensuximide
DB00837,The therapeutic efficacy of Progabide can be decreased when used in combination with Cyclosporine.,Progabide
DB01080,The therapeutic efficacy of Vigabatrin can be decreased when used in combination with Cyclosporine.,Vigabatrin
DB01121,The therapeutic efficacy of Phenacemide can be decreased when used in combination with Cyclosporine.,Phenacemide
DB01511,The therapeutic efficacy of Delorazepam can be decreased when used in combination with Cyclosporine.,Delorazepam
DB02207,The therapeutic efficacy of 7-Nitroindazole can be decreased when used in combination with Cyclosporine.,7-Nitroindazole
DB04165,The therapeutic efficacy of Valpromide can be decreased when used in combination with Cyclosporine.,Valpromide
DB06512,The therapeutic efficacy of Deramciclane can be decreased when used in combination with Cyclosporine.,Deramciclane
DB06527,The therapeutic efficacy of Tramiprosate can be decreased when used in combination with Cyclosporine.,Tramiprosate
DB06554,The therapeutic efficacy of Gaboxadol can be decreased when used in combination with Cyclosporine.,Gaboxadol
DB08329,The therapeutic efficacy of Sulthiame can be decreased when used in combination with Cyclosporine.,Sulthiame
DB08954,The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Cyclosporine.,Ifenprodil
DB09011,The therapeutic efficacy of Beclamide can be decreased when used in combination with Cyclosporine.,Beclamide
DB09117,The therapeutic efficacy of Paraldehyde can be decreased when used in combination with Cyclosporine.,Paraldehyde
DB11549,The therapeutic efficacy of Tiletamine can be decreased when used in combination with Cyclosporine.,Tiletamine
DB11859,The therapeutic efficacy of Brexanolone can be decreased when used in combination with Cyclosporine.,Brexanolone
DB11868,The therapeutic efficacy of Etiracetam can be decreased when used in combination with Cyclosporine.,Etiracetam
DB12338,The therapeutic efficacy of Carisbamate can be decreased when used in combination with Cyclosporine.,Carisbamate
DB13362,The therapeutic efficacy of Pheneturide can be decreased when used in combination with Cyclosporine.,Pheneturide
DB13396,The therapeutic efficacy of Neocitrullamon can be decreased when used in combination with Cyclosporine.,Neocitrullamon
DB13437,The therapeutic efficacy of Medazepam can be decreased when used in combination with Cyclosporine.,Medazepam
DB13455,The therapeutic efficacy of Phenibut can be decreased when used in combination with Cyclosporine.,Phenibut
DB13799,The therapeutic efficacy of Ethadione can be decreased when used in combination with Cyclosporine.,Ethadione
DB14050,The therapeutic efficacy of Cannabidivarin can be decreased when used in combination with Cyclosporine.,Cannabidivarin
DB15203,The therapeutic efficacy of JNJ-26489112 can be decreased when used in combination with Cyclosporine.,JNJ-26489112
DB00230,The therapeutic efficacy of Cyclosporine can be decreased when used in combination with Pregabalin.,Pregabalin
DB01068,The therapeutic efficacy of Clonazepam can be decreased when used in combination with Cyclosporine.,Clonazepam
DB00996,The therapeutic efficacy of Gabapentin can be decreased when used in combination with Cyclosporine.,Gabapentin
DB00906,The therapeutic efficacy of Tiagabine can be decreased when used in combination with Cyclosporine.,Tiagabine
DB01595,The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Cyclosporine.,Nitrazepam
DB06470,The therapeutic efficacy of Clomethiazole can be decreased when used in combination with Cyclosporine.,Clomethiazole
DB12131,The therapeutic efficacy of Vinpocetine can be decreased when used in combination with Cyclosporine.,Vinpocetine
DB00347,The therapeutic efficacy of Trimethadione can be decreased when used in combination with Cyclosporine.,Trimethadione
DB00617,The therapeutic efficacy of Paramethadione can be decreased when used in combination with Cyclosporine.,Paramethadione
DB05246,The therapeutic efficacy of Methsuximide can be decreased when used in combination with Cyclosporine.,Methsuximide
DB05541,The therapeutic efficacy of Brivaracetam can be decreased when used in combination with Cyclosporine.,Brivaracetam
DB01202,The therapeutic efficacy of Levetiracetam can be decreased when used in combination with Cyclosporine.,Levetiracetam
DB00593,The therapeutic efficacy of Ethosuximide can be decreased when used in combination with Cyclosporine.,Ethosuximide
DB11640,The risk or severity of seizure can be increased when Cyclosporine is combined with Amifampridine.,Amifampridine
DB09142,The excretion of Sincalide can be decreased when combined with Cyclosporine.,Sincalide
DB11936,The excretion of Bempedoic acid can be decreased when combined with Cyclosporine.,Bempedoic acid
DB11855,Cyclosporine may decrease the excretion rate of Revefenacin which could result in a higher serum level.,Revefenacin
DB00218,The risk or severity of nephrotoxicity can be increased when Moxifloxacin is combined with Cyclosporine.,Moxifloxacin
DB00365,The risk or severity of nephrotoxicity can be increased when Grepafloxacin is combined with Cyclosporine.,Grepafloxacin
DB00467,The risk or severity of nephrotoxicity can be increased when Enoxacin is combined with Cyclosporine.,Enoxacin
DB00487,The risk or severity of nephrotoxicity can be increased when Pefloxacin is combined with Cyclosporine.,Pefloxacin
DB00685,The risk or severity of nephrotoxicity can be increased when Trovafloxacin is combined with Cyclosporine.,Trovafloxacin
DB00779,The risk or severity of nephrotoxicity can be increased when Nalidixic acid is combined with Cyclosporine.,Nalidixic acid
DB00817,The risk or severity of nephrotoxicity can be increased when Rosoxacin is combined with Cyclosporine.,Rosoxacin
DB00827,The risk or severity of nephrotoxicity can be increased when Cinoxacin is combined with Cyclosporine.,Cinoxacin
DB00978,The risk or severity of nephrotoxicity can be increased when Lomefloxacin is combined with Cyclosporine.,Lomefloxacin
DB01044,The risk or severity of nephrotoxicity can be increased when Gatifloxacin is combined with Cyclosporine.,Gatifloxacin
DB01155,The risk or severity of nephrotoxicity can be increased when Gemifloxacin is combined with Cyclosporine.,Gemifloxacin
DB01165,The risk or severity of nephrotoxicity can be increased when Ofloxacin is combined with Cyclosporine.,Ofloxacin
DB01208,The risk or severity of nephrotoxicity can be increased when Sparfloxacin is combined with Cyclosporine.,Sparfloxacin
DB01405,The risk or severity of nephrotoxicity can be increased when Temafloxacin is combined with Cyclosporine.,Temafloxacin
DB04576,The risk or severity of nephrotoxicity can be increased when Fleroxacin is combined with Cyclosporine.,Fleroxacin
DB05488,The risk or severity of nephrotoxicity can be increased when Technetium Tc-99m ciprofloxacin is combined with Cyclosporine.,Technetium Tc-99m ciprofloxacin
DB06160,The risk or severity of nephrotoxicity can be increased when Garenoxacin is combined with Cyclosporine.,Garenoxacin
DB06600,The risk or severity of nephrotoxicity can be increased when Nemonoxacin is combined with Cyclosporine.,Nemonoxacin
DB08972,The risk or severity of nephrotoxicity can be increased when Flumequine is combined with Cyclosporine.,Flumequine
DB11404,The risk or severity of nephrotoxicity can be increased when Enrofloxacin is combined with Cyclosporine.,Enrofloxacin
DB11443,The risk or severity of nephrotoxicity can be increased when Orbifloxacin is combined with Cyclosporine.,Orbifloxacin
DB11491,The risk or severity of nephrotoxicity can be increased when Sarafloxacin is combined with Cyclosporine.,Sarafloxacin
DB11511,The risk or severity of nephrotoxicity can be increased when Difloxacin is combined with Cyclosporine.,Difloxacin
DB11774,The risk or severity of nephrotoxicity can be increased when Pazufloxacin is combined with Cyclosporine.,Pazufloxacin
DB11892,The risk or severity of nephrotoxicity can be increased when Prulifloxacin is combined with Cyclosporine.,Prulifloxacin
DB11943,The risk or severity of nephrotoxicity can be increased when Delafloxacin is combined with Cyclosporine.,Delafloxacin
DB13261,The risk or severity of nephrotoxicity can be increased when Sitafloxacin is combined with Cyclosporine.,Sitafloxacin
DB13627,The risk or severity of nephrotoxicity can be increased when Oxolinic acid is combined with Cyclosporine.,Oxolinic acid
DB13772,The risk or severity of nephrotoxicity can be increased when Rufloxacin is combined with Cyclosporine.,Rufloxacin
DB13823,The risk or severity of nephrotoxicity can be increased when Pipemidic acid is combined with Cyclosporine.,Pipemidic acid
DB00882,The serum concentration of Cyclosporine can be increased when it is combined with Clomifene.,Clomifene
DB05889,The serum concentration of Cyclosporine can be increased when it is combined with Inotuzumab ozogamicin.,Inotuzumab ozogamicin
DB08930,The serum concentration of Cyclosporine can be increased when it is combined with Dolutegravir.,Dolutegravir
DB08934,The serum concentration of Cyclosporine can be increased when it is combined with Sofosbuvir.,Sofosbuvir
DB09161,The serum concentration of Cyclosporine can be increased when it is combined with Technetium Tc-99m sestamibi.,Technetium Tc-99m sestamibi
DB09296,The serum concentration of Cyclosporine can be increased when it is combined with Ombitasvir.,Ombitasvir
DB11827,The serum concentration of Cyclosporine can be increased when it is combined with Ertugliflozin.,Ertugliflozin
DB11995,The serum concentration of Cyclosporine can be increased when it is combined with Avatrombopag.,Avatrombopag
DB12455,The serum concentration of Cyclosporine can be increased when it is combined with Omadacycline.,Omadacycline
DB12836,The serum concentration of Cyclosporine can be increased when it is combined with Grapiprant.,Grapiprant
DB13007,The serum concentration of Cyclosporine can be increased when it is combined with Enfortumab vedotin.,Enfortumab vedotin
DB06212,The serum concentration of Cyclosporine can be increased when it is combined with Tolvaptan.,Tolvaptan
DB00950,The serum concentration of Cyclosporine can be increased when it is combined with Fexofenadine.,Fexofenadine
DB00295,The serum concentration of Cyclosporine can be increased when it is combined with Morphine.,Morphine
DB01261,The serum concentration of Cyclosporine can be increased when it is combined with Sitagliptin.,Sitagliptin
DB05039,The serum concentration of Cyclosporine can be increased when it is combined with Indacaterol.,Indacaterol
DB06670,The serum concentration of Cyclosporine can be increased when it is combined with Odanacatib.,Odanacatib
DB11362,The serum concentration of Cyclosporine can be increased when it is combined with Selexipag.,Selexipag
DB11575,The serum concentration of Cyclosporine can be increased when it is combined with Grazoprevir.,Grazoprevir
DB14723,The serum concentration of Cyclosporine can be increased when it is combined with Larotrectinib.,Larotrectinib
DB00586,The serum concentration of Diclofenac can be increased when it is combined with Cyclosporine.,Diclofenac
DB00005,Etanercept may increase the immunosuppressive activities of Cyclosporine.,Etanercept
DB00008,Peginterferon alfa-2a may increase the immunosuppressive activities of Cyclosporine.,Peginterferon alfa-2a
DB00011,Interferon alfa-n1 may increase the immunosuppressive activities of Cyclosporine.,Interferon alfa-n1
DB00018,Interferon alfa-n3 may increase the immunosuppressive activities of Cyclosporine.,Interferon alfa-n3
DB00022,Peginterferon alfa-2b may increase the immunosuppressive activities of Cyclosporine.,Peginterferon alfa-2b
DB00026,Anakinra may increase the immunosuppressive activities of Cyclosporine.,Anakinra
DB00033,Interferon gamma-1b may increase the immunosuppressive activities of Cyclosporine.,Interferon gamma-1b
DB00034,"Interferon alfa-2a, Recombinant may increase the immunosuppressive activities of Cyclosporine.","Interferon alfa-2a, Recombinant"
DB00041,Aldesleukin may increase the immunosuppressive activities of Cyclosporine.,Aldesleukin
DB00056,Gemtuzumab ozogamicin may increase the immunosuppressive activities of Cyclosporine.,Gemtuzumab ozogamicin
DB00059,Pegaspargase may increase the immunosuppressive activities of Cyclosporine.,Pegaspargase
DB00065,Infliximab may increase the immunosuppressive activities of Cyclosporine.,Infliximab
DB00068,Interferon beta-1b may increase the immunosuppressive activities of Cyclosporine.,Interferon beta-1b
DB00069,Interferon alfacon-1 may increase the immunosuppressive activities of Cyclosporine.,Interferon alfacon-1
DB00072,Trastuzumab may increase the immunosuppressive activities of Cyclosporine.,Trastuzumab
DB00073,Rituximab may increase the immunosuppressive activities of Cyclosporine.,Rituximab
DB00074,Basiliximab may increase the immunosuppressive activities of Cyclosporine.,Basiliximab
DB00075,Muromonab may increase the immunosuppressive activities of Cyclosporine.,Muromonab
DB00078,Ibritumomab tiuxetan may increase the immunosuppressive activities of Cyclosporine.,Ibritumomab tiuxetan
DB00081,Tositumomab may increase the immunosuppressive activities of Cyclosporine.,Tositumomab
DB00087,Alemtuzumab may increase the immunosuppressive activities of Cyclosporine.,Alemtuzumab
DB00092,Alefacept may increase the immunosuppressive activities of Cyclosporine.,Alefacept
DB00095,Efalizumab may increase the immunosuppressive activities of Cyclosporine.,Efalizumab
DB00098,Antithymocyte immunoglobulin (rabbit) may increase the immunosuppressive activities of Cyclosporine.,Antithymocyte immunoglobulin (rabbit)
DB00105,Interferon alfa-2b may increase the immunosuppressive activities of Cyclosporine.,Interferon alfa-2b
DB00108,Natalizumab may increase the immunosuppressive activities of Cyclosporine.,Natalizumab
DB00111,Daclizumab may increase the immunosuppressive activities of Cyclosporine.,Daclizumab
DB00112,Bevacizumab may increase the immunosuppressive activities of Cyclosporine.,Bevacizumab
DB00120,Phenylalanine may increase the immunosuppressive activities of Cyclosporine.,Phenylalanine
DB00180,Flunisolide may increase the immunosuppressive activities of Cyclosporine.,Flunisolide
DB00188,Bortezomib may increase the immunosuppressive activities of Cyclosporine.,Bortezomib
DB00242,Cladribine may increase the immunosuppressive activities of Cyclosporine.,Cladribine
DB00262,Carmustine may increase the immunosuppressive activities of Cyclosporine.,Carmustine
DB00276,Amsacrine may increase the immunosuppressive activities of Cyclosporine.,Amsacrine
DB00290,Bleomycin may increase the immunosuppressive activities of Cyclosporine.,Bleomycin
DB00291,Chlorambucil may increase the immunosuppressive activities of Cyclosporine.,Chlorambucil
DB00293,Raltitrexed may increase the immunosuppressive activities of Cyclosporine.,Raltitrexed
DB00305,Mitomycin may increase the immunosuppressive activities of Cyclosporine.,Mitomycin
DB00307,Bexarotene may increase the immunosuppressive activities of Cyclosporine.,Bexarotene
DB00309,Vindesine may increase the immunosuppressive activities of Cyclosporine.,Vindesine
DB00322,Floxuridine may increase the immunosuppressive activities of Cyclosporine.,Floxuridine
DB00328,Indomethacin may increase the immunosuppressive activities of Cyclosporine.,Indomethacin
DB00352,Tioguanine may increase the immunosuppressive activities of Cyclosporine.,Tioguanine
DB00361,Vinorelbine may increase the immunosuppressive activities of Cyclosporine.,Vinorelbine
DB00380,Dexrazoxane may increase the immunosuppressive activities of Cyclosporine.,Dexrazoxane
DB00394,Beclomethasone dipropionate may increase the immunosuppressive activities of Cyclosporine.,Beclomethasone dipropionate
DB00398,Sorafenib may increase the immunosuppressive activities of Cyclosporine.,Sorafenib
DB00428,Streptozocin may increase the immunosuppressive activities of Cyclosporine.,Streptozocin
DB00432,Trifluridine may increase the immunosuppressive activities of Cyclosporine.,Trifluridine
DB00441,Gemcitabine may increase the immunosuppressive activities of Cyclosporine.,Gemcitabine
DB00443,Betamethasone may increase the immunosuppressive activities of Cyclosporine.,Betamethasone
DB00444,Teniposide may increase the immunosuppressive activities of Cyclosporine.,Teniposide
DB00445,Epirubicin may increase the immunosuppressive activities of Cyclosporine.,Epirubicin
DB00480,Lenalidomide may increase the immunosuppressive activities of Cyclosporine.,Lenalidomide
DB00488,Altretamine may increase the immunosuppressive activities of Cyclosporine.,Altretamine
DB00495,Zidovudine may increase the immunosuppressive activities of Cyclosporine.,Zidovudine
DB00515,Cisplatin may increase the immunosuppressive activities of Cyclosporine.,Cisplatin
DB00526,Oxaliplatin may increase the immunosuppressive activities of Cyclosporine.,Oxaliplatin
DB00541,Vincristine may increase the immunosuppressive activities of Cyclosporine.,Vincristine
DB00544,Fluorouracil may increase the immunosuppressive activities of Cyclosporine.,Fluorouracil
DB00550,Propylthiouracil may increase the immunosuppressive activities of Cyclosporine.,Propylthiouracil
DB00552,Pentostatin may increase the immunosuppressive activities of Cyclosporine.,Pentostatin
DB00570,Vinblastine may increase the immunosuppressive activities of Cyclosporine.,Vinblastine
DB00588,Fluticasone propionate may increase the immunosuppressive activities of Cyclosporine.,Fluticasone propionate
DB00591,Fluocinolone acetonide may increase the immunosuppressive activities of Cyclosporine.,Fluocinolone acetonide
DB00601,Linezolid may increase the immunosuppressive activities of Cyclosporine.,Linezolid
DB00620,Triamcinolone may increase the immunosuppressive activities of Cyclosporine.,Triamcinolone
DB00631,Clofarabine may increase the immunosuppressive activities of Cyclosporine.,Clofarabine
DB00635,Prednisone may increase the immunosuppressive activities of Cyclosporine.,Prednisone
DB00642,Pemetrexed may increase the immunosuppressive activities of Cyclosporine.,Pemetrexed
DB00687,Fludrocortisone may increase the immunosuppressive activities of Cyclosporine.,Fludrocortisone
DB00688,Mycophenolate mofetil may increase the immunosuppressive activities of Cyclosporine.,Mycophenolate mofetil
DB00694,Daunorubicin may increase the immunosuppressive activities of Cyclosporine.,Daunorubicin
DB00741,Hydrocortisone may increase the immunosuppressive activities of Cyclosporine.,Hydrocortisone
DB00755,Tretinoin may increase the immunosuppressive activities of Cyclosporine.,Tretinoin
DB00762,Irinotecan may increase the immunosuppressive activities of Cyclosporine.,Irinotecan
DB00763,Methimazole may increase the immunosuppressive activities of Cyclosporine.,Methimazole
DB00764,Mometasone may increase the immunosuppressive activities of Cyclosporine.,Mometasone
DB00795,Sulfasalazine may increase the immunosuppressive activities of Cyclosporine.,Sulfasalazine
DB00851,Dacarbazine may increase the immunosuppressive activities of Cyclosporine.,Dacarbazine
DB00853,Temozolomide may increase the immunosuppressive activities of Cyclosporine.,Temozolomide
DB00859,Penicillamine may increase the immunosuppressive activities of Cyclosporine.,Penicillamine
DB00860,Prednisolone may increase the immunosuppressive activities of Cyclosporine.,Prednisolone
DB00877,Sirolimus may increase the immunosuppressive activities of Cyclosporine.,Sirolimus
DB00888,Mechlorethamine may increase the immunosuppressive activities of Cyclosporine.,Mechlorethamine
DB00928,Azacitidine may increase the immunosuppressive activities of Cyclosporine.,Azacitidine
DB00958,Carboplatin may increase the immunosuppressive activities of Cyclosporine.,Carboplatin
DB00970,Dactinomycin may increase the immunosuppressive activities of Cyclosporine.,Dactinomycin
DB00987,Cytarabine may increase the immunosuppressive activities of Cyclosporine.,Cytarabine
DB00993,Azathioprine may increase the immunosuppressive activities of Cyclosporine.,Azathioprine
DB01005,Hydroxyurea may increase the immunosuppressive activities of Cyclosporine.,Hydroxyurea
DB01008,Busulfan may increase the immunosuppressive activities of Cyclosporine.,Busulfan
DB01024,Mycophenolic acid may increase the immunosuppressive activities of Cyclosporine.,Mycophenolic acid
DB01030,Topotecan may increase the immunosuppressive activities of Cyclosporine.,Topotecan
DB01033,Mercaptopurine may increase the immunosuppressive activities of Cyclosporine.,Mercaptopurine
DB01041,Thalidomide may increase the immunosuppressive activities of Cyclosporine.,Thalidomide
DB01073,Fludarabine may increase the immunosuppressive activities of Cyclosporine.,Fludarabine
DB01097,Leflunomide may increase the immunosuppressive activities of Cyclosporine.,Leflunomide
DB01099,Flucytosine may increase the immunosuppressive activities of Cyclosporine.,Flucytosine
DB01101,Capecitabine may increase the immunosuppressive activities of Cyclosporine.,Capecitabine
DB01108,Trilostane may increase the immunosuppressive activities of Cyclosporine.,Trilostane
DB01168,Procarbazine may increase the immunosuppressive activities of Cyclosporine.,Procarbazine
DB01169,Arsenic trioxide may increase the immunosuppressive activities of Cyclosporine.,Arsenic trioxide
DB01177,Idarubicin may increase the immunosuppressive activities of Cyclosporine.,Idarubicin
DB01181,Ifosfamide may increase the immunosuppressive activities of Cyclosporine.,Ifosfamide
DB01196,Estramustine may increase the immunosuppressive activities of Cyclosporine.,Estramustine
DB01206,Lomustine may increase the immunosuppressive activities of Cyclosporine.,Lomustine
DB01222,Budesonide may increase the immunosuppressive activities of Cyclosporine.,Budesonide
DB01229,Paclitaxel may increase the immunosuppressive activities of Cyclosporine.,Paclitaxel
DB01234,Dexamethasone may increase the immunosuppressive activities of Cyclosporine.,Dexamethasone
DB01248,Docetaxel may increase the immunosuppressive activities of Cyclosporine.,Docetaxel
DB01254,Dasatinib may increase the immunosuppressive activities of Cyclosporine.,Dasatinib
DB01257,Eculizumab may increase the immunosuppressive activities of Cyclosporine.,Eculizumab
DB01262,Decitabine may increase the immunosuppressive activities of Cyclosporine.,Decitabine
DB01268,Sunitinib may increase the immunosuppressive activities of Cyclosporine.,Sunitinib
DB01280,Nelarabine may increase the immunosuppressive activities of Cyclosporine.,Nelarabine
DB01281,Abatacept may increase the immunosuppressive activities of Cyclosporine.,Abatacept
DB01285,Corticotropin may increase the immunosuppressive activities of Cyclosporine.,Corticotropin
DB01380,Cortisone acetate may increase the immunosuppressive activities of Cyclosporine.,Cortisone acetate
DB01384,Paramethasone may increase the immunosuppressive activities of Cyclosporine.,Paramethasone
DB01394,Colchicine may increase the immunosuppressive activities of Cyclosporine.,Colchicine
DB01410,Ciclesonide may increase the immunosuppressive activities of Cyclosporine.,Ciclesonide
DB01423,Stepronin may increase the immunosuppressive activities of Cyclosporine.,Stepronin
DB01611,Hydroxychloroquine may increase the immunosuppressive activities of Cyclosporine.,Hydroxychloroquine
DB01816,Castanospermine may increase the immunosuppressive activities of Cyclosporine.,Castanospermine
DB02546,Vorinostat may increase the immunosuppressive activities of Cyclosporine.,Vorinostat
DB02806,2-Methoxyethanol may increase the immunosuppressive activities of Cyclosporine.,2-Methoxyethanol
DB03523,Brequinar may increase the immunosuppressive activities of Cyclosporine.,Brequinar
DB04572,Thiotepa may increase the immunosuppressive activities of Cyclosporine.,Thiotepa
DB04630,Aldosterone may increase the immunosuppressive activities of Cyclosporine.,Aldosterone
DB04845,Ixabepilone may increase the immunosuppressive activities of Cyclosporine.,Ixabepilone
DB04868,Nilotinib may increase the immunosuppressive activities of Cyclosporine.,Nilotinib
DB04951,Pirfenidone may increase the immunosuppressive activities of Cyclosporine.,Pirfenidone
DB04956,Afelimomab may increase the immunosuppressive activities of Cyclosporine.,Afelimomab
DB05015,Belinostat may increase the immunosuppressive activities of Cyclosporine.,Belinostat
DB05109,Trabectedin may increase the immunosuppressive activities of Cyclosporine.,Trabectedin
DB05258,Interferon alfa may increase the immunosuppressive activities of Cyclosporine.,Interferon alfa
DB05259,Glatiramer may increase the immunosuppressive activities of Cyclosporine.,Glatiramer
DB05260,Gallium nitrate may increase the immunosuppressive activities of Cyclosporine.,Gallium nitrate
DB05459,Briakinumab may increase the immunosuppressive activities of Cyclosporine.,Briakinumab
DB05472,omega interferon may increase the immunosuppressive activities of Cyclosporine.,omega interferon
DB05676,Apremilast may increase the immunosuppressive activities of Cyclosporine.,Apremilast
DB05773,Trastuzumab emtansine may increase the immunosuppressive activities of Cyclosporine.,Trastuzumab emtansine
DB06168,Canakinumab may increase the immunosuppressive activities of Cyclosporine.,Canakinumab
DB06273,Tocilizumab may increase the immunosuppressive activities of Cyclosporine.,Tocilizumab
DB06287,Temsirolimus may increase the immunosuppressive activities of Cyclosporine.,Temsirolimus
DB06372,Rilonacept may increase the immunosuppressive activities of Cyclosporine.,Rilonacept
DB06589,Pazopanib may increase the immunosuppressive activities of Cyclosporine.,Pazopanib
DB06603,Panobinostat may increase the immunosuppressive activities of Cyclosporine.,Panobinostat
DB06612,Mepolizumab may increase the immunosuppressive activities of Cyclosporine.,Mepolizumab
DB06616,Bosutinib may increase the immunosuppressive activities of Cyclosporine.,Bosutinib
DB06643,Denosumab may increase the immunosuppressive activities of Cyclosporine.,Denosumab
DB06662,Abetimus may increase the immunosuppressive activities of Cyclosporine.,Abetimus
DB06674,Golimumab may increase the immunosuppressive activities of Cyclosporine.,Golimumab
DB06681,Belatacept may increase the immunosuppressive activities of Cyclosporine.,Belatacept
DB06769,Bendamustine may increase the immunosuppressive activities of Cyclosporine.,Bendamustine
DB06772,Cabazitaxel may increase the immunosuppressive activities of Cyclosporine.,Cabazitaxel
DB06813,Pralatrexate may increase the immunosuppressive activities of Cyclosporine.,Pralatrexate
DB08059,Wortmannin may increase the immunosuppressive activities of Cyclosporine.,Wortmannin
DB08868,Fingolimod may increase the immunosuppressive activities of Cyclosporine.,Fingolimod
DB08870,Brentuximab vedotin may increase the immunosuppressive activities of Cyclosporine.,Brentuximab vedotin
DB08871,Eribulin may increase the immunosuppressive activities of Cyclosporine.,Eribulin
DB08877,Ruxolitinib may increase the immunosuppressive activities of Cyclosporine.,Ruxolitinib
DB08879,Belimumab may increase the immunosuppressive activities of Cyclosporine.,Belimumab
DB08880,Teriflunomide may increase the immunosuppressive activities of Cyclosporine.,Teriflunomide
DB08889,Carfilzomib may increase the immunosuppressive activities of Cyclosporine.,Carfilzomib
DB08895,Tofacitinib may increase the immunosuppressive activities of Cyclosporine.,Tofacitinib
DB08901,Ponatinib may increase the immunosuppressive activities of Cyclosporine.,Ponatinib
DB08904,Certolizumab pegol may increase the immunosuppressive activities of Cyclosporine.,Certolizumab pegol
DB08906,Fluticasone furoate may increase the immunosuppressive activities of Cyclosporine.,Fluticasone furoate
DB08908,Dimethyl fumarate may increase the immunosuppressive activities of Cyclosporine.,Dimethyl fumarate
DB08910,Pomalidomide may increase the immunosuppressive activities of Cyclosporine.,Pomalidomide
DB08935,Obinutuzumab may increase the immunosuppressive activities of Cyclosporine.,Obinutuzumab
DB08970,Fluprednidene may increase the immunosuppressive activities of Cyclosporine.,Fluprednidene
DB08971,Fluocortolone may increase the immunosuppressive activities of Cyclosporine.,Fluocortolone
DB09029,Secukinumab may increase the immunosuppressive activities of Cyclosporine.,Secukinumab
DB09033,Vedolizumab may increase the immunosuppressive activities of Cyclosporine.,Vedolizumab
DB09036,Siltuximab may increase the immunosuppressive activities of Cyclosporine.,Siltuximab
DB09052,Blinatumomab may increase the immunosuppressive activities of Cyclosporine.,Blinatumomab
DB09053,Ibrutinib may increase the immunosuppressive activities of Cyclosporine.,Ibrutinib
DB09054,Idelalisib may increase the immunosuppressive activities of Cyclosporine.,Idelalisib
DB09073,Palbociclib may increase the immunosuppressive activities of Cyclosporine.,Palbociclib
DB09074,Olaparib may increase the immunosuppressive activities of Cyclosporine.,Olaparib
DB09077,Dinutuximab may increase the immunosuppressive activities of Cyclosporine.,Dinutuximab
DB09082,Vilanterol may increase the immunosuppressive activities of Cyclosporine.,Vilanterol
DB09091,Tixocortol may increase the immunosuppressive activities of Cyclosporine.,Tixocortol
DB09122,Peginterferon beta-1a may increase the immunosuppressive activities of Cyclosporine.,Peginterferon beta-1a
DB09312,Antilymphocyte immunoglobulin (horse) may increase the immunosuppressive activities of Cyclosporine.,Antilymphocyte immunoglobulin (horse)
DB09378,Fluprednisolone may increase the immunosuppressive activities of Cyclosporine.,Fluprednisolone
DB09383,Meprednisone may increase the immunosuppressive activities of Cyclosporine.,Meprednisone
DB11466,Tepoxalin may increase the immunosuppressive activities of Cyclosporine.,Tepoxalin
DB11487,Dexamethasone isonicotinate may increase the immunosuppressive activities of Cyclosporine.,Dexamethasone isonicotinate
DB11529,Melengestrol may increase the immunosuppressive activities of Cyclosporine.,Melengestrol
DB11569,Ixekizumab may increase the immunosuppressive activities of Cyclosporine.,Ixekizumab
DB11580,Ravulizumab may increase the immunosuppressive activities of Cyclosporine.,Ravulizumab
DB11616,Pirarubicin may increase the immunosuppressive activities of Cyclosporine.,Pirarubicin
DB11693,Voclosporin may increase the immunosuppressive activities of Cyclosporine.,Voclosporin
DB11708,Peficitinib may increase the immunosuppressive activities of Cyclosporine.,Peficitinib
DB11750,Clobetasol may increase the immunosuppressive activities of Cyclosporine.,Clobetasol
DB11767,Sarilumab may increase the immunosuppressive activities of Cyclosporine.,Sarilumab
DB11776,Brodalumab may increase the immunosuppressive activities of Cyclosporine.,Brodalumab
DB11803,Sirukumab may increase the immunosuppressive activities of Cyclosporine.,Sirukumab
DB11817,Baricitinib may increase the immunosuppressive activities of Cyclosporine.,Baricitinib
DB11834,Guselkumab may increase the immunosuppressive activities of Cyclosporine.,Guselkumab
DB11921,Deflazacort may increase the immunosuppressive activities of Cyclosporine.,Deflazacort
DB11988,Ocrelizumab may increase the immunosuppressive activities of Cyclosporine.,Ocrelizumab
DB12025,Triptolide may increase the immunosuppressive activities of Cyclosporine.,Triptolide
DB12371,Siponimod may increase the immunosuppressive activities of Cyclosporine.,Siponimod
DB12612,Ozanimod may increase the immunosuppressive activities of Cyclosporine.,Ozanimod
DB12617,Mizoribine may increase the immunosuppressive activities of Cyclosporine.,Mizoribine
DB12692,Gusperimus may increase the immunosuppressive activities of Cyclosporine.,Gusperimus
DB12814,Cepeginterferon alfa-2B may increase the immunosuppressive activities of Cyclosporine.,Cepeginterferon alfa-2B
DB12902,Trofosfamide may increase the immunosuppressive activities of Cyclosporine.,Trofosfamide
DB12947,Doxifluridine may increase the immunosuppressive activities of Cyclosporine.,Doxifluridine
DB12991,Deoxyspergualin may increase the immunosuppressive activities of Cyclosporine.,Deoxyspergualin
DB12996,Acteoside may increase the immunosuppressive activities of Cyclosporine.,Acteoside
DB13003,Cortivazol may increase the immunosuppressive activities of Cyclosporine.,Cortivazol
DB13014,Hypericin may increase the immunosuppressive activities of Cyclosporine.,Hypericin
DB13068,9-(N-methyl-L-isoleucine)-cyclosporin A may increase the immunosuppressive activities of Cyclosporine.,9-(N-methyl-L-isoleucine)-cyclosporin A
DB13208,Prednylidene may increase the immunosuppressive activities of Cyclosporine.,Prednylidene
DB13223,Fluocortin may increase the immunosuppressive activities of Cyclosporine.,Fluocortin
DB13241,Begelomab may increase the immunosuppressive activities of Cyclosporine.,Begelomab
DB13491,Fluperolone may increase the immunosuppressive activities of Cyclosporine.,Fluperolone
DB13664,Formocortal may increase the immunosuppressive activities of Cyclosporine.,Formocortal
DB13728,Halometasone may increase the immunosuppressive activities of Cyclosporine.,Halometasone
DB13843,Cloprednol may increase the immunosuppressive activities of Cyclosporine.,Cloprednol
DB13856,Fluclorolone may increase the immunosuppressive activities of Cyclosporine.,Fluclorolone
DB13867,Fluticasone may increase the immunosuppressive activities of Cyclosporine.,Fluticasone
DB14066,Tetrandrine may increase the immunosuppressive activities of Cyclosporine.,Tetrandrine
DB14219,Monomethyl fumarate may increase the immunosuppressive activities of Cyclosporine.,Monomethyl fumarate
DB14512,Mometasone furoate may increase the immunosuppressive activities of Cyclosporine.,Mometasone furoate
DB14538,Hydrocortisone aceponate may increase the immunosuppressive activities of Cyclosporine.,Hydrocortisone aceponate
DB14539,Hydrocortisone acetate may increase the immunosuppressive activities of Cyclosporine.,Hydrocortisone acetate
DB14545,Hydrocortisone succinate may increase the immunosuppressive activities of Cyclosporine.,Hydrocortisone succinate
DB14724,Emapalumab may increase the immunosuppressive activities of Cyclosporine.,Emapalumab
DB14762,Risankizumab may increase the immunosuppressive activities of Cyclosporine.,Risankizumab
DB14919,Rozanolixizumab may increase the immunosuppressive activities of Cyclosporine.,Rozanolixizumab
DB15253,Bleselumab may increase the immunosuppressive activities of Cyclosporine.,Bleselumab
DB00321,The metabolism of Amitriptyline can be decreased when combined with Cyclosporine.,Amitriptyline
DB11823,The risk or severity of hypertension can be increased when Esketamine is combined with Cyclosporine.,Esketamine
DB00437,The serum concentration of Cyclosporine can be increased when it is combined with Allopurinol.,Allopurinol
DB00781,The risk or severity of adverse effects can be increased when Cyclosporine is combined with Polymyxin B.,Polymyxin B
DB14754,The risk or severity of hypertension can be increased when Solriamfetol is combined with Cyclosporine.,Solriamfetol
DB13946,Testosterone undecanoate may increase the hypertensive activities of Cyclosporine.,Testosterone undecanoate
DB12147,The serum concentration of Cyclosporine can be increased when it is combined with Erdafitinib.,Erdafitinib
DB00181,Cyclosporine may decrease the excretion rate of Baclofen which could result in a higher serum level.,Baclofen
DB00537,Cyclosporine may increase the nephrotoxic activities of Ciprofloxacin.,Ciprofloxacin
DB12015,The serum concentration of Alpelisib can be increased when it is combined with Cyclosporine.,Alpelisib
DB00373,The metabolism of Timolol can be decreased when combined with Cyclosporine.,Timolol
DB05154,The serum concentration of Pretomanid can be increased when it is combined with Cyclosporine.,Pretomanid
DB11986,The metabolism of Entrectinib can be decreased when combined with Cyclosporine.,Entrectinib
DB12825,The serum concentration of Lefamulin can be increased when it is combined with Cyclosporine.,Lefamulin
DB06637,The risk or severity of seizure can be increased when Cyclosporine is combined with Dalfampridine.,Dalfampridine
DB11732,The serum concentration of Cyclosporine can be increased when it is combined with Lasmiditan.,Lasmiditan
DB15444,The serum concentration of Elexacaftor can be increased when it is combined with Cyclosporine.,Elexacaftor
DB14541,The risk or severity of adverse effects can be increased when Hydrocortisone cypionate is combined with Cyclosporine.,Hydrocortisone cypionate
DB14631,The risk or severity of adverse effects can be increased when Prednisolone phosphate is combined with Cyclosporine.,Prednisolone phosphate
DB14633,The risk or severity of adverse effects can be increased when Prednisolone hemisuccinate is combined with Cyclosporine.,Prednisolone hemisuccinate
DB14634,The risk or severity of adverse effects can be increased when Fluprednidene acetate is combined with Cyclosporine.,Fluprednidene acetate
DB14644,The risk or severity of adverse effects can be increased when Methylprednisolone hemisuccinate is combined with Cyclosporine.,Methylprednisolone hemisuccinate
DB14646,The risk or severity of adverse effects can be increased when Prednisone acetate is combined with Cyclosporine.,Prednisone acetate
DB14652,The risk or severity of adverse effects can be increased when Clocortolone acetate is combined with Cyclosporine.,Clocortolone acetate
DB14659,The risk or severity of adverse effects can be increased when Melengestrol acetate is combined with Cyclosporine.,Melengestrol acetate
DB14669,The risk or severity of adverse effects can be increased when Betamethasone phosphate is combined with Cyclosporine.,Betamethasone phosphate
DB14681,The risk or severity of adverse effects can be increased when Cortisone is combined with Cyclosporine.,Cortisone
DB00223,The risk or severity of adverse effects can be increased when Diflorasone is combined with Cyclosporine.,Diflorasone
DB00240,The risk or severity of adverse effects can be increased when Alclometasone is combined with Cyclosporine.,Alclometasone
DB00253,The risk or severity of adverse effects can be increased when Medrysone is combined with Cyclosporine.,Medrysone
DB00288,The risk or severity of adverse effects can be increased when Amcinonide is combined with Cyclosporine.,Amcinonide
DB00324,The risk or severity of adverse effects can be increased when Fluorometholone is combined with Cyclosporine.,Fluorometholone
DB00547,The risk or severity of adverse effects can be increased when Desoximetasone is combined with Cyclosporine.,Desoximetasone
DB00596,The risk or severity of adverse effects can be increased when Ulobetasol is combined with Cyclosporine.,Ulobetasol
DB00663,The risk or severity of adverse effects can be increased when Flumethasone is combined with Cyclosporine.,Flumethasone
DB00838,The risk or severity of adverse effects can be increased when Clocortolone is combined with Cyclosporine.,Clocortolone
DB00846,The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Cyclosporine.,Flurandrenolide
DB14596,The risk or severity of adverse effects can be increased when Loteprednol etabonate is combined with Cyclosporine.,Loteprednol etabonate
DB00896,The risk or severity of adverse effects can be increased when Rimexolone is combined with Cyclosporine.,Rimexolone
DB01013,The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Cyclosporine.,Clobetasol propionate
DB01047,The risk or severity of adverse effects can be increased when Fluocinonide is combined with Cyclosporine.,Fluocinonide
DB01130,The risk or severity of adverse effects can be increased when Prednicarbate is combined with Cyclosporine.,Prednicarbate
DB01260,The risk or severity of adverse effects can be increased when Desonide is combined with Cyclosporine.,Desonide
DB06781,The risk or severity of adverse effects can be increased when Difluprednate is combined with Cyclosporine.,Difluprednate
DB06786,The risk or severity of adverse effects can be increased when Halcinonide is combined with Cyclosporine.,Halcinonide
DB09095,The risk or severity of adverse effects can be increased when Difluocortolone is combined with Cyclosporine.,Difluocortolone
DB13158,The risk or severity of adverse effects can be increased when Clobetasone is combined with Cyclosporine.,Clobetasone
DB14540,The risk or severity of adverse effects can be increased when Hydrocortisone butyrate is combined with Cyclosporine.,Hydrocortisone butyrate
DB14543,The risk or severity of adverse effects can be increased when Hydrocortisone probutate is combined with Cyclosporine.,Hydrocortisone probutate
DB14544,The risk or severity of adverse effects can be increased when Hydrocortisone valerate is combined with Cyclosporine.,Hydrocortisone valerate
DB00873,The risk or severity of adverse effects can be increased when Loteprednol is combined with Cyclosporine.,Loteprednol
DB14643,The risk or severity of adverse effects can be increased when Methylprednisolone aceponate is combined with Cyclosporine.,Methylprednisolone aceponate
DB15566,The risk or severity of adverse effects can be increased when Prednisolone acetate is combined with Cyclosporine.,Prednisolone acetate
DB15035,The metabolism of Zanubrutinib can be decreased when combined with Cyclosporine.,Zanubrutinib
DB14975,The serum concentration of Voxelotor can be increased when it is combined with Cyclosporine.,Voxelotor
DB01156,The risk or severity of seizure can be increased when Cyclosporine is combined with Bupropion.,Bupropion
DB00661,The serum concentration of Cyclosporine can be increased when it is combined with Verapamil.,Verapamil
DB06119,The serum concentration of Cenobamate can be decreased when it is combined with Cyclosporine.,Cenobamate
DB00646,The serum concentration of Cyclosporine can be increased when it is combined with Nystatin.,Nystatin
DB09237,The serum concentration of Cyclosporine can be increased when it is combined with Levamlodipine.,Levamlodipine
DB06077,The serum concentration of Lumateperone can be increased when it is combined with Cyclosporine.,Lumateperone
DB15328,The serum concentration of Ubrogepant can be increased when it is combined with Cyclosporine.,Ubrogepant
DB00695,The risk or severity of gouty arthritis can be increased when Cyclosporine is combined with Furosemide.,Furosemide
DB00193,The metabolism of Cyclosporine can be decreased when combined with Tramadol.,Tramadol
DB01137,The serum concentration of Cyclosporine can be increased when it is combined with Levofloxacin.,Levofloxacin
DB12457,The serum concentration of Rimegepant can be increased when it is combined with Cyclosporine.,Rimegepant
DB00994,The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Neomycin.,Neomycin
DB01264,The serum concentration of Cyclosporine can be increased when it is combined with Darunavir.,Darunavir
DB00608,The serum concentration of Cyclosporine can be increased when it is combined with Chloroquine.,Chloroquine
DB14513,The serum concentration of Magnesium can be decreased when it is combined with Cyclosporine.,Magnesium
DB01601,The serum concentration of Cyclosporine can be increased when it is combined with Lopinavir.,Lopinavir
DB00502,The serum concentration of Cyclosporine can be increased when it is combined with Haloperidol.,Haloperidol
DB05990,The risk or severity of adverse effects can be increased when Cyclosporine is combined with Obeticholic acid.,Obeticholic acid
DB11689,The serum concentration of Selumetinib can be increased when it is combined with Cyclosporine.,Selumetinib
DB11652,Cyclosporine may decrease the excretion rate of Tucatinib which could result in a higher serum level.,Tucatinib
DB15102,The metabolism of Pemigatinib can be decreased when combined with Cyclosporine.,Pemigatinib
DB11791,The serum concentration of Cyclosporine can be increased when it is combined with Capmatinib.,Capmatinib
DB12530,The risk or severity of infection can be increased when Cyclosporine is combined with Inebilizumab.,Inebilizumab
DB12674,The serum concentration of Lurbinectedin can be increased when it is combined with Cyclosporine.,Lurbinectedin
DB00627,The metabolism of Cyclosporine can be decreased when combined with Niacin.,Niacin
DB00481,The metabolism of Raloxifene can be decreased when combined with Cyclosporine.,Raloxifene
DB00435,The metabolism of Nitric Oxide can be decreased when combined with Cyclosporine.,Nitric Oxide
DB01275,The metabolism of Hydralazine can be decreased when combined with Cyclosporine.,Hydralazine
DB01685,The metabolism of Topiroxostat can be decreased when combined with Cyclosporine.,Topiroxostat
DB00313,The metabolism of Valproic acid can be decreased when combined with Cyclosporine.,Valproic acid
DB00549,The metabolism of Zafirlukast can be decreased when combined with Cyclosporine.,Zafirlukast
DB00668,The metabolism of Cyclosporine can be decreased when combined with Epinephrine.,Epinephrine
DB00752,The metabolism of Cyclosporine can be decreased when combined with Tranylcypromine.,Tranylcypromine
DB01085,The metabolism of Cyclosporine can be decreased when combined with Pilocarpine.,Pilocarpine
DB01698,The metabolism of Cyclosporine can be decreased when combined with Rutin.,Rutin
DB02709,The metabolism of Cyclosporine can be decreased when combined with Resveratrol.,Resveratrol
DB05814,The metabolism of Cyclosporine can be decreased when combined with GPI-1485.,GPI-1485
DB06174,The metabolism of Cyclosporine can be decreased when combined with Noscapine.,Noscapine
DB06458,The metabolism of Cyclosporine can be decreased when combined with Remacemide.,Remacemide
DB06469,The metabolism of Cyclosporine can be decreased when combined with Lestaurtinib.,Lestaurtinib
DB06774,The metabolism of Cyclosporine can be decreased when combined with Capsaicin.,Capsaicin
DB08811,The metabolism of Cyclosporine can be decreased when combined with Tofisopam.,Tofisopam
DB11198,The metabolism of Cyclosporine can be decreased when combined with Peppermint oil.,Peppermint oil
DB11805,The metabolism of Cyclosporine can be decreased when combined with Saracatinib.,Saracatinib
DB12532,The metabolism of Cyclosporine can be decreased when combined with Oxetacaine.,Oxetacaine
DB13975,The metabolism of Cyclosporine can be decreased when combined with Black cohosh.,Black cohosh
DB00248,The metabolism of Cyclosporine can be decreased when combined with Cabergoline.,Cabergoline
DB00254,The metabolism of Cyclosporine can be decreased when combined with Doxycycline.,Doxycycline
DB00255,The metabolism of Cyclosporine can be decreased when combined with Diethylstilbestrol.,Diethylstilbestrol
DB00353,The metabolism of Cyclosporine can be decreased when combined with Methylergometrine.,Methylergometrine
DB00759,The metabolism of Cyclosporine can be decreased when combined with Tetracycline.,Tetracycline
DB01129,The metabolism of Cyclosporine can be decreased when combined with Rabeprazole.,Rabeprazole
DB01587,The metabolism of Cyclosporine can be decreased when combined with Ketazolam.,Ketazolam
DB05482,The metabolism of Cyclosporine can be decreased when combined with 7-ethyl-10-hydroxycamptothecin.,7-ethyl-10-hydroxycamptothecin
DB09235,The metabolism of Cyclosporine can be decreased when combined with Efonidipine.,Efonidipine
DB12010,The metabolism of Cyclosporine can be decreased when combined with Fostamatinib.,Fostamatinib
DB13950,The metabolism of Cyclosporine can be decreased when combined with WIN 55212-2.,WIN 55212-2
DB14009,The metabolism of Cyclosporine can be decreased when combined with Medical Cannabis.,Medical Cannabis
DB01093,The metabolism of Cyclosporine can be decreased when combined with Dimethyl sulfoxide.,Dimethyl sulfoxide
DB14635,The metabolism of Cyclosporine can be decreased when combined with Curcumin sulfate.,Curcumin sulfate
DB00358,The metabolism of Cyclosporine can be decreased when combined with Mefloquine.,Mefloquine
DB00845,The metabolism of Cyclosporine can be decreased when combined with Clofazimine.,Clofazimine
DB00916,The metabolism of Cyclosporine can be decreased when combined with Metronidazole.,Metronidazole
DB00320,The metabolism of Cyclosporine can be decreased when combined with Dihydroergotamine.,Dihydroergotamine
DB01023,The metabolism of Cyclosporine can be decreased when combined with Felodipine.,Felodipine
DB06643,The risk or severity of adverse effects can be increased when Denosumab is combined with Alefacept.,Denosumab
DB00005,The risk or severity of adverse effects can be increased when Etanercept is combined with Alefacept.,Etanercept
DB00008,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Alefacept.,Peginterferon alfa-2a
DB00011,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Alefacept.,Interferon alfa-n1
DB00018,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Alefacept.,Interferon alfa-n3
DB00022,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Alefacept.,Peginterferon alfa-2b
DB00026,The risk or severity of adverse effects can be increased when Anakinra is combined with Alefacept.,Anakinra
DB00033,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Alefacept.,Interferon gamma-1b
DB00034,"The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Alefacept.","Interferon alfa-2a, Recombinant"
DB00041,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Alefacept.,Aldesleukin
DB00051,The risk or severity of adverse effects can be increased when Adalimumab is combined with Alefacept.,Adalimumab
DB00056,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Alefacept.,Gemtuzumab ozogamicin
DB00059,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Alefacept.,Pegaspargase
DB00065,The risk or severity of adverse effects can be increased when Infliximab is combined with Alefacept.,Infliximab
DB00068,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Alefacept.,Interferon beta-1b
DB00069,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Alefacept.,Interferon alfacon-1
DB00073,The risk or severity of adverse effects can be increased when Rituximab is combined with Alefacept.,Rituximab
DB00074,The risk or severity of adverse effects can be increased when Basiliximab is combined with Alefacept.,Basiliximab
DB00075,The risk or severity of adverse effects can be increased when Muromonab is combined with Alefacept.,Muromonab
DB00078,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Alefacept.,Ibritumomab tiuxetan
DB00081,The risk or severity of adverse effects can be increased when Tositumomab is combined with Alefacept.,Tositumomab
DB00087,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Alefacept.,Alemtuzumab
DB00095,The risk or severity of adverse effects can be increased when Alefacept is combined with Efalizumab.,Efalizumab
DB00098,The risk or severity of adverse effects can be increased when Alefacept is combined with Antithymocyte immunoglobulin (rabbit).,Antithymocyte immunoglobulin (rabbit)
DB00105,The risk or severity of adverse effects can be increased when Alefacept is combined with Interferon alfa-2b.,Interferon alfa-2b
DB00111,The risk or severity of adverse effects can be increased when Alefacept is combined with Daclizumab.,Daclizumab
DB00112,The risk or severity of adverse effects can be increased when Alefacept is combined with Bevacizumab.,Bevacizumab
DB00120,The risk or severity of adverse effects can be increased when Alefacept is combined with Phenylalanine.,Phenylalanine
DB00180,The risk or severity of adverse effects can be increased when Alefacept is combined with Flunisolide.,Flunisolide
DB00188,The risk or severity of adverse effects can be increased when Alefacept is combined with Bortezomib.,Bortezomib
DB00242,The risk or severity of adverse effects can be increased when Alefacept is combined with Cladribine.,Cladribine
DB00262,The risk or severity of adverse effects can be increased when Alefacept is combined with Carmustine.,Carmustine
DB00276,The risk or severity of adverse effects can be increased when Alefacept is combined with Amsacrine.,Amsacrine
DB00290,The risk or severity of adverse effects can be increased when Alefacept is combined with Bleomycin.,Bleomycin
DB00291,The risk or severity of adverse effects can be increased when Alefacept is combined with Chlorambucil.,Chlorambucil
DB00293,The risk or severity of adverse effects can be increased when Alefacept is combined with Raltitrexed.,Raltitrexed
DB00305,The risk or severity of adverse effects can be increased when Alefacept is combined with Mitomycin.,Mitomycin
DB00307,The risk or severity of adverse effects can be increased when Alefacept is combined with Bexarotene.,Bexarotene
DB00309,The risk or severity of adverse effects can be increased when Alefacept is combined with Vindesine.,Vindesine
DB00322,The risk or severity of adverse effects can be increased when Alefacept is combined with Floxuridine.,Floxuridine
DB00328,The risk or severity of adverse effects can be increased when Alefacept is combined with Indomethacin.,Indomethacin
DB00352,The risk or severity of adverse effects can be increased when Alefacept is combined with Tioguanine.,Tioguanine
DB00361,The risk or severity of adverse effects can be increased when Alefacept is combined with Vinorelbine.,Vinorelbine
DB00380,The risk or severity of adverse effects can be increased when Alefacept is combined with Dexrazoxane.,Dexrazoxane
DB00394,The risk or severity of adverse effects can be increased when Alefacept is combined with Beclomethasone dipropionate.,Beclomethasone dipropionate
DB00398,The risk or severity of adverse effects can be increased when Alefacept is combined with Sorafenib.,Sorafenib
DB00428,The risk or severity of adverse effects can be increased when Alefacept is combined with Streptozocin.,Streptozocin
DB00432,The risk or severity of adverse effects can be increased when Alefacept is combined with Trifluridine.,Trifluridine
DB00441,The risk or severity of adverse effects can be increased when Alefacept is combined with Gemcitabine.,Gemcitabine
DB00443,The risk or severity of adverse effects can be increased when Alefacept is combined with Betamethasone.,Betamethasone
DB00444,The risk or severity of adverse effects can be increased when Alefacept is combined with Teniposide.,Teniposide
DB00445,The risk or severity of adverse effects can be increased when Alefacept is combined with Epirubicin.,Epirubicin
DB00446,The risk or severity of adverse effects can be increased when Alefacept is combined with Chloramphenicol.,Chloramphenicol
DB00480,The risk or severity of adverse effects can be increased when Alefacept is combined with Lenalidomide.,Lenalidomide
DB00488,The risk or severity of adverse effects can be increased when Alefacept is combined with Altretamine.,Altretamine
DB00495,The risk or severity of adverse effects can be increased when Alefacept is combined with Zidovudine.,Zidovudine
DB00515,The risk or severity of adverse effects can be increased when Alefacept is combined with Cisplatin.,Cisplatin
DB00526,The risk or severity of adverse effects can be increased when Alefacept is combined with Oxaliplatin.,Oxaliplatin
DB00531,The risk or severity of adverse effects can be increased when Alefacept is combined with Cyclophosphamide.,Cyclophosphamide
DB00541,The risk or severity of adverse effects can be increased when Alefacept is combined with Vincristine.,Vincristine
DB00544,The risk or severity of adverse effects can be increased when Alefacept is combined with Fluorouracil.,Fluorouracil
DB00550,The risk or severity of adverse effects can be increased when Alefacept is combined with Propylthiouracil.,Propylthiouracil
DB00552,The risk or severity of adverse effects can be increased when Alefacept is combined with Pentostatin.,Pentostatin
DB00563,The risk or severity of adverse effects can be increased when Alefacept is combined with Methotrexate.,Methotrexate
DB00564,The risk or severity of adverse effects can be increased when Alefacept is combined with Carbamazepine.,Carbamazepine
DB00570,The risk or severity of adverse effects can be increased when Alefacept is combined with Vinblastine.,Vinblastine
DB00588,The risk or severity of adverse effects can be increased when Alefacept is combined with Fluticasone propionate.,Fluticasone propionate
DB00591,The risk or severity of adverse effects can be increased when Alefacept is combined with Fluocinolone acetonide.,Fluocinolone acetonide
DB00601,The risk or severity of adverse effects can be increased when Alefacept is combined with Linezolid.,Linezolid
DB00619,The risk or severity of adverse effects can be increased when Alefacept is combined with Imatinib.,Imatinib
DB00620,The risk or severity of adverse effects can be increased when Alefacept is combined with Triamcinolone.,Triamcinolone
DB00631,The risk or severity of adverse effects can be increased when Alefacept is combined with Clofarabine.,Clofarabine
DB00635,The risk or severity of adverse effects can be increased when Alefacept is combined with Prednisone.,Prednisone
DB00642,The risk or severity of adverse effects can be increased when Alefacept is combined with Pemetrexed.,Pemetrexed
DB00687,The risk or severity of adverse effects can be increased when Alefacept is combined with Fludrocortisone.,Fludrocortisone
DB00688,The risk or severity of adverse effects can be increased when Alefacept is combined with Mycophenolate mofetil.,Mycophenolate mofetil
DB00694,The risk or severity of adverse effects can be increased when Alefacept is combined with Daunorubicin.,Daunorubicin
DB00755,The risk or severity of adverse effects can be increased when Alefacept is combined with Tretinoin.,Tretinoin
DB00762,The risk or severity of adverse effects can be increased when Alefacept is combined with Irinotecan.,Irinotecan
DB00763,The risk or severity of adverse effects can be increased when Alefacept is combined with Methimazole.,Methimazole
DB00764,The risk or severity of adverse effects can be increased when Alefacept is combined with Mometasone.,Mometasone
DB00773,The risk or severity of adverse effects can be increased when Alefacept is combined with Etoposide.,Etoposide
DB00795,The risk or severity of adverse effects can be increased when Alefacept is combined with Sulfasalazine.,Sulfasalazine
DB00851,The risk or severity of adverse effects can be increased when Alefacept is combined with Dacarbazine.,Dacarbazine
DB00853,The risk or severity of adverse effects can be increased when Alefacept is combined with Temozolomide.,Temozolomide
DB00859,The risk or severity of adverse effects can be increased when Alefacept is combined with Penicillamine.,Penicillamine
DB00860,The risk or severity of adverse effects can be increased when Alefacept is combined with Prednisolone.,Prednisolone
DB00877,The risk or severity of adverse effects can be increased when Alefacept is combined with Sirolimus.,Sirolimus
DB00888,The risk or severity of adverse effects can be increased when Alefacept is combined with Mechlorethamine.,Mechlorethamine
DB00928,The risk or severity of adverse effects can be increased when Alefacept is combined with Azacitidine.,Azacitidine
DB00958,The risk or severity of adverse effects can be increased when Alefacept is combined with Carboplatin.,Carboplatin
DB00959,The risk or severity of adverse effects can be increased when Alefacept is combined with Methylprednisolone.,Methylprednisolone
DB00970,The risk or severity of adverse effects can be increased when Alefacept is combined with Dactinomycin.,Dactinomycin
DB00987,The risk or severity of adverse effects can be increased when Alefacept is combined with Cytarabine.,Cytarabine
DB00993,The risk or severity of adverse effects can be increased when Alefacept is combined with Azathioprine.,Azathioprine
DB00997,The risk or severity of adverse effects can be increased when Alefacept is combined with Doxorubicin.,Doxorubicin
DB01005,The risk or severity of adverse effects can be increased when Alefacept is combined with Hydroxyurea.,Hydroxyurea
DB01008,The risk or severity of adverse effects can be increased when Alefacept is combined with Busulfan.,Busulfan
DB01024,The risk or severity of adverse effects can be increased when Alefacept is combined with Mycophenolic acid.,Mycophenolic acid
DB01030,The risk or severity of adverse effects can be increased when Alefacept is combined with Topotecan.,Topotecan
DB01033,The risk or severity of adverse effects can be increased when Alefacept is combined with Mercaptopurine.,Mercaptopurine
DB01041,The risk or severity of adverse effects can be increased when Alefacept is combined with Thalidomide.,Thalidomide
DB01042,The risk or severity of adverse effects can be increased when Alefacept is combined with Melphalan.,Melphalan
DB01073,The risk or severity of adverse effects can be increased when Alefacept is combined with Fludarabine.,Fludarabine
DB01099,The risk or severity of adverse effects can be increased when Alefacept is combined with Flucytosine.,Flucytosine
DB01101,The risk or severity of adverse effects can be increased when Alefacept is combined with Capecitabine.,Capecitabine
DB01108,The risk or severity of adverse effects can be increased when Alefacept is combined with Trilostane.,Trilostane
DB01168,The risk or severity of adverse effects can be increased when Alefacept is combined with Procarbazine.,Procarbazine
DB01169,The risk or severity of adverse effects can be increased when Alefacept is combined with Arsenic trioxide.,Arsenic trioxide
DB01177,The risk or severity of adverse effects can be increased when Alefacept is combined with Idarubicin.,Idarubicin
DB01181,The risk or severity of adverse effects can be increased when Alefacept is combined with Ifosfamide.,Ifosfamide
DB01196,The risk or severity of adverse effects can be increased when Alefacept is combined with Estramustine.,Estramustine
DB01204,The risk or severity of adverse effects can be increased when Alefacept is combined with Mitoxantrone.,Mitoxantrone
DB01206,The risk or severity of adverse effects can be increased when Alefacept is combined with Lomustine.,Lomustine
DB01222,The risk or severity of adverse effects can be increased when Alefacept is combined with Budesonide.,Budesonide
DB01229,The risk or severity of adverse effects can be increased when Alefacept is combined with Paclitaxel.,Paclitaxel
DB01234,The risk or severity of adverse effects can be increased when Alefacept is combined with Dexamethasone.,Dexamethasone
DB01248,The risk or severity of adverse effects can be increased when Alefacept is combined with Docetaxel.,Docetaxel
DB01254,The risk or severity of adverse effects can be increased when Alefacept is combined with Dasatinib.,Dasatinib
DB01257,The risk or severity of adverse effects can be increased when Alefacept is combined with Eculizumab.,Eculizumab
DB01262,The risk or severity of adverse effects can be increased when Alefacept is combined with Decitabine.,Decitabine
DB01268,The risk or severity of adverse effects can be increased when Alefacept is combined with Sunitinib.,Sunitinib
DB01280,The risk or severity of adverse effects can be increased when Alefacept is combined with Nelarabine.,Nelarabine
DB01281,The risk or severity of adverse effects can be increased when Alefacept is combined with Abatacept.,Abatacept
DB01285,The risk or severity of adverse effects can be increased when Alefacept is combined with Corticotropin.,Corticotropin
DB01380,The risk or severity of adverse effects can be increased when Alefacept is combined with Cortisone acetate.,Cortisone acetate
DB01384,The risk or severity of adverse effects can be increased when Alefacept is combined with Paramethasone.,Paramethasone
DB01394,The risk or severity of adverse effects can be increased when Alefacept is combined with Colchicine.,Colchicine
DB01410,The risk or severity of adverse effects can be increased when Alefacept is combined with Ciclesonide.,Ciclesonide
DB01423,The risk or severity of adverse effects can be increased when Alefacept is combined with Stepronin.,Stepronin
DB01590,The risk or severity of adverse effects can be increased when Alefacept is combined with Everolimus.,Everolimus
DB01611,The risk or severity of adverse effects can be increased when Alefacept is combined with Hydroxychloroquine.,Hydroxychloroquine
DB01816,The risk or severity of adverse effects can be increased when Alefacept is combined with Castanospermine.,Castanospermine
DB02546,The risk or severity of adverse effects can be increased when Alefacept is combined with Vorinostat.,Vorinostat
DB02806,The risk or severity of adverse effects can be increased when Alefacept is combined with 2-Methoxyethanol.,2-Methoxyethanol
DB03523,The risk or severity of adverse effects can be increased when Alefacept is combined with Brequinar.,Brequinar
DB04572,The risk or severity of adverse effects can be increased when Alefacept is combined with Thiotepa.,Thiotepa
DB04630,The risk or severity of adverse effects can be increased when Alefacept is combined with Aldosterone.,Aldosterone
DB04845,The risk or severity of adverse effects can be increased when Alefacept is combined with Ixabepilone.,Ixabepilone
DB04868,The risk or severity of adverse effects can be increased when Alefacept is combined with Nilotinib.,Nilotinib
DB04951,The risk or severity of adverse effects can be increased when Alefacept is combined with Pirfenidone.,Pirfenidone
DB04956,The risk or severity of adverse effects can be increased when Alefacept is combined with Afelimomab.,Afelimomab
DB05015,The risk or severity of adverse effects can be increased when Alefacept is combined with Belinostat.,Belinostat
DB05109,The risk or severity of adverse effects can be increased when Alefacept is combined with Trabectedin.,Trabectedin
DB05258,The risk or severity of adverse effects can be increased when Alefacept is combined with Interferon alfa.,Interferon alfa
DB05259,The risk or severity of adverse effects can be increased when Alefacept is combined with Glatiramer.,Glatiramer
DB05260,The risk or severity of adverse effects can be increased when Alefacept is combined with Gallium nitrate.,Gallium nitrate
DB05459,The risk or severity of adverse effects can be increased when Alefacept is combined with Briakinumab.,Briakinumab
DB05472,The risk or severity of adverse effects can be increased when Alefacept is combined with omega interferon.,omega interferon
DB05676,The risk or severity of adverse effects can be increased when Alefacept is combined with Apremilast.,Apremilast
DB05773,The risk or severity of adverse effects can be increased when Alefacept is combined with Trastuzumab emtansine.,Trastuzumab emtansine
DB06168,The risk or severity of adverse effects can be increased when Alefacept is combined with Canakinumab.,Canakinumab
DB06273,The risk or severity of adverse effects can be increased when Alefacept is combined with Tocilizumab.,Tocilizumab
DB06287,The risk or severity of adverse effects can be increased when Alefacept is combined with Temsirolimus.,Temsirolimus
DB06372,The risk or severity of adverse effects can be increased when Alefacept is combined with Rilonacept.,Rilonacept
DB06589,The risk or severity of adverse effects can be increased when Alefacept is combined with Pazopanib.,Pazopanib
DB06603,The risk or severity of adverse effects can be increased when Alefacept is combined with Panobinostat.,Panobinostat
DB06612,The risk or severity of adverse effects can be increased when Alefacept is combined with Mepolizumab.,Mepolizumab
DB06616,The risk or severity of adverse effects can be increased when Alefacept is combined with Bosutinib.,Bosutinib
DB06662,The risk or severity of adverse effects can be increased when Alefacept is combined with Abetimus.,Abetimus
DB06674,The risk or severity of adverse effects can be increased when Alefacept is combined with Golimumab.,Golimumab
DB06681,The risk or severity of adverse effects can be increased when Alefacept is combined with Belatacept.,Belatacept
DB06769,The risk or severity of adverse effects can be increased when Alefacept is combined with Bendamustine.,Bendamustine
DB06772,The risk or severity of adverse effects can be increased when Alefacept is combined with Cabazitaxel.,Cabazitaxel
DB06813,The risk or severity of adverse effects can be increased when Alefacept is combined with Pralatrexate.,Pralatrexate
DB08059,The risk or severity of adverse effects can be increased when Alefacept is combined with Wortmannin.,Wortmannin
DB08870,The risk or severity of adverse effects can be increased when Alefacept is combined with Brentuximab vedotin.,Brentuximab vedotin
DB08871,The risk or severity of adverse effects can be increased when Alefacept is combined with Eribulin.,Eribulin
DB08877,The risk or severity of adverse effects can be increased when Alefacept is combined with Ruxolitinib.,Ruxolitinib
DB08879,The risk or severity of adverse effects can be increased when Alefacept is combined with Belimumab.,Belimumab
DB08880,The risk or severity of adverse effects can be increased when Alefacept is combined with Teriflunomide.,Teriflunomide
DB08889,The risk or severity of adverse effects can be increased when Alefacept is combined with Carfilzomib.,Carfilzomib
DB08901,The risk or severity of adverse effects can be increased when Alefacept is combined with Ponatinib.,Ponatinib
DB08904,The risk or severity of adverse effects can be increased when Alefacept is combined with Certolizumab pegol.,Certolizumab pegol
DB08906,The risk or severity of adverse effects can be increased when Alefacept is combined with Fluticasone furoate.,Fluticasone furoate
DB08908,The risk or severity of adverse effects can be increased when Alefacept is combined with Dimethyl fumarate.,Dimethyl fumarate
DB08910,The risk or severity of adverse effects can be increased when Alefacept is combined with Pomalidomide.,Pomalidomide
DB08935,The risk or severity of adverse effects can be increased when Alefacept is combined with Obinutuzumab.,Obinutuzumab
DB08970,The risk or severity of adverse effects can be increased when Alefacept is combined with Fluprednidene.,Fluprednidene
DB08971,The risk or severity of adverse effects can be increased when Alefacept is combined with Fluocortolone.,Fluocortolone
DB09029,The risk or severity of adverse effects can be increased when Alefacept is combined with Secukinumab.,Secukinumab
DB09033,The risk or severity of adverse effects can be increased when Alefacept is combined with Vedolizumab.,Vedolizumab
DB09036,The risk or severity of adverse effects can be increased when Alefacept is combined with Siltuximab.,Siltuximab
DB09052,The risk or severity of adverse effects can be increased when Alefacept is combined with Blinatumomab.,Blinatumomab
DB09053,The risk or severity of adverse effects can be increased when Alefacept is combined with Ibrutinib.,Ibrutinib
DB09054,The risk or severity of adverse effects can be increased when Alefacept is combined with Idelalisib.,Idelalisib
DB09073,The risk or severity of adverse effects can be increased when Alefacept is combined with Palbociclib.,Palbociclib
DB09074,The risk or severity of adverse effects can be increased when Alefacept is combined with Olaparib.,Olaparib
DB09077,The risk or severity of adverse effects can be increased when Alefacept is combined with Dinutuximab.,Dinutuximab
DB09082,The risk or severity of adverse effects can be increased when Alefacept is combined with Vilanterol.,Vilanterol
DB09091,The risk or severity of adverse effects can be increased when Alefacept is combined with Tixocortol.,Tixocortol
DB09122,The risk or severity of adverse effects can be increased when Alefacept is combined with Peginterferon beta-1a.,Peginterferon beta-1a
DB09312,The risk or severity of adverse effects can be increased when Alefacept is combined with Antilymphocyte immunoglobulin (horse).,Antilymphocyte immunoglobulin (horse)
DB09378,The risk or severity of adverse effects can be increased when Alefacept is combined with Fluprednisolone.,Fluprednisolone
DB09383,The risk or severity of adverse effects can be increased when Alefacept is combined with Meprednisone.,Meprednisone
DB11466,The risk or severity of adverse effects can be increased when Alefacept is combined with Tepoxalin.,Tepoxalin
DB11487,The risk or severity of adverse effects can be increased when Alefacept is combined with Dexamethasone isonicotinate.,Dexamethasone isonicotinate
DB11529,The risk or severity of adverse effects can be increased when Alefacept is combined with Melengestrol.,Melengestrol
DB11569,The risk or severity of adverse effects can be increased when Alefacept is combined with Ixekizumab.,Ixekizumab
DB11580,The risk or severity of adverse effects can be increased when Alefacept is combined with Ravulizumab.,Ravulizumab
DB11616,The risk or severity of adverse effects can be increased when Alefacept is combined with Pirarubicin.,Pirarubicin
DB11693,The risk or severity of adverse effects can be increased when Alefacept is combined with Voclosporin.,Voclosporin
DB11708,The risk or severity of adverse effects can be increased when Alefacept is combined with Peficitinib.,Peficitinib
DB11750,The risk or severity of adverse effects can be increased when Alefacept is combined with Clobetasol.,Clobetasol
DB11767,The risk or severity of adverse effects can be increased when Alefacept is combined with Sarilumab.,Sarilumab
DB11776,The risk or severity of adverse effects can be increased when Alefacept is combined with Brodalumab.,Brodalumab
DB11803,The risk or severity of adverse effects can be increased when Alefacept is combined with Sirukumab.,Sirukumab
DB11817,The risk or severity of adverse effects can be increased when Alefacept is combined with Baricitinib.,Baricitinib
DB11834,The risk or severity of adverse effects can be increased when Alefacept is combined with Guselkumab.,Guselkumab
DB11921,The risk or severity of adverse effects can be increased when Alefacept is combined with Deflazacort.,Deflazacort
DB11988,The risk or severity of adverse effects can be increased when Alefacept is combined with Ocrelizumab.,Ocrelizumab
DB12025,The risk or severity of adverse effects can be increased when Alefacept is combined with Triptolide.,Triptolide
DB12371,The risk or severity of adverse effects can be increased when Alefacept is combined with Siponimod.,Siponimod
DB12612,The risk or severity of adverse effects can be increased when Alefacept is combined with Ozanimod.,Ozanimod
DB12617,The risk or severity of adverse effects can be increased when Alefacept is combined with Mizoribine.,Mizoribine
DB12692,The risk or severity of adverse effects can be increased when Alefacept is combined with Gusperimus.,Gusperimus
DB12814,The risk or severity of adverse effects can be increased when Alefacept is combined with Cepeginterferon alfa-2B.,Cepeginterferon alfa-2B
DB12902,The risk or severity of adverse effects can be increased when Alefacept is combined with Trofosfamide.,Trofosfamide
DB12947,The risk or severity of adverse effects can be increased when Alefacept is combined with Doxifluridine.,Doxifluridine
DB12991,The risk or severity of adverse effects can be increased when Alefacept is combined with Deoxyspergualin.,Deoxyspergualin
DB12996,The risk or severity of adverse effects can be increased when Alefacept is combined with Acteoside.,Acteoside
DB13003,The risk or severity of adverse effects can be increased when Alefacept is combined with Cortivazol.,Cortivazol
DB13014,The risk or severity of adverse effects can be increased when Alefacept is combined with Hypericin.,Hypericin
DB13068,The risk or severity of adverse effects can be increased when Alefacept is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.,9-(N-methyl-L-isoleucine)-cyclosporin A
DB13208,The risk or severity of adverse effects can be increased when Alefacept is combined with Prednylidene.,Prednylidene
DB13223,The risk or severity of adverse effects can be increased when Alefacept is combined with Fluocortin.,Fluocortin
DB13241,The risk or severity of adverse effects can be increased when Alefacept is combined with Begelomab.,Begelomab
DB13491,The risk or severity of adverse effects can be increased when Alefacept is combined with Fluperolone.,Fluperolone
DB13664,The risk or severity of adverse effects can be increased when Alefacept is combined with Formocortal.,Formocortal
DB13728,The risk or severity of adverse effects can be increased when Alefacept is combined with Halometasone.,Halometasone
DB13843,The risk or severity of adverse effects can be increased when Alefacept is combined with Cloprednol.,Cloprednol
DB13856,The risk or severity of adverse effects can be increased when Alefacept is combined with Fluclorolone.,Fluclorolone
DB13867,The risk or severity of adverse effects can be increased when Alefacept is combined with Fluticasone.,Fluticasone
DB14066,The risk or severity of adverse effects can be increased when Alefacept is combined with Tetrandrine.,Tetrandrine
DB14219,The risk or severity of adverse effects can be increased when Alefacept is combined with Monomethyl fumarate.,Monomethyl fumarate
DB14512,The risk or severity of adverse effects can be increased when Alefacept is combined with Mometasone furoate.,Mometasone furoate
DB14538,The risk or severity of adverse effects can be increased when Alefacept is combined with Hydrocortisone aceponate.,Hydrocortisone aceponate
DB14539,The risk or severity of adverse effects can be increased when Alefacept is combined with Hydrocortisone acetate.,Hydrocortisone acetate
DB14545,The risk or severity of adverse effects can be increased when Alefacept is combined with Hydrocortisone succinate.,Hydrocortisone succinate
DB14724,The risk or severity of adverse effects can be increased when Alefacept is combined with Emapalumab.,Emapalumab
DB14762,The risk or severity of adverse effects can be increased when Alefacept is combined with Risankizumab.,Risankizumab
DB14919,The risk or severity of adverse effects can be increased when Alefacept is combined with Rozanolixizumab.,Rozanolixizumab
DB15253,The risk or severity of adverse effects can be increased when Alefacept is combined with Bleselumab.,Bleselumab
DB00108,The risk or severity of adverse effects can be increased when Alefacept is combined with Natalizumab.,Natalizumab
DB00337,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Alefacept.,Pimecrolimus
DB01656,Roflumilast may increase the immunosuppressive activities of Alefacept.,Roflumilast
DB06688,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Alefacept.,Sipuleucel-T
DB01015,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Alefacept.,Sulfamethoxazole
DB01097,The risk or severity of adverse effects can be increased when Alefacept is combined with Leflunomide.,Leflunomide
DB08895,Alefacept may increase the immunosuppressive activities of Tofacitinib.,Tofacitinib
DB00072,Trastuzumab may increase the neutropenic activities of Alefacept.,Trastuzumab
DB08868,Alefacept may increase the immunosuppressive activities of Fingolimod.,Fingolimod
DB00864,Tacrolimus may increase the immunosuppressive activities of Alefacept.,Tacrolimus
DB04914,The therapeutic efficacy of G17DT can be decreased when used in combination with Alefacept.,G17DT
DB05144,The therapeutic efficacy of PEV3A can be decreased when used in combination with Alefacept.,PEV3A
DB05325,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Alefacept.,INGN 225
DB05374,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Alefacept.,Rindopepimut
DB05440,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Alefacept.,SRP 299
DB05942,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Alefacept.,GI-5005
DB06400,The therapeutic efficacy of Vitespen can be decreased when used in combination with Alefacept.,Vitespen
DB06584,The therapeutic efficacy of TG4010 can be decreased when used in combination with Alefacept.,TG4010
DB09057,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Alefacept.,Anthrax immune globulin human
DB10062,"The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Alefacept.","Rabies virus inactivated antigen, B"
DB10076,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Alefacept.,Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen
DB10276,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Alefacept.,Rotavirus vaccine
DB10283,"The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Alefacept.","Rabies virus inactivated antigen, A"
DB10342,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Alefacept.,Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen
DB10583,The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Alefacept.,Clostridium tetani toxoid antigen (formaldehyde inactivated)
DB10584,The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Alefacept.,Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
DB10600,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Alefacept.,Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated)
DB10769,The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Alefacept.,Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)
DB10794,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Alefacept.,Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated)
DB10803,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Alefacept.,Typhoid Vi polysaccharide vaccine
DB10989,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Alefacept.,Hepatitis A Vaccine
DB10990,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Alefacept.,Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
DB11038,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Alefacept.,Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated)
DB11040,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Alefacept.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated)
DB11041,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Alefacept.,Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)
DB11044,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Alefacept.,Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated)
DB11603,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Alefacept.,Human rabies virus immune globulin
DB11627,The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Alefacept.,Hepatitis B Vaccine (Recombinant)
DB12568,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Alefacept.,Tecemotide
DB14022,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Alefacept.,Typhoid vaccine
DB14384,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Alefacept.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated)
DB14385,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Alefacept.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)
DB14394,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Alefacept.,Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen
DB14445,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Alefacept.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated)
DB14449,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Alefacept.,Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen
DB14619,The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Alefacept.,Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated)
DB14620,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Alefacept.,Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated)
DB14711,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Alefacept.,Vaccinia virus strain new york city board of health live antigen
DB15274,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Alefacept.,Pertussis vaccine
DB15461,The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Alefacept.,Yersinia pestis 195/p antigen (formaldehyde inactivated)
DB13924,The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Alefacept.,Varicella Zoster Vaccine (Recombinant)
DB15483,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Alefacept.,Modified vaccinia ankara
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Alefacept.","Ebola Zaire vaccine (live, attenuated)"
DB10317,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Alefacept.,Rubella virus vaccine
DB10318,The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Alefacept.,Varicella Zoster Vaccine (Live/attenuated)
DB10343,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Alefacept.,Bacillus calmette-guerin substrain tice live antigen
DB10804,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Alefacept.,Bacillus calmette-guerin substrain connaught live antigen
DB10805,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Alefacept.,Yellow Fever Vaccine
DB11003,The risk or severity of infection can be increased when Anthrax vaccine is combined with Alefacept.,Anthrax vaccine
DB11050,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Alefacept.,Typhoid Vaccine Live
DB12386,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Alefacept.,Bacillus calmette-guerin substrain danish 1331 live antigen
DB12768,The risk or severity of infection can be increased when BCG vaccine is combined with Alefacept.,BCG vaccine
DB14409,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Alefacept.,Human adenovirus e serotype 4 strain cl-68578 antigen
DB14443,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Alefacept.,Vibrio cholerae CVD 103-HgR strain live antigen
DB14685,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Alefacept.,Adenovirus type 7 vaccine live
DB00091,Alefacept may increase the immunosuppressive activities of Cyclosporine.,Cyclosporine
DB14513,The serum concentration of Magnesium can be decreased when it is combined with Alefacept.,Magnesium
DB01601,The serum concentration of Alefacept can be increased when it is combined with Lopinavir.,Lopinavir
DB12530,The risk or severity of infection can be increased when Alefacept is combined with Inebilizumab.,Inebilizumab
DB13967,The risk or severity of hypotension can be increased when Patent Blue is combined with Felypressin.,Patent Blue
DB00024,Thyrotropin alfa may increase the vasoconstricting activities of Felypressin.,Thyrotropin alfa
DB00279,Liothyronine may increase the vasoconstricting activities of Felypressin.,Liothyronine
DB00451,Levothyroxine may increase the vasoconstricting activities of Felypressin.,Levothyroxine
DB01583,Liotrix may increase the vasoconstricting activities of Felypressin.,Liotrix
DB03604,Tiratricol may increase the vasoconstricting activities of Felypressin.,Tiratricol
DB09100,"Thyroid, porcine may increase the vasoconstricting activities of Felypressin.","Thyroid, porcine"
DB00281,The risk or severity of hypertension can be increased when Felypressin is combined with Lidocaine.,Lidocaine
DB06643,The risk or severity of adverse effects can be increased when Denosumab is combined with Efalizumab.,Denosumab
DB00005,The risk or severity of adverse effects can be increased when Etanercept is combined with Efalizumab.,Etanercept
DB00008,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Efalizumab.,Peginterferon alfa-2a
DB00011,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Efalizumab.,Interferon alfa-n1
DB00018,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Efalizumab.,Interferon alfa-n3
DB00022,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Efalizumab.,Peginterferon alfa-2b
DB00026,The risk or severity of adverse effects can be increased when Anakinra is combined with Efalizumab.,Anakinra
DB00033,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Efalizumab.,Interferon gamma-1b
DB00034,"The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Efalizumab.","Interferon alfa-2a, Recombinant"
DB00041,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Efalizumab.,Aldesleukin
DB00051,The risk or severity of adverse effects can be increased when Adalimumab is combined with Efalizumab.,Adalimumab
DB00056,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Efalizumab.,Gemtuzumab ozogamicin
DB00059,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Efalizumab.,Pegaspargase
DB00065,The risk or severity of adverse effects can be increased when Infliximab is combined with Efalizumab.,Infliximab
DB00068,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Efalizumab.,Interferon beta-1b
DB00069,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Efalizumab.,Interferon alfacon-1
DB00073,The risk or severity of adverse effects can be increased when Rituximab is combined with Efalizumab.,Rituximab
DB00074,The risk or severity of adverse effects can be increased when Basiliximab is combined with Efalizumab.,Basiliximab
DB00075,The risk or severity of adverse effects can be increased when Muromonab is combined with Efalizumab.,Muromonab
DB00078,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Efalizumab.,Ibritumomab tiuxetan
DB00081,The risk or severity of adverse effects can be increased when Tositumomab is combined with Efalizumab.,Tositumomab
DB00087,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Efalizumab.,Alemtuzumab
DB00092,The risk or severity of adverse effects can be increased when Alefacept is combined with Efalizumab.,Alefacept
DB00098,The risk or severity of adverse effects can be increased when Efalizumab is combined with Antithymocyte immunoglobulin (rabbit).,Antithymocyte immunoglobulin (rabbit)
DB00105,The risk or severity of adverse effects can be increased when Efalizumab is combined with Interferon alfa-2b.,Interferon alfa-2b
DB00111,The risk or severity of adverse effects can be increased when Efalizumab is combined with Daclizumab.,Daclizumab
DB00112,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bevacizumab.,Bevacizumab
DB00120,The risk or severity of adverse effects can be increased when Efalizumab is combined with Phenylalanine.,Phenylalanine
DB00180,The risk or severity of adverse effects can be increased when Efalizumab is combined with Flunisolide.,Flunisolide
DB00188,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bortezomib.,Bortezomib
DB00242,The risk or severity of adverse effects can be increased when Efalizumab is combined with Cladribine.,Cladribine
DB00262,The risk or severity of adverse effects can be increased when Efalizumab is combined with Carmustine.,Carmustine
DB00276,The risk or severity of adverse effects can be increased when Efalizumab is combined with Amsacrine.,Amsacrine
DB00290,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bleomycin.,Bleomycin
DB00291,The risk or severity of adverse effects can be increased when Efalizumab is combined with Chlorambucil.,Chlorambucil
DB00293,The risk or severity of adverse effects can be increased when Efalizumab is combined with Raltitrexed.,Raltitrexed
DB00305,The risk or severity of adverse effects can be increased when Efalizumab is combined with Mitomycin.,Mitomycin
DB00307,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bexarotene.,Bexarotene
DB00309,The risk or severity of adverse effects can be increased when Efalizumab is combined with Vindesine.,Vindesine
DB00322,The risk or severity of adverse effects can be increased when Efalizumab is combined with Floxuridine.,Floxuridine
DB00328,The risk or severity of adverse effects can be increased when Efalizumab is combined with Indomethacin.,Indomethacin
DB00352,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tioguanine.,Tioguanine
DB00361,The risk or severity of adverse effects can be increased when Efalizumab is combined with Vinorelbine.,Vinorelbine
DB00380,The risk or severity of adverse effects can be increased when Efalizumab is combined with Dexrazoxane.,Dexrazoxane
DB00394,The risk or severity of adverse effects can be increased when Efalizumab is combined with Beclomethasone dipropionate.,Beclomethasone dipropionate
DB00398,The risk or severity of adverse effects can be increased when Efalizumab is combined with Sorafenib.,Sorafenib
DB00428,The risk or severity of adverse effects can be increased when Efalizumab is combined with Streptozocin.,Streptozocin
DB00432,The risk or severity of adverse effects can be increased when Efalizumab is combined with Trifluridine.,Trifluridine
DB00441,The risk or severity of adverse effects can be increased when Efalizumab is combined with Gemcitabine.,Gemcitabine
DB00443,The risk or severity of adverse effects can be increased when Efalizumab is combined with Betamethasone.,Betamethasone
DB00444,The risk or severity of adverse effects can be increased when Efalizumab is combined with Teniposide.,Teniposide
DB00445,The risk or severity of adverse effects can be increased when Efalizumab is combined with Epirubicin.,Epirubicin
DB00446,The risk or severity of adverse effects can be increased when Efalizumab is combined with Chloramphenicol.,Chloramphenicol
DB00480,The risk or severity of adverse effects can be increased when Efalizumab is combined with Lenalidomide.,Lenalidomide
DB00488,The risk or severity of adverse effects can be increased when Efalizumab is combined with Altretamine.,Altretamine
DB00495,The risk or severity of adverse effects can be increased when Efalizumab is combined with Zidovudine.,Zidovudine
DB00515,The risk or severity of adverse effects can be increased when Efalizumab is combined with Cisplatin.,Cisplatin
DB00526,The risk or severity of adverse effects can be increased when Efalizumab is combined with Oxaliplatin.,Oxaliplatin
DB00531,The risk or severity of adverse effects can be increased when Efalizumab is combined with Cyclophosphamide.,Cyclophosphamide
DB00541,The risk or severity of adverse effects can be increased when Efalizumab is combined with Vincristine.,Vincristine
DB00544,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluorouracil.,Fluorouracil
DB00550,The risk or severity of adverse effects can be increased when Efalizumab is combined with Propylthiouracil.,Propylthiouracil
DB00552,The risk or severity of adverse effects can be increased when Efalizumab is combined with Pentostatin.,Pentostatin
DB00563,The risk or severity of adverse effects can be increased when Efalizumab is combined with Methotrexate.,Methotrexate
DB00564,The risk or severity of adverse effects can be increased when Efalizumab is combined with Carbamazepine.,Carbamazepine
DB00570,The risk or severity of adverse effects can be increased when Efalizumab is combined with Vinblastine.,Vinblastine
DB00588,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluticasone propionate.,Fluticasone propionate
DB00591,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluocinolone acetonide.,Fluocinolone acetonide
DB00601,The risk or severity of adverse effects can be increased when Efalizumab is combined with Linezolid.,Linezolid
DB00619,The risk or severity of adverse effects can be increased when Efalizumab is combined with Imatinib.,Imatinib
DB00620,The risk or severity of adverse effects can be increased when Efalizumab is combined with Triamcinolone.,Triamcinolone
DB00631,The risk or severity of adverse effects can be increased when Efalizumab is combined with Clofarabine.,Clofarabine
DB00635,The risk or severity of adverse effects can be increased when Efalizumab is combined with Prednisone.,Prednisone
DB00642,The risk or severity of adverse effects can be increased when Efalizumab is combined with Pemetrexed.,Pemetrexed
DB00687,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fludrocortisone.,Fludrocortisone
DB00688,The risk or severity of adverse effects can be increased when Efalizumab is combined with Mycophenolate mofetil.,Mycophenolate mofetil
DB00694,The risk or severity of adverse effects can be increased when Efalizumab is combined with Daunorubicin.,Daunorubicin
DB00755,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tretinoin.,Tretinoin
DB00762,The risk or severity of adverse effects can be increased when Efalizumab is combined with Irinotecan.,Irinotecan
DB00763,The risk or severity of adverse effects can be increased when Efalizumab is combined with Methimazole.,Methimazole
DB00764,The risk or severity of adverse effects can be increased when Efalizumab is combined with Mometasone.,Mometasone
DB00773,The risk or severity of adverse effects can be increased when Efalizumab is combined with Etoposide.,Etoposide
DB00795,The risk or severity of adverse effects can be increased when Efalizumab is combined with Sulfasalazine.,Sulfasalazine
DB00851,The risk or severity of adverse effects can be increased when Efalizumab is combined with Dacarbazine.,Dacarbazine
DB00853,The risk or severity of adverse effects can be increased when Efalizumab is combined with Temozolomide.,Temozolomide
DB00859,The risk or severity of adverse effects can be increased when Efalizumab is combined with Penicillamine.,Penicillamine
DB00860,The risk or severity of adverse effects can be increased when Efalizumab is combined with Prednisolone.,Prednisolone
DB00877,The risk or severity of adverse effects can be increased when Efalizumab is combined with Sirolimus.,Sirolimus
DB00888,The risk or severity of adverse effects can be increased when Efalizumab is combined with Mechlorethamine.,Mechlorethamine
DB00928,The risk or severity of adverse effects can be increased when Efalizumab is combined with Azacitidine.,Azacitidine
DB00958,The risk or severity of adverse effects can be increased when Efalizumab is combined with Carboplatin.,Carboplatin
DB00959,The risk or severity of adverse effects can be increased when Efalizumab is combined with Methylprednisolone.,Methylprednisolone
DB00970,The risk or severity of adverse effects can be increased when Efalizumab is combined with Dactinomycin.,Dactinomycin
DB00987,The risk or severity of adverse effects can be increased when Efalizumab is combined with Cytarabine.,Cytarabine
DB00993,The risk or severity of adverse effects can be increased when Efalizumab is combined with Azathioprine.,Azathioprine
DB00997,The risk or severity of adverse effects can be increased when Efalizumab is combined with Doxorubicin.,Doxorubicin
DB01005,The risk or severity of adverse effects can be increased when Efalizumab is combined with Hydroxyurea.,Hydroxyurea
DB01008,The risk or severity of adverse effects can be increased when Efalizumab is combined with Busulfan.,Busulfan
DB01024,The risk or severity of adverse effects can be increased when Efalizumab is combined with Mycophenolic acid.,Mycophenolic acid
DB01030,The risk or severity of adverse effects can be increased when Efalizumab is combined with Topotecan.,Topotecan
DB01033,The risk or severity of adverse effects can be increased when Efalizumab is combined with Mercaptopurine.,Mercaptopurine
DB01041,The risk or severity of adverse effects can be increased when Efalizumab is combined with Thalidomide.,Thalidomide
DB01042,The risk or severity of adverse effects can be increased when Efalizumab is combined with Melphalan.,Melphalan
DB01073,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fludarabine.,Fludarabine
DB01099,The risk or severity of adverse effects can be increased when Efalizumab is combined with Flucytosine.,Flucytosine
DB01101,The risk or severity of adverse effects can be increased when Efalizumab is combined with Capecitabine.,Capecitabine
DB01108,The risk or severity of adverse effects can be increased when Efalizumab is combined with Trilostane.,Trilostane
DB01168,The risk or severity of adverse effects can be increased when Efalizumab is combined with Procarbazine.,Procarbazine
DB01169,The risk or severity of adverse effects can be increased when Efalizumab is combined with Arsenic trioxide.,Arsenic trioxide
DB01177,The risk or severity of adverse effects can be increased when Efalizumab is combined with Idarubicin.,Idarubicin
DB01181,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ifosfamide.,Ifosfamide
DB01196,The risk or severity of adverse effects can be increased when Efalizumab is combined with Estramustine.,Estramustine
DB01204,The risk or severity of adverse effects can be increased when Efalizumab is combined with Mitoxantrone.,Mitoxantrone
DB01206,The risk or severity of adverse effects can be increased when Efalizumab is combined with Lomustine.,Lomustine
DB01222,The risk or severity of adverse effects can be increased when Efalizumab is combined with Budesonide.,Budesonide
DB01229,The risk or severity of adverse effects can be increased when Efalizumab is combined with Paclitaxel.,Paclitaxel
DB01234,The risk or severity of adverse effects can be increased when Efalizumab is combined with Dexamethasone.,Dexamethasone
DB01248,The risk or severity of adverse effects can be increased when Efalizumab is combined with Docetaxel.,Docetaxel
DB01254,The risk or severity of adverse effects can be increased when Efalizumab is combined with Dasatinib.,Dasatinib
DB01257,The risk or severity of adverse effects can be increased when Efalizumab is combined with Eculizumab.,Eculizumab
DB01262,The risk or severity of adverse effects can be increased when Efalizumab is combined with Decitabine.,Decitabine
DB01268,The risk or severity of adverse effects can be increased when Efalizumab is combined with Sunitinib.,Sunitinib
DB01280,The risk or severity of adverse effects can be increased when Efalizumab is combined with Nelarabine.,Nelarabine
DB01281,The risk or severity of adverse effects can be increased when Efalizumab is combined with Abatacept.,Abatacept
DB01285,The risk or severity of adverse effects can be increased when Efalizumab is combined with Corticotropin.,Corticotropin
DB01380,The risk or severity of adverse effects can be increased when Efalizumab is combined with Cortisone acetate.,Cortisone acetate
DB01384,The risk or severity of adverse effects can be increased when Efalizumab is combined with Paramethasone.,Paramethasone
DB01394,The risk or severity of adverse effects can be increased when Efalizumab is combined with Colchicine.,Colchicine
DB01410,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ciclesonide.,Ciclesonide
DB01423,The risk or severity of adverse effects can be increased when Efalizumab is combined with Stepronin.,Stepronin
DB01590,The risk or severity of adverse effects can be increased when Efalizumab is combined with Everolimus.,Everolimus
DB01611,The risk or severity of adverse effects can be increased when Efalizumab is combined with Hydroxychloroquine.,Hydroxychloroquine
DB01816,The risk or severity of adverse effects can be increased when Efalizumab is combined with Castanospermine.,Castanospermine
DB02546,The risk or severity of adverse effects can be increased when Efalizumab is combined with Vorinostat.,Vorinostat
DB02806,The risk or severity of adverse effects can be increased when Efalizumab is combined with 2-Methoxyethanol.,2-Methoxyethanol
DB03523,The risk or severity of adverse effects can be increased when Efalizumab is combined with Brequinar.,Brequinar
DB04572,The risk or severity of adverse effects can be increased when Efalizumab is combined with Thiotepa.,Thiotepa
DB04630,The risk or severity of adverse effects can be increased when Efalizumab is combined with Aldosterone.,Aldosterone
DB04845,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ixabepilone.,Ixabepilone
DB04868,The risk or severity of adverse effects can be increased when Efalizumab is combined with Nilotinib.,Nilotinib
DB04951,The risk or severity of adverse effects can be increased when Efalizumab is combined with Pirfenidone.,Pirfenidone
DB04956,The risk or severity of adverse effects can be increased when Efalizumab is combined with Afelimomab.,Afelimomab
DB05015,The risk or severity of adverse effects can be increased when Efalizumab is combined with Belinostat.,Belinostat
DB05109,The risk or severity of adverse effects can be increased when Efalizumab is combined with Trabectedin.,Trabectedin
DB05258,The risk or severity of adverse effects can be increased when Efalizumab is combined with Interferon alfa.,Interferon alfa
DB05259,The risk or severity of adverse effects can be increased when Efalizumab is combined with Glatiramer.,Glatiramer
DB05260,The risk or severity of adverse effects can be increased when Efalizumab is combined with Gallium nitrate.,Gallium nitrate
DB05459,The risk or severity of adverse effects can be increased when Efalizumab is combined with Briakinumab.,Briakinumab
DB05472,The risk or severity of adverse effects can be increased when Efalizumab is combined with omega interferon.,omega interferon
DB05676,The risk or severity of adverse effects can be increased when Efalizumab is combined with Apremilast.,Apremilast
DB05773,The risk or severity of adverse effects can be increased when Efalizumab is combined with Trastuzumab emtansine.,Trastuzumab emtansine
DB06168,The risk or severity of adverse effects can be increased when Efalizumab is combined with Canakinumab.,Canakinumab
DB06273,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tocilizumab.,Tocilizumab
DB06287,The risk or severity of adverse effects can be increased when Efalizumab is combined with Temsirolimus.,Temsirolimus
DB06372,The risk or severity of adverse effects can be increased when Efalizumab is combined with Rilonacept.,Rilonacept
DB06589,The risk or severity of adverse effects can be increased when Efalizumab is combined with Pazopanib.,Pazopanib
DB06603,The risk or severity of adverse effects can be increased when Efalizumab is combined with Panobinostat.,Panobinostat
DB06612,The risk or severity of adverse effects can be increased when Efalizumab is combined with Mepolizumab.,Mepolizumab
DB06616,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bosutinib.,Bosutinib
DB06662,The risk or severity of adverse effects can be increased when Efalizumab is combined with Abetimus.,Abetimus
DB06674,The risk or severity of adverse effects can be increased when Efalizumab is combined with Golimumab.,Golimumab
DB06681,The risk or severity of adverse effects can be increased when Efalizumab is combined with Belatacept.,Belatacept
DB06769,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bendamustine.,Bendamustine
DB06772,The risk or severity of adverse effects can be increased when Efalizumab is combined with Cabazitaxel.,Cabazitaxel
DB06813,The risk or severity of adverse effects can be increased when Efalizumab is combined with Pralatrexate.,Pralatrexate
DB08059,The risk or severity of adverse effects can be increased when Efalizumab is combined with Wortmannin.,Wortmannin
DB08870,The risk or severity of adverse effects can be increased when Efalizumab is combined with Brentuximab vedotin.,Brentuximab vedotin
DB08871,The risk or severity of adverse effects can be increased when Efalizumab is combined with Eribulin.,Eribulin
DB08877,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ruxolitinib.,Ruxolitinib
DB08879,The risk or severity of adverse effects can be increased when Efalizumab is combined with Belimumab.,Belimumab
DB08880,The risk or severity of adverse effects can be increased when Efalizumab is combined with Teriflunomide.,Teriflunomide
DB08889,The risk or severity of adverse effects can be increased when Efalizumab is combined with Carfilzomib.,Carfilzomib
DB08901,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ponatinib.,Ponatinib
DB08904,The risk or severity of adverse effects can be increased when Efalizumab is combined with Certolizumab pegol.,Certolizumab pegol
DB08906,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluticasone furoate.,Fluticasone furoate
DB08908,The risk or severity of adverse effects can be increased when Efalizumab is combined with Dimethyl fumarate.,Dimethyl fumarate
DB08910,The risk or severity of adverse effects can be increased when Efalizumab is combined with Pomalidomide.,Pomalidomide
DB08935,The risk or severity of adverse effects can be increased when Efalizumab is combined with Obinutuzumab.,Obinutuzumab
DB08970,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluprednidene.,Fluprednidene
DB08971,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluocortolone.,Fluocortolone
DB09029,The risk or severity of adverse effects can be increased when Efalizumab is combined with Secukinumab.,Secukinumab
DB09033,The risk or severity of adverse effects can be increased when Efalizumab is combined with Vedolizumab.,Vedolizumab
DB09036,The risk or severity of adverse effects can be increased when Efalizumab is combined with Siltuximab.,Siltuximab
DB09052,The risk or severity of adverse effects can be increased when Efalizumab is combined with Blinatumomab.,Blinatumomab
DB09053,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ibrutinib.,Ibrutinib
DB09054,The risk or severity of adverse effects can be increased when Efalizumab is combined with Idelalisib.,Idelalisib
DB09073,The risk or severity of adverse effects can be increased when Efalizumab is combined with Palbociclib.,Palbociclib
DB09074,The risk or severity of adverse effects can be increased when Efalizumab is combined with Olaparib.,Olaparib
DB09077,The risk or severity of adverse effects can be increased when Efalizumab is combined with Dinutuximab.,Dinutuximab
DB09082,The risk or severity of adverse effects can be increased when Efalizumab is combined with Vilanterol.,Vilanterol
DB09091,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tixocortol.,Tixocortol
DB09122,The risk or severity of adverse effects can be increased when Efalizumab is combined with Peginterferon beta-1a.,Peginterferon beta-1a
DB09312,The risk or severity of adverse effects can be increased when Efalizumab is combined with Antilymphocyte immunoglobulin (horse).,Antilymphocyte immunoglobulin (horse)
DB09378,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluprednisolone.,Fluprednisolone
DB09383,The risk or severity of adverse effects can be increased when Efalizumab is combined with Meprednisone.,Meprednisone
DB11466,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tepoxalin.,Tepoxalin
DB11487,The risk or severity of adverse effects can be increased when Efalizumab is combined with Dexamethasone isonicotinate.,Dexamethasone isonicotinate
DB11529,The risk or severity of adverse effects can be increased when Efalizumab is combined with Melengestrol.,Melengestrol
DB11569,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ixekizumab.,Ixekizumab
DB11580,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ravulizumab.,Ravulizumab
DB11616,The risk or severity of adverse effects can be increased when Efalizumab is combined with Pirarubicin.,Pirarubicin
DB11693,The risk or severity of adverse effects can be increased when Efalizumab is combined with Voclosporin.,Voclosporin
DB11708,The risk or severity of adverse effects can be increased when Efalizumab is combined with Peficitinib.,Peficitinib
DB11750,The risk or severity of adverse effects can be increased when Efalizumab is combined with Clobetasol.,Clobetasol
DB11767,The risk or severity of adverse effects can be increased when Efalizumab is combined with Sarilumab.,Sarilumab
DB11776,The risk or severity of adverse effects can be increased when Efalizumab is combined with Brodalumab.,Brodalumab
DB11803,The risk or severity of adverse effects can be increased when Efalizumab is combined with Sirukumab.,Sirukumab
DB11817,The risk or severity of adverse effects can be increased when Efalizumab is combined with Baricitinib.,Baricitinib
DB11834,The risk or severity of adverse effects can be increased when Efalizumab is combined with Guselkumab.,Guselkumab
DB11921,The risk or severity of adverse effects can be increased when Efalizumab is combined with Deflazacort.,Deflazacort
DB11988,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ocrelizumab.,Ocrelizumab
DB12025,The risk or severity of adverse effects can be increased when Efalizumab is combined with Triptolide.,Triptolide
DB12371,The risk or severity of adverse effects can be increased when Efalizumab is combined with Siponimod.,Siponimod
DB12612,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ozanimod.,Ozanimod
DB12617,The risk or severity of adverse effects can be increased when Efalizumab is combined with Mizoribine.,Mizoribine
DB12692,The risk or severity of adverse effects can be increased when Efalizumab is combined with Gusperimus.,Gusperimus
DB12814,The risk or severity of adverse effects can be increased when Efalizumab is combined with Cepeginterferon alfa-2B.,Cepeginterferon alfa-2B
DB12902,The risk or severity of adverse effects can be increased when Efalizumab is combined with Trofosfamide.,Trofosfamide
DB12947,The risk or severity of adverse effects can be increased when Efalizumab is combined with Doxifluridine.,Doxifluridine
DB12991,The risk or severity of adverse effects can be increased when Efalizumab is combined with Deoxyspergualin.,Deoxyspergualin
DB12996,The risk or severity of adverse effects can be increased when Efalizumab is combined with Acteoside.,Acteoside
DB13003,The risk or severity of adverse effects can be increased when Efalizumab is combined with Cortivazol.,Cortivazol
DB13014,The risk or severity of adverse effects can be increased when Efalizumab is combined with Hypericin.,Hypericin
DB13068,The risk or severity of adverse effects can be increased when Efalizumab is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.,9-(N-methyl-L-isoleucine)-cyclosporin A
DB13208,The risk or severity of adverse effects can be increased when Efalizumab is combined with Prednylidene.,Prednylidene
DB13223,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluocortin.,Fluocortin
DB13241,The risk or severity of adverse effects can be increased when Efalizumab is combined with Begelomab.,Begelomab
DB13491,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluperolone.,Fluperolone
DB13664,The risk or severity of adverse effects can be increased when Efalizumab is combined with Formocortal.,Formocortal
DB13728,The risk or severity of adverse effects can be increased when Efalizumab is combined with Halometasone.,Halometasone
DB13843,The risk or severity of adverse effects can be increased when Efalizumab is combined with Cloprednol.,Cloprednol
DB13856,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluclorolone.,Fluclorolone
DB13867,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluticasone.,Fluticasone
DB14066,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tetrandrine.,Tetrandrine
DB14219,The risk or severity of adverse effects can be increased when Efalizumab is combined with Monomethyl fumarate.,Monomethyl fumarate
DB14512,The risk or severity of adverse effects can be increased when Efalizumab is combined with Mometasone furoate.,Mometasone furoate
DB14538,The risk or severity of adverse effects can be increased when Efalizumab is combined with Hydrocortisone aceponate.,Hydrocortisone aceponate
DB14539,The risk or severity of adverse effects can be increased when Efalizumab is combined with Hydrocortisone acetate.,Hydrocortisone acetate
DB14545,The risk or severity of adverse effects can be increased when Efalizumab is combined with Hydrocortisone succinate.,Hydrocortisone succinate
DB14724,The risk or severity of adverse effects can be increased when Efalizumab is combined with Emapalumab.,Emapalumab
DB14762,The risk or severity of adverse effects can be increased when Efalizumab is combined with Risankizumab.,Risankizumab
DB14919,The risk or severity of adverse effects can be increased when Efalizumab is combined with Rozanolixizumab.,Rozanolixizumab
DB15253,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bleselumab.,Bleselumab
DB00108,The risk or severity of adverse effects can be increased when Efalizumab is combined with Natalizumab.,Natalizumab
DB00337,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Efalizumab.,Pimecrolimus
DB01656,Roflumilast may increase the immunosuppressive activities of Efalizumab.,Roflumilast
DB06688,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Efalizumab.,Sipuleucel-T
DB01015,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Efalizumab.,Sulfamethoxazole
DB00255,Diethylstilbestrol may increase the thrombogenic activities of Efalizumab.,Diethylstilbestrol
DB00269,Chlorotrianisene may increase the thrombogenic activities of Efalizumab.,Chlorotrianisene
DB00286,Conjugated estrogens may increase the thrombogenic activities of Efalizumab.,Conjugated estrogens
DB00655,Estrone may increase the thrombogenic activities of Efalizumab.,Estrone
DB00783,Estradiol may increase the thrombogenic activities of Efalizumab.,Estradiol
DB00890,Dienestrol may increase the thrombogenic activities of Efalizumab.,Dienestrol
DB00977,Ethinylestradiol may increase the thrombogenic activities of Efalizumab.,Ethinylestradiol
DB01357,Mestranol may increase the thrombogenic activities of Efalizumab.,Mestranol
DB04573,Estriol may increase the thrombogenic activities of Efalizumab.,Estriol
DB04574,Estrone sulfate may increase the thrombogenic activities of Efalizumab.,Estrone sulfate
DB04575,Quinestrol may increase the thrombogenic activities of Efalizumab.,Quinestrol
DB07931,Hexestrol may increase the thrombogenic activities of Efalizumab.,Hexestrol
DB09070,Tibolone may increase the thrombogenic activities of Efalizumab.,Tibolone
DB09317,"Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Efalizumab.","Synthetic Conjugated Estrogens, A"
DB09318,"Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Efalizumab.","Synthetic Conjugated Estrogens, B"
DB09369,Polyestradiol phosphate may increase the thrombogenic activities of Efalizumab.,Polyestradiol phosphate
DB09381,Esterified estrogens may increase the thrombogenic activities of Efalizumab.,Esterified estrogens
DB11478,Zeranol may increase the thrombogenic activities of Efalizumab.,Zeranol
DB11674,Equol may increase the thrombogenic activities of Efalizumab.,Equol
DB12487,Promestriene may increase the thrombogenic activities of Efalizumab.,Promestriene
DB13143,Methallenestril may increase the thrombogenic activities of Efalizumab.,Methallenestril
DB13386,Epimestrol may increase the thrombogenic activities of Efalizumab.,Epimestrol
DB13418,Moxestrol may increase the thrombogenic activities of Efalizumab.,Moxestrol
DB13952,Estradiol acetate may increase the thrombogenic activities of Efalizumab.,Estradiol acetate
DB13953,Estradiol benzoate may increase the thrombogenic activities of Efalizumab.,Estradiol benzoate
DB13954,Estradiol cypionate may increase the thrombogenic activities of Efalizumab.,Estradiol cypionate
DB13956,Estradiol valerate may increase the thrombogenic activities of Efalizumab.,Estradiol valerate
DB15334,Biochanin A may increase the thrombogenic activities of Efalizumab.,Biochanin A
DB15335,Formononetin may increase the thrombogenic activities of Efalizumab.,Formononetin
DB01097,The risk or severity of adverse effects can be increased when Efalizumab is combined with Leflunomide.,Leflunomide
DB08895,Efalizumab may increase the immunosuppressive activities of Tofacitinib.,Tofacitinib
DB00072,Trastuzumab may increase the neutropenic activities of Efalizumab.,Trastuzumab
DB08868,Efalizumab may increase the immunosuppressive activities of Fingolimod.,Fingolimod
DB00864,Tacrolimus may increase the immunosuppressive activities of Efalizumab.,Tacrolimus
DB04914,The therapeutic efficacy of G17DT can be decreased when used in combination with Efalizumab.,G17DT
DB05144,The therapeutic efficacy of PEV3A can be decreased when used in combination with Efalizumab.,PEV3A
DB05325,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Efalizumab.,INGN 225
DB05374,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Efalizumab.,Rindopepimut
DB05440,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Efalizumab.,SRP 299
DB05942,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Efalizumab.,GI-5005
DB06400,The therapeutic efficacy of Vitespen can be decreased when used in combination with Efalizumab.,Vitespen
DB06584,The therapeutic efficacy of TG4010 can be decreased when used in combination with Efalizumab.,TG4010
DB09057,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Efalizumab.,Anthrax immune globulin human
DB10062,"The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Efalizumab.","Rabies virus inactivated antigen, B"
DB10076,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Efalizumab.,Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen
DB10276,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Efalizumab.,Rotavirus vaccine
DB10283,"The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Efalizumab.","Rabies virus inactivated antigen, A"
DB10342,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Efalizumab.,Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen
DB10583,The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Efalizumab.,Clostridium tetani toxoid antigen (formaldehyde inactivated)
DB10584,The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Efalizumab.,Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
DB10600,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Efalizumab.,Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated)
DB10769,The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Efalizumab.,Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)
DB10794,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Efalizumab.,Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated)
DB10803,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Efalizumab.,Typhoid Vi polysaccharide vaccine
DB10989,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Efalizumab.,Hepatitis A Vaccine
DB10990,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Efalizumab.,Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
DB11038,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Efalizumab.,Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated)
DB11040,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Efalizumab.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated)
DB11041,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Efalizumab.,Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)
DB11044,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Efalizumab.,Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated)
DB11603,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Efalizumab.,Human rabies virus immune globulin
DB11627,The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Efalizumab.,Hepatitis B Vaccine (Recombinant)
DB12568,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Efalizumab.,Tecemotide
DB14022,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Efalizumab.,Typhoid vaccine
DB14384,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Efalizumab.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated)
DB14385,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Efalizumab.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)
DB14394,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Efalizumab.,Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen
DB14445,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Efalizumab.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated)
DB14449,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Efalizumab.,Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen
DB14619,The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Efalizumab.,Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated)
DB14620,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Efalizumab.,Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated)
DB14711,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Efalizumab.,Vaccinia virus strain new york city board of health live antigen
DB15274,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Efalizumab.,Pertussis vaccine
DB15461,The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Efalizumab.,Yersinia pestis 195/p antigen (formaldehyde inactivated)
DB13924,The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Efalizumab.,Varicella Zoster Vaccine (Recombinant)
DB15483,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Efalizumab.,Modified vaccinia ankara
DB10317,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Efalizumab.,Rubella virus vaccine
DB10318,The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Efalizumab.,Varicella Zoster Vaccine (Live/attenuated)
DB10343,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Efalizumab.,Bacillus calmette-guerin substrain tice live antigen
DB10804,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Efalizumab.,Bacillus calmette-guerin substrain connaught live antigen
DB10805,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Efalizumab.,Yellow Fever Vaccine
DB11003,The risk or severity of infection can be increased when Anthrax vaccine is combined with Efalizumab.,Anthrax vaccine
DB11050,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Efalizumab.,Typhoid Vaccine Live
DB12386,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Efalizumab.,Bacillus calmette-guerin substrain danish 1331 live antigen
DB12768,The risk or severity of infection can be increased when BCG vaccine is combined with Efalizumab.,BCG vaccine
DB14409,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Efalizumab.,Human adenovirus e serotype 4 strain cl-68578 antigen
DB14443,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Efalizumab.,Vibrio cholerae CVD 103-HgR strain live antigen
DB14685,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Efalizumab.,Adenovirus type 7 vaccine live
DB00002,The risk or severity of adverse effects can be increased when Cetuximab is combined with Efalizumab.,Cetuximab
DB00028,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Efalizumab.,Human immunoglobulin G
DB00043,The risk or severity of adverse effects can be increased when Omalizumab is combined with Efalizumab.,Omalizumab
DB00054,The risk or severity of adverse effects can be increased when Abciximab is combined with Efalizumab.,Abciximab
DB00057,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Efalizumab.,Indium In-111 satumomab pendetide
DB00076,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Efalizumab.,Digoxin Immune Fab (Ovine)
DB00089,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Efalizumab.,Capromab pendetide
DB00110,The risk or severity of adverse effects can be increased when Efalizumab is combined with Palivizumab.,Palivizumab
DB00113,The risk or severity of adverse effects can be increased when Efalizumab is combined with Technetium Tc-99m arcitumomab.,Technetium Tc-99m arcitumomab
DB01269,The risk or severity of adverse effects can be increased when Efalizumab is combined with Panitumumab.,Panitumumab
DB01270,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ranibizumab.,Ranibizumab
DB04901,The risk or severity of adverse effects can be increased when Efalizumab is combined with Galiximab.,Galiximab
DB04949,The risk or severity of adverse effects can be increased when Efalizumab is combined with Pexelizumab.,Pexelizumab
DB04958,The risk or severity of adverse effects can be increased when Efalizumab is combined with Epratuzumab.,Epratuzumab
DB04962,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bectumomab.,Bectumomab
DB04964,The risk or severity of adverse effects can be increased when Efalizumab is combined with Oregovomab.,Oregovomab
DB04988,The risk or severity of adverse effects can be increased when Efalizumab is combined with IGN311.,IGN311
DB05006,The risk or severity of adverse effects can be increased when Efalizumab is combined with Adecatumumab.,Adecatumumab
DB05097,The risk or severity of adverse effects can be increased when Efalizumab is combined with Labetuzumab.,Labetuzumab
DB05101,The risk or severity of adverse effects can be increased when Efalizumab is combined with Matuzumab.,Matuzumab
DB05111,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fontolizumab.,Fontolizumab
DB05136,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bavituximab.,Bavituximab
DB05139,The risk or severity of adverse effects can be increased when Efalizumab is combined with CR002.,CR002
DB05209,The risk or severity of adverse effects can be increased when Efalizumab is combined with Rozrolimupab.,Rozrolimupab
DB05304,The risk or severity of adverse effects can be increased when Efalizumab is combined with Girentuximab.,Girentuximab
DB05336,The risk or severity of adverse effects can be increased when Efalizumab is combined with Obiltoxaximab.,Obiltoxaximab
DB05405,The risk or severity of adverse effects can be increased when Efalizumab is combined with XTL-001.,XTL-001
DB05437,The risk or severity of adverse effects can be increased when Efalizumab is combined with NAV 1800.,NAV 1800
DB05496,The risk or severity of adverse effects can be increased when Efalizumab is combined with Otelixizumab.,Otelixizumab
DB05545,The risk or severity of adverse effects can be increased when Efalizumab is combined with AMG 108.,AMG 108
DB05550,The risk or severity of adverse effects can be increased when Efalizumab is combined with Iratumumab.,Iratumumab
DB05555,The risk or severity of adverse effects can be increased when Efalizumab is combined with Enokizumab.,Enokizumab
DB05578,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ramucirumab.,Ramucirumab
DB05595,The risk or severity of adverse effects can be increased when Efalizumab is combined with Farletuzumab.,Farletuzumab
DB05656,The risk or severity of adverse effects can be increased when Efalizumab is combined with Veltuzumab.,Veltuzumab
DB05793,The risk or severity of adverse effects can be increased when Efalizumab is combined with PRO-542.,PRO-542
DB05797,The risk or severity of adverse effects can be increased when Efalizumab is combined with TNX-901.,TNX-901
DB05889,The risk or severity of adverse effects can be increased when Efalizumab is combined with Inotuzumab ozogamicin.,Inotuzumab ozogamicin
DB05892,The risk or severity of adverse effects can be increased when Efalizumab is combined with RI 624.,RI 624
DB05915,The risk or severity of adverse effects can be increased when Efalizumab is combined with MYO-029.,MYO-029
DB05916,The risk or severity of adverse effects can be increased when Efalizumab is combined with CT-011.,CT-011
DB05941,The risk or severity of adverse effects can be increased when Efalizumab is combined with Leronlimab.,Leronlimab
DB05996,The risk or severity of adverse effects can be increased when Efalizumab is combined with Glembatumumab vedotin.,Glembatumumab vedotin
DB06043,The risk or severity of adverse effects can be increased when Efalizumab is combined with Olaratumab.,Olaratumab
DB06049,The risk or severity of adverse effects can be increased when Efalizumab is combined with IPH 2101.,IPH 2101
DB06050,The risk or severity of adverse effects can be increased when Efalizumab is combined with TB-402.,TB-402
DB06081,The risk or severity of adverse effects can be increased when Efalizumab is combined with Caplacizumab.,Caplacizumab
DB06101,The risk or severity of adverse effects can be increased when Efalizumab is combined with IMC-1C11.,IMC-1C11
DB06116,The risk or severity of adverse effects can be increased when Efalizumab is combined with Eldelumab.,Eldelumab
DB06162,The risk or severity of adverse effects can be increased when Efalizumab is combined with Lumiliximab.,Lumiliximab
DB06186,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ipilimumab.,Ipilimumab
DB06192,The risk or severity of adverse effects can be increased when Efalizumab is combined with Nimotuzumab.,Nimotuzumab
DB06241,The risk or severity of adverse effects can be increased when Efalizumab is combined with Clenoliximab.,Clenoliximab
DB06304,The risk or severity of adverse effects can be increased when Efalizumab is combined with BIIB015.,BIIB015
DB06305,The risk or severity of adverse effects can be increased when Efalizumab is combined with Sonepcizumab.,Sonepcizumab
DB06310,The risk or severity of adverse effects can be increased when Efalizumab is combined with Motavizumab.,Motavizumab
DB06317,The risk or severity of adverse effects can be increased when Efalizumab is combined with Elotuzumab.,Elotuzumab
DB06318,The risk or severity of adverse effects can be increased when Efalizumab is combined with AVE9633.,AVE9633
DB06322,The risk or severity of adverse effects can be increased when Efalizumab is combined with Carotuximab.,Carotuximab
DB06324,The risk or severity of adverse effects can be increased when Efalizumab is combined with XmAb 2513.,XmAb 2513
DB06342,The risk or severity of adverse effects can be increased when Efalizumab is combined with Coltuximab ravtansine.,Coltuximab ravtansine
DB06343,The risk or severity of adverse effects can be increased when Efalizumab is combined with Teprotumumab.,Teprotumumab
DB06360,The risk or severity of adverse effects can be increased when Efalizumab is combined with Lucatumumab.,Lucatumumab
DB06366,The risk or severity of adverse effects can be increased when Efalizumab is combined with Pertuzumab.,Pertuzumab
DB06371,The risk or severity of adverse effects can be increased when Efalizumab is combined with Siplizumab.,Siplizumab
DB06467,The risk or severity of adverse effects can be increased when Efalizumab is combined with Apolizumab.,Apolizumab
DB06474,The risk or severity of adverse effects can be increased when Efalizumab is combined with Sibrotuzumab.,Sibrotuzumab
DB06550,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bivatuzumab.,Bivatuzumab
DB06557,The risk or severity of adverse effects can be increased when Efalizumab is combined with Lerdelimumab.,Lerdelimumab
DB06599,The risk or severity of adverse effects can be increased when Efalizumab is combined with Lexatumumab.,Lexatumumab
DB06602,The risk or severity of adverse effects can be increased when Efalizumab is combined with Reslizumab.,Reslizumab
DB06606,The risk or severity of adverse effects can be increased when Efalizumab is combined with Teplizumab.,Teplizumab
DB06607,The risk or severity of adverse effects can be increased when Efalizumab is combined with Catumaxomab.,Catumaxomab
DB06647,The risk or severity of adverse effects can be increased when Efalizumab is combined with Volociximab.,Volociximab
DB06650,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ofatumumab.,Ofatumumab
DB08902,The risk or severity of adverse effects can be increased when Efalizumab is combined with Raxibacumab.,Raxibacumab
DB09035,The risk or severity of adverse effects can be increased when Efalizumab is combined with Nivolumab.,Nivolumab
DB09037,The risk or severity of adverse effects can be increased when Efalizumab is combined with Pembrolizumab.,Pembrolizumab
DB09045,The risk or severity of adverse effects can be increased when Efalizumab is combined with Dulaglutide.,Dulaglutide
DB09105,The risk or severity of adverse effects can be increased when Efalizumab is combined with Asfotase alfa.,Asfotase alfa
DB09264,The risk or severity of adverse effects can be increased when Efalizumab is combined with Idarucizumab.,Idarucizumab
DB09302,The risk or severity of adverse effects can be increased when Efalizumab is combined with Alirocumab.,Alirocumab
DB09303,The risk or severity of adverse effects can be increased when Efalizumab is combined with Evolocumab.,Evolocumab
DB09331,The risk or severity of adverse effects can be increased when Efalizumab is combined with Daratumumab.,Daratumumab
DB09559,The risk or severity of adverse effects can be increased when Efalizumab is combined with Necitumumab.,Necitumumab
DB11595,The risk or severity of adverse effects can be increased when Efalizumab is combined with Atezolizumab.,Atezolizumab
DB11604,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tetanus Immune Globulin.,Tetanus Immune Globulin
DB11608,The risk or severity of adverse effects can be increased when Efalizumab is combined with Eftrenonacog alfa.,Eftrenonacog alfa
DB11621,The risk or severity of adverse effects can be increased when Efalizumab is combined with Human Varicella-Zoster Immune Globulin.,Human Varicella-Zoster Immune Globulin
DB11646,The risk or severity of adverse effects can be increased when Efalizumab is combined with Conatumumab.,Conatumumab
DB11657,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tabalumab.,Tabalumab
DB11680,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ficlatuzumab.,Ficlatuzumab
DB11685,The risk or severity of adverse effects can be increased when Efalizumab is combined with Figitumumab.,Figitumumab
DB11714,The risk or severity of adverse effects can be increased when Efalizumab is combined with Durvalumab.,Durvalumab
DB11715,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bapineuzumab.,Bapineuzumab
DB11731,The risk or severity of adverse effects can be increased when Efalizumab is combined with Depatuxizumab mafodotin.,Depatuxizumab mafodotin
DB11746,The risk or severity of adverse effects can be increased when Efalizumab is combined with Onartuzumab.,Onartuzumab
DB11756,The risk or severity of adverse effects can be increased when Efalizumab is combined with Solanezumab.,Solanezumab
DB11771,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tremelimumab.,Tremelimumab
DB11826,The risk or severity of adverse effects can be increased when Efalizumab is combined with Lampalizumab.,Lampalizumab
DB11840,The risk or severity of adverse effects can be increased when Efalizumab is combined with Dalotuzumab.,Dalotuzumab
DB11849,The risk or severity of adverse effects can be increased when Efalizumab is combined with Emibetuzumab.,Emibetuzumab
DB11850,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ublituximab.,Ublituximab
DB11856,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ligelizumab.,Ligelizumab
DB11857,The risk or severity of adverse effects can be increased when Efalizumab is combined with Seribantumab.,Seribantumab
DB11862,The risk or severity of adverse effects can be increased when Efalizumab is combined with Landogrozumab.,Landogrozumab
DB11866,The risk or severity of adverse effects can be increased when Efalizumab is combined with Romosozumab.,Romosozumab
DB11884,The risk or severity of adverse effects can be increased when Efalizumab is combined with Vadastuximab Talirine.,Vadastuximab Talirine
DB11914,The risk or severity of adverse effects can be increased when Efalizumab is combined with Lebrikizumab.,Lebrikizumab
DB11930,The risk or severity of adverse effects can be increased when Efalizumab is combined with Varlilumab.,Varlilumab
DB11945,The risk or severity of adverse effects can be increased when Efalizumab is combined with Avelumab.,Avelumab
DB11959,The risk or severity of adverse effects can be increased when Efalizumab is combined with Crenezumab.,Crenezumab
DB11972,The risk or severity of adverse effects can be increased when Efalizumab is combined with Rilotumumab.,Rilotumumab
DB11976,The risk or severity of adverse effects can be increased when Efalizumab is combined with Anifrolumab.,Anifrolumab
DB12023,The risk or severity of adverse effects can be increased when Efalizumab is combined with Benralizumab.,Benralizumab
DB12034,The risk or severity of adverse effects can be increased when Efalizumab is combined with Gantenerumab.,Gantenerumab
DB12053,The risk or severity of adverse effects can be increased when Efalizumab is combined with Visilizumab.,Visilizumab
DB12077,The risk or severity of adverse effects can be increased when Efalizumab is combined with Urelumab.,Urelumab
DB12089,The risk or severity of adverse effects can be increased when Efalizumab is combined with Lorvotuzumab mertansine.,Lorvotuzumab mertansine
DB12090,The risk or severity of adverse effects can be increased when Efalizumab is combined with Patritumab.,Patritumab
DB12102,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fulranumab.,Fulranumab
DB12104,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tarextumab.,Tarextumab
DB12118,The risk or severity of adverse effects can be increased when Efalizumab is combined with Sotatercept.,Sotatercept
DB12119,The risk or severity of adverse effects can be increased when Efalizumab is combined with Gevokizumab.,Gevokizumab
DB12142,The risk or severity of adverse effects can be increased when Efalizumab is combined with Duligotuzumab.,Duligotuzumab
DB12152,The risk or severity of adverse effects can be increased when Efalizumab is combined with Simtuzumab.,Simtuzumab
DB12157,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fasinumab.,Fasinumab
DB12159,The risk or severity of adverse effects can be increased when Efalizumab is combined with Dupilumab.,Dupilumab
DB12169,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tralokinumab.,Tralokinumab
DB12189,The risk or severity of adverse effects can be increased when Efalizumab is combined with Etrolizumab.,Etrolizumab
DB12202,The risk or severity of adverse effects can be increased when Efalizumab is combined with Zalutumumab.,Zalutumumab
DB12205,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ganitumab.,Ganitumab
DB12213,The risk or severity of adverse effects can be increased when Efalizumab is combined with Etaracizumab.,Etaracizumab
DB12240,The risk or severity of adverse effects can be increased when Efalizumab is combined with Polatuzumab vedotin.,Polatuzumab vedotin
DB12246,The risk or severity of adverse effects can be increased when Efalizumab is combined with Inclacumab.,Inclacumab
DB12250,The risk or severity of adverse effects can be increased when Efalizumab is combined with Cixutumumab.,Cixutumumab
DB12261,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ascrinvacumab.,Ascrinvacumab
DB12274,The risk or severity of adverse effects can be increased when Efalizumab is combined with Aducanumab.,Aducanumab
DB12281,The risk or severity of adverse effects can be increased when Efalizumab is combined with Luspatercept.,Luspatercept
DB12296,The risk or severity of adverse effects can be increased when Efalizumab is combined with GS-5745.,GS-5745
DB12317,The risk or severity of adverse effects can be increased when Efalizumab is combined with Vanucizumab.,Vanucizumab
DB12331,The risk or severity of adverse effects can be increased when Efalizumab is combined with Labetuzumab govitecan.,Labetuzumab govitecan
DB12335,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tanezumab.,Tanezumab
DB12342,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ensituximab.,Ensituximab
DB12344,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fezakinumab.,Fezakinumab
DB12363,The risk or severity of adverse effects can be increased when Efalizumab is combined with Dusigitumab.,Dusigitumab
DB12396,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fresolimumab.,Fresolimumab
DB12413,The risk or severity of adverse effects can be increased when Efalizumab is combined with Indusatumab vedotin.,Indusatumab vedotin
DB12456,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bococizumab.,Bococizumab
DB12489,The risk or severity of adverse effects can be increased when Efalizumab is combined with Mirvetuximab Soravtansine.,Mirvetuximab Soravtansine
DB12498,The risk or severity of adverse effects can be increased when Efalizumab is combined with Mogamulizumab.,Mogamulizumab
DB12520,The risk or severity of adverse effects can be increased when Efalizumab is combined with Plozalizumab.,Plozalizumab
DB12534,The risk or severity of adverse effects can be increased when Efalizumab is combined with Mavrilimumab.,Mavrilimumab
DB12560,The risk or severity of adverse effects can be increased when Efalizumab is combined with Blosozumab.,Blosozumab
DB12584,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bimagrumab.,Bimagrumab
DB12589,The risk or severity of adverse effects can be increased when Efalizumab is combined with Dacetuzumab.,Dacetuzumab
DB12609,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tovetumab.,Tovetumab
DB12683,The risk or severity of adverse effects can be increased when Efalizumab is combined with Lumretuzumab.,Lumretuzumab
DB12698,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ibalizumab.,Ibalizumab
DB12701,The risk or severity of adverse effects can be increased when Efalizumab is combined with Intetumumab.,Intetumumab
DB12718,The risk or severity of adverse effects can be increased when Efalizumab is combined with Carlumab.,Carlumab
DB12734,The risk or severity of adverse effects can be increased when Efalizumab is combined with Demcizumab.,Demcizumab
DB12773,The risk or severity of adverse effects can be increased when Efalizumab is combined with Sifalimumab.,Sifalimumab
DB12775,The risk or severity of adverse effects can be increased when Efalizumab is combined with Abituzumab.,Abituzumab
DB12797,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ecromeximab.,Ecromeximab
DB12807,The risk or severity of adverse effects can be increased when Efalizumab is combined with Naptumomab Estafenatox.,Naptumomab Estafenatox
DB12815,The risk or severity of adverse effects can be increased when Efalizumab is combined with Crotedumab.,Crotedumab
DB12820,The risk or severity of adverse effects can be increased when Efalizumab is combined with Concizumab.,Concizumab
DB12826,The risk or severity of adverse effects can be increased when Efalizumab is combined with Depatuxizumab.,Depatuxizumab
DB12844,The risk or severity of adverse effects can be increased when Efalizumab is combined with Rontalizumab.,Rontalizumab
DB12845,The risk or severity of adverse effects can be increased when Efalizumab is combined with Amatuximab.,Amatuximab
DB12849,The risk or severity of adverse effects can be increased when Efalizumab is combined with Clazakizumab.,Clazakizumab
DB12891,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ozanezumab.,Ozanezumab
DB12893,The risk or severity of adverse effects can be increased when Efalizumab is combined with Sacituzumab govitecan.,Sacituzumab govitecan
DB12917,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bimekizumab.,Bimekizumab
DB12943,The risk or severity of adverse effects can be increased when Efalizumab is combined with Milatuzumab.,Milatuzumab
DB12976,The risk or severity of adverse effects can be increased when Efalizumab is combined with Robatumumab.,Robatumumab
DB13017,The risk or severity of adverse effects can be increased when Efalizumab is combined with Rovalpituzumab Tesirine.,Rovalpituzumab Tesirine
DB13037,The risk or severity of adverse effects can be increased when Efalizumab is combined with Namilumab.,Namilumab
DB13045,The risk or severity of adverse effects can be increased when Efalizumab is combined with Racotumomab.,Racotumomab
DB13073,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tregalizumab.,Tregalizumab
DB13127,The risk or severity of adverse effects can be increased when Efalizumab is combined with Olokizumab.,Olokizumab
DB13140,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bezlotoxumab.,Bezlotoxumab
DB13375,The risk or severity of adverse effects can be increased when Efalizumab is combined with Edrecolomab.,Edrecolomab
DB13535,The risk or severity of adverse effects can be increased when Efalizumab is combined with Nebacumab.,Nebacumab
DB13886,The risk or severity of adverse effects can be increased when Efalizumab is combined with Human cytomegalovirus immune globulin.,Human cytomegalovirus immune globulin
DB13923,The risk or severity of adverse effects can be increased when Efalizumab is combined with Emicizumab.,Emicizumab
DB13976,The risk or severity of adverse effects can be increased when Efalizumab is combined with Sulesomab.,Sulesomab
DB13979,The risk or severity of adverse effects can be increased when Efalizumab is combined with Besilesomab.,Besilesomab
DB14012,The risk or severity of adverse effects can be increased when Efalizumab is combined with Burosumab.,Burosumab
DB14039,The risk or severity of adverse effects can be increased when Efalizumab is combined with Erenumab.,Erenumab
DB14040,The risk or severity of adverse effects can be increased when Efalizumab is combined with Eptinezumab.,Eptinezumab
DB14041,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fremanezumab.,Fremanezumab
DB14042,The risk or severity of adverse effects can be increased when Efalizumab is combined with Galcanezumab.,Galcanezumab
DB14211,The risk or severity of adverse effects can be increased when Efalizumab is combined with Fanolesomab.,Fanolesomab
DB14580,The risk or severity of adverse effects can be increased when Efalizumab is combined with Lecanemab.,Lecanemab
DB14597,The risk or severity of adverse effects can be increased when Efalizumab is combined with Lanadelumab.,Lanadelumab
DB14707,The risk or severity of adverse effects can be increased when Efalizumab is combined with Cemiplimab.,Cemiplimab
DB14776,The risk or severity of adverse effects can be increased when Efalizumab is combined with Camrelizumab.,Camrelizumab
DB14778,The risk or severity of adverse effects can be increased when Efalizumab is combined with Setrusumab.,Setrusumab
DB14784,The risk or severity of adverse effects can be increased when Efalizumab is combined with Gancotamab.,Gancotamab
DB14809,The risk or severity of adverse effects can be increased when Efalizumab is combined with Anetumab ravtansine.,Anetumab ravtansine
DB14811,The risk or severity of adverse effects can be increased when Efalizumab is combined with Isatuximab.,Isatuximab
DB14824,The risk or severity of adverse effects can be increased when Efalizumab is combined with Icrucumab.,Icrucumab
DB14843,The risk or severity of adverse effects can be increased when Efalizumab is combined with Codrituzumab.,Codrituzumab
DB14864,The risk or severity of adverse effects can be increased when Efalizumab is combined with Brolucizumab.,Brolucizumab
DB14871,The risk or severity of adverse effects can be increased when Efalizumab is combined with Xentuzumab.,Xentuzumab
DB14877,The risk or severity of adverse effects can be increased when Efalizumab is combined with Lintuzumab.,Lintuzumab
DB14891,The risk or severity of adverse effects can be increased when Efalizumab is combined with Vobarilizumab.,Vobarilizumab
DB14897,The risk or severity of adverse effects can be increased when Efalizumab is combined with Parsatuzumab.,Parsatuzumab
DB14905,The risk or severity of adverse effects can be increased when Efalizumab is combined with Emactuzumab.,Emactuzumab
DB14907,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bevacizumab zirconium Zr-89.,Bevacizumab zirconium Zr-89
DB14908,The risk or severity of adverse effects can be increased when Efalizumab is combined with Refanezumab.,Refanezumab
DB14947,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bermekimab.,Bermekimab
DB14952,The risk or severity of adverse effects can be increased when Efalizumab is combined with Pamrevlumab.,Pamrevlumab
DB14959,The risk or severity of adverse effects can be increased when Efalizumab is combined with Opicinumab.,Opicinumab
DB14962,The risk or severity of adverse effects can be increased when Efalizumab is combined with Trastuzumab deruxtecan.,Trastuzumab deruxtecan
DB14967,The risk or severity of adverse effects can be increased when Efalizumab is combined with Margetuximab.,Margetuximab
DB14988,The risk or severity of adverse effects can be increased when Efalizumab is combined with Dalantercept.,Dalantercept
DB14997,The risk or severity of adverse effects can be increased when Efalizumab is combined with Pateclizumab.,Pateclizumab
DB15014,The risk or severity of adverse effects can be increased when Efalizumab is combined with Gremubamab.,Gremubamab
DB15022,The risk or severity of adverse effects can be increased when Efalizumab is combined with Apomab.,Apomab
DB15044,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tafasitamab.,Tafasitamab
DB15045,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ipafricept.,Ipafricept
DB15076,The risk or severity of adverse effects can be increased when Efalizumab is combined with Abrilumab.,Abrilumab
DB15089,The risk or severity of adverse effects can be increased when Efalizumab is combined with Frovocimab.,Frovocimab
DB15090,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tezepelumab.,Tezepelumab
DB15101,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tigatuzumab.,Tigatuzumab
DB15104,The risk or severity of adverse effects can be increased when Efalizumab is combined with Telisotuzumab vedotin.,Telisotuzumab vedotin
DB15113,The risk or severity of adverse effects can be increased when Efalizumab is combined with Utomilumab.,Utomilumab
DB15118,The risk or severity of adverse effects can be increased when Efalizumab is combined with Zolbetuximab.,Zolbetuximab
DB15135,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ponezumab.,Ponezumab
DB15160,The risk or severity of adverse effects can be increased when Efalizumab is combined with Asunercept.,Asunercept
DB15172,The risk or severity of adverse effects can be increased when Efalizumab is combined with Suvratoxumab.,Suvratoxumab
DB15225,The risk or severity of adverse effects can be increased when Efalizumab is combined with Mitazalimab.,Mitazalimab
DB15252,The risk or severity of adverse effects can be increased when Efalizumab is combined with Nemolizumab.,Nemolizumab
DB15277,The risk or severity of adverse effects can be increased when Efalizumab is combined with Gedivumab.,Gedivumab
DB15336,The risk or severity of adverse effects can be increased when Efalizumab is combined with Valanafusp alfa.,Valanafusp alfa
DB15349,The risk or severity of adverse effects can be increased when Efalizumab is combined with Sofituzumab vedotin.,Sofituzumab vedotin
DB15354,The risk or severity of adverse effects can be increased when Efalizumab is combined with Evinacumab.,Evinacumab
DB15363,The risk or severity of adverse effects can be increased when Efalizumab is combined with Istiratumab.,Istiratumab
DB15383,The risk or severity of adverse effects can be increased when Efalizumab is combined with Pidilizumab.,Pidilizumab
DB15397,The risk or severity of adverse effects can be increased when Efalizumab is combined with GMA-161.,GMA-161
DB15409,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ladiratuzumab vedotin.,Ladiratuzumab vedotin
DB15415,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tomaralimab.,Tomaralimab
DB15428,The risk or severity of adverse effects can be increased when Efalizumab is combined with Vesencumab.,Vesencumab
DB15432,The risk or severity of adverse effects can be increased when Efalizumab is combined with Pinatuzumab vedotin.,Pinatuzumab vedotin
DB15441,The risk or severity of adverse effects can be increased when Efalizumab is combined with Lulizumab pegol.,Lulizumab pegol
DB15443,The risk or severity of adverse effects can be increased when Efalizumab is combined with Lorukafusp alfa.,Lorukafusp alfa
DB15453,The risk or severity of adverse effects can be increased when Efalizumab is combined with Naratuximab emtansine.,Naratuximab emtansine
DB14004,The risk or severity of adverse effects can be increased when Efalizumab is combined with Tildrakizumab.,Tildrakizumab
DB05679,The risk or severity of adverse effects can be increased when Efalizumab is combined with Ustekinumab.,Ustekinumab
DB15559,The risk or severity of adverse effects can be increased when Efalizumab is combined with Zenocutuzumab.,Zenocutuzumab
DB00091,Efalizumab may increase the immunosuppressive activities of Cyclosporine.,Cyclosporine
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Efalizumab.","Ebola Zaire vaccine (live, attenuated)"
DB14513,The serum concentration of Magnesium can be decreased when it is combined with Efalizumab.,Magnesium
DB01601,The serum concentration of Efalizumab can be increased when it is combined with Lopinavir.,Lopinavir
DB12530,The risk or severity of infection can be increased when Efalizumab is combined with Inebilizumab.,Inebilizumab
DB06643,The risk or severity of adverse effects can be increased when Denosumab is combined with Antithymocyte immunoglobulin (rabbit).,Denosumab
DB00005,The risk or severity of adverse effects can be increased when Etanercept is combined with Antithymocyte immunoglobulin (rabbit).,Etanercept
DB00008,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Antithymocyte immunoglobulin (rabbit).,Peginterferon alfa-2a
DB00011,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Antithymocyte immunoglobulin (rabbit).,Interferon alfa-n1
DB00018,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Antithymocyte immunoglobulin (rabbit).,Interferon alfa-n3
DB00022,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Antithymocyte immunoglobulin (rabbit).,Peginterferon alfa-2b
DB00026,The risk or severity of adverse effects can be increased when Anakinra is combined with Antithymocyte immunoglobulin (rabbit).,Anakinra
DB00033,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Antithymocyte immunoglobulin (rabbit).,Interferon gamma-1b
DB00034,"The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Antithymocyte immunoglobulin (rabbit).","Interferon alfa-2a, Recombinant"
DB00041,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Antithymocyte immunoglobulin (rabbit).,Aldesleukin
DB00051,The risk or severity of adverse effects can be increased when Adalimumab is combined with Antithymocyte immunoglobulin (rabbit).,Adalimumab
DB00056,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Antithymocyte immunoglobulin (rabbit).,Gemtuzumab ozogamicin
DB00059,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Antithymocyte immunoglobulin (rabbit).,Pegaspargase
DB00065,The risk or severity of adverse effects can be increased when Infliximab is combined with Antithymocyte immunoglobulin (rabbit).,Infliximab
DB00068,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Antithymocyte immunoglobulin (rabbit).,Interferon beta-1b
DB00069,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Antithymocyte immunoglobulin (rabbit).,Interferon alfacon-1
DB00073,The risk or severity of adverse effects can be increased when Rituximab is combined with Antithymocyte immunoglobulin (rabbit).,Rituximab
DB00074,The risk or severity of adverse effects can be increased when Basiliximab is combined with Antithymocyte immunoglobulin (rabbit).,Basiliximab
DB00075,The risk or severity of adverse effects can be increased when Muromonab is combined with Antithymocyte immunoglobulin (rabbit).,Muromonab
DB00078,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Antithymocyte immunoglobulin (rabbit).,Ibritumomab tiuxetan
DB00081,The risk or severity of adverse effects can be increased when Tositumomab is combined with Antithymocyte immunoglobulin (rabbit).,Tositumomab
DB00087,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Antithymocyte immunoglobulin (rabbit).,Alemtuzumab
DB00092,The risk or severity of adverse effects can be increased when Alefacept is combined with Antithymocyte immunoglobulin (rabbit).,Alefacept
DB00095,The risk or severity of adverse effects can be increased when Efalizumab is combined with Antithymocyte immunoglobulin (rabbit).,Efalizumab
DB00105,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Interferon alfa-2b.,Interferon alfa-2b
DB00111,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Daclizumab.,Daclizumab
DB00112,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bevacizumab.,Bevacizumab
DB00120,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Phenylalanine.,Phenylalanine
DB00180,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Flunisolide.,Flunisolide
DB00188,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bortezomib.,Bortezomib
DB00242,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cladribine.,Cladribine
DB00262,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Carmustine.,Carmustine
DB00276,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Amsacrine.,Amsacrine
DB00290,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bleomycin.,Bleomycin
DB00291,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Chlorambucil.,Chlorambucil
DB00293,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Raltitrexed.,Raltitrexed
DB00305,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mitomycin.,Mitomycin
DB00307,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bexarotene.,Bexarotene
DB00309,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Vindesine.,Vindesine
DB00322,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Floxuridine.,Floxuridine
DB00328,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Indomethacin.,Indomethacin
DB00352,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tioguanine.,Tioguanine
DB00361,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Vinorelbine.,Vinorelbine
DB00380,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dexrazoxane.,Dexrazoxane
DB00394,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Beclomethasone dipropionate.,Beclomethasone dipropionate
DB00398,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sorafenib.,Sorafenib
DB00428,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Streptozocin.,Streptozocin
DB00432,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Trifluridine.,Trifluridine
DB00441,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Gemcitabine.,Gemcitabine
DB00443,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Betamethasone.,Betamethasone
DB00444,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Teniposide.,Teniposide
DB00445,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Epirubicin.,Epirubicin
DB00446,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Chloramphenicol.,Chloramphenicol
DB00480,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lenalidomide.,Lenalidomide
DB00488,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Altretamine.,Altretamine
DB00495,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Zidovudine.,Zidovudine
DB00515,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cisplatin.,Cisplatin
DB00526,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Oxaliplatin.,Oxaliplatin
DB00531,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cyclophosphamide.,Cyclophosphamide
DB00541,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Vincristine.,Vincristine
DB00544,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluorouracil.,Fluorouracil
DB00550,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Propylthiouracil.,Propylthiouracil
DB00552,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pentostatin.,Pentostatin
DB00563,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Methotrexate.,Methotrexate
DB00564,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Carbamazepine.,Carbamazepine
DB00570,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Vinblastine.,Vinblastine
DB00588,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluticasone propionate.,Fluticasone propionate
DB00591,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluocinolone acetonide.,Fluocinolone acetonide
DB00601,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Linezolid.,Linezolid
DB00619,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Imatinib.,Imatinib
DB00620,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Triamcinolone.,Triamcinolone
DB00631,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Clofarabine.,Clofarabine
DB00635,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Prednisone.,Prednisone
DB00642,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pemetrexed.,Pemetrexed
DB00687,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fludrocortisone.,Fludrocortisone
DB00688,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mycophenolate mofetil.,Mycophenolate mofetil
DB00694,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Daunorubicin.,Daunorubicin
DB00755,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tretinoin.,Tretinoin
DB00762,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Irinotecan.,Irinotecan
DB00763,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Methimazole.,Methimazole
DB00764,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mometasone.,Mometasone
DB00773,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Etoposide.,Etoposide
DB00795,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sulfasalazine.,Sulfasalazine
DB00851,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dacarbazine.,Dacarbazine
DB00853,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Temozolomide.,Temozolomide
DB00859,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Penicillamine.,Penicillamine
DB00860,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Prednisolone.,Prednisolone
DB00877,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sirolimus.,Sirolimus
DB00888,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mechlorethamine.,Mechlorethamine
DB00928,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Azacitidine.,Azacitidine
DB00958,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Carboplatin.,Carboplatin
DB00959,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Methylprednisolone.,Methylprednisolone
DB00970,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dactinomycin.,Dactinomycin
DB00987,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cytarabine.,Cytarabine
DB00993,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Azathioprine.,Azathioprine
DB00997,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Doxorubicin.,Doxorubicin
DB01005,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Hydroxyurea.,Hydroxyurea
DB01008,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Busulfan.,Busulfan
DB01024,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mycophenolic acid.,Mycophenolic acid
DB01030,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Topotecan.,Topotecan
DB01033,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mercaptopurine.,Mercaptopurine
DB01041,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Thalidomide.,Thalidomide
DB01042,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Melphalan.,Melphalan
DB01073,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fludarabine.,Fludarabine
DB01099,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Flucytosine.,Flucytosine
DB01101,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Capecitabine.,Capecitabine
DB01108,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Trilostane.,Trilostane
DB01168,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Procarbazine.,Procarbazine
DB01169,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Arsenic trioxide.,Arsenic trioxide
DB01177,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Idarubicin.,Idarubicin
DB01181,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ifosfamide.,Ifosfamide
DB01196,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Estramustine.,Estramustine
DB01204,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mitoxantrone.,Mitoxantrone
DB01206,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lomustine.,Lomustine
DB01222,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Budesonide.,Budesonide
DB01229,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Paclitaxel.,Paclitaxel
DB01234,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dexamethasone.,Dexamethasone
DB01248,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Docetaxel.,Docetaxel
DB01254,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dasatinib.,Dasatinib
DB01257,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Eculizumab.,Eculizumab
DB01262,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Decitabine.,Decitabine
DB01268,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sunitinib.,Sunitinib
DB01280,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Nelarabine.,Nelarabine
DB01281,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Abatacept.,Abatacept
DB01285,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Corticotropin.,Corticotropin
DB01380,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cortisone acetate.,Cortisone acetate
DB01384,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Paramethasone.,Paramethasone
DB01394,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Colchicine.,Colchicine
DB01410,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ciclesonide.,Ciclesonide
DB01423,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Stepronin.,Stepronin
DB01590,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Everolimus.,Everolimus
DB01611,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Hydroxychloroquine.,Hydroxychloroquine
DB01816,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Castanospermine.,Castanospermine
DB02546,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Vorinostat.,Vorinostat
DB02806,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with 2-Methoxyethanol.,2-Methoxyethanol
DB03523,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Brequinar.,Brequinar
DB04572,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Thiotepa.,Thiotepa
DB04630,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Aldosterone.,Aldosterone
DB04845,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ixabepilone.,Ixabepilone
DB04868,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Nilotinib.,Nilotinib
DB04951,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pirfenidone.,Pirfenidone
DB04956,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Afelimomab.,Afelimomab
DB05015,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Belinostat.,Belinostat
DB05109,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Trabectedin.,Trabectedin
DB05258,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Interferon alfa.,Interferon alfa
DB05259,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Glatiramer.,Glatiramer
DB05260,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Gallium nitrate.,Gallium nitrate
DB05459,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Briakinumab.,Briakinumab
DB05472,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with omega interferon.,omega interferon
DB05676,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Apremilast.,Apremilast
DB05773,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Trastuzumab emtansine.,Trastuzumab emtansine
DB06168,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Canakinumab.,Canakinumab
DB06273,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tocilizumab.,Tocilizumab
DB06287,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Temsirolimus.,Temsirolimus
DB06372,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Rilonacept.,Rilonacept
DB06589,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pazopanib.,Pazopanib
DB06603,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Panobinostat.,Panobinostat
DB06612,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mepolizumab.,Mepolizumab
DB06616,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bosutinib.,Bosutinib
DB06662,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Abetimus.,Abetimus
DB06674,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Golimumab.,Golimumab
DB06681,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Belatacept.,Belatacept
DB06769,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bendamustine.,Bendamustine
DB06772,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cabazitaxel.,Cabazitaxel
DB06813,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pralatrexate.,Pralatrexate
DB08059,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Wortmannin.,Wortmannin
DB08870,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Brentuximab vedotin.,Brentuximab vedotin
DB08871,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Eribulin.,Eribulin
DB08877,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ruxolitinib.,Ruxolitinib
DB08879,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Belimumab.,Belimumab
DB08880,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Teriflunomide.,Teriflunomide
DB08889,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Carfilzomib.,Carfilzomib
DB08901,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ponatinib.,Ponatinib
DB08904,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Certolizumab pegol.,Certolizumab pegol
DB08906,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluticasone furoate.,Fluticasone furoate
DB08908,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dimethyl fumarate.,Dimethyl fumarate
DB08910,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pomalidomide.,Pomalidomide
DB08935,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Obinutuzumab.,Obinutuzumab
DB08970,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluprednidene.,Fluprednidene
DB08971,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluocortolone.,Fluocortolone
DB09029,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Secukinumab.,Secukinumab
DB09033,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Vedolizumab.,Vedolizumab
DB09036,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Siltuximab.,Siltuximab
DB09052,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Blinatumomab.,Blinatumomab
DB09053,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ibrutinib.,Ibrutinib
DB09054,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Idelalisib.,Idelalisib
DB09073,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Palbociclib.,Palbociclib
DB09074,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Olaparib.,Olaparib
DB09077,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dinutuximab.,Dinutuximab
DB09082,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Vilanterol.,Vilanterol
DB09091,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tixocortol.,Tixocortol
DB09122,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Peginterferon beta-1a.,Peginterferon beta-1a
DB09312,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Antilymphocyte immunoglobulin (horse).,Antilymphocyte immunoglobulin (horse)
DB09378,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluprednisolone.,Fluprednisolone
DB09383,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Meprednisone.,Meprednisone
DB11466,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tepoxalin.,Tepoxalin
DB11487,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dexamethasone isonicotinate.,Dexamethasone isonicotinate
DB11529,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Melengestrol.,Melengestrol
DB11569,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ixekizumab.,Ixekizumab
DB11580,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ravulizumab.,Ravulizumab
DB11616,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pirarubicin.,Pirarubicin
DB11693,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Voclosporin.,Voclosporin
DB11708,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Peficitinib.,Peficitinib
DB11750,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Clobetasol.,Clobetasol
DB11767,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sarilumab.,Sarilumab
DB11776,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Brodalumab.,Brodalumab
DB11803,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sirukumab.,Sirukumab
DB11817,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Baricitinib.,Baricitinib
DB11834,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Guselkumab.,Guselkumab
DB11921,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Deflazacort.,Deflazacort
DB12025,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Triptolide.,Triptolide
DB12371,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Siponimod.,Siponimod
DB12612,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ozanimod.,Ozanimod
DB12617,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mizoribine.,Mizoribine
DB12692,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Gusperimus.,Gusperimus
DB12814,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cepeginterferon alfa-2B.,Cepeginterferon alfa-2B
DB12902,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Trofosfamide.,Trofosfamide
DB12947,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Doxifluridine.,Doxifluridine
DB12991,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Deoxyspergualin.,Deoxyspergualin
DB12996,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Acteoside.,Acteoside
DB13003,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cortivazol.,Cortivazol
DB13014,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Hypericin.,Hypericin
DB13068,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.,9-(N-methyl-L-isoleucine)-cyclosporin A
DB13208,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Prednylidene.,Prednylidene
DB13223,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluocortin.,Fluocortin
DB13241,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Begelomab.,Begelomab
DB13491,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluperolone.,Fluperolone
DB13664,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Formocortal.,Formocortal
DB13728,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Halometasone.,Halometasone
DB13843,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cloprednol.,Cloprednol
DB13856,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluclorolone.,Fluclorolone
DB13867,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluticasone.,Fluticasone
DB14066,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tetrandrine.,Tetrandrine
DB14219,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Monomethyl fumarate.,Monomethyl fumarate
DB14512,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mometasone furoate.,Mometasone furoate
DB14538,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Hydrocortisone aceponate.,Hydrocortisone aceponate
DB14539,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Hydrocortisone acetate.,Hydrocortisone acetate
DB14545,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Hydrocortisone succinate.,Hydrocortisone succinate
DB14724,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Emapalumab.,Emapalumab
DB14762,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Risankizumab.,Risankizumab
DB14919,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Rozanolixizumab.,Rozanolixizumab
DB15253,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bleselumab.,Bleselumab
DB00108,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Natalizumab.,Natalizumab
DB00337,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Antithymocyte immunoglobulin (rabbit).,Pimecrolimus
DB01656,Roflumilast may increase the immunosuppressive activities of Antithymocyte immunoglobulin (rabbit).,Roflumilast
DB06688,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Sipuleucel-T
DB01015,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Antithymocyte immunoglobulin (rabbit).,Sulfamethoxazole
DB00255,Diethylstilbestrol may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Diethylstilbestrol
DB00269,Chlorotrianisene may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Chlorotrianisene
DB00286,Conjugated estrogens may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Conjugated estrogens
DB00655,Estrone may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Estrone
DB00783,Estradiol may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Estradiol
DB00890,Dienestrol may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Dienestrol
DB00977,Ethinylestradiol may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Ethinylestradiol
DB01357,Mestranol may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Mestranol
DB04573,Estriol may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Estriol
DB04574,Estrone sulfate may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Estrone sulfate
DB04575,Quinestrol may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Quinestrol
DB07931,Hexestrol may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Hexestrol
DB09070,Tibolone may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Tibolone
DB09317,"Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).","Synthetic Conjugated Estrogens, A"
DB09318,"Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).","Synthetic Conjugated Estrogens, B"
DB09369,Polyestradiol phosphate may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Polyestradiol phosphate
DB09381,Esterified estrogens may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Esterified estrogens
DB11478,Zeranol may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Zeranol
DB11674,Equol may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Equol
DB12487,Promestriene may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Promestriene
DB13143,Methallenestril may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Methallenestril
DB13386,Epimestrol may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Epimestrol
DB13418,Moxestrol may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Moxestrol
DB13952,Estradiol acetate may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Estradiol acetate
DB13953,Estradiol benzoate may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Estradiol benzoate
DB13954,Estradiol cypionate may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Estradiol cypionate
DB13956,Estradiol valerate may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Estradiol valerate
DB15334,Biochanin A may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Biochanin A
DB15335,Formononetin may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit).,Formononetin
DB01097,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Leflunomide.,Leflunomide
DB08895,Antithymocyte immunoglobulin (rabbit) may increase the immunosuppressive activities of Tofacitinib.,Tofacitinib
DB00072,Trastuzumab may increase the neutropenic activities of Antithymocyte immunoglobulin (rabbit).,Trastuzumab
DB08868,Antithymocyte immunoglobulin (rabbit) may increase the immunosuppressive activities of Fingolimod.,Fingolimod
DB00864,Tacrolimus may increase the immunosuppressive activities of Antithymocyte immunoglobulin (rabbit).,Tacrolimus
DB04914,The therapeutic efficacy of G17DT can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,G17DT
DB05144,The therapeutic efficacy of PEV3A can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,PEV3A
DB05325,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,INGN 225
DB05374,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Rindopepimut
DB05440,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,SRP 299
DB05942,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,GI-5005
DB06400,The therapeutic efficacy of Vitespen can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Vitespen
DB06584,The therapeutic efficacy of TG4010 can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,TG4010
DB09057,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Anthrax immune globulin human
DB10062,"The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).","Rabies virus inactivated antigen, B"
DB10076,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen
DB10276,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Rotavirus vaccine
DB10283,"The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).","Rabies virus inactivated antigen, A"
DB10342,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen
DB10583,The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Clostridium tetani toxoid antigen (formaldehyde inactivated)
DB10584,The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
DB10600,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated)
DB10769,The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)
DB10794,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated)
DB10803,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Typhoid Vi polysaccharide vaccine
DB10989,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Hepatitis A Vaccine
DB10990,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
DB11038,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated)
DB11040,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated)
DB11041,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)
DB11044,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated)
DB11603,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Human rabies virus immune globulin
DB11627,The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Hepatitis B Vaccine (Recombinant)
DB12568,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Tecemotide
DB14022,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Typhoid vaccine
DB14384,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated)
DB14385,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)
DB14394,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen
DB14445,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated)
DB14449,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen
DB14619,The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated)
DB14620,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated)
DB14711,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Vaccinia virus strain new york city board of health live antigen
DB15274,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Pertussis vaccine
DB15461,The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Yersinia pestis 195/p antigen (formaldehyde inactivated)
DB13924,The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Varicella Zoster Vaccine (Recombinant)
DB15483,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).,Modified vaccinia ankara
DB11988,Ocrelizumab may increase the immunosuppressive activities of Antithymocyte immunoglobulin (rabbit).,Ocrelizumab
DB10317,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Antithymocyte immunoglobulin (rabbit).,Rubella virus vaccine
DB10318,The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Antithymocyte immunoglobulin (rabbit).,Varicella Zoster Vaccine (Live/attenuated)
DB10343,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Antithymocyte immunoglobulin (rabbit).,Bacillus calmette-guerin substrain tice live antigen
DB10804,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Antithymocyte immunoglobulin (rabbit).,Bacillus calmette-guerin substrain connaught live antigen
DB10805,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Antithymocyte immunoglobulin (rabbit).,Yellow Fever Vaccine
DB11003,The risk or severity of infection can be increased when Anthrax vaccine is combined with Antithymocyte immunoglobulin (rabbit).,Anthrax vaccine
DB11050,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Antithymocyte immunoglobulin (rabbit).,Typhoid Vaccine Live
DB12386,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Antithymocyte immunoglobulin (rabbit).,Bacillus calmette-guerin substrain danish 1331 live antigen
DB12768,The risk or severity of infection can be increased when BCG vaccine is combined with Antithymocyte immunoglobulin (rabbit).,BCG vaccine
DB14409,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Antithymocyte immunoglobulin (rabbit).,Human adenovirus e serotype 4 strain cl-68578 antigen
DB14443,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Antithymocyte immunoglobulin (rabbit).,Vibrio cholerae CVD 103-HgR strain live antigen
DB14685,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Antithymocyte immunoglobulin (rabbit).,Adenovirus type 7 vaccine live
DB00002,The risk or severity of adverse effects can be increased when Cetuximab is combined with Antithymocyte immunoglobulin (rabbit).,Cetuximab
DB00028,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Antithymocyte immunoglobulin (rabbit).,Human immunoglobulin G
DB00043,The risk or severity of adverse effects can be increased when Omalizumab is combined with Antithymocyte immunoglobulin (rabbit).,Omalizumab
DB00054,The risk or severity of adverse effects can be increased when Abciximab is combined with Antithymocyte immunoglobulin (rabbit).,Abciximab
DB00057,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Antithymocyte immunoglobulin (rabbit).,Indium In-111 satumomab pendetide
DB00076,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Antithymocyte immunoglobulin (rabbit).,Digoxin Immune Fab (Ovine)
DB00089,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Antithymocyte immunoglobulin (rabbit).,Capromab pendetide
DB00110,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Palivizumab.,Palivizumab
DB00113,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Technetium Tc-99m arcitumomab.,Technetium Tc-99m arcitumomab
DB01269,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Panitumumab.,Panitumumab
DB01270,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ranibizumab.,Ranibizumab
DB04901,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Galiximab.,Galiximab
DB04949,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pexelizumab.,Pexelizumab
DB04958,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Epratuzumab.,Epratuzumab
DB04962,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bectumomab.,Bectumomab
DB04964,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Oregovomab.,Oregovomab
DB04988,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with IGN311.,IGN311
DB05006,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Adecatumumab.,Adecatumumab
DB05097,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Labetuzumab.,Labetuzumab
DB05101,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Matuzumab.,Matuzumab
DB05111,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fontolizumab.,Fontolizumab
DB05136,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bavituximab.,Bavituximab
DB05139,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with CR002.,CR002
DB05209,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Rozrolimupab.,Rozrolimupab
DB05304,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Girentuximab.,Girentuximab
DB05336,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Obiltoxaximab.,Obiltoxaximab
DB05405,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with XTL-001.,XTL-001
DB05437,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with NAV 1800.,NAV 1800
DB05496,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Otelixizumab.,Otelixizumab
DB05545,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with AMG 108.,AMG 108
DB05550,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Iratumumab.,Iratumumab
DB05555,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Enokizumab.,Enokizumab
DB05578,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ramucirumab.,Ramucirumab
DB05595,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Farletuzumab.,Farletuzumab
DB05656,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Veltuzumab.,Veltuzumab
DB05793,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with PRO-542.,PRO-542
DB05797,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with TNX-901.,TNX-901
DB05889,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Inotuzumab ozogamicin.,Inotuzumab ozogamicin
DB05892,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with RI 624.,RI 624
DB05915,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with MYO-029.,MYO-029
DB05916,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with CT-011.,CT-011
DB05941,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Leronlimab.,Leronlimab
DB05996,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Glembatumumab vedotin.,Glembatumumab vedotin
DB06043,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Olaratumab.,Olaratumab
DB06049,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with IPH 2101.,IPH 2101
DB06050,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with TB-402.,TB-402
DB06081,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Caplacizumab.,Caplacizumab
DB06101,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with IMC-1C11.,IMC-1C11
DB06116,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Eldelumab.,Eldelumab
DB06162,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lumiliximab.,Lumiliximab
DB06186,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ipilimumab.,Ipilimumab
DB06192,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Nimotuzumab.,Nimotuzumab
DB06241,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Clenoliximab.,Clenoliximab
DB06304,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with BIIB015.,BIIB015
DB06305,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sonepcizumab.,Sonepcizumab
DB06310,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Motavizumab.,Motavizumab
DB06317,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Elotuzumab.,Elotuzumab
DB06318,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with AVE9633.,AVE9633
DB06322,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Carotuximab.,Carotuximab
DB06324,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with XmAb 2513.,XmAb 2513
DB06342,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Coltuximab ravtansine.,Coltuximab ravtansine
DB06343,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Teprotumumab.,Teprotumumab
DB06360,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lucatumumab.,Lucatumumab
DB06366,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pertuzumab.,Pertuzumab
DB06371,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Siplizumab.,Siplizumab
DB06467,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Apolizumab.,Apolizumab
DB06474,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sibrotuzumab.,Sibrotuzumab
DB06550,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bivatuzumab.,Bivatuzumab
DB06557,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lerdelimumab.,Lerdelimumab
DB06599,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lexatumumab.,Lexatumumab
DB06602,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Reslizumab.,Reslizumab
DB06606,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Teplizumab.,Teplizumab
DB06607,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Catumaxomab.,Catumaxomab
DB06647,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Volociximab.,Volociximab
DB06650,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ofatumumab.,Ofatumumab
DB08902,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Raxibacumab.,Raxibacumab
DB09035,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Nivolumab.,Nivolumab
DB09037,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pembrolizumab.,Pembrolizumab
DB09045,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dulaglutide.,Dulaglutide
DB09105,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Asfotase alfa.,Asfotase alfa
DB09264,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Idarucizumab.,Idarucizumab
DB09302,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Alirocumab.,Alirocumab
DB09303,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Evolocumab.,Evolocumab
DB09331,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Daratumumab.,Daratumumab
DB09559,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Necitumumab.,Necitumumab
DB11595,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Atezolizumab.,Atezolizumab
DB11604,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tetanus Immune Globulin.,Tetanus Immune Globulin
DB11608,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Eftrenonacog alfa.,Eftrenonacog alfa
DB11621,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Human Varicella-Zoster Immune Globulin.,Human Varicella-Zoster Immune Globulin
DB11646,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Conatumumab.,Conatumumab
DB11657,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tabalumab.,Tabalumab
DB11680,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ficlatuzumab.,Ficlatuzumab
DB11685,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Figitumumab.,Figitumumab
DB11714,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Durvalumab.,Durvalumab
DB11715,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bapineuzumab.,Bapineuzumab
DB11731,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Depatuxizumab mafodotin.,Depatuxizumab mafodotin
DB11746,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Onartuzumab.,Onartuzumab
DB11756,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Solanezumab.,Solanezumab
DB11771,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tremelimumab.,Tremelimumab
DB11826,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lampalizumab.,Lampalizumab
DB11840,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dalotuzumab.,Dalotuzumab
DB11849,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Emibetuzumab.,Emibetuzumab
DB11850,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ublituximab.,Ublituximab
DB11856,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ligelizumab.,Ligelizumab
DB11857,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Seribantumab.,Seribantumab
DB11862,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Landogrozumab.,Landogrozumab
DB11866,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Romosozumab.,Romosozumab
DB11884,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Vadastuximab Talirine.,Vadastuximab Talirine
DB11914,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lebrikizumab.,Lebrikizumab
DB11930,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Varlilumab.,Varlilumab
DB11945,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Avelumab.,Avelumab
DB11959,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Crenezumab.,Crenezumab
DB11972,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Rilotumumab.,Rilotumumab
DB11976,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Anifrolumab.,Anifrolumab
DB12023,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Benralizumab.,Benralizumab
DB12034,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Gantenerumab.,Gantenerumab
DB12053,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Visilizumab.,Visilizumab
DB12077,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Urelumab.,Urelumab
DB12089,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lorvotuzumab mertansine.,Lorvotuzumab mertansine
DB12090,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Patritumab.,Patritumab
DB12102,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fulranumab.,Fulranumab
DB12104,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tarextumab.,Tarextumab
DB12118,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sotatercept.,Sotatercept
DB12119,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Gevokizumab.,Gevokizumab
DB12142,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Duligotuzumab.,Duligotuzumab
DB12152,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Simtuzumab.,Simtuzumab
DB12157,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fasinumab.,Fasinumab
DB12159,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dupilumab.,Dupilumab
DB12169,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tralokinumab.,Tralokinumab
DB12189,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Etrolizumab.,Etrolizumab
DB12202,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Zalutumumab.,Zalutumumab
DB12205,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ganitumab.,Ganitumab
DB12213,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Etaracizumab.,Etaracizumab
DB12240,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Polatuzumab vedotin.,Polatuzumab vedotin
DB12246,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Inclacumab.,Inclacumab
DB12250,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cixutumumab.,Cixutumumab
DB12261,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ascrinvacumab.,Ascrinvacumab
DB12274,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Aducanumab.,Aducanumab
DB12281,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Luspatercept.,Luspatercept
DB12296,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with GS-5745.,GS-5745
DB12317,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Vanucizumab.,Vanucizumab
DB12331,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Labetuzumab govitecan.,Labetuzumab govitecan
DB12335,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tanezumab.,Tanezumab
DB12342,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ensituximab.,Ensituximab
DB12344,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fezakinumab.,Fezakinumab
DB12363,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dusigitumab.,Dusigitumab
DB12396,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fresolimumab.,Fresolimumab
DB12413,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Indusatumab vedotin.,Indusatumab vedotin
DB12456,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bococizumab.,Bococizumab
DB12489,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mirvetuximab Soravtansine.,Mirvetuximab Soravtansine
DB12498,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mogamulizumab.,Mogamulizumab
DB12520,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Plozalizumab.,Plozalizumab
DB12534,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mavrilimumab.,Mavrilimumab
DB12560,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Blosozumab.,Blosozumab
DB12584,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bimagrumab.,Bimagrumab
DB12589,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dacetuzumab.,Dacetuzumab
DB12609,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tovetumab.,Tovetumab
DB12683,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lumretuzumab.,Lumretuzumab
DB12698,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ibalizumab.,Ibalizumab
DB12701,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Intetumumab.,Intetumumab
DB12718,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Carlumab.,Carlumab
DB12734,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Demcizumab.,Demcizumab
DB12773,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sifalimumab.,Sifalimumab
DB12775,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Abituzumab.,Abituzumab
DB12797,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ecromeximab.,Ecromeximab
DB12807,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Naptumomab Estafenatox.,Naptumomab Estafenatox
DB12815,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Crotedumab.,Crotedumab
DB12820,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Concizumab.,Concizumab
DB12826,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Depatuxizumab.,Depatuxizumab
DB12844,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Rontalizumab.,Rontalizumab
DB12845,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Amatuximab.,Amatuximab
DB12849,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Clazakizumab.,Clazakizumab
DB12891,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ozanezumab.,Ozanezumab
DB12893,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sacituzumab govitecan.,Sacituzumab govitecan
DB12917,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bimekizumab.,Bimekizumab
DB12943,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Milatuzumab.,Milatuzumab
DB12976,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Robatumumab.,Robatumumab
DB13017,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Rovalpituzumab Tesirine.,Rovalpituzumab Tesirine
DB13037,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Namilumab.,Namilumab
DB13045,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Racotumomab.,Racotumomab
DB13073,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tregalizumab.,Tregalizumab
DB13127,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Olokizumab.,Olokizumab
DB13140,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bezlotoxumab.,Bezlotoxumab
DB13375,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Edrecolomab.,Edrecolomab
DB13535,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Nebacumab.,Nebacumab
DB13886,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Human cytomegalovirus immune globulin.,Human cytomegalovirus immune globulin
DB13923,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Emicizumab.,Emicizumab
DB13976,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sulesomab.,Sulesomab
DB13979,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Besilesomab.,Besilesomab
DB14012,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Burosumab.,Burosumab
DB14039,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Erenumab.,Erenumab
DB14040,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Eptinezumab.,Eptinezumab
DB14041,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fremanezumab.,Fremanezumab
DB14042,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Galcanezumab.,Galcanezumab
DB14211,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fanolesomab.,Fanolesomab
DB14580,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lecanemab.,Lecanemab
DB14597,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lanadelumab.,Lanadelumab
DB14707,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cemiplimab.,Cemiplimab
DB14776,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Camrelizumab.,Camrelizumab
DB14778,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Setrusumab.,Setrusumab
DB14784,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Gancotamab.,Gancotamab
DB14809,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Anetumab ravtansine.,Anetumab ravtansine
DB14811,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Isatuximab.,Isatuximab
DB14824,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Icrucumab.,Icrucumab
DB14843,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Codrituzumab.,Codrituzumab
DB14864,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Brolucizumab.,Brolucizumab
DB14871,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Xentuzumab.,Xentuzumab
DB14877,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lintuzumab.,Lintuzumab
DB14891,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Vobarilizumab.,Vobarilizumab
DB14897,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Parsatuzumab.,Parsatuzumab
DB14905,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Emactuzumab.,Emactuzumab
DB14907,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bevacizumab zirconium Zr-89.,Bevacizumab zirconium Zr-89
DB14908,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Refanezumab.,Refanezumab
DB14947,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bermekimab.,Bermekimab
DB14952,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pamrevlumab.,Pamrevlumab
DB14959,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Opicinumab.,Opicinumab
DB14962,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Trastuzumab deruxtecan.,Trastuzumab deruxtecan
DB14967,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Margetuximab.,Margetuximab
DB14988,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dalantercept.,Dalantercept
DB14997,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pateclizumab.,Pateclizumab
DB15014,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Gremubamab.,Gremubamab
DB15022,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Apomab.,Apomab
DB15044,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tafasitamab.,Tafasitamab
DB15045,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ipafricept.,Ipafricept
DB15076,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Abrilumab.,Abrilumab
DB15089,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Frovocimab.,Frovocimab
DB15090,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tezepelumab.,Tezepelumab
DB15101,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tigatuzumab.,Tigatuzumab
DB15104,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Telisotuzumab vedotin.,Telisotuzumab vedotin
DB15113,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Utomilumab.,Utomilumab
DB15118,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Zolbetuximab.,Zolbetuximab
DB15135,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ponezumab.,Ponezumab
DB15160,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Asunercept.,Asunercept
DB15172,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Suvratoxumab.,Suvratoxumab
DB15225,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mitazalimab.,Mitazalimab
DB15252,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Nemolizumab.,Nemolizumab
DB15277,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Gedivumab.,Gedivumab
DB15336,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Valanafusp alfa.,Valanafusp alfa
DB15349,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sofituzumab vedotin.,Sofituzumab vedotin
DB15354,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Evinacumab.,Evinacumab
DB15363,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Istiratumab.,Istiratumab
DB15383,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pidilizumab.,Pidilizumab
DB15397,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with GMA-161.,GMA-161
DB15409,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ladiratuzumab vedotin.,Ladiratuzumab vedotin
DB15415,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tomaralimab.,Tomaralimab
DB15428,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Vesencumab.,Vesencumab
DB15432,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pinatuzumab vedotin.,Pinatuzumab vedotin
DB15441,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lulizumab pegol.,Lulizumab pegol
DB15443,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lorukafusp alfa.,Lorukafusp alfa
DB15453,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Naratuximab emtansine.,Naratuximab emtansine
DB14004,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tildrakizumab.,Tildrakizumab
DB05679,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ustekinumab.,Ustekinumab
DB15559,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Zenocutuzumab.,Zenocutuzumab
DB00091,Antithymocyte immunoglobulin (rabbit) may increase the immunosuppressive activities of Cyclosporine.,Cyclosporine
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).","Ebola Zaire vaccine (live, attenuated)"
DB14513,The serum concentration of Magnesium can be decreased when it is combined with Antithymocyte immunoglobulin (rabbit).,Magnesium
DB01601,The serum concentration of Antithymocyte immunoglobulin (rabbit) can be increased when it is combined with Lopinavir.,Lopinavir
DB12530,The risk or severity of infection can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Inebilizumab.,Inebilizumab
DB00290,The risk or severity of pulmonary toxicity can be increased when Filgrastim is combined with Bleomycin.,Bleomycin
DB00531,The risk or severity of pulmonary toxicity can be increased when Filgrastim is combined with Cyclophosphamide.,Cyclophosphamide
DB01030,The risk or severity of neutropenia can be increased when Filgrastim is combined with Topotecan.,Topotecan
DB00309,The risk or severity of peripheral neuropathy can be increased when Filgrastim is combined with Vindesine.,Vindesine
DB00361,The risk or severity of peripheral neuropathy can be increased when Filgrastim is combined with Vinorelbine.,Vinorelbine
DB00541,The risk or severity of peripheral neuropathy can be increased when Filgrastim is combined with Vincristine.,Vincristine
DB00570,The risk or severity of peripheral neuropathy can be increased when Filgrastim is combined with Vinblastine.,Vinblastine
DB05168,The risk or severity of peripheral neuropathy can be increased when Filgrastim is combined with Vintafolide.,Vintafolide
DB11641,The risk or severity of peripheral neuropathy can be increased when Filgrastim is combined with Vinflunine.,Vinflunine
DB13374,The risk or severity of peripheral neuropathy can be increased when Filgrastim is combined with Vincamine.,Vincamine
DB00513,The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Coagulation Factor IX (Recombinant).,Aminocaproic acid
DB00058,Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Coagulation Factor IX (Recombinant).,Alpha-1-proteinase inhibitor
DB00170,Menadione may increase the thrombogenic activities of Coagulation Factor IX (Recombinant).,Menadione
DB00302,Tranexamic acid may increase the thrombogenic activities of Coagulation Factor IX (Recombinant).,Tranexamic acid
DB06692,Aprotinin may increase the thrombogenic activities of Coagulation Factor IX (Recombinant).,Aprotinin
DB11091,Hydrogen peroxide may increase the thrombogenic activities of Coagulation Factor IX (Recombinant).,Hydrogen peroxide
DB13244,Aminomethylbenzoic acid may increase the thrombogenic activities of Coagulation Factor IX (Recombinant).,Aminomethylbenzoic acid
DB13729,Camostat may increase the thrombogenic activities of Coagulation Factor IX (Recombinant).,Camostat
DB12726,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Monteplase.,Monteplase
DB00001,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Lepirudin.,Lepirudin
DB00006,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Bivalirudin.,Bivalirudin
DB00009,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Alteplase.,Alteplase
DB00013,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Urokinase.,Urokinase
DB00015,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Reteplase.,Reteplase
DB00029,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Anistreplase.,Anistreplase
DB00031,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Tenecteplase.,Tenecteplase
DB00054,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Abciximab.,Abciximab
DB00055,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Drotrecogin alfa.,Drotrecogin alfa
DB00086,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Streptokinase.,Streptokinase
DB00266,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Dicoumarol.,Dicoumarol
DB00278,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Argatroban.,Argatroban
DB00407,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Ardeparin.,Ardeparin
DB00498,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Phenindione.,Phenindione
DB00569,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Fondaparinux.,Fondaparinux
DB00682,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Warfarin.,Warfarin
DB00686,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Pentosan polysulfate.,Pentosan polysulfate
DB00945,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Acetylsalicylic acid.,Acetylsalicylic acid
DB00946,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Phenprocoumon.,Phenprocoumon
DB00975,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Dipyridamole.,Dipyridamole
DB01088,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Iloprost.,Iloprost
DB01109,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Heparin.,Heparin
DB01225,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Enoxaparin.,Enoxaparin
DB01240,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Epoprostenol.,Epoprostenol
DB01418,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Acenocoumarol.,Acenocoumarol
DB03410,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with 4-hydroxycoumarin.,4-hydroxycoumarin
DB04665,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Coumarin.,Coumarin
DB04898,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Ximelagatran.,Ximelagatran
DB04925,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Desmoteplase.,Desmoteplase
DB04932,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Defibrotide.,Defibrotide
DB05099,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Ancrod.,Ancrod
DB05229,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Beraprost.,Beraprost
DB05254,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Fibrinolysin.,Fibrinolysin
DB06209,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Prasugrel.,Prasugrel
DB06228,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Rivaroxaban.,Rivaroxaban
DB06271,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Sulodexide.,Sulodexide
DB06406,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Idraparinux.,Idraparinux
DB06441,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Cangrelor.,Cangrelor
DB06543,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Astaxanthin.,Astaxanthin
DB06605,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Apixaban.,Apixaban
DB06635,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Otamixaban.,Otamixaban
DB06679,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Amediplase.,Amediplase
DB06695,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Dabigatran etexilate.,Dabigatran etexilate
DB06754,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Danaparoid.,Danaparoid
DB06779,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Dalteparin.,Dalteparin
DB06822,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Tinzaparin.,Tinzaparin
DB07767,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Ferulic acid.,Ferulic acid
DB08496,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with (R)-warfarin.,(R)-warfarin
DB08794,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Ethyl biscoumacetate.,Ethyl biscoumacetate
DB08813,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Nadroparin.,Nadroparin
DB08814,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Triflusal.,Triflusal
DB08816,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Ticagrelor.,Ticagrelor
DB08994,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Ditazole.,Ditazole
DB09030,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Vorapaxar.,Vorapaxar
DB09075,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Edoxaban.,Edoxaban
DB09125,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Potassium citrate.,Potassium citrate
DB09154,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Sodium citrate.,Sodium citrate
DB09255,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Dextran.,Dextran
DB09258,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Bemiparin.,Bemiparin
DB09259,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Reviparin.,Reviparin
DB09260,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Parnaparin.,Parnaparin
DB09261,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Certoparin.,Certoparin
DB11095,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Desirudin.,Desirudin
DB11154,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Zinc citrate.,Zinc citrate
DB11166,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Antithrombin Alfa.,Antithrombin Alfa
DB11312,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Protein C.,Protein C
DB11598,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Antithrombin III human.,Antithrombin III human
DB11984,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Letaxaban.,Letaxaban
DB12289,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Darexaban.,Darexaban
DB12364,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Betrixaban.,Betrixaban
DB12598,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Nafamostat.,Nafamostat
DB12831,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Gabexate.,Gabexate
DB13136,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Fluindione.,Fluindione
DB13149,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Protein S human.,Protein S human
DB13199,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Brinase.,Brinase
DB13275,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Clorindione.,Clorindione
DB13347,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Diphenadione.,Diphenadione
DB13451,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Tioclomarol.,Tioclomarol
DB13616,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Melagatran.,Melagatran
DB13646,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Saruplase.,Saruplase
DB14055,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with (S)-Warfarin.,(S)-Warfarin
DB14094,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Tocopherylquinone.,Tocopherylquinone
DB14598,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Edetate calcium disodium anhydrous.,Edetate calcium disodium anhydrous
DB14726,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Dabigatran.,Dabigatran
DB06294,The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Semuloparin.,Semuloparin
DB00608,The therapeutic efficacy of Agalsidase beta can be decreased when used in combination with Chloroquine.,Chloroquine
DB00798,The therapeutic efficacy of Agalsidase beta can be decreased when used in combination with Gentamicin.,Gentamicin
DB01118,The therapeutic efficacy of Agalsidase beta can be decreased when used in combination with Amiodarone.,Amiodarone
DB00012,The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Octreotide.,Darbepoetin alfa
DB00016,The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Octreotide.,Erythropoietin
DB08894,The risk or severity of Thrombosis can be increased when Peginesatide is combined with Octreotide.,Peginesatide
DB09107,The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Octreotide.,Methoxy polyethylene glycol-epoetin beta
DB08827,The metabolism of Octreotide can be decreased when combined with Lomitapide.,Lomitapide
DB01200,The serum concentration of Bromocriptine can be increased when it is combined with Octreotide.,Bromocriptine
DB09063,Octreotide may increase the bradycardic activities of Ceritinib.,Ceritinib
DB09083,Octreotide may increase the bradycardic activities of Ivabradine.,Ivabradine
DB00082,The risk or severity of increased transaminases can be increased when Octreotide is combined with Pegvisomant.,Pegvisomant
DB08877,Ruxolitinib may increase the bradycardic activities of Octreotide.,Ruxolitinib
DB09039,The metabolism of Eliglustat can be decreased when combined with Octreotide.,Eliglustat
DB09053,The metabolism of Ibrutinib can be decreased when combined with Octreotide.,Ibrutinib
DB01166,The metabolism of Cilostazol can be decreased when combined with Octreotide.,Cilostazol
DB01394,The metabolism of Colchicine can be decreased when combined with Octreotide.,Colchicine
DB00813,The metabolism of Fentanyl can be decreased when combined with Octreotide.,Fentanyl
DB04946,The metabolism of Iloperidone can be decreased when combined with Octreotide.,Iloperidone
DB01256,The metabolism of Retapamulin can be decreased when combined with Octreotide.,Retapamulin
DB08895,The metabolism of Tofacitinib can be decreased when combined with Octreotide.,Tofacitinib
DB00862,The metabolism of Vardenafil can be decreased when combined with Octreotide.,Vardenafil
DB00402,The metabolism of Eszopiclone can be decreased when combined with Octreotide.,Eszopiclone
DB01198,The metabolism of Zopiclone can be decreased when combined with Octreotide.,Zopiclone
DB00227,The metabolism of Lovastatin can be decreased when combined with Octreotide.,Lovastatin
DB00346,The metabolism of Alfuzosin can be decreased when combined with Octreotide.,Alfuzosin
DB00404,The metabolism of Alprazolam can be decreased when combined with Octreotide.,Alprazolam
DB00682,The serum concentration of Warfarin can be increased when it is combined with Octreotide.,Warfarin
DB01418,The serum concentration of Acenocoumarol can be increased when it is combined with Octreotide.,Acenocoumarol
DB08496,The serum concentration of (R)-warfarin can be increased when it is combined with Octreotide.,(R)-warfarin
DB08735,"The serum concentration of R,S-Warfarin alcohol can be increased when it is combined with Octreotide.","R,S-Warfarin alcohol"
DB08736,"The serum concentration of S,R-Warfarin alcohol can be increased when it is combined with Octreotide.","S,R-Warfarin alcohol"
DB14055,The serum concentration of (S)-Warfarin can be increased when it is combined with Octreotide.,(S)-Warfarin
DB00683,The serum concentration of Midazolam can be increased when it is combined with Octreotide.,Midazolam
DB00864,The serum concentration of Tacrolimus can be increased when it is combined with Octreotide.,Tacrolimus
DB01076,The metabolism of Atorvastatin can be decreased when combined with Octreotide.,Atorvastatin
DB00091,The serum concentration of Cyclosporine can be decreased when it is combined with Octreotide.,Cyclosporine
DB00030,The therapeutic efficacy of Insulin human can be decreased when used in combination with Octreotide.,Insulin human
DB00046,The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Octreotide.,Insulin lispro
DB00047,The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Octreotide.,Insulin glargine
DB00071,The therapeutic efficacy of Insulin pork can be decreased when used in combination with Octreotide.,Insulin pork
DB00197,The therapeutic efficacy of Troglitazone can be decreased when used in combination with Octreotide.,Troglitazone
DB00222,The therapeutic efficacy of Glimepiride can be decreased when used in combination with Octreotide.,Glimepiride
DB00284,The therapeutic efficacy of Acarbose can be decreased when used in combination with Octreotide.,Acarbose
DB00359,The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Octreotide.,Sulfadiazine
DB00412,The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Octreotide.,Rosiglitazone
DB00414,The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Octreotide.,Acetohexamide
DB00491,The therapeutic efficacy of Miglitol can be decreased when used in combination with Octreotide.,Miglitol
DB00672,The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Octreotide.,Chlorpropamide
DB00731,The therapeutic efficacy of Nateglinide can be decreased when used in combination with Octreotide.,Nateglinide
DB00839,The therapeutic efficacy of Tolazamide can be decreased when used in combination with Octreotide.,Tolazamide
DB00912,The therapeutic efficacy of Repaglinide can be decreased when used in combination with Octreotide.,Repaglinide
DB00914,The therapeutic efficacy of Phenformin can be decreased when used in combination with Octreotide.,Phenformin
DB01015,The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Octreotide.,Sulfamethoxazole
DB01067,The therapeutic efficacy of Glipizide can be decreased when used in combination with Octreotide.,Glipizide
DB01120,The therapeutic efficacy of Gliclazide can be decreased when used in combination with Octreotide.,Gliclazide
DB01124,The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Octreotide.,Tolbutamide
DB01132,The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Octreotide.,Pioglitazone
DB01251,The therapeutic efficacy of Gliquidone can be decreased when used in combination with Octreotide.,Gliquidone
DB01252,The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Octreotide.,Mitiglinide
DB01261,The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Octreotide.,Sitagliptin
DB01276,The therapeutic efficacy of Exenatide can be decreased when used in combination with Octreotide.,Exenatide
DB01277,The therapeutic efficacy of Mecasermin can be decreased when used in combination with Octreotide.,Mecasermin
DB01278,The therapeutic efficacy of Pramlintide can be decreased when used in combination with Octreotide.,Pramlintide
DB01289,The therapeutic efficacy of Glisoxepide can be decreased when used in combination with Octreotide.,Glisoxepide
DB01306,The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Octreotide.,Insulin aspart
DB01307,The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Octreotide.,Insulin detemir
DB01309,The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Octreotide.,Insulin glulisine
DB01382,The therapeutic efficacy of Glymidine can be decreased when used in combination with Octreotide.,Glymidine
DB01700,The therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Octreotide.,AICA ribonucleotide
DB04830,The therapeutic efficacy of Buformin can be decreased when used in combination with Octreotide.,Buformin
DB04876,The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Octreotide.,Vildagliptin
DB04878,The therapeutic efficacy of Voglibose can be decreased when used in combination with Octreotide.,Voglibose
DB05115,The therapeutic efficacy of NN344 can be decreased when used in combination with Octreotide.,NN344
DB05819,The therapeutic efficacy of NBI-6024 can be decreased when used in combination with Octreotide.,NBI-6024
DB06011,The therapeutic efficacy of AMG-222 can be decreased when used in combination with Octreotide.,AMG-222
DB06127,The therapeutic efficacy of Bisegliptin can be decreased when used in combination with Octreotide.,Bisegliptin
DB06203,The therapeutic efficacy of Alogliptin can be decreased when used in combination with Octreotide.,Alogliptin
DB06292,The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Octreotide.,Dapagliflozin
DB06335,The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Octreotide.,Saxagliptin
DB06655,The therapeutic efficacy of Liraglutide can be decreased when used in combination with Octreotide.,Liraglutide
DB08382,The therapeutic efficacy of Gosogliptin can be decreased when used in combination with Octreotide.,Gosogliptin
DB08962,The therapeutic efficacy of Glibornuride can be decreased when used in combination with Octreotide.,Glibornuride
DB09022,The therapeutic efficacy of Benfluorex can be decreased when used in combination with Octreotide.,Benfluorex
DB09038,The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Octreotide.,Empagliflozin
DB09043,The therapeutic efficacy of Albiglutide can be decreased when used in combination with Octreotide.,Albiglutide
DB09045,The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Octreotide.,Dulaglutide
DB09198,The therapeutic efficacy of Lobeglitazone can be decreased when used in combination with Octreotide.,Lobeglitazone
DB09199,The therapeutic efficacy of Netoglitazone can be decreased when used in combination with Octreotide.,Netoglitazone
DB09200,The therapeutic efficacy of Rivoglitazone can be decreased when used in combination with Octreotide.,Rivoglitazone
DB09201,The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Octreotide.,Ciglitazone
DB09265,The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Octreotide.,Lixisenatide
DB09456,The therapeutic efficacy of Insulin beef can be decreased when used in combination with Octreotide.,Insulin beef
DB09564,The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Octreotide.,Insulin degludec
DB11567,The therapeutic efficacy of Insulin peglispro can be decreased when used in combination with Octreotide.,Insulin peglispro
DB11568,The therapeutic efficacy of Insulin tregopil can be decreased when used in combination with Octreotide.,Insulin tregopil
DB11698,The therapeutic efficacy of Ipragliflozin can be decreased when used in combination with Octreotide.,Ipragliflozin
DB11723,The therapeutic efficacy of Dutogliptin can be decreased when used in combination with Octreotide.,Dutogliptin
DB11780,The therapeutic efficacy of Allicin can be decreased when used in combination with Octreotide.,Allicin
DB11824,The therapeutic efficacy of Tofogliflozin can be decreased when used in combination with Octreotide.,Tofogliflozin
DB11898,"The therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Octreotide.","2,4-thiazolidinedione"
DB11950,The therapeutic efficacy of Teneligliptin can be decreased when used in combination with Octreotide.,Teneligliptin
DB11992,The therapeutic efficacy of Omarigliptin can be decreased when used in combination with Octreotide.,Omarigliptin
DB12268,The therapeutic efficacy of Carmegliptin can be decreased when used in combination with Octreotide.,Carmegliptin
DB12412,The therapeutic efficacy of Gemigliptin can be decreased when used in combination with Octreotide.,Gemigliptin
DB12417,The therapeutic efficacy of Anagliptin can be decreased when used in combination with Octreotide.,Anagliptin
DB12625,The therapeutic efficacy of Evogliptin can be decreased when used in combination with Octreotide.,Evogliptin
DB12713,The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Octreotide.,Sotagliflozin
DB12781,The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Octreotide.,Balaglitazone
DB12935,The therapeutic efficacy of Remogliflozin etabonate can be decreased when used in combination with Octreotide.,Remogliflozin etabonate
DB13406,The therapeutic efficacy of Carbutamide can be decreased when used in combination with Octreotide.,Carbutamide
DB13446,The therapeutic efficacy of Guar gum can be decreased when used in combination with Octreotide.,Guar gum
DB13675,The therapeutic efficacy of Metahexamide can be decreased when used in combination with Octreotide.,Metahexamide
DB13928,The therapeutic efficacy of Semaglutide can be decreased when used in combination with Octreotide.,Semaglutide
DB14027,The therapeutic efficacy of Taspoglutide can be decreased when used in combination with Octreotide.,Taspoglutide
DB14035,The therapeutic efficacy of Englitazone can be decreased when used in combination with Octreotide.,Englitazone
DB15171,The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Octreotide.,Tirzepatide
DB15217,The therapeutic efficacy of Gastric inhibitory polypeptide can be decreased when used in combination with Octreotide.,Gastric inhibitory polypeptide
DB08882,The therapeutic efficacy of Linagliptin can be decreased when used in combination with Octreotide.,Linagliptin
DB01016,The therapeutic efficacy of Glyburide can be decreased when used in combination with Octreotide.,Glyburide
DB08907,The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Octreotide.,Canagliflozin
DB11827,The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Octreotide.,Ertugliflozin
DB00007,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Leuprolide.,Leuprolide
DB00014,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Goserelin.,Goserelin
DB00195,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Betaxolol.,Betaxolol
DB00218,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Moxifloxacin.,Moxifloxacin
DB00263,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Sulfisoxazole.,Sulfisoxazole
DB00391,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Sulpiride.,Sulpiride
DB00420,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Promazine.,Promazine
DB00433,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Prochlorperazine.,Prochlorperazine
DB00450,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Droperidol.,Droperidol
DB00526,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Oxaliplatin.,Oxaliplatin
DB00537,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ciprofloxacin.,Ciprofloxacin
DB00544,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Fluorouracil.,Fluorouracil
DB00556,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Perflutren.,Perflutren
DB00568,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Cinnarizine.,Cinnarizine
DB00571,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Propranolol.,Propranolol
DB00572,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Atropine.,Atropine
DB00625,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Efavirenz.,Efavirenz
DB00640,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Adenosine.,Adenosine
DB00738,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Pentamidine.,Pentamidine
DB00743,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Gadobenic acid.,Gadobenic acid
DB00748,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Carbinoxamine.,Carbinoxamine
DB00757,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Dolasetron.,Dolasetron
DB00778,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Roxithromycin.,Roxithromycin
DB00779,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Nalidixic acid.,Nalidixic acid
DB00827,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Cinoxacin.,Cinoxacin
DB00889,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Granisetron.,Granisetron
DB00904,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ondansetron.,Ondansetron
DB00922,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Levosimendan.,Levosimendan
DB00933,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Mesoridazine.,Mesoridazine
DB00967,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Desloratadine.,Desloratadine
DB00976,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Telithromycin.,Telithromycin
DB00978,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lomefloxacin.,Lomefloxacin
DB00985,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Dimenhydrinate.,Dimenhydrinate
DB01113,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Papaverine.,Papaverine
DB01114,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Chlorpheniramine.,Chlorpheniramine
DB01115,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Nifedipine.,Nifedipine
DB01155,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Gemifloxacin.,Gemifloxacin
DB01165,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ofloxacin.,Ofloxacin
DB01193,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Acebutolol.,Acebutolol
DB01195,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Flecainide.,Flecainide
DB01580,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Oxprenolol.,Oxprenolol
DB01599,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Probucol.,Probucol
DB01615,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Aceprometazine.,Aceprometazine
DB02638,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Terlipressin.,Terlipressin
DB04825,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Prenylamine.,Prenylamine
DB04842,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Fluspirilene.,Fluspirilene
DB04948,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lofexidine.,Lofexidine
DB04957,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Azimilide.,Azimilide
DB05223,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Pracinostat.,Pracinostat
DB05488,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Technetium Tc-99m ciprofloxacin.,Technetium Tc-99m ciprofloxacin
DB06160,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Garenoxacin.,Garenoxacin
DB06200,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Tedisamil.,Tedisamil
DB06334,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Tucidinostat.,Tucidinostat
DB06402,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Telavancin.,Telavancin
DB06600,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Nemonoxacin.,Nemonoxacin
DB06712,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Nilvadipine.,Nilvadipine
DB08799,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Antazoline.,Antazoline
DB08903,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Bedaquiline.,Bedaquiline
DB08952,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Indenolol.,Indenolol
DB08980,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Fendiline.,Fendiline
DB08992,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Eperisone.,Eperisone
DB09016,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Butriptyline.,Butriptyline
DB09078,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lenvatinib.,Lenvatinib
DB09224,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Melperone.,Melperone
DB09231,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Benidipine.,Benidipine
DB09555,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Dexchlorpheniramine maleate.,Dexchlorpheniramine maleate
DB11640,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Amifampridine.,Amifampridine
DB11830,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Mocetinostat.,Mocetinostat
DB11841,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Entinostat.,Entinostat
DB12141,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Gilteritinib.,Gilteritinib
DB12174,The risk or severity of QTc prolongation can be increased when Octreotide is combined with CUDC-101.,CUDC-101
DB12286,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Simendan.,Simendan
DB12376,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ricolinostat.,Ricolinostat
DB12523,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Mizolastine.,Mizolastine
DB12565,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Abexinostat.,Abexinostat
DB12877,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Oxatomide.,Oxatomide
DB13261,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Sitafloxacin.,Sitafloxacin
DB13273,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Sultopride.,Sultopride
DB13500,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Otilonium.,Otilonium
DB13546,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Nizofenone.,Nizofenone
DB13652,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Bunaftine.,Bunaftine
DB13653,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lorcainide.,Lorcainide
DB13679,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Dexchlorpheniramine.,Dexchlorpheniramine
DB13791,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Penfluridol.,Penfluridol
DB00207,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Azithromycin.,Azithromycin
DB00477,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Chlorpromazine.,Chlorpromazine
DB00199,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Erythromycin.,Erythromycin
DB00243,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ranolazine.,Ranolazine
DB00321,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Amitriptyline.,Amitriptyline
DB00333,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Methadone.,Methadone
DB00343,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Diltiazem.,Diltiazem
DB00393,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Nimodipine.,Nimodipine
DB00458,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Imipramine.,Imipramine
DB00608,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Chloroquine.,Chloroquine
DB00836,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Loperamide.,Loperamide
DB01087,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Primaquine.,Primaquine
DB01137,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Levofloxacin.,Levofloxacin
DB01182,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Propafenone.,Propafenone
DB01211,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Clarithromycin.,Clarithromycin
DB01224,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Quetiapine.,Quetiapine
DB01388,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Mibefradil.,Mibefradil
DB14063,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Dexverapamil.,Dexverapamil
DB01227,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Levacetylmethadol.,Levacetylmethadol
DB01232,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Saquinavir.,Saquinavir
DB01242,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Clomipramine.,Clomipramine
DB00166,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Lipoic acid.,Lipoic acid
DB04884,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Dapoxetine.,Dapoxetine
DB04896,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Milnacipran.,Milnacipran
DB06700,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Desvenlafaxine.,Desvenlafaxine
DB08953,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Indalpine.,Indalpine
DB12693,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Ritanserin.,Ritanserin
DB13233,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Alaproclate.,Alaproclate
DB14025,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Clinafloxacin.,Clinafloxacin
DB00176,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Fluvoxamine.,Fluvoxamine
DB00328,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Indomethacin.,Indomethacin
DB00715,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Paroxetine.,Paroxetine
DB01104,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Sertraline.,Sertraline
DB01149,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Nefazodone.,Nefazodone
DB04832,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Zimelidine.,Zimelidine
DB08918,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Levomilnacipran.,Levomilnacipran
DB09270,The risk or severity of hypoglycemia can be increased when Octreotide is combined with Ubidecarenone.,Ubidecarenone
DB00211,Octreotide may increase the bradycardic activities of Midodrine.,Midodrine
DB00335,Octreotide may increase the bradycardic activities of Atenolol.,Atenolol
DB00436,Octreotide may increase the bradycardic activities of Bendroflumethiazide.,Bendroflumethiazide
DB00528,Octreotide may increase the bradycardic activities of Lercanidipine.,Lercanidipine
DB00598,Octreotide may increase the bradycardic activities of Labetalol.,Labetalol
DB00633,Octreotide may increase the bradycardic activities of Dexmedetomidine.,Dexmedetomidine
DB00653,Octreotide may increase the bradycardic activities of Magnesium sulfate.,Magnesium sulfate
DB00708,Octreotide may increase the bradycardic activities of Sufentanil.,Sufentanil
DB00866,Octreotide may increase the bradycardic activities of Alprenolol.,Alprenolol
DB00899,Octreotide may increase the bradycardic activities of Remifentanil.,Remifentanil
DB00960,Octreotide may increase the bradycardic activities of Pindolol.,Pindolol
DB00968,Octreotide may increase the bradycardic activities of Methyldopa.,Methyldopa
DB00989,Octreotide may increase the bradycardic activities of Rivastigmine.,Rivastigmine
DB01018,Octreotide may increase the bradycardic activities of Guanfacine.,Guanfacine
DB01295,Octreotide may increase the bradycardic activities of Bevantolol.,Bevantolol
DB01297,Octreotide may increase the bradycardic activities of Practolol.,Practolol
DB01359,Octreotide may increase the bradycardic activities of Penbutolol.,Penbutolol
DB04743,Octreotide may increase the bradycardic activities of Nimesulide.,Nimesulide
DB04838,Octreotide may increase the bradycardic activities of Cyclandelate.,Cyclandelate
DB04841,Octreotide may increase the bradycardic activities of Flunarizine.,Flunarizine
DB04861,Octreotide may increase the bradycardic activities of Nebivolol.,Nebivolol
DB04897,Octreotide may increase the bradycardic activities of Lucinactant.,Lucinactant
DB04920,Octreotide may increase the bradycardic activities of Clevidipine.,Clevidipine
DB05885,Octreotide may increase the bradycardic activities of Seletracetam.,Seletracetam
DB06152,Octreotide may increase the bradycardic activities of Nylidrin.,Nylidrin
DB06218,Octreotide may increase the bradycardic activities of Lacosamide.,Lacosamide
DB06415,Octreotide may increase the bradycardic activities of Calfactant.,Calfactant
DB06446,Octreotide may increase the bradycardic activities of Dotarizine.,Dotarizine
DB06726,Octreotide may increase the bradycardic activities of Bufuralol.,Bufuralol
DB06761,Octreotide may increase the bradycardic activities of Beractant.,Beractant
DB06791,Octreotide may increase the bradycardic activities of Lanreotide.,Lanreotide
DB07615,Octreotide may increase the bradycardic activities of Tranilast.,Tranilast
DB08807,Octreotide may increase the bradycardic activities of Bopindolol.,Bopindolol
DB08838,Octreotide may increase the bradycardic activities of Agmatine.,Agmatine
DB09013,Octreotide may increase the bradycardic activities of Befunolol.,Befunolol
DB09113,Octreotide may increase the bradycardic activities of Poractant alfa.,Poractant alfa
DB09204,Octreotide may increase the bradycardic activities of Arotinolol.,Arotinolol
DB09216,Octreotide may increase the bradycardic activities of Tolfenamic acid.,Tolfenamic acid
DB09227,Octreotide may increase the bradycardic activities of Barnidipine.,Barnidipine
DB09230,Octreotide may increase the bradycardic activities of Azelnidipine.,Azelnidipine
DB09232,Octreotide may increase the bradycardic activities of Cilnidipine.,Cilnidipine
DB09234,Octreotide may increase the bradycardic activities of Darodipine.,Darodipine
DB09238,Octreotide may increase the bradycardic activities of Manidipine.,Manidipine
DB09240,Octreotide may increase the bradycardic activities of Niludipine.,Niludipine
DB09351,Octreotide may increase the bradycardic activities of Levobetaxolol.,Levobetaxolol
DB11960,Octreotide may increase the bradycardic activities of Carboxyamidotriazole.,Carboxyamidotriazole
DB12092,Octreotide may increase the bradycardic activities of Naftopidil.,Naftopidil
DB12131,Octreotide may increase the bradycardic activities of Vinpocetine.,Vinpocetine
DB12212,Octreotide may increase the bradycardic activities of Landiolol.,Landiolol
DB12752,Octreotide may increase the bradycardic activities of Bucindolol.,Bucindolol
DB13443,Octreotide may increase the bradycardic activities of Esatenolol.,Esatenolol
DB13508,Octreotide may increase the bradycardic activities of Cloranolol.,Cloranolol
DB13530,Octreotide may increase the bradycardic activities of Mepindolol.,Mepindolol
DB13757,Octreotide may increase the bradycardic activities of Epanolol.,Epanolol
DB13775,Octreotide may increase the bradycardic activities of Tertatolol.,Tertatolol
DB13835,Octreotide may increase the bradycardic activities of Caroverine.,Caroverine
DB13950,Octreotide may increase the bradycardic activities of WIN 55212-2.,WIN 55212-2
DB13961,Octreotide may increase the bradycardic activities of Fish oil.,Fish oil
DB00381,Octreotide may increase the bradycardic activities of Amlodipine.,Amlodipine
DB00612,Octreotide may increase the bradycardic activities of Bisoprolol.,Bisoprolol
DB00661,Octreotide may increase the bradycardic activities of Verapamil.,Verapamil
DB00843,Octreotide may increase the bradycardic activities of Donepezil.,Donepezil
DB01136,Octreotide may increase the bradycardic activities of Carvedilol.,Carvedilol
DB01203,Octreotide may increase the bradycardic activities of Nadolol.,Nadolol
DB08868,Octreotide may increase the bradycardic activities of Fingolimod.,Fingolimod
DB08896,Octreotide may increase the bradycardic activities of Regorafenib.,Regorafenib
DB14064,Octreotide may increase the bradycardic activities of Emopamil.,Emopamil
DB14065,Octreotide may increase the bradycardic activities of Lomerizine.,Lomerizine
DB14066,Octreotide may increase the bradycardic activities of Tetrandrine.,Tetrandrine
DB14068,Octreotide may increase the bradycardic activities of Dexniguldipine.,Dexniguldipine
DB00401,Octreotide may increase the bradycardic activities of Nisoldipine.,Nisoldipine
DB00575,Octreotide may increase the bradycardic activities of Clonidine.,Clonidine
DB00802,Octreotide may increase the bradycardic activities of Alfentanil.,Alfentanil
DB00215,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Citalopram.,Citalopram
DB00261,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Anagrelide.,Anagrelide
DB00280,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Disopyramide.,Disopyramide
DB00283,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Clemastine.,Clemastine
DB00308,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ibutilide.,Ibutilide
DB00313,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Valproic acid.,Valproic acid
DB00365,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Grepafloxacin.,Grepafloxacin
DB00468,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Quinine.,Quinine
DB00489,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Sotalol.,Sotalol
DB00539,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Toremifene.,Toremifene
DB00679,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Thioridazine.,Thioridazine
DB00685,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Trovafloxacin.,Trovafloxacin
DB00834,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Mifepristone.,Mifepristone
DB00875,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Flupentixol.,Flupentixol
DB00907,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Cocaine.,Cocaine
DB01035,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Procainamide.,Procainamide
DB01169,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Arsenic trioxide.,Arsenic trioxide
DB01175,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Escitalopram.,Escitalopram
DB01184,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Domperidone.,Domperidone
DB01208,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Sparfloxacin.,Sparfloxacin
DB01218,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Halofantrine.,Halofantrine
DB01244,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Bepridil.,Bepridil
DB01267,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Paliperidone.,Paliperidone
DB01356,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lithium cation.,Lithium cation
DB01405,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Temafloxacin.,Temafloxacin
DB01624,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Zuclopenthixol.,Zuclopenthixol
DB04844,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Tetrabenazine.,Tetrabenazine
DB06176,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Romidepsin.,Romidepsin
DB06216,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Asenapine.,Asenapine
DB06697,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Artemether.,Artemether
DB06708,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lumefantrine.,Lumefantrine
DB11730,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ribociclib.,Ribociclib
DB11978,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Glasdegib.,Glasdegib
DB12161,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Deutetrabenazine.,Deutetrabenazine
DB13725,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Terodiline.,Terodiline
DB00637,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Astemizole.,Astemizole
DB08881,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Vemurafenib.,Vemurafenib
DB13925,Octreotide may decrease effectiveness of Dotatate gallium Ga-68 as a diagnostic agent.,Dotatate gallium Ga-68
DB13985,The therapeutic efficacy of Lutetium Lu 177 dotatate can be decreased when used in combination with Octreotide.,Lutetium Lu 177 dotatate
DB11637,Octreotide may increase the QTc-prolonging activities of Delamanid.,Delamanid
DB01238,The metabolism of Aripiprazole can be decreased when combined with Octreotide.,Aripiprazole
DB14185,The metabolism of Aripiprazole lauroxil can be decreased when combined with Octreotide.,Aripiprazole lauroxil
DB00230,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Pregabalin.,Pregabalin
DB06663,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Pasireotide.,Pasireotide
DB00107,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Oxytocin.,Oxytocin
DB00187,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Esmolol.,Esmolol
DB00245,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Benzatropine.,Benzatropine
DB00289,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Atomoxetine.,Atomoxetine
DB00347,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Trimethadione.,Trimethadione
DB00354,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Buclizine.,Buclizine
DB00366,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Doxylamine.,Doxylamine
DB00370,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Mirtazapine.,Mirtazapine
DB00374,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Treprostinil.,Treprostinil
DB00405,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Dexbrompheniramine.,Dexbrompheniramine
DB00424,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Hyoscyamine.,Hyoscyamine
DB00427,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Triprolidine.,Triprolidine
DB00434,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Cyproheptadine.,Cyproheptadine
DB00467,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Enoxacin.,Enoxacin
DB00487,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Pefloxacin.,Pefloxacin
DB00529,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Foscarnet.,Foscarnet
DB00582,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Voriconazole.,Voriconazole
DB00674,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Galantamine.,Galantamine
DB00680,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Moricizine.,Moricizine
DB00691,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Moexipril.,Moexipril
DB00697,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Tizanidine.,Tizanidine
DB00710,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ibandronate.,Ibandronate
DB00714,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Apomorphine.,Apomorphine
DB00719,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Azatadine.,Azatadine
DB00753,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Isoflurane.,Isoflurane
DB00808,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Indapamide.,Indapamide
DB00817,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Rosoxacin.,Rosoxacin
DB00822,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Disulfiram.,Disulfiram
DB00825,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Levomenthol.,Levomenthol
DB00835,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Brompheniramine.,Brompheniramine
DB00871,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Terbutaline.,Terbutaline
DB00915,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Amantadine.,Amantadine
DB00920,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ketotifen.,Ketotifen
DB00927,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Famotidine.,Famotidine
DB00934,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Maprotiline.,Maprotiline
DB00949,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Felbamate.,Felbamate
DB00983,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Formoterol.,Formoterol
DB00999,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Hydrochlorothiazide.,Hydrochlorothiazide
DB01001,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Salbutamol.,Salbutamol
DB01036,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Tolterodine.,Tolterodine
DB01044,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Gatifloxacin.,Gatifloxacin
DB01059,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Norfloxacin.,Norfloxacin
DB01071,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Mequitazine.,Mequitazine
DB01074,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Perhexiline.,Perhexiline
DB01075,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Diphenhydramine.,Diphenhydramine
DB01106,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Levocabastine.,Levocabastine
DB01158,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Bretylium.,Bretylium
DB01173,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Orphenadrine.,Orphenadrine
DB01176,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Cyclizine.,Cyclizine
DB01189,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Desflurane.,Desflurane
DB01228,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Encainide.,Encainide
DB01236,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Sevoflurane.,Sevoflurane
DB01246,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Alimemazine.,Alimemazine
DB01274,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Arformoterol.,Arformoterol
DB01403,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Methotrimeprazine.,Methotrimeprazine
DB01426,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ajmaline.,Ajmaline
DB01591,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Solifenacin.,Solifenacin
DB01620,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Pheniramine.,Pheniramine
DB01623,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Thiothixene.,Thiothixene
DB02546,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Vorinostat.,Vorinostat
DB04576,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Fleroxacin.,Fleroxacin
DB04695,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Farnesyl thiopyrophosphate.,Farnesyl thiopyrophosphate
DB04953,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ezogabine.,Ezogabine
DB05246,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Methsuximide.,Methsuximide
DB05465,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Tandutinib.,Tandutinib
DB06217,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Vernakalant.,Vernakalant
DB06282,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Levocetirizine.,Levocetirizine
DB06288,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Amisulpride.,Amisulpride
DB06468,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Cariporide.,Cariporide
DB06691,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Mepyramine.,Mepyramine
DB06699,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Degarelix.,Degarelix
DB06719,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Buserelin.,Buserelin
DB06788,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Histrelin.,Histrelin
DB06825,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Triptorelin.,Triptorelin
DB07780,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Farnesyl diphosphate.,Farnesyl diphosphate
DB07841,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Geranylgeranyl diphosphate.,Geranylgeranyl diphosphate
DB08808,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Bupranolol.,Bupranolol
DB08871,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Eribulin.,Eribulin
DB08936,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Chlorcyclizine.,Chlorcyclizine
DB08972,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Flumequine.,Flumequine
DB09080,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Olodaterol.,Olodaterol
DB09082,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Vilanterol.,Vilanterol
DB09089,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Trimebutine.,Trimebutine
DB09090,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Pinaverium.,Pinaverium
DB09167,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Dosulepin.,Dosulepin
DB09229,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Aranidipine.,Aranidipine
DB09235,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Efonidipine.,Efonidipine
DB09236,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lacidipine.,Lacidipine
DB09488,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Acrivastine.,Acrivastine
DB11390,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Coumaphos.,Coumaphos
DB11397,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Dichlorvos.,Dichlorvos
DB11408,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Famphur.,Famphur
DB11412,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Fenthion.,Fenthion
DB11443,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Orbifloxacin.,Orbifloxacin
DB11448,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Phosmet.,Phosmet
DB11491,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Sarafloxacin.,Sarafloxacin
DB11511,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Difloxacin.,Difloxacin
DB11591,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Bilastine.,Bilastine
DB11614,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Rupatadine.,Rupatadine
DB11774,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Pazufloxacin.,Pazufloxacin
DB11785,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Anisodamine.,Anisodamine
DB11891,The risk or severity of QTc prolongation can be increased when Octreotide is combined with CUDC-907.,CUDC-907
DB11892,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Prulifloxacin.,Prulifloxacin
DB11943,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Delafloxacin.,Delafloxacin
DB12093,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Tetrahydropalmatine.,Tetrahydropalmatine
DB12231,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Temefos.,Temefos
DB12245,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Triclabendazole.,Triclabendazole
DB12645,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Givinostat.,Givinostat
DB12712,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Pilsicainide.,Pilsicainide
DB12766,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Cicletanine.,Cicletanine
DB13358,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Cibenzoline.,Cibenzoline
DB13488,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Bencyclane.,Bencyclane
DB13555,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Prajmaline.,Prajmaline
DB13627,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Oxolinic acid.,Oxolinic acid
DB13651,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lorajmine.,Lorajmine
DB13691,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Acetyldigoxin.,Acetyldigoxin
DB13744,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Piromidic acid.,Piromidic acid
DB13766,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lidoflazine.,Lidoflazine
DB13772,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Rufloxacin.,Rufloxacin
DB13823,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Pipemidic acid.,Pipemidic acid
DB14713,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Inotersen.,Inotersen
DB00938,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Salmeterol.,Salmeterol
DB01072,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Atazanavir.,Atazanavir
DB01151,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Desipramine.,Desipramine
DB00196,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Fluconazole.,Fluconazole
DB00220,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Nelfinavir.,Nelfinavir
DB00270,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Isradipine.,Isradipine
DB00285,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Venlafaxine.,Venlafaxine
DB00334,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Olanzapine.,Olanzapine
DB00341,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Cetirizine.,Cetirizine
DB00344,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Protriptyline.,Protriptyline
DB00358,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Mefloquine.,Mefloquine
DB00373,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Timolol.,Timolol
DB00390,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Digoxin.,Digoxin
DB00503,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ritonavir.,Ritonavir
DB00543,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Amoxapine.,Amoxapine
DB00555,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lamotrigine.,Lamotrigine
DB00613,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Amodiaquine.,Amodiaquine
DB00622,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Nicardipine.,Nicardipine
DB00678,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Losartan.,Losartan
DB00726,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Trimipramine.,Trimipramine
DB00734,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Risperidone.,Risperidone
DB00818,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Propofol.,Propofol
DB00909,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Zonisamide.,Zonisamide
DB00916,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Metronidazole.,Metronidazole
DB01026,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ketoconazole.,Ketoconazole
DB01054,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Nitrendipine.,Nitrendipine
DB01069,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Promethazine.,Promethazine
DB01142,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Doxepin.,Doxepin
DB01167,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Itraconazole.,Itraconazole
DB01233,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Metoclopramide.,Metoclopramide
DB01239,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Chlorprothixene.,Chlorprothixene
DB01259,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lapatinib.,Lapatinib
DB01263,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Posaconazole.,Posaconazole
DB01601,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lopinavir.,Lopinavir
DB01611,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Hydroxychloroquine.,Hydroxychloroquine
DB04846,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Celiprolol.,Celiprolol
DB05039,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Indacaterol.,Indacaterol
DB08893,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Mirabegron.,Mirabegron
DB09239,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Niguldipine.,Niguldipine
DB11770,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Talinolol.,Talinolol
DB12923,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Gallopamil.,Gallopamil
DB00593,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ethosuximide.,Ethosuximide
DB01023,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Felodipine.,Felodipine
DB00540,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Nortriptyline.,Nortriptyline
DB08815,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Lurasidone.,Lurasidone
DB08864,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Rilpivirine.,Rilpivirine
DB11742,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ebastine.,Ebastine
DB00845,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Clofazimine.,Clofazimine
DB00186,The metabolism of Lorazepam can be decreased when combined with Octreotide.,Lorazepam
DB00191,The metabolism of Phentermine can be decreased when combined with Octreotide.,Phentermine
DB00208,The metabolism of Ticlopidine can be decreased when combined with Octreotide.,Ticlopidine
DB00426,The metabolism of Famciclovir can be decreased when combined with Octreotide.,Famciclovir
DB00567,The metabolism of Cephalexin can be decreased when combined with Octreotide.,Cephalexin
DB00717,The metabolism of Norethisterone can be decreased when combined with Octreotide.,Norethisterone
DB01323,The metabolism of St. John's Wort can be decreased when combined with Octreotide.,St. John's Wort
DB01395,The metabolism of Drospirenone can be decreased when combined with Octreotide.,Drospirenone
DB01411,The metabolism of Pranlukast can be decreased when combined with Octreotide.,Pranlukast
DB01431,The metabolism of Allylestrenol can be decreased when combined with Octreotide.,Allylestrenol
DB01656,The metabolism of Roflumilast can be decreased when combined with Octreotide.,Roflumilast
DB06201,The metabolism of Rufinamide can be decreased when combined with Octreotide.,Rufinamide
DB09071,The metabolism of Tasimelteon can be decreased when combined with Octreotide.,Tasimelteon
DB11094,The metabolism of Vitamin D can be decreased when combined with Octreotide.,Vitamin D
DB11273,The metabolism of Dihydroergocornine can be decreased when combined with Octreotide.,Dihydroergocornine
DB12515,The metabolism of 9-aminocamptothecin can be decreased when combined with Octreotide.,9-aminocamptothecin
DB12952,The metabolism of Methylprednisone can be decreased when combined with Octreotide.,Methylprednisone
DB13345,The metabolism of Dihydroergocristine can be decreased when combined with Octreotide.,Dihydroergocristine
DB13385,The metabolism of Dihydroergocryptine can be decreased when combined with Octreotide.,Dihydroergocryptine
DB14009,The metabolism of Medical Cannabis can be decreased when combined with Octreotide.,Medical Cannabis
DB01098,The metabolism of Rosuvastatin can be decreased when combined with Octreotide.,Rosuvastatin
DB00549,The metabolism of Zafirlukast can be decreased when combined with Octreotide.,Zafirlukast
DB15444,The metabolism of Elexacaftor can be decreased when combined with Octreotide.,Elexacaftor
DB00476,The metabolism of Duloxetine can be decreased when combined with Octreotide.,Duloxetine
DB00518,The metabolism of Albendazole can be decreased when combined with Octreotide.,Albendazole
DB00590,The metabolism of Doxazosin can be decreased when combined with Octreotide.,Doxazosin
DB01039,The metabolism of Fenofibrate can be decreased when combined with Octreotide.,Fenofibrate
DB06717,The metabolism of Fosaprepitant can be decreased when combined with Octreotide.,Fosaprepitant
DB09030,The metabolism of Vorapaxar can be decreased when combined with Octreotide.,Vorapaxar
DB09034,The metabolism of Suvorexant can be decreased when combined with Octreotide.,Suvorexant
DB09048,The metabolism of Netupitant can be decreased when combined with Octreotide.,Netupitant
DB00264,The metabolism of Metoprolol can be decreased when combined with Octreotide.,Metoprolol
DB09079,The metabolism of Nintedanib can be decreased when combined with Octreotide.,Nintedanib
DB09299,The metabolism of Tenofovir alafenamide can be decreased when combined with Octreotide.,Tenofovir alafenamide
DB09330,The metabolism of Osimertinib can be decreased when combined with Octreotide.,Osimertinib
DB11952,The metabolism of Duvelisib can be decreased when combined with Octreotide.,Duvelisib
DB12887,The metabolism of Tazemetostat can be decreased when combined with Octreotide.,Tazemetostat
DB14126,The metabolism of Tenofovir can be decreased when combined with Octreotide.,Tenofovir
DB00247,The metabolism of Methysergide can be decreased when combined with Octreotide.,Methysergide
DB00454,The metabolism of Meperidine can be decreased when combined with Octreotide.,Meperidine
DB12371,The metabolism of Siponimod can be decreased when combined with Octreotide.,Siponimod
DB00363,The metabolism of Clozapine can be decreased when combined with Octreotide.,Clozapine
DB06589,The metabolism of Pazopanib can be decreased when combined with Octreotide.,Pazopanib
DB06603,The metabolism of Panobinostat can be decreased when combined with Octreotide.,Panobinostat
DB00530,The metabolism of Erlotinib can be decreased when combined with Octreotide.,Erlotinib
DB00619,The metabolism of Imatinib can be decreased when combined with Octreotide.,Imatinib
DB04868,The metabolism of Nilotinib can be decreased when combined with Octreotide.,Nilotinib
DB05294,The metabolism of Vandetanib can be decreased when combined with Octreotide.,Vandetanib
DB00188,The metabolism of Bortezomib can be decreased when combined with Octreotide.,Bortezomib
DB00342,The metabolism of Octreotide can be decreased when combined with Terfenadine.,Terfenadine
DB00877,The metabolism of Octreotide can be decreased when combined with Sirolimus.,Sirolimus
DB00908,The metabolism of Octreotide can be decreased when combined with Quinidine.,Quinidine
DB01100,The metabolism of Octreotide can be decreased when combined with Pimozide.,Pimozide
DB01118,The metabolism of Octreotide can be decreased when combined with Amiodarone.,Amiodarone
DB01229,The metabolism of Octreotide can be decreased when combined with Paclitaxel.,Paclitaxel
DB01254,The metabolism of Octreotide can be decreased when combined with Dasatinib.,Dasatinib
DB01590,The metabolism of Octreotide can be decreased when combined with Everolimus.,Everolimus
DB04855,The metabolism of Octreotide can be decreased when combined with Dronedarone.,Dronedarone
DB06287,The metabolism of Octreotide can be decreased when combined with Temsirolimus.,Temsirolimus
DB00564,The metabolism of Carbamazepine can be decreased when combined with Octreotide.,Carbamazepine
DB01396,The metabolism of Digitoxin can be decreased when combined with Octreotide.,Digitoxin
DB00204,The metabolism of Dofetilide can be decreased when combined with Octreotide.,Dofetilide
DB00277,The metabolism of Theophylline can be decreased when combined with Octreotide.,Theophylline
DB00604,The metabolism of Cisapride can be decreased when combined with Octreotide.,Cisapride
DB00946,The metabolism of Phenprocoumon can be decreased when combined with Octreotide.,Phenprocoumon
DB01008,The metabolism of Busulfan can be decreased when combined with Octreotide.,Busulfan
DB01223,The metabolism of Aminophylline can be decreased when combined with Octreotide.,Aminophylline
DB01320,The metabolism of Fosphenytoin can be decreased when combined with Octreotide.,Fosphenytoin
DB03410,The metabolism of 4-hydroxycoumarin can be decreased when combined with Octreotide.,4-hydroxycoumarin
DB09289,The metabolism of Tianeptine can be decreased when combined with Octreotide.,Tianeptine
DB13136,The metabolism of Fluindione can be decreased when combined with Octreotide.,Fluindione
DB13275,The metabolism of Clorindione can be decreased when combined with Octreotide.,Clorindione
DB00451,The metabolism of Levothyroxine can be decreased when combined with Octreotide.,Levothyroxine
DB09054,The metabolism of Idelalisib can be decreased when combined with Octreotide.,Idelalisib
DB11633,The metabolism of Isavuconazole can be decreased when combined with Octreotide.,Isavuconazole
DB11963,The metabolism of Dacomitinib can be decreased when combined with Octreotide.,Dacomitinib
DB12015,The metabolism of Alpelisib can be decreased when combined with Octreotide.,Alpelisib
DB05239,The metabolism of Cobimetinib can be decreased when combined with Octreotide.,Cobimetinib
DB01268,The metabolism of Sunitinib can be decreased when combined with Octreotide.,Sunitinib
DB08865,The metabolism of Crizotinib can be decreased when combined with Octreotide.,Crizotinib
DB14568,The metabolism of Ivosidenib can be decreased when combined with Octreotide.,Ivosidenib
DB00398,The metabolism of Sorafenib can be decreased when combined with Octreotide.,Sorafenib
DB00675,The metabolism of Tamoxifen can be decreased when combined with Octreotide.,Tamoxifen
DB08912,The metabolism of Dabrafenib can be decreased when combined with Octreotide.,Dabrafenib
DB00563,The metabolism of Methotrexate can be decreased when combined with Octreotide.,Methotrexate
DB00361,The metabolism of Vinorelbine can be decreased when combined with Octreotide.,Vinorelbine
DB00541,The metabolism of Vincristine can be decreased when combined with Octreotide.,Vincristine
DB00570,The metabolism of Vinblastine can be decreased when combined with Octreotide.,Vinblastine
DB00694,The metabolism of Daunorubicin can be decreased when combined with Octreotide.,Daunorubicin
DB00987,The metabolism of Cytarabine can be decreased when combined with Octreotide.,Cytarabine
DB00997,The metabolism of Doxorubicin can be decreased when combined with Octreotide.,Doxorubicin
DB01108,The metabolism of Trilostane can be decreased when combined with Octreotide.,Trilostane
DB01248,The metabolism of Docetaxel can be decreased when combined with Octreotide.,Docetaxel
DB04572,The metabolism of Thiotepa can be decreased when combined with Octreotide.,Thiotepa
DB05109,The metabolism of Trabectedin can be decreased when combined with Octreotide.,Trabectedin
DB05812,The metabolism of Abiraterone can be decreased when combined with Octreotide.,Abiraterone
DB11363,The metabolism of Alectinib can be decreased when combined with Octreotide.,Alectinib
DB11581,The metabolism of Venetoclax can be decreased when combined with Octreotide.,Venetoclax
DB11641,The metabolism of Vinflunine can be decreased when combined with Octreotide.,Vinflunine
DB11703,The metabolism of Acalabrutinib can be decreased when combined with Octreotide.,Acalabrutinib
DB13874,The metabolism of Enasidenib can be decreased when combined with Octreotide.,Enasidenib
DB15035,The metabolism of Zanubrutinib can be decreased when combined with Octreotide.,Zanubrutinib
DB00248,The metabolism of Cabergoline can be decreased when combined with Octreotide.,Cabergoline
DB00309,The metabolism of Vindesine can be decreased when combined with Octreotide.,Vindesine
DB00444,The metabolism of Teniposide can be decreased when combined with Octreotide.,Teniposide
DB00773,The metabolism of Etoposide can be decreased when combined with Octreotide.,Etoposide
DB01181,The metabolism of Ifosfamide can be decreased when combined with Octreotide.,Ifosfamide
DB04845,The metabolism of Ixabepilone can be decreased when combined with Octreotide.,Ixabepilone
DB05015,The metabolism of Belinostat can be decreased when combined with Octreotide.,Belinostat
DB06595,The metabolism of Midostaurin can be decreased when combined with Octreotide.,Midostaurin
DB06616,The metabolism of Bosutinib can be decreased when combined with Octreotide.,Bosutinib
DB06626,The metabolism of Axitinib can be decreased when combined with Octreotide.,Axitinib
DB08870,The metabolism of Brentuximab vedotin can be decreased when combined with Octreotide.,Brentuximab vedotin
DB08901,The metabolism of Ponatinib can be decreased when combined with Octreotide.,Ponatinib
DB09073,The metabolism of Palbociclib can be decreased when combined with Octreotide.,Palbociclib
DB09143,The metabolism of Sonidegib can be decreased when combined with Octreotide.,Sonidegib
DB09570,The metabolism of Ixazomib can be decreased when combined with Octreotide.,Ixazomib
DB11718,The metabolism of Encorafenib can be decreased when combined with Octreotide.,Encorafenib
DB11828,The metabolism of Neratinib can be decreased when combined with Octreotide.,Neratinib
DB12147,The metabolism of Erdafitinib can be decreased when combined with Octreotide.,Erdafitinib
DB12267,The metabolism of Brigatinib can be decreased when combined with Octreotide.,Brigatinib
DB12483,The metabolism of Copanlisib can be decreased when combined with Octreotide.,Copanlisib
DB12978,The metabolism of Pexidartinib can be decreased when combined with Octreotide.,Pexidartinib
DB06480,The metabolism of Prucalopride can be decreased when combined with Octreotide.,Prucalopride
DB13074,The therapeutic efficacy of Macimorelin can be decreased when used in combination with Octreotide.,Macimorelin
DB00331,The therapeutic efficacy of Metformin can be decreased when used in combination with Octreotide.,Metformin
DB00656,The risk or severity of QTc prolongation can be increased when Trazodone is combined with Octreotide.,Trazodone
DB11986,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Entrectinib.,Entrectinib
DB11642,Pitolisant may increase the QTc-prolonging activities of Octreotide.,Pitolisant
DB12825,Lefamulin may increase the QTc-prolonging activities of Octreotide.,Lefamulin
DB15494,Octreotide may decrease effectiveness of Edotreotide gallium Ga-68 as a diagnostic agent.,Edotreotide gallium Ga-68
DB11732,Lasmiditan may increase the bradycardic activities of Octreotide.,Lasmiditan
DB14975,The serum concentration of Voxelotor can be increased when it is combined with Octreotide.,Voxelotor
DB09237,The serum concentration of Levamlodipine can be increased when it is combined with Octreotide.,Levamlodipine
DB15328,The serum concentration of Ubrogepant can be increased when it is combined with Octreotide.,Ubrogepant
DB00557,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Hydroxyzine.,Hydroxyzine
DB00193,The metabolism of Tramadol can be decreased when combined with Octreotide.,Tramadol
DB00246,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ziprasidone.,Ziprasidone
DB00502,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Haloperidol.,Haloperidol
DB00472,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Fluoxetine.,Fluoxetine
DB06643,The risk or severity of adverse effects can be increased when Denosumab is combined with Interferon alfa-2b.,Denosumab
DB00005,The risk or severity of adverse effects can be increased when Etanercept is combined with Interferon alfa-2b.,Etanercept
DB00008,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Interferon alfa-2b.,Peginterferon alfa-2a
DB00011,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Interferon alfa-2b.,Interferon alfa-n1
DB00018,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Interferon alfa-2b.,Interferon alfa-n3
DB00022,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Interferon alfa-2b.,Peginterferon alfa-2b
DB00026,The risk or severity of adverse effects can be increased when Anakinra is combined with Interferon alfa-2b.,Anakinra
DB00033,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Interferon alfa-2b.,Interferon gamma-1b
DB00034,"The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Interferon alfa-2b.","Interferon alfa-2a, Recombinant"
DB00051,The risk or severity of adverse effects can be increased when Adalimumab is combined with Interferon alfa-2b.,Adalimumab
DB00056,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Interferon alfa-2b.,Gemtuzumab ozogamicin
DB00059,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Interferon alfa-2b.,Pegaspargase
DB00065,The risk or severity of adverse effects can be increased when Infliximab is combined with Interferon alfa-2b.,Infliximab
DB00068,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Interferon alfa-2b.,Interferon beta-1b
DB00069,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Interferon alfa-2b.,Interferon alfacon-1
DB00073,The risk or severity of adverse effects can be increased when Rituximab is combined with Interferon alfa-2b.,Rituximab
DB00074,The risk or severity of adverse effects can be increased when Basiliximab is combined with Interferon alfa-2b.,Basiliximab
DB00075,The risk or severity of adverse effects can be increased when Muromonab is combined with Interferon alfa-2b.,Muromonab
DB00078,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Interferon alfa-2b.,Ibritumomab tiuxetan
DB00081,The risk or severity of adverse effects can be increased when Tositumomab is combined with Interferon alfa-2b.,Tositumomab
DB00087,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Interferon alfa-2b.,Alemtuzumab
DB00092,The risk or severity of adverse effects can be increased when Alefacept is combined with Interferon alfa-2b.,Alefacept
DB00095,The risk or severity of adverse effects can be increased when Efalizumab is combined with Interferon alfa-2b.,Efalizumab
DB00098,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Interferon alfa-2b.,Antithymocyte immunoglobulin (rabbit)
DB00111,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Daclizumab.,Daclizumab
DB00112,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Bevacizumab.,Bevacizumab
DB00120,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Phenylalanine.,Phenylalanine
DB00180,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Flunisolide.,Flunisolide
DB00188,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Bortezomib.,Bortezomib
DB00242,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Cladribine.,Cladribine
DB00262,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Carmustine.,Carmustine
DB00276,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Amsacrine.,Amsacrine
DB00290,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Bleomycin.,Bleomycin
DB00291,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Chlorambucil.,Chlorambucil
DB00293,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Raltitrexed.,Raltitrexed
DB00305,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Mitomycin.,Mitomycin
DB00307,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Bexarotene.,Bexarotene
DB00309,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Vindesine.,Vindesine
DB00322,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Floxuridine.,Floxuridine
DB00328,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Indomethacin.,Indomethacin
DB00352,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Tioguanine.,Tioguanine
DB00361,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Vinorelbine.,Vinorelbine
DB00380,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Dexrazoxane.,Dexrazoxane
DB00394,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Beclomethasone dipropionate.,Beclomethasone dipropionate
DB00398,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Sorafenib.,Sorafenib
DB00428,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Streptozocin.,Streptozocin
DB00432,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Trifluridine.,Trifluridine
DB00441,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Gemcitabine.,Gemcitabine
DB00443,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Betamethasone.,Betamethasone
DB00444,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Teniposide.,Teniposide
DB00445,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Epirubicin.,Epirubicin
DB00446,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Chloramphenicol.,Chloramphenicol
DB00480,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Lenalidomide.,Lenalidomide
DB00488,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Altretamine.,Altretamine
DB00515,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Cisplatin.,Cisplatin
DB00526,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Oxaliplatin.,Oxaliplatin
DB00531,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Cyclophosphamide.,Cyclophosphamide
DB00541,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Vincristine.,Vincristine
DB00544,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fluorouracil.,Fluorouracil
DB00550,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Propylthiouracil.,Propylthiouracil
DB00552,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Pentostatin.,Pentostatin
DB00563,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Methotrexate.,Methotrexate
DB00570,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Vinblastine.,Vinblastine
DB00588,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fluticasone propionate.,Fluticasone propionate
DB00591,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fluocinolone acetonide.,Fluocinolone acetonide
DB00601,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Linezolid.,Linezolid
DB00619,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Imatinib.,Imatinib
DB00620,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Triamcinolone.,Triamcinolone
DB00631,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Clofarabine.,Clofarabine
DB00635,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Prednisone.,Prednisone
DB00642,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Pemetrexed.,Pemetrexed
DB00687,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fludrocortisone.,Fludrocortisone
DB00688,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Mycophenolate mofetil.,Mycophenolate mofetil
DB00694,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Daunorubicin.,Daunorubicin
DB00755,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Tretinoin.,Tretinoin
DB00762,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Irinotecan.,Irinotecan
DB00763,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Methimazole.,Methimazole
DB00764,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Mometasone.,Mometasone
DB00773,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Etoposide.,Etoposide
DB00795,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Sulfasalazine.,Sulfasalazine
DB00851,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Dacarbazine.,Dacarbazine
DB00853,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Temozolomide.,Temozolomide
DB00859,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Penicillamine.,Penicillamine
DB00860,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Prednisolone.,Prednisolone
DB00877,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Sirolimus.,Sirolimus
DB00888,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Mechlorethamine.,Mechlorethamine
DB00928,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Azacitidine.,Azacitidine
DB00958,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Carboplatin.,Carboplatin
DB00959,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Methylprednisolone.,Methylprednisolone
DB00970,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Dactinomycin.,Dactinomycin
DB00987,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Cytarabine.,Cytarabine
DB00993,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Azathioprine.,Azathioprine
DB00997,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Doxorubicin.,Doxorubicin
DB01005,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Hydroxyurea.,Hydroxyurea
DB01008,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Busulfan.,Busulfan
DB01024,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Mycophenolic acid.,Mycophenolic acid
DB01030,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Topotecan.,Topotecan
DB01033,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Mercaptopurine.,Mercaptopurine
DB01041,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Thalidomide.,Thalidomide
DB01042,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Melphalan.,Melphalan
DB01073,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fludarabine.,Fludarabine
DB01099,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Flucytosine.,Flucytosine
DB01101,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Capecitabine.,Capecitabine
DB01108,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Trilostane.,Trilostane
DB01168,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Procarbazine.,Procarbazine
DB01169,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Arsenic trioxide.,Arsenic trioxide
DB01177,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Idarubicin.,Idarubicin
DB01181,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Ifosfamide.,Ifosfamide
DB01196,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Estramustine.,Estramustine
DB01204,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Mitoxantrone.,Mitoxantrone
DB01206,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Lomustine.,Lomustine
DB01222,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Budesonide.,Budesonide
DB01229,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Paclitaxel.,Paclitaxel
DB01234,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Dexamethasone.,Dexamethasone
DB01248,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Docetaxel.,Docetaxel
DB01254,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Dasatinib.,Dasatinib
DB01257,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Eculizumab.,Eculizumab
DB01262,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Decitabine.,Decitabine
DB01268,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Sunitinib.,Sunitinib
DB01280,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Nelarabine.,Nelarabine
DB01281,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Abatacept.,Abatacept
DB01285,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Corticotropin.,Corticotropin
DB01380,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Cortisone acetate.,Cortisone acetate
DB01384,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Paramethasone.,Paramethasone
DB01394,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Colchicine.,Colchicine
DB01410,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Ciclesonide.,Ciclesonide
DB01423,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Stepronin.,Stepronin
DB01590,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Everolimus.,Everolimus
DB01611,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Hydroxychloroquine.,Hydroxychloroquine
DB01816,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Castanospermine.,Castanospermine
DB02546,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Vorinostat.,Vorinostat
DB02806,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with 2-Methoxyethanol.,2-Methoxyethanol
DB03523,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Brequinar.,Brequinar
DB04572,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Thiotepa.,Thiotepa
DB04630,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Aldosterone.,Aldosterone
DB04845,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Ixabepilone.,Ixabepilone
DB04868,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Nilotinib.,Nilotinib
DB04951,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Pirfenidone.,Pirfenidone
DB04956,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Afelimomab.,Afelimomab
DB05015,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Belinostat.,Belinostat
DB05109,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Trabectedin.,Trabectedin
DB05258,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Interferon alfa.,Interferon alfa
DB05259,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Glatiramer.,Glatiramer
DB05260,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Gallium nitrate.,Gallium nitrate
DB05459,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Briakinumab.,Briakinumab
DB05472,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with omega interferon.,omega interferon
DB05676,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Apremilast.,Apremilast
DB05773,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Trastuzumab emtansine.,Trastuzumab emtansine
DB06168,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Canakinumab.,Canakinumab
DB06273,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Tocilizumab.,Tocilizumab
DB06287,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Temsirolimus.,Temsirolimus
DB06372,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Rilonacept.,Rilonacept
DB06589,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Pazopanib.,Pazopanib
DB06603,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Panobinostat.,Panobinostat
DB06612,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Mepolizumab.,Mepolizumab
DB06616,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Bosutinib.,Bosutinib
DB06662,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Abetimus.,Abetimus
DB06674,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Golimumab.,Golimumab
DB06681,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Belatacept.,Belatacept
DB06769,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Bendamustine.,Bendamustine
DB06772,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Cabazitaxel.,Cabazitaxel
DB06813,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Pralatrexate.,Pralatrexate
DB08059,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Wortmannin.,Wortmannin
DB08870,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Brentuximab vedotin.,Brentuximab vedotin
DB08871,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Eribulin.,Eribulin
DB08877,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Ruxolitinib.,Ruxolitinib
DB08879,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Belimumab.,Belimumab
DB08880,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Teriflunomide.,Teriflunomide
DB08889,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Carfilzomib.,Carfilzomib
DB08901,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Ponatinib.,Ponatinib
DB08904,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Certolizumab pegol.,Certolizumab pegol
DB08906,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fluticasone furoate.,Fluticasone furoate
DB08908,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Dimethyl fumarate.,Dimethyl fumarate
DB08910,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Pomalidomide.,Pomalidomide
DB08935,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Obinutuzumab.,Obinutuzumab
DB08970,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fluprednidene.,Fluprednidene
DB08971,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fluocortolone.,Fluocortolone
DB09029,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Secukinumab.,Secukinumab
DB09033,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Vedolizumab.,Vedolizumab
DB09036,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Siltuximab.,Siltuximab
DB09052,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Blinatumomab.,Blinatumomab
DB09053,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Ibrutinib.,Ibrutinib
DB09054,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Idelalisib.,Idelalisib
DB09073,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Palbociclib.,Palbociclib
DB09074,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Olaparib.,Olaparib
DB09077,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Dinutuximab.,Dinutuximab
DB09082,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Vilanterol.,Vilanterol
DB09091,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Tixocortol.,Tixocortol
DB09122,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Peginterferon beta-1a.,Peginterferon beta-1a
DB09312,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Antilymphocyte immunoglobulin (horse).,Antilymphocyte immunoglobulin (horse)
DB09378,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fluprednisolone.,Fluprednisolone
DB09383,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Meprednisone.,Meprednisone
DB11466,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Tepoxalin.,Tepoxalin
DB11487,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Dexamethasone isonicotinate.,Dexamethasone isonicotinate
DB11529,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Melengestrol.,Melengestrol
DB11569,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Ixekizumab.,Ixekizumab
DB11580,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Ravulizumab.,Ravulizumab
DB11616,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Pirarubicin.,Pirarubicin
DB11693,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Voclosporin.,Voclosporin
DB11708,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Peficitinib.,Peficitinib
DB11750,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Clobetasol.,Clobetasol
DB11767,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Sarilumab.,Sarilumab
DB11776,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Brodalumab.,Brodalumab
DB11803,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Sirukumab.,Sirukumab
DB11817,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Baricitinib.,Baricitinib
DB11834,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Guselkumab.,Guselkumab
DB11921,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Deflazacort.,Deflazacort
DB12025,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Triptolide.,Triptolide
DB12371,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Siponimod.,Siponimod
DB12612,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Ozanimod.,Ozanimod
DB12617,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Mizoribine.,Mizoribine
DB12692,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Gusperimus.,Gusperimus
DB12814,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Cepeginterferon alfa-2B.,Cepeginterferon alfa-2B
DB12902,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Trofosfamide.,Trofosfamide
DB12947,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Doxifluridine.,Doxifluridine
DB12991,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Deoxyspergualin.,Deoxyspergualin
DB12996,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Acteoside.,Acteoside
DB13003,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Cortivazol.,Cortivazol
DB13014,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Hypericin.,Hypericin
DB13068,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.,9-(N-methyl-L-isoleucine)-cyclosporin A
DB13208,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Prednylidene.,Prednylidene
DB13223,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fluocortin.,Fluocortin
DB13241,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Begelomab.,Begelomab
DB13491,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fluperolone.,Fluperolone
DB13664,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Formocortal.,Formocortal
DB13728,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Halometasone.,Halometasone
DB13843,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Cloprednol.,Cloprednol
DB13856,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fluclorolone.,Fluclorolone
DB13867,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fluticasone.,Fluticasone
DB14066,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Tetrandrine.,Tetrandrine
DB14219,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Monomethyl fumarate.,Monomethyl fumarate
DB14512,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Mometasone furoate.,Mometasone furoate
DB14538,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Hydrocortisone aceponate.,Hydrocortisone aceponate
DB14539,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Hydrocortisone acetate.,Hydrocortisone acetate
DB14545,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Hydrocortisone succinate.,Hydrocortisone succinate
DB14724,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Emapalumab.,Emapalumab
DB14762,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Risankizumab.,Risankizumab
DB14919,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Rozanolixizumab.,Rozanolixizumab
DB15253,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Bleselumab.,Bleselumab
DB00108,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Natalizumab.,Natalizumab
DB00337,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Interferon alfa-2b.,Pimecrolimus
DB01656,Roflumilast may increase the immunosuppressive activities of Interferon alfa-2b.,Roflumilast
DB06688,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Interferon alfa-2b.,Sipuleucel-T
DB00041,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Aldesleukin.,Aldesleukin
DB00363,The risk or severity of neutropenia can be increased when Interferon alfa-2b is combined with Clozapine.,Clozapine
DB00333,The serum concentration of Methadone can be increased when it is combined with Interferon alfa-2b.,Methadone
DB00811,The risk or severity of anemia can be increased when Interferon alfa-2b is combined with Ribavirin.,Ribavirin
DB00495,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Zidovudine.,Zidovudine
DB00012,The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Interferon alfa-2b.,Darbepoetin alfa
DB00016,The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Interferon alfa-2b.,Erythropoietin
DB08894,The risk or severity of Thrombosis can be increased when Peginesatide is combined with Interferon alfa-2b.,Peginesatide
DB09107,The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Interferon alfa-2b.,Methoxy polyethylene glycol-epoetin beta
DB00315,The metabolism of Zolmitriptan can be decreased when combined with Interferon alfa-2b.,Zolmitriptan
DB01015,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Interferon alfa-2b.,Sulfamethoxazole
DB04817,The risk or severity of myelosuppression can be increased when Metamizole is combined with Interferon alfa-2b.,Metamizole
DB01265,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Telbivudine.,Telbivudine
DB01097,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Leflunomide.,Leflunomide
DB08895,Interferon alfa-2b may increase the immunosuppressive activities of Tofacitinib.,Tofacitinib
DB00072,Trastuzumab may increase the neutropenic activities of Interferon alfa-2b.,Trastuzumab
DB08868,Interferon alfa-2b may increase the immunosuppressive activities of Fingolimod.,Fingolimod
DB00864,Tacrolimus may increase the immunosuppressive activities of Interferon alfa-2b.,Tacrolimus
DB00201,The metabolism of Caffeine can be decreased when combined with Interferon alfa-2b.,Caffeine
DB00651,The metabolism of Dyphylline can be decreased when combined with Interferon alfa-2b.,Dyphylline
DB00806,The metabolism of Pentoxifylline can be decreased when combined with Interferon alfa-2b.,Pentoxifylline
DB01303,The metabolism of Oxtriphylline can be decreased when combined with Interferon alfa-2b.,Oxtriphylline
DB01412,The metabolism of Theobromine can be decreased when combined with Interferon alfa-2b.,Theobromine
DB01482,The metabolism of Fenethylline can be decreased when combined with Interferon alfa-2b.,Fenethylline
DB01667,The metabolism of 8-azaguanine can be decreased when combined with Interferon alfa-2b.,8-azaguanine
DB01978,"The metabolism of 7,9-Dimethylguanine can be decreased when combined with Interferon alfa-2b.","7,9-Dimethylguanine"
DB02134,The metabolism of Xanthine can be decreased when combined with Interferon alfa-2b.,Xanthine
DB02245,The metabolism of 7-Deazaguanine can be decreased when combined with Interferon alfa-2b.,7-Deazaguanine
DB02377,The metabolism of Guanine can be decreased when combined with Interferon alfa-2b.,Guanine
DB02489,The metabolism of 9-Methylguanine can be decreased when combined with Interferon alfa-2b.,9-Methylguanine
DB02568,The metabolism of Peldesine can be decreased when combined with Interferon alfa-2b.,Peldesine
DB04076,The metabolism of Hypoxanthine can be decreased when combined with Interferon alfa-2b.,Hypoxanthine
DB04356,The metabolism of 9-Deazaguanine can be decreased when combined with Interferon alfa-2b.,9-Deazaguanine
DB06479,The metabolism of Propentofylline can be decreased when combined with Interferon alfa-2b.,Propentofylline
DB06575,The metabolism of Valomaciclovir can be decreased when combined with Interferon alfa-2b.,Valomaciclovir
DB07954,The metabolism of 3-isobutyl-1-methyl-7H-xanthine can be decreased when combined with Interferon alfa-2b.,3-isobutyl-1-methyl-7H-xanthine
DB08844,The metabolism of Uric acid can be decreased when combined with Interferon alfa-2b.,Uric acid
DB09273,The metabolism of Doxofylline can be decreased when combined with Interferon alfa-2b.,Doxofylline
DB11919,The metabolism of 6-O-benzylguanine can be decreased when combined with Interferon alfa-2b.,6-O-benzylguanine
DB12406,The metabolism of Lisofylline can be decreased when combined with Interferon alfa-2b.,Lisofylline
DB12531,The metabolism of Lobucavir can be decreased when combined with Interferon alfa-2b.,Lobucavir
DB12926,The metabolism of Cafedrine can be decreased when combined with Interferon alfa-2b.,Cafedrine
DB12927,The metabolism of Theodrenaline can be decreased when combined with Interferon alfa-2b.,Theodrenaline
DB13203,The metabolism of Bamifylline can be decreased when combined with Interferon alfa-2b.,Bamifylline
DB13449,The metabolism of Proxyphylline can be decreased when combined with Interferon alfa-2b.,Proxyphylline
DB13573,The metabolism of Acefylline can be decreased when combined with Interferon alfa-2b.,Acefylline
DB13592,The metabolism of Etamiphylline can be decreased when combined with Interferon alfa-2b.,Etamiphylline
DB13634,The metabolism of Pentifylline can be decreased when combined with Interferon alfa-2b.,Pentifylline
DB13812,The metabolism of Bufylline can be decreased when combined with Interferon alfa-2b.,Bufylline
DB14018,The metabolism of Bromotheophylline can be decreased when combined with Interferon alfa-2b.,Bromotheophylline
DB14029,The metabolism of Furafylline can be decreased when combined with Interferon alfa-2b.,Furafylline
DB14132,The metabolism of 8-chlorotheophylline can be decreased when combined with Interferon alfa-2b.,8-chlorotheophylline
DB15122,The metabolism of PCS-499 can be decreased when combined with Interferon alfa-2b.,PCS-499
DB04914,The therapeutic efficacy of G17DT can be decreased when used in combination with Interferon alfa-2b.,G17DT
DB05144,The therapeutic efficacy of PEV3A can be decreased when used in combination with Interferon alfa-2b.,PEV3A
DB05325,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Interferon alfa-2b.,INGN 225
DB05374,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Interferon alfa-2b.,Rindopepimut
DB05440,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Interferon alfa-2b.,SRP 299
DB05942,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Interferon alfa-2b.,GI-5005
DB06400,The therapeutic efficacy of Vitespen can be decreased when used in combination with Interferon alfa-2b.,Vitespen
DB06584,The therapeutic efficacy of TG4010 can be decreased when used in combination with Interferon alfa-2b.,TG4010
DB09057,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Interferon alfa-2b.,Anthrax immune globulin human
DB10062,"The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Interferon alfa-2b.","Rabies virus inactivated antigen, B"
DB10076,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Interferon alfa-2b.,Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen
DB10276,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Interferon alfa-2b.,Rotavirus vaccine
DB10283,"The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Interferon alfa-2b.","Rabies virus inactivated antigen, A"
DB10342,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Interferon alfa-2b.,Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen
DB10583,The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-2b.,Clostridium tetani toxoid antigen (formaldehyde inactivated)
DB10584,The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-2b.,Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
DB10600,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfa-2b.,Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated)
DB10769,The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-2b.,Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)
DB10794,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-2b.,Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated)
DB10803,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Interferon alfa-2b.,Typhoid Vi polysaccharide vaccine
DB10989,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Interferon alfa-2b.,Hepatitis A Vaccine
DB10990,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Interferon alfa-2b.,Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
DB11038,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfa-2b.,Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated)
DB11040,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfa-2b.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated)
DB11041,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfa-2b.,Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)
DB11044,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfa-2b.,Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated)
DB11603,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Interferon alfa-2b.,Human rabies virus immune globulin
DB11627,The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Interferon alfa-2b.,Hepatitis B Vaccine (Recombinant)
DB12568,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Interferon alfa-2b.,Tecemotide
DB14022,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Interferon alfa-2b.,Typhoid vaccine
DB14384,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-2b.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated)
DB14385,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-2b.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)
DB14394,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Interferon alfa-2b.,Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen
DB14445,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-2b.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated)
DB14449,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Interferon alfa-2b.,Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen
DB14619,The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfa-2b.,Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated)
DB14620,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfa-2b.,Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated)
DB14711,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Interferon alfa-2b.,Vaccinia virus strain new york city board of health live antigen
DB15274,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Interferon alfa-2b.,Pertussis vaccine
DB15461,The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-2b.,Yersinia pestis 195/p antigen (formaldehyde inactivated)
DB13924,The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Interferon alfa-2b.,Varicella Zoster Vaccine (Recombinant)
DB15483,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Interferon alfa-2b.,Modified vaccinia ankara
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Interferon alfa-2b.","Ebola Zaire vaccine (live, attenuated)"
DB00054,The risk or severity of bleeding can be increased when Abciximab is combined with Interferon alfa-2b.,Abciximab
DB00063,The risk or severity of bleeding can be increased when Eptifibatide is combined with Interferon alfa-2b.,Eptifibatide
DB00208,The risk or severity of bleeding can be increased when Ticlopidine is combined with Interferon alfa-2b.,Ticlopidine
DB00775,The risk or severity of bleeding can be increased when Tirofiban is combined with Interferon alfa-2b.,Tirofiban
DB00945,The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Interferon alfa-2b.,Acetylsalicylic acid
DB00975,The risk or severity of bleeding can be increased when Dipyridamole is combined with Interferon alfa-2b.,Dipyridamole
DB01088,The risk or severity of bleeding can be increased when Iloprost is combined with Interferon alfa-2b.,Iloprost
DB01138,The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Interferon alfa-2b.,Sulfinpyrazone
DB01207,The risk or severity of bleeding can be increased when Ridogrel is combined with Interferon alfa-2b.,Ridogrel
DB01236,The risk or severity of bleeding can be increased when Sevoflurane is combined with Interferon alfa-2b.,Sevoflurane
DB01240,The risk or severity of bleeding can be increased when Epoprostenol is combined with Interferon alfa-2b.,Epoprostenol
DB04743,The risk or severity of bleeding can be increased when Nimesulide is combined with Interferon alfa-2b.,Nimesulide
DB04905,The risk or severity of bleeding can be increased when Tesmilifene is combined with Interferon alfa-2b.,Tesmilifene
DB04932,The risk or severity of bleeding can be increased when Defibrotide is combined with Interferon alfa-2b.,Defibrotide
DB05229,The risk or severity of bleeding can be increased when Beraprost is combined with Interferon alfa-2b.,Beraprost
DB05266,The risk or severity of bleeding can be increased when Ibudilast is combined with Interferon alfa-2b.,Ibudilast
DB05767,The risk or severity of bleeding can be increased when Andrographolide is combined with Interferon alfa-2b.,Andrographolide
DB06081,The risk or severity of bleeding can be increased when Caplacizumab is combined with Interferon alfa-2b.,Caplacizumab
DB06209,The risk or severity of bleeding can be increased when Prasugrel is combined with Interferon alfa-2b.,Prasugrel
DB06441,The risk or severity of bleeding can be increased when Cangrelor is combined with Interferon alfa-2b.,Cangrelor
DB07615,The risk or severity of bleeding can be increased when Tranilast is combined with Interferon alfa-2b.,Tranilast
DB08814,The risk or severity of bleeding can be increased when Triflusal is combined with Interferon alfa-2b.,Triflusal
DB08816,The risk or severity of bleeding can be increased when Ticagrelor is combined with Interferon alfa-2b.,Ticagrelor
DB08887,The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Interferon alfa-2b.,Icosapent ethyl
DB09030,The risk or severity of bleeding can be increased when Vorapaxar is combined with Interferon alfa-2b.,Vorapaxar
DB09283,The risk or severity of bleeding can be increased when Trapidil is combined with Interferon alfa-2b.,Trapidil
DB12092,The risk or severity of bleeding can be increased when Naftopidil is combined with Interferon alfa-2b.,Naftopidil
DB12163,The risk or severity of bleeding can be increased when Sarpogrelate is combined with Interferon alfa-2b.,Sarpogrelate
DB12321,The risk or severity of bleeding can be increased when Ifetroban is combined with Interferon alfa-2b.,Ifetroban
DB12445,The risk or severity of bleeding can be increased when Nitroaspirin is combined with Interferon alfa-2b.,Nitroaspirin
DB12465,The risk or severity of bleeding can be increased when Ketanserin is combined with Interferon alfa-2b.,Ketanserin
DB12545,The risk or severity of bleeding can be increased when Indobufen is combined with Interferon alfa-2b.,Indobufen
DB12749,The risk or severity of bleeding can be increased when Butylphthalide is combined with Interferon alfa-2b.,Butylphthalide
DB12771,The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Interferon alfa-2b.,Hydroxytyrosol
DB13036,The risk or severity of bleeding can be increased when Ramatroban is combined with Interferon alfa-2b.,Ramatroban
DB13327,The risk or severity of bleeding can be increased when Picotamide is combined with Interferon alfa-2b.,Picotamide
DB13367,The risk or severity of bleeding can be increased when Cloricromen is combined with Interferon alfa-2b.,Cloricromen
DB13400,The risk or severity of bleeding can be increased when Linsidomine is combined with Interferon alfa-2b.,Linsidomine
DB13510,The risk or severity of bleeding can be increased when Buflomedil is combined with Interferon alfa-2b.,Buflomedil
DB13929,The risk or severity of bleeding can be increased when Relcovaptan is combined with Interferon alfa-2b.,Relcovaptan
DB11988,Ocrelizumab may increase the immunosuppressive activities of Interferon alfa-2b.,Ocrelizumab
DB13200,Interferon alfa-2b may increase the myelosuppressive activities of Lipegfilgrastim.,Lipegfilgrastim
DB10317,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Interferon alfa-2b.,Rubella virus vaccine
DB10318,The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Interferon alfa-2b.,Varicella Zoster Vaccine (Live/attenuated)
DB10343,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Interferon alfa-2b.,Bacillus calmette-guerin substrain tice live antigen
DB10804,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Interferon alfa-2b.,Bacillus calmette-guerin substrain connaught live antigen
DB10805,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Interferon alfa-2b.,Yellow Fever Vaccine
DB11003,The risk or severity of infection can be increased when Anthrax vaccine is combined with Interferon alfa-2b.,Anthrax vaccine
DB11050,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Interferon alfa-2b.,Typhoid Vaccine Live
DB12386,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Interferon alfa-2b.,Bacillus calmette-guerin substrain danish 1331 live antigen
DB12768,The risk or severity of infection can be increased when BCG vaccine is combined with Interferon alfa-2b.,BCG vaccine
DB14409,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Interferon alfa-2b.,Human adenovirus e serotype 4 strain cl-68578 antigen
DB14443,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Interferon alfa-2b.,Vibrio cholerae CVD 103-HgR strain live antigen
DB14685,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Interferon alfa-2b.,Adenovirus type 7 vaccine live
DB00039,The therapeutic efficacy of Palifermin can be decreased when used in combination with Interferon alfa-2b.,Palifermin
DB00176,The metabolism of Fluvoxamine can be decreased when combined with Interferon alfa-2b.,Fluvoxamine
DB00184,The metabolism of Nicotine can be decreased when combined with Interferon alfa-2b.,Nicotine
DB00195,The metabolism of Betaxolol can be decreased when combined with Interferon alfa-2b.,Betaxolol
DB00261,The metabolism of Anagrelide can be decreased when combined with Interferon alfa-2b.,Anagrelide
DB00280,The metabolism of Disopyramide can be decreased when combined with Interferon alfa-2b.,Disopyramide
DB00281,The metabolism of Lidocaine can be decreased when combined with Interferon alfa-2b.,Lidocaine
DB00286,The metabolism of Conjugated estrogens can be decreased when combined with Interferon alfa-2b.,Conjugated estrogens
DB00296,The metabolism of Ropivacaine can be decreased when combined with Interferon alfa-2b.,Ropivacaine
DB00316,The metabolism of Acetaminophen can be decreased when combined with Interferon alfa-2b.,Acetaminophen
DB00334,The metabolism of Olanzapine can be decreased when combined with Interferon alfa-2b.,Olanzapine
DB00356,The metabolism of Chlorzoxazone can be decreased when combined with Interferon alfa-2b.,Chlorzoxazone
DB00365,The metabolism of Grepafloxacin can be decreased when combined with Interferon alfa-2b.,Grepafloxacin
DB00370,The metabolism of Mirtazapine can be decreased when combined with Interferon alfa-2b.,Mirtazapine
DB00379,The metabolism of Mexiletine can be decreased when combined with Interferon alfa-2b.,Mexiletine
DB00382,The metabolism of Tacrine can be decreased when combined with Interferon alfa-2b.,Tacrine
DB00384,The metabolism of Triamterene can be decreased when combined with Interferon alfa-2b.,Triamterene
DB00420,The metabolism of Promazine can be decreased when combined with Interferon alfa-2b.,Promazine
DB00425,The metabolism of Zolpidem can be decreased when combined with Interferon alfa-2b.,Zolpidem
DB00442,The metabolism of Entecavir can be decreased when combined with Interferon alfa-2b.,Entecavir
DB00461,The metabolism of Nabumetone can be decreased when combined with Interferon alfa-2b.,Nabumetone
DB00468,The metabolism of Quinine can be decreased when combined with Interferon alfa-2b.,Quinine
DB00472,The metabolism of Fluoxetine can be decreased when combined with Interferon alfa-2b.,Fluoxetine
DB00476,The metabolism of Duloxetine can be decreased when combined with Interferon alfa-2b.,Duloxetine
DB00477,The metabolism of Chlorpromazine can be decreased when combined with Interferon alfa-2b.,Chlorpromazine
DB00499,The metabolism of Flutamide can be decreased when combined with Interferon alfa-2b.,Flutamide
DB00502,The metabolism of Haloperidol can be decreased when combined with Interferon alfa-2b.,Haloperidol
DB00518,The metabolism of Albendazole can be decreased when combined with Interferon alfa-2b.,Albendazole
DB00533,The metabolism of Rofecoxib can be decreased when combined with Interferon alfa-2b.,Rofecoxib
DB00568,The metabolism of Cinnarizine can be decreased when combined with Interferon alfa-2b.,Cinnarizine
DB00571,The metabolism of Propranolol can be decreased when combined with Interferon alfa-2b.,Propranolol
DB00586,The metabolism of Diclofenac can be decreased when combined with Interferon alfa-2b.,Diclofenac
DB00629,The metabolism of Guanabenz can be decreased when combined with Interferon alfa-2b.,Guanabenz
DB00661,The metabolism of Verapamil can be decreased when combined with Interferon alfa-2b.,Verapamil
DB00715,The metabolism of Paroxetine can be decreased when combined with Interferon alfa-2b.,Paroxetine
DB00730,The metabolism of Thiabendazole can be decreased when combined with Interferon alfa-2b.,Thiabendazole
DB00740,The metabolism of Riluzole can be decreased when combined with Interferon alfa-2b.,Riluzole
DB00744,The metabolism of Zileuton can be decreased when combined with Interferon alfa-2b.,Zileuton
DB00758,The metabolism of Clopidogrel can be decreased when combined with Interferon alfa-2b.,Clopidogrel
DB00783,The metabolism of Estradiol can be decreased when combined with Interferon alfa-2b.,Estradiol
DB00787,The metabolism of Acyclovir can be decreased when combined with Interferon alfa-2b.,Acyclovir
DB00788,The metabolism of Naproxen can be decreased when combined with Interferon alfa-2b.,Naproxen
DB00831,The metabolism of Trifluoperazine can be decreased when combined with Interferon alfa-2b.,Trifluoperazine
DB00850,The metabolism of Perphenazine can be decreased when combined with Interferon alfa-2b.,Perphenazine
DB00857,The metabolism of Terbinafine can be decreased when combined with Interferon alfa-2b.,Terbinafine
DB00863,The metabolism of Ranitidine can be decreased when combined with Interferon alfa-2b.,Ranitidine
DB00898,The metabolism of Ethanol can be decreased when combined with Interferon alfa-2b.,Ethanol
DB00934,The metabolism of Maprotiline can be decreased when combined with Interferon alfa-2b.,Maprotiline
DB00969,The metabolism of Alosetron can be decreased when combined with Interferon alfa-2b.,Alosetron
DB00978,The metabolism of Lomefloxacin can be decreased when combined with Interferon alfa-2b.,Lomefloxacin
DB00980,The metabolism of Ramelteon can be decreased when combined with Interferon alfa-2b.,Ramelteon
DB00998,The metabolism of Frovatriptan can be decreased when combined with Interferon alfa-2b.,Frovatriptan
DB01002,The metabolism of Levobupivacaine can be decreased when combined with Interferon alfa-2b.,Levobupivacaine
DB01012,The metabolism of Cinacalcet can be decreased when combined with Interferon alfa-2b.,Cinacalcet
DB01037,The metabolism of Selegiline can be decreased when combined with Interferon alfa-2b.,Selegiline
DB01056,The metabolism of Tocainide can be decreased when combined with Interferon alfa-2b.,Tocainide
DB01058,The metabolism of Praziquantel can be decreased when combined with Interferon alfa-2b.,Praziquantel
DB01065,The metabolism of Melatonin can be decreased when combined with Interferon alfa-2b.,Melatonin
DB01087,The metabolism of Primaquine can be decreased when combined with Interferon alfa-2b.,Primaquine
DB01094,The metabolism of Hesperetin can be decreased when combined with Interferon alfa-2b.,Hesperetin
DB01115,The metabolism of Nifedipine can be decreased when combined with Interferon alfa-2b.,Nifedipine
DB01136,The metabolism of Carvedilol can be decreased when combined with Interferon alfa-2b.,Carvedilol
DB01166,The metabolism of Cilostazol can be decreased when combined with Interferon alfa-2b.,Cilostazol
DB01182,The metabolism of Propafenone can be decreased when combined with Interferon alfa-2b.,Propafenone
DB01184,The metabolism of Domperidone can be decreased when combined with Interferon alfa-2b.,Domperidone
DB01191,The metabolism of Dexfenfluramine can be decreased when combined with Interferon alfa-2b.,Dexfenfluramine
DB01367,The metabolism of Rasagiline can be decreased when combined with Interferon alfa-2b.,Rasagiline
DB01405,The metabolism of Temafloxacin can be decreased when combined with Interferon alfa-2b.,Temafloxacin
DB01424,The metabolism of Aminophenazone can be decreased when combined with Interferon alfa-2b.,Aminophenazone
DB01435,The metabolism of Antipyrine can be decreased when combined with Interferon alfa-2b.,Antipyrine
DB01558,The metabolism of Bromazepam can be decreased when combined with Interferon alfa-2b.,Bromazepam
DB01623,The metabolism of Thiothixene can be decreased when combined with Interferon alfa-2b.,Thiothixene
DB01628,The metabolism of Etoricoxib can be decreased when combined with Interferon alfa-2b.,Etoricoxib
DB01645,The metabolism of Genistein can be decreased when combined with Interferon alfa-2b.,Genistein
DB02709,The metabolism of Resveratrol can be decreased when combined with Interferon alfa-2b.,Resveratrol
DB03783,The metabolism of Phenacetin can be decreased when combined with Interferon alfa-2b.,Phenacetin
DB04574,The metabolism of Estrone sulfate can be decreased when combined with Interferon alfa-2b.,Estrone sulfate
DB04841,The metabolism of Flunarizine can be decreased when combined with Interferon alfa-2b.,Flunarizine
DB04871,The metabolism of Lorcaserin can be decreased when combined with Interferon alfa-2b.,Lorcaserin
DB04948,The metabolism of Lofexidine can be decreased when combined with Interferon alfa-2b.,Lofexidine
DB06148,The metabolism of Mianserin can be decreased when combined with Interferon alfa-2b.,Mianserin
DB06210,The metabolism of Eltrombopag can be decreased when combined with Interferon alfa-2b.,Eltrombopag
DB06216,The metabolism of Asenapine can be decreased when combined with Interferon alfa-2b.,Asenapine
DB06235,The metabolism of Vadimezan can be decreased when combined with Interferon alfa-2b.,Vadimezan
DB06292,The metabolism of Dapagliflozin can be decreased when combined with Interferon alfa-2b.,Dapagliflozin
DB06594,The metabolism of Agomelatine can be decreased when combined with Interferon alfa-2b.,Agomelatine
DB06626,The metabolism of Axitinib can be decreased when combined with Interferon alfa-2b.,Axitinib
DB06770,The metabolism of Benzyl alcohol can be decreased when combined with Interferon alfa-2b.,Benzyl alcohol
DB06774,The metabolism of Capsaicin can be decreased when combined with Interferon alfa-2b.,Capsaicin
DB08496,The metabolism of (R)-warfarin can be decreased when combined with Interferon alfa-2b.,(R)-warfarin
DB08883,The metabolism of Perampanel can be decreased when combined with Interferon alfa-2b.,Perampanel
DB09071,The metabolism of Tasimelteon can be decreased when combined with Interferon alfa-2b.,Tasimelteon
DB09118,The metabolism of Stiripentol can be decreased when combined with Interferon alfa-2b.,Stiripentol
DB09225,The metabolism of Zotepine can be decreased when combined with Interferon alfa-2b.,Zotepine
DB09288,The metabolism of Propacetamol can be decreased when combined with Interferon alfa-2b.,Propacetamol
DB09290,The metabolism of Ramosetron can be decreased when combined with Interferon alfa-2b.,Ramosetron
DB11967,The metabolism of Binimetinib can be decreased when combined with Interferon alfa-2b.,Binimetinib
DB12026,The metabolism of Voxilaprevir can be decreased when combined with Interferon alfa-2b.,Voxilaprevir
DB12245,The metabolism of Triclabendazole can be decreased when combined with Interferon alfa-2b.,Triclabendazole
DB12332,The metabolism of Rucaparib can be decreased when combined with Interferon alfa-2b.,Rucaparib
DB12945,The metabolism of Dihydralazine can be decreased when combined with Interferon alfa-2b.,Dihydralazine
DB13952,The metabolism of Estradiol acetate can be decreased when combined with Interferon alfa-2b.,Estradiol acetate
DB13953,The metabolism of Estradiol benzoate can be decreased when combined with Interferon alfa-2b.,Estradiol benzoate
DB13954,The metabolism of Estradiol cypionate can be decreased when combined with Interferon alfa-2b.,Estradiol cypionate
DB13955,The metabolism of Estradiol dienanthate can be decreased when combined with Interferon alfa-2b.,Estradiol dienanthate
DB13956,The metabolism of Estradiol valerate can be decreased when combined with Interferon alfa-2b.,Estradiol valerate
DB11757,The metabolism of Istradefylline can be decreased when combined with Interferon alfa-2b.,Istradefylline
DB00972,The metabolism of Azelastine can be decreased when combined with Interferon alfa-2b.,Azelastine
DB00625,The metabolism of Efavirenz can be decreased when combined with Interferon alfa-2b.,Efavirenz
DB01233,The metabolism of Metoclopramide can be decreased when combined with Interferon alfa-2b.,Metoclopramide
DB04889,The metabolism of Bicifadine can be decreased when combined with Interferon alfa-2b.,Bicifadine
DB05708,The metabolism of GTS-21 can be decreased when combined with Interferon alfa-2b.,GTS-21
DB01195,The metabolism of Flecainide can be decreased when combined with Interferon alfa-2b.,Flecainide
DB00977,The metabolism of Ethinylestradiol can be decreased when combined with Interferon alfa-2b.,Ethinylestradiol
DB00321,The metabolism of Amitriptyline can be decreased when combined with Interferon alfa-2b.,Amitriptyline
DB00458,The metabolism of Imipramine can be decreased when combined with Interferon alfa-2b.,Imipramine
DB01142,The metabolism of Doxepin can be decreased when combined with Interferon alfa-2b.,Doxepin
DB00532,The metabolism of Mephenytoin can be decreased when combined with Interferon alfa-2b.,Mephenytoin
DB00540,The metabolism of Nortriptyline can be decreased when combined with Interferon alfa-2b.,Nortriptyline
DB00575,The metabolism of Clonidine can be decreased when combined with Interferon alfa-2b.,Clonidine
DB00924,The metabolism of Cyclobenzaprine can be decreased when combined with Interferon alfa-2b.,Cyclobenzaprine
DB01151,The metabolism of Desipramine can be decreased when combined with Interferon alfa-2b.,Desipramine
DB01242,The metabolism of Clomipramine can be decreased when combined with Interferon alfa-2b.,Clomipramine
DB11689,The metabolism of Selumetinib can be decreased when combined with Interferon alfa-2b.,Selumetinib
DB00277,The metabolism of Theophylline can be decreased when combined with Interferon alfa-2b.,Theophylline
DB00564,The metabolism of Carbamazepine can be decreased when combined with Interferon alfa-2b.,Carbamazepine
DB00682,The metabolism of Warfarin can be decreased when combined with Interferon alfa-2b.,Warfarin
DB00697,The metabolism of Tizanidine can be decreased when combined with Interferon alfa-2b.,Tizanidine
DB01100,The metabolism of Pimozide can be decreased when combined with Interferon alfa-2b.,Pimozide
DB01223,The metabolism of Aminophylline can be decreased when combined with Interferon alfa-2b.,Aminophylline
DB01418,The metabolism of Acenocoumarol can be decreased when combined with Interferon alfa-2b.,Acenocoumarol
DB00530,The metabolism of Erlotinib can be decreased when combined with Interferon alfa-2b.,Erlotinib
DB09256,The metabolism of Tegafur can be decreased when combined with Interferon alfa-2b.,Tegafur
DB13874,The metabolism of Enasidenib can be decreased when combined with Interferon alfa-2b.,Enasidenib
DB00675,The metabolism of Tamoxifen can be decreased when combined with Interferon alfa-2b.,Tamoxifen
DB00001,The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon alfa-2b.,Lepirudin
DB00006,The risk or severity of bleeding can be increased when Bivalirudin is combined with Interferon alfa-2b.,Bivalirudin
DB00009,The risk or severity of bleeding can be increased when Alteplase is combined with Interferon alfa-2b.,Alteplase
DB00013,The risk or severity of bleeding can be increased when Urokinase is combined with Interferon alfa-2b.,Urokinase
DB00015,The risk or severity of bleeding can be increased when Reteplase is combined with Interferon alfa-2b.,Reteplase
DB00029,The risk or severity of bleeding can be increased when Anistreplase is combined with Interferon alfa-2b.,Anistreplase
DB00031,The risk or severity of bleeding can be increased when Tenecteplase is combined with Interferon alfa-2b.,Tenecteplase
DB00055,The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Interferon alfa-2b.,Drotrecogin alfa
DB00086,The risk or severity of bleeding can be increased when Streptokinase is combined with Interferon alfa-2b.,Streptokinase
DB00266,The risk or severity of bleeding can be increased when Dicoumarol is combined with Interferon alfa-2b.,Dicoumarol
DB00278,The risk or severity of bleeding can be increased when Argatroban is combined with Interferon alfa-2b.,Argatroban
DB00407,The risk or severity of bleeding can be increased when Ardeparin is combined with Interferon alfa-2b.,Ardeparin
DB00498,The risk or severity of bleeding can be increased when Phenindione is combined with Interferon alfa-2b.,Phenindione
DB00569,The risk or severity of bleeding can be increased when Fondaparinux is combined with Interferon alfa-2b.,Fondaparinux
DB00686,The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Interferon alfa-2b.,Pentosan polysulfate
DB00946,The risk or severity of bleeding can be increased when Phenprocoumon is combined with Interferon alfa-2b.,Phenprocoumon
DB01109,The risk or severity of bleeding can be increased when Heparin is combined with Interferon alfa-2b.,Heparin
DB01225,The risk or severity of bleeding can be increased when Enoxaparin is combined with Interferon alfa-2b.,Enoxaparin
DB03410,The risk or severity of bleeding can be increased when 4-hydroxycoumarin is combined with Interferon alfa-2b.,4-hydroxycoumarin
DB04665,The risk or severity of bleeding can be increased when Coumarin is combined with Interferon alfa-2b.,Coumarin
DB04898,The risk or severity of bleeding can be increased when Ximelagatran is combined with Interferon alfa-2b.,Ximelagatran
DB04925,The risk or severity of bleeding can be increased when Desmoteplase is combined with Interferon alfa-2b.,Desmoteplase
DB05099,The risk or severity of bleeding can be increased when Ancrod is combined with Interferon alfa-2b.,Ancrod
DB05254,The risk or severity of bleeding can be increased when Fibrinolysin is combined with Interferon alfa-2b.,Fibrinolysin
DB06228,The risk or severity of bleeding can be increased when Rivaroxaban is combined with Interferon alfa-2b.,Rivaroxaban
DB06271,The risk or severity of bleeding can be increased when Sulodexide is combined with Interferon alfa-2b.,Sulodexide
DB06294,The risk or severity of bleeding can be increased when Semuloparin is combined with Interferon alfa-2b.,Semuloparin
DB06406,The risk or severity of bleeding can be increased when Idraparinux is combined with Interferon alfa-2b.,Idraparinux
DB06543,The risk or severity of bleeding can be increased when Astaxanthin is combined with Interferon alfa-2b.,Astaxanthin
DB06605,The risk or severity of bleeding can be increased when Apixaban is combined with Interferon alfa-2b.,Apixaban
DB06635,The risk or severity of bleeding can be increased when Otamixaban is combined with Interferon alfa-2b.,Otamixaban
DB06679,The risk or severity of bleeding can be increased when Amediplase is combined with Interferon alfa-2b.,Amediplase
DB06695,The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Interferon alfa-2b.,Dabigatran etexilate
DB06754,The risk or severity of bleeding can be increased when Danaparoid is combined with Interferon alfa-2b.,Danaparoid
DB06779,The risk or severity of bleeding can be increased when Dalteparin is combined with Interferon alfa-2b.,Dalteparin
DB06822,The risk or severity of bleeding can be increased when Tinzaparin is combined with Interferon alfa-2b.,Tinzaparin
DB07767,The risk or severity of bleeding can be increased when Ferulic acid is combined with Interferon alfa-2b.,Ferulic acid
DB08794,The risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Interferon alfa-2b.,Ethyl biscoumacetate
DB08813,The risk or severity of bleeding can be increased when Nadroparin is combined with Interferon alfa-2b.,Nadroparin
DB08994,The risk or severity of bleeding can be increased when Ditazole is combined with Interferon alfa-2b.,Ditazole
DB09075,The risk or severity of bleeding can be increased when Edoxaban is combined with Interferon alfa-2b.,Edoxaban
DB09125,The risk or severity of bleeding can be increased when Potassium citrate is combined with Interferon alfa-2b.,Potassium citrate
DB09154,The risk or severity of bleeding can be increased when Sodium citrate is combined with Interferon alfa-2b.,Sodium citrate
DB09255,The risk or severity of bleeding can be increased when Dextran is combined with Interferon alfa-2b.,Dextran
DB09258,The risk or severity of bleeding can be increased when Bemiparin is combined with Interferon alfa-2b.,Bemiparin
DB09259,The risk or severity of bleeding can be increased when Reviparin is combined with Interferon alfa-2b.,Reviparin
DB09260,The risk or severity of bleeding can be increased when Parnaparin is combined with Interferon alfa-2b.,Parnaparin
DB09261,The risk or severity of bleeding can be increased when Certoparin is combined with Interferon alfa-2b.,Certoparin
DB11095,The risk or severity of bleeding can be increased when Desirudin is combined with Interferon alfa-2b.,Desirudin
DB11154,The risk or severity of bleeding can be increased when Zinc citrate is combined with Interferon alfa-2b.,Zinc citrate
DB11166,The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Interferon alfa-2b.,Antithrombin Alfa
DB11312,The risk or severity of bleeding can be increased when Protein C is combined with Interferon alfa-2b.,Protein C
DB11598,The risk or severity of bleeding can be increased when Antithrombin III human is combined with Interferon alfa-2b.,Antithrombin III human
DB11984,The risk or severity of bleeding can be increased when Letaxaban is combined with Interferon alfa-2b.,Letaxaban
DB12289,The risk or severity of bleeding can be increased when Darexaban is combined with Interferon alfa-2b.,Darexaban
DB12364,The risk or severity of bleeding can be increased when Betrixaban is combined with Interferon alfa-2b.,Betrixaban
DB12598,The risk or severity of bleeding can be increased when Nafamostat is combined with Interferon alfa-2b.,Nafamostat
DB12726,The risk or severity of bleeding can be increased when Monteplase is combined with Interferon alfa-2b.,Monteplase
DB12831,The risk or severity of bleeding can be increased when Gabexate is combined with Interferon alfa-2b.,Gabexate
DB13136,The risk or severity of bleeding can be increased when Fluindione is combined with Interferon alfa-2b.,Fluindione
DB13149,The risk or severity of bleeding can be increased when Protein S human is combined with Interferon alfa-2b.,Protein S human
DB13199,The risk or severity of bleeding can be increased when Brinase is combined with Interferon alfa-2b.,Brinase
DB13275,The risk or severity of bleeding can be increased when Clorindione is combined with Interferon alfa-2b.,Clorindione
DB13347,The risk or severity of bleeding can be increased when Diphenadione is combined with Interferon alfa-2b.,Diphenadione
DB13451,The risk or severity of bleeding can be increased when Tioclomarol is combined with Interferon alfa-2b.,Tioclomarol
DB13616,The risk or severity of bleeding can be increased when Melagatran is combined with Interferon alfa-2b.,Melagatran
DB13646,The risk or severity of bleeding can be increased when Saruplase is combined with Interferon alfa-2b.,Saruplase
DB14055,The risk or severity of bleeding can be increased when (S)-Warfarin is combined with Interferon alfa-2b.,(S)-Warfarin
DB14094,The risk or severity of bleeding can be increased when Tocopherylquinone is combined with Interferon alfa-2b.,Tocopherylquinone
DB14598,The risk or severity of bleeding can be increased when Edetate calcium disodium anhydrous is combined with Interferon alfa-2b.,Edetate calcium disodium anhydrous
DB14726,The risk or severity of bleeding can be increased when Dabigatran is combined with Interferon alfa-2b.,Dabigatran
DB00232,The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Interferon alfa-2b.,Methyclothiazide
DB00436,The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Interferon alfa-2b.,Bendroflumethiazide
DB00562,The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Interferon alfa-2b.,Benzthiazide
DB00606,The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Interferon alfa-2b.,Cyclothiazide
DB00774,The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Interferon alfa-2b.,Hydroflumethiazide
DB00880,The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Interferon alfa-2b.,Chlorothiazide
DB00999,The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Interferon alfa-2b.,Hydrochlorothiazide
DB01021,The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Interferon alfa-2b.,Trichlormethiazide
DB01324,The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Interferon alfa-2b.,Polythiazide
DB13430,The risk or severity of neutropenia and thrombocytopenia can be increased when Mebutizide is combined with Interferon alfa-2b.,Mebutizide
DB13532,The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Interferon alfa-2b.,Cyclopenthiazide
DB09042,The risk or severity of myelosuppression can be increased when Interferon alfa-2b is combined with Tedizolid phosphate.,Tedizolid phosphate
DB00091,Interferon alfa-2b may increase the immunosuppressive activities of Cyclosporine.,Cyclosporine
DB00268,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Ropinirole.,Ropinirole
DB00115,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Interferon alfa-2b.,Cyanocobalamin
DB00437,The risk or severity of adverse effects can be increased when Allopurinol is combined with Interferon alfa-2b.,Allopurinol
DB12978,Interferon alfa-2b may increase the hepatotoxic activities of Pexidartinib.,Pexidartinib
DB14513,The serum concentration of Magnesium can be decreased when it is combined with Interferon alfa-2b.,Magnesium
DB01601,The serum concentration of Interferon alfa-2b can be increased when it is combined with Lopinavir.,Lopinavir
DB12530,The risk or severity of infection can be increased when Interferon alfa-2b is combined with Inebilizumab.,Inebilizumab
DB00429,Carboprost tromethamine may increase the uterotonic activities of Oxytocin.,Carboprost tromethamine
DB00917,The risk or severity of adverse effects can be increased when Dinoprostone is combined with Oxytocin.,Dinoprostone
DB00929,The risk or severity of adverse effects can be increased when Misoprostol is combined with Oxytocin.,Misoprostol
DB00007,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Leuprolide.,Leuprolide
DB00014,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Goserelin.,Goserelin
DB00195,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Betaxolol.,Betaxolol
DB00199,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Erythromycin.,Erythromycin
DB00207,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Azithromycin.,Azithromycin
DB00218,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Moxifloxacin.,Moxifloxacin
DB00243,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ranolazine.,Ranolazine
DB00263,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sulfisoxazole.,Sulfisoxazole
DB00321,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Amitriptyline.,Amitriptyline
DB00333,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Methadone.,Methadone
DB00343,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Diltiazem.,Diltiazem
DB00363,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Clozapine.,Clozapine
DB00391,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sulpiride.,Sulpiride
DB00393,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nimodipine.,Nimodipine
DB00420,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Promazine.,Promazine
DB00433,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Prochlorperazine.,Prochlorperazine
DB00450,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Droperidol.,Droperidol
DB00458,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Imipramine.,Imipramine
DB00477,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Chlorpromazine.,Chlorpromazine
DB00526,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Oxaliplatin.,Oxaliplatin
DB00537,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ciprofloxacin.,Ciprofloxacin
DB00544,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Fluorouracil.,Fluorouracil
DB00556,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Perflutren.,Perflutren
DB00568,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Cinnarizine.,Cinnarizine
DB00571,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Propranolol.,Propranolol
DB00572,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Atropine.,Atropine
DB00608,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Chloroquine.,Chloroquine
DB00625,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Efavirenz.,Efavirenz
DB00640,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Adenosine.,Adenosine
DB00738,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pentamidine.,Pentamidine
DB00743,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Gadobenic acid.,Gadobenic acid
DB00748,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Carbinoxamine.,Carbinoxamine
DB00757,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dolasetron.,Dolasetron
DB00778,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Roxithromycin.,Roxithromycin
DB00779,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nalidixic acid.,Nalidixic acid
DB00827,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Cinoxacin.,Cinoxacin
DB00836,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Loperamide.,Loperamide
DB00889,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Granisetron.,Granisetron
DB00904,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ondansetron.,Ondansetron
DB00922,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Levosimendan.,Levosimendan
DB00933,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mesoridazine.,Mesoridazine
DB00967,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Desloratadine.,Desloratadine
DB00976,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Telithromycin.,Telithromycin
DB00978,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lomefloxacin.,Lomefloxacin
DB00985,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dimenhydrinate.,Dimenhydrinate
DB01087,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Primaquine.,Primaquine
DB01113,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Papaverine.,Papaverine
DB01114,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Chlorpheniramine.,Chlorpheniramine
DB01115,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nifedipine.,Nifedipine
DB01137,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Levofloxacin.,Levofloxacin
DB01155,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Gemifloxacin.,Gemifloxacin
DB01165,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ofloxacin.,Ofloxacin
DB01182,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Propafenone.,Propafenone
DB01193,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Acebutolol.,Acebutolol
DB01195,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Flecainide.,Flecainide
DB01211,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Clarithromycin.,Clarithromycin
DB01227,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Levacetylmethadol.,Levacetylmethadol
DB01232,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Saquinavir.,Saquinavir
DB01242,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Clomipramine.,Clomipramine
DB01388,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mibefradil.,Mibefradil
DB01580,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Oxprenolol.,Oxprenolol
DB01599,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Probucol.,Probucol
DB01615,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Aceprometazine.,Aceprometazine
DB02638,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Terlipressin.,Terlipressin
DB04825,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Prenylamine.,Prenylamine
DB04842,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Fluspirilene.,Fluspirilene
DB04948,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lofexidine.,Lofexidine
DB04957,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Azimilide.,Azimilide
DB05223,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pracinostat.,Pracinostat
DB05488,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Technetium Tc-99m ciprofloxacin.,Technetium Tc-99m ciprofloxacin
DB06160,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Garenoxacin.,Garenoxacin
DB06200,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Tedisamil.,Tedisamil
DB06334,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Tucidinostat.,Tucidinostat
DB06402,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Telavancin.,Telavancin
DB06589,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pazopanib.,Pazopanib
DB06600,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nemonoxacin.,Nemonoxacin
DB06603,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Panobinostat.,Panobinostat
DB06712,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nilvadipine.,Nilvadipine
DB08799,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Antazoline.,Antazoline
DB08865,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Crizotinib.,Crizotinib
DB08903,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Bedaquiline.,Bedaquiline
DB08952,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Indenolol.,Indenolol
DB08980,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Fendiline.,Fendiline
DB08992,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Eperisone.,Eperisone
DB09016,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Butriptyline.,Butriptyline
DB09063,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ceritinib.,Ceritinib
DB09078,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lenvatinib.,Lenvatinib
DB09224,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Melperone.,Melperone
DB09231,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Benidipine.,Benidipine
DB09555,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dexchlorpheniramine maleate.,Dexchlorpheniramine maleate
DB11640,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Amifampridine.,Amifampridine
DB11830,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mocetinostat.,Mocetinostat
DB11841,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Entinostat.,Entinostat
DB12141,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Gilteritinib.,Gilteritinib
DB12174,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with CUDC-101.,CUDC-101
DB12286,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Simendan.,Simendan
DB12376,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ricolinostat.,Ricolinostat
DB12523,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mizolastine.,Mizolastine
DB12565,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Abexinostat.,Abexinostat
DB12877,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Oxatomide.,Oxatomide
DB13261,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sitafloxacin.,Sitafloxacin
DB13273,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sultopride.,Sultopride
DB13500,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Otilonium.,Otilonium
DB13546,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nizofenone.,Nizofenone
DB13652,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Bunaftine.,Bunaftine
DB13653,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lorcainide.,Lorcainide
DB13679,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dexchlorpheniramine.,Dexchlorpheniramine
DB13791,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Penfluridol.,Penfluridol
DB14063,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dexverapamil.,Dexverapamil
DB14568,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ivosidenib.,Ivosidenib
DB01224,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Quetiapine.,Quetiapine
DB11718,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Encorafenib.,Encorafenib
DB00204,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dofetilide.,Dofetilide
DB00215,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Citalopram.,Citalopram
DB00261,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Anagrelide.,Anagrelide
DB00280,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Disopyramide.,Disopyramide
DB00283,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Clemastine.,Clemastine
DB00308,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ibutilide.,Ibutilide
DB00313,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Valproic acid.,Valproic acid
DB00342,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Terfenadine.,Terfenadine
DB00365,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Grepafloxacin.,Grepafloxacin
DB00468,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Quinine.,Quinine
DB00489,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sotalol.,Sotalol
DB00530,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Erlotinib.,Erlotinib
DB00539,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Toremifene.,Toremifene
DB00604,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Cisapride.,Cisapride
DB00619,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Imatinib.,Imatinib
DB00637,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Astemizole.,Astemizole
DB00679,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Thioridazine.,Thioridazine
DB00685,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Trovafloxacin.,Trovafloxacin
DB00834,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mifepristone.,Mifepristone
DB00875,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Flupentixol.,Flupentixol
DB00907,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Cocaine.,Cocaine
DB00908,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Quinidine.,Quinidine
DB01035,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Procainamide.,Procainamide
DB01100,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pimozide.,Pimozide
DB01118,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Amiodarone.,Amiodarone
DB01169,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Arsenic trioxide.,Arsenic trioxide
DB01175,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Escitalopram.,Escitalopram
DB01184,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Domperidone.,Domperidone
DB01208,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sparfloxacin.,Sparfloxacin
DB01218,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Halofantrine.,Halofantrine
DB01244,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Bepridil.,Bepridil
DB01267,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Paliperidone.,Paliperidone
DB01356,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lithium cation.,Lithium cation
DB01405,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Temafloxacin.,Temafloxacin
DB01624,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Zuclopenthixol.,Zuclopenthixol
DB04844,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Tetrabenazine.,Tetrabenazine
DB04855,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dronedarone.,Dronedarone
DB04868,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nilotinib.,Nilotinib
DB04946,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Iloperidone.,Iloperidone
DB05294,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Vandetanib.,Vandetanib
DB06176,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Romidepsin.,Romidepsin
DB06216,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Asenapine.,Asenapine
DB06697,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Artemether.,Artemether
DB06708,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lumefantrine.,Lumefantrine
DB09039,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Eliglustat.,Eliglustat
DB09083,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ivabradine.,Ivabradine
DB11730,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ribociclib.,Ribociclib
DB11978,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Glasdegib.,Glasdegib
DB12161,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Deutetrabenazine.,Deutetrabenazine
DB13074,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Macimorelin.,Macimorelin
DB13725,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Terodiline.,Terodiline
DB08881,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Vemurafenib.,Vemurafenib
DB11637,Oxytocin may increase the QTc-prolonging activities of Delamanid.,Delamanid
DB00104,The risk or severity of QTc prolongation can be increased when Octreotide is combined with Oxytocin.,Octreotide
DB00187,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Esmolol.,Esmolol
DB00188,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Bortezomib.,Bortezomib
DB00196,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Fluconazole.,Fluconazole
DB00220,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nelfinavir.,Nelfinavir
DB00230,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pregabalin.,Pregabalin
DB00245,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Benzatropine.,Benzatropine
DB00270,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Isradipine.,Isradipine
DB00285,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Venlafaxine.,Venlafaxine
DB00289,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Atomoxetine.,Atomoxetine
DB00334,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Olanzapine.,Olanzapine
DB00341,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Cetirizine.,Cetirizine
DB00344,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Protriptyline.,Protriptyline
DB00346,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Alfuzosin.,Alfuzosin
DB00347,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Trimethadione.,Trimethadione
DB00354,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Buclizine.,Buclizine
DB00358,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mefloquine.,Mefloquine
DB00366,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Doxylamine.,Doxylamine
DB00370,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mirtazapine.,Mirtazapine
DB00373,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Timolol.,Timolol
DB00374,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Treprostinil.,Treprostinil
DB00390,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Digoxin.,Digoxin
DB00398,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sorafenib.,Sorafenib
DB00405,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dexbrompheniramine.,Dexbrompheniramine
DB00424,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Hyoscyamine.,Hyoscyamine
DB00427,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Triprolidine.,Triprolidine
DB00434,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Cyproheptadine.,Cyproheptadine
DB00467,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Enoxacin.,Enoxacin
DB00487,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pefloxacin.,Pefloxacin
DB00503,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ritonavir.,Ritonavir
DB00529,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Foscarnet.,Foscarnet
DB00540,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nortriptyline.,Nortriptyline
DB00543,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Amoxapine.,Amoxapine
DB00555,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lamotrigine.,Lamotrigine
DB00582,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Voriconazole.,Voriconazole
DB00593,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ethosuximide.,Ethosuximide
DB00613,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Amodiaquine.,Amodiaquine
DB00622,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nicardipine.,Nicardipine
DB00674,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Galantamine.,Galantamine
DB00675,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Tamoxifen.,Tamoxifen
DB00678,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Losartan.,Losartan
DB00680,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Moricizine.,Moricizine
DB00691,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Moexipril.,Moexipril
DB00697,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Tizanidine.,Tizanidine
DB00710,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ibandronate.,Ibandronate
DB00714,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Apomorphine.,Apomorphine
DB00719,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Azatadine.,Azatadine
DB00726,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Trimipramine.,Trimipramine
DB00734,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Risperidone.,Risperidone
DB00753,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Isoflurane.,Isoflurane
DB00808,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Indapamide.,Indapamide
DB00817,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Rosoxacin.,Rosoxacin
DB00818,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Propofol.,Propofol
DB00822,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Disulfiram.,Disulfiram
DB00825,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Levomenthol.,Levomenthol
DB00835,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Brompheniramine.,Brompheniramine
DB00862,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Vardenafil.,Vardenafil
DB00864,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Tacrolimus.,Tacrolimus
DB00871,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Terbutaline.,Terbutaline
DB00909,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Zonisamide.,Zonisamide
DB00915,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Amantadine.,Amantadine
DB00916,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Metronidazole.,Metronidazole
DB00920,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ketotifen.,Ketotifen
DB00927,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Famotidine.,Famotidine
DB00934,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Maprotiline.,Maprotiline
DB00938,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Salmeterol.,Salmeterol
DB00949,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Felbamate.,Felbamate
DB00983,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Formoterol.,Formoterol
DB00999,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Hydrochlorothiazide.,Hydrochlorothiazide
DB01001,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Salbutamol.,Salbutamol
DB01015,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sulfamethoxazole.,Sulfamethoxazole
DB01023,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Felodipine.,Felodipine
DB01026,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ketoconazole.,Ketoconazole
DB01036,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Tolterodine.,Tolterodine
DB01044,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Gatifloxacin.,Gatifloxacin
DB01054,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Nitrendipine.,Nitrendipine
DB01059,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Norfloxacin.,Norfloxacin
DB01069,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Promethazine.,Promethazine
DB01071,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mequitazine.,Mequitazine
DB01072,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Atazanavir.,Atazanavir
DB01074,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Perhexiline.,Perhexiline
DB01075,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Diphenhydramine.,Diphenhydramine
DB01106,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Levocabastine.,Levocabastine
DB01142,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Doxepin.,Doxepin
DB01151,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Desipramine.,Desipramine
DB01158,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Bretylium.,Bretylium
DB01166,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Cilostazol.,Cilostazol
DB01167,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Itraconazole.,Itraconazole
DB01173,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Orphenadrine.,Orphenadrine
DB01176,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Cyclizine.,Cyclizine
DB01189,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Desflurane.,Desflurane
DB01228,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Encainide.,Encainide
DB01233,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Metoclopramide.,Metoclopramide
DB01236,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sevoflurane.,Sevoflurane
DB01238,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Aripiprazole.,Aripiprazole
DB01239,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Chlorprothixene.,Chlorprothixene
DB01246,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Alimemazine.,Alimemazine
DB01254,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dasatinib.,Dasatinib
DB01259,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lapatinib.,Lapatinib
DB01263,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Posaconazole.,Posaconazole
DB01268,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sunitinib.,Sunitinib
DB01274,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Arformoterol.,Arformoterol
DB01396,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Digitoxin.,Digitoxin
DB01403,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Methotrimeprazine.,Methotrimeprazine
DB01426,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ajmaline.,Ajmaline
DB01591,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Solifenacin.,Solifenacin
DB01611,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Hydroxychloroquine.,Hydroxychloroquine
DB01620,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pheniramine.,Pheniramine
DB01623,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Thiothixene.,Thiothixene
DB02546,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Vorinostat.,Vorinostat
DB04576,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Fleroxacin.,Fleroxacin
DB04695,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Farnesyl thiopyrophosphate.,Farnesyl thiopyrophosphate
DB04846,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Celiprolol.,Celiprolol
DB04953,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ezogabine.,Ezogabine
DB05039,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Indacaterol.,Indacaterol
DB05246,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Methsuximide.,Methsuximide
DB05465,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Tandutinib.,Tandutinib
DB06217,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Vernakalant.,Vernakalant
DB06282,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Levocetirizine.,Levocetirizine
DB06288,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Amisulpride.,Amisulpride
DB06468,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Cariporide.,Cariporide
DB06663,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pasireotide.,Pasireotide
DB06691,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mepyramine.,Mepyramine
DB06699,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Degarelix.,Degarelix
DB06719,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Buserelin.,Buserelin
DB06788,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Histrelin.,Histrelin
DB06825,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Triptorelin.,Triptorelin
DB07780,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Farnesyl diphosphate.,Farnesyl diphosphate
DB07841,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Geranylgeranyl diphosphate.,Geranylgeranyl diphosphate
DB08808,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Bupranolol.,Bupranolol
DB08815,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lurasidone.,Lurasidone
DB08864,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Rilpivirine.,Rilpivirine
DB08871,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Eribulin.,Eribulin
DB08893,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Mirabegron.,Mirabegron
DB08912,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dabrafenib.,Dabrafenib
DB08936,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Chlorcyclizine.,Chlorcyclizine
DB08972,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Flumequine.,Flumequine
DB09080,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Olodaterol.,Olodaterol
DB09082,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Vilanterol.,Vilanterol
DB09089,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Trimebutine.,Trimebutine
DB09090,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pinaverium.,Pinaverium
DB09167,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dosulepin.,Dosulepin
DB09229,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Aranidipine.,Aranidipine
DB09235,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Efonidipine.,Efonidipine
DB09236,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lacidipine.,Lacidipine
DB09239,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Niguldipine.,Niguldipine
DB09488,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Acrivastine.,Acrivastine
DB11390,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Coumaphos.,Coumaphos
DB11397,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dichlorvos.,Dichlorvos
DB11408,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Famphur.,Famphur
DB11412,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Fenthion.,Fenthion
DB11443,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Orbifloxacin.,Orbifloxacin
DB11448,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Phosmet.,Phosmet
DB11491,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sarafloxacin.,Sarafloxacin
DB11511,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Difloxacin.,Difloxacin
DB11591,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Bilastine.,Bilastine
DB11614,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Rupatadine.,Rupatadine
DB11742,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ebastine.,Ebastine
DB11770,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Talinolol.,Talinolol
DB11774,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pazufloxacin.,Pazufloxacin
DB11785,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Anisodamine.,Anisodamine
DB11891,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with CUDC-907.,CUDC-907
DB11892,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Prulifloxacin.,Prulifloxacin
DB11943,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Delafloxacin.,Delafloxacin
DB12093,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Tetrahydropalmatine.,Tetrahydropalmatine
DB12231,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Temefos.,Temefos
DB12245,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Triclabendazole.,Triclabendazole
DB12645,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Givinostat.,Givinostat
DB12712,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pilsicainide.,Pilsicainide
DB12766,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Cicletanine.,Cicletanine
DB12923,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Gallopamil.,Gallopamil
DB13358,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Cibenzoline.,Cibenzoline
DB13488,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Bencyclane.,Bencyclane
DB13555,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Prajmaline.,Prajmaline
DB13627,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Oxolinic acid.,Oxolinic acid
DB13651,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lorajmine.,Lorajmine
DB13691,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Acetyldigoxin.,Acetyldigoxin
DB13744,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Piromidic acid.,Piromidic acid
DB13766,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lidoflazine.,Lidoflazine
DB13772,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Rufloxacin.,Rufloxacin
DB13823,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Pipemidic acid.,Pipemidic acid
DB14185,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Aripiprazole lauroxil.,Aripiprazole lauroxil
DB14713,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Inotersen.,Inotersen
DB01601,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Lopinavir.,Lopinavir
DB00845,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Clofazimine.,Clofazimine
DB00656,The risk or severity of QTc prolongation can be increased when Trazodone is combined with Oxytocin.,Trazodone
DB11986,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Entrectinib.,Entrectinib
DB11642,Oxytocin may increase the QTc-prolonging activities of Pitolisant.,Pitolisant
DB12825,Lefamulin may increase the QTc-prolonging activities of Oxytocin.,Lefamulin
DB00388,The risk or severity of hypertension can be increased when Oxytocin is combined with Phenylephrine.,Phenylephrine
DB00557,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Hydroxyzine.,Hydroxyzine
DB00246,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ziprasidone.,Ziprasidone
DB00502,The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Haloperidol.,Haloperidol
DB01364,The risk or severity of hypertension can be increased when Oxytocin is combined with Ephedrine.,Ephedrine
DB00472,The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Oxytocin.,Fluoxetine
DB06643,The risk or severity of adverse effects can be increased when Denosumab is combined with Natalizumab.,Denosumab
DB00005,The risk or severity of adverse effects can be increased when Etanercept is combined with Natalizumab.,Etanercept
DB00008,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Natalizumab.,Peginterferon alfa-2a
DB00011,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Natalizumab.,Interferon alfa-n1
DB00018,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Natalizumab.,Interferon alfa-n3
DB00022,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Natalizumab.,Peginterferon alfa-2b
DB00026,The risk or severity of adverse effects can be increased when Anakinra is combined with Natalizumab.,Anakinra
DB00033,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Natalizumab.,Interferon gamma-1b
DB00034,"The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Natalizumab.","Interferon alfa-2a, Recombinant"
DB00041,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Natalizumab.,Aldesleukin
DB00051,The risk or severity of adverse effects can be increased when Adalimumab is combined with Natalizumab.,Adalimumab
DB00056,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Natalizumab.,Gemtuzumab ozogamicin
DB00059,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Natalizumab.,Pegaspargase
DB00065,The risk or severity of adverse effects can be increased when Infliximab is combined with Natalizumab.,Infliximab
DB00068,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Natalizumab.,Interferon beta-1b
DB00069,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Natalizumab.,Interferon alfacon-1
DB00072,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Natalizumab.,Trastuzumab
DB00073,The risk or severity of adverse effects can be increased when Rituximab is combined with Natalizumab.,Rituximab
DB00074,The risk or severity of adverse effects can be increased when Basiliximab is combined with Natalizumab.,Basiliximab
DB00075,The risk or severity of adverse effects can be increased when Muromonab is combined with Natalizumab.,Muromonab
DB00078,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Natalizumab.,Ibritumomab tiuxetan
DB00081,The risk or severity of adverse effects can be increased when Tositumomab is combined with Natalizumab.,Tositumomab
DB00087,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Natalizumab.,Alemtuzumab
DB00092,The risk or severity of adverse effects can be increased when Alefacept is combined with Natalizumab.,Alefacept
DB00095,The risk or severity of adverse effects can be increased when Efalizumab is combined with Natalizumab.,Efalizumab
DB00098,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Natalizumab.,Antithymocyte immunoglobulin (rabbit)
DB00105,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Natalizumab.,Interferon alfa-2b
DB00111,The risk or severity of adverse effects can be increased when Daclizumab is combined with Natalizumab.,Daclizumab
DB00112,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Natalizumab.,Bevacizumab
DB00120,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Natalizumab.,Phenylalanine
DB00180,The risk or severity of adverse effects can be increased when Flunisolide is combined with Natalizumab.,Flunisolide
DB00188,The risk or severity of adverse effects can be increased when Bortezomib is combined with Natalizumab.,Bortezomib
DB00242,The risk or severity of adverse effects can be increased when Cladribine is combined with Natalizumab.,Cladribine
DB00262,The risk or severity of adverse effects can be increased when Carmustine is combined with Natalizumab.,Carmustine
DB00276,The risk or severity of adverse effects can be increased when Amsacrine is combined with Natalizumab.,Amsacrine
DB00290,The risk or severity of adverse effects can be increased when Bleomycin is combined with Natalizumab.,Bleomycin
DB00291,The risk or severity of adverse effects can be increased when Chlorambucil is combined with Natalizumab.,Chlorambucil
DB00293,The risk or severity of adverse effects can be increased when Raltitrexed is combined with Natalizumab.,Raltitrexed
DB00305,The risk or severity of adverse effects can be increased when Mitomycin is combined with Natalizumab.,Mitomycin
DB00307,The risk or severity of adverse effects can be increased when Bexarotene is combined with Natalizumab.,Bexarotene
DB00309,The risk or severity of adverse effects can be increased when Vindesine is combined with Natalizumab.,Vindesine
DB00322,The risk or severity of adverse effects can be increased when Floxuridine is combined with Natalizumab.,Floxuridine
DB00328,The risk or severity of adverse effects can be increased when Indomethacin is combined with Natalizumab.,Indomethacin
DB00352,The risk or severity of adverse effects can be increased when Tioguanine is combined with Natalizumab.,Tioguanine
DB00361,The risk or severity of adverse effects can be increased when Vinorelbine is combined with Natalizumab.,Vinorelbine
DB00380,The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Natalizumab.,Dexrazoxane
DB00394,The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Natalizumab.,Beclomethasone dipropionate
DB00398,The risk or severity of adverse effects can be increased when Sorafenib is combined with Natalizumab.,Sorafenib
DB00428,The risk or severity of adverse effects can be increased when Streptozocin is combined with Natalizumab.,Streptozocin
DB00432,The risk or severity of adverse effects can be increased when Trifluridine is combined with Natalizumab.,Trifluridine
DB00441,The risk or severity of adverse effects can be increased when Gemcitabine is combined with Natalizumab.,Gemcitabine
DB00443,The risk or severity of adverse effects can be increased when Betamethasone is combined with Natalizumab.,Betamethasone
DB00444,The risk or severity of adverse effects can be increased when Teniposide is combined with Natalizumab.,Teniposide
DB00445,The risk or severity of adverse effects can be increased when Epirubicin is combined with Natalizumab.,Epirubicin
DB00446,The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Natalizumab.,Chloramphenicol
DB00480,The risk or severity of adverse effects can be increased when Lenalidomide is combined with Natalizumab.,Lenalidomide
DB00488,The risk or severity of adverse effects can be increased when Altretamine is combined with Natalizumab.,Altretamine
DB00495,The risk or severity of adverse effects can be increased when Zidovudine is combined with Natalizumab.,Zidovudine
DB00515,The risk or severity of adverse effects can be increased when Cisplatin is combined with Natalizumab.,Cisplatin
DB00526,The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Natalizumab.,Oxaliplatin
DB00531,The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Natalizumab.,Cyclophosphamide
DB00541,The risk or severity of adverse effects can be increased when Vincristine is combined with Natalizumab.,Vincristine
DB00544,The risk or severity of adverse effects can be increased when Fluorouracil is combined with Natalizumab.,Fluorouracil
DB00550,The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Natalizumab.,Propylthiouracil
DB00552,The risk or severity of adverse effects can be increased when Pentostatin is combined with Natalizumab.,Pentostatin
DB00563,The risk or severity of adverse effects can be increased when Methotrexate is combined with Natalizumab.,Methotrexate
DB00564,The risk or severity of adverse effects can be increased when Carbamazepine is combined with Natalizumab.,Carbamazepine
DB00570,The risk or severity of adverse effects can be increased when Vinblastine is combined with Natalizumab.,Vinblastine
DB00588,The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Natalizumab.,Fluticasone propionate
DB00591,The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Natalizumab.,Fluocinolone acetonide
DB00601,The risk or severity of adverse effects can be increased when Linezolid is combined with Natalizumab.,Linezolid
DB00619,The risk or severity of adverse effects can be increased when Imatinib is combined with Natalizumab.,Imatinib
DB00620,The risk or severity of adverse effects can be increased when Triamcinolone is combined with Natalizumab.,Triamcinolone
DB00631,The risk or severity of adverse effects can be increased when Clofarabine is combined with Natalizumab.,Clofarabine
DB00635,The risk or severity of adverse effects can be increased when Prednisone is combined with Natalizumab.,Prednisone
DB00642,The risk or severity of adverse effects can be increased when Pemetrexed is combined with Natalizumab.,Pemetrexed
DB00687,The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Natalizumab.,Fludrocortisone
DB00688,The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Natalizumab.,Mycophenolate mofetil
DB00694,The risk or severity of adverse effects can be increased when Daunorubicin is combined with Natalizumab.,Daunorubicin
DB00741,The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Natalizumab.,Hydrocortisone
DB00755,The risk or severity of adverse effects can be increased when Tretinoin is combined with Natalizumab.,Tretinoin
DB00762,The risk or severity of adverse effects can be increased when Irinotecan is combined with Natalizumab.,Irinotecan
DB00763,The risk or severity of adverse effects can be increased when Methimazole is combined with Natalizumab.,Methimazole
DB00764,The risk or severity of adverse effects can be increased when Mometasone is combined with Natalizumab.,Mometasone
DB00773,The risk or severity of adverse effects can be increased when Etoposide is combined with Natalizumab.,Etoposide
DB00795,The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Natalizumab.,Sulfasalazine
DB00851,The risk or severity of adverse effects can be increased when Dacarbazine is combined with Natalizumab.,Dacarbazine
DB00853,The risk or severity of adverse effects can be increased when Temozolomide is combined with Natalizumab.,Temozolomide
DB00859,The risk or severity of adverse effects can be increased when Penicillamine is combined with Natalizumab.,Penicillamine
DB00860,The risk or severity of adverse effects can be increased when Prednisolone is combined with Natalizumab.,Prednisolone
DB00864,The risk or severity of adverse effects can be increased when Tacrolimus is combined with Natalizumab.,Tacrolimus
DB00877,The risk or severity of adverse effects can be increased when Sirolimus is combined with Natalizumab.,Sirolimus
DB00888,The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Natalizumab.,Mechlorethamine
DB00928,The risk or severity of adverse effects can be increased when Azacitidine is combined with Natalizumab.,Azacitidine
DB00958,The risk or severity of adverse effects can be increased when Carboplatin is combined with Natalizumab.,Carboplatin
DB00959,The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Natalizumab.,Methylprednisolone
DB00970,The risk or severity of adverse effects can be increased when Dactinomycin is combined with Natalizumab.,Dactinomycin
DB00987,The risk or severity of adverse effects can be increased when Cytarabine is combined with Natalizumab.,Cytarabine
DB00993,The risk or severity of adverse effects can be increased when Azathioprine is combined with Natalizumab.,Azathioprine
DB00997,The risk or severity of adverse effects can be increased when Doxorubicin is combined with Natalizumab.,Doxorubicin
DB01005,The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Natalizumab.,Hydroxyurea
DB01008,The risk or severity of adverse effects can be increased when Busulfan is combined with Natalizumab.,Busulfan
DB01024,The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Natalizumab.,Mycophenolic acid
DB01030,The risk or severity of adverse effects can be increased when Topotecan is combined with Natalizumab.,Topotecan
DB01033,The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Natalizumab.,Mercaptopurine
DB01041,The risk or severity of adverse effects can be increased when Thalidomide is combined with Natalizumab.,Thalidomide
DB01042,The risk or severity of adverse effects can be increased when Melphalan is combined with Natalizumab.,Melphalan
DB01073,The risk or severity of adverse effects can be increased when Fludarabine is combined with Natalizumab.,Fludarabine
DB01097,The risk or severity of adverse effects can be increased when Leflunomide is combined with Natalizumab.,Leflunomide
DB01099,The risk or severity of adverse effects can be increased when Flucytosine is combined with Natalizumab.,Flucytosine
DB01101,The risk or severity of adverse effects can be increased when Capecitabine is combined with Natalizumab.,Capecitabine
DB01108,The risk or severity of adverse effects can be increased when Trilostane is combined with Natalizumab.,Trilostane
DB01168,The risk or severity of adverse effects can be increased when Procarbazine is combined with Natalizumab.,Procarbazine
DB01169,The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Natalizumab.,Arsenic trioxide
DB01177,The risk or severity of adverse effects can be increased when Idarubicin is combined with Natalizumab.,Idarubicin
DB01181,The risk or severity of adverse effects can be increased when Ifosfamide is combined with Natalizumab.,Ifosfamide
DB01196,The risk or severity of adverse effects can be increased when Estramustine is combined with Natalizumab.,Estramustine
DB01204,The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Natalizumab.,Mitoxantrone
DB01206,The risk or severity of adverse effects can be increased when Lomustine is combined with Natalizumab.,Lomustine
DB01222,The risk or severity of adverse effects can be increased when Budesonide is combined with Natalizumab.,Budesonide
DB01229,The risk or severity of adverse effects can be increased when Paclitaxel is combined with Natalizumab.,Paclitaxel
DB01234,The risk or severity of adverse effects can be increased when Dexamethasone is combined with Natalizumab.,Dexamethasone
DB01248,The risk or severity of adverse effects can be increased when Docetaxel is combined with Natalizumab.,Docetaxel
DB01254,The risk or severity of adverse effects can be increased when Dasatinib is combined with Natalizumab.,Dasatinib
DB01257,The risk or severity of adverse effects can be increased when Eculizumab is combined with Natalizumab.,Eculizumab
DB01262,The risk or severity of adverse effects can be increased when Decitabine is combined with Natalizumab.,Decitabine
DB01268,The risk or severity of adverse effects can be increased when Sunitinib is combined with Natalizumab.,Sunitinib
DB01280,The risk or severity of adverse effects can be increased when Nelarabine is combined with Natalizumab.,Nelarabine
DB01281,The risk or severity of adverse effects can be increased when Abatacept is combined with Natalizumab.,Abatacept
DB01285,The risk or severity of adverse effects can be increased when Corticotropin is combined with Natalizumab.,Corticotropin
DB01380,The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Natalizumab.,Cortisone acetate
DB01384,The risk or severity of adverse effects can be increased when Paramethasone is combined with Natalizumab.,Paramethasone
DB01394,The risk or severity of adverse effects can be increased when Colchicine is combined with Natalizumab.,Colchicine
DB01410,The risk or severity of adverse effects can be increased when Ciclesonide is combined with Natalizumab.,Ciclesonide
DB01423,The risk or severity of adverse effects can be increased when Stepronin is combined with Natalizumab.,Stepronin
DB01590,The risk or severity of adverse effects can be increased when Everolimus is combined with Natalizumab.,Everolimus
DB01611,The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Natalizumab.,Hydroxychloroquine
DB01816,The risk or severity of adverse effects can be increased when Castanospermine is combined with Natalizumab.,Castanospermine
DB02546,The risk or severity of adverse effects can be increased when Vorinostat is combined with Natalizumab.,Vorinostat
DB02806,The risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Natalizumab.,2-Methoxyethanol
DB03523,The risk or severity of adverse effects can be increased when Brequinar is combined with Natalizumab.,Brequinar
DB04572,The risk or severity of adverse effects can be increased when Thiotepa is combined with Natalizumab.,Thiotepa
DB04630,The risk or severity of adverse effects can be increased when Aldosterone is combined with Natalizumab.,Aldosterone
DB04845,The risk or severity of adverse effects can be increased when Ixabepilone is combined with Natalizumab.,Ixabepilone
DB04868,The risk or severity of adverse effects can be increased when Nilotinib is combined with Natalizumab.,Nilotinib
DB04951,The risk or severity of adverse effects can be increased when Pirfenidone is combined with Natalizumab.,Pirfenidone
DB04956,The risk or severity of adverse effects can be increased when Afelimomab is combined with Natalizumab.,Afelimomab
DB05015,The risk or severity of adverse effects can be increased when Belinostat is combined with Natalizumab.,Belinostat
DB05109,The risk or severity of adverse effects can be increased when Trabectedin is combined with Natalizumab.,Trabectedin
DB05258,The risk or severity of adverse effects can be increased when Interferon alfa is combined with Natalizumab.,Interferon alfa
DB05259,The risk or severity of adverse effects can be increased when Glatiramer is combined with Natalizumab.,Glatiramer
DB05260,The risk or severity of adverse effects can be increased when Gallium nitrate is combined with Natalizumab.,Gallium nitrate
DB05459,The risk or severity of adverse effects can be increased when Briakinumab is combined with Natalizumab.,Briakinumab
DB05472,The risk or severity of adverse effects can be increased when omega interferon is combined with Natalizumab.,omega interferon
DB05676,The risk or severity of adverse effects can be increased when Apremilast is combined with Natalizumab.,Apremilast
DB05773,The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Natalizumab.,Trastuzumab emtansine
DB06168,The risk or severity of adverse effects can be increased when Canakinumab is combined with Natalizumab.,Canakinumab
DB06273,The risk or severity of adverse effects can be increased when Tocilizumab is combined with Natalizumab.,Tocilizumab
DB06287,The risk or severity of adverse effects can be increased when Temsirolimus is combined with Natalizumab.,Temsirolimus
DB06372,The risk or severity of adverse effects can be increased when Rilonacept is combined with Natalizumab.,Rilonacept
DB06589,The risk or severity of adverse effects can be increased when Pazopanib is combined with Natalizumab.,Pazopanib
DB06603,The risk or severity of adverse effects can be increased when Panobinostat is combined with Natalizumab.,Panobinostat
DB06612,The risk or severity of adverse effects can be increased when Mepolizumab is combined with Natalizumab.,Mepolizumab
DB06616,The risk or severity of adverse effects can be increased when Bosutinib is combined with Natalizumab.,Bosutinib
DB06662,The risk or severity of adverse effects can be increased when Abetimus is combined with Natalizumab.,Abetimus
DB06674,The risk or severity of adverse effects can be increased when Golimumab is combined with Natalizumab.,Golimumab
DB06681,The risk or severity of adverse effects can be increased when Belatacept is combined with Natalizumab.,Belatacept
DB06769,The risk or severity of adverse effects can be increased when Bendamustine is combined with Natalizumab.,Bendamustine
DB06772,The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Natalizumab.,Cabazitaxel
DB06813,The risk or severity of adverse effects can be increased when Pralatrexate is combined with Natalizumab.,Pralatrexate
DB08059,The risk or severity of adverse effects can be increased when Wortmannin is combined with Natalizumab.,Wortmannin
DB08868,The risk or severity of adverse effects can be increased when Fingolimod is combined with Natalizumab.,Fingolimod
DB08870,The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Natalizumab.,Brentuximab vedotin
DB08871,The risk or severity of adverse effects can be increased when Eribulin is combined with Natalizumab.,Eribulin
DB08877,The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Natalizumab.,Ruxolitinib
DB08879,The risk or severity of adverse effects can be increased when Belimumab is combined with Natalizumab.,Belimumab
DB08880,The risk or severity of adverse effects can be increased when Teriflunomide is combined with Natalizumab.,Teriflunomide
DB08889,The risk or severity of adverse effects can be increased when Carfilzomib is combined with Natalizumab.,Carfilzomib
DB08895,The risk or severity of adverse effects can be increased when Tofacitinib is combined with Natalizumab.,Tofacitinib
DB08901,The risk or severity of adverse effects can be increased when Ponatinib is combined with Natalizumab.,Ponatinib
DB08904,The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Natalizumab.,Certolizumab pegol
DB08906,The risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Natalizumab.,Fluticasone furoate
DB08908,The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Natalizumab.,Dimethyl fumarate
DB08910,The risk or severity of adverse effects can be increased when Pomalidomide is combined with Natalizumab.,Pomalidomide
DB08935,The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Natalizumab.,Obinutuzumab
DB08970,The risk or severity of adverse effects can be increased when Fluprednidene is combined with Natalizumab.,Fluprednidene
DB08971,The risk or severity of adverse effects can be increased when Fluocortolone is combined with Natalizumab.,Fluocortolone
DB09029,The risk or severity of adverse effects can be increased when Secukinumab is combined with Natalizumab.,Secukinumab
DB09036,The risk or severity of adverse effects can be increased when Siltuximab is combined with Natalizumab.,Siltuximab
DB09052,The risk or severity of adverse effects can be increased when Blinatumomab is combined with Natalizumab.,Blinatumomab
DB09053,The risk or severity of adverse effects can be increased when Ibrutinib is combined with Natalizumab.,Ibrutinib
DB09054,The risk or severity of adverse effects can be increased when Idelalisib is combined with Natalizumab.,Idelalisib
DB09073,The risk or severity of adverse effects can be increased when Palbociclib is combined with Natalizumab.,Palbociclib
DB09074,The risk or severity of adverse effects can be increased when Olaparib is combined with Natalizumab.,Olaparib
DB09077,The risk or severity of adverse effects can be increased when Dinutuximab is combined with Natalizumab.,Dinutuximab
DB09082,The risk or severity of adverse effects can be increased when Vilanterol is combined with Natalizumab.,Vilanterol
DB09091,The risk or severity of adverse effects can be increased when Tixocortol is combined with Natalizumab.,Tixocortol
DB09122,The risk or severity of adverse effects can be increased when Peginterferon beta-1a is combined with Natalizumab.,Peginterferon beta-1a
DB09312,The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Natalizumab.,Antilymphocyte immunoglobulin (horse)
DB09378,The risk or severity of adverse effects can be increased when Fluprednisolone is combined with Natalizumab.,Fluprednisolone
DB09383,The risk or severity of adverse effects can be increased when Meprednisone is combined with Natalizumab.,Meprednisone
DB11466,The risk or severity of adverse effects can be increased when Tepoxalin is combined with Natalizumab.,Tepoxalin
DB11487,The risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Natalizumab.,Dexamethasone isonicotinate
DB11529,The risk or severity of adverse effects can be increased when Melengestrol is combined with Natalizumab.,Melengestrol
DB11569,The risk or severity of adverse effects can be increased when Ixekizumab is combined with Natalizumab.,Ixekizumab
DB11580,The risk or severity of adverse effects can be increased when Ravulizumab is combined with Natalizumab.,Ravulizumab
DB11616,The risk or severity of adverse effects can be increased when Pirarubicin is combined with Natalizumab.,Pirarubicin
DB11693,The risk or severity of adverse effects can be increased when Voclosporin is combined with Natalizumab.,Voclosporin
DB11708,The risk or severity of adverse effects can be increased when Peficitinib is combined with Natalizumab.,Peficitinib
DB11750,The risk or severity of adverse effects can be increased when Clobetasol is combined with Natalizumab.,Clobetasol
DB11767,The risk or severity of adverse effects can be increased when Sarilumab is combined with Natalizumab.,Sarilumab
DB11776,The risk or severity of adverse effects can be increased when Brodalumab is combined with Natalizumab.,Brodalumab
DB11803,The risk or severity of adverse effects can be increased when Sirukumab is combined with Natalizumab.,Sirukumab
DB11817,The risk or severity of adverse effects can be increased when Baricitinib is combined with Natalizumab.,Baricitinib
DB11834,The risk or severity of adverse effects can be increased when Guselkumab is combined with Natalizumab.,Guselkumab
DB11921,The risk or severity of adverse effects can be increased when Deflazacort is combined with Natalizumab.,Deflazacort
DB12025,The risk or severity of adverse effects can be increased when Triptolide is combined with Natalizumab.,Triptolide
DB12371,The risk or severity of adverse effects can be increased when Siponimod is combined with Natalizumab.,Siponimod
DB12612,The risk or severity of adverse effects can be increased when Ozanimod is combined with Natalizumab.,Ozanimod
DB12617,The risk or severity of adverse effects can be increased when Mizoribine is combined with Natalizumab.,Mizoribine
DB12692,The risk or severity of adverse effects can be increased when Gusperimus is combined with Natalizumab.,Gusperimus
DB12814,The risk or severity of adverse effects can be increased when Cepeginterferon alfa-2B is combined with Natalizumab.,Cepeginterferon alfa-2B
DB12902,The risk or severity of adverse effects can be increased when Trofosfamide is combined with Natalizumab.,Trofosfamide
DB12947,The risk or severity of adverse effects can be increased when Doxifluridine is combined with Natalizumab.,Doxifluridine
DB12991,The risk or severity of adverse effects can be increased when Deoxyspergualin is combined with Natalizumab.,Deoxyspergualin
DB12996,The risk or severity of adverse effects can be increased when Acteoside is combined with Natalizumab.,Acteoside
DB13003,The risk or severity of adverse effects can be increased when Cortivazol is combined with Natalizumab.,Cortivazol
DB13014,The risk or severity of adverse effects can be increased when Hypericin is combined with Natalizumab.,Hypericin
DB13068,The risk or severity of adverse effects can be increased when 9-(N-methyl-L-isoleucine)-cyclosporin A is combined with Natalizumab.,9-(N-methyl-L-isoleucine)-cyclosporin A
DB13208,The risk or severity of adverse effects can be increased when Prednylidene is combined with Natalizumab.,Prednylidene
DB13223,The risk or severity of adverse effects can be increased when Fluocortin is combined with Natalizumab.,Fluocortin
DB13241,The risk or severity of adverse effects can be increased when Begelomab is combined with Natalizumab.,Begelomab
DB13491,The risk or severity of adverse effects can be increased when Fluperolone is combined with Natalizumab.,Fluperolone
DB13664,The risk or severity of adverse effects can be increased when Formocortal is combined with Natalizumab.,Formocortal
DB13728,The risk or severity of adverse effects can be increased when Halometasone is combined with Natalizumab.,Halometasone
DB13843,The risk or severity of adverse effects can be increased when Cloprednol is combined with Natalizumab.,Cloprednol
DB13856,The risk or severity of adverse effects can be increased when Fluclorolone is combined with Natalizumab.,Fluclorolone
DB13867,The risk or severity of adverse effects can be increased when Fluticasone is combined with Natalizumab.,Fluticasone
DB14066,The risk or severity of adverse effects can be increased when Tetrandrine is combined with Natalizumab.,Tetrandrine
DB14219,The risk or severity of adverse effects can be increased when Monomethyl fumarate is combined with Natalizumab.,Monomethyl fumarate
DB14512,The risk or severity of adverse effects can be increased when Mometasone furoate is combined with Natalizumab.,Mometasone furoate
DB14538,The risk or severity of adverse effects can be increased when Hydrocortisone aceponate is combined with Natalizumab.,Hydrocortisone aceponate
DB14539,The risk or severity of adverse effects can be increased when Hydrocortisone acetate is combined with Natalizumab.,Hydrocortisone acetate
DB14545,The risk or severity of adverse effects can be increased when Hydrocortisone succinate is combined with Natalizumab.,Hydrocortisone succinate
DB14724,The risk or severity of adverse effects can be increased when Emapalumab is combined with Natalizumab.,Emapalumab
DB14762,The risk or severity of adverse effects can be increased when Risankizumab is combined with Natalizumab.,Risankizumab
DB14919,The risk or severity of adverse effects can be increased when Rozanolixizumab is combined with Natalizumab.,Rozanolixizumab
DB15253,The risk or severity of adverse effects can be increased when Bleselumab is combined with Natalizumab.,Bleselumab
DB00337,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Natalizumab.,Pimecrolimus
DB01656,Roflumilast may increase the immunosuppressive activities of Natalizumab.,Roflumilast
DB06688,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Natalizumab.,Sipuleucel-T
DB09033,The risk or severity of adverse effects can be increased when Vedolizumab is combined with Natalizumab.,Vedolizumab
DB01015,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Natalizumab.,Sulfamethoxazole
DB00255,Diethylstilbestrol may increase the thrombogenic activities of Natalizumab.,Diethylstilbestrol
DB00269,Chlorotrianisene may increase the thrombogenic activities of Natalizumab.,Chlorotrianisene
DB00286,Conjugated estrogens may increase the thrombogenic activities of Natalizumab.,Conjugated estrogens
DB00655,Estrone may increase the thrombogenic activities of Natalizumab.,Estrone
DB00783,Estradiol may increase the thrombogenic activities of Natalizumab.,Estradiol
DB00890,Dienestrol may increase the thrombogenic activities of Natalizumab.,Dienestrol
DB00977,Ethinylestradiol may increase the thrombogenic activities of Natalizumab.,Ethinylestradiol
DB01357,Mestranol may increase the thrombogenic activities of Natalizumab.,Mestranol
DB04573,Estriol may increase the thrombogenic activities of Natalizumab.,Estriol
DB04574,Estrone sulfate may increase the thrombogenic activities of Natalizumab.,Estrone sulfate
DB04575,Quinestrol may increase the thrombogenic activities of Natalizumab.,Quinestrol
DB07931,Hexestrol may increase the thrombogenic activities of Natalizumab.,Hexestrol
DB09070,Tibolone may increase the thrombogenic activities of Natalizumab.,Tibolone
DB09317,"Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Natalizumab.","Synthetic Conjugated Estrogens, A"
DB09318,"Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Natalizumab.","Synthetic Conjugated Estrogens, B"
DB09369,Polyestradiol phosphate may increase the thrombogenic activities of Natalizumab.,Polyestradiol phosphate
DB09381,Esterified estrogens may increase the thrombogenic activities of Natalizumab.,Esterified estrogens
DB11478,Zeranol may increase the thrombogenic activities of Natalizumab.,Zeranol
DB11674,Equol may increase the thrombogenic activities of Natalizumab.,Equol
DB12487,Promestriene may increase the thrombogenic activities of Natalizumab.,Promestriene
DB13143,Methallenestril may increase the thrombogenic activities of Natalizumab.,Methallenestril
DB13386,Epimestrol may increase the thrombogenic activities of Natalizumab.,Epimestrol
DB13418,Moxestrol may increase the thrombogenic activities of Natalizumab.,Moxestrol
DB13952,Estradiol acetate may increase the thrombogenic activities of Natalizumab.,Estradiol acetate
DB13953,Estradiol benzoate may increase the thrombogenic activities of Natalizumab.,Estradiol benzoate
DB13954,Estradiol cypionate may increase the thrombogenic activities of Natalizumab.,Estradiol cypionate
DB13956,Estradiol valerate may increase the thrombogenic activities of Natalizumab.,Estradiol valerate
DB15334,Biochanin A may increase the thrombogenic activities of Natalizumab.,Biochanin A
DB15335,Formononetin may increase the thrombogenic activities of Natalizumab.,Formononetin
DB04914,The therapeutic efficacy of G17DT can be decreased when used in combination with Natalizumab.,G17DT
DB05144,The therapeutic efficacy of PEV3A can be decreased when used in combination with Natalizumab.,PEV3A
DB05325,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Natalizumab.,INGN 225
DB05374,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Natalizumab.,Rindopepimut
DB05440,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Natalizumab.,SRP 299
DB05942,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Natalizumab.,GI-5005
DB06400,The therapeutic efficacy of Vitespen can be decreased when used in combination with Natalizumab.,Vitespen
DB06584,The therapeutic efficacy of TG4010 can be decreased when used in combination with Natalizumab.,TG4010
DB09057,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Natalizumab.,Anthrax immune globulin human
DB10062,"The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Natalizumab.","Rabies virus inactivated antigen, B"
DB10076,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Natalizumab.,Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen
DB10276,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Natalizumab.,Rotavirus vaccine
DB10283,"The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Natalizumab.","Rabies virus inactivated antigen, A"
DB10342,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Natalizumab.,Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen
DB10583,The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Natalizumab.,Clostridium tetani toxoid antigen (formaldehyde inactivated)
DB10584,The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Natalizumab.,Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
DB10600,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Natalizumab.,Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated)
DB10769,The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Natalizumab.,Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)
DB10794,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Natalizumab.,Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated)
DB10803,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Natalizumab.,Typhoid Vi polysaccharide vaccine
DB10989,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Natalizumab.,Hepatitis A Vaccine
DB10990,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Natalizumab.,Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
DB11038,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Natalizumab.,Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated)
DB11040,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Natalizumab.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated)
DB11041,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Natalizumab.,Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)
DB11044,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Natalizumab.,Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated)
DB11603,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Natalizumab.,Human rabies virus immune globulin
DB11627,The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Natalizumab.,Hepatitis B Vaccine (Recombinant)
DB12568,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Natalizumab.,Tecemotide
DB14022,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Natalizumab.,Typhoid vaccine
DB14384,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Natalizumab.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated)
DB14385,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Natalizumab.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)
DB14394,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Natalizumab.,Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen
DB14445,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Natalizumab.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated)
DB14449,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Natalizumab.,Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen
DB14619,The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Natalizumab.,Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated)
DB14620,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Natalizumab.,Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated)
DB14711,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Natalizumab.,Vaccinia virus strain new york city board of health live antigen
DB15274,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Natalizumab.,Pertussis vaccine
DB15461,The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Natalizumab.,Yersinia pestis 195/p antigen (formaldehyde inactivated)
DB13924,The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Natalizumab.,Varicella Zoster Vaccine (Recombinant)
DB15483,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Natalizumab.,Modified vaccinia ankara
DB11988,Ocrelizumab may increase the immunosuppressive activities of Natalizumab.,Ocrelizumab
DB10317,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Natalizumab.,Rubella virus vaccine
DB10318,The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Natalizumab.,Varicella Zoster Vaccine (Live/attenuated)
DB10343,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Natalizumab.,Bacillus calmette-guerin substrain tice live antigen
DB10804,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Natalizumab.,Bacillus calmette-guerin substrain connaught live antigen
DB10805,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Natalizumab.,Yellow Fever Vaccine
DB11003,The risk or severity of infection can be increased when Anthrax vaccine is combined with Natalizumab.,Anthrax vaccine
DB11050,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Natalizumab.,Typhoid Vaccine Live
DB12386,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Natalizumab.,Bacillus calmette-guerin substrain danish 1331 live antigen
DB12768,The risk or severity of infection can be increased when BCG vaccine is combined with Natalizumab.,BCG vaccine
DB14409,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Natalizumab.,Human adenovirus e serotype 4 strain cl-68578 antigen
DB14443,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Natalizumab.,Vibrio cholerae CVD 103-HgR strain live antigen
DB14685,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Natalizumab.,Adenovirus type 7 vaccine live
DB00002,The risk or severity of adverse effects can be increased when Cetuximab is combined with Natalizumab.,Cetuximab
DB00028,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Natalizumab.,Human immunoglobulin G
DB00043,The risk or severity of adverse effects can be increased when Omalizumab is combined with Natalizumab.,Omalizumab
DB00054,The risk or severity of adverse effects can be increased when Abciximab is combined with Natalizumab.,Abciximab
DB00057,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Natalizumab.,Indium In-111 satumomab pendetide
DB00076,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Natalizumab.,Digoxin Immune Fab (Ovine)
DB00089,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Natalizumab.,Capromab pendetide
DB00110,The risk or severity of adverse effects can be increased when Natalizumab is combined with Palivizumab.,Palivizumab
DB00113,The risk or severity of adverse effects can be increased when Natalizumab is combined with Technetium Tc-99m arcitumomab.,Technetium Tc-99m arcitumomab
DB01269,The risk or severity of adverse effects can be increased when Natalizumab is combined with Panitumumab.,Panitumumab
DB01270,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ranibizumab.,Ranibizumab
DB04901,The risk or severity of adverse effects can be increased when Natalizumab is combined with Galiximab.,Galiximab
DB04949,The risk or severity of adverse effects can be increased when Natalizumab is combined with Pexelizumab.,Pexelizumab
DB04958,The risk or severity of adverse effects can be increased when Natalizumab is combined with Epratuzumab.,Epratuzumab
DB04962,The risk or severity of adverse effects can be increased when Natalizumab is combined with Bectumomab.,Bectumomab
DB04964,The risk or severity of adverse effects can be increased when Natalizumab is combined with Oregovomab.,Oregovomab
DB04988,The risk or severity of adverse effects can be increased when Natalizumab is combined with IGN311.,IGN311
DB05006,The risk or severity of adverse effects can be increased when Natalizumab is combined with Adecatumumab.,Adecatumumab
DB05097,The risk or severity of adverse effects can be increased when Natalizumab is combined with Labetuzumab.,Labetuzumab
DB05101,The risk or severity of adverse effects can be increased when Natalizumab is combined with Matuzumab.,Matuzumab
DB05111,The risk or severity of adverse effects can be increased when Natalizumab is combined with Fontolizumab.,Fontolizumab
DB05136,The risk or severity of adverse effects can be increased when Natalizumab is combined with Bavituximab.,Bavituximab
DB05139,The risk or severity of adverse effects can be increased when Natalizumab is combined with CR002.,CR002
DB05209,The risk or severity of adverse effects can be increased when Natalizumab is combined with Rozrolimupab.,Rozrolimupab
DB05304,The risk or severity of adverse effects can be increased when Natalizumab is combined with Girentuximab.,Girentuximab
DB05336,The risk or severity of adverse effects can be increased when Natalizumab is combined with Obiltoxaximab.,Obiltoxaximab
DB05405,The risk or severity of adverse effects can be increased when Natalizumab is combined with XTL-001.,XTL-001
DB05437,The risk or severity of adverse effects can be increased when Natalizumab is combined with NAV 1800.,NAV 1800
DB05496,The risk or severity of adverse effects can be increased when Natalizumab is combined with Otelixizumab.,Otelixizumab
DB05545,The risk or severity of adverse effects can be increased when Natalizumab is combined with AMG 108.,AMG 108
DB05550,The risk or severity of adverse effects can be increased when Natalizumab is combined with Iratumumab.,Iratumumab
DB05555,The risk or severity of adverse effects can be increased when Natalizumab is combined with Enokizumab.,Enokizumab
DB05578,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ramucirumab.,Ramucirumab
DB05595,The risk or severity of adverse effects can be increased when Natalizumab is combined with Farletuzumab.,Farletuzumab
DB05656,The risk or severity of adverse effects can be increased when Natalizumab is combined with Veltuzumab.,Veltuzumab
DB05793,The risk or severity of adverse effects can be increased when Natalizumab is combined with PRO-542.,PRO-542
DB05797,The risk or severity of adverse effects can be increased when Natalizumab is combined with TNX-901.,TNX-901
DB05889,The risk or severity of adverse effects can be increased when Natalizumab is combined with Inotuzumab ozogamicin.,Inotuzumab ozogamicin
DB05892,The risk or severity of adverse effects can be increased when Natalizumab is combined with RI 624.,RI 624
DB05915,The risk or severity of adverse effects can be increased when Natalizumab is combined with MYO-029.,MYO-029
DB05916,The risk or severity of adverse effects can be increased when Natalizumab is combined with CT-011.,CT-011
DB05941,The risk or severity of adverse effects can be increased when Natalizumab is combined with Leronlimab.,Leronlimab
DB05996,The risk or severity of adverse effects can be increased when Natalizumab is combined with Glembatumumab vedotin.,Glembatumumab vedotin
DB06043,The risk or severity of adverse effects can be increased when Natalizumab is combined with Olaratumab.,Olaratumab
DB06049,The risk or severity of adverse effects can be increased when Natalizumab is combined with IPH 2101.,IPH 2101
DB06050,The risk or severity of adverse effects can be increased when Natalizumab is combined with TB-402.,TB-402
DB06081,The risk or severity of adverse effects can be increased when Natalizumab is combined with Caplacizumab.,Caplacizumab
DB06101,The risk or severity of adverse effects can be increased when Natalizumab is combined with IMC-1C11.,IMC-1C11
DB06116,The risk or severity of adverse effects can be increased when Natalizumab is combined with Eldelumab.,Eldelumab
DB06162,The risk or severity of adverse effects can be increased when Natalizumab is combined with Lumiliximab.,Lumiliximab
DB06186,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ipilimumab.,Ipilimumab
DB06192,The risk or severity of adverse effects can be increased when Natalizumab is combined with Nimotuzumab.,Nimotuzumab
DB06241,The risk or severity of adverse effects can be increased when Natalizumab is combined with Clenoliximab.,Clenoliximab
DB06304,The risk or severity of adverse effects can be increased when Natalizumab is combined with BIIB015.,BIIB015
DB06305,The risk or severity of adverse effects can be increased when Natalizumab is combined with Sonepcizumab.,Sonepcizumab
DB06310,The risk or severity of adverse effects can be increased when Natalizumab is combined with Motavizumab.,Motavizumab
DB06317,The risk or severity of adverse effects can be increased when Natalizumab is combined with Elotuzumab.,Elotuzumab
DB06318,The risk or severity of adverse effects can be increased when Natalizumab is combined with AVE9633.,AVE9633
DB06322,The risk or severity of adverse effects can be increased when Natalizumab is combined with Carotuximab.,Carotuximab
DB06324,The risk or severity of adverse effects can be increased when Natalizumab is combined with XmAb 2513.,XmAb 2513
DB06342,The risk or severity of adverse effects can be increased when Natalizumab is combined with Coltuximab ravtansine.,Coltuximab ravtansine
DB06343,The risk or severity of adverse effects can be increased when Natalizumab is combined with Teprotumumab.,Teprotumumab
DB06360,The risk or severity of adverse effects can be increased when Natalizumab is combined with Lucatumumab.,Lucatumumab
DB06366,The risk or severity of adverse effects can be increased when Natalizumab is combined with Pertuzumab.,Pertuzumab
DB06371,The risk or severity of adverse effects can be increased when Natalizumab is combined with Siplizumab.,Siplizumab
DB06467,The risk or severity of adverse effects can be increased when Natalizumab is combined with Apolizumab.,Apolizumab
DB06474,The risk or severity of adverse effects can be increased when Natalizumab is combined with Sibrotuzumab.,Sibrotuzumab
DB06550,The risk or severity of adverse effects can be increased when Natalizumab is combined with Bivatuzumab.,Bivatuzumab
DB06557,The risk or severity of adverse effects can be increased when Natalizumab is combined with Lerdelimumab.,Lerdelimumab
DB06599,The risk or severity of adverse effects can be increased when Natalizumab is combined with Lexatumumab.,Lexatumumab
DB06602,The risk or severity of adverse effects can be increased when Natalizumab is combined with Reslizumab.,Reslizumab
DB06606,The risk or severity of adverse effects can be increased when Natalizumab is combined with Teplizumab.,Teplizumab
DB06607,The risk or severity of adverse effects can be increased when Natalizumab is combined with Catumaxomab.,Catumaxomab
DB06647,The risk or severity of adverse effects can be increased when Natalizumab is combined with Volociximab.,Volociximab
DB06650,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ofatumumab.,Ofatumumab
DB08902,The risk or severity of adverse effects can be increased when Natalizumab is combined with Raxibacumab.,Raxibacumab
DB09035,The risk or severity of adverse effects can be increased when Natalizumab is combined with Nivolumab.,Nivolumab
DB09037,The risk or severity of adverse effects can be increased when Natalizumab is combined with Pembrolizumab.,Pembrolizumab
DB09045,The risk or severity of adverse effects can be increased when Natalizumab is combined with Dulaglutide.,Dulaglutide
DB09105,The risk or severity of adverse effects can be increased when Natalizumab is combined with Asfotase alfa.,Asfotase alfa
DB09264,The risk or severity of adverse effects can be increased when Natalizumab is combined with Idarucizumab.,Idarucizumab
DB09302,The risk or severity of adverse effects can be increased when Natalizumab is combined with Alirocumab.,Alirocumab
DB09303,The risk or severity of adverse effects can be increased when Natalizumab is combined with Evolocumab.,Evolocumab
DB09331,The risk or severity of adverse effects can be increased when Natalizumab is combined with Daratumumab.,Daratumumab
DB09559,The risk or severity of adverse effects can be increased when Natalizumab is combined with Necitumumab.,Necitumumab
DB11595,The risk or severity of adverse effects can be increased when Natalizumab is combined with Atezolizumab.,Atezolizumab
DB11604,The risk or severity of adverse effects can be increased when Natalizumab is combined with Tetanus Immune Globulin.,Tetanus Immune Globulin
DB11608,The risk or severity of adverse effects can be increased when Natalizumab is combined with Eftrenonacog alfa.,Eftrenonacog alfa
DB11621,The risk or severity of adverse effects can be increased when Natalizumab is combined with Human Varicella-Zoster Immune Globulin.,Human Varicella-Zoster Immune Globulin
DB11646,The risk or severity of adverse effects can be increased when Natalizumab is combined with Conatumumab.,Conatumumab
DB11657,The risk or severity of adverse effects can be increased when Natalizumab is combined with Tabalumab.,Tabalumab
DB11680,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ficlatuzumab.,Ficlatuzumab
DB11685,The risk or severity of adverse effects can be increased when Natalizumab is combined with Figitumumab.,Figitumumab
DB11714,The risk or severity of adverse effects can be increased when Natalizumab is combined with Durvalumab.,Durvalumab
DB11715,The risk or severity of adverse effects can be increased when Natalizumab is combined with Bapineuzumab.,Bapineuzumab
DB11731,The risk or severity of adverse effects can be increased when Natalizumab is combined with Depatuxizumab mafodotin.,Depatuxizumab mafodotin
DB11746,The risk or severity of adverse effects can be increased when Natalizumab is combined with Onartuzumab.,Onartuzumab
DB11756,The risk or severity of adverse effects can be increased when Natalizumab is combined with Solanezumab.,Solanezumab
DB11771,The risk or severity of adverse effects can be increased when Natalizumab is combined with Tremelimumab.,Tremelimumab
DB11826,The risk or severity of adverse effects can be increased when Natalizumab is combined with Lampalizumab.,Lampalizumab
DB11840,The risk or severity of adverse effects can be increased when Natalizumab is combined with Dalotuzumab.,Dalotuzumab
DB11849,The risk or severity of adverse effects can be increased when Natalizumab is combined with Emibetuzumab.,Emibetuzumab
DB11850,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ublituximab.,Ublituximab
DB11856,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ligelizumab.,Ligelizumab
DB11857,The risk or severity of adverse effects can be increased when Natalizumab is combined with Seribantumab.,Seribantumab
DB11862,The risk or severity of adverse effects can be increased when Natalizumab is combined with Landogrozumab.,Landogrozumab
DB11866,The risk or severity of adverse effects can be increased when Natalizumab is combined with Romosozumab.,Romosozumab
DB11884,The risk or severity of adverse effects can be increased when Natalizumab is combined with Vadastuximab Talirine.,Vadastuximab Talirine
DB11914,The risk or severity of adverse effects can be increased when Natalizumab is combined with Lebrikizumab.,Lebrikizumab
DB11930,The risk or severity of adverse effects can be increased when Natalizumab is combined with Varlilumab.,Varlilumab
DB11945,The risk or severity of adverse effects can be increased when Natalizumab is combined with Avelumab.,Avelumab
DB11959,The risk or severity of adverse effects can be increased when Natalizumab is combined with Crenezumab.,Crenezumab
DB11972,The risk or severity of adverse effects can be increased when Natalizumab is combined with Rilotumumab.,Rilotumumab
DB11976,The risk or severity of adverse effects can be increased when Natalizumab is combined with Anifrolumab.,Anifrolumab
DB12023,The risk or severity of adverse effects can be increased when Natalizumab is combined with Benralizumab.,Benralizumab
DB12034,The risk or severity of adverse effects can be increased when Natalizumab is combined with Gantenerumab.,Gantenerumab
DB12053,The risk or severity of adverse effects can be increased when Natalizumab is combined with Visilizumab.,Visilizumab
DB12077,The risk or severity of adverse effects can be increased when Natalizumab is combined with Urelumab.,Urelumab
DB12089,The risk or severity of adverse effects can be increased when Natalizumab is combined with Lorvotuzumab mertansine.,Lorvotuzumab mertansine
DB12090,The risk or severity of adverse effects can be increased when Natalizumab is combined with Patritumab.,Patritumab
DB12102,The risk or severity of adverse effects can be increased when Natalizumab is combined with Fulranumab.,Fulranumab
DB12104,The risk or severity of adverse effects can be increased when Natalizumab is combined with Tarextumab.,Tarextumab
DB12118,The risk or severity of adverse effects can be increased when Natalizumab is combined with Sotatercept.,Sotatercept
DB12119,The risk or severity of adverse effects can be increased when Natalizumab is combined with Gevokizumab.,Gevokizumab
DB12142,The risk or severity of adverse effects can be increased when Natalizumab is combined with Duligotuzumab.,Duligotuzumab
DB12152,The risk or severity of adverse effects can be increased when Natalizumab is combined with Simtuzumab.,Simtuzumab
DB12157,The risk or severity of adverse effects can be increased when Natalizumab is combined with Fasinumab.,Fasinumab
DB12159,The risk or severity of adverse effects can be increased when Natalizumab is combined with Dupilumab.,Dupilumab
DB12169,The risk or severity of adverse effects can be increased when Natalizumab is combined with Tralokinumab.,Tralokinumab
DB12189,The risk or severity of adverse effects can be increased when Natalizumab is combined with Etrolizumab.,Etrolizumab
DB12202,The risk or severity of adverse effects can be increased when Natalizumab is combined with Zalutumumab.,Zalutumumab
DB12205,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ganitumab.,Ganitumab
DB12213,The risk or severity of adverse effects can be increased when Natalizumab is combined with Etaracizumab.,Etaracizumab
DB12240,The risk or severity of adverse effects can be increased when Natalizumab is combined with Polatuzumab vedotin.,Polatuzumab vedotin
DB12246,The risk or severity of adverse effects can be increased when Natalizumab is combined with Inclacumab.,Inclacumab
DB12250,The risk or severity of adverse effects can be increased when Natalizumab is combined with Cixutumumab.,Cixutumumab
DB12261,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ascrinvacumab.,Ascrinvacumab
DB12274,The risk or severity of adverse effects can be increased when Natalizumab is combined with Aducanumab.,Aducanumab
DB12281,The risk or severity of adverse effects can be increased when Natalizumab is combined with Luspatercept.,Luspatercept
DB12296,The risk or severity of adverse effects can be increased when Natalizumab is combined with GS-5745.,GS-5745
DB12317,The risk or severity of adverse effects can be increased when Natalizumab is combined with Vanucizumab.,Vanucizumab
DB12331,The risk or severity of adverse effects can be increased when Natalizumab is combined with Labetuzumab govitecan.,Labetuzumab govitecan
DB12335,The risk or severity of adverse effects can be increased when Natalizumab is combined with Tanezumab.,Tanezumab
DB12342,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ensituximab.,Ensituximab
DB12344,The risk or severity of adverse effects can be increased when Natalizumab is combined with Fezakinumab.,Fezakinumab
DB12363,The risk or severity of adverse effects can be increased when Natalizumab is combined with Dusigitumab.,Dusigitumab
DB12396,The risk or severity of adverse effects can be increased when Natalizumab is combined with Fresolimumab.,Fresolimumab
DB12413,The risk or severity of adverse effects can be increased when Natalizumab is combined with Indusatumab vedotin.,Indusatumab vedotin
DB12456,The risk or severity of adverse effects can be increased when Natalizumab is combined with Bococizumab.,Bococizumab
DB12489,The risk or severity of adverse effects can be increased when Natalizumab is combined with Mirvetuximab Soravtansine.,Mirvetuximab Soravtansine
DB12498,The risk or severity of adverse effects can be increased when Natalizumab is combined with Mogamulizumab.,Mogamulizumab
DB12520,The risk or severity of adverse effects can be increased when Natalizumab is combined with Plozalizumab.,Plozalizumab
DB12534,The risk or severity of adverse effects can be increased when Natalizumab is combined with Mavrilimumab.,Mavrilimumab
DB12560,The risk or severity of adverse effects can be increased when Natalizumab is combined with Blosozumab.,Blosozumab
DB12584,The risk or severity of adverse effects can be increased when Natalizumab is combined with Bimagrumab.,Bimagrumab
DB12589,The risk or severity of adverse effects can be increased when Natalizumab is combined with Dacetuzumab.,Dacetuzumab
DB12609,The risk or severity of adverse effects can be increased when Natalizumab is combined with Tovetumab.,Tovetumab
DB12683,The risk or severity of adverse effects can be increased when Natalizumab is combined with Lumretuzumab.,Lumretuzumab
DB12698,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ibalizumab.,Ibalizumab
DB12701,The risk or severity of adverse effects can be increased when Natalizumab is combined with Intetumumab.,Intetumumab
DB12718,The risk or severity of adverse effects can be increased when Natalizumab is combined with Carlumab.,Carlumab
DB12734,The risk or severity of adverse effects can be increased when Natalizumab is combined with Demcizumab.,Demcizumab
DB12773,The risk or severity of adverse effects can be increased when Natalizumab is combined with Sifalimumab.,Sifalimumab
DB12775,The risk or severity of adverse effects can be increased when Natalizumab is combined with Abituzumab.,Abituzumab
DB12797,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ecromeximab.,Ecromeximab
DB12807,The risk or severity of adverse effects can be increased when Natalizumab is combined with Naptumomab Estafenatox.,Naptumomab Estafenatox
DB12815,The risk or severity of adverse effects can be increased when Natalizumab is combined with Crotedumab.,Crotedumab
DB12820,The risk or severity of adverse effects can be increased when Natalizumab is combined with Concizumab.,Concizumab
DB12826,The risk or severity of adverse effects can be increased when Natalizumab is combined with Depatuxizumab.,Depatuxizumab
DB12844,The risk or severity of adverse effects can be increased when Natalizumab is combined with Rontalizumab.,Rontalizumab
DB12845,The risk or severity of adverse effects can be increased when Natalizumab is combined with Amatuximab.,Amatuximab
DB12849,The risk or severity of adverse effects can be increased when Natalizumab is combined with Clazakizumab.,Clazakizumab
DB12891,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ozanezumab.,Ozanezumab
DB12893,The risk or severity of adverse effects can be increased when Natalizumab is combined with Sacituzumab govitecan.,Sacituzumab govitecan
DB12917,The risk or severity of adverse effects can be increased when Natalizumab is combined with Bimekizumab.,Bimekizumab
DB12943,The risk or severity of adverse effects can be increased when Natalizumab is combined with Milatuzumab.,Milatuzumab
DB12976,The risk or severity of adverse effects can be increased when Natalizumab is combined with Robatumumab.,Robatumumab
DB13017,The risk or severity of adverse effects can be increased when Natalizumab is combined with Rovalpituzumab Tesirine.,Rovalpituzumab Tesirine
DB13037,The risk or severity of adverse effects can be increased when Natalizumab is combined with Namilumab.,Namilumab
DB13045,The risk or severity of adverse effects can be increased when Natalizumab is combined with Racotumomab.,Racotumomab
DB13073,The risk or severity of adverse effects can be increased when Natalizumab is combined with Tregalizumab.,Tregalizumab
DB13127,The risk or severity of adverse effects can be increased when Natalizumab is combined with Olokizumab.,Olokizumab
DB13140,The risk or severity of adverse effects can be increased when Natalizumab is combined with Bezlotoxumab.,Bezlotoxumab
DB13375,The risk or severity of adverse effects can be increased when Natalizumab is combined with Edrecolomab.,Edrecolomab
DB13535,The risk or severity of adverse effects can be increased when Natalizumab is combined with Nebacumab.,Nebacumab
DB13886,The risk or severity of adverse effects can be increased when Natalizumab is combined with Human cytomegalovirus immune globulin.,Human cytomegalovirus immune globulin
DB13923,The risk or severity of adverse effects can be increased when Natalizumab is combined with Emicizumab.,Emicizumab
DB13976,The risk or severity of adverse effects can be increased when Natalizumab is combined with Sulesomab.,Sulesomab
DB13979,The risk or severity of adverse effects can be increased when Natalizumab is combined with Besilesomab.,Besilesomab
DB14012,The risk or severity of adverse effects can be increased when Natalizumab is combined with Burosumab.,Burosumab
DB14039,The risk or severity of adverse effects can be increased when Natalizumab is combined with Erenumab.,Erenumab
DB14040,The risk or severity of adverse effects can be increased when Natalizumab is combined with Eptinezumab.,Eptinezumab
DB14041,The risk or severity of adverse effects can be increased when Natalizumab is combined with Fremanezumab.,Fremanezumab
DB14042,The risk or severity of adverse effects can be increased when Natalizumab is combined with Galcanezumab.,Galcanezumab
DB14211,The risk or severity of adverse effects can be increased when Natalizumab is combined with Fanolesomab.,Fanolesomab
DB14580,The risk or severity of adverse effects can be increased when Natalizumab is combined with Lecanemab.,Lecanemab
DB14597,The risk or severity of adverse effects can be increased when Natalizumab is combined with Lanadelumab.,Lanadelumab
DB14707,The risk or severity of adverse effects can be increased when Natalizumab is combined with Cemiplimab.,Cemiplimab
DB14776,The risk or severity of adverse effects can be increased when Natalizumab is combined with Camrelizumab.,Camrelizumab
DB14778,The risk or severity of adverse effects can be increased when Natalizumab is combined with Setrusumab.,Setrusumab
DB14784,The risk or severity of adverse effects can be increased when Natalizumab is combined with Gancotamab.,Gancotamab
DB14809,The risk or severity of adverse effects can be increased when Natalizumab is combined with Anetumab ravtansine.,Anetumab ravtansine
DB14811,The risk or severity of adverse effects can be increased when Natalizumab is combined with Isatuximab.,Isatuximab
DB14824,The risk or severity of adverse effects can be increased when Natalizumab is combined with Icrucumab.,Icrucumab
DB14843,The risk or severity of adverse effects can be increased when Natalizumab is combined with Codrituzumab.,Codrituzumab
DB14864,The risk or severity of adverse effects can be increased when Natalizumab is combined with Brolucizumab.,Brolucizumab
DB14871,The risk or severity of adverse effects can be increased when Natalizumab is combined with Xentuzumab.,Xentuzumab
DB14877,The risk or severity of adverse effects can be increased when Natalizumab is combined with Lintuzumab.,Lintuzumab
DB14891,The risk or severity of adverse effects can be increased when Natalizumab is combined with Vobarilizumab.,Vobarilizumab
DB14897,The risk or severity of adverse effects can be increased when Natalizumab is combined with Parsatuzumab.,Parsatuzumab
DB14905,The risk or severity of adverse effects can be increased when Natalizumab is combined with Emactuzumab.,Emactuzumab
DB14907,The risk or severity of adverse effects can be increased when Natalizumab is combined with Bevacizumab zirconium Zr-89.,Bevacizumab zirconium Zr-89
DB14908,The risk or severity of adverse effects can be increased when Natalizumab is combined with Refanezumab.,Refanezumab
DB14947,The risk or severity of adverse effects can be increased when Natalizumab is combined with Bermekimab.,Bermekimab
DB14952,The risk or severity of adverse effects can be increased when Natalizumab is combined with Pamrevlumab.,Pamrevlumab
DB14959,The risk or severity of adverse effects can be increased when Natalizumab is combined with Opicinumab.,Opicinumab
DB14962,The risk or severity of adverse effects can be increased when Natalizumab is combined with Trastuzumab deruxtecan.,Trastuzumab deruxtecan
DB14967,The risk or severity of adverse effects can be increased when Natalizumab is combined with Margetuximab.,Margetuximab
DB14988,The risk or severity of adverse effects can be increased when Natalizumab is combined with Dalantercept.,Dalantercept
DB14997,The risk or severity of adverse effects can be increased when Natalizumab is combined with Pateclizumab.,Pateclizumab
DB15014,The risk or severity of adverse effects can be increased when Natalizumab is combined with Gremubamab.,Gremubamab
DB15022,The risk or severity of adverse effects can be increased when Natalizumab is combined with Apomab.,Apomab
DB15044,The risk or severity of adverse effects can be increased when Natalizumab is combined with Tafasitamab.,Tafasitamab
DB15045,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ipafricept.,Ipafricept
DB15076,The risk or severity of adverse effects can be increased when Natalizumab is combined with Abrilumab.,Abrilumab
DB15089,The risk or severity of adverse effects can be increased when Natalizumab is combined with Frovocimab.,Frovocimab
DB15090,The risk or severity of adverse effects can be increased when Natalizumab is combined with Tezepelumab.,Tezepelumab
DB15101,The risk or severity of adverse effects can be increased when Natalizumab is combined with Tigatuzumab.,Tigatuzumab
DB15104,The risk or severity of adverse effects can be increased when Natalizumab is combined with Telisotuzumab vedotin.,Telisotuzumab vedotin
DB15113,The risk or severity of adverse effects can be increased when Natalizumab is combined with Utomilumab.,Utomilumab
DB15118,The risk or severity of adverse effects can be increased when Natalizumab is combined with Zolbetuximab.,Zolbetuximab
DB15135,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ponezumab.,Ponezumab
DB15160,The risk or severity of adverse effects can be increased when Natalizumab is combined with Asunercept.,Asunercept
DB15172,The risk or severity of adverse effects can be increased when Natalizumab is combined with Suvratoxumab.,Suvratoxumab
DB15225,The risk or severity of adverse effects can be increased when Natalizumab is combined with Mitazalimab.,Mitazalimab
DB15252,The risk or severity of adverse effects can be increased when Natalizumab is combined with Nemolizumab.,Nemolizumab
DB15277,The risk or severity of adverse effects can be increased when Natalizumab is combined with Gedivumab.,Gedivumab
DB15336,The risk or severity of adverse effects can be increased when Natalizumab is combined with Valanafusp alfa.,Valanafusp alfa
DB15349,The risk or severity of adverse effects can be increased when Natalizumab is combined with Sofituzumab vedotin.,Sofituzumab vedotin
DB15354,The risk or severity of adverse effects can be increased when Natalizumab is combined with Evinacumab.,Evinacumab
DB15363,The risk or severity of adverse effects can be increased when Natalizumab is combined with Istiratumab.,Istiratumab
DB15383,The risk or severity of adverse effects can be increased when Natalizumab is combined with Pidilizumab.,Pidilizumab
DB15397,The risk or severity of adverse effects can be increased when Natalizumab is combined with GMA-161.,GMA-161
DB15409,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ladiratuzumab vedotin.,Ladiratuzumab vedotin
DB15415,The risk or severity of adverse effects can be increased when Natalizumab is combined with Tomaralimab.,Tomaralimab
DB15428,The risk or severity of adverse effects can be increased when Natalizumab is combined with Vesencumab.,Vesencumab
DB15432,The risk or severity of adverse effects can be increased when Natalizumab is combined with Pinatuzumab vedotin.,Pinatuzumab vedotin
DB15441,The risk or severity of adverse effects can be increased when Natalizumab is combined with Lulizumab pegol.,Lulizumab pegol
DB15443,The risk or severity of adverse effects can be increased when Natalizumab is combined with Lorukafusp alfa.,Lorukafusp alfa
DB15453,The risk or severity of adverse effects can be increased when Natalizumab is combined with Naratuximab emtansine.,Naratuximab emtansine
DB14004,The risk or severity of adverse effects can be increased when Natalizumab is combined with Tildrakizumab.,Tildrakizumab
DB05679,The risk or severity of adverse effects can be increased when Natalizumab is combined with Ustekinumab.,Ustekinumab
DB15559,The risk or severity of adverse effects can be increased when Natalizumab is combined with Zenocutuzumab.,Zenocutuzumab
DB00091,Natalizumab may increase the immunosuppressive activities of Cyclosporine.,Cyclosporine
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Natalizumab.","Ebola Zaire vaccine (live, attenuated)"
DB14513,The serum concentration of Magnesium can be decreased when it is combined with Natalizumab.,Magnesium
DB01601,The serum concentration of Natalizumab can be increased when it is combined with Lopinavir.,Lopinavir
DB12530,The risk or severity of infection can be increased when Natalizumab is combined with Inebilizumab.,Inebilizumab
DB00503,The serum concentration of Enfuvirtide can be increased when it is combined with Ritonavir.,Ritonavir
DB10317,The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Enfuvirtide.,Rubella virus vaccine
DB10343,The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Enfuvirtide.,Bacillus calmette-guerin substrain tice live antigen
DB10804,The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Enfuvirtide.,Bacillus calmette-guerin substrain connaught live antigen
DB10805,The therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Enfuvirtide.,Yellow Fever Vaccine
DB11003,The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Enfuvirtide.,Anthrax vaccine
DB11050,The therapeutic efficacy of Typhoid Vaccine Live can be decreased when used in combination with Enfuvirtide.,Typhoid Vaccine Live
DB12386,The therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Enfuvirtide.,Bacillus calmette-guerin substrain danish 1331 live antigen
DB12768,The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Enfuvirtide.,BCG vaccine
DB14409,The therapeutic efficacy of Human adenovirus e serotype 4 strain cl-68578 antigen can be decreased when used in combination with Enfuvirtide.,Human adenovirus e serotype 4 strain cl-68578 antigen
DB14443,The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Enfuvirtide.,Vibrio cholerae CVD 103-HgR strain live antigen
DB14685,The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Enfuvirtide.,Adenovirus type 7 vaccine live
DB10318,The therapeutic efficacy of Varicella Zoster Vaccine (Live/attenuated) can be decreased when used in combination with Enfuvirtide.,Varicella Zoster Vaccine (Live/attenuated)
DB00255,Diethylstilbestrol may increase the thrombogenic activities of Palivizumab.,Diethylstilbestrol
DB00269,Chlorotrianisene may increase the thrombogenic activities of Palivizumab.,Chlorotrianisene
DB00286,Conjugated estrogens may increase the thrombogenic activities of Palivizumab.,Conjugated estrogens
DB00655,Estrone may increase the thrombogenic activities of Palivizumab.,Estrone
DB00783,Estradiol may increase the thrombogenic activities of Palivizumab.,Estradiol
DB00890,Dienestrol may increase the thrombogenic activities of Palivizumab.,Dienestrol
DB00977,Ethinylestradiol may increase the thrombogenic activities of Palivizumab.,Ethinylestradiol
DB01357,Mestranol may increase the thrombogenic activities of Palivizumab.,Mestranol
DB04573,Estriol may increase the thrombogenic activities of Palivizumab.,Estriol
DB04574,Estrone sulfate may increase the thrombogenic activities of Palivizumab.,Estrone sulfate
DB04575,Quinestrol may increase the thrombogenic activities of Palivizumab.,Quinestrol
DB07931,Hexestrol may increase the thrombogenic activities of Palivizumab.,Hexestrol
DB09070,Tibolone may increase the thrombogenic activities of Palivizumab.,Tibolone
DB09317,"Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Palivizumab.","Synthetic Conjugated Estrogens, A"
DB09318,"Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Palivizumab.","Synthetic Conjugated Estrogens, B"
DB09369,Polyestradiol phosphate may increase the thrombogenic activities of Palivizumab.,Polyestradiol phosphate
DB09381,Esterified estrogens may increase the thrombogenic activities of Palivizumab.,Esterified estrogens
DB11478,Zeranol may increase the thrombogenic activities of Palivizumab.,Zeranol
DB11674,Equol may increase the thrombogenic activities of Palivizumab.,Equol
DB12487,Promestriene may increase the thrombogenic activities of Palivizumab.,Promestriene
DB13143,Methallenestril may increase the thrombogenic activities of Palivizumab.,Methallenestril
DB13386,Epimestrol may increase the thrombogenic activities of Palivizumab.,Epimestrol
DB13418,Moxestrol may increase the thrombogenic activities of Palivizumab.,Moxestrol
DB13952,Estradiol acetate may increase the thrombogenic activities of Palivizumab.,Estradiol acetate
DB13953,Estradiol benzoate may increase the thrombogenic activities of Palivizumab.,Estradiol benzoate
DB13954,Estradiol cypionate may increase the thrombogenic activities of Palivizumab.,Estradiol cypionate
DB13956,Estradiol valerate may increase the thrombogenic activities of Palivizumab.,Estradiol valerate
DB15334,Biochanin A may increase the thrombogenic activities of Palivizumab.,Biochanin A
DB15335,Formononetin may increase the thrombogenic activities of Palivizumab.,Formononetin
DB00002,The risk or severity of adverse effects can be increased when Cetuximab is combined with Palivizumab.,Cetuximab
DB00028,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Palivizumab.,Human immunoglobulin G
DB00043,The risk or severity of adverse effects can be increased when Omalizumab is combined with Palivizumab.,Omalizumab
DB00051,The risk or severity of adverse effects can be increased when Adalimumab is combined with Palivizumab.,Adalimumab
DB00054,The risk or severity of adverse effects can be increased when Abciximab is combined with Palivizumab.,Abciximab
DB00056,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Palivizumab.,Gemtuzumab ozogamicin
DB00057,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Palivizumab.,Indium In-111 satumomab pendetide
DB00065,The risk or severity of adverse effects can be increased when Infliximab is combined with Palivizumab.,Infliximab
DB00072,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Palivizumab.,Trastuzumab
DB00073,The risk or severity of adverse effects can be increased when Rituximab is combined with Palivizumab.,Rituximab
DB00074,The risk or severity of adverse effects can be increased when Basiliximab is combined with Palivizumab.,Basiliximab
DB00075,The risk or severity of adverse effects can be increased when Muromonab is combined with Palivizumab.,Muromonab
DB00076,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Palivizumab.,Digoxin Immune Fab (Ovine)
DB00078,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Palivizumab.,Ibritumomab tiuxetan
DB00081,The risk or severity of adverse effects can be increased when Tositumomab is combined with Palivizumab.,Tositumomab
DB00087,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Palivizumab.,Alemtuzumab
DB00089,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Palivizumab.,Capromab pendetide
DB00095,The risk or severity of adverse effects can be increased when Efalizumab is combined with Palivizumab.,Efalizumab
DB00098,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Palivizumab.,Antithymocyte immunoglobulin (rabbit)
DB00108,The risk or severity of adverse effects can be increased when Natalizumab is combined with Palivizumab.,Natalizumab
DB00111,The risk or severity of adverse effects can be increased when Palivizumab is combined with Daclizumab.,Daclizumab
DB00112,The risk or severity of adverse effects can be increased when Palivizumab is combined with Bevacizumab.,Bevacizumab
DB00113,The risk or severity of adverse effects can be increased when Palivizumab is combined with Technetium Tc-99m arcitumomab.,Technetium Tc-99m arcitumomab
DB01257,The risk or severity of adverse effects can be increased when Palivizumab is combined with Eculizumab.,Eculizumab
DB01269,The risk or severity of adverse effects can be increased when Palivizumab is combined with Panitumumab.,Panitumumab
DB01270,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ranibizumab.,Ranibizumab
DB04901,The risk or severity of adverse effects can be increased when Palivizumab is combined with Galiximab.,Galiximab
DB04949,The risk or severity of adverse effects can be increased when Palivizumab is combined with Pexelizumab.,Pexelizumab
DB04956,The risk or severity of adverse effects can be increased when Palivizumab is combined with Afelimomab.,Afelimomab
DB04958,The risk or severity of adverse effects can be increased when Palivizumab is combined with Epratuzumab.,Epratuzumab
DB04962,The risk or severity of adverse effects can be increased when Palivizumab is combined with Bectumomab.,Bectumomab
DB04964,The risk or severity of adverse effects can be increased when Palivizumab is combined with Oregovomab.,Oregovomab
DB04988,The risk or severity of adverse effects can be increased when Palivizumab is combined with IGN311.,IGN311
DB05006,The risk or severity of adverse effects can be increased when Palivizumab is combined with Adecatumumab.,Adecatumumab
DB05097,The risk or severity of adverse effects can be increased when Palivizumab is combined with Labetuzumab.,Labetuzumab
DB05101,The risk or severity of adverse effects can be increased when Palivizumab is combined with Matuzumab.,Matuzumab
DB05111,The risk or severity of adverse effects can be increased when Palivizumab is combined with Fontolizumab.,Fontolizumab
DB05136,The risk or severity of adverse effects can be increased when Palivizumab is combined with Bavituximab.,Bavituximab
DB05139,The risk or severity of adverse effects can be increased when Palivizumab is combined with CR002.,CR002
DB05209,The risk or severity of adverse effects can be increased when Palivizumab is combined with Rozrolimupab.,Rozrolimupab
DB05304,The risk or severity of adverse effects can be increased when Palivizumab is combined with Girentuximab.,Girentuximab
DB05336,The risk or severity of adverse effects can be increased when Palivizumab is combined with Obiltoxaximab.,Obiltoxaximab
DB05405,The risk or severity of adverse effects can be increased when Palivizumab is combined with XTL-001.,XTL-001
DB05437,The risk or severity of adverse effects can be increased when Palivizumab is combined with NAV 1800.,NAV 1800
DB05459,The risk or severity of adverse effects can be increased when Palivizumab is combined with Briakinumab.,Briakinumab
DB05496,The risk or severity of adverse effects can be increased when Palivizumab is combined with Otelixizumab.,Otelixizumab
DB05545,The risk or severity of adverse effects can be increased when Palivizumab is combined with AMG 108.,AMG 108
DB05550,The risk or severity of adverse effects can be increased when Palivizumab is combined with Iratumumab.,Iratumumab
DB05555,The risk or severity of adverse effects can be increased when Palivizumab is combined with Enokizumab.,Enokizumab
DB05578,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ramucirumab.,Ramucirumab
DB05595,The risk or severity of adverse effects can be increased when Palivizumab is combined with Farletuzumab.,Farletuzumab
DB05656,The risk or severity of adverse effects can be increased when Palivizumab is combined with Veltuzumab.,Veltuzumab
DB05679,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ustekinumab.,Ustekinumab
DB05773,The risk or severity of adverse effects can be increased when Palivizumab is combined with Trastuzumab emtansine.,Trastuzumab emtansine
DB05793,The risk or severity of adverse effects can be increased when Palivizumab is combined with PRO-542.,PRO-542
DB05797,The risk or severity of adverse effects can be increased when Palivizumab is combined with TNX-901.,TNX-901
DB05889,The risk or severity of adverse effects can be increased when Palivizumab is combined with Inotuzumab ozogamicin.,Inotuzumab ozogamicin
DB05892,The risk or severity of adverse effects can be increased when Palivizumab is combined with RI 624.,RI 624
DB05915,The risk or severity of adverse effects can be increased when Palivizumab is combined with MYO-029.,MYO-029
DB05916,The risk or severity of adverse effects can be increased when Palivizumab is combined with CT-011.,CT-011
DB05941,The risk or severity of adverse effects can be increased when Palivizumab is combined with Leronlimab.,Leronlimab
DB05996,The risk or severity of adverse effects can be increased when Palivizumab is combined with Glembatumumab vedotin.,Glembatumumab vedotin
DB06043,The risk or severity of adverse effects can be increased when Palivizumab is combined with Olaratumab.,Olaratumab
DB06049,The risk or severity of adverse effects can be increased when Palivizumab is combined with IPH 2101.,IPH 2101
DB06050,The risk or severity of adverse effects can be increased when Palivizumab is combined with TB-402.,TB-402
DB06081,The risk or severity of adverse effects can be increased when Palivizumab is combined with Caplacizumab.,Caplacizumab
DB06101,The risk or severity of adverse effects can be increased when Palivizumab is combined with IMC-1C11.,IMC-1C11
DB06116,The risk or severity of adverse effects can be increased when Palivizumab is combined with Eldelumab.,Eldelumab
DB06162,The risk or severity of adverse effects can be increased when Palivizumab is combined with Lumiliximab.,Lumiliximab
DB06168,The risk or severity of adverse effects can be increased when Palivizumab is combined with Canakinumab.,Canakinumab
DB06186,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ipilimumab.,Ipilimumab
DB06192,The risk or severity of adverse effects can be increased when Palivizumab is combined with Nimotuzumab.,Nimotuzumab
DB06241,The risk or severity of adverse effects can be increased when Palivizumab is combined with Clenoliximab.,Clenoliximab
DB06273,The risk or severity of adverse effects can be increased when Palivizumab is combined with Tocilizumab.,Tocilizumab
DB06304,The risk or severity of adverse effects can be increased when Palivizumab is combined with BIIB015.,BIIB015
DB06305,The risk or severity of adverse effects can be increased when Palivizumab is combined with Sonepcizumab.,Sonepcizumab
DB06310,The risk or severity of adverse effects can be increased when Palivizumab is combined with Motavizumab.,Motavizumab
DB06317,The risk or severity of adverse effects can be increased when Palivizumab is combined with Elotuzumab.,Elotuzumab
DB06318,The risk or severity of adverse effects can be increased when Palivizumab is combined with AVE9633.,AVE9633
DB06322,The risk or severity of adverse effects can be increased when Palivizumab is combined with Carotuximab.,Carotuximab
DB06324,The risk or severity of adverse effects can be increased when Palivizumab is combined with XmAb 2513.,XmAb 2513
DB06342,The risk or severity of adverse effects can be increased when Palivizumab is combined with Coltuximab ravtansine.,Coltuximab ravtansine
DB06343,The risk or severity of adverse effects can be increased when Palivizumab is combined with Teprotumumab.,Teprotumumab
DB06360,The risk or severity of adverse effects can be increased when Palivizumab is combined with Lucatumumab.,Lucatumumab
DB06366,The risk or severity of adverse effects can be increased when Palivizumab is combined with Pertuzumab.,Pertuzumab
DB06371,The risk or severity of adverse effects can be increased when Palivizumab is combined with Siplizumab.,Siplizumab
DB06467,The risk or severity of adverse effects can be increased when Palivizumab is combined with Apolizumab.,Apolizumab
DB06474,The risk or severity of adverse effects can be increased when Palivizumab is combined with Sibrotuzumab.,Sibrotuzumab
DB06550,The risk or severity of adverse effects can be increased when Palivizumab is combined with Bivatuzumab.,Bivatuzumab
DB06557,The risk or severity of adverse effects can be increased when Palivizumab is combined with Lerdelimumab.,Lerdelimumab
DB06599,The risk or severity of adverse effects can be increased when Palivizumab is combined with Lexatumumab.,Lexatumumab
DB06602,The risk or severity of adverse effects can be increased when Palivizumab is combined with Reslizumab.,Reslizumab
DB06606,The risk or severity of adverse effects can be increased when Palivizumab is combined with Teplizumab.,Teplizumab
DB06607,The risk or severity of adverse effects can be increased when Palivizumab is combined with Catumaxomab.,Catumaxomab
DB06612,The risk or severity of adverse effects can be increased when Palivizumab is combined with Mepolizumab.,Mepolizumab
DB06643,The risk or severity of adverse effects can be increased when Palivizumab is combined with Denosumab.,Denosumab
DB06647,The risk or severity of adverse effects can be increased when Palivizumab is combined with Volociximab.,Volociximab
DB06650,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ofatumumab.,Ofatumumab
DB06674,The risk or severity of adverse effects can be increased when Palivizumab is combined with Golimumab.,Golimumab
DB08870,The risk or severity of adverse effects can be increased when Palivizumab is combined with Brentuximab vedotin.,Brentuximab vedotin
DB08879,The risk or severity of adverse effects can be increased when Palivizumab is combined with Belimumab.,Belimumab
DB08902,The risk or severity of adverse effects can be increased when Palivizumab is combined with Raxibacumab.,Raxibacumab
DB08904,The risk or severity of adverse effects can be increased when Palivizumab is combined with Certolizumab pegol.,Certolizumab pegol
DB08935,The risk or severity of adverse effects can be increased when Palivizumab is combined with Obinutuzumab.,Obinutuzumab
DB09029,The risk or severity of adverse effects can be increased when Palivizumab is combined with Secukinumab.,Secukinumab
DB09033,The risk or severity of adverse effects can be increased when Palivizumab is combined with Vedolizumab.,Vedolizumab
DB09035,The risk or severity of adverse effects can be increased when Palivizumab is combined with Nivolumab.,Nivolumab
DB09036,The risk or severity of adverse effects can be increased when Palivizumab is combined with Siltuximab.,Siltuximab
DB09037,The risk or severity of adverse effects can be increased when Palivizumab is combined with Pembrolizumab.,Pembrolizumab
DB09045,The risk or severity of adverse effects can be increased when Palivizumab is combined with Dulaglutide.,Dulaglutide
DB09052,The risk or severity of adverse effects can be increased when Palivizumab is combined with Blinatumomab.,Blinatumomab
DB09057,The risk or severity of adverse effects can be increased when Palivizumab is combined with Anthrax immune globulin human.,Anthrax immune globulin human
DB09077,The risk or severity of adverse effects can be increased when Palivizumab is combined with Dinutuximab.,Dinutuximab
DB09105,The risk or severity of adverse effects can be increased when Palivizumab is combined with Asfotase alfa.,Asfotase alfa
DB09264,The risk or severity of adverse effects can be increased when Palivizumab is combined with Idarucizumab.,Idarucizumab
DB09302,The risk or severity of adverse effects can be increased when Palivizumab is combined with Alirocumab.,Alirocumab
DB09303,The risk or severity of adverse effects can be increased when Palivizumab is combined with Evolocumab.,Evolocumab
DB09312,The risk or severity of adverse effects can be increased when Palivizumab is combined with Antilymphocyte immunoglobulin (horse).,Antilymphocyte immunoglobulin (horse)
DB09331,The risk or severity of adverse effects can be increased when Palivizumab is combined with Daratumumab.,Daratumumab
DB09559,The risk or severity of adverse effects can be increased when Palivizumab is combined with Necitumumab.,Necitumumab
DB11569,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ixekizumab.,Ixekizumab
DB11580,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ravulizumab.,Ravulizumab
DB11595,The risk or severity of adverse effects can be increased when Palivizumab is combined with Atezolizumab.,Atezolizumab
DB11604,The risk or severity of adverse effects can be increased when Palivizumab is combined with Tetanus Immune Globulin.,Tetanus Immune Globulin
DB11608,The risk or severity of adverse effects can be increased when Palivizumab is combined with Eftrenonacog alfa.,Eftrenonacog alfa
DB11621,The risk or severity of adverse effects can be increased when Palivizumab is combined with Human Varicella-Zoster Immune Globulin.,Human Varicella-Zoster Immune Globulin
DB11646,The risk or severity of adverse effects can be increased when Palivizumab is combined with Conatumumab.,Conatumumab
DB11657,The risk or severity of adverse effects can be increased when Palivizumab is combined with Tabalumab.,Tabalumab
DB11680,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ficlatuzumab.,Ficlatuzumab
DB11685,The risk or severity of adverse effects can be increased when Palivizumab is combined with Figitumumab.,Figitumumab
DB11714,The risk or severity of adverse effects can be increased when Palivizumab is combined with Durvalumab.,Durvalumab
DB11715,The risk or severity of adverse effects can be increased when Palivizumab is combined with Bapineuzumab.,Bapineuzumab
DB11731,The risk or severity of adverse effects can be increased when Palivizumab is combined with Depatuxizumab mafodotin.,Depatuxizumab mafodotin
DB11746,The risk or severity of adverse effects can be increased when Palivizumab is combined with Onartuzumab.,Onartuzumab
DB11756,The risk or severity of adverse effects can be increased when Palivizumab is combined with Solanezumab.,Solanezumab
DB11767,The risk or severity of adverse effects can be increased when Palivizumab is combined with Sarilumab.,Sarilumab
DB11771,The risk or severity of adverse effects can be increased when Palivizumab is combined with Tremelimumab.,Tremelimumab
DB11776,The risk or severity of adverse effects can be increased when Palivizumab is combined with Brodalumab.,Brodalumab
DB11803,The risk or severity of adverse effects can be increased when Palivizumab is combined with Sirukumab.,Sirukumab
DB11826,The risk or severity of adverse effects can be increased when Palivizumab is combined with Lampalizumab.,Lampalizumab
DB11834,The risk or severity of adverse effects can be increased when Palivizumab is combined with Guselkumab.,Guselkumab
DB11840,The risk or severity of adverse effects can be increased when Palivizumab is combined with Dalotuzumab.,Dalotuzumab
DB11849,The risk or severity of adverse effects can be increased when Palivizumab is combined with Emibetuzumab.,Emibetuzumab
DB11850,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ublituximab.,Ublituximab
DB11856,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ligelizumab.,Ligelizumab
DB11857,The risk or severity of adverse effects can be increased when Palivizumab is combined with Seribantumab.,Seribantumab
DB11862,The risk or severity of adverse effects can be increased when Palivizumab is combined with Landogrozumab.,Landogrozumab
DB11866,The risk or severity of adverse effects can be increased when Palivizumab is combined with Romosozumab.,Romosozumab
DB11884,The risk or severity of adverse effects can be increased when Palivizumab is combined with Vadastuximab Talirine.,Vadastuximab Talirine
DB11914,The risk or severity of adverse effects can be increased when Palivizumab is combined with Lebrikizumab.,Lebrikizumab
DB11930,The risk or severity of adverse effects can be increased when Palivizumab is combined with Varlilumab.,Varlilumab
DB11945,The risk or severity of adverse effects can be increased when Palivizumab is combined with Avelumab.,Avelumab
DB11959,The risk or severity of adverse effects can be increased when Palivizumab is combined with Crenezumab.,Crenezumab
DB11972,The risk or severity of adverse effects can be increased when Palivizumab is combined with Rilotumumab.,Rilotumumab
DB11976,The risk or severity of adverse effects can be increased when Palivizumab is combined with Anifrolumab.,Anifrolumab
DB11988,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ocrelizumab.,Ocrelizumab
DB12023,The risk or severity of adverse effects can be increased when Palivizumab is combined with Benralizumab.,Benralizumab
DB12034,The risk or severity of adverse effects can be increased when Palivizumab is combined with Gantenerumab.,Gantenerumab
DB12053,The risk or severity of adverse effects can be increased when Palivizumab is combined with Visilizumab.,Visilizumab
DB12077,The risk or severity of adverse effects can be increased when Palivizumab is combined with Urelumab.,Urelumab
DB12089,The risk or severity of adverse effects can be increased when Palivizumab is combined with Lorvotuzumab mertansine.,Lorvotuzumab mertansine
DB12090,The risk or severity of adverse effects can be increased when Palivizumab is combined with Patritumab.,Patritumab
DB12102,The risk or severity of adverse effects can be increased when Palivizumab is combined with Fulranumab.,Fulranumab
DB12104,The risk or severity of adverse effects can be increased when Palivizumab is combined with Tarextumab.,Tarextumab
DB12118,The risk or severity of adverse effects can be increased when Palivizumab is combined with Sotatercept.,Sotatercept
DB12119,The risk or severity of adverse effects can be increased when Palivizumab is combined with Gevokizumab.,Gevokizumab
DB12142,The risk or severity of adverse effects can be increased when Palivizumab is combined with Duligotuzumab.,Duligotuzumab
DB12152,The risk or severity of adverse effects can be increased when Palivizumab is combined with Simtuzumab.,Simtuzumab
DB12157,The risk or severity of adverse effects can be increased when Palivizumab is combined with Fasinumab.,Fasinumab
DB12159,The risk or severity of adverse effects can be increased when Palivizumab is combined with Dupilumab.,Dupilumab
DB12169,The risk or severity of adverse effects can be increased when Palivizumab is combined with Tralokinumab.,Tralokinumab
DB12189,The risk or severity of adverse effects can be increased when Palivizumab is combined with Etrolizumab.,Etrolizumab
DB12202,The risk or severity of adverse effects can be increased when Palivizumab is combined with Zalutumumab.,Zalutumumab
DB12205,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ganitumab.,Ganitumab
DB12213,The risk or severity of adverse effects can be increased when Palivizumab is combined with Etaracizumab.,Etaracizumab
DB12240,The risk or severity of adverse effects can be increased when Palivizumab is combined with Polatuzumab vedotin.,Polatuzumab vedotin
DB12246,The risk or severity of adverse effects can be increased when Palivizumab is combined with Inclacumab.,Inclacumab
DB12250,The risk or severity of adverse effects can be increased when Palivizumab is combined with Cixutumumab.,Cixutumumab
DB12261,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ascrinvacumab.,Ascrinvacumab
DB12274,The risk or severity of adverse effects can be increased when Palivizumab is combined with Aducanumab.,Aducanumab
DB12281,The risk or severity of adverse effects can be increased when Palivizumab is combined with Luspatercept.,Luspatercept
DB12296,The risk or severity of adverse effects can be increased when Palivizumab is combined with GS-5745.,GS-5745
DB12317,The risk or severity of adverse effects can be increased when Palivizumab is combined with Vanucizumab.,Vanucizumab
DB12331,The risk or severity of adverse effects can be increased when Palivizumab is combined with Labetuzumab govitecan.,Labetuzumab govitecan
DB12335,The risk or severity of adverse effects can be increased when Palivizumab is combined with Tanezumab.,Tanezumab
DB12342,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ensituximab.,Ensituximab
DB12344,The risk or severity of adverse effects can be increased when Palivizumab is combined with Fezakinumab.,Fezakinumab
DB12363,The risk or severity of adverse effects can be increased when Palivizumab is combined with Dusigitumab.,Dusigitumab
DB12396,The risk or severity of adverse effects can be increased when Palivizumab is combined with Fresolimumab.,Fresolimumab
DB12413,The risk or severity of adverse effects can be increased when Palivizumab is combined with Indusatumab vedotin.,Indusatumab vedotin
DB12456,The risk or severity of adverse effects can be increased when Palivizumab is combined with Bococizumab.,Bococizumab
DB12489,The risk or severity of adverse effects can be increased when Palivizumab is combined with Mirvetuximab Soravtansine.,Mirvetuximab Soravtansine
DB12498,The risk or severity of adverse effects can be increased when Palivizumab is combined with Mogamulizumab.,Mogamulizumab
DB12520,The risk or severity of adverse effects can be increased when Palivizumab is combined with Plozalizumab.,Plozalizumab
DB12530,The risk or severity of adverse effects can be increased when Palivizumab is combined with Inebilizumab.,Inebilizumab
DB12534,The risk or severity of adverse effects can be increased when Palivizumab is combined with Mavrilimumab.,Mavrilimumab
DB12560,The risk or severity of adverse effects can be increased when Palivizumab is combined with Blosozumab.,Blosozumab
DB12584,The risk or severity of adverse effects can be increased when Palivizumab is combined with Bimagrumab.,Bimagrumab
DB12589,The risk or severity of adverse effects can be increased when Palivizumab is combined with Dacetuzumab.,Dacetuzumab
DB12609,The risk or severity of adverse effects can be increased when Palivizumab is combined with Tovetumab.,Tovetumab
DB12683,The risk or severity of adverse effects can be increased when Palivizumab is combined with Lumretuzumab.,Lumretuzumab
DB12698,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ibalizumab.,Ibalizumab
DB12701,The risk or severity of adverse effects can be increased when Palivizumab is combined with Intetumumab.,Intetumumab
DB12718,The risk or severity of adverse effects can be increased when Palivizumab is combined with Carlumab.,Carlumab
DB12734,The risk or severity of adverse effects can be increased when Palivizumab is combined with Demcizumab.,Demcizumab
DB12773,The risk or severity of adverse effects can be increased when Palivizumab is combined with Sifalimumab.,Sifalimumab
DB12775,The risk or severity of adverse effects can be increased when Palivizumab is combined with Abituzumab.,Abituzumab
DB12797,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ecromeximab.,Ecromeximab
DB12807,The risk or severity of adverse effects can be increased when Palivizumab is combined with Naptumomab Estafenatox.,Naptumomab Estafenatox
DB12815,The risk or severity of adverse effects can be increased when Palivizumab is combined with Crotedumab.,Crotedumab
DB12820,The risk or severity of adverse effects can be increased when Palivizumab is combined with Concizumab.,Concizumab
DB12826,The risk or severity of adverse effects can be increased when Palivizumab is combined with Depatuxizumab.,Depatuxizumab
DB12844,The risk or severity of adverse effects can be increased when Palivizumab is combined with Rontalizumab.,Rontalizumab
DB12845,The risk or severity of adverse effects can be increased when Palivizumab is combined with Amatuximab.,Amatuximab
DB12849,The risk or severity of adverse effects can be increased when Palivizumab is combined with Clazakizumab.,Clazakizumab
DB12891,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ozanezumab.,Ozanezumab
DB12893,The risk or severity of adverse effects can be increased when Palivizumab is combined with Sacituzumab govitecan.,Sacituzumab govitecan
DB12917,The risk or severity of adverse effects can be increased when Palivizumab is combined with Bimekizumab.,Bimekizumab
DB12943,The risk or severity of adverse effects can be increased when Palivizumab is combined with Milatuzumab.,Milatuzumab
DB12976,The risk or severity of adverse effects can be increased when Palivizumab is combined with Robatumumab.,Robatumumab
DB13017,The risk or severity of adverse effects can be increased when Palivizumab is combined with Rovalpituzumab Tesirine.,Rovalpituzumab Tesirine
DB13037,The risk or severity of adverse effects can be increased when Palivizumab is combined with Namilumab.,Namilumab
DB13045,The risk or severity of adverse effects can be increased when Palivizumab is combined with Racotumomab.,Racotumomab
DB13073,The risk or severity of adverse effects can be increased when Palivizumab is combined with Tregalizumab.,Tregalizumab
DB13127,The risk or severity of adverse effects can be increased when Palivizumab is combined with Olokizumab.,Olokizumab
DB13140,The risk or severity of adverse effects can be increased when Palivizumab is combined with Bezlotoxumab.,Bezlotoxumab
DB13375,The risk or severity of adverse effects can be increased when Palivizumab is combined with Edrecolomab.,Edrecolomab
DB13535,The risk or severity of adverse effects can be increased when Palivizumab is combined with Nebacumab.,Nebacumab
DB13886,The risk or severity of adverse effects can be increased when Palivizumab is combined with Human cytomegalovirus immune globulin.,Human cytomegalovirus immune globulin
DB13923,The risk or severity of adverse effects can be increased when Palivizumab is combined with Emicizumab.,Emicizumab
DB13976,The risk or severity of adverse effects can be increased when Palivizumab is combined with Sulesomab.,Sulesomab
DB13979,The risk or severity of adverse effects can be increased when Palivizumab is combined with Besilesomab.,Besilesomab
DB14004,The risk or severity of adverse effects can be increased when Palivizumab is combined with Tildrakizumab.,Tildrakizumab
DB14012,The risk or severity of adverse effects can be increased when Palivizumab is combined with Burosumab.,Burosumab
DB14039,The risk or severity of adverse effects can be increased when Palivizumab is combined with Erenumab.,Erenumab
DB14040,The risk or severity of adverse effects can be increased when Palivizumab is combined with Eptinezumab.,Eptinezumab
DB14041,The risk or severity of adverse effects can be increased when Palivizumab is combined with Fremanezumab.,Fremanezumab
DB14042,The risk or severity of adverse effects can be increased when Palivizumab is combined with Galcanezumab.,Galcanezumab
DB14211,The risk or severity of adverse effects can be increased when Palivizumab is combined with Fanolesomab.,Fanolesomab
DB14580,The risk or severity of adverse effects can be increased when Palivizumab is combined with Lecanemab.,Lecanemab
DB14597,The risk or severity of adverse effects can be increased when Palivizumab is combined with Lanadelumab.,Lanadelumab
DB14707,The risk or severity of adverse effects can be increased when Palivizumab is combined with Cemiplimab.,Cemiplimab
DB14724,The risk or severity of adverse effects can be increased when Palivizumab is combined with Emapalumab.,Emapalumab
DB14762,The risk or severity of adverse effects can be increased when Palivizumab is combined with Risankizumab.,Risankizumab
DB14776,The risk or severity of adverse effects can be increased when Palivizumab is combined with Camrelizumab.,Camrelizumab
DB14778,The risk or severity of adverse effects can be increased when Palivizumab is combined with Setrusumab.,Setrusumab
DB14784,The risk or severity of adverse effects can be increased when Palivizumab is combined with Gancotamab.,Gancotamab
DB14809,The risk or severity of adverse effects can be increased when Palivizumab is combined with Anetumab ravtansine.,Anetumab ravtansine
DB14811,The risk or severity of adverse effects can be increased when Palivizumab is combined with Isatuximab.,Isatuximab
DB14824,The risk or severity of adverse effects can be increased when Palivizumab is combined with Icrucumab.,Icrucumab
DB14843,The risk or severity of adverse effects can be increased when Palivizumab is combined with Codrituzumab.,Codrituzumab
DB14864,The risk or severity of adverse effects can be increased when Palivizumab is combined with Brolucizumab.,Brolucizumab
DB14871,The risk or severity of adverse effects can be increased when Palivizumab is combined with Xentuzumab.,Xentuzumab
DB14877,The risk or severity of adverse effects can be increased when Palivizumab is combined with Lintuzumab.,Lintuzumab
DB14891,The risk or severity of adverse effects can be increased when Palivizumab is combined with Vobarilizumab.,Vobarilizumab
DB14897,The risk or severity of adverse effects can be increased when Palivizumab is combined with Parsatuzumab.,Parsatuzumab
DB14905,The risk or severity of adverse effects can be increased when Palivizumab is combined with Emactuzumab.,Emactuzumab
DB14907,The risk or severity of adverse effects can be increased when Palivizumab is combined with Bevacizumab zirconium Zr-89.,Bevacizumab zirconium Zr-89
DB14908,The risk or severity of adverse effects can be increased when Palivizumab is combined with Refanezumab.,Refanezumab
DB14919,The risk or severity of adverse effects can be increased when Palivizumab is combined with Rozanolixizumab.,Rozanolixizumab
DB14947,The risk or severity of adverse effects can be increased when Palivizumab is combined with Bermekimab.,Bermekimab
DB14952,The risk or severity of adverse effects can be increased when Palivizumab is combined with Pamrevlumab.,Pamrevlumab
DB14959,The risk or severity of adverse effects can be increased when Palivizumab is combined with Opicinumab.,Opicinumab
DB14962,The risk or severity of adverse effects can be increased when Palivizumab is combined with Trastuzumab deruxtecan.,Trastuzumab deruxtecan
DB14967,The risk or severity of adverse effects can be increased when Palivizumab is combined with Margetuximab.,Margetuximab
DB14988,The risk or severity of adverse effects can be increased when Palivizumab is combined with Dalantercept.,Dalantercept
DB14997,The risk or severity of adverse effects can be increased when Palivizumab is combined with Pateclizumab.,Pateclizumab
DB15014,The risk or severity of adverse effects can be increased when Palivizumab is combined with Gremubamab.,Gremubamab
DB15022,The risk or severity of adverse effects can be increased when Palivizumab is combined with Apomab.,Apomab
DB15044,The risk or severity of adverse effects can be increased when Palivizumab is combined with Tafasitamab.,Tafasitamab
DB15045,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ipafricept.,Ipafricept
DB15076,The risk or severity of adverse effects can be increased when Palivizumab is combined with Abrilumab.,Abrilumab
DB15089,The risk or severity of adverse effects can be increased when Palivizumab is combined with Frovocimab.,Frovocimab
DB15090,The risk or severity of adverse effects can be increased when Palivizumab is combined with Tezepelumab.,Tezepelumab
DB15101,The risk or severity of adverse effects can be increased when Palivizumab is combined with Tigatuzumab.,Tigatuzumab
DB15104,The risk or severity of adverse effects can be increased when Palivizumab is combined with Telisotuzumab vedotin.,Telisotuzumab vedotin
DB15113,The risk or severity of adverse effects can be increased when Palivizumab is combined with Utomilumab.,Utomilumab
DB15118,The risk or severity of adverse effects can be increased when Palivizumab is combined with Zolbetuximab.,Zolbetuximab
DB15135,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ponezumab.,Ponezumab
DB15160,The risk or severity of adverse effects can be increased when Palivizumab is combined with Asunercept.,Asunercept
DB15172,The risk or severity of adverse effects can be increased when Palivizumab is combined with Suvratoxumab.,Suvratoxumab
DB15225,The risk or severity of adverse effects can be increased when Palivizumab is combined with Mitazalimab.,Mitazalimab
DB15252,The risk or severity of adverse effects can be increased when Palivizumab is combined with Nemolizumab.,Nemolizumab
DB15253,The risk or severity of adverse effects can be increased when Palivizumab is combined with Bleselumab.,Bleselumab
DB15277,The risk or severity of adverse effects can be increased when Palivizumab is combined with Gedivumab.,Gedivumab
DB15336,The risk or severity of adverse effects can be increased when Palivizumab is combined with Valanafusp alfa.,Valanafusp alfa
DB15349,The risk or severity of adverse effects can be increased when Palivizumab is combined with Sofituzumab vedotin.,Sofituzumab vedotin
DB15354,The risk or severity of adverse effects can be increased when Palivizumab is combined with Evinacumab.,Evinacumab
DB15363,The risk or severity of adverse effects can be increased when Palivizumab is combined with Istiratumab.,Istiratumab
DB15383,The risk or severity of adverse effects can be increased when Palivizumab is combined with Pidilizumab.,Pidilizumab
DB15397,The risk or severity of adverse effects can be increased when Palivizumab is combined with GMA-161.,GMA-161
DB15409,The risk or severity of adverse effects can be increased when Palivizumab is combined with Ladiratuzumab vedotin.,Ladiratuzumab vedotin
DB15415,The risk or severity of adverse effects can be increased when Palivizumab is combined with Tomaralimab.,Tomaralimab
DB15428,The risk or severity of adverse effects can be increased when Palivizumab is combined with Vesencumab.,Vesencumab
DB15432,The risk or severity of adverse effects can be increased when Palivizumab is combined with Pinatuzumab vedotin.,Pinatuzumab vedotin
DB15441,The risk or severity of adverse effects can be increased when Palivizumab is combined with Lulizumab pegol.,Lulizumab pegol
DB15443,The risk or severity of adverse effects can be increased when Palivizumab is combined with Lorukafusp alfa.,Lorukafusp alfa
DB15453,The risk or severity of adverse effects can be increased when Palivizumab is combined with Naratuximab emtansine.,Naratuximab emtansine
DB15559,The risk or severity of adverse effects can be increased when Palivizumab is combined with Zenocutuzumab.,Zenocutuzumab
DB10317,The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Palivizumab.,Rubella virus vaccine
DB10343,The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Palivizumab.,Bacillus calmette-guerin substrain tice live antigen
DB10804,The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Palivizumab.,Bacillus calmette-guerin substrain connaught live antigen
DB10805,The therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Palivizumab.,Yellow Fever Vaccine
DB11003,The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Palivizumab.,Anthrax vaccine
DB11050,The therapeutic efficacy of Typhoid Vaccine Live can be decreased when used in combination with Palivizumab.,Typhoid Vaccine Live
DB12386,The therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Palivizumab.,Bacillus calmette-guerin substrain danish 1331 live antigen
DB12768,The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Palivizumab.,BCG vaccine
DB14409,The therapeutic efficacy of Human adenovirus e serotype 4 strain cl-68578 antigen can be decreased when used in combination with Palivizumab.,Human adenovirus e serotype 4 strain cl-68578 antigen
DB14443,The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Palivizumab.,Vibrio cholerae CVD 103-HgR strain live antigen
DB14685,The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Palivizumab.,Adenovirus type 7 vaccine live
DB10318,The therapeutic efficacy of Varicella Zoster Vaccine (Live/attenuated) can be decreased when used in combination with Palivizumab.,Varicella Zoster Vaccine (Live/attenuated)
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Palivizumab.","Ebola Zaire vaccine (live, attenuated)"
DB06643,The risk or severity of adverse effects can be increased when Denosumab is combined with Daclizumab.,Denosumab
DB00005,The risk or severity of adverse effects can be increased when Etanercept is combined with Daclizumab.,Etanercept
DB00008,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Daclizumab.,Peginterferon alfa-2a
DB00011,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Daclizumab.,Interferon alfa-n1
DB00018,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Daclizumab.,Interferon alfa-n3
DB00022,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Daclizumab.,Peginterferon alfa-2b
DB00026,The risk or severity of adverse effects can be increased when Anakinra is combined with Daclizumab.,Anakinra
DB00033,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Daclizumab.,Interferon gamma-1b
DB00034,"The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Daclizumab.","Interferon alfa-2a, Recombinant"
DB00041,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Daclizumab.,Aldesleukin
DB00051,The risk or severity of adverse effects can be increased when Adalimumab is combined with Daclizumab.,Adalimumab
DB00056,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Daclizumab.,Gemtuzumab ozogamicin
DB00059,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Daclizumab.,Pegaspargase
DB00065,The risk or severity of adverse effects can be increased when Infliximab is combined with Daclizumab.,Infliximab
DB00068,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Daclizumab.,Interferon beta-1b
DB00069,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Daclizumab.,Interferon alfacon-1
DB00073,The risk or severity of adverse effects can be increased when Rituximab is combined with Daclizumab.,Rituximab
DB00074,The risk or severity of adverse effects can be increased when Basiliximab is combined with Daclizumab.,Basiliximab
DB00075,The risk or severity of adverse effects can be increased when Muromonab is combined with Daclizumab.,Muromonab
DB00078,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Daclizumab.,Ibritumomab tiuxetan
DB00081,The risk or severity of adverse effects can be increased when Tositumomab is combined with Daclizumab.,Tositumomab
DB00087,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Daclizumab.,Alemtuzumab
DB00092,The risk or severity of adverse effects can be increased when Alefacept is combined with Daclizumab.,Alefacept
DB00095,The risk or severity of adverse effects can be increased when Efalizumab is combined with Daclizumab.,Efalizumab
DB00098,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Daclizumab.,Antithymocyte immunoglobulin (rabbit)
DB00105,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Daclizumab.,Interferon alfa-2b
DB00112,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bevacizumab.,Bevacizumab
DB00120,The risk or severity of adverse effects can be increased when Daclizumab is combined with Phenylalanine.,Phenylalanine
DB00180,The risk or severity of adverse effects can be increased when Daclizumab is combined with Flunisolide.,Flunisolide
DB00188,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bortezomib.,Bortezomib
DB00242,The risk or severity of adverse effects can be increased when Daclizumab is combined with Cladribine.,Cladribine
DB00262,The risk or severity of adverse effects can be increased when Daclizumab is combined with Carmustine.,Carmustine
DB00276,The risk or severity of adverse effects can be increased when Daclizumab is combined with Amsacrine.,Amsacrine
DB00290,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bleomycin.,Bleomycin
DB00291,The risk or severity of adverse effects can be increased when Daclizumab is combined with Chlorambucil.,Chlorambucil
DB00293,The risk or severity of adverse effects can be increased when Daclizumab is combined with Raltitrexed.,Raltitrexed
DB00305,The risk or severity of adverse effects can be increased when Daclizumab is combined with Mitomycin.,Mitomycin
DB00307,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bexarotene.,Bexarotene
DB00309,The risk or severity of adverse effects can be increased when Daclizumab is combined with Vindesine.,Vindesine
DB00322,The risk or severity of adverse effects can be increased when Daclizumab is combined with Floxuridine.,Floxuridine
DB00328,The risk or severity of adverse effects can be increased when Daclizumab is combined with Indomethacin.,Indomethacin
DB00352,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tioguanine.,Tioguanine
DB00361,The risk or severity of adverse effects can be increased when Daclizumab is combined with Vinorelbine.,Vinorelbine
DB00380,The risk or severity of adverse effects can be increased when Daclizumab is combined with Dexrazoxane.,Dexrazoxane
DB00394,The risk or severity of adverse effects can be increased when Daclizumab is combined with Beclomethasone dipropionate.,Beclomethasone dipropionate
DB00398,The risk or severity of adverse effects can be increased when Daclizumab is combined with Sorafenib.,Sorafenib
DB00428,The risk or severity of adverse effects can be increased when Daclizumab is combined with Streptozocin.,Streptozocin
DB00432,The risk or severity of adverse effects can be increased when Daclizumab is combined with Trifluridine.,Trifluridine
DB00441,The risk or severity of adverse effects can be increased when Daclizumab is combined with Gemcitabine.,Gemcitabine
DB00443,The risk or severity of adverse effects can be increased when Daclizumab is combined with Betamethasone.,Betamethasone
DB00444,The risk or severity of adverse effects can be increased when Daclizumab is combined with Teniposide.,Teniposide
DB00445,The risk or severity of adverse effects can be increased when Daclizumab is combined with Epirubicin.,Epirubicin
DB00446,The risk or severity of adverse effects can be increased when Daclizumab is combined with Chloramphenicol.,Chloramphenicol
DB00480,The risk or severity of adverse effects can be increased when Daclizumab is combined with Lenalidomide.,Lenalidomide
DB00488,The risk or severity of adverse effects can be increased when Daclizumab is combined with Altretamine.,Altretamine
DB00495,The risk or severity of adverse effects can be increased when Daclizumab is combined with Zidovudine.,Zidovudine
DB00515,The risk or severity of adverse effects can be increased when Daclizumab is combined with Cisplatin.,Cisplatin
DB00526,The risk or severity of adverse effects can be increased when Daclizumab is combined with Oxaliplatin.,Oxaliplatin
DB00531,The risk or severity of adverse effects can be increased when Daclizumab is combined with Cyclophosphamide.,Cyclophosphamide
DB00541,The risk or severity of adverse effects can be increased when Daclizumab is combined with Vincristine.,Vincristine
DB00544,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluorouracil.,Fluorouracil
DB00550,The risk or severity of adverse effects can be increased when Daclizumab is combined with Propylthiouracil.,Propylthiouracil
DB00552,The risk or severity of adverse effects can be increased when Daclizumab is combined with Pentostatin.,Pentostatin
DB00563,The risk or severity of adverse effects can be increased when Daclizumab is combined with Methotrexate.,Methotrexate
DB00564,The risk or severity of adverse effects can be increased when Daclizumab is combined with Carbamazepine.,Carbamazepine
DB00570,The risk or severity of adverse effects can be increased when Daclizumab is combined with Vinblastine.,Vinblastine
DB00588,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluticasone propionate.,Fluticasone propionate
DB00591,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluocinolone acetonide.,Fluocinolone acetonide
DB00601,The risk or severity of adverse effects can be increased when Daclizumab is combined with Linezolid.,Linezolid
DB00619,The risk or severity of adverse effects can be increased when Daclizumab is combined with Imatinib.,Imatinib
DB00620,The risk or severity of adverse effects can be increased when Daclizumab is combined with Triamcinolone.,Triamcinolone
DB00631,The risk or severity of adverse effects can be increased when Daclizumab is combined with Clofarabine.,Clofarabine
DB00635,The risk or severity of adverse effects can be increased when Daclizumab is combined with Prednisone.,Prednisone
DB00642,The risk or severity of adverse effects can be increased when Daclizumab is combined with Pemetrexed.,Pemetrexed
DB00687,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fludrocortisone.,Fludrocortisone
DB00688,The risk or severity of adverse effects can be increased when Daclizumab is combined with Mycophenolate mofetil.,Mycophenolate mofetil
DB00694,The risk or severity of adverse effects can be increased when Daclizumab is combined with Daunorubicin.,Daunorubicin
DB00755,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tretinoin.,Tretinoin
DB00762,The risk or severity of adverse effects can be increased when Daclizumab is combined with Irinotecan.,Irinotecan
DB00763,The risk or severity of adverse effects can be increased when Daclizumab is combined with Methimazole.,Methimazole
DB00764,The risk or severity of adverse effects can be increased when Daclizumab is combined with Mometasone.,Mometasone
DB00773,The risk or severity of adverse effects can be increased when Daclizumab is combined with Etoposide.,Etoposide
DB00795,The risk or severity of adverse effects can be increased when Daclizumab is combined with Sulfasalazine.,Sulfasalazine
DB00851,The risk or severity of adverse effects can be increased when Daclizumab is combined with Dacarbazine.,Dacarbazine
DB00853,The risk or severity of adverse effects can be increased when Daclizumab is combined with Temozolomide.,Temozolomide
DB00859,The risk or severity of adverse effects can be increased when Daclizumab is combined with Penicillamine.,Penicillamine
DB00860,The risk or severity of adverse effects can be increased when Daclizumab is combined with Prednisolone.,Prednisolone
DB00877,The risk or severity of adverse effects can be increased when Daclizumab is combined with Sirolimus.,Sirolimus
DB00888,The risk or severity of adverse effects can be increased when Daclizumab is combined with Mechlorethamine.,Mechlorethamine
DB00928,The risk or severity of adverse effects can be increased when Daclizumab is combined with Azacitidine.,Azacitidine
DB00958,The risk or severity of adverse effects can be increased when Daclizumab is combined with Carboplatin.,Carboplatin
DB00959,The risk or severity of adverse effects can be increased when Daclizumab is combined with Methylprednisolone.,Methylprednisolone
DB00970,The risk or severity of adverse effects can be increased when Daclizumab is combined with Dactinomycin.,Dactinomycin
DB00987,The risk or severity of adverse effects can be increased when Daclizumab is combined with Cytarabine.,Cytarabine
DB00993,The risk or severity of adverse effects can be increased when Daclizumab is combined with Azathioprine.,Azathioprine
DB00997,The risk or severity of adverse effects can be increased when Daclizumab is combined with Doxorubicin.,Doxorubicin
DB01005,The risk or severity of adverse effects can be increased when Daclizumab is combined with Hydroxyurea.,Hydroxyurea
DB01008,The risk or severity of adverse effects can be increased when Daclizumab is combined with Busulfan.,Busulfan
DB01024,The risk or severity of adverse effects can be increased when Daclizumab is combined with Mycophenolic acid.,Mycophenolic acid
DB01030,The risk or severity of adverse effects can be increased when Daclizumab is combined with Topotecan.,Topotecan
DB01033,The risk or severity of adverse effects can be increased when Daclizumab is combined with Mercaptopurine.,Mercaptopurine
DB01041,The risk or severity of adverse effects can be increased when Daclizumab is combined with Thalidomide.,Thalidomide
DB01042,The risk or severity of adverse effects can be increased when Daclizumab is combined with Melphalan.,Melphalan
DB01073,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fludarabine.,Fludarabine
DB01099,The risk or severity of adverse effects can be increased when Daclizumab is combined with Flucytosine.,Flucytosine
DB01101,The risk or severity of adverse effects can be increased when Daclizumab is combined with Capecitabine.,Capecitabine
DB01108,The risk or severity of adverse effects can be increased when Daclizumab is combined with Trilostane.,Trilostane
DB01168,The risk or severity of adverse effects can be increased when Daclizumab is combined with Procarbazine.,Procarbazine
DB01169,The risk or severity of adverse effects can be increased when Daclizumab is combined with Arsenic trioxide.,Arsenic trioxide
DB01177,The risk or severity of adverse effects can be increased when Daclizumab is combined with Idarubicin.,Idarubicin
DB01181,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ifosfamide.,Ifosfamide
DB01196,The risk or severity of adverse effects can be increased when Daclizumab is combined with Estramustine.,Estramustine
DB01204,The risk or severity of adverse effects can be increased when Daclizumab is combined with Mitoxantrone.,Mitoxantrone
DB01206,The risk or severity of adverse effects can be increased when Daclizumab is combined with Lomustine.,Lomustine
DB01222,The risk or severity of adverse effects can be increased when Daclizumab is combined with Budesonide.,Budesonide
DB01229,The risk or severity of adverse effects can be increased when Daclizumab is combined with Paclitaxel.,Paclitaxel
DB01234,The risk or severity of adverse effects can be increased when Daclizumab is combined with Dexamethasone.,Dexamethasone
DB01248,The risk or severity of adverse effects can be increased when Daclizumab is combined with Docetaxel.,Docetaxel
DB01254,The risk or severity of adverse effects can be increased when Daclizumab is combined with Dasatinib.,Dasatinib
DB01257,The risk or severity of adverse effects can be increased when Daclizumab is combined with Eculizumab.,Eculizumab
DB01262,The risk or severity of adverse effects can be increased when Daclizumab is combined with Decitabine.,Decitabine
DB01268,The risk or severity of adverse effects can be increased when Daclizumab is combined with Sunitinib.,Sunitinib
DB01280,The risk or severity of adverse effects can be increased when Daclizumab is combined with Nelarabine.,Nelarabine
DB01281,The risk or severity of adverse effects can be increased when Daclizumab is combined with Abatacept.,Abatacept
DB01285,The risk or severity of adverse effects can be increased when Daclizumab is combined with Corticotropin.,Corticotropin
DB01380,The risk or severity of adverse effects can be increased when Daclizumab is combined with Cortisone acetate.,Cortisone acetate
DB01384,The risk or severity of adverse effects can be increased when Daclizumab is combined with Paramethasone.,Paramethasone
DB01394,The risk or severity of adverse effects can be increased when Daclizumab is combined with Colchicine.,Colchicine
DB01410,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ciclesonide.,Ciclesonide
DB01423,The risk or severity of adverse effects can be increased when Daclizumab is combined with Stepronin.,Stepronin
DB01590,The risk or severity of adverse effects can be increased when Daclizumab is combined with Everolimus.,Everolimus
DB01611,The risk or severity of adverse effects can be increased when Daclizumab is combined with Hydroxychloroquine.,Hydroxychloroquine
DB01816,The risk or severity of adverse effects can be increased when Daclizumab is combined with Castanospermine.,Castanospermine
DB02546,The risk or severity of adverse effects can be increased when Daclizumab is combined with Vorinostat.,Vorinostat
DB02806,The risk or severity of adverse effects can be increased when Daclizumab is combined with 2-Methoxyethanol.,2-Methoxyethanol
DB03523,The risk or severity of adverse effects can be increased when Daclizumab is combined with Brequinar.,Brequinar
DB04572,The risk or severity of adverse effects can be increased when Daclizumab is combined with Thiotepa.,Thiotepa
DB04630,The risk or severity of adverse effects can be increased when Daclizumab is combined with Aldosterone.,Aldosterone
DB04845,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ixabepilone.,Ixabepilone
DB04868,The risk or severity of adverse effects can be increased when Daclizumab is combined with Nilotinib.,Nilotinib
DB04951,The risk or severity of adverse effects can be increased when Daclizumab is combined with Pirfenidone.,Pirfenidone
DB04956,The risk or severity of adverse effects can be increased when Daclizumab is combined with Afelimomab.,Afelimomab
DB05015,The risk or severity of adverse effects can be increased when Daclizumab is combined with Belinostat.,Belinostat
DB05109,The risk or severity of adverse effects can be increased when Daclizumab is combined with Trabectedin.,Trabectedin
DB05258,The risk or severity of adverse effects can be increased when Daclizumab is combined with Interferon alfa.,Interferon alfa
DB05259,The risk or severity of adverse effects can be increased when Daclizumab is combined with Glatiramer.,Glatiramer
DB05260,The risk or severity of adverse effects can be increased when Daclizumab is combined with Gallium nitrate.,Gallium nitrate
DB05459,The risk or severity of adverse effects can be increased when Daclizumab is combined with Briakinumab.,Briakinumab
DB05472,The risk or severity of adverse effects can be increased when Daclizumab is combined with omega interferon.,omega interferon
DB05676,The risk or severity of adverse effects can be increased when Daclizumab is combined with Apremilast.,Apremilast
DB05773,The risk or severity of adverse effects can be increased when Daclizumab is combined with Trastuzumab emtansine.,Trastuzumab emtansine
DB06168,The risk or severity of adverse effects can be increased when Daclizumab is combined with Canakinumab.,Canakinumab
DB06273,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tocilizumab.,Tocilizumab
DB06287,The risk or severity of adverse effects can be increased when Daclizumab is combined with Temsirolimus.,Temsirolimus
DB06372,The risk or severity of adverse effects can be increased when Daclizumab is combined with Rilonacept.,Rilonacept
DB06589,The risk or severity of adverse effects can be increased when Daclizumab is combined with Pazopanib.,Pazopanib
DB06603,The risk or severity of adverse effects can be increased when Daclizumab is combined with Panobinostat.,Panobinostat
DB06612,The risk or severity of adverse effects can be increased when Daclizumab is combined with Mepolizumab.,Mepolizumab
DB06616,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bosutinib.,Bosutinib
DB06662,The risk or severity of adverse effects can be increased when Daclizumab is combined with Abetimus.,Abetimus
DB06674,The risk or severity of adverse effects can be increased when Daclizumab is combined with Golimumab.,Golimumab
DB06681,The risk or severity of adverse effects can be increased when Daclizumab is combined with Belatacept.,Belatacept
DB06769,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bendamustine.,Bendamustine
DB06772,The risk or severity of adverse effects can be increased when Daclizumab is combined with Cabazitaxel.,Cabazitaxel
DB06813,The risk or severity of adverse effects can be increased when Daclizumab is combined with Pralatrexate.,Pralatrexate
DB08059,The risk or severity of adverse effects can be increased when Daclizumab is combined with Wortmannin.,Wortmannin
DB08870,The risk or severity of adverse effects can be increased when Daclizumab is combined with Brentuximab vedotin.,Brentuximab vedotin
DB08871,The risk or severity of adverse effects can be increased when Daclizumab is combined with Eribulin.,Eribulin
DB08877,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ruxolitinib.,Ruxolitinib
DB08879,The risk or severity of adverse effects can be increased when Daclizumab is combined with Belimumab.,Belimumab
DB08880,The risk or severity of adverse effects can be increased when Daclizumab is combined with Teriflunomide.,Teriflunomide
DB08889,The risk or severity of adverse effects can be increased when Daclizumab is combined with Carfilzomib.,Carfilzomib
DB08901,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ponatinib.,Ponatinib
DB08904,The risk or severity of adverse effects can be increased when Daclizumab is combined with Certolizumab pegol.,Certolizumab pegol
DB08906,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluticasone furoate.,Fluticasone furoate
DB08908,The risk or severity of adverse effects can be increased when Daclizumab is combined with Dimethyl fumarate.,Dimethyl fumarate
DB08910,The risk or severity of adverse effects can be increased when Daclizumab is combined with Pomalidomide.,Pomalidomide
DB08935,The risk or severity of adverse effects can be increased when Daclizumab is combined with Obinutuzumab.,Obinutuzumab
DB08970,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluprednidene.,Fluprednidene
DB08971,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluocortolone.,Fluocortolone
DB09029,The risk or severity of adverse effects can be increased when Daclizumab is combined with Secukinumab.,Secukinumab
DB09033,The risk or severity of adverse effects can be increased when Daclizumab is combined with Vedolizumab.,Vedolizumab
DB09036,The risk or severity of adverse effects can be increased when Daclizumab is combined with Siltuximab.,Siltuximab
DB09052,The risk or severity of adverse effects can be increased when Daclizumab is combined with Blinatumomab.,Blinatumomab
DB09053,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ibrutinib.,Ibrutinib
DB09054,The risk or severity of adverse effects can be increased when Daclizumab is combined with Idelalisib.,Idelalisib
DB09073,The risk or severity of adverse effects can be increased when Daclizumab is combined with Palbociclib.,Palbociclib
DB09074,The risk or severity of adverse effects can be increased when Daclizumab is combined with Olaparib.,Olaparib
DB09077,The risk or severity of adverse effects can be increased when Daclizumab is combined with Dinutuximab.,Dinutuximab
DB09082,The risk or severity of adverse effects can be increased when Daclizumab is combined with Vilanterol.,Vilanterol
DB09091,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tixocortol.,Tixocortol
DB09122,The risk or severity of adverse effects can be increased when Daclizumab is combined with Peginterferon beta-1a.,Peginterferon beta-1a
DB09312,The risk or severity of adverse effects can be increased when Daclizumab is combined with Antilymphocyte immunoglobulin (horse).,Antilymphocyte immunoglobulin (horse)
DB09378,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluprednisolone.,Fluprednisolone
DB09383,The risk or severity of adverse effects can be increased when Daclizumab is combined with Meprednisone.,Meprednisone
DB11466,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tepoxalin.,Tepoxalin
DB11487,The risk or severity of adverse effects can be increased when Daclizumab is combined with Dexamethasone isonicotinate.,Dexamethasone isonicotinate
DB11529,The risk or severity of adverse effects can be increased when Daclizumab is combined with Melengestrol.,Melengestrol
DB11569,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ixekizumab.,Ixekizumab
DB11580,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ravulizumab.,Ravulizumab
DB11616,The risk or severity of adverse effects can be increased when Daclizumab is combined with Pirarubicin.,Pirarubicin
DB11693,The risk or severity of adverse effects can be increased when Daclizumab is combined with Voclosporin.,Voclosporin
DB11708,The risk or severity of adverse effects can be increased when Daclizumab is combined with Peficitinib.,Peficitinib
DB11750,The risk or severity of adverse effects can be increased when Daclizumab is combined with Clobetasol.,Clobetasol
DB11767,The risk or severity of adverse effects can be increased when Daclizumab is combined with Sarilumab.,Sarilumab
DB11776,The risk or severity of adverse effects can be increased when Daclizumab is combined with Brodalumab.,Brodalumab
DB11803,The risk or severity of adverse effects can be increased when Daclizumab is combined with Sirukumab.,Sirukumab
DB11817,The risk or severity of adverse effects can be increased when Daclizumab is combined with Baricitinib.,Baricitinib
DB11834,The risk or severity of adverse effects can be increased when Daclizumab is combined with Guselkumab.,Guselkumab
DB11921,The risk or severity of adverse effects can be increased when Daclizumab is combined with Deflazacort.,Deflazacort
DB12025,The risk or severity of adverse effects can be increased when Daclizumab is combined with Triptolide.,Triptolide
DB12371,The risk or severity of adverse effects can be increased when Daclizumab is combined with Siponimod.,Siponimod
DB12612,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ozanimod.,Ozanimod
DB12617,The risk or severity of adverse effects can be increased when Daclizumab is combined with Mizoribine.,Mizoribine
DB12692,The risk or severity of adverse effects can be increased when Daclizumab is combined with Gusperimus.,Gusperimus
DB12814,The risk or severity of adverse effects can be increased when Daclizumab is combined with Cepeginterferon alfa-2B.,Cepeginterferon alfa-2B
DB12902,The risk or severity of adverse effects can be increased when Daclizumab is combined with Trofosfamide.,Trofosfamide
DB12947,The risk or severity of adverse effects can be increased when Daclizumab is combined with Doxifluridine.,Doxifluridine
DB12991,The risk or severity of adverse effects can be increased when Daclizumab is combined with Deoxyspergualin.,Deoxyspergualin
DB12996,The risk or severity of adverse effects can be increased when Daclizumab is combined with Acteoside.,Acteoside
DB13003,The risk or severity of adverse effects can be increased when Daclizumab is combined with Cortivazol.,Cortivazol
DB13014,The risk or severity of adverse effects can be increased when Daclizumab is combined with Hypericin.,Hypericin
DB13068,The risk or severity of adverse effects can be increased when Daclizumab is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.,9-(N-methyl-L-isoleucine)-cyclosporin A
DB13208,The risk or severity of adverse effects can be increased when Daclizumab is combined with Prednylidene.,Prednylidene
DB13223,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluocortin.,Fluocortin
DB13241,The risk or severity of adverse effects can be increased when Daclizumab is combined with Begelomab.,Begelomab
DB13491,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluperolone.,Fluperolone
DB13664,The risk or severity of adverse effects can be increased when Daclizumab is combined with Formocortal.,Formocortal
DB13728,The risk or severity of adverse effects can be increased when Daclizumab is combined with Halometasone.,Halometasone
DB13843,The risk or severity of adverse effects can be increased when Daclizumab is combined with Cloprednol.,Cloprednol
DB13856,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluclorolone.,Fluclorolone
DB13867,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluticasone.,Fluticasone
DB14066,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tetrandrine.,Tetrandrine
DB14219,The risk or severity of adverse effects can be increased when Daclizumab is combined with Monomethyl fumarate.,Monomethyl fumarate
DB14512,The risk or severity of adverse effects can be increased when Daclizumab is combined with Mometasone furoate.,Mometasone furoate
DB14538,The risk or severity of adverse effects can be increased when Daclizumab is combined with Hydrocortisone aceponate.,Hydrocortisone aceponate
DB14539,The risk or severity of adverse effects can be increased when Daclizumab is combined with Hydrocortisone acetate.,Hydrocortisone acetate
DB14545,The risk or severity of adverse effects can be increased when Daclizumab is combined with Hydrocortisone succinate.,Hydrocortisone succinate
DB14724,The risk or severity of adverse effects can be increased when Daclizumab is combined with Emapalumab.,Emapalumab
DB14762,The risk or severity of adverse effects can be increased when Daclizumab is combined with Risankizumab.,Risankizumab
DB14919,The risk or severity of adverse effects can be increased when Daclizumab is combined with Rozanolixizumab.,Rozanolixizumab
DB15253,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bleselumab.,Bleselumab
DB00108,The risk or severity of adverse effects can be increased when Daclizumab is combined with Natalizumab.,Natalizumab
DB00337,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Daclizumab.,Pimecrolimus
DB01656,Roflumilast may increase the immunosuppressive activities of Daclizumab.,Roflumilast
DB06688,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Daclizumab.,Sipuleucel-T
DB01015,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Daclizumab.,Sulfamethoxazole
DB00255,Diethylstilbestrol may increase the thrombogenic activities of Daclizumab.,Diethylstilbestrol
DB00269,Chlorotrianisene may increase the thrombogenic activities of Daclizumab.,Chlorotrianisene
DB00286,Conjugated estrogens may increase the thrombogenic activities of Daclizumab.,Conjugated estrogens
DB00655,Estrone may increase the thrombogenic activities of Daclizumab.,Estrone
DB00783,Estradiol may increase the thrombogenic activities of Daclizumab.,Estradiol
DB00890,Dienestrol may increase the thrombogenic activities of Daclizumab.,Dienestrol
DB00977,Ethinylestradiol may increase the thrombogenic activities of Daclizumab.,Ethinylestradiol
DB01357,Mestranol may increase the thrombogenic activities of Daclizumab.,Mestranol
DB04573,Estriol may increase the thrombogenic activities of Daclizumab.,Estriol
DB04574,Estrone sulfate may increase the thrombogenic activities of Daclizumab.,Estrone sulfate
DB04575,Quinestrol may increase the thrombogenic activities of Daclizumab.,Quinestrol
DB07931,Hexestrol may increase the thrombogenic activities of Daclizumab.,Hexestrol
DB09070,Tibolone may increase the thrombogenic activities of Daclizumab.,Tibolone
DB09317,"Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Daclizumab.","Synthetic Conjugated Estrogens, A"
DB09318,"Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Daclizumab.","Synthetic Conjugated Estrogens, B"
DB09369,Polyestradiol phosphate may increase the thrombogenic activities of Daclizumab.,Polyestradiol phosphate
DB09381,Esterified estrogens may increase the thrombogenic activities of Daclizumab.,Esterified estrogens
DB11478,Zeranol may increase the thrombogenic activities of Daclizumab.,Zeranol
DB11674,Equol may increase the thrombogenic activities of Daclizumab.,Equol
DB12487,Promestriene may increase the thrombogenic activities of Daclizumab.,Promestriene
DB13143,Methallenestril may increase the thrombogenic activities of Daclizumab.,Methallenestril
DB13386,Epimestrol may increase the thrombogenic activities of Daclizumab.,Epimestrol
DB13418,Moxestrol may increase the thrombogenic activities of Daclizumab.,Moxestrol
DB13952,Estradiol acetate may increase the thrombogenic activities of Daclizumab.,Estradiol acetate
DB13953,Estradiol benzoate may increase the thrombogenic activities of Daclizumab.,Estradiol benzoate
DB13954,Estradiol cypionate may increase the thrombogenic activities of Daclizumab.,Estradiol cypionate
DB13956,Estradiol valerate may increase the thrombogenic activities of Daclizumab.,Estradiol valerate
DB15334,Biochanin A may increase the thrombogenic activities of Daclizumab.,Biochanin A
DB15335,Formononetin may increase the thrombogenic activities of Daclizumab.,Formononetin
DB01097,The risk or severity of adverse effects can be increased when Daclizumab is combined with Leflunomide.,Leflunomide
DB08895,Daclizumab may increase the immunosuppressive activities of Tofacitinib.,Tofacitinib
DB00072,Trastuzumab may increase the neutropenic activities of Daclizumab.,Trastuzumab
DB08868,Daclizumab may increase the immunosuppressive activities of Fingolimod.,Fingolimod
DB00864,Tacrolimus may increase the immunosuppressive activities of Daclizumab.,Tacrolimus
DB04914,The therapeutic efficacy of G17DT can be decreased when used in combination with Daclizumab.,G17DT
DB05144,The therapeutic efficacy of PEV3A can be decreased when used in combination with Daclizumab.,PEV3A
DB05325,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Daclizumab.,INGN 225
DB05374,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Daclizumab.,Rindopepimut
DB05440,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Daclizumab.,SRP 299
DB05942,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Daclizumab.,GI-5005
DB06400,The therapeutic efficacy of Vitespen can be decreased when used in combination with Daclizumab.,Vitespen
DB06584,The therapeutic efficacy of TG4010 can be decreased when used in combination with Daclizumab.,TG4010
DB09057,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Daclizumab.,Anthrax immune globulin human
DB10062,"The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Daclizumab.","Rabies virus inactivated antigen, B"
DB10076,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Daclizumab.,Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen
DB10276,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Daclizumab.,Rotavirus vaccine
DB10283,"The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Daclizumab.","Rabies virus inactivated antigen, A"
DB10342,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Daclizumab.,Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen
DB10583,The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Daclizumab.,Clostridium tetani toxoid antigen (formaldehyde inactivated)
DB10584,The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Daclizumab.,Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
DB10600,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Daclizumab.,Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated)
DB10769,The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Daclizumab.,Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)
DB10794,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Daclizumab.,Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated)
DB10803,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Daclizumab.,Typhoid Vi polysaccharide vaccine
DB10989,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Daclizumab.,Hepatitis A Vaccine
DB10990,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Daclizumab.,Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
DB11038,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Daclizumab.,Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated)
DB11040,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Daclizumab.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated)
DB11041,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Daclizumab.,Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)
DB11044,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Daclizumab.,Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated)
DB11603,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Daclizumab.,Human rabies virus immune globulin
DB11627,The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Daclizumab.,Hepatitis B Vaccine (Recombinant)
DB12568,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Daclizumab.,Tecemotide
DB14022,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Daclizumab.,Typhoid vaccine
DB14384,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Daclizumab.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated)
DB14385,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Daclizumab.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)
DB14394,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Daclizumab.,Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen
DB14445,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Daclizumab.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated)
DB14449,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Daclizumab.,Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen
DB14619,The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Daclizumab.,Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated)
DB14620,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Daclizumab.,Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated)
DB14711,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Daclizumab.,Vaccinia virus strain new york city board of health live antigen
DB15274,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Daclizumab.,Pertussis vaccine
DB15461,The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Daclizumab.,Yersinia pestis 195/p antigen (formaldehyde inactivated)
DB13924,The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Daclizumab.,Varicella Zoster Vaccine (Recombinant)
DB15483,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Daclizumab.,Modified vaccinia ankara
DB11988,Ocrelizumab may increase the immunosuppressive activities of Daclizumab.,Ocrelizumab
DB10317,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Daclizumab.,Rubella virus vaccine
DB10318,The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Daclizumab.,Varicella Zoster Vaccine (Live/attenuated)
DB10343,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Daclizumab.,Bacillus calmette-guerin substrain tice live antigen
DB10804,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Daclizumab.,Bacillus calmette-guerin substrain connaught live antigen
DB10805,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Daclizumab.,Yellow Fever Vaccine
DB11003,The risk or severity of infection can be increased when Anthrax vaccine is combined with Daclizumab.,Anthrax vaccine
DB11050,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Daclizumab.,Typhoid Vaccine Live
DB12386,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Daclizumab.,Bacillus calmette-guerin substrain danish 1331 live antigen
DB12768,The risk or severity of infection can be increased when BCG vaccine is combined with Daclizumab.,BCG vaccine
DB14409,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Daclizumab.,Human adenovirus e serotype 4 strain cl-68578 antigen
DB14443,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Daclizumab.,Vibrio cholerae CVD 103-HgR strain live antigen
DB14685,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Daclizumab.,Adenovirus type 7 vaccine live
DB00002,The risk or severity of adverse effects can be increased when Cetuximab is combined with Daclizumab.,Cetuximab
DB00028,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Daclizumab.,Human immunoglobulin G
DB00043,The risk or severity of adverse effects can be increased when Omalizumab is combined with Daclizumab.,Omalizumab
DB00054,The risk or severity of adverse effects can be increased when Abciximab is combined with Daclizumab.,Abciximab
DB00057,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Daclizumab.,Indium In-111 satumomab pendetide
DB00076,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Daclizumab.,Digoxin Immune Fab (Ovine)
DB00089,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Daclizumab.,Capromab pendetide
DB00110,The risk or severity of adverse effects can be increased when Palivizumab is combined with Daclizumab.,Palivizumab
DB00113,The risk or severity of adverse effects can be increased when Daclizumab is combined with Technetium Tc-99m arcitumomab.,Technetium Tc-99m arcitumomab
DB01269,The risk or severity of adverse effects can be increased when Daclizumab is combined with Panitumumab.,Panitumumab
DB01270,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ranibizumab.,Ranibizumab
DB04901,The risk or severity of adverse effects can be increased when Daclizumab is combined with Galiximab.,Galiximab
DB04949,The risk or severity of adverse effects can be increased when Daclizumab is combined with Pexelizumab.,Pexelizumab
DB04958,The risk or severity of adverse effects can be increased when Daclizumab is combined with Epratuzumab.,Epratuzumab
DB04962,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bectumomab.,Bectumomab
DB04964,The risk or severity of adverse effects can be increased when Daclizumab is combined with Oregovomab.,Oregovomab
DB04988,The risk or severity of adverse effects can be increased when Daclizumab is combined with IGN311.,IGN311
DB05006,The risk or severity of adverse effects can be increased when Daclizumab is combined with Adecatumumab.,Adecatumumab
DB05097,The risk or severity of adverse effects can be increased when Daclizumab is combined with Labetuzumab.,Labetuzumab
DB05101,The risk or severity of adverse effects can be increased when Daclizumab is combined with Matuzumab.,Matuzumab
DB05111,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fontolizumab.,Fontolizumab
DB05136,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bavituximab.,Bavituximab
DB05139,The risk or severity of adverse effects can be increased when Daclizumab is combined with CR002.,CR002
DB05209,The risk or severity of adverse effects can be increased when Daclizumab is combined with Rozrolimupab.,Rozrolimupab
DB05304,The risk or severity of adverse effects can be increased when Daclizumab is combined with Girentuximab.,Girentuximab
DB05336,The risk or severity of adverse effects can be increased when Daclizumab is combined with Obiltoxaximab.,Obiltoxaximab
DB05405,The risk or severity of adverse effects can be increased when Daclizumab is combined with XTL-001.,XTL-001
DB05437,The risk or severity of adverse effects can be increased when Daclizumab is combined with NAV 1800.,NAV 1800
DB05496,The risk or severity of adverse effects can be increased when Daclizumab is combined with Otelixizumab.,Otelixizumab
DB05545,The risk or severity of adverse effects can be increased when Daclizumab is combined with AMG 108.,AMG 108
DB05550,The risk or severity of adverse effects can be increased when Daclizumab is combined with Iratumumab.,Iratumumab
DB05555,The risk or severity of adverse effects can be increased when Daclizumab is combined with Enokizumab.,Enokizumab
DB05578,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ramucirumab.,Ramucirumab
DB05595,The risk or severity of adverse effects can be increased when Daclizumab is combined with Farletuzumab.,Farletuzumab
DB05656,The risk or severity of adverse effects can be increased when Daclizumab is combined with Veltuzumab.,Veltuzumab
DB05793,The risk or severity of adverse effects can be increased when Daclizumab is combined with PRO-542.,PRO-542
DB05797,The risk or severity of adverse effects can be increased when Daclizumab is combined with TNX-901.,TNX-901
DB05889,The risk or severity of adverse effects can be increased when Daclizumab is combined with Inotuzumab ozogamicin.,Inotuzumab ozogamicin
DB05892,The risk or severity of adverse effects can be increased when Daclizumab is combined with RI 624.,RI 624
DB05915,The risk or severity of adverse effects can be increased when Daclizumab is combined with MYO-029.,MYO-029
DB05916,The risk or severity of adverse effects can be increased when Daclizumab is combined with CT-011.,CT-011
DB05941,The risk or severity of adverse effects can be increased when Daclizumab is combined with Leronlimab.,Leronlimab
DB05996,The risk or severity of adverse effects can be increased when Daclizumab is combined with Glembatumumab vedotin.,Glembatumumab vedotin
DB06043,The risk or severity of adverse effects can be increased when Daclizumab is combined with Olaratumab.,Olaratumab
DB06049,The risk or severity of adverse effects can be increased when Daclizumab is combined with IPH 2101.,IPH 2101
DB06050,The risk or severity of adverse effects can be increased when Daclizumab is combined with TB-402.,TB-402
DB06081,The risk or severity of adverse effects can be increased when Daclizumab is combined with Caplacizumab.,Caplacizumab
DB06101,The risk or severity of adverse effects can be increased when Daclizumab is combined with IMC-1C11.,IMC-1C11
DB06116,The risk or severity of adverse effects can be increased when Daclizumab is combined with Eldelumab.,Eldelumab
DB06162,The risk or severity of adverse effects can be increased when Daclizumab is combined with Lumiliximab.,Lumiliximab
DB06186,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ipilimumab.,Ipilimumab
DB06192,The risk or severity of adverse effects can be increased when Daclizumab is combined with Nimotuzumab.,Nimotuzumab
DB06241,The risk or severity of adverse effects can be increased when Daclizumab is combined with Clenoliximab.,Clenoliximab
DB06304,The risk or severity of adverse effects can be increased when Daclizumab is combined with BIIB015.,BIIB015
DB06305,The risk or severity of adverse effects can be increased when Daclizumab is combined with Sonepcizumab.,Sonepcizumab
DB06310,The risk or severity of adverse effects can be increased when Daclizumab is combined with Motavizumab.,Motavizumab
DB06317,The risk or severity of adverse effects can be increased when Daclizumab is combined with Elotuzumab.,Elotuzumab
DB06318,The risk or severity of adverse effects can be increased when Daclizumab is combined with AVE9633.,AVE9633
DB06322,The risk or severity of adverse effects can be increased when Daclizumab is combined with Carotuximab.,Carotuximab
DB06324,The risk or severity of adverse effects can be increased when Daclizumab is combined with XmAb 2513.,XmAb 2513
DB06342,The risk or severity of adverse effects can be increased when Daclizumab is combined with Coltuximab ravtansine.,Coltuximab ravtansine
DB06343,The risk or severity of adverse effects can be increased when Daclizumab is combined with Teprotumumab.,Teprotumumab
DB06360,The risk or severity of adverse effects can be increased when Daclizumab is combined with Lucatumumab.,Lucatumumab
DB06366,The risk or severity of adverse effects can be increased when Daclizumab is combined with Pertuzumab.,Pertuzumab
DB06371,The risk or severity of adverse effects can be increased when Daclizumab is combined with Siplizumab.,Siplizumab
DB06467,The risk or severity of adverse effects can be increased when Daclizumab is combined with Apolizumab.,Apolizumab
DB06474,The risk or severity of adverse effects can be increased when Daclizumab is combined with Sibrotuzumab.,Sibrotuzumab
DB06550,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bivatuzumab.,Bivatuzumab
DB06557,The risk or severity of adverse effects can be increased when Daclizumab is combined with Lerdelimumab.,Lerdelimumab
DB06599,The risk or severity of adverse effects can be increased when Daclizumab is combined with Lexatumumab.,Lexatumumab
DB06602,The risk or severity of adverse effects can be increased when Daclizumab is combined with Reslizumab.,Reslizumab
DB06606,The risk or severity of adverse effects can be increased when Daclizumab is combined with Teplizumab.,Teplizumab
DB06607,The risk or severity of adverse effects can be increased when Daclizumab is combined with Catumaxomab.,Catumaxomab
DB06647,The risk or severity of adverse effects can be increased when Daclizumab is combined with Volociximab.,Volociximab
DB06650,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ofatumumab.,Ofatumumab
DB08902,The risk or severity of adverse effects can be increased when Daclizumab is combined with Raxibacumab.,Raxibacumab
DB09035,The risk or severity of adverse effects can be increased when Daclizumab is combined with Nivolumab.,Nivolumab
DB09037,The risk or severity of adverse effects can be increased when Daclizumab is combined with Pembrolizumab.,Pembrolizumab
DB09045,The risk or severity of adverse effects can be increased when Daclizumab is combined with Dulaglutide.,Dulaglutide
DB09105,The risk or severity of adverse effects can be increased when Daclizumab is combined with Asfotase alfa.,Asfotase alfa
DB09264,The risk or severity of adverse effects can be increased when Daclizumab is combined with Idarucizumab.,Idarucizumab
DB09302,The risk or severity of adverse effects can be increased when Daclizumab is combined with Alirocumab.,Alirocumab
DB09303,The risk or severity of adverse effects can be increased when Daclizumab is combined with Evolocumab.,Evolocumab
DB09331,The risk or severity of adverse effects can be increased when Daclizumab is combined with Daratumumab.,Daratumumab
DB09559,The risk or severity of adverse effects can be increased when Daclizumab is combined with Necitumumab.,Necitumumab
DB11595,The risk or severity of adverse effects can be increased when Daclizumab is combined with Atezolizumab.,Atezolizumab
DB11604,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tetanus Immune Globulin.,Tetanus Immune Globulin
DB11608,The risk or severity of adverse effects can be increased when Daclizumab is combined with Eftrenonacog alfa.,Eftrenonacog alfa
DB11621,The risk or severity of adverse effects can be increased when Daclizumab is combined with Human Varicella-Zoster Immune Globulin.,Human Varicella-Zoster Immune Globulin
DB11646,The risk or severity of adverse effects can be increased when Daclizumab is combined with Conatumumab.,Conatumumab
DB11657,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tabalumab.,Tabalumab
DB11680,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ficlatuzumab.,Ficlatuzumab
DB11685,The risk or severity of adverse effects can be increased when Daclizumab is combined with Figitumumab.,Figitumumab
DB11714,The risk or severity of adverse effects can be increased when Daclizumab is combined with Durvalumab.,Durvalumab
DB11715,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bapineuzumab.,Bapineuzumab
DB11731,The risk or severity of adverse effects can be increased when Daclizumab is combined with Depatuxizumab mafodotin.,Depatuxizumab mafodotin
DB11746,The risk or severity of adverse effects can be increased when Daclizumab is combined with Onartuzumab.,Onartuzumab
DB11756,The risk or severity of adverse effects can be increased when Daclizumab is combined with Solanezumab.,Solanezumab
DB11771,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tremelimumab.,Tremelimumab
DB11826,The risk or severity of adverse effects can be increased when Daclizumab is combined with Lampalizumab.,Lampalizumab
DB11840,The risk or severity of adverse effects can be increased when Daclizumab is combined with Dalotuzumab.,Dalotuzumab
DB11849,The risk or severity of adverse effects can be increased when Daclizumab is combined with Emibetuzumab.,Emibetuzumab
DB11850,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ublituximab.,Ublituximab
DB11856,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ligelizumab.,Ligelizumab
DB11857,The risk or severity of adverse effects can be increased when Daclizumab is combined with Seribantumab.,Seribantumab
DB11862,The risk or severity of adverse effects can be increased when Daclizumab is combined with Landogrozumab.,Landogrozumab
DB11866,The risk or severity of adverse effects can be increased when Daclizumab is combined with Romosozumab.,Romosozumab
DB11884,The risk or severity of adverse effects can be increased when Daclizumab is combined with Vadastuximab Talirine.,Vadastuximab Talirine
DB11914,The risk or severity of adverse effects can be increased when Daclizumab is combined with Lebrikizumab.,Lebrikizumab
DB11930,The risk or severity of adverse effects can be increased when Daclizumab is combined with Varlilumab.,Varlilumab
DB11945,The risk or severity of adverse effects can be increased when Daclizumab is combined with Avelumab.,Avelumab
DB11959,The risk or severity of adverse effects can be increased when Daclizumab is combined with Crenezumab.,Crenezumab
DB11972,The risk or severity of adverse effects can be increased when Daclizumab is combined with Rilotumumab.,Rilotumumab
DB11976,The risk or severity of adverse effects can be increased when Daclizumab is combined with Anifrolumab.,Anifrolumab
DB12023,The risk or severity of adverse effects can be increased when Daclizumab is combined with Benralizumab.,Benralizumab
DB12034,The risk or severity of adverse effects can be increased when Daclizumab is combined with Gantenerumab.,Gantenerumab
DB12053,The risk or severity of adverse effects can be increased when Daclizumab is combined with Visilizumab.,Visilizumab
DB12077,The risk or severity of adverse effects can be increased when Daclizumab is combined with Urelumab.,Urelumab
DB12089,The risk or severity of adverse effects can be increased when Daclizumab is combined with Lorvotuzumab mertansine.,Lorvotuzumab mertansine
DB12090,The risk or severity of adverse effects can be increased when Daclizumab is combined with Patritumab.,Patritumab
DB12102,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fulranumab.,Fulranumab
DB12104,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tarextumab.,Tarextumab
DB12118,The risk or severity of adverse effects can be increased when Daclizumab is combined with Sotatercept.,Sotatercept
DB12119,The risk or severity of adverse effects can be increased when Daclizumab is combined with Gevokizumab.,Gevokizumab
DB12142,The risk or severity of adverse effects can be increased when Daclizumab is combined with Duligotuzumab.,Duligotuzumab
DB12152,The risk or severity of adverse effects can be increased when Daclizumab is combined with Simtuzumab.,Simtuzumab
DB12157,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fasinumab.,Fasinumab
DB12159,The risk or severity of adverse effects can be increased when Daclizumab is combined with Dupilumab.,Dupilumab
DB12169,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tralokinumab.,Tralokinumab
DB12189,The risk or severity of adverse effects can be increased when Daclizumab is combined with Etrolizumab.,Etrolizumab
DB12202,The risk or severity of adverse effects can be increased when Daclizumab is combined with Zalutumumab.,Zalutumumab
DB12205,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ganitumab.,Ganitumab
DB12213,The risk or severity of adverse effects can be increased when Daclizumab is combined with Etaracizumab.,Etaracizumab
DB12240,The risk or severity of adverse effects can be increased when Daclizumab is combined with Polatuzumab vedotin.,Polatuzumab vedotin
DB12246,The risk or severity of adverse effects can be increased when Daclizumab is combined with Inclacumab.,Inclacumab
DB12250,The risk or severity of adverse effects can be increased when Daclizumab is combined with Cixutumumab.,Cixutumumab
DB12261,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ascrinvacumab.,Ascrinvacumab
DB12274,The risk or severity of adverse effects can be increased when Daclizumab is combined with Aducanumab.,Aducanumab
DB12281,The risk or severity of adverse effects can be increased when Daclizumab is combined with Luspatercept.,Luspatercept
DB12296,The risk or severity of adverse effects can be increased when Daclizumab is combined with GS-5745.,GS-5745
DB12317,The risk or severity of adverse effects can be increased when Daclizumab is combined with Vanucizumab.,Vanucizumab
DB12331,The risk or severity of adverse effects can be increased when Daclizumab is combined with Labetuzumab govitecan.,Labetuzumab govitecan
DB12335,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tanezumab.,Tanezumab
DB12342,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ensituximab.,Ensituximab
DB12344,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fezakinumab.,Fezakinumab
DB12363,The risk or severity of adverse effects can be increased when Daclizumab is combined with Dusigitumab.,Dusigitumab
DB12396,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fresolimumab.,Fresolimumab
DB12413,The risk or severity of adverse effects can be increased when Daclizumab is combined with Indusatumab vedotin.,Indusatumab vedotin
DB12456,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bococizumab.,Bococizumab
DB12489,The risk or severity of adverse effects can be increased when Daclizumab is combined with Mirvetuximab Soravtansine.,Mirvetuximab Soravtansine
DB12498,The risk or severity of adverse effects can be increased when Daclizumab is combined with Mogamulizumab.,Mogamulizumab
DB12520,The risk or severity of adverse effects can be increased when Daclizumab is combined with Plozalizumab.,Plozalizumab
DB12534,The risk or severity of adverse effects can be increased when Daclizumab is combined with Mavrilimumab.,Mavrilimumab
DB12560,The risk or severity of adverse effects can be increased when Daclizumab is combined with Blosozumab.,Blosozumab
DB12584,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bimagrumab.,Bimagrumab
DB12589,The risk or severity of adverse effects can be increased when Daclizumab is combined with Dacetuzumab.,Dacetuzumab
DB12609,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tovetumab.,Tovetumab
DB12683,The risk or severity of adverse effects can be increased when Daclizumab is combined with Lumretuzumab.,Lumretuzumab
DB12698,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ibalizumab.,Ibalizumab
DB12701,The risk or severity of adverse effects can be increased when Daclizumab is combined with Intetumumab.,Intetumumab
DB12718,The risk or severity of adverse effects can be increased when Daclizumab is combined with Carlumab.,Carlumab
DB12734,The risk or severity of adverse effects can be increased when Daclizumab is combined with Demcizumab.,Demcizumab
DB12773,The risk or severity of adverse effects can be increased when Daclizumab is combined with Sifalimumab.,Sifalimumab
DB12775,The risk or severity of adverse effects can be increased when Daclizumab is combined with Abituzumab.,Abituzumab
DB12797,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ecromeximab.,Ecromeximab
DB12807,The risk or severity of adverse effects can be increased when Daclizumab is combined with Naptumomab Estafenatox.,Naptumomab Estafenatox
DB12815,The risk or severity of adverse effects can be increased when Daclizumab is combined with Crotedumab.,Crotedumab
DB12820,The risk or severity of adverse effects can be increased when Daclizumab is combined with Concizumab.,Concizumab
DB12826,The risk or severity of adverse effects can be increased when Daclizumab is combined with Depatuxizumab.,Depatuxizumab
DB12844,The risk or severity of adverse effects can be increased when Daclizumab is combined with Rontalizumab.,Rontalizumab
DB12845,The risk or severity of adverse effects can be increased when Daclizumab is combined with Amatuximab.,Amatuximab
DB12849,The risk or severity of adverse effects can be increased when Daclizumab is combined with Clazakizumab.,Clazakizumab
DB12891,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ozanezumab.,Ozanezumab
DB12893,The risk or severity of adverse effects can be increased when Daclizumab is combined with Sacituzumab govitecan.,Sacituzumab govitecan
DB12917,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bimekizumab.,Bimekizumab
DB12943,The risk or severity of adverse effects can be increased when Daclizumab is combined with Milatuzumab.,Milatuzumab
DB12976,The risk or severity of adverse effects can be increased when Daclizumab is combined with Robatumumab.,Robatumumab
DB13017,The risk or severity of adverse effects can be increased when Daclizumab is combined with Rovalpituzumab Tesirine.,Rovalpituzumab Tesirine
DB13037,The risk or severity of adverse effects can be increased when Daclizumab is combined with Namilumab.,Namilumab
DB13045,The risk or severity of adverse effects can be increased when Daclizumab is combined with Racotumomab.,Racotumomab
DB13073,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tregalizumab.,Tregalizumab
DB13127,The risk or severity of adverse effects can be increased when Daclizumab is combined with Olokizumab.,Olokizumab
DB13140,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bezlotoxumab.,Bezlotoxumab
DB13375,The risk or severity of adverse effects can be increased when Daclizumab is combined with Edrecolomab.,Edrecolomab
DB13535,The risk or severity of adverse effects can be increased when Daclizumab is combined with Nebacumab.,Nebacumab
DB13886,The risk or severity of adverse effects can be increased when Daclizumab is combined with Human cytomegalovirus immune globulin.,Human cytomegalovirus immune globulin
DB13923,The risk or severity of adverse effects can be increased when Daclizumab is combined with Emicizumab.,Emicizumab
DB13976,The risk or severity of adverse effects can be increased when Daclizumab is combined with Sulesomab.,Sulesomab
DB13979,The risk or severity of adverse effects can be increased when Daclizumab is combined with Besilesomab.,Besilesomab
DB14012,The risk or severity of adverse effects can be increased when Daclizumab is combined with Burosumab.,Burosumab
DB14039,The risk or severity of adverse effects can be increased when Daclizumab is combined with Erenumab.,Erenumab
DB14040,The risk or severity of adverse effects can be increased when Daclizumab is combined with Eptinezumab.,Eptinezumab
DB14041,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fremanezumab.,Fremanezumab
DB14042,The risk or severity of adverse effects can be increased when Daclizumab is combined with Galcanezumab.,Galcanezumab
DB14211,The risk or severity of adverse effects can be increased when Daclizumab is combined with Fanolesomab.,Fanolesomab
DB14580,The risk or severity of adverse effects can be increased when Daclizumab is combined with Lecanemab.,Lecanemab
DB14597,The risk or severity of adverse effects can be increased when Daclizumab is combined with Lanadelumab.,Lanadelumab
DB14707,The risk or severity of adverse effects can be increased when Daclizumab is combined with Cemiplimab.,Cemiplimab
DB14776,The risk or severity of adverse effects can be increased when Daclizumab is combined with Camrelizumab.,Camrelizumab
DB14778,The risk or severity of adverse effects can be increased when Daclizumab is combined with Setrusumab.,Setrusumab
DB14784,The risk or severity of adverse effects can be increased when Daclizumab is combined with Gancotamab.,Gancotamab
DB14809,The risk or severity of adverse effects can be increased when Daclizumab is combined with Anetumab ravtansine.,Anetumab ravtansine
DB14811,The risk or severity of adverse effects can be increased when Daclizumab is combined with Isatuximab.,Isatuximab
DB14824,The risk or severity of adverse effects can be increased when Daclizumab is combined with Icrucumab.,Icrucumab
DB14843,The risk or severity of adverse effects can be increased when Daclizumab is combined with Codrituzumab.,Codrituzumab
DB14864,The risk or severity of adverse effects can be increased when Daclizumab is combined with Brolucizumab.,Brolucizumab
DB14871,The risk or severity of adverse effects can be increased when Daclizumab is combined with Xentuzumab.,Xentuzumab
DB14877,The risk or severity of adverse effects can be increased when Daclizumab is combined with Lintuzumab.,Lintuzumab
DB14891,The risk or severity of adverse effects can be increased when Daclizumab is combined with Vobarilizumab.,Vobarilizumab
DB14897,The risk or severity of adverse effects can be increased when Daclizumab is combined with Parsatuzumab.,Parsatuzumab
DB14905,The risk or severity of adverse effects can be increased when Daclizumab is combined with Emactuzumab.,Emactuzumab
DB14907,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bevacizumab zirconium Zr-89.,Bevacizumab zirconium Zr-89
DB14908,The risk or severity of adverse effects can be increased when Daclizumab is combined with Refanezumab.,Refanezumab
DB14947,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bermekimab.,Bermekimab
DB14952,The risk or severity of adverse effects can be increased when Daclizumab is combined with Pamrevlumab.,Pamrevlumab
DB14959,The risk or severity of adverse effects can be increased when Daclizumab is combined with Opicinumab.,Opicinumab
DB14962,The risk or severity of adverse effects can be increased when Daclizumab is combined with Trastuzumab deruxtecan.,Trastuzumab deruxtecan
DB14967,The risk or severity of adverse effects can be increased when Daclizumab is combined with Margetuximab.,Margetuximab
DB14988,The risk or severity of adverse effects can be increased when Daclizumab is combined with Dalantercept.,Dalantercept
DB14997,The risk or severity of adverse effects can be increased when Daclizumab is combined with Pateclizumab.,Pateclizumab
DB15014,The risk or severity of adverse effects can be increased when Daclizumab is combined with Gremubamab.,Gremubamab
DB15022,The risk or severity of adverse effects can be increased when Daclizumab is combined with Apomab.,Apomab
DB15044,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tafasitamab.,Tafasitamab
DB15045,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ipafricept.,Ipafricept
DB15076,The risk or severity of adverse effects can be increased when Daclizumab is combined with Abrilumab.,Abrilumab
DB15089,The risk or severity of adverse effects can be increased when Daclizumab is combined with Frovocimab.,Frovocimab
DB15090,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tezepelumab.,Tezepelumab
DB15101,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tigatuzumab.,Tigatuzumab
DB15104,The risk or severity of adverse effects can be increased when Daclizumab is combined with Telisotuzumab vedotin.,Telisotuzumab vedotin
DB15113,The risk or severity of adverse effects can be increased when Daclizumab is combined with Utomilumab.,Utomilumab
DB15118,The risk or severity of adverse effects can be increased when Daclizumab is combined with Zolbetuximab.,Zolbetuximab
DB15135,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ponezumab.,Ponezumab
DB15160,The risk or severity of adverse effects can be increased when Daclizumab is combined with Asunercept.,Asunercept
DB15172,The risk or severity of adverse effects can be increased when Daclizumab is combined with Suvratoxumab.,Suvratoxumab
DB15225,The risk or severity of adverse effects can be increased when Daclizumab is combined with Mitazalimab.,Mitazalimab
DB15252,The risk or severity of adverse effects can be increased when Daclizumab is combined with Nemolizumab.,Nemolizumab
DB15277,The risk or severity of adverse effects can be increased when Daclizumab is combined with Gedivumab.,Gedivumab
DB15336,The risk or severity of adverse effects can be increased when Daclizumab is combined with Valanafusp alfa.,Valanafusp alfa
DB15349,The risk or severity of adverse effects can be increased when Daclizumab is combined with Sofituzumab vedotin.,Sofituzumab vedotin
DB15354,The risk or severity of adverse effects can be increased when Daclizumab is combined with Evinacumab.,Evinacumab
DB15363,The risk or severity of adverse effects can be increased when Daclizumab is combined with Istiratumab.,Istiratumab
DB15383,The risk or severity of adverse effects can be increased when Daclizumab is combined with Pidilizumab.,Pidilizumab
DB15397,The risk or severity of adverse effects can be increased when Daclizumab is combined with GMA-161.,GMA-161
DB15409,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ladiratuzumab vedotin.,Ladiratuzumab vedotin
DB15415,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tomaralimab.,Tomaralimab
DB15428,The risk or severity of adverse effects can be increased when Daclizumab is combined with Vesencumab.,Vesencumab
DB15432,The risk or severity of adverse effects can be increased when Daclizumab is combined with Pinatuzumab vedotin.,Pinatuzumab vedotin
DB15441,The risk or severity of adverse effects can be increased when Daclizumab is combined with Lulizumab pegol.,Lulizumab pegol
DB15443,The risk or severity of adverse effects can be increased when Daclizumab is combined with Lorukafusp alfa.,Lorukafusp alfa
DB15453,The risk or severity of adverse effects can be increased when Daclizumab is combined with Naratuximab emtansine.,Naratuximab emtansine
DB14004,The risk or severity of adverse effects can be increased when Daclizumab is combined with Tildrakizumab.,Tildrakizumab
DB05679,The risk or severity of adverse effects can be increased when Daclizumab is combined with Ustekinumab.,Ustekinumab
DB15559,The risk or severity of adverse effects can be increased when Daclizumab is combined with Zenocutuzumab.,Zenocutuzumab
DB00091,Daclizumab may increase the immunosuppressive activities of Cyclosporine.,Cyclosporine
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Daclizumab.","Ebola Zaire vaccine (live, attenuated)"
DB14513,The serum concentration of Magnesium can be decreased when it is combined with Daclizumab.,Magnesium
DB01601,The serum concentration of Daclizumab can be increased when it is combined with Lopinavir.,Lopinavir
DB12530,The risk or severity of infection can be increased when Daclizumab is combined with Inebilizumab.,Inebilizumab
DB06643,The risk or severity of adverse effects can be increased when Denosumab is combined with Bevacizumab.,Denosumab
DB00005,The risk or severity of adverse effects can be increased when Etanercept is combined with Bevacizumab.,Etanercept
DB00008,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Bevacizumab.,Peginterferon alfa-2a
DB00011,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Bevacizumab.,Interferon alfa-n1
DB00018,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Bevacizumab.,Interferon alfa-n3
DB00022,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Bevacizumab.,Peginterferon alfa-2b
DB00026,The risk or severity of adverse effects can be increased when Anakinra is combined with Bevacizumab.,Anakinra
DB00033,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Bevacizumab.,Interferon gamma-1b
DB00034,"The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Bevacizumab.","Interferon alfa-2a, Recombinant"
DB00041,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Bevacizumab.,Aldesleukin
DB00051,The risk or severity of adverse effects can be increased when Adalimumab is combined with Bevacizumab.,Adalimumab
DB00056,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bevacizumab.,Gemtuzumab ozogamicin
DB00059,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Bevacizumab.,Pegaspargase
DB00065,The risk or severity of adverse effects can be increased when Infliximab is combined with Bevacizumab.,Infliximab
DB00068,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Bevacizumab.,Interferon beta-1b
DB00069,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Bevacizumab.,Interferon alfacon-1
DB00073,The risk or severity of adverse effects can be increased when Rituximab is combined with Bevacizumab.,Rituximab
DB00074,The risk or severity of adverse effects can be increased when Basiliximab is combined with Bevacizumab.,Basiliximab
DB00075,The risk or severity of adverse effects can be increased when Muromonab is combined with Bevacizumab.,Muromonab
DB00078,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bevacizumab.,Ibritumomab tiuxetan
DB00081,The risk or severity of adverse effects can be increased when Tositumomab is combined with Bevacizumab.,Tositumomab
DB00087,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bevacizumab.,Alemtuzumab
DB00092,The risk or severity of adverse effects can be increased when Alefacept is combined with Bevacizumab.,Alefacept
DB00095,The risk or severity of adverse effects can be increased when Efalizumab is combined with Bevacizumab.,Efalizumab
DB00098,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bevacizumab.,Antithymocyte immunoglobulin (rabbit)
DB00105,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Bevacizumab.,Interferon alfa-2b
DB00111,The risk or severity of adverse effects can be increased when Daclizumab is combined with Bevacizumab.,Daclizumab
DB00120,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Phenylalanine.,Phenylalanine
DB00180,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Flunisolide.,Flunisolide
DB00188,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bortezomib.,Bortezomib
DB00242,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Cladribine.,Cladribine
DB00262,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Carmustine.,Carmustine
DB00276,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Amsacrine.,Amsacrine
DB00290,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bleomycin.,Bleomycin
DB00291,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Chlorambucil.,Chlorambucil
DB00293,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Raltitrexed.,Raltitrexed
DB00305,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mitomycin.,Mitomycin
DB00307,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bexarotene.,Bexarotene
DB00309,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Vindesine.,Vindesine
DB00322,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Floxuridine.,Floxuridine
DB00328,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Indomethacin.,Indomethacin
DB00352,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tioguanine.,Tioguanine
DB00361,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Vinorelbine.,Vinorelbine
DB00380,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dexrazoxane.,Dexrazoxane
DB00394,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Beclomethasone dipropionate.,Beclomethasone dipropionate
DB00428,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Streptozocin.,Streptozocin
DB00432,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Trifluridine.,Trifluridine
DB00441,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Gemcitabine.,Gemcitabine
DB00443,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Betamethasone.,Betamethasone
DB00444,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Teniposide.,Teniposide
DB00445,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Epirubicin.,Epirubicin
DB00446,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Chloramphenicol.,Chloramphenicol
DB00480,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lenalidomide.,Lenalidomide
DB00488,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Altretamine.,Altretamine
DB00495,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Zidovudine.,Zidovudine
DB00515,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Cisplatin.,Cisplatin
DB00526,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Oxaliplatin.,Oxaliplatin
DB00531,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Cyclophosphamide.,Cyclophosphamide
DB00541,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Vincristine.,Vincristine
DB00544,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fluorouracil.,Fluorouracil
DB00550,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Propylthiouracil.,Propylthiouracil
DB00552,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pentostatin.,Pentostatin
DB00563,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Methotrexate.,Methotrexate
DB00564,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Carbamazepine.,Carbamazepine
DB00570,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Vinblastine.,Vinblastine
DB00588,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fluticasone propionate.,Fluticasone propionate
DB00591,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fluocinolone acetonide.,Fluocinolone acetonide
DB00601,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Linezolid.,Linezolid
DB00619,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Imatinib.,Imatinib
DB00620,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Triamcinolone.,Triamcinolone
DB00631,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Clofarabine.,Clofarabine
DB00635,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Prednisone.,Prednisone
DB00642,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pemetrexed.,Pemetrexed
DB00687,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fludrocortisone.,Fludrocortisone
DB00688,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mycophenolate mofetil.,Mycophenolate mofetil
DB00694,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Daunorubicin.,Daunorubicin
DB00755,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tretinoin.,Tretinoin
DB00762,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Irinotecan.,Irinotecan
DB00763,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Methimazole.,Methimazole
DB00764,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mometasone.,Mometasone
DB00773,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Etoposide.,Etoposide
DB00795,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sulfasalazine.,Sulfasalazine
DB00851,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dacarbazine.,Dacarbazine
DB00853,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Temozolomide.,Temozolomide
DB00859,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Penicillamine.,Penicillamine
DB00860,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Prednisolone.,Prednisolone
DB00877,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sirolimus.,Sirolimus
DB00888,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mechlorethamine.,Mechlorethamine
DB00928,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Azacitidine.,Azacitidine
DB00958,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Carboplatin.,Carboplatin
DB00959,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Methylprednisolone.,Methylprednisolone
DB00970,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dactinomycin.,Dactinomycin
DB00987,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Cytarabine.,Cytarabine
DB00993,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Azathioprine.,Azathioprine
DB00997,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Doxorubicin.,Doxorubicin
DB01005,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Hydroxyurea.,Hydroxyurea
DB01008,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Busulfan.,Busulfan
DB01024,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mycophenolic acid.,Mycophenolic acid
DB01030,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Topotecan.,Topotecan
DB01033,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mercaptopurine.,Mercaptopurine
DB01041,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Thalidomide.,Thalidomide
DB01042,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Melphalan.,Melphalan
DB01073,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fludarabine.,Fludarabine
DB01099,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Flucytosine.,Flucytosine
DB01101,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Capecitabine.,Capecitabine
DB01108,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Trilostane.,Trilostane
DB01168,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Procarbazine.,Procarbazine
DB01169,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Arsenic trioxide.,Arsenic trioxide
DB01177,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Idarubicin.,Idarubicin
DB01181,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ifosfamide.,Ifosfamide
DB01196,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Estramustine.,Estramustine
DB01204,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mitoxantrone.,Mitoxantrone
DB01206,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lomustine.,Lomustine
DB01222,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Budesonide.,Budesonide
DB01229,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Paclitaxel.,Paclitaxel
DB01234,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dexamethasone.,Dexamethasone
DB01248,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Docetaxel.,Docetaxel
DB01254,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dasatinib.,Dasatinib
DB01257,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Eculizumab.,Eculizumab
DB01262,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Decitabine.,Decitabine
DB01280,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Nelarabine.,Nelarabine
DB01281,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Abatacept.,Abatacept
DB01285,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Corticotropin.,Corticotropin
DB01380,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Cortisone acetate.,Cortisone acetate
DB01384,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Paramethasone.,Paramethasone
DB01394,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Colchicine.,Colchicine
DB01410,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ciclesonide.,Ciclesonide
DB01423,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Stepronin.,Stepronin
DB01590,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Everolimus.,Everolimus
DB01611,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Hydroxychloroquine.,Hydroxychloroquine
DB01816,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Castanospermine.,Castanospermine
DB02546,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Vorinostat.,Vorinostat
DB02806,The risk or severity of adverse effects can be increased when Bevacizumab is combined with 2-Methoxyethanol.,2-Methoxyethanol
DB03523,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Brequinar.,Brequinar
DB04572,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Thiotepa.,Thiotepa
DB04630,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Aldosterone.,Aldosterone
DB04845,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ixabepilone.,Ixabepilone
DB04868,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Nilotinib.,Nilotinib
DB04951,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pirfenidone.,Pirfenidone
DB04956,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Afelimomab.,Afelimomab
DB05015,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Belinostat.,Belinostat
DB05109,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Trabectedin.,Trabectedin
DB05258,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Interferon alfa.,Interferon alfa
DB05259,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Glatiramer.,Glatiramer
DB05260,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Gallium nitrate.,Gallium nitrate
DB05459,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Briakinumab.,Briakinumab
DB05472,The risk or severity of adverse effects can be increased when Bevacizumab is combined with omega interferon.,omega interferon
DB05676,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Apremilast.,Apremilast
DB05773,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Trastuzumab emtansine.,Trastuzumab emtansine
DB06168,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Canakinumab.,Canakinumab
DB06273,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tocilizumab.,Tocilizumab
DB06287,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Temsirolimus.,Temsirolimus
DB06372,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Rilonacept.,Rilonacept
DB06589,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pazopanib.,Pazopanib
DB06603,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Panobinostat.,Panobinostat
DB06612,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mepolizumab.,Mepolizumab
DB06616,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bosutinib.,Bosutinib
DB06662,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Abetimus.,Abetimus
DB06674,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Golimumab.,Golimumab
DB06681,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Belatacept.,Belatacept
DB06769,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bendamustine.,Bendamustine
DB06772,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Cabazitaxel.,Cabazitaxel
DB06813,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pralatrexate.,Pralatrexate
DB08059,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Wortmannin.,Wortmannin
DB08870,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Brentuximab vedotin.,Brentuximab vedotin
DB08871,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Eribulin.,Eribulin
DB08877,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ruxolitinib.,Ruxolitinib
DB08879,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Belimumab.,Belimumab
DB08880,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Teriflunomide.,Teriflunomide
DB08889,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Carfilzomib.,Carfilzomib
DB08901,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ponatinib.,Ponatinib
DB08904,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Certolizumab pegol.,Certolizumab pegol
DB08906,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fluticasone furoate.,Fluticasone furoate
DB08908,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dimethyl fumarate.,Dimethyl fumarate
DB08910,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pomalidomide.,Pomalidomide
DB08935,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Obinutuzumab.,Obinutuzumab
DB08970,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fluprednidene.,Fluprednidene
DB08971,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fluocortolone.,Fluocortolone
DB09029,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Secukinumab.,Secukinumab
DB09033,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Vedolizumab.,Vedolizumab
DB09036,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Siltuximab.,Siltuximab
DB09052,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Blinatumomab.,Blinatumomab
DB09053,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ibrutinib.,Ibrutinib
DB09054,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Idelalisib.,Idelalisib
DB09073,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Palbociclib.,Palbociclib
DB09074,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Olaparib.,Olaparib
DB09077,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dinutuximab.,Dinutuximab
DB09082,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Vilanterol.,Vilanterol
DB09091,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tixocortol.,Tixocortol
DB09122,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Peginterferon beta-1a.,Peginterferon beta-1a
DB09312,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Antilymphocyte immunoglobulin (horse).,Antilymphocyte immunoglobulin (horse)
DB09378,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fluprednisolone.,Fluprednisolone
DB09383,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Meprednisone.,Meprednisone
DB11466,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tepoxalin.,Tepoxalin
DB11487,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dexamethasone isonicotinate.,Dexamethasone isonicotinate
DB11529,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Melengestrol.,Melengestrol
DB11569,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ixekizumab.,Ixekizumab
DB11580,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ravulizumab.,Ravulizumab
DB11616,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pirarubicin.,Pirarubicin
DB11693,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Voclosporin.,Voclosporin
DB11708,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Peficitinib.,Peficitinib
DB11750,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Clobetasol.,Clobetasol
DB11767,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sarilumab.,Sarilumab
DB11776,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Brodalumab.,Brodalumab
DB11803,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sirukumab.,Sirukumab
DB11817,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Baricitinib.,Baricitinib
DB11834,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Guselkumab.,Guselkumab
DB11921,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Deflazacort.,Deflazacort
DB12025,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Triptolide.,Triptolide
DB12371,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Siponimod.,Siponimod
DB12612,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ozanimod.,Ozanimod
DB12617,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mizoribine.,Mizoribine
DB12692,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Gusperimus.,Gusperimus
DB12814,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Cepeginterferon alfa-2B.,Cepeginterferon alfa-2B
DB12902,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Trofosfamide.,Trofosfamide
DB12947,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Doxifluridine.,Doxifluridine
DB12991,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Deoxyspergualin.,Deoxyspergualin
DB12996,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Acteoside.,Acteoside
DB13003,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Cortivazol.,Cortivazol
DB13014,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Hypericin.,Hypericin
DB13068,The risk or severity of adverse effects can be increased when Bevacizumab is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.,9-(N-methyl-L-isoleucine)-cyclosporin A
DB13208,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Prednylidene.,Prednylidene
DB13223,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fluocortin.,Fluocortin
DB13241,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Begelomab.,Begelomab
DB13491,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fluperolone.,Fluperolone
DB13664,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Formocortal.,Formocortal
DB13728,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Halometasone.,Halometasone
DB13843,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Cloprednol.,Cloprednol
DB13856,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fluclorolone.,Fluclorolone
DB13867,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fluticasone.,Fluticasone
DB14066,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tetrandrine.,Tetrandrine
DB14219,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Monomethyl fumarate.,Monomethyl fumarate
DB14512,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mometasone furoate.,Mometasone furoate
DB14538,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Hydrocortisone aceponate.,Hydrocortisone aceponate
DB14539,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Hydrocortisone acetate.,Hydrocortisone acetate
DB14545,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Hydrocortisone succinate.,Hydrocortisone succinate
DB14724,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Emapalumab.,Emapalumab
DB14762,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Risankizumab.,Risankizumab
DB14919,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Rozanolixizumab.,Rozanolixizumab
DB15253,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bleselumab.,Bleselumab
DB00108,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Natalizumab.,Natalizumab
DB00337,The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Bevacizumab.,Pimecrolimus
DB01656,Roflumilast may increase the immunosuppressive activities of Bevacizumab.,Roflumilast
DB06688,The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Bevacizumab.,Sipuleucel-T
DB00012,The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Bevacizumab.,Darbepoetin alfa
DB00016,The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Bevacizumab.,Erythropoietin
DB08894,The risk or severity of Thrombosis can be increased when Peginesatide is combined with Bevacizumab.,Peginesatide
DB09107,The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Bevacizumab.,Methoxy polyethylene glycol-epoetin beta
DB00398,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sorafenib.,Sorafenib
DB01268,The risk or severity of adverse effects can be increased when Sunitinib is combined with Bevacizumab.,Sunitinib
DB01015,The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Bevacizumab.,Sulfamethoxazole
DB00255,Diethylstilbestrol may increase the thrombogenic activities of Bevacizumab.,Diethylstilbestrol
DB00269,Chlorotrianisene may increase the thrombogenic activities of Bevacizumab.,Chlorotrianisene
DB00286,Conjugated estrogens may increase the thrombogenic activities of Bevacizumab.,Conjugated estrogens
DB00655,Estrone may increase the thrombogenic activities of Bevacizumab.,Estrone
DB00783,Estradiol may increase the thrombogenic activities of Bevacizumab.,Estradiol
DB00890,Dienestrol may increase the thrombogenic activities of Bevacizumab.,Dienestrol
DB00977,Ethinylestradiol may increase the thrombogenic activities of Bevacizumab.,Ethinylestradiol
DB01357,Mestranol may increase the thrombogenic activities of Bevacizumab.,Mestranol
DB04573,Estriol may increase the thrombogenic activities of Bevacizumab.,Estriol
DB04574,Estrone sulfate may increase the thrombogenic activities of Bevacizumab.,Estrone sulfate
DB04575,Quinestrol may increase the thrombogenic activities of Bevacizumab.,Quinestrol
DB07931,Hexestrol may increase the thrombogenic activities of Bevacizumab.,Hexestrol
DB09070,Tibolone may increase the thrombogenic activities of Bevacizumab.,Tibolone
DB09317,"Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Bevacizumab.","Synthetic Conjugated Estrogens, A"
DB09318,"Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Bevacizumab.","Synthetic Conjugated Estrogens, B"
DB09369,Polyestradiol phosphate may increase the thrombogenic activities of Bevacizumab.,Polyestradiol phosphate
DB09381,Esterified estrogens may increase the thrombogenic activities of Bevacizumab.,Esterified estrogens
DB11478,Zeranol may increase the thrombogenic activities of Bevacizumab.,Zeranol
DB11674,Equol may increase the thrombogenic activities of Bevacizumab.,Equol
DB12487,Promestriene may increase the thrombogenic activities of Bevacizumab.,Promestriene
DB13143,Methallenestril may increase the thrombogenic activities of Bevacizumab.,Methallenestril
DB13386,Epimestrol may increase the thrombogenic activities of Bevacizumab.,Epimestrol
DB13418,Moxestrol may increase the thrombogenic activities of Bevacizumab.,Moxestrol
DB13952,Estradiol acetate may increase the thrombogenic activities of Bevacizumab.,Estradiol acetate
DB13953,Estradiol benzoate may increase the thrombogenic activities of Bevacizumab.,Estradiol benzoate
DB13954,Estradiol cypionate may increase the thrombogenic activities of Bevacizumab.,Estradiol cypionate
DB13956,Estradiol valerate may increase the thrombogenic activities of Bevacizumab.,Estradiol valerate
DB15334,Biochanin A may increase the thrombogenic activities of Bevacizumab.,Biochanin A
DB15335,Formononetin may increase the thrombogenic activities of Bevacizumab.,Formononetin
DB01097,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Leflunomide.,Leflunomide
DB08895,Bevacizumab may increase the immunosuppressive activities of Tofacitinib.,Tofacitinib
DB00072,Trastuzumab may increase the neutropenic activities of Bevacizumab.,Trastuzumab
DB08868,Bevacizumab may increase the immunosuppressive activities of Fingolimod.,Fingolimod
DB00864,Tacrolimus may increase the immunosuppressive activities of Bevacizumab.,Tacrolimus
DB00282,The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Pamidronic acid.,Pamidronic acid
DB00399,The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Zoledronic acid.,Zoledronic acid
DB00630,The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Alendronic acid.,Alendronic acid
DB00710,The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Ibandronate.,Ibandronate
DB00720,The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Clodronic acid.,Clodronic acid
DB00884,The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Risedronic acid.,Risedronic acid
DB01077,The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Etidronic acid.,Etidronic acid
DB01133,The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Tiludronic acid.,Tiludronic acid
DB06255,The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Incadronic acid.,Incadronic acid
DB00390,Digoxin may decrease the cardiotoxic activities of Bevacizumab.,Digoxin
DB00511,Acetyldigitoxin may decrease the cardiotoxic activities of Bevacizumab.,Acetyldigitoxin
DB01078,Deslanoside may decrease the cardiotoxic activities of Bevacizumab.,Deslanoside
DB01092,Ouabain may decrease the cardiotoxic activities of Bevacizumab.,Ouabain
DB01396,Digitoxin may decrease the cardiotoxic activities of Bevacizumab.,Digitoxin
DB12843,Oleandrin may decrease the cardiotoxic activities of Bevacizumab.,Oleandrin
DB13240,Cymarin may decrease the cardiotoxic activities of Bevacizumab.,Cymarin
DB13307,Proscillaridin may decrease the cardiotoxic activities of Bevacizumab.,Proscillaridin
DB13401,Metildigoxin may decrease the cardiotoxic activities of Bevacizumab.,Metildigoxin
DB13467,Lanatoside C may decrease the cardiotoxic activities of Bevacizumab.,Lanatoside C
DB13537,Gitoformate may decrease the cardiotoxic activities of Bevacizumab.,Gitoformate
DB13691,Acetyldigoxin may decrease the cardiotoxic activities of Bevacizumab.,Acetyldigoxin
DB13756,Peruvoside may decrease the cardiotoxic activities of Bevacizumab.,Peruvoside
DB00675,The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Tamoxifen.,Tamoxifen
DB01217,The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Anastrozole.,Anastrozole
DB06013,The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Aldoxorubicin.,Aldoxorubicin
DB06171,The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Paclitaxel trevatide.,Paclitaxel trevatide
DB13809,The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Paclitaxel poliglumex.,Paclitaxel poliglumex
DB04914,The therapeutic efficacy of G17DT can be decreased when used in combination with Bevacizumab.,G17DT
DB05144,The therapeutic efficacy of PEV3A can be decreased when used in combination with Bevacizumab.,PEV3A
DB05325,The therapeutic efficacy of INGN 225 can be decreased when used in combination with Bevacizumab.,INGN 225
DB05374,The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Bevacizumab.,Rindopepimut
DB05440,The therapeutic efficacy of SRP 299 can be decreased when used in combination with Bevacizumab.,SRP 299
DB05942,The therapeutic efficacy of GI-5005 can be decreased when used in combination with Bevacizumab.,GI-5005
DB06400,The therapeutic efficacy of Vitespen can be decreased when used in combination with Bevacizumab.,Vitespen
DB06584,The therapeutic efficacy of TG4010 can be decreased when used in combination with Bevacizumab.,TG4010
DB09057,The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Bevacizumab.,Anthrax immune globulin human
DB10062,"The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Bevacizumab.","Rabies virus inactivated antigen, B"
DB10076,The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Bevacizumab.,Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen
DB10276,The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Bevacizumab.,Rotavirus vaccine
DB10283,"The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Bevacizumab.","Rabies virus inactivated antigen, A"
DB10342,The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Bevacizumab.,Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen
DB10583,The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Bevacizumab.,Clostridium tetani toxoid antigen (formaldehyde inactivated)
DB10584,The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Bevacizumab.,Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
DB10600,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Bevacizumab.,Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated)
DB10769,The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Bevacizumab.,Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)
DB10794,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Bevacizumab.,Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated)
DB10803,The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Bevacizumab.,Typhoid Vi polysaccharide vaccine
DB10989,The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Bevacizumab.,Hepatitis A Vaccine
DB10990,The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Bevacizumab.,Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
DB11038,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Bevacizumab.,Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated)
DB11040,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Bevacizumab.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated)
DB11041,The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Bevacizumab.,Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)
DB11044,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Bevacizumab.,Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated)
DB11603,The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Bevacizumab.,Human rabies virus immune globulin
DB11627,The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Bevacizumab.,Hepatitis B Vaccine (Recombinant)
DB12568,The therapeutic efficacy of Tecemotide can be decreased when used in combination with Bevacizumab.,Tecemotide
DB14022,The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Bevacizumab.,Typhoid vaccine
DB14384,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Bevacizumab.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated)
DB14385,The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Bevacizumab.,Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)
DB14394,The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Bevacizumab.,Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen
DB14445,The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Bevacizumab.,Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated)
DB14449,The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Bevacizumab.,Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen
DB14619,The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Bevacizumab.,Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated)
DB14620,The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Bevacizumab.,Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated)
DB14711,The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Bevacizumab.,Vaccinia virus strain new york city board of health live antigen
DB15274,The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Bevacizumab.,Pertussis vaccine
DB15461,The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Bevacizumab.,Yersinia pestis 195/p antigen (formaldehyde inactivated)
DB13924,The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Bevacizumab.,Varicella Zoster Vaccine (Recombinant)
DB15483,The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Bevacizumab.,Modified vaccinia ankara
DB11988,Ocrelizumab may increase the immunosuppressive activities of Bevacizumab.,Ocrelizumab
DB10317,The risk or severity of infection can be increased when Rubella virus vaccine is combined with Bevacizumab.,Rubella virus vaccine
DB10318,The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Bevacizumab.,Varicella Zoster Vaccine (Live/attenuated)
DB10343,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Bevacizumab.,Bacillus calmette-guerin substrain tice live antigen
DB10804,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Bevacizumab.,Bacillus calmette-guerin substrain connaught live antigen
DB10805,The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Bevacizumab.,Yellow Fever Vaccine
DB11003,The risk or severity of infection can be increased when Anthrax vaccine is combined with Bevacizumab.,Anthrax vaccine
DB11050,The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Bevacizumab.,Typhoid Vaccine Live
DB12386,The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Bevacizumab.,Bacillus calmette-guerin substrain danish 1331 live antigen
DB12768,The risk or severity of infection can be increased when BCG vaccine is combined with Bevacizumab.,BCG vaccine
DB14409,The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Bevacizumab.,Human adenovirus e serotype 4 strain cl-68578 antigen
DB14443,The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Bevacizumab.,Vibrio cholerae CVD 103-HgR strain live antigen
DB14685,The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Bevacizumab.,Adenovirus type 7 vaccine live
DB00002,The risk or severity of adverse effects can be increased when Cetuximab is combined with Bevacizumab.,Cetuximab
DB00028,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Bevacizumab.,Human immunoglobulin G
DB00043,The risk or severity of adverse effects can be increased when Omalizumab is combined with Bevacizumab.,Omalizumab
DB00054,The risk or severity of adverse effects can be increased when Abciximab is combined with Bevacizumab.,Abciximab
DB00057,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bevacizumab.,Indium In-111 satumomab pendetide
DB00076,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bevacizumab.,Digoxin Immune Fab (Ovine)
DB00089,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bevacizumab.,Capromab pendetide
DB00110,The risk or severity of adverse effects can be increased when Palivizumab is combined with Bevacizumab.,Palivizumab
DB00113,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Technetium Tc-99m arcitumomab.,Technetium Tc-99m arcitumomab
DB01269,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Panitumumab.,Panitumumab
DB01270,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ranibizumab.,Ranibizumab
DB04901,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Galiximab.,Galiximab
DB04949,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pexelizumab.,Pexelizumab
DB04958,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Epratuzumab.,Epratuzumab
DB04962,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bectumomab.,Bectumomab
DB04964,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Oregovomab.,Oregovomab
DB04988,The risk or severity of adverse effects can be increased when Bevacizumab is combined with IGN311.,IGN311
DB05006,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Adecatumumab.,Adecatumumab
DB05097,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Labetuzumab.,Labetuzumab
DB05101,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Matuzumab.,Matuzumab
DB05111,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fontolizumab.,Fontolizumab
DB05136,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bavituximab.,Bavituximab
DB05139,The risk or severity of adverse effects can be increased when Bevacizumab is combined with CR002.,CR002
DB05209,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Rozrolimupab.,Rozrolimupab
DB05304,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Girentuximab.,Girentuximab
DB05336,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Obiltoxaximab.,Obiltoxaximab
DB05405,The risk or severity of adverse effects can be increased when Bevacizumab is combined with XTL-001.,XTL-001
DB05437,The risk or severity of adverse effects can be increased when Bevacizumab is combined with NAV 1800.,NAV 1800
DB05496,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Otelixizumab.,Otelixizumab
DB05545,The risk or severity of adverse effects can be increased when Bevacizumab is combined with AMG 108.,AMG 108
DB05550,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Iratumumab.,Iratumumab
DB05555,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Enokizumab.,Enokizumab
DB05578,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ramucirumab.,Ramucirumab
DB05595,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Farletuzumab.,Farletuzumab
DB05656,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Veltuzumab.,Veltuzumab
DB05793,The risk or severity of adverse effects can be increased when Bevacizumab is combined with PRO-542.,PRO-542
DB05797,The risk or severity of adverse effects can be increased when Bevacizumab is combined with TNX-901.,TNX-901
DB05889,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Inotuzumab ozogamicin.,Inotuzumab ozogamicin
DB05892,The risk or severity of adverse effects can be increased when Bevacizumab is combined with RI 624.,RI 624
DB05915,The risk or severity of adverse effects can be increased when Bevacizumab is combined with MYO-029.,MYO-029
DB05916,The risk or severity of adverse effects can be increased when Bevacizumab is combined with CT-011.,CT-011
DB05941,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Leronlimab.,Leronlimab
DB05996,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Glembatumumab vedotin.,Glembatumumab vedotin
DB06043,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Olaratumab.,Olaratumab
DB06049,The risk or severity of adverse effects can be increased when Bevacizumab is combined with IPH 2101.,IPH 2101
DB06050,The risk or severity of adverse effects can be increased when Bevacizumab is combined with TB-402.,TB-402
DB06081,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Caplacizumab.,Caplacizumab
DB06101,The risk or severity of adverse effects can be increased when Bevacizumab is combined with IMC-1C11.,IMC-1C11
DB06116,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Eldelumab.,Eldelumab
DB06162,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lumiliximab.,Lumiliximab
DB06186,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ipilimumab.,Ipilimumab
DB06192,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Nimotuzumab.,Nimotuzumab
DB06241,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Clenoliximab.,Clenoliximab
DB06304,The risk or severity of adverse effects can be increased when Bevacizumab is combined with BIIB015.,BIIB015
DB06305,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sonepcizumab.,Sonepcizumab
DB06310,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Motavizumab.,Motavizumab
DB06317,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Elotuzumab.,Elotuzumab
DB06318,The risk or severity of adverse effects can be increased when Bevacizumab is combined with AVE9633.,AVE9633
DB06322,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Carotuximab.,Carotuximab
DB06324,The risk or severity of adverse effects can be increased when Bevacizumab is combined with XmAb 2513.,XmAb 2513
DB06342,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Coltuximab ravtansine.,Coltuximab ravtansine
DB06343,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Teprotumumab.,Teprotumumab
DB06360,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lucatumumab.,Lucatumumab
DB06366,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pertuzumab.,Pertuzumab
DB06371,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Siplizumab.,Siplizumab
DB06467,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Apolizumab.,Apolizumab
DB06474,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sibrotuzumab.,Sibrotuzumab
DB06550,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bivatuzumab.,Bivatuzumab
DB06557,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lerdelimumab.,Lerdelimumab
DB06599,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lexatumumab.,Lexatumumab
DB06602,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Reslizumab.,Reslizumab
DB06606,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Teplizumab.,Teplizumab
DB06607,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Catumaxomab.,Catumaxomab
DB06647,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Volociximab.,Volociximab
DB06650,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ofatumumab.,Ofatumumab
DB08902,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Raxibacumab.,Raxibacumab
DB09035,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Nivolumab.,Nivolumab
DB09037,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pembrolizumab.,Pembrolizumab
DB09045,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dulaglutide.,Dulaglutide
DB09105,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Asfotase alfa.,Asfotase alfa
DB09264,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Idarucizumab.,Idarucizumab
DB09302,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Alirocumab.,Alirocumab
DB09303,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Evolocumab.,Evolocumab
DB09331,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Daratumumab.,Daratumumab
DB09559,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Necitumumab.,Necitumumab
DB11595,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Atezolizumab.,Atezolizumab
DB11604,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tetanus Immune Globulin.,Tetanus Immune Globulin
DB11608,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Eftrenonacog alfa.,Eftrenonacog alfa
DB11621,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Human Varicella-Zoster Immune Globulin.,Human Varicella-Zoster Immune Globulin
DB11646,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Conatumumab.,Conatumumab
DB11657,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tabalumab.,Tabalumab
DB11680,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ficlatuzumab.,Ficlatuzumab
DB11685,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Figitumumab.,Figitumumab
DB11714,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Durvalumab.,Durvalumab
DB11715,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bapineuzumab.,Bapineuzumab
DB11731,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Depatuxizumab mafodotin.,Depatuxizumab mafodotin
DB11746,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Onartuzumab.,Onartuzumab
DB11756,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Solanezumab.,Solanezumab
DB11771,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tremelimumab.,Tremelimumab
DB11826,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lampalizumab.,Lampalizumab
DB11840,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dalotuzumab.,Dalotuzumab
DB11849,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Emibetuzumab.,Emibetuzumab
DB11850,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ublituximab.,Ublituximab
DB11856,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ligelizumab.,Ligelizumab
DB11857,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Seribantumab.,Seribantumab
DB11862,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Landogrozumab.,Landogrozumab
DB11866,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Romosozumab.,Romosozumab
DB11884,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Vadastuximab Talirine.,Vadastuximab Talirine
DB11914,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lebrikizumab.,Lebrikizumab
DB11930,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Varlilumab.,Varlilumab
DB11945,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Avelumab.,Avelumab
DB11959,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Crenezumab.,Crenezumab
DB11972,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Rilotumumab.,Rilotumumab
DB11976,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Anifrolumab.,Anifrolumab
DB12023,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Benralizumab.,Benralizumab
DB12034,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Gantenerumab.,Gantenerumab
DB12053,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Visilizumab.,Visilizumab
DB12077,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Urelumab.,Urelumab
DB12089,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lorvotuzumab mertansine.,Lorvotuzumab mertansine
DB12090,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Patritumab.,Patritumab
DB12102,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fulranumab.,Fulranumab
DB12104,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tarextumab.,Tarextumab
DB12118,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sotatercept.,Sotatercept
DB12119,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Gevokizumab.,Gevokizumab
DB12142,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Duligotuzumab.,Duligotuzumab
DB12152,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Simtuzumab.,Simtuzumab
DB12157,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fasinumab.,Fasinumab
DB12159,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dupilumab.,Dupilumab
DB12169,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tralokinumab.,Tralokinumab
DB12189,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Etrolizumab.,Etrolizumab
DB12202,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Zalutumumab.,Zalutumumab
DB12205,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ganitumab.,Ganitumab
DB12213,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Etaracizumab.,Etaracizumab
DB12240,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Polatuzumab vedotin.,Polatuzumab vedotin
DB12246,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Inclacumab.,Inclacumab
DB12250,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Cixutumumab.,Cixutumumab
DB12261,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ascrinvacumab.,Ascrinvacumab
DB12274,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Aducanumab.,Aducanumab
DB12281,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Luspatercept.,Luspatercept
DB12296,The risk or severity of adverse effects can be increased when Bevacizumab is combined with GS-5745.,GS-5745
DB12317,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Vanucizumab.,Vanucizumab
DB12331,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Labetuzumab govitecan.,Labetuzumab govitecan
DB12335,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tanezumab.,Tanezumab
DB12342,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ensituximab.,Ensituximab
DB12344,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fezakinumab.,Fezakinumab
DB12363,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dusigitumab.,Dusigitumab
DB12396,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fresolimumab.,Fresolimumab
DB12413,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Indusatumab vedotin.,Indusatumab vedotin
DB12456,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bococizumab.,Bococizumab
DB12489,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mirvetuximab Soravtansine.,Mirvetuximab Soravtansine
DB12498,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mogamulizumab.,Mogamulizumab
DB12520,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Plozalizumab.,Plozalizumab
DB12534,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mavrilimumab.,Mavrilimumab
DB12560,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Blosozumab.,Blosozumab
DB12584,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bimagrumab.,Bimagrumab
DB12589,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dacetuzumab.,Dacetuzumab
DB12609,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tovetumab.,Tovetumab
DB12683,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lumretuzumab.,Lumretuzumab
DB12698,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ibalizumab.,Ibalizumab
DB12701,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Intetumumab.,Intetumumab
DB12718,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Carlumab.,Carlumab
DB12734,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Demcizumab.,Demcizumab
DB12773,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sifalimumab.,Sifalimumab
DB12775,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Abituzumab.,Abituzumab
DB12797,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ecromeximab.,Ecromeximab
DB12807,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Naptumomab Estafenatox.,Naptumomab Estafenatox
DB12815,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Crotedumab.,Crotedumab
DB12820,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Concizumab.,Concizumab
DB12826,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Depatuxizumab.,Depatuxizumab
DB12844,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Rontalizumab.,Rontalizumab
DB12845,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Amatuximab.,Amatuximab
DB12849,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Clazakizumab.,Clazakizumab
DB12891,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ozanezumab.,Ozanezumab
DB12893,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sacituzumab govitecan.,Sacituzumab govitecan
DB12917,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bimekizumab.,Bimekizumab
DB12943,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Milatuzumab.,Milatuzumab
DB12976,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Robatumumab.,Robatumumab
DB13017,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Rovalpituzumab Tesirine.,Rovalpituzumab Tesirine
DB13037,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Namilumab.,Namilumab
DB13045,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Racotumomab.,Racotumomab
DB13073,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tregalizumab.,Tregalizumab
DB13127,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Olokizumab.,Olokizumab
DB13140,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bezlotoxumab.,Bezlotoxumab
DB13375,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Edrecolomab.,Edrecolomab
DB13535,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Nebacumab.,Nebacumab
DB13886,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Human cytomegalovirus immune globulin.,Human cytomegalovirus immune globulin
DB13923,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Emicizumab.,Emicizumab
DB13976,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sulesomab.,Sulesomab
DB13979,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Besilesomab.,Besilesomab
DB14012,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Burosumab.,Burosumab
DB14039,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Erenumab.,Erenumab
DB14040,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Eptinezumab.,Eptinezumab
DB14041,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fremanezumab.,Fremanezumab
DB14042,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Galcanezumab.,Galcanezumab
DB14211,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fanolesomab.,Fanolesomab
DB14580,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lecanemab.,Lecanemab
DB14597,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lanadelumab.,Lanadelumab
DB14707,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Cemiplimab.,Cemiplimab
DB14776,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Camrelizumab.,Camrelizumab
DB14778,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Setrusumab.,Setrusumab
DB14784,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Gancotamab.,Gancotamab
DB14809,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Anetumab ravtansine.,Anetumab ravtansine
DB14811,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Isatuximab.,Isatuximab
DB14824,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Icrucumab.,Icrucumab
DB14843,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Codrituzumab.,Codrituzumab
DB14864,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Brolucizumab.,Brolucizumab
DB14871,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Xentuzumab.,Xentuzumab
DB14877,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lintuzumab.,Lintuzumab
DB14891,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Vobarilizumab.,Vobarilizumab
DB14897,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Parsatuzumab.,Parsatuzumab
DB14905,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Emactuzumab.,Emactuzumab
DB14907,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bevacizumab zirconium Zr-89.,Bevacizumab zirconium Zr-89
DB14908,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Refanezumab.,Refanezumab
DB14947,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bermekimab.,Bermekimab
DB14952,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pamrevlumab.,Pamrevlumab
DB14959,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Opicinumab.,Opicinumab
DB14962,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Trastuzumab deruxtecan.,Trastuzumab deruxtecan
DB14967,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Margetuximab.,Margetuximab
DB14988,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dalantercept.,Dalantercept
DB14997,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pateclizumab.,Pateclizumab
DB15014,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Gremubamab.,Gremubamab
DB15022,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Apomab.,Apomab
DB15044,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tafasitamab.,Tafasitamab
DB15045,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ipafricept.,Ipafricept
DB15076,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Abrilumab.,Abrilumab
DB15089,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Frovocimab.,Frovocimab
DB15090,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tezepelumab.,Tezepelumab
DB15101,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tigatuzumab.,Tigatuzumab
DB15104,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Telisotuzumab vedotin.,Telisotuzumab vedotin
DB15113,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Utomilumab.,Utomilumab
DB15118,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Zolbetuximab.,Zolbetuximab
DB15135,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ponezumab.,Ponezumab
DB15160,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Asunercept.,Asunercept
DB15172,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Suvratoxumab.,Suvratoxumab
DB15225,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mitazalimab.,Mitazalimab
DB15252,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Nemolizumab.,Nemolizumab
DB15277,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Gedivumab.,Gedivumab
DB15336,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Valanafusp alfa.,Valanafusp alfa
DB15349,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sofituzumab vedotin.,Sofituzumab vedotin
DB15354,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Evinacumab.,Evinacumab
DB15363,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Istiratumab.,Istiratumab
DB15383,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pidilizumab.,Pidilizumab
DB15397,The risk or severity of adverse effects can be increased when Bevacizumab is combined with GMA-161.,GMA-161
DB15409,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ladiratuzumab vedotin.,Ladiratuzumab vedotin
DB15415,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tomaralimab.,Tomaralimab
DB15428,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Vesencumab.,Vesencumab
DB15432,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pinatuzumab vedotin.,Pinatuzumab vedotin
DB15441,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lulizumab pegol.,Lulizumab pegol
DB15443,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lorukafusp alfa.,Lorukafusp alfa
DB15453,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Naratuximab emtansine.,Naratuximab emtansine
DB14004,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Tildrakizumab.,Tildrakizumab
DB05679,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ustekinumab.,Ustekinumab
DB15559,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Zenocutuzumab.,Zenocutuzumab
DB00091,Bevacizumab may increase the immunosuppressive activities of Cyclosporine.,Cyclosporine
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Bevacizumab.","Ebola Zaire vaccine (live, attenuated)"
DB14513,The serum concentration of Magnesium can be decreased when it is combined with Bevacizumab.,Magnesium
DB01601,The serum concentration of Bevacizumab can be increased when it is combined with Lopinavir.,Lopinavir
DB12530,The risk or severity of infection can be increased when Bevacizumab is combined with Inebilizumab.,Inebilizumab
DB00255,Diethylstilbestrol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Diethylstilbestrol
DB00269,Chlorotrianisene may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Chlorotrianisene
DB00286,Conjugated estrogens may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Conjugated estrogens
DB00655,Estrone may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Estrone
DB00783,Estradiol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Estradiol
DB00890,Dienestrol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Dienestrol
DB00977,Ethinylestradiol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Ethinylestradiol
DB01357,Mestranol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Mestranol
DB04573,Estriol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Estriol
DB04574,Estrone sulfate may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Estrone sulfate
DB04575,Quinestrol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Quinestrol
DB07931,Hexestrol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Hexestrol
DB09070,Tibolone may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Tibolone
DB09317,"Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.","Synthetic Conjugated Estrogens, A"
DB09318,"Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.","Synthetic Conjugated Estrogens, B"
DB09369,Polyestradiol phosphate may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Polyestradiol phosphate
DB09381,Esterified estrogens may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Esterified estrogens
DB11478,Zeranol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Zeranol
DB11674,Equol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Equol
DB12487,Promestriene may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Promestriene
DB13143,Methallenestril may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Methallenestril
DB13386,Epimestrol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Epimestrol
DB13418,Moxestrol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Moxestrol
DB13952,Estradiol acetate may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Estradiol acetate
DB13953,Estradiol benzoate may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Estradiol benzoate
DB13954,Estradiol cypionate may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Estradiol cypionate
DB13956,Estradiol valerate may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Estradiol valerate
DB15334,Biochanin A may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Biochanin A
DB15335,Formononetin may increase the thrombogenic activities of Technetium Tc-99m arcitumomab.,Formononetin
DB00002,The risk or severity of adverse effects can be increased when Cetuximab is combined with Technetium Tc-99m arcitumomab.,Cetuximab
DB00028,The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Technetium Tc-99m arcitumomab.,Human immunoglobulin G
DB00043,The risk or severity of adverse effects can be increased when Omalizumab is combined with Technetium Tc-99m arcitumomab.,Omalizumab
DB00051,The risk or severity of adverse effects can be increased when Adalimumab is combined with Technetium Tc-99m arcitumomab.,Adalimumab
DB00054,The risk or severity of adverse effects can be increased when Abciximab is combined with Technetium Tc-99m arcitumomab.,Abciximab
DB00056,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Technetium Tc-99m arcitumomab.,Gemtuzumab ozogamicin
DB00057,The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Technetium Tc-99m arcitumomab.,Indium In-111 satumomab pendetide
DB00065,The risk or severity of adverse effects can be increased when Infliximab is combined with Technetium Tc-99m arcitumomab.,Infliximab
DB00072,The risk or severity of adverse effects can be increased when Trastuzumab is combined with Technetium Tc-99m arcitumomab.,Trastuzumab
DB00073,The risk or severity of adverse effects can be increased when Rituximab is combined with Technetium Tc-99m arcitumomab.,Rituximab
DB00074,The risk or severity of adverse effects can be increased when Basiliximab is combined with Technetium Tc-99m arcitumomab.,Basiliximab
DB00075,The risk or severity of adverse effects can be increased when Muromonab is combined with Technetium Tc-99m arcitumomab.,Muromonab
DB00076,The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Technetium Tc-99m arcitumomab.,Digoxin Immune Fab (Ovine)
DB00078,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Technetium Tc-99m arcitumomab.,Ibritumomab tiuxetan
DB00081,The risk or severity of adverse effects can be increased when Tositumomab is combined with Technetium Tc-99m arcitumomab.,Tositumomab
DB00087,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Technetium Tc-99m arcitumomab.,Alemtuzumab
DB00089,The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Technetium Tc-99m arcitumomab.,Capromab pendetide
DB00095,The risk or severity of adverse effects can be increased when Efalizumab is combined with Technetium Tc-99m arcitumomab.,Efalizumab
DB00098,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Technetium Tc-99m arcitumomab.,Antithymocyte immunoglobulin (rabbit)
DB00108,The risk or severity of adverse effects can be increased when Natalizumab is combined with Technetium Tc-99m arcitumomab.,Natalizumab
DB00110,The risk or severity of adverse effects can be increased when Palivizumab is combined with Technetium Tc-99m arcitumomab.,Palivizumab
DB00111,The risk or severity of adverse effects can be increased when Daclizumab is combined with Technetium Tc-99m arcitumomab.,Daclizumab
DB00112,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Technetium Tc-99m arcitumomab.,Bevacizumab
DB01257,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Eculizumab.,Eculizumab
DB01269,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Panitumumab.,Panitumumab
DB01270,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ranibizumab.,Ranibizumab
DB04901,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Galiximab.,Galiximab
DB04949,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Pexelizumab.,Pexelizumab
DB04956,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Afelimomab.,Afelimomab
DB04958,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Epratuzumab.,Epratuzumab
DB04962,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Bectumomab.,Bectumomab
DB04964,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Oregovomab.,Oregovomab
DB04988,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with IGN311.,IGN311
DB05006,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Adecatumumab.,Adecatumumab
DB05097,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Labetuzumab.,Labetuzumab
DB05101,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Matuzumab.,Matuzumab
DB05111,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Fontolizumab.,Fontolizumab
DB05136,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Bavituximab.,Bavituximab
DB05139,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with CR002.,CR002
DB05209,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Rozrolimupab.,Rozrolimupab
DB05304,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Girentuximab.,Girentuximab
DB05336,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Obiltoxaximab.,Obiltoxaximab
DB05405,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with XTL-001.,XTL-001
DB05437,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with NAV 1800.,NAV 1800
DB05459,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Briakinumab.,Briakinumab
DB05496,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Otelixizumab.,Otelixizumab
DB05545,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with AMG 108.,AMG 108
DB05550,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Iratumumab.,Iratumumab
DB05555,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Enokizumab.,Enokizumab
DB05578,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ramucirumab.,Ramucirumab
DB05595,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Farletuzumab.,Farletuzumab
DB05656,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Veltuzumab.,Veltuzumab
DB05679,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ustekinumab.,Ustekinumab
DB05773,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Trastuzumab emtansine.,Trastuzumab emtansine
DB05793,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with PRO-542.,PRO-542
DB05797,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with TNX-901.,TNX-901
DB05889,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Inotuzumab ozogamicin.,Inotuzumab ozogamicin
DB05892,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with RI 624.,RI 624
DB05915,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with MYO-029.,MYO-029
DB05916,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with CT-011.,CT-011
DB05941,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Leronlimab.,Leronlimab
DB05996,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Glembatumumab vedotin.,Glembatumumab vedotin
DB06043,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Olaratumab.,Olaratumab
DB06049,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with IPH 2101.,IPH 2101
DB06050,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with TB-402.,TB-402
DB06081,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Caplacizumab.,Caplacizumab
DB06101,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with IMC-1C11.,IMC-1C11
DB06116,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Eldelumab.,Eldelumab
DB06162,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Lumiliximab.,Lumiliximab
DB06168,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Canakinumab.,Canakinumab
DB06186,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ipilimumab.,Ipilimumab
DB06192,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Nimotuzumab.,Nimotuzumab
DB06241,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Clenoliximab.,Clenoliximab
DB06273,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tocilizumab.,Tocilizumab
DB06304,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with BIIB015.,BIIB015
DB06305,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Sonepcizumab.,Sonepcizumab
DB06310,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Motavizumab.,Motavizumab
DB06317,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Elotuzumab.,Elotuzumab
DB06318,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with AVE9633.,AVE9633
DB06322,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Carotuximab.,Carotuximab
DB06324,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with XmAb 2513.,XmAb 2513
DB06342,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Coltuximab ravtansine.,Coltuximab ravtansine
DB06343,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Teprotumumab.,Teprotumumab
DB06360,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Lucatumumab.,Lucatumumab
DB06366,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Pertuzumab.,Pertuzumab
DB06371,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Siplizumab.,Siplizumab
DB06467,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Apolizumab.,Apolizumab
DB06474,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Sibrotuzumab.,Sibrotuzumab
DB06550,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Bivatuzumab.,Bivatuzumab
DB06557,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Lerdelimumab.,Lerdelimumab
DB06599,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Lexatumumab.,Lexatumumab
DB06602,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Reslizumab.,Reslizumab
DB06606,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Teplizumab.,Teplizumab
DB06607,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Catumaxomab.,Catumaxomab
DB06612,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Mepolizumab.,Mepolizumab
DB06643,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Denosumab.,Denosumab
DB06647,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Volociximab.,Volociximab
DB06650,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ofatumumab.,Ofatumumab
DB06674,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Golimumab.,Golimumab
DB08870,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Brentuximab vedotin.,Brentuximab vedotin
DB08879,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Belimumab.,Belimumab
DB08902,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Raxibacumab.,Raxibacumab
DB08904,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Certolizumab pegol.,Certolizumab pegol
DB08935,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Obinutuzumab.,Obinutuzumab
DB09029,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Secukinumab.,Secukinumab
DB09033,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Vedolizumab.,Vedolizumab
DB09035,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Nivolumab.,Nivolumab
DB09036,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Siltuximab.,Siltuximab
DB09037,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Pembrolizumab.,Pembrolizumab
DB09045,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Dulaglutide.,Dulaglutide
DB09052,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Blinatumomab.,Blinatumomab
DB09057,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Anthrax immune globulin human.,Anthrax immune globulin human
DB09077,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Dinutuximab.,Dinutuximab
DB09105,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Asfotase alfa.,Asfotase alfa
DB09264,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Idarucizumab.,Idarucizumab
DB09302,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Alirocumab.,Alirocumab
DB09303,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Evolocumab.,Evolocumab
DB09312,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Antilymphocyte immunoglobulin (horse).,Antilymphocyte immunoglobulin (horse)
DB09331,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Daratumumab.,Daratumumab
DB09559,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Necitumumab.,Necitumumab
DB11569,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ixekizumab.,Ixekizumab
DB11580,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ravulizumab.,Ravulizumab
DB11595,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Atezolizumab.,Atezolizumab
DB11604,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tetanus Immune Globulin.,Tetanus Immune Globulin
DB11608,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Eftrenonacog alfa.,Eftrenonacog alfa
DB11621,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Human Varicella-Zoster Immune Globulin.,Human Varicella-Zoster Immune Globulin
DB11646,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Conatumumab.,Conatumumab
DB11657,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tabalumab.,Tabalumab
DB11680,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ficlatuzumab.,Ficlatuzumab
DB11685,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Figitumumab.,Figitumumab
DB11714,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Durvalumab.,Durvalumab
DB11715,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Bapineuzumab.,Bapineuzumab
DB11731,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Depatuxizumab mafodotin.,Depatuxizumab mafodotin
DB11746,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Onartuzumab.,Onartuzumab
DB11756,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Solanezumab.,Solanezumab
DB11767,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Sarilumab.,Sarilumab
DB11771,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tremelimumab.,Tremelimumab
DB11776,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Brodalumab.,Brodalumab
DB11803,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Sirukumab.,Sirukumab
DB11826,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Lampalizumab.,Lampalizumab
DB11834,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Guselkumab.,Guselkumab
DB11840,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Dalotuzumab.,Dalotuzumab
DB11849,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Emibetuzumab.,Emibetuzumab
DB11850,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ublituximab.,Ublituximab
DB11856,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ligelizumab.,Ligelizumab
DB11857,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Seribantumab.,Seribantumab
DB11862,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Landogrozumab.,Landogrozumab
DB11866,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Romosozumab.,Romosozumab
DB11884,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Vadastuximab Talirine.,Vadastuximab Talirine
DB11914,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Lebrikizumab.,Lebrikizumab
DB11930,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Varlilumab.,Varlilumab
DB11945,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Avelumab.,Avelumab
DB11959,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Crenezumab.,Crenezumab
DB11972,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Rilotumumab.,Rilotumumab
DB11976,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Anifrolumab.,Anifrolumab
DB11988,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ocrelizumab.,Ocrelizumab
DB12023,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Benralizumab.,Benralizumab
DB12034,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Gantenerumab.,Gantenerumab
DB12053,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Visilizumab.,Visilizumab
DB12077,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Urelumab.,Urelumab
DB12089,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Lorvotuzumab mertansine.,Lorvotuzumab mertansine
DB12090,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Patritumab.,Patritumab
DB12102,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Fulranumab.,Fulranumab
DB12104,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tarextumab.,Tarextumab
DB12118,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Sotatercept.,Sotatercept
DB12119,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Gevokizumab.,Gevokizumab
DB12142,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Duligotuzumab.,Duligotuzumab
DB12152,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Simtuzumab.,Simtuzumab
DB12157,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Fasinumab.,Fasinumab
DB12159,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Dupilumab.,Dupilumab
DB12169,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tralokinumab.,Tralokinumab
DB12189,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Etrolizumab.,Etrolizumab
DB12202,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Zalutumumab.,Zalutumumab
DB12205,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ganitumab.,Ganitumab
DB12213,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Etaracizumab.,Etaracizumab
DB12240,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Polatuzumab vedotin.,Polatuzumab vedotin
DB12246,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Inclacumab.,Inclacumab
DB12250,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Cixutumumab.,Cixutumumab
DB12261,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ascrinvacumab.,Ascrinvacumab
DB12274,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Aducanumab.,Aducanumab
DB12281,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Luspatercept.,Luspatercept
DB12296,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with GS-5745.,GS-5745
DB12317,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Vanucizumab.,Vanucizumab
DB12331,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Labetuzumab govitecan.,Labetuzumab govitecan
DB12335,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tanezumab.,Tanezumab
DB12342,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ensituximab.,Ensituximab
DB12344,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Fezakinumab.,Fezakinumab
DB12363,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Dusigitumab.,Dusigitumab
DB12396,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Fresolimumab.,Fresolimumab
DB12413,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Indusatumab vedotin.,Indusatumab vedotin
DB12456,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Bococizumab.,Bococizumab
DB12489,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Mirvetuximab Soravtansine.,Mirvetuximab Soravtansine
DB12498,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Mogamulizumab.,Mogamulizumab
DB12520,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Plozalizumab.,Plozalizumab
DB12530,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Inebilizumab.,Inebilizumab
DB12534,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Mavrilimumab.,Mavrilimumab
DB12560,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Blosozumab.,Blosozumab
DB12584,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Bimagrumab.,Bimagrumab
DB12589,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Dacetuzumab.,Dacetuzumab
DB12609,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tovetumab.,Tovetumab
DB12683,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Lumretuzumab.,Lumretuzumab
DB12698,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ibalizumab.,Ibalizumab
DB12701,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Intetumumab.,Intetumumab
DB12718,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Carlumab.,Carlumab
DB12734,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Demcizumab.,Demcizumab
DB12773,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Sifalimumab.,Sifalimumab
DB12775,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Abituzumab.,Abituzumab
DB12797,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ecromeximab.,Ecromeximab
DB12807,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Naptumomab Estafenatox.,Naptumomab Estafenatox
DB12815,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Crotedumab.,Crotedumab
DB12820,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Concizumab.,Concizumab
DB12826,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Depatuxizumab.,Depatuxizumab
DB12844,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Rontalizumab.,Rontalizumab
DB12845,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Amatuximab.,Amatuximab
DB12849,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Clazakizumab.,Clazakizumab
DB12891,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ozanezumab.,Ozanezumab
DB12893,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Sacituzumab govitecan.,Sacituzumab govitecan
DB12917,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Bimekizumab.,Bimekizumab
DB12943,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Milatuzumab.,Milatuzumab
DB12976,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Robatumumab.,Robatumumab
DB13017,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Rovalpituzumab Tesirine.,Rovalpituzumab Tesirine
DB13037,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Namilumab.,Namilumab
DB13045,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Racotumomab.,Racotumomab
DB13073,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tregalizumab.,Tregalizumab
DB13127,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Olokizumab.,Olokizumab
DB13140,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Bezlotoxumab.,Bezlotoxumab
DB13375,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Edrecolomab.,Edrecolomab
DB13535,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Nebacumab.,Nebacumab
DB13886,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Human cytomegalovirus immune globulin.,Human cytomegalovirus immune globulin
DB13923,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Emicizumab.,Emicizumab
DB13976,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Sulesomab.,Sulesomab
DB13979,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Besilesomab.,Besilesomab
DB14004,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tildrakizumab.,Tildrakizumab
DB14012,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Burosumab.,Burosumab
DB14039,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Erenumab.,Erenumab
DB14040,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Eptinezumab.,Eptinezumab
DB14041,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Fremanezumab.,Fremanezumab
DB14042,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Galcanezumab.,Galcanezumab
DB14211,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Fanolesomab.,Fanolesomab
DB14580,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Lecanemab.,Lecanemab
DB14597,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Lanadelumab.,Lanadelumab
DB14707,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Cemiplimab.,Cemiplimab
DB14724,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Emapalumab.,Emapalumab
DB14762,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Risankizumab.,Risankizumab
DB14776,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Camrelizumab.,Camrelizumab
DB14778,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Setrusumab.,Setrusumab
DB14784,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Gancotamab.,Gancotamab
DB14809,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Anetumab ravtansine.,Anetumab ravtansine
DB14811,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Isatuximab.,Isatuximab
DB14824,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Icrucumab.,Icrucumab
DB14843,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Codrituzumab.,Codrituzumab
DB14864,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Brolucizumab.,Brolucizumab
DB14871,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Xentuzumab.,Xentuzumab
DB14877,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Lintuzumab.,Lintuzumab
DB14891,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Vobarilizumab.,Vobarilizumab
DB14897,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Parsatuzumab.,Parsatuzumab
DB14905,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Emactuzumab.,Emactuzumab
DB14907,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Bevacizumab zirconium Zr-89.,Bevacizumab zirconium Zr-89
DB14908,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Refanezumab.,Refanezumab
DB14919,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Rozanolixizumab.,Rozanolixizumab
DB14947,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Bermekimab.,Bermekimab
DB14952,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Pamrevlumab.,Pamrevlumab
DB14959,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Opicinumab.,Opicinumab
DB14962,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Trastuzumab deruxtecan.,Trastuzumab deruxtecan
DB14967,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Margetuximab.,Margetuximab
DB14988,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Dalantercept.,Dalantercept
DB14997,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Pateclizumab.,Pateclizumab
DB15014,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Gremubamab.,Gremubamab
DB15022,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Apomab.,Apomab
DB15044,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tafasitamab.,Tafasitamab
DB15045,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ipafricept.,Ipafricept
DB15076,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Abrilumab.,Abrilumab
DB15089,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Frovocimab.,Frovocimab
DB15090,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tezepelumab.,Tezepelumab
DB15101,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tigatuzumab.,Tigatuzumab
DB15104,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Telisotuzumab vedotin.,Telisotuzumab vedotin
DB15113,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Utomilumab.,Utomilumab
DB15118,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Zolbetuximab.,Zolbetuximab
DB15135,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ponezumab.,Ponezumab
DB15160,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Asunercept.,Asunercept
DB15172,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Suvratoxumab.,Suvratoxumab
DB15225,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Mitazalimab.,Mitazalimab
DB15252,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Nemolizumab.,Nemolizumab
DB15253,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Bleselumab.,Bleselumab
DB15277,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Gedivumab.,Gedivumab
DB15336,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Valanafusp alfa.,Valanafusp alfa
DB15349,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Sofituzumab vedotin.,Sofituzumab vedotin
DB15354,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Evinacumab.,Evinacumab
DB15363,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Istiratumab.,Istiratumab
DB15383,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Pidilizumab.,Pidilizumab
DB15397,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with GMA-161.,GMA-161
DB15409,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ladiratuzumab vedotin.,Ladiratuzumab vedotin
DB15415,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Tomaralimab.,Tomaralimab
DB15428,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Vesencumab.,Vesencumab
DB15432,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Pinatuzumab vedotin.,Pinatuzumab vedotin
DB15441,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Lulizumab pegol.,Lulizumab pegol
DB15443,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Lorukafusp alfa.,Lorukafusp alfa
DB15453,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Naratuximab emtansine.,Naratuximab emtansine
DB15559,The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Zenocutuzumab.,Zenocutuzumab
DB15595,"The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Technetium Tc-99m arcitumomab.","Ebola Zaire vaccine (live, attenuated)"
DB00446,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Chloramphenicol.,Chloramphenicol
DB01394,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Colchicine.,Colchicine
DB00091,Cyclosporine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cyclosporine
DB00229,Cefotiam may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefotiam
DB00244,Mesalazine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Mesalazine
DB00267,Cefmenoxime may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefmenoxime
DB00274,Cefmetazole may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefmetazole
DB00282,Pamidronic acid may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Pamidronic acid
DB00300,Tenofovir disoproxil may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Tenofovir disoproxil
DB00369,Cidofovir may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cidofovir
DB00384,Triamterene may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Triamterene
DB00430,Cefpiramide may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefpiramide
DB00438,Ceftazidime may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Ceftazidime
DB00447,Loracarbef may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Loracarbef
DB00456,Cefalotin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefalotin
DB00461,Nabumetone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Nabumetone
DB00465,Ketorolac may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Ketorolac
DB00469,Tenoxicam may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Tenoxicam
DB00482,Celecoxib may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Celecoxib
DB00493,Cefotaxime may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefotaxime
DB00500,Tolmetin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Tolmetin
DB00529,Foscarnet may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Foscarnet
DB00533,Rofecoxib may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Rofecoxib
DB00554,Piroxicam may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Piroxicam
DB00567,Cephalexin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cephalexin
DB00573,Fenoprofen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Fenoprofen
DB00577,Valaciclovir may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Valaciclovir
DB00580,Valdecoxib may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Valdecoxib
DB00586,Diclofenac may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Diclofenac
DB00605,Sulindac may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Sulindac
DB00626,Bacitracin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Bacitracin
DB00681,Amphotericin B may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Amphotericin B
DB00689,Cephaloglycin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cephaloglycin
DB00712,Flurbiprofen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Flurbiprofen
DB00718,Adefovir dipivoxil may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Adefovir dipivoxil
DB00738,Pentamidine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Pentamidine
DB00742,Mannitol may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Mannitol
DB00749,Etodolac may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Etodolac
DB00784,Mefenamic acid may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Mefenamic acid
DB00787,Acyclovir may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Acyclovir
DB00788,Naproxen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Naproxen
DB00795,Sulfasalazine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Sulfasalazine
DB00812,Phenylbutazone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Phenylbutazone
DB00814,Meloxicam may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Meloxicam
DB00821,Carprofen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Carprofen
DB00833,Cefaclor may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefaclor
DB00861,Diflunisal may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Diflunisal
DB00903,Etacrynic acid may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Etacrynic acid
DB00923,Ceforanide may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Ceforanide
DB00936,Salicylic acid may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Salicylic acid
DB00939,Meclofenamic acid may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Meclofenamic acid
DB00945,Acetylsalicylic acid may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Acetylsalicylic acid
DB00991,Oxaprozin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Oxaprozin
DB00999,Hydrochlorothiazide may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Hydrochlorothiazide
DB01009,Ketoprofen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Ketoprofen
DB01014,Balsalazide may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Balsalazide
DB01050,Ibuprofen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Ibuprofen
DB01066,Cefditoren may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefditoren
DB01072,Atazanavir may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Atazanavir
DB01111,Colistimethate may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Colistimethate
DB01112,Cefuroxime may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefuroxime
DB01139,Cefapirin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefapirin
DB01140,Cefadroxil may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefadroxil
DB01150,Cefprozil may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefprozil
DB01212,Ceftriaxone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Ceftriaxone
DB01250,Olsalazine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Olsalazine
DB01283,Lumiracoxib may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Lumiracoxib
DB01326,Cefamandole may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefamandole
DB01327,Cefazolin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefazolin
DB01328,Cefonicid may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefonicid
DB01329,Cefoperazone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefoperazone
DB01330,Cefotetan may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefotetan
DB01331,Cefoxitin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefoxitin
DB01332,Ceftizoxime may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Ceftizoxime
DB01333,Cefradine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefradine
DB01397,Magnesium salicylate may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Magnesium salicylate
DB01399,Salsalate may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Salsalate
DB01401,Choline magnesium trisalicylate may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Choline magnesium trisalicylate
DB01413,Cefepime may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefepime
DB01414,Cefacetrile may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefacetrile
DB01415,Ceftibuten may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Ceftibuten
DB01416,Cefpodoxime may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefpodoxime
DB01419,Antrafenine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Antrafenine
DB01424,Aminophenazone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Aminophenazone
DB01435,Antipyrine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Antipyrine
DB01600,Tiaprofenic acid may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Tiaprofenic acid
DB01601,Lopinavir may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Lopinavir
DB01628,Etoricoxib may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Etoricoxib
DB02247,Hydrolyzed Cephalothin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Hydrolyzed Cephalothin
DB03450,Cephalothin Group may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cephalothin Group
DB03585,Oxyphenbutazone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Oxyphenbutazone
DB04552,Niflumic acid may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Niflumic acid
DB04570,Latamoxef may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Latamoxef
DB04743,Nimesulide may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Nimesulide
DB04812,Benoxaprofen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Benoxaprofen
DB04817,Metamizole may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Metamizole
DB04828,Zomepirac may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Zomepirac
DB04918,Ceftobiprole may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Ceftobiprole
DB05095,Cimicoxib may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cimicoxib
DB06590,Ceftaroline fosamil may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Ceftaroline fosamil
DB06725,Lornoxicam may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Lornoxicam
DB06736,Aceclofenac may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Aceclofenac
DB06737,Zaltoprofen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Zaltoprofen
DB07402,Azapropazone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Azapropazone
DB07477,Felbinac may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Felbinac
DB08439,Parecoxib may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Parecoxib
DB08797,Salicylamide may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Salicylamide
DB08940,Kebuzone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Kebuzone
DB08942,Isoxicam may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Isoxicam
DB08951,Indoprofen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Indoprofen
DB08955,Ibuproxam may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Ibuproxam
DB08976,Floctafenine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Floctafenine
DB08981,Fenbufen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Fenbufen
DB08984,Etofenamate may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Etofenamate
DB08991,Epirizole may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Epirizole
DB09008,Cefaloridine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefaloridine
DB09062,Cefminox may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefminox
DB09084,Benzydamine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Benzydamine
DB09212,Loxoprofen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Loxoprofen
DB09213,Dexibuprofen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Dexibuprofen
DB09214,Dexketoprofen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Dexketoprofen
DB09215,Droxicam may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Droxicam
DB09216,Tolfenamic acid may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Tolfenamic acid
DB09217,Firocoxib may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Firocoxib
DB09218,Clonixin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Clonixin
DB09285,Morniflumate may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Morniflumate
DB09288,Propacetamol may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Propacetamol
DB09295,Talniflumate may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Talniflumate
DB09299,Tenofovir alafenamide may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Tenofovir alafenamide
DB11367,Cefroxadine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefroxadine
DB11455,Robenacoxib may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Robenacoxib
DB11466,Tepoxalin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Tepoxalin
DB11518,Flunixin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Flunixin
DB11935,Flomoxef may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Flomoxef
DB12151,Brincidofovir may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Brincidofovir
DB12445,Nitroaspirin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Nitroaspirin
DB12545,Indobufen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Indobufen
DB13001,Tinoridine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Tinoridine
DB13167,Alclofenac may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Alclofenac
DB13217,Fentiazac may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Fentiazac
DB13232,Suxibuzone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Suxibuzone
DB13266,Cefatrizine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefatrizine
DB13286,Bumadizone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Bumadizone
DB13314,Alminoprofen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Alminoprofen
DB13317,Flunoxaprofen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Flunoxaprofen
DB13364,Feprazone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Feprazone
DB13371,Difenpiramide may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Difenpiramide
DB13407,Nifenazone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Nifenazone
DB13432,Lonazolac may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Lonazolac
DB13461,Cefcapene may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefcapene
DB13470,Cefodizime may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefodizime
DB13481,Tenidap may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Tenidap
DB13499,Cefsulodin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefsulodin
DB13501,Bendazac may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Bendazac
DB13504,Cefetamet may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefetamet
DB13514,Pranoprofen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Pranoprofen
DB13524,Propyphenazone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Propyphenazone
DB13527,Proglumetacin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Proglumetacin
DB13538,Guacetisal may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Guacetisal
DB13544,Ethenzamide may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Ethenzamide
DB13612,Carbaspirin calcium may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Carbaspirin calcium
DB13629,Mofebutazone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Mofebutazone
DB13638,Cefbuperazone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefbuperazone
DB13649,Proquazone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Proquazone
DB13657,Benorilate may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Benorilate
DB13667,Cefozopran may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefozopran
DB13682,Cefpirome may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefpirome
DB13722,Pirprofen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Pirprofen
DB13778,Cefazedone may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cefazedone
DB13783,Acemetacin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Acemetacin
DB13821,Ceftezole may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Ceftezole
DB13860,Imidazole salicylate may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Imidazole salicylate
DB13868,Adefovir may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Adefovir
DB14059,SC-236 may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,SC-236
DB14060,NS-398 may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,NS-398
DB14126,Tenofovir may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Tenofovir
DB14713,Inotersen may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Inotersen
DB01438,Phenazopyridine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Phenazopyridine
DB15066,Givosiran may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Givosiran
DB01356,Lithium cation may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Lithium cation
DB14507,Lithium citrate may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Lithium citrate
DB00501,Cimetidine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Cimetidine
DB00007,Leuprolide may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Leuprolide
DB00014,Goserelin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Goserelin
DB00017,Salmon calcitonin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Salmon calcitonin
DB00035,Desmopressin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Desmopressin
DB00080,Daptomycin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Daptomycin
DB00176,Cyanocobalamin may decrease the excretion rate of Fluvoxamine which could result in a higher serum level.,Fluvoxamine
DB00181,Cyanocobalamin may decrease the excretion rate of Baclofen which could result in a higher serum level.,Baclofen
DB00182,Cyanocobalamin may decrease the excretion rate of Amphetamine which could result in a higher serum level.,Amphetamine
DB00185,Cyanocobalamin may decrease the excretion rate of Cevimeline which could result in a higher serum level.,Cevimeline
DB00186,Cyanocobalamin may decrease the excretion rate of Lorazepam which could result in a higher serum level.,Lorazepam
DB00190,Cyanocobalamin may decrease the excretion rate of Carbidopa which could result in a higher serum level.,Carbidopa
DB00193,Cyanocobalamin may decrease the excretion rate of Tramadol which could result in a higher serum level.,Tramadol
DB00196,Cyanocobalamin may decrease the excretion rate of Fluconazole which could result in a higher serum level.,Fluconazole
DB00198,Cyanocobalamin may decrease the excretion rate of Oseltamivir which could result in a higher serum level.,Oseltamivir
DB00200,Cyanocobalamin may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level.,Hydroxocobalamin
DB00206,Cyanocobalamin may decrease the excretion rate of Reserpine which could result in a higher serum level.,Reserpine
DB00208,Cyanocobalamin may decrease the excretion rate of Ticlopidine which could result in a higher serum level.,Ticlopidine
DB00213,Cyanocobalamin may decrease the excretion rate of Pantoprazole which could result in a higher serum level.,Pantoprazole
DB00225,Cyanocobalamin may decrease the excretion rate of Gadodiamide which could result in a higher serum level.,Gadodiamide
DB00230,Cyanocobalamin may decrease the excretion rate of Pregabalin which could result in a higher serum level.,Pregabalin
DB00231,Cyanocobalamin may decrease the excretion rate of Temazepam which could result in a higher serum level.,Temazepam
DB00235,Cyanocobalamin may decrease the excretion rate of Milrinone which could result in a higher serum level.,Milrinone
DB00237,Cyanocobalamin may decrease the excretion rate of Butabarbital which could result in a higher serum level.,Butabarbital
DB00243,Cyanocobalamin may decrease the excretion rate of Ranolazine which could result in a higher serum level.,Ranolazine
DB00245,Cyanocobalamin may decrease the excretion rate of Benzatropine which could result in a higher serum level.,Benzatropine
DB00254,Cyanocobalamin may decrease the excretion rate of Doxycycline which could result in a higher serum level.,Doxycycline
DB00264,Cyanocobalamin may decrease the excretion rate of Metoprolol which could result in a higher serum level.,Metoprolol
DB00270,Cyanocobalamin may decrease the excretion rate of Isradipine which could result in a higher serum level.,Isradipine
DB00271,Cyanocobalamin may decrease the excretion rate of Diatrizoate which could result in a higher serum level.,Diatrizoate
DB00273,Cyanocobalamin may decrease the excretion rate of Topiramate which could result in a higher serum level.,Topiramate
DB00279,Cyanocobalamin may decrease the excretion rate of Liothyronine which could result in a higher serum level.,Liothyronine
DB00280,Cyanocobalamin may decrease the excretion rate of Disopyramide which could result in a higher serum level.,Disopyramide
DB00284,Cyanocobalamin may decrease the excretion rate of Acarbose which could result in a higher serum level.,Acarbose
DB00285,Cyanocobalamin may decrease the excretion rate of Venlafaxine which could result in a higher serum level.,Venlafaxine
DB00286,Cyanocobalamin may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level.,Conjugated estrogens
DB00289,Cyanocobalamin may decrease the excretion rate of Atomoxetine which could result in a higher serum level.,Atomoxetine
DB00290,Cyanocobalamin may decrease the excretion rate of Bleomycin which could result in a higher serum level.,Bleomycin
DB00292,Cyanocobalamin may decrease the excretion rate of Etomidate which could result in a higher serum level.,Etomidate
DB00294,Cyanocobalamin may decrease the excretion rate of Etonogestrel which could result in a higher serum level.,Etonogestrel
DB00296,Cyanocobalamin may decrease the excretion rate of Ropivacaine which could result in a higher serum level.,Ropivacaine
DB00303,Cyanocobalamin may decrease the excretion rate of Ertapenem which could result in a higher serum level.,Ertapenem
DB00308,Cyanocobalamin may decrease the excretion rate of Ibutilide which could result in a higher serum level.,Ibutilide
DB00312,Cyanocobalamin may decrease the excretion rate of Pentobarbital which could result in a higher serum level.,Pentobarbital
DB00316,Cyanocobalamin may decrease the excretion rate of Acetaminophen which could result in a higher serum level.,Acetaminophen
DB00319,Cyanocobalamin may decrease the excretion rate of Piperacillin which could result in a higher serum level.,Piperacillin
DB00323,Cyanocobalamin may decrease the excretion rate of Tolcapone which could result in a higher serum level.,Tolcapone
DB00325,Cyanocobalamin may decrease the excretion rate of Nitroprusside which could result in a higher serum level.,Nitroprusside
DB00327,Cyanocobalamin may decrease the excretion rate of Hydromorphone which could result in a higher serum level.,Hydromorphone
DB00330,Cyanocobalamin may decrease the excretion rate of Ethambutol which could result in a higher serum level.,Ethambutol
DB00331,Cyanocobalamin may decrease the excretion rate of Metformin which could result in a higher serum level.,Metformin
DB00333,Cyanocobalamin may decrease the excretion rate of Methadone which could result in a higher serum level.,Methadone
DB00339,Cyanocobalamin may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.,Pyrazinamide
DB00341,Cyanocobalamin may decrease the excretion rate of Cetirizine which could result in a higher serum level.,Cetirizine
DB00349,Cyanocobalamin may decrease the excretion rate of Clobazam which could result in a higher serum level.,Clobazam
DB00351,Cyanocobalamin may decrease the excretion rate of Megestrol acetate which could result in a higher serum level.,Megestrol acetate
DB00355,Cyanocobalamin may decrease the excretion rate of Aztreonam which could result in a higher serum level.,Aztreonam
DB00356,Cyanocobalamin may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level.,Chlorzoxazone
DB00359,Cyanocobalamin may decrease the excretion rate of Sulfadiazine which could result in a higher serum level.,Sulfadiazine
DB00363,Cyanocobalamin may decrease the excretion rate of Clozapine which could result in a higher serum level.,Clozapine
DB00364,Cyanocobalamin may decrease the excretion rate of Sucralfate which could result in a higher serum level.,Sucralfate
DB00372,Cyanocobalamin may decrease the excretion rate of Thiethylperazine which could result in a higher serum level.,Thiethylperazine
DB00373,Cyanocobalamin may decrease the excretion rate of Timolol which could result in a higher serum level.,Timolol
DB00377,Cyanocobalamin may decrease the excretion rate of Palonosetron which could result in a higher serum level.,Palonosetron
DB00401,Cyanocobalamin may decrease the excretion rate of Nisoldipine which could result in a higher serum level.,Nisoldipine
DB00402,Cyanocobalamin may decrease the excretion rate of Eszopiclone which could result in a higher serum level.,Eszopiclone
DB00404,Cyanocobalamin may decrease the excretion rate of Alprazolam which could result in a higher serum level.,Alprazolam
DB00412,Cyanocobalamin may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.,Rosiglitazone
DB00413,Cyanocobalamin may decrease the excretion rate of Pramipexole which could result in a higher serum level.,Pramipexole
DB00415,Cyanocobalamin may decrease the excretion rate of Ampicillin which could result in a higher serum level.,Ampicillin
DB00418,Cyanocobalamin may decrease the excretion rate of Secobarbital which could result in a higher serum level.,Secobarbital
DB00422,Cyanocobalamin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.,Methylphenidate
DB00432,Cyanocobalamin may decrease the excretion rate of Trifluridine which could result in a higher serum level.,Trifluridine
DB00435,Cyanocobalamin may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.,Nitric Oxide
DB00437,Cyanocobalamin may decrease the excretion rate of Allopurinol which could result in a higher serum level.,Allopurinol
DB00440,Cyanocobalamin may decrease the excretion rate of Trimethoprim which could result in a higher serum level.,Trimethoprim
DB00476,Cyanocobalamin may decrease the excretion rate of Duloxetine which could result in a higher serum level.,Duloxetine
DB00477,Cyanocobalamin may decrease the excretion rate of Chlorpromazine which could result in a higher serum level.,Chlorpromazine
DB00490,Cyanocobalamin may decrease the excretion rate of Buspirone which could result in a higher serum level.,Buspirone
DB00492,Cyanocobalamin may decrease the excretion rate of Fosinopril which could result in a higher serum level.,Fosinopril
DB00499,Cyanocobalamin may decrease the excretion rate of Flutamide which could result in a higher serum level.,Flutamide
DB00502,Cyanocobalamin may decrease the excretion rate of Haloperidol which could result in a higher serum level.,Haloperidol
DB00535,Cyanocobalamin may decrease the excretion rate of Cefdinir which could result in a higher serum level.,Cefdinir
DB00537,Cyanocobalamin may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.,Ciprofloxacin
DB00548,Cyanocobalamin may decrease the excretion rate of Azelaic acid which could result in a higher serum level.,Azelaic acid
DB00553,Cyanocobalamin may decrease the excretion rate of Methoxsalen which could result in a higher serum level.,Methoxsalen
DB00555,Cyanocobalamin may decrease the excretion rate of Lamotrigine which could result in a higher serum level.,Lamotrigine
DB00558,Cyanocobalamin may decrease the excretion rate of Zanamivir which could result in a higher serum level.,Zanamivir
DB00569,Cyanocobalamin may decrease the excretion rate of Fondaparinux which could result in a higher serum level.,Fondaparinux
DB00571,Cyanocobalamin may decrease the excretion rate of Propranolol which could result in a higher serum level.,Propranolol
DB00583,Cyanocobalamin may decrease the excretion rate of Levocarnitine which could result in a higher serum level.,Levocarnitine
DB00591,Cyanocobalamin may decrease the excretion rate of Fluocinolone acetonide which could result in a higher serum level.,Fluocinolone acetonide
DB00597,Cyanocobalamin may decrease the excretion rate of Gadoteridol which could result in a higher serum level.,Gadoteridol
DB00598,Cyanocobalamin may decrease the excretion rate of Labetalol which could result in a higher serum level.,Labetalol
DB00603,Cyanocobalamin may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.,Medroxyprogesterone acetate
DB00608,Cyanocobalamin may decrease the excretion rate of Chloroquine which could result in a higher serum level.,Chloroquine
DB00612,Cyanocobalamin may decrease the excretion rate of Bisoprolol which could result in a higher serum level.,Bisoprolol
DB00624,Cyanocobalamin may decrease the excretion rate of Testosterone which could result in a higher serum level.,Testosterone
DB00628,Cyanocobalamin may decrease the excretion rate of Clorazepic acid which could result in a higher serum level.,Clorazepic acid
DB00633,Cyanocobalamin may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level.,Dexmedetomidine
DB00635,Cyanocobalamin may decrease the excretion rate of Prednisone which could result in a higher serum level.,Prednisone
DB00651,Cyanocobalamin may decrease the excretion rate of Dyphylline which could result in a higher serum level.,Dyphylline
DB00657,Cyanocobalamin may decrease the excretion rate of Mecamylamine which could result in a higher serum level.,Mecamylamine
DB00660,Cyanocobalamin may decrease the excretion rate of Metaxalone which could result in a higher serum level.,Metaxalone
DB00661,Cyanocobalamin may decrease the excretion rate of Verapamil which could result in a higher serum level.,Verapamil
DB00665,Cyanocobalamin may decrease the excretion rate of Nilutamide which could result in a higher serum level.,Nilutamide
DB00669,Cyanocobalamin may decrease the excretion rate of Sumatriptan which could result in a higher serum level.,Sumatriptan
DB00672,Cyanocobalamin may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.,Chlorpropamide
DB00683,Cyanocobalamin may decrease the excretion rate of Midazolam which could result in a higher serum level.,Midazolam
DB00688,Cyanocobalamin may decrease the excretion rate of Mycophenolate mofetil which could result in a higher serum level.,Mycophenolate mofetil
DB00690,Cyanocobalamin may decrease the excretion rate of Flurazepam which could result in a higher serum level.,Flurazepam
DB00692,Cyanocobalamin may decrease the excretion rate of Phentolamine which could result in a higher serum level.,Phentolamine
DB00698,Cyanocobalamin may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.,Nitrofurantoin
DB00706,Cyanocobalamin may decrease the excretion rate of Tamsulosin which could result in a higher serum level.,Tamsulosin
DB00709,Cyanocobalamin may decrease the excretion rate of Lamivudine which could result in a higher serum level.,Lamivudine
DB00713,Cyanocobalamin may decrease the excretion rate of Oxacillin which could result in a higher serum level.,Oxacillin
DB00716,Cyanocobalamin may decrease the excretion rate of Nedocromil which could result in a higher serum level.,Nedocromil
DB00722,Cyanocobalamin may decrease the excretion rate of Lisinopril which could result in a higher serum level.,Lisinopril
DB00730,Cyanocobalamin may decrease the excretion rate of Thiabendazole which could result in a higher serum level.,Thiabendazole
DB00731,Cyanocobalamin may decrease the excretion rate of Nateglinide which could result in a higher serum level.,Nateglinide
DB00733,Cyanocobalamin may decrease the excretion rate of Pralidoxime which could result in a higher serum level.,Pralidoxime
DB00743,Cyanocobalamin may decrease the excretion rate of Gadobenic acid which could result in a higher serum level.,Gadobenic acid
DB00759,Cyanocobalamin may decrease the excretion rate of Tetracycline which could result in a higher serum level.,Tetracycline
DB00760,Cyanocobalamin may decrease the excretion rate of Meropenem which could result in a higher serum level.,Meropenem
DB00775,Cyanocobalamin may decrease the excretion rate of Tirofiban which could result in a higher serum level.,Tirofiban
DB00780,Cyanocobalamin may decrease the excretion rate of Phenelzine which could result in a higher serum level.,Phenelzine
DB00782,Cyanocobalamin may decrease the excretion rate of Propantheline which could result in a higher serum level.,Propantheline
DB00783,Cyanocobalamin may decrease the excretion rate of Estradiol which could result in a higher serum level.,Estradiol
DB00789,Cyanocobalamin may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level.,Gadopentetic acid
DB00790,Cyanocobalamin may decrease the excretion rate of Perindopril which could result in a higher serum level.,Perindopril
DB00800,Cyanocobalamin may decrease the excretion rate of Fenoldopam which could result in a higher serum level.,Fenoldopam
DB00804,Cyanocobalamin may decrease the excretion rate of Dicyclomine which could result in a higher serum level.,Dicyclomine
DB00806,Cyanocobalamin may decrease the excretion rate of Pentoxifylline which could result in a higher serum level.,Pentoxifylline
DB00811,Cyanocobalamin may decrease the excretion rate of Ribavirin which could result in a higher serum level.,Ribavirin
DB00820,Cyanocobalamin may decrease the excretion rate of Tadalafil which could result in a higher serum level.,Tadalafil
DB00828,Cyanocobalamin may decrease the excretion rate of Fosfomycin which could result in a higher serum level.,Fosfomycin
DB00829,Cyanocobalamin may decrease the excretion rate of Diazepam which could result in a higher serum level.,Diazepam
DB00839,Cyanocobalamin may decrease the excretion rate of Tolazamide which could result in a higher serum level.,Tolazamide
DB00841,Cyanocobalamin may decrease the excretion rate of Dobutamine which could result in a higher serum level.,Dobutamine
DB00842,Cyanocobalamin may decrease the excretion rate of Oxazepam which could result in a higher serum level.,Oxazepam
DB00863,Cyanocobalamin may decrease the excretion rate of Ranitidine which could result in a higher serum level.,Ranitidine
DB00871,Cyanocobalamin may decrease the excretion rate of Terbutaline which could result in a higher serum level.,Terbutaline
DB00894,Cyanocobalamin may decrease the excretion rate of Testolactone which could result in a higher serum level.,Testolactone
DB00897,Cyanocobalamin may decrease the excretion rate of Triazolam which could result in a higher serum level.,Triazolam
DB00900,Cyanocobalamin may decrease the excretion rate of Didanosine which could result in a higher serum level.,Didanosine
DB00911,Cyanocobalamin may decrease the excretion rate of Tinidazole which could result in a higher serum level.,Tinidazole
DB00915,Cyanocobalamin may decrease the excretion rate of Amantadine which could result in a higher serum level.,Amantadine
DB00918,Cyanocobalamin may decrease the excretion rate of Almotriptan which could result in a higher serum level.,Almotriptan
DB00934,Cyanocobalamin may decrease the excretion rate of Maprotiline which could result in a higher serum level.,Maprotiline
DB00951,Cyanocobalamin may decrease the excretion rate of Isoniazid which could result in a higher serum level.,Isoniazid
DB00953,Cyanocobalamin may decrease the excretion rate of Rizatriptan which could result in a higher serum level.,Rizatriptan
DB00960,Cyanocobalamin may decrease the excretion rate of Pindolol which could result in a higher serum level.,Pindolol
DB00961,Cyanocobalamin may decrease the excretion rate of Mepivacaine which could result in a higher serum level.,Mepivacaine
DB00962,Cyanocobalamin may decrease the excretion rate of Zaleplon which could result in a higher serum level.,Zaleplon
DB00968,Cyanocobalamin may decrease the excretion rate of Methyldopa which could result in a higher serum level.,Methyldopa
DB00980,Cyanocobalamin may decrease the excretion rate of Ramelteon which could result in a higher serum level.,Ramelteon
DB00988,Cyanocobalamin may decrease the excretion rate of Dopamine which could result in a higher serum level.,Dopamine
DB00993,Cyanocobalamin may decrease the excretion rate of Azathioprine which could result in a higher serum level.,Azathioprine
DB00995,Cyanocobalamin may decrease the excretion rate of Auranofin which could result in a higher serum level.,Auranofin
DB01001,Cyanocobalamin may decrease the excretion rate of Salbutamol which could result in a higher serum level.,Salbutamol
DB01002,Cyanocobalamin may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.,Levobupivacaine
DB01004,Cyanocobalamin may decrease the excretion rate of Ganciclovir which could result in a higher serum level.,Ganciclovir
DB01010,Cyanocobalamin may decrease the excretion rate of Edrophonium which could result in a higher serum level.,Edrophonium
DB01011,Cyanocobalamin may decrease the excretion rate of Metyrapone which could result in a higher serum level.,Metyrapone
DB01015,Cyanocobalamin may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.,Sulfamethoxazole
DB01018,Cyanocobalamin may decrease the excretion rate of Guanfacine which could result in a higher serum level.,Guanfacine
DB01020,Cyanocobalamin may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.,Isosorbide mononitrate
DB01024,Cyanocobalamin may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.,Mycophenolic acid
DB01032,Cyanocobalamin may decrease the excretion rate of Probenecid which could result in a higher serum level.,Probenecid
DB01036,Cyanocobalamin may decrease the excretion rate of Tolterodine which could result in a higher serum level.,Tolterodine
DB01039,Cyanocobalamin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.,Fenofibrate
DB01043,Cyanocobalamin may decrease the excretion rate of Memantine which could result in a higher serum level.,Memantine
DB01046,Cyanocobalamin may decrease the excretion rate of Lubiprostone which could result in a higher serum level.,Lubiprostone
DB01048,Cyanocobalamin may decrease the excretion rate of Abacavir which could result in a higher serum level.,Abacavir
DB01060,Cyanocobalamin may decrease the excretion rate of Amoxicillin which could result in a higher serum level.,Amoxicillin
DB01067,Cyanocobalamin may decrease the excretion rate of Glipizide which could result in a higher serum level.,Glipizide
DB01068,Cyanocobalamin may decrease the excretion rate of Clonazepam which could result in a higher serum level.,Clonazepam
DB01069,Cyanocobalamin may decrease the excretion rate of Promethazine which could result in a higher serum level.,Promethazine
DB01093,Cyanocobalamin may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.,Dimethyl sulfoxide
DB01105,Cyanocobalamin may decrease the excretion rate of Sibutramine which could result in a higher serum level.,Sibutramine
DB01115,Cyanocobalamin may decrease the excretion rate of Nifedipine which could result in a higher serum level.,Nifedipine
DB01124,Cyanocobalamin may decrease the excretion rate of Tolbutamide which could result in a higher serum level.,Tolbutamide
DB01129,Cyanocobalamin may decrease the excretion rate of Rabeprazole which could result in a higher serum level.,Rabeprazole
DB01133,Cyanocobalamin may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.,Tiludronic acid
DB01135,Cyanocobalamin may decrease the excretion rate of Doxacurium which could result in a higher serum level.,Doxacurium
DB01137,Cyanocobalamin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.,Levofloxacin
DB01148,Cyanocobalamin may decrease the excretion rate of Flavoxate which could result in a higher serum level.,Flavoxate
DB01149,Cyanocobalamin may decrease the excretion rate of Nefazodone which could result in a higher serum level.,Nefazodone
DB01156,Cyanocobalamin may decrease the excretion rate of Bupropion which could result in a higher serum level.,Bupropion
DB01157,Cyanocobalamin may decrease the excretion rate of Trimetrexate which could result in a higher serum level.,Trimetrexate
DB01166,Cyanocobalamin may decrease the excretion rate of Cilostazol which could result in a higher serum level.,Cilostazol
DB01170,Cyanocobalamin may decrease the excretion rate of Guanethidine which could result in a higher serum level.,Guanethidine
DB01183,Cyanocobalamin may decrease the excretion rate of Naloxone which could result in a higher serum level.,Naloxone
DB01203,Cyanocobalamin may decrease the excretion rate of Nadolol which could result in a higher serum level.,Nadolol
DB01205,Cyanocobalamin may decrease the excretion rate of Flumazenil which could result in a higher serum level.,Flumazenil
DB01213,Cyanocobalamin may decrease the excretion rate of Fomepizole which could result in a higher serum level.,Fomepizole
DB01215,Cyanocobalamin may decrease the excretion rate of Estazolam which could result in a higher serum level.,Estazolam
DB01221,Cyanocobalamin may decrease the excretion rate of Ketamine which could result in a higher serum level.,Ketamine
DB01222,Cyanocobalamin may decrease the excretion rate of Budesonide which could result in a higher serum level.,Budesonide
DB01224,Cyanocobalamin may decrease the excretion rate of Quetiapine which could result in a higher serum level.,Quetiapine
DB01233,Cyanocobalamin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.,Metoclopramide
DB01240,Cyanocobalamin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.,Epoprostenol
DB01241,Cyanocobalamin may decrease the excretion rate of Gemfibrozil which could result in a higher serum level.,Gemfibrozil
DB01249,Cyanocobalamin may decrease the excretion rate of Iodixanol which could result in a higher serum level.,Iodixanol
DB01261,Cyanocobalamin may decrease the excretion rate of Sitagliptin which could result in a higher serum level.,Sitagliptin
DB01267,Cyanocobalamin may decrease the excretion rate of Paliperidone which could result in a higher serum level.,Paliperidone
DB01273,Cyanocobalamin may decrease the excretion rate of Varenicline which could result in a higher serum level.,Varenicline
DB01274,Cyanocobalamin may decrease the excretion rate of Arformoterol which could result in a higher serum level.,Arformoterol
DB01275,Cyanocobalamin may decrease the excretion rate of Hydralazine which could result in a higher serum level.,Hydralazine
DB01359,Cyanocobalamin may decrease the excretion rate of Penbutolol which could result in a higher serum level.,Penbutolol
DB01367,Cyanocobalamin may decrease the excretion rate of Rasagiline which could result in a higher serum level.,Rasagiline
DB01409,Cyanocobalamin may decrease the excretion rate of Tiotropium which could result in a higher serum level.,Tiotropium
DB01420,Cyanocobalamin may decrease the excretion rate of Testosterone propionate which could result in a higher serum level.,Testosterone propionate
DB01427,Cyanocobalamin may decrease the excretion rate of Amrinone which could result in a higher serum level.,Amrinone
DB01428,Cyanocobalamin may decrease the excretion rate of Oxybenzone which could result in a higher serum level.,Oxybenzone
DB01431,Cyanocobalamin may decrease the excretion rate of Allylestrenol which could result in a higher serum level.,Allylestrenol
DB01550,Cyanocobalamin may decrease the excretion rate of Fenproporex which could result in a higher serum level.,Fenproporex
DB01558,Cyanocobalamin may decrease the excretion rate of Bromazepam which could result in a higher serum level.,Bromazepam
DB01563,Cyanocobalamin may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.,Chloral hydrate
DB01577,Cyanocobalamin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.,Metamfetamine
DB01587,Cyanocobalamin may decrease the excretion rate of Ketazolam which could result in a higher serum level.,Ketazolam
DB01610,Cyanocobalamin may decrease the excretion rate of Valganciclovir which could result in a higher serum level.,Valganciclovir
DB01638,Cyanocobalamin may decrease the excretion rate of Sorbitol which could result in a higher serum level.,Sorbitol
DB01656,Cyanocobalamin may decrease the excretion rate of Roflumilast which could result in a higher serum level.,Roflumilast
DB01685,Cyanocobalamin may decrease the excretion rate of Topiroxostat which could result in a higher serum level.,Topiroxostat
DB04574,Cyanocobalamin may decrease the excretion rate of Estrone sulfate which could result in a higher serum level.,Estrone sulfate
DB04871,Cyanocobalamin may decrease the excretion rate of Lorcaserin which could result in a higher serum level.,Lorcaserin
DB04895,Cyanocobalamin may decrease the excretion rate of Pegaptanib which could result in a higher serum level.,Pegaptanib
DB04896,Cyanocobalamin may decrease the excretion rate of Milnacipran which could result in a higher serum level.,Milnacipran
DB04920,Cyanocobalamin may decrease the excretion rate of Clevidipine which could result in a higher serum level.,Clevidipine
DB04948,Cyanocobalamin may decrease the excretion rate of Lofexidine which could result in a higher serum level.,Lofexidine
DB04953,Cyanocobalamin may decrease the excretion rate of Ezogabine which could result in a higher serum level.,Ezogabine
DB05018,Cyanocobalamin may decrease the excretion rate of Migalastat which could result in a higher serum level.,Migalastat
DB05541,Cyanocobalamin may decrease the excretion rate of Brivaracetam which could result in a higher serum level.,Brivaracetam
DB05676,Cyanocobalamin may decrease the excretion rate of Apremilast which could result in a higher serum level.,Apremilast
DB06154,Cyanocobalamin may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.,Pentaerythritol tetranitrate
DB06186,Cyanocobalamin may decrease the excretion rate of Ipilimumab which could result in a higher serum level.,Ipilimumab
DB06196,Cyanocobalamin may decrease the excretion rate of Icatibant which could result in a higher serum level.,Icatibant
DB06203,Cyanocobalamin may decrease the excretion rate of Alogliptin which could result in a higher serum level.,Alogliptin
DB06209,Cyanocobalamin may decrease the excretion rate of Prasugrel which could result in a higher serum level.,Prasugrel
DB06211,Cyanocobalamin may decrease the excretion rate of Doripenem which could result in a higher serum level.,Doripenem
DB06228,Cyanocobalamin may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.,Rivaroxaban
DB06230,Cyanocobalamin may decrease the excretion rate of Nalmefene which could result in a higher serum level.,Nalmefene
DB06262,Cyanocobalamin may decrease the excretion rate of Droxidopa which could result in a higher serum level.,Droxidopa
DB06282,Cyanocobalamin may decrease the excretion rate of Levocetirizine which could result in a higher serum level.,Levocetirizine
DB06335,Cyanocobalamin may decrease the excretion rate of Saxagliptin which could result in a higher serum level.,Saxagliptin
DB06402,Cyanocobalamin may decrease the excretion rate of Telavancin which could result in a higher serum level.,Telavancin
DB06480,Cyanocobalamin may decrease the excretion rate of Prucalopride which could result in a higher serum level.,Prucalopride
DB06623,Cyanocobalamin may decrease the excretion rate of Flupirtine which could result in a higher serum level.,Flupirtine
DB06637,Cyanocobalamin may decrease the excretion rate of Dalfampridine which could result in a higher serum level.,Dalfampridine
DB06695,Cyanocobalamin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.,Dabigatran etexilate
DB06700,Cyanocobalamin may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level.,Desvenlafaxine
DB06702,Cyanocobalamin may decrease the excretion rate of Fesoterodine which could result in a higher serum level.,Fesoterodine
DB06705,Cyanocobalamin may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.,Gadofosveset trisodium
DB06710,Cyanocobalamin may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.,Methyltestosterone
DB06767,Cyanocobalamin may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.,Ammonium chloride
DB06782,Cyanocobalamin may decrease the excretion rate of Dimercaprol which could result in a higher serum level.,Dimercaprol
DB06796,Cyanocobalamin may decrease the excretion rate of Mangafodipir which could result in a higher serum level.,Mangafodipir
DB06800,Cyanocobalamin may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.,Methylnaltrexone
DB06809,Cyanocobalamin may decrease the excretion rate of Plerixafor which could result in a higher serum level.,Plerixafor
DB06813,Cyanocobalamin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.,Pralatrexate
DB06823,Cyanocobalamin may decrease the excretion rate of Tiopronin which could result in a higher serum level.,Tiopronin
DB06824,Cyanocobalamin may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.,Triethylenetetramine
DB08824,Cyanocobalamin may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.,Ioflupane I-123
DB08826,Cyanocobalamin may decrease the excretion rate of Deferiprone which could result in a higher serum level.,Deferiprone
DB08840,Cyanocobalamin may decrease the excretion rate of N-methylnicotinamide which could result in a higher serum level.,N-methylnicotinamide
DB08872,Cyanocobalamin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.,Gabapentin enacarbil
DB08893,Cyanocobalamin may decrease the excretion rate of Mirabegron which could result in a higher serum level.,Mirabegron
DB08894,Cyanocobalamin may decrease the excretion rate of Peginesatide which could result in a higher serum level.,Peginesatide
DB08897,Cyanocobalamin may decrease the excretion rate of Aclidinium which could result in a higher serum level.,Aclidinium
DB08899,Cyanocobalamin may decrease the excretion rate of Enzalutamide which could result in a higher serum level.,Enzalutamide
DB08900,Cyanocobalamin may decrease the excretion rate of Teduglutide which could result in a higher serum level.,Teduglutide
DB08904,Cyanocobalamin may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.,Certolizumab pegol
DB08905,Cyanocobalamin may decrease the excretion rate of Formestane which could result in a higher serum level.,Formestane
DB08909,Cyanocobalamin may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.,Glycerol phenylbutyrate
DB08911,Cyanocobalamin may decrease the excretion rate of Trametinib which could result in a higher serum level.,Trametinib
DB08918,Cyanocobalamin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.,Levomilnacipran
DB08932,Cyanocobalamin may decrease the excretion rate of Macitentan which could result in a higher serum level.,Macitentan
DB08934,Cyanocobalamin may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.,Sofosbuvir
DB08964,Cyanocobalamin may decrease the excretion rate of Gemeprost which could result in a higher serum level.,Gemeprost
DB09027,Cyanocobalamin may decrease the excretion rate of Ledipasvir which could result in a higher serum level.,Ledipasvir
DB09050,Cyanocobalamin may decrease the excretion rate of Ceftolozane which could result in a higher serum level.,Ceftolozane
DB09066,Cyanocobalamin may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level.,Corifollitropin alfa
DB09068,Cyanocobalamin may decrease the excretion rate of Vortioxetine which could result in a higher serum level.,Vortioxetine
DB09071,Cyanocobalamin may decrease the excretion rate of Tasimelteon which could result in a higher serum level.,Tasimelteon
DB09075,Cyanocobalamin may decrease the excretion rate of Edoxaban which could result in a higher serum level.,Edoxaban
DB09081,Cyanocobalamin may decrease the excretion rate of Idebenone which could result in a higher serum level.,Idebenone
DB09082,Cyanocobalamin may decrease the excretion rate of Vilanterol which could result in a higher serum level.,Vilanterol
DB09089,Cyanocobalamin may decrease the excretion rate of Trimebutine which could result in a higher serum level.,Trimebutine
DB09091,Cyanocobalamin may decrease the excretion rate of Tixocortol which could result in a higher serum level.,Tixocortol
DB09103,Cyanocobalamin may decrease the excretion rate of Ancestim which could result in a higher serum level.,Ancestim
DB09104,Cyanocobalamin may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.,Magnesium hydroxide
DB09106,Cyanocobalamin may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.,Hydroxyethyl Starch
DB09111,Cyanocobalamin may decrease the excretion rate of Pentastarch which could result in a higher serum level.,Pentastarch
DB09118,Cyanocobalamin may decrease the excretion rate of Stiripentol which could result in a higher serum level.,Stiripentol
DB09121,Cyanocobalamin may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.,Aurothioglucose
DB09123,Cyanocobalamin may decrease the excretion rate of Dienogest which could result in a higher serum level.,Dienogest
DB09132,Cyanocobalamin may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.,Gadoteric acid
DB09133,Cyanocobalamin may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.,Iothalamic acid
DB09134,Cyanocobalamin may decrease the excretion rate of Ioversol which could result in a higher serum level.,Ioversol
DB09135,Cyanocobalamin may decrease the excretion rate of Ioxilan which could result in a higher serum level.,Ioxilan
DB09136,Cyanocobalamin may decrease the excretion rate of Isosulfan blue which could result in a higher serum level.,Isosulfan blue
DB09137,Cyanocobalamin may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level.,Technetium Tc-99m mebrofenin
DB09139,Cyanocobalamin may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level.,Technetium Tc-99m oxidronate
DB09148,Cyanocobalamin may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.,Florbetaben (18F)
DB09149,Cyanocobalamin may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.,Florbetapir (18F)
DB09156,Cyanocobalamin may decrease the excretion rate of Iopromide which could result in a higher serum level.,Iopromide
DB09163,Cyanocobalamin may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.,Technetium Tc-99m exametazime
DB09165,Cyanocobalamin may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.,Technetium Tc-99m pyrophosphate
DB09185,Cyanocobalamin may decrease the excretion rate of Viloxazine which could result in a higher serum level.,Viloxazine
DB09194,Cyanocobalamin may decrease the excretion rate of Etoperidone which could result in a higher serum level.,Etoperidone
DB09195,Cyanocobalamin may decrease the excretion rate of Lorpiprazole which could result in a higher serum level.,Lorpiprazole
DB09204,Cyanocobalamin may decrease the excretion rate of Arotinolol which could result in a higher serum level.,Arotinolol
DB09205,Cyanocobalamin may decrease the excretion rate of Moxisylyte which could result in a higher serum level.,Moxisylyte
DB09209,Cyanocobalamin may decrease the excretion rate of Pholcodine which could result in a higher serum level.,Pholcodine
DB09210,Cyanocobalamin may decrease the excretion rate of Piracetam which could result in a higher serum level.,Piracetam
DB09219,Cyanocobalamin may decrease the excretion rate of Bisoxatin which could result in a higher serum level.,Bisoxatin
DB09220,Cyanocobalamin may decrease the excretion rate of Nicorandil which could result in a higher serum level.,Nicorandil
DB09223,Cyanocobalamin may decrease the excretion rate of Blonanserin which could result in a higher serum level.,Blonanserin
DB09224,Cyanocobalamin may decrease the excretion rate of Melperone which could result in a higher serum level.,Melperone
DB09241,Cyanocobalamin may decrease the excretion rate of Methylene blue which could result in a higher serum level.,Methylene blue
DB09244,Cyanocobalamin may decrease the excretion rate of Pirlindole which could result in a higher serum level.,Pirlindole
DB09245,Cyanocobalamin may decrease the excretion rate of Toloxatone which could result in a higher serum level.,Toloxatone
DB09255,Cyanocobalamin may decrease the excretion rate of Dextran which could result in a higher serum level.,Dextran
DB09256,Cyanocobalamin may decrease the excretion rate of Tegafur which could result in a higher serum level.,Tegafur
DB09257,Cyanocobalamin may decrease the excretion rate of Gimeracil which could result in a higher serum level.,Gimeracil
DB09262,Cyanocobalamin may decrease the excretion rate of Imidafenacin which could result in a higher serum level.,Imidafenacin
DB09264,Cyanocobalamin may decrease the excretion rate of Idarucizumab which could result in a higher serum level.,Idarucizumab
DB09265,Cyanocobalamin may decrease the excretion rate of Lixisenatide which could result in a higher serum level.,Lixisenatide
DB09268,Cyanocobalamin may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level.,Picosulfuric acid
DB09276,Cyanocobalamin may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.,Sodium aurothiomalate
DB09277,Cyanocobalamin may decrease the excretion rate of Choline C 11 which could result in a higher serum level.,Choline C 11
DB09281,Cyanocobalamin may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.,Magnesium trisilicate
DB09292,Cyanocobalamin may decrease the excretion rate of Sacubitril which could result in a higher serum level.,Sacubitril
DB09301,Cyanocobalamin may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.,Chondroitin sulfate
DB09317,"Cyanocobalamin may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level.","Synthetic Conjugated Estrogens, A"
DB09318,"Cyanocobalamin may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level.","Synthetic Conjugated Estrogens, B"
DB09320,Cyanocobalamin may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.,Procaine benzylpenicillin
DB09324,Cyanocobalamin may decrease the excretion rate of Sulbactam which could result in a higher serum level.,Sulbactam
DB09329,"Cyanocobalamin may decrease the excretion rate of Antihemophilic Factor (Recombinant), PEGylated which could result in a higher serum level.","Antihemophilic Factor (Recombinant), PEGylated"
DB09344,Cyanocobalamin may decrease the excretion rate of Invert sugar which could result in a higher serum level.,Invert sugar
DB09394,Cyanocobalamin may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.,Phosphoric acid
DB09395,Cyanocobalamin may decrease the excretion rate of Sodium acetate which could result in a higher serum level.,Sodium acetate
DB09407,Cyanocobalamin may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.,Magnesium chloride
DB09418,Cyanocobalamin may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.,Potassium perchlorate
DB09472,Cyanocobalamin may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.,Sodium sulfate
DB09477,Cyanocobalamin may decrease the excretion rate of Enalaprilat which could result in a higher serum level.,Enalaprilat
DB09488,Cyanocobalamin may decrease the excretion rate of Acrivastine which could result in a higher serum level.,Acrivastine
DB09496,Cyanocobalamin may decrease the excretion rate of Octinoxate which could result in a higher serum level.,Octinoxate
DB09502,Cyanocobalamin may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.,Fludeoxyglucose (18F)
DB09546,Cyanocobalamin may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.,Iobenguane sulfate I-123
DB09570,Cyanocobalamin may decrease the excretion rate of Ixazomib which could result in a higher serum level.,Ixazomib
DB11077,Cyanocobalamin may decrease the excretion rate of Polyethylene glycol 400 which could result in a higher serum level.,Polyethylene glycol 400
DB11090,Cyanocobalamin may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.,Potassium nitrate
DB11098,Cyanocobalamin may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level.,Potassium bicarbonate
DB11102,Cyanocobalamin may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.,N-acetyltyrosine
DB11114,Cyanocobalamin may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.,Eucalyptus oil
DB11130,Cyanocobalamin may decrease the excretion rate of Opium which could result in a higher serum level.,Opium
DB11145,Cyanocobalamin may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.,Oxyquinoline
DB11156,Cyanocobalamin may decrease the excretion rate of Pyrantel which could result in a higher serum level.,Pyrantel
DB11164,Cyanocobalamin may decrease the excretion rate of Bicisate which could result in a higher serum level.,Bicisate
DB11278,Cyanocobalamin may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level.,DL-Methylephedrine
DB11328,Cyanocobalamin may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.,Tetradecyl hydrogen sulfate (ester)
DB11338,Cyanocobalamin may decrease the excretion rate of Clove oil which could result in a higher serum level.,Clove oil
DB11358,Cyanocobalamin may decrease the excretion rate of Evening primrose oil which could result in a higher serum level.,Evening primrose oil
DB11364,Cyanocobalamin may decrease the excretion rate of Pidotimod which could result in a higher serum level.,Pidotimod
DB11560,Cyanocobalamin may decrease the excretion rate of Lesinurad which could result in a higher serum level.,Lesinurad
DB11577,Cyanocobalamin may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.,Indigotindisulfonic acid
DB11587,Cyanocobalamin may decrease the excretion rate of Etafedrine which could result in a higher serum level.,Etafedrine
DB11598,Cyanocobalamin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.,Antithrombin III human
DB11642,Cyanocobalamin may decrease the excretion rate of Pitolisant which could result in a higher serum level.,Pitolisant
DB11691,Cyanocobalamin may decrease the excretion rate of Naldemedine which could result in a higher serum level.,Naldemedine
DB11699,Cyanocobalamin may decrease the excretion rate of Tropisetron which could result in a higher serum level.,Tropisetron
DB11817,Cyanocobalamin may decrease the excretion rate of Baricitinib which could result in a higher serum level.,Baricitinib
DB11901,Cyanocobalamin may decrease the excretion rate of Apalutamide which could result in a higher serum level.,Apalutamide
DB11915,Cyanocobalamin may decrease the excretion rate of Valbenazine which could result in a higher serum level.,Valbenazine
DB11943,Cyanocobalamin may decrease the excretion rate of Delafloxacin which could result in a higher serum level.,Delafloxacin
DB11989,Cyanocobalamin may decrease the excretion rate of Benznidazole which could result in a higher serum level.,Benznidazole
DB12007,Cyanocobalamin may decrease the excretion rate of Isoflavone which could result in a higher serum level.,Isoflavone
DB12107,Cyanocobalamin may decrease the excretion rate of Vaborbactam which could result in a higher serum level.,Vaborbactam
DB12161,Cyanocobalamin may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.,Deutetrabenazine
DB12278,Cyanocobalamin may decrease the excretion rate of Propiverine which could result in a higher serum level.,Propiverine
DB12783,Cyanocobalamin may decrease the excretion rate of Benserazide which could result in a higher serum level.,Benserazide
DB13025,Cyanocobalamin may decrease the excretion rate of Tiapride which could result in a higher serum level.,Tiapride
DB13139,Cyanocobalamin may decrease the excretion rate of Levosalbutamol which could result in a higher serum level.,Levosalbutamol
DB13156,Cyanocobalamin may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.,Inosine pranobex
DB13185,Cyanocobalamin may decrease the excretion rate of Oxabolone cipionate which could result in a higher serum level.,Oxabolone cipionate
DB13191,Cyanocobalamin may decrease the excretion rate of Phosphocreatine which could result in a higher serum level.,Phosphocreatine
DB13269,Cyanocobalamin may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.,Dichlorobenzyl alcohol
DB13293,Cyanocobalamin may decrease the excretion rate of Ipecac which could result in a higher serum level.,Ipecac
DB13595,Cyanocobalamin may decrease the excretion rate of Almasilate which could result in a higher serum level.,Almasilate
DB13873,Cyanocobalamin may decrease the excretion rate of Fenofibric acid which could result in a higher serum level.,Fenofibric acid
DB13884,Cyanocobalamin may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.,Albutrepenonacog alfa
DB13909,Cyanocobalamin may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level.,Bismuth subgallate
DB13943,Cyanocobalamin may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level.,Testosterone cypionate
DB13944,Cyanocobalamin may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level.,Testosterone enanthate
DB13946,Cyanocobalamin may decrease the excretion rate of Testosterone undecanoate which could result in a higher serum level.,Testosterone undecanoate
DB13952,Cyanocobalamin may decrease the excretion rate of Estradiol acetate which could result in a higher serum level.,Estradiol acetate
DB13954,Cyanocobalamin may decrease the excretion rate of Estradiol cypionate which could result in a higher serum level.,Estradiol cypionate
DB13955,Cyanocobalamin may decrease the excretion rate of Estradiol dienanthate which could result in a higher serum level.,Estradiol dienanthate
DB13956,Cyanocobalamin may decrease the excretion rate of Estradiol valerate which could result in a higher serum level.,Estradiol valerate
DB13967,Cyanocobalamin may decrease the excretion rate of Patent Blue which could result in a higher serum level.,Patent Blue
DB14006,Cyanocobalamin may decrease the excretion rate of Choline salicylate which could result in a higher serum level.,Choline salicylate
DB14007,Cyanocobalamin may decrease the excretion rate of Pentetic acid which could result in a higher serum level.,Pentetic acid
DB14498,Cyanocobalamin may decrease the excretion rate of Potassium acetate which could result in a higher serum level.,Potassium acetate
DB14499,Cyanocobalamin may decrease the excretion rate of Potassium sulfate which could result in a higher serum level.,Potassium sulfate
DB14526,Cyanocobalamin may decrease the excretion rate of Chromic citrate which could result in a higher serum level.,Chromic citrate
DB14527,Cyanocobalamin may decrease the excretion rate of Chromic nitrate which could result in a higher serum level.,Chromic nitrate
DB14528,Cyanocobalamin may decrease the excretion rate of Chromium gluconate which could result in a higher serum level.,Chromium gluconate
DB14529,Cyanocobalamin may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level.,Chromium nicotinate
DB14530,Cyanocobalamin may decrease the excretion rate of Chromous sulfate which could result in a higher serum level.,Chromous sulfate
DB14754,Cyanocobalamin may decrease the excretion rate of Solriamfetol which could result in a higher serum level.,Solriamfetol
DB06815,Cyanocobalamin may decrease the excretion rate of Pyrithione which could result in a higher serum level.,Pyrithione
DB11121,Cyanocobalamin may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.,Chloroxylenol
DB11085,Cyanocobalamin may decrease the excretion rate of Resorcinol which could result in a higher serum level.,Resorcinol
DB15593,Cyanocobalamin may decrease the excretion rate of Golodirsen which could result in a higher serum level.,Golodirsen
DB00321,Cyanocobalamin may decrease the excretion rate of Amitriptyline which could result in a higher serum level.,Amitriptyline
DB00458,Cyanocobalamin may decrease the excretion rate of Imipramine which could result in a higher serum level.,Imipramine
DB01142,Cyanocobalamin may decrease the excretion rate of Doxepin which could result in a higher serum level.,Doxepin
DB00318,Cyanocobalamin may decrease the excretion rate of Codeine which could result in a higher serum level.,Codeine
DB00454,Cyanocobalamin may decrease the excretion rate of Meperidine which could result in a higher serum level.,Meperidine
DB00813,Cyanocobalamin may decrease the excretion rate of Fentanyl which could result in a higher serum level.,Fentanyl
DB00879,Cyanocobalamin may decrease the excretion rate of Emtricitabine which could result in a higher serum level.,Emtricitabine
DB01151,Cyanocobalamin may decrease the excretion rate of Desipramine which could result in a higher serum level.,Desipramine
DB01242,Cyanocobalamin may decrease the excretion rate of Clomipramine which could result in a higher serum level.,Clomipramine
DB08996,Cyanocobalamin may decrease the excretion rate of Dimetacrine which could result in a higher serum level.,Dimetacrine
DB14506,Cyanocobalamin may decrease the excretion rate of Lithium hydroxide which could result in a higher serum level.,Lithium hydroxide
DB00452,Framycetin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Framycetin
DB00479,Amikacin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Amikacin
DB00684,Tobramycin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Tobramycin
DB00798,Gentamicin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Gentamicin
DB00955,Netilmicin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Netilmicin
DB01082,Streptomycin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Streptomycin
DB01172,Kanamycin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Kanamycin
DB01421,Paromomycin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Paromomycin
DB03615,Ribostamycin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Ribostamycin
DB04263,Geneticin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Geneticin
DB04626,Apramycin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Apramycin
DB04729,Gentamicin C1a may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Gentamicin C1a
DB04808,Neamine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Neamine
DB06696,Arbekacin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Arbekacin
DB08437,Puromycin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Puromycin
DB11512,Dihydrostreptomycin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Dihydrostreptomycin
DB11520,Hygromycin B may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Hygromycin B
DB12604,Sisomicin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Sisomicin
DB13270,Dibekacin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Dibekacin
DB13274,Micronomicin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Micronomicin
DB13540,Isepamicin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Isepamicin
DB13673,Bekanamycin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.,Bekanamycin
DB13145,Cyanocobalamin may decrease the excretion rate of Nedaplatin which could result in a higher serum level.,Nedaplatin
DB00314,Cyanocobalamin may decrease the excretion rate of Capreomycin which could result in a higher serum level.,Capreomycin
DB00390,Cyanocobalamin may decrease the excretion rate of Digoxin which could result in a higher serum level.,Digoxin
DB00512,Cyanocobalamin may decrease the excretion rate of Vancomycin which could result in a higher serum level.,Vancomycin
DB00682,Cyanocobalamin may decrease the excretion rate of Warfarin which could result in a higher serum level.,Warfarin
DB00908,Cyanocobalamin may decrease the excretion rate of Quinidine which could result in a higher serum level.,Quinidine
DB00982,Cyanocobalamin may decrease the excretion rate of Isotretinoin which could result in a higher serum level.,Isotretinoin
DB01035,Cyanocobalamin may decrease the excretion rate of Procainamide which could result in a higher serum level.,Procainamide
DB12615,Cyanocobalamin may decrease the excretion rate of Plazomicin which could result in a higher serum level.,Plazomicin
DB14509,Cyanocobalamin may decrease the excretion rate of Lithium carbonate which could result in a higher serum level.,Lithium carbonate
DB00524,Cyanocobalamin may increase the excretion rate of Metolazone which could result in a lower serum level and potentially a reduction in efficacy.,Metolazone
DB00695,Cyanocobalamin may increase the excretion rate of Furosemide which could result in a lower serum level and potentially a reduction in efficacy.,Furosemide
DB00808,Cyanocobalamin may increase the excretion rate of Indapamide which could result in a lower serum level and potentially a reduction in efficacy.,Indapamide
DB00887,Cyanocobalamin may increase the excretion rate of Bumetanide which could result in a lower serum level and potentially a reduction in efficacy.,Bumetanide
DB00909,Cyanocobalamin may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.,Zonisamide
DB08907,Cyanocobalamin may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.,Canagliflozin
DB09338,Cyanocobalamin may increase the excretion rate of Mersalyl which could result in a lower serum level and potentially a reduction in efficacy.,Mersalyl
DB00214,Torasemide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Torasemide
DB00232,Methyclothiazide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Methyclothiazide
DB00310,Chlorthalidone may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Chlorthalidone
DB00311,Ethoxzolamide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Ethoxzolamide
DB00421,Spironolactone may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Spironolactone
DB00436,Bendroflumethiazide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Bendroflumethiazide
DB00562,Benzthiazide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Benzthiazide
DB00594,Amiloride may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Amiloride
DB00606,Cyclothiazide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Cyclothiazide
DB00700,Eplerenone may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Eplerenone
DB00703,Methazolamide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Methazolamide
DB00774,Hydroflumethiazide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Hydroflumethiazide
DB00819,Acetazolamide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Acetazolamide
DB00872,Conivaptan may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Conivaptan
DB00880,Chlorothiazide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Chlorothiazide
DB01021,Trichlormethiazide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Trichlormethiazide
DB01119,Diazoxide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Diazoxide
DB01144,Diclofenamide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Diclofenamide
DB01324,Polythiazide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Polythiazide
DB01325,Quinethazone may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Quinethazone
DB01395,Drospirenone may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Drospirenone
DB01412,Theobromine may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Theobromine
DB02925,Piretanide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Piretanide
DB04831,Tienilic acid may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Tienilic acid
DB05034,Ularitide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Ularitide
DB06212,Tolvaptan may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Tolvaptan
DB06292,Dapagliflozin may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Dapagliflozin
DB06370,Indisulam may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Indisulam
DB08961,Azosemide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Azosemide
DB09015,Canrenoic acid may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Canrenoic acid
DB09125,Potassium citrate may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Potassium citrate
DB09235,Efonidipine may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Efonidipine
DB09401,Isosorbide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Isosorbide
DB11827,Ertugliflozin may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Ertugliflozin
DB12221,Canrenone may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Canrenone
DB12670,Rolofylline may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Rolofylline
DB12704,Spiradoline may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Spiradoline
DB12766,Cicletanine may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Cicletanine
DB13284,Meticrane may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Meticrane
DB13316,Ibopamine may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Ibopamine
DB13405,Mefruside may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Mefruside
DB13430,Mebutizide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Mebutizide
DB13532,Cyclopenthiazide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Cyclopenthiazide
DB13617,Clorexolone may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Clorexolone
DB13663,Clofenamide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Clofenamide
DB13708,Fenquizone may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Fenquizone
DB13792,Clopamide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Clopamide
DB13801,Muzolimine may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Muzolimine
DB13803,Xipamide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Xipamide
DB13989,Epitizide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Epitizide
DB14018,Bromotheophylline may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.,Bromotheophylline
DB00008,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Peginterferon alfa-2a.,Peginterferon alfa-2a
DB00011,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Interferon alfa-n1.,Interferon alfa-n1
DB00018,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Interferon alfa-n3.,Interferon alfa-n3
DB00022,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Peginterferon alfa-2b.,Peginterferon alfa-2b
DB00033,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Interferon gamma-1b.,Interferon gamma-1b
DB00034,"The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Interferon alfa-2a, Recombinant.","Interferon alfa-2a, Recombinant"
DB00041,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Aldesleukin.,Aldesleukin
DB00056,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Gemtuzumab ozogamicin.,Gemtuzumab ozogamicin
DB00068,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Interferon beta-1b.,Interferon beta-1b
DB00069,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Interferon alfacon-1.,Interferon alfacon-1
DB00073,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Rituximab.,Rituximab
DB00078,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Ibritumomab tiuxetan.,Ibritumomab tiuxetan
DB00081,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Tositumomab.,Tositumomab
DB00087,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Alemtuzumab.,Alemtuzumab
DB00105,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Interferon alfa-2b.,Interferon alfa-2b
DB00120,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Phenylalanine.,Phenylalanine
DB00188,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Bortezomib.,Bortezomib
DB00242,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Cladribine.,Cladribine
DB00262,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Carmustine.,Carmustine
DB00276,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Amsacrine.,Amsacrine
DB00291,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Chlorambucil.,Chlorambucil
DB00293,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Raltitrexed.,Raltitrexed
DB00305,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Mitomycin.,Mitomycin
DB00307,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Bexarotene.,Bexarotene
DB00309,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Vindesine.,Vindesine
DB00322,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Floxuridine.,Floxuridine
DB00328,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Indomethacin.,Indomethacin
DB00352,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Tioguanine.,Tioguanine
DB00361,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Vinorelbine.,Vinorelbine
DB00380,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Dexrazoxane.,Dexrazoxane
DB00398,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Sorafenib.,Sorafenib
DB00428,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Streptozocin.,Streptozocin
DB00441,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Gemcitabine.,Gemcitabine
DB00444,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Teniposide.,Teniposide
DB00445,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Epirubicin.,Epirubicin
DB00480,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Lenalidomide.,Lenalidomide
DB00488,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Altretamine.,Altretamine
DB00495,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Zidovudine.,Zidovudine
DB00515,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Cisplatin.,Cisplatin
DB00526,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Oxaliplatin.,Oxaliplatin
DB00531,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Cyclophosphamide.,Cyclophosphamide
DB00544,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Fluorouracil.,Fluorouracil
DB00550,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Propylthiouracil.,Propylthiouracil
DB00552,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Pentostatin.,Pentostatin
DB00563,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Methotrexate.,Methotrexate
DB00564,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Carbamazepine.,Carbamazepine
DB00570,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Vinblastine.,Vinblastine
DB00601,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Linezolid.,Linezolid
DB00619,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Imatinib.,Imatinib
DB00631,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Clofarabine.,Clofarabine
DB00642,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Pemetrexed.,Pemetrexed
DB00694,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Daunorubicin.,Daunorubicin
DB00762,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Irinotecan.,Irinotecan
DB00763,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Methimazole.,Methimazole
DB00773,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Etoposide.,Etoposide
DB00851,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Dacarbazine.,Dacarbazine
DB00853,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Temozolomide.,Temozolomide
DB00859,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Penicillamine.,Penicillamine
DB00864,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Tacrolimus.,Tacrolimus
DB00877,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Sirolimus.,Sirolimus
DB00888,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Mechlorethamine.,Mechlorethamine
DB00928,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Azacitidine.,Azacitidine
DB00958,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Carboplatin.,Carboplatin
DB00970,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Dactinomycin.,Dactinomycin
DB00987,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Cytarabine.,Cytarabine
DB00997,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Doxorubicin.,Doxorubicin
DB01005,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Hydroxyurea.,Hydroxyurea
DB01008,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Busulfan.,Busulfan
DB01030,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Topotecan.,Topotecan
DB01033,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Mercaptopurine.,Mercaptopurine
DB01041,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Thalidomide.,Thalidomide
DB01042,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Melphalan.,Melphalan
DB01073,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Fludarabine.,Fludarabine
DB01099,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Flucytosine.,Flucytosine
DB01101,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Capecitabine.,Capecitabine
DB01168,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Procarbazine.,Procarbazine
DB01169,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Arsenic trioxide.,Arsenic trioxide
DB01177,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Idarubicin.,Idarubicin
DB01181,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Ifosfamide.,Ifosfamide
DB01204,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Mitoxantrone.,Mitoxantrone
DB01206,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Lomustine.,Lomustine
DB01229,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Paclitaxel.,Paclitaxel
DB01248,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Docetaxel.,Docetaxel
DB01254,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Dasatinib.,Dasatinib
DB01262,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Decitabine.,Decitabine
DB01280,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Nelarabine.,Nelarabine
DB01590,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Everolimus.,Everolimus
DB02546,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Vorinostat.,Vorinostat
DB04572,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Thiotepa.,Thiotepa
DB04845,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Ixabepilone.,Ixabepilone
DB04868,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Nilotinib.,Nilotinib
DB05015,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Belinostat.,Belinostat
DB05109,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Trabectedin.,Trabectedin
DB05258,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Interferon alfa.,Interferon alfa
DB05472,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with omega interferon.,omega interferon
DB05773,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Trastuzumab emtansine.,Trastuzumab emtansine
DB06287,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Temsirolimus.,Temsirolimus
DB06616,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Bosutinib.,Bosutinib
DB06769,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Bendamustine.,Bendamustine
DB06772,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Cabazitaxel.,Cabazitaxel
DB08871,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Eribulin.,Eribulin
DB08877,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Ruxolitinib.,Ruxolitinib
DB08889,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Carfilzomib.,Carfilzomib
DB08895,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Tofacitinib.,Tofacitinib
DB08901,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Ponatinib.,Ponatinib
DB08910,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Pomalidomide.,Pomalidomide
DB08935,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Obinutuzumab.,Obinutuzumab
DB09042,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Tedizolid phosphate.,Tedizolid phosphate
DB09052,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Blinatumomab.,Blinatumomab
DB09053,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Ibrutinib.,Ibrutinib
DB09073,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Palbociclib.,Palbociclib
DB09074,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Olaparib.,Olaparib
DB09077,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Dinutuximab.,Dinutuximab
DB09122,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Peginterferon beta-1a.,Peginterferon beta-1a
DB12814,The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Cepeginterferon alfa-2B.,Cepeginterferon alfa-2B
DB00994,Neomycin can cause a decrease in the absorption of Cyanocobalamin resulting in a reduced serum concentration and potentially a decrease in efficacy.,Neomycin
DB01320,The serum concentration of Fosphenytoin can be decreased when it is combined with Tetrahydrofolic acid.,Fosphenytoin
DB00293,The therapeutic efficacy of Raltitrexed can be decreased when used in combination with Tetrahydrofolic acid.,Raltitrexed
DB00795,The serum concentration of Tetrahydrofolic acid can be decreased when it is combined with Sulfasalazine.,Sulfasalazine
DB00252,The serum concentration of Phenytoin can be decreased when it is combined with Tetrahydrofolic acid.,Phenytoin
DB08898,The serum concentration of the active metabolites of Tetrahydrofolic acid can be reduced when Tetrahydrofolic acid is used in combination with Glucarpidase resulting in a loss in efficacy.,Glucarpidase
DB01174,The serum concentration of Phenobarbital can be decreased when it is combined with Tetrahydrofolic acid.,Phenobarbital
DB00794,The serum concentration of Primidone can be decreased when it is combined with Tetrahydrofolic acid.,Primidone
DB00205,The therapeutic efficacy of Pyrimethamine can be decreased when used in combination with Tetrahydrofolic acid.,Pyrimethamine
DB00250,The therapeutic efficacy of Dapsone can be decreased when used in combination with Tetrahydrofolic acid.,Dapsone
DB00440,The therapeutic efficacy of Trimethoprim can be decreased when used in combination with Tetrahydrofolic acid.,Trimethoprim
DB00563,The therapeutic efficacy of Methotrexate can be decreased when used in combination with Tetrahydrofolic acid.,Methotrexate
DB00642,The therapeutic efficacy of Pemetrexed can be decreased when used in combination with Tetrahydrofolic acid.,Pemetrexed
DB01131,The therapeutic efficacy of Proguanil can be decreased when used in combination with Tetrahydrofolic acid.,Proguanil
DB01157,The therapeutic efficacy of Trimetrexate can be decreased when used in combination with Tetrahydrofolic acid.,Trimetrexate
DB03695,The therapeutic efficacy of Piritrexim can be decreased when used in combination with Tetrahydrofolic acid.,Piritrexim
DB04655,The therapeutic efficacy of Metoprine can be decreased when used in combination with Tetrahydrofolic acid.,Metoprine
DB06358,The therapeutic efficacy of Iclaprim can be decreased when used in combination with Tetrahydrofolic acid.,Iclaprim
DB06813,The therapeutic efficacy of Pralatrexate can be decreased when used in combination with Tetrahydrofolic acid.,Pralatrexate
DB08878,The therapeutic efficacy of Aminopterin can be decreased when used in combination with Tetrahydrofolic acid.,Aminopterin
DB12769,The therapeutic efficacy of Lometrexol can be decreased when used in combination with Tetrahydrofolic acid.,Lometrexol
DB12912,The therapeutic efficacy of Nolatrexed can be decreased when used in combination with Tetrahydrofolic acid.,Nolatrexed
DB13795,The therapeutic efficacy of Brodimoprim can be decreased when used in combination with Tetrahydrofolic acid.,Brodimoprim
DB14763,The therapeutic efficacy of Cycloguanil can be decreased when used in combination with Tetrahydrofolic acid.,Cycloguanil
DB00313,The serum concentration of Tetrahydrofolic acid can be decreased when it is combined with Valproic acid.,Valproic acid
DB00375,The serum concentration of Tetrahydrofolic acid can be decreased when it is combined with Colestipol.,Colestipol
DB00564,The serum concentration of Carbamazepine can be decreased when it is combined with Tetrahydrofolic acid.,Carbamazepine
DB00544,The risk or severity of adverse effects can be increased when Tetrahydrofolic acid is combined with Fluorouracil.,Fluorouracil
DB01099,The risk or severity of adverse effects can be increased when Tetrahydrofolic acid is combined with Flucytosine.,Flucytosine
DB01101,The risk or severity of adverse effects can be increased when Tetrahydrofolic acid is combined with Capecitabine.,Capecitabine
DB01629,The risk or severity of adverse effects can be increased when Tetrahydrofolic acid is combined with 5-fluorouridine.,5-fluorouridine
DB03419,The risk or severity of adverse effects can be increased when Tetrahydrofolic acid is combined with Uracil.,Uracil
DB09256,The risk or severity of adverse effects can be increased when Tetrahydrofolic acid is combined with Tegafur.,Tegafur
DB12947,The risk or severity of adverse effects can be increased when Tetrahydrofolic acid is combined with Doxifluridine.,Doxifluridine
DB00228,The metabolism of Enflurane can be decreased when combined with Ademetionine.,Enflurane
DB00347,The metabolism of Trimethadione can be decreased when combined with Ademetionine.,Trimethadione
DB00356,The metabolism of Chlorzoxazone can be decreased when combined with Ademetionine.,Chlorzoxazone
DB00753,The metabolism of Isoflurane can be decreased when combined with Ademetionine.,Isoflurane
DB00898,The metabolism of Ethanol can be decreased when combined with Ademetionine.,Ethanol
DB01028,The metabolism of Methoxyflurane can be decreased when combined with Ademetionine.,Methoxyflurane
DB01159,The metabolism of Halothane can be decreased when combined with Ademetionine.,Halothane
DB01236,The metabolism of Sevoflurane can be decreased when combined with Ademetionine.,Sevoflurane
DB06712,The metabolism of Nilvadipine can be decreased when combined with Ademetionine.,Nilvadipine
DB06728,The metabolism of Aniline can be decreased when combined with Ademetionine.,Aniline
DB06770,The metabolism of Benzyl alcohol can be decreased when combined with Ademetionine.,Benzyl alcohol
DB00949,The metabolism of Felbamate can be decreased when combined with Ademetionine.,Felbamate
DB06119,The metabolism of Cenobamate can be decreased when combined with Ademetionine.,Cenobamate
DB01136,The metabolism of Carvedilol can be decreased when combined with Ademetionine.,Carvedilol
DB00252,The metabolism of Phenytoin can be decreased when combined with Ademetionine.,Phenytoin
DB08868,The metabolism of Fingolimod can be decreased when combined with Ademetionine.,Fingolimod
DB00593,The metabolism of Ethosuximide can be decreased when combined with Ademetionine.,Ethosuximide
DB11689,The metabolism of Selumetinib can be decreased when combined with Ademetionine.,Selumetinib
DB00908,The metabolism of Quinidine can be decreased when combined with Ademetionine.,Quinidine
DB00675,The metabolism of Tamoxifen can be decreased when combined with Ademetionine.,Tamoxifen
DB05109,The metabolism of Trabectedin can be decreased when combined with Ademetionine.,Trabectedin
DB00316,Ademetionine may increase the hepatotoxic activities of Acetaminophen.,Acetaminophen
DB09288,Ademetionine may increase the hepatotoxic activities of Propacetamol.,Propacetamol
DB06643,The risk or severity of adverse effects can be increased when Denosumab is combined with Phenylalanine.,Denosumab
DB00005,The risk or severity of adverse effects can be increased when Etanercept is combined with Phenylalanine.,Etanercept
DB00008,The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Phenylalanine.,Peginterferon alfa-2a
DB00011,The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Phenylalanine.,Interferon alfa-n1
DB00018,The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Phenylalanine.,Interferon alfa-n3
DB00022,The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Phenylalanine.,Peginterferon alfa-2b
DB00026,The risk or severity of adverse effects can be increased when Anakinra is combined with Phenylalanine.,Anakinra
DB00033,The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Phenylalanine.,Interferon gamma-1b
DB00034,"The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Phenylalanine.","Interferon alfa-2a, Recombinant"
DB00041,The risk or severity of adverse effects can be increased when Aldesleukin is combined with Phenylalanine.,Aldesleukin
DB00051,The risk or severity of adverse effects can be increased when Adalimumab is combined with Phenylalanine.,Adalimumab
DB00056,The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Phenylalanine.,Gemtuzumab ozogamicin
DB00059,The risk or severity of adverse effects can be increased when Pegaspargase is combined with Phenylalanine.,Pegaspargase
DB00065,The risk or severity of adverse effects can be increased when Infliximab is combined with Phenylalanine.,Infliximab
DB00068,The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Phenylalanine.,Interferon beta-1b
DB00069,The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Phenylalanine.,Interferon alfacon-1
DB00073,The risk or severity of adverse effects can be increased when Rituximab is combined with Phenylalanine.,Rituximab
DB00074,The risk or severity of adverse effects can be increased when Basiliximab is combined with Phenylalanine.,Basiliximab
DB00075,The risk or severity of adverse effects can be increased when Muromonab is combined with Phenylalanine.,Muromonab
DB00078,The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Phenylalanine.,Ibritumomab tiuxetan
DB00081,The risk or severity of adverse effects can be increased when Tositumomab is combined with Phenylalanine.,Tositumomab
DB00087,The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Phenylalanine.,Alemtuzumab
DB00092,The risk or severity of adverse effects can be increased when Alefacept is combined with Phenylalanine.,Alefacept
DB00095,The risk or severity of adverse effects can be increased when Efalizumab is combined with Phenylalanine.,Efalizumab
DB00098,The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Phenylalanine.,Antithymocyte immunoglobulin (rabbit)
DB00105,The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Phenylalanine.,Interferon alfa-2b
DB00111,The risk or severity of adverse effects can be increased when Daclizumab is combined with Phenylalanine.,Daclizumab
DB00112,The risk or severity of adverse effects can be increased when Bevacizumab is combined with Phenylalanine.,Bevacizumab
DB00180,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Flunisolide.,Flunisolide
DB00188,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Bortezomib.,Bortezomib
DB00242,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Cladribine.,Cladribine
DB00262,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Carmustine.,Carmustine
DB00276,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Amsacrine.,Amsacrine
DB00290,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Bleomycin.,Bleomycin
DB00291,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Chlorambucil.,Chlorambucil
DB00293,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Raltitrexed.,Raltitrexed
DB00305,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Mitomycin.,Mitomycin
DB00307,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Bexarotene.,Bexarotene
DB00309,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Vindesine.,Vindesine
DB00322,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Floxuridine.,Floxuridine
DB00328,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Indomethacin.,Indomethacin
DB00352,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Tioguanine.,Tioguanine
DB00361,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Vinorelbine.,Vinorelbine
DB00380,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Dexrazoxane.,Dexrazoxane
DB00394,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Beclomethasone dipropionate.,Beclomethasone dipropionate
DB00398,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Sorafenib.,Sorafenib
DB00428,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Streptozocin.,Streptozocin
DB00432,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Trifluridine.,Trifluridine
DB00441,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Gemcitabine.,Gemcitabine
DB00443,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Betamethasone.,Betamethasone
DB00444,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Teniposide.,Teniposide
DB00445,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Epirubicin.,Epirubicin
DB00446,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Chloramphenicol.,Chloramphenicol
DB00480,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Lenalidomide.,Lenalidomide
DB00488,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Altretamine.,Altretamine
DB00495,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Zidovudine.,Zidovudine
DB00515,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Cisplatin.,Cisplatin
DB00526,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Oxaliplatin.,Oxaliplatin
DB00531,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Cyclophosphamide.,Cyclophosphamide
DB00541,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Vincristine.,Vincristine
DB00544,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Fluorouracil.,Fluorouracil
DB00550,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Propylthiouracil.,Propylthiouracil
DB00552,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Pentostatin.,Pentostatin
DB00563,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Methotrexate.,Methotrexate
DB00564,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Carbamazepine.,Carbamazepine
DB00570,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Vinblastine.,Vinblastine
DB00588,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Fluticasone propionate.,Fluticasone propionate
DB00591,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Fluocinolone acetonide.,Fluocinolone acetonide
DB00601,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Linezolid.,Linezolid
DB00619,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Imatinib.,Imatinib
DB00620,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Triamcinolone.,Triamcinolone
DB00631,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Clofarabine.,Clofarabine
DB00635,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Prednisone.,Prednisone
DB00642,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Pemetrexed.,Pemetrexed
DB00687,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Fludrocortisone.,Fludrocortisone
DB00688,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Mycophenolate mofetil.,Mycophenolate mofetil
DB00694,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Daunorubicin.,Daunorubicin
DB00755,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Tretinoin.,Tretinoin
DB00762,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Irinotecan.,Irinotecan
DB00763,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Methimazole.,Methimazole
DB00764,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Mometasone.,Mometasone
DB00773,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Etoposide.,Etoposide
DB00795,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Sulfasalazine.,Sulfasalazine
DB00851,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Dacarbazine.,Dacarbazine
DB00853,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Temozolomide.,Temozolomide
DB00859,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Penicillamine.,Penicillamine
DB00860,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Prednisolone.,Prednisolone
DB00877,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Sirolimus.,Sirolimus
DB00888,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Mechlorethamine.,Mechlorethamine
DB00928,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Azacitidine.,Azacitidine
DB00958,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Carboplatin.,Carboplatin
DB00959,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Methylprednisolone.,Methylprednisolone
DB00970,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Dactinomycin.,Dactinomycin
DB00987,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Cytarabine.,Cytarabine
DB00993,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Azathioprine.,Azathioprine
DB00997,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Doxorubicin.,Doxorubicin
DB01005,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Hydroxyurea.,Hydroxyurea
DB01008,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Busulfan.,Busulfan
DB01024,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Mycophenolic acid.,Mycophenolic acid
DB01030,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Topotecan.,Topotecan
DB01033,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Mercaptopurine.,Mercaptopurine
DB01041,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Thalidomide.,Thalidomide
DB01042,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Melphalan.,Melphalan
DB01073,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Fludarabine.,Fludarabine
DB01099,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Flucytosine.,Flucytosine
DB01101,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Capecitabine.,Capecitabine
DB01108,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Trilostane.,Trilostane
DB01168,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Procarbazine.,Procarbazine
DB01169,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Arsenic trioxide.,Arsenic trioxide
DB01177,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Idarubicin.,Idarubicin
DB01181,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Ifosfamide.,Ifosfamide
DB01196,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Estramustine.,Estramustine
DB01204,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Mitoxantrone.,Mitoxantrone
DB01206,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Lomustine.,Lomustine
DB01222,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Budesonide.,Budesonide
DB01229,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Paclitaxel.,Paclitaxel
DB01234,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Dexamethasone.,Dexamethasone
DB01248,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Docetaxel.,Docetaxel
DB01254,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Dasatinib.,Dasatinib
DB01257,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Eculizumab.,Eculizumab
DB01262,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Decitabine.,Decitabine
DB01268,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Sunitinib.,Sunitinib
DB01280,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Nelarabine.,Nelarabine
DB01281,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Abatacept.,Abatacept
DB01285,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Corticotropin.,Corticotropin
DB01380,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Cortisone acetate.,Cortisone acetate
DB01384,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Paramethasone.,Paramethasone
DB01394,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Colchicine.,Colchicine
DB01410,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Ciclesonide.,Ciclesonide
DB01423,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Stepronin.,Stepronin
DB01590,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Everolimus.,Everolimus
DB01611,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Hydroxychloroquine.,Hydroxychloroquine
DB01816,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Castanospermine.,Castanospermine
DB02546,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Vorinostat.,Vorinostat
DB02806,The risk or severity of adverse effects can be increased when Phenylalanine is combined with 2-Methoxyethanol.,2-Methoxyethanol
DB03523,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Brequinar.,Brequinar
DB04572,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Thiotepa.,Thiotepa
DB04630,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Aldosterone.,Aldosterone
DB04845,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Ixabepilone.,Ixabepilone
DB04868,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Nilotinib.,Nilotinib
DB04951,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Pirfenidone.,Pirfenidone
DB04956,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Afelimomab.,Afelimomab
DB05015,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Belinostat.,Belinostat
DB05109,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Trabectedin.,Trabectedin
DB05258,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Interferon alfa.,Interferon alfa
DB05259,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Glatiramer.,Glatiramer
DB05260,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Gallium nitrate.,Gallium nitrate
DB05459,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Briakinumab.,Briakinumab
DB05472,The risk or severity of adverse effects can be increased when Phenylalanine is combined with omega interferon.,omega interferon
DB05676,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Apremilast.,Apremilast
DB05773,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Trastuzumab emtansine.,Trastuzumab emtansine
DB06168,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Canakinumab.,Canakinumab
DB06273,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Tocilizumab.,Tocilizumab
DB06287,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Temsirolimus.,Temsirolimus
DB06372,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Rilonacept.,Rilonacept
DB06589,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Pazopanib.,Pazopanib
DB06603,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Panobinostat.,Panobinostat
DB06612,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Mepolizumab.,Mepolizumab
DB06616,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Bosutinib.,Bosutinib
DB06662,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Abetimus.,Abetimus
DB06674,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Golimumab.,Golimumab
DB06681,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Belatacept.,Belatacept
DB06769,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Bendamustine.,Bendamustine
DB06772,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Cabazitaxel.,Cabazitaxel
DB06813,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Pralatrexate.,Pralatrexate
DB08059,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Wortmannin.,Wortmannin
DB08870,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Brentuximab vedotin.,Brentuximab vedotin
DB08871,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Eribulin.,Eribulin
DB08877,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Ruxolitinib.,Ruxolitinib
DB08879,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Belimumab.,Belimumab
DB08880,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Teriflunomide.,Teriflunomide
DB08889,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Carfilzomib.,Carfilzomib
DB08901,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Ponatinib.,Ponatinib
DB08904,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Certolizumab pegol.,Certolizumab pegol
DB08906,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Fluticasone furoate.,Fluticasone furoate
DB08908,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Dimethyl fumarate.,Dimethyl fumarate
DB08910,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Pomalidomide.,Pomalidomide
DB08935,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Obinutuzumab.,Obinutuzumab
DB08970,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Fluprednidene.,Fluprednidene
DB08971,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Fluocortolone.,Fluocortolone
DB09029,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Secukinumab.,Secukinumab
DB09033,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Vedolizumab.,Vedolizumab
DB09036,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Siltuximab.,Siltuximab
DB09052,The risk or severity of adverse effects can be increased when Phenylalanine is combined with Blinatumomab.,Blinatumomab
